14P00001606T0076|0 9|Comparison
14P00001606T0076|14 34|alkaline phosphatases
14P00001606T0076|37 50|5-nucleotidase
14P00008171T0000|30 47|hyperbilirubinemia
14P00008997A0472|4 6|CSF
14P00008997A0472|8 11|HCO3
14P00008997A0472|34 41|CSF PCO2
14P00010943A0733|0 9|Flurazepam
14P00010943A0733|81 88|practice
14P00012653T0045|0 3|Beta
14P00013683A0210|18 28|CO2 removal
14P00013683A0210|40 53|CO2 production
14P00013683A0210|54 57|VCO2
14P00015731A0090|11 24|administration
14P00015731A0090|44 63|anhydrase inhibitors
14P00015731A0090|64 76|acetazolamide
14P00015731A0090|78 90|methazolamide
14P00015731A0090|92 107|dichlorphenamide
14P00015731A0090|109 117|sulthiame
14P00022143T0000|20 30|etoperidone
14P00022143T0000|42 47|rabbit
14P00023348A0601|10 15|polyps
14P00024600A0522|11 28|HMG dosage regimen
14P00025557A0100|7 17|CO2 content
14P00027739T0000|0 30|Serum gamma glutamyltransferase
14P00027967A0207|20 32|HI antibodies
14P00027967A0207|97 105|formation
14P00027967A0207|124 133|antibodies
14P00029555A0861|102 136|shellfish microbiology laboratories
14P00029953T0045|0 14|Characteristics
14P00030183T0000|0 7|Takayasu
14P00030183T0000|33 38|HLA-B5
14P00030937A0119|0 3|SGPT
14P00030937A0119|5 8|SGOT
14P00030937A0119|13 47|alkaline phosphatase concentrations
14P00033873T0001|0 28|Gamma glutamyl transpeptidase
14P00033873T0001|28 31|GGTP
14P00034935A0545|0 7|Patients
14P00034935A0545|12 20|Parkinson
14P00034935A0545|77 90|drug treatment
14P00038408T0000|29 47|alpha-autoreceptors
14P00038408T0000|70 85|alpha-methyldopa
14P00038408T0000|89 91|FLA
14P00039271T0000|20 27|diazepam
14P00039271T0000|49 59|application
14P00041512T0067|0 8|Abstracts
14P00048373A0377|0 6|Removal
14P00048373A0377|78 87|epithelium
14P00050628A0202|2 4|IgG
14P00050628A0202|15 24|gammopathy
14P00050628A0202|71 81|proteinuria
14P00052597T0000|0 6|Studies
14P00052597T0000|9 24|immunoglobulin E
14P00052597T0000|48 63|Professor Dan H.
14P00054900A0226|10 24|reaction stains
14P00055040A0000|19 37|pustulosis palmaris
14P00055040A0000|70 87|immunofluorescence
14P00055040A0000|138 157|degradation products
14P00055040A0000|158 167|FR-antigen
14P00055040A0000|238 240|HPF
14P00055040A0000|263 279|plasma fibrinogen
14P00056837A0000|5 21|mediastinoscopies
14P00056837A0000|74 84|operability
14P00056901A0308|27 46|hydroxy-ethyl-starch
14P00060529A0695|12 24|control group
14P00060529A0695|27 42|acquisition-rate
14P00060529A0695|75 85|0acteriuria
14P00060529A0695|145 163|practice population
14P00060529A0695|215 218|A.B.
14P00061478T0000|4 16|complications
14P00061478T0000|19 33|catheterisation
14P00063680T0000|19 31|galactosaemia
14P00064414A1098|0 4|Sings
14P00064414A1098|36 49|erythropoiesis
14P00066874T0000|21 50|fluid alpha fetoprotein levels
14P00072928T0000|0 13|Serum-ferritin
14P00072928T0000|27 42|haemochromatosis
14P00073344A0367|14 36|phytomitogen reactivity
14P00074758T0000|0 7|Patients
14P00074758T0000|16 29|hypothyroidism
14P00083846T0000|0 6|Albumin
14P00083846T0000|16 25|AMP levels
14P00084275T0063|0 6|Preface
14P00086313A0000|20 31|Legionnaires
14P00086313A0000|33 48|disease bacteria
14P00086313A0000|143 158|antibody testing
14P00088391A0181|10 20|hand factor
14P00088391A0181|43 60|coumarin treatment
14P00089778A0000|18 38|alpha 2-macroglobulin
14P00089778A0000|39 57|alpha 1-antitrypsin
14P00089778A0000|70 82|C3-complement
14P00089778A0000|84 114|fibrinogen degradation products
14P00089778A0000|114 116|FDP
14P00089778A0000|199 203|Fuchs
14P00089778A0000|298 314|cataract patients
14P00092689A0352|12 19|patients
14P00092689A0352|35 39|times
14P00094639A0313|0 7|Prazosin
14P00094639A0313|43 50|patients
14P00096241A0087|0 1|T4
14P00096241A0087|5 8|FT4I
14P00096241A0087|136 138|EGA
14P00096241A0087|145 156|term infants
14P00097989A0106|23 37|treatment plans
14P00100540T0000|0 18|Aspirin intolerance
14P00100540T0000|44 67|platelet cyclo-oxygenase
14P00100791A0425|24 41|cynomolgus monkeys
14P00100791A0425|87 100|rhesus monkeys
14P00101300A0257|37 38|T1
14P00101300A0257|40 41|T2
14P00101300A0257|43 44|T3
14P00101300A0257|46 47|N0
14P00101300A0257|49 50|N1
14P00105401A0635|11 13|CBZ
14P00105401A0635|17 19|DPH
14P00105401A0635|52 74|thyroid hormone binding
14P00105401A0635|75 77|TBG
14P00105401A0635|137 152|thyroid hormones
14P00105401A0635|183 202|premedication levels
14P00105401A0635|204 206|FT4
14P00105401A0635|210 212|FT3
14P00105903A0288|45 63|polyethylene glycol
14P00105903A0288|67 69|PEG
14P00111174A0351|26 35|properties
14P00111174A0351|45 51|neurons
14P00111174A0351|74 80|neurons
14P00111174A0351|93 99|stimuli
14P00111174A0351|115 121|neurons
14P00111174A0351|146 152|stimuli
14P00111174A0351|157 163|neurons
14P00111174A0351|181 187|stimuli
14P00112627A0542|0 12|Pentobarbital
14P00112627A0542|49 59|combination
14P00112627A0542|86 98|normeperidine
14P00112627A0542|111 121|anileridine
14P00112627A0542|132 143|alphaprodine
14P00113657A0628|0 6|Pb foil
14P00113657A0628|39 49|improvement
14P00114144A0189|56 70|result emphasis
14P00114144A0189|130 133|Type
14P00114144A0189|136 159|glycogen storage disease
14P00114144A0189|159 166|Andersen
14P00114144A0189|220 232|enzyme defect
14P00115974A0576|3 8|groups
14P00115974A0576|35 38|maze
14P00115974A0576|59 62|days
14P00117748T0000|0 11|Erythromycin
14P00117748T0000|15 36|clindamycin resistance
14P00117748T0000|38 64|Corynebacterium diphtheriae
14P00118044A0000|14 26|displacements
14P00118044A0000|83 84|M2
14P00118044A0000|89 96|M3 peaks
14P00118044A0000|115 126|EMG activity
14P00118810T0001|9 15|disease
14P00119339A0400|75 89|T. cruzi stocks
14P00119339A0400|118 128|myocarditis
14P00119339A0400|142 153|degeneration
14P00119339A0400|170 179|oesophagus
14P00122718A0500|13 21|MRF units
14P00129659T0000|0 10|Variability
14P00129659T0000|17 20|Down
14P00129659T0000|63 77|sex differences
14P00129659T0000|79 81|IQs
14P00130573T0054|0 2|VII
14P00131739T0001|48 57|Uzbekistan
14P00133214T0064|40 43|USSR
14P00136175A1137|3 13|maintenance
14P00136175A1137|140 150|enlargement
14P00136175A1137|153 155|ECA
14P00137671A0896|50 59|VIII-ratio
14P00139624A0318|18 31|administration
14P00139624A0318|48 72|serum ceruloplasmin level
14P00139827A0000|0 16|Radioimmunoassays
14P00139827A0000|19 30|pregnenolone
14P00139827A0000|32 43|progesterone
14P00139827A0000|45 66|dehydroepiandrosterone
14P00139827A0000|68 70|DHA
14P00139827A0000|74 90|alpha-hydroxy-DHA
14P00142718A0156|93 102|99mTc-EHDP
14P00142718A0156|115 131|chest radiographs
14P00146327A0147|3 10|majority
14P00146327A0147|37 44|cavities
14P00146327A0147|65 74|incidences
14P00146327A0147|110 121|stem bronchi
14P00149899T0001|0 9|Prediction
14P00149899T0001|29 39|development
14P00150066A0100|11 20|fibrinogen
14P00150066A0100|33 43|coagulation
14P00150066A0554|16 27|haemorrhages
14P00150066A0554|35 44|prostheses
14P00154430A0906|3 20|Southern technique
14P00154430A0906|35 46|localization
14P00154430A0906|73 85|transcription
14P00155973A0387|116 143|carbon dioxide concentration
14P00155973A0387|172 185|gas flow rates
14P00155973A0387|213 230|minute ventilation
14P00159600A0871|0 1|SV
14P00159600A0871|17 19|SHR
14P00159600A0871|84 86|SHR
14P00163384A0000|28 43|Bubo virginianus
14P00163384A0000|80 86|Ontario
14P00167544A0067|25 39|microdissection
14P00167544A0067|111 129|electron microscopy
14P00167544A0067|157 182|surface specimen technique
14P00168176A0000|0 6|Patulin
14P00168176A0000|22 41|apple butter samples
14P00168176A0000|44 56|ethyl acetate
14P00168176A0000|83 99|silica gel column
14P00168431T0000|0 19|Steroid glucuronides
14P00172199A0270|50 59|morphology
14P00172199A0270|74 83|appearance
14P00172199A0270|101 116|cross striations
14P00173860A0475|0 9|Riboflavin
14P00173860A0475|80 97|excretion patterns
14P00173860A0475|129 140|disturbances
14P00173860A0475|143 153|elimination
14P00176742T0000|0 10|Polyglactin
14P00176742T0000|14 30|suture absorption
14P00183063A0300|14 27|DNCB reactions
14P00183063A0300|42 46|Stage
14P00183063A0300|95 99|Stage
14P00183063A0300|172 176|Stage
14P00188387A0975|0 6|Studies
14P00188387A0975|75 76|FH
14P00188387A0975|92 104|heart disease
14P00193088A0196|34 43|Metyrapone
14P00193587T0000|0 14|EEG theta waves
14P00196255A0000|0 16|REM dream content
14P00196255A0000|114 126|verbalization
14P00196255A0000|176 186|bizarreness
14P00198510T0000|0 10|Innervation
14P00198510T0000|44 61|Locusta migratoria
14P00199012T0000|7 19|ACTH syndrome
14P00201881A0487|63 69|PI ACTH
14P00201881A0487|72 83|MSH contents
14P00205074A0000|7 22|hypophosphatemia
14P00209664A0836|10 20|correlation
14P00209664A0836|95 105|correlation
14P00209664A0836|132 149|parallel phenomena
14P00210220X0000|9 22|neurochemistry
14P00211881A0602|0 6|Efforts
14P00211881A0602|52 65|kidney lesions
14P00211881A0602|126 128|PBB
14P00216939T0001|0 5|Effect
14P00216939T0001|45 72|acid dehydrogenase reactions
14P00219533T0001|0 11|Distribution
14P00219533T0001|15 26|correlations
14P00219533T0001|29 43|serum uric-acid
14P00219533T0001|59 69|populations
14P00219565A0172|14 32|hepatitis B antigen
14P00219565A0172|40 50|transfusion
14P00219674A0000|0 13|Technetium-99m
14P00219674A0000|22 34|pyrophosphate
14P00219674A0000|45 55|scintigrams
14P00219674A0000|146 155|infarction
14P00221136A0984|8 17|phenomenon
14P00221725A0523|25 42|cytochrome oxidase
14P00221725A0523|43 52|peroxidase
14P00221725A0523|61 73|lipid content
14P00221725A0523|85 95|neutrophils
14P00222102A0227|0 8|Treatment
14P00222102A0227|24 52|pseudohypoparathyroidism type
14P00222102A0227|72 99|alpha-Hydroxycholecalciferol
14P00222827A0000|0 6|Workers
14P00222827A0000|33 44|diisocyanate
14P00222827A0000|46 48|TDI
14P00222827A0000|107 121|hyperreactivity
14P00224013A0661|5 7|VO2
14P00224013A0661|95 104|beta-Block
14P00224013A0661|145 154|resistance
14P00224013A0661|216 226|utilization
14P00224013A0661|260 269|comparison
14P00224013A0661|294 310|extraction ratios
14P00224013A0661|335 360|beta-Vasodilator receptors
14P00224013A0661|392 405|vasodilatation
14P00225352T0000|21 31|alterations
14P00225352T0000|37 46|metabolism
14P00225352T0000|50 51|3H
14P00225352T0000|53 62|vitamin D3
14P00227393T0000|12 46|25-hydroxyvitamin D3-24-hydroxylase
14P00227393T0000|63 99|cytochrome P-450 monooxygenase system
14P00227610A1593|31 38|DBP mRNA
14P00227610A1593|66 69|SV40
14P00227610A1593|73 87|polyoma viruses
14P00231555T0001|0 5|Effect
14P00231555T0001|46 62|combination drugs
14P00231555T0001|74 77|ACTH
14P00231555T0001|81 99|cortisol production
14P00232354A0286|0 9|Serum ACTH
14P00232456T0000|0 6|Anatomy
14P00232456T0000|12 14|RNA
14P00232456T0000|18 30|gene products
14P00232456T0000|32 35|MC29
14P00232456T0000|39 41|MH2
14P00232456T0000|60 72|tumor viruses
14P00234206T0000|0 7|Bertioga
14P00234206T0000|9 19|Guama group
14P00234206T0000|23 29|Anhembi
14P00234206T0000|31 46|Bunyamwera group
14P00234206T0000|75 83|Sao Paulo
14P00234206T0000|84 89|Brazil
14P00234264A0164|0 37|Gamma glutamyl transpeptidase activity
14P00234626T0036|0 2|XXI
14P00239014A0000|38 50|determination
14P00239014A0000|79 82|CPIB
14P00239014A0000|90 101|blood plasma
14P00239169T0000|0 25|Dopamine receptor blockade
14P00240016T0033|0 1|V.
14P00240518A0000|33 45|determination
14P00240518A0000|51 76|fungicide 5-fluorocytosine
14P00242427T0001|4 8|field
14P00242427T0001|11 16|stress
14P00242427T0001|34 38|nurse
14P00254537T0000|5 13|graduates
14P00254537T0000|32 39|programs
14P00254537T0000|49 60|state boards
14P00261981A0434|18 36|serum somatomedin A
14P00264240A1843|24 41|X. borealis oocyte
14P00264240A1843|50 57|5S genes
14P00264240A1843|112 121|T clusters
14P00264240A1843|152 174|X. laevis oocyte 5S DNA
14P00265964A0562|34 47|grain boundary
14P00267764A0651|40 57|treatment failures
14P00267764A0651|73 82|philosophy
14P00267764A0651|91 100|management
14P00294502T0001|0 8|Diagnosis
14P00294502T0001|12 29|treatment planning
14P00294502T0001|31 38|Class II
14P00300314A0132|54 76|degrees F. granulocytes
14P00300314A0132|96 110|hospitalization
14P00300314A0132|149 166|calcium leucovorin
14P00300314A0132|203 214|methotrexate
14P00300314A0132|227 242|treatment cycles
14P00303189A0247|45 59|serum chemistry
14P00303189A0247|79 86|efficacy
14P00304240A0369|43 50|presence
14P00304240A0369|66 72|disease
14P00304310A0000|3 11|end-stage
14P00304310A0000|54 64|retinopathy
14P00304310A0000|76 88|stabilization
14P00304806A0760|12 38|serum alpha1AT quantitation
14P00304806A0760|107 120|concentrations
14P00313766A0666|2 9|patients
14P00313766A0666|53 62|depression
14P00313766A0666|65 72|function
14P00313766A0666|83 89|control
14P00316723A0558|0 6|Changes
14P00316723A0558|9 19|body weight
14P00321261A0104|20 35|prostaglandin E2
14P00321261A0104|36 39|PGE2
14P00321261A0104|44 64|prostaglandin F2alpha
14P00330364A0132|10 20|BCG strains
14P00330364A0132|74 76|BCG
14P00330364A0132|138 152|BCG-vaccination
14P00330364A0132|183 197|BCG-vaccination
14P00331128A0000|12 27|serum calcitonin
14P00331936T0000|44 80|immunoperoxidase antiglobulin technic
14P00336354A0543|22 38|arginine infusion
14P00336354A0543|74 85|hypoglycemia
14P00336547A0000|46 64|Nocardia asteroides
14P00336547A0000|67 98|Nocardia brasiliensis infections
14P00336547A0000|130 132|ICR
14P00336547A0000|136 149|C3H/eB origins
14P00336547A0000|233 241|C57/BL/6J
14P00336547A0000|243 259|New Zealand Black
14P00336547A0000|259 264|BALB/c
14P00336547A0000|266 272|CBA/LAC
14P00336547A0000|277 282|C3H/eB
14P00337102T0058|0 7|Williams
14P00337102T0058|10 15|August
14P00339289T0049|0 2|Use
14P00340692T0033|10 40|John Henri Roosegaarde Bisschop
14P00342623A0228|20 39|whole-virus vaccines
14P00342623A0228|49 62|type B antigen
14P00350465T0000|9 17|diagnosis
14P00350465T0000|34 42|disorders
14P00352569A0000|7 19|oxygen supply
14P00352569A0000|30 45|blood parameters
14P00352569A0000|105 113|endotoxin
14P00354315T0000|32 52|ataxia telangiectasia
14P00358945A0225|10 15|period
14P00358945A0225|18 26|treatment
14P00361059T0000|32 54|diflucortolone valerate
14P00361059T0000|69 89|clobetasol propionate
14P00361340A0529|29 42|osteodystrophy
14P00361340A0529|65 84|vitamin D deficiency
14P00361340A0529|114 142|1,25-dihydroxycholecalciferol
14P00361340A0529|187 205|hyperparathyroidism
14P00369397A0280|5 7|FSH
14P00369397A0280|11 19|LH levels
14P00369397A0280|56 71|GnRH stimulation
14P00369397A0280|82 84|FSH
14P00369397A0280|88 96|LH values
14P00369683T0000|0 9|Adriamycin
14P00369683T0000|11 20|comparison
14P00369683T0000|73 85|breast cancer
14P00377466A0188|38 39|LH
14P00377466A0188|42 69|follicle stimulating hormone
14P00377466A0188|69 71|FSH
14P00377466A0188|84 87|HPRL
14P00377466A0188|101 102|E2
14P00377466A0188|155 167|healing phase
14P00378492A0475|0 12|Renin studies
14P00378492A0475|98 118|plasma renin activity
14P00378492A0475|122 145|plasma aldosterone level
14P00378492A0475|200 214|artery stenosis
14P00378735A0000|90 103|marrow culture
14P00378735A0000|114 124|amoxycillin
14P00378735A0000|128 142|dosage schedule
14P00378735A0000|188 202|chloramphenicol
14P00378735A0000|226 245|temperature response
14P00378735A0000|270 282|relapse rates
14P00381783T0000|0 31|Bone marrow transplantation-1979
14P00383169A0000|46 62|dopamine receptor
14P00383169A0000|80 90|apomorphine
14P00383169A0000|97 107|derivatives
14P00383169A0000|119 139|rye-ergot derivatives
14P00383169A0000|198 207|properties
14P00384744T0000|23 34|hypofunction
14P00385457A0187|8 17|inhibition
14P00385457A0187|70 78|influence
14P00385457A0187|84 90|healing
14P00386251A0899|3 21|IDF standard method
14P00386251A0899|83 103|sulphonamide residues
14P00390932T0001|8 15|antigens
14P00393598A0198|11 25|endotoxin fever
14P00393598A0198|47 49|ALS
14P00397806T0039|4 17|Algerian cases
14P00401521A0138|20 27|patients
14P00401521A0138|39 49|ticarcillin
14P00401676A0414|35 42|patients
14P00401676A0414|71 82|radiotherapy
14P00406585T0001|8 17|hematology
14P00409927A0570|0 7|Neomycin
14P00409927A0570|32 44|staphylococci
14P00409927A0570|66 77|streptococci
14P00411465A0142|27 33|section
14P00411465A0142|51 60|trabeculae
14P00411465A0142|67 73|contact
14P00411465A0142|86 93|cavities
14P00413854A0958|0 6|Changes
14P00413854A0958|9 19|tissue PCO2
14P00414575T0000|10 19|evaluation
14P00415543A0320|0 10|Recognition
14P00415543A0320|13 21|emphysema
14P00415543A0320|33 43|radiographs
14P00415543A0320|133 144|lung disease
14P00416758T0001|0 8|Isolation
14P00416758T0001|11 30|T. gambiense strains
14P00416758T0001|31 35|Zaire
14P00416758T0001|56 73|laboratory animals
14P00417166T0000|24 33|clonazepam
14P00417166T0000|36 49|rhesus monkeys
14P00417301T0001|11 20|mechanisms
14P00417301T0001|30 40|brucellosis
14P00418341T0000|10 19|adaptation
14P00420460A0291|34 47|drug treatment
14P00420460A0291|48 81|log baseline plasma renin activity
14P00420460A0291|93 106|blood pressure
14P00420460A0291|111 112|SQ
14P00423649A0259|5 14|techniques
14P00423649A0259|78 87|innovation
14P00425547A0000|2 9|patients
14P00425547A0000|21 33|osteomyelitis
14P00425547A0000|91 100|cephalexin
14P00427715A0000|22 28|Hodgkin
14P00427715A0000|65 70|Stages
14P00427715A0000|99 115|radiation therapy
14P00427715A0000|125 134|University
14P00427715A0000|137 143|Florida
14P00429151T0000|0 3|Year
14P00429151T0000|24 35|practitioner
14P00429151T0000|59 70|Glasgow area
14P00429893A0000|30 41|round window
14P00429893A0000|49 60|implantation
14P00429893A0000|109 121|scala tympani
14P00429893A0000|164 174|stimulation
14P00429949A0000|17 41|World Health Organization
14P00429949A0000|44 59|Expert Committee
14P00429949A0000|61 86|Biological Standardization
14P00429949A0000|161 195|International Reference Preparation
14P00429949A0000|195 197|IRP
14P00430889T0001|15 22|fistulas
14P00431832T0001|0 17|Plasma ion changes
14P00431832T0001|42 63|beta receptor blockers
14P00432615A0541|57 78|heterophile antibodies
14P00432615A0541|151 165|Sephadex system
14P00432615A0541|167 170|RIST
14P00435187T0000|14 26|flowers bloom
14P00437749A0242|7 26|treatment modalities
14P00437749A0242|54 63|psychology
14P00437749A0242|75 84|physiology
14P00439618T0001|0 16|Lethal Tachmalcor
14P00439618T0001|23 36|diethylamino-2
14P00439618T0001|39 51|hydroxypropyl
14P00439716T0001|32 50|blood flow velocity
14P00445259T0000|0 27|Serum ferritin concentration
14P00445720A0263|28 30|SPG
14P00445720A0263|56 57|LV
14P00445720A0263|73 74|LA
14P00445720A0263|91 124|high-fidelity pressure transducers
14P00450367T0000|26 37|hysterectomy
14P00450367T0000|39 50|hysterectomy
14P00450367T0000|89 100|hysterectomy
14P00450367T0000|120 128|carcinoma
14P00450559A0269|43 51|Clinitemp
14P00450559A0269|94 104|thermometer
14P00450760T0001|0 15|Cryoglobulinemia
14P00450760T0001|18 24|Raynaud
14P00451192A0248|0 3|Data
14P00451192A0248|100 120|LV region-of-interest
14P00453780A0430|15 32|serum IgA response
14P00453780A0430|44 61|patient population
14P00453780A0430|155 157|IgA
14P00454780A0340|0 18|Ultimate strengthes
14P00454780A0340|36 53|cast cobalt alloys
14P00454780A0340|60 74|titanium alloys
14P00454780A0340|81 82|Ta
14P00454780A0340|101 113|fatigue limit
14P00456424A0000|26 34|injection
14P00456424A0000|45 53|clonidine
14P00456424A0000|56 69|microgram kg-1
14P00456424A0000|72 85|blood pressure
14P00456424A0000|88 97|heart rate
14P00456424A0000|154 167|cisterna magna
14P00463973A0000|0 14|Platelet number
14P00463973A0000|120 122|SGA
14P00463973A0000|166 178|birth weights
14P00464387A1185|6 17|measurements
14P00464387A1185|58 73|disease activity
14P00464387A1185|75 78|ABPA
14P00465223A0373|17 35|difference betweent
14P00465223A0373|90 91|SD
14P00465681A0000|7 30|hemoglobin concentration
14P00465681A0000|72 82|blood serum
14P00465681A0000|106 120|oxygen pressure
14P00465829T0000|0 5|Nernst
14P00465829T0000|8 30|Planck analog equations
14P00473229T0000|0 6|Effects
14P00473229T0000|9 26|methylene chloride
14P00473229T0000|27 41|trichloroethane
14P00473229T0000|43 59|trichloroethylene
14P00473229T0000|61 79|tetrachloroethylene
14P00473229T0000|108 120|chick embryos
14P00473249T0000|0 5|Effect
14P00473249T0000|24 37|administration
14P00473249T0000|40 53|streptolysin O
14P00473249T0000|58 77|electroencephalogram
14P00474064A0205|18 37|convlusion threshold
14P00474064A0205|44 53|substances
14P00474064A0205|77 88|mg.kg-1 I.V.
14P00474064A0205|89 99|piritramide
14P00474064A0205|115 127|phenoperidine
14P00474064A0205|148 157|sufentanil
14P00474064A0205|177 180|I.V.
14P00476020T0000|3 14|biochemistry
14P00476572A0139|113 124|radiodensity
14P00477794T0000|0 6|Effects
14P00477794T0000|41 57|response patterns
14P00477794T0000|81 98|nuclei principalis
14P00478714T0000|33 57|alcohol treatment program
14P00479222A0682|0 9|Resistance
14P00479222A0682|35 45|environment
14P00479222A0682|101 115|immersion times
14P00479222A0682|143 146|PECF
14P00479246T0000|28 40|osteomyelitis
14P00481612A1121|23 31|receptors
14P00481612A1121|58 66|ventricle
14P00481612A1121|110 117|fentanyl
14P00483716A0366|57 70|carotid artery
14P00483716A0366|97 107|anastomosis
14P00484177A0242|26 45|laminar flow regimen
14P00484177A0242|76 83|CT value
14P00484177A0242|97 99|VT.
14P00485615A0935|19 27|existence
14P00485615A0935|89 98|importance
14P00485615A0935|116 123|syndrome
14P00485615A0935|141 150|occurrence
14P00485615A0935|158 169|pancreatitis
14P00485615A0935|176 186|performance
14P00488534A0308|22 51|Treatment X Strain interaction
14P00488534A0308|113 119|MR rats
14P00488534A0308|147 153|MR rats
14P00490336A0181|5 23|conduction velocity
14P00493818A0422|34 52|patient intolerance
14P00493818A0422|120 128|insertion
14P00494659A0391|33 47|3-carboxyphenyl
14P00494659A0391|52 80|hydroxymethyl-2-oxazolidinone
14P00495097A0663|5 19|characteristics
14P00495097A0663|63 77|fiber synthesis
14P00497494A0112|32 36|PACO2
14P00499588T0000|0 22|Carbohydrate metabolism
14P00503336A0285|16 19|CAEC
14P00503336A0285|29 30|CC
14P00503336A0285|34 37|CIEC
14P00503336A0285|81 100|alkaline phosphatase
14P00503336A0285|103 115|transaminases
14P00506559A0000|12 30|inhalation toxicity
14P00506649T0000|0 6|Changes
14P00506649T0000|19 42|serum protein components
14P00509703A0581|5 15|differences
14P00509703A0581|54 62|textbooks
14P00510341T0036|11 20|E.O.R.T.C.
14P00512215A0000|38 58|difference tone level
14P00512215A0000|60 64|f2-f1
14P00512215A0000|110 111|f1
14P00512215A0000|113 117|f2/f1
14P00512215A0000|119 120|f2
14P00512215A0000|132 133|f1
14P00512215A0000|136 137|L1
14P00512215A0000|139 140|L2
14P00512215A0000|145 146|L1
14P00512215A0000|148 149|L2
14P00513284A0000|38 41|DOTC
14P00513284A0000|43 52|Vibramycin
14P00513284A0000|54 59|Pfizer
14P00513284A0000|76 87|tetracycline
14P00513284A0000|112 124|drip infusion
14P00513284A0000|146 161|pediatrics field
14P00513284A0000|191 194|DOTC
14P00513284A0000|224 239|glucose solution
14P00513284A1255|23 35|DOTC infusion
14P00513284A1255|36 51|laboratory tests
14P00516545T0001|10 24|characteristics
14P00516545T0001|30 49|erythrocyte membrane
14P00516545T0001|50 71|peroxidation processes
14P00516545T0001|114 131|glomerulonephritis
14P00517890A0468|35 46|transmission
14P00517890A0468|50 60|hepatitis A
14P00517890A0468|79 105|hepatitis A virus excretion
14P00519173A0126|5 12|patients
14P00519173A0126|29 36|evidence
14P00519173A0126|39 50|oesophagitis
14P00521732T0000|27 44|oestradiol-17 beta
14P00521732T0000|81 109|steroid sulphatase deficiency
14P00524451A0136|22 39|locomotor activity
14P00524451A0136|72 82|amphetamine
14P00524451A0136|108 120|hexobarbitone
14P00524451A0136|143 151|depletion
14P00524451A0136|154 167|catecholamines
14P00528144T0000|11 21|transferrin
14P00528144T0000|35 41|gallium
14P00528144T0000|44 54|tumor cells
14P00534613A0000|0 10|Irradiation
14P00534613A0000|18 32|blood platelets
14P00534613A0000|36 39|UV-A
14P00535520A0239|11 20|exceptions
14P00535520A0239|74 88|cholangiography
14P00540707A0255|58 70|complications
14P00540707A0255|108 123|tip displacement
14P00540707A0255|126 140|pouch haematoma
14P00540707A0255|165 171|Authors
14P00540707A0255|215 230|PMK implantation
14P00540707A0255|257 270|vena cephalica
14P00541752A1032|7 20|determinations
14P00541752A1032|76 82|October
14P00541752A1032|128 129|SD
14P00550399A0615|15 20|causes
14P00550399A0615|23 27|death
14P00550399A0615|50 55|groups
14P00553858A0000|8 12|Grice
14P00553858A0000|15 23|operation
14P00553858A0000|91 100|literature
14P00553858A0000|111 122|publications
14P00553858A0000|134 142|technique
14P00553858A0000|195 204|principles
14P00553858A0000|215 223|operation
14P00555492A1034|42 51|blood flow
14P00555492A1034|74 82|injection
14P00555492A1034|85 94|cimetidine
14P00555492A1034|106 114|injection
14P00555492A1034|152 165|blood pressure
14P00555495T0000|0 4|Study
14P00555495T0000|7 22|re-establishment
14P00555495T0000|39 49|termination
14P00555495T0000|88 100|re-appearance
14P00555583T0000|0 15|Pharmacokinetics
14P00555583T0000|18 30|Carbamazepine
14P00557559A0170|53 79|N-methylnitrone 1,4-dioxide
14P00564032A0724|0 6|Changes
14P00564032A0724|54 63|mechanisms
14P00564943A0444|0 5|Calves
14P00564943A0444|9 16|MCT-milk
14P00564943A0444|38 54|blood cholesterol
14P00564943A0444|71 78|SBO-milk
14P00565136T0000|55 58|CH2O
14P00565136T0000|60 65|SO2Cl2
14P00565136T0000|70 72|Br2
14P00565314A0293|0 10|Guinea pigs
14P00569989A0239|5 24|halothane anesthesia
14P00569989A0239|28 48|flow pneumocardiogram
14P00569989A0239|49 52|PnCG
14P00569989A0239|75 103|acceleration pneumocardiogram
14P00569989A0239|154 169|pneumotachograph
14P00574222T0000|16 27|implications
14P00574222T0000|31 41|development
14P00574222T0000|51 60|prostheses
14P00574956A0304|17 26|stereotypy
14P00574956A0304|115 125|equilibrium
14P00574956A0304|195 202|dopamine
14P00574956A0304|226 236|development
14P00574956A0304|253 265|manifestation
14P00575231A0422|0 3|None
14P00575231A0422|9 23|cystometrograms
14P00575231A0422|41 61|detrusor contractions
14P00577440A0298|60 81|3H-alpha-acetyldigoxin
14P00578648T0048|34 47|administration
14P00580106T0000|0 8|Treatment
14P00580106T0000|11 16|Graves
14P00580151A0706|61 72|testosterone
14P00580151A0706|83 93|se-T levels
14P00580151A0706|117 127|convenience
14P00580151A0706|133 139|patient
14P00580151A0706|183 189|effects
14P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
14P00583004A0445|35 60|1,8,9-triacetoxyanthracene
14P00583004A0445|64 87|1,8-diacetoxy-9-anthrone
14P00583522T0001|52 63|inflammation
14P00587791T0054|0 6|Nursing
14P00589073A0000|15 45|plasma prolactin concentrations
14P00589073A0000|173 183|infertility
14P00590594T0000|7 25|allotransplantation
14P00592887T0000|18 35|Patent Blue Violet
14P00593119T0001|0 8|Screening
14P00593119T0001|11 25|asthma patients
14P00593119T0001|27 39|determination
14P00593119T0001|42 44|IgE
14P00593119T0001|50 62|comprehension
14P00593119T0001|90 103|IgE antibodies
14P00594466T0001|25 35|Papio papio
14P00594466T0001|45 56|allylglycine
14P00594466T0001|66 76|combination
14P00594466T0001|99 109|stimulation
14P00594617A0192|69 88|degradation products
14P00594617A0192|89 91|FDP
14P00594617A0192|129 141|insufficiency
14P00594617A0192|186 190|Godal
14P00594617A0192|193 217|ethanol-gelification test
14P00594617A0192|275 277|ESR
14P00597715A0256|0 8|One-third
14P00597715A0256|21 31|azoospermia
14P00597715A0256|39 51|sperm density
14P00597715A0256|79 91|FSH elevation
14P00598012A0174|2 23|girls prolactin levels
14P00598012A0174|84 99|prolactin levels
14P00599601A0260|37 46|procedures
14P00599601A0260|64 75|pinealectomy
14P00599601A0260|104 114|alterations
14P00599601A0260|132 141|physiology
14P00600943T0001|13 31|lymphomononucleosis
14P00601401A0181|6 24|hemoglobin solution
14P00601401A0181|70 80|Bohr effect
14P00601401A0181|96 123|delta log Po2/delta pH ratio
14P00602622A0362|9 21|ulcer therapy
14P00602622A0362|36 42|Vikalin
14P00602622A0362|44 48|Roter
14P00602702A0309|33 53|estriol concentration
14P00602702A0309|108 128|estriol concentration
14P00603783A0647|0 11|Serum levels
14P00603783A0647|13 15|IgG
14P00603783A0647|19 21|IgM
14P00603783A0647|68 87|observers IgA levels
14P00606849T0000|20 32|heart disease
14P00606849T0000|41 54|thromboxane A2
14P00614915T0001|0 9|Vitrectomy
14P00616575A0000|34 49|brain structures
14P00616575A0000|86 100|decimeter waves
14P00616575A0000|101 103|EMF
14P00616575A0000|106 107|DW
14P00616575A0000|117 129|investigation
14P00616575A0000|138 150|unit activity
14P00617815A0215|12 26|L-R differences
14P00618078A0367|14 30|lysozyme activity
14P00618078A0367|54 64|improvement
14P00619305A0759|47 55|dimension
14P00619305A0759|70 79|dimensions
14P00619782A0058|73 93|ultraviolet radiation
14P00619782A0058|94 97|UV-A
14P00619948A0000|46 52|Motival
14P00619948A0000|74 85|fluphenazine
14P00619948A0000|94 106|nortriptyline
14P00619948A0000|135 143|variation
14P00619948A0000|145 147|CNV
14P00619948A0000|150 162|reaction time
14P00619948A0000|163 172|heart rate
14P00619948A0000|173 186|blood pressure
14P00619948A0000|209 217|alertness
14P00619948A0000|235 244|detachment
14P00619948A0000|248 257|depression
14P00619948A0000|314 324|propranolol
14P00621626T0000|0 13|Stress effects
14P00621626T0000|15 37|affiliation preferences
14P00621626T0000|82 97|behavior pattern
14P00622556A0111|16 23|collagen
14P00622556A0111|30 35|tissue
14P00622556A0111|64 69|tendon
14P00623361A0221|0 6|Smoking
14P00623361A0221|28 39|contribution
14P00626014T0001|3 11|malignity
14P00626014T0001|20 26|lentigo
14P00627039T0000|25 67|Louisiana paper manufacturing plant workers
14P00627129A0944|5 13|responses
14P00627129A0944|65 74|conditions
14P00627129A0944|123 131|labetalol
14P00627129A0944|174 191|beta-adrenoceptors
14P00627202T0000|0 8|Diuretics
14P00627202T0000|23 34|pharmacology
14P00628990A0000|63 76|reconstruction
14P00628990A0000|86 104|ureteroureterostomy
14P00628990A0000|119 138|ureteroneocystostomy
14P00628990A0000|170 181|ureterostomy
14P00630713T0000|15 43|Du Pont aca ammonia procedure
14P00633909A0000|35 40|Rotter
14P00633909A0000|43 65|Internal-External Locus
14P00633909A0000|67 79|Control Scale
14P00635143T0001|0 5|Action
14P00635143T0001|33 47|Cyprinus carpio
14P00635194A0093|0 14|Kodak XV-2 film
14P00635194A0093|65 81|dose distribution
14P00636526T0033|0 8|Diagnosis
14P00637637T0000|27 47|plasma renin activity
14P00639410T0000|0 8|Cortisone
14P00639410T0000|43 63|lipid clearing agents
14P00640584A0250|17 25|principle
14P00640584A0250|46 54|stability
14P00641395A0441|4 16|blood samples
14P00641395A0441|30 47|hyperbilirubinemia
14P00641395A0441|80 82|ZPP
14P00641395A0441|150 166|extraction method
14P00644314T0000|7 22|hypersensitivity
14P00644314T0000|46 60|anticoagulation
14P00644539A0783|18 27|inhalation
14P00644539A0783|53 56|FEV1
14P00644539A0783|115 123|reactions
14P00644539A0783|129 142|test solutions
14P00646023T0058|21 35|virus excretion
14P00646023T0058|51 62|transmission
14P00646193T0000|0 6|Potency
14P00646193T0000|9 17|enflurane
14P00646193T0000|25 34|comparison
14P00646193T0000|39 47|halothane
14P00646193T0000|51 60|isoflurane
14P00656008T0000|0 9|Prevention
14P00656008T0000|17 33|paraquat toxicity
14P00656008T0000|41 60|superoxide dismutase
14P00657551T0000|0 10|Measurement
14P00657551T0000|13 32|magnesium absorption
14P00657551T0000|48 51|26Mg
14P00659962T0000|16 35|riboflavin excretion
14P00663166A0000|150 173|patent ductus arteriosus
14P00663166A0000|173 175|PDA
14P00663166A0000|181 202|Eisenmenger physiology
14P00664320T0000|7 15|detectors
14P00664320T0000|32 38|pathway
14P00665053A0276|39 43|06a6b
14P00665053A0276|45 47|K13
14P00665053A0276|49 50|H1
14P00665053A0276|67 81|group affection
14P00665214A0374|45 54|physiology
14P00665336A0908|43 57|EEG-information
14P00668122A0414|0 7|Analysis
14P00668122A0414|10 31|liver biopsy specimens
14P00668122A0414|81 97|mean iron content
14P00668122A0414|101 124|liver ferritin molecules
14P00669800A0579|42 50|infection
14P00676416A0320|42 55|liver biopsies
14P00676790T0000|0 17|Angiotensin effect
14P00681550A0000|0 6|Procion
14P00681550A0000|51 65|auditory fibers
14P00681550A0000|92 103|relationship
14P00681550A0000|114 126|response type
14P00681550A0000|153 163|termination
14P00681571T0028|54 77|eccrine sweat duct units
14P00682762T0001|0 18|Silicosis mortality
14P00685922A0451|71 73|IHB
14P00686836A0000|0 6|Pentane
14P00686836A0000|33 50|lipid peroxidation
14P00686836A0000|71 88|gas chromatography
14P00686836A0000|90 103|breath samples
14P00686836A0000|172 191|IU vitamin E acetate
14P00693987T0001|0 13|Thromboplastic
14P00693987T0001|52 65|administration
14P00693987T0001|68 77|intralipid
14P00693987T0001|106 115|infarction
14P00696680A0000|36 43|findings
14P00696680A0000|71 87|rhabdomyosarcomas
14P00696680A0000|107 117|endometrium
14P00696858A0000|22 37|porcine secretin
14P00696858A0000|116 131|porcine pancreas
14P00701144T0000|9 16|analysis
14P00701144T0000|30 39|lens power
14P00701144T0000|56 65|emmetropia
14P00701144T0000|79 86|implants
14P00701462A0722|0 15|Urine antibodies
14P00702773A0327|0 10|Althoug RBF
14P00702773A0327|84 86|RBF
14P00702773A0327|88 90|GFR
14P00703350A0418|0 12|99mTc phytate
14P00703350A0418|13 25|198Au colloid
14P00703350A0418|29 33|99mTc
14P00703932A0000|15 32|glomerulonephritis
14P00703932A0000|35 45|association
14P00704675A0199|9 11|UO2
14P00704675A0199|46 56|bifurcation
14P00704675A0199|90 99|inhalation
14P00710217T0001|18 26|hip joint
14P00710372A0302|82 94|GH deficiency
14P00712117A0521|16 26|influenza A
14P00712117A0521|49 56|February
14P00712117A0521|71 79|A/Texas/1
14P00712117A0521|107 118|A/Victoria/3
14P00713525A0268|21 36|disfluency rates
14P00713525A0268|38 47|stutterers
14P00713525A0268|69 80|presentation
14P00713525A0268|91 104|stimulus words
14P00715180T0074|0 5|Effect
14P00715180T0074|53 81|plutonium-239 dioxide aerosol
14P00715753A0241|2 24|biopsies CK-MB fraction
14P00715753A0241|40 42|CPK
14P00715753A0241|53 70|total-CPK activity
14P00715753A0241|115 119|CK-MB
14P00716366T0001|0 4|Value
14P00716366T0001|22 52|alkaline phosphatase isoenzymes
14P00716366T0001|106 120|liver cirrhosis
14P00722298A0619|8 15|analysis
14P00722298A0619|18 25|variance
14P00722298A0619|63 73|differences
14P00722298A0619|102 117|field dependence
14P00722298A0619|124 135|significance
14P00722298A0619|158 164|females
14P00722652A0118|11 34|2nd-generation schizonts
14P00725257A0452|40 42|DHE
14P00725257A0452|52 53|M.
14P00725336T0000|0 35|Newcastle disease virus surveillance
14P00725534A0888|40 48|M. leprae
14P00725534A0888|66 80|IgA immunocytes
14P00725534A0888|139 152|IgA deficiency
14P00725752T0001|0 8|Treatment
14P00725752T0001|11 22|hypertension
14P00725752T0001|54 76|beta receptor blockader
14P00726581T0122|0 5|Orthop
14P00728718T0000|0 14|Thyroid disease
14P00729003A1182|0 7|Residues
14P00729003A1182|19 29|transcripts
14P00733067A0188|132 143|construction
14P00733067A0188|149 159|anastomosis
14P00733067A0188|182 189|creation
14P00733067A0188|207 218|valve system
14P00733067A0188|233 243|anastomosis
14P00733067A0188|246 264|spiral introflexion
14P00733067A0188|290 297|stitches
14P00736376A0371|27 35|mortality
14P00736376A0371|43 50|ischemia
14P00736376A0371|75 81|urgency
14P00736376A0371|87 95|operation
14P00737422A0832|0 8|Pathogens
14P00737422A0832|144 151|patients
14P00740409A0000|3 16|histochemistry
14P00740409A0000|20 33|ultrastructure
14P00740409A0000|45 63|cerebellar deposits
14P00740409A0000|74 78|Tonge
14P00741476A0000|24 42|Ergotamine Tartrate
14P00743335T0001|0 13|Reaction times
14P00745775A0170|45 57|arteriography
14P00745775A0170|88 100|complications
14P00745775A0170|121 129|Urografin
14P00745775A0170|133 134|M.
14P00747722A0486|40 51|B1 injection
14P00747722A0486|52 56|Phase
14P00747722A0486|98 107|parameters
14P00748978T0000|0 19|Serum relaxin levels
14P00748978T0000|20 35|prostaglandin E2
14P00753237A0000|77 87|body weight
14P00753237A0000|90 93|PAIN
14P00753237A0000|133 139|Plantar
14P00753237A0000|162 164|PPU
14P00753237A0000|177 187|combination
14P00753237A0000|190 202|INSENSITIVITY
14P00753237A0000|206 214|TRAUMATIS
14P00753237A0000|243 253|body weight
14P00753237A0000|325 340|PNEUMATIC INSOLE
14P00753237A0000|371 381|compression
14P00753237A0000|436 452|blood circulation
14P00753237A0000|468 478|prophylaxis
14P00753237A0000|481 483|PPU
14P00755245A0000|0 5|Effect
14P00755245A0000|8 16|indoramin
14P00755245A0000|41 54|vasomotor loci
14P00755245A0000|70 79|chloralose
14P00755671A0485|40 60|recalcification times
14P00755869A0216|0 22|Contingency contracting
14P00755869A0216|44 61|parents/caregivers
14P00755869A0216|98 112|self-monitoring
14P00756511T0036|0 8|Dietetics
14P00757244A0000|3 9|results
14P00757244A0000|48 56|membranes
14P00757244A0000|62 70|placentas
14P00759049A0185|60 88|bathophenanthroline chromogen
14P00759049A0185|93 96|ICSH
14P00759400T0000|0 17|Platelet serotonin
14P00759400T0000|18 21|5-HT
14P00759400T0000|26 29|5-HT
14P00762763A0253|21 24|SIDS
14P00764737X0000|3 16|vigilance task
14P00764737X0000|22 32|measurement
14P00767155T0001|3 10|December
14P00767155T0001|24 29|Moscow
14P00767161A0837|11 19|increases
14P00767161A0837|26 47|serum E2 concentration
14P00767161A0837|87 100|administration
14P00768220X0000|3 12|motor unit
14P00771729X0000|29 38|variations
14P00771729X0000|41 49|responses
14P00771729X0000|52 59|hormones
14P00775582T0000|10 19|properties
14P00775582T0000|22 30|sumithion
14P00779272T0001|20 29|antibodies
14P00779272T0001|61 73|mononucleosis
14P00780639X0000|24 26|CEA
14P00792847A0000|21 43|antilymphocyte globulin
14P00792847A0000|44 46|ALG
14P00799988A0554|19 37|assessment patients
14P00799988A0554|61 70|preference
14P00799988A0554|74 83|imipramine
14P00803867A0315|0 7|Patients
14P00803867A0315|105 112|patients
14P00806295A0193|0 9|Absorption
14P00806295A0193|47 56|absorption
14P00807356T0001|40 60|hydroxy-9 ellipticine
14P00808266T0000|0 7|Advances
14P00808266T0000|44 60|radiation therapy
14P00808898A0000|79 82|IPRF
14P00811852T0001|8 19|satisfaction
14P00811852T0001|32 40|encounter
14P00811852T0001|61 68|patients
14P00812183T0000|10 24|transfer factor
14P00818380A0239|30 43|antibody tests
14P00818380A0239|69 77|reactions
14P00818380A0239|80 91|gold therapy
14P00818380A0239|128 138|populations
14P00819176T0001|35 51|swimming activity
14P00819176T0001|81 101|Anomalocera patersoni
14P00819176T0001|102 122|Pontella mediterranea
14P00819176T0001|123 143|Labidocera wollastoni
14P00821833A0000|50 63|howler monkeys
14P00821833A0000|64 80|Alouatta palliata
14P00821833A0000|120 125|Panama
14P00822611A0467|18 25|patients
14P00822611A0467|77 89|binephrectomy
14P00823087A0608|0 7|Deflunia
14P00825571T0031|0 2|III
14P00827364A0000|4 13|instrument
14P00827364A0000|32 48|freeze-fracturing
14P00830568A0000|39 52|emptying rates
14P00830568A0000|70 72|LTM
14P00830568A0000|141 158|gastroduodenostomy
14P00830568A0000|160 165|STG-BI
14P00830568A0000|173 189|gastrojejunostomy
14P00830568A0000|191 197|STG-BII
14P00830568A0000|248 250|V&P
14P00832096T0000|8 25|calcium metabolism
14P00833472A0907|35 44|gallstones
14P00833472A0907|54 64|institution
14P00833472A0907|67 76|colestipol
14P00833472A0907|78 87|saturation
14P00833472A0907|90 105|gallbladder bile
14P00833472A0907|109 119|cholesterol
14P00836637A0000|65 79|music-listening
14P00836637A0000|111 132|arithmetic performance
14P00836637A0000|134 145|EMR children
14P00836637A0000|172 184|reinforcement
14P00837262A0000|3 16|responsiveness
14P00837262A0000|32 33|VC
14P00837262A0000|57 58|SC
14P00837262A0000|107 108|ON
14P00837262A0000|113 115|OFF
14P00837811A0675|12 13|MS
14P00837811A0675|56 86|fluid gamma globulin elevations
14P00838152A0863|14 34|mean temperature rise
14P00838152A0863|109 121|disappearance
14P00838152A0863|134 147|qualifications
14P00838152A0863|153 166|triplet groups
14P00838152A0863|175 186|predominance
14P00838152A0863|203 216|qualifications
14P00839378A0649|11 16|Viso V
14P00839378A0649|21 29|RDS group
14P00839378A0649|54 70|airway resistance
14P00842406A0771|57 79|visuomotor coordination
14P00842406A0771|83 98|recognition task
14P00842522T0000|18 27|intubation
14P00842522T0000|33 42|management
14P00842522T0000|76 84|emphysema
14P00843232A0100|3 12|background
14P00843232A0100|59 67|character
14P00843232A0100|81 90|epithelium
14P00843670T0000|3 7|sense
14P00843670T0000|10 13|self
14P00846559A0000|15 27|Fusarium poae
14P00846559A0000|30 48|F. sporotrichioides
14P00846559A0000|55 62|U.S.S.R.
14P00846559A0000|96 118|F. sporotrichioides var
14P00846559A0000|132 137|U.S.A.
14P00846559A0000|141 146|France
14P00846559A0000|187 195|T-2 toxin
14P00847967T0000|35 44|tomography
14P00847967T0000|55 62|medicine
14P00851041A0000|31 37|Ebstein
14P00851286A0375|0 5|Deaths
14P00851286A0375|25 45|copper concentrations
14P00857024A0888|0 9|Recurrence
14P00857024A0888|12 25|bladder tumors
14P00857024A0888|76 91|properdin levels
14P00863184T0043|0 9|Adaptation
14P00863184T0043|24 40|transport maximum
14P00863773T0000|0 6|Dangers
14P00863773T0000|14 32|live-virus vaccines
14P00866577A0579|0 8|Treatment
14P00866577A0579|21 42|plasminogen activators
14P00868301A0043|2 23|diethyl ether solution
14P00868301A0043|41 72|2-benzylidenamio-1-phenylpropane
14P00868903A0000|0 7|Amikacin
14P00868903A0000|53 62|infections
14P00870859A0121|60 68|direction
14P00870859A0121|71 83|recirculation
14P00871237A0601|6 13|activity
14P00871237A0601|21 27|patient
14P00871237A0601|37 42|angina
14P00872442T0000|0 9|Estimation
14P00872442T0000|12 20|L-alanine
14P00872442T0000|44 69|LKB reaction rate analyser
14P00872922A0204|22 31|hydrolysis
14P00872922A0204|82 89|activity
14P00874942T0000|12 21|amnionitis
14P00874942T0000|25 35|prematurity
14P00875778T0000|18 40|Gravigard IUCD inserter
14P00876722T0000|9 18|meningitis
14P00876722T0000|30 36|abscess
14P00877857A0763|0 12|Serum amylase
14P00877857A0763|40 48|CU/100 ml
14P00879329A0176|5 23|control preparation
14P00879329A0176|88 90|Pci
14P00879329A0176|148 150|IIp
14P00879829A0564|0 6|Infants
14P00879829A0564|36 38|IVH
14P00879829A0564|61 74|birth asphyxia
14P00881630A0000|28 39|snake venoms
14P00881630A0000|40 46|N. naja
14P00881630A0000|49 61|A. piscivorus
14P00881630A0000|81 86|Factor
14P00881630A0000|90 104|Phospholipase-A
14P00881630A0000|127 133|N. naja
14P00881630A0000|169 185|cremaster vessels
14P00885562A0281|5 8|GAGs
14P00885562A0281|27 42|cartilage matrix
14P00885562A0281|78 91|osteoarthrosis
14P00885562A0281|121 133|GAG synthesis
14P00890028A0507|3 15|length scales
14P00890028A0507|51 65|Reynolds number
14P00890028A0507|104 120|Taylor microscale
14P00890028A0507|140 156|Kolmogoroff scale
14P00891370A0000|15 26|arteriograms
14P00891370A0000|52 66|xeroradiography
14P00891370A0000|94 108|contrast-medium
14P00892353A0686|2 12|hypotension
14P00892353A0686|23 30|patients
14P00892353A0686|68 77|degrees C.
14P00898500A0246|56 57|HD
14P00898500A0246|60 74|mites skin test
14P00898500A0246|114 117|RAST
14P00898500A0246|143 163|IgE antibody activity
14P00903772A0359|0 7|Wherever
14P00903772A0359|20 43|conditioning stimulation
14P00903772A0359|49 61|modifications
14P00909114A0000|0 17|Diallylnitrosamine
14P00909114A0000|19 21|DAN
14P00909114A0000|35 46|nitrosamines
14P00909114A0000|126 137|tract tumors
14P00910823A0196|26 35|conditions
14P00910823A0196|53 63|blood gases
14P00910823A0196|67 73|uterine
14P00910823A0196|86 96|blood flows
14P00911590T0000|35 50|bocurarine block
14P00911590T0000|54 81|atropine-neostigmine mixture
14P00913623A0242|43 55|diphosphonate
14P00913623A0242|69 72|EHDP
14P00913623A0242|88 100|pyrophosphate
14P00913623A0242|113 123|capillaries
14P00913623A0242|134 150|passive diffusion
14P00915090A0536|20 28|injection
14P00915090A0536|39 44|Tc-99m
14P00915090A0536|85 94|sperm hads
14P00915090A0536|110 116|control
14P00916099A0000|0 16|Self-emasculation
14P00917572T0001|0 10|Possibility
14P00917572T0001|47 60|hypothyroidism
14P00917721A0484|52 71|presleep suggestions
14P00917721A0484|93 105|dream content
14P00918556A0000|15 41|hepatitis B surface antigen
14P00918556A0000|40 44|HBsAg
14P00918556A0000|97 123|radio-immunoassay technique
14P00918965A0728|72 82|ventilation
14P00918965A0728|90 101|componenents
14P00918965A0728|171 174|PAO2
14P00920381T0000|16 23|glycogen
14P00920381T0000|43 51|injection
14P00921032T0000|43 48|Beagle
14P00921911A0159|0 5|Levels
14P00921911A0159|12 14|PGF
14P00921911A0159|18 21|PGFM
14P00926272A0000|25 37|deterioration
14P00926272A0000|60 66|patient
14P00926604A0504|0 10|Propranolol
14P00926604A0504|12 18|Inderal
14P00926604A0504|98 108|development
14P00926604A0504|157 170|strophanthin K
14P00926604A0504|199 208|myocardium
14P00926751A0000|25 34|rat larynx
14P00926751A0000|59 68|evaluation
14P00926751A0000|71 79|irritancy
14P00926751A0000|89 97|materials
14P00927633T0001|27 40|investigations
14P00927633T0001|57 64|Reissner
14P00927633T0001|74 86|Rattus rattus
14P00928529T0001|0 15|Feeding behavior
14P00928529T0001|39 57|hibernation rhythms
14P00929418T0001|0 3|Role
14P00929418T0001|9 37|infectious-disease specialist
14P00930947A0629|13 29|drug interactions
14P00930947A0629|50 59|probenecid
14P00930947A0629|78 80|PZA
14P00931089T0001|22 35|operating room
14P00932738A0116|25 26|BP
14P00932738A0116|37 54|C02 responsiveness
14P00932738A0116|99 100|BP
14P00932817A0499|0 9|Iodine-123
14P00932817A0499|44 46|MEC
14P00932817A0499|50 68|pinhole collimators
14P00932817A0499|87 96|MTF values
14P00932817A0499|124 128|99mTc
14P00933251T0000|7 16|meningioma
14P00933251T0000|49 57|ear tumor
14P00935526A0000|3 14|difficulties
14P00935526A0000|24 37|prostaglandins
14P00935526A0000|39 40|PG
14P00935526A0000|54 67|chromatography
14P00935526A0000|91 101|sensitivity
14P00938594A0149|13 27|steroid therapy
14P00938594A0149|61 74|manifestations
14P00938594A0149|89 104|osteoarthropathy
14P00938594A0149|106 108|HOA
14P00938594A0149|129 147|laboratory features
14P00938594A0149|169 170|RA
14P00941050T0000|17 39|procainamide absorption
14P00947327A0000|75 81|Bavaria
14P00947327A0000|121 136|sulfamethoxazole
14P00947327A0000|138 140|SMZ
14P00947327A0000|155 157|TMP
14P00947327A0000|266 267|N1
14P00947327A0000|295 307|sulfanilamide
14P00947327A0000|325 337|2,4-diamino-5
14P00947327A0000|340 362|3,4,5-trimethoxy-benzyl
14P00947327A0000|403 404|CN
14P00947327A0000|410 414|Nevin
14P00947327A0000|416 424|Supristol
14P00947327A0000|455 461|TMP/SMZ
14P00947834X0000|0 6|RESULTS
14P00947834X0000|13 22|IgE levels
14P00951909X0001|12 24|loop syndrome
14P00951909X0001|80 92|loop syndrome
14P00951909X0001|135 157|Billroth-II gastrectomy
14P00952734T0000|0 5|Letter
14P00952734T0000|90 93|PECL
14P00954819A1041|72 83|intoxication
14P00954819A1041|88 92|Soman
14P00954819A1041|95 99|Sarin
14P00954819A1041|128 140|AChE activity
14P00956364A0138|0 13|Batch cultures
14P00956364A0138|15 32|S. mutans serotype
14P00956364A0138|54 61|MSB agar
14P00956554A0414|45 65|solid-phase allergens
14P00956554A0414|95 108|IgE antibodies
14P00958550T0001|0 5|Crisis
14P00958550T0001|38 44|Britain
14P00959656A0250|39 50|antithrombin
14P00961711T0000|0 17|Hematology problem
14P00962222A0633|67 93|erythrocyte characteristics
14P00962222A0633|102 119|progesterone phase
14P00962277T0000|0 12|Haemodilution
14P00962277T0000|42 60|gelatine derivative
14P00964758T0001|14 25|plasmacytoma
14P00964758T0001|31 43|parotid gland
14P00967223T0059|0 1|I.
14P00968181A0264|31 38|immunity
14P00968181A0264|57 65|challenge
14P00968181A0264|90 98|infection
14P00970320A0000|33 62|chemical cartridge respirators
14P00970320A0000|64 66|SO2
14P00970488A0105|39 49|DA turnover
14P00970488A0105|75 94|DA receptor blocking
14P00970839A0118|0 12|Rainbow trout
14P00970839A0118|39 48|trout farm
14P00974901A0080|0 10|Stimulation
14P00974901A0080|13 31|macrophage function
14P00974901A0080|39 64|Bordetella pertussis cells
14P00975314T0001|7 17|amenorrhoea
14P00975314T0001|56 64|karyotype
14P00975314T0001|82 95|gonadoblastoma
14P00975540T0000|54 73|mass fragmentography
14P00975540T0000|75 96|high-accuracy analyses
14P00980255T0000|0 10|Application
14P00980255T0000|16 39|2-deoxy-D-glucose method
14P00984209A0614|0 19|Serum gastrin levels
14P00984209A0614|52 90|background serum gastrin concentrations
14P00984209A0614|115 126|V&P patients
14P00984209A0614|130 141|V&A patients
14P00985110T0001|8 18|projections
14P00985110T0001|31 37|portion
14P00985110T0001|43 49|putamen
14P00985110T0001|82 88|regions
14P00985276A0000|0 8|Preflight
14P00985276A0000|22 55|postflight exercise response tests
14P00985276A0000|92 105|Skylab mission
14P00985276A0000|106 111|Skylab
14P00985276A0000|170 183|weightlessness
14P00985279A0493|0 3|Mean
14P00985279A0493|15 39|hemoglobin concentrations
14P00985279A0493|91 99|CO2 group
14P00986800A0325|3 11|Cu values
14P00986800A0325|55 70|saturation level
14P00986800A0325|73 85|mug Cu/g diet
14P00986800A0325|91 99|exception
14P00986925A0002|55 66|pentagastrin
14P00986925A0002|80 111|plasma 47Ca radioactivity curves
14P00986925A0002|133 136|47Ca
14P00987649T0001|0 4|State
14P00987649T0001|16 24|disorders
14P00987649T0001|66 76|hypokinesia
14P00988572A0000|0 13|Oxygen tension
14P00988572A0000|23 35|lymph vessels
14P00988572A0000|36 39|PLO2
14P00988572A0000|46 61|rabbit hind limb
14P00988572A0000|121 149|catheter-tip oxygen electrode
14P00989973A0000|16 38|plasma fibrinogen level
14P00989973A0000|66 75|turpentine
14P00992316A0178|21 35|pressure curves
14P00992316A0178|49 58|activities
14P00993176A0066|50 62|heme pigments
14P00993176A0066|134 136|NH4
14P00993176A0066|138 150|2SO4 solution
14P00996272A0397|39 49|variability
14P00996272A0397|62 74|investigation
14P00996272A0397|101 112|instructions
14P00996364X0000|0 0|E
14P00999494A0000|18 26|diagnosis
14P00999494A0000|91 107|agent propranolol
14P01000378T0000|0 5|Effect
14P01000378T0000|16 30|plasma glucagon
14P01000378T0000|33 54|insulin concentrations
14P01003819A0498|14 25|nomogram one
14P01003819A0498|38 47|refraction
14P01003819A0498|53 63|axis length
14P01003819A0498|66 82|corneal curvature
14P01004298A0744|4 13|up-grading
14P01004298A0744|34 45|CA component
14P01009451A0728|23 24|UB
14P01009451A0728|28 35|OCS rats
14P01009739T0001|0 5|Effect
14P01009739T0001|50 52|ECG
14P01009841T0001|4 14|innervation
14P01009841T0001|29 41|trunk muscles
14P01009841T0001|43 56|lamprey larvae
14P01010638A0161|3 6|feed
14P01012640T0001|7 21|characteristics
14P01012640T0001|24 34|eye changes
14P01012640T0001|48 63|pheochromocytoma
14P01012640T0001|73 78|Sipple
14P01012904A0333|13 31|interference effect
14P01012904A0333|82 92|Stroop test
14P01019207A0232|30 39|conditions
14P01019207A0232|47 56|dependence
14P01019207A0232|73 84|betaI% value
14P01019207A0232|113 126|mug ruscogenin
14P01021091T0000|45 57|blood vessels
14P01021091T0000|62 71|rabbit ear
14P01021091T0000|98 108|vasopressin
14P01021091T0000|110 120|Octapressin
14P01027644T0001|10 13|test
14P01030985T0090|0 1|I.
14P01035457A0623|20 35|nipple discharge
14P01035457A0623|45 54|importance
14P01035457A0623|61 69|diagnosis
14P01035457A0623|73 81|treatment
14P01036714A0072|0 6|Studies
14P01036714A0072|83 92|chrysotile
14P01036714A0072|123 137|cell population
14P01044338A0240|8 19|measurements
14P01044338A0240|22 40|temperature changes
14P01047417T0000|8 34|National Health Dis-service
14P01047895T0001|13 24|patient care
14P01047895T0001|63 70|Patients
14P01047895T0001|102 113|patient care
14P01048020T0000|31 42|Test Anxiety
14P01048020T0000|45 60|Credit/No Credit
14P01048020T0000|62 80|A-F Grade Condition
14P01048020T0000|113 130|Course Information
14P01048968A0152|44 56|staphylococci
14P01048968A0152|72 83|penicillin G
14P01048968A0152|84 95|erythromycin
14P01048968A0152|108 121|beta-lactamase
14P01050144A0297|66 76|antibiotics
14P01050144A0297|114 124|83A complex
14P01050400T0000|0 10|Improvement
14P01050400T0000|13 31|nursing instruction
14P01057137A0192|2 11|difference
14P01057137A0192|25 37|acceptability
14P01064124A0560|9 18|subsurface
14P01064124A0560|64 72|specimens
14P01067493A0119|16 22|pattern
14P01067493A0119|51 57|percent
14P01067493A0119|78 84|methods
14P01071715A0903|36 60|blood pressure recordings
14P01075075T0038|0 1|I.
14P01078982A0227|52 67|cyclophosphamide
14P01078982A0227|69 91|antilymphocyte globulin
14P01078982A0227|92 94|ALG
14P01078982A0227|109 126|ALG administration
14P01078982A0227|150 165|cyclophosphamide
14P01080374A0709|0 7|Evidence
14P01080374A0709|23 27|Leber
14P01080374A0709|38 55|aneurysm retinitis
14P01080374A0709|92 96|Coats
14P01081904A0198|59 80|pull-out arteriography
14P01082726A0248|44 49|DC-ERG
14P01082833A0000|40 45|Y-8004
14P01082833A0000|83 94|indomethacin
14P01082833A0000|96 97|IM
14P01082833A0000|149 159|guinea pigs
14P01082833A0000|160 176|carrageenin edema
14P01082833A0000|238 248|peritonitis
14P01083321X0000|17 25|dominance
14P01083321X0000|47 59|subalpine fir
14P01083321X0000|115 126|productivity
14P01083375T0000|0 18|Alpha-1 antitrypsin
14P01083375T0000|27 45|childhood cirrhosis
14P01083784T0000|0 24|Lymphocyte subpopulations
14P01083784T0000|41 57|eosinophil counts
14P01084413A0271|43 45|EMI
14P01087288T0000|1 10|comparison
14P01087288T0000|46 59|radiation dose
14P01087288T0000|80 89|iodine-131
14P01087288T0000|93 109|thyroid carcinoma
14P01088654T0001|0 8|Technique
14P01090210A0417|0 3|Mean
14P01090210A0417|9 21|lung capacity
14P01090210A0417|95 113|mean closing volume
14P01090210A0417|116 126|lung volume
14P01090210A0417|217 231|airway pressure
14P01090210A0417|232 242|differences
14P01092248T0000|15 29|zinc deficiency
14P01092248T0000|34 45|pathogenesis
14P01093055T0000|0 6|Calcium
14P01093055T0000|10 30|phosphorus metabolism
14P01093845A0208|0 13|Modern studies
14P01093845A0208|27 37|Delta-9-THC
14P01093845A0208|48 58|voluntaries
14P01093845A0208|107 119|modifications
14P01093847A0000|21 45|tropatepine hydrochloride
14P01093847A0000|82 93|neuroleptics
14P01096741X0000|54 67|chickpea haulm
14P01096741X0000|82 96|supplementation
14P01097100A0217|3 10|patients
14P01097100A0217|30 37|regimens
14P01098179A0167|0 6|Results
14P01098179A0167|44 55|preparations
14P01098179A0167|76 93|dissolution curves
14P01098179A0167|126 140|chloramphenicol
14P01098592A0567|0 9|IgG levels
14P01099693T0000|7 18|Perspectives
14P01099693T0000|21 47|bone marrow transplantation
14P01101272T0000|0 9|Assessment
14P01101272T0000|15 29|carcinogenicity
14P01101272T0000|57 66|Cyclamates
14P01101272T0000|70 84|cyclohexylamine
14P01103390A0149|13 21|behaviour
14P01103390A0149|53 62|occurrence
14P01103390A0149|69 75|animals
14P01103390A0149|101 108|increase
14P01103390A0149|114 124|parasitemia
14P01107226A0808|8 21|amphotericin B
14P01107226A0808|83 98|mg/ml dose level
14P01113908A0475|15 22|increase
14P01113908A0475|30 40|transferrin
14P01113908A0475|90 99|experiment
14P01116254A0000|20 33|administration
14P01116254A0000|48 60|concentration
14P01116254A0000|63 81|tracer thallium-201
14P01116254A0000|82 93|potassium-43
14P01116254A0000|98 108|rubidium-81
14P01116254A0000|161 173|concentration
14P01116254A0000|179 188|myocardium
14P01116254A0000|211 219|potassium
14P01116466A0185|0 18|Thromboplastin time
14P01116466A0185|26 44|thromboplastin time
14P01116466A0185|45 57|thrombin time
14P01116466A0185|79 93|clot retraction
14P01116466A0185|97 112|clotting factors
14P01116466A0185|117 120|VIII
14P01116466A0185|133 146|platelet count
14P01118293A0150|17 22|notion
14P01118293A0150|27 37|suppression
14P01118293A0150|40 45|images
14P01118293A0150|61 67|rivalry
14P01119586A0337|0 19|Glycogen utilization
14P01119586A0337|49 66|creatine phosphate
14P01119586A0337|67 69|ATP
14P01119658A0000|73 86|cell carcinoma
14P01119658A0000|177 197|lymph node metastases
14P01119658A0000|202 203|N1
14P01119658A0000|205 207|N2A
14P01119658A0000|211 213|N2B
14P01119658A0000|230 243|neck treatment
14P01119658A0000|262 278|radiation therapy
14P01122015A0467|30 35|values
14P01122015A0467|43 49|mumol/1
14P01122015A0467|55 63|mg/100 ml
14P01122015A0467|70 76|mumol/1
14P01122015A0467|82 90|mg/100 ml
14P01123658A0000|21 29|technique
14P01123658A0000|47 56|tomography
14P01123658A0000|83 93|description
14P01123658A0000|137 139|L-4
14P01124944A0830|15 22|attitude
14P01124944A0830|28 39|protein diet
14P01125117A0183|18 24|attacks
14P01125117A0183|36 42|attacks
14P01125117A0183|74 80|changes
14P01125117A0183|112 117|groups
14P01128985A0000|27 32|method
14P01128985A0000|76 82|periods
14P01128985A0000|101 108|patients
14P01130186A0568|47 61|insulin release
14P01130186A0568|73 83|tolbutamide
14P01130531A0224|0 16|Nerve stimulation
14P01130531A0224|71 73|CBF
14P01131946T0001|0 5|Effect
14P01131946T0001|19 28|Norbiogest
14P01138215T0001|0 3|Risk
14P01138330A0204|52 56|N HC1
14P01138330A0204|98 108|% solutions
14P01138330A0204|110 131|acetylcholine chloride
14P01140184A0342|0 15|Liver microsomes
14P01140184A0342|48 71|epoxide hydrase activity
14P01140184A0342|115 130|liver microsomes
14P01141114A0188|68 70|P50
14P01141114A0188|76 79|PH-v
14P01141114A0188|83 93|degrees C-v
14P01141114A0188|99 104|Pv-CO2
14P01141114A0188|155 165|temperature
14P01145884T0028|34 38|study
14P01147436T0000|11 35|Burkitt Lymphoma Registry
14P01147502T0000|0 9|Vitrectomy
14P01147502T0000|27 43|instrument system
14P01148868A0284|12 25|clearance rate
14P01148868A0284|51 54|S.E.
14P01148868A0284|56 60|1/day
14P01150658A0683|63 68|Sairam
14P01150658A0683|70 71|M.
14P01156631A0658|3 34|mean plasma sodium concentration
14P01156631A0658|50 51|SD
14P01156631A0658|138 139|SD
14P01156814T0000|0 8|Editorial
14P01156814T0000|49 70|thromboembolic disease
14P01157191A0536|13 23|dose levels
14P01157191A0536|28 43|sodium saccharin
14P01157191A0536|46 61|sodium cyclamate
14P01157191A0536|77 87|carcinogens
14P01157191A0536|110 124|bladder tumours
14P01157614T0000|0 6|Effects
14P01157614T0000|32 54|matrix task performance
14P01158512T0000|19 31|dehydrogenase
14P01158512T0000|33 38|G-6-PD
14P01158838A0438|49 57|flow rate
14P01159822A0353|12 20|epithelia
14P01159822A0353|39 45|animals
14P01159822A0353|71 84|ultrastructure
14P01159822A0353|91 103|invaginations
14P01159822A0353|125 132|increase
14P01159822A0353|153 161|lysosomes
14P01159822A0353|200 206|numbers
14P01159822A0353|235 242|granules
14P01168607A0672|10 23|administration
14P01168607A0672|86 101|prothrombin time
14P01168607A0672|104 117|serum vitamins
14P01168908A0000|0 15|Prostaglandins F
14P01168908A0000|16 18|PGF
14P01168908A0000|175 200|plasma progesterone levels
14P01168956A0552|43 53|weight gain
14P01168956A0552|64 74|sensitivity
14P01168956A0552|121 143|maximum weight decrease
14P01170143A0247|0 5|Groups
14P01170143A0247|26 36|saline mice
14P01171020A0711|26 48|nucleus accumbens septi
14P01171935A0313|25 42|movement disorders
14P01171935A0313|101 113|manifestation
14P01171935A0313|134 167|dopamine receptor site sensitivity
14P01172734T0035|0 10|Association
14P01172734T0035|19 22|W-27
14P01172917T0000|0 5|Letter
14P01172917T0000|7 29|Lactose tolerance tests
14P01174873T0000|0 13|Retinoblastoma
14P01176905A0094|10 18|melatonin
14P01176905A0094|20 34|serum melatonin
14P01176905A0094|59 67|mid-light
14P01178153A0056|0 1|D.
14P01178637T0001|0 14|Atherosclerosis
14P01185956A0722|33 52|Doppler-cardiography
14P01185956A0722|97 109|stroke volume
14P01186344A0303|3 12|attainment
14P01186344A0303|21 28|maturity
14P01186344A0303|53 67|characteristics
14P01186344A0303|72 81|production
14P01186344A0303|84 94|spermatozoa
14P01186344A0303|151 160|end-points
14P01190120A0832|15 27|% lengthening
14P01190120A0832|39 57|thromboplastin time
14P01190251A0335|0 6|Caution
14P01190251A0335|46 56|lymphograms
14P01191955A0077|36 47|incompetence
14P01191955A0077|71 77|varices
14P01191964A0000|44 56|thyroidectomy
14P01191964A0000|60 65|Graves
14P01191964A0000|162 176|serum thyroxine
14P01191964A0000|177 179|T-4
14P01191964A0000|253 284|serum thyrotrophin concentration
14P01193458T0001|7 25|isotope cystography
14P01193458T0001|33 49|Tc sulfur colloid
14P01193770T0000|0 13|Air ion action
14P01194673A0652|36 46|chemography
14P01201977T0000|3 16|interpretation
14P01201977T0000|29 46|disc sensitivities
14P01202616A0466|9 21|retransfusion
14P01202616A0466|91 104|lamina propria
14P01206772T0000|8 18|chromosomes
14P01206772T0000|21 31|lymphocytes
14P01206772T0000|36 43|patients
14P01206772T0000|55 64|hycanthone
14P01206896T0001|0 14|Characteristics
14P01206896T0001|45 66|emergency lung surgery
14P01208811T0001|0 4|Study
14P01208811T0001|49 77|citrate solution-blood system
14P01209618A0409|0 9|Tobramycin
14P01209618A0409|76 94|potentiating effect
14P01209618A0409|107 120|d-tubocurarine
14P01211754A0192|29 37|operation
14P01211754A0192|60 70|improvement
14P01211754A0192|74 81|patients
14P01211754A0192|116 123|deafness
14P01215067A0000|21 30|resistance
14P01215067A0000|74 86|conductometry
14P01215067A0000|98 117|meningitis purulenta
14P01215067A0000|127 143|meningitis serosa
14P01215067A0000|153 164|encephalitis
14P01217450A0295|2 19|Chemical occlusion
14P01224116A0576|35 55|serum immunoglobulins
14P01224116A0576|63 65|IgG
14P01224116A0576|74 78|Russe
14P01224116A0576|80 84|Busey
14P01224116A0576|88 94|Barbeau
14P01225339A0590|17 26|occlusions
14P01225339A0590|49 58|infarction
14P01228258A0000|25 30|OK-432
14P01228258A0000|116 126|Mitomycin-C
14P01228258A0000|128 131|5-FU
14P01228258A0000|135 154|Cytosine arabinoside
14P01228882A0437|47 60|concentrations
14P01228882A0437|63 81|CSF immunoglobulins
14P01233561T0001|8 16|lactation
14P01235347T0001|12 25|cardiotoxicity
14P01236224T0001|8 16|pathology
14P01237206A0199|0 12|Demonstration
14P01237206A0199|88 92|Stamp
14P01237206A0199|96 112|auramine staining
14P01237206A0199|124 141|antibody technique
14P01237206A0199|146 161|Coxiella content
14P01241437A0152|42 47|NLA II
14P01241437A0152|81 87|Micoren
14P01241588A1470|16 19|5-HT
14P01241588A1470|23 35|5-HIAA levels
14P01241588A1470|102 105|IDPN
14P01241588A1470|108 120|neurotoxicity
14P01241866A0682|15 30|leukocyte-counts
14P01241866A0682|44 57|administration
14P01242636A0678|81 99|beryllium retention
14P01243628A0286|44 66|blood carboxyhemoglobin
14P01243628A0286|67 70|COHb
14P01244236A1122|40 49|blood flow
14P01244236A1122|78 87|resistance
14P01244236A1122|101 109|gestation
14P01244236A1122|120 127|increase
14P01244236A1122|165 184|vasomotor reactivity
14P01244236A1122|197 204|increase
14P01244236A1122|243 251|thickness
14P01245162A0262|0 8|Reduction
14P01245162A0262|109 127|transaminase levels
14P01246210A0648|3 15|calcium ratio
14P01246210A0648|16 25|mean ratio
14P01246210A0648|49 52|TBCa
14P01247475A0000|5 13|diagnosis
14P01247475A0000|16 29|retinoblastoma
14P01247475A0000|82 94|deterioration
14P01248124A0281|5 15|cholesterol
14P01248124A0281|71 79|gestation
14P01249198A1097|3 25|serum FT3 concentration
14P01249198A1097|80 91|GTD patients
14P01249198A1097|106 120|hyperthyroidism
14P01252223A0347|59 76|trait correlations
14P01252223A0347|101 105|Winch
14P01252223A0347|124 138|complementarity
14P01253191T0000|10 45|phase-plane technique representation
14P01256410T0001|1 10|activities
14P01256410T0001|16 21|factor
14P01256410T0001|24 31|molecule
14P01256410T0001|44 49|infant
14P01259027A0416|23 37|identifiability
14P01259027A0416|79 94|model parameters
14P01259027A0416|174 182|procedure
14P01259027A0416|192 200|extension
14P01259027A0416|271 284|design problem
14P01261005A0711|93 119|bandpass spectrophotometers
14P01262596T0000|11 20|compromise
14P01264640T0028|15 20|Saigon
14P01265443A0159|45 65|Heidenhain pouch dogs
14P01265443A0159|113 126|acid secretion
14P01265887T0001|8 28|factor VIII inhibitor
14P01267446A0210|0 15|Biohydrogenation
14P01272816A0000|10 27|calcium metabolism
14P01272816A0000|86 99|administration
14P01272816A0000|102 105|47Ca
14P01275335A0158|10 15|agents
14P01275335A0158|35 39|semen
14P01275335A0158|66 70|phase
14P01275541A0405|21 32|CPK activity
14P01276105A0313|2 9|contrast
14P01276105A0313|14 29|insulin response
14P01276105A0313|81 90|puerperium
14P01278251A0000|83 94|polyethylene
14P01278251A0000|109 128|tetraphenylbutadiene
14P01278251A0000|130 132|TPB
14P01279197T0000|44 68|Mason-Pfizer monkey virus
14P01279197T0000|74 95|saturation mutagenesis
14P01279352A0297|8 10|PAL
14P01279352A0297|29 50|bp sequence GGGGAGGAGG
14P01279352A0473|124 127|PROX
14P01279352A0473|131 143|PAL sequences
14P01279352A0473|181 196|target sequences
14P01279352A1197|16 17|NF
14P01279352A1197|110 124|promoter region
14P01279352A1197|133 164|beta-galactosidase reporter gene
14P01279374A0396|118 123|PET122
14P01279696A0862|25 32|Hisanaga
14P01279696A0862|34 35|S.
14P01279696A0862|37 44|Kusubata
14P01279696A0862|46 47|M.
14P01279696A0862|49 55|Okumura
14P01279696A0862|57 58|E.
14P01279696A0862|60 68|Kishimoto
14P01279696A0862|70 71|T.
14P01280413T0001|0 8|Treatment
14P01280413T0001|53 66|microorganisms
14P01280807A0575|18 43|MetRS/CAU operator complex
14P01280807A0575|80 105|ThrRS/CGU operator complex
14P01281322A0604|18 29|relationship
14P01281322A0604|51 70|percent area density
14P01281322A0604|89 102|percent change
14P01281472T0000|0 5|Rabbit
14P01281472T0000|14 30|muscle glycogenin
14P01281771T0000|0 15|Characterization
14P01281771T0000|57 74|expression pattern
14P01282014A0275|0 6|Animals
14P01282014A0275|19 23|DSP-4
14P01282638A0934|3 18|prophylactic use
14P01282638A0934|23 32|medication
14P01282638A0934|75 86|chemotherapy
14P01282638A0934|90 98|agreement
14P01282638A0934|106 114|estimates
14P01282638A0934|137 153|health care costs
14P01282638A0934|208 219|continuation
14P01282638A0934|249 260|interruption
14P01282638A0934|279 293|life expectancy
14P01284032A0213|0 1|AP
14P01284032A0213|47 60|concentrations
14P01284032A0213|84 87|GDOC
14P01284595A0102|35 48|identification
14P01284595A0102|54 65|Y-231 cosmid
14P01284595A0102|77 79|CpG
14P01284595A0102|94 104|HTF islands
14P01284828T0001|0 27|Tissue plasminogen activator
14P01284828T0001|59 70|fibrinolysis
14P01285009A0000|0 14|Gene constructs
14P01285009A0000|31 44|growth hormone
14P01285009A0000|90 110|mouse metallothionein
14P01285009A0000|121 136|thymidine kinase
14P01285009A0000|142 160|rat cholecystokinin
14P01285009A0000|169 186|chicken beta-actin
14P01285009A0000|235 245|medaka eggs
14P01285358A0396|0 12|Serum gastrin
14P01285358A0396|15 24|AFP levels
14P01285554T0000|0 8|Prospects
14P01285807A0365|11 12|SD
14P01285807A0365|14 17|PaO2
14P01285807A0365|99 103|PaCO2
14P01286732A0572|6 17|hepatomegaly
14P01286732A0572|91 101|involvement
14P01286732A0572|134 152|liver cell necrosis
14P01286732A0572|172 183|complication
14P01286732A0572|186 206|P. falciparum malaria
14P01287197A0761|27 34|decrease
14P01287197A0761|37 52|plasma potassium
14P01287197A0761|62 71|salbutamol
14P01287197A0761|148 156|decrement
14P01292230A0283|6 10|drugs
14P01292230A0283|42 48|filling
14P01294345A0591|25 35|improvement
14P01294345A0591|44 57|administration
14P01294345A0591|60 68|Bromergon
14P01294345A0591|104 119|overreactiveness
14P01294345A0591|128 143|prolactin levels
14P01294345A0591|171 181|weight gain
14P01294345A0591|184 200|breast tenderness
14P01295373A0651|3 11|magnitude
14P01295373A0651|22 29|response
14P01295373A0651|46 58|% baseline RL
14P01295373A0651|65 66|SE
14P01295500A0366|47 53|Attacks
14P01295500A0366|89 96|Deficits
14P01296815A0059|31 34|LD78
14P01296815A0059|42 51|LD78 gamma
14P01296815A0059|57 73|sequence analysis
14P01297332A0983|26 38|consideration
14P01297332A0983|44 47|SCBs
14P01297332A0983|118 135|consensus sequence
14P01297332T0000|21 32|DNA sequence
14P01297332T0000|49 63|gene expression
14P01298173A0153|10 16|history
14P01298173A0153|24 30|lesions
14P01298173A0153|44 53|efficiency
14P01298173A0153|68 77|treatments
14P01298173A0153|98 109|chemotherapy
14P01298173A0153|111 118|survival
14P01298173A0153|147 156|modalities
14P01298173A0153|168 174|measure
14P01298398A0461|25 37|determination
14P01298398A0461|40 57|nadolol racemate A
14P01298398A0461|73 89|phase composition
14P01299489A0788|62 76|supplementation
14P01299489A0788|87 97|performance
14P01299489A0788|128 131|RDIs
14P01300914A1066|72 82|variability
14P01300914A1066|191 194|ACRV
14P01300914A1066|275 285|arrhythmias
14P01300914A1066|320 321|VT
14P01300914A1066|366 376|sensitivity
14P01300914A1066|389 399|stimulation
14P01300914A1066|429 438|potentials
14P01300914A1066|448 464|amplification ECG
14P01300914A1066|510 520|sensitivity
14P01300914A1066|611 626|RV abnormalities
14P01301171A0979|35 57|c-myc bearing sequences
14P01302765A0999|29 30|R2
14P01302765A0999|54 56|R2s
14P01304515A0178|34 46|control group
14P01304515A0178|55 64|volunteers
14P01304809T0001|24 52|Friedrich Schiller University
14P01304809T0001|53 56|Jena
14P01309244A0798|25 33|positions
14P01309244A0798|64 74|orientation
14P01309244A0798|87 96|cell types
14P01309244A0798|99 105|species
14P01309244A0798|115 121|context
14P01309244A0798|137 144|promoter
14P01309587A0715|31 44|BMRF1 promoter
14P01309587A0715|49 67|Z/c-myb combination
14P01309587A0715|101 109|Z protein
14P01309593A0095|3 19|UCR core sequence
14P01309593A0095|19 27|CGCCATTTT
14P01309593A0095|89 110|MuLV promoter activity
14P01309593A1092|20 24|UCRBP
14P01309593A1092|39 51|target motifs
14P01309593A1092|73 81|UCR motif
14P01309593A1092|101 117|virus P5 promoter
14P01309593A1092|132 151|immunoglobulin light
14P01309593A1092|199 211|protein genes
14P01309815A0972|12 26|scr1-1 mutation
14P01309815A0972|39 56|signal recognition
14P01309815A0972|130 142|AEP synthesis
14P01309860A0559|32 47|integration site
14P01309860A0559|62 71|% identity
14P01309860A0559|103 117|mouse L1 family
14P01309894A0807|4 8|Rep78
14P01309894A0807|12 16|Rep68
14P01309894A0807|31 42|AAV sequence
14P01309910A0428|0 27|Nucleotide sequence analysis
14P01309910A0428|74 86|CREB2 protein
14P01310154A0879|72 86|transrepression
14P01310154A0879|89 99|FBR protein
14P01310154A0879|163 182|protein modification
14P01310154A0879|187 201|gene regulation
14P01310154A0879|203 213|FBR protein
14P01310178A0876|3 30|JS78 mutation changes Gln243
14P01310178A0876|162 188|host transcription shut-off
14P01310879A0000|1 17|patient suffering
14P01310879A0000|39 54|thrombocytopenia
14P01310879A0000|56 58|HAT
14P01310879A0000|70 86|arteriothromboses
14P01310899A0339|12 29|receptor structure
14P01310899A0339|89 108|transmembrane domain
14P01310899A0339|133 162|serine/threonine kinase domain
14P01310935T0000|10 14|UbcD1
14P01310935T0000|84 102|protein degradation
14P01312005A0600|0 7|Analysis
14P01312005A0600|49 52|MDP1
14P01312005A0600|71 81|chick mtDNA
14P01312005A0600|128 139|target sites
14P01312005A0600|285 286|OH
14P01312005A0600|290 300|replication
14P01313715A0461|97 100|HL60
14P01313715A0461|104 107|U937
14P01313715A0461|171 192|B-lymphocyte cell line
14P01313715A0461|192 198|EBV-BCL
14P01313715A0461|229 239|CGD patient
14P01313846A0850|0 9|Comparison
14P01313846A0850|17 34|sequence databanks
14P01313846A0850|42 48|Tactile
14P01313846A0850|63 93|immunoglobulin gene superfamily
14P01313846A0850|130 147|melanoma Ag MUC-18
14P01313846A0850|175 183|Ag family
14P01313846A0850|187 205|poliovirus receptor
14P01313846A0850|218 239|cell adhesion molecule
14P01313894A1179|54 74|LMP2B mRNA expression
14P01313894A1179|78 88|transcripts
14P01313909A0526|18 38|ICP0 nonsense mutants
14P01313909A0526|140 154|nonsense mutant
14P01314457T0000|0 7|Analysis
14P01314457T0000|10 28|nucleotide sequence
14P01314457T0000|49 67|herpesvirus saimiri
14P01314457T0000|68 70|HVS
14P01314457T0000|72 76|L-DNA
14P01314457T0000|125 127|HVS
14P01314841A0724|0 8|Treatment
14P01314841A0724|13 18|MK-801
14P01314841A0724|27 43|burst suppression
14P01314841A0724|48 50|EEG
14P01314953A1266|11 40|gel mobility shift experiments
14P01314953A1266|60 63|HAP2
14P01314953A1266|66 69|HAP3
14P01315706A0000|42 63|adenovirus E1a protein
14P01315706A0000|67 89|rat L6 muscle cell line
14P01316125A0176|37 39|1O2
14P01316125A0176|66 67|OH
14P01316125A0176|71 74|YHPD
14P01316125A0176|99 102|YHPD
14P01316125A0176|136 138|1O2
14P01316125A0176|140 143|YHPD
14P01316125A0176|152 155|BHPD
14P01316125A0176|183 184|OH
14P01316125A0176|186 189|YHPD
14P01316125A0176|201 204|BHPD
14P01316125A0382|54 57|YHPD
14P01316125A0382|81 83|1O2
14P01316125A0382|110 111|OH
14P01316125A0382|115 118|YHPD
14P01316125A0382|164 167|YHPD
14P01316125A0382|188 191|BHPD
14P01316125A0382|254 256|1O2
14P01316125A0382|296 297|OH
14P01316459A0311|0 3|Acad
14P01316461A1083|23 32|S2 protein
14P01316461A1083|67 68|S2
14P01316461A1083|167 176|expression
14P01316476A0842|13 26|TATA sequences
14P01316476A0842|53 55|VZV
14P01316476A1428|3 5|ORF
14P01316476A1428|40 42|ORF
14P01316680A0643|17 23|IR5 ORF
14P01316680A0643|25 29|EHV-1
14P01316680A0643|63 75|CAYWCCLGHAFAC
14P01316680A0643|101 127|consensus zinc finger motif
14P01316680A0643|126 141|C-X2-4-C-X2-15-C
14P01316680A0643|143 150|H-X2-4-C
14P01316900A0000|3 14|DNA sequence
14P01316900A0000|19 42|sulfate activation locus
14P01316903A0296|25 38|RNA polymerase
14P01316903A0296|52 54|IIA
14P01316903A0296|96 98|IIO
14P01316903A1040|0 17|RNA polymerase IIA
14P01316903A1040|97 114|RNA polymerase IIA
14P01317376A0981|0 20|Fructokinase activity
14P01317376A0981|45 54|Z. mobilis
14P01317376A0981|119 133|frk mRNA levels
14P01318310A0000|0 15|Plasma membranes
14P01318310A0000|41 58|affinity receptors
14P01318310A0000|65 83|density lipoprotein
14P01318310A0000|84 86|HDL
14P01318739A0410|15 34|patients vincristine
14P01318739A0410|58 62|VM-26
14P01320255A0795|74 84|L1 sequence
14P01320255A0795|97 110|factor binding
14P01320255A0795|143 155|transcription
14P01320255A0795|163 164|L1
14P01320640A0336|0 10|Tumor cells
14P01320640A0336|80 82|VIP
14P01321277A0342|52 54|SRC
14P01321277A0342|56 58|ROS
14P01321277A0342|71 96|chicken embryo fibroblasts
14P01321277A0342|96 98|CEF
14P01321277A0342|103 126|spindle shape morphology
14P01321277A0342|141 143|UR2
14P01321277A0664|0 2|ROS
14P01321277A0664|4 6|SRC
14P01321280A0494|31 32|E6
14P01321280A0494|36 51|E7 gene products
14P01321280A0494|95 125|immunoprecipitation experiments
14P01321280A0494|165 172|BPV-1 E6
14P01321280A0494|175 192|E7 fusion proteins
14P01321332A0970|9 27|transfection assays
14P01321332A0970|69 71|RXR
14P01321332A0970|86 100|transactivation
14P01321332A0970|135 154|hepatoma HepG2 cells
14P01321332A0970|168 169|RA
14P01321332A0970|181 195|transactivation
14P01321332A0970|241 245|ARP-1
14P01321336A0000|3 17|enhancer region
14P01321336A0000|19 21|Akv
14P01321336A0000|52 74|sequence motif ACAGATGG
14P01321336A0731|3 17|splice variants
14P01321336A0731|19 27|ALF1 cDNA
14P01321337A0318|15 23|component
14P01321337A0318|68 77|properties
14P01321337A0318|101 105|45Ca2
14P01321337A0318|165 175|calcineurin
14P01321337A0318|196 204|antiserum
14P01321337A0318|224 234|calcineurin
14P01321337A1161|26 39|MATa cna1 cna2
14P01321337A1161|52 68|MATa cnb1 mutants
14P01324172A0880|0 9|Antibodies
14P01324172A0880|44 47|RIM1
14P01324385A0329|0 6|METHODS
14P01324385A0329|8 21|IgG antibodies
14P01324385A0329|23 27|HHV-6
14P01324385A0329|68 85|immunofluorescence
14P01324385A0329|91 94|IVDA
14P01324385A0329|130 134|HIV-1
14P01324385A0329|164 168|IV-C1
14P01324385A0329|171 173|CDC
14P01324404A0813|21 37|activation domain
14P01324404A0813|93 109|carboxyl terminus
14P01324404A0813|114 131|HNF-3 beta protein
14P01324404A1208|0 9|HNF-3 beta
14P01324404A1208|75 89|transactivation
14P01324404A1208|121 133|participation
14P01324404A1208|139 158|region II-III domain
14P01324406A1250|15 18|RAD5
14P01324406A1250|27 54|ATPase/DNA helicase activity
14P01324406A1250|55 64|DNA repair
14P01324639T0000|0 15|Susceptibilities
14P01324639T0000|64 78|amoxicillin-BRL
14P01324639T0000|85 107|amoxicillin-clavulanate
14P01325221A0870|18 28|DU249 cells
14P01325221A0870|76 85|MBP kinase
14P01325221A0870|104 117|p41 MAP kinase
14P01325386A0766|3 17|hit1-1 mutation
14P01325386A0766|49 66|heat shock protein
14P01326329A0703|44 51|CAP site
14P01326329A0703|86 93|TATA box
14P01326329A0703|127 134|GC boxes
14P01326329A0703|135 145|CACCC boxes
14P01326329A0703|146 156|CCAAT boxes
14P01326329A0703|193 224|glucocorticoid response elements
14P01326329A0703|224 227|GREs
14P01326329A0703|246 266|AMP response elements
14P01326329A0703|266 269|CREs
14P01326557T0000|0 6|Cloning
14P01326557T0000|74 105|chondroitin sulfate proteoglycan
14P01327280A0000|25 34|chloralose
14P01327280A0000|38 44|changes
14P01327280A0000|75 90|cord dorsal horn
14P01327280A0000|125 134|electrodes
14P01327758A0000|0 10|Replication
14P01327758A0000|19 34|papillomavirus-1
14P01327758A0000|36 40|BPV-1
14P01327758A0000|42 44|DNA
14P01327758A0000|77 86|E1 protein
14P01327758A0000|103 112|E2 protein
14P01327967A0668|11 22|inactivation
14P01327967A0668|68 96|agent methylmethane sulfonate
14P01328197A0985|27 64|MAP kinase activator/MAP kinase system
14P01328197A0985|91 122|ras signal transduction pathways
14P01328219A1397|0 5|NSCL-1
14P01328681A0149|47 67|c-myc hyperexpression
14P01328681A0149|89 101|transcription
14P01328681A0149|180 196|protein synthesis
14P01328681A0149|197 198|A.
14P01328681A0348|0 6|Ruddell
14P01328681A0348|8 9|M.
14P01328854T0000|7 16|MEF-2 site
14P01328854T0000|110 137|phosphoglycerate mutase gene
14P01328884T0000|0 18|Truncation variants
14P01328884T0000|40 48|MHC class
14P01328884T0000|66 80|sequence motifs
14P01329039A0239|11 25|E-box consensus
14P01329039A0239|45 50|CANNTG
14P01329039A0239|86 92|E-boxes
14P01329039A0951|0 18|Intermediate levels
14P01329039A0951|47 59|TnI enhancers
14P01329039A0951|69 75|E-boxes
14P01329039A0951|90 92|MCK
14P01329039A0951|97 106|E-box site
14P01329039A0951|115 131|Ig kappa E2 E-box
14P01330077A0000|0 19|T-cell receptor beta
14P01330077A0000|19 26|TCR beta
14P01330077A0000|27 45|gene rearrangements
14P01330077A0000|99 102|ALLs
14P01330309A1134|3 15|CANNTG motifs
14P01330309A1134|30 33|MyoD
14P01330309A1134|37 60|myogenin fusion proteins
14P01330975T0000|10 23|polyneuropathy
14P01331057A0000|24 28|COX12
14P01331057A0000|82 101|cytochrome c oxidase
14P01331060A0768|17 34|calcineurin A gene
14P01331060A0768|73 86|cDNA sequences
14P01331086T0000|8 24|promoter elements
14P01331086T0000|32 59|cytochrome c oxidase subunit
14P01331086T0000|121 141|transcription factors
14P01331292A1425|23 31|instances
14P01331292A1425|44 58|oligonucleotide
14P01331292A1425|109 122|vaccinia virus
14P01331501A0397|71 73|E1A
14P01331501A0397|105 108|p107
14P01331501A0397|121 124|p130
14P01331516A0103|26 51|3T6 mouse fibroblast cells
14P01331516A0103|91 113|coinfection experiments
14P01331516A0103|115 126|C2 myoblasts
14P01332589A0666|3 6|MICs
14P01332589A0666|78 86|S. aureus
14P01332589A0666|125 137|micrograms/ml
14P01332964A0247|23 35|RII beta gene
14P01333035T0000|10 43|cAMP receptor protein contact site
14P01333035T0000|74 87|RNA polymerase
14P01333047A0404|23 35|growth factor
14P01333047A0404|53 77|growth factor stimulation
14P01333047A0404|109 123|phosphorylation
14P01333047A0404|126 136|Nck protein
14P01333047A0404|157 174|threonine residues
14P01333053A0110|22 59|steroid hydroxylase gene transcription
14P01333053A0110|121 124|ACTH
14P01333125A0000|25 41|sequence analysis
14P01333125A0000|74 85|conservation
14P01333125A0000|96 113|structure elements
14P01333125A0000|139 141|UTR
14P01333125A0000|150 162|enteroviruses
14P01333125A0000|166 177|rhinoviruses
14P01333317A1008|38 40|Sp1
14P01333317A1008|98 102|PRF-I
14P01334428A1102|0 1|Km
14P01334428A1102|5 8|Vmax
14P01334428A1102|52 54|Glu
14P01334428A1102|56 58|Tyr
14P01334428A1102|81 96|mumol min-1 mg-1
14P01334428A1102|110 125|mumol min-1 mg-1
14P01334493A0289|20 23|HGFr
14P01334493A0289|36 38|HGF
14P01334518T0000|0 9|Strategies
14P01334518T0000|13 27|blood screening
14P01334518T0000|33 49|hepatitis C virus
14P01334518T0000|62 83|immunodeficiency virus
14P01337142A2043|13 47|glycoprotein alpha-subunit promoter
14P01337142A2043|65 67|FSK
14P01337142A2043|70 76|GH4 rat
14P01337142A2043|92 99|ABSTRACT
14P01337142A2043|114 118|WORDS
14P01338867A0503|0 9|Comparison
14P01338867A0503|47 55|treatment
14P01338867A0503|69 78|antagonist
14P01338867A0503|130 142|fatiguability
14P01338867A0503|168 177|activation
14P01339125A0153|0 17|Laboratory studies
14P01339125A0153|22 25|Ca45
14P01339125A0153|114 125|bleach teeth
14P01339373T0000|0 8|Structure
14P01339373T0000|33 52|Arabidopsis thaliana
14P01339373T0000|77 95|SNF1 protein kinase
14P01339391A0000|42 62|DNA surrounding HRAS1
14P01339468A0272|3 14|ORF1 protein
14P01339468A0272|55 79|potexvirus RNA replicases
14P01339468A0272|79 82|ORF2
14P01339773A0000|11 18|patients
14P01339773A0000|64 72|diagnosis
14P01339773A0000|93 103|capnography
14P01339773A0000|105 114|spirometry
14P01339773A0000|127 134|analysis
14P01339773A0778|49 51|CO2
14P01339773A0778|116 142|ventilation-perfusion ratio
14P01339815A1545|13 24|correlations
14P01339815A1545|27 34|peak VO2
14P01340470A0000|67 87|RNA recognition motif
14P01340470A0000|91 97|Arg-Ser
14P01340470A0000|103 104|RS
14P01341119A0450|4 19|research studies
14P01341119A0450|70 82|H2 inhibitors
14P01341119A0450|85 98|others antacid
14P01346262A0377|27 42|protein profiles
14P01346262A0377|53 70|S. entomophila UC9
14P01346262A0377|78 81|UC21
14P01346534T0000|0 15|Characterization
14P01347476T0000|0 6|Mapping
14P01347476T0000|12 26|mouse ornithine
14P01347476T0000|47 61|sequence family
14P01347664A1026|50 57|CAD mRNA
14P01347908T0000|37 47|stimulation
14P01347908T0000|62 70|Parkinson
14P01347944A0964|37 60|homeodomain binding site
14P01348504A0757|8 32|pol alpha-primase complex
14P01348508A0313|59 68|comparison
14P01348508A0313|112 121|activities
14P01348508A0313|136 145|literature
14P01348508A0313|153 161|TGM1 gene
14P01348590A0000|110 120|HIV-disease
14P01348590A0000|125 127|CD4
14P01348590A0000|188 199|radiotherapy
14P01349705T0000|0 6|Effects
14P01349705T0000|18 33|thyroid function
14P01349837T0000|18 37|Arabidopsis thaliana
14P01349837T0000|40 47|Zea mays
14P01349837T0000|60 75|chaperonin HSP60
14P01349837T0000|78 92|gene expression
14P01349837T0000|98 113|seed germination
14P01350780A0184|0 29|Amino acid sequence comparison
14P01350780A0184|87 108|gamma-glutamyl kinases
14P01350932A1123|44 53|C-terminus
14P01350932A1123|59 80|N-glycosylation sequon
14P01350932A1123|81 91|Asn-Cys-Ser
14P01350932A1123|100 102|Cys
14P01350932A1123|115 131|disulphide bridge
14P01352113A0002|37 52|nitrogen dioxide
14P01352113A0002|53 54|NO
14P01352113A0002|95 110|inhalation model
14P01352113A0231|62 79|NO2 concentrations
14P01352113A0231|128 141|exposure times
14P01353478T0000|24 42|IAP retrotransposon
14P01353478T0000|47 68|A20/2J B cell lymphoma
14P01354506T0000|52 64|understanding
14P01354506T0000|67 78|cytogenetics
14P01354506T0000|80 93|histopathology
14P01357190A0726|38 59|membrane anchor domain
14P01357190A0726|73 85|glycoproteins
14P01357528A0084|3 17|subunit protein
14P01357528A0084|48 61|amino terminus
14P01357528A0084|63 68|SEF-17
14P01357528A0084|73 87|subunit protein
14P01357528A0084|192 209|surface organelles
14P01357528A0084|211 224|enterobacteria
14P01358190A0654|0 11|Substitution
14P01358190A0654|17 30|DR1 beta chain
14P01358190A0654|33 43|H-2E beta k
14P01358190A0654|74 97|alpha chain substitution
14P01358592A0752|22 28|pathway
14P01358592A0752|57 65|cell fate
14P01358592A0752|114 119|region
14P01358592A0752|125 130|embryo
14P01358758A0000|21 38|rat insulin I gene
14P01358758A0000|47 49|DNA
14P01358758A0000|61 77|sequence elements
14P01358758A0000|81 83|Far
14P01358758A0000|87 99|FLAT elements
14P01358880A0251|10 28|amino acid sequence
14P01358880A0251|65 89|transglutaminase sequence
14P01359588A0375|4 14|computation
14P01359588A0375|73 80|elements
14P01360180A0513|35 47|baculoviruses
14P01360180A0513|88 99|recombinants
14P01360180A0513|152 159|mutation
14P01360180A1568|27 44|P68 amino terminus
14P01360180A1568|135 155|reporter gene product
14P01360180A1568|176 178|RNA
14P01360294A0000|4 9|August
14P01360294A0000|16 22|October
14P01360294A0000|104 115|antithrombin
14P01363080A0710|69 80|sulfonamides
14P01363080A0710|95 113|agent metronidazole
14P01363080A0710|143 162|anhydrase inhibitors
14P01363166T0001|0 15|Currents aspects
14P01363166T0001|17 39|H2 receptor antagonists
14P01364100A0377|18 36|subrepeat structure
14P01370281A0461|0 9|Sequencing
14P01370281A0461|30 42|reading frame
14P01370446A0818|26 57|keratan sulfate attachment sites
14P01371181A0688|13 20|plasmids
14P01371181A0688|26 36|pLS1 family
14P01371181A0688|87 101|characteristics
14P01371181A0688|108 117|regulation
14P01371181A0688|125 136|copy numbers
14P01371272A1167|0 11|Perturbation
14P01371272A1167|38 56|frameshift fidelity
14P01371272A1167|72 97|yeast DNA polymerase alpha
14P01371275T0000|12 21|expression
14P01371275T0000|55 60|ATPase
14P01371413A0742|51 72|Southern blot analysis
14P01371413A0742|76 94|segregation pattern
14P01371413A0742|104 127|rodent-human hybrid DNAs
14P01371863A0000|70 98|protozoan parasite Leishmania
14P01372365A1202|34 35|Cl
14P01372365A1202|37 50|concentrations
14P01372365A1202|105 114|conditions
14P01372456A0426|0 7|Necrosis
14P01372456A0426|22 32|TA infusion
14P01372456A0426|102 111|% necrosis
14P01372802A1481|23 24|C3
14P01372802A1481|38 56|amino acid residues
14P01372802A1481|107 108|C3
14P01372802A1481|155 166|C3 fragments
14P01372802A1481|191 210|fluid-phase fragment
14P01372802A1481|272 273|C3
14P01372802A1481|321 322|C3
14P01372900A0448|65 83|amino acid residues
14P01372900A0448|91 115|alpha s1-casein variant A
14P01372900A0448|132 133|F.
14P01372900A1017|54 92|goat alpha s1-casein transcription unit
14P01372900A1017|101 137|polymerase chain reaction experiments
14P01373374A0735|0 9|Homodimers
14P01373374A0735|52 62|G-box motif
14P01373374A0735|67 70|GBF1
14P01373374A0735|74 85|GBF3 binding
14P01374331A0636|62 81|nuclease S1 analysis
14P01374392A0341|3 21|hydrophobicity plot
14P01374392A0341|23 27|NHE-3
14P01374392A0341|49 53|NHE-1
14P01374392A0341|57 61|NHE-2
14P01374398A0951|10 28|translation protein
14P01374398A0951|79 100|amino acid composition
14P01374398A0951|138 156|amino acid residues
14P01374688A0471|33 47|% pentafraction
14P01374688A0471|49 61|% pentastarch
14P01374688A0471|96 110|micrograms/kg/0
14P01375224A0152|55 68|transformation
14P01375224A0152|71 96|chicken embryo fibroblasts
14P01375224A0152|147 163|growth regulation
14P01375913A0484|32 51|DNA oligonucleotides
14P01375913A0484|94 124|T7 RNA polymerase promoter site
14P01376319T0000|0 3|Gene
14P01376319T0000|43 70|mannose 6-phosphate receptor
14P01377696A0000|23 54|surface glycoprotein neurofascin
14P01377696A0000|107 139|antibody perturbation experiments
14P01377764A0309|3 11|carcinoma
14P01377764A0309|34 43|epithelium
14P01377818A0468|11 20|C/EBP beta
14P01377818A0468|23 33|C/EBP gamma
14P01377818A0468|79 89|C/EBP alpha
14P01377962A1012|2 9|contrast
14P01377962A1012|11 22|tobacco GS-2
14P01377962A1012|34 41|subunits
14P01378052A0594|77 79|CAC
14P01378052A0594|82 84|N11
14P01378052A0594|87 89|N18
14P01378052A0594|92 94|GTG
14P01378052A0594|98 100|TGT
14P01378052A0594|103 105|N10
14P01378052A0594|108 110|N14
14P01378052A0594|113 115|ACA
14P01378052A0594|153 156|NtrC
14P01378052A0594|160 163|NifA
14P01378052A0594|172 190|activator sequences
14P01378127A0841|23 40|calcium supplement
14P01378127A0841|42 59|calcium antagonist
14P01378431A0202|0 1|C.
14P01378431A0202|3 5|Sun
14P01378431A0202|7 8|J.
14P01378431A0202|10 12|Hsu
14P01378431A0202|14 18|M.-Y.
14P01378431A0202|20 34|Vallejo-Ramirez
14P01378431A0202|36 37|J.
14P01378431A0202|39 44|Inouye
14P01378431A0202|46 47|S.
14P01378431A0202|52 57|Inouye
14P01378431A0202|59 60|M.
14P01378506A0884|16 35|full-deletion mutant
14P01378506A0884|82 83|NC
14P01378506A0884|96 109|virus assembly
14P01378526A0535|29 47|FK506 plasma levels
14P01379032A0495|6 12|percent
14P01379032A0495|15 22|patients
14P01379032A0495|40 47|steroids
14P01379032A0495|62 73|steroid dose
14P01379032A0495|94 101|steroids
14P01379032A0495|112 121|prednisone
14P01379150A0996|5 15|cibenzoline
14P01379150A0996|126 133|patients
14P01379150A0996|157 172|risk arrhythmias
14P01380062A0097|0 8|T antigen
14P01380062A0097|45 56|T lymphocyte
14P01380062A0097|57 59|CTL
14P01380062A0097|61 80|recognition epitopes
14P01380062A0097|97 110|CTL clones Y-1
14P01380062A0097|110 112|Y-2
14P01380062A0097|114 116|Y-3
14P01380062A0097|121 123|Y-5
14P01380076A0165|42 61|paired-ion technique
14P01380076A0165|71 85|docusate sodium
14P01380454A0451|65 84|DNA binding activity
14P01380454A0451|85 104|Fos-Jun heterodimers
14P01380454A0451|105 122|Jun-Jun homodimers
14P01380454A0451|125 147|Hela cell AP-1 proteins
14P01380454A0451|171 191|transcription factors
14P01380454A0451|200 209|NF-kappa B
14P01380454A0451|228 242|ATF/CREB family
14P01380716A0174|77 91|calcium hydrate
14P01380825A0622|0 21|Northern blot analyses
14P01383690A1023|3 16|ARG SH2 domain
14P01383690A1023|49 51|BCR
14P01383690A1023|105 118|ABL SH2 domain
14P01383695A0100|12 27|EBV B-cell clone
14P01383695A0100|27 31|E29.1
14P01383695A0100|79 87|IgM kappa
14P01383695A0100|90 99|IgM lambda
14P01384040A1043|18 27|activation
14P01384040A1043|81 91|orientation
14P01384165A0000|50 64|vascularization
14P01384165A0000|82 93|regeneration
14P01384165A0000|106 115|epithelium
14P01384165A0000|144 160|tracheal grafting
14P01384229A0175|57 71|oligonucleotide
14P01384229A0175|105 114|BF-IV gene
14P01384229A0175|167 184|herpes TK promoter
14P01384229A0175|197 230|chloramphenicol acetyl transferase
14P01384229A0175|230 232|CAT
14P01385462A0151|103 120|acid determination
14P01385462A0151|132 144|determination
14P01386210A0293|100 117|GM2 gangliosidosis
14P01386897A0000|0 4|Entry
14P01386897A0000|41 45|Start
14P01386897A0000|65 76|CDC28 kinase
14P01386897A0000|121 124|CLN1
14P01386897A0000|128 131|CLN2
14P01387105A0933|7 28|Southern blot analyses
14P01387105A0933|29 31|DNA
14P01387105A0933|95 106|cell hybrids
14P01387105A0933|171 184|loci Cycb1-rs1
14P01387105A0933|186 194|Cycb1-rs9
14P01387105A0933|208 224|mouse chromosomes
14P01388160A1102|5 19|residue Glu-381
14P01388160A1102|68 82|epsilon peptide
14P01388160A1102|106 121|peptide sequence
14P01388160A1102|148 154|Ser-106
14P01388160A1102|156 162|Ser-107
14P01388160A1102|166 172|Ser-108
14P01389362T0000|0 8|Porcelain
14P01389362T0000|34 48|dentin adhesive
14P01389573A1071|0 3|TBPf
14P01389573A1071|73 76|TBPf
14P01389573A1071|79 80|P1
14P01389573A1071|82 83|P2
14P01389573A1071|87 88|A1
14P01389573A1071|90 91|A2
14P01389585A0825|18 27|Scotchbond
14P01389585A0825|32 52|Prisma Universal Bond
14P01389585A0825|73 94|dentine bonding agents
14P01391001A0583|26 39|yeasts species
14P01391001A0583|67 76|ATB method
14P01392012A0228|33 48|oxytocin content
14P01392012A0228|63 76|pressor effect
14P01392012A0228|85 92|Dekanski
14P01392012A0228|144 147|Hays
14P01392277A0000|0 7|Comments
14P01392277A0000|64 77|swimming pools
14P01392277A0000|113 127|KOK regulations
14P01392277A0000|163 165|DIN
14P01392277A0000|167 169|No.
14P01392358A0389|21 37|telephone contact
14P01392358A0389|39 49|home visits
14P01394200A0592|3 17|treatment group
14P01394200A0592|33 49|T-cell activation
14P01394200A0592|84 104|rebound lymphocytosis
14P01394200A0592|124 142|subset markers CD25
14P01394200A0592|166 171|CD45RO
15P01394655A0615b|0 14|Urease activity
15P01394655A0615b|34 51|ammonia production
15P01394655A0615b|89 91|S/N
15P01394655A0615b|101 121|Jack bean meal urease
14P01395755A1023|24 34|differences
14P01395755A1023|84 96|oxygen uptake
14P01395755A1023|137 151|oxygen delivery
14P01395755A1023|220 224|L/min
14P01395755A1023|236 240|L/min
14P01396432A0388|82 91|assessment
14P01396432A0388|94 111|memory performance
14P01396444A0934|3 13|experiments
14P01396444A0934|29 39|micromilieu
14P01396444A0934|72 73|AM
14P01396444A0934|95 111|activation states
14P01396572A0320|21 33|plasmid pUC19
14P01396572A0320|74 86|plasmid pUC19
14P01396572A0320|87 88|CG
14P01396572A0320|126 131|Z-form
14P01396583A0204|1 12|cDNA library
14P01396583A0204|14 25|tumour cells
14P01396583A0204|42 52|interleukin
14P01396592A1113|28 35|SCL gene
14P01396592A1113|62 88|transcription factor GATA-1
14P01396592A1113|97 112|SCL gene product
14P01396601A0986|30 35|Sec12p
14P01396601A0986|37 41|Stl1p
14P01396601A0986|45 49|Stl2p
14P01398068A0948|0 8|Complexes
14P01398068A0948|57 68|p53 proteins
14P01398068A0948|98 113|RGC DNA sequence
14P01398071A0526|77 89|BRF1 activity
14P01398071A0526|130 144|RNA polymerases
14P01398071A0526|152 154|III
14P01398073A0986|54 66|TFIID protein
14P01398073A0986|109 126|activation domains
14P01398074A0697|44 46|RNA
14P01398074A0697|75 103|RNase MRP enzyme preparations
14P01398074A1081|3 20|RNase MRP RNA gene
14P01398074A1081|127 135|RNase MRP
14P01398098A0770|0 19|Clone pSRc200 hybrid
14P01398104A0834|17 21|CBF-A
14P01398104A0834|30 37|CArG box
14P01398106A0754|0 7|Cleavage
14P01398106A0754|34 39|I-CreI
14P01398106A0754|63 83|intron insertion site
14P01398106A0754|186 195|OH termini
14P01398140A0488|16 30|Xenopus U7 gene
14P01398140A0488|104 106|PSE
14P01399206A0375|35 56|collagenase inhibitors
14P01399206A0375|78 94|blister formation
14P01399206A0375|115 135|epidermolysis bullosa
14P01400217T0000|29 66|IncP alpha plasmid transfer genes traF
14P01400217T0000|91 107|phage sensitivity
14P01400396A1265|35 48|phorbol esters
14P01400396A1265|109 129|protein kinase C beta
14P01400401A0065|13 34|AMP deaminase variants
14P01400401A0065|59 60|E1
14P01400401A0065|65 66|E2
14P01400401A0065|68 78|erythrocyte
14P01400401A0854|0 20|Western blot analyses
14P01400401A0854|40 55|immunoreactivity
14P01400401A0854|128 137|AMPD3 cDNA
14P01400775A0435|37 49|N-methylation
14P01400775A0435|66 83|N-methylsalsolinol
14P01402647A0114|0 12|DR1 molecules
14P01402647A0114|80 96|peptide sequences
14P01403222A0391|73 86|blood donation
14P01403222A0391|101 111|transfusion
14P01403391T0000|7 17|hepatitis B
14P01404401A0740|9 22|ATPase cluster
14P01404612A0303|26 28|Ads
14P01404612A0303|53 55|HIV
14P01404612A0303|93 110|vaccine candidates
14P01406630A0545|0 8|Alignment
14P01406630A0545|50 67|consensus sequence
14P01406630A0545|137 152|binding analysis
14P01406630A0545|165 177|DNA sequences
14P01406630A0545|185 204|sequence specificity
14P01406630A0965|12 14|p50
14P01406630A0965|152 169|NF-kappa B complex
14P01406656A1075|39 49|mouse alpha
14P01406656A1075|96 98|DNA
14P01406656A1075|129 139|fibroblasts
14P01406677A0000|23 38|control elements
14P01406677A0000|87 100|myoglobin gene
14P01406677A0000|150 169|nucleotide positions
14P01406677A0000|231 245|luciferase gene
14P01406688A0898|0 18|Sequencing analysis
14P01406688A0898|54 70|nonsense mutation
14P01406703A1435|12 31|Y1 cell cDNA library
14P01406703A1435|58 65|H-2RIIBP
14P01406703A1435|73 93|hormone receptor cDNA
14P01407286A0427|0 6|Autopsy
14P01407286A0427|61 71|integration
14P01407286A0427|146 165|tyrosine hydroxylase
14P01408090A0572|17 33|TEE visualization
14P01408137A0974|3 10|sequence
14P01408137A0974|32 42|G+C content
14P01408137A0974|102 111|mRNA start
14P01408219A0670|43 58|lymph-adenopathy
14P01408219A0670|60 62|PGL
14P01408219A0670|129 139|hyperplasia
14P01408474A0531|0 13|PaO2 threshold
14P01408474A0531|47 61|sensor catheter
14P01409581A0206|18 20|E26
14P01409581A0206|68 76|factor PU
14P01409643A0618|7 28|lambda gt11 expression
14P01409643A0618|38 53|oligonucleotides
14P01409643A0618|77 98|immunodeficiency virus
14P01409643A0618|99 110|TATA element
14P01409643A0618|205 216|TATA element
14P01409643A0618|233 235|TMF
14P01410071T0000|0 11|Blood levels
14P01410071T0000|86 110|platelet serotonin uptake
14P01413984A0737|30 47|FA supplementation
14P01413984A0737|66 80|HDL cholesterol
14P01413984A0737|81 95|LDL cholesterol
14P01413984A0737|108 112|HbA1C
14P01413984A0737|160 190|plasminogen activator inhibitor
14P01413984A0737|190 217|tissue plasminogen activator
14P01413984A0737|219 253|von Willebrand factor concentration
14P01414219A0319|55 57|AUC
14P01414219A0319|59 84|peak plasma concentrations
14P01414219A0319|112 114|OXC
14P01414219A0319|149 151|ERY
14P01418272A1072|26 36|sensitivity
14P01418272A1072|39 41|CEA
14P01418494T0000|8 13|spikes
14P01418494T0000|26 33|function
14P01418542A0000|19 36|beta-glycyrrhetate
14P01418542A0000|38 40|SGA
14P01418834A0987|12 30|hematocrit decrease
14P01418834A0987|71 84|blood pressure
14P01418860A0797|48 59|potentiation
14P01418860A0797|165 188|calcium channel blockade
14P01418860A0797|204 215|interactions
14P01419945A1386|0 11|Localization
14P01419945A1386|38 53|nerve stimulator
14P01419945A1386|76 87|interscalene
14P01420177A1065|0 11|Substitution
14P01420177A1065|20 24|Val33
14P01420177A1065|28 30|Gly
14P01420177A1065|34 38|Gly28
14P01420177A1065|42 44|Ser
14P01420177A1065|81 95|protein kinases
14P01420223T0000|0 11|Significance
14P01420223T0000|32 54|latissimus dorsi muscle
14P01420363A0818|3 6|TIMP
14P01420363A0818|16 23|AP1 site
14P01420363A0818|51 65|c-Fos/c-Jun AP1
14P01420363A0818|127 137|AP1 factors
14P01420363A0818|142 154|consensus TRE
14P01420363A0818|207 219|consensus TRE
14P01420363T0000|0 10|Involvement
14P01420363T0000|13 15|AP1
14P01420363T0000|19 36|PEA3 binding sites
14P01420363T0000|75 94|metalloproteinases-1
14P01420363T0000|96 101|TIMP-1
14P01420579A0292|5 22|serum neutralizing
14P01420579A0292|23 24|SN
14P01420579A0292|84 94|SN antibody
14P01421145A1190|0 12|Fractionation
14P01421145A1190|37 66|heparin-agarose chromatography
14P01421145A1190|79 84|PCAT-1
14P01421390T0000|90 105|body irradiation
14P01421390T0000|115 126|chemotherapy
14P01421390T0000|141 167|bone marrow transplantation
14P01421609A1067|24 27|DMVA
14P01421609A1067|64 66|CPB
14P01422265A0263|3 22|IgG subclass profile
14P01422265A0263|32 46|coeliac disease
14P01422265A0263|85 88|IgG1
14P01422265A0263|102 105|IgG2
14P01422265A0263|107 110|IgG3
14P01422265A0263|112 115|IgG4
14P01422265A0263|153 170|subclass responses
14P01422265A0263|186 201|coeliac patients
14P01423454A0309|0 10|Examination
14P01423454A0309|13 16|ANCA
14P01423454A0309|38 49|contribution
14P01423454A0309|152 164|effectiveness
14P01423738A0639|20 31|pinealectomy
14P01423738A0639|104 115|deceleration
14P01423738A0639|129 142|mean delta tau
14P01424674A0000|11 20|pemphigoid
14P01424674A0000|84 96|cicatrization
14P01425653T0000|23 40|caffeine ingestion
14P01425653T0000|60 77|oxygen consumption
14P01425921A1286|38 55|amino acid changes
14P01425921A1286|71 85|lysine deletion
14P01425921A1286|103 120|consensus sequence
14P01425921A1286|161 164|V1J1
14P01426635A0496|18 22|ZFH-2
14P01426635A0496|34 36|CNS
14P01426635A0496|63 65|DDC
14P01426635A0496|88 103|dopamine neurons
14P01427034A0440|42 54|protein genes
14P01427034A0440|90 98|S13 genes
14P01427034A0440|120 132|DNA sequences
14P01427457A0000|76 77|SC
14P01427457A0000|100 114|calcium heparin
14P01427457A0000|131 144|sodium heparin
14P01427457A0000|188 190|DVT
14P01428490A0671|10 19|prevalence
14P01428490A0671|30 40|pet allergy
14P01428490A0671|61 67|attacks
14P01428490A0671|70 78|shortness
14P01428490A0671|135 142|children
14P01428513A0440|45 51|persons
14P01429596A1669|88 123|18K agglutination-aggregation factor
14P01429624A0328|26 36|temperature
14P01429624A0328|87 94|activity
14P01429624A0328|97 111|adenylylcyclase
14P01429714A0730|0 3|Clin
14P01429724A0664|46 50|Nmt1p
14P01429724A0664|67 71|Ile59
14P01429724A0664|75 79|Phe96
14P01429724A0664|83 88|Gly451
14P01429724A0664|92 97|Leu455
14P01429740A1065|39 49|presequence
14P01429740A1065|122 128|E2 gene
14P01429768T0000|5 23|neutrophil response
14P01429768T0000|45 48|F-75
14P01429836A0457|0 9|Disruption
14P01429836A0457|12 23|microtubules
14P01429836A0457|67 81|protein sorting
14P01429836A0457|96 109|Vps1p function
14P01429836A0457|125 136|microtubules
14P01429836A1205|13 17|Vps1p
14P01429836A1205|73 87|protein sorting
14P01431380A0244|14 27|field research
14P01431380A0244|147 163|group rickettsiae
14P01431380A0244|164 167|SFGR
14P01431380A0244|201 214|tick emulsions
14P01431380A0244|225 235|rickettsiae
14P01431380A0244|246 257|patient sera
14P01431380A0244|296 299|JSFR
14P01431380A0244|305 319|hemolymph cells
14P01431380A0244|355 366|observations
14P01431380A0244|369 372|SFGR
14P01431602A0229|36 52|sensitivity range
14P01431602A0229|62 82|micrograms phosphorus
14P01431602A0229|93 109|microliters HClO4
14P01431809T0000|0 18|Nucleotide sequence
14P01431809T0000|65 81|Spodoptera exigua
14P01431809T0000|88 105|polyhedrosis virus
14P01432453T0000|0 9|Validation
14P01432453T0000|30 46|system definition
14P01433391A0594|3 13|consequence
14P01433391A0594|20 26|rearing
14P01433391A0594|40 46|density
14P01433391A0594|57 63|neurons
14P01433391A0594|127 133|kittens
14P01433502A1163|5 11|results
14P01433502A1163|38 54|enhancer activity
14P01433502A1163|162 170|repressor
14P01433524A0788|51 53|IE1
14P01435698A0000|23 41|blood compatibility
14P01435698A0000|63 65|AVG
14P01435698A0000|77 88|prostacyclin
14P01435698A0000|90 93|PGI2
14P01435698A0000|135 146|implantation
14P01436261A0145|0 26|Subcutaneous administration
14P01436261A0145|31 51|somatostatin analogue
14P01436261A0145|181 197|calcitonin levels
14P01437562A0462|8 17|antibodies
14P01437562A0462|49 61|C.fasciculata
14P01437562A0462|100 118|nucleotide sequence
14P01438224A0749|49 50|J.
14P01438287T0000|14 28|vaccinia vector
14P01441120T0000|0 2|Use
14P01441818T0001|0 14|Interferon type
14P01441818T0001|56 75|Klebsiella infection
14P01443047A0773|29 50|differentiation status
14P01443047A0773|79 95|Id-SCL expression
14P01443745T0000|11 21|interaction
14P01443745T0000|33 42|anesthesia
14P01443745T0000|58 66|midazolam
14P01443748A1190|3 10|pressure
14P01443748A1190|43 54|excitability
14P01443748A1190|60 67|tadpoles
14P01443748A1190|128 136|movements
14P01446132A0328|3 14|air embolism
14P01446132A0328|63 74|complication
14P01446828A1088|13 16|ADH5
14P01446828A1088|25 47|consensus binding sites
14P01446828A1088|90 92|AP2
14P01446828A1088|94 98|LF-A1
14P01446828A1088|100 103|NF-1
14P01446828A1088|105 109|NF-A2
14P01446828A1088|114 118|NF-E1
14P01447139A0208|0 1|V.
14P01447189A1546|21 29|RNK-Met-1
14P01447189A1546|33 47|serine protease
14P01447189T0000|0 11|Purification
14P01447189T0000|30 44|serine protease
14P01447189T0000|45 53|RNK-Met-1
14P01447189T0000|83 102|killer cell leukemia
14P01448107A0361|24 37|GCN2 mutations
14P01448107A0361|61 75|GCN4 expression
14P01448107A0361|89 109|amino acid starvation
14P01448806A0135|0 13|Administration
14P01448806A0135|16 29|growth hormone
14P01448806A0135|62 76|bone maturation
14P01448917A0775|0 10|Comparisons
14P01448917A0775|27 44|amino acid residue
14P01448917A0775|47 66|sequence information
14P01448917A0775|81 88|CPMV RNA
14P01448917A0775|123 145|clover mottle virus RNA
14P01448917A0775|155 163|CPSMV RNA
14P01448917A0775|211 229|proteinase cofactor
14P01448917A0775|230 232|58K
14P01448917A0775|250 252|VPg
14P01448917A0775|281 284|RNAs
14P01448917A0775|286 299|24K proteinase
14P01448917A0775|303 305|87K
14P01448917A0775|340 353|cleavage sites
14P01448932T0000|0 46|Rice dwarf phytoreovirus segment S12 transcript
14P01449183A0795|28 44|transferrin assay
14P01449183A0795|73 86|fluid otorrhea
14P01449301A0710|0 16|Cold cardioplegia
14P01450815A0337|29 32|IPRK
14P01450815A0337|69 71|RPF
14P01450815A0337|75 77|GFR
14P01451771A0619|27 42|family variables
14P01451771A0619|95 113|components analysis
14P01451771A0619|114 116|PCA
14P01451771A0619|137 152|scaling analysis
14P01451771A0619|153 155|MDS
14P01451771A0619|174 186|health scores
14P01452037A0000|26 65|glyceraldehyde-3-phosphate dehydrogenase
14P01452037A0000|66 70|GAPDH
14P01452037A0000|98 100|PGK
14P01452037A0000|124 148|triosephosphate isomerase
14P01452037A0000|149 151|TIM
14P01452037A0000|167 192|Bacillus megaterium DSM319
14P01452584T0000|40 50|retardation
14P01452584T0000|53 65|wound healing
14P01452584T0000|73 86|Lindberg Award
14P01452703A0782|0 17|Laboratory studies
14P01452703A0782|151 160|ELISA kits
14P01454518A0336|135 159|stringency hybridizations
14P01454518A0336|191 200|ERCC3 cDNA
14P01454819A0000|0 20|Mono-ADP-ribosylation
14P01454819A0000|61 63|NAD
14P01454819A0000|65 96|arginine ADP-ribosyltransferases
14P01454819A0000|97 98|EC
14P01454819A0000|141 142|EC
14P01454819A0000|186 207|ADP-ribosylation cycle
14P01456888A0074|58 68|HIV-1 group
14P01456888A0074|76 95|core antigen p55 gag
14P01456888A0074|132 149|expression systems
14P01456888A0074|227 242|core protein p55
14P01456888A0074|281 310|myristylation consensus signal
14P01457380A0000|3 11|tramtrack
14P01457380A0000|55 62|proteins
14P01457380A0000|81 88|splicing
14P01457380A0000|101 114|ttk transcript
15P01457695T0000a|0 6|Removal
15P01457695T0000a|9 28|beta 2-microglobulin
15P01457695T0000a|45 58|hemofiltration
15P01457695T0000b|0 6|Removal
15P01457695T0000b|9 28|beta 2-microglobulin
15P01457695T0000b|45 58|hemofiltration
14P01458170A0155|0 9|Adapromine
14P01458170A0155|82 95|theta-activity
14P01458170A0155|98 110|power spectra
14P01458170A0155|115 117|EEG
14P01458170A0155|163 175|wave activity
14P01459447A0484|5 13|sequences
14P01459447A0484|69 75|library
14P01459451A0478|18 31|antirepression
14P01459451A0478|68 83|co-antirepressor
14P01459885A0705|13 33|haloperidol treatment
14P01459885A0705|83 90|increase
14P01459885A0705|104 111|decrease
14P01459921A0000|36 52|Hampshire wethers
14P01459921A0000|105 124|linoleoyl methionine
14P01459921A0000|127 143|calcium linoleate
14P01459921A0000|192 196|C18:2
14P01460054A0478|9 13|ICSBP
14P01460054A0478|71 73|ICS
14P01460054A0478|105 122|DNA binding domain
14P01460054A0968|10 14|ICSBP
14P01460772T0001|35 48|hypothyroidism
14P01460772T0001|65 84|interferon treatment
14P01462786T0000|0 22|Dynamic decision making
14P01464329T0000|61 80|prophase chromosomes
14P01464606A0344|66 79|chromatography
14P01464606A0344|82 99|detergent extracts
14P01464606A0344|125 148|fragment affinity column
14P01464606A0344|161 164|EDTA
14P01467088T0075|0 8|Abstracts
14P01467828A0542|29 39|involvement
14P01467828A0542|52 66|opioid peptides
14P01467828A0542|100 108|ischaemia
14P01467828A0542|112 122|reperfusion
14P01467828A0542|140 148|receptors
14P01467828A0542|162 171|antagonism
14P01468625A0282|16 19|LEU2
14P01468625A0282|23 32|HIS3 cDNAs
14P01468625A1080|11 14|ACT1
14P01468625A1080|39 42|NSR1
14P01469042A0355|5 15|CENP-B gene
14P01469042A0355|47 58|CENP-B boxes
14P01469042A0355|72 101|mouse centromere satellite DNA
14P01469042A0355|192 210|centromere function
14P01469047A1606|61 90|% amino acid sequence identity
14P01469047A1606|140 157|acid decarboxylase
14P01470243A0871|13 20|subgroup
14P01470243A0871|31 32|Ht
14P01470243A0871|69 77|reduction
14P01470243A0871|91 99|mortality
14P01470243A0871|141 148|increase
14P01470243A0871|151 162|independence
14P01470243A0871|199 207|reduction
14P01470243A0871|213 221|viscosity
14P01470243A0871|231 243|haemodilution
14P01470243A0871|248 254|albumin
14P01470243A0871|265 280|viscosity effect
14P01470741T0062|0 11|Distribution
14P01471602A0362|30 51|bile acid sequestrants
14P01471602A0362|113 119|HMG-CoA
14P01471602A0362|121 140|reductase inhibitors
14P01471602A0362|216 226|conjunction
14P01473196A1016|19 30|reabsorption
14P01473196A1016|51 59|clearance
14P01473207A0582|45 57|prematuration
14P01473207A0582|61 70|hypoplasia
14P01473234A1001|0 11|Green pepper
14P01473234A1001|65 78|acid formation
14P01474990A0000|30 32|DNA
14P01474990A0000|68 78|Trypanosoma
14P01474990A0000|84 98|trypomastigotes
14P01474990A0000|155 168|trypomastigote
14P01474990A0000|172 188|epimastigote cDNA
14P01475381T0001|0 10|Brucellosis
14P01476376T0000|0 4|Assay
14P01477021A0394|0 6|RESULTS
14P01477021A0394|13 21|AGA group
14P01477021A0394|42 70|serum prolactin concentration
14P01478672A0795|3 13|phage clone
14P01478672A0795|37 55|alpha satellite DNA
14P01480183A0000|30 45|lactoferrin gene
14P01480183A1689|37 51|estrogen action
14P01480183A1689|64 90|lactoferrin gene expression
14P01480470A0323|0 5|BiP670
14P01480470A0323|21 23|Ca2
14P01482912A0617|3 5|CEM
14P01482912A0617|14 33|registration updates
14P01482912A0617|38 48|HL7 message
14P01482912A0617|60 76|data dependencies
14P01482912A0617|102 120|relational database
14P01483755A0000|8 29|resonance spectroscopy
14P01483755A0000|30 32|MRS
14P01483755A0000|45 47|MRI
14P01483771A1335|22 23|NA
14P01483771A1335|46 72|plasma epinephrine response
14P01485648A0000|50 69|Pharmacia CAP System
14P01485648A0000|69 92|Pharmacia Diagnostics AB
14P01485648A0000|92 98|Uppsala
14P01485648A0000|100 105|Sweden
14P01485648A0000|156 169|IgE antibodies
14P01485648A0000|185 188|RAST
14P01486836A0774|0 7|Patients
14P01486836A0774|17 19|VPA
14P01486836A0774|49 70|visuomotor performance
14P01486836A0774|91 110|discrimination tasks
14P01486836A0774|112 113|T1
14P01486836A0774|117 138|visuomotor performance
14P01486836A0774|140 141|T2
14P01486836A0774|160 161|T3
14P01486836A0774|197 198|T4
14P01487144A0505|14 25|gene segment
14P01487144A0505|107 130|transcription terminator
14P01487144A0505|136 148|myeloma cells
14P01487144A0505|151 168|L cell fibroblasts
14P01490493A0416|15 25|examination
14P01490493A0416|39 55|serum cholesterol
14P01490493A0416|69 87|triglyceride levels
14P01492463T0001|0 4|Alena
14P01492463T0001|15 20|Prague
14P01493864A0619|0 15|Dopamine neurons
14P01493864A0619|37 42|6-OHDA
14P01493864A0619|75 83|GBR-12909
14P01495069A0392|0 3|DIBA
14P01495069A0392|92 95|DFAT
14P01496348A0000|0 5|Caries
14P01496348A0000|9 20|parodontitis
14P01496784A0939|36 51|strongyloidiasis
14P01497582A0593|19 27|disorders
14P01497582A0593|30 38|pregnancy
14P01497582A0593|49 55|effects
14P01497582A0593|58 67|infections
14P01497582A0593|86 94|pathogens
14P01497582A0593|127 134|placenta
14P01498607A0000|9 28|nucleotide sequences
14P01498607A0000|79 112|parsley chalcone synthase promoter
14P01499213A0185|65 85|hyperextension injury
14P01499213A0185|141 156|L2-L3 disk space
14P01499616A0136|7 16|blood flow
14P01499616A0136|27 34|foreskin
14P01499616A0136|96 104|induction
14P01499616A0136|107 116|anesthesia
14P01499616A0136|169 181|foreskin flap
14P01502157A0000|0 4|ME1a1
14P01502157A0000|71 103|P2 transcription initiation sites
14P01504178T0000|20 29|prevention
14P01504178T0000|38 44|country
14P01504178T0000|46 54|visionary
14P01504178T0000|56 62|complex
14P01504853A0299|9 12|LHRH
14P01504853A0299|36 50|mating behavior
14P01505488A0231|41 43|EVL
14P01505488A0231|63 68|August
14P01505488A0231|76 79|July
14P01505516A0928|47 53|alanine
14P01505516A0928|56 69|valine residue
14P01505516A0928|76 84|formation
14P01506705A0282|6 15|V-A bypass
14P01506746A0476|0 20|Greater rupture force
14P01509798A0520|33 34|UT
14P01509798A0520|52 53|AT
14P01509798A0520|62 64|UEA
14P01511231A0085|17 30|smoking habits
14P01511231A0085|62 84|smoking cessation trial
14P01511231A0085|98 112|placebo patches
14P01511950T0000|0 7|Exposure
14P01511950T0000|10 26|hepatitis B virus
14P01511950T0000|49 56|Hisayama
14P01511950T0000|58 62|Japan
14P01511950T0000|96 122|hepatitis B surface antigen
14P01512259A0867|19 28|phenomenon
14P01512259A0867|61 74|cysteine motif
14P01512259A0867|104 110|Dfurin2
14P01512654A0503|39 54|saline injection
14P01512654A0503|61 62|ES
14P01512654A0503|73 86|KLH challenges
14P01512654A0503|91 92|ES
14P01512654A0503|118 132|threshold level
14P01512941A0000|58 61|LVFX
14P01512941A0000|63 69|DR-3355
14P01512941A0000|130 133|CPFX
14P01512941A0000|146 149|OFLX
14P01512941A0000|166 169|NFLX
14P01513114A1133|7 29|serum creatinine levels
14P01513114A1133|49 51|SPK
14P01513114A1133|56 58|KTA
14P01513114A1133|69 76|ABSTRACT
14P01513114A1133|91 95|WORDS
14P01513213A0231|0 16|Model predictions
14P01513213A0231|44 62|survival experience
14P01513213A0231|74 82|HIP trial
14P01513213A0231|128 135|HIP data
14P01516427T0000|23 32|tomography
14P01516427T0000|38 46|diagnosis
14P01516427T0000|56 67|tuberculosis
14P01516829A0113|23 26|SNF2
14P01516829A0113|28 31|SNF5
14P01516829A0113|36 48|SNF6 function
14P01516829A0460|10 18|LexA-GAL4
14P01516829A0460|33 47|fusion proteins
14P01516829A0460|65 68|SNF2
14P01516829A0460|70 73|SNF5
14P01516829A0460|78 81|SNF6
14P01518396T0000|0 8|George T.
14P01518833A0397|1 24|lambda gt10 cDNA library
14P01518833A0397|48 50|RNA
14P01518849A0165|0 1|NE
14P01518849A0165|5 7|PR3
14P01518849A0165|150 187|alpha 1-proteinase inhibitor complexes
14P01518926T0000|25 39|ultrasonography
14P01522699A0092|0 6|Methods
14P01522699A0092|36 47|menu weights
14P01522699A0092|51 65|recipe analysis
14P01523111A0769|0 6|Factors
14P01523111A0769|56 66|temperature
14P01524549A0241|4 16|GH deficiency
14P01524549A0241|114 126|GH deficiency
14P01524549A0241|152 161|GH therapy
14P01525153A0359|13 18|T2AG3T
14P01525153A0359|25 29|T2G4T
14P01525153A0359|54 71|monomer structures
14P01525153A0359|84 105|K cation concentration
14P01525153A0359|125 127|Sen
14P01525153A0359|129 130|D.
14P01525153A0359|133 139|Gilbert
14P01525153A0359|141 142|W.
14P01525966T0000|25 30|stones
14P01526658A0454|0 2|IFI
14P01526658A0454|86 95|B lineages
14P01526690T0000|26 33|warfarin
14P01526690T0000|36 46|lymphocytes
14P01527020A0511|33 62|rat AdoMet decarboxylase genes
14P01529530T0000|24 38|gene expression
14P01529530T0000|92 118|ISGF3 transcription complex
14P01531086A0127|16 28|reading frame
14P01531086A0127|33 43|amino acids
14P01531214A0885|9 12|LD50
14P01531214A0885|21 26|RP-170
14P01531214A0885|69 82|administration
14P01531632A0000|104 107|SSB1
14P01531632A0000|111 114|NSR1
14P01531632A0000|149 158|GAR domain
14P01531632A0000|182 198|arginine residues
14P01532229A1264|58 62|HF-1a
14P01532229A1264|68 80|muscle factor
14P01532229A1264|81 85|HF-1b
14P01532229A1264|87 91|MEF-2
14P01532796A0107|0 8|Mutations
14P01532796A0107|57 58|F1
14P01532796A0107|78 90|beta subunits
14P01532796A0107|104 115|mitochondria
14P01532796A0107|137 144|Ackerman
14P01532796A0107|146 147|S.
14P01532914A0067|0 6|Expense
14P01532914A0067|21 40|hepatitis B vaccines
14P01532914A0067|62 73|immunization
14P01533760T0000|0 27|Estrogen replacement therapy
14P01535242A0557|9 14|FDC-P1
14P01535242A0557|16 24|MAC cells
14P01535242A0557|36 40|M-CSF
14P01535242A0557|43 48|GM-CSF
14P01535242A0557|102 117|factor switching
14P01536153A0574|29 38|difference
14P01536153A0574|44 53|prevalence
14P01536153A0574|89 107|animal food workers
14P01536153A0574|129 138|skin tests
14P01536153A0574|153 162|fish flour
14P01536153A0574|195 197|IgE
14P01536575A1213|134 146|transcription
14P01536575A1213|152 174|cytochrome P450IA1 gene
14P01536575A1213|174 179|CYPIA1
14P01536575A1213|204 228|detoxification/activation
14P01536575A1213|249 260|hydrocarbons
14P01537334A0507|15 24|TRP-2 maps
14P01537334A0507|26 41|mouse chromosome
14P01537334A0507|60 85|coat colour mutation slaty
14P01537845A0571|20 31|c-myb clones
14P01537845A0571|51 74|c-myb gene transcription
14P01537845A0571|75 88|mRNA stability
14P01538401A1244|3 27|base-pair oligonucleotide
14P01538401A1244|60 69|S RNA gene
14P01538401A1244|158 170|DNA fragments
14P01538403A1058|49 71|transcription complexes
14P01538403A1058|83 99|protein fractions
14P01538403A1058|121 125|TFIID
14P01538403A1058|162 178|complex formation
14P01538403A1058|184 204|H5 promoter mutations
14P01538403A1058|213 220|TATA-box
14P01539996A0588|16 34|amino acid sequence
14P01539996A0588|38 59|T. thermophilus enzyme
14P01539996A0588|147 157|Ser residue
14P01539996A0588|276 285|C terminus
14P01539996A0588|290 311|T. thermophilus enzyme
14P01541556A1040|73 90|lipid modification
14P01541556A1040|101 114|Cys-22 residue
14P01541577A0000|15 16|Ss
14P01541577A0000|35 54|volunteer hearing Ss
14P01541577A0000|58 74|Stanford Hypnotic
14P01541577A0000|82 86|Scale
14P01541577A0000|88 91|SHCS
14P01541577A0000|95 100|Morgan
14P01541577A0000|104 105|J.
14P01542565A0220|6 24|tobacco L12 protein
14P01542565A0220|28 48|% amino acid identity
14P01542565T0000|47 63|Nicotiana tabacum
14P01542565T0000|64 79|characterization
14P01542565T0000|110 126|sequence analysis
14P01542667A0125|15 23|IFN-gamma
14P01542667A0125|61 76|enhancer element
14P01542686A0000|21 41|polypeptide component
14P01542686A0000|62 86|p75 nucleoprotein complex
14P01542686A0000|121 123|p65
14P01542686A0000|134 144|NF-kappa B.
14P01542730A1982|99 106|AV block
14P01542730A1982|109 118|DDD pacing
14P01542730A1982|198 201|DDDR
14P01542730A1982|257 264|ABSTRACT
14P01542730A1982|279 283|WORDS
14P01543909A0787|30 39|K562 cells
14P01543909A0787|44 45|Lg
14P01543909A0787|117 131|characteristics
14P01543909A0787|201 216|ferritin subunit
14P01544854A0699|29 37|WR-168643
14P01544854A0699|62 64|DMF
14P01544918A1240|0 15|Characterization
14P01544918A1240|23 32|R subunits
14P01544918A1240|39 73|8-azido-cAMP photoaffinity labeling
14P01544918A1240|178 196|gel electrophoresis
14P01544918A1240|197 204|SDS-PAGE
14P01544918A1240|230 237|RII beta
14P01544918A1240|255 277|RII alpha dephosphoform
14P01544918A1240|294 301|RI alpha
14P01544928A1252|0 9|Comparison
14P01544928A1252|22 33|DNA sequence
14P01544928A1252|156 169|cassette model
14P01545523A0000|16 30|quantifications
14P01545523A0000|105 122|antistreptolysin O
14P01545787A0345|72 76|DNase
14P01545787A0345|89 94|NFAT-1
14P01545787A0345|98 104|NFIL-2B
14P01545792A0000|10 29|myosin light chain-2
14P01545792A0000|29 33|MLC-2
14P01545792A0000|35 47|gene promoter
14P01545792A0492|0 19|Deletion mutagenesis
14P01545792A0492|87 110|MLC-2 gene transcription
14P01545797A0587|0 19|Disruption mutations
14P01545797A0587|43 51|SLK1 gene
14P01545806T0000|49 74|recombination genes REC102
14P01545806T0000|76 86|REC107/MER2
14P01545818A0696|3 6|p130
14P01545818A0696|10 12|p62
14P01545818A0696|114 124|Rat-2 cells
14P01545818A0696|159 174|v-Src SH2 domain
14P01546522A0000|0 7|Probable
14P01546522A0000|29 47|leukoencephalopathy
14P01546522A0000|49 51|PML
14P01546522A0000|103 119|resonance imaging
14P01547775A1024|122 124|RNA
14P01547775A1024|150 163|PLRV replicase
14P01547775A1024|168 197|ORF2a/ORF2b transframe protein
14P01547787A0548|0 20|Proprotein processing
14P01547942A0120|12 14|LAP
14P01547942A0120|29 47|dimerization domain
14P01547942A0120|121 127|CHOP-10
14P01547957A1083|16 39|oligodeoxyribonucleotide
14P01547957A1083|143 146|CYP1
14P01547957A1083|150 153|CYP2
14P01547957A1083|198 209|DNA fragment
14P01547957A1083|226 250|polymerase chain reaction
14P01547957A1083|250 252|PCR
14P01547957A1083|259 262|GL81
14P01547957A1083|270 272|DNA
14P01548756A1102|24 28|EHS-1
14P01548756A1102|49 51|DNA
14P01548756A1102|72 81|EHS-1 loci
14P01548756A1102|94 96|DNA
14P01548756A1102|153 169|rhesus monkey DNA
14P01548891A0635|62 78|thyroid carcinoma
14P01548891A0635|115 131|thyroid carcinoma
14P01549118A0000|3 43|Caenorhabditis elegans vitellogenin genes
14P01549118A0000|126 148|hermaphrodite intestine
14P01549123A0480|3 11|MET4 gene
14P01549123A0480|105 114|activators
14P01549125A0140|43 46|IAPP
14P01549125A0140|51 67|beta GK promoters
14P01549125A0140|106 123|DNA binding assays
14P01549129A0356|75 86|interactions
14P01549129A0356|108 118|functioning
14P01549129A0356|121 123|Src
14P01549346A0000|3 21|c-Ets-1 oncoprotein
14P01549346A0000|24 46|transcription activator
14P01549346A0000|69 71|DNA
14P01549465A0122|8 34|transactivation experiments
14P01549465A0122|83 85|Gly
14P01549465A0122|87 89|Ser
14P01549465A0122|93 95|Val
14P01549465A0122|129 142|discrimination
14P01551176A0000|0 7|GR63178A
14P01551176A0000|58 71|pyrroloquinone
14P01551568A1476|0 21|Marker rescue analysis
14P01551568A1476|79 88|Rif domain
14P01551898A1084|63 72|expression
14P01551898A1084|116 125|LAPP/liter
14P01551898A1084|128 141|culture medium
14P01551910A0313|0 19|Competition analysis
14P01551910A0313|21 54|gel mobility shift electrophoresis
14P01551910A0313|117 137|transcription factors
14P01551910A0978|4 12|DNA motif
14P01552052A0139|0 8|OBJECTIVE
14P01552052A0139|56 66|alterations
14P01552052A0139|69 84|serum creatinine
14P01552052A0139|128 139|cyclosporine
14P01552457T0000|0 23|Intrapocket chemotherapy
14P01552457T0000|96 100|PT-01
14P01552662A0398|25 26|BF
14P01552662A0398|77 79|LAD
14P01552853A1377|5 15|temperature
14P01552853A1377|44 52|induction
14P01552853A1377|58 68|yop regulon
14P01553407T0000|0 7|Problems
14P01553407T0000|49 63|risk assessment
14P01554334A0000|20 35|gamma-interferon
14P01554334A0000|37 45|IFN-gamma
14P01554334A0000|131 139|Committee
14P01554334A0000|142 152|Agriculture
14P01554334A0000|161 169|Australia
14P01555556A0565|0 14|Control Tmuscle
14P01555556A0565|63 64|SD
14P01555556A0565|69 74|W.kg-1
14P01556068A0000|3 32|Klebsiella aerogenes gene maoA
14P01556068A0000|62 78|monoamine oxidase
14P01556068A0000|146 168|ammonium ion repression
14P01556111A0241|13 19|regions
14P01556111A0241|25 31|plasmid
14P01557217A0272|33 39|lesions
14P01557217A0272|73 78|h p.i.
14P01557411A1282|13 20|D1A gene
14P01558942A1369|7 18|observations
14P01559209T0000|0 12|Preceptorship
14P01559209T0000|15 26|CNS students
14P01560021A0379|32 42|differences
14P01560021A0379|63 80|brain AE3 variants
14P01560774A0885|14 21|fragment
14P01560774A0885|60 68|fliA gene
14P01562659A0676|0 10|Institution
14P01562659A0676|185 194|C. immitis
14P01562659A0676|198 211|CNS vasculitis
14P01562659A0676|277 296|C. immitis infection
14P01562659A0676|307 309|CNS
14P01563343A0548|0 12|Lac operators
14P01563343A0548|55 66|CAB promoter
14P01563635T0000|0 13|Overproduction
14P01563635T0000|48 72|M.HinfI methyltransferase
14P01564653A0307|7 15|companies
14P01565093A0179|4 8|March
14P01565093A0179|17 23|October
14P01565093A0179|69 85|blood lead levels
14P01565093A0179|85 88|BLLs
14P01565093A0179|136 162|disease surveillance system
14P01565093A0179|176 193|Alabama Department
14P01565093A0179|195 207|Public Health
14P01565093A0179|208 211|ADPH
14P01565882A0737|23 39|perfusion defects
14P01565882A0737|49 50|RD
14P01565882A0737|54 63|ReI images
14P01565882A0737|93 96|Type
14P01565882A0737|99 114|perfusion defect
14P01565882A0737|119 126|RD image
14P01565882A0737|153 156|Type
14P01565882A0737|189 204|perfusion defect
14P01565882A0737|221 222|Ia
14P01565882A0737|239 240|Ib
14P01565882A0737|251 258|RD image
14P01566576A0605|0 3|Keck
14P01566576A0605|5 8|C.J.
14P01567649A0139|18 24|infants
14P01567649A0139|47 56|hemorrhage
14P01567649A0139|117 126|evaluation
14P01567649A0139|134 140|infancy
14P01568960A1129|95 108|corner vessels
14P01568960A1129|126 137|VA/Q regions
14P01569015A0120|15 19|FRAME
14P01569015A0120|53 66|reading frames
14P01569015A0120|67 70|ORFs
14P01569102A0708|0 5|Domain
14P01569102A0708|31 42|LDL receptor
14P01569344A0404|68 82|New Orleans age
14P01569344A0404|97 116|HTLV-I/II prevalence
14P01569344A0404|148 156|Baltimore
14P01569581A0482|135 163|translation initiation region
14P01569581A0482|183 214|translation initiation frequency
14P01569584A0672|0 17|Hybridization data
14P01569584A0672|29 33|6F6.2
14P01569584A0672|73 87|m6F6 cDNA clone
14P01569584A0672|93 97|6F6.1
14P01569584A0672|101 105|6F6.3
14P01569584A0672|113 117|6F6.2
14P01569945A0529|3 11|SEN1 gene
14P01569945A0529|37 49|reading frame
14P01572549A0000|0 23|Protein tyrosine kinases
14P01572549A0000|23 26|PTKs
14P01572549A0000|145 162|signal transducers
14P01572549A0000|168 190|growth factor receptors
14P01573270A0000|3 9|IA4 mAb
14P01573270A0000|54 64|BALB/c mice
14P01573270A0000|89 97|HLA class
14P01573270A0000|136 138|LAK
14P01573270A0000|152 172|EBV-B lymphocyte line
14P01577056A0178|44 51|subjects
14P01577056A0178|60 71|theophylline
14P01577056A0178|73 79|mg.kg-1
14P01577056A0178|90 99|omeprazole
14P01577056A0178|121 127|placebo
14P01577056A0178|137 143|periods
14P01577056A0178|169 182|washout period
14P01577740A1111|0 15|Primer extension
14P01577740A1111|29 47|S1 nuclease mapping
14P01577740A1111|63 92|transcription initiation sites
14P01577740A1111|112 128|Northern analyses
14P01577819A0709|10 30|PRP-precursor alleles
14P01579472A1018|16 31|enhancer element
14P01579537A0000|37 51|botulinum toxin
14P01579537A0000|59 68|neurotoxin
14P01580738T0001|0 8|Allagille
14P01581409A0398|0 10|Sensitivity
14P01581409A0398|45 64|Pharmacia CAP System
14P01581409A0398|69 86|DPC AlaSTAT System
14P01581577A1186|0 4|PSI-G
14P01581577A1186|8 12|PSI-K
14P01581577A1186|37 52|gene duplication
14P01581965A0388|5 14|C-terminus
14P01581965A0388|85 122|breakpoint cluster region gene product
14P01581965A0388|182 193|GAP activity
14P01581965A0388|200 206|GTPases
14P01582413A0192|173 183|DNA binding
14P01582413A0192|186 207|hetero-oligomerization
14P01582413A0759|0 11|Dimerization
14P01582413A0759|14 18|Myf-5
14P01582413A0759|91 93|DNA
14P01582413A0759|111 125|transactivation
14P01582413A0759|141 151|DNA binding
14P01582500A0178|12 22|rhythmicity
14P01583819A0377|0 2|SEA
14P01583819A0377|46 47|HZ
14P01583819A0377|57 58|Hz
14P01583819A0377|64 76|Simson method
14P01584812T0000|100 126|transcription factor NGFI-C
14P01585014A0000|45 57|gonadotrophin
14P01585014A0000|78 92|micrograms GnRH
14P01585014A0000|108 133|progestagen sponge removal
14P01585014A0000|258 271|sponge removal
14P01585014A0000|303 313|Merino ewes
14P01585014A0000|347 350|I.U.
14P01585014A0000|359 382|mare serum gonadotrophin
14P01585014A0000|382 385|PMSG
14P01585014A0000|392 422|mg follicle stimulating hormone
14P01585014A0000|421 425|FSH-P
14P01586901A0000|9 20|interactions
14P01586901A0000|43 50|patients
14P01586901A0000|68 78|medications
14P01587267A1144|3 15|sequence data
14P01587267A1144|33 46|interpretation
14P01587267A1144|52 56|X-ray
14P01587267A1144|109 118|expression
14P01587267A1144|166 176|mutagenesis
14P01587763A0402|5 20|body irradiation
14P01587763A0402|71 79|fractions
14P01588270A1029|1 9|reduction
14P01588270A1029|12 25|blood pressure
14P01588270A1029|124 126|DBP
14P01588315A0356|0 5|AgMNPV
14P01588315A0356|9 33|Orgyia pseudotsugata MNPV
14P01588315A0356|33 38|OpMNPV
14P01588315A0356|59 76|promoter structure
14P01588315A0356|111 125|polyhedrin gene
14P01588913A0000|81 93|transcription
14P01588913A0000|127 135|P. putida
14P01588961A0000|0 3|STP1
14P01588963A1153|77 89|Cdc25 protein
14P01588965A0000|0 17|GCR1 gene function
14P01589576A0170|3 14|decay curves
14P01589576A0170|16 39|chlorophyll fluorescence
14P01589576A0170|46 58|superposition
14P01589576A0170|101 114|time constants
14P01589576A0170|116 117|T1
14P01589576A0170|129 130|T2
14P01589576A0170|144 145|T3
14P01592545A0726|21 34|blood pressure
14P01592545A0726|40 46|average
14P01592545A0726|54 61|patients
14P01592545A0726|124 131|patients
14P01594554A0845|41 43|CCK
14P01594554A0845|47 64|trypsin inhibitors
14P01594554A0845|94 109|feedback control
14P01596007A0908|30 35|Stages
14P01596007A0908|46 48|REM
14P01596007A0908|83 96|gamma OH study
14P01596007A0908|121 135|control studies
14P01596007A0908|187 189|SWS
14P01596007A0908|203 210|ABSTRACT
14P01596007A0908|225 229|WORDS
14P01597170A0000|45 49|CoCl2
14P01597170A0000|73 74|Cr
14P01597170A0000|76 78|NO3
14P01597170A0000|90 91|Cr
14P01597170A0000|151 163|control group
14P01597272A0077|40 58|withdrawal symptoms
14P01597462A0457|0 9|Disruption
14P01597462A0457|26 30|CDC14
14P01600531A0483|32 46|phosphocreatine
14P01600531A0483|60 72|control group
14P01601181A0842|3 17|60A transcripts
14P01601181A0842|55 66|gastrulation
14P01601869A1389|59 63|E-box
14P01601869A1389|175 189|BC3H1 myoblasts
14P01603088A1121|45 46|TR
14P01605038T0001|0 8|Influence
14P01605038T0001|53 56|GABA
14P01607223A0000|6 19|investigations
14P01607223A0000|45 61|release technique
14P01607223A0000|76 86|laser light
14P01607223A0000|177 187|vasculature
14P01608239T0001|13 20|barriers
14P01611699A0000|5 26|pyridoxine derivatives
14P01611699A0000|64 90|Albizzia julibrissin DURAZZ
14P01612085A0624|3 22|serum erythropoietin
14P01612085A0624|23 25|EPO
14P01612085A0624|27 40|concentrations
14P01612085A0624|65 70|U.ml-1
14P01612085A0624|111 126|distance runners
14P01612085A0624|131 136|U.ml-1
14P01613640A0158|3 19|coating materials
14P01613640A0158|82 85|Brij
14P01615049A0000|12 28|drinking patterns
14P01615049A0000|60 71|h light/12 h
14P01615182A0206|28 38|improvement
14P01615182A0206|41 58|sputum amoxycillin
14P01615182A0206|76 93|combination tablet
14P01615182A0206|108 118|bromhexeine
14P01615493A0408|3 4|HC
14P01615493A0408|18 31|antigen levels
14P01615493A0975|0 9|Argatroban
14P01615493A0975|36 37|HC
14P01615493A0975|80 96|thrombin activity
14P01616475A0756|42 45|NFPD
14P01616475A0756|48 62|CP/NCA patients
14P01616475A0756|149 175|panic disorder presentation
14P01617242T0000|0 14|FDA regulations
14P01617776A0343|50 60|arrhythmias
14P01617776A0343|74 83|infarction
14P01617776A0343|112 122|innervation
14P01617776A0343|186 192|reentry
14P01617776A0343|219 228|infarction
14P01617801A0088|0 5|DESIGN
14P01617801A0088|7 23|Serum aldosterone
14P01617801A0088|26 46|plasma renin activity
14P01618027A1108|14 24|transcripts
14P01618027A1108|104 115|E10 fragment
14P01618027A1108|148 156|remainder
14P01618243T0000|11 29|amine pressor tests
14P01618256A0521|26 38|concentration
14P01618256A0521|61 74|micrograms.l-1
14P01618256A0521|118 131|micrograms.l-1
14P01619114A0383|35 38|SMSP
14P01619114A0383|67 87|Mini Speech Processor
14P01619114A0383|87 89|MSP
14P01619642A0131|4 10|parents
14P01620118A0470|89 98|activation
14P01620118A0470|109 130|immunodeficiency virus
14P01620129A0417|40 52|factor HiNF-D
14P01620129A0417|71 86|promoter element
14P01620129A0417|91 103|H4-FO108 gene
14P01620129A0417|144 145|J.
14P01620610A1070|31 32|TI
14P01620610A1070|45 63|expression problems
14P01620610A1070|185 197|MTI subregion
14P01620781A0611|89 90|A1
14P01620781A0611|95 96|B2
14P01620781A0611|101 102|A3
14P01620781A0611|107 108|B4
14P01620781A0611|113 114|A5
14P01621584A0183|0 5|UF-021
14P01621584A0183|97 109|IOP reduction
14P01621584A0183|140 147|IOP rise
14P01623900A0670|5 18|blood pressure
14P01623900A0670|65 77|plasma levels
14P01623900A0670|98 111|norepinephrine
14P01623900A0670|136 143|Pl group
14P01623900A0670|191 205|blood pressures
14P01623900A0670|232 251|norepinephrine level
14P01623900A0670|263 286|norepinephrine excretion
14P01623900A0670|314 330|dF administration
14P01624425A0907|49 61|substitutions
14P01624425A0907|67 87|consensus amino acids
14P01625131A0452|28 37|stoma site
14P01625131A0452|63 71|rejection
14P01625527A0000|5 26|blood serotonin levels
14P01625527A0000|44 56|control group
14P01625527A0000|87 102|failure patients
14P01625527A0000|118 134|treatment regimen
14P01625527A0000|166 190|maintenance haemodialysis
14P01625527A0000|209 223|transplantation
14P01626372T0000|0 6|Tissues
14P01626372T0000|105 133|trimethoprim-sulfamethoxazole
14P01626430A1112|20 24|RAD16
14P01626430A1112|26 30|RAD54
14P01626430A1112|34 37|SNF2
14P01626430A1112|95 110|Drosophila genes
14P01626440A0449|6 26|application solutions
14P01626440A0449|28 51|instrument disinfectants
14P01626631A0557|5 17|Rett syndrome
14P01626631A0557|45 56|disturbances
14P01626631A0557|62 71|brain stem
14P01627106A0320|33 60|nitrofurazone administration
14P01627106A0320|63 86|S. enteritidis challenge
14P01627106A0320|134 152|isolation frequency
14P01627828A0475|49 58|SmN probes
14P01627828A0475|156 163|SmN gene
14P01627830A0000|16 30|casein kinase-1
14P01627830A0000|51 68|yeast cDNA library
14P01627830A0000|76 79|CKI1
14P01627830A0000|83 86|CKI2
14P01628201A0824|0 13|Incidence rate
14P01628806A1347|11 28|sequence variation
14P01628806A1347|44 46|ORF
14P01628806A1347|76 78|ORF
14P01628806A1347|99 113|helicase region
14P01628904A0386|8 16|screening
14P01628904A0386|42 49|kilobase
14P01628904A0386|54 59|insert
14P01629768A0131|0 6|Lesions
14P01629768A0131|17 34|pressure injection
14P01629768A0131|53 55|SOC
14P01629768A0131|89 106|glass micropipette
14P01630454A0635|55 76|Act1 promoter activity
14P01630455A0448|27 39|NFIL-1 beta A
14P01630455A0448|39 47|NF beta A
14P01630455A0448|80 91|DNA sequence
14P01630455A0448|121 134|TATA box motif
14P01630455A0448|156 170|IL-1 beta genes
14P01630569A0605|7 20|amphotericin B
14P01630569A0605|21 23|AmB
14P01631229T0000|0 12|Cutis aplasia
14P01633435A0743|3 7|DRF-2
14P01633435A0743|25 39|characteristics
14P01633435A0743|91 95|MEF-2
14P01633435A0743|97 102|Buskin
14P01633435A0743|106 113|Hauschka
14P01633435A0743|119 125|Gossett
14P01633816A0667|22 35|EcoRI fragment
14P01633816A0667|157 181|primer extension analysis
14P01633816A0667|183 201|S1 nuclease mapping
14P01634308A0191|0 26|Cardiovascular risk factors
14P01634400A1101|0 15|Production costs
14P01634400A1101|55 77|replacement stock costs
14P01634464A0163|26 45|factor VII inhibitor
14P01634464A0163|65 89|penicillin administration
14P01634861A1336|33 54|oxygen debt hypothesis
14P01634861A1336|86 102|lactate clearance
14P01636339A0200|0 6|Account
14P01636339A0200|100 112|pollen grains
14P01636339A0200|120 128|fragments
14P01636714A0845|48 50|MBF
14P01636714A0845|110 112|MBF
14P01636714A0845|143 145|CLP
14P01637758A0532|2 9|addition
14P01637758A0532|18 27|proportion
14P01637758A0532|65 74|dilatation
14P01637758A0532|103 113|examination
14P01637758A0532|119 129|labour ward
14P01637758A0532|152 153|OR
14P01639092A0776|0 4|Lewis
14P01639092A0776|6 7|N.
14P01639724A0452|1 13|control group
14P01639724A0452|45 58|contraceptives
14P01639724A0452|60 70|Nordette-28
14P01639724A0452|102 111|pill cycle
14P01640778A0485|34 42|MLPA test
14P01641628A0869|3 12|modalities
14P01641628A0869|21 36|reference values
14P01641628A0869|156 171|reference values
14P01642060A0471|44 57|Phthalocyanine
14P01642060A0471|121 128|FIGO III
14P01643943A0300|11 29|lung cancer tissues
14P01643943A0300|38 41|67Ga
14P01643943A0300|55 57|TFR
14P01644751A0590|67 83|sequence analysis
14P01644751A0590|100 116|msgB gene product
14P01644796A0374|6 10|study
14P01644796A0374|52 56|furin
14P01644796A0374|75 80|medium
14P01644796A0374|88 92|cells
14P01644814A0068|55 69|immortalization
14P01644814A0068|72 78|T cells
14P01644821A1259|58 69|CAT activity
14P01644821A1259|195 205|PSG1-I gene
14P01644821A1259|219 235|butyrate response
14P01644831A0824|2 12|examination
14P01644831A0824|27 43|carboxyl terminus
14P01644831A0824|55 60|NGFI-B
14P01644831A0824|162 178|carboxyl terminus
14P01645902A1462|37 39|Syn
14P01645902A1462|114 115|TK
14P01645902A1462|119 120|UL
14P01645902A1462|139 150|syn mutation
14P01645902A1462|188 189|TK
14P01645905A0341|0 12|Nucleoprotein
14P01645905A0341|42 55|vaccinia virus
14P01645905A0341|58 61|TGEV
14P01645905A0341|88 89|Mr
14P01645905A0341|134 143|C-terminus
14P01645905A0341|160 177|breakdown products
14P01646157A0414|29 54|alpha-GalNAc cDNA sequence
14P01646157A0414|110 128|amino acid homology
14P01646157A0414|166 186|alpha-galactosidase A
14P01646487A0874|0 7|Patients
14P01646487A0874|73 75|IgA
14P01646487A0874|77 79|IgG
14P01646487A0874|81 83|IgM
14P01646487A0874|89 101|B lymphocytes
14P01646487A0874|127 137|neutrophils
14P01646753A0336|39 55|hydroxyl radicals
14P01646753A0336|88 105|reduction proceeds
14P01646753A0336|114 116|N2O
14P01646753A0336|167 168|EO
14P01646753A0336|170 176|N2O/N2O
14P01646753A0336|184 185|V.
14P01647070A0232|9 22|JCV T antigens
14P01647070A0232|28 30|JCV
14P01647070A0232|34 45|SV40 origins
14P01647070A0232|47 61|DNA replication
14P01647656A0000|70 71|LV
14P01647656A0000|135 152|LV volume overload
14P01647656A0000|175 187|regurgitation
14P01647813A0512|9 18|transcript
14P01647813A0512|41 47|protein
14P01647813A0512|53 62|complexity
14P01647813A0512|126 132|control
14P01647813A0512|135 144|expression
14P01648142A1170|101 107|CAV arm
14P01648142A1170|133 138|PE arm
14P01648530A0000|14 21|M region
14P01648530A0000|42 48|Xenopus
14P01648530A0000|56 74|actin gene promoter
14P01648530A0000|133 163|actin-beta-globin reporter gene
14P01649173A0160|72 82|nucleotides
14P01649173A0160|109 132|transcription start site
14P01649173A0160|172 182|nucleotides
14P01649318A0734|74 130|herpes simplex virus TK promoter transcription start site
14P01649318A1222|50 66|cell DNA fragment
14P01649318A1222|91 96|EBNA-2
14P01649318A1222|111 123|transcription
14P01649539T0000|0 15|Plasma vitamin E
14P01649539T0000|29 50|myeloperoxidase levels
14P01649835A0822|27 38|PBR/IBP cDNA
14P01649835A0822|42 52|COS-7 cells
14P01649835A0822|106 107|3H
14P01649835A0822|109 110|PK
14P01649835A0822|154 161|Ro5-4864
14P01650524A0837|70 84|LTB4 production
14P01650524A0837|116 140|5-LO inhibitors phenidone
14P01650524A0837|140 145|BW A4C
14P01650524A0837|146 151|A63162
14P01650524A0837|156 158|ICI
14P01650557T0000|22 45|latex agglutination test
14P01650557T0000|61 91|cytomegalovirus antibody status
14P01650557T0000|99 115|transplant donors
14P01651232A0152|34 49|uridine residues
14P01651232A0152|85 87|UTP
14P01651918A0000|80 98|amino acid sequence
14P01651918A0000|99 129|rat testis fructose-6-phosphate
14P01652372A0153|16 19|SWI5
14P01652372A0153|29 47|localization signal
14P01652372A0153|48 50|NLS
14P01652515A0379|35 56|avoidance conditioning
14P01652515A0379|89 103|microinjections
14P01652515A0379|119 120|DA
14P01652755A1492|18 41|transfection experiments
14P01652755A1492|43 52|HeLa cells
14P01652755A1492|79 120|retinoblastoma susceptibility gene product
14P01652755A1492|119 120|RB
14P01652755A1492|155 158|IL-6
14P01652755A1492|243 246|IL-6
14P01652755A1492|276 278|MHC
14P01653173A0619|44 45|E2
14P01653173A0619|85 106|P105 promoter TATA box
14P01653173A0619|143 171|HPV-18 P105 promoter template
14P01653173A0619|215 235|preinitiation complex
14P01653236A0895|14 16|p50
14P01653236A0895|40 62|glucocorticoid receptor
14P01653236A0895|64 70|L cells
14P01653236A0895|92 114|glucocorticoid receptor
14P01653236A0895|123 141|hamster ovary cells
14P01653238A1062|11 47|12-O-tetradecanoyl-phorbol-13-acetate
14P01653238A1062|49 51|TPA
14P01653238A1062|104 128|transcription factor AP-1
14P01653238A1062|131 148|consensus sequence
14P01653238A1062|163 180|growth factor beta
14P01653238A1062|181 188|TGF-beta
14P01653238A1715|0 2|TPA
14P01653238A1715|6 13|TGF-beta
14P01653918A0286|105 126|corneal pain threshold
14P01654349A0327|0 10|Feed intake
14P01654349A0327|33 35|KCl
14P01654349A0327|38 59|NaHCO3 supplementation
14P01654349A0327|131 136|NaHCO3
14P01655126T0000|0 19|Extraction procedure
14P01655126T0000|38 55|butyltin compounds
14P01655126T0000|87 89|HBr
14P01655713A0294|69 77|phenotype
14P01655713A0294|95 97|Tn1
14P01655713A0294|111 113|Tn1
14P01656220T0000|52 65|leukemia cells
14P01656220T0000|79 102|receptor tyrosine kinase
14P01656221A1319|0 8|Alignment
14P01656221A1319|14 33|amino acid sequences
14P01656221A1319|43 49|Tyr-766
14P01656221A1319|81 85|FGFRs
14P01656221A1319|103 119|tyrosine residues
14P01656221A1319|141 151|FGFR family
14P01656235A0946|83 93|CCAAT motif
14P01656675A0236|0 17|Capnography curves
14P01656675A0236|21 32|HVS patients
14P01657246A0325|3 31|transcription initiation site
14P01657246A0325|77 79|Met
14P01657249A1019|18 19|CA
14P01657249A1019|38 40|VH4
14P01657249A1019|62 63|CA
14P01657249A1019|93 95|VH4
14P01657249A1019|115 132|region determinant
14P01657249A1019|139 146|VH4-HV2a
14P01657415A0837|0 15|Intron K1 cox1.2
14P01657415A0837|68 76|K. lactis
14P01657594A0472|39 60|complementation groups
14P01657969A1420|77 100|amino acid substitutions
14P01657969A1420|157 174|calmodulin binding
14P01658356A1369|67 83|FeLV recombinants
14P01658356A1369|87 92|FeLV-C
14P01658356A1369|117 131|3201B cell line
14P01658356T0000|0 12|Recombination
14P01658356T0000|26 50|leukemia virus subgroup B
14P01658375A0854|3 22|nucleotide sequences
14P01658375A0854|172 181|LAT intron
14P01658375A0854|183 184|GC
14P01658375A0854|197 217|consensus sequence GT
14P01658468A0123|28 36|isolation
14P01658468A0123|39 50|C. kutscheri
14P01658741A1047|47 65|nucleotide sequence
14P01658741A1047|93 95|ADE
14P01659685T0000|60 76|Dd ras expression
14P01659685T0000|77 89|Dictyostelium
14P01660486A1756|49 63|gene cotransfer
14P01660486A1756|68 92|aminoglycoside resistance
14P01660486A1756|147 164|control mechanisms
14P01660486A1756|173 183|PKC pathway
14P01660486A1756|204 218|gene expression
14P01660925T0000|0 17|Transfer RNA genes
14P01660925T0000|20 43|Dictyostelium discoideum
14P01661369A0825|20 29|strE genes
14P01661369A0825|71 78|presence
14P01661369A0825|93 100|capacity
14P01661369A0825|117 124|moieties
14P01662609A0398|18 29|polypeptides
14P01662609A0398|35 45|amino acids
14P01662609A0398|46 52|M.HgiCI
14P01662609A0398|60 70|amino acids
14P01662609A0398|71 77|R.HgiCI
14P01662794A0640|0 9|Expression
14P01662794A0640|48 58|COS-1 cells
14P01662807A1182|24 34|TR promoter
14P01662807A1182|51 66|SV40 chromosomes
14P01662884A1029|0 11|Temafloxacin
14P01662884A1029|105 115|prostatitis
14P01664192A1577|42 50|ED90 dose
14P01669611A0142|47 54|aneurysm
14P01669611A0142|71 85|pleuropneumonia
14P01669611A0142|99 106|diseases
14P01671675A0483|101 121|hybridization methods
14P01671675A0483|124 140|sequence analysis
14P01671675A0483|166 178|cDNA sequence
14P01671675A0483|197 211|CAD polypeptide
14P01671675A0905|28 53|Northern blotting analysis
14P01671675A0905|76 83|CAD gene
14P01673220A0578|32 42|cDNA clones
14P01673220A0578|64 65|Sn
14P01673220A0578|67 77|bol3 allele
14P01674177T0001|0 19|Histamine-2 blockade
14P01674242A0358|79 90|erythromycin
14P01674242A0358|92 105|troleandomycin
14P01674242A0358|107 127|triacetyloleandomycin
14P01674242A0358|130 142|roxithromycin
14P01674242A0358|153 165|ciprofloxacin
14P01674242A0358|178 188|norfloxacin
14P01674242A0358|215 220|T-3262
14P01674242A0358|258 268|propranolol
14P01674242A0358|361 371|allopurinol
14P01674242A0358|373 383|ticlopidine
14P01674242A0358|385 396|idrocilamide
14P01674242A0358|398 410|thiabendazole
14P01674242A0358|436 450|BCG-vaccination
14P01674242A0358|475 492|half-life increase
14P01674369A0417|53 68|restriction site
14P01674662A0000|33 46|heroin addicts
14P01674662A0000|104 118|lymphadenopathy
14P01674662A0000|176 179|AIDS
14P01674662A0000|195 197|ARC
14P01674662A0000|201 204|AIDS
14P01674817A0862|25 29|RNA14
14P01674817A0862|33 37|RNA15
14P01674817A0862|47 51|RNA14
14P01674817T0000|0 8|Mutations
14P01674817T0000|27 37|RNA15 genes
14P01674817T0000|69 85|sequence analysis
14P01674817T0000|116 128|RNA15 protein
14P01675154T0000|10 19|infarction
14P01675154T0000|42 55|bypass surgery
14P01675424A0991|35 37|NAD
14P01675424A0991|41 53|H-NR sequence
14P01675424A0991|67 83|NADH-NR sequences
14P01675424A0991|104 122|pyridine nucleotide
14P01675637T0033|7 27|amino acid difference
14P01675637T0033|84 107|receptor dimer formation
14P01675763A1389|37 39|CD4
14P01678287A1308|15 40|Antp TATAA binding protein
14P01678392A0648|5 23|% confidence values
14P01678392A0648|23 25|2SD
14P01678392A0648|41 43|Ros
14P01679068A0000|27 36|care units
14P01679068A0000|154 163|Klebsiella
14P01679068A0000|166 181|Enterobacter spp
14P01679124A1368|43 55|ChAT activity
14P01679124A1368|128 141|norepinephrine
14P01679124A1368|143 144|NE
14P01679124A1368|151 168|dorsal hippocampus
14P01679124A1368|170 183|MS/HSI animals
14P01679124A1368|185 192|ABSTRACT
14P01679124A1368|207 211|WORDS
14P01679749A1171|21 38|proteoglycan locus
14P01679749A1171|77 81|RFLPs
14P01679749A1171|136 158|HSPG2 proteoglycan gene
14P01681075A0429|11 30|dobutamine injection
14P01681075A0429|45 64|pimobendan injection
14P01681075A0429|99 111|determination
14P01681075A0429|117 129|tissue levels
14P01681075A0429|153 175|carbohydrate metabolism
14P01682484A0680|142 149|LCX flow
14P01682484A0680|156 167|hemodynamics
14P01682484A0680|178 195|lactate metabolism
14P01682509A0539|45 48|IE72
14P01682509A0539|53 56|IE55
14P01682509A0539|88 94|HIV LTR
14P01682509A0539|97 107|T-cell line
14P01682509A0539|108 113|HUT-78
14P01682542A0690|22 35|HIV prevalence
14P01684791A0000|29 55|glucocorticoid inducibility
14P01684791A0000|60 92|chicken glutamine synthetase gene
14P01686909A0299|11 18|increase
14P01686909A0299|28 36|excretion
14P01686909A0299|66 76|elimination
14P01686909A0299|79 87|bretylium
14P01687050T0000|30 51|fluid immunoglobulin G
14P01687050T0000|51 53|IgG
14P01688841A0430|0 9|Expression
14P01688841A0430|89 102|regulator virF
14P01688972A0803|9 10|VT
14P01690703A0285|0 9|Venkatesan
14P01690703A0285|14 15|D.
14P01690728A1166|103 129|Northern blot hybridization
14P01690728A1166|129 156|S1 nuclease protection assay
14P01690728A1166|161 185|polymerase chain reaction
14P01690812A0000|30 32|DNA
14P01690812A0000|98 102|S RNA
14P01690812A0000|111 125|gene insertions
14P01691184A0995|0 5|Gap b3
14P01691184A0995|18 35|polypeptide chains
14P01691184A0995|36 37|Mr
14P01691184A0995|81 97|cleavage products
14P01691184A0995|108 122|disulfide bonds
14P01691184A0995|127 143|precursor protein
14P01692135A0783|11 39|rtFc gamma R alpha cDNA clone
14P01692135A0783|93 105|CRNK-16 cells
14P01692135A0783|126 133|Fc gamma
14P01692837A0390|31 37|introns
14P01692837A0390|81 94|kilobase pairs
14P01692837A0390|131 139|kilobases
14P01692962A0980|40 52|s polypeptide
14P01692962A0980|61 73|hamster ovary
14P01692962A0980|74 76|CHO
14P01692962A0980|110 123|cAMP synthesis
14P01692962A0980|140 162|protein kinase activity
14P01694009A0112|78 92|signal sequence
14P01694009A0112|97 107|polypeptide
14P01694014A0716|0 8|Treatment
14P01694014A0716|48 78|phorbol 12-myristate 13-acetate
14P01694014A0716|78 80|PMA
14P01694014A0716|118 133|RNA hybridizable
14P01694014A0716|135 143|LD78 cDNA
14P01694280A0000|23 37|ventriculoscope
14P01694280A0000|41 51|observation
14P01694280A0000|57 66|ventricles
14P01694525A0000|0 24|Isopenicillin N isomerase
14P01694525A0000|84 102|amino acid sequence
14P01694525A0000|106 115|N-terminus
14P01695098A1116|0 8|Serum IgG
14P01695116A0078|45 47|CR1
14P01695116A0078|65 76|chemotherapy
14P01695314A0762|14 15|NS
14P01695314A0762|18 31|glucose levels
14P01695314T0000|0 19|Platelet aggregation
14P01695314T0000|54 81|calcium antagonist treatment
14P01695314T0000|88 104|diabetes mellitus
14P01695322A0000|0 4|Wnt-1
14P01695322A0000|66 68|DNA
14P01695322A0000|86 96|tumor virus
14P01695378A1406|0 8|Induction
14P01695378A1406|11 16|Jurkat
14P01695378A1406|25 31|T cells
14P01695378A1406|35 65|phorbol 12-myristate 13-acetate
14P01695378A1406|98 106|FKBP mRNA
14P01695905A0480|0 9|GLUT5 mRNA
14P01695905A0480|98 111|adipose tissue
14P01697611A0738|20 25|tumors
14P01697611A0738|61 67|growths
14P01697683T0000|0 13|Identification
14P01697683T0000|17 32|characterization
14P01697683T0000|52 66|cytotactin gene
14P01697928A1214|22 38|sequence homology
14P01697928A1214|57 61|Ly-6E
14P01697928A1214|115 130|response element
14P01698761A1059|15 32|DNA rearrangements
14P01698761A1059|124 127|AlgP
14P01698772A0238|6 7|J.
14P01699944A1538|59 83|CArG box binding proteins
14P01699944A1538|117 132|promoter element
14P01699944A1538|137 140|VLC1
14P01700272A0838|0 14|Polyadenylation
14P01700272A0838|17 22|B4 RNA
14P01701088A1335|0 11|Co-existence
14P01701088A1335|64 75|AP-2 element
14P01701088A1335|77 85|CCAAT box
14P01702361A0621|35 52|collagen synthesis
14P01702361A0621|86 108|angiogenesis inhibitors
14P01702426A0196|61 70|regulation
14P01702426A0196|76 85|expression
14P01702426A0196|138 155|acid synthase gene
14P01702426A1006|61 95|lambda-ZAP goose liver cDNA library
14P01702426A1006|149 157|DNA clone
14P01702432A1296|0 25|Northern blotting analysis
14P01702972A0613|7 24|cDNA hybridization
14P01702972A0613|33 41|DNA blots
14P01702972A0613|67 77|G0S19 genes
14P01702972A0613|131 140|G0S30 cDNA
14P01703335T0000|40 56|immunosuppression
14P01703335T0000|61 62|FK
14P01703335T0000|94 114|transplant population
14P01703632T0000|13 22|suppressor
14P01703632T0000|42 52|polypeptide
14P01703632T0000|57 63|regions
14P01703632T0000|91 98|proteins
14P01707659A0458|60 66|HLA-5.4
14P01707659A0458|76 90|chimpanzee gene
14P01707659A0458|91 94|Ch28
14P01707800A0354|11 36|N13-N20 interpeak interval
14P01707800A0354|96 110|conduction time
14P01707800A0354|122 136|onset latencies
14P01707800A0354|138 140|N11
14P01707800A0354|144 146|N20
14P01708098A0922|18 43|complex DNA binding assays
14P01708098A0922|62 89|alpha promoter DNA sequences
14P01708098A0922|141 142|GR
14P01708771A1215|0 21|Sequence determination
14P01708771A1215|52 57|Asn120
14P01708771A1215|73 77|Asn65
14P01708771A1215|81 86|Asn109
14P01708771A1215|132 136|Asn72
14P01708774A0203|3 14|DNA sequence
14P01708774A0203|24 36|AP-1 activity
14P01709486A0000|9 16|mutation
14P01709486A0000|48 61|proto-oncogene
14P01709933T0000|0 8|Isolation
14P01709933T0000|12 27|characterization
14P01709933T0000|55 65|polypeptide
14P01710766A0349|72 93|amino acids C terminal
14P01710766A0349|109 124|initiation codon
14P01710768A1172|108 117|expression
14P01710768A1172|123 133|HLA-B7 gene
14P01710768A1172|167 182|gamma interferon
14P01710979T0000|3 5|SH2
14P01710979T0000|9 19|SH3 domains
14P01710979T0000|92 95|p110
14P01710985A0315|0 3|Chem
14P01711041A0348|69 82|C5 alpha-chain
14P01711041A0348|93 102|beta-chain
14P01711041A0962|3 16|C5 alpha-chain
14P01711041A0962|60 69|beta-chain
14P01711048T0000|69 74|COL1A2
14P01711048T0000|94 105|RNA splicing
14P01711048T0000|114 136|osteogenesis imperfecta
14P01712296A0157|3 22|nucleotide sequences
14P01712296A0157|76 97|amino acid differences
14P01713213A0000|42 68|pim-1 proto-oncogene shares
14P01713213A0000|93 124|serine/threonine protein kinases
14P01713213A0000|138 149|Pim-1 enzyme
14P01713213A0000|183 214|protein tyrosine kinase activity
14P01713213A0488|73 85|Pim-1 protein
14P01713213A0488|123 147|glutathione S-transferase
14P01713213A0488|148 150|GST
14P01714322A0969|4 9|report
14P01714322A0969|44 51|kDa hsps
14P01714322A0969|61 68|products
14P01714358A0990|55 79|wheat etioplast membranes
14P01714358A0990|92 94|ATP
14P01714452A0559|0 7|Homology
14P01714452A0559|47 59|repeat domain
14P01714452A0559|73 84|conservation
14P01714452A0559|131 153|carbohydrate attachment
14P01714902A0221|39 89|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
14P01714902A0221|100 107|CD3 zeta
14P01714902A0221|130 153|interleukin-2 production
14P01714902A0221|158 172|TCR stimulation
14P01714902A0221|189 214|histocompatibility complex
14P01715593A0838|4 14|desipramine
14P01715593A0838|36 55|fluoxetine injection
14P01715593A0838|56 67|brain levels
14P01715593A0838|69 79|desipramine
14P01715975A0885|17 20|CYP1
14P01716292A0000|35 41|HLA-DR1
14P01716292A0000|53 74|T cell allorecognition
14P01716292A0000|155 159|DRB/H
14P01716292A0000|162 169|Eb genes
14P01716292A0000|186 193|DR alpha
14P01716292A0000|195 204|H-2E alpha
14P01716629A0000|52 78|matrix glycoprotein undulin
14P01717718A1255|31 47|Gag-Pol PR domain
14P01717718A1255|67 68|RT
14P01717718A1255|88 89|PR
14P01717718A1255|132 140|PR domain
14P01717718A1255|142 148|Gag-Pol
14P01717718A1255|178 179|RT
14P01717833A1223|3 24|alpha inhibin promoter
14P01717833A1223|41 43|CRE
14P01717833A1223|102 113|CREB protein
14P01717833T0000|0 9|Regulation
14P01717833T0000|15 32|alpha inhibin gene
14P01717833T0000|54 66|monophosphate
14P01717833T0000|88 106|rat granulosa cells
14P01717925A0477|0 9|Comparison
14P01717925A0477|15 34|nucleotide sequences
14P01717925A0477|58 60|DNA
14P01717925A0477|74 92|sequence similarity
14P01717994T0000|0 6|Cloning
14P01717994T0000|48 62|complementation
14P01718043A0384|14 26|osteomyelitis
14P01718043A0384|48 59|PMN elastase
14P01718043A0384|121 150|erythrocyte sedimentation rate
14P01718983A1640|0 1|E.
14P01718983A1640|3 9|Hession
14P01718983A1640|11 12|C.
14P01718983A1640|14 17|Goff
14P01718983A1640|19 20|D.
14P01718983A1640|22 30|Griffiths
14P01718983A1640|32 33|B.
14P01718983A1640|35 40|Tizard
14P01718983A1640|42 43|R.
14P01718983A1640|45 50|Newman
14P01718983A1640|52 53|B.
14P01718983A1640|55 63|Chi-Rosso
14P01718983A1640|65 66|G.
14P01718983A1640|71 74|Lobb
14P01718983A1640|76 77|R.
14P01718983A1640|85 88|Cell
14P01719684A0494|148 165|sphincter function
14P01720555A1087|25 37|B2 transcript
14P01720843A1506|27 42|sulfhydryl group
14P01720843A1506|72 88|enzyme inhibitors
14P01720843A1506|127 147|nitrovasodilator EDRF
14P01721261T0000|0 15|Pharmacokinetics
14P01721261T0000|18 19|FK
14P01721261T0000|25 43|transplant patients
14P01721884A0962|72 85|ribonuclease H
14P01721884A0962|86 92|RNase H
14P01721884A0962|160 172|investigators
14P01721884A0962|186 192|RNase H
14P01721884A0962|207 209|Pol
14P01721884A0962|255 279|RNase H crystal structure
14P01722319A0849|0 7|Analysis
14P01722319A0849|20 38|amino acid sequence
14P01722319A0849|49 62|CHIP28 protein
14P01722319A0849|118 138|N-glycosylation sites
14P01722319A0849|159 167|C termini
14P01722479A0302|14 27|concentrations
14P01722479A0302|30 32|HCG
14P01722479A0302|37 47|sensitivity
14P01722479A0302|59 69|specificity
14P01723619A0766|16 27|F absorption
14P01723619A0766|42 63|plasma F concentration
14P01723619A0766|162 173|F absorption
14P01723962A0165|3 10|activity
14P01723962A0165|13 24|serum lipase
14P01723962A0165|88 96|injection
14P01723962A0165|99 103|Na-Tc
14P01724982A0237|43 53|HCV EIA kit
14P01724982A0237|53 63|Abbott Lab.
14P01724982A0237|64 76|North Chicago
14P01724982A0237|77 78|IL
14P01725547A0354|0 8|Diltiazem
14P01725547A0354|86 95|blood flow
14P01725547A0354|96 98|CBF
14P01725622A0292|30 47|platelet increment
14P01725622A0292|51 55|Gpt/l
14P01725622A0292|57 59|CCI
14P01726211A0502|5 16|risk factors
14P01726211A0502|63 69|factors
14P01726211A0502|100 106|factors
14P01726631T0001|0 11|Epidemiology
14P01726631T0001|27 45|hospital infections
14P01726631T0001|50 66|Local Health Unit
14P01726631T0001|67 73|Sassari
14P01727488A1146|36 46|stimulation
14P01727488A1146|82 96|gene expression
14P01727494A0000|0 13|Vaccinia virus
14P01727494A0000|14 15|VV
14P01727494A0000|50 60|VV proteins
14P01730412T0000|0 2|Max
14P01730412T0000|24 34|interaction
14P01730747A0205|15 16|G1
14P01730747A0205|19 25|S phase
14P01730747A0205|26 31|Reilly
14P01730747A0205|33 34|C.
14P01731107A0928|0 12|Substitutions
14P01731107A0928|44 53|ICR2 motif
14P01731107A0928|68 83|pRNA replication
15P01731933T0000a|0 1|Zn
15P01731933T0000a|6 32|coordination domain mutants
15P01731933T0000a|33 39|T4 gene
15P01731933T0000b|0 1|Zn
15P01731933T0000b|6 32|coordination domain mutants
15P01731933T0000b|33 39|T4 gene
14P01731979A1408|79 112|CaMV 35S domain B enhancer element
14P01732033A0000|3 17|pathophysiology
14P01732033A0000|29 38|management
14P01732033A0000|46 57|brain injury
14P01732033A0000|69 77|childhood
14P01732033A0000|109 120|brain injury
14P01732736A1076|0 10|Transcripts
14P01732736A1076|22 36|POU-domain gene
14P01732736A1076|37 42|Oct-25
14P01732752A0156|11 17|B cells
14P01732752A0156|20 26|Abelson
14P01732752A0156|58 73|pre-B-cell lines
14P01732752A0156|74 80|LT mRNA
14P01733105A0127|11 23|Thogoto virus
14P01733358A0240|63 80|cystadenocarcinoma
14P01733358A0240|85 87|III
14P01733358A0240|89 102|adenocarcinoma
14P01733358A0240|107 122|mucin production
14P01734020A1318|0 13|Immunostaining
14P01734020A1318|147 155|PKC alpha
14P01734283A0817|27 39|RAP74 protein
14P01734283A0817|51 60|HeLa cells
14P01734283A0817|83 85|DNA
14P01734283A0817|101 119|translation product
14P01734283A0817|134 138|RAP30
14P01734570T0000|0 6|Effects
14P01734570T0000|9 41|thromboxane synthetase inhibition
14P01735347A0482|51 59|treatment
14P01735347A0482|84 96|plasma lipase
14P01735347A0482|102 112|development
14P01735347A0482|127 135|extension
14P01735347A0482|151 158|necrosis
14P01735447A0271|74 90|pre-super-pro-PrB
14P01735447A0271|105 117|sec61 mutants
14P01735447A0271|122 134|translocation
14P01735447A0833|8 27|active-site mutation
14P01735447A0833|93 95|PrB
14P01735721A0185|12 30|amino acid sequence
14P01735721A0185|57 89|Bacillus stearothermophilus TyrTS
14P01735721A0185|116 120|TyrTS
14P01735721A0185|151 172|B. subtilis TyrTS gene
14P01736093A0731|14 25|CAT activity
14P01736093A0731|97 107|CCAAT boxes
14P01736093A0731|117 119|HSE
14P01736651A0104|9 13|Women
14P01736651A0104|15 21|Infants
14P01736651A0104|26 41|Children clinics
14P01736651A0104|43 53|Minneapolis
14P01736651A0104|55 59|Minn.
14P01736844T0000|0 11|Testosterone
14P01736844T0000|17 28|testosterone
14P01736844T0000|66 77|testosterone
14P01736844T0000|86 99|androgen index
14P01736844T0000|105 128|testosterone measurement
14P01737741A0000|0 9|BACKGROUND
14P01737741A0000|29 56|monoamine oxidase inhibitors
14P01737741A0000|56 60|MAOIs
14P01737789A0800|64 83|acceptor splice site
14P01737789A0800|93 126|down-stream alpha-delta breakpoint
14P01738470A0441|0 7|Patients
14P01738470A0441|20 24|PDDAT
14P01738470A0441|86 103|recognition memory
14P01738653T0014|0 3|Bone
14P01738936A0292|14 29|plasma C-peptide
14P01739439A0257|0 6|Complex
14P01739439A0257|17 26|discharges
14P01739439A0257|79 88|discharges
14P01739439A0257|96 108|abnormalities
14P01739439A0257|138 149|control mice
14P01739956A0638|0 9|Management
14P01739956A0638|31 45|calcium channel
14P01740121A0136|54 94|baculovirus/insect cell expression system
14P01740330A0329|0 1|J.
14P01740437A0851|14 25|core protein
14P01740437A0851|30 51|liver HSPG preparation
14P01740437A0851|130 140|fibroglycan
14P01740448A1735|14 34|transmembrane regions
14P01740448A1735|72 91|amino acid stretches
14P01740682A0703|0 7|Toxicity
14P01740682A0703|75 84|leukopenia
14P01740682A0703|87 111|World Health Organization
14P01740682A0703|162 177|thrombocytopenia
14P01741249A0177|0 3|W.G.
14P01742341A0499|66 79|transportation
14P01742341A0499|100 110|Beagle dogs
14P01742606A0000|1 25|mouse brain beta-spectrin
14P01742606A0000|50 79|lambda Gt11 expression library
14P01742606A0000|124 148|kDa spectrin beta-subunit
14P01742879A0471|0 6|RESULTS
14P01742879A0471|8 27|Plasma AVP responses
14P01742879A0471|116 129|water drinking
14P01744039A0511|39 63|polymerase chain reaction
14P01744039A0511|75 93|gel electrophoresis
14P01744039A0511|114 138|conformation polymorphism
14P01744042A1355|3 13|csbA fusion
14P01744042A1355|74 84|Luria broth
14P01744042A1355|109 119|% glutamine
14P01744119A0757|16 44|primase recognition sequences
14P01744119A0757|44 76|nucleotide substrate requirements
14P01744119A0757|111 139|oligoribonucleotide synthesis
14P01747972T0000|40 56|artery dissection
14P01748067A0000|45 52|patients
14P01748067A0000|131 141|replacement
14P01748067A0000|177 185|arthritis
14P01748067A0000|188 195|fracture
14P01748194A0767|34 45|hemisections
14P01748194A0767|124 139|cord transection
14P01748287T0000|16 23|proteins
14P01748287T0000|36 45|properties
14P01748292A0000|37 59|G protein alpha subunit
14P01748292A0000|68 90|Lycopersicon esculentum
14P01748630A0125|0 24|Growth factor stimulation
14P01748630A0125|39 53|phosphorylation
14P01748630A0125|79 95|activation domain
14P01748630A0125|97 101|Ser62
14P01748630A0125|165 174|Myc family
14P01748630A0125|175 181|Alvarez
14P01748630A0125|183 184|E.
14P01748630A0125|186 194|Northwood
14P01748630A0125|196 199|I.C.
14P01748630A0125|201 208|Gonzalez
14P01748630A0125|210 211|F.
14P01751163A0000|44 56|complications
14P01751163A0000|68 79|implantation
14P01751163A0000|107 118|Sarns/3M-VAD
14P01751255A0529|14 15|CO
14P01751255A0529|61 70|MBBF group
14P01751970A0209|0 18|Amino acid residues
14P01752441A0000|30 46|HIV-1 Tat protein
14P01752441A0000|74 92|hexanucleotide loop
14P01752441A0000|95 113|trinucleotide bulge
14P01752441A0000|118 144|TAR RNA stem-loop structure
14P01752792A0000|53 68|time differences
14P01752792A0000|69 72|ITDs
14P01752792A0000|138 148|albino rats
14P01753317A0879|46 48|TTC
14P01753317A0879|66 69|FDBA
14P01753317A0879|81 94|bone formation
14P01754381A0000|25 40|characterization
14P01754381A0000|54 68|DNA polymerases
14P01754381A0000|134 144|Trypanosoma
14P01754381A0000|146 156|Trypanozoon
14P01754381A0000|188 207|DNA polymerase alpha
14P01756195A1117|2 9|addition
14P01756195A1117|31 38|increase
14P01756195A1117|66 79|concentrations
14P01756539A0354|9 20|hypertension
14P01756539A0354|51 59|narrowing
14P01756539A0354|71 79|condition
14P01756539A0354|103 112|infarction
14P01757341A0591|3 17|volume fraction
14P01757341A0591|18 19|Vv
14P01757341A0591|35 36|Na
14P01757341A0591|127 146|alkaline phosphatase
14P01758750A0000|0 14|Airway pressure
14P01758750A0000|81 91|ventilators
14P01759052A0786|0 3|Appl
14P01759282A0000|0 5|Issues
14P01759282A0000|8 19|distribution
14P01759282A0000|63 81|contact interaction
14P01759282A0000|127 138|biomechanics
14P01760166A0963|0 9|CONCLUSION
14P01760166A0963|21 24|SpO2
14P01761736A0158|0 8|Diltiazem
14P01761736A0158|26 39|body clearance
14P01761736A0158|101 121|elimination half-life
14P01761736A0158|168 177|antipyrine
14P01761736A0158|205 216|distribution
14P01762053A0557|3 10|granules
14P01762053A0557|26 33|material
14P01762053A0557|73 81|particles
14P01762914A1218|9 20|uPA promoter
14P01762914A1218|85 106|translation start site
14P01762917A0615|13 15|Ser
14P01762917A0615|19 23|Gly69
14P01762917A0615|27 29|Glu
14P01762917A0615|33 35|Lys
14P01762917A0615|52 68|TGEK tetrapeptide
14P01762917A0615|80 85|TFIIIA
14P01762917A0615|105 115|DNA binding
14P01763065A0913|0 1|P.
14P01763106A0070|17 24|behavior
14P01763106A0070|49 58|locomotion
14P01763106A0070|84 95|test session
14P01764899A0399|40 57|water fluoridation
14P01764899A0399|59 75|caries prevalence
14P01764899A0399|114 125|cavity level
14P01765095A0680|0 35|12-O-Tetradecanoylphorbol 13-acetate
14P01765266A0000|2 15|Xenopus laevis
14P01765266A0000|34 58|elongation factor 1-alpha
14P01765266A0000|64 75|EF-1 alpha O
14P01765269A0308|37 52|pre-mRNA introns
14P01765269A0308|78 96|consensus sequences
14P01765375A0290|31 39|rat cells
14P01765375A0290|51 64|clathrin clone
14P01765375A0290|72 82|transcripts
14P01765375A0290|163 170|clathrin
14P01765386A0305|24 35|DNA sequence
14P01765386A0305|101 109|junctions
14P01765407A0866|52 71|plasma concentration
14P01765407A0866|77 88|postexposure
14P01765407A0866|122 140|mmol/mol creatinine
14P01766666A0788|0 9|Antibodies
14P01766666A0788|41 63|nucleoprotein complexes
14P01766666A0788|102 112|interaction
14P01766876A0000|56 65|chain gene
14P01766876A0000|78 90|co-conversion
14P01766876A0000|94 104|co-exchange
14P01766876A0000|109 122|point mutation
14P01766876A0000|155 172|replacement vector
14P01766999A0000|20 52|allergen extract Ambrosia elatior
14P01766999A0000|51 52|AE
14P01767060A0000|35 54|c-DDP administration
14P01767060A0000|71 82|radiotherapy
14P01767060A0000|96 104|frequency
14P01767060A0000|108 115|duration
14P01767060A0000|127 135|responses
14P01767060A0000|145 152|survival
14P01767060A0000|156 163|patients
14P01767060A0000|207 216|carcinomas
14P01767592A0682|34 53|DNA binding proteins
14P01767592A0682|86 125|HAP2/HAP3 consensus recognition sequence
14P01767592A0682|143 177|BAF1 consensus recognition sequence
14P01767899A0136|6 21|thrombocytopenia
14P01767899A0136|34 49|serum fibrinogen
14P01767899A0136|91 109|thromboplastin time
14P01767899A0136|161 172|envenomation
14P01768648A0853|24 43|LexA fusion proteins
14P01768648A0853|52 63|dimerization
14P01769189A0000|0 11|Plasma lipid
14P01769189A0000|14 33|lipoprotein profiles
14P01769189A0000|68 69|RU
14P01769189A0000|107 123|training distance
14P01769189A0000|139 144|VO2max
14P01769189A0000|151 163|ml kg-1 min-1
14P01769189A0000|170 171|SD
14P01769189A0000|202 203|UT
14P01769189A0000|237 242|VO2max
14P01769189A0000|249 261|ml kg-1 min-1
14P01769919A0393|8 23|threshold shifts
14P01769919A0393|53 70|brainstem response
14P01770651T0001|34 53|equilibrium dialysis
14P01770651T0001|55 77|radioimmunoassay system
14P01771593A1152|14 15|TA
14P01771593A1152|41 43|AGD
14P01771593A1152|46 47|GD
14P01771593A1152|74 76|PCD
14P01771593A1232|43 51|genitalia
14P01771593A1232|64 72|offspring
14P01771959A0442|5 8|PTCA
14P01771959A0442|10 26|ejection fraction
14P01771959A0442|141 144|PTCA
14P01771959A0442|161 164|PTCA
14P01771959A0442|220 223|PTCA
14P01771959A0442|238 241|PTCA
14P01772201T0001|12 18|patient
14P01772201T0001|33 44|subjectivity
14P01772341A0852|45 76|thromboxane synthetase inhibitor
14P01772341A0852|79 109|thromboxane receptor antagonist
14P01772341A0852|140 159|digoxin intoxication
14P01774062A0257|7 9|YAC
14P01774062A0257|11 16|A148A7
14P01774062A0257|32 45|HLA-DQA1 locus
14P01774062A0257|55 61|Y3/Ring
14P01774062A0257|104 112|YAC B1D12
14P01774063A0161|13 30|backcross analysis
14P01774063A0161|63 84|C57BL/6J x Mus spretus
14P01774063A0161|83 84|F1
14P01774063A0161|86 98|C57BL/6J mice
14P01774063A0161|114 132|thrombospondin gene
14P01774063A0161|152 155|Fshb
14P01774063A0161|157 161|Actcl
14P01774063A0161|163 165|Ltk
14P01774063A0161|170 177|B2M loci
14P01774093T0000|41 71|Chlamydia trachomatis infection
14P01774822A0289|40 61|LV time-density curves
14P01776306A0572|19 20|VT
14P01776715A0489|25 38|centrifugation
14P01776715A0489|45 55|measurement
14P01776715A0489|81 83|CO2
14P01776715A0489|85 97|equilibration
14P01776715A0489|114 124|gas mixture
14P01776715A0489|139 142|PCO2
14P01776715A0489|160 170|measurement
14P01777841A0744|11 20|mechanisms
14P01777841A0744|31 41|differences
14P01777841A0744|56 62|effects
14P01777841A0744|85 93|afferents
14P01777841A0744|105 112|neonates
14P01779299A0000|51 69|Periplaneta brunnea
14P01779299A0000|101 125|Moniliformis moniliformis
14P01779433A0694|28 44|Alu family repeat
14P01779433A0694|164 180|Alu family repeat
14P01779433A0694|180 182|Alu
14P01779433A0694|251 267|Alu family repeat
14P01779433A0694|298 314|Alu family repeat
14P01779769A0000|16 30|repressor locus
14P01779769A0000|38 49|Streptomyces
14P01779769A0000|105 117|reading frame
14P01779769A0000|128 138|kDa protein
14P01780235A0094|3 12|EPO levels
14P01781923A0744|29 30|DB
14P01781923A0744|65 66|DB
14P01781923A0744|94 95|LS
14P01781923A0744|139 168|barbiturate brain distribution
14P01782424A0278|14 37|threshold concentrations
14P01782669A0496|30 41|temperatures
14P01782669A0496|57 62|A23187
14P01782982A0155|0 9|Felodipine
14P01782982A0155|95 97|AMP
14P01782982A0155|105 123|bronchoconstriction
14P01783088A1136|109 122|micrograms.l-1
14P01783088A1136|126 136|fibronectin
14P01783088A1136|160 173|micrograms.l-1
14P01783088A1136|235 242|ABSTRACT
14P01783088A1136|257 261|WORDS
14P01783375A1066|114 138|translocation breakpoints
14P01784589A0000|41 63|5-HT2 receptor activity
14P01785749A0695|5 11|changes
14P01785749A0695|49 56|children
14P01785749A0695|70 75|weight
14P01786094T0001|7 14|contents
14P01786094T0001|23 28|copper
14P01787085A0331|10 20|experiments
14P01787085A0331|39 50|control rats
14P01788002T0001|0 13|Magnetotherapy
14P01788002T0001|16 26|hepatitis A
14P01791363A0208|5 11|results
14P01791363A0208|35 42|patients
14P01791363A0208|69 75|sutures
14P01791363A0208|86 92|testing
14P01791754T0000|75 90|secretion signal
14P01791754T0000|107 116|haemolysin
14P01792580A0198|5 16|blood donors
14P01792580A0198|21 28|Republic
14P01792580A0198|31 36|Serbia
14P01792580A0198|59 73|blood donations
14P01792580A0198|150 161|blood donors
14P01792914T0000|23 40|childhood leukemia
14P01797459A0103|0 9|Mycoplasma
14P01797467A0000|0 4|RU486
14P01797467A0000|8 10|ONO
14P01798407A1011|18 30|abnormalities
14P01798407A1011|58 67|hypothesis
14P01798407A1011|144 160|laughing seizures
14P01804671A1001|27 31|QS/QC
14P01804671A1001|140 173|ventilation/perfusion distribution
14P01804671A1001|201 206|CDCSF6
14P01806314A0322|77 84|antibody
14P01806314A0322|92 103|muscle actin
14P01808049A0262|0 15|CT abnormalities
14P01808049A0262|22 32|term babies
14P01808049A0262|40 49|hemorrhage
14P01808049A0262|88 98|hypodensity
14P01808049A0262|135 145|hypodensity
14P01808049A0262|150 159|hemorrhage
14P01808136T0000|12 25|contrast media
14P01808136T0000|27 48|coagulation factor XII
14P01808186A0984|0 3|Pigs
14P01808186A0984|61 63|Exp
14P01808602A0000|38 49|hypertension
14P01808602A0000|68 87|nifedipine treatment
14P01808602A0000|110 118|excretion
14P01808829A0510|0 3|TPTA
14P01808829A0510|12 27|brain congestion
14P01809854A0106|0 7|Examples
14P01809854A0106|40 54|research design
14P01809854A0106|65 84|consensus statements
14P01809854A0106|91 103|meta-analysis
14P01810108A0000|4 18|phase slug flow
14P01810108A0000|24 37|heat exchanger
14P01810108A0000|71 92|Listeria monocytogenes
14P01810154A0491|7 14|children
14P01811243A0000|0 7|Regional
14P01811243A0000|16 25|blood flow
14P01811243A0000|31 42|measurements
14P01811243A0000|97 104|patients
14P01811243A0000|214 227|rCBF technique
14P01811948A0289|85 102|LpS1 beta promoter
14P01811948A0289|108 115|sequence
14P01811948A0289|142 152|cis-element
14P01812102A0101|10 22|study reports
14P01812102A0101|54 69|pattern reversal
14P01812102A0101|70 74|VEP-P
14P01812102A0101|129 139|NPN complex
14P01812690A0475|8 10|SMF
14P01814182A0000|16 35|15-methyl-PGF2 alpha
14P01814182A0000|63 72|luteolysis
14P01814182A0000|99 108|treatments
14P01816655T0000|0 5|Review
14P01816655T0000|11 20|literature
14P01817497A0715|0 9|Resolution
14P01817497A0715|50 56|Delta T
14P01822581A0533|25 41|alcohol responses
14P01822581A0533|81 95|microgram/100ml
14P01822581A0533|99 112|breath samples
14P01822995T0000|0 27|Maize rbcS promoter activity
14P01823520A0183|0 11|Measurements
14P01823520A0183|35 63|haematofluorometer Buchler ZF
14P01823524A0238|72 81|complexity
14P01823524A0238|180 190|differences
14P01823524A0238|193 206|susceptibility
14P01823524A0238|209 228|xenobiotics toxicity
14P01824713A0964|3 17|12S E1A product
14P01824713A0964|32 43|TRE sequence
14P01824713A0964|47 60|cotransfection
14P01824944A0988|18 28|tunicamycin
14P01824944A0988|33 45|transfectants
14P01824944A0988|74 85|polypeptides
14P01824944A0988|104 106|IgE
14P01825027T0000|0 3|PAS1
14P01825027T0000|26 46|peroxisome biogenesis
14P01825027T0000|85 91|ATPases
14P01826003A0694|14 23|base pairs
14P01826003A0694|57 66|SIG family
14P01826003A0694|70 81|beta TG gene
14P01826043A0431|3 33|pp90rsk-protein kinase activity
14P01826043A0431|92 125|signal transducing protein kinases
14P01826043A0431|178 200|protein kinase C family
14P01827068T0000|5 10|GATA-3
14P01827068T0000|31 50|transcription factor
14P01827068T0000|81 106|T cell receptor alpha gene
14P01827203A0136|18 38|transcription factors
14P01827203A0136|58 60|DNA
14P01828248A0189|15 26|UvrA protein
14P01828248A0189|42 53|UvrB protein
14P01828248A0189|111 113|DNA
14P01828248A0189|123 135|UvrAB complex
14P01828248A0189|145 161|helicase activity
14P01829060A0649|3 13|ED30 values
14P01829060A0649|75 76|ED
14P01829460A0329|0 25|Southwestern blot analysis
14P01830114A1587|24 26|NS1
14P01830114A1587|52 65|P4 transcripts
14P01830114A1587|77 89|amplification
14P01830114A1587|92 107|gene copy number
14P01830928A0361|21 38|microtubule motors
14P01830928A0361|117 134|attachment domains
14P01832019A0265|61 67|animals
14P01832152A0000|3 37|incompatibility group W plasmid pSa
14P01832152A0000|44 81|Agrobacterium tumefaciens oncogenicity
14P01832152A0902|47 50|ORF1
14P01832152A0902|54 57|ORF2
14P01832197T0001|9 28|D2 dopamine receptor
14P01833185A0547|3 20|Thr161Val mutation
14P01833185A0547|47 59|fission yeast
14P01833185A0547|102 107|Thr161
14P01833185A0547|145 159|phosphorylation
14P01833185A0547|167 180|uncoordination
14P01833637A0531|14 24|transcripts
14P01833637A0531|110 120|temperature
14P01833637A0531|137 146|transcript
14P01833637A0531|155 164|HSP82 gene
14P01833716A0990|0 11|Deregulation
14P01833716A0990|81 96|HTLV-1 infection
14P01837787T0000|9 19|Mov-34 gene
14P01837787T0000|45 56|organization
14P01837842A1410|0 3|CREB
14P01837842A1410|27 44|protein components
14P01837842A1410|58 76|gel shift complexes
14P01837842A1410|95 97|CRE
14P01839414T0000|56 60|Sabah
14P01840513A1019|29 38|SL-2 cells
14P01840513A1019|116 157|chloramphenicol acetyltransferase activity
14P01840513A1019|192 203|8-bromo-cAMP
14P01840607A0294|25 28|UTRs
14P01840607A0294|105 107|PFP
14P01840608A0823|3 12|N-terminus
14P01840608A0823|88 117|amino acid sequence comparison
14P01840711A0000|3 12|RNA genome
14P01840711A0000|44 47|RHDV
14P01840902A1089|95 113|transport machinery
14P01842498A0000|21 22|R2
14P01842498A0000|76 93|phytohemagglutinin
14P01842498A0000|95 97|PHA
14P01842498A0000|100 116|phorbol myristate
14P01842498A0000|134 145|Jurkat cells
14P01842498A0000|199 215|blood lymphocytes
14P01842867A0696|29 48|regeneration ability
14P01844017A0410|48 91|glucose-6-phosphatase dehydrogenase activity
14P01844878A0000|43 69|neomycin phosphotransferase
14P01844878A0000|90 107|promoter sequences
14P01844878A0000|131 143|DNA fragments
14P01844982A0324|0 5|Chagas
14P01844982A0324|23 35|leishmaniasis
14P01844982A0324|56 70|schistosomiasis
14P01845829A0158|8 15|analysis
14P01845829A0158|26 33|sequence
14P01845829A0158|69 75|domains
14P01845829A0158|102 108|factors
14P01845829A0158|123 133|brain cells
14P01845885A1003|39 42|UL26
14P01845885A1003|187 220|UL26 transcription initiation site
14P01845885A1003|240 266|methionine initiation codon
14P01845885A1003|292 295|UL26
14P01845899A0000|25 27|AAV
14P01845899A0000|56 60|Rep78
14P01845899A0000|62 66|Rep68
14P01845899A0000|68 72|Rep52
14P01845899A0000|77 81|Rep40
14P01845899A0000|94 112|AAV DNA replication
14P01845899A0000|114 132|AAV gene regulation
14P01846206A0665|28 34|CMV dbp
14P01846489A1119|34 48|protease domain
14P01846489A1119|65 80|protease domains
14P01846491A0459|33 40|VV genes
14P01846491A0459|41 59|genus Orthopoxvirus
14P01846491A0459|99 102|ORFs
14P01846491A0459|105 107|SFV
14P01846491A0459|109 128|genus Leporipoxvirus
14P01846491A0459|140 161|complex rearrangements
14P01846491A0459|163 165|DNA
14P01846803A0688|22 36|phosphorylation
14P01846803A0688|39 41|Thr
14P01846803A0688|50 52|Tyr
14P01846803A0688|63 85|p34cdc2 kinase activity
14P01846803A0688|138 153|ATP binding site
14P01847464A0856|12 26|cotransfections
14P01847464A0856|29 44|pFRTK-CAT target
14P01847464A0856|80 89|EBV origin
14P01847464A0856|91 109|plasmid replication
14P01847464A0856|152 170|EBNA-1 construction
14P01847464A0856|218 236|localization signal
14P01847665A1079|55 68|PDGF receptors
14P01847665A1079|70 81|glioma cells
14P01847665A1079|178 195|glia cell lineages
14P01848300A0910|49 67|peptide utilization
14P01848871A0392|32 45|sodium channel
14P01848871A0392|106 121|amplitude signal
14P01848871A0392|149 159|QRS complex
14P01848871A0392|166 177|prolongation
14P01848871A0392|234 244|tachycardia
14P01849509T0000|37 79|Rhizobium meliloti insertion sequence ISRm3
14P01849509T0000|125 129|ISRm3
14P01849509T0000|167 171|IS256
14P01849509T0000|175 204|Thiobacillus ferrooxidans IST2
14P01849675A0167|52 63|DNA sequence
14P01849675A0167|65 66|KV
14P01849734A1063|8 27|PR55 beta transcript
14P01849734A1063|66 78|neuroblastoma
14P01849734A1063|86 101|cell line LA-N-1
14P01850096A0662|0 11|Heterodimers
14P01850096A0662|25 27|E12
14P01850096A0662|31 34|MyoD
14P01850096A0662|38 40|E12
14P01850096A0662|60 79|restriction fragment
14P01850096A0662|129 153|alpha-actin transcription
14P01850105A1093|65 79|differentiation
14P01850105A1093|95 96|Id
14P01850105A1093|118 139|muscle differentiation
14P01850127A0000|19 26|U2 snRNP
14P01850127A0000|33 52|branchpoint sequence
14P01850127A0000|111 130|polypyrimidine tract
14P01850893A0286|17 26|antibodies
14P01850893A0286|49 55|rabbits
14P01851386T0092|10 31|Lung Cancer Task Force
14P01851386T0092|30 36|FONICAP
14P01851527T0000|36 75|Alzheimer beta-amyloid precursor protein
14P01851527T0000|74 76|APP
14P01851756A0743|0 3|Biol
14P01851862A0273|0 19|Nucleotide sequences
14P01851862A0273|42 44|LTR
14P01851862A0273|47 51|SFV-1
14P01851876A0129|28 38|EMBL3 mouse
14P01852438A0928|3 11|MVV-value
14P01852603A0000|11 27|DNA repair mutant
14P01852603A0000|88 89|UV
14P01853796T0000|0 5|Review
14P01853796T0000|7 19|deterioration
14P01853796T0000|22 38|glucose tolerance
14P01853796T0000|55 72|insulin resistance
14P01854339A0221|22 40|sequence similarity
14P01854339A0221|57 75|consensus promoters
14P01855255T0000|42 45|RCC1
14P01855255T0000|61 66|GTPase
14P01856021A0577|34 43|laboratory
14P01856021A0577|77 85|procedure
14P01856021A0577|102 108|control
14P01856021A0577|123 130|exposure
14P01856021A0577|133 139|toluene
14P01857143A0351|35 46|skin lesions
14P01857143A0351|57 65|diagnosis
14P01857143A0351|68 80|myelofibrosis
14P01857326A0160|0 9|Oculus-500
14P01857326A0160|24 48|resolution imaging boards
14P01857326A0160|57 62|IBM-AT
14P01860846A0663|36 62|tumor necrosis factor-alpha
14P01860846A0663|82 106|MARCKS gene transcription
14P01860846A0663|128 150|leukemia cell line HL60
14P01861034A0798|47 58|contact area
14P01861034A0798|87 103|scaphoid fragment
14P01861188A0000|0 11|Plate luting
14P01861188A0000|53 56|PMMA
14P01861188A0000|280 302|ASIF compression plates
14P01862027A0212|53 77|Rothmund-Thomson syndrome
14P01862455T0000|0 15|Thyroid lymphoma
14P01863768A0649|19 24|ORF113
14P01863887A0174|0 16|Space limitations
14P01863887A0174|54 68|pharmaceuticals
14P01863887A0174|76 93|tissue plasminogen
14P01863887A0174|143 156|growth hormone
14P01863887A0174|157 170|erythropoietin
14P01863887A0174|173 188|clotting factors
14P01863887A0174|192 205|blood products
14P01864510A0946|0 9|Dd PK1 RNA
14P01864510A0946|26 35|starvation
14P01864821A0000|23 34|cell disease
14P01864821A0000|67 78|globin chain
14P01864821A0000|95 104|conditions
14P01864821A0000|144 154|blood cells
14P01864821A0000|157 167|obstruction
14P01864821A0000|170 182|blood vessels
14P01864837A1029|72 87|mouse contrapsin
14P01864837A1029|124 153|rat alpha 1-protease inhibitor
14P01865010A0000|0 7|Patterns
14P01865010A0000|10 20|connections
14P01865010A0000|45 55|integration
14P01865010A0000|112 122|Fluoro-Gold
14P01865010A0000|178 192|representations
14P01867069A0000|5 13|CD-1 mice
14P01867069A0000|35 52|% nicotine sulfate
14P01867069A0000|138 148|development
14P01869565A1254|0 2|USF
14P01869565A1254|41 58|translation system
14P01869565A1254|72 83|ADH promoter
14P01869565A1254|96 98|MLP
14P01869907A2146|3 22|across-fiber pattern
14P01869907A2146|47 60|NaCl solutions
14P01869907A2146|108 115|ABSTRACT
14P01869907A2146|130 134|WORDS
14P01869968A0000|8 28|radioactivity content
14P01869968A0000|63 67|HMPAO
14P01869968A0673|6 24|regression analysis
14P01869968A0673|79 83|HMPAO
14P01869968A0673|109 120|significance
14P01870194A0302|5 31|immunodeficiency virus type
14P01870194A0302|32 36|HIV-1
14P01870428A0677|0 10|Thigh girth
14P01870428A0677|34 36|HDL
14P01870428A0677|40 45|HDL2-C
14P01870428A0677|61 77|LDL particle size
14P01870500A0276|0 12|Contributions
14P01870500A0276|33 54|target volume elements
14P01870500A0276|68 75|S values
14P01870500A0276|202 220|reciprocity theorem
14P01871033A0434|0 4|Tests
14P01871033A0434|71 91|laboratory simulation
14P01871033A0434|99 113|clearing cement
14P01871033A0434|116 129|testing cement
14P01871135A0295|22 34|reading frame
14P01871135A0295|68 78|amino acids
14P01871135A0295|119 128|% identity
14P01871135A0295|130 150|rat liver glucokinase
14P01871971A0836|0 7|Analysis
14P01871971A0836|47 55|NFIII/OCT
14P01871971A0836|82 90|ATF motif
14P01872856A0277|0 7|Recovery
14P01872856A0277|23 24|BA
14P01872856A0277|92 104|radioactivity
14P01872856A0277|133 140|recovery
14P01873999A0000|47 58|model system
14P01873999A0000|115 129|gene expression
14P01873999A0000|135 151|secretion process
14P01873999A0000|168 177|production
14P01874195A0139|25 35|GH receptor
14P01874195A0139|60 78|sequence similarity
14P01874195A0139|98 127|signal transduction mechanisms
14P01874195A0139|167 190|tyrosine kinase activity
14P01874752A0948|41 59|conditions cdc2/p58
14P01874752A0948|84 94|differences
14P01875922A0770|0 16|Mutation analysis
14P01876836T0000|0 13|Identification
14P01876836T0000|46 63|GA binding protein
14P01878489A0959|80 101|NADPH oxidase activity
14P01878755A0496|11 21|enterotoxin
14P01878755A0496|41 53|disappearance
14P01878755A0496|82 97|blood appearance
14P01878755A0496|115 125|chloroquine
14P01881595A0476|0 7|Formalin
14P01881595A0476|21 26|SNO NS
14P01881595A0476|29 40|NnS neurones
14P01881595A0476|63 73|NS neurones
14P01881595A0476|116 127|NnS neurones
14P01881671T0001|0 5|Uptake
14P01882240A0526|84 87|AIDS
14P01882240A0526|111 121|communities
14P01882386A0000|18 36|alpha-mercapto-beta
14P01882386A0000|39 45|2-furyl
14P01882386A0000|59 61|MFA
14P01882386A0000|66 101|N-benzyl-N-dithiocarboxy-D-glucamine
14P01882386A0000|103 105|NaB
14P01883992A0922|66 74|regulator
14P01883992A0922|80 89|expression
14P01883992A0922|95 108|beta-zein gene
14P01883992A0922|120 134|maize endosperm
14P01884435A0088|29 39|hypovolemia
14P01884435A0088|65 81|ptH distributions
14P01884435A0088|91 102|tissue sites
14P01884435A0088|135 148|microelectrode
14P01884435A0088|174 185|measurements
14P01884998A1135|42 54|transcription
14P01884998A1135|59 67|promoters
14P01885006A0995|20 34|superactivation
14P01885006A0995|88 97|activation
14P01885613A1298|0 10|Information
14P01885613A1298|62 71|regulation
14P01885613A1298|90 102|collagen gene
14P01885752A0198|0 20|Chlamydia trachomatis
14P01885752A0198|23 40|Chlamydia psittaci
14P01885915A0000|43 63|Pasteurella multocida
14P01885915A0000|104 117|P. haemolytica
14P01886043A0380|3 5|SMX
14P01886043A0380|44 47|HPCD
14P01886043A0380|96 98|SMX
14P01886043A0380|145 163|inclusion complexes
14P01886043A0380|170 173|HPCD
14P01886368A0000|0 15|PO2 measurements
14P01886368A0000|36 62|recess type microelectrodes
14P01886774A0000|33 36|Oct3
14P01886774A0000|51 65|Echerichia coli
14P01886774A0000|68 83|characterization
14P01886774A0000|86 96|DNA binding
14P01886774A0000|101 116|octamer sequence
14P01888896A0505|1 15|deletion series
14P01888896A0505|96 110|initiation site
14P01889753A0441|3 12|nucleotide
14P01889753A0441|17 25|sequences
14P01889753A0441|48 57|boundaries
14P01889753A0441|82 88|regions
14P01890362A0305|38 54|eye complications
14P01890989A1392|55 72|estrogen induction
14P01890989A1392|99 108|amphibians
14P01892680A0907|0 7|Toxicity
14P01893195A0000|35 42|hamsters
14P01893195A0000|85 94|properties
14P01893195A0000|101 115|virus Issyk-Kul
14P01893927A0704|32 53|phenylephrine infusion
14P01893927A0704|86 88|NMA
14P01893927A0704|92 94|NNA
14P01894696A0301|0 1|J.
14P01895358A0000|0 5|Limits
14P01895358A0000|8 22|energy turnover
14P01895358A0000|42 52|performance
14P01895358A0000|108 125|training programme
14P01895358A0000|141 154|energy balance
14P01895358A0000|165 179|energy turnover
14P01895370A0199|12 21|reductions
14P01895370A0199|62 95|maximum shifted-frequency envelope
14P01895384A0746|3 18|IE0 gene product
14P01895384A0746|38 49|IE1 promoter
14P01895393A0745|29 36|TATA box
14P01895393A0745|50 58|Sp1 sites
14P01895393A0745|60 68|Sp1 sites
14P01895393A0745|83 90|TATA box
14P01895393A0745|125 138|RNA polymerase
14P01895555T0001|0 9|Evaluation
14P01895555T0001|72 82|Tc-99m-MIBI
14P01896777T0000|0 16|Ivermectin uptake
14P01896777T0000|91 109|Onchocerca volvulus
14P01897515A0348|0 24|Bone marrow abnormalities
14P01897515A0348|25 31|Hodgkin
14P01898113A0265|60 62|BCF
14P01898113A0265|66 78|SWA killifish
14P01898164A0839|114 134|aorta diameter ratios
14P01898164A0839|134 145|arch indices
14P01898928A0260|0 25|DNA hybridization analysis
14P01898928A0260|87 95|DNA locus
14P01899209A0883|0 8|Increases
14P01899209A0883|14 27|perfusate PCO2
14P01899209A0883|114 131|oxygen consumption
14P01899209A0883|132 133|r2
14P01899287A0726|0 9|Expression
14P01899287A0726|49 58|RNA levels
15P01899409T0000a|0 11|Determinants
15P01899409T0000a|35 62|revascularisation procedures
15P01899409T0000a|94 121|tissue plasminogen activator
14P01899846A0862|13 27|rbcL-rbcS locus
14P01899846A0862|65 73|condition
14P01900194T0000|0 11|Relationship
14P01900194T0000|32 56|NADH-ubiquinone reductase
14P01901405A0694|0 7|Analysis
14P01901405A0694|33 38|AT-BP1
14P01901405A0694|42 47|AT-BP2
14P01901443A0297|28 48|maintenance valproate
14P01901443A0297|181 188|O stains
14P01901664T0064|1 5|cases
14P01901859A0000|0 6|UDP-Gal
14P01901859A0000|8 15|Gal beta
14P01901859A0000|20 32|4GlcNAc alpha
14P01901859A0000|37 59|3-galactosyltransferase
14P01901859A0000|71 89|glycosyltransferase
14P01901859A0000|177 193|Old World monkeys
14P01901946A0243|38 49|SRE sequence
14P01901946A0243|56 80|mouse c-fos gene promoter
14P01901946A0243|132 151|mobility shift assay
14P01901946A0243|153 164|Southwestern
14P01901946A0243|166 176|DNA-protein
14P01901946A0243|218 240|affinity chromatography
14P01901950T0000|0 20|Sequence requirements
14P01901950T0000|32 51|transcription arrest
14P01901950T0000|76 91|mouse c-fos gene
14P01903404A0688|15 31|ejection fraction
14P01903404A0688|191 207|ejection fraction
14P01903404A0688|232 247|perfusion status
14P01903841A0125|8 22|lysine residues
14P01903841A0125|34 43|spermidine
14P01903841A0125|77 88|modification
14P01903841A1449|3 27|plasmid shuffle technique
14P01903841A1449|99 109|yeast cells
14P01904154A0164|16 29|identification
14P01904154A0164|33 48|characterization
14P01904154A0164|69 75|Ig loci
14P01904154A0164|112 137|gene rearrangement process
14P01904437A0000|0 12|Transcription
14P01904437A0000|93 109|metR gene product
14P01904437A0000|110 128|DNA binding protein
14P01904546A0671|0 9|Disruption
14P01904546A0671|26 34|AAR1 gene
14P01904546A0671|93 108|a/alpha diploids
14P01905199A0210|11 18|ICRF-187
14P01905199A0210|24 41|antitumor response
14P01905199A0210|66 68|ADR
14P01905199A0210|72 74|WBH
14P01905199A0210|166 183|modality treatment
14P01905517A1076|3 5|ORF
14P01905517A1076|54 72|sequence data bases
14P01906111A1295|114 129|toxicity profile
14P01906166A0119|0 10|Mitomycin-C
14P01906166A0119|108 126|drug administration
14P01906509A0072|54 65|nidogen gene
14P01906692A0321|0 12|INTERVENTIONS
14P01906692A0321|14 21|Patients
14P01907265A0670|109 129|DNA cleavage activity
14P01907941A0275|13 26|I kappa B beta
14P01907941A0275|31 45|I kappa B alpha
14P01907941A0275|69 71|Rel
14P01909027A0922|0 16|Sequence analysis
14P01909027A0922|30 47|DNA binding domain
14P01909027A0922|48 50|ILF
14P01909027A0922|90 117|fork head DNA binding domain
14P01909027A0922|142 158|protein fork head
14P01909027A0922|194 198|HNF-3
14P01909621A0119|18 29|hemodialyses
14P01909621A0119|49 56|lithemia
14P01909960A0134|52 64|noradrenaline
14P01909960A0134|66 67|NA
14P01909960A0134|69 80|biosynthesis
14P01909960A0134|108 120|concentration
14P01909960A0134|123 137|normetanephrine
14P01909960A0134|139 141|NMN
14P01909960A0134|160 168|NA levels
14P01910505A0000|6 23|wuzi yanzong pills
14P01910505A0000|50 65|cyclophosphamide
14P01911767T0000|0 8|Mutations
14P01911767T0000|28 59|ribulosebisphosphate carboxylase
14P01913955A0177|60 67|increase
14P01913955A0177|105 119|muscularization
14P01913955A0177|122 136|precursor cells
14P01913955A0177|137 145|pericytes
14P01913955A0177|231 241|muscle cell
14P01913955A0177|274 284|hypertrophy
14P01913955A0177|288 298|hyperplasia
14P01913955A0177|307 318|muscle cells
14P01913955A0177|326 337|accumulation
14P01913955A0177|354 361|collagen
14P01913955A0177|381 388|collagen
14P01915580A0889|23 28|NZ-107
14P01915580A0889|97 112|airway responses
14P01915580A0889|115 136|airway hyperreactivity
14P01916168A0969|12 35|correlation coefficients
14P01916168A0969|45 61|ISO2 measurements
14P01916405A0242|9 24|mucosa tattooing
14P01916405A0242|93 94|PC
14P01916405A0242|96 97|DB
14P01916632A0431|20 23|PBMC
15P01917943A0621a|0 16|Sequence analysis
15P01917943A0621a|65 73|TATAA box
15P01917943A0621a|104 127|transfection experiments
15P01917943A0621a|185 226|chloramphenicol acetyltransferase reporter
15P01917943A0621b|0 16|Sequence analysis
15P01917943A0621b|65 73|TATAA box
15P01917943A0621b|104 127|transfection experiments
15P01917943A0621b|185 226|chloramphenicol acetyltransferase reporter
14P01917962A0152|28 77|immunoglobulin gene recombination signal sequences
14P01917962A0152|114 126|IL-2R L chain
14P01917962A0152|168 180|SV40 promoter
14P01918010A0000|0 17|Lipoprotein lipase
14P01918010A0000|18 20|LPL
14P01918010A0000|41 62|lipoprotein metabolism
14P01918010A1730|0 7|Deletion
14P01918010A1730|21 40|octanucleotide motif
14P01918010A1730|84 95|LPL promoter
14P01918010A1730|158 174|3T3-L1 adipocytes
14P01918010A1730|177 193|HepG2 hepatocytes
14P01918070A0281|30 46|T3 receptor alpha
14P01918070A0281|46 54|T3R alpha
14P01918070A0281|193 203|T3R binding
14P01918073A0150|0 9|Comparison
14P01918073A0150|34 64|TnIcardiac amino acid sequences
14P01918073A0150|71 83|TnI sequences
14P01918073A0150|123 140|extension sequence
14P01918073A0150|153 196|protein kinase A phosphorylation target site
14P01918073A0150|260 262|TnI
14P01918073A0150|358 360|TnC
14P01918073A0150|417 419|TnI
14P01918073A0150|423 425|TnC
14P01918073A0150|444 453|TnIcardiac
14P01918073A0150|462 478|actin/TnC-binding
14P01918073A0150|480 500|actomyosin-inhibitory
14P01918073A0150|524 542|sequence divergence
14P01918073A0150|555 574|TnIcardiac sequences
14P01918073A0150|597 624|protein kinase C target site
14P01918073A0150|654 656|TnI
14P01919831T0000|11 29|management casebook
14P01921463T0000|2 18|ASSEMBLER routine
14P01921463T0000|79 91|microcomputer
14P01922082A0149|0 9|Expression
14P01922082A0149|15 33|mouse TSH beta gene
14P01922734T0000|0 10|Habituation
14P01922734T0000|66 76|stimulation
14P01922739A0336|17 20|ROSP
14P01922739A0336|39 50|fluctuations
14P01922739A0336|75 84|directions
14P01922739A0336|109 117|amplitude
14P01922739A0336|151 159|operation
14P01922739A0336|206 209|ROSP
14P01922739A0336|238 247|electrodes
14P01922739A0336|272 281|dura mater
14P01922739A0336|301 310|electrodes
14P01922739A0336|335 343|pia mater
14P01923167A0000|0 28|Blood flow velocity waveforms
14P01923167A0000|46 64|Doppler examination
14P01923628T0001|22 24|DNA
14P01923628T0001|30 43|flow cytometry
14P01923766A0485|0 16|Sequence analysis
14P01923766A0485|70 81|mRNA species
14P01923766A0485|160 170|nucleotides
14P01923803A0609|0 7|Position
14P01923803A0609|37 59|SsoL12 protein sequence
14P01923803A0609|68 76|AUA codon
14P01923985A0111|0 7|Symptoms
14P01923985A0111|24 42|mastocyte mediators
14P01924315A0158|34 46|copper levels
14P01924315A0158|76 90|SOD1 expression
14P01924920A0115|18 30|Mobiluncus SP
14P01924920A0115|57 69|Gram staining
14P01924920A0115|87 99|microorganism
14P01925092A0000|8 20|investigators
14P01925092A0000|98 105|meshwork
14P01925092A0304|86 113|tissue plasminogen activator
14P01927421A0181|16 27|examinations
14P01927421A0181|55 63|nystagmus
14P01927421A0181|78 86|nystagmus
14P01927421A0181|97 105|nystagmus
14P01927845A0107|8 17|morphology
14P01927845A0107|58 66|disorders
14P01927845A0107|68 72|Bowen
14P01928923A0000|0 12|Equine amnion
14P01928923A0000|19 39|yeast cell derivative
14P01928923A0000|85 100|wound medicament
14P01930470A0337|44 46|PTH
14P01930470A0337|58 77|American Association
14P01930470A0337|79 89|Blood Banks
14P01930470A0337|90 93|AABB
14P01930660T0000|26 30|IGF-1
14P01931966A0490|0 5|Fusion
14P01931966A0490|8 16|ubiquitin
14P01932650A0435|50 63|drainage blood
14P01932650A0435|97 109|concentration
14P01932650A0435|123 126|MBRS
14P01932695A1155|45 60|expression assay
14P01932695A1155|79 95|barley endosperms
14P01933614A0406|11 27|salmon calcitonin
14P01933614A0406|59 70|osteoporosis
14P01934378A1219|8 38|muscle metaboreceptor responses
14P01934378T0000|8 47|muscle metaboreceptor exercise responses
14P01936213T0000|0 9|Evaluation
14P01936213T0000|37 53|membrane fluidity
14P01936348A0155|3 14|examinations
14P01936348A0155|49 56|AmF/SnF2
14P01936997A0795|0 18|RNA gel retardation
14P01936997A0795|51 65|TRP-185 binding
14P01936997A0795|89 110|TAR RNA loop sequences
14P01937790A0292|3 9|vaccine
14P01937790A0292|45 52|children
14P01937790A0292|56 61|adults
14P01937989A0383|31 39|induction
14P01937989A0383|66 67|R2
14P01938178T0000|0 11|Applications
14P01938178T0000|52 55|P300
14P01939131A0871|29 34|BW2001
14P01939131A0871|49 60|strain cells
14P01939199A0588|16 20|TFIID
14P01939199A0588|106 119|TFIID fraction
14P01939199A0588|123 132|HeLa cells
14P01939827A0150|10 21|pretreatment
14P01939827A0150|42 60|oxide surface layer
14P01939827A0150|62 76|titanium powder
14P01939827A0150|96 108|precipitation
14P01939827A0150|133 144|mmol/L CaCl2
14P01939827A0150|146 158|mmol/L KH2PO4
14P01939827A0150|161 172|mmol/L Hepes
14P01939827A0150|190 202|precipitation
14P01939827A0150|239 250|mmol/L CaCl2
14P01939827A0150|254 266|mmol/L KH2PO4
14P01939827A0150|269 280|mmol/L Hepes
14P01939827A0150|291 300|degrees C.
14P01939878A0765|14 27|solidification
14P01939878A0765|107 114|patients
14P01939899A2043|107 118|perturbation
14P01939899A2043|121 128|ABSTRACT
14P01939899A2043|143 147|WORDS
14P01939906A0233|4 17|generalization
14P01939906A0233|20 22|MFP
14P01939906A0233|67 79|cost function
14P01939906A0233|96 107|search space
14P01939906A0233|159 171|wave equation
14P01939906A0233|194 212|optimization method
14P01939906A0233|223 241|parameter landscape
14P01939906A0233|265 277|cost function
14P01942033T0000|0 12|Determination
14P01942033T0000|17 29|RNA structure
14P01942033T0000|39 57|splicing inhibition
14P01943184A1050|26 35|University
14P01943184A1050|38 55|Wisconsin solution
14P01945430A0660|106 119|labyrinthotomy
14P01945430A0660|131 146|neuroma suspects
14P01947449A0191|11 30|diffusion limitation
14P01947449A0191|62 82|uptake/O2 requirement
14P01947449A0191|196 198|PO2
14P01947449A0191|201 203|PO2
14P01947449A1082|3 22|Diffusion limitation
14P01947449A1082|61 77|requirement value
14P01947449A1082|188 204|cylinder diameter
14P01948783A0000|27 33|Estulic
14P01952827A0215|14 20|seizure
14P01952827A0215|25 31|patient
14P01952827A0215|47 57|test phrase
14P01954355A0997|0 18|Monitoring patients
14P01954355A0997|38 41|IL-1
14P01954355A0997|45 54|TNF levels
14P01954835A0000|0 22|Echinococcus granulosus
14P01954835A0000|47 65|aspiration cytology
14P01954835A0000|107 114|Missouri
14P01956285A0000|109 139|choline-glycine betaine pathway
14P01956491A0095|17 30|amphotericin B
14P01956491A0095|79 93|filtration rate
14P01956491A0095|94 96|GFR
14P01956491A0095|127 146|creatinine clearance
14P01958368A0556|0 8|Evolution
14P01958368A0556|86 111|vitelliform classification
14P01958821T0000|8 30|fluorescence microscopy
14P01960974A0000|0 6|Toluene
14P01961213A0150|23 32|HCB-levels
14P01961747A0000|1 31|herpesvirus proteinase activity
14P01961747A0000|122 140|transfection assays
14P01961996A0522|0 6|Adult H
14P01961996A0522|37 46|preference
14P01961996A0522|65 75|opportunity
14P01963419A0501|7 27|silver liquid chamber
14P01963419A0501|47 57|MeV protons
14P01963419A0501|94 96|13N
14P01963419A0501|102 104|16O
14P01963419A0501|114 125|13N reaction
14P01963419A0501|128 130|18F
14P01963419A0501|132 143|fluoride ion
14P01963419A0501|148 150|18O
14P01963419A0501|156 167|18F reaction
14P01963438T0000|13 29|electron transfer
14P01963438T0000|31 42|cytochrome c
14P01963438T0000|55 65|polypyrrole
14P01963438T0000|82 97|polypyrrole film
14P01963858T0001|21 40|adrenaline secretion
14P01963858T0001|57 71|neuroglycopenia
14P01963858T0001|83 95|microdialysis
14P01964989A0145|0 14|Urine specimens
14P01964989A0145|30 42|phencyclidine
14P01964989A0145|44 46|PCP
14P01964989A0145|102 111|9-THC-COOH
14P01964989A0145|132 146|sodium chloride
14P01964989A0145|162 180|potassium hydroxide
14P01964989A0145|192 201|2-propanol
14P01967130A0645|103 122|DNA binding proteins
14P01968043A0908|20 30|cDNA clones
14P01968043A0908|88 99|orientations
14P01968061A0371|0 2|Sci
14P01968156T0000|0 19|Dose standardisation
14P01968224A0119|3 17|coding sequence
14P01968224A0119|35 53|residue polypeptide
14P01968224A0119|128 146|amino acid sequence
14P01968224A0119|160 163|PCNA
14P01968224A0119|192 208|PCNA polypeptides
14P01970560A1024|120 144|beta-Galactosidase assays
14P01970560A1024|172 191|aroF-lacZ expression
14P01970560A1024|212 225|TyrR repressor
14P01970801A0925|39 42|Ly-1
14P01970801A0925|46 49|CD20
14P01970801A0925|51 54|OSBP
14P01970926A0000|6 15|exercise K
14P01970926A0000|58 76|concentration rises
14P01970984A0668|19 40|serum estradiol levels
14P01971191A1271|40 52|isoproterenol
14P01971191A1271|63 71|influence
14P01971191A1271|82 92|capacitance
14P01971191A1271|95 106|liver volume
14P01971191A1271|129 146|outflow resistance
14P01971191A1271|170 178|histamine
14P01972379T0042|0 11|DNA sequence
14P01972379T0042|28 37|CPS domain
14P01973384A0206|28 40|binding sites
14P01973384A0206|86 98|transcription
14P01974550A0362|14 16|CBF
14P01974550A0362|32 52|hexamethonium bromide
14P01974550A0362|63 81|ipratropium bromide
14P01974550A0362|85 99|microgram/kg iv
14P01974876A1051|15 54|restriction fragment length polymorphism
14P01974876A1051|67 69|DNA
14P01975157A0836|10 23|transformation
14P01975428A0151|0 8|Telomeres
14P01975428A0151|85 96|DNA molecule
14P01975428A0151|121 133|cell division
14P01976638A1135|68 76|sequences
14P01977585A0222|107 114|subunits
14P01977585A0222|135 148|protein kinase
14P01977856A1036|21 25|BSPMs
14P01977856A1036|52 54|AMI
14P01978834A0076|7 39|abomasum lambda gt11 cDNA library
14P01978834A0076|86 115|rabbit H,K-ATPase beta subunit
14P01978857A0504|14 31|laboratory testing
14P01978857A0504|53 67|CD4 cell counts
14P01982061A0615|9 16|TATA box
14P01982061A0615|50 78|transcription initiation site
14P01982061T0000|0 15|Characterization
14P01982061T0000|53 68|hamster CAD gene
14P01982190T0001|5 13|cirrhosis
14P01982190T0001|22 29|modality
14P01982190T0001|35 43|evolution
14P01982190T0001|51 59|hepatitis
14P01982997A1104|0 10|Examination
14P01982997A1104|28 58|transcription factor expression
14P01982997A1104|66 76|MDI regimen
14P01982997A1104|88 89|RA
14P01982997A1104|182 192|Jun-B mRNAs
14P01983026A0483|85 101|CA concentrations
14P01983026A0483|121 132|study period
14P01984665T0000|0 9|Processing
14P01984665T0000|24 39|immunoreactivity
14P01984665T0000|68 99|dengue-2 virus envelope proteins
14P01985301T0000|19 24|MK-801
14P01985301T0000|61 72|brain damage
14P01985920A0156|19 40|rat liver cDNA library
14P01985920A0156|44 64|oligonucleotide probe
14P01985920A0156|78 102|rat SCP2 protein sequence
14P01985920A0156|151 171|SCP2 protein sequence
14P01985920T0000|0 6|Cloning
14P01985920T0000|22 40|nucleotide sequence
14P01985920T0000|42 73|rat liver sterol carrier protein
14P01985924A0554|3 10|addition
14P01985924A0554|59 66|subunits
14P01985924A0554|85 94|holoenzyme
14P01985924A0554|109 122|chromatography
14P01985924A0554|128 135|presence
14P01985924A0554|168 186|initiation activity
14P01986225A0250|31 33|HSF
14P01986241A0117|0 8|Induction
14P01986241A0117|20 36|ACE1 gene product
14P01986241A0117|85 93|CUP1 gene
14P01986254A0452|0 24|Gel mobility shift assays
14P01986254A0452|37 44|E6 motif
14P01986254A0452|113 119|T cells
14P01986254A0452|122 131|HeLa cells
14P01986360A0000|19 61|interferon response element binding factors
14P01986360A0000|79 119|mouse fibroblast lambda gt11 cDNA library
14P01986360A0000|166 223|oligoadenylate synthetase gene interferon response element
14P01988041A0281|55 72|BAL cDNA structure
14P01989561A0100|3 13|application
14P01989561A0100|21 31|instruments
14P01989561A0100|38 46|occlusion
14P01989561A0100|80 96|perfusion cannula
14P01989999A0000|27 29|IMP
14P01989999A0000|31 48|L-aspartate ligase
14P01989999A0000|49 51|GDP
14P01989999A0000|54 55|EC
14P01989999A0000|86 104|purine biosynthesis
14P01989999A0000|142 144|IMP
14P01989999A0000|147 149|AMP
14P01990254A0791|0 16|Immunophenotyping
14P01990266A0678|11 34|UV cross-linking studies
14P01990266A0678|46 50|UHF-1
14P01990266A0678|81 94|sodium dodecyl
14P01991521A0481|23 32|conclusion
14P01991521A0481|77 86|G4 content
14P01992459A0000|64 90|immunodeficiency virus mRNA
14P01992459A0000|90 92|RRE
14P01992459A0000|97 116|Rev response element
14P01992742A0000|13 19|records
14P01992742A0000|25 32|patients
14P01992742A0000|42 49|neuritis
14P01992953A0247|23 33|abnormality
14P01992953A0247|71 81|specificity
14P01992953A0247|110 117|patients
14P01992953T0000|0 23|Alanine aminotransferase
14P01993181T0000|0 27|Nucleotide sequence analysis
14P01993181T0000|48 79|PpG7 salicylate hydroxylase gene
14P01993656A1860|6 14|ARF cDNAs
14P01995951A0000|22 24|LTR
14P01995951A0000|36 57|immunodeficiency virus
14P01995951A0000|58 60|HIV
14P01996312A0454|0 2|DNA
14P01996312A0454|7 9|PCR
14P01996312A0454|43 65|lambda gt11 cDNA clones
14P01996312A0454|91 101|Dd kinase-2
14P01997465A0276|58 73|collagen content
14P01997465A0276|93 103|irradiation
14P01999035A0383|57 66|Caerphilly
14P01999035A0383|80 88|Speedwell
14P01999035A0383|98 107|IHD events
14P01999459A0795|0 1|A.
14P01999999T0001|9 16|luxation
14P01999999T0001|62 70|treatment
14P02000093A0794|0 8|Landsberg
14P02000093A0794|10 13|La-O
14P02001033A1907|26 39|concentrations
14P02001033A1907|41 50|desflurane
14P02001033A1907|54 63|isoflurane
14P02001033A1907|145 152|reflexes
14P02001033A1907|154 163|desflurane
14P02001033A1907|188 195|activity
14P02001033A1907|211 218|decrease
14P02001033A1907|229 236|pressure
14P02002051A0276|38 47|cDNA clone
14P02002051A0276|95 103|C-subunit
14P02002051T0000|0 13|Isoform C beta
14P02002051T0000|70 83|protein kinase
14P02002511A0637|21 34|PB-PK modeling
14P02004521A0266|0 7|Patients
14P02004521A0266|27 42|CT abnormalities
14P02004705A0686|3 15|cdr1 sequence
14P02004705A0686|38 48|amino acids
14P02004705A0686|100 101|Mr
14P02005547A0121|15 27|understanding
14P02005547A0121|90 100|development
14P02005547A0121|115 132|hyperbilirubinemia
14P02005547A0121|161 172|practitioner
14P02006558A0000|0 22|Displacement thresholds
14P02007045A0092|3 9|authors
14P02007045A0092|40 49|irrigation
14P02007045A0092|53 62|brain cyst
14P02007045A0092|100 107|distress
14P02008982A0463|0 4|ELISA
14P02010912A0366|73 90|MalT binding sites
14P02010912A0366|129 143|pulCp promoters
14P02011924A0729|74 79|MU/day
14P02011924A0729|132 144|cell leukemia
14P02012097T0000|45 73|Plasmodium falciparum malaria
14P02012789A0051|10 23|family history
14P02014928T0000|21 39|rhinoconjunctivitis
14P02014928T0000|73 92|serum albumin powder
14P02015921A0523|8 18|subdivision
14P02015921A0523|21 32|Category pN1
14P02015921A0523|41 50|metastasis
14P02016053A0752|0 30|Amino acid sequence comparisons
14P02016053A0752|165 184|DNA binding activity
14P02016769A0720|22 30|strengths
14P02016769A0720|36 44|promoters
14P02016769A0720|67 74|contexts
14P02017159A0646|0 5|Grasso
14P02017159A0646|10 11|A.
14P02017271A0502|21 31|improvement
14P02017271A0502|34 41|strength
14P02017271A0502|73 80|patients
14P02017271A0502|93 100|controls
14P02017414A0307|0 2|Age
14P02017414A0307|5 7|POI
14P02017414A0307|40 48|Line RBC2
14P02017414A0307|55 61|Line F.
14P02019572A0000|13 25|DNA sequences
14P02019572A0000|59 83|rat liver pyruvate kinase
14P02019572A0000|122 169|chloramphenicol acetyltransferase reporter genes
14P02019572A0000|308 327|hepatoma HepG2 cells
14P02019572A0000|327 341|rat hepatocytes
14P02019572A0000|386 396|C2C12 cells
14P02019572A0000|400 408|CHO cells
14P02020082A0356|3 13|disturbance
14P02020082A0356|25 36|gas exchange
14P02020082A0356|63 67|AaDO2
14P02020082A0356|98 108|dysfunction
14P02020082A0356|113 117|AaDO2
14P02020082A0356|134 145|relationship
14P02020082A0356|208 221|plasma colloid
14P02020082A0356|239 241|PCW
14P02020314A1290|12 35|micrograms/kg/day GM-CSF
14P02020314A1290|69 84|thrombocytopenia
14P02020314A1290|90 130|carboplatin-cyclophosphamide chemotherapy
14P02021630A1104|79 81|DNA
14P02021630A1104|92 107|guanine N7 sites
14P02021630A1104|124 126|DNA
14P02021630A1104|144 174|DNA phosphodiester conformation
14P02022188A0112|38 48|BJ1 protein
14P02022188A0112|129 131|DNA
14P02022188A0112|160 182|mobility group proteins
14P02022188A0112|182 185|HMGs
14P02022188A1463|17 29|gene products
14P02022188A1463|81 95|order structure
14P02022188A1463|98 109|prerequisite
14P02022188A1463|123 137|gene expression
14P02022920A0334|3 17|C4BP alpha gene
14P02022920A0334|86 88|UTR
14P02023097A0000|8 34|immunodeficiency virus type
14P02023097A0000|35 39|HIV-1
14P02023097A0000|41 51|Rev protein
14P02023097A0000|136 152|virus replication
14P02023421A0343|7 19|proliferation
14P02023421A0343|22 32|fibroblasts
14P02023421A0343|36 53|collagen synthesis
14P02023421A0343|110 122|wound healing
14P02023904A0120|3 11|CDC7 gene
14P02023904A0120|25 34|AUG codons
14P02023904A0120|44 66|translation start sites
14P02024252A0000|47 65|disability pensions
14P02024252A0000|70 81|municipality
14P02024252A0000|84 92|Nordreisa
14P02024252A0000|103 108|Norway
14P02024488A0506|0 3|HeLa
14P02024488A0506|7 23|Jurkat cell lines
14P02024488A0506|51 62|CMV promoter
14P02024488A0506|67 75|HIV-1 LTR
14P02024488A0506|103 121|neomycin resistance
14P02024625A0202|0 10|Differences
14P02024625A0202|24 35|presentation
14P02024625A0202|47 56|appearance
14P02024625A0202|86 97|similarities
14P02024791A0582|0 11|MEASUREMENTS
14P02024791A0582|15 26|MAIN RESULTS
14P02024791A0582|83 99|FEV1 measurements
14P02024791A0582|104 115|L atropine/0
14P02024791A0582|118 133|L metaproterenol
14P02024816A0521|7 11|ELISA
14P02024816A0521|43 46|SP-A
14P02024816A0521|72 89|pneumonia patients
14P02025515A0979|16 19|t1/2
14P02026144A0741|17 30|GUS expression
14P02026144A0741|78 81|NRS1
14P02026144A0741|97 100|NRS2
14P02026147A0000|11 13|Ca2
14P02026147A0000|27 29|CaM
14P02026147A0000|41 54|protein kinase
14P02026147A0000|55 64|CaM kinase
14P02026147A0000|138 148|CaM kinases
14P02026461A0760|44 54|individuals
14P02026491A0399|41 43|NMF
14P02027839A0250|3 9|muscles
14P02027839A0250|65 70|values
14P02027839A0250|83 89|density
14P02027839A0250|93 101|capillary
14P02027839A0250|104 114|fiber ratio
14P02027839A0250|150 157|distance
14P02028125A0101|51 63|AIDS patients
14P02028125A0101|89 103|tumour response
14P02028125A0101|112 125|cancer therapy
14P02029468A0296|0 23|Serum TNF concentrations
14P02029468A0296|75 90|reference limits
14P02030910A0000|33 41|ETS1 gene
14P02030910A1070|0 33|Polymerase chain reaction analysis
14P02030910A1070|33 41|ETS1 cDNA
14P02033038A0309|23 37|E3 polypeptides
14P02033038A0309|108 109|E3
14P02033062A1169|6 22|promotor function
14P02033062A1169|69 81|chicken IGF-I
14P02033062A1169|92 94|DNA
14P02033062A1169|110 125|reporter plasmid
14P02034655A1224|47 65|transfection assays
14P02034655T0000|0 15|Characterization
14P02034655T0000|27 48|integrin gene promoter
14P02034669A0293|13 22|transcript
14P02034669A0293|57 66|expression
14P02034676A0267|18 31|rhombotin gene
14P02035805T0000|0 27|Angina haemorrhagica bullosa
14P02036066A0000|57 92|hemoglobin polyoxyethylene conjugate
14P02036066A0000|92 94|PHP
14P02038293A0919|0 9|Conclusion
14P02038293A0919|11 24|inlet type VSD
14P02038293A0919|127 137|VSD closure
14P02038326A0538|3 19|gcd2-503 mutation
14P02038326A0538|69 71|80S
14P02038326A0538|141 169|translation initiation factor
14P02038326A0538|183 199|43S-48S particles
14P02038784A0317|17 19|ARC
14P02041088A1053|30 33|DR60
14P02041088A1053|78 81|DR60
14P02041088A1053|101 147|reporter chloramphenicol acetyltransferase gene
14P02044785A0000|15 28|adenocarcinoma
14P02044785A0000|40 54|retroperitoneal
14P02044950A0258|8 32|polymerase chain reaction
14P02044950A0258|45 56|U6 RNA genes
14P02044975A0380|8 13|volume
14P02044975A0380|87 98|instillation
14P02044975A0380|126 136|application
14P02044975A0380|142 147|volume
14P02045366A1149|0 22|Hydrophobicity analysis
14P02045366A1149|45 61|KlaB polypeptides
14P02045366A1149|92 107|KlaC polypeptide
14P02045524A0000|15 26|availability
14P02045524A0000|62 65|Food
14P02045524A0000|69 87|Drug Administration
14P02045524A0000|88 90|FDA
14P02045524A0000|173 184|end-of-phase
14P02045524A0000|202 214|drug sponsors
14P02045809A0331|25 46|B. sphaericus products
14P02045809A0331|46 53|ABG-6184
14P02045809A0331|72 76|BSP-2
14P02046202A0625|26 40|IgA nephropathy
14P02047597A0149|48 62|field condition
14P02052544A0641|15 28|DNA polymerase
14P02052544A0641|100 113|DNA polymerase
14P02052544A0641|130 133|DPB2
14P02052592A0000|74 86|bone turnover
14P02052592A0000|193 212|estrogen replacement
14P02052592A0000|252 255|IL-1
14P02052592A0000|260 286|tumor necrosis factor alpha
14P02052592A0000|285 293|TNF-alpha
14P02052592A0000|303 320|phytohemagglutinin
14P02052592A0000|388 393|GM-CSF
14P02053289A0701|15 28|nt differences
14P02053289A0701|83 96|nt differences
14P02054754A0919|65 75|Sandostatin
14P02055484A0538|9 20|PCR products
14P02055484A0538|40 43|ATG1
14P02055484A0538|50 53|ATG2
14P02056553T0000|28 40|translocation
14P02056553T0000|44 54|swine model
14P02060052A0954|41 48|radicals
14P02060052A0954|64 74|hepatocytes
14P02060052A0954|78 89|mitochondria
14P02061282A0447|16 28|pMxL1 plasmid
14P02061282A0447|96 106|orientation
14P02061282A0447|145 171|recombination junction site
14P02061333A0784|2 9|evidence
14P02061333A0784|16 23|presence
14P02061333A0784|26 32|introns
14P02061333A0784|42 50|acvA gene
14P02061333A1359|56 90|phosphopantetheine-attachment sites
14P02061333A1359|102 118|thioesterase site
14P02061333A1359|149 165|reaction sequence
14P02061333A1359|189 202|ACV tripeptide
14P02062116A0688|0 8|Pargyline
14P02062116A0688|11 37|monoamine oxidase inhibitor
14P02062933A0738|67 69|AOF
14P02062933A0738|71 87|flutamide females
14P02064119A1172|43 47|L/min
14P02064119A1172|83 87|L/min
14P02064119A1172|116 123|ABSTRACT
14P02064119A1172|138 142|WORDS
14P02065022A0747|9 17|deletions
14P02065022A0747|61 81|transforming activity
14P02066246A0258|51 79|Massachusetts Cancer Registry
14P02068085A1273|76 78|Mlu
14P02068085A1273|88 106|activation sequence
14P02069738A0000|22 37|stimulus control
14P02069873X0000|0 8|Mechanism
14P02069873X0000|26 42|vav protooncogene
14P02069873X0000|140 162|differentiation lineage
14P02070227T0000|11 22|cell seeding
14P02072238T0000|0 16|Menetrier disease
14P02072798A0330|16 28|stabilization
14P02072798A0330|39 45|therapy
14P02073222A0269|20 34|amitriptyline n
14P02073222A0269|38 50|moclobemide n
14P02073222A0269|69 81|week protocol
14P02075876A0408|3 20|stimulus threshold
14P02075876A0408|23 25|EER
14P02075876T0001|0 7|Analysis
14P02075876T0001|37 39|EER
14P02076620A0548|12 35|plasma fibrinogen levels
14P02076620A0548|85 95|gemfibrozil
14P02076620T0000|0 10|Gemfibrozil
14P02076816T0000|82 109|IME1 transcript accumulation
14P02077560T0000|35 51|safety assessment
14P02078080T0040|16 25|Madagascar
14P02078080T0040|40 52|disadvantages
14P02078570A0287|21 30|expression
14P02078570A0287|50 58|integrins
14P02079811A0407|39 45|EMB AZS
14P02079811A0407|107 121|acid production
14P02080902A0183|54 71|avoidance response
14P02081463A0110|28 45|Spec gene activity
14P02081463A0110|63 67|Spec1
14P02081463A0110|83 97|initiation site
14P02083199A1175|0 21|Phosphopeptide mapping
14P02083199A1175|36 60|autophosphorylation sites
14P02083199A1175|70 76|EGFR-IC
14P02083199A1175|105 108|EGFR
14P02083230A0938|34 47|signal peptide
14P02083230A0938|76 100|amino acid residue domain
14P02083230A0938|103 123|N-glycosylation sites
14P02083253A1512|3 26|TCF-1 alpha binding site
14P02083253A1512|42 68|TCR alpha enhancer activity
14P02083253A1512|139 149|TCF-1 alpha
14P02083546A0000|95 105|amine oxime
14P02083546A0000|106 116|99mTc-HMPAO
14P02083546A0000|139 163|photon emission tomograms
14P02083546A0000|196 204|Alzheimer
14P02083546A0000|282 302|motor neurone disease
14P02088781A0653|3 9|results
14P02088781A0653|59 71|density units
14P02088781A0653|77 85|influence
14P02088781A0653|101 108|accuracy
14P02088781A0653|114 120|absence
14P02088781A0653|126 137|compensation
14P02089054A0121|0 2|IdB
14P02089054A0121|26 47|liquid-solid partition
14P02089054A0121|165 175|UV detector
14P02091890A0614|12 22|eltoprazine
14P02091890A0614|81 90|aggression
14P02091890A0614|102 112|interaction
14P02091890A0614|116 126|exploration
14P02091890A0614|158 167|inactivity
14P02091890A0614|180 187|sedation
14P02092131T0000|40 55|hypersensitivity
14P02092131T0000|66 80|transfer factor
14P02093033T0001|0 5|Effect
14P02093033T0001|36 48|plutonium-239
14P02093033T0001|50 68|hexachlorobutadiene
14P02093033T0001|72 89|tributyl phosphate
14P02093033T0001|94 105|thymus gland
14P02093741A0211|0 14|Data collection
14P02093741A0211|112 118|MAXITAB
14P02093741A0211|149 166|analysis technique
14P02093888A0293|0 4|ARPIA
14P02093888A0293|41 44|DBMS
14P02094221A0247|0 7|Diuresis
14P02094257T0000|17 44|adenosine deaminase activity
14P02095150T0000|7 23|strain adaptation
14P02095150T0000|33 47|hip replacement
14P02095150T0000|78 96|ingrowth components
14P02099622A1046|0 19|Immuno-cytochemistry
14P02099622A1046|41 60|Campylobacter jejuni
14P02099622A1046|178 194|Campylobacter spp
14P02102823A0492|0 18|Promoter activities
14P02102823A0492|57 83|neomycin phosphotransferase
14P02102823A0492|85 105|reporter gene systems
14P02102831A1282|22 40|soybean actin genes
14P02102831A1282|75 76|CT
14P02102831A1282|118 120|DNA
14P02103140A1088|10 17|patients
14P02103140A1088|149 165|retransplantation
14P02103403A0149|2 8|patient
14P02103403A0149|13 19|history
14P02103403A0149|28 41|alcohol intake
14P02103403A0149|80 87|steroids
14P02105497A1092|26 45|amino acid sequences
14P02105497A1092|48 61|HSP70 proteins
14P02105497A1092|86 94|BiP genes
14P02105497A1092|137 147|HSP70 genes
14P02106287A0478|0 12|Spore inocula
14P02106287A0478|52 57|0.5-in
14P02107073A0584|31 34|STE4
14P02107073A0584|38 51|STE18 proteins
14P02107073A0584|74 91|pheromone response
14P02107073A0584|111 114|STE4
14P02107073A0584|147 151|STE18
14P02107548A0727|7 23|transcription-PCR
14P02107548A0727|59 61|RNA
14P02107548A0727|130 132|ARF
14P02109544A0000|30 44|screening tests
14P02109544A0000|47 67|Chlamydia trachomatis
14P02109544A0000|97 119|decision analysis model
14P02109544A0000|132 169|leukocyte esterase urine dipstick test
14P02109544A0000|214 216|DFA
14P02110145T0000|0 9|Sequencing
14P02110145T0000|59 62|CfiA
14P02110145T0000|68 78|Bacteroides
14P02110145T0000|87 93|TAL2480
14P02110145T0000|124 127|CfiA
14P02110145T0000|131 160|Bacillus cereus beta-lactamase
14P02110148A0423|9 24|HindIII fragment
14P02110148A0423|40 60|DNA sequence analysis
14P02110148A0423|89 111|B. subtilis IF2 protein
14P02110148A0423|200 203|ClaI
14P02110148A0423|242 244|IF2
14P02111015A0574|82 100|sequence similarity
14P02111015A0574|115 134|IFN response factors
14P02111015A0574|134 138|IRF-1
14P02111015A0574|142 146|IRF-2
14P02113015A0295|8 15|seizures
14P02113015A0295|33 41|pregnancy
14P02113174A0064|56 79|transcription factor Sp1
14P02113174A0957|0 6|Krox-24
14P02113455A0207|18 28|variability
14P02113455A0207|55 67|consideration
14P02113455A0207|97 112|threshold levels
14P02113699A0372|3 10|patients
14P02113699A0372|27 35|subgroups
14P02113699A0372|43 50|patients
14P02113699A0372|88 89|IM
14P02113699A0372|98 105|patients
14P02113699A0372|157 164|patients
14P02113901A0000|8 10|CO2
14P02113901A0000|36 46|normocapnia
14P02113901A0000|96 99|PaO2
14P02115111T0000|0 9|Expression
14P02115111T0000|11 29|nucleotide sequence
14P02115111T0000|59 72|reading frames
14P02115111T0000|77 91|nif gene region
14P02115111T0000|92 102|Anabaena sp
14P02115111T0000|103 116|strain PCC7120
14P02115115A1053|66 73|CAR1 URS
14P02115115A1053|128 138|yeast genes
14P02115116A1137|22 35|sequence match
14P02115116A1137|61 77|promoter elements
14P02115118A0565|112 155|sucrose density gradient ultracentrifugation
14P02115121A0000|0 12|Yeast mutants
14P02115121A0000|25 54|pet complementation group G104
14P02115121A0000|86 107|dehydrogenase activity
14P02115121A0000|132 161|dihydrolipoyl transsuccinylase
14P02115121A0000|162 164|KE2
14P02115122A0562|8 15|residues
14P02115122A0562|27 36|repression
14P02115122A0562|68 78|amino acids
14P02115122A0562|109 119|truncations
14P02115572A1323|17 35|V lambda pseudogene
14P02115572A1323|69 84|U266 lambda gene
14P02115889A0436|29 37|structure
14P02115889A0436|52 59|Gx alpha
14P02115889A0436|80 88|kilobases
14P02116071A0000|43 56|stage children
14P02116071A0000|92 121|type hypersensitivity reaction
14P02116071A0000|172 174|IgE
14P02116071A0000|322 324|IgG
14P02116537A1237|53 55|MIC
14P02116537A1237|58 60|AMK
15P02117799T0000a|0 3|Uses
15P02117799T0000a|6 20|orthoclone OKT3
15P02117799T0000a|79 100|kidney transplantation
15P02117799T0000b|0 3|Uses
15P02117799T0000b|6 20|orthoclone OKT3
15P02117799T0000b|79 100|kidney transplantation
14P02118519A0516|32 47|consensus motifs
14P02118519A0516|104 131|nerve growth factor receptor
14P02118519A0516|141 161|neurofilament protein
14P02118525A0737|36 47|CCK promoter
14P02118525A0737|117 162|herpes simplex virus thymidine kinase promoter
14P02118612A0629|15 30|supine restraint
14P02118612A0629|39 58|DOPAC concentrations
14P02119530T0000|0 8|Influence
14P02119530T0000|11 30|metoprolol treatment
14P02119626A0471|47 56|dimensions
14P02119946T0000|27 38|care setting
14P02119946T0000|41 52|introduction
14P02120707A0594|40 43|Raji
14P02120707A0594|74 83|V elements
14P02120707A0594|103 131|HLA-DRA X-box oligonucleotide
14P02120833A0000|2 8|Denmark
14P02120833A0000|45 58|hepatitis NANB
14P02120833A0000|59 66|TAH-NANB
14P02121371T0000|3 11|NF1 locus
14P02121371T0000|56 58|GAP
14P02121371T0000|62 79|yeast IRA proteins
14P02122454A1042|9 19|replacement
14P02122454A1042|22 27|Phe-62
14P02122454A1042|32 34|Ser
14P02122454A1042|55 65|determinant
14P02123029A0478|16 34|Raja immunoglobulin
14P02123029A0478|76 94|spleen cDNA library
14P02123029A0478|107 113|Raja VH
14P02123293A0227|0 4|Petko
14P02123293A0227|9 10|S.
14P02123295A0645|0 9|Disruption
14P02123295A0645|12 15|ARF2
14P02123300T0000|75 87|hemophilia A.
14P02123300T0000|98 120|Factor VIII Study Group
14P02123466A0272|32 35|AP-4
14P02123466A0272|115 125|DNA binding
14P02123467A0811|81 85|MyoD1
14P02123467A0811|89 91|Sp1
14P02123467A0811|178 180|Sp1
14P02123467A0811|184 188|MyoD1
14P02123820A0000|0 6|Effects
14P02123820A0000|19 35|monoamine oxidase
14P02123820A0000|36 38|MAO
14P02123820A0000|74 88|MAO-B inhibitor
14P02123820A0000|115 127|MAO inhibitor
14P02123820A0000|184 186|FIA
14P02123875A0223|96 120|signal peptidase cleavage
14P02123875A0223|143 155|translocation
14P02123875A0223|172 195|amino acid substitutions
14P02123875A0223|201 213|COOH terminus
14P02123875A0223|241 253|substitutions
14P02123875A0223|259 270|NH2 terminus
14P02123877A1452|29 39|egr-1 mRNAs
14P02123877A1452|79 89|liver cells
14P02123877A1452|156 176|serum response factor
14P02123877A1452|191 200|regulation
14P02123877A1452|218 231|gene induction
14P02124433A0235|80 86|Group A
14P02124433A0235|95 97|MMC
14P02124433A0235|99 102|5-FU
14P02124433A0235|104 115|chemotherapy
14P02124433A0235|141 143|MMC
14P02124433A0235|145 148|5-FU
14P02124433A0235|150 155|OK-432
14P02124433A0235|158 160|PSK
14P02124433A0235|162 179|immunochemotherapy
14P02124710A0193|38 57|c-jun protooncogenes
14P02124710A0193|78 97|proliferation period
14P02124710A0193|99 130|osteoblast phenotype development
14P02124710A1624|41 55|Fos-Jun complex
14P02124710A1624|59 67|AP-1 site
14P02124710A1624|82 98|collagen promoter
14P02124710A1624|140 143|VDRE
14P02125016A0145|0 3|PBSX
14P02125016A0145|35 46|SOS response
14P02125153A0410|32 40|treatment
14P02125153A0410|69 70|R3
14P02125153A0410|80 81|R5
14P02125153A0410|96 106|Z5 patients
14P02125153A0410|110 118|organisms
14P02125153A0410|130 141|streptomycin
14P02125153A0410|145 153|isoniazid
14P02126417A0408|66 81|control subjects
14P02126417A0408|93 95|VHF
14P02126504A0602|10 22|Rh-antibodies
14P02126504A0602|78 86|Rh-system
14P02129338A0568|10 28|amino acid sequence
14P02129338A0568|64 100|alga Scenedemus obliquus plastocyanin
14P02131652A0883|13 39|serum gastrin concentration
14P02131652A0883|108 115|AUC0-120
14P02131652A0883|170 175|VTP-HM
14P02131652A0883|185 191|VTP-Cas
14P02131666A0483|33 52|examinees class II/2
14P02131902A0000|77 79|TEE
14P02131902A0000|140 143|S-LV
14P02132636A0188|0 7|Subjects
14P02132636A0188|52 66|DST suppressors
14P02133731A1572|4 5|S3
14P02133731A1572|7 9|CBF
14P02133731A1572|20 21|S5
14P02133731A1572|23 25|CBF
14P02133731A1572|39 43|1/TPC
14P02133731A1572|47 49|1/T
14P02133731A1572|90 103|control levels
14P02135343A0131|67 78|distribution
14P02135343A0131|81 92|maloclusions
14P02135343A0131|123 134|relationship
14P02135343A0131|169 189|ANGLE3 classification
14P02135536A0621|21 34|brush abrasion
14P02135536A0621|88 90|MPa
14P02135536A0621|117 118|Hk
14P02135536A0621|120 135|water absorption
14P02135536A0621|139 152|micrograms/mm3
14P02135536A0621|163 183|expansion coefficient
14P02137704A0000|76 86|association
14P02137704A0000|101 127|blood pressure measurements
14P02137704A0000|156 169|blood pressure
14P02137704A0000|205 218|blood pressure
14P02137704A0000|227 238|office visit
14P02137704A0000|245 258|blood pressure
14P02137704A0000|269 280|office visit
14P02137704A0000|287 300|blood pressure
14P02137704A0000|356 374|target organ damage
14P02137704A0000|438 451|wall thickness
14P02137704A0000|460 473|wall thickness
14P02137704A0000|482 495|wall thickness
14P02137704A0000|539 557|wall thickness/left
14P02137704A0000|577 590|diameter ratio
14P02138707A0198|39 68|lambda gt11 expression library
14P02138707A0198|150 194|histocompatibility complex A alpha gene X box
14P02138707A0198|200 220|transcription element
14P02138915A1060|3 10|p36 gene
14P02138915A1060|102 109|ABSTRACT
14P02138915A1060|124 128|WORDS
14P02138992A0911|17 25|treatment
14P02138992A0911|80 91|modification
14P02138992A0911|122 129|approach
14P02139473A1603|84 101|Fur concentrations
14P02139473A1603|161 183|Shine-Dalgarno sequence
14P02139891A0532|68 70|EIV
14P02139891A0532|96 105|TAGA motif
14P02139891A0532|119 126|TATA box
14P02139891A0532|130 139|EIIF sites
14P02139891A0532|175 187|ATF/CREB site
14P02141425A0175|15 32|fingertip-to-floor
14P02141425A0175|34 37|MFTF
14P02141425A0175|87 98|measurements
14P02142240A0506|37 50|response rates
14P02142240A0506|64 76|concentration
14P02142240A0506|79 96|estrogen receptors
14P02142240A0506|108 128|progesteron receptors
14P02142486A0367|0 10|Teicoplanin
14P02142486A0367|74 84|bacteraemia
14P02142921T0000|11 50|hormone-releasing hormone analog therapy
14P02142955A0248|2 12|Experiments
14P02142955A0248|90 99|appearance
14P02142955A0248|129 137|exemplars
14P02142993A0176|81 93|leishmaniasis
14P02142993A0176|102 111|L. tropica
14P02142993A0176|148 158|L. infantum
14P02142993A0176|196 201|France
14P02143023A0729|18 33|octamer elements
14P02143023A0729|38 54|adenovirus genome
14P02143023A0729|104 119|octamer elements
14P02143023A0729|137 152|repeat sequences
14P02143186A0867|38 41|AHA3
14P02143186A0867|43 46|AHA2
14P02143186A0867|122 134|coding region
14P02143186A1306|0 21|Northern blot analysis
14P02143186A1306|33 41|AHA2 mRNA
14P02143186A1306|64 66|RNA
14P02143768T0000|0 8|Impaction
14P02143768T0000|11 26|gastrostomy tube
14P02143961A0400|4 18|antidepressants
14P02143961A0400|30 43|pain threshold
14P02143961A0400|56 67|pretreatment
14P02144290A1444|0 2|Sci
14P02144558A1022|1 16|needs assessment
14P02144610A1306|0 8|TCR alpha
14P02144610A1306|11 30|beta gene expression
14P02144610A1306|57 62|T-cell
14P02144610A1306|87 92|T beta
14P02144610A1306|119 130|AMP response
14P02144610A1306|174 180|T alpha
14P02144610A1306|198 215|TCR alpha enhancer
14P02144610A1306|220 234|decamer element
14P02144610A1306|271 288|TCR beta promoters
14P02145195A0253|85 96|binding site
14P02145195A0253|99 109|Sm proteins
14P02145268A0746|10 28|nucleotide sequence
14P02145268A0746|70 81|organization
14P02145268A0746|92 105|collagen genes
14P02145268A0746|143 153|COL3A1 gene
14P02145268A1454|36 50|EDS-IV collagen
14P02145268A1454|52 67|cyanogen bromide
14P02145268A1454|79 99|collagenase digestion
14P02146266A0000|13 34|BamHI-HindIII fragment
14P02146266A0000|51 98|Neurospora crassa CuZn superoxide dismutase gene
14P02146266A0000|162 188|deoxyoligonucleotide probes
14P02146266A0000|215 243|N. crassa amino acid sequence
14P02146495A0706|85 105|leucine zipper domain
14P02146495A0706|139 141|CRE
14P02147223A1047|14 16|CRE
14P02147223A1047|27 40|c-fos promoter
14P02147223A1047|77 79|E1a
14P02147223A1047|86 89|HeLa
14P02147223A1047|93 102|PC12 cells
14P02147422A0000|49 68|U1-70K snRNP protein
14P02148219A0508|19 28|hypothesis
14P02148219A0508|78 85|rigidity
14P02148219A0508|95 102|extensor
14P02148219A0508|130 136|muscles
14P02148291A0173|25 44|HSE oligonucleotides
14P02148291A0173|76 94|HSE binding domains
14P02148291A0173|110 146|tomato lambda gt11 expression library
14P02148508A0374|6 9|AVLF
14P02148508A1478|44 46|TCM
14P02148799A0000|47 70|nitrogen control circuit
14P02148799A0000|71 87|Neurospora crassa
14P02149487A0348|4 38|days dexamethasone suppression test
14P02149487A0348|66 96|dehydroepiandrosterone-sulphate
14P02149487A0348|143 164|androstenedione levels
14P02149566A0478|10 19|P-31 NMR-S
14P02149566A0478|46 47|Pi
14P02149566A0478|51 65|phosphocreatine
14P02149566A0478|67 69|PCr
14P02149566A0478|102 112|LVH baboons
14P02149570T0000|31 50|protein S deficiency
14P02150473T0067|8 12|study
14P02151229A0000|0 7|Regional
14P02151229A0000|41 72|N-isopropyl-123I-iodoamphetamine
14P02151229A0000|117 118|CT
14P02151229A0000|160 176|diabetes mellitus
14P02151229A0000|177 181|NIDDM
14P02151229A0000|210 231|fasting plasma glucose
14P02151229A0921|0 17|Mean ROI-A/B ratio
14P02153243A0965|76 106|fibroblast growth factor family
14P02153683A1579|81 90|uvomorulin
14P02153683A1579|93 94|Na
14P02153683A1579|100 105|ATPase
14P02153977A0364|42 51|initiation
14P02153977A0364|54 64|development
14P02153977A0364|114 124|culmination
14P02154467A0709|3 13|PC2 protein
14P02154467A0709|82 99|furin gene product
14P02154474A1504|39 57|cAMP responsiveness
14P02154474A1504|77 84|P-450scc
14P02154474A1504|109 119|P-450 genes
14P02154599A0382|33 63|gel mobility retardation assays
14P02154599A0382|95 113|Zta fusion proteins
14P02154599A0382|154 156|DSL
14P02154599T0000|3 20|zta transactivator
14P02154599T0000|46 66|cycle gene expression
14P02154599T0000|115 118|AP-1
14P02154599T0000|122 130|ZRE sites
14P02154599T0000|132 146|target promoter
14P02154599T0000|149 164|enhancer regions
14P02154602A0092|24 39|mouse Mx protein
14P02154602A0092|60 74|influenza virus
14P02154686A0185|0 8|Fragments
14P02154686A0185|97 124|beta-galactosidase synthesis
14P02154686A0185|149 176|polyomavirus enhancer region
14P02154885A0153|19 29|mutagenesis
14P02154885A0153|83 96|loop structure
14P02154885A0153|116 136|substrate recognition
14P02155017A1106|21 31|LMW heparin
14P02155017A1106|72 91|hypertriglyceridemia
14P02155017A1106|143 160|observation period
14P02155017A1106|191 203|complications
14P02156828A0164|10 28|amino acid sequence
14P02157067A0610|0 6|Summers
14P02157067A0610|8 15|Virology
14P02157141A0923|16 24|T antigen
14P02157141A0923|39 51|topoisomerase
14P02157141A0923|69 71|DNA
14P02157141A0923|133 135|DNA
14P02157764A1115|1 16|rabbit antiserum
14P02157764A1115|104 116|cDNA sequence
14P02157882T0000|0 11|Conservation
14P02157882T0000|73 86|transformation
14P02158099A0487|11 31|cotransfection assays
14P02158099A0487|36 52|Chang liver cells
14P02158099A0487|52 54|CCL
14P02158099A0487|125 148|pSV2CAT reporter plasmid
14P02158927A0000|52 62|COR segment
14P02158927A0000|96 99|CYC1
14P02158927A0000|101 104|UTR1
14P02158927A0000|106 109|UTR3
14P02158927A0000|111 114|OSM1
14P02158927A0000|121 123|Gly
14P02158927A0000|128 131|RAD7
14P02159470A1432|20 34|protein factors
14P02159470A1432|63 74|Mt sequences
14P02159470A1432|112 121|regulation
14P02159470A1432|127 139|transcription
14P02159470A1432|206 220|phosphorylation
14P02159559A0779|48 64|DNA amplification
14P02160502A0471|2 31|recombination signal sequences
14P02160622A0000|57 71|hot-plate tests
14P02160622A0000|78 90|motor effects
14P02160622A0000|120 151|benzodiazepine agonist midazolam
14P02160955A0899|0 9|Constructs
14P02160955A0899|27 32|AATAAA
14P02162049A0291|66 77|DNA sequence
14P02162103A0000|42 44|RNA
14P02162103A0000|55 68|phosphoprotein
14P02162103A0000|79 96|parainfluenza type
14P02162103A0000|103 107|PIV-2
14P02162103A0000|130 132|RNA
14P02162103A0000|140 150|nucleotides
14P02162103A0000|204 217|reading frames
14P02162103A0000|244 254|amino acids
14P02162467A0311|10 24|cytR expression
14P02162467A0311|51 62|CytR protein
14P02162467A0311|88 103|cAMP/CAP complex
14P02162754A0339|31 49|amino acid sequence
14P02162754A0339|53 85|3T3-L1 adipocyte insulin receptor
14P02162754A0801|0 2|PAO
14P02162754A0801|22 37|phosphoryl group
14P02162754A0801|95 113|signal transmission
14P02162754A0801|133 156|glucose-transport system
14P02162835A0989|17 37|sequence similarities
14P02162835A0989|80 97|heme binding sites
14P02162835A0989|102 120|copper binding site
14P02163347A0472|3 15|cDNA sequence
14P02163347A0472|30 42|reading frame
14P02163347A0472|43 45|ORF
14P02163347A0472|61 79|amino acid sequence
14P02163347A0472|138 150|ets-1 protein
14P02163382A0169|17 29|O7-LPS region
14P02163382A0169|44 58|cosmids pJHCV31
14P02163382A0169|85 106|transposon mutagenesis
14P02163382A0169|110 117|Tn3HoHo1
14P02163382A0169|206 225|target DNA sequences
14P02163394T0000|37 60|Bacillus subtilis shares
14P02163394T0000|92 106|antiterminators
14P02164585A0416|3 14|TraD protein
14P02164585A0416|21 22|Da
14P02164585A0814|3 17|protein product
14P02164585A0814|43 50|tra gene
14P02164585A0814|84 94|amino acids
14P02164585A0814|111 117|alanine
14P02164585A0814|121 127|leucine
14P02164588A0266|13 20|HN genes
14P02164588A0266|160 174|HN glycoprotein
14P02164604A0399|43 65|E2 transactivation gene
14P02164604A1574|25 35|E2 proteins
14P02164604A1574|77 89|BPV-1 mutants
14P02164604A1574|106 120|acceptor mutant
14P02164604A1574|147 159|E2 expression
14P02164637A0515|0 9|Disruption
14P02164637A0515|15 23|IRA2 gene
14P02164637A0515|70 88|nitrogen starvation
14P02164637A0515|93 111|sporulation defects
14P02165181A0299|4 9|cohort
14P02165181A0299|12 19|patients
14P02165589A0000|52 56|2C1-3
14P02165589A0000|80 91|X-chromosome
14P02165589A0000|126 153|hormone receptor superfamily
14P02165589A0888|10 18|Region II
14P02165589A0888|45 61|c-jun oncoprotein
14P02165589A0888|63 76|leucine zipper
14P02165589A0888|115 137|heterodimerization site
14P02165589A0888|153 168|fos oncoproteins
14P02166040A0385|38 61|PEPCK gene transcription
14P02166040A0385|129 150|carboxykinase promoter
14P02166040A0385|221 238|phosphotransferase
14P02166040A0385|246 278|chloramphenicol acetyltransferase
14P02166040A0385|295 308|hepatoma cells
14P02166040A0385|343 349|Moloney
14P02166040A0385|422 435|neo expression
14P02166040A0385|462 495|chloroamphenicol acetyltransferase
14P02166416A0419|21 32|tuberculosis
14P02166416A0419|67 70|ARDS
14P02166825A0198|34 41|elements
14P02166825A0198|47 54|promoter
14P02166825A0198|113 130|promoter mutations
14P02166825A0198|176 184|mutations
14P02166825A0198|200 214|promoter region
14P02167321T0000|1 9|DNA motif
14P02167321T0000|60 78|activator protein-2
14P02167321T0000|99 145|tissue-type plasminogen activator gene promoter
14P02167467T0000|3 18|26S rRNA binding
14P02167467T0000|26 43|protein equivalent
14P02167784A0109|127 141|CO2 measurement
14P02168640A0268|11 22|correlations
14P02168640A0268|51 54|SSEP
14P02168640A0268|108 119|disturbances
14P02169887A0360|57 68|capstructure
14P02169887A0360|85 92|EMCV-RNA
14P02170687A0000|3 16|E6/E7 promoter
14P02170687A0000|33 48|papillomaviruses
14P02170687A0000|85 102|transforming genes
14P02172672T0001|7 17|Goodpasture
14P02173399A0333|63 80|tissue radiographs
14P02173399A0333|81 84|STRs
14P02173399A0333|105 115|specificity
14P02173399A0333|122 132|sensitivity
14P02173405A0270|13 23|abnormality
14P02173405A0270|76 89|calcifications
14P02174105A1232|19 26|analysis
14P02174105A1232|36 45|rat organs
14P02174105A1232|55 62|staining
14P02174427A1574|103 148|ubiquinol-cytochrome c oxidoreductase activity
14P02174861A0736|0 9|Regulation
14P02174861A0736|24 34|V. cholerae
14P02174861A0736|154 156|Fur
14P02174974A0000|0 12|Transcription
14P02174974A0000|68 78|TOL plasmid
14P02174974A0000|113 129|xylR gene product
14P02175433A0575|31 48|beta A-globin gene
14P02175433A0575|64 83|Ylp vector sequences
14P02175908A0805|48 62|Ulysses element
14P02176021T0000|0 12|Determination
14P02176021T0000|44 79|electron spin resonance spectroscopy
14P02176152A0896|14 15|RA
14P02176152A0896|77 79|TPA
14P02176152A0896|90 105|AP1 binding site
14P02176152A0896|114 128|HSV tk promoter
14P02176209A0954|21 23|EFI
14P02176209A0954|25 28|NF-Y
14P02176209A0954|32 39|CBF DNAs
14P02176209A0954|58 81|gel retardation patterns
14P02176232T0001|0 11|Risk factors
14P02176232T0001|22 43|lymph nodes metastasis
14P02176232T0001|69 72|IIIA
14P02176822A0000|15 28|protein kinase
14P02176822A0000|29 32|MFPK
14P02176822A0000|85 86|BT
14P02176822A0000|90 91|BS
14P02176822A0000|159 175|glycogen synthase
14P02179052A1044|26 42|sequence families
14P02179052A1044|84 104|sequence interactions
14P02179188A1223|22 37|motile responses
14P02179188A1223|69 81|dinitrophenol
14P02179188A1223|84 98|cytochalasin B.
14P02179815A0582|6 13|p59v-rel
14P02179815A0582|39 41|CEF
14P02179815A0582|51 68|immunofluorescence
14P02179815A0582|79 86|p68c-rel
14P02179815A0582|107 109|CEF
14P02179815A0582|180 187|p68c-rel
14P02179815A0582|273 280|p59v-rel
14P02180935A0535|87 97|HL-60 cells
14P02180935A0535|125 169|chondroitin sulfate proteoglycan intermediate
14P02181760A0311|0 9|Blood flow
14P02181760A0311|34 51|Doppler ultrasound
14P02181760A0311|118 137|cotyledon resistance
14P02182240A0355|11 18|patients
14P02182240A0355|27 38|anistreplase
14P02182240A0355|53 59|heparin
14P02182240A0355|109 116|symptoms
14P02182323A0121|15 25|transcripts
14P02182323A0121|41 43|Val
14P02182323A0121|46 48|UAC
14P02182323A0121|89 105|growth conditions
14P02182618A0168|3 19|promoter activity
14P02182618A0168|55 87|chloramphenicol acetyltransferase
14P02182618A0168|88 90|CAT
14P02182618A0168|119 134|deletion mutants
14P02183467A0668|15 18|ORFs
14P02183467A0668|39 41|BIV
14P02183467A0668|83 92|similarity
14P02183467A0668|150 161|lentiviruses
14P02183467A0668|188 191|ORFs
14P02185140A0000|26 34|14DM gene
14P02185140A0000|43 68|cytochrome P450 lanosterol
14P02185140A0000|69 85|alpha-demethylase
14P02185140A0000|87 90|14DM
14P02185140A0000|177 205|yeast transcription promoters
14P02185250A0726|0 10|Truncations
14P02185250A0726|74 91|reticulum membrane
14P02187091A0721|41 57|ejection fraction
14P02187091A0721|87 103|relaxation period
14P02187871T0000|47 88|protein synthesis initiation factor eIF-4D
14P02188096A0955|3 14|contribution
14P02188096A0955|30 44|splicing events
14P02188096A0955|46 61|c-myb expression
14P02188096A0955|70 83|c-myb function
14P02188168A0000|0 9|Serum beta
14P02188168A0000|56 67|drug addicts
14P02188168A0000|102 117|HIV-1 antibodies
14P02188168A0000|164 178|lymphadenopathy
14P02188168A0000|180 185|P.G.L.
14P02190122A0633|4 15|emancipation
14P02190122A0633|50 58|influence
14P02190122A0633|76 85|motivation
14P02190122A0633|96 104|regulator
14P02190122A0633|115 122|primates
14P02190134A0572|77 108|laser photocoagulation treatment
14P02190134A0572|167 179|complications
14P02193033A0195|0 1|R.
14P02194273A0913|8 28|hyperimmune globulins
14P02194273A0913|69 81|Streptococcus
14P02194972T0000|30 31|HR
14P02194972T0000|69 89|Enterococcus faecalis
14P02195025T0000|0 9|Regulation
14P02195715A0143|10 20|individuals
14P02195715A0143|35 51|purpura fulminans
14P02195715A0143|92 102|individuals
14P02195715A0143|130 139|thrombosis
14P02195715T0000|19 38|protein C deficiency
14P02196176A0749|0 4|TREB7
14P02196176A0749|8 13|TREB36
14P02196176A0749|51 55|TREB5
14P02196311A1034|24 31|KE X 3/W
14P02196311A1034|64 81|antitumor immunity
14P02196311A1034|83 85|RNL
14P02196450A0870|0 7|Analysis
14P02196450A0870|17 32|deletion mutants
14P02196450A0870|48 68|sequence requirements
14P02196450A0870|80 82|QBP
14P02196450A0870|131 140|Q activity
14P02196450A0870|169 171|QBP
14P02196565A0606|30 33|GRFI
14P02196565A0606|36 75|repressor/activator site binding protein
14P02196565A0606|75 78|RAP1
14P02196565A0606|107 109|TUF
14P02196565A0606|138 157|MAT alpha expression
14P02196565A0606|174 177|PYK1
14P02196565A0606|206 218|GRFI/RAP1/TUF
14P02196565T0000|0 18|Yeast Gal11 protein
14P02196565T0000|116 178|factor I/repressor/activator site binding protein 1/translation
14P02198259A0685|0 7|Deletion
14P02198259A0685|94 106|reading frame
14P02198259A0685|118 126|initiator
14P02198259A0685|146 153|activity
14P02198289A0436|34 44|amino acids
14P02198289A0436|70 80|amino acids
14P02198289A0436|117 119|DNA
14P02199311A0620|7 28|transcription extracts
14P02199311A0620|73 105|transcription termination signals
14P02199311A0620|117 126|RET1 cells
14P02200150A1381|82 91|oncologist
14P02200150A1381|93 102|geneticist
14P02200150A1381|104 114|pathologist
14P02200150A1381|116 130|psychotherapist
14P02200150A1381|134 148|plastic surgeon
14P02200315A0278|0 2|IgG
14P02200315A0278|6 26|IgM antibody activity
14P02200315A0278|85 95|A60 antigen
14P02200736A1003|64 67|AP-4
14P02200736A1003|71 74|MLTF
14P02200736A1003|89 102|CACCTGTC motif
14P02201770A0188|24 42|genus Anomiopsyllus
14P02201770A0188|43 57|Anomiopsyllinae
14P02201770A0188|59 72|Anomiopsyllini
14P02201901A0229|59 70|SSN6 protein
14P02201905A1004|31 42|ABFI protein
14P02201905A1004|50 61|RAP1 protein
14P02201905A1004|123 137|gene expression
14P02202496T0000|8 16|nutrition
14P02203672A1542|22 35|cytocentrifuge
14P02204029A0184|0 22|RNase protection assays
14P02204029A0184|77 81|N-ras
14P02204029A0184|150 162|transcription
14P02204621T0000|0 8|Isolation
14P02204621T0000|52 78|tRNA nucleotidyltransferase
14P02204621T0000|105 131|tRNA nucleotidyltransferase
14P02204623A0000|3 22|juxtamembrane region
14P02204623A0000|27 42|insulin receptor
14P02204623A0000|43 44|IR
14P02204623A0000|84 98|tyrosyl residue
14P02204623A0000|99 104|Tyr960
14P02204623A0000|142 164|tyrosyl phosphorylation
14P02204623A0000|220 224|White
14P02204623A0000|226 229|M.F.
14P02204623A0000|231 240|Livingston
14P02204623A0000|242 245|J.N.
14P02204623A0000|247 252|Backer
14P02204623A0000|254 257|J.M.
14P02204623A0000|259 264|Lauris
14P02204623A0000|266 267|V.
14P02204623A0000|269 272|Dull
14P02204623A0000|274 277|T.J.
14P02204623A0000|279 285|Ullrich
14P02204623A0000|287 288|A.
14P02204623A0000|293 296|Kahn
14P02204623A0000|298 301|C.R.
14P02204625A1130|33 39|members
14P02204625A1130|63 70|response
14P02204625A1130|73 79|insulin
14P02204625A1130|88 95|mitogens
14P02204810A1080|12 14|GA2
14P02206430A0197|0 3|Pups
14P02206430A0197|79 89|DA turnover
14P02206789A0002|40 62|anaesthetic preparation
14P02206858A0000|10 18|protein C
14P02206858A0000|19 20|PC
14P02206858A0000|22 31|deficiency
14P02206858A0000|89 97|diagnoses
14P02208762A0228|3 13|grandfather
14P02208762A0228|20 32|granddaughter
14P02208762A0228|40 47|microtia
14P02208762A0228|75 82|daughter
14P02208762A0228|135 144|appendages
14P02209237A0239|31 33|IPS
14P02209237A0239|94 102|99mTc-MAA
14P02209237A0239|142 156|liver cirrhosis
14P02209243A0237|31 33|BUN
14P02209243A0237|37 39|SCr
14P02209540A1362|14 17|Ets1
14P02209540A1362|21 24|Ets2
14P02209540A1362|38 50|transcription
14P02209605A0510|21 29|MSAS gene
14P02209605A0510|61 73|reading frame
14P02209605A0510|116 117|Da
14P02209811T0000|24 42|permeability marker
14P02209811T0000|63 76|iliac arteries
14P02212540A0473|101 116|light microscopy
14P02212540A0473|121 152|transmission electron microscopy
14P02213566A0000|12 23|coenzyme Q10
14P02213566A0000|24 26|CoQ
14P02213566A0000|31 39|captopril
14P02213566A0000|61 72|hemodynamics
14P02213566A0000|144 153|infarction
14P02217307T0000|0 7|Evidence
14P02217307T0000|62 78|emptying response
14P02217741T0001|3 15|interrelation
14P02217741T0001|29 43|glucocorticoids
14P02218094A0395|33 34|Ft
14P02218094A0395|55 65|utilization
14P02218094A0395|67 68|Fm
14P02219751A0517|55 58|FEMs
14P02220102A0271|0 8|Incidence
14P02220102A0271|37 47|hygiene und
14P02220304A0501|26 30|Alcoy
14P02220304A0501|34 54|medium MS risk region
14P02220304A0501|74 79|Kurzke
14P02220304A0501|93 100|MS areas
14P02220304A0501|129 143|MS distribution
14P02220304A0501|153 158|Europe
14P02223652A0939|4 26|antithrombin unit basis
14P02223652A0939|26 27|CY
14P02223652A0939|34 35|CY
14P02223652A0939|70 71|UH
14P02223773A0000|0 38|Chick brain actin depolymerizing factor
14P02223773A0000|36 38|ADF
14P02223928T0069|22 38|serotonin agonist
14P02225687A0546|0 17|Comprehensive care
14P02225687A0546|115 142|pregnancy management options
14P02227438A0492|0 24|Primer extension analysis
14P02227438A0492|26 39|RNA sequencing
14P02227438A0492|58 82|transcription start point
14P02227438A0492|122 130|A residue
14P02228615A0974|3 6|85Sr
14P02228615A0974|28 52|distribution coefficients
14P02228615A0974|69 90|desorption experiments
14P02228615A0974|131 149|metal-oxyhydroxides
14P02229068A0156|0 14|Gene constructs
14P02229068A0156|89 99|COS-1 cells
14P02229068A0156|101 115|precursor SU-TM
14P02229068A0156|123 124|SU
14P02229068A0156|126 127|TM
14P02229072A1012|4 16|growth arrest
14P02229072A1012|56 65|conditions
14P02229072A1012|112 121|metabolism
14P02229282A0454|0 7|Patients
14P02229282A0454|22 37|serum TNF levels
14P02229282A0454|57 79|serum T3 concentrations
14P02229541T0000|0 4|Giant
14P02229541T0000|15 23|carcinoma
14P02229541T0000|45 54|literature
14P02231162T0000|43 55|tooth contact
14P02231479A0585|67 79|conversations
14P02231479A0585|101 112|conversation
14P02231479A0585|128 140|task activity
14P02233626T0000|63 80|strabismus surgery
14P02233680A1115|85 108|HaG3-A helianthinin gene
14P02233715A0914|14 31|pseudorabies virus
14P02233715A0914|35 48|IL-6 construct
14P02233715A0914|61 73|IL-6 TATA box
14P02233715A0914|78 91|RNA start site
14P02233715A0914|124 133|MRE region
14P02233715A0914|151 153|Dex
14P02233715A0914|178 179|GR
14P02233729A1065|21 24|Dhfr
14P02233729A1065|90 105|Dhfr transcripts
14P02233729A1065|148 163|Dhfr transcripts
14P02234345A0215|8 16|cyst wall
14P02234345A0215|51 60|epithelium
14P02234731A0503|55 66|inflammation
14P02234731A0503|86 93|findings
14P02234731A0503|96 106|condylomata
14P02234731A0503|118 126|dysplasia
14P02236002A0958|24 43|nucleotide diversity
14P02236002A0958|112 133|chicken TCR beta cDNAs
14P02236022A0000|3 21|protooncogene c-myb
14P02236022A0000|36 55|transcription factor
14P02236022A0000|66 68|DNA
14P02236060A1671|0 11|Modification
14P02236064A1178|0 19|S6 kinase activation
14P02236064A1178|107 121|phosphorylation
14P02236276T0000|0 3|Rats
14P02237431A0000|0 9|Expression
14P02237431A0000|20 34|T cell receptor
14P02237431A0000|34 36|TCR
14P02237431A0000|134 153|C alpha gene segment
14P02237431A0833|3 20|Ets-1 binding site
14P02237431A0833|69 75|T alpha
14P02241742A0766|50 51|HD
14P02241892A0681|0 10|Utilization
14P02241892A0681|24 46|polyadenylation signals
14P02242222T0000|12 18|address
14P02243093A0000|5 30|T-cell leukemia virus type
14P02243093A0000|30 35|HTLV-I
14P02243093A0000|66 68|Tax
14P02243093A0000|134 142|U3 region
14P02243386A0113|52 54|MHV
14P02243386A0113|62 67|DI RNA
14P02243386A0113|68 72|DIssF
14P02246362T0000|3 25|Jenkins Activity Survey
14P02246447A0460|28 44|regression slopes
14P02246447A0460|70 82|portion sizes
14P02246447A0460|112 120|r2 values
14P02246447A0460|134 146|portion sizes
14P02246803A0692|37 46|TTD method
14P02247069A0261|3 11|TUP1 gene
14P02247069A0261|62 65|V.L.
14P02247072A0794|3 27|SUP44 suppressor mutation
14P02247081A0223|29 39|VPS34 locus
14P02247081A0223|101 110|VPS34 gene
14P02247081A0223|154 172|growth temperatures
14P02247924A0078|47 60|amphotericin B
14P02247924A0078|63 73|nephrectomy
14P02248732A1113|93 100|LC cells
14P02248732A1113|152 153|NA
14P02248732A1113|167 179|DOPAC changes
14P02249872A1051|4 14|interaction
14P02249872A1051|41 50|parameters
14P02249872A1051|55 68|charge density
14P02249872A1051|86 95|microC/cm2
14P02250919A0404|0 10|Perceptions
14P02250919A0404|13 33|illness intrusiveness
14P02250919A0404|78 94|headache symptoms
14P02250919A0404|117 136|assessment intervals
14P02251119A0319|0 6|Results
14P02251119A0319|49 51|U14
14P02251119A0319|123 143|hsc70 heat shock gene
14P02252891T0000|13 19|protein
14P02252891T0000|36 46|interleukin
14P02252891T0000|48 58|stimulation
14P02252953A0300|47 55|EAT score
14P02252953A0300|108 121|susceptibility
14P02252953A0300|157 167|mood states
14P02252953A0300|174 189|eating behaviour
14P02253274A0000|3 14|Mauriceville
14P02253274A0000|18 23|Varkud
14P02253274A0000|78 81|DNAs
14P02253274A0000|116 130|characteristics
14P02253274A0000|133 145|mtDNA introns
14P02253663A0687|47 56|difference
14P02253663A0687|97 116|serum concentrations
14P02254282T0000|0 7|Sequence
14P02254282T0000|33 62|Zymomonas mobilis gene cluster
14P02254282T0000|87 104|glucose metabolism
14P02254418A0641|18 31|S. lugdunensis
14P02254418A0641|40 54|delta hemolysin
14P02254418A0641|88 90|CNS
14P02254749A0133|26 28|60K
14P02254749A0133|30 32|87K
14P02254749A0133|34 37|110K
14P02254749A0133|41 52|170K protein
14P02254749A0133|89 103|ATG start codon
14P02254749A0133|125 127|60K
14P02254749A0133|147 149|TAA
14P02256678A1224|22 42|footprinting analysis
14P02256678A1224|89 98|HSC82 gene
14P02256678A1224|131 147|protein complexes
14P02257251T0000|0 14|Pathophysiology
14P02257899T0000|15 25|interaction
14P02257899T0000|31 40|generation
14P02257899T0000|43 50|saccades
14P02258918A0242|47 55|disectors
14P02258918A0242|91 107|sampling fraction
14P02259334A0205|11 18|promoter
14P02259334A0205|43 50|sequence
14P02259334A0205|87 88|Mr
14P02259334A0205|103 110|function
14P02259795A0570|10 20|consumption
14P02259795A0570|55 66|calculations
14P02259795A0570|81 89|water PO2
14P02261254A0168|0 10|Experiments
14P02261254A0168|47 57|circulation
14P02261254A0168|63 72|conditions
14P02261254A0168|89 99|circulation
14P02261254A0168|115 125|development
14P02262439A0508|0 11|MCh infusion
14P02262439A0508|51 67|airway resistance
14P02262439A0508|77 79|QBA
14P02264601A0000|0 21|Taste reactivity tests
14P02264601A0000|87 107|alcohol nonpreferring
14P02264601A0000|108 109|NP
14P02265055A0417|0 20|Plasma concentrations
14P02265055A0417|59 73|micrograms ml-1
14P02265055A0417|85 99|micrograms ml-1
14P02265055A0417|113 129|CSF concentration
14P02266679A0740|0 8|Plasma Al
14P02266679A0740|40 50|drug course
14P02268461A0224|3 10|survival
14P02268461A0224|27 34|patients
14P02269281A1276|3 12|occurrence
14P02269281A1276|14 24|maintenance
14P02269281A1276|36 46|involvement
14P02269281A1276|62 70|sequences
14P02269281A1276|103 112|structures
14P02269281A1276|164 178|control signals
14P02269426A0428|0 2|IST
14P02269426A0428|11 20|RNA target
14P02269426A0428|21 23|TAR
14P02269426A0428|28 47|Tat trans-activation
14P02269426A0428|108 110|IST
14P02269426A0428|136 146|RNA targets
14P02269426A0428|149 168|Tat trans-activation
14P02270096T0000|36 46|nitrosamine
14P02270587A0000|13 26|treatment need
14P02270587A0000|56 64|magnitude
14P02270834A0123|21 30|HML method
14P02272095A0832|22 32|involvement
14P02272095A0832|45 55|enkephalins
14P02272095A0832|58 72|pain modulation
14P02272095A0832|94 109|cluster headache
14P02273690T0001|0 6|Effects
14P02274343A0064|6 21|foot pathologies
14P02274343A0064|33 45|metatarsalgia
14P02274343A0064|47 56|hammertoes
14P02274343A0064|77 90|hallux rigidus
14P02274343A0064|108 123|nail pathologies
14P02274343A0064|137 148|neuropathies
14P02274509A0623|0 16|Liver dysfunction
14P02274509A0623|101 123|indicator liver enzymes
14P02276891T0000|0 11|Coenzyme Q10
14P02276891T0000|12 23|blood levels
14P02277005A0227|3 20|CT characteristics
14P02277319A0211|19 31|preservatives
14P02277319A0211|88 104|product sterility
14P02277319A0211|106 121|bioburden levels
14P02277452A0116|16 30|angina pectoris
14P02277452A0116|43 46|LVEF
14P02277452A0116|48 52|LVESV
14P02277452A0116|56 64|PSP/LVESV
14P02277452A0116|166 168|ECG
14P02278217A0372|22 39|management failure
14P02278217A0372|66 75|medication
14P02278217A0372|87 98|section lead
14P02278474A0000|0 32|Serum Fibrin Degradation Products
14P02278474A0000|31 33|FDP
14P02280777T0000|3 22|uteroglobin promoter
14P02281118A1191|0 33|Prostaglandin synthesis inhibitors
14P02281330A0556|14 33|oxygen concentration
14P02281330A0556|40 43|FiO2
14P02281330A0556|51 67|Horowitz quotient
14P02281948A0245|10 30|mineral oil emulsions
14P02281948A0245|102 110|ingestion
14P02282815T0000|0 11|Significance
14P02282815T0000|28 45|basement membranes
14P02283148T0000|0 11|Significance
14P02283148T0000|14 32|cytokine production
14P02283148T0000|35 52|adhesion molecules
14P02283378A0385|97 116|ultrafiltration tube
14P02283378T0000|15 27|determination
14P02283378T0000|33 53|cephalosporin DQ-2556
14P02283378T0000|95 108|chromatography
14P02283873A0308|15 25|adolescents
14P02283873A0308|63 75|parents smoke
14P02283873A0308|84 94|involvement
14P02283873A0308|97 114|smoking prevention
14P02284393A0751|74 106|EE/low EE research classification
14P02284573A0943|25 33|BAL fluid
14P02284573A0943|74 93|methenamine staining
14P02284573A0943|95 97|BAL
14P02284573A0943|99 101|TBB
14P02287860T0001|47 62|parenchyma cells
14P02287860T0001|81 94|X-ray exposure
14P02289102A0114|7 24|audiotape cassette
14P02289102A0114|53 66|hallucinations
14P02289639A0989|15 18|HbA1
14P02289639A0989|85 97|control group
14P02290216T0001|0 5|Effect
14P02290216T0001|42 59|serum SPan-1 level
14P02291144A0493|88 104|reference methods
14P02291144A0493|114 118|MCHCH
14P02291144A0493|122 135|basophil count
14P02291628A0264|40 51|applications
14P02291628A0264|71 73|NMR
14P02291628A0264|110 119|literature
14P02291628A0264|151 163|endocrinology
14P02292272T0000|0 21|Interlimb coordination
14P02293019A0000|0 18|Antileukoproteinase
14P02293019A0000|20 22|ALP
14P02293019A0000|127 146|proteinases elastase
14P02293664A0946|36 52|vimentin promoter
14P02293664A0946|88 97|base pairs
14P02293664A0946|121 130|base pairs
14P02293664A0946|143 155|mRNA cap site
14P02294048A0881|20 53|% amino acid sequence similarities
14P02294048A0881|93 111|Bacillus megaterium
14P02295521A0922|37 47|correlation
14P02295521A0922|65 82|trapezius activity
14P02295521A0922|139 162|muscle activity patterns
14P02295521A0922|185 195|risk factor
14P02295521A0922|198 208|development
14P02296509A0997|18 34|household members
14P02296509A0997|81 97|serum p24 antigen
14P02298741A0809|0 7|Analysis
14P02298741A0809|104 106|PKC
14P02298741A0809|121 128|JK cells
14P02298741A0809|137 146|JKPE cells
14P02298741A0809|226 239|alpha antibody
14P02299543A0317|43 49|outlook
14P02300541A0000|87 99|dose inhalers
14P02300541A0000|100 103|MDIs
14P02300541A0000|140 149|surfactant
14P02300541A0000|180 188|rat lungs
14P02300577A0852|41 59|glycosylation sites
14P02300577A0852|63 87|endoglycosidase digestion
14P02300759A0000|32 55|Gustave Roussy Institute
14P02300759A0000|116 121|T1B-T2
14P02303158T0000|19 28|expression
14P02303158T0000|68 79|trk oncogene
14P02303470A0242|3 9|introns
14P02303874A1643|14 29|titration period
14P02303874A1643|32 41|adjustment
14P02303874A1643|96 112|micrograms/24 hrs
14P02303874A1643|120 136|micrograms/24 hrs
14P02305014A0226|18 28|experiments
14P02305014A0226|81 94|guide cannulas
14P02305014A0226|111 119|ventricle
14P02306539T0000|5 29|Selenastrum capricornutum
14P02306539T0000|32 41|Microfeast
14P02306539T0000|51 63|Daphnia pulex
14P02307067A1348|40 56|families Tydeidae
14P02307067A1348|57 70|Nanorchestidae
14P02307067A1348|74 85|Tarsonemidae
14P02307067A1348|113 136|concentration treatments
14P02307371A0263|43 75|transcription elongation blockage
14P02307371A0263|86 103|c-myc deregulation
14P02307371A0263|105 111|Burkitt
14P02307371A0263|133 154|transcription patterns
14P02307371A0263|178 184|Burkitt
14P02307371A0263|187 208|lymphoma c-myc alleles
14P02307371A0263|225 238|Xenopus oocyte
14P02307613A0783|0 39|Erythrocyte protoporphyrin concentration
14P02307848A0347|23 31|Crry gene
14P02307848A0347|50 52|DNA
14P02307848A0347|110 124|Eco-R1 fragment
14P02307848T0042|28 37|complexity
14P02307848T0042|43 46|Crry
14P02307850A0000|6 31|RNK-16 lambda-gt11 library
14P02307850A0000|63 87|cDNA rat NK cell protease
14P02307850A0000|86 91|RNKP-1
14P02307850A1197|14 30|RNKP-1 expression
14P02307850A1197|89 90|NK
14P02307850A1197|114 141|killer lymphocyte activities
14P02308496A0000|55 58|ACTH
14P02308496A0000|60 62|STH
14P02308496A0000|64 66|TSH
14P02308496A0000|77 78|T3
14P02308496A0000|88 96|C-peptide
14P02308496A0000|174 179|GHM-10
14P02310261A0115|3 9|abscess
14P02310261A0115|71 81|pericardium
14P02310300A0298|38 39|CT
14P02310350A0221|34 42|intensity
14P02310350A0221|82 85|ABRs
14P02310496X0000|7 24|memory impairments
14P02310496X0000|66 70|Broca
14P02310496X0000|74 88|nucleus basalis
14P02310496X0000|104 117|memory defects
14P02310496X0000|126 148|nucleus basalis lesions
14P02310496X0000|212 226|nucleus basalis
14P02310496X0000|227 228|NB
14P02310496X0000|268 272|Broca
14P02310496X0000|274 280|MS-VDBB
14P02310496X0000|285 305|place navigation task
14P02310496X0000|313 328|reference memory
14P02311544A0086|0 6|Studies
14P02311544A0086|25 36|relationship
14P02311544A0086|47 55|MSMR cyst
14P02312470A0774|3 15|BAL-to-plasma
14P02312470A0774|57 58|Na
14P02312470A0774|94 96|ELF
14P02312470A0774|112 113|Na
14P02312470A0774|173 174|Na
14P02312470A0774|195 205|circulation
14P02312689A0360|3 19|kappa coefficient
14P02312689A0360|40 51|Patho Dx Kit
14P02312689A0360|56 70|standard method
14P02315151T0020|6 12|systems
14P02315151T0020|24 29|health
14P02315151T0020|33 39|illness
14P02315472A0583|17 28|imaging time
14P02315472A0583|68 71|RASE
14P02315472A0583|78 80|C/A
14P02317413A0364|0 7|Patients
14P02317413A0364|46 66|plasma concentrations
14P02317413A0364|68 86|neutrophil elastase
14P02317413A0364|188 200|heart disease
14P02317554T0000|0 12|Determination
14P02317554T0000|32 49|imaging properties
14P02317554T0000|57 73|microscope system
14P02318208A0817|33 43|CACGTGACCCG
14P02318208A0817|73 101|transcription initiation site
14P02318208A0817|140 156|promoter sequence
14P02318208A0817|158 163|Ad2MLP
14P02319610A1527|11 19|relevance
14P02319610A1527|54 64|observation
14P02319610A1527|99 103|P.HCl
14P02320008A0651|0 5|TMBr-1
14P02320008A0651|27 50|muscle alpha-tropomyosin
14P02320999A0606|43 56|particle board
14P02320999A0606|67 78|gypsum board
14P02320999A0606|106 125|polyurethane lacquer
14P02320999A0606|149 164|emission factors
14P02320999A0606|165 174|mg m-2 h-1
14P02322535A0658|0 5|Intron
14P02323517A0557|65 90|prostaglandin E2 synthesis
14P02323517A0557|113 146|prostaglandin generation technique
14P02324102A1157|0 9|Comparison
14P02324102A1157|79 82|48K5
14P02324102A1157|92 107|lung fibroblasts
14P02324102A1157|108 114|Marynen
14P02324102A1157|116 117|P.
14P02324102A1157|119 123|Zhang
14P02324102A1157|125 126|J.
14P02324102A1157|128 135|Cassiman
14P02324102A1157|137 138|J.
14P02324102A1157|140 152|Vanden Berghe
14P02324102A1157|153 154|H.
14P02324102A1157|159 163|David
14P02324102A1157|165 166|C.
14P02324104A0151|40 66|phosphotransferase activity
14P02324104A0151|149 158|C. elegans
14P02324104A0516|12 21|C subunits
14P02324104A0516|73 83|development
14P02324104A0929|13 21|C subunit
14P02324104A0929|22 32|CeCAT alpha
14P02324104A0929|133 142|C pre-mRNA
14P02324104A1195|36 52|carboxyl terminus
14P02324104A1195|59 81|translation stop signal
14P02324104A1195|159 169|CeCAT alpha
14P02325208A0209|0 5|French
14P02325208A0209|7 8|M.
15P02325895T0000b|19 43|mechanoreceptor discharge
15P02325895T0000b|81 92|displacement
15P02325895T0000b|119 138|squirrel monkey hand
14P02326716A0139|0 6|Methods
14P02326716A0139|18 27|Cobb angle
14P02326716A0139|51 56|T7-T12
14P02326716A0139|75 101|concave rib-vertebra angles
14P02326716A0139|101 104|RVAs
14P02326716A0139|119 135|angle differences
14P02326716A0139|136 140|RVADs
14P02326946T0000|0 42|Plasma lecithin/cholesterol acyltransferase
14P02326946T0000|42 45|LCAT
14P02326946T0000|90 108|allograft viability
14P02326946T0000|118 138|liver transplantation
14P02327159T0001|0 3|Lars
14P02327159T0001|7 10|AIDS
14P02328328A0419|20 54|tumour progesterone receptor status
14P02328328A0419|64 79|tumour detection
14P02329840A0383|3 13|application
14P02329840A0383|21 35|microelectrodes
14P02329840A0383|41 51|measurement
14P02330041A0335|0 9|Expression
14P02330041A0335|19 30|localization
14P02330041A0335|41 61|transcription studies
14P02330041A0335|141 155|control element
14P02330041A0335|167 184|rRNA gene promoter
14P02330041A0335|193 205|transcription
14P02330110A1085|17 34|laboratory studies
14P02330333A0325|0 12|Accumulations
14P02330333A0325|15 18|Tl+1
14P02330333A0325|20 30|202Tl label
14P02330333A0325|49 50|Ga
14P02331361A0268|29 44|myocyte diameter
14P02331361A0268|72 88|autopsy specimens
14P02332018A0538|42 44|EIA
14P02332018A0538|60 65|WH air
14P02332018A0538|110 127|mean GH increments
14P02332798A0725|53 67|EVS stimulation
14P02333239T0000|15 21|problem
14P02333545A0313|3 14|distribution
14P02333545A0313|22 38|fibrinogen levels
14P02333545A0313|74 85|distribution
14P02333749A0411|19 37|regression analysis
14P02333749A0411|39 41|SPT
14P02333749A0411|45 53|RAST data
14P02333749A0411|69 88|serum IgE antibodies
14P02333749A0411|89 101|P. orbiculare
14P02334972A0145|3 13|examination
14P02334972A0145|26 35|assessment
14P02334972A0145|63 72|evaluation
14P02334972A0145|78 88|development
14P02334972A0145|92 100|incidence
14P02334972A0145|103 114|risk factors
14P02334972A0145|123 135|complications
14P02335034A0584|81 84|LBNP
14P02335521T0000|13 42|vitellogenin activator element
14P02335521T0000|87 122|Xenopus laevis vitellogenin promoter
14P02335713A0905|38 40|PbB
14P02335713A0905|44 56|ALAD activity
14P02335713A0905|61 76|stearate workers
14P02335815A0530|5 21|carboxyl terminus
14P02335815A0530|66 68|TRF
14P02335815A0530|70 79|C assembly
14P02336338A0931|12 25|mean luminance
14P02336338A0931|52 61|expression
14P02339005T0000|0 5|Effect
14P02339005T0000|8 20|hyperglycemia
14P02339005T0000|23 36|pain threshold
14P02339447A0162|30 32|OHA
14P02339447A0162|141 158|serum level 19-OHA
14P02339447A0162|173 236|gas chromatography/mass spectrometry-mass fragmentography method
14P02340595A0124|0 16|Sequence analysis
14P02340595A0124|106 123|plant mitochondria
14P02341669A0000|0 10|Experiments
14P02341669A0000|66 70|BAERs
14P02341669A0000|96 120|pseudorandom pulse trains
14P02341669A0000|120 143|maximum length sequences
14P02341669A0000|143 145|MLS
14P02341669A0000|150 167|Legendre sequences
14P02341669A0000|168 170|LGS
14P02342477A1292|8 11|UfAP
14P02342477A1292|15 18|UTMP
14P02342477A1292|107 123|P4-responsiveness
14P02342477A1292|168 185|recognition marker
14P02342477A1292|201 219|sequence similarity
14P02342477A1292|223 226|UfAP
14P02342477A1292|233 236|UTMP
14P02343033A0000|15 27|dates infants
14P02343033A0000|35 43|placentae
14P02343033A0000|85 93|placentae
14P02344529T0000|40 53|erythropoietin
14P02347102A0000|3 25|pseudolymphoma syndrome
14P02347102A0000|73 87|lymphadenopathy
14P02347407A0217|49 57|SE-sector
14P02347655A0193|61 73|gas exchanges
14P02347655A0193|99 120|blood inlet conditions
14P02347655A0193|120 134|blood flow rate
14P02347655A0193|134 144|temperature
14P02347655A0193|146 156|composition
14P02347655A0193|162 172|gas mixture
14P02347655A0193|179 189|ventilation
14P02347655A0193|191 212|blood tissue perfusion
14P02347655A0193|214 224|consumption
14P02348225A0192|0 3|Mean
14P02348225A0192|8 9|SE
14P02348225A0192|11 22|measurements
14P02348225A0192|116 127|distribution
14P02348225A0192|150 153|L/m2
14P02348408A0126|0 8|Attitudes
14P02348728A1153|14 23|DNA ploidy
14P02349827A0193|28 36|Videoplan
14P02349942A0287|13 19|factors
14P02349942A0287|47 53|cohorts
14P02349942A0287|83 88|recall
14P02349998A0297|0 20|Dopamine SERS spectra
14P02351239A0693|25 40|hypergastrinemia
14P02351239A0693|130 141|HDC activity
14P02351239A0693|142 164|histamine concentration
14P02351239A0693|167 182|ECL cell density
14P02351239A0693|183 198|hypergastrinemia
14P02351239A0693|218 233|gastrin infusion
14P02351239A0693|268 284|antisecretagogues
14P02351297A0000|20 36|toxicity research
14P02351297A0000|64 100|atmosphere metal corrosion inhibitors
14P02353453A1249|13 26|helicase motif
14P02353453A1249|32 51|nsP3 homology region
14P02353453A1249|55 64|RUB genome
14P02353453A1249|90 106|alphavirus genome
14P02353453A1249|128 140|rearrangement
14P02353875A0800|17 26|followings
14P02353875A0800|35 45|eosinophils
14P02353875A0800|49 59|neutrophils
14P02353875A0800|73 86|hypersecretion
14P02353875A0800|116 126|eosinophils
14P02354381A0207|10 19|treatments
14P02354381A0207|21 27|control
14P02354381A0207|76 94|fiberglass rollaway
14P02354381A0207|148 150|H/S
14P02354381A0207|154 161|nest box
14P02355293A0749|18 28|differences
14P02355293A0749|52 74|failure characteristics
14P02355293A0749|133 148|bath environment
14P02355765A0220|24 44|benzathine penicillin
14P02355765A0220|54 61|U weekly
14P02355920A0681|1 22|consensus binding site
14P02355920A0681|27 50|transcription factor SP1
14P02355920A0681|87 125|proenkephalin germ cell cap site region
14P02356823A0063|43 56|sets technique
14P02356823A0063|96 111|alarm properties
14P02357537A0451|3 9|effects
14P02357537A0451|18 26|latencies
14P02357537A0451|58 65|naloxone
14P02357537A0451|111 117|animals
14P02358975A0709|92 104|gluten intake
14P02358975A0709|120 133|IgA deficiency
14P02360336A0574|0 3|Drug
14P02360336A0574|7 21|personnel costs
14P02360336A0574|36 54|batch manufacturing
14P02360336A0574|63 77|multidose vials
14P02361008T0000|0 6|Changes
14P02361008T0000|9 17|prognosis
14P02361575T0000|17 31|carcinogenicity
14P02361575T0000|66 77|Fischer rats
14P02361575T0000|80 90|B6C3F1 mice
14P02361812A1110|30 44|baseline values
14P02361812A1110|50 57|EX group
14P02361812A1110|117 118|EX
14P02361812A1110|134 135|DE
14P02362161T0000|0 5|MK-927
14P02362161T0000|48 66|anhydrase inhibitor
14P02362803A0608|56 69|U3 snRNA genes
14P02362803A0608|89 99|Arabidopsis
14P02368931A0587|2 34|addition serum IgE concentrations
14P02370571A0663|3 10|findings
14P02370571A0663|31 47|iodine deficiency
14P02370571A0663|82 91|immigrants
14P02370571A0663|122 131|population
14P02371273A0144|54 67|kilobase pairs
14P02371517A0747|8 15|patients
14P02372496A0782|0 16|Co-administration
14P02372496A0782|19 21|5FU
14P02372496A0782|39 50|microspheres
14P02372496A0782|79 91|drug exposure
14P02372496A0782|159 176|5FU administration
14P02372712A0002|16 17|TW
14P02372712A0002|32 33|CW
14P02372712A0002|70 83|carbon dioxide
14P02372712A0002|84 87|PCO2
14P02372712A0002|92 105|plasma lactate
14P02373686T0000|29 58|chicken progesterone receptors
14P02373686T0000|147 163|receptor isoforms
14P02373810A1118|2 9|contrast
14P02373810A1118|33 44|risk factors
14P02374886A0305|3 28|Community Adjustment Scale
14P02374886A0305|35 46|outcome data
14P02374886A0305|75 86|productivity
14P02374886A0305|110 122|relationships
14P02374886A0305|127 142|presence/absence
14P02374886A0305|145 158|symptomatology
14P02376023A0307|51 54|IgG1
14P02376023A0307|75 78|IgG4
14P02376023A0307|126 128|IgE
14P02378615A0807|3 18|protein sequence
14P02378615A0807|48 66|glycosylation sites
14P02378615A0807|141 152|carbohydrate
14P02378945A0487|4 13|adaptation
14P02378945A0487|94 103|vagal tone
14P02383693A0301|83 94|Triton X-100
14P02383693A0301|102 115|M KOH solution
14P02383693A0301|136 161|chemiluminescence detector
14P02383771A0544|12 22|examination
14P02383771A0544|34 43|epithelium
14P02383771A0544|94 103|epithelium
14P02383771A0544|115 126|distribution
14P02383771A0544|158 166|cytoplasm
14P02384265A0947|57 70|polyp patients
14P02384265A0947|76 86|possibility
14P02384265A0947|89 107|prophylactic effect
14P02384265A0947|109 119|polypectomy
14P02384389A0854|27 28|YG
14P02384389A0854|42 43|YG
14P02386485A0554|3 21|nucleotide sequence
14P02386485A0554|124 130|bp poly
14P02386895A0496|0 9|Toxicities
14P02386895A0496|19 33|nausea/vomiting
14P02386895A0496|40 47|headache
14P02386895A0496|72 82|tumor sites
14P02386895A0496|88 98|hypotension
14P02386895A0496|108 119|hypertension
14P02388685A0577|32 59|oyster shell supplementation
14P02388685A0577|76 104|alkaline phosphatase activity
14P02388685A0577|104 122|bone mineralization
14P02388685A0577|187 188|CV
14P02388685A0577|228 245|phosphorus content
14P02390538A0000|38 46|gestation
14P02390538A0000|80 88|anomalies
14P02390538A0000|136 145|fiberscope
14P02390538A0000|147 160|Olympus PF18 S
14P02390633T0000|5 16|encephalitis
14P02390989A0745|29 36|GPB gene
14P02390989A0745|47 54|GPE gene
14P02390989A0745|69 83|point mutations
14P02390989A0745|131 143|reading frame
14P02391344T0000|31 62|rat NADH-cytochrome b5 reductase
14P02392032A0657|46 62|relaxation curves
14P02392032A0657|70 80|information
14P02392032A0657|86 99|distance scale
14P02392032A0657|107 118|architecture
14P02392032A0657|124 133|pore space
14P02392032A0657|171 181|ambiguities
14P02392511T0000|0 31|Serotonin 5-HT2 receptor binding
14P02393001A0324|34 37|BMIs
14P02393001A0324|69 79|definitions
14P02393001A0324|96 99|BMIs
14P02393001A0324|107 118|densitometry
14P02393895A0918|3 11|RF values
14P02393895A0918|83 95|insufficiency
14P02393895A0918|168 182|differentiation
14P02393895A0918|207 220|regurgitations
14P02394707A0789|0 16|Promoter elements
14P02394707A0789|33 40|TATA box
14P02394707A0789|41 44|GTTA
14P02394707A0789|50 58|CCAAT box
14P02394707A0789|116 120|CCAAT
14P02394707A0789|122 126|ATTGG
14P02394707A0789|150 169|nucleotide stretches
14P02394718A0130|48 70|hybridization screening
14P02394718A0130|79 105|deoxyoligonucleotide probes
14P02394718A0130|134 152|amino acid sequence
14P02395868A0322|22 31|zinc sites
14P02395868A0322|56 63|sequence
14P02395868A0322|103 115|hydrogen bond
14P02396415T0001|0 6|Results
14P02396415T0001|21 31|observation
14P02396415T0001|66 77|hypertension
14P02398897A0000|10 30|transcription factors
14P02398897A0000|43 56|RNA polymerase
14P02398897A0000|128 137|RNA chains
14P02399053A0153|63 64|RA
14P02399053A0153|99 100|RA
14P02399053A1032|3 4|Lm
14P02399053A1032|41 55|recoil pressure
14P02400070T0000|0 9|Comparison
14P02400070T0000|23 33|thiopentone
14P02400457A0469|2 11|Experiment
14P02400457A0469|35 48|supine cycling
14P02400457A0469|83 97|LBNP conditions
14P02400457A0469|215 227|Experiment I.
14P02402678A0463|43 61|% lambdacyhalothrin
14P02402678A0463|91 93|ULV
14P02402678A0463|98 119|aerosol space-spraying
14P02402678A0463|125 139|diesel/kerosene
14P02402678A0463|170 186|application rates
14P02402678A0463|202 217|mosquito control
14P02402678A0463|230 245|housefly control
14P02403035A0621|9 21|reading frame
14P02403035A0621|44 52|precursor
14P02403634A0788|0 16|Sequence analysis
14P02403634A0788|43 45|ATA
14P02403634A0788|49 54|GC box
14P02403634A0788|146 153|CArG box
14P02403634A0788|207 229|binding site homologies
14P02403634A0788|253 282|muscle-CAAT consensus sequence
14P02403926A0000|38 70|breast carcinoma cell line MDA-MB
14P02403926A0000|79 94|DNA-transfection
14P02403926A0000|99 110|NIH3T3 cells
14P02403926A0000|124 164|trk proto-oncogene receptor kinase domain
14P02403926A0000|220 226|Redmond
14P02403926A0000|235 244|Xiao-Chang
14P02403926A0307|0 9|Antibodies
14P02403926A0307|43 85|beta gal-trk receptor kinase fusion protein
14P02403926A0307|182 193|NIH3T3 cells
14P02404451A1532|15 40|scanning-deletion analysis
14P02404451A1532|90 96|Cys-118
14P02404451A1532|104 110|Cys-118
14P02404451A1532|158 172|Cys-118 residue
14P02404451A1532|233 238|GM-CSF
14P02405393T0000|22 37|characterization
14P02405393T0000|53 56|ETS2
14P02405589A0000|0 10|Information
14P02405589A0000|27 43|drug interactions
14P02405589A0000|78 95|drug-use decisions
14P02405818A0550|0 15|Branch occlusion
14P02405818A0550|17 23|Heubner
14P02405818A0550|35 45|perforators
14P02406570A0466|52 54|UAS
14P02406570A0466|83 95|test plasmids
14P02406570A0898|50 53|ARS1
14P02406570A0898|80 83|ABFI
14P02406570A0898|107 121|DNA replication
14P02406570A0898|123 126|ARS1
14P02406992A0192|64 78|amaurosis fugax
14P02406992A0192|151 168|laboratory studies
14P02406992A0192|183 204|carotid artery studies
14P02408248A0414|53 69|enzyme inhibitors
14P02409297A0984|33 46|fusion protein
14P02409297A0984|102 116|virus particles
14P02409297A0984|155 172|HBsAg determinants
14P02411513A0667|5 19|characteristics
14P02411513A0667|22 28|N22/P22
14P02411513A0667|114 130|dorsal negativity
14P02417023T0001|0 3|Role
14P02417023T0001|6 25|superoxide dismutase
14P02417023T0001|67 79|determination
14P02417669A0218|2 25|maximum photosensitivity
14P02417669A0218|136 155|amino acid aspartate
14P02418701A0000|14 23|likelihood
14P02418701A0000|77 85|intensity
14P02418701A0000|104 119|antigen staining
14P02418701A0000|121 129|specimens
14P02418701A0000|197 210|diverticulitis
14P02418701A0000|244 252|technique
14P02419327A0998|3 18|priming activity
14P02419327A0998|20 22|DNA
14P02419327A0998|162 164|DNA
14P02419588A0284|0 1|A.
14P02420432A1060|12 22|conjunction
14P02420432A1060|36 49|pregnancy test
14P02420432A1060|106 123|serum PAPP-A level
14P02423533A1314|136 149|rat PC12 cells
14P02423533A1314|162 180|nerve growth factor
14P02423533A1790|58 68|chicken DNA
14P02423533A1790|79 81|DNA
14P02423533A1790|104 113|sea urchin
14P02423773T0001|12 17|method
14P02423773T0001|31 38|glycerin
14P02423850A0292|0 16|Deletion analysis
14P02423850A0292|101 115|yeast CYC1 gene
14P02424743A0280|3 4|N1
14P02424743A0280|8 9|P2
14P02427024X0000|0 8|Tolerance
14P02427024X0000|11 31|fenfluramine anorexia
14P02427024X0000|99 119|fenfluramine anorexia
14P02427797A0199|30 37|pancreas
14P02427797A0199|80 88|cessation
14P02427797A0199|91 100|blood flow
14P02427797A0199|113 120|ischemia
14P02427797A0199|152 161|time point
14P02427797A0199|188 194|Ringers
14P02427797A0199|196 202|lactate
14P02427797A0199|228 234|vessels
14P02427812A0865|30 38|clonidine
14P02427812A0865|42 47|6-OHDA
14P02427812A0865|75 89|pressor actions
14P02427869A0939|63 65|BHT
14P02431314A0834|14 19|Hansel
14P02431314A0834|64 77|eosinophiluria
14P02431314A0834|92 97|Wright
14P02436005A0707|83 91|Ca influx
14P02436005A0707|107 118|mobilization
14P02436005A0707|121 122|Ca
14P02437625A0197|41 63|histoplasmosis syndrome
14P02437625A0197|64 67|POHS
14P02437625A0197|103 105|AMD
14P02437792T0000|0 9|Comparison
14P02437792T0000|56 71|immunoreactivity
14P02437792T0000|93 104|pancreatitis
14P02437895A0000|12 31|potentials procedure
14P02437895A0000|81 91|hemispheres
14P02437895A0000|99 111|language task
14P02437895A0000|166 167|LH
14P02437895A0000|206 216|dysarthrics
14P02437895A0000|234 235|RH
14P02438637T0000|0 17|Mucolipidosis type
14P02442837A0060|51 73|calcium channel blocker
14P02442837A0060|108 130|calcium channel blocker
14P02442837A0060|179 194|bypass procedure
14P02443028A0695|45 67|muscle microvasculature
14P02443924A0083|7 14|patients
14P02443924A0083|93 100|survival
14P02444507A0240|0 16|Lysozyme activity
14P02445751A0925|16 27|measurements
14P02445751A0925|39 50|state levels
14P02445751A0925|70 87|cytochrome oxidase
14P02445751A0925|93 104|beta subunit
14P02445751A0925|106 114|F1 ATPase
14P02445751A0925|130 140|hem2 mutant
14P02446871A1021|83 91|LSU rRNAs
14P02449431A1121|0 21|ATP gamma S inhibition
14P02449431A1121|54 56|ATP
14P02451872A0391|21 35|methoxydextrane
14P02452313A0114|0 7|ASL-8123
14P02452313A0114|54 70|blocking activity
14P02452313A0114|80 101|guinea pig right atria
14P02452313A0114|168 181|concentrations
14P02452313A0114|184 191|ASL-8123
14P02452313A0114|214 215|M.
14P02454390T0000|0 7|Enhancer
14P02454390T0000|11 27|promoter elements
14P02454390T0000|49 73|glucocorticoid repression
14P02454390T0000|78 101|alpha 1-fetoprotein gene
14P02454976A0944|12 18|results
14P02454976A0944|21 28|relation
14P02454976A0944|39 45|systems
14P02454976A0944|111 121|possibility
14P02454976A0944|126 134|divisions
14P02454976A0944|230 237|primates
14P02455821A0099|37 75|AccI-EcoRI restriction fragment mapping
14P02455821A0099|106 114|UL region
14P02455821A0099|119 130|EHV-1 genome
14P02456827A0899|3 6|4-AP
14P02456827A0899|84 86|TEA
14P02456827A0899|89 91|Ba2
14P02457922A0991|0 12|Hybridization
14P02457922A0991|59 62|RNAs
14P02457922A0991|106 117|2.8-kilobase
14P02458080T0000|0 8|Prognosis
14P02458234T0000|38 51|sleep spindles
14P02458234T0000|76 89|EEG recordings
14P02458699A0650|0 7|Svensson
14P02459309T0000|27 35|serotonin
14P02459309T0000|69 83|caudate-putamen
14P02459309T0000|117 124|dialysis
14P02459309T0000|156 169|chromatography
14P02459309T0000|186 194|detection
14P02461368A0162|66 80|type X collagen
14P02461368A0162|97 106|sequencing
14P02461368A0162|123 125|DNA
14P02462047A0208|6 15|flap areas
14P02462047A0208|47 62|pedicle ligation
14P02462047A0208|112 128|flap replantation
14P02462305A1071|3 18|size discrepancy
14P02462305A1071|28 40|glycosylation
14P02462305A1071|43 57|phosphorylation
14P02462305A1071|60 63|Ag35
14P02462523A0394|7 24|KpnI-SalI fragment
14P02462523A0394|36 46|DNA changes
14P02462523A0394|63 64|Hw
14P02462523A0394|107 108|Hw
14P02462523A0394|148 171|germ-line transformation
14P02463050A0514|3 47|corticosterone synthesis inhibitor metyrapone
14P02464097T0000|12 15|L655
14P02464097T0000|45 81|prostaglandin endoperoxide antagonist
14P02466414A0000|26 41|plasma viscosity
14P02466414A0000|42 43|Ep
14P02466414A0000|75 89|blood viscosity
14P02466414A0000|90 91|Ea
14P02466414A0000|126 145|exchange transfusion
14P02466414A0000|193 206|weight dextran
14P02466665A0202|19 25|protein
14P02468795A1086|0 4|Serum
14P02468795A1086|14 36|acid phosphatase levels
14P02468795A1086|76 88|cancer volume
14P02469451A0239|88 111|MAO-B inhibitor deprenyl
14P02470955A0101|47 61|CSF AP activity
14P02473156A0000|22 53|lymphocyte cell surface molecule
14P02473156A0000|126 142|adhesion proteins
14P02473198A0613|0 7|Dopamine
14P02473198A0613|24 39|potassium efflux
14P02473198A0613|49 52|86Rb
14P02473619A0202|11 23|sensitization
14P02473619A0202|64 78|control animals
14P02473619A0202|123 135|sensitization
14P02473619A0202|220 233|IgE antibodies
14P02473693A0174|48 53|HGB F.
14P02473718A0000|3 15|investigation
14P02473718A0000|35 46|relationship
14P02473718A0000|86 98|catecholamine
14P02473718A0000|100 105|5-HIAA
14P02473718A0000|109 111|VMA
14P02473718A0000|114 120|T-cells
14P02473718A0000|122 125|OKT3
14P02473718A0000|129 136|T-helper
14P02473718A0000|138 141|OKT4
14P02473718A0000|145 156|T-suppressor
14P02473718A0000|158 161|OKT8
14P02473718A0000|167 173|B-cells
14P02473907A1338|7 11|C mAb
14P02473907A1338|28 30|IgE
14P02473907A1338|63 74|Fc epsilon R
14P02473907A1338|109 111|IgE
14P02473907A1338|147 158|Fc epsilon R
14P02473942A1207|99 120|transmembrane segments
14P02474093T0000|0 10|Angiotensin
14P02474093T0000|21 37|enzyme inhibitors
14P02474110A1039|37 50|blood pressure
14P02474110A1039|82 84|ACE
14P02474110A1039|86 103|inhibitor ramipril
14P02474110A1039|191 207|resonance imaging
14P02474110A1039|210 225|echocardiography
14P02474204A0105|34 42|Grimelius
14P02474204A0105|61 74|immunostaining
14P02474204A0105|78 89|chromogranin
14P02474356A0559|10 22|radioactivity
14P02474356A0559|58 64|N ratio
14P02474356A0559|106 117|microspheres
14P02474356A0559|142 152|circulation
14P02475506A0878|42 76|polymerase chain reaction technique
14P02475717A0565|0 14|Tissue necrosis
14P02475717A0565|31 59|triphenyltetrazolium staining
14P02475717A0565|82 100|baseline predictors
14P02476030A0000|68 92|laser scanning tomography
14P02476664A0563|54 56|K14
14P02476664A0563|58 59|D.
14P02477373A0930|10 17|TATA box
14P02477373A0930|55 83|transcription initiation site
14P02479635A0659|0 13|Cotransfection
14P02479635A0659|51 53|PKI
14P02479823A0727|0 16|Sequence analysis
14P02479823A0727|52 59|GC boxes
14P02479823A0727|76 83|TATA box
14P02480419A0735|13 21|cirrhosis
14P02480419A0735|71 81|hepatitis B
14P02480419A0735|88 96|infection
14P02480959A0470|4 16|P-450scc mRNA
14P02480959A0470|28 38|consequence
14P02480959A0470|148 160|gonadotropins
14P02480959A0470|177 186|modulation
14P02480959A0470|189 197|prolactin
14P02481230A1258|23 44|bovine alpha transgene
14P02481429T0000|6 23|staining technique
14P02481429T0000|26 45|Leishmania parasites
14P02481779A0213|0 6|NIK-244
14P02481779A0213|54 64|arrhythmias
14P02481779A0213|88 108|plasma concentrations
14P02481779A0213|111 121|arrhythmias
14P02481779A0213|256 267|microgram/ml
14P02481779A0213|289 290|SD
14P02482293A1518|15 41|T24 bladder carcinoma cells
14P02482293A1518|40 42|TNF
14P02482293A1518|56 93|EGF-R tyrosine protein kinase activity
14P02482293A1518|102 104|EGF
14P02482511A0860|5 32|phosphodiesterase inhibitors
14P02482511A0860|135 153|withdrawal syndrome
14P02483210A0000|20 30|blood serum
14P02483210A0000|67 79|exacerbations
14P02483210A0000|89 110|relapsing pancreatitis
14P02483438A0498|44 54|inodilators
14P02483438A0498|75 102|phosphodiesterase inhibitors
14P02484714T0000|40 62|mouse estrogen receptor
14P02484994T0001|11 25|gamma globulins
14P02485188A0415|9 25|chondroitinase AC
14P02485188A0415|28 40|ABC digestion
14P02485188A0415|89 104|dermatan sulfate
14P02485188A0415|228 247|chondroitin sulfates
14P02486634A0632|61 78|contrast injection
14P02486634A0632|129 150|collateral development
14P02487898A0315|4 21|NGF administration
14P02487898A0315|80 97|NGF administration
14P02488148A1156|26 37|RSNA meeting
14P02489032A0000|0 13|Immunoglobulin
14P02489032A0000|25 27|IgL
14P02489032A0000|111 112|VL
14P02489032A0000|125 126|JL
14P02489032A0000|160 174|diversification
14P02489032A0000|190 198|VL region
14P02489753A0581|41 52|EMG activity
14P02489753A0581|54 61|FB group
14P02489753A0581|117 118|CG
14P02489753A0581|122 129|GF group
14P02489895T0001|0 12|Muscle action
14P02492111A0670|28 43|bone lead values
14P02492111A0670|52 55|LXRF
14P02492111A0868|188 202|U.S. guidelines
14P02492111A0868|226 249|blood lead concentration
14P02492111A0868|252 264|micrograms/dl
14P02493644A0588|9 17|3T3 cells
14P02493644A0588|78 90|transcription
14P02493644A0588|117 136|serum growth factors
14P02495745T0000|30 62|tissue-type plasminogen activator
14P02495745T0000|62 67|AK-124
14P02496090A0252|5 7|CO2
14P02496090A0252|13 29|tracheostomy tube
14P02496090A0252|56 72|mass spectrometry
14P02496090A0252|108 125|sampling technique
14P02496100T0000|43 54|aflatoxin B1
14P02496100T0000|56 74|cottonseed products
14P02496109A0754|23 32|S1 mapping
14P02496109A0754|52 67|gene disruptions
14P02496109A0754|72 83|alpha region
14P02496109A0754|114 126|fusion vector
14P02496109A0754|233 244|alpha operon
14P02496109A0754|295 297|IF1
14P02496109A0754|300 311|L17 interval
14P02497340A0989|49 50|JH
14P02497340A0989|54 55|VH
14P02497340A0989|79 80|Jk
14P02497340A0989|84 85|Vk
14P02498322A0226|47 68|gel retardation assays
14P02498322A0226|72 80|HeLa cell
14P02498322A0226|100 120|oligonucleotide probe
14P02498652A0460|26 51|TSH beta promoter activity
14P02498652A0460|96 98|GH3
14P02500432A1416|32 45|CAT expression
14P02500432A1416|84 86|DNA
14P02500432A1416|168 175|CAT gene
14P02502096A0462|56 74|excretion processes
14P02502602A0323|0 8|Tonometry
14P02502602A0323|68 87|acid-base quantities
14P02502602A0323|119 121|p50
14P02502960A0762|8 9|p.
14P02504603T0000|0 8|Isolation
14P02504603T0000|11 26|Weeksella virosa
14P02504603T0000|35 47|CDC group IIf
14P02505087A1037|15 38|dimerization specificity
14P02505087A1037|91 94|GCN4
14P02506390T0001|0 5|Growth
14P02506390T0001|16 26|anastomoses
14P02506740A0742|35 42|recovery
14P02506740A0742|81 87|hypoxia
14P02506740A0742|98 107|blood flow
14P02507523A0791|3 14|ORF1 product
14P02507523A0791|44 47|ORF2
14P02507523A0791|74 77|ORF1
14P02507815A0000|0 7|Kindling
14P02507815A0000|33 34|VC
14P02508306A0528|8 19|infiltration
14P02508306A0528|22 32|lymphocytes
14P02508306A0528|36 47|plasma cells
14P02508306A0528|75 83|carcinoma
14P02508306A0528|114 122|follicles
14P02508726A0498|5 16|case reports
14P02508726A0498|42 46|LiCO3
14P02508726A0498|59 68|medication
14P02508726A0498|74 82|treatment
14P02508726A0498|115 125|instability
14P02508726A0498|131 142|brain injury
14P02508726A0498|166 174|potential
14P02508726A0498|178 190|neurotoxicity
14P02508726A0498|197 206|population
14P02508726A0498|230 240|conjunction
14P02509123A0371|18 20|IFN
14P02509123A0371|37 50|P100 component
14P02509123A0371|55 57|VEP
14P02509123A0371|82 100|baseline conditions
14P02510242A0313|54 70|hepatitis B virus
14P02510242A0313|96 101|HBs Ag
14P02510242A0313|209 211|CMV
14P02511069A0532|87 88|Df
14P02511069A0532|90 91|3L
14P02511069A0532|93 95|RR2
14P02511069A0532|111 120|DRE region
14P02511069A0532|136 160|polytene chromosome bands
14P02511150T0025|22 33|perspectives
14P02511207A0282|0 1|K.
14P02511430A0000|56 83|immunoglobulin gene enhancer
14P02511898A0000|46 59|Chagas disease
14P02512010A0801|3 20|PETCO2 measurement
14P02512010A0801|68 81|defibrillation
14P02514498A0000|7 14|CO2/HCO3
14P02514498A0000|63 76|acid secretion
14P02514498A0000|99 118|pCO2/pH measurements
14P02514498A0000|160 180|Henderson-Hasselbalch
14P02515953A0459|30 37|patients
14P02515953A0459|42 54|effectiveness
14P02517008A0481|8 15|patients
14P02517008A0481|55 65|monotherapy
14P02518645T0001|8 21|Chagas disease
14P02518645T0001|22 41|laboratory diagnosis
14P02518691A0251|12 41|IL2R alpha promoter constructs
14P02518691A0251|65 82|DNA binding assays
14P02518691A0251|200 225|IL2R alpha gene expression
14P02519327T0001|11 20|rheumatism
14P02519679T0000|0 9|Inefficacy
14P02519679T0000|12 31|phosphine fumigation
14P02520622A0200|65 77|transit times
14P02520622A0200|114 132|cimetropium bromide
14P02520622A0200|193 204|group design
14P02521217A1035|55 72|membrane fractions
14P02521217A1035|74 85|mitochondria
14P02521674T0000|0 6|Mapping
14P02521674T0000|9 11|RNA
14P02521674T0000|56 86|complementation group F mutants
14P02522297A0000|28 31|TXA2
14P02522297A0000|34 79|prostaglandin endoperoxide receptor antagonist
14P02522297A0000|78 79|SQ
14P02523800A1178|36 44|CHS1 gene
14P02523800A1178|79 104|TGAAACA consensus sequence
14P02523800A1178|150 162|BAR1 promoter
14P02523800A1178|163 170|Kronstad
14P02525044A1026|3 16|recovery index
14P02525044A1026|17 23|T25-T75
14P02525044A1026|108 120|suxamethonium
14P02526165X0000|9 20|Leser-Trelat
14P02526165X0000|43 54|Leser-Trelat
14P02527365T0000|0 14|Xenopus homolog
14P02527365T0000|19 35|mos protooncogene
14P02527365T0000|87 101|Xenopus oocytes
14P02527745A0865|0 21|Southern blot analyses
14P02527745A0865|73 84|conservation
14P02528329A0000|5 20|missense mutants
14P02528329A0000|50 60|F1F0-ATPase
14P02528329A0000|94 118|hydroxylamine mutagenesis
14P02528730A1073|9 16|exons 2a
14P02528730A1073|35 42|sequence
14P02528730A1073|86 103|donor splice sites
14P02529378A0536|0 19|S1 nuclease analysis
14P02529378A0536|20 22|RNA
14P02529378A0536|55 68|HIV constructs
14P02529378A0536|72 81|HeLa cells
14P02529378A0536|137 139|SP1
14P02529378A0536|141 144|TATA
14P02529378A0536|253 259|HIV LTR
14P02530413A0195|2 16|supine position
14P02530413A0195|17 33|plasma ANP levels
14P02530470A0604|22 32|HBV markers
14P02530470A0604|46 58|staff members
14P02531203A0241|98 107|SSTS model
14P02532032A0385|0 20|Plasma concentrations
14P02532032A0385|22 24|ANF
14P02532032A0385|44 46|PAC
14P02532032A0385|57 59|PRC
14P02532210A0000|3 21|adenovirus E1A gene
14P02534067A0316|0 13|Administration
14P02534067A0316|72 92|alpha OH progesterone
14P02534067A0316|94 112|beta-desoxycortisol
14P02534067A0316|114 126|DHEA sulphate
14P02534067A0316|127 141|androstenedione
14P02534067A0316|212 231|beta OH androsterone
14P02534067A0316|231 245|etiocholanolone
14P02534067A0316|247 250|DHEA
14P02535460A1443|0 14|RNA transcripts
14P02536096A0327|43 67|herpes simplex virus type
14P02536096A0327|66 90|thymidine kinase promoter
14P02536096A0327|100 137|chloramphenicol acetyltransferase gene
14P02536096A0327|181 205|thymidine kinase promoter
14P02536096A0327|221 258|chloramphenicol acetyltransferase gene
14P02536160A0518|32 36|Ren1d
14P02536160A0518|60 76|sense orientation
14P02536160A0518|90 103|CAT expression
14P02536160A0518|110 120|TK promoter
14P02537441A0231|0 3|None
14P02537441A0231|46 61|varicella-zoster
14P02537485A0841|5 17|formalin test
14P02537485A0841|44 61|morphine analgesia
14P02537485A0841|106 123|morphine analgesia
14P02538450A0000|78 101|Na,K-ATPase beta subunit
14P02538656A0172|27 36|E1 mutants
14P02538656A0172|56 64|R regions
14P02538656A0172|120 140|transforming activity
14P02538656A0172|142 157|mouse C127 cells
14P02538720A0582|0 3|UbiA
14P02538720A0582|26 44|polyubiquitin genes
14P02541251A1327|9 15|T2 gene
14P02541251A1327|67 90|transcription factor SP1
14P02541251A1327|95 98|TATA
14P02541251A1327|101 115|CCAAT sequences
14P02541251A1327|192 198|T1 gene
14P02541882A0251|0 16|Radiation therapy
14P02542194A1496|24 31|patients
14P02542194A1496|55 65|irradiation
14P02542194A1496|83 94|astrocytomas
14P02542194A1496|113 123|ependymomas
14P02542194A1496|140 147|survival
14P02542270A0000|26 41|chloroplast DNAs
14P02542270A0000|100 122|C4 photosynthesis genes
14P02542270A0000|126 138|bundle sheath
14P02542270A0000|141 155|mesophyll cells
14P02542612A0530|0 19|S1 nuclease analysis
14P02542612A0530|20 22|RNA
14P02542612A0530|44 54|B95-8 cells
14P02542612A0530|61 70|Vero cells
14P02542612A0530|87 110|NotI repeat promoter-CAT
14P02542612A0530|123 139|Z transactivation
14P02542612A0530|183 197|RNA transcripts
14P02543226A1559|20 29|likelihood
14P02543226A1559|60 70|hyperplasia
14P02543226A1559|87 110|adipose tissue component
14P02543226A1559|124 138|breast biopsies
14P02543226A1559|211 225|breast biopsies
14P02543226A1559|281 290|parenchyma
14P02543226A1559|373 383|hyperplasia
14P02543621A0788|0 7|Analysis
14P02543621A0788|13 15|DNA
14P02543621A0788|48 52|Wilms
14P02543621A0788|99 122|translocation breakpoint
14P02543679A1291|45 56|P initiators
14P02543679A1291|68 71|DnaJ
14P02543679A1291|75 98|DnaK heat shock proteins
14P02543679A1291|129 146|lambda replication
14P02543734A0414|9 24|oligonucleotides
14P02543734A0414|85 107|IE1/2 enhancer/promoter
14P02543734A0414|109 129|cotransfection assays
14P02544059A0377|0 6|Effects
14P02544059A0377|18 20|PN2
14P02544059A0377|28 30|MPa
14P02544059A0377|42 44|PHe
14P02544059A0377|53 55|MPa
14P02545357A0000|3 32|mustard chloroplast gene rps16
14P02545903A0639|0 9|Antibodies
14P02545903A0639|30 32|NS3
14P02545903A0639|65 67|NS3
14P02545903A0639|71 74|NS3A
14P02545903A0639|92 100|BHK cells
14P02545903A0639|116 137|BTV-10 virus particles
14P02546234A1382|26 36|tachycaydia
14P02547079A0910|11 25|calcium balance
14P02547079A0910|29 48|hyperparathyroidemia
14P02547079A0910|76 89|administration
14P02547079A0910|92 93|Cd
14P02547611A0318|0 7|Clone 4c
14P02547611A0318|48 56|clone 22c
14P02547706A0928|16 18|ISH
14P02547706A0928|22 24|IHC
14P02547706A0928|100 105|CMV-IP
14P02547706A0928|109 111|IIP
14P02547706T0001|0 7|Validity
14P02547706T0001|10 24|immunohistology
14P02547706T0001|75 99|cytomegalovirus pneumonia
14P02547706T0001|147 173|bone marrow transplantation
14P02547778A0786|34 37|ANT1
14P02547778A0786|53 68|control elements
14P02548683T0001|31 38|Shanghai
14P02548683T0001|46 56|hepatitis A
14P02549036A0000|3 29|Bacillus subtilis phage phi
14P02549343A1008|2 12|consequence
14P02549343A1008|67 81|characteristics
14P02549343A1008|141 167|immunoprecipitation pattern
14P02549343A1008|200 210|polypeptide
14P02549343A1008|288 308|neutralizing activity
14P02549343A1008|340 349|complement
14P02549417A0000|53 74|acristate mitochondria
14P02550118A0610|33 45|infiltrations
14P02550682A0411|23 40|type IIc carcinoma
14P02550682A0411|57 59|IIc
14P02551886A0332|0 15|Restriction maps
14P02552143A0748|0 2|VP5
14P02552143A0748|52 89|chloramphenicol acetyltransferase gene
14P02552316A0526|26 35|caretakers
14P02552316A0526|103 121|seroconversion rate
14P02554310A0419|2 9|contrast
14P02554310A0419|19 26|fragment
14P02554310A0419|49 54|region
14P02554310A0419|75 80|effect
14P02555177A0488|14 17|LEU2
14P02555177A0488|78 99|COX1 introns aI5 alpha
14P02555177A0488|124 143|COX3 gene expression
14P02555177A0488|150 167|COX1 mRNA splicing
14P02555418A0973|0 6|Insert2
14P02555519A0798|58 61|CDR3
14P02555519A0798|63 96|complementarity determining region
14P02555519A0798|112 119|H-chains
14P02555519A0798|148 165|D-region structure
14P02555703T0000|0 24|Tyrosine kinase oncogenes
14P02555703T0000|31 54|interleukin-3 dependence
14P02555703T0000|81 98|signaling pathways
14P02555703T0000|136 154|c-myc transcription
14P02556264A0278|4 17|TC-II enhanson
14P02556264A0278|57 76|kappa chain enhancer
14P02556264A0278|167 182|cell specificity
14P02556269A0187|3 11|DNA helix
14P02556269A0187|33 46|13mer sequence
14P02556269A0187|87 102|hypersensitivity
14P02556269A0187|190 192|DNA
14P02556269A0187|226 244|gel electrophoresis
14P02556603A0606|72 89|gallbladder cancer
14P02556603A0606|104 119|bile duct cancer
14P02557217A0000|0 13|Beta-endorphin
14P02557217A0000|15 18|ACTH
14P02557217A0000|22 39|cortisol secretion
14P02557217A0000|86 105|spray administration
14P02557217A0000|108 127|IU salmon calcitonin
14P02557217A0398|80 110|corticotrophin-cortisol release
14P02557350A0632|3 15|DNA sequences
14P02557350A0632|33 39|SRP54sc
14P02557350A0632|43 49|SRP54sp
14P02557350A0632|77 84|SRP54mam
14P02559630A0270|50 69|thromboplastin times
14P02559630A0270|70 86|prothrombin times
14P02559630A0270|130 167|fibrin/fibrinogen degradation products
14P02560415T0012|23 32|metastasis
14P02560415T0012|47 58|face regions
14P02562787A0637|35 37|NBP
14P02562787A0637|40 43|CNBP
14P02562825A0413|0 13|Responsiveness
14P02562825A0413|16 37|beta-2 agonist therapy
14P02565405T0000|0 7|Drug use
14P02565405T0000|9 22|trauma victims
14P02565683A0841|9 18|heart rate
14P02565683A0841|71 79|instances
14P02565683A0841|82 90|reentrant
14P02565683A0841|108 118|tachycardia
14P02565683A0841|140 150|tachycardia
14P02565807A1198|14 31|neu proto-oncogene
14P02565807A1198|41 55|kinase activity
14P02565807A1198|109 121|NIH 3T3 cells
14P02565807A1198|122 129|ABSTRACT
14P02565807A1198|144 148|WORDS
14P02566613A0831|60 62|CRE
14P02566613A0831|64 71|TGACGTCA
14P02566613T0000|0 27|Somatostatin gene expression
14P02566613T0000|73 92|DNA control elements
14P02566680A0820|27 43|agonists fentanyl
14P02566680A0820|53 63|I-methadone
14P02566680A0820|67 77|levorphanol
14P02566680A0820|178 191|response rates
14P02567030A0482|30 43|discrimination
14P02567030A0482|71 80|difficulty
14P02568930T0000|0 8|Isolation
14P02568930T0000|12 27|characterization
14P02568930T0000|93 105|CD2 structure
14P02568930T0000|112 124|T lymphocytes
14P02569411A0151|5 15|termination
14P02569411A0151|18 27|medication
14P02569411A0151|66 81|nucleus amygdala
14P02571924A0000|45 75|yeast Rhodosporidium toruloides
14P02571924A0000|82 97|mating pheromone
14P02571924A0000|145 163|S-farnesyl cysteine
14P02571924A0000|168 183|carboxy terminus
14P02572777T0000|0 21|Tumour necrosis factor
14P02572928T0000|0 9|Monitoring
14P02573303A0000|29 30|LV
14P02573303A0000|81 84|PEEP
14P02573303A0000|112 113|LV
14P02573303A0000|134 150|contractile state
14P02573336A0000|32 34|ROF
14P02573336A0000|178 180|ROF
14P02573829T0000|12 23|conservation
14P02573829T0000|92 109|transcription unit
14P02573829T0000|124 140|segmentation gene
14P02573836A0244|38 40|NBS
14P02573836A0244|53 77|drug resistance phenotype
14P02573836A0244|104 127|amino acid substitutions
14P02573836A0244|131 153|core consensus sequence
14P02573836A0244|155 172|nucleotide binding
14P02573836A0244|173 178|GXGKST
14P02574016A0428|20 22|TOF
14P02574016A0428|52 64|control value
14P02574016A0428|65 75|neostigmine
14P02574016A0428|90 102|micrograms/kg
14P02574016A0428|114 126|micrograms/kg
14P02574052A0910|45 60|Type A behaviour
14P02574052A0910|62 87|beta-adrenoceptor blockade
14P02574193A0663|0 8|Selection
14P02574193A0663|34 80|Institute Withdrawal Assessment-Benzodiazepines
14P02574193A0663|80 85|CIWA-B
14P02574193A0663|158 175|withdrawal periods
14P02574193A0663|268 285|contingency tables
14P02574193A0663|296 314|regression analysis
14P02574551T0000|0 13|Antihistamines
14P02575174A0229|46 54|doxazosin
14P02575174A0229|117 128|hypertension
14P02575174A0229|144 161|airflow limitation
14P02575490A1021|0 21|Northern blot analysis
14P02575490A1021|36 53|oIGF-I transcripts
14P02575567T0001|0 24|Materials science studies
14P02575959A0643|3 14|latency time
14P02575959A0643|20 40|lactate concentration
14P02575959A0643|87 88|T2
14P02576405A0223|21 23|VAD
14P02576405A0223|69 83|CBV combination
14P02576405A0223|84 110|cyclophosphamide-BCNU-VP-16
14P02576405A0223|116 127|EDAP regimen
14P02576405A0223|128 132|VP-16
14P02577458A0412|69 85|enzyme inhibitors
14P02577458A0412|102 118|receptor blockers
14P02577458A0412|122 140|calcium antagonists
14P02577867T0000|28 40|oncogene jun.
14P02580830A1131|66 73|AFP gene
14P02580830A1131|81 92|% similarity
14P02580830A1131|123 136|mouse AFP gene
14P02582240A1009|4 17|ATP/GTP ratios
14P02582240A1009|37 56|RNA primer synthesis
14P02582240A1009|81 94|ATP/GTP ratios
14P02582918A0000|5 36|hepatitis B vaccine immunization
14P02582918A0000|35 57|serum antibody response
14P02582918A0000|104 106|S/N
14P02582918A0000|108 121|S/N Ratio Unit
14P02582918A0000|123 124|T0
14P02582918A0000|179 180|T1
14P02582918A0000|182 183|T2
14P02582918A0000|185 186|T0
14P02582918A0000|190 192|T12
14P02584969A0119|42 57|regression model
14P02584969A0119|68 77|treatments
14P02584969A0119|110 124|protection time
14P02585492A1005|13 33|complementation tests
14P02585492A1005|46 56|P7 proteins
14P02585492A1005|77 83|P1 parA
14P02585492A1005|103 113|P1 proteins
14P02585492A1005|132 143|P7 mutations
14P02586485A0511|0 4|GN101
14P02586485A0511|6 12|YC819-9
14P02586485A0511|17 19|SB3
14P02586513A0622|0 7|Analysis
14P02586513A0622|34 46|ama-1 product
14P02586513A0622|95 98|RNAP
14P02586513A0622|143 159|zinc finger motif
14P02586513A0622|165 178|amino terminus
14P02586513A0622|244 260|consensus Tyr Ser
14P02586513A0622|262 268|Thr Ser
14P02586513A0622|271 273|Ser
14P02590097A0093|7 17|involvement
14P02590097A0093|34 45|infiltration
14P02590097A0093|71 83|lobe bronchus
14P02590097A0093|129 131|IgA
14P02590097A0093|134 143|Type Kappa
14P02590391A0442|0 3|None
14P02590391A0442|28 41|heart contents
14P02590391A0442|62 74|phospholipids
14P02590391A0442|76 94|phosphatidylcholine
14P02590391A0442|96 119|phosphatidylethanolamine
14P02590391A0442|121 142|diphosphatidylglycerol
14P02590391A0442|144 156|sphingomyelin
14P02590391A0442|165 180|acid composition
14P02590391A0442|186 203|phospholipid class
14P02590540A0741|46 47|CA
14P02590540A0741|69 72|U/ml
14P02590540A0741|94 97|U/ml
14P02590615A0636|98 113|pharmacokinetics
14P02590615A0636|116 125|nifedipine
14P02590869A0743|53 55|IgA
14P02590869A0743|68 77|LNA titers
14P02590869A0743|83 95|lavage fluids
14P02590869A0743|115 121|SC dose
14P02591078A0000|33 42|Grenz rays
14P02591078A0000|64 90|contact dermatitis reaction
14P02591078A0000|106 121|Langerhans cells
14P02591078A0000|134 148|OKT6 antibodies
14P02591078A0000|151 169|electron microscopy
14P02591969A0961|25 50|glucocorticoid stimulation
14P02591969A0961|52 73|ADH gene transcription
14P02592543A0106|38 52|characteristics
14P02592543A0106|54 81|Kanagawa hemolysin reactions
14P02592543A0106|84 99|plasmid profiles
14P02592640A0466|16 22|retinol
14P02592640A0466|26 38|beta-carotene
14P02592640A0466|57 63|cheeses
14P02592640A0466|223 229|retinol
14P02592640A0466|238 250|beta-carotene
14P02592961A0327|0 5|COGLAB
14P02592961A0327|65 87|psychomotor performance
14P02595451A1136|31 33|AN2
14P02595451A1136|48 73|T-cell leukemia breakpoint
14P02595451A1136|73 76|TCL2
14P02595451A1136|115 118|MIC1
14P02595451T0000|33 46|chromosome 11p
14P02595451T0000|57 73|J1 series hybrids
14P02597484A0624|22 32|diffusivity
14P02597484A0624|45 46|De
14P02597484A0624|54 71|surface reactivity
14P02597484A0624|98 108|differences
14P02597549A0964|54 65|dipyridamole
14P02597549A0964|69 78|mg X 3/day
14P02597549A0964|111 125|recovery period
14P02597549A0964|157 167|prothrombin
14P02597549A0964|178 197|thromboplastin times
14P02598034A0000|0 22|Middle-latency auditory
14P02598034A0000|39 43|MAEPs
14P02598745A0251|24 38|Sylvius fissure
14P02599995A1031|13 28|activity studies
14P02599995A1031|47 55|times MBC
14P02599995A1031|60 69|penicillin
14P02599995A1031|115 127|staphylococci
14P02600306A0140|59 82|envelope phase disparity
14P02600306A0140|138 145|AM tones
14P02601707A0986|0 21|Gel retardation assays
14P02601707A0986|32 36|DNase
14P02601707A0986|53 86|diethyl pyrocarbonate interference
14P02601707A0986|127 137|C2 myotubes
14P02601707A0986|140 153|BC3H1 myocytes
14P02602150A0993|62 78|sequence elements
14P02602150A0993|87 111|replication origin region
14P02602150A0993|121 132|construction
14P02602150A0993|161 178|gene amplification
14P02602150A0993|202 215|virus replicon
14P02603374A0383|37 52|dorsal rhinotomy
14P02603374A0383|60 76|patient morbidity
14P02603374A0383|97 109|complications
14P02603923A0220|18 31|skin incisions
14P02603923A0220|109 121|growth factor
14P02603923A0220|138 143|Ringer
14P02603923A0220|146 161|lactate solution
14P02604420A0234|6 14|challenge
14P02604420A0234|16 23|rebiopsy
14P02604420A0234|35 54|reticulin antibodies
14P02604420A0234|113 122|year study
14P02605160A0000|11 21|iron intake
14P02605160A0000|23 37|59Fe absorption
14P02605160A0000|78 86|Fe status
14P02605182A0936|10 25|protein sequence
14P02605182A0936|75 88|signal peptide
14P02605679A0306|0 7|Analysis
14P02605679A0306|13 26|rate constants
14P02605679A0306|42 63|isomerization rate k12
14P02605679A0306|96 111|degradation rate
14P02605679A0306|148 162|hydrolysis rate
14P02607766A0000|41 56|characterization
14P02607766A0000|60 83|quality control material
14P02607766A0000|83 85|QCM
14P02607766A0000|106 118|concentration
14P02607766A0000|129 130|Cd
14P02607766A0000|156 157|Pb
14P02607766A0000|164 176|micrograms/dL
14P02607766A0000|206 208|QCM
14P02607766A0000|219 220|Cd
14P02607766A0000|225 236|micrograms/L
14P02607766A0000|247 248|Hg
14P02607766A0000|255 266|micrograms/L
14P02607766A0000|272 273|Pb
14P02607766A0000|279 291|micrograms/dL
14P02607766A0000|325 341|spiking-solutions
14P02607766A0000|361 362|Cd
14P02607766A0000|364 365|Hg
14P02607766A0000|370 371|Pb
14P02609112A0000|0 13|Reagent strips
14P02609112A0000|45 63|laboratory medicine
14P02614668A0971|19 31|concentration
14P02615078A0283|38 50|actinomycetes
14P02615078A0283|54 57|M.f.
14P02617623A0740|0 5|LON-72
14P02617623A0740|19 24|LON-73
14P02617623A0740|29 34|LON-71
14P02617623A0740|41 46|LON-10
14P02620085A0656|0 5|Animal
14P02620085A0656|29 40|applications
14P02620085A0656|74 93|replacement implants
14P02621983T0001|0 11|Significance
14P02621983T0001|34 46|acid analysis
14P02623038A0632|32 42|performance
14P02623038A0632|70 86|saline injections
14P02627159A0899|19 31|IgG4 antibody
14P02627159A0899|59 71|immunotherapy
14P02629109A0000|11 27|fertility decline
14P02629109A0000|52 68|Mississippi Delta
14P02629109A0000|206 216|1880 levels
14P02630543A0210|16 32|staining affinity
14P02630543A0210|41 50|antibodies
14P02630543A0210|64 75|tissue cells
14P02630543A0210|143 158|cell populations
14P02631505A0382|0 9|Ampicillin
14P02631505A0382|11 13|AMP
14P02631505A0382|28 41|aminoglycoside
14P02631505A0382|43 45|AMI
14P02631566A0151|0 13|Alkoxymetgyl-3
14P02631566A0151|17 44|dimethylpyridinium chlorides
14P02631566A0151|69 88|3,4-dimethylpyridine
14P02631566A0151|93 117|chloromethyl alkyl ethers
14P02631566A0151|201 224|1-ethyloxymethylimidazol
14P02631566A0151|229 255|chloromethyl alkyl sulfides
14P02631743A0275|38 53|color deficiency
14P02631743A0275|58 64|Koreans
14P02631743A0275|75 79|H-R-R
14P02631887A0000|26 29|HGGM
14P02632904A0619|18 23|VE/VO2
14P02632904A0619|27 31|Q/VO2
14P02632904A0619|58 68|correlation
14P02634490A0186|81 94|CT examination
14P02634490A0186|114 126|ATB treatment
14P02634872A0000|0 9|Retrograde
14P02634872A0000|34 51|endodontics system
14P02636920T0001|28 74|Pharmacopoeia Heparin Sodium Reference Standard
14P02637597A0362|28 40|relapse stage
14P02637597A0362|77 79|IgA
14P02637597A0362|83 91|IgM level
14P02637597A0362|101 103|IgG
14P02637597A0362|117 118|C3
14P02637597A0362|122 123|C4
14P02638964A0372|3 16|maximum stress
14P02638964A0372|35 45|examination
14P02638964A0372|51 59|composite
14P02638964A0372|75 85|equilibrium
14P02638964A0372|109 117|composite
14P02641762T0001|31 58|exercise stress thallium-201
14P02641762T0001|93 97|SPECT
14P02642466T0000|0 16|Sequence analysis
14P02642466T0000|47 64|membrane immunogen
14P02642976A1474|9 27|consensus sequences
14P02644735A0427|2 10|FP mutant
14P02644735A0427|11 19|AcFP875-2
14P02644735A0427|43 59|S. frugiperda DNA
14P02644735A0427|95 105|S1 analysis
14P02644735A0427|133 150|host cell sequence
14P02645276T0088|0 11|Construction
14P02645276T0088|15 34|RIP1 deletion strain
14P02645431A1562|20 33|hypocitraturia
14P02645431A1562|53 60|acidosis
14P02645431A1562|94 101|function
14P02646007T0000|76 95|protein C deficiency
14P02647403A0000|11 24|hallucinations
14P02647403A0000|37 51|psychopathology
14P02647918A0423|21 22|GH
14P02647918A0423|26 45|somatomedin-C levels
14P02647918A0423|147 150|U/ml
14P02647918A0588|0 10|Application
14P02647918A0588|71 79|GH levels
14P02647918A0588|115 134|somatomedin-C values
14P02647918A0588|161 174|GH suppression
14P02647918A0588|196 199|OGTT
14P02647918A0588|252 264|disappearance
14P02647918A0588|281 291|GH response
14P02647918A0588|293 305|TRH/GnRH test
14P02647937A0191|11 18|sequence
14P02647937A0191|29 36|planning
14P02647937A0191|88 95|problems
14P02648396A0565|2 13|Rat-1a cells
14P02648396A0565|16 25|expression
14P02648396A0565|33 42|c-jun mRNA
14P02648396A0565|92 102|form tumors
14P02648396A1033|40 43|RECs
14P02648396A1033|92 142|tumor promoter phorbol 12-tetradecanoate 13-acetate
14P02648646A0216|0 25|Platelet activating factor
14P02648646A0216|46 61|minute intervals
14P02648646A0216|64 78|airway response
14P02648646A0216|103 117|expiratory flow
14P02648646A0216|138 141|Vp30
14P02648646A0932|39 64|baseline PC40 methacholine
14P02648646A0932|82 85|Vp30
14P02648646A0932|150 175|platelet activating factor
14P02649445A0412|4 5|BG
14P02649445A0412|9 26|IRI concentrations
14P02649445A0412|35 38|OGTT
14P02649811T0000|25 45|family planning study
14P02650663A0178|62 71|impairment
14P02650663A0178|96 109|Alzheimer type
14P02650663A0178|157 165|diagnosis
14P02651448A0000|55 65|dissolution
14P02651448A0000|102 117|depolymerization
14P02651448A0000|119 124|Type A
14P02651448A0000|148 163|depolymerization
14P02651448A0000|165 170|Type B
14P02651487A0000|25 48|calcium channel blockers
14P02651487A0000|126 156|excitation contraction coupling
14P02651487A0000|206 221|glucagon release
14P02655381A0000|28 38|possibility
14P02655381A0000|106 130|laboratory investigations
14P02655381A0000|135 146|hypogonadism
14P02655381A0000|148 165|hyperprolactinemia
14P02655381A0000|230 241|incompetence
14P02655381A0000|254 265|neuropathies
14P02656257A0000|16 39|DNA inversion system Cin
14P02656257A0000|98 116|crossing-over sites
14P02657388A1011|3 19|terminator region
14P02657388A1011|63 78|RNA polymerase I
14P02657883A0000|0 9|US-Doppler
14P02657883A0000|106 108|FAV
14P02657883T0001|0 6|Doppler
14P02664229A0138|155 168|Arap procedure
14P02664229A0138|188 197|advantages
14P02664229A0138|240 258|hypospadias repairs
14P02666034A1520|56 85|vasodilator calcium antagonist
14P02666034A1520|109 120|vasodilation
14P02666034A1520|172 185|placebo course
14P02666404A0220|3 23|galactose transporter
14P02666404A0220|79 96|sugar transporters
14P02666404A0220|117 133|HepG2-erythrocyte
14P02666404A0220|142 168|muscle glucose transporters
14P02666404A0220|182 207|liver glucose transporters
14P02666404A0220|234 252|arabinose permeases
14P02666404A0220|290 311|galactose transporters
14P02666568A0000|55 69|protocol TCL821
14P02667259A0331|32 40|reactions
14P02667259A0331|42 45|ADRs
14P02667259A0331|71 79|dizziness
14P02668691A0570|4 7|mRNA
14P02668691A0570|23 26|nagB
14P02668691A0570|30 33|nagA
14P02668691A0570|76 80|genes
14P02668691A0570|82 85|nagC
14P02668691A0570|89 92|nagD
14P02669199A0000|0 20|Tumor necrosis factor
14P02669199A0000|20 22|TNF
14P02669199A0000|88 90|LPS
14P02670457T0000|3 21|calcium requirement
14P02674141A1202|27 30|CTSE
14P02674141A1202|49 73|activation peptide region
14P02674327A0493|3 5|p34
14P02674327A0493|22 37|codon usage bias
14P02674327A0493|75 89|polyhedrin gene
14P02674671A0601|20 36|DNA transformants
14P02674671A0601|76 88|met2 mutation
14P02674674A1308|64 75|OBF1 protein
14P02674674A1308|96 107|ARS function
14P02674679A1237|12 42|S1 nuclease protection analysis
14P02674679A1237|42 57|RNA preparations
14P02674679A1237|164 185|start site utilization
14P02675492A0806|55 67|Ritchie-Index
14P02675492A0806|79 81|ESR
14P02675492A0806|85 87|CRP
14P02677002A0205|37 39|ATP
14P02677002A0205|63 96|equilibrium N-carbamyl-L-aspartate
14P02677002A0205|97 101|C-Asp
14P02677002A0205|114 131|carbamyl phosphate
14P02677002A0205|138 161|equilibrium Pi exchanges
14P02677429A0366|0 13|Survival rates
14P02677429A0366|27 41|treatment group
14P02677429A0366|100 114|treatment group
14P02677429A0366|219 222|AIDS
14P02677429A0366|302 316|treatment group
14P02677666A0356|0 6|Mapping
14P02677666A0356|30 50|complementation group
14P02679804A2000|13 23|genes ura10
14P02679804A2000|71 93|orotidine monophosphate
14P02680843A0724|21 22|RS
14P02680843A0724|26 36|REM latency
14P02684159A0870|0 21|Hybridization analysis
14P02684585T0001|0 24|Agranulocytosis treatment
14P02685331A0523|3 27|R. meliloti nifH promoter
14P02685331A0523|34 35|K.
14P02685331A0523|81 102|methylation protection
14P02685331A0523|104 119|guanine residues
14P02685461A0380|13 20|symptoms
14P02685461A0380|26 32|disease
14P02685461A0380|57 64|patients
14P02685565A0165|118 128|c-myb genes
14P02686588A0592|71 73|BUN
14P02686588A0592|77 96|alkaline phosphatase
14P02686749A0000|11 29|health significance
14P02686749A0000|161 180|beta 2-microglobulin
14P02686749A0000|182 204|retinol binding protein
14P02686980A0000|40 51|organization
14P02686980A0000|67 75|nucleolus
14P02686980A0000|123 132|components
14P02686985A0811|1 36|transcription factor exclusion assay
14P02686985A0811|54 66|PCF1 mutation
14P02686985A0811|133 149|complex formation
14P02688772T0000|0 9|Psychiatry
14P02689136A1851|12 18|effects
14P02689439A0000|12 37|glutathione S-transferases
14P02689439A0000|38 41|GSTs
14P02689439A0000|43 44|EC
14P02689439A0402|30 36|regions
14P02689439A0402|67 74|homology
14P02689439A0402|93 104|rat Yb1 gene
14P02689439A0402|140 147|homology
14P02689439A0402|177 188|rat Yb2 gene
14P02689544A0456|0 4|Model
14P02691557A0273|3 11|incidence
14P02691557A0273|19 37|breathing movements
14P02691557A0273|106 119|concentrations
14P02691557A0273|122 131|plasma PGE
14P02691557A0273|172 180|gestation
14P02691811A0355|29 44|plasma potassium
14P02691811A0355|79 92|blood acidosis
14P02691811A0355|129 141|concentration
14P02691998A0672|107 126|bolus administration
14P02691998A0672|128 131|ET-1
14P02692881A0354|2 11|comparison
14P02692881A0354|71 73|PIH
14P02692881A0354|92 101|heart rate
14P02692881A0354|161 171|derangement
14P02692881A0354|225 233|reduction
14P02692881A0354|236 251|sodium excretion
14P02692881A0354|272 288|calcium excretion
14P02692881A0354|305 320|sodium excretion
14P02693208A0166|26 38|recombination
14P02693208A0166|59 67|mutations
14P02693208A0166|90 109|repeat recombination
14P02693208A0166|145 153|sequences
14P02693593A0866|21 35|leader sequence
14P02693593A0866|39 49|amino acids
14P02694731A0241|15 23|knowledge
14P02694731A0241|29 40|epidemiology
14P02694731A0241|43 51|Parkinson
14P02694731A0241|93 102|hypotheses
14P02694731A0241|113 122|hypotheses
14P02695914T0000|3 19|stereoselectivity
14P02700977A0444|0 9|Scotchbond
14P02700977A0444|69 81|XR bond/Silus
14P02702566A0000|1 11|combination
14P02702566A0000|26 39|5-fluorouracil
14P02702566A0000|113 123|neck cancer
14P02702849A0418|0 30|Metformin plasma concentrations
14P02702849A0418|117 146|patients plasma concentrations
14P02703121T0000|0 8|Diagnosis
14P02703121T0000|18 39|sclerosing cholangitis
14P02703121T0000|64 93|serum alanine aminotransferase
14P02703925A0359|65 90|sedimentation coefficients
14P02703925A0359|93 115|polydispersity profiles
14P02703925A0359|157 180|proteoglycan aggregation
14P02703925A0359|183 197|sedimentability
14P02703925A0359|227 254|cartilage matrix degradation
14P02703925A0359|263 270|S values
14P02703925A0359|273 285|proteoglycans
14P02703925A0359|302 303|HW
14P02703925A0359|355 356|LW
14P02703925A0359|398 414|cartilage samples
14P02703925A0359|455 472|matrix degradation
14P02703925A0359|490 499|HW regions
14P02703925A0359|550 569|S value distribution
14P02703925A0359|574 592|cartilage thickness
14P02703925A0359|624 643|proteoglycan content
14P02703925A0359|694 708|cartilage layer
14P02703925A0359|775 789|sedimentability
14P02704579A1078|68 73|CRS/BW
14P02704579A1078|77 99|gas exchange parameters
14P02704579A1078|99 102|FIO2
14P02704579A1078|166 179|lung mechanics
14P02705072A0464|0 9|End points
14P02705072A0464|63 64|MI
14P02705296A0231|32 42|polyprotein
14P02705296A0231|52 55|ORF1
14P02705296A0231|60 70|kilodaltons
14P02705556A1049|4 5|RV
14P02705556A1049|22 23|RC
14P02707909A0209|2 19|alternative method
14P02707909A0209|21 23|UKM
14P02707909A0209|72 85|dialysate flow
14P02708288A0139|0 20|Liquid chromatography
14P02708288A0139|46 50|LC/AD
14P02708288A0139|109 123|base hydrolysis
14P02708288A0139|125 139|fluazifop-butyl
14P02708288A0621|3 17|dichloromethane
14P02708288A0621|81 92|PRP-1 liquid
14P02708288A0621|249 262|oxidation mode
14P02708353A1080|0 27|Primer extension experiments
14P02708353A1080|42 70|transcription initiation site
14P02708353A1080|149 159|P-450e gene
14P02708353A1452|17 41|polymerase chain reaction
14P02708353A1452|105 122|polysome fractions
14P02709081T0000|0 9|Validation
14P02709081T0000|35 49|profile measure
14P02709081T0000|54 77|type A behaviour pattern
14P02709819A0495|7 9|ADR
14P02709819A0495|32 52|ciprofloxacin therapy
14P02711145T0000|0 17|HIV infectiousness
14P02711145T0000|23 26|AIDS
14P02711167A0818|25 33|PFB-group
14P02711167A0818|55 77|serum pepsinogen levels
14P02711601A0601|28 52|acid phosphatase activity
14P02711601A0601|73 83|guinea pigs
14P02712246T0042|29 43|characteristics
14P02712450A0989|12 16|PACO2
14P02712450A0989|92 95|Type
14P02712450A0989|143 146|Type
14P02712450A0989|162 172|hypercapnia
14P02713310T0000|0 13|Fundus changes
14P02713310T0000|40 57|glomerulonephritis
14P02713520T0000|7 18|dose effects
14P02713520T0000|20 35|methyl parathion
14P02713520T0000|48 61|cholinesterase
14P02713520T0000|65 79|ptilochronology
14P02713994A0482|14 21|HSV type
14P02713994A0482|29 36|HSV type
14P02714525A0529|0 12|Kidney weight
14P02714525A0529|29 40|weight ratio
14P02714525A0529|77 86|dose level
14P02714525A0529|115 125|dose levels
14P02714852T0000|18 22|HLA-B
14P02714852T0000|26 40|HLA-C sequences
14P02714852T0000|60 72|HLA-B alleles
14P02717133T0001|28 49|development conditions
14P02717133T0001|51 76|summary oxygen consumption
14P02717349A0311|0 2|Men
14P02718683A0142|0 19|Handgrip dynamometry
14P02720966A0455|23 25|ADA
14P02720966A0455|35 47|concentration
14P02720966A0455|91 100|meningitis
14P02720966A0455|127 137|sensitivity
14P02720966A0455|143 153|specificity
14P02720966A0455|161 170|efficiency
14P02721169A0171|0 8|NERVTRACK
14P02721169A0171|99 111|relationships
14P02723503T0000|0 8|Swim-over
14P02723503T0000|12 29|alternative method
14P02724227T0000|0 16|Perfusion washout
14P02724227T0000|45 58|flap tolerance
14P02725495A0929|26 38|U2 RNA region
14P02725495A0929|56 87|pre-mRNA branchpoint recognition
14P02725495A0929|115 130|metazoan U2 RNAs
14P02725513A0617|25 43|CHO spacer promoter
14P02725513A0617|79 101|metazoan RNA polymerase
14P02725513A0617|118 126|G residue
14P02727909A0383|86 88|ADP
14P02727909A0383|131 137|IIb HLP
14P02727909A0383|142 144|CHD
14P02727909A0383|152 154|HLP
14P02729666A0267|11 32|intergroup differences
14P02729666A0267|81 104|tissue profile variables
14P02731611A0134|145 169|Mental Research Institute
14P02731671A0000|33 35|NiO
14P02731671A0000|38 63|nickel sulfate hexahydrate
14P02731671A0000|63 67|NiSO4
14P02731671A0000|70 72|H2O
14P02731671A0000|78 94|nickel subsulfide
14P02731671A0000|95 99|Ni3S2
14P02731671A0000|113 123|F344/N rats
14P02731671A0000|126 136|B6C3F1 mice
14P02731671A0000|141 159|inhalation exposure
14P02732341A0000|156 177|chloroacetate esterase
14P02732341A0000|198 206|diagnosis
14P02733116T0000|7 25|National Institutes
14P02733690T0000|19 34|characterisation
14P02733690T0000|74 82|reductase
14P02735364A1330|69 96|progesterone receptor status
14P02736482A0550|26 42|radiation therapy
14P02736482A0550|43 58|brain metastases
14P02739739T0000|0 24|COUP transcription factor
14P02739739T0000|37 64|steroid receptor superfamily
14P02740196A0704|2 11|Experiment
14P02740196A0704|25 38|classification
14P02740196A0704|90 103|target numbers
14P02740347A0644|0 12|Cosmid clones
14P02740347A0644|26 39|VNTR sequences
14P02740347A0644|57 75|restriction mapping
14P02740627A0137|16 18|VO2
14P02740627A0137|21 41|carbon dioxide output
14P02740627A0137|41 44|VCO2
14P02740627A0137|67 84|minute ventilation
14P02740627A0137|85 86|VE
14P02740627A0137|109 110|VA
14P02740627A0137|121 135|oxygen pressure
14P02740627A0137|136 139|PAO2
14P02740627A0137|145 156|VE/VO2 ratio
14P02740627A0137|196 197|VT
14P02740627A0137|225 226|VD
14P02740874A0957|70 72|SO2
14P02740955A0333|30 43|mortality rate
14P02740955A0333|86 95|deliveries
14P02743842A0000|34 47|prostaglandins
14P02743842A0000|49 59|cytoprotect
14P02743842A0000|102 118|stress ulceration
14P02743842A0000|132 140|influence
14P02743842A0000|157 172|prostaglandin E2
14P02743842A0000|181 184|PGE2
14P02743842A0000|207 222|lesion formation
14P02743842A0000|235 243|tissue pH
14P02743842A0000|246 259|back-diffusion
14P02743842A0000|271 280|blood flow
14P02743981A0347|0 10|Transcripts
14P02743981A0347|74 98|L1e-L10e-L12e transcripts
14P02743981A0347|126 133|NAB-L11e
14P02743981A0347|150 164|NAB transcripts
14P02743981A0347|181 183|ORF
14P02744123A0237|55 67|rhesus monkey
14P02744123A0237|175 194|background luminance
14P02744490A0894|0 7|Evidence
14P02744490A0894|54 64|S1 nuclease
14P02744490A0894|67 90|primer extension studies
14P02744490A0894|117 126|PTHrP gene
14P02744490A0894|144 174|mRNA transcription start points
14P02745280A0276|13 16|PaO2
14P02745280A0276|83 103|lactate concentration
14P02745280A0276|127 140|concentrations
14P02745280A0276|162 176|phosphocreatine
14P02745280A0276|181 183|ATP
14P02745280A0276|196 198|31P
14P02745280A0276|207 228|resonance spectroscopy
14P02745444A0391|3 31|transcription initiation site
14P02745444A0391|45 63|S1 nuclease mapping
14P02745666A0000|22 38|plasma oestradiol
14P02745666A0000|39 40|E2
14P02745666A0000|45 56|progesterone
14P02745666A0000|58 59|P4
14P02745666A0000|100 125|replacement therapy cycles
14P02746099A0000|3 10|mobility
14P02746099A0000|29 37|premolars
14P02746099A0000|64 71|relation
14P02746099A0000|90 96|contact
14P02747653A0910|19 25|protein
14P02747653A0910|50 57|staining
14P02747653A0910|67 74|tadpoles
14P02747653A0910|84 92|beginning
14P02747653A0910|95 107|metamorphosis
14P02748188A0091|33 34|PT
14P02748188A0091|38 39|Ss
14P02748188A0091|113 114|PS
14P02748188A0091|118 119|Ss
14P02748595A0492|17 34|baboon liver class
14P02748595A0492|34 36|ADH
14P02748595A0492|74 81|ADH-beta
14P02749215A0000|8 18|proteinuria
14P02749215A0000|31 39|hematuria
14P02751080A0176|20 26|bullets
14P02751080A0176|35 41|minutes
14P02751080A0176|47 61|intensity level
14P02752303A0000|0 13|Lithium delays
14P02752303A0000|64 84|plasma concentrations
14P02752629A0163|0 6|Dynamic
14P02752629A0163|46 68|methylene diphosphonate
14P02752651A0480|16 25|department
14P02752651A0480|28 36|September
14P02752651A0480|74 84|paraparesis
14P02752651A0480|89 98|impairment
14P02752651A0480|111 120|modalities
14P02752651A0480|136 137|Th
14P02752651A0480|150 160|disturbance
14P02756731T0001|0 13|Prostaglandins
14P02756878A0075|42 52|occurrences
14P02756878A0075|59 68|arrhythmia
14P02756878A0075|125 126|AF
14P02757033A0905|91 105|heterochromatin
14P02757033A0905|127 141|position effect
14P02757033A0905|144 156|transcription
14P02757862T0000|22 35|microprocessor
14P02757862T0000|58 70|defibrillator
14P02758382A0478|0 6|Obesity
14P02758382A0478|116 143|sex hormone binding globulin
14P02758382A0478|142 145|SHBG
14P02760922A0000|20 36|ribonucleoprotein
14P02760922A0000|44 58|core protein A1
14P02760922A0000|92 102|S particles
14P02761008X0000|0 28|Brain cholinesterase activity
14P02761008X0000|101 120|brain cholinesterase
14P02761008X0000|121 123|ChE
14P02761008X0000|180 195|organophosphorus
14P02761008X0000|198 217|carbamate pesticides
14P02761150A0000|11 25|zinc deficiency
14P02761150A0000|27 38|trace metals
14P02761150A0000|63 70|pancreas
14P02761150A0000|74 81|duodenum
14P02761150A0000|102 108|control
14P02761150A0000|149 157|pregnancy
14P02761492A0124|3 10|findings
14P02761492A0124|42 48|genesis
14P02761492A0124|61 71|involvement
14P02761492A0124|80 87|patients
14P02761537A0168|0 12|Heating cells
14P02761537A0168|81 93|control level
14P02761537A0168|114 125|% inhibition
14P02761537A0168|127 151|transcription termination
14P02761537A0168|168 178|nucleotides
14P02761537A0168|201 208|28S rRNA
14P02761537A0168|213 223|readthrough
14P02761537A0168|245 262|transcription unit
14P02761540A0873|0 16|Deletion analysis
14P02761540A0873|29 34|NF-4FA
14P02761540A0873|36 41|NF-4FB
14P02761540A0873|46 59|AP-1 sequences
14P02762006A0071|0 3|Cord
14P02762198T0001|0 3|Reye
14P02762198T0001|6 13|syndrome
14P02763467A0903|19 36|polyacrylamide gel
14P02763467A0903|62 64|35S
14P02763467A0903|259 265|N1L ORF
14P02764797A0182|0 4|PULSE
14P02764797A0182|20 22|NMR
14P02764797A0182|103 116|sampling times
14P02764797A0182|124 141|imaging parameters
14P02764797A0182|143 156|rf pulse shape
14P02764797A0182|158 175|gradient waveforms
14P02765001A0105|8 11|JPsA
14P02765001A0105|36 44|arthritis
14P02765001A0105|112 120|arthritis
14P02765001A0105|150 159|dactylitis
14P02765001A0105|194 207|family history
14P02765001A0105|209 217|psoriasis
14P02765214A0486|12 16|Kurti
14P02765214A0486|45 54|importance
14P02766330A0779|90 108|calcium antagonists
14P02766330A0779|125 135|application
14P02766508A0421|1 23|correlation coefficient
14P02766508A0421|84 97|mean IQRST map
14P02766745T0000|25 36|relationship
14P02766745T0000|52 59|placenta
14P02766745T0000|63 70|mastitis
14P02766745T0000|73 82|dairy cows
14P02767166A0368|17 34|lipid peroxidation
14P02767166A0368|52 62|development
14P02767166A0368|92 102|consequence
14P02767166A0368|128 139|pathogenesis
14P02767733A0690|46 47|G1
14P02767733A0690|51 52|G2
14P02767733A0690|56 57|G3
14P02772495A0641|0 5|Asthma
14P02772495A0641|45 53|ASA group
14P02772495A0641|65 66|AT
14P02772495A0641|81 90|INTR group
14P02773507A0750|48 63|sample estimates
14P02773507A0750|75 76|CL
14P02773507A0750|121 136|sample estimates
14P02773507A0750|167 171|CLunb
14P02773930T0000|33 47|hyperfiltration
14P02774271A0000|0 8|Halothane
14P02774271A0000|62 73|end products
14P02774271A0000|94 97|TFAA
14P02774271A0000|110 111|Br
14P02774808A0194|69 85|micrograms/100 ml
14P02775136A1151|23 30|HAPE-S-S
14P02775136A1151|59 76|breathing patterns
14P02775136A1151|128 130|AMS
14P02775136A1151|182 199|breathing patterns
14P02775136A1151|220 222|AMS
14P02775333A1137|0 9|Buflomedil
14P02775333A1137|38 45|increase
14P02775333A1137|86 92|changes
14P02775333A1137|121 128|decrease
14P02775333A1137|148 155|increase
14P02776471A0235|26 32|animals
14P02776471A0235|47 56|responders
14P02776471A0235|71 77|pattern
14P02776471A0235|93 100|response
14P02776742A0000|0 9|Heart rate
14P02776742A0000|10 11|HR
14P02776742A0000|32 34|Tre
14P02776742A0000|37 50|blood pressure
14P02776742A0000|73 88|humidity changes
14P02776742A0000|158 164|VO2 max
14P02776742A0000|172 184|ml kg-1 min-1
14P02776742A0000|213 214|SU
14P02776742A0000|279 297|breathing apparatus
14P02776742A0000|298 299|FE
14P02776823A0000|23 38|pharmacokinetics
14P02776823A0000|41 43|FCE
14P02776823A0000|57 58|5R
14P02776823A0000|60 61|6S
14P02776823A0000|68 69|1R
14P02776823A0000|88 127|carbamoyloxymethyl-2-penem-3-carboxylate
14P02777797A0720|0 21|DNA blot hybridization
14P02777797A0720|77 99|PtdIns transfer protein
14P02778237A0585|36 37|IA
14P02778237A0585|73 74|IA
14P02778237A0585|84 113|maintenance prednisone therapy
14P02778873A0761|16 19|CRL3
14P02778873A0761|47 63|enhancer function
14P02778873A0761|97 101|DR-A1
14P02778873A0761|105 109|DR-A2
14P02779752A0000|3 12|1-Naphthyl
14P02779752A0000|25 28|1-NP
14P02779752A0000|51 81|serotonin antagonist properties
14P02779752A0000|85 97|5-HT2 subtype
14P02779752A0000|161 170|5-HT1 site
14P02779752A0776|3 16|m-Chlorophenyl
14P02779752A0776|53 75|m-trifluoromethylphenyl
14P02779752A0776|88 92|TFMPP
14P02779752A0776|135 145|5-HT1 sites
14P02779752A0776|194 205|methysergide
14P02779752A0776|211 214|1-NP
14P02780157A0576|34 51|spleen MP function
14P02780157A0576|64 66|VHA
14P02780157A0576|81 97|HBsAg carriership
14P02780157A0576|232 240|MP system
14P02780157A0576|276 280|HBsAg
14P02781495T0001|0 6|Changes
14P02781495T0001|9 33|xanthine oxidase activity
14P02781567A0544|22 29|solution
14P02781567A0544|63 77|stratum corneum
14P02783181A0000|44 61|antacid magaldrate
14P02783181A0000|62 70|ES Riopan
14P02783181A0000|117 132|mucus secretions
14P02784507A0000|8 34|immunodeficiency virus type
14P02784507A0000|35 39|HIV-1
14P02784507A0000|62 64|CD4
14P02784507A0000|66 78|T lymphocytes
14P02787430A0124|36 51|biopsy specimens
14P02787430A0124|55 70|cytophagocytosis
14P02789062A0000|22 24|4F2
14P02789062A0000|36 40|4F2HC
14P02789062A0000|49 60|model system
14P02789062A0000|135 149|gene expression
14P02789062A0000|166 182|T-cell activation
14P02789062A1420|16 46|NF-4FB enhancer binding protein
14P02789062A1420|69 92|lambda gt11 cDNA library
14P02789062A1420|141 167|NF-4FB recognition sequence
14P02789180A0407|36 46|hypertrophy
14P02789180A0407|74 84|hypertrophy
14P02789217A1323|6 21|IL6 mRNA species
14P02789217A1323|45 59|polyadenylation
14P02790009A0375|0 18|Sequencing analysis
14P02790009A1052|90 115|serine protease inhibitors
14P02792270A1220|13 27|EPSP components
14P02792270A1220|91 108|flexor motoneurons
14P02792430A0000|0 10|Experiments
14P02792430A0000|29 39|guinea pigs
14P02792430A0000|85 94|inhibition
14P02792430A0000|97 120|prostaglandins synthesis
14P02792430A0000|129 139|development
14P02792430A0000|204 214|guinea pigs
14P02793216A0876|21 32|conservation
14P02793216A0876|38 65|membrane attachment sequence
14P02793216A0876|131 133|CgA
14P02793620A0214|67 75|Charolais
14P02793620A0214|79 92|Red Poll bulls
14P02793753A0354|18 30|PA dispersion
14P02793753A0354|46 48|CFV
14P02793753A0354|77 78|PA
14P02794828A0214|52 64|microcomputer
14P02794828A0214|103 111|pacemaker
14P02795923A0000|36 49|CT appearances
14P02796216A0063|39 55|jaundice syndrome
14P02796216A0063|62 74|enterorrhagia
14P02796216A0063|82 91|appearance
14P02796988A0735|3 26|transcription factor Sp1
14P02796988A0735|59 77|footprinting assays
14P02796988A0735|80 97|gel shift analysis
14P02796988A0735|108 110|Sp1
14P02797877A0475|3 17|combination PIP
14P02797877A0475|30 32|PEF
14P02797877A0475|102 112|antibiotics
14P02798953A0307|66 75|instrument
14P02798953A0307|77 81|WPL-R
14P02798953A0307|112 122|consistency
14P02798953A0307|135 149|days postpartum
14P02798953A0307|168 182|administrations
14P02799892A0154|40 44|WRBCs
14P02799892A0154|111 113|PNH
14P02800417A0332|72 86|PC20 PGF2 alpha
14P02800417A0332|88 103|histamine values
14P02800435A0000|5 15|experiments
14P02800435A0000|113 115|PMF
14P02802280A0495|43 44|TS
14P02802280A0495|51 53|PTS
14P02805945A0000|30 41|growth rates
14P02805945A0000|118 145|Scripsiella trochoidea Stein
14P02805945A0000|163 183|laboratory conditions
14P02805945A0000|279 294|microEin m-2 s-1
14P02806916A0000|8 16|DNA clone
14P02806916A0000|38 39|Oc
14P02806916A0000|43 71|cysteine proteinase inhibitor
14P02806916A0000|103 128|lambda EMBL3 phage library
14P02806916A0000|141 146|Sau3AI
14P02806916A0000|178 180|DNA
14P02807780A0143|31 44|methylene blue
14P02807780A0143|54 59|M NaCl
14P02807780A0143|108 110|CIS
14P02808232A0681|16 28|micrograms/kg
14P02808232A0681|57 67|reliability
14P02809116A0237|74 81|husbands
14P02809116A0237|83 92|retirement
14P02809116A0237|105 116|satisfaction
14P02809651A0492|37 49|meta-analysis
14P02809651A0492|59 68|clinicians
14P02809651A0492|72 84|policy makers
14P02809651A0492|98 106|questions
14P02809722A0926|67 78|GH secretion
14P02809831A0799|14 17|PPSF
14P02809831A0799|19 26|DBP side
14P02809831A0799|46 59|bone formation
14P02810911A0372|34 46|neuroblastoma
14P02810911A0372|66 82|131I-MIBG imaging
14P02810911A0372|92 104|tumor markers
14P02811378A0250|45 51|infants
14P02811378A0250|66 71|mucosa
14P02811378A0250|108 114|maxilla
14P02811378A0250|120 127|mandible
14P02811378A0379|53 64|S100 protein
14P02811378A0379|80 90|cell tumors
14P02811378A0379|132 144|cell epulides
14P02813369A0390|61 71|territories
14P02813369A0390|126 134|neighbors
14P02813404T0000|13 24|antigen gene
14P02813404T0000|77 91|spermatogenesis
14P02814182A1211|38 42|4-EPI
14P02814182A1211|57 64|ABSTRACT
14P02814182A1211|79 83|WORDS
14P02814820A0967|9 17|Roux limb
14P02814820A0967|107 119|Billroth dogs
14P02814820A0967|120 123|t1/2
14P02814820A0967|130 133|Roux
14P02814820A0967|150 157|Billroth
14P02815229A0139|3 12|treatments
14P02815229A0139|93 95|MBq
14P02815229A0139|97 99|14C
14P02816251A0397|25 35|capillaries
14P02816251A0397|143 152|ventricles
14P02817724A0075|3 13|examination
14P02817724A0075|25 26|T1
14P02817724A0075|30 41|T2 sequences
14P02818122A0000|12 22|information
14P02818122A0000|39 48|morphology
14P02818122A0000|54 62|claustrum
14P02818122A0000|72 85|animal species
14P02818122A0000|107 118|distribution
14P02818122A0000|122 134|relationships
14P02818260T0000|9 14|glioma
14P02820128A1333|9 28|sequence repetitions
14P02820128A1333|61 81|hexanucleotide ATTGTT
14P02820128A1333|106 118|dyad symmetry
14P02820128A1333|136 142|ORF T3C
14P02820128A1670|3 14|significance
14P02820128A1670|46 48|ORF
14P02820128A1670|64 74|coincidence
14P02820128A1670|129 144|protein sequence
14P02820128A1670|166 172|B chain
14P02820128A1670|196 206|palindromes
14P02820128A1670|219 228|T2 protein
14P02821340A0434|26 28|DCR
14P02821340A0434|34 40|UT dogs
14P02821340A0434|79 98|mm Hg X ml-1 X min-1
14P02821340A0434|107 126|mm Hg X ml-1 X min-1
14P02824334A0972|23 43|G-protein gene family
14P02825139A0661|16 18|DNA
14P02825139A0661|66 79|acid sequences
14P02825750A0260|13 20|patients
14P02825750A0260|24 36|response rate
14P02825750A0260|58 65|response
14P02826127A0709|50 67|SV40 octamer motif
14P02826127A0709|93 106|protein oct-B2
14P02826717A0179|0 5|Anoxia
14P02826717A0179|76 85|water flow
14P02826729A0790|0 5|Growth
14P02826729A0790|7 10|4-PA
14P02826729A0790|14 30|14C turnover data
14P02826729A0790|42 43|WB
14P02826729A0790|57 66|B-6 intake
14P02828926A1870|127 147|actin gene expression
14P02828926A1870|166 187|muscle differentiation
14P02829183A0117|0 20|DNA sequence analysis
14P02830214A0000|25 27|ACZ
14P02830214A0000|31 34|HCO3
14P02830214A0000|39 40|Cl
14P02830214A0000|97 118|microelectrode methods
14P02830265A0341|0 5|RPA190
14P02830265A0341|14 30|polypeptide chain
14P02830282A0155|13 22|A1 protein
14P02830282A0155|51 61|UP1 protein
14P02830282A0155|96 107|V-8 protease
14P02831398A0346|0 6|Irmiere
14P02831398A0346|11 12|W.
14P02831556A0173|5 13|offspring
14P02831556A0173|19 27|alpha-MSH
14P02831556A0173|35 41|mothers
14P02831556A0173|99 106|response
14P02831556A0173|109 116|morphine
14P02831796A0000|6 27|immunodeficiency virus
14P02831796A0000|28 30|SIV
14P02831796A0000|93 114|immunodeficiency virus
14P02831796A0000|142 166|immunodeficiency syndrome
14P02831796A0000|167 170|AIDS
14P02832149A1009|120 128|insertion
14P02832149A1009|143 153|amino acids
14P02832149A1009|164 178|myb transcripts
14P02832149A1009|184 194|consequence
14P02832149A1009|211 220|activation
14P02832149A1009|226 243|mouse myb oncogene
14P02832293T0000|8 13|CRF-41
14P02832293T0000|42 48|Cushing
14P02832744A0403|10 24|mos transcripts
14P02832744A0403|26 33|Northern
14P02832744A0403|35 37|RNA
14P02832744A0403|49 51|RNA
14P02832744A0403|74 86|quail ovaries
14P02833012A0428|12 17|L mRNA
14P02833012A0428|91 99|L protein
14P02833012A0428|130 131|MW
14P02833021A1185|24 35|organization
14P02833021A1185|95 105|enhancement
14P02833021A1185|158 174|promoter function
14P02833049A0630|0 9|Variations
14P02833049A0630|23 24|U3
14P02833049A1041|21 36|state RNA levels
14P02833049A1041|105 115|transcripts
14P02833049A1041|167 177|RD-114 mRNA
14P02833101T0000|22 35|cell disorders
14P02833101T0000|36 55|bone marrow necrosis
14P02833101T0000|62 81|parvovirus infection
14P02833517A0467|24 32|sequences
14P02833517A0467|43 50|cleavage
14P02833517A0467|61 67|element
14P02834478A0000|12 26|weight heparins
14P02834478A0000|97 105|Xa factor
14P02834843A0000|31 51|rifamycin derivatives
14P02834843A0000|63 65|RBU
14P02834843A0000|68 70|FCE
14P02834843A0000|77 79|F22
14P02834843A0000|94 96|RPE
14P02834843A0000|99 101|CGP
14P02834843A0000|108 110|C29
14P02834843A0000|113 115|CGP
14P02834843A0000|121 123|C70
14P02834843A0000|128 130|CGP
14P02834843A0000|137 139|C27
14P02834843A0000|155 157|RMP
14P02834843A0000|263 288|Mycobacterium tuberculosis
14P02834843A0000|289 293|H37Rv
14P02836623A1094|0 1|Mo
14P02836623A1094|3 4|SV
14P02836623A1094|50 71|months postinoculation
14P02836623A1094|87 88|SV
14P02836623A1094|134 155|months postinoculation
14P02837575A0979|0 13|Sodium dodecyl
14P02837575A0979|49 61|topoisomerase
14P02837575A0979|119 121|DNA
14P02837763A0259|0 18|Amino acid sequence
14P02837763A0259|38 42|HL-14
14P02837763A0259|75 100|muscle phosphatase 2A cDNA
14P02837763A0259|105 125|% nucleotide identity
14P02838246A0225|0 21|Herpes virus infection
14P02838246A0225|52 62|T4/T8 ratio
14P02838246A0225|110 122|proliferation
14P02838246A0225|128 143|T8 subpopulation
14P02838246A0225|188 203|rejection crises
14P02838319A0527|0 3|RVEF
14P02838319A0527|7 10|LVEF
14P02838710A0299|11 16|NPY-ir
14P02839488A1314|50 58|alpha s-1
14P02839488A1314|96 116|erythrocyte type-1 Gs
14P02839716A0673|13 23|E2 proteins
14P02839716A0673|86 114|HPV-11 enhancer-SV40 promoter
14P02839716A1907|19 22|E2-C
14P02839716A1907|44 60|enhancer activity
14P02839716A1907|93 94|E2
14P02839716A1907|145 152|ABSTRACT
14P02839716A1907|167 171|WORDS
14P02840034A1266|8 17|evaluation
14P02840034A1266|53 72|lung cancer patients
14P02840376A0461|13 18|Holmer
14P02843495A0544|0 11|Introduction
14P02843495A0544|24 28|CSF-1
14P02843495A0544|44 63|macrophage cell line
14P02843495A0544|69 87|factor independence
14P02843694T0001|7 25|E-B virus infection
14P02844767A0191|22 36|cotranscription
14P02844767A0191|63 72|Rieske-FeS
14P02844767A0191|100 112|apocytochrome
14P02844767A0191|149 154|Kallas
14P02844767A0191|156 157|T.
14P02844767A0191|159 165|Spiller
14P02844767A0191|167 168|S.
14P02844767A0191|173 178|Malkin
14P02844767A0191|180 181|R.
14P02844767A0596|3 20|Nostoc petBD genes
14P02844767A0596|137 153|chloroplast genes
14P02844767A1022|0 22|RNA blot hybridizations
14P02844767A1022|51 63|cytochrome b6
14P02844797A1225|10 23|muscle isoform
14P02844797A1225|66 89|sequence Ala-Ile-Leu-Glu
14P02844797A1225|184 196|acid sequence
14P02844797A1225|218 237|transmembrane domain
14P02844797A1225|248 265|consensus sequence
14P02844797A1225|278 295|glycosylation site
14P02845654A0510|0 11|Substitution
14P02845654A0510|15 31|threonine residue
14P02845654A0510|35 49|alanine residue
14P02845654A0510|62 63|P2
14P02845654A0510|71 83|cleavage site
14P02845654A0510|123 138|tyrosine residue
14P02845654A0510|141 161|phenylalanine residue
14P02845654A0510|163 181|amino acid position
14P02845654A0510|183 184|P1
14P02845654A0510|191 203|cleavage site
14P02846640A0643|37 55|indoxyl phosphatase
14P02846852A1459|40 56|E strand promoter
14P02846852A1459|94 110|L strand promoter
14P02848842A0643|9 21|RNA molecules
14P02848842A0643|34 47|kilobase range
14P02849100A0441|57 65|extremity
14P02849100A0441|114 128|plasma membrane
14P02849759A0865|3 15|SV40 enhancer
14P02850472A0112|42 56|DNA replication
14P02850967T0000|0 8|Induction
14P02850967T0000|11 42|proto-oncogene fos transcription
14P02850967T0000|51 75|adenylate cyclase pathway
14P02850971A0180|7 26|oligodeoxynucleotide
14P02850971A0180|55 78|VtHb amino acid sequence
14P02850971A0180|86 104|hybridization probe
14P02850971A0180|113 124|Vitreoscilla
14P02850971A0180|168 187|cosmid vector pVK102
14P02852805A0216|35 49|characteristics
14P02852805A0216|58 66|influence
14P02852805A0216|78 87|treatments
14P02852894T0000|0 5|Causes
14P02852894T0000|60 72|Thai villages
14P02853799T0001|3 13|progression
14P02853799T0001|27 35|hepatitis
14P02853799T0001|60 73|transformation
14P02853799T0001|90 98|carcinoma
14P02853922A0596|8 10|IOP
14P02856622T0001|0 2|Use
14P02856622T0001|5 37|serum thyroglobulin determination
14P02859434T0000|0 12|Poor response
14P02859434T0000|45 57|serum lithium
14P02861067A0000|54 64|ipratropium
14P02861067A0000|128 148|bronchodilator effect
14P02861067A0000|151 167|beta agonist drug
14P02861144A0242|21 32|DNA fragment
14P02861144A0242|61 77|encoding proteins
14P02861238T0000|7 11|virus
14P02862656T0000|0 6|Changes
14P02862656T0000|9 37|dopamine receptor sensitivity
14P02863492A0544|13 23|differences
14P02863492A0544|37 52|treatment groups
14P02863492A0544|121 129|IgG index
14P02863747T0000|0 10|Replacement
14P02863747T0000|18 30|histone genes
14P02865502T0000|40 72|tissue-type plasminogen activator
14P02868446A0184|21 24|CTDs
14P02868446A0184|31 48|RPase beta subunit
14P02868446A0184|50 60|DNA primase
14P02868446A0184|147 157|RPase alpha
14P02868446A0184|228 247|core enzyme subunits
14P02868848A0167|8 17|vancomycin
14P02868848A0167|21 30|fosfomycin
14P02868848A0167|74 81|activity
14P02868848A0167|104 115|penicillin G
14P02868848A0167|118 125|imipenem
14P02868848A0167|154 165|gas gangrene
14P02869125A0120|0 7|Fentanyl
14P02869125A0120|29 44|receptor agonist
14P02869125A0120|118 138|locomotor stimulation
14P02870249T0000|12 23|chemotherapy
14P02870720A0188|0 9|Bisoprolol
14P02870720A0188|33 60|beta-adrenoceptor antagonist
14P02870720A0188|104 119|guinea pig atria
14P02870720A0188|121 135|tracheal muscle
14P02870851A0349|0 5|Output
14P02870851A0349|8 15|99mTcO-4
14P02870851A0349|62 85|parotid saliva flow rate
14P02872786A0147|19 26|equation
14P02872786A0147|61 69|parasites
14P02872786A0147|103 111|sandflies
14P02872786A0147|114 123|blood flow
14P02873593A0581|92 94|BZP
14P02873593A0581|168 187|5-HT uptake blockers
14P02874078A0252|13 35|luteal phase deficiency
14P02874635T0000|21 37|fungicide dinocap
14P02874635T0000|53 63|torticollis
14P02874635T0000|65 74|ballooning
14P02874635T0000|78 89|cleft palate
14P02875224A1059|0 10|Reperfusion
14P02875224A1059|116 128|contractility
14P02875224A1059|134 141|instance
14P02875967A0377|3 13|sensitivity
14P02875967A0377|32 41|adrenaline
14P02875967A0377|67 77|guinea pigs
14P02875967A0377|97 110|fertility rate
14P02876820A0841|11 18|acidosis
14P02876820A0841|34 44|stimulation
14P02876899A0568|2 5|Days
14P02876899A0568|73 104|bevantolol plasma concentrations
14P02876899A0568|108 123|absorption phase
14P02877124A0000|12 16|B6AF1
14P02877124A0000|20 30|B6D2F1 mice
14P02877124A0000|58 73|promethazine HCl
14P02877124A0000|92 120|H1 receptor blocking activity
14P02877124A0000|120 135|chlorpheniramine
14P02877124A0000|139 148|H1 blocker
14P02877124A0000|151 165|trifluoperazine
14P02877124A0000|187 206|H1 blocking activity
14P02877124A0000|213 226|drinking water
14P02877124A0000|255 274|bone mineral content
14P02877124A0000|322 335|body retention
14P02877124A0000|337 338|Tc
14P02877124A0000|342 364|methylene diphosphonate
14P02877124A0000|365 366|Tc
14P02877124A0000|370 372|MDP
14P02877124A0000|387 401|bone metabolism
14P02878100A0674|40 49|inhibition
14P02878100A0674|62 73|transmission
14P02878100A0674|76 84|diltiazem
14P02878100A0674|100 108|diltiazem
14P02878100A0674|179 190|transmission
14P02879906A0000|0 6|Studies
14P02879906A0000|93 130|beta adrenoceptor subtype distribution
14P02879906A0000|164 180|nerve innervation
14P02879951T0000|0 6|Effects
14P02879951T0000|35 42|SGB-1534
14P02879951T0000|46 69|rat platelet aggregation
14P02880841A0313|19 21|TF1
14P02880841A0313|73 75|TF1
14P02880841A0313|104 115|beta subunit
14P02880841A0313|132 150|nucleotide sequence
14P02880841A0313|220 221|F1
14P02880841A0313|246 257|chloroplasts
14P02880841A0313|262 273|mitochondria
14P02882893A0301|0 15|Body temperature
14P02882893A0301|69 83|P. s. campbelli
14P02883327A0413|3 23|polyadenylation sites
14P02883327A0413|72 74|DNA
14P02883871A1075|9 11|ISA
14P02883871A1075|27 40|beta receptors
14P02883871A1075|95 115|drug hypersensitivity
14P02883871A1075|140 142|ISA
14P02883963A0000|20 25|T-cell
14P02883963A0000|49 54|HTLV-I
14P02883963A0000|78 80|HAM
14P02884860A0329|0 8|Terazosin
14P02884860A0329|56 68|adrenoceptors
14P02885517T0000|7 18|blood donors
14P02885517T0000|32 40|hepatitis
14P02889352A0000|20 33|blood pressure
14P02889352A0000|34 35|BP
14P02889352A0000|91 102|beta blocker
14P02889352A0000|113 128|enzyme inhibitor
14P02889352A0000|130 147|calcium antagonist
14P02889495A0000|38 59|episode schizophrenics
14P02889495A0000|78 89|flupenthixol
14P02889495A0000|135 145|mg pimozide
14P02889495A0000|150 164|mg flupenthixol
14P02890200T0001|48 61|Recklinghausen
14P02890200T0001|64 80|neurofibromatosis
14P02892762A0296|17 31|repeat elements
14P02892762A0296|50 60|nucleotides
14P02892762A0296|73 85|promoter site
14P02894689A0000|27 39|DNA fragments
14P02894689A0000|51 65|chromatin loops
14P02894689A0000|84 103|extraction procedure
14P02894689A0000|124 139|diiodosalicylate
14P02894741A0000|52 68|muscle relaxation
14P02894741A0000|84 101|NLA II anaesthesia
14P02894789A0954|11 26|recovery indexes
14P02894789A0954|58 62|T1/T0
14P02894789A0954|66 70|T4/T1
14P02895472A0178|85 87|BiP
14P02895472A0178|105 120|mRNA translation
14P02895566A0187|0 2|DPA
14P02895566A0187|54 77|pressure pain components
14P02895566A0187|90 106|ischemia duration
14P02895566A0187|128 150|pressure pain component
14P02895754A0000|8 28|percent isoproterenol
14P02895754A0000|46 85|phosphodiesterase inhibitor theophylline
14P02895754A0000|226 231|Horner
14P02897651A0000|0 14|Hyperthyroidism
14P02898752A0683|43 48|CFU-GM
14P02898752A0683|71 82|granulocytes
14P02898752A0683|86 103|platelets recovery
14P02899177A0605|27 48|low-frequency kindling
14P02899177A0605|135 146|excitability
14P02899792T0000|0 8|Oestrogen
14P02900760A0073|5 21|sequence elements
14P02900760A0073|64 88|transcription termination
14P02900760A0073|90 105|RNA polymerase I
14P02900760A0073|133 152|transcription system
14P02900760A0073|180 203|rDNA minigene constructs
14P02900760A0073|206 214|3T6 cells
14P02901498A0354|3 14|biosynthesis
14P02901498A0354|83 94|erbB protein
14P02901498A0354|135 160|chicken embryo fibroblasts
14P02901763A0977|0 10|Codon usage
14P02901763A0977|12 38|C. reinhardtii mitochondria
14P02901763A0977|162 181|C. reinhardtii mtDNA
14P02901763A0977|243 259|protein synthesis
14P02902615A0000|22 30|treatment
14P02902615A0000|44 56|polyarteritis
14P02902615A0000|80 88|treatment
14P02902615A0000|104 114|hepatitis B
14P02902656A0481|39 49|hypointense
14P02902656A0481|76 90|repetition time
14P02902656A0481|91 92|TR
14P02902656A0481|106 107|TE
14P02902656A0481|123 134|hyperintense
14P02902656A0481|158 172|TR/TE sequences
14P02902844A1219|99 109|atp operons
14P02902844A1219|118 130|bacterium PS3
14P02902844A1219|133 145|cyanobacteria
14P02902927A0145|38 58|rat GHF-1 cDNA clones
14P02903500A0278|22 31|properties
14P02903500A0278|37 43|protein
14P02903500A0278|67 77|fusion gene
14P02903500A0278|129 135|portion
14P02903500A0278|140 153|immunoglobulin
14P02904322A0002|49 62|model ruminant
14P02906027A0553|2 20|sequence comparison
14P02906027A0553|92 101|CpG island
14P02906027A0553|128 144|CpG dinucleotides
14P02906027A1156|12 19|features
14P02906027A1156|59 67|sequences
14P02906027A1156|85 90|intron
14P02906249A1195|87 97|application
14P02906249A1195|100 105|Oxy-Hb
14P02906249A1195|108 117|PGF2 alpha
14P02906673T0000|0 7|Efficacy
14P02906673T0000|28 49|Bacillus thuringiensis
14P02906673T0000|58 70|B. sphaericus
14P02906673T0000|77 97|floodwater mosquitoes
14P02906673T0000|99 108|California
14P02907308T0001|26 49|Richner-Hanhart syndrome
14P02907533A0362|24 41|drug concentration
14P02907533A0362|45 61|correction factor
14P02907533A0362|94 115|diazepam concentration
14P02907533T0000|0 6|Effects
14P02907533T0000|27 42|blood substitute
14P02907533T0000|44 59|diazepam binding
14P02909528A1081|7 23|promoter activity
14P02909528A1081|80 90|start sites
14P02910496A0583|20 32|CGA-CCCCUCC-3
14P02910496A0583|120 132|RNA substrate
14P02910496A0583|147 160|RNAase MRP RNA
14P02910989T0000|0 6|Effects
14P02910989T0000|17 40|beta-adrenergic-blockade
14P02910989T0000|59 72|QT/QS2 changes
14P02911540A0478|1 7|patient
14P02911540A0478|22 26|wound
14P02911540A0478|47 51|hands
14P02911540A0478|65 72|perineum
14P02913368A1037|0 19|Pharmacology studies
14P02913368A1037|23 40|potassium chloride
14P02913368A1037|43 55|acetylcholine
14P02913368A1037|81 98|calcium antagonist
14P02914422A0409|0 16|Computer analysis
14P02914422A0409|78 92|frequency bands
14P02914422A0409|113 127|frequency range
14P02914492A0183|16 18|ICU
14P02914492A0183|45 58|hypomagnesemia
14P02914492A0183|110 124|normomagnesemia
14P02914492A0183|169 183|hypermagnesemia
14P02916764A0253|3 14|risk factors
14P02916764A0253|33 44|hypertension
14P02916764A0253|46 62|diabetes mellitus
14P02916764A0253|63 82|hypercholesterolemia
14P02916764A0253|84 100|cigarette smoking
14P02916764A0253|124 137|family history
14P02918474A0817|7 15|verapamil
14P02918474A0817|19 28|nifedipine
14P02918474A0817|36 45|collateral
14P02918474A0817|56 65|blood flow
14P02918474A0817|85 98|subendocardium
14P02918474A0817|126 138|subepicardium
14P02919483A0091|48 57|half years
14P02919530A0000|28 38|reperfusion
14P02919530A0000|49 58|myocardium
14P02919530A0000|84 99|artery occlusion
14P02919530A0000|150 160|wall motion
14P02919530A0000|184 194|alterations
14P02919832A0144|32 37|M-mode
14P02919832A0144|74 97|Doppler echocardiography
14P02920591A0251|50 63|administration
14P02920591A0251|75 87|micrograms/kg
14P02920591A0251|106 122|micrograms/kg/min
14P02923687A0218|17 28|relationship
14P02923687A0218|45 53|sinusitis
14P02923687A0218|60 69|cleft side
14P02923687A0218|93 104|cleft palate
14P02925013A1112|87 98|accumulation
14P02925013A1112|111 124|citrate ligand
14P02925568A0460|17 30|father absence
14P02925568A0460|42 51|conditions
14P02925568A0460|130 145|family stressors
14P02925568A0460|155 169|psychopathology
14P02926499A0340|32 43|analog model
14P02926499A0340|94 103|expression
14P02926499A0340|107 109|CBF
14P02926499A0340|125 127|CBF
14P02926499A0340|129 130|Cb
14P02927391A0238|49 71|founder SWR/J-RF/J mice
14P02927391A0238|164 174|integration
14P02928112T0000|36 37|U2
14P02928376A0312|56 57|H2
14P02928376A0312|80 90|heat defect
14P02929056T0000|15 38|transureteroureterostomy
14P02929056T0000|48 67|ureterosigmoidostomy
14P02930623A0404|6 21|flexion whiplash
14P02930623A0404|63 71|direction
14P02934778A0702|19 26|presence
14P02934778A0702|29 33|5-HT2
14P02934778A0702|46 54|receptors
14P02934889A0558|0 10|Oxfendazole
14P02934889A0558|79 81|May
14P02934889A0558|101 114|cent reduction
14P02934889A0558|116 133|Ostertagia species
14P02934889A0558|145 158|cent reduction
14P02934889A0558|160 170|D viviparus
14P02934891A0845|47 54|extracts
14P02934891A0845|140 150|nucleotides
14P02934891A0845|169 170|Mu
14P02935638A0000|63 102|sea urchin Strongylocentrotus purpuratus
14P02936163T0000|0 16|Platelet function
14P02936163T0000|90 119|platelet lipoxygenase activity
14P02936284A0357|11 21|degradation
14P02936284A0357|24 33|atracurium
14P02936284A0357|59 69|elimination
14P02936284A0357|97 117|elimination half-life
14P02938185A0223|36 38|E1a
14P02938185A0223|41 43|E1a
14P02938185A0223|47 63|E1b gene products
14P02938185A0223|225 234|CREF cells
14P02939260A1553|17 44|amino acid sequence analysis
14P02939260A1553|55 57|43K
14P02939260A1553|61 74|42K T antigens
14P02939260A1553|124 135|DNA sequence
14P02939260A1553|173 185|39K T antigen
14P02939260A1553|209 225|Edman degradation
14P02940334A0141|0 6|Group A
14P02940334A0141|63 66|HBIG
14P02941237A0160|32 44|serum calcium
14P02941237A0160|47 76|phosphorous ion concentrations
14P02941237A0160|85 96|blood supply
14P02941237A0160|152 171|alkaline phosphatase
14P02941237A0160|174 188|pyrophosphatase
14P02943562T0000|0 23|Penicillinase production
14P02947866A1416|27 45|thallium-201 uptake
14P02947866A1416|123 133|angioplasty
14P02949170A0184|46 73|micrograms ethinyl estradiol
14P02949170A0184|76 97|mg cyproterone acetate
14P02949170A0184|135 162|sex hormone binding globulin
14P02949170A0184|161 164|SHBG
14P02949170A0184|167 181|androstenedione
14P02949170A0184|200 217|testosterone index
14P02950216A0084|31 53|laser Doppler flowmetry
14P02950216A0084|53 55|LDF
14P02950216A0084|82 96|blood cell flux
14P02950216A0084|96 98|BCF
14P02957125A0601|37 49|haemodialysis
14P02957125A0601|72 85|cent reduction
14P02957125A0601|87 110|plasma ANP concentration
14P02958204A0175|39 41|HDL
14P02958204A0175|53 57|HDL-C
14P02958204A0175|59 75|HDL phospholipids
14P02958204A0175|76 81|HDL-PL
14P02958204A0175|108 125|HDL-C subfractions
14P02958204A0175|126 131|HDL2-C
14P02958204A0175|135 140|HDL3-C
14P02958233A0123|21 41|laboratory parameters
14P02958233A0123|60 82|serum sickness reaction
14P02958660A1094|44 60|conversion factor
14P02958660A1094|63 72|LDF signal
14P02959089T0000|18 25|ONO-3708
14P02960012A0838|14 25|PPNG strains
14P02962859A0276|36 68|beta-galactosidase fusion protein
14P02962859A0276|94 95|U1
14P02962859A0276|110 118|A antigen
14P02963517A0453|66 69|PTCA
14P02963517A0453|77 86|dilatation
14P02964329A0000|24 37|Joint Mobility
14P02964329A0000|38 40|LJM
14P02964329A0000|125 139|microangiopathy
14P02965149A0727|17 22|Brandl
14P02965149A0727|24 25|C.
14P02966671A0151|15 24|end points
14P02966671A0151|77 90|treatment size
14P02966671A0151|94 101|survival
14P02966671A0151|104 113|stem cells
14P02966671A0151|139 152|breathing rate
14P02966671A0151|201 209|treatment
14P02966671A0551|0 7|Schedule
14P02966671A0551|20 30|mg/kg c-DDP
14P02966671A0551|62 66|X-ray
14P02966671A0551|111 121|enhancement
14P02966671A0551|124 139|radiation effect
14P02966671A0551|188 198|enhancement
14P02966671A0551|214 224|mg/kg c-DDP
14P02966671A0551|272 283|radiotherapy
14P02967496A0182|16 25|transcript
14P02967496A0182|43 56|reading frames
14P02967496A0182|96 109|leader segment
14P02967915A0000|15 46|hormone 1,25-dihydroxyvitamin D3
14P02967915A0000|76 98|calcium binding protein
14P02967915A0968|14 36|calbindin-D28K promoter
14P02968055A0984|3 5|HOI
14P02968055A0984|38 40|ANF
14P02969316A0002|46 66|plasma concentrations
14P02969316A0002|93 95|ANP
14P02969316A0002|118 142|plasma ANP concentrations
14P02969819A0814|0 21|Ig D-JH recombinations
14P02969819A0814|30 51|TcR gene recombination
14P02969819A0814|103 117|Cmu transcripts
14P02970061A0271|3 12|RAD18 gene
14P02970061A0271|16 28|reading frame
14P02970640A0341|6 33|absorption spectrophotometry
14P02970640A0341|62 73|E1A proteins
14P02971603A0883|4 11|patients
14P02971603A0883|21 27|tablets
14P02971603A0883|30 38|injection
14P02971710A0734|0 4|Plots
14P02971710A0734|7 8|RV
14P02971710A0734|10 11|LV
14P02971710A0734|17 25|2A weight
14P02971710A0734|134 135|CO
14P02971957A0287|41 51|improvement
14P02971957A0287|84 93|techniques
14P02971957A0287|113 120|bleeding
14P02973304A0000|20 39|Budd-Chiari syndrome
14P02973304A0000|107 123|patient suffering
14P02973304A0000|142 156|cardiosclerosis
14P02975680A0000|8 26|accommodation night
14P02975680A0000|27 46|sleep EEG recordings
14P02975680A0000|131 146|anxiety disorder
14P02975680A0000|147 149|GAD
14P02975680A0000|227 229|GAD
14P02975680A0000|272 274|MDD
14P02975753A1333|0 26|Oligonucleotide mutagenesis
14P02975753A1333|33 47|binding domains
14P02975753A1333|106 116|E3 promoter
14P02976332A1277|18 21|PGI2
14P02979426T0000|0 20|Organ transplantation
14P02979834T0000|26 61|maltose tetrapalmitate immunotherapy
14P02979834T0000|61 89|cyclophosphamide chemotherapy
14P02981457A0368|0 1|D.
14P02981840A0907|9 21|pair sequence
14P02981840A0907|62 72|nucleotides
14P02981840A0907|92 93|AC
14P02982332T0001|0 4|Phase
14P02982332T0001|14 18|VP-16
14P02983316A0310|47 81|complementarity-determining regions
14P02983316A0310|106 120|probe sequences
14P02983316A0310|167 178|caiman genes
14P02983316A0310|267 278|preservation
14P02983316A0310|281 299|nucleotide sequence
14P02983331T0000|0 7|Evidence
14P02983331T0000|70 83|immobilization
14P02985812A0984|9 15|feature
14P02985812A0984|80 92|reading frame
14P02985820A1287|9 25|sequence elements
14P02985820A1287|106 122|retroviruses CMII
14P02985820A1287|123 126|MC29
14P02985820A1287|130 132|MH2
14P02986279A0000|2 13|milk samples
14P02986279A0000|79 88|occurrence
14P02986279A0000|91 105|cytomegalovirus
14P02986279A0000|107 109|CMV
14P02987220A0472|0 9|Subcloning
14P02987220A0472|12 24|DNA fragments
14P02987220A0472|72 83|DNA fragment
14P02987220A0472|110 112|FBP
14P02987777A0000|30 43|cell carcinoma
14P02988457A0650|42 53|potentiality
14P02988457A0650|56 73|Bestatin treatment
14P02989637A0671|51 81|zona glomerulosa corticosteroid
14P02989637A0671|88 102|renin secretion
14P02989637A0671|134 150|cord transections
14P02989637A0671|227 252|metoclopramide stimulation
14P02989637A0671|268 282|renin secretion
14P02989786A0328|14 31|enhancer sequences
14P02989786A0328|35 53|adenovirus E1A gene
14P02989786A0328|67 82|CATase synthesis
14P02991060A0465|5 18|IgG antibodies
14P02991060A0465|51 58|delivery
14P02993630A1190|17 32|nucleotide level
14P02993630A1190|66 76|nuclease S1
14P02993630A1190|88 101|enzyme attacks
14P02993630A1190|127 129|G-A
14P02994253A0482|25 41|mean NTE activity
14P02994253A0482|108 121|control values
14P02994253A0482|129 143|hr postexposure
14P02994253A0482|163 176|cord pathology
14P02994253A0482|178 194|days postexposure
14P02994336A0864|0 1|FK
14P02994336A0864|83 95|bromocriptine
14P02994336A0864|97 102|CB-154
14P02995967T0000|73 99|growth factor-receptor gene
14P02995967T0000|128 147|gland adenocarcinoma
14P02995999A0000|3 19|sequence analysis
14P02995999A0000|63 82|recombination events
14P02995999A0000|97 109|recombination
14P02995999A0000|206 224|recombination event
14P02995999A0000|241 258|base-pair deletion
14P02995999A0000|269 288|recombination events
14P02995999A0000|316 338|base-pair substitutions
14P02997622A0916|44 62|SCLC cell line DNAs
14P02997622A0916|68 87|SCLC tumour specimen
14P02997777A0609|17 27|experiments
14P02997777A0609|59 73|delta top1 top2
14P02997777A0609|123 136|top2 ts strain
14P02997777A0609|214 224|temperature
14P02997777A0609|233 242|treatments
14P02997777A0609|269 278|cell death
14P02997777A0609|283 300|delta top1 top2 ts
14P02998016A0527|3 10|homology
14P02998016A0527|39 46|sequence
14P02998016A0527|101 111|nucleotides
14P02998016A0527|129 142|nonsense codon
14P02998016A0527|165 177|reading frame
14P02998043A1199|0 10|Examination
14P02998043A1199|29 53|Punta Toro M gene product
14P02998043A1199|121 136|carboxy-proximal
14P02998043A1199|156 157|G2
14P02999267A0606|8 10|FAP
14P02999267A0606|22 32|amyloidosis
14P02999267A0885|32 41|Tc-99m-PYP
14P02999267A0885|175 176|GS
14P02999267A0885|249 250|GS
14P03000457A1554|6 18|kDa precursor
14P03000457A1554|57 66|processing
14P03000457A1554|101 107|species
14P03000489A0822|8 18|lymphocytes
14P03000489A0822|62 65|AIDS
14P03000489A0822|98 100|CGL
14P03000489A0822|144 153|activation
14P03000489A0822|172 188|blood lymphopenia
14P03001054A0703|25 29|nicks
14P03001054A0703|65 69|sites
14P03001084A0406|3 10|sequence
14P03001084A0406|45 51|segment
14P03001084A0406|79 86|cap site
14P03001084A0406|88 92|alpha
14P03001084A0406|105 113|psi alpha
14P03001086A0587|12 30|amino acid sequence
14P03001086A0587|87 99|Xenopus hsp70
14P03001086A0587|145 161|dnaK gene product
14P03001110A0546|4 18|phosphorylation
14P03001110A0546|30 47|peptide substrates
14P03001110A0546|71 99|receptor self-phosphorylation
14P03001110A0546|100 123|tyrosine kinase activity
14P03001353A0146|27 40|transformation
14P03001353A0146|42 50|6m2 cells
14P03001353A0146|57 62|P58gag
14P03001353A0146|99 108|RNA genome
14P03001353A0146|111 120|P85gag-mos
14P03001645A0785|11 20|his3 genes
14P03001645A0785|49 64|initiation sites
14P03001705T0000|9 22|transformation
14P03001705T0000|43 67|herpes simplex virus type
14P03001705T0000|66 68|DNA
14P03001952A0958|66 68|HSV
14P03001952A0958|87 97|determinant
14P03001952A0958|110 120|recurrences
14P03001952A0958|175 185|recurrences
14P03002501A1327|0 9|Comparison
14P03002501A1327|44 75|guinea-pig alpha s1-casein mRNAs
14P03002786A0143|32 40|midazolam
14P03002786A0143|45 51|mg kg-1
14P03002786A0143|55 62|atropine
14P03002786A0143|70 76|mg i.m.
14P03003695A0395|0 9|Comparison
14P03003695A0395|32 47|c-sis cDNA clone
14P03003695A0395|47 53|Collins
14P03003695A0395|60 65|Nature
14P03003695A0395|102 115|kbp DNA region
14P03004364A0775|52 54|ADM
14P03004364A0775|58 60|MMC
14P03004364A0775|63 68|FAMLIP
14P03004364A0775|81 85|FULIP
14P03004364A0775|87 92|ADRLIP
14P03004364A0775|96 101|MMCLIP
14P03004739A0753|17 30|G transversion
14P03004739A0753|52 70|CAT pentanucleotide
14P03004739A0753|148 166|CAT binding protein
14P03004982A0199|3 21|nucleotide sequence
14P03004982A0199|37 50|R. sphaeroides
14P03004982A0199|61 63|DNA
14P03004982A1094|49 59|FeS protein
14P03004982A1094|91 108|fbcF reading frame
14P03005231A0649|22 30|sequences
14P03005231A0649|52 60|sequences
14P03005231A0649|81 90|initiation
14P03005231A0649|94 104|termination
14P03005231A0649|107 119|transcription
14P03005231A0649|141 149|promoters
14P03005231A0649|188 196|sequences
14P03006066A0653|6 20|P135gag-myb-ets
14P03006066A0653|27 28|Mr
14P03006066A0653|35 53|translation product
14P03006066A0653|61 68|P75c-myb
14P03006066A0653|95 102|P54c-ets
14P03007281A0905|3 14|Dox-A2 locus
14P03007281A0905|37 38|Df
14P03007281A0905|40 41|2L
14P03007281A0905|43 57|OD15 breakpoint
14P03008094A0697|22 32|polypeptide
14P03008094A0697|60 68|sequences
14P03008405A0532|60 64|HVC-1
14P03009366A0438|59 62|Type
14P03009366A0438|65 75|pneumocytes
14P03009366A0438|94 102|radiation
14P03009366A0438|118 127|surfactant
14P03009366A0438|155 162|exposure
14P03009826A0201|38 57|base-pair dimer unit
14P03010281A0220|42 51|activation
14P03010281A0220|54 68|gene expression
14P03011793A0582|7 20|reading frames
14P03011793A0582|69 87|amino acid residues
14P03013477A0000|28 40|iron overload
14P03013477A0000|72 74|PMN
14P03013477A0000|105 116|hemodialysis
14P03013477A0000|130 145|superoxide anion
14P03013477A0000|152 154|PMN
14P03013477A0000|239 249|individuals
14P03013477A0000|254 274|serum ferritin levels
14P03013477A0000|306 316|individuals
14P03013477A0000|321 341|serum ferritin levels
14P03013841A0207|0 7|Cattaneo
14P03013841A0207|12 13|J.
14P03014515T0000|5 25|alpha-galactosidase A
14P03014515T0000|26 44|nucleotide sequence
14P03014593A0681|0 7|Diazepam
14P03014593A0681|29 30|Ro
14P03014593A0681|67 75|Ro 5-4864
14P03015611A0331|3 21|amino acid sequence
14P03015611A0331|60 73|lysine residue
14P03015628A1078|0 10|Osteocalcin
14P03015628A1078|62 81|hyperphosphatasaemia
14P03015628A1078|169 203|serum alkaline phosphatase activity
14P03015953T0000|0 7|Analysis
14P03015953T0000|54 82|mouse glucocorticoid receptor
14P03015953T0000|94 102|DNA clone
14P03016301A0605|8 19|v-myc codons
14P03016301A0605|57 64|terminus
14P03016301A0605|76 85|c-myc exon
14P03016506A0611|19 22|p410
14P03016506A0611|100 111|B95-8 strain
14P03016506A0611|144 157|antigen EBNA-1
14P03016506A0611|187 202|BamHI-C fragment
14P03016506A0611|243 258|G-418 resistance
14P03016883A0000|35 59|herpes simplex virus type
14P03016883A0000|59 63|HSV-2
14P03016883A0000|133 147|virus isolation
14P03017225A0706|29 42|leather bottle
14P03017225A0706|43 63|linitis plastica type
14P03017225A0706|85 96|II c portion
14P03017225A0706|193 200|Nakamura
14P03017996A0731|9 20|biosynthesis
14P03017996A0731|37 48|polypeptides
14P03017996A0731|53 66|signal peptide
14P03017996A0731|145 146|X3
14P03017996A0731|150 162|cleavage site
14P03018491A0840|3 16|hexanucleotide
14P03018491A0840|20 27|TGTCCT-3
14P03018491A0840|53 64|GRE activity
14P03018491A0840|183 198|receptor binding
14P03019505A0390|4 11|patients
14P03019505A0390|31 36|spread
14P03020001A0781|16 31|mini-Mu elements
14P03020001A0781|40 53|kilobase pairs
14P03020001A0781|78 90|DNA fragments
14P03020001A0781|100 113|kilobase pairs
14P03020001A0781|139 152|kilobase pairs
14P03020001A0781|201 214|kilobase pairs
14P03020513T0000|22 41|T4 DNA topoisomerase
14P03021050A0501|32 43|quantitation
14P03021050A0501|46 54|sulbactam
14P03021088A0135|29 37|exclusion
14P03021088A0135|43 52|occurrence
14P03021088A0135|86 96|gastrectomy
14P03021088A0135|101 108|Billroth
14P03021088A0135|117 130|reconstruction
14P03022129A0842|30 37|MPE X Fe
14P03022129A0842|37 38|II
14P03022129A0842|108 120|accessibility
14P03022129A0842|166 183|transcription rate
14P03023067A0779|0 10|Translation
14P03023067A0779|63 73|transcripts
14P03023679A0624|34 41|proteins
14P03023679A0624|88 95|proteins
14P03023679A0624|129 140|modification
14P03023682A0271|0 8|Insertion
14P03023682A0271|21 24|SV40
14P03023682A0271|48 80|chloramphenicol acetyltransferase
14P03023682A0271|81 83|CAT
14P03023859A0000|5 8|DNAs
14P03023859A0000|43 59|leukemia patients
14P03023859A0000|102 115|Ph1 chromosome
14P03023859A0000|154 178|breakpoint cluster region
14P03023887A0470|0 20|Nuclease footprinting
14P03023887A0470|40 62|glucocorticoid receptor
14P03023887A0470|156 157|Sa
14P03023970A0922|24 41|termination signal
14P03023970A0922|113 123|p53 product
14P03024343A0372|33 46|neuroendocrine
14P03024703A1036|21 31|nucleotides
14P03024703A1036|46 62|polypeptide chain
14P03024703A1036|67 77|amino acids
14P03024703A1036|114 127|hsp108 protein
14P03025606T0000|15 29|control signals
14P03025606T0000|32 56|herpes simplex virus type
14P03025655T0000|95 115|transforming activity
14P03025655T0000|117 150|Fujinami sarcoma virus P130gag-fps
14P03025661A0260|0 6|Gluzman
14P03025661A0260|8 14|EMBO J.
14P03025862A0860|40 50|amino acids
14P03025862A0860|55 63|ssd chain
14P03025862A0860|118 130|addition site
14P03026915A1024|65 75|yeast genes
14P03026915A1024|107 125|lacZ fusion vectors
14P03027661A0000|18 26|D protein
14P03027661A0000|31 43|miniF plasmid
14P03027779A0000|0 16|SPECT examination
14P03027779A0000|21 23|TMJ
14P03027779A0000|32 37|Tc-MDP
14P03027905A0632|0 20|Plasma renin activity
14P03027905A0632|29 52|plasma aldosterone level
14P03029111A0155|40 64|pet complementation group
14P03031602A1001|26 33|elements
14P03031602A1001|56 61|region
14P03032143A0218|44 46|DNA
14P03032143A0218|99 115|sequence elements
14P03032143A0218|155 166|conformation
14P03032143A0218|185 201|yeast kinetochore
14P03032964T0000|12 19|function
14P03032964T0000|42 49|promoter
14P03032964T0000|60 68|sequences
14P03032964T0000|81 88|activity
14P03033283A0837|54 62|IE68 gene
14P03033283A0837|64 67|HCMV
14P03033283A0837|75 77|DNA
14P03033283A0837|95 106|DNA sequence
14P03033283A0837|109 146|competition filter binding experiments
14P03033283A0837|177 199|consensus binding sites
14P03033283A1415|61 75|repeat elements
14P03033283A1415|284 292|SCMV IE94
14P03033283A1415|304 312|HCMV IE68
14P03034570A0943|53 85|chloramphenicol acetyltransferase
14P03034570A0943|146 151|ORF E7
14P03034570A0943|161 179|papillomavirus type
14P03034956A0666|2 9|contrast
14P03034956A0666|28 42|androgen levels
14P03034956A0666|91 98|subjects
14P03034956A0666|125 134|prednisone
14P03035056T0000|15 47|kappa antibody gene rearrangement
14P03035056T0000|47 53|Abelson
14P03035218T0000|0 13|Identification
14P03035218T0000|64 89|T-cell leukemia virus type
14P03035658A0355|38 40|VO2
14P03035658A0355|109 129|plasma concentrations
14P03035658A0355|145 147|VO2
14P03035658A0355|176 178|VO2
14P03036415T0000|11 36|cyclo-oxygenase inhibition
14P03036415T0000|41 69|leukotriene receptor blockade
14P03036415T0000|87 122|pressure/cardiac index relationships
14P03036817A0213|52 72|NdeI restriction site
14P03036817A0213|83 85|ATG
14P03036933A0774|0 11|ACTH release
14P03036933A0774|62 75|ACTH treatment
14P03037334A0932|33 48|promoter element
14P03037334A0932|53 68|yeast RP39A gene
14P03037334A0932|91 105|sequence motifs
14P03038643A1374|38 51|alpha-spectrin
14P03038643A1374|61 71|duplication
14P03038643A1374|80 89|divergence
14P03038891A0935|0 16|Northern analyses
14P03038891A0935|18 21|RNAs
14P03038891A0935|63 77|p11 mRNA levels
14P03039177A0503|77 94|IR2 repeat element
14P03039177A0503|102 130|restriction site polymorphism
14P03039387A0920|30 45|cyclophosphamide
14P03039387A0920|50 52|BCG
14P03039387A0920|152 154|BCG
14P03039387A0920|158 173|cyclophosphamide
14P03040023A0113|0 7|Morphine
14P03040403A0155|3 10|PSS gene
14P03040403A0155|59 70|YEp13 vector
14P03041046A0127|7 12|A-MuLV
14P03041046A0127|49 60|Moloney MuLV
14P03041046A0127|102 107|A-MuLV
14P03041046A0127|145 150|BALB/c
14P03041046A0127|169 172|MuLV
14P03041046A0127|219 220|N.
14P03041802A0975|24 42|platelet aggregates
14P03041802A0975|61 76|fibrinopeptide A
14P03041802A0975|78 93|cleavage product
14P03041802A0975|114 132|platelet activation
14P03041802A0975|168 179|pathogenesis
14P03042778A0643|21 25|yeast
14P03042778A0643|36 41|growth
14P03045117A0936|82 94|growth factor
14P03045117A0936|133 137|Glu24
14P03045117A0936|156 160|Asp27
14P03045117A0936|191 193|Thr
14P03045117A0936|205 209|Tyr29
14P03045117A0936|228 232|Leu47
14P03045725A0872|38 53|prolactin levels
14P03045725A0872|76 97|breast cancer patients
14P03045725A0872|121 137|tumor sensitivity
14P03046655A0000|9 24|prevalence study
14P03046655A0000|74 81|patients
14P03046655A0000|94 102|keratitis
14P03046931A0247|82 102|nucleotide difference
14P03048024A0418|54 55|IB
14P03048024A0418|63 70|NIB rats
14P03049570A1242|33 43|E2 proteins
14P03050147A0896|50 66|E1a-E1b functions
14P03050147A0896|113 130|mRNA transcription
14P03050147A1520|37 50|scanning model
14P03050147A1520|147 165|initiator AUG codon
14P03050147A1520|170 178|C protein
14P03052327A1474|33 63|pancreas-kidney transplantation
14P03052327A1474|97 100|Type
14P03052641A0204|14 22|compounds
14P03052641A0204|35 42|vehicles
14P03053713A0752|0 13|DNA sequencing
14P03053713A0752|18 26|DPM1 gene
14P03057259A0514|3 14|relationship
14P03057259A0514|68 78|thyroiditis
14P03059171A1232|0 13|Administration
14P03059171A1232|16 29|anticoagulants
14P03059171A1232|44 59|prostaglandin E1
14P03059171A1232|134 146|deterioration
14P03060846T0000|23 37|L1 binding site
14P03060846T0000|38 45|23S rRNA
14P03060953A0481|0 6|Animals
14P03060953A0481|27 37|vaccination
14P03061301A0624|0 21|Prostacyclin formation
14P03061301A0624|60 99|metabolite 6-keto-prostaglandin F1 alpha
14P03061301A0624|118 133|radioimmunoassay
14P03061301A1409|8 16|excretion
14P03061301A1409|39 46|F1 alpha
14P03061301A1409|86 99|contraceptives
14P03061301A1409|124 133|creatinine
14P03061383A0000|97 111|beta-lactamases
14P03061383A0000|117 121|TEM-1
14P03061383A0000|123 127|Oxa-1
14P03061383A0000|173 195|agar dilution technique
14P03062370A0000|0 3|GCN4
14P03062370A0384|24 35|GCN3 product
14P03062370A0384|75 89|GCN4 expression
14P03062370A0384|100 122|amino acid availability
14P03064524A0160|3 10|efficacy
14P03064811A0485|3 21|amino acid sequence
14P03064811A0485|25 41|S. aureus peptide
14P03064811A0485|51 66|phosphoryl group
14P03064811A0485|150 152|Asp
14P03065140A0273|31 42|GAL4 protein
14P03065140A0273|46 63|DNA binding domain
14P03065140A0273|69 99|transcription activation domain
14P03065141A0448|112 137|Tn3411 nucleotide sequence
14P03065610A0375|58 78|Western blot analysis
14P03065621T0000|0 8|Structure
14P03065621T0000|74 78|MRP13
14P03066131A0000|59 67|treatment
14P03066131A0000|70 88|behaviour disorders
14P03066131A0000|143 154|hypothalamus
14P03066131A0000|179 189|experiences
14P03066131A0000|197 206|operations
14P03066131A0000|244 257|aggressiveness
14P03066208A0310|12 22|examination
14P03066208A0310|71 84|cell carcinoma
14P03066625A0756|65 77|contributions
14P03066625A0756|88 99|risk factors
14P03066625A0756|123 134|risk factors
14P03066625A0756|177 185|questions
14P03067505A0688|5 16|prostacyclin
14P03067505A0688|60 70|ear vessels
14P03069046A0126|28 36|precision
14P03069046A0126|48 58|sensitivity
14P03069980T0000|0 6|Factors
14P03069980T0000|21 33|bond strength
14P03069980T0000|40 58|glass polyalkenoate
14P03072021A0696|3 22|amino acid sequences
14P03072021A0696|56 74|targeting sequences
14P03072580A0455|0 11|Van der Ende
14P03072580A0455|11 12|R.
14P03073091A0338|6 21|insulin infusion
14P03073091A0338|25 43|% dextrose solution
14P03073091A0338|55 63|Biostator
14P03073091A0449|0 6|Amounts
14P03073091A0449|48 68|hour insulin infusion
14P03073091A0449|108 116|treatment
14P03073091A0449|141 149|mg/kg/min
14P03073091A0449|156 169|spironolactone
14P03073091A0449|195 203|mg/kg/min
14P03073091A0449|210 222|indomethacine
14P03073091A0449|244 252|mg/kg/min
14P03073091A0449|295 303|mg/kg/min
14P03073192T0000|0 52|Mycobacterium avium-intracellulare complex infections
14P03075154T0000|0 9|Recurrence
14P03075154T0000|12 29|oxalate deposition
14P03075154T0000|53 73|ciclosporin A therapy
14P03076124A0496|3 24|bile acid sequestrants
14P03076124A0496|24 37|cholestyramine
14P03076124A0496|93 124|hydroxymethylglutaryl coenzyme A
14P03076124A0496|124 130|HMG CoA
14P03076124A0496|220 240|hypercholesterolaemia
14P03076124A0496|259 279|plasma concentrations
14P03076124A0496|289 303|LDL-cholesterol
14P03078268A0529|45 57|acidification
14P03078268A0529|93 107|acidosis models
14P03078268A0529|127 150|amphotericin B treatment
14P03078268A0529|218 230|acidification
14P03079276T0029|0 7|Analysis
14P03080793T0000|0 8|Statement
14P03080793T0000|55 71|AIDS transmission
14P03083441T0000|0 12|Modifications
14P03083441T0000|29 43|postcontraction
14P03088643A0000|77 78|CS
14P03088643A0000|105 116|control rats
14P03090237A0202|10 18|schedules
14P03090237A0202|31 42|response run
14P03090237A0202|90 101|response key
14P03090237A0202|102 109|work key
14P03090237A0202|140 151|response key
14P03090372A0607|11 33|glucose tolerance tests
14P03090372A0607|75 77|CyA
14P03091849A0000|12 25|glutaraldehyde
14P03091849A0000|28 37|dimensions
14P03091849A0000|41 54|ultrastructure
14P03091849A0000|76 88|rat mesentery
14P03091849A0000|111 120|experiment
14P03091849A0000|138 145|fixative
14P03091849A0000|162 170|perfusion
14P03091849A0000|174 181|pressure
14P03091849A0000|195 205|superfusion
14P03091849A0000|233 240|membrane
14P03097509A0654|14 26|RNA molecules
14P03097643A1357|8 18|BALB/c gene
14P03097643A1357|57 72|octamer sequence
14P03098018A0139|8 15|findings
14P03098018A0139|72 85|P2-A2 pilosity
14P03098018A0139|88 97|micropenis
14P03102289A0786|48 65|hCG administration
14P03102289A0786|67 74|midcycle
14P03102289A0786|99 107|follicles
14P03102289A0786|124 133|ultrasound
14P03102289A0786|136 144|cycle day
14P03102289A0786|166 180|serum E2 levels
14P03102289A0786|203 210|follicle
14P03104245A0402|4 11|patients
14P03104245A0402|21 25|Ir192
14P03104245A0402|35 42|addition
14P03104245A0402|53 61|radiation
14P03104245A0402|84 91|survival
14P03104248A0322|6 13|Stage IA
14P03104248A0322|52 53|G1
14P03104248A0322|95 96|G2
14P03104248A0322|136 137|G3
14P03104914T0000|0 8|Mechanism
14P03104914T0000|33 45|translocation
14P03104982A0690|15 31|hemoglobin levels
14P03104982A0690|86 99|sex difference
14P03108171A0088|0 9|Ritanserin
14P03108171A0088|44 60|blocking activity
14P03108171A0088|62 73|S2 receptors
14P03108171A0088|76 79|5-HT
14P03109147A0000|0 14|Ethylene glycol
14P03109147A0000|17 33|diethylene glycol
14P03109147A0000|96 104|NMRI mice
14P03109147T0127|0 7|Research
14P03109147T0127|10 24|ethylene glycol
14P03109147T0127|27 43|diethylene glycol
14P03109954A0945|94 95|OC
14P03109954A0945|126 147|artery atherosclerosis
14P03109954A0945|192 227|plasma HDL cholesterol concentration
14P03110119A0267|6 7|BH
14P03110119A0267|11 20|ventilator
14P03110119A0267|40 48|bias flow
14P03110119A0267|87 96|side ports
14P03110119A0267|134 144|cm cephalad
14P03110678A0702|0 9|Comparison
14P03110678A0702|50 70|polysulphone membrane
14P03110678A0702|73 85|haemodialysis
14P03110678A0702|89 103|haemofiltration
14P03110678A0702|113 132|beta 2-microglobulin
14P03110678A0702|191 205|treatment modes
14P03110678A0702|230 243|urea clearance
14P03110692A0156|16 17|SD
14P03110692A0156|80 87|patients
14P03110692A0156|92 101|bone cysts
14P03110692A0156|141 148|duration
14P03110692A0156|151 158|dialysis
14P03110692A0156|198 205|patients
14P03110692A0156|210 219|bone cysts
14P03110692A0156|250 257|patients
14P03110692A0156|270 277|dialysis
14P03110692A0156|310 321|urine volume
14P03110746A0146|36 48|triglycerides
14P03110746A0146|66 79|adipose tissue
14P03110746A0146|80 85|PLASAT
14P03110794A0991|2 10|overdoses
14P03110794A0991|16 28|g fluvoxamine
14P03110801A0532|20 44|plasma prolactin response
14P03111946A0309|2 7|effect
14P03111946A0309|26 33|behavior
14P03112028A0404|15 22|patients
14P03112028A0404|68 77|parameters
14P03112412A0985|72 90|synthetase mutation
14P03112412A0985|105 125|thr operon expression
14P03112412A0985|143 153|temperature
14P03114188A0907|89 106|chest wall sarcoma
14P03114188A0907|144 145|Gy
14P03114829T0000|21 30|correlates
14P03114829T0000|33 44|panic states
14P03114995T0000|0 6|Effects
14P03114995T0000|39 53|gastrin release
14P03115087A0515|16 32|height velocities
14P03115087A0515|52 59|standard
14P03115787A0633|22 37|cyclophosphamide
14P03115787A0633|39 56|hexamethylmelamine
14P03115787A0633|58 67|adriamycin
14P03115787A0633|81 86|CHAP-5
14P03117046T0000|0 8|Isolation
14P03117046T0000|12 27|characterization
14P03117046T0000|31 43|vinculin cDNA
14P03117147A1059|32 40|agreement
14P03117147A1059|58 73|oesophageal EMGd
14P03117147A1059|91 102|surface EMGd
14P03117147A1059|138 150|investigation
14P03118631A0140|2 12|differences
14P03118631A0140|15 30|fixation quality
14P03118631A0140|77 85|perfusion
14P03118631A0140|121 129|perfusion
14P03119227A0079|3 14|DNA sequence
14P03119227A0079|49 65|sequence homology
14P03119227A0079|75 102|c-abl proto-oncogene product
14P03119227A0079|182 205|tyrosine kinase activity
14P03119485A0476|3 13|requirement
14P03119485A0476|46 53|patients
14P03119485A0476|73 81|nutrition
14P03119485A0476|109 116|interest
14P03119485A0476|133 143|development
14P03119485A0476|147 155|prognosis
14P03119485A0476|188 204|distress syndrome
14P03120334A0893|18 21|vein
14P03120334A0893|41 46|origin
14P03120334A0893|64 67|vein
14P03120334A0893|77 82|system
14P03120334A0893|100 104|veins
14P03123310A0000|25 33|Gart gene
14P03123310A0000|54 63|activities
14P03123983T0000|9 23|neuroplasticity
14P03123983T0000|29 36|response
14P03125420A0421|0 3|Biol
14P03125422A0202|58 76|activator sequences
14P03125422A0202|77 79|UAS
14P03126531T0000|0 7|Reversal
14P03126531T0000|67 75|REM sleep
14P03126531T0000|89 118|dopamine agonist pretreatments
14P03127034A0591|3 12|heart rate
14P03127034A0591|58 67|resistance
14P03127463A1017|21 30|COS7 cells
14P03127463A1017|47 58|CSF activity
14P03127463A1017|79 95|bone marrow cells
14P03127463A1017|134 138|My-10
14P03127463A1017|148 163|cord blood cells
14P03132498A0730|4 11|patients
14P03132498A0730|17 21|PaCO2
14P03132498A0730|79 90|asthma score
14P03132498A0730|104 108|PaCO2
14P03133250A0000|56 66|stimulation
14P03133250A0000|86 97|gonadotropin
14P03133250A0000|155 167|fertilization
14P03133250A0000|171 185|embryo transfer
14P03133250A0000|186 191|IVF-ET
14P03133360A1215|45 69|transcription attenuation
14P03134872T0029|0 6|Apropos
14P03137105A0146|1 22|prostaglandin analogue
14P03137105A0146|60 71|gonadotropin
14P03137105A0146|163 179|oocyte collection
14P03137105A0146|207 219|oocyte donors
14P03137105A0146|222 238|embryo recipients
14P03137346A0319|3 16|nucleolin gene
14P03137346A0319|78 96|amino acid residues
14P03137601A0212|8 36|L-threo-dihydroxyphenylserine
14P03137601A0212|38 41|DOPS
14P03137601A0212|71 72|NE
14P03137601A0212|119 122|DOPS
14P03137601A0212|185 202|NE neurotoxin DSP4
14P03138190A0347|64 76|Kupffer cells
14P03138190A0347|80 91|target cells
14P03138190A0347|124 134|inoculation
14P03138449A0759|32 54|desaturation activities
14P03138449A0759|88 90|C18
14P03138449A0759|93 101|w6 supply
14P03139750A0000|40 50|VH allotype
14P03142875A0366|23 46|6-kilobase cDNA sequence
14P03143048A1091|0 14|HDL-cholesterol
14P03143048A1091|36 53|apolipoprotein A-I
14P03143048A1091|71 84|concentrations
14P03143485A0366|3 9|Euglena
14P03143485A0366|19 38|protein gene cluster
14P03143485A0366|62 75|protein operon
14P03143485A0366|94 110|gene organization
14P03143485A0366|173 201|liverwort chloroplast genomes
14P03144705A0859|3 14|distribution
14P03144705A0859|42 51|resolution
14P03144705A0859|96 114|sequence divergence
14P03144705A0859|208 225|Alu family repeats
14P03146017A0983|3 21|nucleotide sequence
14P03146017A0983|44 45|M.
14P03146017A0983|52 58|ORFtrpA
14P03146017A0983|98 100|ORF
14P03146017A0983|119 125|ORFtrpB
14P03146017A0983|139 160|amino acid polypeptide
14P03146150T0000|0 11|Potentiation
14P03146150T0000|61 73|Pro-urokinase
14P03146784A0158|92 108|stretch receptors
14P03146784A0158|147 163|stretch receptors
14P03146784A0158|164 166|PSR
14P03146784A0158|210 223|chemoreceptors
14P03146784A0158|225 227|IPC
14P03147912A0422|11 26|hyperventilators
14P03147912A0422|67 78|fluctuations
14P03147912A0422|126 131|PETCO2
14P03149774A0173|5 11|IA task
14P03149774A0173|178 199|bicuculline methiodide
14P03149774A0173|201 224|GABA receptor antagonist
14P03150015T0001|8 15|research
14P03150015T0001|45 53|hepatitis
14P03150296A0594|35 54|creatinine clearance
14P03150296A0594|77 91|filtration rate
14P03150296A0594|92 94|GFR
14P03150296A0594|181 196|serum creatinine
14P03150296A0594|217 236|creatinine clearance
14P03154072A0862|3 18|protein mixtures
14P03154072A0862|20 31|sesame flour
14P03154072A0862|34 46|soybean flour
14P03159903A0352|65 83|amino acid sequence
14P03159903A0352|103 121|amino acid sequence
14P03159903A0352|122 124|IHF
14P03166458A1356|1 17|protein footprint
14P03166458A1356|38 51|GC box element
14P03167060A0000|12 24|growth factor
14P03167060A0000|27 31|IGFII
14P03167060A0000|45 55|polypeptide
14P03167060A0000|105 114|derivation
14P03168709A0000|40 52|glaucoma eyes
14P03168709A0000|86 108|suprathreshold strategy
14P03171221A0531|3 13|variability
14P03171221A0531|75 93|elastin transcripts
14P03171279A0158|12 21|conclusion
14P03171279A0158|39 44|artery
14P03171279A0158|60 65|toe MP
14P03171279A0158|70 75|grafts
14P03171279A0158|108 113|artery
14P03171279A0158|127 133|toe PIP
14P03171279A0158|138 143|grafts
14P03171279A0158|170 175|dorsal
14P03172863T0000|0 5|Effect
14P03172863T0000|15 28|undernutrition
14P03172863T0000|31 44|susceptibility
14P03175942A0706|4 9|effect
14P03175942A0706|74 83|experiment
14P03178097A0000|3 20|CHARGE association
14P03178161A0000|51 70|blood concentrations
14P03178161A0000|72 85|micronutrients
14P03178161A0000|98 100|B12
14P03178161A0000|174 175|EC
14P03178161A0000|179 186|Transkei
14P03178161A0000|190 195|Ciskei
14P03178161A0000|197 211|Southern Africa
14P03178626A0137|0 7|Aviators
14P03178626A0137|20 30|Attack Wing
14P03178626A0137|31 37|Pacific
14P03178626A0137|80 92|aircraft type
14P03179496T0000|0 9|Evaluation
14P03179496T0000|26 53|modified-hemoglobin solution
14P03179496T0000|78 101|blood volume replacement
14P03180595A1040|7 31|gallbladder visualization
14P03180595A1040|45 61|ejection fraction
14P03181276A0422|2 15|micrograms PAF
14P03181276A0422|72 89|allergen challenge
14P03182802A0278|0 2|Sci
14P03182872A1122|0 3|Chem
14P03183103A0000|10 24|MR examinations
14P03183127A0068|69 70|CT
14P03183127A0068|84 102|CT ventriculography
14P03183127A0068|106 127|CT myelocisternography
14P03184267A0000|19 34|broiler chickens
14P03184267A0000|122 131|infections
14P03184267A0000|163 176|food poisoning
14P03185322A1305|5 15|correlation
14P03185322A1305|108 116|diagnosis
14P03185322A1305|123 136|class-2 smears
14P03185322A1305|165 173|dysplasia
14P03185540T0000|49 62|RNA polymerase
14P03185540T0000|100 129|TATA box-promoter interactions
14P03185540T0000|130 134|TFIID
14P03186091T0000|0 5|Change
14P03186091T0000|8 35|plasma cystyl aminopeptidase
14P03186270T0001|10 18|diagnosis
14P03190481A0292|35 46|quantitation
14P03190481A0292|49 59|macrophages
14P03190481A0292|79 100|infiltration area unit
14P03190481A0292|133 143|correlation
14P03190481A0292|170 180|macrophages
14P03190914A0149|12 34|migration differentials
14P03190914A0149|61 74|responsiveness
14P03192537A0370|54 58|HMG-I
14P03192537A0370|92 110|amino acid sequence
14P03192537A0370|116 120|HMG-I
14P03192724A0000|13 29|style differences
14P03192724A0000|62 65|Ryan
14P03192724A0000|93 113|FIRO-B interpretation
14P03192799T0000|0 8|Statement
14P03192799T0000|14 29|American Academy
14P03192799T0000|31 47|Implant Dentistry
14P03192950A0566|0 3|Sera
14P03192950A0566|54 63|TSH levels
14P03194410A0771|2 12|UOxase mRNA
14P03194410A0771|60 77|tissue specificity
14P03194410A0771|95 105|UOxase gene
14P03195167A0104|3 24|platelet adhesion rate
14P03195167A0104|73 90|haemocompatibility
14P03195167A0104|96 122|basic-polymers polyurethane
14P03195167A0104|123 125|PUR
14P03195167A0104|128 144|polyvinylchloride
14P03195167A0104|146 148|PVC
14P03195167A0104|166 167|PS
14P03198436T0000|23 39|bladder carcinoma
14P03198436T0000|48 57|cystectomy
14P03198525A0164|8 20|feedlot trial
14P03198525A0164|101 103|MGA
14P03198525A0164|130 132|MGA
14P03198525A0164|136 143|DEPO-MGA
14P03199043A0248|0 8|Existence
14P03199043A0248|49 71|boundary value problems
14P03199043A0248|101 125|permeability coefficients
14P03199043A0248|128 142|transport rates
14P03199043A0248|150 171|diffusion coefficients
14P03199436A1060|29 53|photosynthesis components
14P03199436A1060|62 80|psbB-psbH-petB-petD
14P03199436A1060|87 104|psbE-psbF clusters
14P03200488A0439|30 32|TIQ
14P03200488A0439|43 55|turnover rate
14P03200488A0439|73 88|dopamine neurons
14P03200488A0439|101 114|administration
14P03200844A1211|36 52|pore glycoprotein
14P03200844A1211|63 72|similarity
14P03200844A1211|161 178|pore glycoproteins
14P03207975A0709|21 34|administration
14P03207975A0709|47 67|plasma concentrations
14P03208493A0849|13 27|filtration rate
14P03208493A0849|42 58|lithium clearance
14P03209019A0662|14 31|promotion bioassay
14P03209019A0662|46 54|CD-1 mice
14P03209019A0662|93 96|DMBA
14P03209019A0662|163 175|test material
14P03212551T0001|3 14|pathogenesis
14P03212551T0001|17 25|Dupuytren
14P03212929A0000|2 16|ELISA procedure
14P03212929A0000|52 63|IgE response
14P03212929A0000|71 99|Dirofilaria immitis infection
14P03214709A0559|42 69|plasma corticosterone levels
14P03216131A0559|16 35|Aeromonas hydrophila
14P03218714A0000|31 55|Dandy-Walker malformation
14P03218714A0000|56 58|DWM
14P03218714A0000|85 90|Fallot
14P03218714A0000|92 94|TOF
14P03219107A0212|3 11|incidence
14P03219107A0212|27 37|convulsions
14P03220077A0274|9 16|survival
14P03220077A0274|58 62|years
14P03223123T0001|8 17|evaluation
14P03223123T0001|27 33|methods
14P03223123T0001|47 53|markers
14P03223123T0001|61 68|maturity
14P03227288A0542|7 13|infants
14P03227288A0542|55 60|months
14P03227568T0001|0 6|Variety
14P03227568T0001|39 53|dermatoglyphics
14P03227568T0001|55 62|patterns
14P03228518A0339|55 62|Academic
14P03228518A0339|64 86|Personal Responsibility
14P03228785A1047|0 7|Recovery
14P03228785A1047|31 41|improvement
14P03228785A1047|194 201|ABSTRACT
14P03228785A1047|216 220|WORDS
14P03229917A0099|57 73|remnant infection
14P03232410A1467|40 50|lung cancer
14P03232410A1467|89 95|smoking
14P03233862T0000|0 19|Neuromyelitis optica
14P03234790T0001|0 5|Effect
14P03234790T0001|29 42|administration
14P03234790T0001|45 66|methyl isobutyl ketone
14P03235487A0404|0 12|Incorporation
14P03235487A0404|23 51|M sodium dihydrogen phosphate
14P03237446A0377|0 3|None
14P03237446A0377|34 43|infections
14P03237446A0377|62 72|lymphopenia
14P03239106A0856|13 30|phosphorus content
14P03239106A0856|50 61|reabsorption
14P03243027T0000|41 63|protein gene expression
14P03243027T0000|81 104|Dictyostelium discoideum
14P03243920A0591|20 60|plasma concentration-effect relationships
14P03246999A0483|13 22|amplitudes
14P03246999A0483|43 59|adaptation period
14P03249792A0241|21 31|development
14P03249792A0241|43 56|symptomatology
14P03249792A0241|63 78|group activities
14P03249792A0241|90 103|group dynamics
14P03249792A0241|111 124|stress factors
14P03249792A0241|174 187|manifestations
14P03249840A0411|0 20|Baseline measurements
14P03249840A0411|49 52|FEV1
14P03249840A0411|63 80|airway conductance
14P03249840A0411|81 84|SGaw
14P03249840A0411|140 143|SGaw
14P03249840A0411|145 148|PD35
14P03249840A0411|169 172|FEV1
14P03249840A0411|174 177|PD20
14P03251210A0981|16 18|BGC
14P03251210A0981|36 46|development
14P03251210A0981|51 64|calcifications
14P03251210A0981|113 123|dysfunction
14P03253219T0000|40 67|anthracycline cardiomyopathy
14P03256150A1866|3 9|results
14P03256150A1866|32 43|requirements
14P03257146A1037|24 28|CSFHU
14P03257146A1037|40 56|neutrophil counts
14P03257146A1037|93 120|marrow neutrophil precursors
14P03258069A0000|52 60|intensity
14P03258069A0000|65 73|frequency
14P03258069A0000|98 114|nerve stimulation
14P03258069A0000|125 142|acupuncture points
14P03258069A0000|156 169|pain threshold
14P03259437A0140|13 46|neonates serum alpha-amylase value
14P03259437A0140|66 78|starch method
14P03259437A0140|137 140|IU/l
14P03259437A0140|223 226|IU/l
14P03261005A0216|0 6|Records
14P03261005A0216|23 26|AIDS
14P03261223A0644|64 68|SPECT
14P03261223A0644|76 78|TCT
14P03261331A0563|0 4|SPECT
14P03261331A0563|37 57|AIDS dementia complex
14P03263357A0112|29 40|relationship
14P03263357A0112|68 83|body temperature
14P03263357A0112|102 122|plasma concentrations
14P03263357A0112|145 160|leukocyte counts
14P03263357A0112|164 181|plasma interleukin
14P03263357A0112|183 186|IL-1
14P03263465T0000|9 17|MHC class
14P03263465T0000|24 28|H-2Dq
14P03263465T0000|32 36|H-2Lq
14P03263465T0000|73 77|H-2Ld
14P03264073A0224|9 19|derivatives
14P03264073A0224|69 76|activity
14P03264073A0224|111 121|albino mice
14P03264073A0224|135 142|activity
14P03264073A0224|145 155|albino rats
14P03264299A0679|28 35|activity
14P03264299A0679|48 58|macrophages
14P03264299A0679|90 101|ip injection
14P03264886A0000|6 15|population
14P03264886A0000|24 31|children
14P03264886A0000|94 100|Germany
14P03264886A0000|146 158|months period
14P03264886A0000|174 183|physicians
14P03267732A0788|15 33|Ga-fbg scintigraphy
14P03268555T0000|22 37|biocompatibility
14P03268555T0000|60 82|millipore filter method
14P03270085A0382|0 13|Hypomagnesemia
14P03270085A0382|22 38|magnesium wasting
14P03274204A0642|0 11|Dentalplaque
14P03274204A0642|93 111|cent alkaline fuxin
14P03275867A0187|0 3|GRFI
14P03275867A0187|73 94|mating type loci HML E
14P03275867A0187|94 98|HMR E
14P03275867A0187|133 135|UAS
14P03275867A0187|166 180|MAT alpha genes
14P03275873A0379|28 41|RNA polymerase
14P03275873A0379|118 127|resistance
14P03275873A0379|133 144|transfection
14P03276246A0037|64 70|TAC-WBC
14P03276246A0037|93 104|appendicitis
14P03276924A0090|29 41|rearrangement
14P03276924A0090|75 89|MoMuLV provirus
14P03278829A0082|3 13|indications
14P03278829A0082|65 73|candidate
14P03278829A0082|80 89|tip grafts
14P03278829A0082|120 128|deformity
14P03280021A1615|65 70|M NaCl
14P03280021A1615|88 93|M NaBr
14P03280021A1615|96 128|measure alpha log Kobsd/alpha log
14P03280021A1615|126 129|NaBr
14P03280021A1615|165 167|T/O
14P03280807A0000|0 8|Mutations
14P03280807A0000|88 107|frameshift mutations
14P03280807A0000|117 119|GGX
14P03280807A0000|132 134|CCX
14P03280807A0000|151 153|UGA
14P03280807A0000|157 178|UAG nonsense mutations
14P03280807A1447|13 28|suf12-null/SUF12
14P03280807A1447|30 42|heterozygotes
14P03280807A1447|120 130|suppression
14P03280807A1447|216 220|SUF12
14P03280912T0000|0 22|Antituberculosis agents
14P03280946A0375|11 26|immunity protein
14P03280946A0375|46 48|35S
14P03280946A0375|118 137|lac promoter control
14P03280946A0375|167 184|expression vectors
14P03280946A0375|202 226|bacteriophage T7 promoter
14P03282232A0743|0 9|Antibodies
14P03282232A0743|47 56|DP1A clone
14P03282232A0743|79 82|DP-I
14P03282813A0794|27 29|QO2
14P03282813A0794|31 47|oxygen extraction
14P03282813A0794|71 74|ARDS
14P03283881A0216|24 37|hypersecretion
14P03283881A0216|62 73|inflammation
14P03285764A0675|0 18|Hyperprolactinaemia
14P03285764A0675|28 39|hypogonadism
14P03285764A0675|54 65|neuropathies
14P03285764A0675|166 177|consequences
14P03286611A1198|0 3|Yang
14P03286611A1198|7 8|H.
14P03287597T0000|22 35|prostate gland
14P03292076A0820|7 17|endotoxemia
14P03292076A0820|75 86|permeability
14P03292076A0820|118 128|circulation
14P03292076A0820|157 170|refractoriness
14P03292076A0820|193 204|hemodynamics
14P03292076A0820|208 230|eicosanoid biosynthesis
14P03292082A0486|2 9|contrast
14P03292082A0486|25 38|concentrations
14P03292082A0486|47 54|patients
14P03292082A0486|103 112|meningioma
14P03292082A0486|119 130|glioblastoma
14P03292082A0486|141 149|neurinoma
14P03293844T0000|0 3|Diet
14P03296019T0000|0 17|Time delay effects
14P03296019T0000|54 63|Silicoater
14P03296212A0603|23 32|interferon
14P03296212A0603|60 66|Efforts
14P03296212A0603|179 187|potential
14P03296212A0603|190 192|IFN
14P03296212A0603|269 283|tumor debulking
14P03296212A0603|297 305|diagnosis
14P03296212A0603|317 325|community
14P03296212A0603|386 394|potential
14P03296254A0556|5 15|differences
14P03296254A0556|29 37|latamoxef
14P03296254A0556|61 69|elevation
14P03296254A0556|72 87|prothrombin time
14P03296254A0556|112 121|depression
14P03296254A0556|135 144|factor VII
14P03297181A0127|62 63|RR
14P03297181A0127|65 81|quinidine sulfate
14P03297181A0127|99 100|SR
14P03297181A0127|102 120|quinidine bisulfate
14P03297181A0127|157 160|SR-F
14P03298134A0000|35 52|interferon alfa-2b
14P03298134A0000|53 60|Intron A
14P03298134A0000|61 75|Schering-Plough
14P03298134A0000|98 110|cell leukemia
14P03298134A0000|111 113|HCL
14P03300118A0392|0 14|Oxygen delivery
14P03304015T0000|8 16|chemistry
14P03304866T0001|0 16|Revascularization
14P03305875T0000|20 29|management
14P03305875T0000|32 42|microstomia
14P03306340A0537|29 37|carcinoma
14P03306340A0537|58 65|invasion
14P03306340A0537|68 76|carcinoma
14P03306340A0537|78 85|hardness
14P03306340A0537|103 113|obstruction
14P03306340A0537|146 160|pancreaticogram
14P03308909A0485|9 15|enzymes
14P03308909A0485|27 35|cartilage
14P03309892A0637|37 38|S.
14P03309892A0637|93 113|actin gene transcript
14P03309892A0637|149 169|initiation start site
14P03311954A0000|34 45|institutions
14P03311954A0000|90 99|ranitidine
14P03311954A0000|103 111|mg b.i.d.
14P03311954A0000|114 123|ranitidine
14P03311954A0000|139 147|treatment
14P03311954A0000|150 168|reflux oesophagitis
14P03312033A0501|0 10|Monotherapy
14P03312033A0501|73 91|combination therapy
14P03312514A0756|3 9|N3 wave
14P03312514A0756|14 17|SSEP
14P03312514A0756|102 122|preischemia amplitude
14P03312514A0756|202 216|control animals
14P03315359A0732|0 10|Proctoscopy
14P03315359A0732|59 68|evaluation
14P03315359A0732|112 122|suppuration
14P03317796A0853|5 17|control group
14P03317796A0853|48 61|osteoarthritis
14P03319621A0707|2 9|contrast
14P03319621A0707|34 49|beta actin mRNAs
14P03319621A0707|68 76|myoblasts
14P03319621A0707|80 87|myotubes
14P03319646T0000|0 20|Plasma renin activity
14P03319912A0000|0 9|Cephradine
14P03319912A0000|44 63|prophylactic measure
14P03319912A0000|175 183|frequency
14P03320875A2090|24 31|Supramid
14P03320875A2090|55 74|tissue compatibility
14P03322829A0952|35 53|compliance category
14P03322829A0952|66 79|digoxin marker
14P03322829A0952|108 115|patients
14P03322829A0952|173 181|deviation
14P03322829A0952|203 214|prescription
14P03325081A0524|7 17|keratopathy
14P03325081A0524|81 91|keratopathy
14P03325081A0524|93 95|PBK
14P03325081A0524|127 137|keratopathy
14P03326381A0423|45 63|C-peptide excretion
14P03329716A0187|16 36|EGF receptor promoter
14P03329716A0187|51 61|E1A protein
14P03329716A0187|64 82|receptor RNA levels
14P03330711T0000|34 54|Azadirachta indica A.
14P03331525T0001|16 30|dentin adhesion
14P03331525T0001|49 66|urethane molecules
14P03331525T0001|82 91|isocyanate
14P03331933T0048|2 15|Felix Lagrange
14P03332022A1094|8 33|cysteine clustering region
14P03332022A1094|87 105|nucleotide sequence
14P03332022A1094|113 138|cysteine clustering region
14P03332022A1094|200 215|protein kinase C
14P03332022A1094|235 251|cysteine clusters
14P03332848A0000|25 38|Doppler probes
14P03332848A0000|94 116|carotid artery stenosis
14P03334950A0000|3 16|German Society
14P03334950A0000|18 35|Pediatric Oncology
14P03334950A0000|53 69|Cooperative Ewing
14P03334950A0000|71 83|Sarcoma Study
14P03334950A0000|84 87|CESS
14P03335127A0176|34 38|BASIC
14P03335398A0568|17 32|immunoglobulin G
14P03335398A0568|70 72|NVS
14P03335398A0568|91 118|passive transfer experiments
14P03335444A0000|53 57|241Am
14P03335444A0000|61 62|Pu
14P03335651A0000|30 48|parameter weighting
14P03335651A0000|68 69|MR
14P03335651A0000|185 186|T1
14P03335651A0000|188 189|T2
14P03335651A0000|194 211|hydrogen weighting
14P03335923A0257|63 74|presentation
14P03335923A0257|134 151|reflux gastropathy
14P03335923A0257|152 154|DRG
14P03335923A0257|204 206|RUD
14P03335923A0257|226 233|Moynihan
14P03337024A0000|34 50|pharmaco-dynamics
14P03337024A0000|64 75|procainamide
14P03337024A0000|139 146|practice
14P03338154T0000|4 17|concentrations
14P03338154T0000|36 52|trypsin inhibitor
14P03340548A1018|5 17|chicken liver
14P03340548A1018|26 40|chicken MT mRNA
14P03340548A1018|66 68|Cd2
14P03340548A1018|71 73|Zn2
14P03340548A1018|76 78|Cu2
14P03340548A1018|82 96|glucocorticoids
14P03340548A1018|100 117|lipopolysaccharide
14P03340726A1103|16 20|Evans
14P03340726A1103|47 65|barrier alterations
14P03340726A1103|101 102|Gy
14P03340774A0328|10 18|estimates
14P03340774A0328|71 72|Gy
14P03340774A0328|125 126|Gy
14P03343730A0486|31 44|family history
14P03343730A0486|88 109|calcium stone patients
14P03344586T0000|0 15|New technologies
14P03344586T0000|29 42|classification
14P03344812A0924|33 34|BP
14P03344812A0924|38 52|HR measurements
14P03344812A0924|176 177|BP
14P03344812A0924|181 189|HR values
14P03344812A0924|293 294|BP
14P03344812A0924|298 306|HR levels
14P03345706A0561|21 25|PaCO2
14P03345706A0561|29 33|PtcO2
14P03345706A0561|36 38|RDS
14P03346157A0000|34 42|ABCC/RERF
14P03346157A0000|71 88|Adult Health Study
14P03346157A0000|88 90|AHS
14P03346157A0000|195 198|RERF
14P03346210A0000|25 27|EGF
14P03346210A0000|60 91|protein tyrosine kinase activity
14P03346210A0000|120 148|self-phosphorylation reaction
14P03346210A0000|157 170|EGF activation
14P03348382A0785|42 45|HCO3
14P03351478A0371|8 14|regions
14P03351478A0371|41 52|% G residues
14P03352254A0203|15 23|structure
14P03352254A0203|32 41|prediction
14P03352254A0203|80 88|syllables
14P03352439T0000|5 33|cord abduction rehabilitation
14P03352727T0000|0 1|UK
14P03352947T0001|27 33|ARC/LAS
14P03352947T0001|38 50|health worker
14P03354295A0157|25 32|patients
14P03354295A0157|50 57|serum Tg
14P03354295A0157|70 81|micrograms/l
14P03354341A0177|13 27|filtration rate
14P03354341A0177|44 54|plasma flow
14P03354341A0177|79 94|clearance method
14P03355122A0238|29 49|plasma glucose levels
14P03359860A0000|54 68|characteristics
14P03359860A0000|94 108|undercompliance
14P03359860A0000|184 210|New York Longitudinal Study
14P03360667A0000|21 28|altitude
14P03360667A0000|50 60|development
14P03360667A0000|139 146|grouping
14P03360667A0000|159 167|sea level
14P03360667A0000|174 181|subjects
14P03360667A0000|184 195|mid-altitude
14P03360667A0000|203 210|subjects
14P03360667A0000|220 227|altitude
14P03360667A0000|235 242|subjects
14P03360948A0477|10 12|CAP
14P03360948A0477|103 105|CAP
14P03360948A0477|112 119|MHI Loss
14P03360948A0477|121 154|Behavioral/Emotional Control scale
14P03361653A0459|33 52|contour digitization
14P03361653A0459|79 89|limitations
14P03366720A1335|37 47|utilization
14P03366720A1335|91 100|metabolism
14P03366720A1335|113 122|glycolysis
14P03366864A0099|3 11|skin site
14P03366864A0099|47 54|segments
14P03366864A0099|60 67|catheter
14P03368701A0113|17 27|reliability
14P03368701A0113|41 53|arteriography
14P03368701A0113|91 108|imaging techniques
14P03370815T0000|5 13|detection
14P03370815T0000|45 54|test serum
14P03370815T0000|60 69|radioassay
14P03370815T0000|72 82|vitamin B12
14P03371139A0829|36 43|material
14P03371139A0829|63 68|groups
14P03371806A0000|10 24|data processing
14P03371806A0000|25 27|EDP
14P03371806A0000|29 45|latex immunoassay
14P03371806A0000|67 82|acid phosphatase
14P03371806A0000|130 149|organ identification
14P03371894A0355|0 18|Vimentin positivity
14P03372422A0558|3 21|maximum deflections
14P03372422A0558|33 34|Ar
14P03372422A0558|38 39|N2
14P03372422A0558|121 145|tracer gas concentrations
14P03373755T0001|6 17|developments
14P03373755T0001|94 120|gastrin receptor blockaders
14P03375184A0000|3 24|spermicide nonoxynol-9
14P03375184A0000|54 76|alkylphenol-ethoxylates
14P03375184A0000|78 95|polyethoxyethanols
14P03375184A0000|106 125|formula C9H19-C6H6-O
14P03375184A0000|127 133|CH2CH2O
14P03377864A0000|80 92|Lorentz force
14P03377864A0000|95 108|Maxwell stress
14P03377891A0652|43 59|life stress group
14P03377891A0652|103 116|severity index
14P03377891A0652|121 140|Symptom Checklist-90
14P03377891A0652|234 255|psychoticism subscales
14P03378994T0000|7 20|administration
14P03378994T0000|23 36|sodium cyanate
14P03378994T0000|47 62|extraction ratio
14P03379058A0188|0 20|Nucleotide sequencing
14P03379058A0188|37 55|E1 alpha cDNA clone
14P03379058A0188|90 102|reading frame
14P03380547A0169|0 2|SPA
14P03380547A0169|7 15|PAG sites
14P03381039A0364|14 16|MAN
14P03381039A0364|39 50|distribution
14P03382310A0903|8 20|technetium Tc
14P03382310A0903|72 86|polyarthralgias
14P03382310A0903|108 118|arthropathy
14P03382310A0903|132 151|management decisions
14P03382772A0319|0 17|Practical interest
14P03382772A0319|62 71|parameters
14P03382855A0368|3 13|artery cuff
14P03382855A0368|70 78|adhesions
14P03382855A0368|101 107|picture
14P03383897A0189|29 45|radiation therapy
14P03383897A0189|86 97|leukopoiesis
14P03383897A0189|128 137|conditions
14P03383897A0189|161 169|treatment
14P03384033A0155|46 47|Hz
14P03384033A0155|83 95|otolith input
14P03384033A0155|170 179|modalities
14P03384272A0145|14 21|location
14P03384272A0145|59 71|presentations
14P03387665A0000|31 41|Trypanosoma
14P03387665A0000|53 59|T vivax
14P03387665A0000|62 69|T brucei
14P03387665A0000|131 158|Glossina morsitans centralis
14P03390074A0000|0 18|Electroglottography
14P03395009A1750|48 63|cord compression
14P03395009A1750|77 88|group-1 dogs
14P03395009A1750|175 187|cord sections
14P03395009A1750|207 209|T12
14P03395009A1750|212 213|L1
14P03395009A1750|224 226|T11
14P03395009A1750|228 233|T11-12
14P03395009A1750|235 238|L1-2
14P03395009A1750|243 244|L2
14P03395009A1750|265 276|intervention
14P03395164A0000|50 51|FU
14P03395249A1044|48 60|proliferation
14P03395249A1044|89 101|proliferation
14P03395249A1044|170 177|ABSTRACT
14P03395249A1044|192 196|WORDS
14P03396437A0321|7 14|problems
14P03396437A0321|36 42|strains
14P03396628A0207|9 26|observation period
14P03396628A0207|67 75|ventricle
14P03396628A0207|78 88|BALB/c mice
14P03396628A0207|146 154|incidence
14P03398433T0001|51 59|infection
14P03398714A0594|13 14|RH
14P03398714A0594|48 61|peroxy radical
14P03398714A0594|106 133|propagation transition state
14P03398823A0459|24 37|administration
14P03398823A0459|43 56|mg/kg p-xylene
14P03398823A0459|105 112|p-xylene
14P03398823A0459|150 157|exposure
14P03400694A0245|0 7|PATIENTS
14P03400694A0245|11 17|METHODS
14P03400694A0245|19 30|Thallium-201
14P03401060A0000|4 12|melanomas
14P03402183A0171|3 11|TA muscle
14P03402183A0171|97 99|MVC
14P03402183A0171|105 107|MVC
14P03402183A0171|171 172|Hz
14P03402183A0171|185 203|voltage stimulation
14P03403313A0298|17 29|control rates
14P03403313A0298|49 64|treatment groups
14P03403313A0298|137 153|radiation therapy
14P03403412A0000|20 27|implants
14P03403412A0000|35 45|composition
14P03403412A0000|58 67|efficiency
14P03403412A0000|98 106|fed diets
14P03403412A0000|124 136|grain content
14P03403480A0299|9 18|suspension
14P03403480A0299|58 70|configuration
14P03403480A0299|76 93|femur middiaphysis
14P03403480A0299|149 159|alterations
14P03403480A0299|194 216|collagen concentrations
14P03403826T0000|201 249|exercise/redistribution thallium-201 scintigraphy
14P03404334T0000|0 12|Water content
14P03404334T0000|15 41|equilibrium water partition
14P03404495A0172|0 21|Thyroid function tests
14P03406054A0351|0 3|Data
14P03406054A0351|9 28|line spread function
14P03406054A0351|28 30|LSF
14P03406054A0351|135 145|polystyrene
14P03407676A0585|7 15|infection
14P03407843T0000|0 5|Papers
14P03407843T0000|11 17|Society
14P03407843T0000|37 43|Surgery
14P03413681A0659|8 20|heart disease
14P03413681A0659|59 65|patient
14P03413681A0659|90 99|predictors
14P03413681A0659|113 120|function
14P03413890T0001|0 8|Prognosis
14P03413890T0001|11 15|Bowen
14P03417104A0536|35 50|chlorphentermine
14P03417104A0536|78 93|stimulus effects
14P03417588T0000|0 5|Liquid
14P03417588T0000|30 42|determination
14P03417588T0000|45 57|citreoviridin
14P03417668A1233|25 43|autophosphorylation
14P03417668A1233|46 51|Thr286
14P03417668A1233|53 65|alpha subunit
14P03417668A1233|69 74|Thr287
14P03417668A1233|116 128|CaM-kinase II
14P03417668A1233|133 135|Ca2
14P03418727A0992|21 31|penetration
14P03418727A0992|59 70|chemotherapy
14P03418727A0992|93 102|myelopathy
14P03418727A0992|120 129|treatments
14P03420266A0000|3 13|interaction
14P03420266A0000|28 39|hyperthermia
14P03420266A0000|69 82|Dunning R3327G
14P03420266A0000|91 104|adenocarcinoma
14P03420266A0000|119 130|animal model
14P03420324A0178|33 41|following
14P03420324A0178|53 54|N2
14P03420324A0178|99 107|pregnancy
14P03420324A0178|119 120|N2
14P03420324A0178|134 148|h/day beginning
14P03420324A0178|170 171|N2
14P03420466A0000|14 30|cryptosporidiosis
14P03420466A0000|99 105|Kinyoun
14P03421425A0878|34 47|hypothyroidism
14P03421425A0878|72 85|determinations
14P03423732A0341|0 7|Addition
14P03423732A0341|22 27|De-Nol
14P03423732A0341|57 70|HCO3 secretion
14P03423732A0341|119 131|HCO3 response
14P03423732A0341|147 150|PGE2
14P03427474A0853|15 26|control rats
14P03427474A0853|71 84|concentrations
14P03427474A0853|87 105|saccharin solutions
14P03427613A0659|44 50|vessels
14P03427613A0659|75 86|pineal organ
14P03427613A0659|94 101|portions
14P03428084A0430|4 18|degrees stimuli
14P03428084A0430|35 53|scalp distributions
14P03428084A0430|59 79|pattern reversal P100
14P03428084A0430|84 99|pattern onset C1
14P03428274A0000|17 21|NFIII
14P03428274A0000|37 46|HeLa cells
14P03428274A0000|75 89|adenovirus type
14P03428274A0000|91 93|Ad2
14P03428274A0000|95 109|DNA replication
14P03428274A0000|129 147|nucleotide sequence
14P03428274A0000|186 201|recognition site
14P03429306T0000|1 11|Golgi study
14P03429371A1051|14 34|cephalothin clearance
14P03430221A1236|3 10|findings
14P03430221A1236|42 51|properties
14P03430221A1236|66 74|detectors
14P03434347A0358|0 8|Mean rCBF
14P03436119A0000|51 70|bone mineral content
14P03436119A0000|93 107|reproducibility
14P03436529A1066|3 11|structure
14P03436529A1066|78 98|oligodeoxynucleotides
14P03436529A1066|131 142|nt positions
14P03436877A0950|0 1|Kf
14P03436877A0950|7 8|CT
14P03436877A0950|74 93|lung mass % delta Kf
14P03436877A0950|192 204|relationships
14P03436877A0950|225 244|blocker pretreatment
14P03436877A0950|246 253|ABSTRACT
14P03436877A0950|268 272|WORDS
14P03439248A0000|31 42|dipyridamole
14P03439248A0000|46 66|exercise thallium-201
14P03439248A0000|76 92|perfusion imaging
14P03439248A0000|120 134|artery stenosis
14P03439248A0000|179 192|artery disease
14P03440780A0779|34 37|EDLF
14P03440780A0779|46 71|vasoconstrictor properties
14P03440780A0779|99 122|calcium entry mechanisms
14P03440780A0779|152 174|vasoconstrictor effects
14P03440780A0779|176 180|EDLFs
14P03441587A0000|0 7|Research
14P03441587A0000|58 65|patients
14P03441587A0000|92 102|polystyrene
14P03441587A0000|113 124|erythrocytes
14P03441587A0000|173 181|reference
14P03443144A0409|4 28|aspirin esterase activity
14P03443566A0675|37 54|gain-to-feed ratio
14P03443566A0675|68 69|TR
14P03443566A0675|73 74|CR
14P03443573A0329|7 19|least-squares
14P03443573A0329|45 62|longissimus muscle
14P03443609A0000|22 41|fluid chromatography
14P03443609A0000|42 44|SFC
14P03443609A0000|138 155|column methodology
14P03446332A0831|0 12|Nitrofurazone
14P03446332A0831|42 43|LH
14P03446332A0831|53 56|LHRH
14P03448035T0000|15 23|pregnancy
14P03449358T0001|22 34|polyarteritis
14P03450438A0446|0 6|X2 test
14P03450438A0446|11 26|Yates correction
14P03451761A0215|6 19|baseline study
14P03451761A0215|20 31|WPW syndrome
14P03451761A0215|109 111|RNV
14P03452920T0001|0 2|Man
14P03457330A0271|17 18|CA
14P03459385T0000|0 6|Allergy
14P03459385T0000|10 17|Tourette
14P03459736A0184|3 11|criterion
14P03459736A0184|30 37|sessions
14P03459736A0184|41 54|generalization
14P03459736A0184|75 82|capsules
14P03463537T0001|20 28|treatment
14P03463537T0001|31 35|Class
14P03463537T0001|46 54|anomalies
14P03463543A1613|0 7|Enoxacin
14P03463543A1613|57 59|UTI
14P03465957A1008|0 20|Mean fluorosis scores
14P03466730A0210|9 20|dysfunctions
14P03473253A0000|28 49|cohort mortality study
14P03473253A0000|123 152|chloromethyl ether manufacture
14P03473253A0000|159 172|U.S. companies
14P03473379A0183|3 11|diagnosis
14P03473379A0183|14 24|amyloidosis
14P03473379A0183|57 68|gland biopsy
14P03476002A0148|0 3|Hair
14P03476002A0148|7 19|blood samples
14P03476002A0148|44 66|placebo supplementation
14P03478354A0436|29 40|d postpartum
14P03478354A0436|45 57|corpus luteum
14P03478354A0436|65 86|prostaglandin F2 alpha
14P03479897A0961|28 36|angle ANB
14P03479897A0961|89 97|Class III
14P03484075T0001|0 18|Emergency treatment
14P03484894A0782|10 17|isolates
14P03484894A0782|90 97|biotypes
14P03484894A0782|103 104|V.
14P03485064A0135|11 24|EVS treatments
14P03486405A0341|31 51|precursor polypeptide
14P03486405A0341|98 107|IL-1 alpha
14P03487348A0000|20 26|Kernell
14P03487348A0000|59 80|afterhyperpolarization
14P03487348A0000|82 84|AHP
14P03488532A0235|53 68|dermatomal signs
14P03488532A0235|83 101|acyclovir treatment
14P03491190A0233|3 15|detectability
14P03491190A0233|30 32|RCA
14P03491190A0233|35 44|LAD region
14P03491190A0233|74 87|stress studies
14P03493240T0000|13 22|properties
14P03494649A0472|52 54|CBF
14P03494649A0472|80 83|MABP
14P03499608A1054|46 67|heterozygote detection
14P03499608A1054|91 117|beta-hydroxylase deficiency
14P03499657A0000|0 10|Osteocalcin
14P03499657A0000|12 33|serum bone-Gla protein
14P03499657A0000|39 64|serum alkaline phosphatase
14P03499657A0000|78 108|hydroxyproline/creatinine ratio
14P03499657A0000|109 127|uOH-Prol/creatinine
14P03499657A0000|168 186|hyperparathyroidism
14P03499657A0000|188 191|PHPT
14P03499657A0000|241 242|HM
14P03499822A0182|20 38|regression analysis
14P03499822A0182|51 64|seropositivity
14P03499822A0182|93 102|prevalence
14P03499822A0182|105 115|hepatitis B
14P03504971A0000|0 5|Hexsyn
14P03504971A0000|11 23|Goodyear Tire
14P03504971A0000|26 49|Rubber Company tradename
14P03504971A0000|52 68|polyolefin rubber
14P03504971A0000|98 114|% methylhexadiene
14P03507689A0000|8 39|phage-plasmid expression vectors
14P03507689A0000|57 73|pUC18/19 plasmids
14P03507689A0000|98 100|DNA
14P03507689A0000|159 183|bacteriophage T7 promoter
14P03507689A0000|191 213|beta-galactosidase gene
14P03508698A0535|24 37|finger flexors
14P03508698A0535|49 57|adductors
14P03508698A0535|62 77|triceps reflexes
14P03510185A0187|0 4|Natl.
14P03513989A0580|44 58|UROD-deficiency
14P03513989A1149|57 67|disturbance
14P03513989A1149|70 89|porphyrin metabolism
14P03513989A1149|136 147|pathogenesis
14P03515840A0000|41 48|symptoms
14P03515840A0000|60 68|granuloma
14P03515840A0000|95 107|histiocytosis
14P03515840A0000|159 172|generalization
14P03516189A0406|23 35|suxamethonium
14P03516189A0406|39 50|mg kg-1 i.v.
14P03517388A0763|23 33|CK-MB level
14P03517388A0763|45 46|BC
14P03517388A0763|48 49|BC
14P03517388A0763|62 63|CC
14P03520729A0381|43 55|plasma levels
14P03520729A0381|57 70|renin activity
14P03520729A0381|73 97|aldosterone concentration
14P03522105A1011|4 34|trough serum TOB concentrations
14P03526279T0000|23 34|nursing R.N.
14P03528748A0414|3 17|maxicell system
14P03531317A0930|22 31|recessives
14P03531317A0930|56 69|hypergeometric
14P03531317A0930|92 97|Fisher
14P03534581A0976|73 86|5-fluorouracil
14P03534581A0976|88 98|doxorubicin
14P03534581A0976|103 118|cyclophosphamide
14P03534581A0976|138 150|control group
14P03536682A0572|0 8|Ovulation
14P03536864A0000|10 13|work
14P03537686A0099|29 46|mutagenesis marker
14P03537686A0099|50 74|supF suppressor tRNA gene
14P03537686A0099|182 193|transfection
14P03537686A0099|214 224|plasmid DNA
14P03537711A0181|0 1|W.
14P03537721A0491|24 48|recombination experiments
14P03537721A0491|60 68|PEP4 gene
14P03537721A0491|78 81|GAL4
14P03537721A0876|53 71|precursor molecules
14P03537721A0876|86 108|PEP4 gene self-activate
14P03537727A0243|22 24|RNA
14P03540591A0330|20 22|RNA
14P03540591A0330|64 77|P0 transcripts
14P03540591A0330|149 161|reading frame
14P03540853A0652|13 31|amino acid sequence
14P03540853A0652|58 77|DNA binding proteins
14P03541263A0368|10 19|techniques
14P03541263A0368|54 61|diabetes
14P03542945T0000|0 12|Ciprofloxacin
14P03543485A0069|62 81|space flight effects
14P03543936A0000|78 96|ras oncogene family
14P03544858A0374|59 65|VO2 max
14P03544858A0374|102 116|HDL-cholesterol
14P03545955A0751|3 15|glucose areas
14P03545955A0751|27 35|ingestion
14P03545955A0751|51 55|Study
14P03545955A0751|130 139|mmol X h/l
14P03545955A0751|139 143|Study
14P03545955A0751|186 196|apple juice
14P03545955A0751|199 208|mmol X h/l
14P03545955A0751|208 212|Study
14P03545955A0751|227 235|ice cream
14P03545955A0751|260 269|mmol X h/l
14P03545955A1378|3 24|serum insulin response
14P03549045A0878|0 2|SCL
14P03549045A0878|38 49|sinus arrest
14P03550444T0000|0 10|Development
14P03550444T0000|14 25|yeast system
14P03550444T0000|42 52|specificity
14P03552363A0568|11 30|serum insulin levels
14P03552363A0568|83 103|blood pressure levels
14P03552363A0568|206 225|blood pressure level
14P03553149A0299|30 40|mutagenesis
14P03553149A0299|55 58|MucA
14P03553149A0299|81 93|cleavage site
14P03553149A0299|95 98|LexA
14P03553439A0404|32 35|Type
14P03553439A0404|43 54|tumor tissue
14P03553439A0404|90 100|tumor cells
14P03553439A0404|101 104|Type
14P03553439A0404|113 124|tumor tissue
14P03553439A0404|156 166|tumor cells
14P03553439A0404|167 170|Type
14P03553439A0404|183 193|tumor cells
14P03555318T0000|3 14|pharmacology
14P03555318T0000|17 25|carnitine
14P03556834T0000|5 23|inhalation toxicity
14P03556834T0000|25 37|T-2 mycotoxin
14P03559193A0000|10 22|investigation
14P03559193A0000|66 80|Framingham Type
14P03559193A0000|87 90|FTAS
14P03559232T0000|27 35|arthritis
14P03559287T0000|0 9|Legionella
14P03561036T0000|0 9|Lymphatics
14P03561036T0000|46 56|oil extract
14P03561036T0000|57 66|lipofundin
14P03561622A0659|80 106|DiaTAP button graft complex
14P03561622A0659|164 177|blood cultures
14P03561622A0659|186 208|term vancomycin therapy
14P03563399A0534|3 18|signal durations
14P03563399A0534|42 45|SoNo
14P03563399A0534|49 65|S pi No threshold
14P03563604A1075|3 13|spleen rate
14P03563604A1075|34 35|RK
14P03563604A1075|59 71|parasite rate
14P03563604A1075|85 101|drug intervention
14P03567017A0000|38 47|indoprofen
14P03567017A0000|99 107|half-life
14P03567017A0000|109 112|t1/2
14P03567017A0000|123 139|drug accumulation
14P03568311A0273|50 63|wedge pressure
14P03568311A0273|64 66|PWP
14P03568311A0273|69 71|RAP
14P03568311A0273|76 78|IPP
14P03568311A1361|24 46|pericardiocentesis data
14P03568311A1361|62 78|stroke work index
14P03568311A1361|106 110|TMFP1
14P03568311A1361|121 125|TMFP2
14P03568311A1361|143 147|TMFP3
14P03570455A0433|0 6|Rabbits
14P03570455A0433|24 35|hypocalcemia
14P03570455A0433|103 108|TSST-1
14P03571135T0000|21 28|features
14P03571135T0000|31 38|language
14P03571135T0000|77 84|children
14P03572706A0329|19 33|interpretations
14P03572706A0329|120 138|treatment condition
14P03572706A0329|159 169|F-K indices
14P03572706A0329|179 190|MMPI profile
14P03575656A0120|25 37|chemical form
14P03575656A0120|38 41|90Sr
14P03577670A0102|59 78|matter hypodensities
14P03577670A0236|27 40|leukodystrophy
14P03577670A0236|42 44|MLD
14P03577670A0236|75 89|arylsulfatase A
14P03577670A0236|90 92|ASA
14P03578948A0448|10 20|ventilation
14P03578948A0448|54 62|ml X kg-1
14P03578948A0448|77 85|c X min-1
14P03581160A0583|18 38|heart rate reactivity
14P03581160A0583|79 110|artery pulse amplitude responses
14P03581160A0583|132 142|TH subjects
14P03582149T0001|34 46|valve disease
14P03582149T0001|84 98|school students
14P03582149T0001|100 115|Jiangxi Province
14P03582184A0448|0 4|Drugs
14P03582184A0448|61 77|dosage adjustment
14P03582982A0000|27 28|U4
14P03582982A0000|41 43|RNA
14P03583001A0111|19 27|procedure
14P03583001A0111|39 51|gas injection
14P03583001A0111|121 128|drainage
14P03583001A0111|148 157|vitrectomy
14P03584426A0706|16 26|enterotoxin
14P03584426A0706|28 29|LT
14P03584426A0706|50 63|stool isolates
14P03584426A0706|131 143|suckling mice
14P03586925T0001|68 102|Roentgenology and Medical Radiology
14P03586925T0001|112 127|Medinform system
14P03590911T0001|45 61|light sensitivity
15P03591464A0840a|37 52|disease activity
15P03591464A0840a|68 95|calcium antagonist treatment
15P03591464A0840b|37 52|disease activity
15P03591464A0840b|68 95|calcium antagonist treatment
14P03592297A0138|0 16|Dorsal foot TcpO2
14P03592297A0138|61 80|surface temperatures
14P03592297A0138|155 168|vasomotor tone
14P03592297A0138|171 175|TcpO2
14P03592297A0138|223 234|vasodilation
14P03592297A0138|263 274|vasodilation
14P03592297A0679|19 30|quadriplegia
14P03592297A0679|75 85|cord trauma
14P03592297A0679|86 90|TcpO2
14P03592297A0679|106 123|vasodilation index
14P03592297A0679|154 158|TcpO2
14P03595418A0688|3 22|nucleotide sequences
14P03595418A0688|41 69|ornithine decarboxylase mRNAs
14P03597218A0901|11 24|concentrations
14P03597218A0901|41 49|inhibitor
14P03597218A0901|51 71|alpha 2-macroglobulin
14P03597218A0901|75 86|antithrombin
14P03597218A0901|138 151|concentrations
14P03597218A0901|181 192|plasma water
14P03597218A0901|225 234|inhibitors
14P03597269A0409|27 37|exponential
14P03597269A0409|42 49|constant
14P03597269A0409|55 61|form La
14P03600633A1069|0 3|Cell
14P03600705T0000|0 5|Timing
14P03600705T0000|19 34|oocyst excretion
14P03600705T0000|41 57|cryptosporidiosis
14P03601275A0601|5 21|dopamine infusion
14P03601275A0601|82 93|state levels
14P03601275A0601|95 109|plasma dopamine
14P03601275A0601|110 123|norepinephrine
14P03601275A0601|138 160|dopamine/norepinephrine
14P03601533T0001|36 58|complement constituents
14P03602261A0238|31 39|condition
14P03602261A0238|62 73|correlations
14P03602261A0238|110 123|blood pressure
14P03602261A0238|126 133|dopamine
14P03602261A0238|143 156|norepinephrine
14P03602261A0238|168 178|epinephrine
14P03602261A0238|211 222|correlations
14P03602261A0238|230 238|melatonin
14P03602261A0238|242 249|dopamine
14P03602261A0238|260 273|norepinephrine
14P03602261A0238|286 299|growth hormone
14P03605895A0888|16 39|carboxyhemoglobin levels
14P03605895A0888|70 94|carbon monoxide poisoning
14P03607109A0370|8 16|processes
14P03607109A0370|55 63|pregnancy
14P03607109A0370|80 86|picture
14P03607109A0370|92 99|controls
14P03607961T0001|28 41|zhuang qi gong
14P03607961T0001|58 74|diabetes mellitus
14P03608916A0790|10 20|degrees HPT
14P03608916A0790|36 37|OH
14P03608916A0790|39 46|2D level
14P03608989A0668|14 24|amino acids
14P03608989A0668|50 61|interactions
14P03608989A0668|93 110|filament formation
14P03610663A0201|41 51|calculation
14P03610663A0201|54 73|nutrient utilization
14P03610663A0201|111 119|precision
14P03610674T0000|18 32|zinc deficiency
14P03610674T0000|42 59|fiber zinc content
14P03610674T0000|63 77|rat hippocampus
14P03612316A0102|31 41|low-protein
14P03612316A0102|73 78|saline
14P03612316A0102|81 89|thyroxine
14P03612648A0085|22 40|lupus anticoagulant
14P03612648A0085|68 86|thromboplastin time
14P03615550A0000|45 63|antagonist naloxone
14P03615550A0000|97 120|fixed-consecutive-number
14P03615550A0000|122 124|FCN
14P03615550A1094|38 43|U50488
14P03615550A1094|79 88|mg/kg dose
14P03615763A0170|0 3|Data
14P03615763A0170|42 52|angiography
14P03615763A0170|62 72|opportunity
14P03615763A0170|87 98|associations
14P03615763A0170|140 154|atherosclerosis
14P03615763A0170|189 200|hypertension
14P03615763A0170|202 218|serum cholesterol
14P03615763A0170|243 256|family history
14P03615763A0170|258 270|heart disease
14P03615763A0170|271 293|Type A behavior pattern
14P03616174A1069|20 30|temperature
14P03616174A1069|45 53|degrees C
14P03616174A1069|83 92|blood flow
14P03616174A1069|111 120|blood flow
14P03616174A1069|180 190|circulation
14P03616237T0001|10 27|status epilepticus
14P03618039A0126|52 64|noradrenaline
14P03618039A0126|103 133|catecholamine biotransformation
14P03619249A0428|89 91|HBV
14P03619249A0428|93 98|HBs Ag
14P03619249A0428|101 106|HBe Ag
14P03619249A0428|146 148|HBs
14P03619249A0428|152 157|HBc Ag
14P03619249A0428|191 192|Ag
14P03619249A0428|243 244|Ag
14P03622423A0000|0 5|Groups
14P03622423A0000|21 27|Fischer
14P03622423A0000|36 46|B6C3F1 mice
14P03622423A0000|50 68|Hartley guinea pigs
14P03622423A0000|94 107|concentrations
14P03622423A0000|144 160|methyl isocyanate
14P03622423A0000|161 163|MIC
14P03622571A0208|0 17|Radionuclide study
14P03625688A0372|0 13|Immobilization
14P03625688A0372|39 48|cuff sling
14P03625762A0308|0 9|Comparison
14P03625762A0308|191 201|vitamin B12
14P03625762A0308|203 226|behaviour problem rating
14P03626129T0001|0 6|Effects
14P03626129T0001|20 29|laser beam
14P03627720A0196|26 33|features
14P03627720A0196|48 55|sac cyst
14P03628532A0000|21 36|taste perception
14P03628532A0000|63 73|experiments
14P03628596A0000|0 6|Samples
14P03628596A0000|70 94|acid alpha 1-glycoprotein
14P03628713A0961|27 29|AIB
14P03628713A0961|33 45|86RbCl uptake
14P03628713A0961|47 58|36B-10 cells
14P03628713A0961|85 98|Gy irradiation
14P03628713A0961|117 130|radiation dose
14P03628713A0961|171 172|Rb
14P03628794A0648|62 84|I-131 MIBG scintigraphy
14P03629973A0240|0 1|W.
14P03629974A1468|0 9|Comparison
14P03629974A1468|15 33|amino acid sequence
14P03629974A1468|37 49|M RNA product
14P03629974A1468|50 64|Uukuniemi virus
14P03629974A1468|74 83|Punta Toro
14P03629974A1468|86 110|Rift Valley fever viruses
14P03632739T0000|0 21|Cyclosporine treatment
14P03635597A0377|2 9|addition
14P03635597A0377|16 21|Cohler
14P03637037T0000|13 28|teaching booklet
14P03645733T0001|0 14|Hyperthyroidism
14P03649340A1119|69 80|splice sites
14P03649340A1119|90 103|exon sequences
14P03649340A1119|137 152|splicing process
14P03651330T0000|22 28|lesions
14P03651840A0266|6 24|MAO inhibition data
14P03651840A0266|32 37|DPGPEA
14P03651840A0266|55 59|MAO-B
14P03652083A0720|21 39|vessel pyridinoline
14P03653226A0833|22 46|tissue-distribution study
14P03658866A0081|8 26|lupus erythematosus
14P03659603A0797|50 52|CO2
14P03659603A0797|78 92|CO2 sensitivity
14P03659805A0404|14 25|significance
14P03659805A0404|31 47|prognosis factors
14P03659805A0404|109 111|Cox
14P03659805A0404|128 139|IMB computer
14P03659994A0150|47 57|abnormality
14P03659994A0150|90 105|signal intensity
14P03659994A0150|107 108|T1
14P03659994A0150|143 158|signal intensity
14P03659994A0150|160 161|T2
14P03663789A0568|53 56|RHAL
14P03663789A0568|117 120|RHAL
14P03663789A0568|123 125|HAL
14P03664038A0000|61 91|Gudjonsson Suggestibility Scale
14P03664038A0000|91 93|GSS
14P03664038A0000|95 98|Form
14P03666957A0219|0 8|Organisms
14P03666957A0219|29 39|conjunctiva
14P03666957A0219|95 103|infection
14P03666957A0219|129 137|infection
14P03668003T0000|21 30|microscopy
14P03668003T0000|42 53|skin lesions
14P03668396A0171|5 25|equilibrium solutions
14P03668396A0171|72 88|convex polyhedron
14P03668736A0177|10 19|deviations
14P03668736A0177|25 36|X-ray counts
14P03672532A1111|24 30|effects
14P03673640A0533|3 14|MAO subjects
14P03673640A0533|44 60|KSP Impulsiveness
14P03673640A0533|61 75|EPQ Neuroticism
14P03673640A0533|79 81|KSP
14P03673640A0533|89 95|Anxiety
14P03673640A0533|99 110|Irritability
14P03673640A0533|127 143|KSP Socialization
14P03673640A0533|154 173|personality profiles
14P03673640A0533|206 223|suicide attempters
14P03673640A0533|243 263|platelet MAO activity
14P03673881A0000|46 47|CW
14P03673881A0000|56 81|pulse repetition frequency
14P03673881A0000|81 84|HPRF
14P03673881A0000|86 92|Doppler
14P03673881A0000|125 142|pressure gradients
14P03673881A0000|143 162|Doppler examinations
14P03676054A0865|9 11|Paw
14P03676054A0865|20 23|PaO2
14P03676054A0865|25 28|Vinj
14P03676054A0865|32 33|VT
14P03676054A0865|134 149|injector cannula
14P03676174A0730|2 7|calves
14P03676174A0730|53 59|g DM/kg
14P03676174A0730|60 71|milk intakes
14P03676174A0730|106 111|calves
14P03678269A0633|0 4|Today
14P03678269A0633|31 55|plasma cholesterol levels
14P03678269A0633|83 94|modification
14P03678372A0170|3 8|number
14P03678372A0170|16 22|pellets
14P03678372A0170|54 64|pellets/day
14P03678372A0170|102 108|pellets
14P03678372A0170|125 131|pellets
14P03679407A0556|23 41|N-nitroso compounds
14P03679407A0556|99 109|association
14P03679407A0556|159 172|bladder cancer
14P03679756A0830|10 28|nerve fiber defects
14P03679756A0830|53 64|architecture
14P03680791A0230|13 17|grade
14P03680791A0230|51 56|hearts
14P03680791A0230|82 86|sites
14P03680791A0230|96 100|heart
14P03682805A0375|0 11|Serum levels
14P03682805A0375|33 60|coagulation protein activity
14P03682805A0375|107 123|skin lymph levels
14P03682805A0375|136 138|Day
14P03684378A0653|36 46|correlation
14P03684378A0653|49 58|vitamin K1
14P03684378A0653|60 70|cholesterol
14P03684378A0653|129 139|cholesterol
14P03684378A0653|145 153|secretion
14P03684378A0653|156 165|vitamin K1
14P03684517A0462|9 16|training
14P03684517A0462|29 36|increase
14P03684517A0462|39 47|stiffness
14P03684517A0462|63 70|decrease
14P03685073A0200|22 34|physostigmine
14P03685073A0200|38 67|acetylcholinesterase inhibitor
14P03685073A0200|105 118|atropine doses
14P03687078T0001|0 9|References
14P03687078T0001|34 44|adolescents
14P03687148T0187|0 7|Salzburg
14P03687148T0187|13 21|September
14P03687313A0000|6 27|glucosidase inhibitors
14P03687313A0000|28 32|BAY m
14P03687313A0000|39 43|BAY o
14P03688202A0377|57 59|PBB
14P03688202A0377|63 64|CN
14P03688301A0129|31 36|spread
14P03688301A0129|51 58|invasion
14P03688301A0129|60 65|type A
14P03688301A0129|104 112|extension
14P03688301A0129|114 119|type B
14P03688301A0129|139 148|carcinomas
14P03688301A0129|154 160|bladder
14P03688676A0487|8 18|conversions
14P03688676A0487|77 85|infection
14P03690262A0428|3 19|maximum amplitude
14P03690262A0428|83 84|T2
14P03690262A0428|146 156|stimulation
14P03690262A0428|159 160|T1
14P03690262A0428|162 163|T3
14P03690262A0428|165 166|T4
14P03690262A0428|170 171|T5
14P03691316A0560|17 31|contact allergy
14P03691316A0560|33 36|K-CG
14P03692331A0000|3 8|effect
14P03692331A0000|29 38|antagonist
14P03692331A0000|40 47|pindolol
14P03692331A0000|64 69|muscle
14P03693543A0405|35 53|Rhodococcus species
14P03693543A0405|108 120|elution times
14P03693543A0405|134 152|Nocardia asteroides
14P03693543A0405|153 171|N. otitidiscaviarum
14P03693543A0405|175 189|N. brasiliensis
14P03694102A0000|70 90|ECG computer programs
14P03696899T0001|0 31|Blood serum erythropoietin level
14P03697587T0000|3 26|XXXXY chromosome anomaly
14P03697587T0000|44 54|Klinefelter
14P03697798T0001|0 10|Contraction
14P03697798T0001|46 62|stretch receptors
14P03697971A0311|3 16|selenium level
14P03697971A0311|19 49|glutathione peroxidase activity
14P03697971A0311|68 81|stomach mucosa
14P03698251T0000|0 14|Oxygen delivery
14P03698251T0000|31 33|P50
14P03700952A0273|0 6|Infants
14P03700952A0273|31 32|PL
14P03700952A0273|74 81|McDonald
14P03700952A0273|90 107|laboratory setting
14P03701640A1178|81 90|FR30 FI600
14P03701640A1178|150 157|ABSTRACT
14P03701640A1178|172 176|WORDS
14P03703493A0654|67 94|RPE-choriocapillaris complex
14P03704087A0394|92 102|Spielberger
14P03704087A0394|105 137|State-Trait Personality Inventory
14P03704087A0394|140 161|Anger Expression Scale
14P03704087A0394|167 192|State Anger Reaction Scale
14P03709191A0125|77 85|asymmetry
14P03709191A0125|94 109|side differences
14P03709627A0247|3 10|subjects
14P03709627A0247|37 54|acetaminophen i.v.
14P03709627A0247|57 70|concentrations
14P03709627A0247|140 149|production
14P03709627A0247|152 162|metabolites
14P03710973A0817|0 3|Mean
14P03710973A0817|12 27|skin temperature
14P03710973A0817|28 30|Tsk
14P03710973A0817|132 150|Tre-to-Tsk gradient
14P03712050T0000|0 27|Indium-111 leukocyte imaging
14P03712106A0000|11 38|L-methionine supplementation
14P03712106A0000|57 75|soy protein isolate
14P03712106A0000|75 77|SPI
14P03712106A0000|103 126|nitrogen balance studies
14P03712153T0000|15 51|Haemophilus influenzae type b disease
14P03713187A0691|34 47|lamina propria
14P03713187A0691|67 75|frequency
14P03713187A0691|78 87|occurrence
14P03713187A0691|143 152|carcinomas
14P03713187A0691|190 198|frequency
14P03713187A0691|228 237|comparison
14P03714348A0833|0 6|Factors
14P03714348A0833|49 51|CIC
14P03714348A0833|85 98|CIC population
14P03714348A0833|106 114|NIH score
14P03714348A0833|138 162|peak expiratory flow rate
14P03714473A0496|0 8|Induction
14P03717475A0208|0 2|New
14P03717475A0208|35 51|immunodiagnostics
14P03717475A0208|53 65|immunotherapy
14P03717475A0208|70 86|immunoprophylaxis
14P03717936A0252|0 7|Amikacin
14P03717936A0252|54 67|aminoglycoside
14P03720615A0434|47 57|birthweight
14P03720615A0434|61 69|gestation
14P03720615A0434|79 85|infants
14P03720966A1043|16 32|acid N absorption
14P03720966A1043|39 46|N intake
14P03721594A0000|0 7|Adhesion
14P03721594A0000|96 114|exudate neutrophils
14P03721594A0000|129 144|fibrinogen level
14P03721594A0000|177 207|dilution protamine sulfate test
14P03721594A0000|226 236|New Zealand
14P03721594A0000|273 293|Shwartzman phenomenon
14P03721666A0000|0 5|Nickel
14P03721666A0000|36 53|contact dermatitis
14P03721666A0000|55 63|Singapore
14P03721666A0000|95 105|patch tests
14P03722016A0797|3 12|FFA levels
14P03728230A0104|12 19|hospital
14P03732252A0556|54 56|VO2
14P03732252A0556|92 97|VO2max
14P03732252A0556|138 155|m race performance
14P03732252A0556|220 229|m run time
14P03732252A0556|249 259|combination
14P03732252A0556|285 294|m run time
14P03733563A0716|12 36|herd X period interaction
14P03733563A0716|78 103|cholesterol concentrations
14P03733563A0820|10 34|serum NEFA concentrations
14P03734641A0203|3 9|results
14P03734641A0203|80 86|failure
14P03734641A0203|100 111|biomechanics
14P03736081A0465|15 28|sinus pressure
14P03736081A0465|62 69|decrease
14P03736081A0465|107 114|L/min/m2
14P03736081A0465|140 149|blood flow
14P03736081A0465|221 228|pressure
14P03736081A0465|275 282|increase
14P03736081A0465|306 315|difference
14P03736081A0465|342 353|% saturation
14P03738919A0000|0 13|Calcifications
14P03738919A0000|69 77|vertebrae
14P03738919A0000|121 130|tomography
14P03743683A0000|58 59|PP
14P03743683A0000|74 84|individuals
14P03743702A0158|18 28|cell bodies
14P03743702A0158|37 43|neurons
14P03743702A0158|74 83|structures
14P03743702A0158|102 109|alveolar
14P03743702A0158|111 117|lingual
14P03743702A0158|207 208|SD
14P03744168T0001|86 110|methano-1H-4-benz azonine
14P03745833A0258|2 11|transition
14P03745833A0258|25 31|voltage
14P03745833A0258|66 73|pressure
14P03745833A0258|83 90|increase
14P03745833A0258|140 151|arborization
14P03745833A0258|166 174|formation
14P03745833A0258|192 199|cerebrum
14P03745833A0258|203 212|cerebellum
14P03746053A0670|0 7|Findings
14P03746053A0670|38 39|N1
14P03746053A0670|111 112|N2
14P03746053A0670|123 135|dorsal column
14P03746107A0192|41 47|tumours
14P03746508A0390|0 7|Failures
14P03746601A0299|17 24|problems
14P03746601A0299|26 38|extravasation
14P03746601A0299|61 68|hematoma
14P03746601A0299|96 103|exposure
14P03746896A0890|51 61|possibility
14P03746896A0890|107 120|susceptibility
14P03746896A0890|143 157|Type A behavior
14P03746906A0000|44 74|student Jenkins Activity Survey
14P03746906A0000|73 75|JAS
14P03746906A0000|78 98|questionnaire measure
14P03746906A0000|100 114|Type A behavior
14P03747493A0000|14 21|patients
14P03747493A0000|73 82|infections
14P03749226A0506|4 16|phencyclidine
14P03749226A0506|45 57|response rate
14P03750700T0001|0 12|Possibilities
14P03750700T0001|36 49|endoprosthesis
14P03751308T0001|0 4|Study
14P03751308T0001|10 26|energy metabolism
14P03751308T0001|31 47|sensomotor cortex
14P03751308T0001|67 69|14C
14P03751308T0001|71 91|2-deoxyglucose method
14P03753022A0000|9 16|lymphoma
14P03753022A0000|58 65|behavior
14P03755623A1233|7 20|investigations
14P03755623A1233|86 89|DLIS
14P03755673A0054|12 16|cases
14P03757294A0414|14 16|PLD
14P03757294A0414|64 67|APCD
14P03757294A0414|81 91|liver cysts
14P03758250A0000|106 117|EMG activity
14P03759330A0713|16 17|F1
14P03759330A0713|21 22|F2
14P03759330A0713|49 51|CHD
14P03759330A0713|69 70|G1
14P03759330A0713|102 116|trunk adiposity
14P03759731A0992|43 44|m2
14P03759731A0992|75 76|m2
14P03761122T0000|19 33|type A behavior
14P03761122T0000|83 84|IQ
14P03761523A0000|31 37|effects
14P03761523A0000|51 61|utilization
14P03761523A0000|76 83|emulsion
14P03763241A0446|34 44|extremities
14P03763836T0001|0 6|Results
14P03763836T0001|9 24|electron therapy
14P03765552A0582|94 96|RES
14P03765552A0582|98 117|Fc receptor blockade
14P03765552A0582|144 161|antibody synthesis
14P03765731A0918|0 9|Incidences
14P03765731A0918|48 66|angina pectoris und
14P03766370A0546|64 65|LV
14P03768208A0879|58 77|bone formation rates
14P03769224A0000|40 58|Lupus Erythematosus
14P03769224A0000|59 61|SLE
14P03770143A1209|3 13|possibility
14P03770143A1209|65 79|fibre structure
14P03771670T0058|0 9|Prevention
14P03771670T0058|13 32|heparin-antithrombin
14P03771703A0000|13 36|trimethylsilylcarbamates
14P03771749A0465|0 3|MICs
14P03771749A0465|27 42|5-fluorocytosine
14P03771749A0465|115 129|Candida species
14P03771749A0465|177 209|microtiter broth dilution systems
14P03772471A1054|11 18|patients
14P03772471A1054|23 30|Group II
14P03772471A1054|48 59|tumor biopsy
14P03772471A1054|98 106|diagnosis
14P03774111T0000|0 7|Evidence
14P03776080A0400|15 37|post-mortem examination
14P03776080A0400|104 106|E/S
14P03776080A0400|110 121|CWE antigens
14P03776438A0000|0 13|Glucocorticoid
14P03776438A0000|21 32|hypertension
14P03776438A0000|70 71|Na
14P03776438A0000|86 102|mineralocorticoid
14P03776438A0000|110 121|hypertension
14P03776438A0000|130 131|Na
14P03776779A0238|21 29|treatment
14P03776779A0238|42 49|steroids
14P03777398A0156|0 7|Examples
14P03777398A0156|30 41|therapy unit
14P03779182A0370|10 21|drug problem
14P03779182A0370|66 76|hepatitis B
14P03779205A0459|9 16|patients
14P03779205A0459|82 93|presentation
14P03779205A0459|99 106|patients
14P03779205A0459|120 130|secondaries
14P03780248A0274|8 18|differences
14P03780248A0274|107 117|ventilation
14P03780248A0274|119 121|IMV
14P03780248A0274|213 223|PCO2 values
14P03780371A0792|55 79|cytochrome P-450PBc2 gene
14P03780704A0573|16 28|serum ketones
14P03780704A0573|126 127|WW
14P03780704A0573|141 142|CW
14P03780704A0573|151 152|CC
14P03781000A0101|10 20|correlation
14P03781000A0101|31 40|variations
14P03781000A0101|55 62|activity
14P03781000A0101|81 88|implants
14P03781000A0101|118 124|disease
14P03781948T0000|11 20|adaptation
14P03781948T0000|30 36|hypoxia
14P03783160A0285|0 7|Compound
14P03783160A0285|17 29|21-O-angeloyl
14P03783160A0285|43 55|R1-barrigenol
14P03783160A0285|59 70|21-O-tigloyl
14P03783160A0285|85 97|R1-barrigenol
14P03785212A0091|15 43|hamster S14 protein sequences
14P03785212A1128|0 12|RPS14 introns
14P03785212A1128|28 40|Alu sequences
14P03788231A0802|20 26|aspects
14P03788231A0802|51 58|survival
14P03788231A0802|94 105|implantation
14P03788231A0802|167 175|placement
14P03788231A0802|188 197|ventricles
14P03789052A0527|13 27|tissue response
14P03789052A0527|40 57|cyanoacrylate site
14P03789052A0527|119 133|tissue adhesive
14P03791645A1124|71 73|MAL
14P03791645A1124|89 91|OSA
14P03795488A0487|73 74|PR
14P03795488A0487|81 93|response rate
14P03799323A0501|25 39|flow conditions
14P03799323A0501|49 74|oxygen saturation decrease
14P03799323A0501|101 112|sickle cells
14P03799790A0146|8 15|examiner
14P03799790A0146|27 34|interior
14P03799790A0146|55 68|ophthalmoscopy
14P03799790A0146|73 84|point source
14P03799790A0146|108 117|light pipe
14P03802195A0481|5 19|fusion proteins
14P03802195A0481|78 96|DNA binding domains
14P03802195A0481|100 111|ToxR protein
14P03805090A0645|56 64|incidence
14P03805090A0645|76 89|chondrosarcoma
14P03805090A0645|173 184|degeneration
14P03805090A0645|194 202|certainty
14P03805090A0645|220 236|Maffucci syndrome
14P03806696A0000|29 33|HgCl2
14P03806696A0000|46 52|CH3HgCl
14P03806696A0000|54 69|mercury chloride
14P03806696A0000|83 90|Coturnix
14P03806696A0000|92 105|Japanese quail
14P03806696A0000|106 122|Coturnix japonica
14P03810361A0576|29 54|plasma cortisol estimation
14P03810361A0576|94 119|plasma cortisol estimation
14P03810361A0576|159 165|Cushing
14P03810867A0305|45 48|T3-4
14P03810867A0305|77 86|TNM system
14P03810867A0305|87 103|Lederman-Gadeberg
14P03810867A0305|105 116|Sisson-Jesse
14P03811852A0109|15 27|complications
14P03811852A0109|82 92|combination
14P03811852A0109|95 111|magnesium sulfate
14P03811852A0109|148 169|adrenocortico-steroids
14P03814493T0000|0 11|Chlorambucil
14P03818467A0180|0 7|Selenium
14P03818467A0180|22 26|IU/kg
14P03818467A0180|28 42|supplementation
14P03818467A0180|69 85|plasma tocopherol
14P03818467A0180|88 104|Se concentrations
14P03818467A0180|122 150|plasma glutathione peroxidase
14P03818467A0180|150 155|GSH-Px
14P03818866A0116|0 14|Framingham Type
14P03818866A0116|59 72|blood pressure
14P03820222A0203|23 29|potency
14P03824908A0116|3 17|M reading frame
14P03824908A0116|102 133|arginine amino acid substitution
14P03824908A0116|138 153|carboxy-terminus
14P03824908A0116|171 180|M proteins
14P03824908A0116|182 196|paramyxoviruses
14P03826871A0000|44 49|Br ion
14P03826871A0000|61 70|Greyhounds
14P03827071T0040|0 1|II
14P03828209T0000|14 20|changes
14P03828209T0000|42 51|intubation
14P03828500T0001|0 14|Intensification
14P03828500T0001|32 51|contractile activity
14P03829848T0001|0 18|Autotransplantation
14P03829848T0001|22 33|vein segment
14P03829848T0001|74 86|insufficiency
14P03830147A0000|38 53|lactate increase
14P03830147A0000|54 70|lactate threshold
14P03830147A0000|71 72|LT
14P03830147A0000|78 80|VO2
14P03830147A0000|88 114|blood lactate concentration
14P03830147A0000|182 184|LT1
14P03830147A0000|189 191|VO2
14P03830147A0000|245 247|LT2
14P03830147A0000|252 254|VO2
14P03830147A0000|262 288|blood lactate concentration
14P03830147A0000|319 344|blood lactate accumulation
14P03830147A0000|344 347|OBLA
14P03830147A0000|352 354|VO2
14P03830147A0000|434 439|VO2max
14P03830255A0074|55 66|distribution
14P03835413A0616|3 13|observation
14P03835413A0616|32 43|irradiations
14P03835413A0616|51 63|space flights
14P03835413A0616|70 81|difficulties
14P03835413A0616|128 149|duration space flights
14P03836777T0001|0 12|Practical use
14P03836777T0001|36 54|hepatitis B markers
14P03836777T0001|71 85|HBs Ag carriers
14P03836853A0204|12 30|year survival rates
14P03836854T0000|0 9|Inhibition
14P03836854T0000|54 55|RP
14P03837609T0000|42 52|blood cells
14P03837609T0000|64 76|mononucleosis
14P03838797A0903|0 16|Northern blotting
14P03838797A0903|33 47|oligonucleotide
14P03838797A0903|110 121|cDNA library
14P03840480T0000|46 62|peptide sequences
14P03841627T0001|0 11|Chemotherapy
14P03843496A0919|95 103|chemicals
14P03843496A0919|132 145|extrapolations
14P03843496A0919|154 168|risk assessment
14P03843676A0381|6 18|extrapolation
14P03848527T0020|0 12|Hisako Minowa
14P03857577A0413|0 23|Deletion mapping studies
14P03857577A0413|45 57|DNA sequences
14P03857577A0413|96 114|level transcription
14P03857577A0413|116 125|HeLa cells
14P03860162A0000|0 12|Incorporation
14P03860162A0000|35 48|amphotericin B
14P03860162A0000|49 51|AMB
14P03860162A0000|91 103|drug toxicity
14P03861687A0000|88 96|treatment
14P03861687A0000|119 129|alterations
14P03861687A0000|169 186|system stimulation
14P03862898A0563|0 8|Serum IgM
14P03862898A0563|11 28|IgE concentrations
14P03862898A0563|46 55|IgE scores
14P03862898A0563|62 77|tumor E2R status
14P03862898A0563|111 129|risk classification
14P03863231A0530|3 13|M-3 subtype
14P03863561A0405|9 13|Strep
14P03863561A0405|15 26|mutans group
14P03863561A0405|53 62|difference
14P03863561A0405|70 74|Strep
14P03863561A0405|76 87|mutans/Strep
14P03863561A0405|129 138|clump size
14P03865743A0859|24 27|T.C.
14P03865743A0859|29 34|LDL-C.
14P03865743A0859|36 41|HDL-C.
14P03865743A0859|43 49|HDL2-C.
14P03865743A0859|56 70|apo A-I/B ratio
14P03865743A0859|72 87|apo A-II/B ratio
14P03866085A0795|26 48|suppository formulation
14P03866085A0795|50 54|CZX-S
14P03869442A0223|17 28|hypertension
14P03869442A0223|58 70|abnormalities
14P03869442A0223|84 95|hypertension
14P03869442A0223|131 149|vasopressin therapy
14P03871298A0217|6 20|photon emission
14P03871298A0217|43 47|SPECT
14P03871298A0217|78 91|representation
14P03871298A0217|104 109|Tl-201
14P03871298A0217|149 151|CAD
14P03871445T0000|0 7|Computer
14P03871445T0000|55 81|positron emission tomograms
14P03873141A0304|4 20|patients vagotomy
14P03873141A0304|73 78|Visick
14P03873141A0304|99 112|mortality rate
14P03874921A0862|0 12|Documentation
14P03874921A0862|38 50|fertilization
14P03874921A0862|112 113|EP
14P03875231A0627|0 2|MRI
14P03875231A0627|35 47|abnormalities
14P03875231A0627|101 115|differentiation
14P03875231A0627|161 170|hemorrhage
14P03875231A0627|203 215|abnormalities
14P03877298A0718|59 79|Cremophor formulation
14P03877298A0718|119 132|recovery times
14P03877298A0718|147 166|emulsion formulation
14P03878585A0507|3 26|percentage RFR reduction
14P03878585A0507|35 37|CPB
14P03878585A0507|72 83|CPB duration
14P03878585A0507|94 115|oxygen flow rate index
14P03878585A0507|114 117|OFRI
14P03878585A0507|137 160|bubble oxygenator/m2 bsa
14P03878585A0507|173 193|blood flow rate index
14P03878585A0507|192 195|BFRI
14P03878585A0507|248 274|machine/min CPB time/m2 bsa
14P03880838T0000|0 8|Diagnosis
14P03880838T0000|44 67|captopril administration
14P03881260A0000|64 110|arginine pathway carbamoyl-phosphate synthetase
14P03882029A0000|60 76|granuloma complex
14P03882029A0000|119 128|antibodies
14P03882029A0000|131 140|components
14P03882029A0000|149 162|cat epithelium
14P03883052T0001|10 28|Magdelaine Comtesse
14P03883541A0200|3 25|H2 receptor antagonists
14P03885983A0254|39 47|Class III
14P03887085A0000|49 63|pharmaceuticals
14P03887085A0000|111 120|conditions
14P03887085A0000|168 178|CBA X C57Bl
14P03887085A0000|178 184|F1 mice
14P03887769A0093|3 6|Mean
14P03887769A0093|21 37|micrograms J/g Cr
14P03887769A0093|48 64|micrograms J/g Cr
14P03887769A0584|42 51|population
14P03887769A0584|54 70|iodine deficiency
14P03887769A0584|89 105|iodine deficiency
14P03888621A0185|20 30|hydrogenase
14P03888621A0185|39 53|protein product
14P03888621A0185|73 74|Da
14P03890486A0000|19 40|lymph node enlargement
14P03890486A0000|74 90|imaging confusion
14P03890486A0000|157 167|obstruction
14P03891766A1473|0 11|Interference
14P03891766A1473|52 56|ELISA
14P03891766A1473|93 108|latex adsorbents
14P03894482A0549|30 49|serum IgE antibodies
14P03894482A0549|58 72|soybean extract
14P03894482A0549|73 86|binding values
14P03894482A0549|125 137|control serum
14P03896991T0000|0 13|New techniques
14P03896991T0000|19 35|mass spectrometry
14P03898382A0000|16 34|subtraction imaging
14P03898382A0000|50 61|67Ga citrate
14P03898382A0000|64 68|99mTc
14P03898382A0000|137 155|radiogallium survey
14P03898382A0000|172 185|sulfur colloid
14P03904004A1577|34 58|medium energy collimation
14P03904004A1577|83 100|keV 123I photopeak
14P03904004A1577|123 142|breakthrough signals
14P03904004A1577|157 171|Compton scatter
14P03904004A1577|203 206|124I
14P03904952T0000|0 16|Nursing education
14P03904952T0000|21 39|computer obligation
14P03908196T0000|0 18|Shear bond strength
14P03908493A0246|53 78|immunoperoxidase technique
14P03910310A0666|26 38|understanding
14P03910310A0666|44 52|pathology
14P03911052A0909|14 19|DIL-CP
14P03911052A0909|39 40|CP
14P03911052A0909|43 54|CABG surgery
14P03911052A0909|78 79|CP
14P03911052A0909|102 113|CABG surgery
14P03911702A0530|74 95|microembolism syndrome
14P03911702A0530|174 183|anesthesia
14P03911702A0530|201 210|conditions
14P03911965A0513|101 112|Galphimia D6
14P03911965A0513|120 137|Galphimia dilution
14P03912247A0282|46 67|collateral circulation
14P03912247A0282|135 144|blood flow
14P03912247A0282|149 157|flap ages
14P03913522A0000|29 43|function change
14P03914875T0001|4 14|candidiasis
14P03915540A0863|14 30|gcd1-101 mutation
14P03915540A0863|71 84|GCN4-lacZ mRNA
14P03920700A0491|46 59|responsiveness
14P03920700A0491|93 105|adrenoceptors
14P03921727A0523|3 16|concentrations
14P03921727A0523|28 35|apo A-II
14P03921727A0523|37 46|abstainers
14P03921727A0523|106 113|controls
14P03922116A0197|3 14|distribution
14P03922116A0197|53 65|gamma-therapy
14P03922116A0197|91 103|gamma-therapy
14P03922116A0197|113 127|lymphadenectomy
14P03922116A0197|155 173|radiation treatment
14P03922116A0197|210 230|luc type installation
14P03922116A0197|232 252|iliac lymphadenectomy
14P03923828A1031|3 14|availability
14P03923828A1031|17 31|cryoprecipitate
14P03923828A1031|35 39|DDAVP
14P03923976T0001|0 15|Thrombophlebitis
14P03923976T0001|48 68|factor XII deficiency
14P03925712A0229|0 7|Biopsies
14P03925712A0229|43 57|enzyme activity
14P03925712A0229|73 92|transport mechanisms
14P03928357A0340|0 19|Laboratory pyrolyses
14P03928357A0340|38 41|PCBs
14P03928357A0340|65 69|PCDFs
14P03928357A0340|96 100|PCDFs
14P03928357A0340|104 108|PCDDs
14P03928442A0463|61 70|Mtase gene
14P03928442A0463|122 145|modification specificity
14P03928678T0000|36 46|contraction
14P03928678T0000|49 56|urethral
14P03929486A0309|38 41|COCM
14P03929486A0309|43 53|NYHA II-III
14P03929486A0309|58 69|sinus rhythm
14P03929486A0309|88 104|ejection fraction
14P03929486A0309|105 109|LV-EF
14P03929486A0309|169 172|PLAC
14P03929486A0309|190 191|SR
14P03929610A0268|11 20|discomfort
14P03929610A0268|35 42|patients
14P03930549A0209|32 45|centrifugation
14P03930549A0209|63 73|supernatant
14P03930549A0209|105 113|injection
14P03930549A0209|121 137|gas chromatograph
14P03930894T0000|0 6|Changes
14P03930894T0000|19 41|acetylcholine receptors
14P03930894T0000|73 82|inhalation
14P03930894T0000|96 109|administration
14P03931293A0437|19 29|stabilizers
14P03931293A0437|66 81|thermoresistance
14P03931293A0437|97 105|% albumin
14P03931797A0134|10 19|prevalence
14P03931797A0134|22 30|psoriasis
14P03933232T0000|5 14|classicism
14P03933232T0000|56 72|animal morphology
14P03933784A0420|26 38|CSF prolactin
14P03934667A0124|16 29|crsA mutations
14P03934667A0124|73 87|gene conversion
14P03934667A0124|97 122|B. subtilis plasmid pRPD11
14P03934667A0124|204 229|B. subtilis RNA polymerase
14P03935117T0000|34 66|prostaglandin E2 pharmacokinetics
14P03935375A0414|49 58|morphology
14P03935375A0414|72 83|biochemistry
14P03935375A0414|113 121|pathology
14P03935375A0414|136 138|RPN
14P03935375A0414|194 205|degeneration
14P03935375A0414|218 226|carcinoma
14P03935797A0183|60 77|sry messenger RNAs
14P03935797A0183|93 99|embryos
14P03935797A0183|184 190|regions
14P03936828T0000|33 47|B-cell lymphoma
14P03936828T0000|52 64|thyroid gland
14P03937294A0404|0 21|Plasma secretin levels
14P03937294A0404|41 54|administration
14P03937294A0404|57 73|ethanol solutions
14P03937294A0404|113 126|acid secretion
14P03937481T0001|18 30|microanalysis
14P03937481T0001|78 89|preparations
14P03939317A0352|62 72|HS promoter
14P03939317A0352|77 100|soybean HS-protein genes
14P03940426A0618|0 6|Results
14P03940426A0618|30 32|GLC
14P03940426A0618|65 75|agar medium
14P03940426A0618|116 119|Gram
14P03940426A0618|177 196|genus identification
14P03940426A0618|213 224|agar culture
14P03940733A0755|26 35|absorption
14P03940733A0755|48 56|vitamin A
14P03940733A0755|90 97|approach
14P03940733A0755|100 109|assessment
14P03940733A0755|115 127|malabsorption
14P03940818T0000|28 38|HBV carrier
14P03944212A0166|0 14|Tissue pressure
14P03944212A0166|23 35|water content
14P03944212A0166|104 116|MCA territory
14P03944212A0166|127 130|MCAO
14P03944239A0780|49 78|plasma thyroid hormone changes
14P03944239A0780|90 107|amiodarone therapy
14P03944239A0780|121 122|T4
14P03944239A0780|128 129|T4
14P03944239A0780|149 150|T3
14P03946125T0000|0 3|Drug
14P03946125T0000|7 27|nutrient interactions
14P03952387A0336|6 16|compartment
14P03952387A0336|81 93|oxyhemoglobin
14P03952387A0336|95 98|HbO2
14P03953361A0000|80 98|serial measurements
14P03953361A0000|110 124|creatine kinase
14P03953361A0000|125 126|CK
14P03953361A0000|139 140|Ca
14P03953361A0000|153 154|CK
14P03953361A0000|169 170|LA
14P03953361A0000|172 185|concentrations
14P03956647A1063|0 10|Dissolution
14P03956647A1063|21 42|%Ir microelectrode tip
14P03956647A1063|54 81|scanning electron microscopy
14P03956647A1063|82 97|charge densities
14P03956647A1063|107 121|microC/cm2 X ph
14P03956647A1063|122 126|A/cm2
14P03956647A1063|154 176|iridium microelectrodes
14P03956647A1063|230 244|microC/cm2 X ph
14P03956647A1063|246 250|A/cm2
14P03956695A0617|0 17|Cortisol excretion
14P03959045A0000|84 113|Medical College Admission Test
14P03959045A0000|112 115|MCAT
14P03963860A0137|49 52|MY-1
14P03964489A1195|18 21|PaO2
14P03964489A1195|23 26|NADH
14P03964855A0254|0 10|Angiography
14P03964855A0254|35 44|rCBF study
14P03964855A0254|83 92|angiograms
14P03965012A0163|97 110|heart diseases
14P03965012A0163|111 121|ICD A83-A84
14P03965012A0163|145 160|reference cohort
14P03965012A0163|162 179|paper mill workers
14P03966687A0000|20 35|childhood asthma
14P03966687A0000|58 62|Vance
14P03966687A0000|66 71|Taylor
14P03966687A0000|91 96|Annals
14P03966687A0000|99 105|Allergy
14P03967144T0001|0 12|Hypersplenism
14P03970191A0275|52 69|electrocorticogram
14P03970191A0275|71 74|ECoG
14P03970191A0275|89 90|DC
14P03972038A0000|16 27|trajectories
14P03972038A0000|33 50|commissural fibers
14P03972038A0000|78 80|STR
14P03972185A0137|38 55|insulin deficiency
14P03972185A0137|56 68|plasma levels
14P03972185A0137|94 106|hyperglycemia
14P03972185A0137|122 142|plasma glucose levels
14P03974790A0053|10 20|CT findings
14P03976323A0821|30 50|blood pressure change
14P03976323A0821|52 61|SCR-change
14P03977577T0000|0 23|Shoulder forearm support
14P03977603A0326|0 8|Piroxicam
14P03977603A0326|68 79|indomethacin
14P03978045A0857|45 46|0T
14P03978045A0857|48 49|0N
14P03978045A0857|74 76|VWF
14P03978045A0857|99 113|hyperreactivity
14P03978045A0857|136 142|Raynaud
14P03978045A0857|223 233|alterations
14P03978132A0108|2 15|MCCP functions
14P03978132A0108|35 52|surface reflection
14P03978132A0108|53 77|photoacceptor sensitivity
14P03978132A0108|103 121|distribution curves
14P03979084A1019|85 88|IMPK
14P03979084A1019|91 94|IBPK
14P03980386A0000|38 48|angiotensin
14P03980386A0000|51 58|infusion
14P03980386A0000|61 72|distribution
14P03980386A0000|75 84|blood flow
14P03980386A0000|104 117|perfusion lung
14P03981421A0246|1 9|flow rate
14P03981421A0246|43 50|receptor
14P03981421A0246|52 57|volume
14P03981421A0246|76 82|results
14P03981640A0168|21 24|ends
14P03981640A0168|46 50|mRNAs
14P03981952T0000|39 56|chloride titrators
14P03981952T0000|78 88|salt intake
14P03982288T0000|0 14|Doctor Berglund
14P03982288T0000|28 41|union pitfalls
14P03984683A0000|5 14|appearance
14P03984683A0000|17 27|hemiparesis
14P03984683A0000|30 39|hemiplegia
14P03984683A0000|57 66|spasticity
14P03984683A0000|81 95|stroke patients
14P03985849A0221|14 27|rhinosinusitis
14P03985849A0221|86 99|rhinosinusitis
14P03985849A0221|126 129|CVID
14P03985849A0221|196 209|IgA deficiency
14P03987818A0440|20 23|AP-A
14P03987818A0440|63 75|heart failure
14P03987857A0733|28 39|floor region
14P03987857A0733|86 94|mass unit
14P03987857A0733|108 116|intensity
14P03987857A0733|119 129|stimulation
14P03988001A0227|21 47|rat blood chloroform levels
14P03988001A0227|89 92|ClO2
14P03989827T0000|14 31|lactase phenotypes
14P03989827T0000|33 47|Aymara children
14P03992022A0330|0 9|Activities
14P03992022A0330|84 100|TMO N-demethylase
14P03992022A0330|103 130|aniline hydroxylase activity
14P03992022A0330|223 239|enzyme activities
14P03995513T0000|0 10|Doxorubicin
14P03995513T0000|39 54|cyclophosphamide
14P03995513T0000|95 108|leiomyosarcoma
14P03997467A0000|20 38|antagonist naloxone
14P03998071T0000|0 24|Electrochemical detection
14P03998813A0406|12 22|experiments
14P03998813A0406|78 85|activity
14P03998813A0406|95 102|ontogeny
14P03998813A0406|105 120|frequency tuning
14P03999219A0463|0 13|Ultrastructure
14P03999219A0463|85 99|alum irrigation
14P03999219A0463|181 195|alum irrigation
14P04000347A0442|112 114|BEN
14P04000347A0442|140 142|BEN
14P04000347A0442|150 160|individuals
14P04001413A0093|93 106|breath-holding
14P04001490T0001|3 16|POEMS syndrome
14P04001490T0001|17 30|Polyneuropathy
14P04001490T0001|32 43|Organomegaly
14P04001490T0001|45 58|Endocrinopathy
14P04002131A0506|7 23|disease remission
14P04002131A0506|43 55|GAG secretion
14P04002131A0506|75 90|hyperheparinuria
14P04002667A0181|56 70|tumor diameters
14P04002667A0181|95 106|localization
14P04002667A0181|109 119|lung tissue
14P04002667A0181|132 140|cm tumors
14P04002667A0181|150 164|lung parenchyma
14P04004168A0000|38 73|triosephosphate isomerase deficiency
14P04004168A0000|186 209|motor neuron involvement
14P04005190A1288|23 33|PCA content
14P04011338A0620|7 14|patients
14P04011338A0620|30 35|degree
14P04011338A0620|38 48|steatorrhea
14P04011338A0620|52 59|decrease
14P04011338A0620|91 102|relationship
14P04011338A0620|143 148|extent
14P04011338A0620|159 167|acid loss
14P04011338A0620|169 175|placebo
14P04011338A0620|182 189|decrease
14P04011338A0620|202 208|taurine
14P04011466T0000|6 14|diameters
14P04011466T0000|17 23|infants
14P04011466T0000|32 39|children
14P04013576A0981|10 22|investigation
14P04013576A0981|41 52|distribution
14P04013576A0981|74 97|Leptospira phospholipids
14P04013576A0981|113 124|distribution
14P04013576A0981|127 136|Leptospira
14P04013576A0981|194 205|carbon atoms
14P04013576A0981|223 235|phospholipids
14P04013604A0412|77 89|patient-years
14P04013604A0412|92 114|slow-release tablet use
14P04014833A0400|0 13|Hydrocortisone
14P04014833A0400|77 93|blood lymphocytes
14P04014833A0400|95 112|phytohemagglutinin
14P04014861A0000|9 19|feasibility
14P04014861A0000|105 124|superoxide dismutase
14P04014861A0000|125 127|SOD
14P04014861A0000|150 164|oxygen toxicity
14P04015988T0000|0 19|Marrow cell necrosis
14P04015988T0000|20 35|anorexia nervosa
14P04017295A0139|3 12|comparison
14P04017295A0139|25 31|heparin
14P04017295A0139|47 54|dialyses
14P04017295A0139|64 71|patients
14P04018444A0000|63 84|cholesterol gallstones
14P04019066A0000|13 28|field potentials
14P04019066A0000|79 81|MRF
14P04019066A0000|96 97|CG
14P04019066A0000|122 124|SCX
14P04021281T0001|0 13|Ultrastructure
14P04021281T0001|19 30|heart muscle
14P04021305A0530|15 30|desympathization
14P04021305A0530|41 51|development
14P04021305A0530|54 69|hyper-reactivity
14P04021305A0530|79 88|pacemakers
14P04021305A0530|91 103|noradrenaline
14P04021305A0530|141 150|regulation
14P04021305A0530|186 199|catecholamines
14P04021431A0000|0 3|OODG
14P04021431A0000|51 62|pulse curves
14P04021431A0000|74 86|determination
14P04021431A0000|89 103|blood pressures
14P04021431A0000|161 175|blood pressures
14P04021437A0000|5 14|infections
14P04021437A0000|71 86|ear dysfunctions
14P04024685A0650|18 27|parameters
14P04024685A0650|55 62|RS index
14P04024685A0650|108 110|EDD
14P04024685A0650|150 151|HV
14P04024685A0650|194 196|EDV
14P04024685A0650|238 240|RBV
14P04025178A0126|81 82|LV
14P04025178A0126|97 108|volume index
14P04025178A0126|109 112|EDVI
14P04025179A0955|8 13|adults
14P04025179A0955|25 33|variables
14P04026903A0512|0 10|Polysorbate
14P04026903A0512|41 55|relaxant effect
14P04026903A0512|63 78|guinea pig ileum
14P04026903A0512|113 124|contractions
14P04026903A0512|134 146|acetylcholine
14P04026903A0512|165 183|5-hydroxytryptamine
14P04026972T0000|10 34|alcohol reaction profiles
14P04027182T0000|0 7|Vitiligo
14P04027182T0000|10 26|diabetes mellitus
14P04028871A0133|3 18|pharmacokinetics
14P04028871A0133|25 36|tetracycline
14P04028871A0133|61 73|blister fluid
14P04028871A0133|106 119|mg lymecycline
14P04028871A0133|124 137|mg doxycycline
14P04031488A1091|13 23|correlation
14P04031488A1091|46 55|conception
14P04031488A1091|58 75|brain localization
14P04031488A1091|95 103|syndromes
14P04032268A0358|7 17|UV detector
14P04032268A0358|47 48|EC
14P04032268A0358|87 102|Ag/AgCl/3 M NaCl
14P04032349A0000|44 59|graft thromboses
14P04032349A0000|134 142|Urokinase
14P04032349A0000|148 160|units/kg/hour
14P04032349A0000|165 179|Lys Plasminogen
14P04032716A0299|3 22|mean transfer ratios
14P04032716A0299|56 68|concentration
14P04032716A0299|109 122|transfer ratio
14P04032716A0299|190 199|myometrium
14P04033402A1112|38 67|HDL-cholesterol concentrations
14P04033402A1112|73 100|HDL2-cholesterol subfraction
14P04033402A1112|127 154|triglyceride lipase activity
14P04034220A0205|81 93|H. influenzae
14P04034220A0205|112 129|tolerance Cefaclor
14P04034220A0205|165 180|tract infections
14P04034666T0000|5 28|extremity weight bearing
14P04034666T0000|39 57|standing conditions
14P04036838A0918|47 51|RV/LV
14P04036838A0918|60 74|pressure ratios
14P04036838A0918|126 145|pressure differences
14P04037809A0964|38 44|KW-2083
14P04038454A0984|22 41|plasma retinol level
14P04038454A0984|57 59|RBP
14P04038454A0984|98 112|micrograms dl-1
14P04038454A0984|141 157|cancer recurrence
14P04038454A0984|204 218|micrograms dl-1
14P04038702A0768|45 53|tethering
14P04038702A0768|97 106|experience
14P04038702A0768|190 200|disruptions
14P04038702A0768|272 294|cortisol concentrations
14P04039109A0139|44 55|fluid medium
14P04039109A0139|94 101|diameter
14P04039109A0139|119 131|power density
14P04039109A0139|137 141|W/cm2
14P04039307A0613|7 18|progesterone
14P04039307A0613|77 92|treatment groups
14P04039439A0000|45 57|ppm manganese
14P04039439A0000|58 59|Mn
14P04039439A0000|74 88|manganese oxide
14P04039439A0000|89 93|Mn3O4
14P04039439A0842|67 80|Mn3O4 exposure
14P04039525A0475|0 5|Plasma
14P04039525A0475|9 38|bladder platinum concentration
14P04039525A0475|70 72|DDP
14P04039525A0475|142 156|blood chemistry
14P04039525A0475|207 209|DDP
14P04039667T0000|28 47|Walker carcinoma-256
14P04039667T0000|49 67|Sprague-Dawley rats
14P04039744A0141|44 52|D mothers
14P04039744A0141|87 96|supplement
14P04039744A0141|100 118|i.u. vitamin D3/day
14P04039744A0141|135 143|lactation
14P04040083A0000|0 10|Rabbit eyes
14P04040307A0145|81 89|NE levels
14P04040339T0001|0 17|Monitoring changes
14P04040339T0001|105 111|Pre-par
14P04040858A0000|5 13|September
14P04040858A0000|20 23|June
14P04041307A0614|24 41|calcium antagonist
14P04041307A0614|42 50|diltiazem
14P04041307A0614|73 82|isoflurane
14P04041346T0000|16 26|arrhythmias
14P04041346T0000|39 47|quinidine
14P04043489A0648|0 6|Visidex
14P04048245A0331|0 8|Treatment
14P04048245A0331|13 29|oxyphenylbutazone
14P04048245A0331|33 46|hydrocortisone
14P04048245A0331|71 86|serum CPN levels
14P04050771A0474|3 5|Cox
14P04050771A0474|18 30|hazards model
14P04050821A0531|16 25|mechanisms
14P04050821A0531|66 78|oxygen demand
14P04051521T0001|0 7|Duration
14P04051521T0001|36 50|cancer patients
14P04051521T0001|78 80|MTX
14P04051521T0001|84 87|5-FU
14P04052919A0205|20 41|progesterone secretion
14P04052919A0205|70 81|luteal phase
14P04052919A0205|93 101|frequency
14P04052919A0205|166 184|progesterone levels
14P04052919A0205|227 236|thresholds
14P04052919A0205|253 263|measurement
14P04052919A0205|266 277|progesterone
14P04052919A0205|318 326|indicator
14P04052919A0205|329 337|ovulation
14P04052919A0205|340 348|threshold
14P04055593A0523|23 32|processing
14P04055593A0523|38 39|N2
14P04055593A0523|43 54|flow signals
14P04055593A0523|81 92|compensation
14P04055593A0523|97 107|corrections
14P04055593A0523|132 146|gas composition
14P04055593A0523|149 159|temperature
14P04056218A0463|51 52|L1
14P04056218A0463|54 55|L2
14P04056256A0416|0 19|Histamine reactivity
14P04056256A0416|50 67|nifedipine aerosol
14P04056256A0416|95 107|concentration
14P04056256A0416|133 150|airway conductance
14P04058985A0000|20 29|vitamin B6
14P04058985A0000|83 98|plasma prolactin
14P04061342A0512|30 38|elevation
14P04061342A0512|61 76|min postexercise
14P04062128T0028|20 68|Health Consensus Development Conference Statement
14P04063732A0509|2 9|controls
14P04063732A0509|20 25|output
14P04063732A0509|33 39|conduit
14P04063732A0509|59 66|activity
14P04066194A0163|0 18|Greater attenuation
14P04066194A0163|23 27|N1-P2
14P04066194A0163|31 51|baseline-P2 amplitude
14P04066194A0163|82 95|probe stimulus
14P04066194A0163|180 202|stimulation arrangement
14P04066274A0265|77 89|parotidectomy
14P04066274A0265|91 96|T.C.P.
14P04066274A0265|108 111|S.P.
14P04066274A0265|124 125|En
14P04067540A0413|3 13|comparisons
14P04067540A0413|48 59|perpetrators
14P04067540A0413|100 106|victims
14P04067540A0413|143 150|ex-lover
14P04067540A0413|195 206|suicide note
14P04067540A0413|214 220|weekend
14P04067540A0413|279 285|victims
14P04068663A0452|21 35|mouse CRF-flora
14P04068663A0452|86 95|parameters
14P04068663A0452|107 119|unsuitability
14P04068663A0452|122 136|mouse CRF flora
14P04068774A1292|7 19|relationships
14P04068774A1292|31 32|Zn
14P04068774A1292|35 36|Mg
14P04068969A0300|0 4|L3-L4
14P04069756T0025|0 8|Diagnosis
14P04069756T0025|31 49|leukoencephalopathy
14P04070725A0442|0 13|Component P100
14P04071063A0863|10 20|differences
14P04071063A0863|45 59|platelet counts
14P04071063A0863|79 95|fibrinogen levels
14P04073848T0000|0 6|Failure
14P04073848T0000|9 30|stapedius reflexometry
14P04073848T0000|46 62|myasthenia gravis
14P04074214A0000|0 6|Factors
14P04074214A0000|18 38|semen characteristics
14P04075021T0000|1 3|14C
14P04075021T0000|6 24|beta-phenethylamine
14P04075021T0000|46 59|administration
14P04075021T0000|97 124|monoamine oxidase inhibitors
14P04075061A0355|3 9|runners
14P04075061A0355|16 20|total
14P04075061A0355|29 33|water
14P04079738A0677|15 24|energy use
14P04079738A0677|32 33|SD
14P04079738A0677|57 66|kJ X min-1
14P04079738A0677|124 133|degrees C.
14P04081425T0016|8 14|aspects
14P04081425T0016|18 24|therapy
14P04082267A0720|19 28|incubation
14P04082267A0720|37 45|degrees C
14P04082267A0720|50 58|degrees C
14P04082267A0720|59 60|Ae
14P04082592T0000|0 16|Blood eosinophils
14P04082592T0000|30 35|Taenia
14P04084607A0663|3 14|imino proton
14P04084607A0663|16 17|T3
14P04084607A0663|23 27|O6meG
14P04084607A0663|39 40|G3
14P04084607A0663|46 50|O6meG
14P04084607A0663|90 106|modification site
14P04084607A0663|158 170|imino protons
14P04084607A0663|172 194|Watson-Crick base pairs
14P04084896A0569|3 16|recommendation
14P04084896A0569|99 121|intervention strategies
15P04085589A0264a|28 42|secretor status
15P04085589A0264a|60 82|spirometry measurements
15P04085589A0264a|94 114|serum lysozyme levels
15P04085589A0264a|133 150|tract colonization
15P04085589A0264b|28 42|secretor status
15P04085589A0264b|60 82|spirometry measurements
15P04085589A0264b|94 114|serum lysozyme levels
15P04085589A0264b|133 150|tract colonization
14P04086403A1016|0 4|Gains
14P04086403A1016|35 49|feed conversion
14P04086403A1016|89 96|% AS-VFA
14P04086403A1016|115 129|feed conversion
14P04086657T0000|19 29|development
14P04086993T0000|0 4|Daily
14P04086993T0000|16 26|rhythmicity
14P04086993T0000|32 42|methylation
14P04086993T0000|58 66|compounds
14P04086993T0000|109 118|conditions
14P04088233A0309|3 14|transit time
14P04088396A0145|8 28|patients grades 1-2-3
14P04088396A0145|68 78|abnormality
14P04088733T0001|0 7|Activity
14P04088733T0001|10 24|acid hydrolases
14P04088733T0001|36 51|blood leukocytes
14P04088936T0001|46 75|plasminogen activator activity
14P04088936T0001|88 103|thrombophlebitis
14P04093211A0560|51 59|attitudes
14P04093211A0560|63 74|orientations
14P04101003T0001|0 8|Relations
14P04101003T0001|34 41|activity
14P04101003T0001|62 69|activity
14P04102280T0000|0 8|Treatment
14P04102280T0000|11 15|Paget
14P04103248T0000|0 10|Improvement
14P04103248T0000|16 26|CRT display
14P04113011T0000|3 17|desensitization
14P04113011T0000|22 38|ragweed hay fever
14P04114211T0000|5 13|excretion
14P04114211T0000|16 29|sulphadimidine
14P04115870T0000|0 10|Experiences
14P04115870T0000|46 64|Urat-I lithotriptor
14P04123217T0000|0 8|Formation
14P04123217T0000|36 57|Cryptococcus laurentii
14P04123662T0000|0 9|Evaluation
14P04123662T0000|12 27|thyroid function
14P04138224T0095|12 26|tissue emulsion
14P04138224T0095|49 62|gamma-globulin
14P04138224T0095|68 82|blood clearance
14P04139081T0001|4 13|antibodies
14P04139081T0001|30 37|patients
14P04139943T0001|0 12|Demonstration
14P04139943T0001|33 48|guinea pig organ
14P04139943T0001|49 53|Corti
14P04139943T0001|78 92|silver staining
14P04140567T0001|0 19|Histamine metabolism
14P04143528A0394|26 37|nomenclature
14P04145244T0000|0 9|Relaxation
14P04152725T0001|0 6|Studies
14P04160980T0000|12 18|control
14P04160980T0000|29 39|circulation
14P04164595T0020|0 7|Evidence
14P04164669T0000|24 38|kinin formation
14P04172166T0000|0 12|Poliomyelitis
14P04175007T0001|5 11|problem
14P04175007T0001|17 27|stimulation
14P04175007T0001|63 69|animals
14P04175007T0001|105 115|antibiotics
14P04176249T0001|0 9|Assessment
14P04176268T0000|0 14|Aluminium resin
14P04176268T0000|34 45|hyperkalamia
14P04176625T0000|0 4|Value
14P04176625T0000|10 12|EMG
14P04176625T0000|30 43|cardiomyopathy
14P04179445T0036|0 1|D.
14P04189158T0000|0 9|Prevention
14P04189158T0000|20 35|Rh sensitization
14P04194466T0000|0 15|Serotonin levels
14P04194466T0000|17 37|infant hypothyroidism
14P04196986T0000|13 29|fluid transferrin
14P04196986T0000|48 56|disorders
14P04213917T0001|13 27|D-penicillamine
14P04214345T0000|22 44|serum IgG concentration
14P04214345T0000|56 72|xylose absorption
14P04214345T0000|74 95|Zambian African adults
14P04226360T0001|0 8|Disorders
14P04226360T0001|11 27|platelet function
14P04239041T0045|11 25|anticonvulsants
14P04239041T0045|54 59|ATPase
14P04246054T0028|30 60|rabbit-anti-lymphocyte globulin
14P04246054T0028|61 65|RAMLG
14P04246054T0028|106 127|incubation temperature
14P04247472T0001|37 45|mountains
14P04247472T0001|48 56|Kirghizia
14P04247966T0000|0 8|Lactation
14P04247966T0000|25 48|protein maintenance diet
14P04262268T0001|0 6|Studies
14P04262268T0001|32 43|ear ossicles
14P04263748T0042|21 26|review
14P04281856T0001|0 2|Age
14P04281856T0001|42 67|Ornithodoros tatarovski Ol
14P04282315T0001|0 12|Sensitization
14P04282315T0001|15 29|hyperlactatemia
14P04284435T0000|0 9|Vitamin D3
14P04284435T0000|12 29|calcium absorption
14P04289156T0000|3 11|incidence
14P04289156T0000|14 20|tumours
14P04289156T0000|28 35|chickens
14P04291759T0048|0 17|Laboratory aspects
14P04295031T0062|16 25|guinea pig
14P04305850T0000|0 8|Androgens
14P04308979T0000|0 5|Effect
14P04308979T0000|20 32|time interval
14P04308979T0000|52 54|BCG
14P04308979T0000|58 68|quartz dust
14P04308979T0000|70 82|translocation
14P04308979T0000|85 95|quartz dust
14P04308979T0000|122 132|lymph nodes
14P04311951T0001|43 53|association
14P04311951T0001|61 73|instillations
14P04315233T0128|21 30|experiment
14P04316696T0001|0 5|Enzyme
14P04321861T0001|8 39|glutathione reductase deficiency
14P04321861T0001|51 71|glutathione synthesis
14P04323641T0000|0 6|Studies
14P04323641T0000|9 27|swine enteroviruses
14P04325736T0001|0 12|Serodiagnosis
14P04325736T0001|27 41|laboratory mice
14P04328746T0073|0 16|Ultrasound effect
14P04328746T0073|21 47|cytochrome oxidase activity
14P04335965T0000|0 9|Metastasis
14P04335965T0000|12 26|colon carcinoma
14P04350410T0000|0 6|Genesis
14P04350410T0000|35 48|administration
14P04350410T0000|51 58|Cloforex
14P04364369T0000|0 21|Pre-beta-1 lipoprotein
14P04369884T0000|0 9|Conditions
14P04369884T0000|61 63|CSF
14P04371279T0000|0 6|Absence
14P04371279T0000|9 25|action potentials
14P04371279T0000|35 47|muscle fibres
14P04371279T0000|58 72|botulinum toxin
14P04377003A0000|48 68|polyamines putrescine
14P04377003A0000|111 113|CSF
14P04377003A0000|131 141|CSF samples
14P04377003A0000|180 182|CNS
14P04377328T0027|0 1|I.
14P04385060T0000|0 9|Disulfiram
14P04387103T0000|0 8|Particles
14P04387103T0000|19 29|microbodies
14P04392584T0000|34 51|hemisphere monkeys
14P04394290T0000|24 32|receptors
14P04394290T0000|38 43|rectum
14P04394290T0000|63 71|sphincter
14P04407649T0000|63 85|99mTc brainscintigraphy
14P04418687T0000|0 6|Effects
14P04418687T0000|20 34|glucocorticoids
14P04418687T0000|47 57|development
14P04423347T0001|0 5|Copper
14P04423347T0001|9 29|ceruloplasmin content
14P04428800T0001|0 5|Effect
14P04428800T0001|36 38|LAP
14P04428800T0001|42 53|GPT activity
14P04428981T0000|0 7|Kinetics
14P04428981T0000|10 27|calcium metabolism
14P04429269T0000|5 13|transport
14P04429269T0000|36 44|simulants
14P04429269T0000|55 61|systems
14P04437406T0000|36 57|reflection coefficient
14P04445874T0001|0 8|Pathology
14P04446923T0001|42 62|Platynothrus peltifer
14P04460692T0000|16 41|laboratory animal medicine
14P04468264T0053|0 7|Problems
14P04468264T0053|29 42|anesthesiology
14P04482661T0001|17 28|nursing care
14P04482661T0001|42 56|decubitus ulcer
14P04482661T0001|81 95|buckwheat chaff
14P04487835T0001|2 8|parents
14P04487920T0001|7 36|Icelandic Red Cross activities
14P04488232T0001|0 6|Effects
14P04488271T0001|0 8|Treatment
14P04488271T0001|23 39|diabetes mellitus
14P04495034T0000|12 24|methylbenzene
14P04495034T0000|49 68|Ancylostomum caninum
14P04506738T0000|0 8|Junctions
14P04506738T0000|31 42|enamel organ
14P04510102T0000|0 17|Electrocardiograms
14P04511139T0001|0 9|Composites
14P04511139T0001|12 32|restoration materials
14P04512496T0000|0 6|Hodgkin
14P04515631T0000|0 4|Value
14P04515631T0000|7 15|Normotest
14P04515631T0000|49 62|liver function
14P04518624T0000|0 21|Glutathione peroxidase
14P04524081T0000|53 79|aluminum chloride solutions
14P04524081T0000|80 108|tissue displacement materials
14P04533208T0083|0 6|Changes
14P04536964T0000|16 25|H ion flux
14P04536964T0000|27 56|H ion permeability coefficient
14P04536964T0000|56 74|bullfrog toe muscle
14P04539552T0001|22 27|SF-837
14P04543036T0001|0 9|Directives
14P04544430T0001|0 10|Proceedings
14P04544430T0001|68 80|heart defects
14P04544704T0001|0 5|Method
14P04544704T0001|8 16|synthesis
14P04546974T0000|0 9|Variations
14P04546974T0000|42 58|bundle recordings
14P04547933T0000|13 28|fibril formation
14P04547933T0000|63 70|junction
14P04548483T0001|0 14|Blood platelets
14P04548483T0001|15 33|coagulation factors
14P04548483T0001|83 96|rhesus monkeys
14P04551650T0001|0 13|Cell viability
14P04552263T0000|32 35|R.N.
14P04562038T0001|7 19|investigation
14P04562038T0001|36 44|influence
14P04562038T0001|62 72|lymphocytes
14P04563045T0000|0 6|1,3-bis
14P04563045T0000|8 20|2-chloroethyl
14P04563045T0000|50 61|nitrosoureas
14P04563045T0000|64 79|cancer treatment
14P04578686T0000|0 11|Pneumothorax
14P04578686T0000|42 59|transplant patient
14P04579436T0000|39 59|Brevibacterium linens
14P04580044T0047|8 20|relationships
14P04580044T0047|27 43|development phase
14P04583791T0000|28 32|Lagos
14P04583791T0000|34 40|Nigeria
14P04598670T0000|5 21|graft irradiation
14P04598670T0000|47 63|immunosuppression
14P04600603T0001|0 5|Letter
14P04613073T0001|0 3|Role
14P04613073T0001|36 53|Shigella virulence
14P04615525T0001|31 39|formation
14P04615525T0001|42 56|transplantation
14P04615525T0001|74 81|immunity
14P04615828T0001|14 39|colonel prof. e.cerny m.d.
14P04621188T0000|0 9|Morphology
14P04621188T0000|28 45|Klebsiella bacilli
14P04622430T0000|43 55|Rhesus monkey
14P04624863T0001|0 8|Mechanism
14P04624863T0001|11 23|immunogenesis
14P04624863T0001|26 36|vaccination
14P04624863T0001|72 82|salmonellae
14P04627477T0001|0 17|Resistance pattern
14P04627477T0001|19 44|Mycobacterium tuberculosis
14P04632967T0000|42 53|patas monkey
14P04632967T0000|67 80|administration
14P04632967T0000|83 99|aminorex fumarate
14P04638365T0001|0 5|Effect
14P04640155T0045|0 8|Sex ratio
14P04645078T0001|12 20|processes
14P04645078T0001|26 37|cervix uteri
14P04646045T0001|27 35|esophagus
14P04653144T0000|0 15|General formulae
14P04653144T0000|28 39|heritability
14P04654249T0000|0 10|Measurement
14P04654249T0000|43 53|stimulation
14P04656185T0000|0 25|Glucose disappearance rate
14P04656185T0000|36 51|plasma nutrients
14P04661961T0001|36 46|bone marrow
14P04661961T0001|65 71|hamster
14P04676734T0000|3 14|relationship
14P04676734T0000|48 60|plasma levels
14P04676734T0000|62 76|corticosteroids
14P04679438T0001|10 15|effect
14P04679438T0001|28 32|heviz
14P04679807T0000|8 25|acid concentration
14P04679807T0000|39 58|breathalyzer ampules
14P04704137T0001|0 3|Role
14P04704137T0001|31 41|prophylaxis
14P04704186T0000|0 13|Range behavior
14P04704186T0000|15 22|Hereford
14P04704186T0000|24 31|Hereford
14P04704186T0000|33 40|Holstein
14P04704186T0000|44 51|Holstein
14P04712626T0000|0 20|Chemical constituents
14P04712626T0000|65 89|Swertia chirata Buch.-Ham
14P04718233T0000|0 26|Methyl mercury intoxication
14P04727344T0000|0 17|Microdetermination
14P04727344T0000|50 63|isotope method
14P04729063T0000|62 68|Koreans
14P04730467T0000|0 6|Effects
14P04730467T0000|51 67|enzyme activities
14P04730467T0000|69 88|epiphyseal cartilage
14P04733391T0000|0 27|Metal coordination compounds
14P04746559T0053|0 9|Estimation
14P04746559T0053|12 31|renin secretion rate
14P04746559T0053|70 86|vein renin levels
14P04752455T0000|0 19|Disability insurance
14P04753073T0000|0 5|Choice
14P04753286T0000|0 10|Suppression
14P04753286T0000|13 23|food intake
14P04757217T0000|0 6|Studies
14P04757217T0000|23 26|LP-X
14P04757217T0000|50 64|LCAT deficiency
14P04758799T0000|0 11|Pneumothorax
14P04758799T0000|32 48|steroid treatment
14P04759722T0000|0 16|Polycythemia-1973
14P04760826T0000|17 33|Vietnam returnees
14P04760826T0000|36 49|undergraduates
14P04764049T0001|16 31|nephronophthisis
14P04766888T0000|5 19|heparin therapy
14P04766888T0000|40 54|meningococcemia
14P04778129T0000|0 17|9,11-Seco steroids
14P04778129T0000|28 51|estradiol 3-methyl ether
14P04782788T0001|13 24|examinations
14P04782788T0001|46 65|kidney insufficiency
14P04784432T0001|0 12|Possibilities
14P04784432T0001|25 38|administration
14P04787472T0001|0 5|Change
14P04787716T0000|0 11|Observations
14P04787716T0000|35 56|Chrysops caecutiens L.
14P04788701T0001|0 10|Combination
14P04789916T0001|0 7|Analysis
14P04789916T0001|10 24|clearance curve
14P04791420T0000|0 10|Proceedings
14P04791420T0000|12 18|Barrels
14P04794218T0001|11 18|K agents
14P04796997T0000|6 17|reproduction
14P04796997T0000|46 72|medroxyprogesterone acetate
14P04801663T0049|27 36|properties
14P04803629T0001|13 18|system
14P04803629T0001|34 40|allergy
14P04810131T0000|7 34|Aryl hydrocarbon hydroxylase
14P04813394T0000|0 9|Evaluation
14P04813394T0000|12 30|1,10-phenanthroline
14P04813394T0000|50 68|acid determinations
14P04820791T0001|39 48|conditions
14P04820791T0001|56 63|diseases
14P04820791T0001|66 73|children
14P04824747T0000|0 16|Nonteratogenicity
14P04826272T0074|0 2|VII
14P04828587T0000|0 8|Isolation
14P04837183T0000|0 11|Observations
14P04837183T0000|46 57|hypergravity
14P04839176T0001|23 31|SHF field
14P04839176T0001|36 59|blood coagulation system
14P04843031T0000|11 40|galactosyltransferase activity
14P04852635T0000|0 3|Lack
14P04852635T0000|17 44|appetite stimulant pizotifen
14P04852635T0000|44 45|BC
14P04852635T0000|67 87|isonicotinylhydrazine
14P04863895T0000|0 11|Relationship
14P04863895T0000|86 88|CRD
14P04871589T0001|7 14|solution
14P04871589T0001|27 35|ankylosis
14P04878680T0000|0 6|Effects
14P04878680T0000|17 25|radiation
14P04878680T0000|49 58|oropharynx
14P04884060T0000|3 23|Twentieth Anniversary
14P04884060T0000|28 53|Pomeranian Medical Academy
14P04890336T0001|29 45|Wassermann reagin
14P04890336T0001|84 87|RPCF
14P04890336T0001|91 104|FTA antibodies
14P04909355T0000|15 29|Actinomycetales
14P04911925T0001|0 33|Electrocardiographic QRS complexes
14P04919613T0001|0 4|Study
14P04919613T0001|34 59|immunofluorescence technic
14P04919613T0001|61 77|collagen diseases
14P04921762T0000|7 18|preservation
14P04925617T0000|6 8|bar
14P04941419T0000|0 27|Yusuf Dawood Docrat L.R.C.P.
14P04941951T0000|0 2|Dr.
14P04942414T0000|30 43|5-fluorouracil
14P04947347T0000|0 12|Spleen weight
14P04947347T0000|24 36|tumour growth
14P04947347T0000|41 59|homograft rejection
14P04948325T0000|0 8|Isolation
14P04948325T0000|11 17|Proteus
14P04948325T0000|26 30|MC-63
14P04948325T0000|69 83|Crocker sarcoma
14P04948325T0000|89 105|Ehrlich carcinoma
14P04959816T0000|19 27|detection
14P04959816T0000|34 42|component
14P04967824T0000|0 6|Effects
14P04967824T0000|9 19|temperature
14P04967824T0000|38 54|melanin synthesis
14P04970131T0001|4 21|reflexions apropos
14P04970918T0069|0 9|LA-3848-MS
14P04973523T0000|14 20|studies
14P04973523T0000|33 40|antigens
14P04975676T0000|26 36|alterations
14P04975676T0000|58 76|allotransplantation
14P04976988T0000|0 12|Heterogeneity
14P04989251T0000|0 7|Analysis
14P04989251T0000|10 24|corticosteroids
14P04990556T0000|0 11|Reactivities
14P04992478T0000|0 17|Plasma histaminase
14P04992478T0000|70 83|administration
14P04999086T0001|46 53|analyzer
14P04999086T0001|69 79|ontogenesis
14P04999086T0001|87 93|monkeys
14P05000171T0000|41 62|horseradish peroxidase
14P05000171T0000|92 114|toad bladder epithelium
14P05005311T0000|0 13|Immunogenicity
14P05005311T0000|23 34|mycobacteria
14P05005311T0000|62 77|cross-protection
14P05012220T0000|8 17|experience
14P05012220T0000|31 45|proctocolectomy
14P05015678T0000|17 27|tautomerism
14P05015678T0000|30 39|porphyrins
14P05020660T0000|0 6|Factors
14P05020660T0000|31 42|phagocytosis
14P05020660T0000|45 58|chlorpromazine
14P05021912T0000|16 26|sensitivity
14P05021912T0000|67 76|pigeon eye
14P05025918T0000|0 10|Angiography
14P05027295T0034|0 13|Cholinesterase
14P05027799T0000|0 17|Sodium restriction
14P05028628T0001|23 34|examinations
14P05028628T0001|37 53|occlusion disease
14P05031074T0001|0 18|Serum lipid changes
14P05031074T0001|41 62|calcium administration
14P05031659T0000|21 31|candidiasis
14P05031659T0000|36 50|transfer factor
14P05034373T0000|24 53|function oxidase enzyme system
14P05045351T0000|8 16|breathing
14P05045351T0000|34 40|infants
14P05049711T0000|7 20|session report
14P05060388T0000|17 23|studies
14P05060388T0000|36 41|tumors
14P05065548T0075|19 38|Dryopteris polylepis
14P05066316T0001|0 7|Relation
14P05066316T0001|43 53|composition
14P05066316T0001|80 95|aluminosilicates
14P05068271T0000|0 8|Influence
14P05068271T0000|24 36|VMA excretion
14P05075857T0000|0 30|Oscilloscope triggering circuit
14P05081814T0000|0 10|Derivatives
14P05083872T0000|23 39|training programs
14P05083872T0000|41 56|speech pathology
14P05087496T0000|8 15|arteries
14P05091970T0000|9 14|agents
14P05093030T0001|0 9|Separation
14P05093030T0001|68 94|medium-tension intophoresis
14P05093030T0001|97 120|partition chromatography
14P05095988T0001|37 51|system injuries
14P05101762T0000|0 13|Spasmus nutans
14P05110049T0001|29 35|therapy
14P05110049T0001|38 48|scleroderma
14P05114515T0000|15 28|enzyme release
14P05114515T0000|34 46|normalization
14P05114515T0000|72 84|polyarthritis
14P05119546T0001|0 8|Treatment
14P05120197T0000|12 23|pancreatitis
14P05123884T0000|21 42|4-chlorophenoxyacetate
14P05124707T0001|0 7|Dynamics
14P05124707T0001|10 22|hospital stay
14P05124707T0001|30 43|ulcer patients
14P05124972T0042|0 1|I.
14P05128149T0001|0 17|Surgical treatment
14P05132558T0000|55 82|monoamine oxidase inhibitors
14P05133723T0000|0 5|Effect
14P05133723T0000|20 34|gluconeogenesis
14P05135168T0000|0 12|New alkaloids
14P05135168T0000|22 43|Erythrophleum ivorense
14P05138738T0001|7 22|M hemoglobinosis
14P05145925T0000|54 62|potential
14P05145925T0000|73 84|spleen cells
14P05152314T0001|25 46|gas dilution indicator
14P05154132T0000|19 25|sources
14P05154132T0000|28 35|nitrogen
14P05162342T0001|17 25|childhood
14P05170106T0034|0 6|Results
14P05170106T0034|62 80|enzyme preparations
14P05170106T0034|90 101|chymotrypsin
14P05170106T0034|129 130|NF
14P05172320T0001|0 6|Studies
14P05172320T0001|53 61|reference
14P05172320T0001|64 75|interdigital
14P05172970T0001|12 22|disablement
14P05172970T0001|37 48|tuberculosis
14P05172970T0001|64 71|analysis
14P05172970T0001|106 111|Gdansk
14P05174753T0001|13 22|dysostosis
14P05177935T0001|0 8|Proposals
14P05177935T0001|11 23|authorization
14P05203499T0001|19 31|scintillation
14P05203499T0001|48 50|BSP
14P05203499T0001|69 81|thyroid gland
14P05203499T0001|112 119|131-I-RB
14P05210791T0001|0 8|Pneumonia
14P05253274T0001|0 11|Osteosarcoma
14P05253274T0001|20 34|3,4-benzopyrene
14P05274128T0001|12 22|glucosamine
14P05274128T0001|26 38|galactosamine
14P05274526T0000|0 6|Relapse
14P05276380T0000|0 8|Influence
14P05276380T0000|11 27|cigarette smoking
14P05276380T0000|33 55|blood coagulation tests
14P05284310T0000|13 20|fluoride
14P05284310T0000|35 48|plasma calcium
14P05285978T0076|26 39|Cancer Society
14P05299993T0000|0 11|Modification
14P05299993T0000|25 35|Tetrahymena
14P05303700T0066|0 11|SAM-TR-68-54
14P05305671T0000|18 35|color deficiencies
14P05308271T0000|0 2|BIM
14P05309471T0000|0 7|Problems
14P05309471T0000|13 25|determination
14P05309471T0000|49 66|influenza vaccines
14P05316745T0000|0 12|Aedes aegypti
14P05316745T0000|19 34|Aedes albopictus
14P05316745T0000|35 39|Skuse
14P05316745T0000|43 56|Singapore City
14P05322558T0000|0 17|Homograft response
14P05322558T0000|20 43|hemagglutinin production
14P05322747T0034|27 34|overload
14P05322747T0034|40 50|tolbutamide
14P05322747T0034|54 63|tolazamide
14P05322747T0034|83 90|subjects
14P05340801T0000|0 9|Mycotoxins
14P05344097T0000|25 59|skin permeability factor production
14P05344097T0000|59 73|Vibrio cholerae
14P05353667T0000|6 24|cord representation
14P05356107T0001|19 26|kinetics
14P05356107T0001|32 42|elimination
14P05356107T0001|45 57|tritium oxide
14P05357390T0001|0 3|Auto
14P05357390T0001|20 30|conjunctiva
14P05359464T0000|0 7|Pitfalls
14P05359464T0000|18 47|chromosome aberration analysis
14P05359464T0000|59 77|radiation dosimetry
14P05362866T0000|0 14|Renin secretion
14P05363816T0001|34 42|expertise
14P05363816T0001|81 87|actions
14P05364951T0001|0 13|Histopathology
14P05368978T0000|0 10|CNS effects
14P05368978T0000|60 75|amine mechanisms
14P05372511T0105|0 17|Diethylene benzene
14P05379901T0000|0 12|Midge control
14P05388567T0000|12 21|taloximine
14P05388567T0000|25 37|aminophylline
14P05389125T0000|14 22|behaviour
14P05394352T0000|0 11|Genitography
14P05394461T0001|0 13|Tolerance test
14P05394461T0001|15 16|HB
14P05394461T0001|22 39|animal experiments
14P05410590T0000|38 60|bladder tumor formation
14P05410641T0000|14 25|Venturi mask
14P05410641T0000|38 51|airway disease
14P05412122T0000|3 8|Methyl
14P05412122T0000|10 17|8-methyl
14P05412122T0000|22 41|8-phenyl derivatives
14P05412687T0000|40 60|collateral inhibition
14P05412687T0000|71 84|tract neurones
14P05413428T0000|3 14|distribution
14P05413428T0000|17 27|body fluids
14P05413428T0000|49 61|resuscitation
14P05413428T0000|64 80|combat casualties
14P05414186T0001|8 26|Hong Kong influenza
14P05414186T0001|30 40|Netherlands
14P05417431T0001|5 14|disagnosis
14P05417431T0001|39 46|patients
14P05421537T0001|0 11|Difficulties
14P05421537T0001|30 45|sputum viscosity
14P05424220T0001|0 18|Lipid concentration
14P05424220T0001|21 35|lipase activity
14P05424220T0001|97 110|sodium content
14P05425195T0001|0 7|Behavior
14P05425195T0001|10 35|aspartate aminotransferase
14P05425195T0001|36 37|EC
14P05425195T0001|49 72|alanine aminotransferase
14P05425195T0001|73 74|EC
14P05425195T0001|115 132|radiation syndrome
14P05425195T0001|146 163|body X-irradiation
14P05437405T0000|27 42|dilator capacity
14P05437405T0000|77 90|salt retention
14P05441564T0001|0 6|Studies
14P05441564T0001|27 30|ECHO
14P05441564T0001|33 36|HILL
14P05445187T0000|15 27|heat exchange
14P05445187T0000|43 50|passages
14P05445187T0000|68 79|heat balance
14P05451324T0000|0 10|Calibration
14P05451324T0000|51 53|Po2
14P05451324T0000|57 69|CO saturation
14P05456002T0000|0 7|Mae West
14P05456002T0000|13 27|doctor shortage
14P05460466T0001|0 10|Elimination
14P05460466T0001|13 29|gamma-irradiation
14P05460466T0001|55 71|drug preparations
14P05463837T0023|11 23|configuration
14P05463837T0023|26 28|C-2
14P05466177T0001|20 32|actinomycin D
14P05471866T0000|3 37|plasma growth hormone concentration
14P05472485T0000|7 30|cochlear response curves
14P05474466T0001|4 24|hemagglutination test
14P05488121T0000|0 15|CO2 assimilation
14P05492285T0000|12 31|Hyostrongylus ruidus
14P05496619T0000|17 48|air pollution control activities
14P05497793T0000|0 6|Effects
14P05497793T0000|16 36|metaraminol treatment
14P05497793T0000|110 121|environments
14P05500957T0001|3 13|association
14P05500957T0001|38 46|Brinedine
14P05501347T0001|14 29|dosage radiation
14P05501347T0001|31 40|metabolism
14P05501347T0001|57 66|rat kidney
14P05502054T0000|0 7|Leukemia
14P05525652T0064|11 16|report
14P05529283T0000|0 11|Quantitation
14P05529283T0000|22 24|IgA
14P05532854T0001|16 29|manifestations
14P05533214T0001|0 16|Iodine metabolism
14P05536803T0001|5 14|body water
14P05536803T0001|15 29|rhodanide space
14P05536803T0001|71 80|furosemide
14P05544291T0031|0 1|V.
14P05552149T0000|0 2|18F
14P05552149T0000|6 21|85Sr scintimetry
14P05552149T0000|40 52|arthropathies
14P05552642T0000|0 10|Propagation
14P05552642T0000|14 31|hormone production
14P05553261T0000|0 5|Health
14P05555149T0001|41 42|SH
14P05555149T0001|47 56|S-S-groups
14P05556977T0001|0 12|Morphogenesis
14P05556977T0001|62 89|phasmid Carausius morosus Br
14P05560428T0001|27 36|expression
14P05560428T0001|54 64|wakefulness
14P05560428T0001|67 74|reptiles
14P05567721T0000|0 12|Sensitivities
14P05567721T0000|32 52|factor VII deficiency
14P05572662T0000|0 6|Central
14P05572662T0000|49 65|electrocardiogram
14P05574818T0000|3 5|Lab
14P05574818T0000|7 25|computer programmes
14P05574818T0000|66 92|contractile characteristics
14P05593469T0001|14 21|injuries
14P05594277T0051|17 26|P32 uptake
14P05594277T0051|33 46|Jensen sarcoma
14P05595036T0001|0 7|Students
14P05621339T0001|28 44|Cs137 irradiation
14P05627251T0000|21 35|skin potentials
14P05642051T0000|17 37|department management
14P05671267T0000|3 21|Dimethylaminopropyl
14P05671267T0000|30 45|dihydro-5H-benzo
14P05672903T0001|0 22|Osteogenesis imperfecta
14P05683363T0001|0 12|Investigation
14P05683363T0001|28 31|Ca45
14P05683363T0001|65 79|analysis method
14P05683809T0000|0 5|Effect
14P05683809T0000|45 74|surface charge characteristics
14P05684081T0001|0 11|Measurements
14P05684081T0001|44 59|chamber VA-K-254
14P05684081T0001|64 78|osimeter VA-J18
14P05689427T0052|3 36|N-Alkyl-N-2-chloroethylaminomethyl
14P05692759T0001|0 10|Nephrectomy
14P05693602T0001|0 9|Evaluation
14P05693602T0001|21 39|blood cell counters
14P05693605T0001|0 12|Determination
14P05715613T0000|0 6|Sterols
14P05718386T0001|18 26|skin flap
14P05718386T0001|31 42|complication
14P05718386T0001|48 56|treatment
14P05718500T0001|12 23|observations
14P05718500T0001|53 61|pregnancy
14P05718994T0000|11 25|fibro-elastosis
14P05718994T0000|33 44|incompetence
14P05718994T0000|49 59|coarctation
14P05719031T0000|0 6|Studies
14P05719031T0000|20 33|size reduction
14P05719746T0001|0 7|Children
14P05722341T0000|0 13|Identification
14P05722341T0000|29 43|monosaccharides
14P05722341T0000|47 59|disaccharides
14P05722341T0000|79 92|chromatography
14P05725509T0000|0 7|Steroids
14P05727222T0000|43 60|oxygen consumption
14P05727222T0000|62 77|Callionymus lyra
14P05732641T0001|0 5|Trials
14P05732641T0001|8 22|sevine activity
14P05732641T0001|29 43|mosquito larvae
14P05733952T0001|3 14|significance
14P05733952T0001|55 73|antibody production
14P05733953T0001|58 66|Paramecia
14P05734847T0000|24 48|Glossina morsitans colony
14P05740389T0001|0 8|Relations
14P05742879T0000|0 14|Transformations
14P05749438T0001|44 71|methyl-amino cyclohexane HCL
14P05749438T0001|71 76|CI-581
14P05750950T0001|0 5|Estrus
14P05751819T0000|40 48|frequency
14P05751819T0000|80 91|Hariana cows
14P05758469T0001|0 19|Hemodynamics changes
14P05760665T0000|0 16|Caries prevention
14P05763287T0063|0 1|I.
14P05763347T0000|8 19|applications
14P05763347T0000|22 31|inhibition
14P05763347T0000|49 57|receptors
14P05763347T0000|62 72|propranolol
14P05769307T0000|0 17|Automatic view box
14P05774062T0000|0 10|Measurement
14P05774062T0000|20 33|acid secretion
14P05779953T0000|0 5|Effect
14P05779953T0000|42 44|FSH
14P05781385T0000|20 50|phenolphthalein sulphatase test
14P05781385T0000|89 104|Nocardia species
14P05782943T0001|0 11|Relationship
14P05782943T0001|25 45|sarcoidosis granuloma
14P05787318T0000|18 27|clofibrate
14P05787318T0000|29 37|Atromid-S
14P05787318T0000|41 52|serum lipids
14P05789870T0001|0 41|Phosphate glucose dehydrogenase deficiency
14P05792868T0000|0 36|Evidence forthe electroosmosis theory
14P05792911T0000|0 6|Effects
14P05792911T0000|24 40|receptor blockade
14P05792911T0000|42 59|airway conductance
14P05794247T0000|0 5|Effect
14P05794247T0000|20 31|inactivation
14P05794247T0000|34 57|serum lipoprotein lipase
14P05796272T0000|12 35|chlorpromazine cataracts
14P05797287T0069|0 1|I.
14P05798063T0000|0 9|Specialist
14P05798063T0000|12 26|family practice
14P05799686T0001|3 13|possibility
14P05799686T0001|25 36|chemotherapy
14P05799686T0001|87 99|cytodiagnosis
14P05799686T0001|103 115|incorporation
14P05799686T0001|124 134|idoxuridine
14P05805644T0001|0 8|Variation
14P05805644T0001|44 48|228Ra
14P05805644T0001|52 56|224Ra
14P05805644T0001|62 64|RES
14P05805644T0001|107 120|colloidal ThO2
14P05806615T0001|9 19|degradation
14P05806615T0001|22 41|adrenaline solutions
14P05806936T0000|0 9|Absorption
14P05806936T0000|12 23|electrolytes
14P05807222T0052|0 12|Ion injection
14P05810259T0001|0 16|Polyvinyl alcohol
14P05819249T0000|0 5|Mining
14P05822499T0034|3 11|structure
14P05822499T0034|14 25|digiprogenin
14P05823624T0031|17 24|hospital
14P05826818T0098|0 1|I.
14P05833022T0001|5 13|character
14P05833022T0001|28 42|enzyme activity
14P05833022T0001|47 58|brain tissue
14P05836483T0000|14 21|teratoma
14P05836483T0000|31 39|childhood
14P05837169T0001|0 13|Methoxyflurane
14P05839844T0000|0 13|Histochemistry
14P05839844T0000|17 35|electron microscopy
14P05839844T0000|63 74|Aflatoxin B1
14P05847772T0001|10 18|disorders
14P05847772T0001|50 56|surgery
14P05850652T0001|0 4|Study
14P05850652T0001|10 20|alterations
14P05850652T0001|33 42|absorption
14P05850652T0001|53 66|I-131-triolein
14P05857301T0000|0 7|Chemical
14P05857301T0000|49 53|CC1-4
14P05857301T0000|73 86|administration
14P05858571T0000|18 24|1,3-bis
14P05858571T0000|26 38|2-chloroethyl
14P05858571T0000|55 64|NSC-409962
14P05859016T0000|0 25|Hydroxypropyl methacrylate
14P05859016T0000|62 80|electron microscopy
14P05879595T0094|0 9|Statistics
14P05881833T0001|53 64|Lower Saxony
14P05884183T0001|0 9|Experience
14P05884183T0001|30 53|agglutination properties
14P05884183T0001|103 111|Rzhaninov
14P05890093T0000|0 4|Study
14P05890093T0000|7 17|micromelias
14P05890093T0000|23 33|mouse fetus
14P05890093T0000|41 51|x-radiation
14P05890093T0000|82 99|hypervitaminosis-A
14P05890093T0000|104 117|mother animals
14P05890351T0001|5 21|antitetanus serum
14P05893495T0001|0 6|Studies
14P05896996T0001|2 11|catabolism
14P05896996T0001|14 25|aminoketones
14P05901778T0000|18 25|patterns
14P05901778T0000|31 40|deposition
14P05902458T0001|0 10|Naphthalene
14P05902458T0001|14 32|paradichlorobenzene
14P05909034T0000|0 6|Studies
14P05917315T0026|1 11|case report
14P05919308T0001|0 11|Interactions
14P05919308T0001|46 73|monoamine oxidase inhibitors
14P05930797T0000|27 46|isoprecipitin system
14P05930797T0000|47 63|Australia antigen
14P05933228T0000|19 28|indicators
14P05933228T0000|31 44|neurosecretion
14P05938720T0000|0 4|Story
14P05938720T0000|29 56|employee orientation program
14P05939748T0000|15 23|Pap smear
14P05942953T0049|0 1|I.
14P05947377T0001|9 19|test iodine
14P05947377T0001|20 24|I-132
14P05947377T0001|58 74|growth deficiency
14P05949971T0000|0 10|Persistence
14P05959588T0000|0 6|Studies
14P05959588T0000|9 24|Coxsackie B Type
14P05959588T0000|24 39|virus infections
14P05960999T0001|0 4|Value
14P05960999T0001|18 41|passive hemagglutination
14P05960999T0001|45 60|polysaccharide C
14P05960999T0001|100 112|precipitation
14P05960999T0001|129 144|slide latex test
14P05967610T0000|10 23|nerve function
14P05967610T0000|24 42|noradrenaline level
14P05967610T0000|45 64|noradrenaline uptake
14P05967610T0000|93 111|reserpine treatment
14P05969185T0001|0 9|Concussion
14P05982700T0000|0 4|Study
14P05982700T0000|23 44|Cysticercus pisiformis
14P05985275T0000|36 48|acorn extract
14P05992157T0001|18 39|Achromobacter puntatum
14P05994421T0045|0 12|Consanguinity
14P05994421T0045|52 56|Nunoa
14P05994421T0045|58 65|Santiago
14P05995140T0001|14 25|significance
14P05995140T0001|40 52|glucose level
14P05999607T0001|0 6|Studies
14P05999607T0001|9 19|lipogenesis
14P05999607T0001|30 39|precursors
14P06012827T0000|15 21|studies
14P06012827T0000|41 46|system
14P06027841T0000|13 17|249Bk
14P06027841T0000|25 43|hyperfine structure
14P06027841T0000|48 64|emission spectrum
14P06035001T0000|7 18|observations
14P06035001T0000|21 30|resorption
14P06035001T0000|33 43|guinea pigs
14P06035001T0000|52 61|injections
14P06035001T0000|64 74|trypan blue
14P06048505T0000|0 10|Derivatives
14P06051644T0000|6 9|Slot
14P06051644T0000|32 44|determination
14P06051644T0000|47 56|creatinine
14P06054411T0000|0 17|Retention behavior
14P06054411T0000|29 46|gas chromatography
14P06054411T0000|59 77|combination columns
14P06065507T0000|17 27|hypertrophy
14P06070204T0025|0 2|XXI
14P06072512T0000|7 16|evaluation
14P06072512T0000|31 36|action
14P06073427T0001|15 30|characteriaztion
14P06073427T0001|46 55|interferon
14P06074093T0001|0 3|Iron
14P06074093T0001|7 23|folate deficiency
14P06074640T0001|0 8|Symposium
14P06074640T0001|26 41|encephalopathies
14P06084279A0218|43 55|serum amylase
14P06084279A0218|64 67|ERCP
14P06084810A0169|27 42|polysome complex
14P06084810A0169|79 80|D.
14P06084864T0001|16 33|alpha fetoproteins
14P06085839A0721|18 28|possibility
14P06088722A0171|0 6|Courses
14P06088722A0171|40 55|myelosuppression
14P06089575A0464|0 10|Stimulation
14P06089575A0464|15 17|MCh
14P06090369A0000|41 47|WR-2721
14P06090369A0000|50 54|Phase
14P06090458A0407|3 25|PEPCK promoter fragment
14P06090458A0407|86 92|TK gene
14P06091914A0000|38 48|tumor virus
14P06091914A0000|49 52|MMTV
14P06091914A0000|115 124|expression
14P06092048A1111|13 20|asbestos
14P06092048A1111|38 43|burden
14P06092048A1111|54 61|fibrosis
14P06092588T0000|0 16|Hepatitis B virus
14P06093354A0000|16 25|DNA clones
14P06093354A0000|70 82|DNA sequences
14P06093354A0000|130 145|Balb/c mouse DNA
14P06093363A0612|0 2|USA
14P06093363A0612|36 47|% identities
14P06093363A0612|54 72|amino acid sequence
14P06094591A0000|3 24|envelope glycoproteins
14P06094591A0000|26 43|Rous sarcoma virus
14P06094591A0000|43 45|RSV
14P06094591A0000|171 186|carboxy terminus
14P06095372A0435|56 74|radiation treatment
14P06095774T0001|12 18|aspects
14P06095774T0001|32 39|nephroma
14P06096246T0000|0 5|Effect
14P06096380A0662|22 54|phosphoenolpyruvate carboxykinase
14P06096863T0000|28 36|CYC1 gene
14P06096863T0000|114 121|TATA box
14P06097027A0000|32 57|erythroblastosis virus E26
14P06097027A0000|103 122|myeloblastosis virus
14P06097027A0000|123 125|AMV
14P06097285A1077|17 27|haloperidol
14P06097285A1077|97 111|motor behaviour
14P06098719A0369|28 46|laboratory findings
14P06098828A0352|45 48|SV40
14P06098828A0352|90 103|RNA polymerase
14P06099656T0000|0 11|Construction
14P06099656T0000|53 87|adenovirus DNA binding protein gene
14P06099656T0000|109 121|HSV-1 tk gene
14P06101359T0000|0 8|Diagnosis
14P06108610A0518|0 7|Theories
14P06108610A0518|32 52|modality shift effect
14P06109017A0000|54 69|4-hydroxyphenoxy
14P06109017A0000|72 96|isopropylamino-2-propanol
14P06109017A0000|104 114|prenalterol
14P06109017A0000|149 160|measurements
14P06109017A0000|179 180|LV
14P06110026T0000|0 9|Endorphins
14P06111283T0032|0 14|Trial treatment
14P06111283T0032|33 55|des-Tyr-gamma-endorphin
14P06113084T0000|34 57|calcium binding activity
14P06113443T0000|0 9|Separation
14P06113443T0000|28 39|erythrocytes
14P06113443T0000|91 110|separation technique
14P06119262T0000|3 16|roll-over test
14P06119262T0000|34 42|pregnancy
14P06120429T0000|3 21|thyroglobulin assay
14P06120429T0000|79 92|thyroid cancer
14P06121577A0280|12 21|reductions
14P06121577A0280|41 54|blood pressure
14P06121577A0280|151 159|decreases
14P06121577A0280|162 171|heart rate
14P06121577A0280|174 194|plasma renin activity
14P06130348T0000|0 8|Isolation
14P06130348T0000|11 19|Aeromonas
14P06131038A0000|0 5|Plasma
14P06131038A0000|9 32|erthrocyte lipid profile
14P06131038A0000|34 60|lipoprotein lipase activity
14P06131038A0000|61 78|postheparin plasma
14P06131038A0000|131 145|atherosclerosis
14P06131378A0818|68 76|DHFR cDNA
14P06131378A0818|89 111|polyadenylation signals
14P06131378A0818|128 136|DHFR cDNA
14P06136374A0151|6 23|water temperatures
14P06136374A0151|24 26|VO2
14P06136374A0151|58 74|swimming velocity
14P06137028A0624|0 10|Propranolol
14P06138015T0114|5 10|report
14P06138313A0948|3 20|distribution phase
14P06138313A0948|34 50|elimination phase
14P06138313A0948|75 84|mean value
14P06138313A0948|103 114|distribution
14P06141764A0339|0 27|Hybrid-selection experiments
14P06141764A0339|51 53|RNA
14P06142279T0000|0 3|Risk
14P06142279T0000|6 19|HTLV infection
14P06143734T0000|7 16|metabolism
14P06143734T0000|19 30|progesterone
14P06147504A0086|3 10|patients
14P06147504A0086|23 29|therapy
14P06147504A0086|45 51|reasons
14P06150069A0422|19 21|VCR
14P06150069A0422|49 65|dose modification
14P06150069A0422|68 80|neurotoxicity
14P06151518A0000|31 34|LD50
14P06151518A0000|57 67|sodium salt
14P06151518A0000|118 127|injections
14P06151942A0235|0 4|Serum
14P06151942A0235|44 54|association
14P06151942A0235|67 80|blood pressure
14P06151942A0235|88 99|risk factors
14P06151942A0235|108 121|blood pressure
14P06151942A0235|127 137|cholesterol
14P06151942A0235|139 150|triglyceride
14P06152670T0000|0 14|Plasma secretin
14P06152670T0000|69 84|failure patients
14P06152844T0000|0 5|Effect
14P06152844T0000|20 33|growth hormone
14P06152844T0000|36 54|prolactin secretion
14P06153936A0784|24 26|SjS
14P06153936A0784|42 59|gland examinations
14P06153936A0784|76 88|year interval
14P06155967A1132|3 14|radiologists
14P06155967A1132|42 59|reporting terminal
14P06155967A1132|99 111|abnormalities
14P06158844A0000|0 10|Thalamotomy
14P06158844A0000|22 34|CM-Pf complex
14P06158844A0000|54 70|gamma irradiation
14P06161823A0129|41 57|ethinyl estradiol
14P06161823A0129|109 119|hypertrophy
14P06162419A0118|85 95|development
14P06162419A0118|98 116|lymphadenosis NK/Li
14P06163433T0000|0 5|Effect
14P06163433T0000|11 24|p-chlorophenyl
14P06163433T0000|26 41|cyclopropylamine
14P06163433T0000|75 100|monoamine oxidase activity
14P06165068A0547|41 48|duodenum
14P06165132A0000|2 11|experiment
14P06165132A0000|85 95|spray lento
14P06165132A0000|145 154|pseodopest
14P06165132A0000|162 165|RIHA
14P06165132A0000|178 189|pseudoplague
14P06165551A0793|6 22|inappropriateness
14P06165551A0793|33 44|segmentation
14P06165551A0793|51 59|isolation
14P06165551A0793|135 144|transients
14P06165551A0793|195 209|autocorrelation
14P06165551A0793|232 253|segmentation algorithm
14P06167806A0000|19 24|UM-272
14P06167806A0000|26 44|dimethylpropranolol
14P06167806A0000|98 113|tachyarrhythmias
14P06167806A0000|179 189|stimulation
14P06173032T0000|11 23|echothiophate
14P06173032T0000|37 44|response
14P06173032T0000|59 66|pressure
14P06173032T0000|69 78|dipivefrin
14P06173860A0000|54 72|segment depressions
14P06173860A0000|82 100|contralateral leads
14P06173860A0000|129 146|segment elevations
14P06175691T0000|0 30|Bacillus cereus cross-infection
14P06181216A0070|52 75|serum IgA concentrations
14P06182979A0807|55 77|anthracycline analogues
14P06182979A0807|104 134|cisplatinum diammine dichloride
14P06184276T0001|15 27|plasmocytosis
14P06184487A1485|38 61|HindIII-P/EcoRI-B region
14P06184487A1485|66 74|AcNPV map
14P06184487A1485|102 113|30K proteins
14P06184487A1485|141 152|30K proteins
14P06184487A1485|166 168|RNA
14P06184487A1485|182 210|HindIII-A/EcoRI-C/SstI-G cDNA
14P06185014A0642|19 39|complement factor C3c
14P06185014A0642|58 76|alpha 1-antitrypsin
14P06185493A0468|1 17|polypeptide chain
14P06185493A0468|41 65|yeast amino acid sequence
14P06185493A0468|100 115|ADP binding site
14P06185493A0468|122 143|muscle pyruvate kinase
14P06189698A0246|3 16|P165 component
14P06189698A0246|130 131|N2
14P06189698A0246|135 147|P3 amplitudes
14P06191243T0000|12 23|drawing size
14P06191243T0000|47 58|brain damage
14P06193351A1010|16 29|administration
14P06193351A1010|70 71|VF
14P06193351A1010|108 123|artery occlusion
14P06198241A0209|26 33|plasmids
14P06198241A0209|61 79|replication origins
14P06198532A0982|76 77|MS
14P06198532A0982|100 102|RHD
14P06198532A0982|162 176|thromboembolism
14P06198532A0982|196 198|RHD
14P06199132A0179|0 7|Toxicity
14P06199132A0179|60 62|WBC
14P06200300A0409|32 45|VEP amplitudes
14P06200300A0409|56 71|scalp electrodes
14P06203843A0757|0 7|Products
14P06203843A0757|27 41|transfer factor
14P06203843A0757|44 54|lymphokines
14P06204120T0001|0 2|Use
14P06204120T0001|8 32|immunofluorescence method
14P06208024A0168|37 41|DNase
14P06208024A0168|46 53|RNase T1
14P06208477A0000|47 49|DNA
14P06208477A0000|76 82|Pietras
14P06208477A0000|96 104|Acids Res
14P06209403A0562|38 47|U2/4 locus
14P06209499A0682|18 36|transmitter release
14P06209499A0682|56 58|MAP
14P06209499A0682|74 87|pressor effect
14P06212776A0000|2 7|Cabras
14P06212776A0000|9 16|Oristano
14P06212776A0000|55 66|thalassaemia
14P06212776A0000|70 84|G6PD deficiency
14P06214605A0123|11 18|elements
14P06214605A0123|45 57|configuration
14P06214605A0123|83 93|experiments
14P06216125A0470|51 52|ET
14P06217859T0000|0 9|Experience
14P06218005A0948|30 37|L-L size
14P06218005A0948|47 58|A-P diameter
14P06223586A0000|0 17|Immunochemotherapy
14P06223586A0000|36 38|SPG
14P06223586A0460|24 34|mitomycin C
14P06223586A0460|74 87|administration
14P06223586A0460|90 92|SPG
14P06224974A0833|0 3|Data
14P06224974A0833|58 60|CPA
14P06225279A0498|12 18|surface
14P06225279A0498|84 89|tissue
14P06227570A0523|13 23|LL patients
14P06227570A0523|29 31|ENL
14P06227570A0523|47 65|suppressor response
14P06229542T0045|10 25|characterization
14P06229542T0045|69 89|template rescue assay
14P06230499A0128|36 46|irradiation
14P06230499A0128|61 73|fractionation
14P06230499A0128|95 96|Gy
14P06230499A0128|114 125|summary dose
14P06230499A0128|129 130|Gy
14P06230499A0128|174 184|irradiation
14P06230499A0128|211 221|performance
14P06230499A0128|316 333|dose fractionation
14P06233924T0000|0 10|Fibrin gels
14P06233924T0000|40 59|surface hemorheology
14P06234369T0000|11 21|vaccination
14P06234786A0606|0 19|Radiogallium imaging
14P06237518A0117|12 27|coupling reagent
14P06237518A0117|85 88|CNCl
14P06237518A0117|133 135|KCN
14P06238540A0798|32 60|mean wall stress relationship
14P06238540A0798|60 62|LVH
14P06238540A0798|97 117|wall muscle stiffness
14P06238540A0798|122 150|mean wall stress relationship
14P06238540A0798|150 152|LVH
14P06238704T0001|0 8|Synthesis
14P06238704T0001|23 39|acid diethylamide
14P06239545A0649|0 10|Weight loss
14P06240448A0652|85 91|LV mass
14P06240448A0652|147 156|resistance
14P06240448A0652|187 193|LV mass
14P06240448A0652|226 243|pretreatment level
14P06240448A0652|288 297|resistance
14P06241900A0000|42 52|hypothermia
14P06241900A0000|56 76|chemical cardioplegia
14P06241900A0000|125 134|rat hearts
14P06241900A0000|169 177|ischaemia
14P06241980A0855|0 14|Oxygen profiles
14P06241980A0855|30 40|Krogh model
14P06242113T0001|0 19|Cultivation technics
14P06242113T0001|22 40|Codonopsis pilosula
14P06244732T0000|0 15|Radioimmunoassay
14P06244732T0000|18 50|serum creatine kinase B isoenzyme
14P06245672T0000|9 29|macrophage inhibition
14P06246254A0676|0 17|Restriction enzyme
14P06246254A0676|20 40|heteroduplex analyses
14P06246254A0676|70 73|FeSV
14P06246254A0676|75 87|src sequences
14P06246254A0676|114 124|FeSV genome
14P06246254A0676|146 159|kilobase pairs
14P06251469A0830|17 32|library isolates
14P06251469A0830|52 60|IAP units
14P06251469A0830|65 81|restriction sites
14P06252520T0000|0 13|Catecholamines
14P06252883A0100|41 44|O149
14P06252883A0100|46 48|K88
14P06252883A0100|50 52|H10
14P06252883A0100|90 92|PWD
14P06254403A0000|31 45|SA-11 rotavirus
14P06254973A1757|0 3|Poly
14P06254973A1757|20 34|calf thymus DNA
14P06254973A1757|63 77|polynucleotides
14P06254973A1757|95 106|accumulation
14P06254973A1757|111 113|HDP
14P06254973A1757|219 230|binding site
14P06254973A1757|242 244|HDP
14P06254973A1757|246 257|accumulation
14P06258699T0000|33 43|Polybactrin
14P06258699T0000|51 71|GU bladder irrigation
14P06258806A0963|17 25|insertion
14P06258806A0963|41 47|element
14P06258806A0963|57 64|terminus
14P06258806A0963|106 115|expression
14P06259220A0000|4 14|experiments
14P06259220A0000|26 34|influence
14P06259220A0000|43 53|antagonists
14P06259220A0000|82 89|reaction
14P06259220A0000|109 116|exposure
14P06259220A0000|159 166|reaction
14P06259220A0000|181 190|reexposure
14P06259220A0000|218 231|shock exposure
14P06259220A0464|0 9|Experiment
14P06259220A0464|70 83|administration
14P06259220A0464|86 95|naltrexone
14P06259220A0464|103 112|reexposure
14P06259389A0000|19 21|May
14P06259389A0000|24 29|August
14P06259389A0000|60 72|mouth disease
14P06259389A0000|73 76|HFMD
14P06259389A0000|88 102|Gifu prefecture
14P06270347A0740|1 15|22K polypeptide
14P06270347A0740|29 47|translation product
14P06270347A0740|53 55|RNA
14P06270347A0740|76 87|DNA fragment
14P06272844A0000|25 28|SV40
14P06272844A0000|133 137|MNase
14P06272844A0000|202 215|SV40 chromatin
14P06277159T0033|1 10|hypothesis
14P06278424A0145|38 51|CH gene switch
14P06278424A0145|126 131|MPC-11
14P06278544T0027|0 9|Physiology
14P06278544T0027|13 27|Physiopathology
14P06279309A0000|16 37|erythroblastosis virus
14P06279309A0000|103 112|activities
14P06279309A0000|138 148|oncogenesis
14P06281759A1086|7 11|RNase
14P06281759A1086|40 53|sib regulation
14P06281759A1086|69 75|PL mRNA
14P06281759A1086|86 101|endoribonuclease
14P06281759A1086|110 123|int mRNA decay
14P06281759A1086|133 145|int synthesis
14P06281786A1222|16 25|lambda HHG
14P06281786A1222|52 64|histone genes
14P06281786A1222|102 104|RNA
14P06281786A1222|121 131|nucleotides
14P06281891A0399|78 95|complex modulation
14P06281891A0399|97 113|pain transmission
14P06286191T0000|0 10|Restoration
14P06286443A0498|13 29|serum ACTH levels
14P06286549A0000|0 6|WR-2721
14P06286549A0000|8 10|S-2
14P06286549A0000|14 29|aminopropylamino
14P06286549A0000|124 135|fibrosarcoma
14P06286549A0000|137 139|FSa
14P06286549A0000|141 153|tumor nodules
14P06286549A0000|174 195|gamma-radiation injury
14P06287212A1352|68 77|AUG codons
14P06287212A1352|101 103|VP1
14P06287212A1352|130 160|transcription initiation events
14P06287212A1352|206 209|AUGs
14P06287231A0914|11 28|TRP1 RI Circle DNA
14P06287231A0914|101 120|bulk yeast chromatin
14P06287737A0477|22 32|transfusion
14P06287737A0477|157 181|posttransfusion hepatitis
14P06287737A0477|221 234|liver diseases
14P06287737A0477|280 291|transfusions
14P06287737A0477|339 352|type B disease
14P06290859A0426|5 24|hepatitis B patients
14P06290859A0426|50 74|hepatitis Bs antigenaemia
14P06290859A0426|131 144|liver function
14P06290899T0000|0 5|Survey
14P06290899T0000|23 50|egg drop syndrome-1976 virus
14P06290899T0000|68 72|Japan
14P06291369A0000|23 50|equilibrium ventriculography
14P06291369A0000|60 74|catheterization
14P06291369A0000|169 185|ejection fraction
14P06291369A0000|186 189|RVEF
14P06295429A0412|16 19|MISO
14P06295429A0412|23 29|WR-2721
14P06295429A0412|103 115|sensitization
14P06296833A0000|28 58|cuticle protein gene expression
14P06298014A0647|3 11|ensembles
14P06298014A0647|44 51|activity
14P06298014A0647|104 110|columns
14P06298720A0893|73 93|integration mechanism
14P06298720A0893|96 108|VL30 elements
14P06298720A0893|111 125|MuLV proviruses
14P06300662T0000|1 19|cDNA cloning vector
14P06300662T0000|41 52|cDNA inserts
14P06300836A0285|0 12|Hybridization
14P06300836A0285|49 60|RR1 colonies
14P06300836A0285|115 139|DNA clones representative
14P06300836A0285|175 194|constituent segments
14P06304771A1284|16 23|GGGXGGAG
14P06304771A1284|118 132|DNA replication
14P06304771A1284|167 178|JCV sequence
14P06306342A1156|37 40|LiCl
14P06306342A1156|80 93|acid secretion
14P06306342A1156|169 184|Heidenhain pouch
14P06307099A1005|0 11|Lung density
14P06308536T0001|3 28|hepatitis A virus antibody
14P06308607A0375|60 80|DNA sequence analysis
14P06308607A0375|104 115|p30 sequence
14P06308607A0375|141 159|polymerase sequence
14P06309020A0473|0 7|Naloxone
14P06309020A0473|22 36|mg X kg-1 X h-1
14P06309020A0473|67 84|lipopolysaccharide
14P06309855T0000|0 20|Gel route preparation
14P06309969T0055|0 1|I.
14P06310159A0000|5 7|RNA
14P06310159A0000|34 36|DNA
14P06310457A0000|13 22|recordings
14P06310457A0000|46 51|tectum
14P06310553T0000|53 69|muscle actin gene
14P06310608A0749|57 66|M-MuLV DNA
14P06310608A0749|68 70|DNA
14P06310608A0749|105 116|Ableson MuLV
14P06310608A0749|117 123|Ab-MuLV
14P06310608A0749|128 134|Moloney
14P06310608A0749|141 153|sarcoma virus
14P06310608A0749|154 158|M-MSV
14P06314276T0000|0 7|Plasmids
14P06314276T0000|84 87|SV40
14P06314276T0000|99 111|gene promoter
14P06314312A0359|14 28|soybean protein
14P06314312A0359|101 107|sources
14P06314312A0359|128 135|purities
14P06314312A0359|145 155|weight gain
14P06314312A0359|165 171|average
14P06314312A0359|188 202|feed efficiency
14P06314312A0359|204 210|average
14P06316347A0852|72 98|beta-galactosidase activity
14P06316623A0188|7 17|prevalences
14P06316623A0188|20 27|antibody
14P06316623A0188|99 118|immunodiffusion test
14P06318078T0000|0 9|Expression
14P06318078T0000|12 36|herpes simplex virus beta
14P06318078T0000|94 111|alpha gene product
14P06318091A0395|3 22|splice acceptor site
14P06318322A0350|39 41|SSV
14P06318322A0350|56 68|recombination
14P06318322A0350|84 86|DNA
14P06318322A0350|189 201|messenger RNA
14P06319040A1627|35 49|system activity
14P06319040A1627|56 76|carotid chemoreceptor
14P06319040A1627|82 91|activation
14P06319040A1627|146 155|blood flow
14P06319071A0173|55 75|calcium stone-formers
14P06319071A0173|99 108|AMP levels
14P06319071A0173|181 183|AMP
14P06319072A0711|90 109|cell receptor number
14P06319072A0711|162 187|beta-adrenoceptor function
14P06319421A0937|11 21|desipramine
14P06319421A0937|75 87|amitriptyline
14P06319421A0937|91 108|mianserin blockade
14P06319421A0937|140 162|alpha 2-adrenoreceptors
14P06319740A1331|60 72|amplification
14P06319740A1331|85 108|erythroblast hyperplasia
14P06319740A1331|147 162|Rauscher disease
14P06320380T0001|0 17|Surgical treatment
14P06321505A0401|1 17|promoter sequence
14P06321505A0401|18 33|Goldberg-Hogness
14P06321505A0401|36 43|TATA box
14P06321505A0401|127 145|S1 nuclease mapping
14P06321634A0123|40 54|leader sequence
14P06321634A0123|134 150|TRs/IRs sequences
14P06321770A1353|15 47|chloramphenicol acetyltransferase
14P06322183A1070|0 15|NPT II synthesis
14P06322183A1070|25 41|agar plate assays
14P06322183A1070|42 61|kanamycin resistance
14P06322183A1070|66 84|immunoprecipitation
14P06322183A1070|90 103|NPT II protein
14P06323556A0126|37 51|EOE-13 infusion
14P06323556A0126|70 86|perfusion pattern
14P06324089A0453|24 27|GAL7
14P06324121A0256|9 10|MW
14P06324121A0256|12 14|12K
14P06324121A0256|38 45|IEmRNA-5
14P06324121A0256|75 87|reading frame
14P06325415A0757|31 33|Ad7
14P06325415A0757|37 44|Ad5 DBPs
14P06325415A0757|62 72|Ad7 protein
14P06325415A0757|129 139|Ad5 protein
14P06327039A0743|13 23|correlation
14P06327039A0743|39 41|LVM
14P06327039A0743|44 57|wall thickness
14P06327039A0743|60 76|body surface area
14P06327039A0743|80 93|blood pressure
14P06327039A0743|169 179|wall stress
14P06327039A0743|187 190|CD25
14P06327039A0743|215 228|catecholamines
14P06327292A0846|14 37|Shine-Dalgarno sequences
14P06327638A0155|49 81|chloramphenicol acetyltransferase
14P06327638A0155|96 107|1.1-kilobase
14P06327638A0155|114 116|DNA
14P06328002A0000|34 37|MPSV
14P06328002A0000|60 80|Moloney sarcoma virus
14P06328002A0000|80 86|Mo-MuSV
14P06328012A0549|13 24|EBNA protein
14P06328012A0549|73 79|BamHI-K
14P06328012A0549|84 97|kilobase pairs
14P06328012A0549|108 122|I1f subfragment
14P06328485A0277|23 41|nucleotide sequence
14P06328485A0277|107 113|MH2 DNA
14P06328485A0277|236 257|chicken proto-myc gene
14P06328504A0161|0 2|USA
14P06328504A0161|38 55|clone lambda PGK-1
14P06328504A0161|93 115|phosphoglycerate kinase
14P06328504A0161|116 118|PGK
14P06330082A0329|0 1|A.
14P06330478A0304|3 10|patients
14P06330478A0304|19 28|cimetidine
14P06330478A0304|32 40|mg q.i.d.
14P06331684A0607|32 45|tumor antigens
14P06331684A0607|48 56|screening
14P06331684A0607|77 90|stomach cancer
14P06333433A0000|27 43|influenzae type b
14P06333433A0000|80 107|H. influenzae type b disease
14P06333433A0000|155 172|lipopolysaccharide
14P06333433A0000|174 176|LPS
14P06333878T0000|11 23|acid overdose
15P06336045A0261a|0 8|Frog type
15P06336045A0261a|10 13|Ft I
15P06336045A0261a|28 29|Ft
15P06336045A0261a|48 49|SA
15P06336045A0261a|79 95|indentation phase
15P06336045A0261a|102 125|threshold response phase
15P06336045A0261a|125 127|TRP
15P06336045A0261b|0 8|Frog type
15P06336045A0261b|10 13|Ft I
15P06336045A0261b|28 29|Ft
15P06336045A0261b|48 49|SA
15P06336045A0261b|79 95|indentation phase
15P06336045A0261b|102 125|threshold response phase
15P06336045A0261b|125 127|TRP
14P06340643A0598|0 3|DMCM
14P06340643A0598|29 41|possibilities
14P06340703A0324|0 8|Grimelius
14P06340703A0324|26 39|Masson Fontana
14P06341139A0213|0 12|Blood glucose
14P06341139A0213|15 28|plasma insulin
14P06341139A0213|84 92|ingestion
14P06341139A0213|97 105|g glucose
14P06341139A0213|106 113|fructose
14P06341139A0213|164 171|potatoes
14P06341139A0213|176 183|g apples
14P06341139A0213|188 196|g carrots
14P06341661T0001|35 45|acid suture
14P06341661T0001|47 61|Blalock-Taussig
14P06342141A0226|34 46|understanding
14P06342141A0226|49 70|family pathophysiology
14P06342141A0226|76 86|sensitivity
14P06342141A0226|90 100|specificity
14P06342141A0226|113 122|techniques
14P06342141A0226|161 170|modalities
14P06342141A0226|181 198|family health care
14P06342141A0226|290 305|value judgements
14P06342141A0226|327 336|importance
14P06342141A0226|354 365|consequences
14P06342141A0226|372 398|health care delivery system
14P06342141A0226|424 440|literature review
14P06345840A0348|27 28|CI
14P06345840A0348|34 35|CI
14P06345840A0348|117 119|TPR
14P06346427A0000|23 36|insulin levels
14P06346427A0000|96 105|test-meals
14P06349364A1051|70 83|serum globulin
14P06349364A1051|103 131|group B Streptococcus antigen
14P06350092A0916|24 26|AMI
14P06350092A0916|38 41|CCHD
14P06350092A0916|68 71|VPBs
14P06354594A0114|5 11|oranges
14P06354594A0114|13 20|mandarin
14P06354594A0114|22 31|grapefruit
14P06354594A0114|65 74|processing
14P06355483A0134|56 64|sequences
14P06355483A0134|82 91|base-pairs
14P06355483A0134|108 117|base-pairs
14P06360426A0501|10 19|hydrolysis
14P06360426A0501|72 84|colour change
14P06360426A0501|89 100|pH indicator
14P06361318A0440|11 24|efficacy rates
14P06361318A0440|44 54|KS-R1 group
14P06361318A0440|103 119|committee members
14P06361318A0440|134 144|KS-R1 group
14P06361318A1127|0 10|Side effect
14P06361318A1127|81 91|KS-R1 group
14P06361318A1127|127 140|incidence rate
14P06361318A1127|159 169|KS-R1 group
14P06362143A0565|0 20|Plasma renin activity
14P06362143A0565|56 76|isoprenaline infusion
14P06362239T0001|0 12|Martin Luther
14P06362602T0001|0 10|Enhancement
14P06362602T0001|49 65|vaccine additives
14P06362602T0001|79 90|immunization
14P06364265T0062|7 28|gamma-ray spectroscopy
14P06367414A0000|0 7|Bepridil
14P06367414A0000|10 27|calcium antagonist
14P06367414A0000|113 127|crossover trial
14P06369355A0834|0 7|Analysis
14P06369355A0834|92 101|A2 protein
14P06369355A0834|127 145|replication protein
14P06369954T0000|0 6|Effects
14P06369954T0000|49 60|hemodynamics
14P06370553A0444|7 27|plasma norepinephrine
14P06370553A0444|28 29|NE
14P06370553A0444|34 44|epinephrine
14P06370553A0444|94 103|withdrawal
14P06370553A0444|105 114|guanfacine
14P06370553A0444|126 134|plasma NE
14P06372563T0000|15 23|captopril
14P06372563T0000|32 44|heart failure
14P06372563T0000|51 60|furosemide
14P06372563T0000|63 73|natriuresis
14P06372563T0000|87 98|hyponatremia
14P06373409A1163|0 8|Lauciello
14P06373409A1163|80 91|restorations
14P06373855A0000|6 21|biopsy specimens
14P06373855A0000|81 102|pityriasis lichenoides
14P06373855A0000|123 127|PLEVA
14P06373855A0000|148 165|immunofluorescence
14P06373855A0000|169 193|immunoperoxidase technics
14P06374369A1112|35 43|reduction
14P06374369A1112|46 56|food intake
14P06374369A1112|125 130|events
14P06374418A0877|3 10|aspirate
14P06374418A0877|61 66|amount
14P06374418A0877|80 86|hormone
14P06376227A0217|0 2|EGV
14P06376227A0217|26 37|PP secretion
14P06379363A0415|34 39|HDL-2M
14P06379363A0415|104 120|diabetes mellitus
14P06381438A1280|0 27|Lung prostacyclin production
14P06382374A0206|25 46|insulin administration
14P06382374A0206|64 77|glucose levels
14P06382374A0206|198 213|control subjects
14P06384983T0000|0 9|Management
14P06385474T0001|8 16|treatment
14P06385474T0001|19 26|children
14P06385474T0001|42 48|allergy
14P06388189T0001|0 14|Transplantation
14P06388818A0000|31 37|Hodgkin
14P06388818A0000|111 131|chemotherapy regimens
14P06388818A0000|169 171|HDC
14P06388818A0000|213 232|bone marrow infusion
14P06388818A0000|232 235|ABMT
14P06391496T0000|0 5|Effect
14P06391496T0000|29 40|polypeptides
14P06391496T0000|46 61|antacid activity
14P06394228T0073|0 6|Results
14P06394347A1024|0 11|Hydrallazine
14P06394347A1024|39 59|plasma renin activity
14P06394347A1024|79 91|noradrenaline
14P06395804A0382|0 14|Urease activity
14P06397009A0204|5 15|description
14P06397009A0204|35 45|explanation
14P06397009A0204|56 72|conductor Bozzini
14P06397009A0204|97 105|invention
14P06397009A0204|113 121|physician
14P06397009A0204|172 184|possibilities
14P06401749T0000|39 68|arginine vasopressin secretion
14P06402480A0373|3 16|susceptibility
14P06402480A0373|22 33|PPNG strains
14P06402480A0373|77 91|plasmid pattern
14P06402480A0373|127 138|surveillance
14P06402480A0373|188 202|recommendations
14P06402859A0000|0 15|Antithrombin III
14P06402859A0000|25 38|plasma protein
14P06404842A0127|8 15|patients
14P06404842A0127|54 62|treatment
14P06404842A0127|67 84|depot testosterone
14P06404842A0127|129 136|duration
14P06406060A0000|14 22|cisplatin
14P06406060A0000|74 80|Sarcoma
14P06407348A0516|0 2|New
14P06407348A0516|79 88|situations
14P06407348A0516|136 144|receptors
14P06407348A0516|169 184|muscle receptors
14P06411659A0264|2 11|facilities
14P06411659A0264|15 26|measurements
14P06411659A0264|31 41|consumption
14P06411659A0793|20 32|energy intake
14P06411659A0793|50 67|energy expenditure
14P06411659A0793|73 80|N intake
14P06412385A0356|22 33|lung disease
14P06412385A0356|44 58|muscle weakness
14P06412385A0356|115 127|lung capacity
14P06412385A0356|147 157|ventilation
14P06412385A0356|208 229|carbon dioxide tension
14P06412385A0356|229 233|PaCO2
14P06412385A0356|246 255|likelihood
14P06412385A0356|258 267|dependence
14P06412385A0356|270 280|ventilators
14P06412385A0356|282 292|atelectasis
14P06413492A0990|0 5|Commun
14P06414990A0057|30 37|TRH test
14P06414990A0057|118 137|thyrotropin response
14P06415299A0233|22 32|doxorubicin
14P06419251T0000|0 19|Movement programming
14P06426493A0331|22 38|state anaesthesia
14P06426493A0331|49 60|measurements
14P06426493A0331|63 65|IOP
14P06426493A0331|94 97|FIO2
14P06426493A0331|99 103|FE'CO
14P06426493A0331|108 110|CVP
14P06428116T0000|33 46|hypothyroidism
14P06428116T0000|68 78|thyroiditis
14P06429992T0000|0 18|Gonadotropin levels
14P06429992T0000|46 53|DZ twins
14P06433442T0000|0 7|Freezing
14P06433442T0000|48 49|C.
14P06434572A0157|65 77|GH deficiency
14P06434572A0157|93 107|hypopituitarism
14P06434572A0157|128 145|growth retardation
14P06434572A0157|283 292|GH reserve
14P06434587A0551|24 25|LH
14P06434587A0551|29 38|FSH levels
14P06434587A0551|79 80|LH
14P06434587A0551|84 96|FSH responses
14P06434587A0551|98 100|LRH
14P06435565A0648|5 11|changes
14P06435565A0648|19 24|result
14P06435565A0648|28 35|decrease
14P06435565A0648|38 46|afterload
14P06435565A0648|58 65|pressure
14P06435565A0648|132 141|resistance
14P06435565A0648|172 179|dynes/cm
14P06437579A0727|0 9|Cimetidine
14P06437579A0727|67 78|dose regimen
14P06437579A0727|88 105|patient compliance
14P06439114A0677|0 10|Ceftazidime
14P06439114A0677|76 85|infections
14P06439135A0250|0 11|Regional CBF
14P06439135A0250|89 98|procedures
14P06441624A0263|41 51|measurement
14P06441624A0263|54 68|bone metabolism
14P06443550T0000|3 12|management
14P06443639T0001|0 4|Study
14P06443639T0001|53 70|circuit television
14P06443714T0001|9 30|Rhodnius prolixus Stal
14P06444119A0340|41 50|preference
14P06444119A0340|54 64|requirement
14P06444119A0340|68 78|temperature
14P06444119A0340|100 108|nutrients
14P06444119A0340|113 126|growth factors
14P06444119A0340|133 147|toxin formation
14P06446048A0356|32 38|by-pass
14P06446048A0356|48 55|solution
14P06446048A0356|102 108|problem
14P06451557A0777|0 10|Deformities
14P06451557A0777|73 80|De Palma
14P06451557A0777|85 90|Jordan
14P06451557A0777|96 102|Ahlberg
14P06451557A0777|108 114|Weseloh
14P06452461A0930|32 37|LVM/M2
14P06452461A0930|41 44|PWVn
14P06452461A0930|58 73|post AVR studies
14P06452827T0001|28 45|Huntington choreas
14P06453290A0000|3 13|development
14P06453290A0000|32 43|organization
14P06453290A0000|100 107|material
14P06454625A0000|18 34|animal experiment
14P06454625A0000|109 136|Infrared-Contact-Coagulation
14P06454625A0000|161 185|magnification angiography
14P06454625A0000|186 205|magnification factor
14P06459831T0001|0 13|Cardiovascular
14P06459831T0001|59 75|tobacco poisoning
14P06460889A0111|23 27|SG-75
14P06460889A0111|72 74|SBP
14P06460889A0111|145 147|PBF
14P06460889A0512|27 31|SG-75
14P06460889A0512|57 70|pulse pressure
14P06460889A0512|121 123|LVP
14P06460889A0512|128 138|LVdP/dt max
14P06463429A0414|7 8|VE
14P06466804A0686|0 7|Exposure
14P06466804A0686|10 20|endothelium
14P06466804A0686|32 45|shear stresses
14P06466804A0686|58 71|tape recording
14P06466804A0686|86 99|flow waveforms
14P06466804A0686|149 158|denudation
14P06467241A0000|0 20|Modern cancer therapy
14P06467241A0000|80 92|immunotherapy
14P06467797A0233|14 24|correlation
14P06467797A0233|32 47|plasma clearance
14P06467797A0233|49 50|NT
14P06467797A0233|53 68|10-hydroxylation
14P06467797A0233|91 98|D/4-OH-D
14P06467797A0233|112 120|Ghanaians
14P06467797A0233|148 153|Swedes
14P06468565A0000|3 21|response properties
14P06468565A0000|36 50|canal afferents
14P06468565A0000|100 113|time constants
14P06468565A0000|122 145|frequency gain constants
14P06468565A0000|145 146|G1
14P06468565A0000|158 181|frequency gain constants
14P06468565A0000|181 182|Gm
14P06468632A0135|0 10|Endothelium
14P06468632A0135|23 32|ear artery
14P06468632A0135|72 85|artery forceps
14P06468673A0358|23 39|E2 concentrations
14P06468673A0358|56 67|mucus scores
14P06468694A0441|0 10|Stimulation
14P06468694A0441|16 30|caudate nucleus
14P06468694A0441|70 83|administration
14P06468694A0441|98 107|micrograms
14P06468694A0441|126 138|deterioration
14P06468694A0441|168 177|components
14P06473219T0000|0 4|Value
14P06473219T0000|7 25|urine glucose tests
14P06473219T0000|47 63|diabetes mellitus
14P06473252A1073|53 66|egg production
14P06473252A1073|89 96|ABSTRACT
14P06473252A1073|111 115|WORDS
14P06479362A0680|0 13|Hydrocortisone
14P06479362A0680|40 62|postdenervation changes
14P06479362A0680|67 81|muscle membrane
14P06479362A0680|136 150|muscle membrane
14P06479976A0386|19 29|differences
14P06479976A0386|69 71|AMB
14P06479976A0386|82 94|survival time
14P06479976A0386|158 168|nerve signs
14P06480542A0000|23 32|apalcillin
14P06480542A0000|49 56|patients
14P06482179A0497|0 14|Catch-up growth
14P06482318A0117|0 19|Thrombocyte function
14P06482318A0117|70 90|platelet shape change
14P06482665A0735|26 44|AMPH administration
14P06482665A0735|112 126|caudate nucleus
14P06482665A0735|128 142|pigtail monkeys
14P06483863A0000|31 40|BALB/cCrgl
14P06483863A0000|43 61|BALB/cfC3HCrgl mice
14P06483863A0000|107 120|beta-estradiol
14P06483863A0000|219 229|Experiments
14P06483863A0000|246 255|Experiment
14P06486932A0000|22 30|occurring
14P06486932A0000|62 76|Malumfashi area
14P06486932A0000|86 92|Nigeria
14P06487290A0000|24 33|E2-17 beta
14P06487290A0000|37 48|progesterone
14P06487290A0000|73 99|radioimmunoassay techniques
14P06492188A0615|33 38|effect
14P06492188A0615|44 49|number
14P06492188A0615|52 59|implants
14P06493655A0415|8 24|FHR decelerations
14P06493655A0415|26 37|bradycardias
14P06493655A0415|57 71|nonstress tests
14P06494215A0248|3 16|response chain
14P06494215A0248|46 62|food presentation
14P06494297A0939|64 74|acquisition
14P06494297A0939|77 82|HPC SS
14P06494297A0939|114 124|stimulation
14P06494766A0241|38 58|Hiss bundle fragments
14P06495195A0536|51 53|U/l
14P06495195A0536|57 76|alkaline phosphatase
14P06495195A0536|143 154|liver damage
14P06497671T0001|0 6|Changes
14P06497671T0001|9 29|plasma cortisol level
14P06501086A0165|120 142|vas deferens granulomas
14P06501086A0165|205 225|serum electrophoresis
14P06501086A0165|238 269|sperm agglutinin antibody titers
14P06503132A0784|0 2|SFP
14P06503132A0784|29 30|Hn
14P06503329A0588|47 48|SD
14P06503329A0588|67 79|control group
14P06503329A0588|90 91|SD
14P06503885A0342|4 16|machine drift
14P06503885A0342|61 71|temperature
14P06503885A0342|115 129|x-ray tube heat
14P06503885A0342|154 167|overestimation
14P06503885A0342|205 226|xenon/CT rCBF protocol
14P06503885A0342|267 285|interscan intervals
14P06505014A1192|5 17|uncertainties
14P06505014A1192|34 37|Y-12
14P06505014A1192|41 45|Vinca
14P06506074A0456|0 12|E2 treatments
14P06506074A0456|20 32|hen plasma TG
14P06506074A0456|36 37|PL
14P06506074A0456|74 75|PL
14P06506074A0456|88 89|X.
14P06507629A0717|79 81|NH3
14P06507629A0717|113 131|mumol X min-1 X g-1
14P06508393T0000|0 12|Serodiagnosis
14P06508393T0000|53 79|card agglutination test set
14P06508393T0000|78 89|Testryp CATT
14P06513456T0001|0 22|Adenyl cyclase activity
14P06516369T0001|0 10|Proteinuria
14P06516847A0393|34 44|pneumococci
14P06516847A0393|55 63|mortality
14P06516847A0393|68 78|pneumococci
14P06516977T0000|0 7|Reaction
14P06517816A0388|0 1|HA
14P06517816A0388|36 38|Tre
14P06517816A0388|55 56|HR
14P06517816A0388|96 98|Msw
14P06517816A0388|102 114|g X m-2 X h-1
14P06517816A0388|121 138|saline experiments
14P06520418A0325|41 58|valve orifice area
14P06520418A0325|58 60|MVA
14P06520418A0325|111 136|LVIT flow velocity pattern
14P06521802A0251|0 21|Scientific cooperation
14P06521802A0251|23 43|CMEA member countries
14P06521802A0251|92 116|Cancer Research Institute
14P06521802A0251|116 129|Slovak Academy
14P06521802A0251|140 153|Czechoslovakia
14P06521802A0251|175 178|CMEA
14P06521999A0677|46 54|melanomas
14P06521999A0677|64 74|enucleation
14P06524202A0167|16 29|EMG-BFB method
14P06524202A0167|30 41|multichannel
14P06524202A0167|179 196|motor coordination
14P06524727A0601|0 10|Lymphocytes
14P06524727A0601|93 109|incubation period
14P06524727A0601|121 134|blood dilution
14P06524761A0596|58 73|body weight loss
14P06524761A0596|107 131|killed-toxoplasma vaccine
14P06524761A0596|164 173|T-1 strain
14P06524761A0596|225 247|live-toxoplasma vaccine
14P06524761A0596|274 282|RH strain
14P06527379T0044|11 34|proline/alanine sequence
14P06527379T0044|74 85|DNA sequence
14P06527872T0000|23 33|projections
14P06527872T0000|81 101|substantia gelatinosa
14P06527872T0000|154 169|acid phosphatase
14P06527872T0000|170 172|ACP
14P06531286A0382|0 6|Removal
14P06531286A0382|9 23|lipid fractions
14P06531286A0382|25 41|plant extractions
14P06531286A0382|82 92|HPLC column
14P06535384A1115|107 117|possibility
14P06535384A1115|143 150|ABSTRACT
14P06535384A1115|165 169|WORDS
14P06539738T0000|28 45|chlorofluorocarbon
14P06539738T0000|49 51|CFC
14P06541019A0555|3 10|patients
14P06541019A0555|27 34|toxicity
14P06541019A0555|42 49|response
14P06541932A0000|0 6|Methods
14P06541932A0000|32 42|algesimetry
14P06541932A0000|120 129|analgesics
14P06542372A0159|36 48|discrepancies
14P06542372A0159|70 80|terminology
14P06542372A0159|110 119|additivity
14P06542372A0159|123 134|potentiation
14P06542372A0159|147 156|similarity
14P06542918A1131|25 38|discrimination
14P06542918A1131|114 125|P3 latencies
14P06545651A0346|0 20|Ammonia concentration
14P06545651A0346|96 123|protein nitrogen degradation
14P06545651A0346|144 146|NH3
14P06546392A0542|22 43|protein concentrations
14P06546392A0542|71 100|erythrocyte sedimentation rate
14P06548953T0001|5 22|thyroid stimulator
14P06548953T0001|23 25|HTS
14P06548953T0001|29 44|thyroid diseases
14P06555107A1227|14 27|administration
14P06555107A1227|33 60|calcium antagonist Verapamil
14P06568939A0000|0 8|Brainstem
14P06568939A0000|33 37|BAERs
14P06568939A0000|62 81|eye movement studies
14P06571587T0000|0 6|Effects
14P06571587T0000|45 67|body tissue oxygenation
14P06579147A0060|40 49|management
14P06579147A0060|62 71|approaches
14P06579147A0060|77 90|reconstruction
14P06579147A0060|99 109|deformities
14P06579152A1061|30 32|NPF
14P06579152A1061|62 84|velopharyngeal activity
14P06579152A1061|97 113|feed-back control
14P06582285A0222|32 34|U-P
14P06582285A0222|38 40|D&E
14P06582285A0222|57 59|U-P
14P06582285A0222|68 80|D&E abortions
14P06584416A0157|5 16|radiologists
14P06584416A0157|70 79|angiograms
14P06584416A0157|89 100|examinations
14P06584416A0157|108 110|PGF
14P06585277A0000|36 46|association
14P06585277A0000|67 91|acid phosphatase activity
14P06585277A0000|120 131|bone lesions
14P06585277A0000|133 147|roentgenography
14P06588306A0076|17 38|prophylactic treatment
14P06588306A0076|69 71|AIL
14P06588306A0076|73 87|AIEOP protocols
14P06588501T0059|23 27|study
14P06591992A0569|2 13|anisotropism
14P06593862T0001|0 18|Hepatitis B vaccine
14P06594105A0560|21 29|lambda tb
14P06594105A0560|33 41|degrees C
14P06594105A0560|49 64|cent haematocrit
14P06594105A0560|161 169|lambda cp
14P06594105A0560|181 189|lambda tp
14P06594105A0560|203 213|temperature
14P06594105A0560|233 242|degrees C.
14P06597709A0596|35 44|asbestosis
14P06597709A0596|60 71|lung volumes
14P06597709A0596|84 98|transfer factor
14P06597709A0596|141 152|measurements
14P06599282T0001|28 41|cell carcinoma
14P06600533T0000|0 10|Azygos vein
14P06600533T0000|75 84|CT variant
14P06602580A0664|31 43|complications
14P06602580A0664|105 134|alpha 1-antitrypsin deficiency
14P06602600A0582|3 11|Sarns 51F
14P06606043A0598|29 39|6-positions
14P06606043A0598|52 62|replacement
14P06606043A0598|68 79|phenyl group
14P06607427A0000|5 15|experiments
14P06607427A0000|117 127|projections
14P06607427A0000|144 155|hypothalamus
14P06607427A0000|183 201|body weight changes
14P06607427A0000|215 223|behaviour
14P06607714T0000|0 14|Limb allografts
14P06607714T0000|40 53|cyclosporin A.
14P06609166A0209|54 65|acetonitrile
14P06609166A0209|130 154|C18 reversed-phase column
14P06610347A0581|22 32|AV junction
14P06610347A0581|85 91|AV node
14P06612373A0000|71 82|prescription
14P06612373A0000|117 121|1960s
14P06612373A0000|130 134|1970s
14P06615053A0202|41 53|resuscitation
14P06615053A0202|100 103|RVEF
14P06615053A0202|142 147|RVEDVI
14P06615403A0718|13 25|LAD occlusion
14P06615403A0718|56 66|microns TMs
14P06615403A0718|116 126|microns TMs
14P06625058A0666|3 12|population
14P06625058A0666|67 72|capita
14P06627123A0000|6 16|Wistar rats
14P06627123A0000|35 42|Sustacal
14P06627569T0001|0 1|HL
14P06627569T0001|4 29|type oculomotor stimulator
14P06629370A0252|28 56|basement membrane nephropathy
14P06629370A0252|106 122|basement membrane
14P06629370A0252|148 153|Alport
14P06630319A0244|0 7|Brain pH
14P06630319A0244|101 111|barbiturate
14P06630319A0244|115 134|halothane anesthesia
14P06634712A0557|82 84|PTH
14P06634712A0557|88 89|CT
14P06643612A0000|25 31|methods
14P06643612A0000|62 68|studies
14P06643612A0000|71 80|imipramine
14P06648156T0034|12 18|remarks
14P06652293A0353|36 44|responses
14P06652293A0353|57 67|sensitivity
14P06652293A0353|88 98|specificity
14P06653755A0192|5 27|clofelin administration
14P06653755A0192|30 51|autoregulation borders
14P06653755A0192|85 93|AP levels
14P06654047A0694|4 13|phenomenon
14P06654047A0694|58 67|cell death
14P06654047A0694|89 97|apoptosis
14P06654047A0694|150 165|rhabdomyosarcoma
14P06654686T0001|0 10|Combination
14P06654686T0001|14 31|Shwachman syndrome
14P06654686T0001|42 70|granulocyte function disorder
14P06655634A0195|37 39|TOL
14P06655634A0195|62 80|cesarean deliveries
14P06656249T0000|0 22|Nursing home discharges
14P06657559A0489|0 4|Trial
14P06657559A0489|6 21|broiler chickens
14P06657559A0489|37 48|control feed
14P06657559A0489|137 148|control feed
14P06657559A0489|167 182|ppm ochratoxin A
14P06657559A0489|185 194|heart rate
14P06657559A0489|197 210|blood pressure
14P06657559A0489|227 235|half hour
14P06658029A0086|3 21|carcinogen bioassay
14P06658029A0086|93 109|hazard evaluation
14P06658445A0140|7 13|effects
14P06658445A0140|16 22|animals
14P06658445A0140|66 72|amounts
14P06658445A0140|75 80|intake
14P06658586T0001|0 22|Angionephroscintigraphy
14P06659982A0231|30 41|sleep period
14P06659982A0231|101 102|DS
14P06659982A0231|109 110|QS
14P06659982A0231|142 151|parameters
14P06659982A0231|195 196|PS
14P06662623A0124|1 4|82Br
14P06662623A0124|6 9|MISO
14P06662623A0124|43 49|Br-MISO
14P06662623A0124|53 68|SLOWPOKE reactor
14P06667015A0832|31 41|sensitivity
14P06667015A0832|66 74|ischaemia
14P06667015A0832|131 147|serum CK-MB level
14P06667868T0001|116 127|BR-1 benzene
14P06668316A0178|18 38|reversed-phase column
14P06668316A0178|43 58|phosphate buffer
14P06668316A0178|60 71|acetonitrile
14P06668316A0178|84 102|baseline separation
14P06668316A0178|118 128|metabolites
14P06669864T0001|3 7|liver
14P06670732A0000|32 34|ASA
14P06670732A0000|82 89|Fentanyl
14P06670732A0000|114 121|Fentanyl
14P06670732A0000|132 141|Droperidol
14P06670732A0000|148 154|Innovar
14P06670732A0000|156 165|Thalamonal
14P06670732A0000|170 177|Atropine
14P06671047A1124|39 41|NOM
14P06671047A1124|135 139|CD/LD
14P06671047A1124|141 142|LD
14P06671047A1124|146 148|DOM
14P06671047A1124|187 199|Prolactinomas
14P06671047A1124|225 226|DA
14P06671065A0000|0 11|Serum lipids
14P06671065A0000|14 25|lipoproteins
14P06671385A0856|3 4|NA
14P06671385A0856|36 56|plasma renin activity
14P06671385A0856|62 63|PA
14P06671385A0856|115 133|body sodium content
14P06671925T0000|0 22|Amikacin concentrations
14P06671925T0000|32 44|blister fluid
14P06672094A0390|3 10|subgroup
14P06672094A0390|75 92|oculomotor nucleus
14P06672094A0390|137 146|fasciculus
14P06674374T0000|0 31|Hepatitis B vaccination strategy
14P06674374T0000|74 95|hepatitis B endemicity
14P06674516A0350|13 25|drip infusion
14P06674516A0350|27 29|AMK
14P06674977A1181|10 17|families
14P06674977A1181|34 42|pregnancy
14P06674977A1181|78 86|diagnosis
14P06674977A1181|88 95|table VI
14P06675047A0000|23 34|interference
14P06675047A0000|70 78|Berthelot
14P06675047A0000|89 97|Berthelot
14P06675047A0000|113 125|determination
14P06683807A0160|42 51|prevalence
14P06683807A0160|54 64|alcohol use
14P06683876A0244|29 36|diameter
14P06683876A0244|67 74|clusters
14P06683876A0244|86 99|daughter cells
14P06684624A0298|16 26|mortalities
14P06684624A0298|80 87|diet 41B
14P06684624A0736|7 38|N-acetylglucosaminidase activity
14P06685004A0000|3 14|associations
14P06685004A0000|41 57|globulin capacity
14P06685004A0000|58 61|SHBG
14P06685004A0000|68 82|body mass index
14P06685004A0000|82 84|BMI
14P06685177T0000|0 11|Dipetalonema
14P06685177T0000|13 22|Alafilaria
14P06685177T0000|24 42|hydrochoerus subgen
14P06685536A0502|32 38|control
14P06685536A0502|76 86|enucleation
14P06685643A0179|3 16|concentrations
14P06685643A0179|19 20|C4
14P06685643A0179|24 29|C1-INH
14P06685643A0179|84 94|mean values
14P06686454A0585|80 102|Klebsiella-Enterobacter
14P06686454A0585|104 111|Shigella
14P06686454A0585|129 147|Serratia marcescens
14P06686454A0585|150 156|Proteus
14P06687953T0000|10 25|defence capacity
14P06687953T0000|43 59|leukocyte enzymes
14P06689413A0174|24 29|Am-241
14P06689413A0174|59 69|Ge detector
14P06689413A0174|92 98|K alpha
14P06689413A0174|127 129|KeV
14P06689513T0001|24 34|retinopathy
14P06691304A0284|10 29|serum concentrations
14P06691304A0284|65 74|deviations
14P06691304A0284|129 138|age groups
14P06692517T0000|82 108|indium-111 platelet imaging
14P06692517T0000|125 140|echocardiography
14P06692631A0129|41 64|microstress distribution
14P06694380A1483|0 8|Plasma NE
14P06694380A1483|56 57|SD
14P06694380A1483|89 96|ABSTRACT
14P06694380A1483|111 115|WORDS
14P06694778A0000|11 31|hemodialysis patients
14P06694778A0000|46 72|redistribution thallium-201
14P06698047A0445|3 18|Prolactin levels
14P06698047A0445|64 66|TRH
14P06700231A0259|12 26|tumor resection
14P06700231A0259|50 62|tumor nodules
14P06700469T0000|7 28|hospital accreditation
14P06702257T0001|0 15|Antithrombin III
14P06702643A0000|8 20|infant hearts
14P06702643A0000|35 51|arch interruption
14P06702643A0000|111 117|Celoria
14P06702643A0000|121 126|Patton
14P06702643A0000|154 155|SA
14P06704467A0539|13 23|sensitivity
14P06704467A0539|26 36|photoperiod
14P06704467A0539|89 100|pineal gland
14P06705456A0346|0 9|Absorption
14P06707357A0180|13 24|observations
14P06707357A0180|59 71|regurgitation
14P06707357A0180|92 108|valve replacement
14P06707357A0180|119 129|differences
14P06707357A0180|171 185|volume overload
14P06709310A0000|21 29|nystagmus
14P06709310A0000|36 40|onset
14P06709700A0230|67 91|Hamilton Depression Scale
14P06709700A0230|96 112|Melancholia Scale
14P06709700A0230|167 181|outcome measure
14P06711642A0093|11 28|immunoglobulinuria
14P06711642A0093|48 58|development
14P06711642A0093|92 111|creatinine clearance
14P06711642A0093|123 133|proteinuria
14P06711642A0093|200 215|urine collection
14P06712314A0148|50 61|institutions
14P06713200A0630|0 20|Epileptiform activity
14P06713200A0630|93 103|projections
14P06713204A0867|3 15|AD components
14P06713204A0867|77 88|V1 component
14P06714298X0000|75 85|nisoldipine
14P06714298X0000|90 114|micrograms X kg-1 X min-1
14P06714298X0000|114 136|calcium channel blocker
14P06714298X0000|156 165|nifedipine
14P06714298X0000|229 238|resistance
14P06714298X0000|252 261|maxLVdP/dt
14P06714354A0194|0 6|Monkeys
14P06715792A0295|0 16|HBB concentration
14P06716977A0136|29 49|ethanol concentration
14P06718064T0001|0 17|Plasma lactoferrin
14P06719057A0181|3 12|importance
14P06719057A0181|29 45|vein phlebography
14P06719057A0181|50 59|evaluation
14P06719057A0181|85 98|filing defects
14P06720371T0000|0 10|Pilot study
14P06720371T0000|12 28|blood coagulation
14P06721188A0200|34 39|F test
14P06721188A0200|49 56|Snedecor
14P06721188A0200|59 71|contrast test
14P06723849A0197|42 50|Formation
14P06723849A0197|52 54|MRF
14P06726257A1179|22 40|5-hydroxytryptophan
14P06726257A1179|42 46|5-HTP
14P06726257A1179|62 64|LSD
14P06726257A1179|184 215|autoreceptor antagonist activity
14P06726257A1179|237 244|ABSTRACT
14P06726257A1179|259 263|WORDS
14P06726257T0000|0 6|Effects
14P06726257T0000|32 48|acid diethylamide
14P06726257T0000|50 66|serotonin release
14P06726257T0000|76 94|serotonin synthesis
14P06726257T0000|119 149|serotonin autoreceptor function
14P06728580A0291|26 32|El Paso
14P06728580A0291|33 34|TX
14P06731302A0930|13 27|bradyarrhythmia
14P06731302A0930|36 38|SCD
14P06731302A0930|79 90|branch block
14P06732946A0281|3 13|measurement
14P06732946A0281|44 55|fibrinolysis
14P06732946A0281|107 119|magnification
14P06732946A0281|129 142|image analyser
14P06732946A0281|143 151|Videoplan
14P06734713T0000|0 9|Diclofenac
14P06735247A0803|12 46|plasma enteroglucagon concentration
14P06738410T0000|0 13|Blood pressure
14P06740373A0891|39 48|cynomolgus
14P06740373A0891|105 122|drug testing model
14P06740697A0318|23 33|sensitivity
14P06740697A0318|45 62|guinea pig strains
14P06740919A0162|5 21|Amblyomma lepidum
14P06740919A0162|80 82|Bos
14P06743061A0239|10 16|percent
14P06743061A0239|24 31|patients
14P06743061A0239|45 51|disease
14P06743061A0239|85 92|tinnitus
14P06744024A0000|0 7|Morphine
14P06744024A0000|30 38|ventricle
14P06744024A0000|65 73|analgesia
14P06744024A0000|79 91|formalin test
14P06748227A0423|9 12|Case
14P06748227A0423|25 31|maximum
14P06749072A0116|7 21|urate excretion
14P06749072A0116|97 111|water immersion
14P06749072A0116|142 156|water immersion
14P06750608A1442|0 8|Mutations
14P06751455A0117|26 35|gallstones
14P06751455A0117|55 63|remainder
14P06751455A0117|67 74|patients
14P06751455A0117|83 90|glucagon
14P06753902A0437|115 117|IIS
14P06754662T0001|7 31|angiolymphoid hyperplasia
14P06755468A0180|0 6|Regions
14P06755468A0180|26 39|reading frames
14P06755468A0180|89 107|amino acid homology
14P06755986A0382|48 64|toxico-infections
14P06755986A0382|122 140|hospital infections
14P06760394T0001|37 39|ITI
14P06760394T0001|41 76|International Team fur Implantologie
14P06762025A0171|3 35|13,14-dihydro-15-keto-metabolites
14P06762025A0171|38 41|PGE2
14P06762025A0171|45 54|PGF2 alpha
14P06762321T0000|0 18|Nucleotide sequence
14P06762321T0000|20 45|DNA controlling expression
14P06762321T0000|54 80|maltosaccharide utilization
14P06762321T0000|82 94|Streptococcus
14P06763897A0216|27 29|PRA
14P06763897A0216|70 72|AII
14P06763897A0216|81 84|Sar1
14P06763897A0216|86 89|Ile8
14P06763897A0216|91 93|ALL
14P06764669T0001|12 24|determination
14P06764669T0001|51 64|deferoxamine B
14P06767648A0734|0 11|Measurements
14P06772370A0342|0 5|Volume
14P06772370A0342|8 19|distribution
14P06772370A0342|27 30|DMDZ
14P06772370A0342|65 68|DMDZ
14P06772370A0342|87 101|protein binding
14P06772612A0000|0 6|Effects
14P06772612A0000|43 53|haloperidol
14P06772612A0000|71 97|carotid body chemoreceptors
14P06772612A0000|108 118|hypercapnia
14P06775834A0000|0 4|HLA-A
14P06775834A0000|8 19|B phenotypes
14P06776918T0000|0 16|Trypanosoma cruzi
14P06777229A0243|3 10|subjects
14P06777229A0243|33 40|subjects
14P06777229A0243|46 53|patients
14P06777229A0243|72 78|disease
14P06781339A0501|45 53|follow-up
14P06781339A0501|73 81|treatment
14P06781339A0501|84 91|patients
14P06781339A0501|104 118|hypoventilation
14P06781728A0690|16 30|differentiation
14P06781728A0690|33 53|osteoprogenitor cells
14P06781728A0690|78 91|mineralization
14P06781728A0690|128 141|bone formation
14P06781728A0690|154 174|fluorochrome labeling
14P06782612A0142|62 73|urine volume
14P06782612A0142|85 101|lithium clearance
14P06782612A0142|102 104|CLi
14P06782869A0263|0 15|Nitrogen balance
14P06782869A0263|77 79|BUN
14P06782869A0263|97 116|creatinine clearance
14P06782869A0263|126 129|SGOT
14P06782869A0263|131 134|SGPT
14P06782869A0263|148 173|serum alkaline phosphatase
14P06784123A0286|0 9|Production
14P06784123A0286|12 20|C mu RNAs
14P06784123A0286|48 60|recombination
14P06784123A0286|82 83|JH
14P06784123A0771|9 16|C mu RNA
14P06784123A0771|28 50|sequence characteristic
14P06784123T0000|0 10|Transcripts
14P06784123T0000|16 39|immunoglobulin C mu gene
14P06785113A0337|42 49|activity
14P06785113A0337|92 99|patients
14P06786756T0000|9 25|DNA rearrangement
14P06786756T0000|39 52|RNA processing
14P06786756T0000|69 94|immunoglobulin delta genes
14P06788388A0000|30 37|ICRF-159
14P06790572A0330|28 37|lincomycin
14P06790572A0330|57 70|amphotericin B
14P06790572A0330|71 90|trimethoprim lactate
14P06790572A0330|91 101|polymyxin B
14P06790572A0330|105 114|anisomycin
14P06791500A0622|23 39|fluid delta OD450
14P06791500A0622|57 67|cornerstone
14P06793764T0001|0 10|Host lipids
14P06794480A0785|24 33|difference
14P06794480A0785|41 49|age group
14P06794666A0208|14 36|neuroeffector influence
14P06794666A0208|55 58|ATCI
14P06794666A0208|100 128|neurotransmitter biosynthesis
14P06794666A0208|141 169|cardiomyocyte adrenoreceptors
14P06795119T0000|0 20|Lens aldose reductase
14P06795654A0434|0 11|Fenfluramine
14P06795654A0434|70 97|self-administration behavior
14P06795654A0434|109 127|minimum requirement
14P06795654A0434|128 129|FR
14P06795832A0148|13 23|Hepatitis A
14P06795832A0148|30 40|HBe-antigen
14P06795832A0148|49 51|HBc
14P06795832A0148|72 85|HBe-antibodies
14P06795900A0000|19 61|acid cyclo-oxygenase inhibitor indomethacin
14P06795900A0000|79 81|CBF
14P06795900A0000|112 116|CMRO2
14P06795971A0000|3 13|rat incisor
14P06795971A0000|26 37|model system
14P06795971A0000|51 61|amelgenesis
14P06796300A0759|18 33|prolactin levels
14P06796300A0759|73 97|oestradiol administration
14P06797063A0000|0 5|Factor
14P06797063A0000|10 30|procoagulant activity
14P06797063A0000|31 51|antigen concentration
14P06797063A0000|54 76|von Willebrand activity
14P06797063A0000|77 95|ristocetin cofactor
14P06797063A0000|137 139|DIC
14P06798609A0000|74 89|gamma-vinyl GABA
14P06798609A0000|90 92|GVG
14P06801778T0001|0 11|Significance
14P06801778T0001|26 46|gas exchange reaction
14P06801778T0001|98 111|commissurotomy
14P06802500T0001|0 17|Thyreoliberin VUFB
14P06802500T0001|19 37|thyroid gammagraphy
14P06803634A0810|23 35|relationships
14P06803634A0810|90 113|blood gas determinations
14P06803634A0810|144 148|Paco2
14P06805504A0629|19 26|N values
14P06805504A0629|92 102|N excretion
14P06805537T0001|0 7|Advances
14P06805537T0001|10 29|hemophilia treatment
14P06807149A0222|71 73|DSG
14P06807149A0222|81 83|EIB
14P06807149T0000|0 9|Comparison
14P06807149T0000|26 37|preparations
14P06807149T0000|40 60|disodium cromoglycate
14P06807149T0000|93 104|bronchospasm
14P06807192A0312|0 3|LCBF
14P06807192A0312|59 77|glucose utilization
14P06807192A0312|78 81|LCGU
14P06807192A0312|126 130|Duffy
14P06807659T0001|0 11|Phagocytosis
14P06808287T0001|0 8|Detection
14P06808287T0001|11 31|hemophilia A carriers
14P06808529A0167|14 32|isoniazid solutions
14P06808529A0167|63 65|NTA
14P06808529A0167|68 85|EDTA concentration
14P06809474A1156|0 13|Bile bilirubin
14P06809474A1156|37 49|haem infusion
14P06809474A1156|77 89|investigation
14P06809586T0000|0 27|Autoimmune manipulation aids
14P06810070A0502|17 18|Hg
14P06810070A0502|23 31|Cd-spores
14P06810070A0502|52 65|control spores
14P06810694A0328|13 27|HDL-cholesterol
14P06810694A0328|42 59|VLDL-triglycerides
14P06810694A1000|0 12|Apo A-I level
14P06810694A1000|45 63|ethanol consumption
14P06812389A0658|0 4|TEMTU
14P06812389A0658|8 11|DPTU
14P06815368A0203|18 25|mannitol
14P06815368A0203|45 52|patients
14P06816053A0849|29 42|drug reactions
14P06816053A0849|83 96|mast cell test
14P06816123A0526|0 7|Selenium
14P06816123A0526|12 22|constituent
14P06816123A0526|25 46|glutathione peroxidase
14P06816123A0526|73 87|defense systems
14P06816442T0001|17 31|serum myoglobin
14P06816609A0639|4 29|% blood pressure reduction
14P06816609A0639|28 31|PCO2
14P06816609A0639|86 93|CBF fall
14P06817410A0982|47 58|epidemiology
14P06817410A0982|69 79|hepatitis A
14P06817410A0982|111 118|increase
14P06817410A0982|124 132|incidence
14P06817410A0982|145 153|hepatitis
14P06817410A0982|159 170|drug addicts
14P06818113A0384|102 125|corticosteroid treatment
14P06818113A0384|152 172|plasminogen activator
14P06818113A0384|175 189|clotting factor
14P06821147A0468|0 18|Sulphur amino acids
14P06822645T0039|10 40|increase growth hormone release
14P06823837A0562|32 41|wavefronts
14P06823837A0562|105 117|outflow tract
14P06825641A0076|11 29|landfill operations
14P06825641A0076|108 118|containment
14P06826813A0264|0 7|Vesicles
14P06826813A0264|49 51|UVA
14P06828396A0095|10 22|contamination
14P06828396A0095|60 84|biopsy fixation technique
14P06829082A0187|76 109|brain tissues glutaminase activity
14P06829082A0187|119 141|incubation temperatures
14P06830033A0661|7 18|observations
14P06830033A0661|41 52|pneumothorax
14P06830351A0397|11 17|Sugiura
14P06830351A0397|20 33|classification
14P06830351A0397|50 56|Type Ia
14P06830351A0397|62 68|Type Ib
14P06830351A0397|74 77|Type
14P06830351A0397|89 92|Type
14P06833047A0000|108 118|ventilation
14P06833047A0000|120 123|HFOV
14P06833422T0000|0 12|Determination
14P06833422T0000|17 36|alpha-hydroxy-9 beta
14P06833422T0000|39 52|alpha-pregna-4
14P06833422T0000|84 97|ion monitoring
14P06835516A0000|13 27|epidermoid cyst
14P06835914A0192|0 16|Copper treatments
14P06835914A0192|58 70|copper intake
14P06835914A0192|89 99|differences
14P06835914A0192|107 117|feed intake
14P06837312A0000|86 87|IU
14P06837312A0000|90 102|vitamin D3/kg
14P06837312A0000|116 130|months duration
14P06837312A0000|148 168|vitamin D3 withdrawal
14P06838388A0896|15 25|development
14P06838388A0896|41 52|tissue scars
14P06838388A0896|94 109|parenchyma areas
14P06838388A0896|119 131|normalization
14P06838388A0896|144 152|structure
14P06840803A0397|30 37|reaction
14P06840803A0397|66 79|i.v. challenge
14P06842629A0446|11 25|GMBF reductions
14P06842629A0446|51 66|treatment groups
14P06848729A0000|17 29|neuroblastoma
14P06848729A0000|39 41|St.
14P06849842T0000|0 32|Penicillin-G degradation products
14P06851280A0144|0 16|Plasma fibrinogen
14P06851327A0000|64 80|Neisseria species
14P06853042A0282|13 25|acidification
14P06853042A0282|59 82|bicarbonate reabsorption
14P06854957T0066|0 8|Detection
14P06854957T0066|43 58|echocardiography
14P06856306T0000|3 19|Tullio phenomenon
14P06856306T0000|35 43|Hennebert
14P06856669A1004|44 53|metabolism
14P06856669A1004|56 59|5-HT
14P06856669A1004|78 83|5-HIAA
14P06856669A1004|123 133|circulation
14P06858449A0335|0 11|Disturbances
14P06858640A0262|29 36|findings
14P06858640A0262|49 55|amyloid
14P06858640A0262|87 97|fibroblasts
14P06858805A0314|39 54|hypersensitivity
14P06858805A0314|59 66|Candidin
14P06858805A0314|68 78|Trycophytin
14P06858805A0314|82 91|Tuberculin
14P06858967A0167|0 26|Serum lactate dehydrogenase
14P06858967A0167|28 45|haptoglobin levels
14P06863087A0664|23 24|DB
14P06863087A0664|63 71|parameter
14P06864837T0000|18 45|spine immobilization methods
14P06864955T0000|12 15|MMWR
14P06868345A0000|13 23|visna-maedi
14P06868345A0000|26 30|Italy
14P06869215A0347|12 13|IC
14P06869215A0347|35 52|hypocomplementemia
14P06869986A0000|11 19|platelets
14P06869986A0000|57 64|collagen
14P06869986A0000|82 88|lesions
14P06869986A0000|103 111|ruminants
14P06872800T0000|45 57|HBV infection
14P06873504T0000|55 83|sodium metabolism alterations
14P06875478A0542|1 20|microU/l thyrotropin
14P06876006A0930|0 14|Echosismography
14P06876006A0930|68 77|sonography
14P06876317T0033|0 12|Relationships
14P06876317T0033|34 52|deficiency syndrome
14P06880563A0516|3 12|prevalence
14P06880563A0516|15 18|CPAF
14P06880563A0516|119 133|administrations
14P06880563A0516|152 165|administration
14P06880563A0516|168 181|chlorpropamide
14P06880604A0167|1 12|reassessment
14P06880604A0167|18 32|prevalence data
14P06880604A0167|68 74|Uusimaa
14P06880604A0167|100 104|Vaasa
14P06880604A0167|109 122|prevalence day
14P06880604A0167|127 133|January
14P06880650A0316|3 9|results
14P06880650A0316|45 55|researchers
14P06882578A0464|5 24|ultramarathon runner
14P06882578A0464|27 45|testosterone levels
14P06882578A0464|75 90|training session
14P06882578A0464|199 212|hours training
14P06883385A0509|54 73|neopterine excretion
14P06884450A0234|46 47|FB
14P06884450A0234|58 60|TBN
14P06886031A0898|5 14|PGE levels
14P06886031A0898|64 76|patient group
14P06886948A0750|13 23|weight gain
14P06886948A0750|43 56|energy intakes
14P06886948A0750|73 84|requirements
14P06890622A0067|110 121|hypertension
14P06890622A0067|134 144|coagulation
14P06890622A0067|158 170|pre-eclampsia
14P06890935T0001|0 5|Behcet
14P06891051A0587|0 7|Survival
14P06891051A0587|85 98|platelet count
14P06891270A0000|35 37|EPS
14P06891270A0000|51 63|extensibility
14P06891270A0000|67 79|contractility
14P06895559A0000|0 10|Terbutaline
14P06895559A0000|54 80|phosphodiesterase inhibitor
14P06895559A0000|119 132|rabbit fetuses
14P06895663A0810|51 53|RBT
14P06895663A0810|57 59|RLF
14P06897114A0240|49 72|DNA sequence recognition
14P06897114A0240|73 75|CAP
14P06902722T0000|44 53|infarction
14P06911559T0000|0 9|Statistics
14P06911559T0000|13 26|nurse managers
14P06916588A0304|3 16|infection rate
14P06916588A0304|49 65|Hickman catheters
14P06919347T0001|25 45|Laboratory Assistants
14P06919347T0001|46 51|School
14P06919347T0001|54 62|Stockholm
14P06919347T0001|79 99|laboratory assistants
14P06928974T0000|3 19|electrocardiogram
14P06931124A0109|24 40|complex formation
14P06931124A0109|43 51|NH4Mg PO4
14P06931124A0109|53 55|H2O
14P06935514A0000|3 9|Authors
14P06935514A0000|53 63|preparation
14P06935514A0000|100 111|desametazone
14P06935514A0000|133 143|alterations
14P06935514A0000|149 162|dentinogenesis
14P06938948T0001|9 11|IgA
14P06938948T0001|15 35|serum immunoglobulins
14P06946314T0000|0 15|Serum IgE levels
14P06946314T0000|16 32|Tauranga children
14P06946693T0000|0 2|Use
14P06946693T0000|5 26|prostaglandin F2 alpha
14P06946693T0000|26 35|PGF2 alpha
14P06948398A0523|20 29|management
14P06948398A0523|63 72|importance
14P06948493T0026|0 4|Range
14P06948868A0082|32 42|reliability
14P06948868A0082|45 63|faculty evaluations
14P06950004T0047|0 4|Study
14P06950004T0047|7 18|distribution
14P06950004T0047|45 57|iontophoresis
14P06953957A0503|7 30|creatine kinase activity
14P06953957A0503|166 176|correlation
14P06957125T0000|15 24|blood flow
14P06957125T0000|56 72|stimulating drugs
14P06957633T0001|0 10|Development
14P06957633T0001|54 69|erythroblastosis
14P06959130A0996|3 23|arginyl peptide bonds
14P06959130A0996|74 76|IXa
14P06959130A0996|104 116|Arg145-Ala146
14P06959130A0996|120 132|Arg180-Val181
14P06962492A0612|37 44|eruption
14P06962492A0612|78 87|hypotrophy
14P06962492A0612|99 108|bone bases
14P06962634A0190|49 71|porphyrin binding sites
14P06962634A0190|97 115|porphyrin transport
14P06963337T0000|39 49|hyperplasia
14P06963337T0000|54 65|hypertension
14P06966678A0523|24 32|clearance
14P06966678A0523|35 40|tracer
14P06966678A0523|58 64|portion
14P06966678A0523|87 91|curve
14P06966678A0523|102 111|metabolism
14P06966678A0523|146 151|lipids
14P06966678A0523|183 189|changes
14P06966678A0523|204 208|index
14P06966678A0523|214 223|injections
14P06966678A0523|235 240|atrium
14P06966678A0523|260 265|atrium
14P06966678A0523|283 290|ear vein
14P06969638A0180|40 56|CNS abnormalities
14P06969638A0180|79 98|meningeal infections
14P06969638A0180|163 175|complications
14P06972179A0556|8 17|IgE levels
14P06972443A0375|15 24|evaluation
14P06972443A0375|60 72|abnormalities
14P06972501A0615|0 10|Correlation
14P06973664A0000|15 31|cleavage syndrome
14P06975206A0279|8 21|administration
14P06975206A0279|24 36|betamethasone
14P06975206A0279|68 77|absorption
14P06975206A0279|90 98|phosphate
14P06975206A0279|110 120|growth rate
14P06977605T0000|0 9|Endorphins
14P06978566A0197|33 41|F344 rats
14P06978566A0197|51 62|lung lesions
14P06978566A0197|80 91|maximum dose
14P06978566A0197|123 133|M. pulmonis
14P06981991A0756|0 13|Aneurysmectomy
14P06981991A0756|33 36|CABG
14P06981991A0756|84 94|ECG changes
14P06981991A0756|166 176|ECG changes
14P06981991A0756|199 212|artery disease
14P06984225A0367|0 4|REV I
14P06984225A0367|35 46|patent graft
14P06986168A0304|103 113|V8 protease
14P06992600A0405|3 25|extraction measurements
14P06993660A0000|22 35|norepinephrine
14P06993660A0000|65 82|relaxant responses
14P06993660A0000|84 96|isoproterenol
14P06993660A0000|100 109|papaverine
14P06993660A0000|198 200|AHR
14P06994035T0001|2 17|line calculation
14P06994035T0001|19 40|steroid concentrations
14P06994035T0001|42 57|radioimmunoassay
14P06994049T0001|0 8|Detection
14P06994049T0001|21 34|hypothyroidism
14P06997203A0325|2 17|rubella patients
14P06997203A0325|30 41|confirmation
14P06997203A0325|44 45|HI
14P06997203A0325|111 118|PHA test
14P06997203A0325|126 144|antibody conversion
14P07004236A0741|22 37|folate compounds
14P07004236A0741|45 64|formate accumulation
14P07004236A0741|90 106|formate oxidation
14P07004236A0741|108 118|utilization
14P07004236A0741|186 203|methanol poisoning
14P07007181T0000|11 26|sodium saccharin
14P07007181T0000|43 52|microflora
14P07007591A0324|3 19|residue functions
14P07007591A0324|28 35|C-11 CPZ
14P07007591A0324|38 56|In-113m transferrin
14P07007591A0324|111 113|CPZ
14P07007591A0324|203 204|RT
14P07007591A0324|209 210|RR
14P07007591A0324|219 220|RR
14P07007591A0324|231 232|RT
14P07007591A0324|236 237|RR
14P07007591A0324|254 270|residue functions
14P07007591A0324|273 275|CPZ
14P07015018A0395|38 57|migration inhibition
14P07015262A0396|9 26|cefadroxil therapy
14P07015262A0396|61 75|tract infection
14P07015262A0396|78 87|CRP values
14P07015262A0396|109 120|microgram/ml
14P07016141A0238|21 23|RBF
14P07016141A0238|45 47|NBF
14P07016141A0238|62 66|Xenon
14P07018810A0002|0 25|Plasma renin concentration
14P07021505A0510|5 15|acclimation
14P07021505A0510|40 42|DPB
14P07026328A0369|5 13|diabetics
14P07026328A0369|15 17|Ca2
14P07026328A0369|19 27|infusions
14P07026328A0369|42 51|plasma Ca2
14P07026328A0369|92 99|glucagon
14P07026328A0369|132 138|glucose
14P07034479A1050|11 13|RMI
14P07034479A1050|68 75|AC group
14P07037479T0000|4 16|cracked-tooth
14P07038189A2301|27 29|CXD
14P07038684A1050|7 30|peptide map similarities
14P07038684A1050|104 106|p60
14P07038684A1050|110 112|p62
14P07038684A1050|126 145|amino acid sequences
14P07038684A1050|165 188|p60 initiator methionine
14P07038684A1050|199 201|p62
14P07040659A0212|16 28|control group
14P07040659A0212|46 56|improvement
14P07040659A0212|64 67|PEFR
14P07040659A0212|111 121|improvement
14P07044389T0000|0 4|Facts
14P07044389T0000|10 34|Economic Recovery Tax Act
14P07044562T0000|4 6|Pap
14P07044562T0000|9 12|ApUp
14P07044842A2062|3 14|relationship
14P07044842A2062|29 41|complications
14P07044842A2062|62 76|pathophysiology
14P07044842A2062|79 85|Bartter
14P07045156A0204|59 68|GBS sepsis
14P07045156A0204|93 106|immunoglobulin
14P07049690T0000|24 33|allografts
14P07053251A0666|29 35|effects
14P07053251A0666|37 47|bone marrow
14P07061263A0293|21 24|Pvas
14P07061263A0293|61 73|air inflation
14P07061263A0293|82 83|Px
14P07061350A0042|7 13|Science
14P07061350A0042|69 72|COCB
14P07061350A0042|100 117|distortion product
14P07061350A0042|118 122|f2-f1
14P07062036A0072|0 3|Rats
14P07062036A0072|32 45|sham operation
14P07062269A0798|35 42|receptor
14P07062269A0798|54 61|naloxone
14P07062269A0798|64 72|tolerance
14P07062269A0798|90 100|l-methadone
14P07062269A0798|140 148|mechanism
14P07063606T0000|0 8|Microwave
14P07063606T0000|40 58|barrier alterations
14P07064662A0222|41 50|occurrence
14P07064662A0222|53 65|target fibres
14P07064662A0222|108 117|neurolysis
14P07064662A0222|123 134|dorsal roots
14P07064923T0000|11 46|phenylalanine hydroxylase deficiency
14P07065206A0398|4 16|control sheep
14P07065206A0398|20 44|plasma TXB2 concentration
14P07065206A0398|60 74|ng/ml prebypass
14P07068493A0414|98 109|CO2 pressure
14P07068493A0414|129 132|Torr
14P07068493A0414|145 147|SIP
14P07068493A0636|27 44|oxygen consumption
14P07068493A0636|98 100|SIP
14P07068496A0000|60 70|water space
14P07068496A0000|84 101|sucrose indicators
14P07068496A0000|124 135|rabbit lungs
14P07068496A0000|149 158|techniques
14P07068887A0000|38 51|dimensionality
14P07068887A0000|108 141|Michigan Alcoholism Screening Test
14P07068887A0000|172 185|symptomatology
14P07072635A0000|48 61|administration
14P07072635A0000|64 78|desferrioxamine
14P07072635A0000|80 81|DF
14P07073520A0153|18 31|hemofiltration
14P07073520A0153|37 54|substitution fluid
14P07073520A0153|59 60|Na
14P07073520A0153|62 74|concentration
14P07073520A0153|110 121|fluid volume
14P07073520A0153|152 163|fluid volume
14P07075024A0540|58 61|CMIR
14P07075438T0000|11 32|serial xeroradiography
14P07076222A0543|0 14|Recommendations
14P07078263T0000|0 2|Use
14P07078263T0000|17 28|deferoxamine
14P07078263T0000|41 55|hemochromatosis
14P07079595A0848|20 30|correlation
14P07079595A0848|103 123|diameter measurements
14P07079595A0848|165 180|sperm production
14P07080496A0097|15 27|investigation
14P07080496A0097|30 41|lipoproteins
14P07080496A0097|88 90|HDL
14P07080496A0097|159 170|lipoproteins
14P07080496A0097|172 174|LDL
14P07081327A0546|39 52|concentrations
14P07081327A0546|55 64|phosphorus
14P07081327A0546|78 88|differences
14P07084198T0000|0 14|Selenium status
14P07084198T0000|34 47|United Kingdom
14P07084617A0204|12 20|follow-up
14P07084617A0204|22 30|parasites
14P07084617A0204|45 52|patients
14P07084617A0204|88 96|treatment
14P07084814T0000|0 10|Preparation
14P07084814T0000|20 39|phospholipid reagent
14P07084814T0000|42 59|coagulation assays
14P07088195T0019|11 22|consequences
14P07088195T0019|25 33|UV vision
14P07090151A0165|32 44|release bolus
14P07090151A0165|45 48|MSRB
14P07094856A0115|31 37|fetuses
14P07094856A0115|57 65|intervals
14P07094856A0115|79 87|gestation
14P07094905A0644|43 44|KA
14P07094905A0644|99 107|CA3 field
14P07096587A0267|52 67|training program
14P07097182A0480|3 10|duration
14P07097182A0480|17 25|amplitude
14P07097182A0480|39 47|potential
14P07097182A0480|93 102|overgrowth
14P07105635A0412|0 6|Samples
14P07105635A0412|25 34|volunteers
14P07106323A0560|24 34|possibility
14P07106323A0560|66 75|production
14P07106323A0560|78 84|E3-16-G
14P07106323A0560|92 100|pregnancy
14P07106534A0160|34 48|growth function
14P07106534A0160|74 79|length
14P07106534A0160|81 88|increase
14P07106534A0160|115 122|increase
14P07107287A1083|62 76|99Mo generators
14P07107462A0202|27 44|dissociation curve
14P07107462A0202|67 81|training period
14P07107462A0202|92 95|Hill
14P07107773A0000|189 204|amine precursors
14P07107773A0000|222 239|gas chromatography
14P07107773A0000|245 272|resolution mass spectrometry
14P07107773A0000|303 349|trifluoroethyl-pentafluoropropionyl derivatives
14P07109788A0333|13 20|patients
14P07109788A0333|45 52|vagotomy
14P07109788A0333|56 67|pyloroplasty
14P07110999A0160|36 47|tetraparesis
14P07110999A0160|49 60|incontinence
14P07110999A0160|64 83|oculomotor paralysis
14P07112320A0086|0 31|CSF adenosine deaminase activity
14P07112320A0086|30 32|ADA
14P07112471A0639|0 19|Histamine reactivity
14P07112654A0388|38 47|difference
14P07112654A0388|58 67|prevalence
14P07112654A0388|103 116|hospital staff
14P07113365A0737|0 4|Ficat
14P07113365A0737|8 12|Bizou
14P07113365A0737|53 65|surface angle
14P07113365A0737|67 76|Brattstrom
14P07113897A0285|22 32|differences
14P07113897A0285|35 36|EF
14P07113897A0285|98 99|NS
14P07113897A0285|146 147|NS
14P07113897A0285|170 180|correlation
14P07113897A0285|228 237|exercise r
14P07114083A0153|5 16|MOPP therapy
14P07114083A0153|36 42|Hodgkin
14P07114083A0153|86 109|glucocerebrosidase level
14P07114083A0153|127 133|Gaucher
14P07116298A1079|114 135|Corynebacterium parvum
14P07116298A1079|176 178|BCG
14P07116298A1079|225 227|BCG
14P07116298A1079|229 232|DTIC
14P07116298A1079|264 267|DTIC
14P07116962A0299|3 19|COP-PAWP gradient
14P07119890T0000|0 1|Re
14P07119890T0000|43 53|blood cells
14P07119890T0000|57 62|Tc-99m
14P07124743A1223|16 32|glassware factory
14P07124743A1223|33 46|As2O3 exposure
14P07124743A1223|59 69|measurement
14P07124743A1223|96 108|determination
14P07124743A1223|132 141|evaluation
14P07124743A1223|151 169|mouth contamination
14P07124743A1223|247 268|microgram/g creatinine
14P07124743A1223|354 363|absorption
14P07125064T0000|67 87|Schistosoma japonicum
14P07125064T0000|89 107|Schistosoma mansoni
14P07125238T0000|3 11|pia mater
14P07125238T0000|32 44|blood vessels
14P07126067T0000|12 23|reproduction
14P07126067T0000|51 61|Bali cattle
14P07126413A0000|9 23|delivery system
14P07126413A0000|129 138|Eudragit S
14P07130335A1081|0 13|Administration
14P07130335A1081|19 48|dopamine agonist bromocriptine
14P07130335A1081|109 128|plasma 18-OHB levels
14P07132408A0387|30 51|magnesium cardioplegia
14P07134924A0640|20 32|malformations
14P07134924A0640|37 47|eye defects
14P07135112T0000|0 5|Repair
14P07136524A0180|97 108|osteosarcoma
14P07136524A0180|120 143|retinoblastoma survivors
14P07136569A0000|2 6|Malmo
14P07136569A0000|8 13|Sweden
14P07136569A0000|21 35|school children
14P07137927A0000|10 19|immunology
14P07137927A0000|22 30|Singapore
14P07137927A0000|64 72|diagnosis
14P07140060T0000|15 25|dislocation
14P07140493A1045|21 29|secretion
14P07140493A1045|32 42|bicarbonate
14P07140493A1045|53 59|stomach
14P07140493A1045|99 112|acid secretion
14P07141130A0615|12 21|evaluation
14P07141130A0615|46 53|increase
14P07141130A0615|141 157|cells/100 microns
14P07141130A0615|178 188|mean height
14P07143347T0000|0 5|Cramps
14P07147622T0000|13 27|storage disease
14P07149047A0260|27 30|Q/Dk
14P07149047A0260|55 62|Torr/cm2
14P07149303T0000|33 35|CNS
14P07154928T0001|0 11|Modification
14P07155579T0001|12 26|bacteriospermia
14P07158726T0001|0 6|Triumph
14P07160491A0547|76 82|LD50/30
14P07160491A0547|90 110|dose reduction factor
14P07162146A0000|16 30|ultrafiltration
14P07162146A0000|33 50|sample preparation
14P07162146A0000|67 80|quantification
14P07162146A0000|83 97|ethylene glycol
14P07162146A0000|107 124|gas chromatography
14P07165767T0000|0 11|Mastocytosis
14P07168531T0001|4 21|Onchocerca species
14P07168531T0001|50 56|Senegal
14P07169630A0983|21 27|absence
14P07169630A0983|40 50|differences
14P07169630A0983|58 67|conditions
14P07169630A0983|87 96|complexity
14P07172690A0547|44 59|energy transport
14P07172690A0547|60 77|creatine phosphate
14P07172690A0547|78 99|creatine phosphokinase
14P07172690A0547|120 121|Ca
14P07172690A0547|125 130|ATPase
14P07172690A0547|158 160|SPR
14P07172690A0547|234 246|% restriction
14P07173729A0000|7 23|penetration tests
14P07173729A0000|83 93|interaction
14P07174046T0000|0 15|Vibrio fluvialis
14P07174046T0000|31 41|Maharashtra
14P07174122A0000|0 20|Serum creatine kinase
14P07174122A0000|20 22|SCK
14P07174122A0000|93 109|bicycle ergometry
14P07174437A0181|0 8|Organisms
14P07175474A0102|70 77|findings
14P07175474A0102|90 95|manner
14P07175474A0102|125 132|official
14P07175474A0102|137 146|difficulty
14P07179412A1131|29 38|population
14P07179412A1131|42 43|US
14P07180901A0539|63 86|prostaglandin synthetase
14P07181985A0107|8 25|mg mitomycin/20 ml
14P07181985A0107|42 49|mg/40 ml
14P07181985A0107|101 108|catheter
14P07182523A0462|31 33|SOA
14P07182523A0462|60 76|SOA concentration
14P07183576A0157|16 28|concentration
14P07183576A0157|31 44|flucloxacillin
14P07183576A0157|71 83|micrograms/ml
14P07183576A0157|85 86|SD
14P07183576A0157|124 125|SD
14P07183576A0157|158 159|SD
14P07183576A0157|200 201|SD
14P07184375T0001|31 42|methotrexate
14P07184375T0001|47 58|prednisolone
14P07184375T0001|60 61|VM
14P07184375T0001|65 88|combination chemotherapy
14P07184598T0001|19 33|hyperthyroidism
14P07184774T0000|0 13|Re-examination
14P07184774T0000|19 28|ED01 study
14P07184795A0517|10 23|determinations
14P07184795A0517|39 56|serum CPK activity
14P07184795A0517|67 70|I.U.
14P07190627T0000|15 43|plasminogen activator release
14P07190869A0316|0 3|CDDP
14P07191183A0505|0 8|Treatment
14P07191183A0505|11 21|meat muscle
14P07191183A0505|74 85|autoxidation
14P07191804A0000|34 54|bicycle exercise test
14P07191972A0391|11 21|temperature
14P07191972A0391|26 34|degrees C
14P07191972A0391|38 46|responses
14P07192369T0000|65 78|administration
14P07192369T0000|81 102|l-alpha-acetylmethadol
14P07192722A0682|23 39|parathyroidectomy
14P07192722A0682|63 79|serum iPTH levels
14P07192722A0682|86 87|CL
14P07192722A0682|96 99|PMNs
14P07192722A0682|142 143|CL
14P07192722A0682|152 155|PMNs
14P07194905A0332|0 2|TCZ
14P07194905A0332|52 66|tissue necrosis
14P07194905A0332|118 133|brain maturation
14P07195615A0087|60 76|Cd administration
14P07195615A0087|78 88|association
14P07195615A0087|100 111|accumulation
14P07195615A0087|114 115|Cd
14P07195880A0621|37 41|means
14P07195880A0621|49 55|leprosy
14P07202224A0452|3 13|preferences
14P07202224A0452|69 70|TP
14P07202224A0452|92 105|attractiveness
14P07202525A0200|28 33|buzzer
14P07202525A0200|41 47|seconds
14P07202525A0200|61 67|stimuli
14P07202525A0200|91 97|seconds
14P07202525A0200|115 122|stimulus
14P07202919A0142|0 4|Ulcer
14P07202919A0142|63 72|ulcer scar
14P07202919A0142|77 85|42nd week
14P07203410T0000|0 12|Family visits
14P07203410T0000|50 63|state hospital
14P07205120T0000|42 55|ECG wave forms
14P07205967T0000|7 14|reaction
14P07205967T0000|37 43|partner
14P07205967T0000|46 53|response
14P07205967T0000|56 66|improvement
14P07205967T0000|92 98|partner
14P07208984A0000|0 4|Brain
14P07208984A0000|50 58|MAA brain
14P07208984A0000|74 91|tomography studies
14P07208984A0000|92 93|CT
14P07214230T0000|0 9|Inhibition
14P07214230T0000|12 35|Fusarium moniliforme var
14P07214230T0000|85 114|soil bacterium Arthrobacter sp
14P07214665A0000|25 58|fluorouracil imidazole carboxamide
14P07214665A0000|86 112|bis-chloroethyl nitrosourea
14P07214665A0000|127 130|FIVB
14P07217329A0000|36 48|determination
14P07217329A0000|53 72|alpha-acetylmethadol
14P07217329A0000|74 77|LAAM
14P07217329A0000|105 121|noracetylmethadol
14P07217329A0000|123 141|dinoracetylmethadol
14P07217329A0000|167 179|dinormethadol
14P07217329A0000|217 230|chromatography
14P07217329A0000|259 269|UV detector
14P07217523A0364|0 6|Results
14P07217523A0364|12 27|recognition task
14P07217523A0364|83 95|vowel context
14P07217523A0364|105 115|recognition
14P07218008T0000|6 24|response properties
14P07218008T0000|77 93|Aotus trivirgatus
14P07219297T0000|21 35|standardization
14P07219821T0028|21 34|considerations
14P07221179A0156|21 32|GABA content
14P07221179A0156|44 56|GABA decrease
14P07221179A0156|79 92|administration
14P07221354T0000|0 5|Theory
14P07221354T0000|9 20|applications
14P07221354T0000|23 34|pulse dosing
14P07225300A0968|5 11|results
14P07225300A0968|23 29|neonate
14P07225300A0968|51 57|respect
14P07225300A0968|67 72|nature
14P07225300A0968|75 81|effects
14P07225300A0968|94 104|sensitivity
14P07225540A0193|31 63|electron capture detection method
14P07226440T0000|3 14|hemodynamics
14P07226440T0000|45 51|failure
14P07228955A0000|48 68|theophylline analysis
14P07228955A0000|83 102|1,7-dimethylxanthine
14P07234308A0121|5 17|drug regimens
14P07234308A0121|21 26|C-MOPP
14P07234308A0121|28 31|CHOP
14P07234308A0121|35 39|BACOP
14P07234308A0121|49 63|remission rates
14P07234755A0838|28 35|Hematrak
14P07234974T0000|23 35|Jat dentition
14P07235317T0000|37 54|Phadebas RAST test
14P07235355A0462|23 26|COPD
14P07235355A0462|100 109|flow rates
14P07235355A0462|111 128|density dependence
14P07236351A0812|36 38|EEG
14P07236351A0812|89 91|CA4
14P07237123T0000|24 37|unit responses
14P07237123T0000|48 60|nerve volleys
14P07237560A1038|61 70|inactivity
14P07237560A1038|89 100|substitution
14P07237560A1038|134 149|Hind III linkers
14P07237560A1038|156 165|gene units
14P07237560A1038|173 185|transcription
14P07237817T0000|0 15|Cross reactivity
14P07237817T0000|17 36|theophylline RIA kit
14P07240343A0000|0 11|Strontium-90
14P07240343A0000|48 62|post conception
14P07242929T0001|0 8|Recording
14P07242929T0001|47 57|extremities
14P07243380A0327|9 16|acidosis
14P07243380A0327|50 57|decrease
14P07243380A0327|60 62|P50
14P07247059A0775|0 15|Catheter transit
14P07247059A0775|34 46|step increase
14P07247059A0775|48 60|concentration
14P07247059A0775|112 123|transit time
14P07247059A0775|183 184|N2
14P07249497A0688|36 47|estrogen PPI
14P07249497A0688|96 107|estrogen use
14P07249497A0688|109 111|PPI
14P07249544A0343|28 55|serum creatine kinase levels
14P07249660T0000|0 12|Determination
14P07249660T0000|21 34|distensibility
14P07249895A0177|18 31|prostaglandins
14P07249895A0177|73 87|LES hypotension
14P07249895A0177|127 138|indomethacin
14P07249895A0177|143 155|micrograms/kg
14P07249895A0177|189 211|prostaglandin synthesis
14P07251564A0569|82 94|ASDC nosology
14P07252346A0223|9 17|technique
14P07252346A0223|35 41|problem
14P07253335T0000|0 6|Effects
14P07253335T0000|9 32|prostaglandin inhibitors
14P07253335T0000|66 77|stroke-prone
14P07256543A0814|41 57|inhalation injury
14P07256543A0814|96 119|carboxyhemoglobin levels
14P07256543A0814|147 158|space injury
14P07256543A0814|191 203|airway injury
14P07259325A0394|0 7|Survival
14P07259325A0394|59 67|diagnosis
14P07260389A0221|0 11|Methisergide
14P07260389A0221|38 56|serotonin receptors
14P07260389A0221|69 79|development
14P07260987A0336|3 18|plasma half-life
14P07260987A0336|24 50|disposition phase t1/2 beta
14P07262239T0000|0 6|Effects
14P07262239T0000|23 33|deprivation
14P07262239T0000|36 46|development
14P07262239T0000|67 77|projections
14P07262625A0000|0 21|Corticosteroid therapy
14P07262625A0000|55 70|occult infection
14P07262625A0000|95 120|host parasite relationship
14P07262625A0000|171 188|protozoal parasite
14P07262625A0000|189 201|Giardia muris
14P07262625A0000|223 237|corticosteroids
14P07263374T0000|6 18|lung function
14P07263374T0000|32 44|pneumonectomy
14P07263421A0351|4 7|Sair
14P07263421A0351|11 13|So2
14P07263745T0000|9 29|Charnley arthroplasty
14P07264787A0351|8 15|patients
14P07264787A0351|42 49|evidence
14P07264787A0351|59 69|thyroiditis
14P07264787A0351|100 114|hyperthyroidism
14P07266969A0246|44 52|Tamoxifen
14P07266969A0246|56 79|breast cancer management
14P07267675A0000|24 36|cephalosporin
14P07267675A0000|38 40|CGP
14P07268828A0000|1 17|fluoroimmunoassay
14P07268828A0000|24 36|determination
14P07268828A0000|46 58|plasma levels
14P07268828A0000|60 70|propranolol
14P07268828A0000|100 110|propranolol
14P07268828A0000|132 152|solid-phase particles
14P07268828A0000|174 184|propranolol
14P07270163A0684|24 34|projections
14P07270163A0684|68 70|CNF
14P07270163A0684|181 183|CNF
14P07270991A0149|4 18|pollen allergen
14P07270991A0149|27 39|grass species
14P07274042A0249|0 2|DMI
14P07274042A0249|14 27|concentrations
14P07274428A0000|83 96|contrast agent
14P07274428A0000|97 99|RCA
14P07274428A0000|116 131|cholecystography
14P07274428A0000|135 145|Bengal pink
14P07274428A0000|180 192|RCA triombrin
14P07274428A0000|209 222|indigo-carmine
14P07274428A0000|249 250|PM
14P07274482A0000|9 15|neurons
14P07274482A0000|55 65|selectivity
14P07274482A0000|73 87|afterdischarges
14P07274482A0000|90 97|movement
14P07274482A0000|109 116|velocity
14P07274482A0000|122 129|movement
14P07274505A0660|21 31|differences
14P07276210T0000|0 4|Assay
14P07276210T0000|40 50|blood spots
14P07276210T0000|61 69|detection
14P07277222A1391|40 49|motor unit
14P07277222A1391|65 74|oscillator
14P07277222A1391|95 104|occurrence
14P07277222A1391|137 145|existence
14P07277222A1391|160 171|interactions
14P07278104T0001|0 24|Leukocyte enzyme activity
14P07278104T0001|26 62|blood lymphocyte blast transformation
14P07278578T0001|15 26|chemotherapy
14P07278578T0001|30 36|Hodgkin
14P07280654A0000|16 18|HBE
14P07280654A0000|53 68|averaging method
14P07282444A0075|10 14|cases
14P07282444A0075|37 44|approach
14P07282444A0075|50 55|tumour
14P07282444A0075|65 69|cases
14P07282444A0075|90 94|shunt
14P07282552A0990|2 8|Group V
14P07282552A0990|109 121|subepicardium
14P07282552A0990|132 145|subendocardium
14P07282943A0097|38 55|superfusate oxygen
14P07282943A0097|71 73|PO2
14P07282943A0097|101 103|PO2
14P07283110A0000|8 9|B1
14P07283110A0000|11 20|deficiency
14P07286057A0159|7 27|AUC infinity analyses
14P07286057A0159|30 45|pharmacokinetics
14P07286057A0159|149 162|administration
14P07293100T0001|0 16|Gastrin secretion
14P07293100T0001|22 37|food stimulation
14P07293327T0001|0 23|Fibrinogen determination
14P07293327T0001|31 41|KZM-1 meter
14P07295033A0513|5 10|period
14P07295033A0513|15 18|days
14P07295033A0513|27 30|dose
14P07295033A0513|58 63|faeces
14P07295033A0513|76 80|urine
14P07295417A0092|46 54|ventricle
14P07295417A0092|90 98|technique
14P07295417A0092|101 113|phase imaging
14P07296303A0418|0 8|Responses
14P07296303A0418|45 63|lateralis posterior
14P07296997A0125|49 51|OCG
14P07296997A0125|67 94|Tc-99m-PyG cholescintigraphy
14P07297576A0454|18 42|drinking water ad libitum
14P07297576A0454|62 68|Aludrox
14P07297978A0570|30 41|case history
14P07297978A0570|42 55|smoking habits
14P07297978A0570|83 84|C.
14P07298209A0291|26 45|performance capacity
14P07298209A0291|55 58|W170
14P07298209A0291|78 84|VO2 max
14P07298209A0291|129 145|bicycle ergometer
14P07298259T0000|0 12|Determination
14P07298523T0000|0 5|Effect
14P07298523T0000|23 44|prostaglandin F2 alpha
14P07299857A0294|0 10|LD50 values
14P07299857A0294|19 20|KP
14P07299857A0294|69 74|KP-CMC
14P07299857A0294|143 148|KP-T10
14P07299857A0294|164 177|intrarectally.
14P07299857A0294|191 204|administration
14P07299857A0294|207 212|KP-CMC
14P07299857A0294|219 229|LD50 values
14P07299857A0294|273 274|KP
14P07304905A0336|0 14|Autotransfusion
14P07304905A0336|37 49|Heparin-ACD-B
14P07304905A0336|51 61|Heparin-DPD
14P07304905A0336|63 80|Heparin-ACD-B etc.
14P07306839T0001|0 7|Electron
14P07306839T0001|61 69|degrees C
14P07308849A0817|12 22|differences
14P07308849A0817|41 62|sham operation animals
14P07309562T0000|36 48|determination
14P07310206A0154|17 32|microvasculature
14P07310206A0154|67 94|scanning electron microscopy
14P07310206A0154|102 121|resin casting method
14P07311881T0000|0 11|MSMS Council
14P07312707T0000|0 7|Chordoma
14P07312707T0000|26 33|F344 rat
14P07320153T0000|0 4|Micro
14P07320153T0000|105 122|injection analysis
14P07320153T0000|124 137|catecholamines
14P07320153T0000|140 150|body fluids
14P07323063A0000|94 97|SHRs
14P07323063A0000|154 175|mg/kg dl-isoproterenol
14P07323063A0000|198 208|time course
14P07323573A0644|26 37|dissociation
14P07326596A0061|3 16|IgA deficiency
14P07326596A0061|33 35|IgE
14P07327097A0647|2 8|PB mice
14P07327097A0647|132 144|granule cells
14P07328000T0000|0 20|Nutritional cataracts
14P07330073T0000|0 9|Prevention
14P07330073T0000|12 32|transfusion reactions
14P07337609A0531|43 57|antibody titers
14P07337609A0531|58 60|GMT
14P07337609A0531|164 175|immunization
14P07337609A0531|186 197|immunization
14P07340196T0001|30 34|HBSAG
14P07340196T0001|80 105|hepatitis B virus carriers
14P07341346A0174|16 28|shunt vessels
14P07341346A0174|63 70|arteries
14P07345217A0000|10 22|complications
14P07345217A0000|75 84|malignancy
14P07347728T0000|0 13|Arachnoid cyst
14P07349416A0337|16 26|summer coat
14P07354367A0162|0 10|Hypotension
14P07355527A0467|23 34|Lich-Gregoir
14P07356273T0022|24 38|cell carcinomas
14P07365183A0000|163 167|MMECT
14P07365183A0000|206 209|SECT
14P07369183T0000|26 44|coagulation testing
14P07369458A0606|62 79|muscle temperature
14P07369458A0606|117 132|amputation level
14P07372433A0000|24 36|relationships
14P07372433A0000|39 55|guinea pig ureter
14P07372928A0105|0 4|Tests
14P07372928A0105|30 45|Mossbauer source
14P07372928A0105|94 123|signal-transmission properties
14P07375836T0000|12 18|work-up
14P07375836T0000|22 28|patient
14P07375836T0000|44 53|metastasis
14P07375836T0000|64 72|carcinoma
14P07375864A0431|22 35|nonspecificity
14P07375864A0431|41 52|platelet MAO
14P07375864A0431|63 71|correlate
14P07375864A0431|107 119|schizophrenia
14P07375864A0431|174 185|platelet MAO
14P07376165T0001|0 6|Ecthyma
14P07377378A0143|0 19|Estrogen replacement
14P07377378A0143|30 43|beta-estradiol
14P07377378A0143|46 70|beta-estradiol-3-benzoate
14P07377378A0143|135 149|heat production
14P07377954A0117|116 133|oxygen consumption
14P07377954A0117|134 136|VO2
14P07377954A0117|155 171|health volunteers
14P07377954A0117|175 186|emg activity
14P07377954A0117|210 230|gastrocnemius muscles
14P07377954A0117|271 305|postexercise ankle pressure changes
14P07379334A0503|0 6|Changes
14P07379334A0503|20 29|reactivity
14P07379334A0503|49 63|transfer factor
14P07380615A0478|31 41|possibility
14P07380615A0478|61 71|collar jobs
14P07380615A0478|159 173|work efficiency
14P07380615A0478|206 215|efficiency
14P07380615A0478|245 258|collar workers
14P07385543T0001|0 9|Importance
14P07385543T0001|26 48|blood sulfhydryl groups
14P07385920A0189|27 42|blood lead level
14P07385920A0189|64 80|blood haemoglobin
14P07385920A0189|110 120|delta amino
14P07385933A0085|9 20|iv injection
14P07385933A0085|25 35|g galactose
14P07385933A0085|38 51|kg body weight
14P07385933A0085|99 103|14CO2
14P07386500A0174|8 29|clotting factor assays
14P07386500A0174|93 106|determinations
14P07386864T0000|20 27|dialysis
14P07387242A0236|0 14|Blood variables
14P07387242A0236|88 102|plasma proteins
14P07387242A0236|136 153|clotting functions
14P07392519T0001|26 36|retinopathy
14P07392519T0001|39 46|children
14P07393856A0314|32 47|acid ethyl ester
14P07393856A0314|64 81|reference standard
14P07393856A0314|83 93|Experiments
14P07393976A0000|12 31|sodium phenobarbital
14P07393976A0000|43 57|sodium barbital
14P07393976A0000|76 89|taste aversion
14P07393976A0000|129 142|discrimination
14P07393976A0000|148 173|bottle taste aversion task
14P07393976A0000|177 203|% sodium saccharin solution
14P07394364A0738|25 47|gas exchange parenchyma
14P07394364A0738|213 215|VO2
14P07395750A0294|0 15|Underestimations
14P07395750A0294|66 78|methodologies
14P07396545A0217|0 11|Chemotherapy
14P07397066T0000|0 14|Drug inhibition
14P07397066T0000|21 42|blood aspirin esterase
14P07401318A0823|15 25|temperature
14P07401318A0823|96 97|Hz
14P07405701T0000|32 57|platelet monoamine oxidase
14P07406527A0212|33 51|porphyrin excretion
14P07406527A0212|57 73|porphyrin content
14P07406527A0212|148 159|HCB controls
14P07408970A0706|20 33|administration
14P07408970A0706|43 44|Gf
14P07408970A0706|48 54|Cv mice
14P07408970A0706|99 108|difference
14P07410037A0752|8 20|stone-formers
14P07410037A0752|55 74|magnesium metabolism
14P07410037A0752|105 117|control group
14P07410037A0752|215 224|propensity
14P07413144T0018|0 7|Analysis
14P07413242A0000|26 36|paraplegics
14P07413242A0000|60 64|T1-L3
14P07413441T0070|16 27|localisation
14P07413441T0070|41 52|distribution
14P07413781A0169|11 21|stimulation
14P07413781A0169|44 63|stimulus preexposure
14P07413781A0169|71 81|attenuation
14P07413781A0169|106 116|stimulation
14P07413781A0169|132 143|conditioning
14P07413781A0169|149 159|preexposure
14P07413806T0000|15 22|amygdala
14P07413806T0000|33 41|pathology
14P07414817T0001|0 18|Cataract extraction
14P07415340A0280|0 5|Number
14P07415340A0280|39 53|pneumocytes typ
14P07416204A0437|65 79|pacing interval
14P07416204A0437|80 81|t0
14P07416204A0437|113 114|t1
14P07416204A0437|120 121|t0
14P07416204A0437|140 141|t1
14P07416204A0437|181 182|t1
14P07416204A0437|201 202|t0
14P07418498A0217|21 33|complications
14P07418498A0217|36 50|corticosteroids
14P07418498A0217|116 129|amphotericin B
14P07418498A0217|153 164|lung abscess
14P07418829A0191|0 11|Implications
14P07419485A0158|16 25|transition
14P07419485A0158|73 80|solution
14P07419485A0158|144 157|simplification
14P07423803T0001|0 8|Treatment
14P07425838A0182|15 30|pheochromocytoma
14P07425838A0182|56 64|trimester
14P07425838A0182|67 75|pregnancy
14P07426101A0124|16 47|lipoprotein lipid concentrations
14P07426101A0124|47 88|adipose tissue lipoprotein lipase activity
14P07426101A0124|86 104|anthropometric data
14P07426101A0124|105 123|alcohol consumption
14P07426604A0397|3 7|C18:1
14P07426604A0397|9 17|C10 value
14P07426745A0177|20 52|blood erythrocyte membrane injury
14P07426745A0177|91 106|gamma-irradiaton
14P07426745A0177|124 125|Gy
14P07428037A0989|36 52|mouse mt 12S rRNA
14P07428037A0989|70 89|bp hairpin structure
14P07428037A0989|137 139|RNA
14P07428037A0989|199 215|mRNA binding site
14P07428037A0989|215 220|ACCUCC
14P07428037A0989|238 259|corn chloroplast rRNAs
14P07429009T0121|21 44|cell population dynamics
14P07431059A0000|6 19|cadaver brains
14P07431059A0000|42 54|magnification
14P07431059A0000|98 110|pineal region
14P07431059A0000|126 137|relationship
14P07431059A0000|143 153|pineal body
14P07431059A0000|186 202|cerebellar artery
14P07431059A0000|209 213|Galen
14P07431059A0000|226 234|Rosenthal
14P07432288A0218|0 19|Serum antibody titre
14P07432288A0218|54 68|recurrence rate
14P07434431A0203|13 21|refeeding
14P07434431A0203|38 46|mechanism
14P07434431A0203|50 59|activation
14P07434431A0203|74 83|infections
14P07434456A0286|40 50|blood cells
14P07434456A0286|97 114|% glycerol content
14P07434456A0286|117 128|measurements
14P07434456A0286|183 191|osmometry
14P07435185A0074|3 10|symptoms
14P07435185A0074|23 30|findings
14P07435185A0074|53 60|lymphoma
14P07435185A0074|68 76|diagnosis
14P07435185A0074|96 107|drill biopsy
14P07436187A0147|27 33|studies
14P07436187A0147|66 71|entity
14P07436187A0147|132 138|factors
14P07436187A0147|141 150|disability
14P07436459A0245|95 115|vitamin B6 deficiency
14P07436459A0245|151 171|tryptophan metabolism
14P07436702A0156|3 17|control persons
14P07436702A0156|37 40|DNFB
14P07436794A0148|25 40|carotid arteries
14P07436794A0148|41 43|CCA
14P07438346A0381|15 38|lidocaine concentrations
14P07438346A0381|115 118|Vmax
14P07438482A0145|44 56|blood samples
14P07438482A0145|72 84|determination
14P07438482A0145|96 97|E1
14P07438482A0145|113 114|E2
14P07440085T0061|0 17|Arm function tests
14P07440430A1074|12 21|B breeding
14P07440430A1074|43 51|Hb levels
14P07440430A1074|81 88|NB lambs
14P07440430A1074|93 103|S x B lambs
14P07440430A1074|117 125|Hb levels
14P07440430A1074|132 142|D x B lambs
14P07440430A1074|144 150|B lambs
14P07440430A1074|185 209|hemoglobin concentrations
14P07445971A0241|28 37|acrylamide
14P07445971A0241|61 74|nerve ligation
14P07449221A0086|3 11|operation
14P07449221A0086|25 32|excision
14P07449221A0086|71 76|repair
14P07449221A0086|82 87|tendon
14P07449253A0411|27 34|pressure
14P07449253A0411|92 99|diuresis
14P07449253A0411|109 116|decrease
14P07449253A0411|119 130|blood volume
14P07450031A0691|6 22|sedative activity
14P07450031A0691|74 89|benzothiazepin-6
14P07450031A0691|101 104|NF19
14P07450031A0691|152 167|benzothiazepin-6
14P07450031A0691|179 182|NF20
14P07450388A0406|22 27|CCK-PZ
14P07450388A0406|87 101|pressure sensor
14P07450388A0406|107 123|duodenofiberscope
14P07453919A0000|16 21|Horton
14P07453919A0000|45 58|investigations
14P07453919A0000|77 92|blood cell count
14P07453919A0000|106 119|determinations
14P07453919A0000|132 147|acid phosphatase
14P07453919A0000|195 197|IgM
14P07453919A0000|201 211|IgG binding
14P07453919A0000|237 253|blood neutrophils
14P07455042A0457|71 99|Dynamic Spatial Reconstructor
14P07455042A0457|123 140|density resolution
14P07455042A0457|166 179|contrast agent
14P07455521A0414|3 6|ESEG
14P07455521A0414|30 39|NEXT study
14P07456774A0448|26 30|drugs
14P07457931A0655|34 42|injection
14P07457931A0655|45 51|5-OH-DA
14P07458171A0086|30 43|Platyhelmintha
14P07458171A0086|48 55|Nematoda
14P07458171A0086|63 71|Crustacea
14P07461226A0958|63 80|plasma epinephrine
14P07461226A0958|82 102|norepinephrine levels
14P07461848A0230|18 31|concentrations
14P07461848A0230|52 64|tobacco smoke
14P07461848A0230|68 69|CO
14P07461848A0230|78 79|NO
14P07461848A0230|87 89|NO2
14P07461848A0230|109 121|micrograms/m3
14P07461848A0230|144 156|micrograms/m3
14P07462481A0422|10 32|backscatter coefficient
14P07462481A0422|88 96|occlusion
14P07462481A0422|144 152|occlusion
14P07463294A1216|13 25|tumor relapse
14P07463294A1216|45 54|responders
14P07463294A1216|104 113|responders
14P07463465A0297|5 13|infection
14P07463465A0297|34 46|control women
14P07466831A0714|0 16|Pentachlorophenol
14P07466831A0714|38 50|HCB porphyria
14P07466831A0714|89 107|porphyrin excretion
14P07466831A0714|141 157|porphyrin pattern
14P07467975A0316|0 14|Family planning
14P07467975A0316|89 102|contraceptives
14P07467975A0316|139 149|percentages
14P07467975A0316|152 161|primiparae
14P07467975A0316|165 176|secundiparae
14P07467975A0316|203 212|percentage
14P07467975A0316|215 228|multigravidity
14P07467975A0316|232 241|parameters
14P07467975A0316|262 273|reproduction
14P07467975A0316|298 315|behaviour patterns
14P07467975A0316|317 322|Europe
14P07469692A0000|3 24|term osteomesopycnosis
14P07469692A0000|48 59|bone disease
14P07469692A0000|71 81|inheritance
14P07471210A0384|3 13|87K protein
14P07471210A0384|106 119|messenger RNAs
14P07472582A0993|3 16|identification
14P07472582A0993|43 59|99mTc-tetrofosmin
14P07472582A0993|63 67|201Tl
14P07472736A0278|11 19|component
14P07472736A0278|59 66|eminence
14P07473169A0133|0 4|EUK-8
14P07473169A0133|82 101|superoxide dismutase
14P07473169A0133|104 122|catalase activities
14P07473742A0187|56 66|GATA family
14P07473742A0187|68 99|vertebrate transcription factors
14P07474078A0838|46 64|integration studies
14P07474078A0838|95 109|CA dinucleotide
14P07474078A0838|158 177|integration activity
14P07474085A0932|12 20|R protein
14P07474085A0932|55 69|frameshift site
14P07474085A0932|74 82|V protein
14P07474124A1360|35 37|PI2
14P07474124A1360|41 51|PI3 viruses
14P07474124A1360|66 90|parainfluenza virus genus
14P07474124A1360|184 197|F glycoprotein
14P07474140A1036|51 55|ICP27
14P07474140A1036|66 84|amino acid residues
14P07474140A1036|113 126|ICP27 homologs
14P07474140A1036|147 151|D-357
14P07474140A1036|153 157|E-358
14P07474140A1036|159 163|H-479
14P07474140A1036|165 169|C-400
14P07474140A1036|171 175|C-483
14P07474140A1036|180 184|C-488
14P07474451A0000|8 24|resonance imaging
14P07474451A0000|25 27|MRI
14P07474451A0000|93 108|signal intensity
14P07474617A1035|0 7|Patients
14P07474617A1035|54 63|PRL levels
14P07474772A0274|3 31|Laser Scanning Ophthalmoscope
14P07475733T0000|0 6|Malaria
14P07475733T0000|19 36|HIV-1 transmission
14P07475733T0000|45 50|Africa
14P07475793T0000|0 2|BSE
14P07476164A1602|41 57|resonance studies
14P07476164A1602|61 64|F17A
14P07476164A1602|66 69|K13Q
14P07476164A1602|71 74|F15Y
14P07476164A1602|78 81|F27Y
14P07476164A1602|145 156|CspB protein
14P07476701A0654|24 37|IgE antibodies
14P07476701A0654|86 99|correspondence
14P07476963A0000|0 9|Peroxisome
14P07476963A0000|42 46|PPARs
14P07476963A0000|51 70|retinoid X receptors
14P07476963A0000|70 73|RXRs
14P07476963A0000|85 101|hormone receptors
14P07476971A0381|35 50|SKUT-1B-20 cells
14P07476971A0381|57 82|transcription factor Pit-1
14P07476975A0492|11 21|lactotropes
14P07476975A0492|23 34|somatotropes
14P07476975A0492|36 46|thyrotropes
14P07476975A0492|51 62|gonadotropes
14P07476975A0492|121 129|pituitary
14P07476975A0492|170 181|distribution
14P07476975A0492|184 193|cell types
14P07477245A0625|13 26|A. parasiticus
14P07477245A0625|41 62|aflatoxins B1 B2 G1 G2
14P07477245A0625|85 89|AF B1
14P07477245A0625|90 91|G1
14P07477245A0625|101 114|concentrations
14P07478514A0237|40 44|clone
14P07478523A0551|32 47|amino acid forms
14P07478523A0551|124 142|RET protein isoform
14P07478525A1177|13 26|MHBst proteins
14P07479004A0421|17 37|mobility shift assays
14P07479004A0421|40 43|PERE
14P07479004A0421|70 71|P1
14P07479004A0421|73 74|P2
14P07479004A0421|78 79|P3
14P07479004A0421|114 117|HeLa
14P07482069A0606|19 21|MTX
14P07482069A0606|56 74|vasculitis symptoms
14P07483276A0139|0 7|Analysis
14P07483276A0139|53 56|ORFs
14P07483276A0139|76 78|UL1
14P07483276A0139|80 82|UL2
14P07483276A0139|84 86|UL3
14P07483276A0139|91 93|UL3
14P07483276A0139|130 151|herpes simplex virus-1
14P07483276A0139|151 155|HSV-1
14P07483276A0139|158 175|pseudorabies virus
14P07483276A0139|176 178|PRV
14P07483276A0139|204 225|varicella-zoster virus
14P07483285A0322|5 21|HPV16 E6/E7 cDNAs
14P07483285A0322|38 59|SV40 enhancer/promoter
14P07483285A0322|65 72|MMTV LTR
14P07483285A0322|149 161|DNA synthesis
14P07483285A0322|184 198|E7 gene product
14P07483857A0350|0 23|Correlation coefficients
14P07483857A0350|52 54|NIT
14P07483857A0350|95 137|connective-tissue-protein frei meat protein
14P07483857A0350|150 174|connective-tissue-protein
14P07487067A0592|3 22|translation products
14P07487067A0592|55 58|APS1
14P07487067A0592|154 169|transit peptides
14P07487067A0592|172 191|plastid localization
14P07487363A0447|3 14|serum levels
14P07487363A0447|16 18|IgE
14P07487363A0447|31 35|IgG-4
14P07487363A0447|51 64|food allergens
14P07487811A0000|112 131|Systems Experiment-1
14P07487811A0000|132 136|PSE-1
14P07487811A0000|165 169|PSE-2
14P07487908A0230|61 92|chloramphenicol acetyltranferase
14P07487908A0230|93 95|CAT
14P07487908A0230|127 132|AR-42J
14P07487908A0230|170 172|Rat
14P07487908A0230|177 179|IEC
14P07488247T0000|20 44|aryl hydrocarbon receptor
14P07488247T0000|50 74|translocator interactions
14P07488247T0000|78 102|aryl hydrocarbon receptor
14P07488291A0934|56 78|triamcinolone acetonide
14P07488291A0934|134 156|triamcinolone acetonide
14P07488959T0000|35 51|lymphocytopoiesis
14P07489502A0000|3 29|influenza virus NS1 protein
14P07489502A0000|151 167|pre-mRNA splicing
14P07490079A0825|78 81|STEP
14P07490079A0825|107 115|STEP gene
14P07490079T0000|53 63|phosphatase
14P07490079T0000|65 68|STEP
14P07490083A0000|8 18|anhydrase V
14P07490083A0000|19 22|CA V
14P07490156A0647|0 9|Vitamin D3
14P07490156A0647|13 30|nicotine treatment
14P07490156A0647|102 112|correlation
14P07490278A0799|45 49|Num1p
14P07490278A0799|55 72|mother cell cortex
14P07490742A0636|43 63|dsRNA binding domains
14P07490766T0000|64 66|Max
14P07490766T0000|70 90|c-Myc leucine zippers
14P07490766T0000|125 136|interactions
14P07490766T0000|167 184|heterodimerization
14P07490770A0267|0 9|Comparison
14P07490770A0267|154 169|DNA endonuclease
14P07491111A0221|12 13|GR
14P07491111A0221|16 27|DMS-79 cells
14P07491305A0102|27 38|localization
14P07491305A0102|43 59|accessory pathway
14P07491305A0102|98 108|QRS complex
14P07491305A0102|114 125|sinus rhythm
14P07491305A0102|153 171|delta wave polarity
14P07491791A0263|3 19|promoter mutation
14P07491791A0263|42 53|E1A products
14P07491791A0263|70 91|helper adenovirus type
14P07491791A0263|92 94|Ad5
14P07493327A0507|53 54|U2
14P07493327A0507|56 57|U4
14P07493327A0507|62 70|U6 snRNAs
14P07493627A0882|0 8|Treatment
14P07493627A0882|11 14|PCC4
14P07493627A0882|80 88|EC-1 mRNA
14P07493627A0882|135 149|EC-1 expression
14P07494244A0335|14 19|E1A243
14P07494244A0335|21 23|YY1
14P07494244A0335|93 109|ATF/CREB proteins
14P07494244A0335|122 124|CRE
14P07494274A1015|10 20|experiments
14P07494274A1015|66 76|virus yield
14P07494274A1015|94 104|temperature
14P07494274A1015|116 126|disfunction
14P07494274A1015|165 181|virion maturation
14P07494293A0585|53 86|T-cell signal transduction cascade
14P07494293A0585|101 103|Lck
14P07494303A0000|5 31|immunodeficiency virus type
14P07494303A0000|31 33|Vpr
14P07494303A0000|116 136|monocytes/macrophages
14P07494306A0240|28 31|VP16
14P07494306A0240|47 58|interactions
14P07494306A0240|99 102|VP16
14P07494306A0240|208 219|protein VP22
14P07494314A1287|40 63|kinase interaction sites
14P07494314A1287|66 89|tyrosine phosphorylation
14P07494314A1287|94 107|LMP2A homologs
14P07494314A1287|142 164|sequences heterogeneity
14P07494314A1287|223 226|EBVs
14P07495059T0078|12 43|ECAT Angina Pectoris Study Group
14P07495120A0260|22 26|Phase
14P07495120A0260|79 89|cryosurgery
14P07495120A0260|99 115|radiation therapy
14P07495120A0260|129 138|recurrence
14P07495726A1189|19 27|Chi motif
14P07495726A1189|66 93|recombination hotspot region
14P07495726A1189|97 116|Bcl-2 proto-oncogene
14P07495726A1189|150 160|T-ALL lines
14P07496184T0001|50 56|Charite
14P07496184T0001|63 86|Vienna University Clinic
14P07496400A0525|35 44|HMGR1 mRNA
14P07496400A0525|45 55|HMGR1S mRNA
14P07496400A0525|107 117|HMGR1L mRNA
14P07496400A0525|201 214|inflorescences
14P07498727A0724|46 48|G.C
14P07498727A0724|52 68|T.A transversions
14P07498727A0724|73 85|rad18 mutator
14P07498727A0724|107 119|substitutions
14P07498727A0724|153 155|G.C
14P07498727A0724|159 174|T.A transversion
14P07498791A0680|74 77|PBS2
14P07498791A0680|100 113|protein kinase
14P07498791A0680|135 159|osmolarity stress pathway
14P07499242A0898|49 64|RAFTK expression
14P07499252A0150|2 17|hGM-CSF receptor
14P07499252A0150|38 55|consensus sequence
14P07499252A0150|67 77|PI 3-kinase
14P07499252A0150|143 153|PI 3-kinase
14P07499394A0187|0 1|J.
14P07499401A0444|3 10|identity
14P07499401A0444|18 25|hnRNPs H
14P07499409A0367|0 3|TPBF
14P07499409A0367|86 95|N terminus
14P07499409A0367|107 124|targeting sequence
14P07499421A0237|59 82|rat hepatocytes plasmids
14P07499421A0237|93 98|CYP3A1
14P07499421A0237|127 176|chloramphenicol acetyltransferase reporter plasmid
14P07499848A0409|37 43|B cells
14P07499848A0409|63 71|Sf9 cells
14P07499848A0409|78 92|germ-line gamma
14P07499848A0409|96 114|epsilon transcripts
14P07500386A0870|12 34|GapIII protein activity
14P07500386A0870|154 157|IRA1
14P07500597A0212|22 25|BPVs
14P07500597A0212|71 72|SD
14P07500950A0000|42 76|Agrobacterium rhizogenes Ri-plasmid
14P07500950A0000|100 122|Nicotiana tabacum L. cv
14P07500953A0305|4 19|ADR1 gene dosage
14P07500953A0305|101 109|ADR1 gene
14P07501016T0000|34 52|galaxy TXFS2226-184
14P07501458A0578|15 37|C/EBP family inhibitors
14P07501458A0578|44 46|LIP
14P07501458A0578|50 56|CHOP-10
14P07501700A0000|24 43|pretreatment regimen
14P07501700A0000|47 68|monophosphoryl lipid A
14P07501700A0000|68 70|MLA
14P07501700A0000|74 91|micrograms/kg i.v.
14P07501992A0125|26 42|scanning electron
14P07501992A0125|69 89|spectroscopy analysis
14P07501992A0125|90 96|SEM-EDS
14P07504171A0715|17 38|growth factor receptor
14P07504171A0715|38 43|PDGF-R
14P07504171A0715|103 116|Src SH2 domain
14P07504171A0715|136 154|PDGF-R binding site
14P07504171A1214|16 30|Src SH2 mutants
14P07504171A1214|37 54|binding properties
14P07504171A1214|100 125|crystal structure solution
14P07504171A1214|130 143|Src SH2 domain
14P07504712A0843|21 41|actin plaque assembly
14P07504712A0843|51 73|cell substrate adhesion
14P07505349A0702|8 16|lethality
14P07505349A0702|32 39|resectio
14P07505349A0702|64 71|survival
14P07505349A0702|78 83|months
14P07505798A0000|32 58|type A influenza A/Japan/57
14P07505798A0000|76 77|HA
14P07505798A0000|111 136|histocompatibility complex
14P07505798A0000|137 139|MHC
14P07505798A0000|167 179|T lymphocytes
14P07505798A0000|180 183|CTLs
14P07506253A0742|28 30|K19
14P07506253A0742|34 35|TK
14P07506253A0742|52 61|HeLa cells
14P07507187T0000|0 8|Mechanism
14P07507187T0000|24 37|DNA expression
14P07507187T0000|49 65|cointernalization
14P07507207A0991|17 32|IRF binding site
14P07507207A0991|48 61|IRF-2 promoter
14P07507207A0991|80 89|IRF-2 gene
14P07507207A0991|124 139|IRF-1 expression
14P07507458A0250|84 100|hepatitis C virus
14P07507458A0250|100 102|HCV
14P07507458A0250|122 126|ELISA
14P07507458A0250|130 141|RIBA methods
14P07508082A0821|10 17|decrease
14P07508082A0821|29 36|activity
14P07508082A0821|61 69|bleaching
14P07508082A0821|89 96|chlorine
14P07508140A0448|0 26|Hepatitis B surface antigen
14P07508140A0448|59 84|hepatitis C virus antibody
14P07508250A0537|30 40|correlation
14P07508250A0537|53 67|selenium intake
14P07508250A0537|70 97|liver selenium concentration
14P07508250A0537|138 156|time liver selenium
14P07508250A0537|182 192|correlation
14P07508250A0537|231 243|investigation
14P07508441A0487|0 9|Antibodies
14P07508441A0487|86 100|56K autoantigen
14P07508441A0487|103 119|HeLa cell extract
14P07508441A0487|119 133|cDNA sequencing
14P07508441A0487|148 162|56K cDNA shares
14P07508441A0487|206 224|amino acid sequence
14P07508441A0487|267 274|56K cDNA
14P07508441A0487|322 323|Ca
14P07508441A0487|350 371|binding protein family
14P07508954A0000|16 33|complex peroxidase
14P07508954A0000|34 38|ABC-P
14P07508954A0000|61 79|Mycobacterium bovis
14P07508954A0000|127 139|Ziehl-Neelsen
14P07508954A0000|141 142|ZN
14P07509053A0139|14 22|processes
14P07509053A0139|38 45|function
14P07509053A0139|77 89|establishment
14P07509053A0139|108 114|lineage
14P07509449A0000|29 46|sarcoma virus CT10
14P07509449A0000|67 76|p47gag-crk
14P07509449A0000|100 112|Gag sequences
14P07509449A0000|157 176|Src homology regions
14P07509449A0000|181 183|SH2
14P07509449A0000|187 199|SH3 sequences
14P07509450A0705|12 30|methylation pattern
14P07509450A0705|53 63|HSV tk gene
14P07509450A0705|84 100|cytosine residues
14P07509450A0705|109 127|nucleotide sequence
14P07509450A0705|155 174|HSV tk gene activity
14P07509472A1320|0 9|CONCLUSION
14P07509472A1320|54 71|neovascularization
14P07509472A1320|88 113|alpha interferon treatment
14P07509624T0000|22 33|11q23 region
14P07509624T0000|43 64|chromosome aberrations
14P07509624T0000|91 109|gel electrophoresis
14P07509811A1357|0 3|GTRE
14P07509811A1357|5 7|TRE
14P07509811A1357|12 31|CRE oligonucleotides
14P07509811A1357|176 179|GTRE
14P07509811A1357|181 183|TRE
14P07509811A1357|188 207|CRE oligonucleotides
14P07509811A1357|225 228|GTRE
14P07509811A1357|230 232|TRE
14P07509811A1357|237 256|CRE oligonucleotides
14P07509811A1357|315 321|Jun/Fos
14P07509811A1357|373 393|transcription factors
14P07509811A1357|394 401|CREB/ATF
14P07509811A1357|413 433|transcription factors
14P07510461A0731|20 37|test abnormalities
14P07510635A0479|86 98|transcription
14P07510635A0479|190 192|Pol
14P07510635A0479|197 199|Pol
14P07510724A1208|3 13|lymph nodes
14P07510724A1208|47 55|arthritis
14P07510724A1208|84 94|granulomata
14P07510724A1208|122 132|association
14P07510724A1208|140 150|sarcoidosis
14P07510724A1208|164 172|arthritis
14P07511444A0728|0 12|HCV infection
14P07511444A0728|33 35|BMT
14P07511444A0728|133 135|BMT
14P07511444T0000|0 26|Hepatitis C virus infection
14P07511444T0000|82 108|bone marrow transplantation
14P07511496A1511|4 24|plasma concentrations
14P07511496A1511|33 42|E-selectin
14P07511818A0485|30 45|cell populations
14P07511818A0485|91 93|IFN
14P07511818A0485|179 192|control vector
14P07511818A0485|206 222|IFN-beta sequence
14P07512159A0992|0 10|Improvement
14P07512159A0992|16 35|polypyrimidine tract
14P07512159A0992|51 69|splicing efficiency
14P07512159A0992|117 136|branchpoint mutation
14P07512258A0441|0 20|Liver transplantation
14P07512258A0441|78 86|PMN count
14P07512258A0441|138 142|G-CSF
14P07512552A0270|0 3|Joys
14P07512552A0270|7 8|F.
14P07513703T0000|29 56|protein tyrosine phosphatase
14P07513703T0000|56 62|SH-PTP2
14P07513703T0000|111 138|insulin receptor substrate-1
14P07514295A0000|0 23|Tyrosine phosphorylation
14P07514295A0000|80 102|T-cell antigen receptor
14P07514295A0000|102 104|TCR
14P07514295A0000|154 172|signaling machinery
14P07514301A0000|34 47|protein kinase
14P07514301A0000|48 50|PKR
14P07514301A0000|162 182|tumor suppressor gene
14P07516337A1119|9 11|Lck
14P07516337A1119|50 55|p95Vav
14P07516337A1119|112 123|Jurkat cells
14P07516466A1054|83 86|PP2A
14P07516466A1054|121 145|phosphoprotein substrates
14P07516466A1054|162 182|phosphorylation state
14P07516466A1054|184 187|CREB
14P07516466A1054|214 226|NIH 3T3 cells
14P07516469A1025|7 9|Src
14P07516597A1017|51 53|MVE
14P07516597A1017|67 85|polyprotein segment
14P07516597A1017|118 135|antigen processing
14P07516597A1017|155 157|MVE
14P07516597A1017|174 191|T cell determinant
14P07516866A0000|12 23|PRL receptor
14P07516866A0000|24 27|PRLR
14P07516866A0000|42 44|DNA
14P07516866A0000|78 102|pigeon crop sac libraries
14P07516866A0000|136 160|polymerase chain reaction
14P07517544A0515|23 32|regression
14P07517544A0515|49 59|alterations
14P07517544A0515|90 101|pancreatitis
14P07517544A0515|117 124|recovery
14P07517544A0515|139 146|function
14P07517544A0515|152 159|pancreas
14P07517544A0515|199 203|L-364
14P07517544A0515|242 250|mg/kg/day
14P07517869A0411|14 30|dephosphorylation
14P07517869A0411|70 80|C/EBP-delta
14P07517869A0411|143 164|phosphatase inhibitors
14P07517869A0411|185 204|sodium orthovanadate
14P07518257A0351|28 46|S1 nuclease mapping
14P07518257A0351|46 47|P1
14P07518257A0351|100 101|P2
14P07518426A0000|0 12|Interleukin-8
14P07518426A0000|14 17|IL-8
14P07518426A0000|72 87|C-X-C chemokines
14P07518460A0771|31 35|PTP1C
14P07518460A0771|84 94|mutagenesis
14P07518460A0771|119 129|phosphatase
14P07518561A0496|22 51|p72syk protein tyrosine kinase
14P07518561A0496|78 92|TCR/CD3 complex
14P07518561A0496|177 182|p56lck
14P07518578A0000|24 41|Rous sarcoma virus
14P07518578A0000|147 158|localization
14P07518578A0000|174 188|binding ability
14P07519447T0000|0 11|Organization
14P07519447T0000|55 68|oxide synthase
14P07519463A0000|37 51|work efficiency
14P07519463A0000|52 72|segment work/regional
14P07519481A1275|8 9|Sl
14P07519481A1275|16 17|Sl
14P07519481A1275|35 54|follicle development
14P07519481A1275|110 122|KL expression
14P07519481A1275|124 137|follicle cells
14P07519481A1275|163 175|oocyte growth
14P07519606A1269|0 12|Anti-NPROSP-C
14P07519606A1269|71 83|proSP-C forms
14P07519606A1269|85 99|lamellar bodies
14P07520098A0211|15 16|Db
14P07520098A0211|23 33|B6.CH-2bm13
14P07520098A0211|62 63|Db
14P07521009A0377|49 56|MW104-1B
14P07521009A0377|112 125|DNA mismatches
14P07521009A0377|126 128|G/T
14P07521009A0377|130 132|A/C
14P07521009A0377|134 136|G/G
14P07521009A0377|150 155|Kramer
14P07521009A0377|162 166|1989a
14P07521285A1109|63 65|GBS
14P07521285A1109|69 72|CIDP
14P07521285A1109|110 139|motor conduction abnormalities
14P07521285A1109|173 189|F wave parameters
14P07521285A1109|201 216|chronodispersion
14P07521285A1109|268 282|minimum latency
14P07521285A1109|303 316|F wave studies
14P07521601A0000|13 26|growth factors
14P07521601A0000|63 74|myelopoiesis
14P07521601A0000|93 104|chemotherapy
14P07521601A0000|107 121|cancer patients
14P07521916T0000|0 6|Effects
14P07521916T0000|56 82|immunodeficiency virus type
14P07522163T0000|0 11|Presentation
14P07522163T0000|15 40|horse cytochrome c peptide
14P07522163T0000|48 57|H-2b class
14P07522163T0000|63 88|histocompatibility complex
14P07522163T0000|89 91|MHC
14P07522163T0000|135 147|T lymphocytes
14P07522163T0000|165 182|MHC anchor residue
14P07522163T0000|215 229|CTL recognition
14P07523363A0440|91 122|USF2 translation initiation site
14P07523710T0000|0 8|Diagnosis
14P07523710T0000|40 53|serum prostate
14P07523710T0000|82 92|examination
14P07523710T0000|107 121|ultrasonography
14P07524265T0000|27 44|stimulating factor
14P07524265T0000|45 49|G-CSF
14P07524265T0000|80 92|complications
14P07525548A1380|30 46|ligand affinities
14P07525548A1380|89 108|fibronectin variants
14P07525548A1380|118 120|CS1
14P07525548A1380|128 147|fibronectin variants
14P07525596A0584|61 64|Fpr3
14P07525596A0584|122 136|PPIase activity
14P07525843A0859|0 8|Dilutions
14P07525843A0859|11 14|H-2b
14P07525843A0859|17 32|H-2d NP peptides
14P07525843A0859|55 69|H-2b NP peptide
14P07525843A0859|169 172|H-2b
14P07525843A0859|176 179|H-2d
14P07525843A0859|185 220|histocompatibility complex molecules
14P07525843A0859|268 273|NP CTL
14P07525843A0859|278 286|H-2b mice
14P07525843A0859|309 317|H-2d mice
14P07525843A0859|336 337|NP
14P07526609A0736|30 31|S4
14P07526609A0736|35 40|UTR/S1
14P07526609A0736|59 80|PKR activator sequence
14P07526609A0736|83 84|S1
14P07526609A0736|97 99|UTR
14P07526609A0736|102 103|S4
14P07526609A0736|137 138|S4
14P07527168A0524|0 11|Microvessels
14P07527168A0524|26 35|x200 field
14P07528028A1192|39 66|FGF-1 cell surface receptors
14P07528028A1192|143 147|FGF-1
14P07528028A1192|195 202|ABSTRACT
14P07528028A1192|217 221|WORDS
14P07528325A0165|45 55|GH receptor
14P07528325A0165|67 71|Stat1
14P07528325A0165|85 104|transcription factor
14P07528325A0165|195 207|DNA sequences
14P07528325A0165|217 231|gene expression
14P07528531A0904|7 16|infections
14P07528531A0904|18 22|G-CSF
14P07528531A0904|78 94|blood cell counts
14P07528531A0904|110 120|neutrophils
14P07528531A0904|140 142|CRP
14P07528667A0834|5 20|initiation sites
14P07528746A1049|0 25|Phosphoamino acid analysis
14P07528746A1049|38 51|ASGPR subunits
14P07528746A1049|61 63|Ser
14P07528746A1049|104 106|Thr
14P07528746A1049|135 151|phosphoamino acid
14P07528746A1049|193 195|Tyr
14P07528746A1049|218 221|RHL1
14P07528772A0616|43 60|ZAP-70 interaction
14P07528772A0616|67 69|TCR
14P07528772A0616|111 151|glutathione S-transferase fusion proteins
14P07528772A0616|162 164|NH2
14P07528772A0616|185 195|SH2 domains
14P07528772A0616|197 202|ZAP-70
14P07528772A0616|273 286|TCR zeta chain
14P07528772A0616|286 297|TCR zeta cyt
14P07528772A0616|309 316|TCR zeta
14P07528772A0616|319 340|CD3 epsilon TAM motifs
14P07528772A1539|35 46|TAM peptides
14P07528772A1539|93 103|SH2 domains
14P07528772A1539|105 110|ZAP-70
14P07529124A0119|31 32|RT
14P07529124A0119|67 77|heterodimer
14P07529124A0119|176 195|amino acid sequences
14P07529504A0000|71 100|X-ray contrast agent iopromide
14P07529504A0000|99 107|Ultravist
14P07529504A0000|109 111|CAS
14P07529516A0474|59 62|EDXR
14P07530128A0578|37 45|serum PSA
14P07530502A0974|0 7|Addition
14P07530502A0974|33 35|SLF
14P07530502A0974|38 54|SI4-h220 cultures
14P07530502A0974|106 124|protein degradation
14P07530502T0000|14 25|Steel factor
14P07530502T0000|46 71|tyrosine kinase activation
14P07530549A0956|0 7|Analysis
14P07530549A0956|29 33|BLAST
14P07530549A0956|37 50|GRAIL programs
14P07531321A0369|23 34|PVC/24 hours
14P07531321A0369|63 65|PVC
14P07531321A0369|69 81|CI evaluation
14P07532278A0833|0 6|Horvath
14P07532278A0833|8 9|I.
14P07533527A0128|0 9|Cell lines
14P07533527A0128|60 72|hybridization
14P07533527A0128|121 123|PCR
14P07533758A1038|3 22|amino acid sequences
14P07533758A1038|35 38|RfbA
14P07533758A1038|42 54|RfbB homologs
14P07533758A1038|60 69|identities
14P07533758A1038|88 97|similarity
14P07533758A1038|118 127|similarity
14P07533858A1503|16 36|alanine substitutions
14P07533858A1503|92 106|oligomerization
14P07533858A1503|121 128|GP64 EFP
14P07533880T0000|3 14|FinO protein
14P07533880T0000|16 28|IncF plasmids
14P07533880T0000|33 36|FinP
14P07533880T0000|46 48|RNA
14P07533880T0000|82 97|duplex formation
14P07534285A0155|43 66|tyrosine phosphorylation
14P07534285A0155|68 77|BaF3 cells
14P07534285A0155|105 116|Mpl receptor
14P07534285A0155|117 125|BaF3/mMpl
14P07534286A0842|1 21|chicken paxillin cDNA
14P07534297A0141|21 45|pair HindIII DNA fragment
14P07534297A0141|74 93|AP endonuclease gene
14P07534297A0141|93 95|APE
14P07534297A0141|102 134|chloramphenicol acetyltransferase
14P07534297A0141|135 137|CAT
14P07534306A0444|27 42|GrsA derivatives
14P07534306A0444|94 109|deletion mutants
14P07534306A0444|163 183|amino acid activation
14P07534306A0444|183 210|carboxyl thioester formation
14P07534306A0444|275 282|D-isomer
14P07535593A0714|0 2|CD7
14P07535593A0714|5 7|CD3
14P07535593A0714|9 25|T-cell precursors
14P07535593A0714|32 47|V delta 2D delta
14P07535768A1076|0 8|HVH2 mRNA
14P07535768A1076|16 33|expression pattern
14P07535768A1076|45 49|CL100
14P07535768A1076|80 83|PAC1
14P07535768A1076|108 130|MAP kinase phosphatases
14P07537267A2094|74 88|HPFH-3 deletion
14P07537267A2094|167 177|specificity
14P07537267A2094|188 205|gamma-globin genes
14P07537362A1112|24 52|Shb-SH3 domain proteins v-Src
14P07537362A1112|70 90|coimmunoprecipitation
14P07537736A0453|40 43|Jak2
14P07537736A0453|47 50|PRLR
14P07537736A0453|166 194|cytokine receptor superfamily
14P07537851A0000|0 12|Transcription
14P07537851A0000|26 47|cell adhesion molecule
14P07537851A0000|48 53|VCAM-1
14P07537851A0000|88 105|lipopolysaccharide
14P07537851A0000|124 151|cytokines interleukin-1 beta
14P07537851A0000|153 179|tumor necrosis factor alpha
14P07537851A0000|178 186|TNF-alpha
14P07537851A0891|0 10|Experiments
14P07537851A0891|44 50|p50/p65
14P07537851A0891|120 124|IRF-1
14P07537851A0891|130 138|VCAM1 IRF
14P07537851A0891|156 160|IRF-1
14P07537851A0891|185 187|p50
14P07538068A1094|29 43|control element
14P07538068A1094|44 45|AX
14P07538068A1094|81 94|Hox expression
14P07538068A1094|109 123|Hoxa-7 enhancer
14P07538122A0800|37 48|Fab fragment
14P07538122A0800|49 54|Fab A8
14P07538173A0307|0 8|MBP-Rep68
14P07538173A0307|23 47|DNA-RNA helicase activity
14P07538173A0307|54 67|ATP hydrolysis
14P07538818A0197|34 59|growth signal transduction
14P07538818A0197|92 115|amino acid substitutions
14P07538818A0197|221 224|IL-3
14P07538818A0197|236 240|Ba/F3
14P07538818A0197|244 258|FDCP cell lines
14P07539119A0291|51 69|c-abl kinase domain
14P07539119A0291|70 81|NH2-terminus
14P07539119A0291|86 99|G128R mutation
14P07539119A0291|106 119|transformation
14P07539119A0291|155 166|G128R mutant
14P07539119A0985|44 57|Abl SH3 domain
14P07539119A0985|70 84|target proteins
14P07539314T0000|0 6|Changes
14P07539314T0000|56 66|fingerlings
14P07539314T0000|87 98|nifurpirinol
14P07539314T0000|100 107|Furanace
14P07539314T0000|109 114|P-7138
14P07540607A0709|0 10|Retreatment
14P07540607A0709|68 81|immunoglobulin
14P07540773A0576|11 13|NSE
14P07540773A0576|17 19|MBP
14P07540773A0576|25 28|IJVB
14P07540773A0576|53 55|PVB
14P07540866A1069|55 73|MAP kinase activity
14P07540866A1069|87 99|A/K1018 cells
14P07540866A1069|125 134|Y/F2 cells
14P07541589A0652|28 40|cancer volume
14P07541589A0652|84 99|vesicle invasion
14P07541589A0652|103 123|lymph node metastasis
14P07541912A0485|0 16|Sequence analysis
14P07541912A0485|37 44|CAAT box
14P07541912A0485|67 85|G-C content regions
14P07541912A0485|94 95|P1
14P07541912A0485|99 100|P2
14P07542577A0438|3 17|fusion proteins
14P07542577A0438|29 33|ELISA
14P07542577A0438|37 46|reactivity
14P07542616A0313|0 4|GCD10
14P07542616A0313|61 64|GCN4
14P07542616A0486|0 4|GCD10
14P07542616A0486|10 12|RNA
14P07542616A0486|99 123|yeast initiation factor-3
14P07542616A0486|171 192|translation initiation
14P07542698A0137|0 6|Sources
14P07542698A0137|43 54|preparations
14P07542698A0137|83 94|probe RH-414
14P07543592A0624|48 57|E5 protein
14P07543592A0624|84 116|receptor tyrosine phosphorylation
14P07543684A1027|32 34|PKA
14P07543684A1027|65 84|CFTR gene expression
14P07543684A1027|109 112|CFTR
14P07543868A0414|11 27|restriction sites
14P07543868A0414|62 74|cDNA fragment
14P07544357A0808|4 8|PPC-1
14P07544357A0808|12 24|ALVA-31 cells
14P07544357A0808|77 87|LNCap cells
14P07544357A0808|147 158|CD44 variant
14P07544357A0808|159 163|CD44v
14P07544357A0808|188 210|prostate tumor behavior
14P07545510A0735|3 14|gene product
14P07545510A0735|47 53|Cot40-2
14P07545510A0735|56 63|SDS-PAGE
14P07545510A0735|67 80|immunoblotting
14P07545920A1336|80 82|DNA
14P07546256A0000|58 65|injuries
14P07546256A0000|71 78|children
14P07546256A0000|112 121|Casablanca
14P07546293A0968|21 35|protein binding
14P07546293A0968|48 56|sequences
14P07546293A0968|71 80|expression
14P07546294A0000|3 16|RAD6/UBC2 gene
14P07546294A0000|88 97|DNA repair
14P07546794A0100|0 15|Echocardiography
14P07546794A0100|58 61|RVDC
14P07547220A0229|10 29|screening programmes
14P07547220A0229|33 47|Haemoccult test
14P07547500A0066|23 36|fusion protein
14P07547500A0066|37 44|GAL4-p40
14P07547500A0066|78 81|GAL4
14P07547500A0066|96 118|chicken l kappa B-alpha
14P07547500A0066|117 119|p40
14P07547510A0261|56 74|HNF-3 beta promoter
14P07547510A0261|206 215|LF-H3 beta
14P07547510A0261|244 269|HNF-3 beta gene expression
14P07548425A0000|92 94|Sur
14P07548425A0000|137 159|tail muscle motoneurons
14P07548425A0000|200 209|S2-3 level
14P07548858A0000|3 11|flow rate
14P07548858A0000|13 21|phosphate
14P07548858A0000|63 70|function
14P07548858A0000|80 87|pressure
14P07549005A0530|8 28|parallax measurements
14P07549005A0530|55 67|Epon sections
14P07550216A0195|20 25|limits
14P07550216A0195|27 33|latency
14P07551787A0917|15 26|optimization
14P07551787A0917|57 69|investigation
14P07551787A0917|127 148|radiotherapy technique
14P07552974A0217|8 19|requirements
14P07552974A0217|37 47|amino acids
14P07552974A0217|48 56|glutamine
14P07553942A0810|3 18|pea rps10 intron
14P07553942A0810|57 66|Marchantia
14P07553942A0810|95 115|Marchantia rps10 gene
14P07554541A0587|16 26|CHF patient
14P07554541A0587|68 91|electrolyte disturbances
14P07555373A0000|0 14|Serum magnesium
14P07557091A0314|0 6|METHODS
14P07557091A0314|21 33|serum albumin
14P07557276A0526|0 23|Alanine aminotransferase
14P07557276A0526|24 26|ALT
14P07557387A0241|38 47|C/EBP beta
14P07557387A0241|95 104|C/EBP beta
14P07557387A0241|120 138|NIH-3T3 fibroblasts
14P07557424A0124|0 3|XYL1
14P07557424A0124|67 80|fusion library
14P07557446T0000|7 17|transcripts
14P07557446T0000|37 46|VCSA1 gene
14P07557446T0000|77 86|processing
14P07557717A0184|21 38|chest wall muscles
14P07557717A0184|49 57|diathermy
14P07557717A0184|88 96|morbidity
14P07558263T0000|0 6|Closure
14P07558263T0000|29 55|guillotine amputation wound
14P07558583A0562|40 50|derivatives
14P07558583A0562|84 101|peptide substrates
14P07558583A0562|137 160|tyrosine kinase activity
14P07558583A0562|181 190|inhibitors
14P07559233A0534|0 24|Citrate synthase activity
14P07559233A0534|98 119|triceps brachii muscle
14P07559233A0534|120 125|R rats
14P07559347A0000|26 37|operon bglPH
14P07559347A0000|39 55|Bacillus subtilis
14P07559355A0066|40 54|urease activity
14P07559355A0066|99 110|organization
14P07559355A0066|148 167|Proteus gene cluster
14P07559356T0000|21 57|Rhizobium leguminosarum biovar viciae
14P07559402A0622|18 19|VT
14P07559402A0622|59 74|protein kinase C
14P07559402A0622|74 76|PKC
14P07559402A0622|94 109|protein kinase A
14P07559402A0622|109 111|PKA
14P07559430A0909|0 1|R.
14P07559478A0389|13 19|O'Neill
14P07559478A0389|21 22|T.
14P07559488A0440|0 18|Control experiments
14P07559488A0440|32 45|fusion protein
14P07559488A0440|53 73|affinity binding site
14P07559488A0440|75 91|estradiol-17 beta
14P07559510A0000|8 41|Micrococcus luteus UV endonuclease
14P07559510A0000|120 135|bacteriophage T4
14P07559510A0000|136 141|Gordon
14P07559510A0000|143 144|L.
14P07559524A0000|48 67|G1 phase progression
14P07559524A0741|0 26|Cyclin D1 promoter activity
14P07559524A0741|86 92|p41MAPK
14P07559555A0557|7 9|ERM
14P07559555A0557|45 51|EBS-CRE
14P07559563A0282|36 38|Ca2
14P07559639A0996|14 35|R206S HSF substitution
14P07559639A0996|97 100|HSE2
14P07559640A1230|89 99|UAS element
14P07559640A1230|137 146|core motif
14P07559650A0558|27 35|PCNA gene
14P07559650A0558|56 58|E2F
14P07560137T0000|28 51|MMPI-2 depression scales
14P07560662A0496|25 40|saline challenge
14P07562775A0596|10 20|eosinophils
14P07562775A0596|35 40|number
14P07562775A0596|58 68|blood cells
14P07563072A0773|0 10|Comparisons
14P07563072A0773|13 35|rrnB P1-lacZ expression
14P07563072A0773|80 84|P504L
14P07563072A0773|108 123|hypersensitivity
14P07563076A0766|5 19|intron chimeras
14P07563076A0766|37 45|sequences
14P07563076A0766|52 59|elements
14P07563076A0766|73 84|splice sites
14P07563076A0766|111 118|activity
14P07563076A0766|136 143|portions
14P07563076A0766|229 245|splicing proteins
14P07563090A0124|43 55|DNA synthesis
14P07563090A0124|60 76|yeast Ty1 element
14P07563090A0124|144 147|PPT1
14P07563090A0124|206 209|PPT2
14P07563090A0624|0 15|Characterization
14P07563090A0624|43 55|DNA fragments
14P07563090A0624|105 108|PPT2
14P07563090A0624|181 193|DNA fragments
14P07563090A0624|219 237|primer binding site
14P07563090A0624|286 310|RNA reverse transcription
14P07563994A0488|21 24|VTLB
14P07563994A0488|63 66|VTLB
14P07563994A0488|86 88|OLB
14P07563994A0488|130 133|VTLB
14P07563994A0488|149 151|OLB
14P07564004A0292|17 32|Cr2O3 inhalation
14P07564004A0292|33 38|FEV1.0
14P07564210A0557|34 40|regimen
14P07564210A0557|49 59|anaesthesia
14P07564210A0557|63 71|analgesia
14P07565031A0454|6 18|food products
14P07565031A0454|38 51|V. cholerae O1
14P07565031A0454|51 55|Ogawa
14P07565031A0454|97 108|cream cheese
14P07565031A0454|109 125|apricot marmelade
14P07565031A0454|133 141|marmelade
14P07565031A0454|143 152|mayonnaise
14P07565031A0454|170 178|empanadas
14P07565031A0454|196 207|meat sausage
14P07565031A0454|215 229|spinach ravioli
14P07565031A0454|230 238|margarine
14P07565031A0454|240 251|milk dessert
14P07565031A0454|266 279|milk confiture
14P07565031A0454|289 297|additives
14P07565031A0454|308 316|tuna fish
14P07565049A1032|89 90|NB
14P07565104A0084|48 51|ToxR
14P07565104A0084|59 62|ToxT
14P07565113A0000|29 45|transposon Tn4451
14P07565113A0000|87 107|parent plasmid plP401
14P07565113A0000|108 130|Clostridium perfringens
14P07565669T0000|0 9|Ras p21Val
14P07565669T0000|45 55|DNA binding
14P07565672A0798|30 39|expression
14P07565672A0798|68 77|expression
14P07565672A0798|124 133|components
14P07565685A0420|3 19|peptide sequences
14P07565685A0420|48 57|GABP alpha
14P07565685A0420|60 68|GABP beta
14P07565685A0420|73 75|Ets
14P07565685A0420|79 90|Notch motifs
14P07565688A0797|0 28|Immunofluorescence microscopy
14P07565688A0797|31 57|cell fractionation analyses
14P07565688T0000|0 9|Expression
14P07565688T0000|13 22|regulation
14P07565688T0000|25 34|interferon
14P07565688T0000|66 84|adenosine deaminase
14P07565709A0000|0 16|T-cell hybridomas
14P07565709A0000|31 37|T cells
14P07565709A0000|98 112|T-cell receptor
14P07565712A0286|0 8|Deletions
14P07565712A0286|26 34|LYS2 gene
14P07565712A0286|138 153|quasipalindromes
14P07565713A0634|0 13|Overexpression
14P07565713A0634|16 19|SCS1
14P07565713A0634|40 56|HSP60-null allele
14P07565713A0634|107 120|Hsp60 activity
14P07565720A0256|3 20|DNA binding domain
14P07565720A0256|60 84|glutathione S-transferase
14P07565720A0256|86 106|Schistosoma japonicum
14P07565723A0200|35 49|phosphorylation
14P07565723A0200|55 57|CTD
14P07565723A0200|79 93|differentiation
14P07565731A1629|28 43|mRNA degradation
14P07565731A1629|96 113|ribonucleoproteins
14P07565736A2134|51 80|GM-CSF receptor alpha promoter
14P07565740T0000|0 10|Endocytosis
14P07565740T0000|22 32|degradation
14P07565740T0000|62 65|Pdr5
14P07565740T0000|94 104|transporter
14P07565775A1265|83 85|GTP
14P07565775A1265|114 126|EpG formation
14P07565775A1265|143 145|GMP
14P07565775A1265|158 160|RNA
14P07565775T0000|67 77|GTP binding
14P07565775T0000|107 118|GMP transfer
14P07565775T0000|120 122|RNA
14P07565776A0612|0 9|Disruption
14P07565776A0612|15 18|HOG1
14P07565776A0612|22 31|PBS2 genes
14P07565776A0612|60 77|HSP12 inducibility
14P07565776A0612|104 117|overproduction
14P07565776A0612|120 123|Hog1
14P07565776A0612|190 207|salt concentration
14P07565797A0116|0 7|Deletion
14P07565797A0116|24 27|CRY1
14P07565797A0116|64 72|CRY2 mRNA
14P07567079A0014|14 23|separation
14P07567079A0014|26 44|Cryptosporidium spp
14P07567079A0014|89 104|density gradient
14P07567079A0014|162 170|C. parvum
14P07567079A0014|181 193|contamination
14P07567300T0000|14 24|enterotoxin
14P07567300T0000|26 36|involvement
14P07567830A0072|0 6|METHODS
14P07567979A1266|3 10|findings
14P07567979A1266|36 46|development
14P07567979A1266|78 92|testis receptor
14P07567980T0000|4 6|p53
14P07567980T0000|73 75|DNA
14P07568026A0622|3 13|Stat5b mRNA
14P07568026A0622|51 61|amino acids
14P07568116A0902|3 17|hydropathy plot
14P07568116A0902|86 99|signal peptide
14P07568118A1267|44 62|Shc phosphorylation
14P07568118A1267|104 120|p21ras activation
14P07568118A1267|152 190|growth factor tyrosine kinase receptors
14P07568576A0074|41 55|Type A behavior
14P07568576A0074|67 84|emotion dimensions
14P07568865A0305|22 34|contamination
14P07568865A0305|96 101|CFU/ml
14P07568865A0305|172 177|CFU/ml
14P07568865A0305|179 184|Figure
14P07569075A0585|16 35|lung cancer patients
14P07569075A0585|35 36|CR
14P07569075A0585|68 69|PR
14P07569075A0585|110 126|chest radiography
14P07569075A0585|127 128|CT
14P07569075A0585|130 132|FBS
14P07569532T0001|0 8|Pediatric
14P07569532T0001|16 26|emergencies
14P07569640A0539|0 22|Protein electrophoresis
14P07569640A0539|37 50|albumin levels
14P07569640A0539|80 81|G2
14P07569770A0298|0 6|METHODS
14P07569770A0298|18 31|non-responders
14P07569770A0298|86 97|immunization
14P07569770A0298|102 113|booster dose
14P07571766A0122|83 97|catheterization
14P07571766A0122|140 161|ST-segment depressions
14P07571953T0000|28 39|mycobacteria
14P07572582A0000|0 9|Mibefradil
14P07572582A0000|11 12|Ro
14P07572582A0000|29 46|calcium antagonist
14P07572582A0000|54 67|chemical class
14P07572582A0000|110 124|calcium channel
14P07574064A1416|24 47|concentration anesthesia
14P07574064A1416|84 85|VE
14P07574064A1416|89 92|PCO2
14P07574064A1416|165 185|response relationship
14P07574682T0000|51 70|alkaline phosphatase
14P07575416A0000|0 15|Protein kinase C
14P07575416A0000|15 17|PKC
14P07575416A0000|154 172|tissue distribution
14P07575416A0000|184 195|localization
14P07575416A1970|63 77|oligonucleotide
14P07575416A1970|98 110|PKC zeta mRNA
14P07575438A1409|56 65|E1 element
14P07575947T0000|13 21|electives
14P07576178A0000|0 25|Polypeptide growth factors
14P07576179A0781|37 53|CpG dinucleotides
14P07576307A0144|72 85|rat enkephalin
14P07576307A0144|113 122|regulation
14P07576307A0144|128 147|enkephalin phenotype
14P07576307A1654|116 130|tumor cell line
14P07576307A1654|130 133|HeLa
14P07576307A1654|155 157|ENK
14P07577904A0141|26 36|persistence
14P07577904A0141|76 86|dislocation
14P07577904A0141|92 104|camera aquosa
14P07577904A0141|116 126|buphthalmos
14P07577904A0141|142 155|microphthalmos
14P07577904A0141|160 170|dislocation
14P07579023A0214|9 20|dose-finding
14P07579023A0214|61 70|medication
14P07579023A0214|120 132|liver enzymes
14P07579164A0409|41 58|RNA editing events
14P07579328A0653|0 4|MZF-1
14P07579328A0653|14 41|CAT reporter gene expression
14P07579328A0653|42 59|GAL4 binding sites
14P07579328A1345|21 38|DNA binding domain
14P07579328A1345|38 42|MZF-1
14P07579328A1345|52 75|reporter gene expression
14P07579683A0660|0 7|Analyses
14P07579683A0660|10 34|hGMR beta subunit mutants
14P07579683A0660|86 99|c-myc promoter
14P07579695A0336|57 60|MIF2
14P07579695A0336|97 131|yeast centromere protein genes-CEP1
14P07579695A0336|130 138|CBF1/CPF1
14P07579695A0336|140 149|NDC10/CBF2
14P07579695A0336|154 163|CEP3/CBF3B
14P07579695A0693|37 48|Mif2 protein
14P07579695A0693|61 65|Cep1p
14P07579695A0693|91 106|yeast centromere
14P07579704A0085|17 28|actin cables
14P07579704A0085|63 72|cell cycle
14P07579704A0085|89 98|components
14P07579704A0085|120 130|cell growth
14P07580058A0000|12 30|Codonopsis pilosula
14P07580058A0000|41 44|CPOL
14P07580058A0000|48 80|tissue-type plasminogen activator
14P07580058A0000|88 118|plasminogen activator inhibitor
14P07580058A0000|118 120|PAI
14P07580330A0331|22 25|EDIs
14P07580330A0331|61 63|HCH
14P07580330A0331|138 140|DDT
14P07580330A0331|161 163|HCB
14P07580782T0000|0 15|Imaging features
14P07580782T0000|24 38|epidermoid cyst
14P07581364A0500|39 41|SMA
14P07581364A0500|74 79|Ag1-CA
14P07581364A0500|83 86|C212
14P07582316A0696|66 88|IS6110 banding patterns
14P07582316A0696|115 125|MTB strains
14P07582592A0545|0 3|HRES
14P07582592A0545|109 111|LES
14P07582592A0545|121 134|administration
14P07582592A0545|151 175|botulinum toxin injection
14P07583190A0306|105 120|brain potentials
14P07583190A0306|158 184|phrase structure violations
14P07583562A1826|9 11|BMI
14P07583562A1826|19 20|OR
14P07583562A1826|43 44|TG
14P07583562A1826|75 76|RP
14P07583562A1826|112 113|TG
14P07583562A1826|115 119|LDL-C
14P07585246T0000|0 17|SL1 trans-splicing
14P07585246T0000|44 46|RNA
14P07585246T0000|67 97|Caenorhabditis elegans pre-mRNA
14P07585559A0000|28 38|6-methoxy-4
14P07585559A0000|45 60|2-hydroxyethoxyl
14P07585559A0000|78 96|methyl-1M-pyrazo lo
14P07585559A0000|97 101|3,4-b
14P07585559A0000|113 115|SCH
14P07585559A0000|175 210|muscle alpha-actin promoter activity
14P07586403A0765|28 54|risk factor-selection scale
14P07586403A0765|54 57|RFSS
14P07588240A0000|3 50|Caenorhabditis elegans death susceptibility gene
14P07588240A0000|121 129|IL-1 beta
14P07588240A0000|148 150|ICE
14P07588240A0000|166 170|CPP32
14P07588245T0000|0 9|Repression
14P07588245T0000|80 103|thyroid hormone receptor
14P07588245T0000|103 104|TR
14P07588245T0000|108 109|TR
14P07588603A1054|30 40|flexibility
14P07588603A1054|60 61|DH
14P07588608A1687|0 10|Obstruction
14P07588608A1687|16 37|ERF repressor function
14P07588608A1687|85 99|i.e.gag-myb-ets
14P07588608A1687|145 162|cell proliferation
14P07588628A0318|0 13|Overexpression
14P07588628A0318|25 27|p53
14P07588628A0318|52 54|LCL
14P07588633A0362|19 45|c-fos protooncogene product
14P07588633A0362|168 180|NIH 3T3 cells
14P07588633A0362|182 184|Mos
14P07588750T0061|0 6|Cloning
14P07588750T0061|66 82|Pyrococcus woesei
14P07588750T0061|102 117|characterization
14P07588777A1524|41 44|RNAP
14P07588777A1524|47 49|CTD
14P07588777A1524|86 92|p42mapk
14P07588777A1524|96 114|p44mapk MAP kinases
14P07589069A1245|49 56|CD6 cDNA
14P07589069A1245|146 158|reading frame
14P07589069A1245|160 166|CD6-PB1
14P07590264A0373|30 40|differences
14P07590264A0373|43 57|polyadenylation
14P07590264A0373|87 90|DHFR
14P07590264A0373|160 170|differences
14P07590264A0373|175 192|end RNA processing
14P07590264A0373|250 264|gene expression
14P07590268A0350|38 39|Dm
14P07590268A0350|81 99|sequence similarity
14P07590268A0350|113 121|MAPKAPK-2
14P07590268A0740|7 23|MAPKAPK-2 message
14P07590283A0820|25 27|TdT
14P07590283A0820|30 45|Pol beta protein
14P07590283A0820|82 100|polymerase activity
14P07590283A0820|120 127|Pol beta
14P07590283A0820|140 159|template utilization
14P07590283A0820|168 190|polymerization reaction
14P07590283A0820|252 259|Pol beta
14P07590283A0820|290 294|Kumar
14P07590283A0820|301 302|J.
14P07590525A0811|29 40|revertants/g
14P07590525A0811|47 56|hamburgers
14P07590657A0624|0 14|Cholangiography
14P07590744A0829|17 29|cDNA sequence
14P07590744A0829|95 103|GAR1 gene
14P07592072A0217|2 6|Trial
14P07592072A0217|52 53|NF
14P07592072A0217|122 143|prostaglandin F2 alpha
14P07592220A0846|9 11|PO2
14P07592220A0846|25 42|minute ventilation
14P07592220A0846|44 61|oxygen consumption
14P07592220A0846|62 67|VE/VO2
14P07592220A0846|83 88|PETCO2
14P07592220A0846|101 103|Hyp
14P07592337A0891|25 28|NfxB
14P07592337A0891|55 64|expression
14P07592439A0000|0 3|A511
14P07592439A0000|43 64|Listeria monocytogenes
14P07592467A0000|14 37|peroxisome proliferation
14P07592485A0734|15 29|gene expression
14P07592485A0734|95 109|NCR sensitivity
14P07592485A0734|148 166|ure2 delta mutation
14P07592647A0797|18 50|DNA Pur alpha recognition element
14P07592647T0000|33 54|retinoblastoma protein
14P07592647T0000|94 126|DNA Pur alpha recognition element
14P07592658A0309|54 72|p50/p65 heterodimer
14P07592676A0466|83 92|NIP region
14P07592676A0466|122 139|repressor activity
14P07592706A1465|0 7|Exchange
14P07592706A1465|13 15|LPL
14P07592706A1465|19 25|HL lids
14P07592710T0000|23 40|protein kinase PKR
14P07592710T0000|78 102|immunoglobulin kappa gene
14P07592711T0000|57 90|G protein alpha subunit deficiency
14P07592721A0827|79 81|DNA
14P07592723A0814|0 13|Phorbol esters
14P07592723A0814|40 55|CSK 35H proteins
14P07592723A0814|102 121|PKC binding activity
14P07592723A0814|134 147|PKC substrates
14P07592730A0204|0 5|Levels
14P07592730A0204|8 21|TSG-14 protein
14P07592730A0204|32 36|PTX-3
14P07592730A0204|104 121|lipopolysaccharide
14P07592730A0204|155 168|phase proteins
14P07592730A0204|178 193|TSG-14 synthesis
14P07592771A0258|3 12|mouse beta
14P07592771A0258|32 40|kilobases
14P07592771A0258|75 84|homologues
14P07592771A0258|103 110|position
14P07592790A1457|29 32|PEDF
14P07592946A0261|33 46|p44 MAP kinase
14P07592946A0261|91 103|determination
14P07592946A0261|109 130|intron/exon boundaries
14P07592946A0261|137 152|characterization
14P07592946A0997|23 32|TATA boxes
14P07592946A0997|52 69|start sites region
14P07592946A0997|72 79|AP-1 box
14P07592946A0997|83 90|AP-2 box
14P07592946A0997|94 101|Malt box
14P07592946A0997|105 112|GAGA box
14P07592946A0997|170 172|Sp1
14P07592946A0997|207 213|CTF-NF1
14P07592946A0997|220 222|Myb
14P07592946A0997|229 231|p53
14P07592946A0997|238 242|Ets-1
14P07592946A0997|249 254|NF-IL6
14P07592946A0997|261 264|MyoD
14P07592946A0997|271 275|Zeste
14P07593266A1174|71 89|pair stem structure
14P07593896A1053|21 41|measurement technique
14P07593896A1053|66 81|P0.1 measurement
14P07594047T0000|0 6|Effects
14P07594047T0000|39 58|afterdepolarizations
14P07594047T0000|120 130|QT syndrome
14P07594592A0755|13 45|NF-IL6 beta leucine zipper domain
14P07595221A0733|35 39|CIITA
14P07595221A0733|51 59|MHC class
14P07595221A0733|97 105|MHC class
14P07595374A1215|12 16|EBNA2
14P07595374A1215|202 214|LMP1 promoter
14P07595857A0521|3 17|peak velocities
14P07595857A0521|46 56|transmitral
14P07595857A0521|75 89|flow velocities
14P07595857A0521|94 96|PVA
14P07595857A0521|132 135|PVS1
14P07595857A0521|284 296|cardioversion
14P07595857A0521|334 346|cardioversion
14P07595857A0521|389 402|cardiomyopathy
14P07596283A0396|27 34|activity
14P07596283A0396|42 54|triglycerides
14P07596283A0396|72 81|tributyrin
14P07596283A0396|100 108|emulsions
14P07596287A0183|3 21|nucleotide sequence
14P07596287A0183|72 75|ORF5
14P07596287A0183|79 82|ORF1
14P07596287A0183|96 111|protein products
14P07596287A0183|160 195|cassette membrane transport proteins
14P07596287A1724|3 12|ORF3 probe
14P07596287A1724|67 70|ORF3
14P07596287A1724|94 109|mutagenesis data
14P07596558A0824|26 39|concentrations
14P07596558A0824|42 50|IL-1 beta
14P07596697A0971|24 34|polypeptide
14P07596697A0971|38 54|motilin responses
14P07596697A0971|112 124|control group
14P07597030A0260|48 63|characterization
14P07597030A0260|92 96|TFIID
14P07597488T0000|22 36|G6PD deficiency
14P07597804A1007|3 13|transcripts
14P07597804A1007|68 89|glycoprotein gene EUS4
14P07598106A0709|0 18|Mean growth changes
14P07598106A0709|23 27|Class
14P07598106A0709|94 98|Class
14P07598106A0709|100 112|malocclusions
14P07598303A1728|58 84|bone marrow transplantation
14P07598303A1728|102 117|survival benefit
14P07599449A0445|3 17|fracture groups
14P07599449A0445|75 88|control groups
14P07599653A0898|2 9|addition
14P07599653A0898|18 28|differences
14P07599653A0898|34 40|binding
14P07599653A0898|50 56|factors
14P07599653A0898|85 93|agreement
14P07599653A0898|110 119|activities
14P07599653A0898|125 132|promoter
14P07600111A0000|32 59|immunodeficiency virus types
14P07600111A0000|64 68|HIV-1
14P07600111A0000|70 74|HIV-2
14P07600111A0000|113 121|HTLV-I/II
14P07600111A0000|211 225|police officers
14P07600111A0000|227 239|Guinea-Bissau
14P07600986A0605|9 28|immunoprecipitations
14P07600986A0605|32 47|gel shift assays
14P07600986A0605|139 157|transcription units
14P07601078A1003|0 7|Subjects
14P07601078A1003|18 34|postexposure time
14P07601078A1003|38 50|dioxin burden
14P07601078A1003|128 129|OR
14P07601078A1003|164 165|OR
14P07601121A0153|0 7|Analysis
14P07601121A0153|107 119|transcription
14P07601121A0153|153 161|sequences
14P07601445A0207|16 39|BAT1 translation product
14P07601445A0207|79 105|WM6 Drosophila gene product
14P07601445A0207|128 149|Caenorhabditis elegans
14P07601445A0207|197 209|RNA helicases
14P07601827A0778|7 18|lacZ fusions
14P07601827A0778|45 57|DNA sequences
14P07601828A0095|26 41|characterization
14P07601828A0095|59 73|flagellar genes
14P07601828A0095|87 101|orfX-fliP locus
14P07603726T0000|10 29|adaptation exercises
14P07603726T0000|64 80|neuroma resection
14P07603956A0115|44 54|arrangement
14P07603956A0115|57 66|treatments
14P07603956A0115|91 103|incorporation
14P07603956A0115|106 108|RSB
14P07604047A0704|36 37|GA
14P07604047A0704|91 114|transcription-PCR method
14P07604047A0704|232 235|GA53
14P07604047A0704|238 241|GA44
14P07604047A0704|245 248|GA19
14P07604047A0704|251 254|GA20
14P07604783A0952|45 60|acid composition
14P07604783A0952|84 104|bile acid composition
14P07604794A0958|5 15|cholesterol
14P07604794A0958|48 53|mg/day
14P07604794A0958|69 74|mg/day
14P07604794A0958|102 107|mg/day
14P07604794A0958|124 129|mg/day
14P07605990A1110|60 64|PEBP2
14P07605990A1110|70 93|GM-CSF promoter activity
14P07605990A1110|162 175|PEBP2 isoforms
14P07605990A1110|201 217|promoter activity
14P07606548T0000|0 7|Benefits
14P07606548T0000|19 37|board certification
14P07606548T0000|39 53|pharmacotherapy
14P07606587A0266|0 22|Piperacillin-tazobactam
14P07607197A1048|5 25|plasma renin activity
14P07607197A1048|25 27|PRA
14P07607213A0140|23 53|structure/activity relationship
14P07607233A0186|44 55|epilancin K7
14P07607233A0186|84 85|K7
14P07607233A0186|101 119|nucleotide sequence
14P07607342A0703|70 96|aldose reductase inhibitors
14P07607342A0703|154 164|drug trials
14P07607537A0954|98 119|VP16 activation domain
14P07607607T0000|0 7|Increase
14P07607607T0000|39 55|fructose infusion
14P07607669A1112|27 28|GC
14P07607669A1112|46 57|CpG doublets
14P07607669A1112|92 94|Sp1
14P07608268A0194|32 46|GnRH deficiency
14P07608268A0194|70 97|melatonin secretion profiles
14P07608268A0194|137 138|DP
14P07608649A1429|28 40|CyA treatment
14P07608649A1429|67 77|ET-1 levels
14P07608968A0836|0 7|Analysis
14P07608968A0836|17 27|Tat mutants
14P07608968A0836|149 151|TBP
14P07609037A0775|22 26|Oct-1
14P07609037A0775|98 115|DNA affinity resin
14P07609037A0775|130 142|transcription
14P07609037A0775|159 171|MMTV promoter
14P07609079A0387|0 14|Transactivation
14P07609079A0387|20 28|HIV-1 LTR
14P07609079A0387|30 38|T3R alpha
14P07609079A0387|101 110|A/B region
14P07609079A0387|112 120|T3R alpha
14P07609079A0387|148 173|transcription factor TFIIB
14P07609079A0387|257 259|LTR
14P07609372A0261|0 5|M.M.C.
14P07609372A0261|38 48|HR patients
14P07609372A0261|51 61|LR patients
14P07609372A0261|89 99|HR patients
14P07609372A0261|102 112|LR patients
14P07610052A1064|39 41|C25
14P07610052A1064|43 45|C30
14P07610052A1064|49 61|C35 complexes
14P07610052A1064|102 112|SAA element
14P07610052A1064|114 129|EMSA experiments
14P07610052A1064|203 218|rat APP promoter
14P07610324A0319|124 137|reconstruction
14P07610716A0117|16 32|prevalence values
14P07610716A0117|57 68|MS-frequency
14P07610735A1471|0 8|Diltiazem
14P07610735A1471|65 74|conversion
14P07610735A1471|77 88|sinus rhythm
14P07612174A1064|77 80|PCBs
14P07612557A0635|13 20|children
14P07612557A0635|42 50|pathology
14P07612557A0635|87 94|children
14P07614762A0224|46 64|latex agglutination
14P07615541T0000|20 26|DNase-I
14P07615541T0000|51 92|mouse porphobilinogen deaminase gene locus
14P07615634A0535|5 15|transcripts
14P07615634A0535|62 69|sequence
14P07615634A0535|89 95|protein
14P07616056A0278|40 58|feedback inhibition
14P07616056A0278|65 88|chain gene rearrangement
14P07616563A0532|8 11|CarP
14P07616563A0532|29 48|carAB control region
14P07616563A0532|65 69|DNase
14P07616563A0532|143 155|GATC sequence
14P07616569A0168|42 59|cytochrome oxidase
14P07616569A0168|69 83|apocytochrome b
14P07616569A0168|107 132|NADH dehydrogenase complex
14P07616569A0168|150 164|ATPase subunits
14P07616569A0168|192 195|RNAs
14P07616802A0315|22 29|increase
14P07616802A0315|32 45|platelet count
14P07616802A0315|71 78|patients
14P07616802A0315|138 154|heparin cessation
14P07616802A0315|164 173|responders
14P07618280A0550|55 85|density gradient centrifugation
14P07618548T0000|3 25|Babcock Surgical Clinic
14P07620491T0000|0 8|Resources
14P07622058A0411|3 22|PEBP2 alpha proteins
14P07622058A0411|96 117|segmentation gene runt
14P07622060A0967|43 53|ME activity
14P07622060A0967|90 105|thyroid hormones
14P07622521A0418|27 53|G beta gamma binding region
14P07622521A0418|89 97|PH domain
14P07622521A0418|136 152|carboxyl terminus
14P07622521A0418|206 217|G beta gamma
14P07622521A0418|219 230|PIP2 binding
14P07622932T0000|17 24|features
14P07622932T0000|35 41|leprosy
14P07623807A0162|14 23|mechanisms
14P07623807A0162|43 56|Raf-1 proteins
14P07623807A0162|96 111|plasma membranes
14P07623814A1040|2 11|CV-1 cells
14P07623814A1040|12 25|cotransfection
14P07623814A1040|42 59|estrogen receptors
14P07623814A1040|132 142|ER activity
14P07623814A1040|155 173|breast cancer cells
14P07623821A0649|18 22|HRF-1
14P07623821T0000|0 9|Regulation
14P07623821T0000|12 42|Gax homeobox gene transcription
14P07623825T0000|20 41|transactivation domain
14P07623825T0000|43 59|heat shock factor
14P07623838A1112|0 1|D.
14P07623840A0352|49 52|GCN2
14P07623840A0352|143 163|amino acid limitation
14P07623844A0639|14 18|Bcl-2
14P07623844A0639|25 40|E1B 19K proteins
14P07623844A0639|125 137|DNA synthesis
14P07623844A0639|140 157|cell proliferation
14P07623844A0639|193 195|p53
14P07624119A0528|12 15|PAX3
14P07624119A0528|27 59|PAX3-FKHR transactivation domains
14P07624119A0528|106 109|GAL4
14P07624581A0312|26 28|ECG
14P07624581A0312|40 67|blood pressure determination
14P07624581A0312|83 85|TSH
14P07624581A0312|87 101|thyroid hormone
14P07624581A0312|102 104|PRL
14P07624581A0312|134 155|glutamine transaminase
14P07624581A0312|170 196|triglycerides plasma levels
14P07624581A0312|209 210|T0
14P07624581A0312|234 236|T30
14P07624581A0312|261 263|T45
14P07624615A0267|15 30|body temperature
14P07624615A0267|31 32|TB
14P07624615A0267|41 45|PaCO2
14P07624615A0267|66 69|HCO3
14P07624615A0267|141 142|OH
14P07624615A0267|184 186|SID
14P07624615A0267|191 194|Atot
14P07624615A0267|225 226|PT
14P07624615A0267|250 251|Pi
14P07626378T0000|0 18|Hepatitis B vaccine
14P07626469A1341|44 52|M1 domain
14P07626469A1341|68 91|mouse Leydig tumor cells
14P07626469A1341|90 93|MLTC
14P07626469A1341|117 125|CHO cells
14P07626806A1098|3 11|RAT3 gene
14P07627317A1502|3 4|Al
14P07627317A1502|64 76|concentration
14P07627317A1502|100 121|microgram/g creatinine
14P07628389A0145|0 26|Tumor necrosis factor-alpha
14P07628389A0145|26 34|TNF alpha
14P07628389A0145|84 106|testosterone production
14P07628438T0000|13 36|insulin receptor homolog
14P07628438T0000|83 99|receptor isoforms
14P07628438T0000|112 130|signaling potential
14P07628451A0114|14 15|RA
14P07628451A0114|19 21|E1A
14P07628451A0114|28 42|phosphorylation
14P07628451A0114|76 79|p300
14P07628451A0114|90 104|differentiation
14P07628451A0114|107 114|F9 cells
14P07628456A0000|18 35|RNA binding domain
14P07628456A0000|60 75|amino acid motif
14P07628456A0000|140 142|RNA
14P07628456A0000|165 169|RNase
14P07628456A0000|201 203|PKR
14P07629103T0000|22 42|protein isoforms beta
14P07629103T0000|112 136|beta-casein gene promoter
14P07629113A0726|0 2|SCA
14P07629113A0726|48 63|metalloproteases
14P07629113A0726|84 99|N-ethylmaleimide
14P07629122A0323|39 59|phosphorylation sites
14P07629122A0323|66 69|NIMA
14P07629122A0323|71 75|NIM-1
14P07629122A0323|115 118|NIMA
14P07629123A0885|27 41|leucine residue
14P07629123A0885|84 101|heterodimerization
14P07629123A0885|103 113|DNA binding
14P07629150A0155|0 9|Expression
14P07629150A0155|15 26|CYP11A1 gene
14P07629150A0155|54 72|adrenocorticotropin
14P07629150A0155|114 127|growth factors
14P07629150A0155|202 229|signal transduction pathways
14P07629163A0770|0 2|NH2
14P07629163A0770|55 56|PH
14P07629163A0770|68 109|guanine nucleotide exchange factor domains
14P07629196A0274|63 75|alpha 12Q229L
14P07629196A0274|86 98|alpha 13Q226L
14P07629196A0274|127 129|Jun
14P07629196A0274|153 166|protein kinase
14P07629196A0274|167 174|JNK/SAPK
14P07630687A0010|54 63|conditions
14P07630687A0010|65 78|family history
14P07630687A0010|84 103|catheter association
14P07630687A0010|121 130|evaluation
14P07630687A0010|132 142|development
14P07630687A0010|154 164|involvement
14P07630687A0010|166 175|prevalence
14P07630687A0010|178 189|antithrombin
14P07630687A0010|205 226|protein S deficiencies
14P07630687A0010|229 248|lupus anticoagulants
14P07630934A0343|0 4|Harel
14P07630934A0343|6 9|E.M.
14P07631267T0001|0 11|Radiotherapy
14P07631267T0001|20 30|orchiectomy
14P07633444T0000|38 55|expression pattern
14P07633444T0000|60 86|mouse WD-repeat gene DMR-N9
14P07633756A0690|3 23|ARX2 procedure models
14P07633756A0690|68 90|background EEG activity
14P07633756A0690|165 180|reference signal
14P07633756A0690|254 273|artefact propagation
14P07635140A0172|3 12|expression
14P07635140A0172|40 44|CYP19
14P07635140A0172|82 90|promoters
14P07635140A0172|126 135|mechanisms
14P07635312A0692|5 15|mutagenesis
14P07635312A0692|36 44|mutations
14P07635312A0692|97 110|act1 mutations
14P07635572A1153|0 9|CIITA mRNA
14P07635572A1153|30 38|IFN-gamma
14P07635572A1153|108 109|RB
14P07635572A1153|123 149|CIITA mRNA induction levels
14P07636179A0000|9 18|cell cycle
14P07636179A0000|73 83|protein pRb
14P07636179A0000|87 96|G1 cyclins
14P07636179A0000|132 141|inhibitors
14P07636187A0585|17 39|protein expression data
14P07636187A0585|39 44|V beta
14P07636187A0585|47 62|gene transcripts
14P07636337A0687|70 90|serum estradiol level
14P07636337A0687|91 93|HRT
14P07636408T0000|0 9|Comparison
14P07636408T0000|15 19|Tesla
14P07636408T0000|27 46|Tesla field strength
14P07636408T0000|53 69|resonance imaging
14P07636408T0000|112 134|intervertebral foramina
14P07636648A1229|16 39|DTaP booster vaccination
14P07636648A1229|74 102|serum antibody concentrations
14P07636648A1229|153 170|pertussis antigens
14P07636962A1288|66 78|HSV-alpha TIF
15P07636962A1883b|30 47|DNA binding domain
15P07636962A1883b|48 51|GAL4
15P07636962A1883b|82 94|BHV-alpha TIF
15P07636962A1883b|115 130|carboxyl termini
14P07636984A1349|31 33|SP1
14P07637718A0218|14 27|messenger RNAs
14P07637718A0218|35 50|trans-sialidases
14P07637718A0218|86 98|epimastigotes
14P07637718A0218|115 129|trypomastigotes
14P07638517A0000|4 6|May
14P07638517A0000|52 72|Sao Paulo City Morgue
14P07638517A0000|82 105|individuals AIDS victims
14P07638517A0000|135 155|police investigations
14P07639106A0678|44 48|TBBMD
14P07639106A0678|104 113|body TBBMC
14P07639703A1703|17 31|thyroid hormone
14P07639703A1703|142 167|islet cell differentiation
14P07640309A0000|13 29|peptide sequences
14P07640309A0000|76 78|HMG
14P07640309A0000|81 110|box transcription factor TCF-1
14P07640309A0000|134 150|splice mechanisms
14P07640309A0000|173 174|X.
14P07640422A0649|0 13|Thromboxane B2
14P07640422A0649|92 103|hemodialysis
14P07640422A0649|114 125|hemodialysis
14P07640422A0649|145 152|Wilcoxon
14P07642490A0318|4 9|vector
14P07642490A0318|11 17|pHBK280
14P07642490A0318|46 53|analysis
14P07642538A0138|23 36|RSK activation
14P07642538A0138|49 56|RSK cDNA
14P07642538A0138|57 60|RSK3
14P07642538A0138|114 124|RSK mutants
14P07642538A0138|125 128|K91A
14P07642538A0138|130 134|N-Lys
14P07642538A0138|167 171|K444A
14P07642538A0138|173 177|C-Lys
14P07642538A0138|211 217|N/C-Lys
14P07642538A0138|243 247|T570A
14P07642538A0138|249 253|C-Thr
14P07642538A0138|274 298|MAPK phosphorylation site
14P07642538A0138|308 311|VIII
14P07642538A0138|317 324|C-domain
14P07642538A0138|327 331|S218A
14P07642538A0138|333 337|N-Ser
14P07642538A0744|15 19|C-Lys
14P07642538A0744|23 27|C-Thr
14P07642538A0744|48 62|kinase activity
14P07642538A0744|90 100|stimulation
14P07642544A0868|83 100|phenylarsine oxide
14P07642544A0868|127 145|NF-kappa B activity
14P07642633T0000|53 73|transcription factors
14P07642633T0000|120 150|transcription enhancer factor-1
14P07642633T0000|150 154|TEF-1
14P07644127A0000|158 182|rat substantia innominata
14P07644127A0000|182 183|SI
14P07644127A0000|195 208|microinjection
14P07644127A0000|237 257|acetylcholine agonist
14P07644466A0578|36 53|NS3-4A polyprotein
14P07644466A0578|54 56|NS3
14P07644466A0578|61 84|serine proteinase domain
14P07644466A0578|110 112|NS3
14P07644466A0578|121 133|NS4A cofactor
14P07644466A0578|179 194|trans-processing
14P07644503A0729|11 25|over-expression
14P07644503A0729|28 35|RAR beta
14P07644503A0729|53 67|differentiation
14P07644503A0729|91 99|RAR gamma
14P07646439A0535|31 48|platelet membranes
14P07646439A0535|91 121|mAb F11 affinity chromatography
14P07647303T0000|3 20|homeobox gene ATK1
14P07647303T0000|21 40|Arabidopsis thaliana
14P07647303T0000|93 105|inflorescence
14P07647570A0713|13 23|explanation
14P07647570A0713|68 80|Kupffer cells
14P07647570A0713|119 122|Type
14P07647570A0713|124 133|deiodinase
14P07648338A0815|71 87|cytokine profiles
14P07648338A0815|102 113|TNF response
14P07648338A0815|127 145|SMA occlusion model
14P07649098A0676|52 73|transfection construct
14P07649098A0676|132 134|UTR
14P07649098A0676|162 180|reporter expression
14P07649098A0676|201 219|reporter expression
14P07649098A0676|285 298|IGF-I promoter
14P07649098A0676|318 362|IGF-I promoter-luciferase-reporter constructs
14P07649098A0676|454 456|PKA
14P07649098A0676|498 511|PGE2 treatment
14P07649098A0676|579 581|PKA
14P07649098A0676|619 637|reporter expression
14P07650958A0123|45 60|electromyography
14P07650958A0123|76 92|motor improvement
14P07651131A1407|19 23|DNase
14P07651131A1407|25 48|footprinting experiments
14P07651131A1407|63 83|kDa repressor isoform
14P07651131A1407|95 98|CIRs
14P07651141A0265|6 13|terminus
14P07651141A0265|19 31|p-gvpF-M mRNA
14P07651141A0265|44 54|nucleotides
14P07651340A0286|0 15|Retransformation
14P07651340A0286|112 113|UV
14P07651340A0286|117 130|MMS resistance
14P07651386A0925|30 42|p53 induction
14P07651398A0257|58 67|Drosophila
14P07651398A0257|77 106|growth factor receptor homolog
14P07651398A0257|105 107|DER
14P07651398A0257|149 151|DER
14P07651398A0803|27 41|dShc PTB domain
14P07651398A0803|51 58|Tyr-1228
14P07651398A0803|61 63|DER
14P07651398T0000|53 80|DER receptor tyrosine kinase
14P07651400A0335|4 13|inhibition
14P07651400A0335|58 68|splice site
14P07651400A0335|110 127|consensus sequence
14P07651424A0487|11 18|analysis
14P07651424A0487|28 32|Ssm1p
14P07651424A0487|128 135|proteins
14P07651424A0743|17 33|SSM1b transcripts
14P07651424A0743|60 76|SSM1a transcripts
14P07651424A0743|91 95|SSM1b
14P07651424A0743|128 137|Ssm1p pool
14P07651734A0961|0 21|Northern blot analysis
14P07651734A0961|43 53|LIMK-1 mRNA
14P07651734A0961|94 104|LIMK-2 mRNA
14P07651835A0652|19 34|binding affinity
14P07652066A0677|24 30|concept
14P07652066A0677|48 56|procedure
14P07652066A0677|83 91|anchoring
14P07652066A0677|97 104|arm flap
14P07652066A0677|156 168|system repair
14P07652066A0677|170 178|incisions
14P07652066A0677|207 215|migration
14P07652066A0677|235 242|contours
14P07652575A0435|69 96|Rho inhibitor C3 transferase
14P07652575A0435|114 126|DNA synthesis
14P07652582A0000|0 16|INF-alpha therapy
14P07652582A0000|56 58|CML
14P07653094A0169|22 37|deletion mutants
14P07653094A0169|38 40|d10
14P07653094A0169|42 44|d20
14P07653094A0169|46 48|d27
14P07653094A0169|50 52|d31
14P07653094A0169|54 56|d40
14P07653094A0169|58 60|d44
14P07653094A0169|65 67|d73
14P07653094A0169|95 117|cell surface expression
14P07653094A0169|214 230|pcDL-SR alpha-296
14P07653094A0169|233 236|CV-1
14P07653094A0169|240 249|HeLa cells
14P07653812T0000|11 42|acetyl cholinesterase inhibitors
14P07653892A0306|16 29|isoflurane MAC
14P07653892A0306|31 40|triplicate
14P07653892A0306|74 81|morphine
14P07653892A0306|110 116|U50488H
14P07654239A0698|0 2|Max
14P07654239A0698|54 75|cell cycle progression
14P07654712A0774|3 14|yeast enzyme
14P07654712A0774|45 51|enzymes
14P07654712A0774|122 129|analysis
14P07654712A0774|134 142|degrees C
14P07654740A0563|0 8|Key areas
14P07654740A0563|13 29|selection process
14P07654740A0563|70 84|transplantation
14P07654740A0563|105 122|transplant work-up
14P07654740A0563|131 148|inclusion criteria
14P07654740A0563|194 211|disease etiologies
14P07654740A0563|214 227|co-morbidities
14P07654740A0563|246 262|contraindications
14P07655184A0852|44 64|transmembrane protein
14P07655184A0852|79 96|ER leader sequence
14P07655184A0852|147 157|ER sequence
14P07655505A0527|21 32|GT-2 protein
14P07655505A0527|167 195|phytochrome A gene expression
14P07655509T0000|21 33|motif signals
14P07655509T0000|103 115|Pisum sativum
14P07656588A0101|11 31|DNA sequence analysis
14P07656588A0101|39 69|Genethon microsatellite D19S596
14P07656588A0101|106 109|FUT1
14P07656588A0101|161 164|FUT1
14P07656588A0101|168 177|FUT2 genes
14P07656588A0101|197 203|D19S412
14P07656588A0101|234 240|D19S571
14P07657162A1412|14 37|transcription activation
14P07657162A1412|39 43|LEF-1
14P07657162A1412|103 125|trans-activation domain
14P07657162A1412|140 149|HMG domain
14P07657668A0642|0 13|TH-SH3 binding
14P07657668A0642|48 71|amino acid substitutions
14P07657668A0642|79 91|Btk TH domain
14P07657668A0642|95 108|Fyn SH3 domain
14P07657705A1181|24 33|K-glypican
14P07657705A1181|54 57|HSPG
14P07658262A0944|0 15|Protein S levels
14P07658262A0944|115 124|correction
14P07658262A0944|132 143|procoagulant
14P07658471A0000|3 21|plant hormone auxin
14P07658777A0400|45 61|contraindications
14P07659085A1520|13 54|transcription factor Oct-1 forms complexes
14P07659085A1520|82 85|FPIV
14P07659085A1520|88 105|gel shift analysis
14P07659085A1520|137 141|Oct-1
14P07659085A1520|179 197|androgen regulation
14P07659515T0000|84 120|Crithidia fasciculata miniexon arrays
14P07659529A0135|25 43|transfection assays
14P07659529A0135|47 70|reporter gene constructs
14P07659529A0135|81 110|transcription control elements
14P07659529A0135|140 148|EpoR gene
14P07659746A1464|3 32|CVA16.4 proteolipid transcript
14P07659746A1464|57 76|proteolipid messages
14P07659757A0191|0 9|Incubation
14P07659757A0191|23 37|fusion proteins
14P07659757A0191|52 54|ATP
14P07659757A0191|106 124|autophosphorylation
14P07660712A0118|87 96|risk group
14P07660712A0118|109 111|VHB
14P07663138A0835|50 52|PBV
14P07663138A0835|56 58|PBF
14P07663160A0287|12 23|DNA sequence
14P07663160A0287|85 87|16S
14P07663160A0287|97 99|RNA
14P07663160A0287|172 189|protein expression
14P07663963A1588|10 26|system activation
14P07663963A1588|38 67|metanephrine/epinephrine ratio
14P07663963A1588|124 135|cohabitation
14P07663963A1588|179 193|control animals
14P07663998T0000|14 19|repair
14P07663998T0000|51 59|aneurysms
14P07664278A0135|0 1|A.
14P07665172A0000|0 20|Transcription factors
14P07665187A0208|0 15|Primer extension
14P07665187A0208|67 77|Nramp1 mRNA
14P07665187A0824|0 15|Primer extension
14P07665187A0824|18 48|S1 nuclease mapping experiments
14P07665187A0824|65 93|transcription initiation site
14P07665477A0901|0 3|EsaR
14P07665477A0901|20 29|expression
14P07665477A0901|54 63|expression
14P07665567A0495|0 16|Sequence analysis
14P07665567A0495|43 51|CD69 gene
14P07665567A0495|82 93|TATA element
14P07665567A0495|122 150|transcription initiation site
14P07665567A0495|167 183|binding sequences
14P07665567A0495|195 215|transcription factors
14P07665567A0495|216 225|NF-kappa B
14P07665567A0495|226 230|Egr-1
14P07665567A0495|232 235|AP-1
14P07665605A1127|80 88|DD dimers
14P07665633A0284|60 83|agar dilution procedures
14P07665633A0284|97 114|National Committee
14P07665633A0284|125 144|Laboratory Standards
14P07665948A0591|0 9|IgE levels
14P07665948A0591|43 53|individuals
14P07665948A0591|57 66|IgE levels
14P07665948A0591|78 92|children groups
14P07666414A0614|71 95|promoter/lacZ fusion gene
14P07666414A0614|101 120|immunohistochemistry
14P07666414A0614|160 176|anti-tropomyosins
14P07666415A0000|3 21|nucleotide sequence
14P07666415A0000|41 43|DNA
14P07666415A0000|54 61|Zea mays
14P07666523T0000|0 12|Investigation
14P07666523T0000|48 65|mRNA transcription
14P07666523T0000|98 112|RNA transcripts
14P07666538A0000|0 9|Initiation
14P07666538A0000|33 49|hepatitis C virus
14P07666538A0000|49 51|HCV
14P07666538A0000|53 62|RNA genome
14P07666538A0000|118 120|NCR
14P07666966A0207|0 3|Mean
14P07666966A0207|16 24|extension
14P07667097A0267|16 19|p255
14P07667097A0267|24 41|splicing complexes
14P07667097A0267|102 118|immunoprecipitate
14P07667097A0267|132 134|RNA
14P07667097A0267|138 154|splicing products
14P07667195A0146|0 4|L-735
14P07667195A0146|19 30|sulfate salt
14P07667195A0146|81 92|dosage forms
14P07667195A0146|105 115|Beagle dogs
14P07667621T0001|0 25|Doppler ultrasound studies
14P07668009A0172|24 43|hepatitis A diseases
14P07669351A1278|23 39|SSB-ssDNA complex
14P07670504A0834|41 55|banding pattern
14P07670504A0834|95 99|G-box
14P07670504A0834|117 129|binding assay
14P07670504A0834|152 154|GBF
14P07670943A0308|44 46|CAD
14P07670943A0308|130 132|CAD
14P07672821A0763|23 26|FHR2
14P07672821A0763|33 46|factor H genes
14P07672821A0763|93 111|complement factor H
14P07672822T0000|58 76|receptor alpha gene
14P07673128A0989|28 48|cAMP response element
14P07673128A0989|48 50|CRE
14P07673154A0688|33 40|CAK beta
14P07673154A0688|55 68|trypsinization
14P07673154A0688|100 108|3Y1 cells
14P07673178A0982|30 48|muscle gene E-boxes
14P07673178A0982|102 124|MDF/bH-L-H heterodimers
14P07673178A0982|132 149|MCK-L type E-boxes
14P07674649A0508|24 27|ABAB
14P07674649A0508|70 92|treatment effectiveness
14P07675445A0463|51 52|CA
14P07675445A0463|70 97|sequence length polymorphism
14P07675445A0463|97 100|SSLP
14P07675449A0848|5 26|glioblastoma cell line
14P07675449A0848|41 44|p190
14P07675449A0848|72 76|PDGFR
14P07676492A1000|70 90|transplant recipients
14P07676492A1000|112 114|IHD
14P07676587T0000|10 22|certification
14P07676587T0000|26 41|livestock export
14P07676655A0214|3 21|serum concentration
14P07676655A0214|40 41|HD
14P07677573A0000|12 22|correlation
14P07677573A0000|49 58|parameters
14P07677573A0000|68 76|secretion
14P07677573A0000|78 86|incretion
14P07677573A0000|134 141|patients
14P07677573A0000|153 161|gastritis
14P07677715A1076|3 12|TAF factor
14P07677715A1076|48 50|OCD
14P07677836A1356|12 24|matter injury
14P07677836A1356|91 109|leukoencephalopathy
14P07677836A1356|140 151|chemotherapy
14P07678006A0472|0 24|RNase protection analyses
14P07678006A0472|47 58|CaM PDE mRNA
14P07678006A0472|106 121|CaM PDE isoforms
14P07678006A0901|71 83|kidney cortex
14P07678006A0901|93 104|T-lymphocyte
14P07678006A0901|110 112|RNA
14P07678051A1303|3 15|PDGFR mutants
14P07678051A1303|40 48|PLC gamma
14P07678051A1303|97 115|inositol phosphates
14P07678242A0473|14 24|correlation
14P07678242A0473|43 55|transcription
14P07678242A0473|61 69|acc genes
14P07678593A0708|21 33|V. vulnificus
14P07678593A0708|44 46|DNA
14P07678593A0708|60 81|V. cholerae fur mutant
14P07678602A0153|22 45|B lymphoblast cell lines
14P07678695A0604|10 19|expression
14P07678695A0604|22 26|Oct-3
14P07678695A0604|31 42|hybrid cells
14P07678695A0604|98 107|activation
14P07679390A0721|0 15|RNase protection
14P07679390A0721|18 40|primer extension assays
14P07679390A0721|86 99|DDT1 aFGF mRNA
14P07679390A0721|111 134|transcription start site
14P07679836A0387|23 24|FK
14P07679836A0387|61 82|kidney transplantation
14P07680035A0221|32 34|AMP
14P07680035A0221|49 61|GnRH response
14P07680120A1008|0 5|RT-PCR
14P07680120A1008|77 82|D mRNA
14P07680120A1008|133 144|aFGF protein
14P07680629T0000|19 34|characterization
14P07680629T0000|60 84|cell surface glycoprotein
14P07680629T0000|114 137|Dictyostelium discoideum
14P07681147A1420|49 63|phosphorylation
14P07681147A1420|66 71|Ser-12
14P07681147A1420|75 80|Ser-48
14P07681147A1420|177 186|signalling
14P07681513A0000|0 9|Piroximone
14P07681513A0000|16 32|phosphodiesterase
14P07681513A0000|69 90|vasodilator properties
14P07681539A0000|33 43|lymphocytes
14P07681539A0000|48 63|hospital workers
14P07681539A0000|82 90|radiation
14P07682842A0294|27 44|fMLF-R transcripts
14P07682842A0294|75 88|receptor genes
14P07682842A0294|107 128|fMLF-R gene expression
14P07682842A0294|143 153|copy number
14P07682842A0294|184 195|organization
14P07682842A0294|229 239|fMLF-R gene
14P07682842A0771|43 50|sequence
14P07682842A0771|72 77|coding
14P07682842A0771|96 104|sequences
14P07683131A0885|37 46|SRC-family
14P07683131A0885|70 91|exon/intron boundaries
14P07683375A0000|28 41|growth factors
14P07683375A0000|66 67|E2
14P07683375A0000|119 135|estrogen receptor
14P07683375A0000|136 137|ER
14P07683375A0000|199 213|protein kinases
14P07683375A0000|252 253|ER
14P07685263A0503|8 32|polymerase chain reaction
14P07685263A0503|48 60|DNA fragments
14P07685263A0503|92 108|Whipple bacterium
14P07685263A0503|109 128|Tropheryma whippelii
14P07685823A1234|0 13|RNA polymerase
14P07685823A1234|26 35|A promoter
14P07685823A1234|55 72|base-pair sequence
14P07685823A1234|76 80|DNase
14P07685874A0258|26 49|magnesium concentrations
14P07685874A0258|77 88|SLE patients
14P07685874A0258|100 118|lupus erythematosus
14P07685874A0258|143 164|protein concentrations
14P07685874A0258|167 182|amylase activity
14P07686619A0704|0 3|Chem
14P07687320A0526|11 24|plasmid pFV100
14P07687320A0526|61 88|complement B-band expression
14P07687541A0200|43 55|fission yeast
14P07687541A0200|120 134|mtr1/prp20/srm1
14P07687541A0200|168 170|RNA
14P07687541A0200|175 184|degrees C.
14P07687541A0992|5 9|RCC1p
14P07687541A0992|16 19|GNRP
14P07687541A0992|40 45|GTPase
14P07687541A0992|113 116|CNR1
14P07687541A0992|120 123|CNR2
14P07687745T0000|20 24|FK506
14P07687745T0000|33 49|amino acid import
14P07688112A0274|0 7|Prostate
14P07688112A0274|84 99|acid phosphatase
14P07689154A0168|0 22|Protein phosphorylation
14P07689154A0168|50 68|uPA gene expression
14P07689154A0168|80 93|protein kinase
14P07689154A0168|105 118|phorbol esters
14P07689154A0168|186 188|AMP
14P07689154A0168|260 274|uPA mRNA levels
14P07689501A0420|7 14|carriers
14P07691837A1359|30 44|K3 keratin gene
14P07691837A1359|157 179|NFkB consensus sequence
14P07691837A1359|193 198|GC box
14P07691885T0000|0 13|Identification
14P07691885T0000|49 68|proto-oncogene c-kit
14P07691885T0000|76 103|mast cell leukemia cell line
14P07692366A0000|0 9|BACKGROUND
14P07692366A0000|11 21|Delineation
14P07692366A0000|78 81|ARMD
14P07692668A0326|42 44|RNA
14P07692668A0326|85 88|RNAs
14P07692668A0326|139 156|blot hybridization
14P07692668A0326|183 204|transcription strategy
14P07692668A0326|229 232|ORFs
14P07692754T0000|0 11|Risk factors
14P07692754T0000|46 72|hepatitis C virus infection
14P07693132A0100|39 47|Zm-ERabp1
14P07693132A0100|49 57|Zm-ERabp4
14P07693132A0100|62 76|Zm-ERabp5 genes
14P07693372A0115|60 68|mechanism
14P07693372A0115|92 103|cyclosporine
14P07693672A0259|0 4|DNase
14P07693672A0259|6 17|footprinting
14P07693699A0831|25 51|nucleotide binding function
14P07693708A0000|42 49|IGF-BP-2
14P07693708A0000|51 63|transcription
14P07693967A0905|16 17|RV
14P07693967A0905|23 33|SL sequence
14P07693975A1418|82 91|N terminus
14P07693975A1418|93 94|PR
14P07693975T0000|23 41|protease activities
14P07693975T0000|48 85|leukosis virus Gag-Pol fusion proteins
14P07695629A0489|13 26|mck1 mds1 mrk1
14P07695629A0489|31 40|disruptant
14P07696183A0567|33 35|Rak
14P07696183A0567|86 88|Rak
14P07696183A0567|199 210|colon origin
14P07696183A0567|214 216|Rak
14P07696183A0567|264 276|myristylation
14P07696183A0567|280 300|membrane localization
14P07696183A0567|307 309|Rak
14P07696183A0567|344 362|localization signal
14P07696183A0567|367 376|SH2 domain
14P07696183A0567|391 411|fractionation studies
14P07696183A0567|423 428|p54rak
14P07696450A0271|0 7|PATIENTS
14P07696450A0271|11 17|METHODS
14P07696450A0271|129 136|TGF-beta
14P07696450A0271|156 159|Diet
14P07696450A0271|161 174|Nestle-Clintec
14P07696450A0271|176 180|Vevey
14P07696450A0271|182 192|Switzerland
14P07696878A0222|3 17|leader sequence
14P07696878A0222|63 76|reading frames
14P07696878A0222|89 104|initiation codon
14P07696878A0222|120 132|reading frame
14P07696878A0222|144 162|homeodomain protein
14P07697294A0329|14 25|HSP81-1 mRNA
14P07698219A0551|0 12|Cell adhesion
14P07698219A0551|15 30|migration assays
14P07698219A0551|66 81|laminin receptor
14P07698219A0551|99 106|F9 cells
14P07698219A0551|124 131|PE cells
14P07698727A0386|64 76|HIV infection
14P07699632A0522|27 40|Chukcha-Eskimo
14P07699632A0522|86 88|PsA
14P07699632A0715|3 17|data complement
14P07699632A0715|93 95|SPA
14P07699632A0715|99 105|HLA-B27
14P07699845A0537|8 21|studies SY5555
14P07699845A0537|88 98|pharyngitis
14P07699845A0537|110 120|tonsillitis
14P07699845A0537|127 145|lacunar tonsillitis
14P07699845A0537|160 169|bronchitis
14P07699845A0537|216 234|impetigo contagiosa
14P07699845A0537|252 267|tract infections
14P07699845A0537|273 287|balanoposthitis
14P07699845A0537|308 320|lymphadenitis
14P07699845A0537|322 329|S.S.S.S.
14P07700361A0125|20 31|interactions
14P07700361A0125|63 71|molecules
14P07701266A0808|0 6|RESULTS
14P07701266A0808|8 19|Closure time
14P07701266A0808|48 50|TPN
14P07701266A0808|142 144|TPN
14P07702327T0000|46 73|tissue plasminogen activator
14P07702378A0668|76 78|VO2
14P07702752A0545|30 49|rat P450c17 promoter
14P07702752A0545|90 107|gene transcription
14P07702752A0545|108 126|deletion constructs
14P07702752A0545|177 179|DNA
14P07702752A0545|187 202|rat P450c17 gene
14P07702752A0545|235 258|reporter gene luciferase
14P07702752A0545|278 293|mouse cell lines
14P07702752A0545|300 308|Y-1 cells
14P07702752A0545|322 339|Leydig MA-10 cells
14P07702808A0427|14 27|BP differences
14P07702808A0427|44 61|corn oil treatment
14P07702808A0427|74 80|Dinamap
14P07702808A0427|116 118|ABP
14P07704040A0000|27 41|mouse NMO1 cDNA
14P07704040A0000|56 58|NAD
14P07704040A0000|64 87|menadione oxidoreductase
14P07704040A0000|98 100|NAD
14P07704040A0000|107 122|quinone acceptor
14P07704040A0000|123 136|oxidoreductase
14P07704040A0000|138 154|quinone reductase
14P07704040A0000|171 183|DT diaphorase
14P07704040A0000|184 185|EC
14P07704273A0000|15 20|JRG582
14P07704273A0000|25 53|ampD ampE deletion derivative
14P07704273A0000|125 143|beta-lactamase gene
14P07704273A0000|145 164|Citrobacter freundii
14P07704456A1014|22 33|acceleration
14P07704456A1014|126 137|HMS subjects
14P07704689T0000|8 21|thyroid nodule
14P07704730T0000|4 16|contraception
14P07705476A0292|10 20|food intake
14P07705476A0292|59 71|protein level
14P07705476A0292|72 83|water intake
14P07705476A0292|86 97|urine volume
14P07705627A1107|13 15|Mad
14P07705627A1107|19 23|Medea
14P07705627A1107|63 74|dpp pathways
14P07706273T0000|43 64|ATPase B2 subunit gene
14P07706273T0000|79 89|THP-1 cells
14P07706287A0698|28 30|RNA
14P07706287A0698|95 113|cell division cycle
14P07706291T0000|2 14|E box element
14P07706291T0000|75 85|ftz-f1 gene
14P07706291T0000|122 132|development
14P07706299A0563|0 16|Inhibition assays
14P07706299A0563|166 196|oligosaccharide-protein binding
14P07706307A0914|3 21|amino acid sequence
14P07706307A0914|48 65|specificity pocket
14P07706307A0914|82 83|S.
14P07706307A0914|107 108|C.
14P07706396T0000|0 8|Mutations
14P07706396T0000|14 23|VPS45 gene
14P07706396T0000|25 38|SEC1 homologue
14P07706396T0000|93 109|membrane vesicles
14P07707523A0704|26 45|NF-kappa B inhibitor
14P07707523A0704|45 59|I kappa B-alpha
14P07707523A0704|90 92|LMP
14P07707531A0550|51 62|displacement
14P07707531A0550|76 87|binding site
14P07707531A0550|110 127|gene transcription
14P07707531A0550|129 132|ICP4
14P07707544T0000|35 62|channel catfish virus genome
14P07707544T0000|61 76|characterization
14P07708058A0178|3 5|GRE
14P07708058A0178|34 36|GRE
14P07708058A0178|66 84|activator protein-1
14P07708058A0178|85 88|AP-1
14P07708058A0178|101 115|c-jun homodimer
14P07708058A0178|118 140|c-jun/c-fos heterodimer
14P07708488A0151|55 70|sequence variant
14P07708497A0000|27 41|thyroid hormone
14P07708497A0000|42 43|T3
14P07708497A0000|75 85|T3 receptor
14P07708497A0000|86 87|TR
14P07708497A0000|92 111|T3 response elements
14P07708497A0000|111 114|TREs
14P07708497A0000|155 160|AGGTCA
14P07711667A0766|56 58|WBC
14P07711667A0766|118 128|FAB subtype
14P07711667A0766|140 166|remission induction courses
14P07711667A0766|185 203|maintenance therapy
14P07711667A0766|204 224|consolidation therapy
14P07711667A0766|225 240|marrow cell dose
14P07711667A0766|259 282|GVHD prophylaxis regimen
14P07711667A0766|296 310|decontamination
14P07711730A0000|0 29|Carnitine palmitoyltransferase
14P07711730A0000|30 32|CPT
14P07711730A0000|80 95|lipid metabolism
15P07713421A1435a|20 43|gain-of-function mutants
15P07713421A1435a|86 109|sex determination signal
15P07713421A1435a|113 117|SxlM4
15P07713421A1435a|138 142|SxlM1
15P07713421A1435b|20 43|gain-of-function mutants
15P07713421A1435b|86 109|sex determination signal
15P07713421A1435b|113 117|SxlM4
15P07713421A1435b|138 142|SxlM1
14P07713936A0393|0 6|Binding
14P07713936A0393|35 47|transcription
14P07713936A0393|61 74|response genes
14P07713936A0393|94 106|transcription
14P07714608A1252|13 23|differences
14P07714608A1252|57 61|PaCO2
14P07714608A1252|84 93|heart rate
14P07714608A1252|94 110|brain temperature
14P07714608A1252|113 126|glucose levels
14P07714758A1193|0 13|Blood pressure
14P07715200A0000|0 16|Anesthesiologists
14P07715200A0000|60 74|target response
14P07715200A0000|89 102|blood pressure
14P07715602A1088|17 34|gene cluster codes
14P07715602A1088|58 80|cytochrome c haem lyase
14P07715922A0188|13 22|comparison
14P07715922A0188|121 123|PRK
14P07717823A0328|0 25|Standard reference sources
14P07719527T0000|4 16|allergenicity
14P07719527T0000|46 51|REVASC
14P07720572A0701|2 9|contrast
14P07720572A0701|15 27|myoD promoter
14P07720572A0701|31 43|myoD enhancer
14P07720572A0701|56 67|conservation
14P07720572A0701|97 104|sequence
14P07720572A0701|117 124|position
14P07720572A1584|49 60|10T1/2 cells
14P07720572A1584|94 112|chromatin structure
14P07720572A1584|128 145|myoD core enhancer
14P07720572A1584|162 174|myoD enhancer
14P07720572A1584|209 220|10T1/2 cells
14P07720709A0755|23 31|3T3 cells
14P07720709A0755|60 61|RA
14P07720709A0755|119 136|cell proliferation
14P07720709A0755|167 183|growth inhibition
14P07720709A0755|197 215|AP1 transrepression
14P07720710A0861|9 21|HMG2 proteins
14P07721074A0766|75 99|patient treatment program
14P07721074A0766|114 125|multiplicity
14P07721074A0766|137 151|trigger factors
14P07721422A0241|0 27|Primer extension experiments
14P07721422A0241|47 76|transcription initiation sites
14P07721878A1163|19 31|Fc epsilon R1
14P07721878A1163|39 61|tyrosine phosphoprotein
14P07721878A1163|68 70|p33
14P07721878A1163|125 148|Fc epsilon R1 beta chain
14P07723247A0187|42 63|transmembrane transfer
14P07723247A0187|111 122|computerized
14P07723247A0187|130 143|dialysis model
14P07723247A0187|166 183|pressure recording
14P07723247A0187|224 236|outflow ports
14P07723247A1161|42 47|IL-1Ra
14P07723247A1161|51 59|IL-1 beta
14P07724452A0344|11 19|treatment
14P07724452A0344|50 55|chicks
14P07728201A0660|49 75|sickle-hemoglobin C disease
14P07728201A0660|148 169|penicillin prophylaxis
14P07729427A0942|0 16|Deletion analysis
14P07729427A0942|29 31|TBP
14P07729427A0942|100 102|TBP
14P07730273A1309|10 22|NarQ proteins
14P07730273A1309|26 49|amino acid substitutions
14P07730273A1309|67 84|histidine position
14P07730273A1309|115 128|NarL-phosphate
14P07730328A0000|39 45|changes
14P07730328A0000|58 67|activation
14P07730328A0000|77 86|expression
14P07730328A0000|90 97|spectrum
14P07730336A0606|7 11|ATF-1
14P07730336A0606|15 18|CREM
14P07730336A0606|35 56|cAMP response elements
14P07730336A0606|56 58|CRE
14P07730336A0606|103 105|CRE
14P07730337A1439|3 8|Ng/RC3
14P07730337A1439|12 26|PKC-gamma genes
14P07730337A1439|38 55|expression pattern
14P07730337T0000|0 8|Structure
14P07730337T0000|57 72|protein kinase C
14P07730337T0000|92 102|RC3 protein
14P07730795A0104|3 22|amino acid sequences
14P07730795A0104|48 52|DdRPs
14P07731686A0000|3 12|TTG-2 gene
14P07731686A0000|72 86|T-cell leukemia
14P07731686A0000|89 93|T-ALL
14P07731898A0823|50 65|bicarbonate ions
14P07731898A0823|170 197|superoxide anions generation
14P07731898A0823|197 213|erythrocyte SOD-1
14P07731898A0823|216 234|catalase activities
14P07731898A0823|237 275|erythrocyte membrane lipid peroxidation
14P07733075A1200|16 25|omeprazole
14P07733075A1200|38 51|clarithromycin
14P07733075A1200|68 70|CBS
14P07733075A1200|104 114|combination
14P07733075A1200|132 149|% eradication rate
14P07733075A1200|150 158|H. pylori
14P07733075A1200|169 187|ulcer healing rates
14P07733075A1200|209 218|omeprazole
14P07735590A0990|3 15|concentration
14P07735590A0990|62 73|p milligrams
14P07735590A0990|103 114|cat allergen
14P07735590A0990|141 167|micrograms Fel d milligrams
14P07735590A0990|193 219|micrograms Fel d milligrams
14P07735833A1078|0 10|CONCLUSIONS
14P07735833A1078|28 49|LysU crystal structure
14P07737024A1003|5 20|bowel irrigation
14P07737024A1003|40 48|technique
14P07737118A0317|3 6|MPS1
14P07737118A0317|55 66|LexA protein
14P07737118A0317|71 81|GST protein
14P07737508A0649|4 5|Tb
14P07737508A0649|7 8|U6
14P07737508A0649|33 42|tRNA genes
14P07737944A0000|13 26|growth factors
14P07737944A0000|58 77|transfusion practice
14P07737944A0000|113 135|blood cell transfusions
14P07737944A0000|203 216|erythropoietin
14P07738026A0216|63 65|ADH
14P07738839A0173|6 15|IC breaths
14P07738839A0173|27 28|EC
14P07738839A0173|32 41|VC breaths
14P07738839A0173|57 68|CO2 pressure
14P07738839A0173|69 71|PET
14P07738839A0173|73 75|CO2
14P07739382A0457|24 43|amino acid sequences
14P07739382A0457|52 64|protein types
14P07739520A1250|29 48|Surfeit gene cluster
14P07739520A1250|80 81|D.
14P07739520A1250|94 99|Surf-3
14P07739542A1419|66 80|G1/S transition
14P07739542A1419|98 128|retinoblastoma protein function
14P07739544A0364|12 30|amino acid sequence
14P07739544A0364|34 50|SGC1 gene product
14P07739544A0364|127 136|Myc family
14P07739566A1076|10 35|Pax-6-BSAP fusion proteins
14P07739566A1076|61 78|amino acid stretch
14P07740487A0167|46 62|dysfibrinogenemia
14P07740487A0167|153 168|SSC Subcommittee
14P07740487A0167|170 179|Fibrinogen
14P07740487A0167|185 205|International Society
14P07740487A0167|207 216|Thrombosis
14P07740487A0167|220 230|Haemostasis
14P07740490T0000|10 18|estrogens
14P07740490T0000|40 46|uraemia
14P07740490T0000|63 71|serotonin
14P07741255A0194|8 16|districts
14P07741255A0194|46 55|population
14P07742024A0121|11 18|symptoms
14P07742024A0121|26 41|imaging features
14P07742024A0121|42 59|operation findings
14P07742024A0121|92 101|directions
14P07742363A0135|48 50|HCR
14P07742363A0135|114 119|Ser-51
14P07742363A0135|125 137|alpha subunit
14P07742363A0135|173 183|nucleotides
14P07742363A0941|7 9|Ser
14P07742363A0941|13 15|Ala
14P07742363A0941|28 44|yeast eIF-2 alpha
14P07742363A0941|108 131|casein kinase activities
14P07742550A0407|51 53|DAL
14P07742550A0407|173 175|TFL
14P07742550A0407|208 209|FL
14P07742550A0407|214 234|mantle cell lymphomas
14P07742550A0407|234 236|MCL
14P07742550A0407|259 272|cell lymphomas
14P07742550A0407|273 276|SNCL
14P07742917T0001|0 6|Icterus
14P07742917T0001|10 25|beta-thalassemia
14P07742917T0001|47 57|Brazzaville
14P07743472A0181|59 87|Roswell Park Cancer Institute
14P07743472A0181|86 89|RPCI
14P07743472A0181|93 99|Buffalo
14P07743472A0181|101 108|New York
14P07743472A0181|138 162|cigarette smoking history
14P07743515A0223|17 35|tissue distribution
14P07743515A0223|37 40|AAMP
14P07743515A0223|92 107|cytotrophoblasts
14P07743515A0223|132 157|colon adenocarcinoma cells
14P07743697A0703|0 3|Data
14P07743697A0703|11 16|V-HeFT
14P07743697A0703|63 83|plasma norepinephrine
14P07743697A0703|100 113|treatment arms
14P07743697A0703|195 210|enzyme inhibitor
14P07743697A0703|223 241|vasodilator therapy
14P07743697A0703|245 276|hydralazine/isosorbide dinitrate
14P07744763A0514|0 15|Binding activity
14P07744763A0514|53 68|orphan receptors
14P07744763A0514|80 117|electromobility supershift experiments
14P07744763A0514|181 187|CYP2C11
14P07744763A0514|198 202|HNF-4
14P07744776A0617|0 18|Transcript analysis
14P07744776A0617|35 55|B block substitutions
14P07744776A0617|60 75|U6 RNA synthesis
14P07744846A1006|0 7|Analysis
14P07744846A1006|10 14|Bcl-2
14P07744846A1006|16 37|Bcl-2 homodimerization
14P07744846A1006|53 66|binding assays
14P07744846A1006|144 148|Bcl-2
14P07744846A1006|150 171|Bcl-2 homodimerization
14P07744846A1006|216 223|A domain
14P07744846A1006|289 297|C domains
14P07744954A0418|75 77|NH2
14P07744954A0418|81 92|COOH termini
14P07745008A0892|0 18|Radioligand binding
14P07745311A0264|0 8|Diagnosis
14P07745311A0264|11 14|FHCS
14P07745684T0000|5 23|papillomavirus type
14P07745684T0000|30 44|gene expression
14P07745684T0000|94 107|RNA processing
14P07745685A1442|88 105|accessory proteins
14P07745685A1442|113 114|SN
14P07745685A1442|118 136|CAT fusion partners
14P07745693A0914|0 6|Studies
14P07745693A0914|32 44|Lb proteinase
14P07745693A0914|57 67|stimulation
14P07745693A0914|81 91|translation
14P07745693A0914|105 115|proteolysis
14P07745696A0932|0 27|Restriction mapping analysis
14P07745696A0932|48 53|HHV-6A
14P07745696A0932|55 59|U1102
14P07745696A0932|68 83|BamHI G fragment
14P07745696A0932|137 142|SalI L
14P07745696A0932|145 160|SalI O fragments
14P07745726A0960|3 33|replication reporter constructs
14P07745726A0960|37 38|E1
14P07745726A0960|42 43|E2
14P07745726A0960|77 94|expression vectors
14P07745726A1496|69 99|nucleotide sequence information
14P07745726A1496|101 110|E1 binding
14P07745726A1496|134 153|E1 recognition motif
14P07746397A0233|0 6|METHODS
14P07746397A0233|33 47|anticoagulation
14P07746397A0233|55 58|July
14P07746397A0233|66 73|December
14P07746397A0233|167 185|thromboplastin time
14P07746794A0000|50 62|Cyclosporin A
14P07746794A0000|63 71|Sandimmun
14P07746794A0000|100 111|Cremophor EL
14P07746937A0100|0 18|Lung function tests
14P07746937A0100|18 20|EFR
14P07747462A0332|0 19|Sequence comparisons
14P07747462A0332|32 45|RCR initiators
14P07747462A0332|100 122|metal coordination site
14P07747462A0332|200 218|replicator proteins
14P07748451A0343|15 25|discrepancy
14P07748451A0343|39 50|restorations
14P07748451A0343|65 76|restorations
14P07748451A0343|115 128|vinyl siloxane
14P07748451A0343|133 153|medium-viscosity poly
14P07748451A0343|154 167|vinyl siloxane
14P07748493A1045|16 30|Aplysia Afurin2
14P07748493A1045|33 44|candidate PC
14P07748493A1045|105 107|ELH
14P07748502A0794|0 3|Rats
14P07748502A0794|15 23|8-OH-DPAT
14P07748502A0794|67 80|discrimination
14P07748848A0263|19 39|papillary haemangioma
14P07748952A0462|32 36|PmiaA
14P07748952A0462|40 44|P1hfq
14P07748952A0462|115 137|translation start sites
14P07748952A1329|37 50|hfq expression
14P07748952A1329|104 118|cotranscription
14P07748952A1329|157 173|promoter strength
14P07748952A1329|179 194|RNase E activity
14P07749088A0119|8 9|T1
14P07749088A0119|13 14|T2
14P07749461A0632|47 64|sGTH alpha subunit
14P07749461A0632|108 120|sGTH alpha-G1
14P07749461A1022|23 49|sGTH alpha subunit promoter
14P07749461A1022|61 72|transfection
14P07749461A1022|82 95|sGTH alpha/CAT
14P07749461A1022|115 127|rainbow trout
14P07750217T0000|0 25|Indium-111 OncoScint CR/OV
14P07750217T0000|56 76|carcinoma recurrences
14P07751848A0222|3 32|carnitine palmitoyltransferase
14P07751848A0222|33 35|CPT
14P07751848A0222|68 86|nmol/min/mg protein
14P07751848A0222|138 156|nmol/min/mg protein
14P07752223A0960|3 8|Myc LZ
14P07752223A0960|63 75|Myc inability
14P07752454A0341|23 25|CNS
14P07752454A0341|46 61|resistance rates
14P07752454A0341|75 79|DMPPC
14P07752644A1031|5 6|VF
14P07752644A1031|18 31|defibrillation
14P07752644A1031|71 87|plasma drug level
14P07752886A0595|17 31|FecR derivative
14P07752886A0595|42 60|amino acid residues
14P07752886A0595|96 99|FecR
14P07753027A0240|3 22|gene pairs psbB-psbT
14P07753030A0173|0 20|Hybridization signals
14P07753030A0173|45 48|DNAs
14P07753030A0173|51 76|Rhizobium leguminosarum bv
14P07753030A0173|85 106|Rhodobacter capsulatus
14P07753030A0173|138 162|Xanthomonas campestris pv
14P07753796A0625|12 30|amino acid sequence
14P07753796A0625|94 119|liver eIF-2B alpha subunit
14P07753796A0743|0 9|Expression
14P07753796A0743|80 102|SDS/polyacrylamide gels
14P07753837A0724|4 6|RNA
14P07753837A0724|57 71|plakoglobin RNA
14P07753837A0724|106 117|accumulation
14P07754713A0227|10 13|NUC1
14P07754713A0227|15 19|PRP21
14P07754713A0227|31 35|SPP91
14P07754713A0227|38 41|CDC6
14P07754713A0227|43 46|CRY2
14P07755884A0000|106 126|sensorimotor deficits
14P07755884A0000|165 179|dopamine system
14P07755914A0000|0 8|OBJECTIVE
14P07755914A0000|117 120|AIDS
14P07755914A0000|136 162|Mycobacterium avium complex
14P07755914A0000|162 165|DMAC
14P07757315A1227|57 72|drug application
14P07757315A1227|103 120|observation period
14P07757315A1227|122 129|ABSTRACT
14P07757315A1227|144 148|WORDS
14P07758167A1488|0 12|Growth curves
14P07758167A1488|25 37|proliferation
14P07758167A1488|98 107|clone ME10
14P07758246A0469|3 9|protein
14P07758246A0469|16 21|region
14P07758246A0469|49 54|intron
14P07758246A0469|62 66|exons
14P07758459A1277|3 5|UAS
14P07758459A1277|11 19|AAC2 gene
14P07758459A1277|126 152|core HAP2/3/4 binding motif
14P07758459A1277|171 201|ABF1 consensus binding sequence
14P07758837A1118|49 64|GH receptor gene
14P07758837A1118|133 147|intron boundary
14P07758837A1118|222 232|P1 promoter
14P07759094A0634|25 29|GT/CA
14P07759094A0634|52 62|NHE5 cosmid
14P07759094A0634|92 116|microsatellite PCR marker
14P07759525A0417|54 74|protein kinase domain
14P07759525A0417|102 114|casein kinase
14P07759529A0288|37 43|CDP/cut
14P07759529A0288|64 88|gp91-phox gene expression
14P07760790A0327|0 14|Serum induction
14P07760790A0327|17 34|MEF2 reporter gene
14P07760790A0327|56 68|NIH 3T3 cells
14P07760790A0327|82 107|MEF2 site binding activity
14P07760819A0731|59 87|PDGF beta receptor activation
14P07760819A0731|113 130|cell proliferation
14P07760841A0221|0 3|UAS1
14P07760841A0221|41 55|regulator Adr1p
14P07760841A0647|17 20|ADH2
14P07760841A0647|55 58|UAS1
14P07760841A0647|83 86|ADH2
14P07760841A0647|92 108|promoter elements
14P07760841A0647|123 137|gene activation
14P07760844A0413|0 8|Induction
14P07760844A0413|11 26|AP-1 DNA binding
14P07760844A0413|51 69|GH trans-activation
14P07761091A0294|0 11|Inactivation
14P07761091A0294|14 24|MAP kinases
14P07761091A0294|54 58|MKP-1
14P07761216T0000|12 33|amphotericin B therapy
14P07761420A0909|42 46|CCaMK
14P07761420A0909|60 62|Ca2
14P07761434A1084|5 8|AP-1
14P07761434A1084|32 52|tumor promoter action
14P07761467A0666|43 60|protein components
14P07762431A0356|3 9|protein
14P07762431A0356|53 66|culture medium
14P07762504A0648|24 37|administration
14P07762504A0648|44 53|amiodarone
14P07762504A0648|57 65|mg/kg/day
14P07763727A1035|0 14|Plasmids pAMS12
14P07763727A1035|50 66|laboratory strain
14P07763727A1035|141 158|wine yeast strains
14P07765118A0967|3 19|maximum induction
14P07765118A0967|21 43|ACC-oxidase transcripts
14P07765118A0967|82 104|maximum enzyme activity
14P07766885A0405|11 27|polypeptide chain
14P07766885A0405|75 84|plant CDPK
14P07766885A0405|160 174|junction region
14P07767011A0689|0 5|Repair
14P07767011A0689|12 20|insertion
14P07767011A0689|33 45|recombination
14P07767011A0689|70 79|hprt locus
14P07768824A0167|11 29|fla gene expression
14P07768824A0167|74 87|RNA polymerase
14P07768836A1126|0 27|Primer extension experiments
14P07768836A1126|41 69|transcription initiation site
14P07768848A1880|0 11|Polypeptides
14P07768848A1880|97 104|products
14P07768848A1880|110 120|cotJ operon
14P07768848A1880|143 151|formation
14P07768848A1880|202 211|components
14P07768898A0492|27 36|divergence
14P07768898A0492|39 55|apobec1 sequences
14P07768898A0492|103 115|suhstitutions
14P07768953T0039|0 3|EEA1
14P07768953T0039|39 54|membrane protein
14P07768953T0039|110 117|IQ motif
14P07770033A0978|0 19|Nucleotide sequences
14P07770033A0978|84 86|ORF
14P07770033A0978|163 202|Neurospora crassa copper metallothionein
14P07771671T0000|44 60|carbon electrodes
14P07771745A0442|0 8|Elevation
14P07771745A0442|94 103|cheekbones
14P07772036A1000|43 50|USF/MLTF
14P07772036A1000|69 103|transcription factor/nuclear factor
14P07772036A1000|104 110|CTF/NF1
14P07774137A0000|46 56|Strep A OIA
14P07774137A0000|115 119|GABHS
14P07774137A0000|121 131|pharyngitis
14P07774807A0405|46 55|activators
14P07774807A0405|87 98|heterodimers
14P07774807A0405|134 147|family members
14P07774925A0084|0 2|YAC
14P07774925A0084|6 19|cosmid contigs
14P07774925A0084|30 41|BRCA1 region
14P07774925A0084|108 117|HeLa cells
14P07774925A0084|127 133|T cells
14P07775428A0172|18 22|Ash-m
14P07775428A0172|32 51|nucleotide sequences
14P07775428A0172|64 73|Ash-l cDNA
14P07776685A0000|20 30|feasibility
14P07776685A0000|34 41|toxicity
14P07776685A0000|52 64|immunotherapy
14P07776685A0000|86 96|lymphocytes
14P07776685A0000|111 123|interleukin-2
14P07776685A0000|128 135|patients
14P07776685A0000|148 156|resection
14P07776685A0000|182 192|lung cancer
14P07776711A0295|0 7|MATERIAL
14P07776711A0295|11 17|METHODS
14P07776711A0295|94 108|neuropathy type
14P07776711A0295|137 150|polyneuropathy
14P07776882A0000|27 46|cell volume dynamics
14P07776882A0000|53 62|rat hearts
14P07776882A0000|85 95|reperfusion
14P07776979A0702|11 17|COUP-TF
14P07776979A0702|53 74|reporter gene activity
14P07777518A0483|0 13|DNA sequencing
14P07777518A0483|16 37|Southern blot analyses
14P07779558T0000|0 21|Muscle GSH-Px activity
14P07779558T0000|55 78|selenium supplementation
14P07779811A0901|0 7|Mutation
14P07779811A0901|13 23|Sp1 element
14P07779811A0901|38 48|Sp1 binding
14P07779811A0901|79 95|reporter activity
14P07779812A0000|3 12|c-myc gene
14P07779812A0000|30 36|variety
14P07779812A0000|39 49|tumor types
14P07779812A0000|110 119|cell types
14P07780148A1153|11 13|PML
14P07780148A1153|43 44|G2
14P07780148A1153|49 56|M phases
14P07780148A1153|88 95|G1 phase
14P07780525A0495|0 8|Schooling
14P07780525A0495|62 72|differences
14P07780525A0495|85 97|health inputs
14P07780719A0477|25 31|driving
14P07780738A0091|8 11|Cdks
14P07780738A0091|17 18|G1
14P07780738A0091|22 29|S phases
14P07780738A0091|90 93|PCNA
14P07780738A0091|104 118|DNA replication
14P07782087A0559|19 48|transcription initiation sites
14P07782087A0559|122 144|ribonuclease protection
14P07782087A0559|166 178|RACE analyses
14P07782113A0726|3 21|roxithromycin doses
14P07782113A0726|72 83|blood levels
14P07782302A0479|25 39|DEDDDL sequence
14P07782302A0479|49 51|GDP
14P07782302A0479|98 117|affinity interaction
14P07782302A0479|141 152|HTF9A/RanBP1
14P07782775A0889|11 14|ORFs
14P07782775A0889|83 99|BBTV coat protein
14P07783064A0452|14 26|strength data
14P07783064A0452|60 76|creatinine kinase
14P07783064A0452|77 78|CK
14P07783641A0591|0 3|CodY
14P07783822A0000|0 8|OBJECTIVE
14P07783822A0000|98 114|district hospital
14P07784061A0894|20 29|G proteins
14P07784061A0894|59 61|TTF
14P07784078A1064|34 48|gene expression
14P07784078A1064|72 80|RAR alpha
14P07784078A1064|82 84|PML
14P07784078A1064|98 112|APL cell growth
14P07784079A1018|0 11|Transfection
14P07784079A1018|25 41|expression vector
14P07784079A1018|45 56|NIH3T3 cells
14P07784079A1018|118 134|expression vector
14P07784079A1018|181 183|FGF
14P07784197A0827|68 86|mouse fibrosarcomas
14P07784197A0827|94 100|HeLa S3
14P07784197A0827|120 127|TGF-beta
14P07784197A0827|176 203|BALB/c 3T3 mouse fibroblasts
14P07784199A0000|23 36|gene promoters
14P07784199A0000|124 143|gene regulator Rap1p
14P07784199A0000|181 185|Abf1p
14P07784870A0119|91 101|information
14P07784870A0119|125 138|investigations
14P07784870A0119|156 169|histochemistry
14P07784870A0119|181 199|electron microscopy
14P07784870A0119|200 219|immunohistochemistry
14P07784870A0119|226 237|microbiology
14P07784942T0001|11 24|thrombomodulin
14P07786820A0284|0 5|CPT-11
14P07786820A0284|33 45|i.v. infusion
14P07786821A2292|0 9|CONCLUSION
14P07786821A2292|14 16|MTD
14P07786821A2292|20 25|CPT-11
14P07786821A2292|42 80|consecutive-days-every-3 weeks schedule
14P07787179A0312|14 22|X1 region
14P07787179A0312|28 42|PRB-1b promoter
14P07787179A0312|99 121|ethylene responsiveness
14P07789275A0325|24 26|E74
14P07789275A0325|86 111|loss-of-function mutations
14P07789275A0325|125 142|transcription unit
14P07789342A1352|35 39|TSH-R
14P07789342A1352|59 74|affinity binding
14P07789342A1352|76 78|TSH
14P07789342A1352|119 138|transmembrane domain
14P07789342A1352|148 158|TSH binding
14P07789396A0504|0 7|Lipiodol
14P07789396A0504|35 38|EDTB
14P07789809A1246|9 21|Western blots
14P07789809A1246|50 52|Ypt
14P07789809A1246|59 60|Cr
14P07789809A1246|64 65|Vc
14P07789809A1246|86 88|Ypt
14P07789809A1246|99 117|household functions
14P07789809A1246|131 147|vesicle transport
14P07789809A1246|168 182|differentiation
14P07789971A0758|26 38|hybridization
14P07789971A0758|108 118|pseudogenes
14P07789971A0758|208 212|GSTT2
14P07790271A1185|23 37|Gy/25 fractions
14P07790377A0561|0 9|Antibodies
14P07790377A0561|20 24|PTS1R
14P07790377A0561|67 79|hamster cells
14P07790719A0098|56 70|family violence
14P07791760A0424|0 13|GnRH treatment
14P07791760A0424|69 72|MAPK
14P07791760A0424|86 98|MAPK activity
14P07791760A0424|121 140|complex kinase assay
14P07791763T0000|29 54|insulin receptor substrate
14P07791763T0000|79 107|phosphatidylinositol 3-kinase
14P07791763T0000|124 148|Xenopus oocyte maturation
14P07791764A0357|26 39|Jurkat T cells
14P07791764A0357|39 41|Cbl
14P07791764A0357|80 99|adapter protein Grb2
14P07791768A0930|16 36|cell cycle regulators
14P07791768A0930|60 79|hmr delta A mutation
14P07791768A0930|96 109|clb5 mutations
14P07791768A0930|132 135|SIR1
14P07791768A0930|163 175|establishment
14P07791769A0826|0 3|ICP4
14P07791769A0826|61 64|TATA
14P07791769A0826|86 90|TFIIB
14P07791769A0826|93 95|DNA
14P07791769A0826|108 124|ICP4 binding site
14P07791769A0826|127 134|TATA box
14P07791771A0183|0 3|Otte
14P07791771A0183|5 7|Mol
14P07791776T0000|0 15|Characterization
14P07791783A0000|56 58|HMG
14P07791783A0000|67 86|leucine zipper motif
14P07791783A0000|104 109|SOX-LZ
14P07791783A0000|127 159|rainbow trout testis cDNA library
14P07793783A0189|0 10|Scalp flaps
14P07793783A0189|80 103|scalp flap transposition
14P07794556A0000|5 10|Center
14P07794556A0000|19 26|Genetics
14P07794556A0000|29 34|Leuven
14P07794556A0000|46 56|DNA-testing
14P07794556A0000|60 69|Huntington
14P07794556A0000|113 120|November
14P07794556A0000|137 147|DNA-linkage
14P07794556A0000|171 187|mutation analysis
14P07795104T0000|0 4|Risks
14P07795104T0000|31 57|hepatitis B virus infection
14P07795576A0126|0 10|Examination
14P07795576A0126|91 111|plasma renin activity
14P07796935A0284|207 210|TREs
14P07796935A0284|213 219|TRE-PAL
14P07796935A0284|221 222|DR
14P07796935A0284|228 234|TRE-LAP
14P07797077A0842|36 38|Pip
14P07797077A0842|132 134|IRF
14P07797077A0842|156 160|IRF-1
14P07797077A0842|162 166|IRF-2
14P07797077A0842|168 172|ICSBP
14P07797077A0842|177 187|ISGF3 gamma
14P07797346T0000|12 22|hepatitis A
14P07797346T0000|42 50|Amsterdam
14P07797476A1001|3 15|RAP74 subunit
14P07797476A1001|17 21|TFIIF
14P07797583A0222|22 39|base substitutions
14P07797583A0222|70 72|DRE
14P07797583A0222|74 93|nucleotide positions
14P07797583A0222|118 146|transcription initiation site
14P07797583A0222|151 159|PCNA gene
14P07797583A0222|215 218|DREF
14P07797583A0222|241 249|PCNA gene
14P07797583A0222|274 292|Drosophila Kc cells
14P07798134T0000|3 19|hsp70 gene family
14P07798134T0000|20 36|Neurospora crassa
14P07798134T0000|45 61|sequence analysis
14P07798207A0759|10 29|amino acid sequences
14P07798207A0759|39 55|W3A1 ETF subunits
14P07798207A0759|122 124|ETF
14P07798207A0759|142 165|Paracoccus denitrificans
14P07798217T0000|10 24|phosphorylation
14P07798217T0000|27 33|CREB341
14P07798217T0000|36 41|Ser129
14P07798217T0000|80 94|gene expression
14P07798217T0095|8 33|glycogen synthase kinase-3
14P07798217T0095|46 60|gene expression
14P07798271A0330|113 125|Ets-1 protein
14P07799437A0656|41 51|replication
14P07799437A0656|54 63|pNeo.Myc-2
14P07799437A0656|93 108|control plasmids
14P07799925A0526|0 13|Reconstitution
14P07799925A0526|35 37|p62
14P07799925A0526|44 67|src family kinase p59fyn
14P07799925A0526|67 76|HeLa cells
14P07799925A0526|118 141|tyrosine phosphorylation
14P07799925A0526|143 145|p62
14P07799925A0526|169 171|SH3
14P07799925A0526|175 185|SH2 domains
14P07799925A0526|187 192|p59fyn
14P07799931A0287|63 78|L7 gene insights
14P07799931A0287|84 93|mechanisms
14P07799931A0287|122 133|organization
14P07799931A1232|31 33|Nrl
14P07799931A1232|53 65|c-Maf actions
14P07799939A0628|45 75|serine/threonine phosphoprotein
14P07799939A0628|123 131|3T3 cells
14P07799948A0777|66 77|Raf-1 kinase
14P07799948A0777|79 81|Src
14P07799948A0777|95 97|Src
14P07799948A0777|101 103|Ras
14P07799948A0777|115 119|Raf-1
14P07799950A0282|55 57|CRE
14P07799950A0282|63 88|somatostatin gene promoter
14P07799950A0282|141 144|CREB
14P07800479A0201|13 16|NSR1
14P07800479A0201|78 91|RNA maturation
14P07800505T0000|0 15|Characterization
14P07800505T0000|54 74|phospholipase A2 gene
14P07801180A0197|21 30|advantages
14P07801180A0197|34 44|limitations
14P07801180A0197|54 69|study approaches
14P07802355T0000|38 53|blood cell count
14P07802355T0000|81 92|Coulter STKS
14P07802355T0000|93 101|Sysmex NE
14P07802355T0000|108 120|Technicon H-1
14P07802655T0000|0 15|Characterization
14P07802655T0000|18 25|FIII/YY1
14P07802655T0000|28 41|Xenopus laevis
14P07802655T0000|61 75|protein binding
14P07802655T0000|91 92|L1
14P07802655T0000|96 98|L14
14P07803809A1852|88 122|tyrosine kinase inhibitor genistein
14P07803809A1852|126 160|protein kinase C inhibitor Compound
14P07803809A1852|160 167|ABSTRACT
14P07803809A1852|182 186|WORDS
14P07806492A1162|4 12|structure
14P07806492A1162|15 23|cucumisin
14P07806492A1162|71 79|precursor
14P07806507A0121|34 48|CD3-TCR complex
14P07806507A0121|93 100|CD3 zeta
14P07806507A0121|103 113|CD3 epsilon
14P07806507A0121|141 157|recognition event
14P07806507A0121|198 215|activation cascade
14P07806532A0659|0 12|Protein cHMGI
14P07806532A0659|40 42|DNA
14P07806532A0659|48 68|half-saturation value
14P07806651A0097|61 77|Mexican-Americans
14P07806651A0097|102 110|MF scales
14P07806651A0097|115 120|MMPI-2
14P07806820A0091|34 40|pedicle
14P07806820A0091|102 112|fascia flap
14P07807002A0500|19 21|DNA
14P07807002A0500|41 56|initiation sites
14P07807002A0500|59 78|germline epsilon RNA
14P07807002A0500|91 114|luciferase reporter gene
14P07807002A0500|134 151|mouse B cell lines
14P07807002A0500|182 184|IgE
14P07808210A1510|43 49|NCEP I.
14P07809128T0000|22 30|E2F1 gene
14P07809410A0606|33 48|serum TSH levels
14P07809410A0606|48 73|serum thyroglobulin values
14P07809410A0606|76 87|131I protein
14P07809410A0606|101 108|131I-PBI
14P07811639A0222|0 17|Endo16 transcripts
14P07811639A0222|65 77|stage embryos
14P07811639A0222|80 93|gastrula stage
14P07811639A0222|125 135|archenteron
14P07811964A1252|22 35|repeat element
14P07811964A1252|74 79|EmBP-1
14P07811964A1252|119 130|dimerization
14P07812450A0849|11 13|ORF
14P07813466A0074|3 11|U14 genes
14P07813466A0074|44 50|Xenopus
14P07813466A0074|135 146|protein gene
14P07813786A0641|61 77|XMyoDa TATA motif
14P07814321A0850|0 7|Deletion
14P07814321A0850|69 90|sporulation efficiency
14P07814323A0313|0 8|Inclusion
14P07814323A0313|43 46|FliQ
14P07814323A0313|50 53|FliR
14P07814323A0313|72 85|export pathway
14P07814323A0313|96 113|flagellum assembly
14P07814388A0662|8 23|L-cell membranes
14P07814388A0662|49 55|M6P/IGF
14P07814388A0662|98 131|pertussis toxin substrate activity
14P07814403A0433|0 3|Chem
14P07814405A1170|36 50|point mutations
14P07814405A1170|59 80|plasma membrane family
14P07814405A1170|81 106|guanylyl cyclase receptors
14P07814717A0669|0 7|Increase
14P07814717A0669|47 64|AA supplementation
14P07814717A0669|79 92|concentrations
14P07814717A0669|95 97|Lys
14P07814717A0669|100 102|Met
14P07815546A0411|0 4|Virol
15P07815811A1487b|8 23|vasoconstriction
15P07815811A1487b|32 43|endothelin-1
15P07815811A1487b|56 75|ischemia-reperfusion
15P07815811A1487b|81 94|norepinephrine
15P07815811A1487b|104 117|concentrations
14P07816025A0196|0 9|Comparison
14P07816025A0196|22 40|amino acid sequence
14P07816025A0196|41 53|gamma-kafirin
14P07816025A0196|81 95|gamma-prolamins
14P07816025A0196|107 110|Coix
14P07816049A0686|0 5|Atcys1
14P07816049A0686|7 12|Athyp1
14P07816049A0686|14 19|AKin10
14P07816049A0686|26 28|ORF
14P07816049A0686|211 223|transcription
14P07816049A1157|0 38|Southern blot hybridization experiments
14P07816049A1157|65 70|Atcys1
14P07816049A1157|72 77|Athyp1
14P07816049A1157|81 86|AKin10
14P07816049A1157|107 128|Northern blot analysis
14P07816617A0763|23 26|HAC1
14P07816619A0000|20 51|Arabidopsis thaliana cDNA clones
14P07816619A0000|141 162|cAMP phosphodiesterase
14P07816619A0872|15 28|identification
14P07816619A0872|49 58|A.thaliana
14P07816619A0872|156 179|transcription initiation
14P07816619A0872|191 193|Dr1
14P07816630A1333|52 77|translation terminator TGA
14P07816630A1333|95 98|BTU2
14P07816630A1333|138 146|H4-I gene
14P07816808A1102|27 36|STR family
14P07816808A1102|127 136|Arthropoda
14P07816808A1102|140 147|Chordata
14P07818416A0895|23 48|haemoglobin concentrations
14P07818416A0895|115 117|THR
14P07819225A1094|78 93|Asn-285 mutation
14P07819225A1094|100 106|Lys-220
14P07819225A1094|110 116|Gln-220
14P07819225A1094|140 153|Asn-285 mutant
14P07819225A1094|166 188|tetracycline resistance
14P07819225A1094|190 197|ABSTRACT
14P07819225A1094|212 216|WORDS
14P07820057A0000|0 26|Tumor necrosis factor alpha
14P07820057A0000|66 79|growth control
14P07821790A1084|12 16|UCRBP
14P07821790A1084|86 90|UCRBP
14P07821790A1084|145 156|UCR elements
14P07821790A1084|166 187|co-transfection assays
14P07822161A1172|13 24|monkey opsin
14P07822161A1172|61 70|nucleotide
14P07822161A1172|77 93|amino acid levels
14P07822161A1172|117 127|differences
14P07822329A0773|3 9|complex
14P07822329A0773|52 56|cells
14P07822329A0773|73 79|binding
14P07822329A0773|99 104|factor
14P07822333A0376|0 3|Chem
14P07823919A1422|40 42|RAR
14P07823919A1422|44 59|RXR heterodimers
14P07823919A1422|83 87|EAR-3
14P07823919A1422|89 96|COUP-TFI
14P07823919A1422|102 106|ARP-1
14P07823951A1100|27 30|EKLF
14P07823951A1100|47 70|transactivation function
14P07823951A1100|73 89|globin expression
14P07823951A1100|119 122|EKLF
14P07823951A1100|147 151|CACCC
14P07823953A0777|15 37|I kappa B alpha mutants
14P07823953A0777|66 89|I kappa B alpha molecule
14P07823953A0777|118 132|I kappa B alpha
14P07823953A0777|192 210|localization signal
14P07823953A0777|274 284|DNA binding
14P07823964A0922|86 91|Pho81p
14P07824325A0714|29 38|procedures
14P07824325A0714|40 53|thorax opening
14P07824325A0714|126 150|vancomycin concentrations
14P07824325A0714|177 179|MIC
14P07824325A0714|207 217|microgram/g
14P07824325A0714|249 260|micrograms/g
14P07824464A0169|26 37|tissue flaps
14P07824464A0169|82 104|artery wall dissections
14P07824464A0169|104 118|plaque ruptures
14P07824464A0169|123 134|fissurations
14P07824464A0169|149 160|haemorrhages
14P07824464A0169|227 241|artery stenosis
14P07824657A1456|11 28|cysteine formation
14P07824657A1456|31 42|pCSK4F plant
14P07824726A0454|25 33|subgroups
14P07824726A0454|93 109|fatty replacement
14P07824726A0454|134 150|fatty replacement
14P07824726A0454|175 191|fatty replacement
14P07825888A0715|21 38|dementia disorders
14P07825888A0715|78 92|cortisol levels
14P07826412T0112|4 13|hypothesis
14P07826412T0112|16 25|mechanisms
14P07826412T0112|58 71|gamma-subunits
14P07826412T0112|75 84|activation
14P07826412T0112|88 97|holoenzyme
14P07826412T0112|100 109|transducin
14P07826625X0000|20 42|transcription apparatus
14P07826625X0000|43 56|RNA polymerase
14P07826625X0000|86 103|activation domains
14P07826625X0000|136 138|CTD
14P07826625X0000|142 155|RNA polymerase
14P07826625X0000|167 181|enhancer domain
14P07826625X0000|183 189|Regions
14P07826625X0000|216 231|proline residues
14P07826625X0000|258 275|activation domains
14P07826625X0000|361 383|polyglutamine stretches
14P07828584A0681|0 10|Mutagenesis
14P07828584A0681|13 15|IM1
14P07828584A0681|53 72|AP1 bearing promoter
14P07828600A0095|0 6|Binding
14P07828600A0095|9 11|SSP
14P07828600A0095|17 38|stage selector element
14P07828600A0095|38 40|SSE
14P07828600A0095|55 75|gamma-globin promoter
14P07828600A0095|149 169|stage erythroleukemia
14P07828600A0095|170 173|K562
14P07828811A0556|29 39|G1/S arrest
14P07828811A0556|63 79|thermosensitivity
14P07828824A0307|0 8|Mutations
14P07828824A0307|18 45|photoreceptor cell structure
14P07828852A0153|19 27|telomeres
14P07828852A0153|55 63|functions
14P07829057A1097|32 38|RH maps
14P07829057T0000|0 26|Integrated mapping analysis
14P07829057T0000|30 51|Werner syndrome region
14P07829097A0000|16 20|DXS52
14P07829097A0000|24 29|Factor
14P07829097A0000|48 51|Xq28
14P07829097A0000|76 78|G+C
14P07829102T0000|0 16|Haplotype mapping
14P07829102T0000|19 35|sequence analysis
14P07829102T0000|40 55|mouse Nramp gene
14P07829102T0000|61 74|susceptibility
14P07829519A1251|4 14|utilization
14P07829519A1251|27 46|polyadenylation site
14P07829519A1251|64 73|exon usage
14P07829519A1251|145 161|immunoglobulin mu
14P07829554A0257|50 64|system response
14P07829554A0257|98 115|protein conjugates
14P07829554A0257|128 140|wear products
14P07829554A0257|211 215|ELISA
14P07830112A0532|27 29|PFR
14P07830112A0532|63 65|EDV
14P07830112A0532|70 82|stroke volume
14P07830112A0532|83 84|SV
14P07830112A0532|110 119|PFR-to-PER
14P07830112A0532|145 147|PFR
14P07830112A0532|149 152|TPFR
14P07831310A0000|8 29|complementation system
14P07831310A0000|48 65|tobacco etch virus
14P07831310A0000|65 67|TEV
14P07831310A0000|80 82|NIb
14P07831310A0000|155 165|TEV mutants
14P07831799T0000|0 18|Nucleotide sequence
14P07831799T0000|49 67|DNA polymerase gene
14P07831799T0000|85 102|polyhedrosis virus
14P07831829A1324|0 9|Comparison
14P07831829A1324|24 27|PMTV
14P07831829A1324|29 33|BNYVV
14P07831829A1324|38 42|SBWMV
14P07831829A1324|97 115|genome organization
14P07832086A1023|3 18|drug sensitivity
14P07832086A1023|39 41|VCM
14P07832086A1023|59 61|IMP
14P07832086A1023|80 83|MINO
14P07832086A1023|101 103|AMK
14P07832086A1023|125 127|FOM
14P07832779A0719|0 14|Deglycosylation
14P07832779A0719|19 35|endoglycosidase H
14P07832779A0719|84 105|oligosaccharide chains
14P07834582A0115|7 16|supplement
14P07834582A0115|21 28|fish oil
14P07834582A0115|38 45|n-3 EFAs
14P07834582A0115|84 91|property
14P07834582A0115|136 147|hypertension
14P07835088A0238|3 8|HSD3B1
14P07835088A0238|12 23|HSD3B2 genes
14P07835088A0238|46 64|beta-HSD isoenzymes
14P07835088A0238|130 153|chromosome 1p13.1 region
14P07835214A0603|12 22|prevalences
14P07835214A0603|41 43|GDM
14P07835273A0000|18 34|glucose transport
14P07835273A0000|61 76|insulin receptor
14P07835273A0411|50 64|EGFR expression
14P07835273A0411|153 169|3T3-L1 adipocytes
14P07835273A0411|171 179|5000/cell
14P07835710T0000|25 41|porcine I kappa B
14P07835826A0195|0 7|Fraction
14P07835826A0195|22 23|OH
14P07835826A0195|25 36|2-vitamin D3
14P07835826A0195|50 51|OH
14P07835826A0195|74 75|OH
14P07835826A0195|77 88|3-vitamin D3
14P07835886A0894|3 18|kallistatin gene
14P07835886A0894|58 77|chromosome 14q31-q32
14P07835886A0894|109 132|alpha 1-antichymotrypsin
14P07835886A0894|133 151|protein C inhibitor
14P07835886A0894|151 169|alpha 1-antitrypsin
14P07835888A0402|19 25|XD gene
14P07835888A0402|36 37|Xd
14P07835888A0402|65 80|mouse chromosome
14P07835888A0402|84 101|haplotype analysis
14P07835888A0402|119 132|backcross mice
14P07836218A0128|35 56|beta-endorphin release
14P07836218A0128|69 83|exertion levels
14P07836218A0128|144 157|beta-endorphin
14P07836228A1052|13 25|communication
14P07836228A1052|50 60|LV function
14P07836364A0000|0 3|Self
14P07836364A0000|66 91|histocompatibility complex
14P07836364A0000|92 94|MHC
14P07836364A0000|125 148|antigen presenting cells
14P07836364A0000|148 150|APC
14P07836390A1152|3 17|characteristics
14P07836390A1152|43 59|cleavage reaction
14P07836390A1152|105 117|IncP plasmids
14P07836390A1152|139 162|transfer DNA replication
14P07836406A0884|49 53|MHC-B
14P07836406A0884|98 111|phosphopeptide
14P07836406A0884|163 176|chromatography
14P07836471A0375|10 25|protein sequence
14P07836471A0375|72 89|osteosarcoma cells
14P07838156A0789|8 29|cotransfection studies
14P07838156A0789|41 43|RVR
14P07838156A0789|80 103|hormone response element
14P07838156A0789|169 186|ROR alpha function
14P07840643A1006|16 50|Flavobacterium glycosylasparaginase
14P07840643A1006|64 83|glycosylasparaginase
14P07841230T0000|0 11|Dissociation
14P07841230T0000|47 60|antimicrobials
14P07841663A0685|0 19|Superoxide dismutase
14P07841663A0685|20 22|SOD
14P07841663A0845|77 90|oxygen species
14P07841663A0845|99 110|SOD activity
14P07841663A0845|148 159|sperm motion
14P07844142A0640|44 50|SR beta
14P07844142A0640|62 68|SR beta
14P07844142A0640|99 106|SR alpha
14P07844142A0640|109 113|SRP54
14P07844142A0640|129 146|GTPase superfamily
14P07844155A0327|40 60|tyrosine phosphatases
14P07844155A0327|98 109|LAR isoforms
14P07844155A0327|180 182|LAR
14P07844201T0000|0 12|Sex selection
14P07844201T0000|15 29|albumin columns
14P07844425A0289|3 10|students
14P07844425A0289|32 41|eggs/10 ml
14P07844425A0289|65 73|eggs/10ml
14P07844555A0406|20 29|E mu pim-1
14P07844555A0406|64 83|lymphoma development
14P07844555A0406|108 113|M-MuLV
14P07845672A0368|0 9|Comparison
14P07845672A0368|26 38|blk sequences
14P07845672A0368|62 82|% amino acid identity
14P07846153A0403|0 9|Chrispeels
14P07846153A0403|16 21|EMBO J
14P07846163A0422|13 21|GRF genes
14P07846199A0000|25 47|sensorimotor reactivity
14P07846199A0000|80 95|startle response
14P07846942A0717|0 19|Digitalis glycosides
14P07846942A0717|21 45|beta-receptor antagonists
14P07846942T0001|6 17|fibrillation
14P07847036A0353|42 54|haemophiliacs
14P07847036A0353|62 70|inhibitor
14P07848358A0254|15 49|aspartate aminotransferase activity
14P07851643A1365|65 77|proliferation
14P07851643A1365|86 99|germline cells
14P07851643A1365|112 133|oocyte differentiation
14P07851758A0330|8 25|analysis maps SAL6
14P07851758A0330|26 39|chromosome XVI
14P07851758A0330|46 49|TPK2
14P07852037A0548|15 31|DCT method yields
14P07852037A0548|53 55|TBF
14P07852361A0868|0 6|Removal
14P07852361A0868|9 12|PDMP
14P07852361A0868|53 70|cell cycle changes
14P07852361A0868|93 99|S phase
14P07852400A0519|0 29|Rho GDP/GTP exchange inhibitor
14P07853448A0601|13 29|sports scientists
14P07853448A0601|86 100|sport performer
14P07853476A0159|0 6|Schnell
14P07853476A0159|8 9|J.
14P07853488T0000|0 12|Encapsidation
14P07853488T0000|15 34|poliovirus replicons
14P07853488T0000|58 84|immunodeficiency virus type
14P07853488T0000|99 120|complementation system
14P07853488T0000|136 152|P1 capsid protein
14P07853524A1944|12 21|GST domain
14P07853524A1944|25 31|GST-Tax
14P07853524A1944|80 108|Tax-CREB-21-bp-repeat complex
14P07853524A1944|110 117|ABSTRACT
14P07853524A1944|132 136|WORDS
14P07854130A1387|16 19|PilE
14P07854130A1387|22 37|pilus biogenesis
14P07854130A1387|79 100|pilE insertion mutants
14P07854130A1387|112 129|twitching-motility
14P07854130T0000|3 19|pilE gene product
14P07854130T0000|69 103|shares amino acid sequence identity
14P07854130T0000|107 115|N-termini
14P07854130T0000|123 139|prepilin proteins
14P07854324A0281|36 62|cell cycle control elements
14P07854324A0281|77 91|vertebrate wee1
14P07854324A0742|3 12|expression
14P07854324A0742|69 82|cell phenotype
14P07854324A0742|101 117|growth conditions
14P07856102A1616|21 35|phosphorylation
14P07856102A1616|38 46|M protein
14P07856102A1616|84 97|virus assembly
14P07857086A0949|19 25|Insulin
14P07857086A0949|55 75|Non Insulin Dependent
14P07857086A0949|84 90|H White
14P07857086A0949|92 96|Class
14P07857163A0551|13 30|6-fluoroquinolones
14P07857344A0591|76 108|pidotimod administration schedule
14P07857762A0611|3 20|MAP kinase cascade
14P07858986A0310|30 43|interferometry
14P07858986A0310|81 102|Carpentier-Edwards SAV
14P07858986A0310|106 115|BioImplant
14P07858986A0310|122 127|Valcor
14P07858986A0310|168 191|glutaraldehyde treatment
14P07859238A1150|9 20|side effects
14P07859301A0325|70 90|leucine-zipper motifs
14P07859301A0325|121 147|transcription factor family
14P07859371A1246|58 72|mouse fragments
14P07859371A1246|90 97|extracts
14P07859665A0498|3 13|mean jitter
14P07859665A0498|19 31|fiber density
14P07859665A0498|75 86|microseconds
14P07859665A0498|117 128|microseconds
14P07859739T0000|6 27|cyclin D-Cdk complexes
14P07859739T0000|70 112|p16INK4/MTS1 tumour suppressor gene product
14P07859777A0000|16 28|serum albumin
14P07859777A0000|52 63|fermentation
14P07859777A0000|90 102|microcapsules
14P07859777A0000|152 165|technetium-99m
14P07859777A0000|175 183|reduction
14P07860208A0000|26 43|interleukin-1 beta
14P07860208A0000|44 47|IL-1
14P07860208A0000|52 79|tumour necrosis factor-alpha
14P07860208A0000|79 81|TNF
14P07860208A0000|132 149|lipopolysaccharide
14P07860208A0000|151 153|LPS
14P07860208A0000|224 241|glomerulonephritis
14P07860208A0000|243 245|AGN
14P07860646A1363|6 17|intervention
14P07860646A1363|96 100|FGF-2
14P07862092A0302|44 54|suppressors
14P07862092A0302|61 70|ts mutants
14P07862092A0302|78 93|mutation pol3-14
14P07862092A0302|105 120|mutation pol3-11
14P07862092A0302|150 164|haploid strains
14P07862092A0302|178 191|pol3-11 sdp5-1
14P07862092A0302|211 219|libraries
14P07862092A0302|222 231|singlecopy
14P07862108A0987|0 27|UV cross-linking experiments
14P07862108A0987|34 36|TEP
14P07862129A1391|50 71|HNF-3 alpha expression
14P07862129A1391|132 139|TTR gene
14P07862141A0317|55 63|cAPK lead
14P07862141A0317|68 76|inability
14P07862141A0317|92 106|differentiation
14P07862141A1412|22 25|RFX1
14P07862141A1412|30 49|transcription factor
14P07862150A0429|114 138|TGF-beta binding activity
14P07862150A0429|194 201|TGF-beta
14P07862154A0340|0 6|Cloning
14P07862154A0340|9 23|complementation
14P07862154A0340|83 86|RAF1
14P07862162A0408|61 69|OPI1 gene
14P07862162A0408|78 90|transcription
14P07862162A0408|104 117|UASINO element
14P07862165A0184|10 25|monkey COS cells
14P07862165A0184|28 43|oligonucleotides
14P07862165A0184|110 113|SV40
14P07862165A0184|166 180|helix formation
14P07862168A0000|15 34|receptor alpha-chain
14P07862168A0000|35 45|IL-2R alpha
14P07862168A0000|79 85|T cells
14P07862533A0000|3 7|Wilms
14P07862533A0000|9 33|tumour suppressor protein
14P07862533A0000|33 35|WT1
14P07862533A0000|132 148|sequence homology
14P07862533A0000|158 174|growth response-1
14P07862533A0000|175 179|EGR-1
14P07863047A0229|0 9|OBJECTIVES
14P07863047A0229|24 41|serum ACE activity
14P07863047A0229|54 57|COPD
14P07863047A0229|113 116|CAOT
14P07863047A0229|162 164|ACE
14P07863619A0098|23 29|contour
14P07863619A0098|45 50|system
14P07863619A0098|75 83|fragments
14P07863619A0098|105 110|object
14P07863619A0098|123 131|fragments
14P07863619A0098|145 151|objects
14P07863992A0908|12 19|patients
14P07863992A0908|70 77|evidence
14P07863992A0908|90 102|heart disease
14P07863992A0908|103 116|mean follow-up
14P07863992A0908|144 151|episodes
14P07863992A0908|179 188|medication
14P07863992A0908|218 225|exercise
14P07864652A0753|0 9|Constructs
14P07864652A0753|34 37|E2L1
14P07864652A0753|45 48|E2L1
14P07864652A0753|50 51|H1
14P07864652A0753|60 63|E2L2
14P07864652A0753|74 77|E2H1
14P07864652A0753|79 80|L2
14P07864652A0753|93 96|E2L1
14P07864652A0753|98 99|H1
14P07864652A0753|101 102|L2
14P07864652A0753|143 161|amino acid sequence
14P07864652A0753|179 190|E2 component
14P07864652A1901|25 41|domain constructs
14P07864652A1901|85 88|E2L1
14P07864652A1901|92 95|E2L2
14P07864709A0324|0 6|METHODS
14P07864709A0324|11 21|influenza A
14P07864709A0324|22 25|H3N2
14P07864709A0324|100 110|rimantadine
14P07864709A0324|122 139|enzyme immunoassay
14P07864709A0324|213 222|M2 protein
14P07865129A0293|16 22|ATF/CRE
14P07865129A0293|26 49|TBP/TATA sequence motifs
14P07865786A0457|0 14|Gene expression
14P07865787A1086|39 52|octamer motifs
14P07865787A1086|77 86|regulation
14P07865787A1086|141 150|expression
14P07865787A1086|156 176|wheat histone H3 gene
14P07865876A1292|30 46|DP family members
14P07865876A1292|73 91|DP/E2F heterodimers
14P07865876A1292|105 113|DRTF1/E2F
14P07865888A1309|21 31|cells PBP74
14P07865888A1309|47 57|pre-protein
14P07865888A1309|107 118|mitochondria
14P07865888A1309|125 134|maturation
14P07865895A0896|34 53|lung clearance assay
14P07865895A0896|85 96|LGL/NK cells
14P07865895A0896|124 135|LGL/NK cells
14P07865917A0191|0 8|Treatment
14P07865917A0191|20 23|FSGS
14P07865917A0191|75 77|CSA
14P07865917A0191|98 111|ACE inhibitors
14P07867604A1777|31 50|inhibin/activin beta
14P07867604A1777|92 107|initiation sites
14P07867604A1777|228 241|phorbol esters
14P07867604A1777|249 258|conditions
14P07867622X0000|0 14|Promoter region
14P07867622X0000|46 62|alpha 1-chimaerin
14P07867622X0000|106 111|p21rac
14P07867622X0000|113 129|alpha 1-chimaerin
14P07867622X0000|174 179|p21rac
14P07867944A0365|0 7|Upstream
14P07867944A0365|15 39|transcription start point
14P07867944A0365|45 63|nucleotide sequence
14P07867944A0365|84 107|consensus sequence motif
14P07869721A0000|40 52|closing phase
14P07869721A0000|89 110|heart valve prosthesis
14P07869913A1076|6 20|ISO+AT infusion
14P07869913A1076|86 99|control values
14P07869937A1142|16 35|kilogram body weight
14P07869937A1142|39 41|GIT
14P07869937A1142|84 86|RMR
14P07869937A1142|133 139|P group
14P07870305A1015|26 76|thalami-nucleus ventralis lateralis thalami neurons
14P07870305A1015|98 121|nucleus entopeduncularis
14P07870305A1015|188 208|haloperidol influence
14P07871718A1132|33 45|CGGAAR motifs
14P07871718A1132|52 64|ICP4 promoter
14P07871718A1132|74 91|factors GABP alpha
14P07871721A0000|12 24|reading frame
14P07871721A0000|38 54|scorch carlavirus
14P07871721A0000|55 59|BBScV
14P07871721A0000|121 124|p223
14P07871721A0392|4 22|sequence alignments
14P07871721A0392|93 96|p223
14P07871721A0392|118 134|proteinase domain
14P07871721A0392|170 182|histidine1075
14P07871754A0857|62 80|HPV gene expression
14P07871754A0857|142 154|cooperativity
14P07871755A0521|16 19|VLPs
14P07871755A0521|64 79|characterization
14P07871757A0846|0 7|Analysis
14P07871757A0846|35 50|initiation codon
14P07871757A0846|71 87|promotor sequence
14P07871891A0227|0 4|SUP46
14P07871891A0227|19 38|translation fidelity
14P07872673A0332|49 50|Rb
14P07872673A0332|63 80|expression plasmid
14P07872673A0332|133 153|SV40 promoter complex
14P07872788A1717|15 31|sequence identity
14P07872788A1717|43 53|hydrolase B
14P07872788A1717|132 148|carboxylesterases
14P07872788A1717|158 168|duplication
14P07872788A1717|172 181|divergence
14P07873631A0114|15 28|tooth fracture
14P07873831T0000|19 29|involvement
14P07873831T0000|32 48|mycosis fungoides
14P07873876A1035|3 12|NR2 hybrid
14P07874060A0810|0 4|TDEYA
14P07874060A0810|50 65|xanthine oxidase
14P07874060A0810|66 67|XO
14P07874060A0810|82 95|stomach tissue
14P07874060A0810|111 124|administration
14P07875595A0910|14 29|PITSLRE PK genes
14P07875595A0910|96 99|FISH
14P07875595A0910|134 156|chicken microchromosome
14P07876134A0348|16 31|characterization
14P07876134A0348|64 71|AFAP-110
14P07876134A0348|116 128|reading frame
14P07876191A0808|0 9|Expression
14P07876191A0808|19 26|ADH mRNA
14P07876192A0443|2 10|ICE gamma
14P07876192A0443|102 119|ICE autoprocessing
14P07876194T0000|0 10|Endocytosis
14P07876194T0000|43 65|growth factor receptors
14P07876194T0000|110 131|tyrosine kinase domain
14P07876210A0275|147 164|Barbie box element
14P07876210A0751|0 7|Mutation
14P07876210A0751|13 31|P450BM-3 Barbie box
14P07876210A0751|71 78|P450BM-3
14P07876210A0751|82 86|Bm3P1
14P07876210A0751|124 136|P450BM-3 gene
14P07876300A0994|55 68|protein import
14P07876562A1646|62 75|responsiveness
14P07876562A1646|86 92|T cells
14P07876562A1646|128 142|HIV-1 infection
14P07877308A1175|7 14|protocol
14P07877308A1175|31 38|patients
14P07877308A1175|53 58|cohort
14P07877619A1284|61 82|zif268 gene expression
14P07877619A1284|101 129|base pair nucleotide sequence
14P07878029A0721|10 14|CBF-A
14P07878029A0721|18 22|CBF-C
14P07878029A0721|51 69|CBF-A-CBF-C complex
14P07878029A0721|76 80|CBF-B
14P07878029A0721|100 104|CBF-A
14P07878029A0721|107 111|CBF-C
14P07878029A0721|150 168|CBF-A-CBF-C complex
14P07878040A0505|21 29|sequences
14P07878040A0505|46 59|mouse enhancer
14P07878040A0505|93 100|activity
14P07879204T0000|0 15|OKT3 prophylaxis
14P07879204T0000|148 157|US studies
14P07880442A0236|8 45|PKC beta transcription initiation site
14P07880442A0236|75 96|S1 nuclease protection
14P07880449A0091|24 42|dose X-rays effects
14P07880449A0091|57 59|ICR
14P07880449A0091|90 100|suppression
14P07880449A0091|129 144|body irradiation
14P07880650A0493|26 46|diffraction intensity
14P07880650A0493|124 143|diffraction patterns
14P07880650A0493|172 195|crotoxin complex crystal
14P07881077A0195|0 32|Supplementary Phase Contraste RSE
14P07881077A0195|47 56|Excitation
14P07883167A0157|24 27|UPF1
14P07883167A0157|31 40|UPF3 genes
14P07883167A0157|58 70|decay pathway
14P07883167A0157|98 111|identification
14P07883167A0157|115 130|characterization
14P07883168A0090|0 8|Mutations
14P07883168A0090|11 19|UPF1 lead
14P07883168A0090|33 45|stabilization
14P07883168A0090|68 85|nonsense mutations
14P07883193A0000|1 12|DNA fragment
14P07883193A0000|119 132|pGEX-KT vector
14P07883193A0000|175 199|glutathione S-transferase
14P07883754A0993|5 26|gel retardation assays
14P07883754A0993|29 33|HepG2
14P07883754A0993|107 118|NRE fragment
14P07885999A0000|72 92|mouse tyrosinase gene
14P07885999A0000|122 152|methylation interference assays
14P07886610A0000|5 14|population
14P07886610A0000|58 69|hemophilia A
14P07886610A0000|71 75|India
14P07886610A0000|85 94|prevalence
14P07886610A0000|106 115|population
14P07887226A0858|32 56|hemoglobin determinations
14P07887226A0858|60 91|serum transferrin receptor assay
14P07887226A0858|179 193|iron deficiency
14P07887226A0858|215 217|IDA
14P07887859A0315|85 87|ABI
14P07887859A0315|105 107|TBI
14P07887859A0998|0 16|TcPO2 measurement
14P07887859A0998|70 85|ulcer management
14P07888156A0169|12 30|University Hospital
14P07888156A0169|32 37|Tromso
14P07888156A0169|73 78|Norway
14P07888156A0169|96 110|section service
14P07888156A0169|125 141|video conferences
14P07888156T0000|15 27|telepathology
14P07888306A1659|0 9|Expression
14P07888306A1659|12 15|h6.1
14P07888306A1659|18 28|COS-1 cells
14P07888306A1659|62 73|PDE activity
14P07888306A1659|148 150|Ca2
14P07888306A1659|153 155|CaM
14P07888306A1659|182 195|concentrations
14P07888306A1659|208 215|ABSTRACT
14P07888306A1659|230 234|WORDS
14P07888623A0721|0 13|PMEK1 displays
14P07888623A0721|62 87|Arabidopsis ATMPK1 kinases
14P07888623A0721|122 144|plant MAP kinase MsERK1
14P07888629A0344|0 10|Translation
14P07888629A0344|48 53|MsPRP2
14P07888629A0344|88 107|Da cell wall protein
14P07888629A0344|125 139|signal sequence
14P07888629A0344|237 259|lipid transfer proteins
14P07888788A1010|18 33|hypersensitivity
14P07888788A1010|47 59|aspergillomas
14P07888788A1010|158 168|Aspergillus
14P07888788A1010|175 187|aspergillomas
14P07888828A0765|27 40|identification
14P07888828A0765|65 72|primates
14P07890485A0827|10 21|illumination
14P07890485A0827|36 48|photoreceptor
14P07890485A0827|50 52|QO2
14P07890485A0827|104 106|QO2
14P07890599A0132|17 34|mouse cDNA library
14P07890599A0132|37 50|MIN6 cell line
14P07890599A0132|202 229|Caenorhabditis elegans unc18
14P07890599A0132|255 259|Sec1p
14P07890674A0916|17 19|APC
14P07890674A0916|23 32|E-cadherin
14P07890674A0916|54 56|APC
14P07890674A0916|60 69|E-cadherin
14P07890680A1193|18 36|core DNA polymerase
14P07890680A1193|80 89|holoenzyme
14P07890680A1193|100 110|replacement
14P07890680A1193|130 144|primer terminus
14P07890740A0997|3 11|PSD2 gene
14P07890740A0997|50 66|Sf-9 insect cells
14P07890740A0997|121 132|PSD activity
14P07891638T0000|49 65|chest radiographs
14P07891685A1051|68 72|Cat8p
14P07891685A1051|109 113|Cat4p
14P07891685A1051|115 119|Mig1p
14P07891685A1051|128 140|CAT8 promoter
14P07891708A0690|4 6|Epo
14P07891708A0690|8 12|HNF-4
14P07891708A0690|42 52|Hep3B cells
14P07891708A0690|60 69|HeLa cells
14P07891708A1192|52 59|Epo gene
14P07891708A1192|86 96|Hep3B cells
14P07891708A1192|117 130|HNF-4 delta C.
14P07891709A1542|5 16|observations
14P07891709A1542|45 54|mechanisms
14P07891709A1542|74 83|transcript
14P07891709A1542|106 118|deadenylation
14P07891713T0000|5 16|Maf proteins
14P07891713T0000|74 99|NF-E2 transcription factor
14P07891720A0818|26 28|C1F
14P07891720A0818|52 64|concentration
14P07891720A0818|67 78|calcium ions
14P07892076A0578|0 7|Survival
14P07892076A0578|47 49|P-2
14P07892076A0578|65 81|transmission mode
14P07892353A0667|34 45|correlations
14P07892353A0667|139 146|patterns
14P07892353A0667|149 160|correlations
14P07892353A0667|174 186|brain regions
14P07894021A1130|36 38|DS2
14P07894021A1130|69 71|DNA
14P07894359T0000|10 21|hemodynamics
14P07894359T0000|45 46|RU
14P07894761A0000|84 93|hemorrhage
14P07894761A0000|95 97|ECH
14P07896088A0720|32 51|telomere maintenance
14P07896088A0720|74 77|RAP1
14P07896088A0720|146 169|RIF1 interaction domains
14P07896088A0720|189 203|telomere length
14P07896291A0693|82 97|characterization
14P07896291A0693|127 139|WAGR syndrome
14P07896615A0554|46 58|nm absorption
14P07896615A0554|110 127|laser flow Doppler
14P07896615A0554|129 142|NIR recordings
14P07896615A0554|151 165|water immersion
14P07896817A0204|65 68|BAEC
14P07896817A0204|83 103|phospholipase C-gamma
14P07896817A0204|104 112|PLC-gamma
14P07896817A0204|132 169|SDS-polyacrylamide gel electrophoresis
14P07896817A0204|184 194|Immobilon-P
14P07896846T0000|79 95|suppressor region
14P07896846T0000|105 115|beta-myosin
14P07896846T0000|121 130|chain gene
14P07896852T0000|18 45|growth response factor Egr-1
14P07896852T0000|45 80|apolipoprotein AI gene transcription
14P07897359A0354|32 40|F protein
14P07897359A0354|55 60|BHK-21
14P07897359A0354|64 76|HeLa T4 cells
14P07897359A0354|118 137|T7 polymerase system
14P07897696A0000|0 10|Erythrocyte
14P07897696A0000|31 46|acid dehydratase
14P07897696A0000|47 50|ALAD
14P07897696A0000|61 91|erythrocyte zinc protoporphyrin
14P07897696A0000|91 93|ZPP
14P07897696A0000|116 129|coproporphyrin
14P07897696A0000|131 132|UC
14P07898178A0849|17 26|graft loss
14P07898178A0849|31 40|conversion
14P07898178A0849|43 54|azathioprine
14P07898178A0849|67 76|graft loss
14P07898178A0849|81 90|conversion
14P07898178A0849|93 104|azathioprine
14P07898178A0849|117 139|cyclosporin maintenance
14P07898178A0849|177 189|patient death
14P07898275A0254|73 92|31P MRS measurements
14P07898275A0254|177 182|1H MRS
14P07898275A0254|267 270|ISIS
14P07898275A0254|273 300|volume localization sequence
14P07898275A0254|301 308|31P MRS.
14P07898589T0000|4 16|tobacco issue
14P07898840X0000|0 18|Pregnancy screening
14P07898840X0000|27 52|artery Doppler velocimetry
14P07898840X0000|80 88|OBJECTIVE
14P07898840X0000|112 126|Doppler studies
14P07898840X0000|246 263|growth restriction
14P07898840X0000|264 266|FGR
14P07899581A0000|14 42|Ca entry blocker nitrendipine
14P07899581A0000|55 74|superoxide dismutase
14P07899581A0000|75 77|SOD
14P07899581A0000|112 131|superoxide dismutase
14P07899634A0000|0 6|PURPOSE
14P07899634A0000|80 93|surface effect
14P07899634A0000|97 110|alloy Ti Al Va
14P07900915A0000|66 76|restitution
14P07900915A0000|79 90|blood volume
14P07900915A0000|93 106|plasma protein
14P07900915A0000|111 120|hemorrhage
14P07900915A0000|159 167|ml.kg-1 x
14P07900915A0000|168 183|min-1 hemorrhage
14P07900915A0000|187 197|restitution
14P07900915A0000|200 211|blood volume
14P07900915A0000|224 228|Evans
14P07900915A0000|249 258|hematocrit
14P07901121T0000|0 23|Cooperative dimerization
14P07901121T0000|50 52|DNA
14P07901125A0416|32 51|aa sequence homology
14P07901125A0416|57 62|DAHPSs
14P07901125A0416|90 104|ARO3 homologues
14P07901125A0416|121 142|yeast Candida albicans
14P07902532A0312|29 35|BOX DNA
14P07902532A0312|63 78|thymidine kinase
14P07902532A0312|79 80|TK
14P07902532A0312|99 106|EC cells
14P07902532A1655|0 16|Deletion analyses
14P07902532A1655|60 69|BOXF1 gene
14P07902532A1655|82 88|BOX DNA
14P07902532A1655|121 128|EC cells
14P07902583A0545|0 7|Analysis
14P07902583A0545|10 29|disassociation rates
14P07902583A0545|45 66|Grf10-Swi5-DNA complex
14P07902583A0545|124 127|Swi5
14P07902583A0545|130 134|Grf10
14P07903099A0918|42 51|IVS2C beta
14P07903099A0918|92 106|splice acceptor
14P07903670A1202|20 39|alpha 1-tubulin gene
14P07905413A0585|13 21|treatment
14P07905413A0585|27 47|plasma concentrations
14P07905413A0585|110 127|segment depression
14P07905413A0585|153 160|workload
14P07905453A0281|18 51|transcription-translation analysis
14P07905453A0281|95 97|ORF
14P07906265A0897|11 21|experiments
14P07906265A0897|60 71|fasD mutants
14P07906265A0897|77 84|products
14P07906265A0897|121 128|assembly
14P07906616A0191|53 63|stimulation
14P07906616A0191|67 68|Hz
14P07906616A0191|122 132|anaesthesia
14P07907846A0623|0 4|Group
14P07907846A0623|55 80|cholinesterase degradation
14P07907846A0623|91 116|bupivacaine administration
14P07907846A0623|120 124|Group
14P07907846A0623|148 173|physostigmine pretreatment
14P07908012A0678|27 42|LNNB performance
14P07908012A0678|153 169|medication levels
14P07908012A0678|172 182|LNNB scores
14P07908187T0000|0 3|ISIS
14P07908827A1200|36 49|identification
14P07908827A1200|59 66|RAR beta
14P07908827A1200|132 135|RARs
14P07908827A1200|149 157|COS cells
14P07908827A1200|212 214|RAR
14P07909936A0672|10 27|treatment strategy
14P07909936A0672|97 113|radiochemotherapy
14P07909936A0672|125 149|stem-cell transplantation
14P07910716A0359|3 15|study cohorts
14P07910716A0359|47 54|SC rIL-2
14P07910716A0359|78 86|IU/m2/day
14P07910716A0359|140 152|rIFN-alpha 2b
14P07910716A0359|168 182|U/m2/day thrice
14P07910716A0359|231 246|SC rIFN-alpha 2b
14P07910716A0359|257 271|U/m2/day thrice
14P07910716A0359|281 288|SC rIL-2
14P07910716A0359|306 314|IU/m2/day
14P07910716A0359|347 355|IU/m2/day
14P07910946A0323|0 7|Analysis
14P07910946A0323|16 34|deletion constructs
14P07910946A0323|45 63|transfection assays
14P07910946A0323|84 96|reporter gene
14P07910946A0323|170 186|promoter activity
14P07910946A0323|203 210|L2 cells
14P07911736A1715|5 7|MTD
14P07911736A1715|58 73|myelosuppression
14P07912123A0711|15 38|lymphocyte proliferation
14P07913080A0564|1 32|decanucleotide promoter sequence
14P07913891A0174|130 138|Hox genes
14P07913891A0174|146 166|transcription factors
14P07913891A0174|204 221|tissue specificity
14P07913926A0878|0 16|Northern analysis
14P07913926A0878|18 28|RNA samples
14P07914192A0211|0 24|HER2 overexpressing cells
14P07914192A0211|45 49|DNase
14P07914192A0211|106 125|ets response element
14P07914192A0211|125 130|GAGGAA
14P07914192A0211|165 172|CAAT box
14P07914192A0211|190 197|TATA box
14P07914192A0211|207 219|HER2 promoter
14P07914192A0844|0 15|Gel-shift assays
14P07914192A0844|37 61|oligonucleotide sequences
14P07914192A0844|172 175|HER2
14P07914192A0844|215 237|GAGGAA response element
14P07914507A1029|0 9|Comparison
14P07914507A1029|12 25|cDNA sequences
14P07914507A1029|43 54|mRNA species
14P07914507A1029|92 105|addition sites
14P07914700A0000|26 51|eIF-2 alpha protein kinase
14P07914700A0000|50 52|PKR
14P07914700A0000|81 83|DNA
14P07915144A0000|0 13|High-frequency
14P07915144A0000|24 34|stimulation
14P07915144A0000|40 50|hippocampus
14P07916003A0688|48 57|CD79 alpha
14P07916003A0688|63 70|TATA box
14P07916003A0688|85 100|mouse CD79 alpha
14P07916326A0000|17 28|organization
14P07916326A0000|106 110|Msx-1
14P07916327A0250|32 45|goosecoid gene
14P07916327A0250|46 48|GSC
14P07916577A0190|24 38|candidate genes
14P07916577A0190|50 58|disorders
14P07916577A0190|82 96|gene expression
14P07916577A0190|122 130|sequences
14P07916588A0471|41 69|passion fruit woodiness virus
14P07916588A0471|68 70|PWV
14P07916588A0471|83 93|CP sequence
14P07916588A0471|117 119|CPs
14P07916588A0471|145 147|PWV
14P07916588A0471|206 208|PWV
14P07916685A0455|23 45|arogenate dehydrogenase
14P07916685A0455|53 76|prephenate dehydrogenase
14P07916689A0312|11 21|POT1 clones
14P07916689A0312|37 50|kb RNA species
14P07916689A1407|3 15|Y. lipolytica
14P07916689A1407|22 30|POT1 gene
14P07916689A1407|89 91|DNA
14P07916689A1407|104 126|Y. lipolytica LEU2 gene
14P07916729T0000|1 21|leucine zipper domain
14P07916729T0000|83 99|enhancer function
14P07916983A0623|17 18|CT
14P07916983A0623|58 75|N1-N3 neck disease
14P07917016A0581|24 58|zinc finger domain protein sequence
14P07917540A0000|50 58|vindesine
14P07917540A0000|61 70|mg/m2/week
14P07917540A0000|76 94|interferon-alpha 2b
14P07917540A0000|96 99|U/m2
14P07917540A0000|116 124|vindesine
14P07917540A0000|134 143|interferon
14P07917540A0000|155 163|treatment
14P07918097T0000|8 34|Notch homologue mouse Notch
14P07918097T0000|55 75|growth factor-repeats
14P07918128A0000|0 9|BACKGROUND
14P07918128A0000|38 40|MDL
14P07918128A0000|47 48|EF
14P07918128A0000|55 71|hydroxytryptamine
14P07918128A0000|74 78|5-HT3
14P07918128A0000|80 98|receptor antagonist
14P07918494A1163|39 49|thioredoxin
14P07918494A1163|51 71|thioredoxin reductase
14P07918494A1163|75 79|NADPH
14P07919540A0240|66 68|p64
14P07919540A0240|98 106|AUG codon
14P07919540A1119|52 64|c-Myc protein
14P07919540A1119|74 86|transcription
14P07919540A1119|108 125|reporter construct
14P07922709T0000|10 19|activities
14P07922709T0000|35 48|growth factors
14P07922709T0000|72 82|application
14P07925022A0285|0 9|Expression
14P07925022A0285|35 37|CNS
14P07925097A1205|14 23|AR content
14P07925097A1205|36 46|COS-1 cells
14P07925097A1205|74 82|8-Br-cAMP
14P07925282A0705|0 9|Disruption
14P07925282A0705|58 69|SRP proteins
14P07925282A0705|106 126|protein translocation
14P07925282A0705|135 145|ER membrane
14P07926729A0000|36 65|signal transduction mechanisms
14P07926729A0000|137 154|gene transcription
14P07926739A0766|3 20|expression pattern
14P07926739A0766|22 24|GL2
14P07926739A0766|103 118|progenitor cells
14P07926739A0766|143 162|trichome development
14P07926748A0383|0 3|NOT4
14P07926748A0383|17 20|NOT1
14P07926748A0383|24 27|NOT3
14P07926748A0383|68 71|NOT3
14P07926748A0383|74 77|NOT4
14P07926749A0471|66 74|ROR alpha
14P07926749A0471|78 86|ROR alpha
14P07926749A0471|99 101|DNA
14P07926749A0471|114 138|hormone response elements
14P07926749A0471|186 203|core motif PuGGTCA
14P07926749A0471|203 206|RORE
14P07926774A0652|3 26|p73pct1/p85cdc10 complex
14P07926774A0652|53 55|MCB
14P07926774A0652|62 64|SCB
14P07926775A0895|63 74|slp activity
14P07926775A0895|86 96|requirement
14P07926775A0895|100 110|maintenance
14P07926775A0895|113 125|wg expression
14P07926775A0895|142 157|wg transcription
14P07926789A0960|3 14|DNA sequence
14P07926789A0960|67 78|fusion genes
14P07927130A0625|0 32|CMV hyperimmunoglobulin treatment
14P07927130A0625|32 39|Cytotect
14P07927130A0625|41 47|Biotest
14P07927130A0625|153 159|CMV-DNA
14P07927267T0000|65 76|regeneration
14P07927267T0000|90 98|rat liver
14P07927267T0000|110 120|hepatectomy
14P07927711A0698|0 2|ORF
14P07927711A0698|49 50|Da
14P07927838A0000|88 103|prevalence rates
14P07927838A0000|134 136|VWF
14P07927838A0000|157 165|stiffness
14P07927838A0000|184 194|extremities
14P07928954A0545|0 20|DNA sequence analysis
14P07928954A0545|136 161|lipoprotein signal peptide
14P07928954A0545|163 202|consensus prolipoprotein processing site
14P07929165T0000|0 11|DNA sequence
14P07929165T0000|103 104|A3
14P07929238A0734|6 13|Genomics
14P07929411A0087|25 44|polypeptide sequence
14P07929411A0087|49 66|Drosophila protein
14P07929411A0087|202 216|enzyme activity
14P07929431A0949|60 106|reporter gene chloramphenicol acetyltransferase
14P07929431A0949|149 159|INS-1 cells
14P07929559A0000|107 113|variety
14P07929559A0000|129 137|movements
14P07929559A0000|166 174|transport
14P07929559A0000|177 186|organelles
14P07929560T0000|0 13|Identification
14P07929560T0000|68 82|plaque assembly
14P07929560T0000|97 114|filament anchorage
14P07931490A0237|0 7|PATIENTS
14P07931490A0237|11 17|METHODS
14P07931490A0237|139 155|granisetron doses
14P07931490A0237|168 180|micrograms/kg
14P07932095A0000|42 48|VII-XII
14P07932095A0000|88 89|VI
14P07932095A0000|91 94|XIII
14P07932095A0000|125 145|Oroxylum indicum Vent
14P07932943A0113|52 69|awareness strategy
14P07932943A0113|100 126|Five-Step Approach strategy
14P07932943A0113|132 148|control condition
14P07933066T0000|33 47|adenovirus E4-6
14P07933066T0000|62 88|retinoblastoma gene product
14P07933066T0000|108 112|E2F-1
14P07933066T0000|116 119|DP-1
14P07933076A0211|18 22|EBNA2
14P07933076A0211|65 81|membrane proteins
14P07933095A0000|52 67|retrovirus Rev-T
14P07933095A0000|138 161|transcription factor Sp1
14P07933095A0000|162 187|chicken embryo fibroblasts
14P07933095A0000|187 188|S.
14P07933101A0131|38 49|TATA element
14P07933101A0131|81 101|HIV-1 gene expression
14P07933107A0991|16 34|nucleotide sequence
14P07933107A0991|39 46|p54 gene
14P07933107A0991|66 77|ASFV strains
14P07933107A0991|78 80|E70
14P07933107A0991|84 86|E75
14P07933116A0412|3 10|p55 mRNA
14P07933116A0412|47 58|T-cell lines
14P07933116A0412|86 89|U937
14P07934331T0037|7 18|registration
14P07934331T0037|23 31|incentive
14P07934331T0037|35 45|improvement
14P07934666A0158|13 25|magnetization
14P07934666A0158|70 71|T2
14P07934666A0158|77 79|T2f
14P07934666A0158|85 86|T2
14P07934666A0158|92 94|T2s
14P07935094A0516|0 6|RESULTS
14P07935094A0516|30 39|FDG images
14P07935094A0516|68 86|Tl-201 counterparts
14P07935094A0516|121 129|FDG study
14P07935370A0000|26 28|CD4
14P07935370A0000|32 34|CD8
14P07935370A0000|41 58|T-cell development
14P07935370A0000|101 106|T cell
14P07935375A1197|0 9|Expression
14P07935375A1197|47 66|TIS10/PGS2 induction
14P07935379A0347|60 66|changes
14P07935379A0347|98 106|apoptosis
14P07935383A0108|7 11|RNase
14P07935383A0108|22 38|mapping technique
14P07935383A0108|67 70|CstF
14P07935383A0108|141 153|cleavage site
14P07935383A0108|178 200|adenovirus L3 pre-mRNAs
14P07935395A0094|41 58|zinc finger motifs
14P07935395A0094|85 92|clusters
14P07935395A0094|112 119|molecule
14P07935415T0000|15 24|expression
14P07935415T0000|46 54|inhibitor
14P07935415T0000|88 96|structure
14P07935415T0000|101 112|localization
14P07935418A0447|6 17|v-erbA probe
14P07935418A0447|73 77|RLD-1
14P07935426A0714|40 57|zinc finger domain
14P07935426A0714|87 106|TdT promoter binding
14P07935447A0972|35 37|USF
14P07935447A0972|72 92|leucine zipper family
14P07935447A0972|99 102|MLE1
14P07935447A0972|104 108|HF-1a
14P07935447A0972|113 123|PRE B sites
14P07935447A0972|153 169|protein complexes
14P07935447A0972|210 215|MLC-2v
14P07935451T0000|5 30|T-cell leukemia virus type
14P07935451T0000|29 42|Tax activation
14P07935451T0000|44 57|NF-kappa B/Rel
14P07935451T0000|96 110|I kappa B alpha
14P07935451T0000|116 118|p65
14P07935468T0000|0 9|Activation
14P07935468T0000|12 32|c-fos gene expression
14P07935468T0000|59 80|growth factor receptor
14P07935471A0613|17 19|HSF
14P07935471A0613|81 91|Xenopus HSF
14P07935471A0613|115 129|mapping regions
14P07935471A0613|157 167|maintenance
14P07935472A0276|0 8|Enhancers
14P07935472A0276|28 32|Ets-1
14P07935472A0276|66 82|expression assays
14P07935472A0276|93 107|T-cell line EL4
14P07935472A0276|107 108|E1
14P07935472A0276|126 136|LVb element
14P07935472A0276|156 172|enhancer activity
14P07935472A0276|197 199|LVb
14P07935472A0276|202 212|LVc element
14P07935472A0276|241 257|enhancer activity
14P07935472A0790|14 29|binding activity
14P07935472A0790|35 39|Ets-1
14P07935472A0790|99 119|mobility shift assays
14P07935491A0495|5 16|RZR subtypes
14P07935491A0495|98 112|gene expression
14P07935491A1182|80 125|acid receptor-retinoid-X receptor heterodimers
14P07935577A0305|0 8|Treatment
14P07935577A0305|13 26|amphotericin B
14P07935577A0305|90 104|micro-organisms
14P07935577A0305|131 133|CSF
14P07935626A1249|36 38|CCA
14P07935626A1249|41 55|gene transcript
14P07935626A1249|57 68|mitochondria
14P07935997A0000|43 63|serum immunoglobulins
14P07935997A0000|134 149|cervix carcinoma
14P07935997A0000|150 159|Stages IIB
14P07935997A0000|162 165|IIIB
14P07936635A1134|0 7|Mutation
14P07936635A1134|10 13|KRKR
14P07936635A1134|16 19|NGER
14P07936635A1134|27 30|MO15
14P07936640A0900|75 95|footprinting analysis
14P07936640A0900|113 130|TGF alpha promoter
14P07936650A0656|70 86|activating region
14P07936650A0656|88 97|p58c-ets-2
14P07936650A0656|113 115|BEC
14P07936650A0656|119 128|Ets-1-beta
14P07936650A1752|37 46|ets-2 gene
14P07936650A1752|48 56|evolution
14P07936650A1752|107 115|evidences
14P07937106A0100|3 16|v-ets oncogene
14P07937106A0100|26 39|retrovirus E26
14P07937106A0100|61 81|progenitor p68c-ets-1
14P07937106A0100|86 109|amino acid substitutions
14P07937108A0325|52 68|RNA polymerase I.
14P07937112A0220|23 24|Ku
14P07937112A0220|72 83|denaturation
14P07937112A0220|125 126|Ku
14P07937127A0645|53 70|activation domains
14P07937127A0645|103 115|herpesviruses
14P07937127A0645|123 140|pseudorabies virus
14P07937127A0645|149 159|herpesvirus
14P07937132A0819|11 13|U21
14P07937132A0819|43 57|complementarity
14P07937132A0819|86 93|28S rRNA
14P07937147A0205|35 52|pi protein mutants
14P07937147A0205|75 76|IR
14P07937147A0205|80 81|DR
14P07937147A0205|83 86|York
14P07937147A0205|93 96|Gene
14P07937147A0205|98 101|Amst
14P07937147A0205|118 121|York
14P07937147A0205|125 134|Filutowicz
14P07937147A0205|136 137|J.
14P07937656A0182|0 9|Univariate
14P07937656A0182|36 57|Kaplan-Meier-estimates
14P07937656A0182|61 73|Log-Rank-Test
14P07937656A0182|131 143|disease stage
14P07937656A0182|153 167|NSE serum level
14P07937656A0182|198 223|serum alkaline phosphatase
14P07937656A0182|233 235|U/l
14P07937656A0182|252 264|serum albumin
14P07937656A0182|276 289|activity index
14P07937841A0790|67 76|cell cycle
14P07937841A0790|108 126|myb oncogene family
14P07937954A0612|0 2|HBx
14P07937954A0612|36 38|Ras
14P07937954A0612|66 68|Raf
14P07937954A0612|108 117|MAP kinase
14P07937965T0000|0 3|Role
14P07937965T0000|51 63|DNA synthesis
14P07937965T0000|74 97|3T3-L1 mouse fibroblasts
14P07938137A0384|39 46|naloxone
14P07938137A0384|73 83|environment
14P07938137A0384|115 124|withdrawal
14P07941174T0001|0 12|Laser therapy
14P07941739A0000|5 15|kb fragment
14P07941739A0000|20 31|yeast genome
14P07941739A0000|67 80|chromosome XIV
14P07941750A0344|54 70|hydantoinase HyuA
14P07941750A0344|89 104|hydatoinase HyuB
14P07942076A0497|14 37|estradiol concentrations
14P07942076A0497|50 67|estradiol valerate
14P07942076A0497|80 98|estradiol ingestion
14P07942448A1227|20 29|NYHA class
14P07942448A1227|47 54|ABSTRACT
14P07942448A1227|69 73|WORDS
14P07942722T0000|0 11|Constipation
14P07942722T0000|18 28|risk factor
14P07942722T0000|31 41|hemorrhoids
14P07943556A0694|58 68|Og4C3 assay
14P07944461A0321|0 5|TG-day
14P07944461A0321|9 16|TG-night
14P07944542T0000|0 19|Vibrio cholerae O139
14P07945134A0079|3 12|volunteers
14P07945134A0079|136 150|head microphone
14P07945330A0103|4 18|differentiation
14P07945330A0103|36 37|RA
14P07945330A0103|58 67|Rex-1 gene
14P07945937A0358|0 16|Sequence analysis
14P07945937A0358|21 34|zebrafish egr1
14P07945937A0358|97 106|Egr1 genes
14P07945937A0358|144 177|triplet nucleotide repeat sequence
14P07945937A0358|198 211|amino terminus
14P07945937A0358|216 227|Egr1 protein
14P07947930A0499|3 12|fibrinogen
14P07947930A0499|14 27|serum proteins
14P07947930A0499|28 41|sodium heparin
14P07947930A0499|44 51|membrane
14P07947930A0499|65 66|Cm
14P07948129A0297|74 107|chloramphenicol acetyl transferase
14P07948129A0297|107 109|CAT
14P07948129A0297|149 158|SV40 virus
14P07948129A0297|188 214|neomycin phosphotransferase
14P07948129A0297|217 219|NEO
14P07948921A0051|0 5|Optima
14P07948921A0051|54 75|stilbene synthase cDNA
14P07949137A0000|67 68|BM
14P07949137A0000|90 95|ASTA Z
14P07949137A0000|113 119|January
14P07949137A0000|126 132|January
14P07949137A0532|34 49|cyclophosphamide
14P07949137A0532|68 83|body irradiation
14P07949164A0799|42 45|IL-6
14P07949164A0799|47 57|CAT plasmid
14P07949164A0799|90 111|IL-6 promoter activity
14P07949205A0286|10 23|testololactone
14P07949205A0286|55 71|aminoglutethimide
14P07949205A0286|90 105|breast carcinoma
14P07949551A0000|0 2|Use
14P07949551A0000|44 66|cadaver transplantation
14P07949770T0000|39 54|prostaglandin E1
14P07949770T0000|63 83|liver transplantation
14P07951235A0277|72 77|muscle
14P07951410A0647|3 6|HeLa
14P07951410A0647|12 15|U937
14P07951410A0647|20 29|A549 cells
14P07951410A0647|30 42|participation
14P07951410A0647|45 49|E2F-1
14P07951410A0647|51 54|DP-1
14P07951410A0647|67 68|RB
14P07951410A0647|119 131|participation
14P07951410A0647|154 158|E2F-1
14P07951410A0647|161 164|DP-1
14P07951410A1332|0 17|E1A autoactivation
14P07951410A1332|106 117|E1A promoter
14P07951874A0320|0 15|Cestode invasion
14P07951874A0320|27 39|host organism
14P07953785A0648|104 113|H/L ratios
14P07953785A0648|136 166|marble spleen disease infection
14P07954475A0714|0 7|Analyses
14P07954475A0714|64 79|A/J x C3H/HeJ F1
14P07954475A0714|93 97|AC3F1
14P07954475A0714|102 117|C3H/HeJ x A/J F1
14P07954475A0714|131 135|C3AF1
14P07954475A0714|207 227|tumor suppressor gene
14P07954891T0000|0 3|ERV1
14P07956578A0851|0 15|Lesion diameters
14P07956578A0851|55 68|configurations
14P07956869A0000|37 56|breast cancer tissue
14P07956869A0000|90 109|Pathology laboratory
14P07956869A0000|111 113|Dar
14P07956869A0000|177 186|DNA ploidy
14P07956869A0000|189 204|S-phase fraction
14P07957085A0207|0 3|Cbf3
14P07957085A0207|26 30|Cbf3a
14P07957085A0207|32 36|Cbf3b
14P07957085A0207|40 44|Cbf3c
14P07957106A0471|38 59|GST-POU fusion protein
14P07957106A0471|65 89|glutathione-agarose beads
14P07957106A0875|49 71|HSV transactivator VP16
14P07957106A0875|100 112|VP16 contacts
14P07957158A1532|13 27|filtration rate
14P07957158A1532|171 185|Starling forces
14P07957243A1316|13 20|residues
14P07957243A1316|42 48|domains
14P07957559A1557|41 52|Ba/F3-EpoRgp
14P07957559A1557|63 71|MEL cells
14P07957559A1557|90 111|p70 S6 kinase activity
14P07957632A0000|28 29|2S
14P07957632A0000|80 85|DCG-IV
14P07957632A0000|117 135|glutamate receptors
14P07957632A0000|181 200|halothane anesthesia
14P07957632A0000|203 212|dose range
14P07958446A0000|29 33|HNF-3
14P07958446A0000|116 130|gene regulators
14P07958446A0000|163 185|helix DNA binding motif
14P07958865A1152|34 46|abnormalities
14P07958865A1152|49 65|heart development
14P07958865A1152|97 99|Tek
14P07958865A1152|136 147|interactions
14P07958865A1152|154 164|development
14P07958898A1050|91 111|transcription factors
14P07958898A1050|120 122|Sp1
14P07958898A1050|124 127|VP16
14P07958898A1050|132 136|NTF-1
14P07958911A0500|7 28|trithorax binding site
14P07958911A0500|64 77|fork head gene
14P07958915A1507|35 37|Ca2
14P07958915A1507|106 118|transcription
14P07958915A1507|159 161|Ca2
14P07958915A1507|184 198|protein kinases
14P07958920A1157|0 9|Antibodies
14P07958920A1157|28 39|SNM1 protein
14P07958920A1157|57 69|RNase MRP RNA
14P07958920A1157|147 157|RNase P RNA
15P07959011A0379a|0 10|C/EBP alpha
15P07959011A0379a|39 58|rat class-I ADH gene
15P07959011A0379a|83 88|Potter
15P07959011A0379a|95 98|Arch
15P07959011A0379b|0 10|C/EBP alpha
15P07959011A0379b|39 58|rat class-I ADH gene
15P07959011A0379b|83 88|Potter
15P07959011A0379b|95 98|Arch
14P07959015A0478|21 23|ORF
14P07959015A0478|41 51|amino acids
14P07959015A0478|99 108|identities
14P07959015A0478|131 139|nt levels
14P07959734A0194|58 75|peptide sequencing
14P07959734A0194|101 118|glycoprotein Gp135
14P07959760A0763|14 23|YAC contig
14P07959760A0763|52 55|YACs
14P07959760A0763|88 91|STSs
14P07959760A0763|113 114|Mb
14P07959760A0763|126 149|Ewing sarcoma breakpoint
14P07959760A0763|158 162|Fli-1
14P07959760A0763|227 229|DNA
14P07959760A0763|277 290|microsatellite
14P07959760A0763|292 298|D11S912
14P07959760A0763|300 301|CA
14P07959760A0763|334 343|Fli-1 gene
14P07959952A1446|54 77|mouse mast cell chymases
14P07959952A1446|88 126|polymerase chain reaction amplification
14P07959953A0423|0 4|IFI16
14P07959953A0423|80 82|DNA
14P07960608A0228|0 6|Courses
14P07960796A0154|0 10|Peter Elfer
14P07960796A0154|21 32|implications
14P07961545A1314|22 31|incidences
14P07961545A1314|70 78|dizziness
14P07961545A1314|80 91|constipation
14P07961545A1314|93 100|sweating
14P07961545A1314|102 112|nervousness
14P07961545A1314|125 135|ejaculation
14P07961755A0474|0 7|Homology
14P07961755A0474|41 64|transit peptide sequence
14P07961755A0474|65 83|cysteine synthase C
14P07961957A1565|44 48|TEF-1
14P07961957A1565|96 120|alpha-MHC gene EM element
14P07961958T0000|0 26|Rat kidney carboxylesterase
14P07963540A0795|11 25|I-kappa B alpha
14P07963540A0795|33 53|kappa B motif binding
14P07963540A0795|60 74|factor-kappa B1
14P07963540A0795|75 78|RelA
14P07963540A0795|113 114|UV
14P07963540A0795|185 207|kappa B oligonucleotide
14P07963782A0000|22 30|stability
14P07963782A0000|34 44|combination
14P07963782A0000|111 119|treatment
14P07964162A0941|46 63|MAP kinase cascade
14P07964458A0179|1 14|candidate gene
14P07964458A0179|17 19|Bcg
14P07964458A0179|59 76|macrophage protein
14P07964458A0179|77 81|Nramp
14P07964458A0179|140 155|membrane protein
14P07964459A0845|38 47|LIM domain
14P07964459A0845|53 70|RING finger family
14P07964624A0491|3 10|P131 ORF
14P07964624A0491|37 39|ORF
14P07964624A0491|89 109|UGA termination codon
14P07964624A0491|113 120|P131 ORF
14P07964624A0491|154 157|P191
14P07964770A0172|15 22|patients
14P07964770A0172|47 58|arthroplasty
14P07964814T0000|16 29|hallucinations
14P07964918A0000|3 11|influence
14P07964918A0000|52 62|variability
14P07964918A0000|68 77|evaluation
14P07965152A0764|0 7|Segments
14P07965152A0764|23 34|BMIPP uptake
14P07965152A0764|38 48|MIBI uptake
14P07965152A0764|125 146|dobutamine stimulation
14P07966565A0901|31 41|nucleotides
14P07966565A0901|74 76|RNA
14P07966565A0901|99 115|replication cycle
14P07966583A1268|9 21|transfections
14P07966583A1268|47 60|RNA transcript
14P07966583A1268|82 90|D17 cells
14P07966583A1268|112 119|Env/Mlvi
14P07966583A1268|122 135|fusion protein
14P07966602A0130|0 6|Roizman
14P07966602A0130|8 9|J.
14P07966873A0693|0 7|Articles
14P07966873A0693|26 38|heart disease
14P07966873A0693|40 52|heart failure
14P07966873A0693|90 95|Chagas
14P07967360A1048|42 57|TGBM nephropathy
14P07967360A1048|77 91|IgA nephropathy
14P07967360A1048|116 133|glomerulonephritis
14P07967725A0262|107 127|ligand binding domain
14P07967725A0262|131 147|carboxyl terminus
14P07968409A0123|69 86|Outpatient Service
14P07968409A0123|101 108|Diseases
14P07968409A0123|116 122|Bologna
14P07968409A0123|126 142|Ospedale Maggiore
14P07968409A0123|143 158|General Hospital
14P07968409A0123|185 188|July
14P07969115A0000|7 34|organello footprint analysis
14P07969115A0000|190 200|DNA origins
14P07969115A0000|206 221|promoter regions
14P07969116A0196|3 15|Nur77 protein
14P07969116A0196|30 52|transcription activator
14P07969132A0268|10 17|plasmids
14P07969132A0268|62 72|suppression
14P07969132A0268|100 108|histidine
14P07969132A0268|115 122|plasmids
14P07969132A0268|134 146|gcn2 deletion
14P07969132A0268|183 190|gcn2-507
14P07969135A0913|21 36|Cln2 PEST domain
14P07969136A0273|15 35|mobility shift assays
14P07969136A0273|114 128|NF-kappa B site
14P07969152A0721|26 28|HSF
14P07969152A0721|44 60|activation domain
14P07969152A0721|88 105|CUP1 transcription
14P07969152A0721|121 137|heat shock stress
14P07969152A0721|139 156|glucose starvation
14P07969152A0721|192 212|heat shock activation
14P07969181A0313|34 41|CKB mRNA
14P07969181A0313|43 52|HeLa cells
14P07969181A0313|123 133|p53 protein
14P07969181A0313|142 151|HeLa cells
14P07969954T0000|11 31|motor neuron syndrome
14P07969954T0000|91 103|immunotherapy
14P07969954T0000|115 129|plasma exchange
14P07969954T0000|143 158|cyclophosphamide
14P07971282A0000|0 9|Regulators
14P07971282A0000|63 94|pre-mRNA splicing characteristic
14P07971709A0907|15 22|response
14P07971709A0907|56 62|rhG-CSF
14P07971709A0907|70 77|activity
14P07972012A0956|34 49|rat lung library
14P07972012A0956|97 110|amino terminus
14P07972012A0956|140 151|ANP-receptor
14P07972012A0956|187 203|carboxyl terminus
14P07972012A0956|226 243|phosphatase domain
14P07972237A0665|16 30|restriction map
14P07972237A0665|53 55|DNA
14P07972237A0665|66 70|N-myc
14P07972237A0665|89 103|subcloning YACs
14P07972831A0563|0 11|PAI-1 levels
14P07973364A0325|69 91|carcinogenicity studies
14P07973364A0325|109 111|OFA
14P07973364A0325|139 149|Wistar rats
14P07973364A0325|168 170|OF1
14P07973364A0325|174 182|NMRI mice
14P07973397T0001|0 12|Determination
14P07973397T0001|15 30|potassium iodide
14P07973825A0445|3 16|recovery value
14P07973825A0445|67 80|pulse pressure
14P07975763A0000|15 31|hepatitis C virus
14P07975763A0000|31 33|HCV
14P07975763A0000|61 73|liver disease
14P07975763A0000|94 105|introduction
14P07975763A0000|117 133|detection methods
14P07975882T0000|5 19|adenovirus type
14P07977239A1283|0 18|Outflow obstruction
14P07977239A1283|194 205|pancreatitis
14P07977239A1283|273 283|dorsal duct
14P07977648A0880|0 9|Sequencing
14P07977648A0880|15 30|TP53 transcripts
14P07978229T0000|9 20|complication
14P07978406A0998|5 13|ISO group
14P07978406A0998|24 26|CBF
14P07978406A0998|95 98|PCO2
14P07978406A0998|121 128|ABSTRACT
14P07978406A0998|143 147|WORDS
14P07979810A0340|17 26|parameters
14P07979810A0340|58 73|penetration test
14P07979810A0340|126 134|pregnancy
14P07979827A0722|0 6|KRN2391
14P07980440A0138|2 25|H4IIE rat hepatoma cells
14P07980440A0138|61 63|AMP
14P07980440A0138|70 102|increase PEPCK gene transcription
14P07980468A0298|0 3|Acta
14P07980669A0373|5 21|plasma AVP levels
14P07980669A0373|23 33|AVP release
14P07980669A0373|68 84|plasma NPY levels
14P07981143A0633|40 45|IL-4RE
14P07981143A0633|59 75|IL-4 inducibility
14P07981143A0633|84 106|nucleoprotein complexes
14P07981246A0112|29 43|pertussis toxin
14P07981246A0112|44 46|IAP
14P07981246A0112|80 88|G-protein
14P07981246A0112|114 128|differentiation
14P07981246A0112|131 143|hormones/IBMX
14P07981246A0112|158 172|c-fos induction
14P07982964A1017|40 92|phosphodiesterase substrate p-nitrophenyl thymidine-5
14P07982995A0000|59 71|growth factor
14P07982995A0000|72 75|PDGF
14P07982995A0000|77 89|beta-receptor
14P07982995A0000|107 108|Na
14P07982995A0000|170 174|NMuMG
14P07982995A0000|186 198|hamster ovary
14P07982995A0000|199 201|CHO
14P07983011A0617|0 16|Sequence analysis
14P07983011A0617|69 92|serine/threonine kinases
14P07983011A0617|150 178|protein kinase kinase kinases
14P07983011A0617|182 221|fibroblast growth factor receptor family
14P07983011A0617|245 265|leucine zipper motifs
14P07983011A0617|427 429|SH3
14P07983011A0617|431 452|domain binding regions
14P07983704A0330|0 3|Type
14P07983704A0330|111 130|retrovirus ancestors
14P07983704A0330|135 147|HERV-K family
14P07983712A0914|49 55|plasmid
14P07983712A0914|69 79|replication
14P07983715A0996|0 14|Point mutations
14P07983715A0996|47 50|NF-Y
14P07983715A0996|109 119|P4 promoter
14P07983715A0996|140 156|complex formation
14P07983715A0996|160 162|USF
14P07983715A0996|193 209|expression assays
14P07983715A0996|217 240|luciferase reporter gene
14P07983716A1082|13 20|Northern
14P07983716A1082|22 24|RNA
14P07983716A1082|48 65|transcriptase-PCRs
14P07983716A1082|94 98|COS-7
14P07983716A1082|101 110|HeLa cells
14P07983716A1082|124 127|RNAs
14P07983716A1082|140 143|Y88S
14P07983716A1082|147 155|Y88L RNAs
14P07983744A0920|27 31|IE110
14P07983744A0920|65 69|IE175
14P07983744A0920|81 99|punctate structures
14P07983744A0920|121 125|IE110
14P07983744A0920|155 159|IE175
14P07983744A0920|173 191|punctate structures
14P07984088A0592|0 12|Transcription
14P07984088A0592|66 87|virulence gene cluster
14P07984088A0592|88 98|L. ivanovii
14P07984088A0592|113 116|PrfA
14P07984105A1509|31 44|WA fyuA mutant
14P07984105A1509|63 83|yersiniabactin uptake
14P07984261A0536|3 6|ICBF
14P07985305T0001|3 11|treatment
14P07985305T0001|14 27|hydronephrosis
14P07987924A0670|56 81|USCI Tuohy-Borst Y adaptor
14P07988559A0836|20 30|RBP-J kappa
14P07988730A0220|8 24|promoter strength
14P07988730A0220|63 71|U5 region
14P07988730A0220|76 78|LTR
14P07988730A0220|92 124|chloramphenicol acetyltransferase
14P07988730A0220|125 127|CAT
14P07988730A0220|158 167|HeLa cells
14P07988730A0220|169 182|Jurkat T-cells
14P07988730A0220|211 236|transactivator tax protein
14P07988731A0002|142 158|promoter activity
14P07988731A0002|174 178|G-box
14P07988731A0002|180 187|CCACGTGG
14P07988731A1301|27 30|GF14
14P07988731A1301|69 87|GBF protein complex
14P07988945T0000|0 2|New
14P07988945T0000|26 45|lupus anticoagulants
14P07990136A1124|21 49|selectivity arrest elongation
14P07990136A1124|83 110|tRNA gene transcription unit
14P07990136A1124|123 136|identification
14P07991437A1032|0 10|Propafenone
15P07991582A1023b|20 29|yeast CEG1
15P07991582A1023b|95 109|enzyme function
14P07992027A0485|1 8|patients
14P07992027A0485|28 36|morbidity
14P07992027A0485|67 81|transplantation
14P07993559A0233|13 32|Fluorosis Risk Index
14P07993559A0233|43 49|Pendrys
14P07994021A1223|64 79|PECAM-1 isoforms
14P07994021A1223|94 108|phosphorylation
14P07994021A1223|137 155|affinity modulation
14P07995173A0585|0 7|Transfer
14P07995910A0119|4 12|technique
14P07995910A0119|17 27|sensitivity
14P07995910A0119|32 42|specificity
14P07995910A0119|95 105|involvement
14P07995910A0119|116 125|laparotomy
14P07997174A0936|27 41|phosphorylation
14P07997174A0936|44 50|His-304
14P07997174A0936|92 109|A. vinelandii NifL
14P07999066A0238|9 15|HIV tat
14P07999066A0238|53 55|LTR
14P07999066A0238|74 96|IL-2 gene transcription
14P07999066A0238|192 203|Jurkat cells
14P07999066A0238|218 221|IL-2
14P07999066A0238|246 282|acetyltransferase reporter constructs
14P07999363A0000|35 60|transmembrane FGF receptor
14P07999363A0000|60 63|FGFR
14P07999363A0000|118 137|juxtamembrane domain
14P07999604A0139|20 27|patients
14P07999604A0139|67 73|lesions
14P07999982A0086|9 26|maximum lod scores
14P07999982A0086|32 35|FRDA
14P07999982A0086|39 42|D9S5
14P07999982A0086|53 56|FRDA
14P07999982A0086|60 64|D9S15
14P07999982A0086|97 118|recombination fraction
14P07999982A0086|136 155|recombination events
14P07999995A0000|14 27|protein kinase
14P07999995A0000|28 33|OsPK10
14P07999995A0000|57 68|Oryza sativa
14P08000074A0162|1 8|sequence
14P08000074A0162|50 57|sequence
14P08000074A0162|71 81|translation
14P08000074A0162|94 107|reading frames
14P08000074A0162|132 139|fragment
14P08000112T0000|0 10|Goodpasture
14P08000112T0000|51 77|membrane oxygenator support
14P08000427A0000|1 15|cDNA clone pCZ1
14P08000427A0000|60 84|tobacco cell cDNA library
14P08000497A0179|0 6|METHODS
14P08000497A0179|39 67|methacholine provocation test
14P08000497A0179|124 126|VTG
14P08001136T0000|0 11|Relationship
14P08001136T0000|37 50|RNA polymerase
14P08001136T0000|52 73|CTD kinase TFIIH/TFIIK
14P08001792A0284|53 69|adenylate cyclase
14P08001792A0284|90 125|adenylate cyclase activation pathway
14P08001966A0563|66 68|CNC
14P08001966A0563|146 167|Caenorhabditis elegans
14P08002564A0249|0 20|DNA sequence analysis
14P08002564A0249|78 90|alpha subunit
14P08002564A0249|100 114|leucine residue
14P08002857A1070|0 10|CONCLUSIONS
14P08002857A1070|51 72|oesophageal surfactant
14P08003700T0000|36 49|cDNA libraries
14P08003700T0000|108 128|genome rearrangements
14P08004442A0265|45 62|locomotor activity
14P08004442A0265|129 131|HPA
14P08004442A0265|170 193|corticosterone secretion
14P08004442A0265|205 217|adrenalectomy
14P08005230A0222|9 28|reporter gene system
14P08005230A0222|76 89|c-fos promoter
14P08005230A0222|146 164|luciferase activity
14P08005412A0608|21 35|gene expression
14P08005412A0608|72 86|protein complex
14P08005412A0608|116 123|PS sites
14P08005412A0608|169 171|DNA
14P08005438A1185|0 4|SPP41
14P08005438A1185|87 101|suppressor srn1
14P08005438A1185|134 148|gene expression
14P08006101A1142|0 38|Standard curve correlation coefficients
14P08006101A1142|70 91|validation experiments
14P08006772A0000|8 21|pulse oximeter
14P08006773A0836|22 42|plasma concentrations
14P08006773A0836|44 47|PGI2
14P08006773A0836|60 63|TxA2
14P08006773A0836|84 97|blood pressure
14P08006773A0836|160 179|plasma concentration
14P08006773A0836|181 184|PGI2
14P08006773A0836|220 223|TxA2
14P08007835A0538|26 34|variables
14P08007835A0538|48 56|formation
14P08007835A0538|59 69|FB memories
14P08007835A0538|105 114|importance
14P08007954A0374|0 15|Deletion studies
14P08007954A0374|32 47|response element
14P08007954A0374|70 86|cytokine response
14P08007975A0000|3 11|IPL1 gene
14P08007975A0000|24 59|high-fidelity chromosome segregation
14P08011017A0169|8 24|oxygen saturation
14P08011017A0169|25 28|SaO2
14P08011017A0169|81 83|EEG
14P08011017A0169|105 126|repeat polysomnography
14P08011166A0207|11 27|gene organization
14P08011166A0207|98 113|characterization
14P08011166A0207|116 131|polymerase chain
14P08012448T0000|0 3|INO2
14P08012448T0000|80 100|bud pattern formation
14P08012566A0254|3 30|pentafluorobenzyl derivative
14P08012566A0254|32 47|clonidine yields
14P08012566A0254|56 67|ion fragment
14P08012566A0254|123 135|plasma sample
14P08013348A0143|9 12|ABPs
14P08013348A0143|16 20|SHBGs
14P08013348A0143|60 77|binding properties
14P08013457A0342|12 13|SH
14P08013457A0342|71 114|tyrosine kinase receptor signal transduction
14P08014228A0278|0 15|Sample treatment
14P08014228A0278|64 89|labetalol diastereoisomers
14P08014377A1277|12 21|conditions
14P08014377A1277|23 37|activity levels
14P08014377A1277|131 141|interaction
14P08014377A1277|174 182|divisions
14P08014919A0530|49 59|progression
14P08014919A0530|124 132|direction
14P08014919A0530|149 151|DGR
14P08015672A1282|2 17|control patients
14P08015672A1282|18 32|baseline images
14P08015672A1282|41 44|Type
14P08015672A1282|51 54|Type
14P08015672A1282|67 70|Type
14P08015672A1282|87 90|Type
14P08015672A1282|118 121|Type
14P08015850A1076|23 35|dose response
14P08015850A1076|49 65|Ga administration
14P08015850A1076|77 86|postinjury
14P08015850A1076|92 103|availability
14P08015850A1076|106 107|Ga
14P08016102A1238|47 67|transcription factors
14P08016102A1238|73 82|NF-kappa B
14P08016102A1238|85 88|AP-2
14P08016102A1238|201 204|HO-1
14P08016102A1238|214 231|defense mechanisms
14P08016102A1238|238 250|tissue injury
14P08016189A0741|0 10|Granisetron
14P08016189A0741|62 73|intervention
14P08017290A1347|25 40|sinus difference
14P08017290A1347|70 73|PCO2
14P08017290A1347|77 97|potassium differences
14P08018361A0636|29 43|neutron fluency
14P08020702A0000|0 10|Endotoxemia
14P08020702A0000|101 109|component
14P08020702A0137|78 89|disturbances
14P08020702A0137|95 105|endotoxemia
14P08020702A0137|108 122|dog experiments
14P08020702A0137|144 168|antibodies administration
14P08020806A0187|44 51|patients
14P08020806A0187|62 66|Crohn
14P08020806A0187|108 115|outcomes
14P08020806A0187|123 132|amino acid
14P08020806A0187|167 178|feeding tube
14P08020962A1226|24 35|V beta locus
14P08020962A1226|69 80|DNA elements
14P08020962A1226|83 85|Alu
14P08020962A1226|92 93|L1
14P08020962A1226|100 102|MER
14P08020965A0465|19 24|region
14P08020965A0465|71 80|transcript
14P08020965A0465|117 126|transcript
14P08021175A0486|98 117|AMP receptor protein
14P08021175A0486|119 141|integration host factor
14P08021177A0000|15 30|fes-entF operons
14P08021177A0000|35 56|enterobactin synthesis
14P08021177A0000|59 74|transport system
14P08021177A0000|148 168|Fur repressor protein
14P08021225A0000|0 16|Sequence analysis
14P08021225A0000|33 46|EcoRI-fragment
14P08021225A0000|49 69|Alcaligenes eutrophus
14P08021225A0000|142 150|DNA probe
14P08022212A0071|39 51|AC excitation
14P08022212A0071|77 97|admittance locus plot
14P08022212A0071|97 99|ALP
14P08022212A0071|106 125|low-frequency region
14P08022212A0071|131 132|Hz
14P08022212A0071|238 259|phase angle alpha pi/2
14P08022212A0071|299 302|1/R0
14P08022212A0071|307 329|ion relaxation time tau
14P08023662T0000|43 61|thromboplastin time
14P08023662T0000|64 79|prothrombin time
14P08024139A0393|2 9|addition
14P08024139A0393|28 37|hypothesis
14P08024139A0393|99 109|differences
14P08024139A0393|158 166|solutions
14P08024139A0393|182 191|impairment
14P08025074A0000|62 81|laser energy density
14P08025074A0000|89 100|suture lysis
14P08025074A0000|134 139|Dacron
14P08025669A0724|3 10|proteins
14P08025669A0724|69 76|activity
14P08028671A0687|16 29|microinjection
14P08028671A0687|42 50|antiserum
14P08028671A0687|55 65|fibroblasts
14P08028671A0687|76 88|transcription
14P08029001A1020|47 64|activator proteins
14P08029001A1020|67 80|RNA polymerase
14P08029001A1020|173 195|transcription machinery
14P08029334T0000|0 6|Cloning
14P08029334T0000|15 27|plant omega-3
14P08029334T0000|32 47|acid desaturases
14P08030239A0833|60 78|amino acid residues
14P08030239A0833|126 142|activation domain
14P08030239A0833|167 183|EHV-1 tk promoter
14P08030239A0833|221 237|EHV-1 IE promoter
14P08030243A1011|25 41|RNA capture assay
14P08030243A1011|118 121|NS35
14P08030704A1503|0 9|CONCLUSION
14P08030704A1503|62 98|progesterone/17 beta-estradiol ratios
14P08031424T0000|0 7|Ketamine
14P08031424T0000|24 35|bronchospasm
14P08031424T0000|52 62|ventilation
14P08033490A0875|43 64|O-desmethylvenlafaxine
14P08033490A0875|106 122|dosage adjustment
14P08033490A0875|148 174|creatinine clearance values
14P08034318A0724|76 83|UBE site
14P08034318A0724|129 139|NF-1 family
14P08034318A0724|141 161|transcription factors
14P08034486A0579|14 18|HSV-2
14P08034486A0579|36 40|HSV-2
14P08034486A0579|42 61|HSV-1 antibody ratio
14P08034680A0180|35 44|NF-kappa B
14P08034680A0180|88 103|I kappa B kinase
14P08034680A0180|168 177|I kappa B.
14P08034682T0000|27 72|inositol 1,4,5-trisphosphate receptor subunits
14P08034708A0000|20 29|commitment
14P08034708A0000|32 42|progenitors
14P08034708A0000|48 65|eosinophil lineage
14P08034708A0000|68 77|mechanisms
14P08034708A0000|139 153|differentiation
14P08034741A0000|11 24|identification
14P08034741A0000|28 43|characterization
14P08034741A0000|120 135|border myosin I.
14P08034742A0307|0 1|M.
14P08034742A0307|6 7|D.
14P08035498A0833|11 27|computer analysis
14P08035498A0833|60 73|A stem element
14P08035498A0833|96 115|AAV promoter regions
14P08035499A0941|83 99|dissociation rate
14P08035499A0941|104 119|A stem substrate
14P08035499A0941|196 197|TR
14P08035505A0586|0 9|Processing
14P08035505A0586|15 17|NS3
14P08035505A0586|21 33|B polyprotein
14P08035517A0753|31 35|IEP86
14P08035517A0753|77 81|IEP72
14P08035796A0890|0 12|32Pi labeling
14P08035796A0890|43 53|eIF-2 alpha
14P08035796A0890|68 80|casein kinase
14P08035796A0890|102 116|phosphorylation
14P08035796A0890|119 129|eIF-2 alpha
14P08035796A0890|165 175|eIF-2 alpha
14P08035796A0890|226 242|growth conditions
14P08035833A1556|5 8|YMIP
14P08035833A1556|31 34|RMIP
14P08035833A1556|84 99|import machinery
14P08036004A0292|3 11|R2 region
14P08036004A0292|99 114|binding activity
14P08036004A0292|191 200|expression
14P08037338A0000|0 6|PURPOSE
14P08037338A0000|31 44|erythropoietin
14P08037338A0000|46 48|EPO
14P08037338A0000|73 84|pathogenesis
14P08037338A0000|117 126|EPO levels
14P08039422A0000|3 31|nerve growth factor beta gene
14P08039422A0000|29 32|NGFB
14P08039422A0000|87 102|mouse Chromosome
14P08040336A0435|30 45|collagen element
14P08040336A0435|84 106|LAP binding cis-element
14P08040336A0435|110 125|albumin promoter
14P08040391T0000|0 5|Number
14P08040391T0000|71 81|correlation
14P08040391T0000|109 124|tumour behaviour
14P08040468A0303|15 37|mast cell degranulation
14P08040468A0303|89 114|fibroblast enzyme activity
14P08041362T0000|19 40|cysteine synthase cDNA
14P08041362T0000|81 95|complementation
14P08041362T0000|115 117|Cys
14P08041793A0242|127 131|COX5b
14P08043523A0000|16 27|serum levels
14P08043523A0000|29 38|antibodies
14P08043523A0000|53 74|acetylcholine receptor
14P08043523A0000|136 145|dyskinesia
14P08043523A0000|151 160|antibodies
14P08044794A0000|3 18|tumor suppressor
14P08044794A0000|36 45|factor p53
14P08044800A0550|4 35|DNA containing promoter activity
14P08044802A0462|8 20|Southern blot
14P08044802A0462|23 40|karyotype analyses
14P08044802A0462|111 118|p53 gene
14P08044802A0462|128 130|p53
14P08045431A0894|0 3|HupI
14P08045431A0894|26 35|rubredoxin
14P08045834A0783|3 22|PCr resynthesis rate
14P08045834A0783|70 82|ATP synthesis
14P08046923A0000|2 12|examination
14P08046923A0000|62 73|osteomalacia
14P08046923A0000|90 98|resection
14P08048582A0821|16 19|MVO2
14P08048582A0821|54 56|CFX
14P08048582A0821|83 99|ml O2.min-1 times
14P08048582A0821|111 120|LAD region
14P08048582A0821|146 162|ml O2.min-1 times
14P08048916A0000|0 4|IGF I
14P08048916A0000|7 23|insulin receptors
14P08049401A0428|0 15|Immunodepression
14P08049401A0428|44 66|glucocorticoid activity
14P08049401A0428|109 124|thyroid hormones
14P08049444A0351|18 42|peptide sequence analysis
14P08049444A0351|123 137|binding protein
14P08049444A0351|139 143|SATB1
14P08049444A0351|210 212|DNA
14P08049444A0351|214 222|MARs/SARs
14P08049521T0000|8 30|protein phosphorylation
14P08049885T0000|19 37|multisystem disease
14P08051019A0365|8 19|biosynthesis
14P08051019A0365|52 60|mechanism
14P08051059A1000|24 36|rhlA promoter
14P08051059A1000|81 93|binding sites
14P08051059A1000|99 112|RhlR regulator
14P08051074A0000|69 90|immunodeficiency virus
14P08051074A0000|97 101|HIV-1
14P08051074A0000|136 140|DNase
14P08051102A0532|0 6|Heparin
14P08051102A0532|20 32|rAC-st myosin
14P08051102A0532|37 62|chain phosphatase activity
14P08051151A0347|11 19|abundance
14P08051151A0347|96 109|chain reaction
14P08051151A0347|133 142|cell lines
14P08053697A0000|0 9|BACKGROUND
14P08053697A0000|13 18|DESIGN
14P08053697A0000|64 80|hyperpigmentation
14P08054281A0731|3 17|retention index
14P08054281A0731|19 29|201Tl SPECT
14P08054281A0731|138 149|relationship
14P08054281A0731|157 168|201Tl uptake
14P08055939A0159|62 73|H1 molecules
14P08055939A0159|121 137|hexapeptide motif
14P08055939A0159|170 181|H1 molecules
14P08055939A0707|3 10|location
14P08055939A0707|72 88|Arabidopsis genes
14P08055941A1264|3 10|topology
14P08055941A1264|31 43|beta subunits
14P08055941A1264|48 63|artifactual beta
14P08056474A0438|7 10|NMSC
14P08057356A0531|34 45|substitution
14P08057356A0531|47 50|V88A
14P08057356A0531|72 89|response regulator
14P08057356A1824|0 10|Comparisons
14P08057356A1824|20 41|operon control regions
14P08057356A1824|62 75|NarL heptamers
14P08057421A1583|44 65|oligonucleotide probes
14P08057421A1583|90 107|CBF1 binding sites
14P08057421A1583|119 122|CBF1
14P08057421A1583|148 160|CD23 promoter
14P08057421A1583|166 189|EBV LMP-1 promoter sites
14P08057762A0878|24 38|reproducibility
14P08057762A0878|47 48|T1
14P08057762A0878|55 56|T2
14P08057762A0878|72 86|reproducibility
14P08057762A0878|113 114|T1
14P08057762A0878|122 123|T2
14P08057833A0573|6 18|ParA proteins
14P08057833A0573|55 76|translation initiation
14P08058326A0463|36 45|mechanisms
14P08058326A0463|57 72|tal-1 expression
14P08058326A0463|89 97|sequences
14P08058326A0463|140 151|counterparts
14P08058948A0810|0 9|CONCLUSION
14P08058948A0810|91 93|CRF
14P08062824A0626|28 34|FKBP-33
14P08062824A0626|75 92|isomerase activity
14P08062824A0626|134 140|FKBP-12
14P08062833A0000|25 53|transcription initiation site
14P08062833A0000|57 73|mouse desmin gene
14P08062833A0000|87 91|E box
14P08062833A0000|92 93|E1
14P08063108A0109|3 11|acfD gene
14P08063108A0109|70 76|protein
14P08063766A0595|16 18|PKC
14P08063766A0595|40 55|envelope lamin B
14P08063766A0595|75 83|alpha PKC
14P08063775T0000|0 9|Regulation
14P08063775T0000|46 50|PTHrP
14P08063775T0000|52 66|gene expression
14P08063791A1370|57 71|sequence motifs
14P08063791A1370|91 103|modifications
14P08063791A1370|120 131|Ras proteins
14P08063836A0904|28 46|c-myc transcription
14P08063836A0904|76 86|DNA binding
14P08064351A1020|0 11|Long-latency
14P08065310A1144|47 64|heterodimerization
14P08065310A1144|109 119|interaction
14P08065310A1144|168 187|receptor gene family
14P08065324A0458|73 75|USE
14P08065324A0458|79 91|TATA elements
14P08065324A0458|124 136|transcription
14P08065327A0000|9 25|DNA rearrangement
14P08065327A0000|82 103|germ line micronucleus
14P08065331A0279|16 39|site selection procedure
14P08065331A0279|56 68|DNA sequences
14P08065331A0279|98 100|HLF
14P08065331A0279|112 127|E2A-HLF proteins
14P08065338T0000|3 7|Oct-2
14P08065338T0000|37 54|activation domains
14P08065338T0000|113 125|transcription
14P08065365A0000|0 6|Binding
14P08065365A0000|9 10|U2
14P08065365A0000|23 39|ribonucleoprotein
14P08065366A0918|32 36|Dbf8p
14P08065366A0918|59 80|chromosome segregation
14P08065368A0839|0 4|Ariga
14P08065368A0839|6 12|Biochem
14P08065901A0997|25 35|KRAB domain
14P08065901A0997|69 77|ZFP genes
14P08065901A0997|156 168|KRAB-A domain
14P08066094T0000|0 10|Marine oils
14P08067013T0001|27 59|creatine phosphokinase antibodies
14P08067123A0248|49 73|assay systems ORTHO ELISA
14P08067123A0248|74 87|ABBOTT HCV EIA
14P08067123A0248|87 89|USA
14P08067123A0248|95 108|detection rate
14P08067123A0248|110 124|anti-HCV-C100-3
14P08067123A0248|150 155|Moscow
14P08067123A0248|195 208|HBsAg carriers
14P08067123A0248|232 246|anti-HCV-C100-3
14P08067546A0000|38 56|vasomotor responses
14P08067546A0000|68 70|ETO
14P08067546A0000|90 106|sodium thiopental
14P08067546A0000|107 109|STP
14P08067546A0000|171 172|NO
14P08067546A0000|184 199|vasodilator tone
14P08067546A0000|220 243|vasoconstrictor activity
14P08067607A0568|24 34|CBC results
14P08067607A0568|37 59|serum CRP concentration
14P08067607A0568|71 85|baseline values
14P08069298A0492|16 30|splice variants
14P08069298A0492|44 46|RNA
14P08069298A0492|90 110|leptomeningeal tissue
14P08069298A0492|132 151|leptomeningeal cells
14P08069298A0492|152 154|LMC
14P08069427T0000|0 26|Roux-en-Y gastroenterostomy
14P08069481A0736|12 22|experiments
14P08069481A0736|43 54|calf muscles
14P08070004A0782|32 48|PCZ plasma levels
14P08070004A0782|76 91|plasma half-life
14P08070004A0782|92 101|t1/2 alpha
14P08070393A0631|10 15|effect
14P08070393A0631|28 36|ng/ml EGF
14P08070393A0631|42 49|time lag
14P08070654A0000|0 3|KAR1
14P08070654A0000|57 59|SPB
14P08070654A0000|90 104|SPB duplication
14P08070654A0574|0 4|CDC31
14P08070654A0574|18 32|SPB duplication
14P08070654A0574|91 108|caltractin/centrin
14P08070654A0574|135 147|Chlamydomonas
14P08071356A0232|6 26|transcript elongation
14P08071356A0232|40 52|DNA footprint
14P08071356A0232|73 92|transcription bubble
14P08071356A0232|109 131|transcription complexes
14P08071356A0232|148 165|template positions
14P08071982T0000|32 39|syndrome
14P08072352A0567|51 69|aspirin sensitivity
14P08072352A0567|80 91|eosinophilia
14P08072352A0567|119 128|IgE levels
14P08072547A0690|0 2|Ras
14P08072547A0690|30 44|protein kinases
14P08072547A0690|68 82|serine residues
14P08072547A1009|33 56|JNK phosphorylation site
14P08072547A1009|94 110|activation domain
14P08072547T0000|55 68|protein kinase
14P08072547T0000|80 82|JNK
14P08072547T0000|86 88|ERK
14P08073505T0000|16 42|information retrieval tools
14P08073505T0000|70 86|ExPASy WWW server
14P08075070A1632|43 45|DNA
14P08075070A1632|69 82|operator sites
14P08075070A1632|86 102|repressor domains
14P08075070A1632|109 127|sequence homologies
14P08075070A1632|151 153|HTH
15P08075421A0621a|10 12|ORF
15P08075421A0621a|39 48|C terminus
15P08075421A0621a|50 54|HrpJ2
15P08075421A0621b|10 12|ORF
15P08075421A0621b|39 48|C terminus
15P08075421A0621b|50 54|HrpJ2
14P08076631A0000|12 36|transcription factor AP-1
14P08076631A0000|38 55|vitamin D receptor
14P08076631A0000|55 57|VDR
14P08076631A0000|73 76|AP-1
14P08076631A0000|116 119|AP-1
14P08076631A0000|121 124|VDRE
14P08076631A0000|191 195|MG-63
14P08076631A0000|220 225|SaOs-2
14P08076631A0000|232 254|osteosarcoma cell lines
14P08076937A0851|40 60|restriction digestion
14P08076937A0851|82 84|DNA
14P08076937A0851|87 101|mismatch primer
14P08076937A0851|137 158|Tru9I restriction site
14P08077236A0243|0 8|Wild type
14P08077236A0243|17 25|Epo cDNAs
14P08077236A0243|63 66|COS1
14P08077236A0243|70 79|COS7 cells
14P08078167A0000|0 8|OBJECTIVE
14P08078167A0000|28 38|hepatitis A
14P08078416A0581|23 35|disinfectants
14P08078416A0581|43 55|biofilm cells
14P08078416A0581|102 115|concentrations
14P08078416A0581|121 133|disinfectants
14P08078473A1107|0 9|Expression
14P08078473A1107|12 21|ME31B cDNA
14P08078473A1107|23 24|S.
14P08079268T0028|0 2|Use
14P08079268T0028|5 27|Medi-Jector EZ dermojet
14P08082215A0230|19 32|past-infection
14P08082215A0230|35 49|cytomegalovirus
14P08082215A0230|65 68|RTID
14P08082286A0748|0 17|Acupuncture effect
14P08082292T0000|7 17|NK activity
14P08082292T0000|46 48|HIV
14P08082360A0411|0 14|Smoking history
14P08082360A0411|22 38|oxygen saturation
14P08082360A0411|39 42|SaO2
15P08082440A0339a|1 4|LH P
15P08082440A0339a|10 17|LH/FSH P
14P08083011A0584|72 87|R-L brain weight
14P08083011A0584|95 96|RH
14P08083011A0584|111 126|R-L brain weight
14P08083011A0584|141 152|testosterone
14P08083220A0988|17 33|complex formation
14P08083220A0988|75 93|c-fos protooncogene
14P08083220A0988|161 174|serum response
14P08083963A0795|26 28|VBP
14P08083963A0795|30 35|a1/EBP
14P08083963A0795|40 45|B-cell
14P08083963A0795|99 103|DNase
14P08083963A0795|121 151|methylation interference assays
15P08083998A1723a|23 40|leader-mRNA fusion
15P08083998A1723a|42 66|coronavirus transcription
15P08083998A1723a|86 104|RNA-RNA interaction
15P08083998A1723b|23 40|leader-mRNA fusion
15P08083998A1723b|42 66|coronavirus transcription
15P08083998A1723b|86 104|RNA-RNA interaction
14P08083999A0501|0 7|Vaccinia
14P08083999A0501|43 48|HPV-16
14P08083999A0501|52 68|BPV-1 E2 proteins
14P08083999A0501|73 89|consensus E2 site
14P08083999A0501|115 116|Kd
14P08084339A0907|85 91|J alpha
14P08084339A0907|145 162|TCR C alpha region
14P08084339A0907|185 206|amino acid polypeptide
14P08084592A0145|2 5|HeLa
14P08084592A0145|7 29|fibroblast cell hybrids
14P08084592A0145|55 68|tumorigenicity
14P08085228A0000|11 25|characteristics
14P08085228A0000|29 44|risk factor data
14P08085228A0000|119 140|immunodeficiency virus
14P08085228A0000|141 143|HIV
14P08085228A0000|169 186|testing facilities
14P08085228A0000|188 194|Houston
14P08085228A0000|196 199|Tex.
14P08085609A0384|0 6|Results
14P08085609A0384|19 24|KNM-LU
14P08085609A0384|51 64|chimpanzee M1s
14P08085609A0384|117 137|crown fissure termini
14P08085782A0164|12 16|cases
14P08085782A0164|30 34|tumor
14P08086450A0467|0 9|Comparison
14P08086450A0467|87 102|guanine-cytosine
14P08086450A0467|104 105|GC
14P08086450A0467|134 147|binding motifs
14P08086450A0467|178 180|Sp1
14P08086450A0467|182 185|AP-2
14P08086450A0467|190 192|GCF
14P08086453T0000|0 8|Structure
14P08086453T0000|10 26|promoter analysis
14P08086453T0000|60 68|APEX gene
14P08087887A1067|3 20|polyubiquitin gene
14P08087887A1067|47 63|Volvox life cycle
14P08087887A1067|123 136|post-inversion
14P08088022A1417|31 37|disease
14P08088022A1417|56 68|heart disease
14P08088022A1417|144 151|ischemia
14P08088513A0419|89 106|DEAH protein Prp16
14P08088513A0419|112 113|U6
14P08088513A0419|117 118|U2
14P08088777A0754|3 22|consensus gene order
14P08088777A0754|60 65|D2Mit1
14P08088777A0754|68 70|Dbh
14P08088777A0754|72 77|Notch1
14P08088777A0754|81 86|Col5a1
14P08088777A0754|88 91|Rxra
14P08088777A0754|94 103|Spna2-Ab l
14P08088777A0754|105 107|Ak1
14P08088777A0754|109 112|Fpgs
14P08088777A0754|116 120|Grp78
14P08088777A0754|122 125|Pbx3
14P08088777A0754|136 137|Hc
14P08088777A0754|139 141|Gsn
14P08088777A0754|144 147|Acra
14P08088818A1053|58 61|YACs
14P08088818A1053|140 149|RAD52 gene
14P08089184A0825|14 28|megabase region
14P08089184A0825|42 51|dagA locus
14P08089834A0561|65 82|amino acid residue
14P08089887A0742|9 23|OUTCOME MEASURE
14P08090571T0001|0 10|Elimination
14P08090746A1288|15 22|ATTTCAAA
14P08090746A1288|77 94|promoter sequences
14P08090746A1288|105 127|ethylene responsiveness
14P08090746A1288|134 162|tomato fruit-ripening E4 gene
14P08090767A0000|21 40|DNA polymerase delta
14P08090767A0000|143 162|base excision repair
14P08090767A0000|172 193|DNA methylation damage
14P08091655A0000|26 38|Disease Virus
14P08091655A0000|39 41|MDV
14P08091655A0000|57 72|EcoRI-B fragment
14P08091655A0000|74 79|MDV-GA
14P08091655A0000|87 89|DNA
14P08091665T0000|0 11|Cowpox virus
14P08091665T0000|80 91|TNF receptor
14P08091669A0828|18 20|P35
14P08091669A0828|37 48|39k promoter
14P08091669A0828|62 64|IE1
14P08091669A0828|69 71|p35
14P08093450A0688|0 10|Mutagenesis
14P08093450A0688|17 27|NRF-1 motif
14P08093450A0688|32 44|ALAS promoter
14P08093450A0688|76 119|chloramphenicol acetyltransferase expression
14P08093450A0688|143 154|NRF-1 motifs
14P08093616A1214|0 4|DNase
14P08093616A1214|6 26|footprinting analysis
14P08093616A1214|39 42|DREF
14P08093616A1214|58 67|DRE region
14P08093616A1214|72 96|DNA polymerase alpha gene
14P08093616T0000|5 24|8-base pair sequence
14P08093616T0000|34 36|DNA
14P08093616T0000|75 88|binding factor
14P08093616T0000|131 150|DNA polymerase alpha
14P08093642A0600|12 45|microsatellite repeat polymorphism
14P08093642A0600|73 81|RET locus
14P08093642A0600|85 124|restriction fragment length polymorphism
14P08093642A0600|175 186|D10S94 locus
14P08094464A0869|51 58|promoter
14P08094464A0869|87 93|portion
14P08094464A2014|15 31|attenuator region
14P08094464A2014|81 93|configuration
14P08094464A2014|105 127|base-residue divergence
14P08094498A0614|52 60|diagnosis
14P08094498A0614|64 72|prognosis
14P08094927A0311|25 33|mutations
14P08094927A0311|39 48|6K protein
14P08095698T0000|0 9|Metabolism
14P08095698T0000|100 121|nephropathia epidemica
14P08095872A1672|117 131|LONG/CIRC ratio
14P08095872A1672|159 178|contraction efficacy
14P08095875T0000|0 6|Effects
14P08095875T0000|17 27|hypercapnia
14P08095875T0000|30 40|hypothermia
14P08095875T0000|54 58|He-O2
14P08096066A0623|3 15|RFLP patterns
14P08096066A0623|123 133|development
14P08096066A0623|136 150|drug resistance
14P08096944A0951|22 32|stimulation
14P08096944A0951|58 67|indication
14P08096944A0951|79 88|assessment
14P08096944A0951|131 141|stimulation
14P08097666A1135|0 5|A23187
14P08097666A1135|21 33|modifications
14P08097732A0000|0 9|Activation
14P08097732A0000|38 48|Spec2a gene
14P08097732A0000|64 81|sea urchin embryos
14P08097732A0000|137 152|sequence element
14P08097732A0000|153 155|RSR
14P08097732A0000|174 190|Spec1/Spec2 genes
14P08098228A0625|38 40|PPO
14P08098842A0660|0 8|Mutations
14P08098842A0660|55 78|transcription start site
14P08098842A0660|205 219|gene expression
14P08098842A0660|234 243|regulation
14P08098882T0001|12 26|desensitization
14P08098914A0400|18 33|Pes-Ves relation
14P08098914A0400|90 92|Ees
14P08098914A0400|130 131|SD
14P08099443A0359|10 12|HRI
14P08099443A0359|37 53|yeast eIF-2 alpha
14P08099443A0359|96 107|GCN2 protein
14P08099443A0359|118 133|GCN4 translation
14P08100057A0577|45 55|populations
14P08100057A0577|71 81|macrophages
14P08100057A0577|99 109|dendrocytes
14P08100765A0361|25 53|transgene expression patterns
14P08100843A0134|0 16|Southern analysis
14P08100843A0134|25 27|DNA
14P08100843A0134|70 82|mouse strains
14P08100843A0134|115 124|Cd22 locus
14P08101134A0376|3 16|concentrations
14P08101134A0376|65 78|MPTP treatment
14P08101171A0924|36 52|Pc group products
14P08101171A0924|84 93|boundaries
14P08101171A0924|137 146|regulators
14P08101839A0000|16 25|regulation
14P08101839A0000|28 37|expression
14P08101839A0000|73 85|mdr1 promoter
14P08101839A0000|104 121|cell proliferation
14P08101843A0151|3 27|tyrosine hydroxylase gene
14P08101843A0151|27 28|TH
14P08101843A0151|99 127|transcription initiation site
14P08102364A0000|0 6|Tobacco
14P08102364A0000|35 55|Nicotiana tabacum var
14P08103379A0577|45 55|MADS domain
14P08103379A0577|106 129|amino acid substitutions
14P08103935T0000|30 51|SRF accessory proteins
14P08104189A1168|24 39|proSRIF cleavage
14P08104189A1168|55 57|TGN
14P08104189A1168|145 150|ATPase
14P08105727A0099|0 9|Fenoldopam
14P08105727A0099|12 36|dopamine receptor agonist
14P08105727A0099|51 68|animal experiments
14P08105994T0000|32 63|serum gamma-glutamyl transferase
14P08106087A0139|28 40|kDa zein gene
14P08106087A0139|135 155|polyadenylation sites
14P08106245A0325|9 27|radon concentration
14P08106245A0325|69 74|Bq m-3
14P08106245A0325|125 130|Bq m-3
14P08106245A0325|147 158|measurements
14P08106245A0325|174 179|Bq m-3
14P08106245A0325|220 225|Bq m-3
14P08106245A0325|265 276|measurements
14P08106313A1492|68 71|HrpR
14P08106313A1492|75 78|HrpS
14P08106313A1492|87 96|expression
14P08106313A1492|106 109|HrpL
14P08106313A1492|120 131|sigma factor
14P08106313A1492|139 148|expression
14P08106325A0000|0 3|DtxR
14P08106325A0000|100 118|nucleotide sequence
14P08106325A0000|140 160|diphtheria toxin gene
14P08106369A0000|0 10|Vasopressin
14P08106369A0000|12 14|AVP
14P08106369A0000|108 125|membrane receptors
14P08106369A0000|167 169|V1a
14P08106369A0000|171 173|V1b
14P08106369A0000|178 179|V2
14P08106398A1003|38 51|leader peptide
14P08106398A1003|66 81|nisin maturation
14P08106512A0522|7 21|promoter region
14P08106512A0522|47 59|reporter gene
14P08106512A0522|74 88|promoter region
14P08106512A0522|105 115|interferons
14P08106512A0522|117 132|interferon-alpha
14P08107167A0222|0 5|Anti-B
14P08107167A0222|45 62|parkeri antibodies
14P08107167A0222|105 107|IFA
14P08107167A0222|145 157|serum samples
14P08107167A0222|178 184|IFA-ABS
14P08107208A0673|88 90|EBV
14P08107208A0673|104 107|DNAs
14P08107208A0673|109 110|B.
14P08108099T0000|0 9|Evaluation
14P08108099T0000|12 23|desmopressin
14P08108099T0000|33 43|extractions
14P08108343A0000|57 60|GnRH
14P08108343A0000|136 147|hypogonadism
14P08108343A0000|189 201|insufficiency
14P08108343A0000|212 220|diagnosis
14P08108343A0000|251 271|gonadotropin reserves
14P08108413A0964|90 104|PANG expression
14P08111035A0098|40 59|bp promoter fragment
14P08111035A0098|61 81|B. napus oleosin gene
14P08111035A0098|103 120|beta-glucuronidase
14P08111035A0098|122 124|GUS
14P08111035A0098|173 192|oleosin promoter-GUS
14P08111974A1034|36 37|CX
14P08111974A1034|62 73|tubulin mRNA
14P08111974A1034|152 163|trans-factor
14P08112341A1128|0 1|L.
14P08112341A1128|3 7|Greer
14P08112341A1128|9 10|J.
14P08112341A1128|12 17|Carter
14P08112341A1128|19 20|G.
14P08112526A0443|26 46|calcium concentration
14P08112526A0443|54 75|detrusor contractility
14P08112601T0000|10 21|organization
14P08112601T0000|47 55|lipocalin
14P08112601T0000|73 81|synthesis
14P08112611A0404|26 38|reading frame
14P08112611A0404|59 69|amino acids
14P08112870A0484|0 15|Western blotting
14P08112870A0484|16 29|immunoblotting
14P08112870A0484|56 58|SOD
14P08113736A0309|3 19|gene organization
14P08113736A0309|21 30|CRSV RNA-1
14P08113736A0309|72 76|RCNMV
14P08113736A0309|107 111|SCNMV
14P08113736A0309|147 156|CRSV RNA-1
14P08113736A0309|188 190|ORF
14P08114702A0000|0 6|Members
14P08114702A0000|52 55|MEF2
14P08114702A0000|65 85|transcription factors
14P08114702A0000|120 134|control regions
14P08114710A0137|25 29|LBP-1
14P08114710A0137|39 57|HIV-1 transcription
14P08114710A0137|81 85|TFIID
14P08114710A0137|91 98|TATA box
14P08114745A0953|40 41|La
14P08114745A0953|44 57|RNA production
14P08114745A0953|92 108|termination sites
14P08114745A0953|158 180|transcription complexes
14P08115744A0462|45 62|laser densitometer
14P08115744A0846|99 123|quality assurance program
14P08116245A0174|12 14|RNA
14P08118044A0318|0 10|GATA-1 mRNA
14P08118044A0318|79 90|FDC-P1 cells
14P08119149A0000|0 26|Tumor necrosis factor-alpha
14P08119149A0000|26 34|TNF alpha
14P08119907A0000|35 48|p21ras protein
14P08119907A0000|72 86|growth factor-I
14P08119907A0000|87 91|IGF-I
14P08119907A0000|93 110|signaling pathways
14P08119958A0273|12 20|C2 domain
14P08119958A0273|25 26|Ca
14P08119958A0273|41 44|PKCs
14P08119958A0273|102 115|signal peptide
14P08119958A0273|149 154|PKC mu
14P08119958A0273|191 194|PKCs
14P08119995A0814|36 55|T3R-RXR heterodimers
14P08119995A0814|57 73|response elements
14P08119995A0814|115 125|orientation
14P08119995A0814|135 145|nucleotides
14P08120019A1500|13 23|Hm1 mutants
14P08120019A1500|63 73|PI turnover
14P08120029A0864|19 41|decay reaction mixtures
14P08120029A0864|64 83|sense RNA transcript
14P08120029A0864|107 116|R2 message
14P08122364A0954|0 16|Deletion analyses
14P08122364A0954|42 60|promoter constructs
14P08122364A0954|110 123|pCD41 sequence
14P08122370A0331|32 33|US
14P08122370A0331|36 54|herpes simplex type
14P08122370A0331|55 59|HSV-1
14P08122370A0331|62 79|pseudorabies virus
14P08122370A0331|80 82|PRV
14P08122370A0331|111 115|EHV-1
14P08123787A0554|11 29|amino acid sequence
14P08123787A0554|47 58|HemB protein
14P08123787A0554|94 119|metal cofactor requirement
14P08123787A0554|164 177|overexpression
14P08124785A0445|0 6|METHODS
14P08124785A0445|10 16|RESULTS
14P08124785A0445|61 86|circumflex artery stenosis
14P08124785A0445|193 218|mean transit time Tmicro-1
14P08124912A0456|38 46|SF levels
14P08124912A0456|48 51|IL-8
14P08124912A0456|71 73|LDH
14P08124912A0456|75 94|beta 2-microglobulin
14P08124956T0000|43 54|pancreatitis
14P08124956T0000|75 85|oxygenation
14P08125258A0142|48 56|CHOP gene
14P08125258A0142|119 129|deprivation
14P08125258A0142|142 154|perturbations
14P08125319A1085|3 12|ipiO genes
14P08125319A1085|80 88|sequences
14P08125319A1085|98 111|data libraries
14P08125337A0940|0 14|Sterol analysis
14P08125337A0940|91 105|Erg24p activity
14P08125949A1162|43 58|spinach L12 mRNA
14P08125949A1162|73 82|AUG codons
14P08125949A1162|113 123|Arabidopsis
14P08125949A1162|180 203|L12/chloroplast ribosome
14P08126096A0478|7 17|experiments
14P08126096A0478|44 52|functions
14P08126096A0478|92 101|homologies
14P08126096A0478|123 131|sequences
14P08126096A0478|176 191|domain antiserum
14P08126096A1071|3 19|alpha 7A form RNA
14P08126096A1071|64 69|B form
14P08126096A1071|80 92|coding region
14P08126096A1071|101 111|B form RNAs
14P08126096A1071|127 140|reading frames
14P08127950A0000|64 66|HPT
14P08127950A0000|117 135|0800h plasma levels
14P08127950A0000|150 152|FT4
14P08127950A0000|159 174|triiodothyronine
14P08127950A0000|176 178|FT3
14P08127950A0000|184 210|thyroid stimulating hormone
14P08127950A0000|210 212|TSH
14P08127950A0000|251 258|TSH-IRMA
14P08128629A1164|0 11|CRS function
14P08128629A1164|26 46|gene expression assay
14P08128629A1164|75 80|p60CRS
14P08128629A1164|84 89|p40CRS
14P08128629A1164|106 112|LTR RNA
14P08129955A0572|14 23|troponin T
14P08129955A0572|39 43|CK-MB
14P08129955A0572|80 89|unclamping
14P08130942A0051|0 14|Regionalization
14P08130942A0051|17 29|drug delivery
14P08131545A0158|31 47|community members
14P08131545A0158|158 167|Mycoplasma
14P08131545A0158|179 200|Legionella pneumophila
14P08131545A0158|201 215|cytomegalovirus
14P08131545A0158|228 244|Coxiella burnetii
14P08131545A0158|248 256|Chlamydia
14P08131746A0140|0 2|MEK
14P08131746A0140|23 44|serine phosphorylation
14P08131746A0140|54 70|activator kinases
14P08131746A0140|92 101|MEK kinase
14P08132541A0000|7 16|DNA clones
14P08132541A0000|49 56|MAL gene
14P08132574A0831|0 6|Members
14P08132574A0831|9 11|SVA
14P08132574A0831|31 48|complement C2 gene
14P08132574A0831|80 82|RP1
14P08132574A0831|88 90|HLA
14P08132574A0831|99 120|cytochrome CYP1A1 gene
14P08132667T0000|22 55|proprotein processing enzyme furin
14P08133502T0105|0 28|European Community Huntington
14P08133502T0105|29 61|Disease Collaborative Study Group
14P08134108A0277|19 44|alpha-actin gene promoters
14P08134108A0277|50 66|YY1 binding sites
14P08134115A1161|0 5|MSSP-1
14P08134115A1161|42 44|GST
14P08134115A1161|86 91|TCTTAT
14P08134115A1161|101 103|H-P
14P08134115A1161|111 117|ACT-ATT
14P08134115A1161|130 132|H-P
14P08134115A1161|174 182|A/TCTA/TA
14P08134115A1161|184 185|TT
14P08136383A0359|18 30|MR tomography
14P08138180A0593|90 102|SPT10 protein
14P08138364T0000|0 8|Varieties
14P08139001A1235|33 47|carboxy termini
14P08139001A1235|52 71|NS1 protein molecule
14P08139001A1235|119 134|tubule formation
14P08139004A0278|5 7|UTR
14P08139004A0278|68 80|UGC sequences
14P08139017A1465|38 47|initiation
14P08139017A1465|68 83|primer extension
14P08139017A1465|111 126|Ets-1 cDNA clone
14P08139017A1465|191 201|Tpl-1 locus
14P08139031A1168|85 101|cysteine residues
14P08139031A1168|106 121|ORF4 polypeptide
14P08139031A1168|126 130|C-421
14P08139031A1168|134 138|C-426
14P08139031A1168|154 176|transactivator function
14P08139031A1168|195 211|cysteine residues
14P08139031A1168|287 303|acid interactions
14P08139031A1168|312 328|ORF4 inducibility
14P08139539A0446|2 13|Rat 1a cells
14P08139539A0446|13 27|m1R stimulation
14P08139539A0446|29 48|phospholipase C beta
14P08139539A0446|101 103|AMP
14P08139539A0446|146 162|protein kinase A.
14P08139542A1229|39 42|CPA1
14P08139542T0000|25 38|leader peptide
14P08139542T0000|43 51|CPA1 gene
14P08139542T0000|93 113|yeast gene transcript
14P08139543A0427|35 51|SLK1-SLT2 pathway
14P08139543A0427|68 85|suppression screen
14P08139543A1520|41 45|NHP6A
14P08139543A1520|49 62|NHP6B function
14P08139543A1520|74 77|SLT2
14P08139562A0404|71 74|GCN4
14P08139562A0404|140 154|GCN4 start site
14P08139577T0000|21 51|yeast transcription factor IIIB
14P08139577T0000|91 94|TATA
14P08139914A0554|30 46|dnHLH protein Id1
14P08139914A0554|53 67|differentiation
14P08139928T0000|0 3|RNP1
14P08139928T0000|9 30|ribonucleoprotein gene
14P08140847X0001|0 4|Crohn
14P08140847X0001|160 164|Crohn
14P08140847X0001|167 182|disease patients
14P08140847X0001|203 206|CDAI
14P08140847X0001|235 245|body weight
14P08142875A0877|17 26|dissection
14P08142875A0877|93 104|intervention
14P08143198T0001|0 10|Restoration
14P08143198T0001|54 86|composites dorsal pedal skin flap
14P08143198T0001|93 119|m. extensor hallucis brevis
14P08143236A1055|7 21|ethanol regimen
14P08143236A1055|40 50|alternation
14P08143236A1055|59 72|g ethanol.kg-1
14P08143236A1055|73 85|day-1 regimen
14P08143667A0222|38 40|IVP
14P08143667A0222|60 76|closure pressures
14P08143667A0222|77 80|MUCP
14P08143667A0222|152 155|MUCP
14P08143667A0222|159 161|IVP
14P08144035A0387|52 61|N terminus
14P08144035A0387|71 80|C terminus
14P08144037A0000|0 10|Thioredoxin
14P08144037A0000|12 13|TR
14P08144470A0711|20 33|asgB480 allele
14P08144470A0711|100 111|substitution
14P08144470A0711|126 140|protein product
14P08144497T0000|24 35|raf-1 kinase
14P08144497T0000|104 110|GTP-ras
14P08144504T0064|32 45|ATP hydrolysis
14P08144572A0786|0 2|ATP
14P08144572A0786|22 40|polypeptide binding
14P08144572A0786|42 48|Ssb1/2p
14P08144572A0786|101 118|Ssa Hsp70 proteins
14P08144572A0786|126 128|BiP
14P08144572A0786|132 135|DnaK
14P08144615A0533|0 8|Digestion
14P08144615A0533|11 16|NF-IL6
14P08144615A0533|21 38|endoprotease Asp-N
14P08144615A0533|67 69|TCD
14P08144615A0533|71 89|NF-IL6 bZIP domains
14P08144615A0533|89 92|NFBD
14P08144615A0533|155 157|DNA
14P08144631A0000|0 8|Signaling
14P08144631A0000|11 26|tyrosine kinases
14P08144631A0000|71 82|Src homology
14P08144631A0000|84 86|SH2
14P08144631A0000|105 128|tyrosine phosphorylation
14P08144668A0802|87 99|reading frame
14P08144668A0802|114 117|GPHe
14P08144668A0802|119 120|P2
14P08144668A0802|162 179|membrane anchoring
14P08144852A0000|18 32|stress hormones
14P08144852A0000|42 57|11-deoxycortisol
14P08144852A0000|59 62|ACTH
14P08144852A0000|76 78|AVP
14P08144852A0000|84 96|corticotropin
14P08144852A0000|113 115|CRF
14P08144852A0000|159 177|cortisol deficiency
14P08145646T0000|0 8|Structure
14P08145646T0000|50 53|RpoN
14P08145646T0000|57 78|Rhodobacter capsulatus
14P08145646T0000|118 139|nifU2-rpoN superoperon
14P08145770A1078|53 55|PKC
14P08145770A1078|59 75|retinoid pathways
14P08145770A1078|133 157|differentiation processes
14P08148463A0000|29 32|CSFs
14P08148463A0000|96 110|granulocyte CSF
14P08148463A0000|133 135|CSF
14P08148463A0000|137 150|macrophage CSF
14P08148756A0358|11 26|lung destruction
14P08148756A0358|50 59|hemorrhage
14P08148756A0358|82 99|hemoglobin content
14P08149484A0151|0 18|Expression plasmids
14P08149484A0151|54 62|PKC alpha
14P08149484A0151|65 73|PKC delta
14P08149484A0151|74 84|PKC alpha K
14P08149484A0151|86 96|PKC delta K
14P08149484A1551|28 36|PKC alpha
14P08149484A1551|57 65|PKC delta
14P08149484A1551|98 110|transcription
14P08149484A1551|142 145|AP-1
14P08150970A0434|19 24|TSST-1
14P08150970A0434|90 95|TSST-1
14P08151787A0355|0 8|Insertion
14P08151787A0355|16 31|oligonucleotides
14P08151787A0355|48 80|amino acid motifs 726-GRKRKSP-732
14P08151787A0355|82 86|IE175
14P08151787A0355|90 104|500-VRPRKRR-506
14P08151787A0355|109 113|IE110
14P08151787T0000|22 41|localization domains
14P08151787T0000|55 81|colocalization interactions
14P08151787T0000|91 95|IE110
14P08151787T0000|99 103|IE175
14P08151787T0000|111 133|transactivator proteins
14P08151787T0000|135 154|herpes simplex virus
14P08151790A0354|3 22|revertant TATA boxes
14P08151790A0354|45 59|HIV replication
14P08151790A0354|86 88|LTR
14P08151790A0354|100 111|Sp1 mutation
14P08151790A0354|182 184|HIV
14P08151980T0001|10 18|emphysema
14P08152800A0357|8 17|ETS domain
14P08152800A0357|108 111|PEA3
14P08152800A0357|115 118|ER81
14P08152800A0357|154 156|Ets
14P08152800A0357|164 181|Molecule PEA3-like
14P08152800A0357|183 185|ERM
14P08152800A0709|0 17|Gel shift analysis
14P08152800A0709|43 53|ERM protein
14P08152800A0709|109 147|consensus nucleotide core sequence GGAA
14P08153130T0000|0 6|Effects
14P08153130T0000|20 30|worm burden
14P08153130T0000|43 52|leukocytes
14P08153146A0327|0 9|Dotarizine
14P08153146A0327|60 70|circulation
14P08153146A0327|90 99|resistance
14P08153146A0327|118 128|artery flow
14P08153146A0327|151 161|artery mean
14P08154171A0649|26 30|LMWHs
14P08154171A0649|53 62|thrombosis
14P08154171A0649|75 84|infarction
14P08154171A0649|92 102|conjunction
14P08154182A0955|34 59|lambda AD5 cloning vectors
14P08154182A0955|91 122|Neurospora crassa cDNA libraries
14P08156332T0000|23 35|sympathectomy
14P08156332T0000|46 54|treatment
14P08156332T0000|76 84|ischaemia
14P08157009A0264|0 19|Sequence comparisons
14P08157009A0264|96 107|AP-1 complex
14P08157009A0264|140 173|plasma membrane AP-2 sigma subunit
14P08157009T0000|26 34|APS1 gene
14P08157009T0000|80 100|clathrin AP-1 complex
14P08157009T0000|149 161|Golgi complex
14P08157663A0882|49 60|organization
14P08157663A0882|64 78|vertebrate gene
14P08157663A0882|96 111|membrane protein
14P08157663A0882|158 169|polypeptides
14P08157663A0882|181 189|evolution
14P08157674T0000|11 26|characterization
14P08157674T0000|56 88|protein tyrosine kinase substrate
14P08159174A0581|41 57|Southern analysis
14P08160054A0224|15 28|deterioriation
14P08160054A0224|66 78|liver enzymes
14P08160054A0224|91 116|alanine aminotransaminases
14P08160054A0224|126 137|coagulopathy
14P08160387T0000|19 29|development
14P08160387T0000|75 84|experience
14P08160387T0000|90 96|rearing
14P08160387T0000|109 119|deprivation
14P08160905A0217|34 60|hepatitis B surface antigen
14P08160905A0217|59 63|HBsAg
14P08163183T0000|39 71|Clostridium thermosaccharolyticum
14P08163183T0000|104 115|XylA enzymes
14P08163498A0789|3 17|phosphopeptides
14P08163498A0789|31 32|RS
14P08163498A0789|35 37|32P
14P08163498A0789|39 52|SGASGLLTSEHHSR
14P08163498A0789|59 61|32P
14P08163498A0789|63 76|SGASGLLTSEHHSR
14P08163498A0789|109 123|phosphorylation
14P08163528T0000|13 41|Mas70p signal anchor sequence
14P08163546A1230|31 36|Ypt51p
14P08163546A1230|38 43|Ypt52p
14P08163546A1230|48 53|Ypt53p
14P08163546A1230|157 168|intersection
14P08163546A1230|198 212|sorting pathway
14P08164302A0547|13 25|TPN solutions
14P08164302A0547|57 76|nutrient composition
14P08164661A0414|13 24|TFIIIC alpha
14P08164661A0414|135 148|RNA polymerase
14P08164679A0809|0 21|Transactivation domain
14P08164679A0809|59 78|runt homology region
14P08164679A0809|93 103|Runt domain
14P08164680A1086|17 33|protease activity
14P08164680A1086|64 70|B cells
14P08164684A1266|12 14|RXR
14P08166402A0631|0 18|Cerebral125 albumin
14P08166402A0631|74 88|hyperosmolality
14P08167396A0154|65 94|substantia nigra pars compacta
14P08167555A0972|0 7|Response
14P08167555A0972|10 18|treatment
14P08167555A0972|46 57|pretreatment
14P08167555A0972|71 80|treatments
14P08169201A0291|48 59|carA product
14P08169201A0291|90 108|nucleotide sequence
14P08169201A0291|154 164|amino acids
14P08169709T0000|10 18|bone cyst
14P08169709T0000|28 35|analysis
14P08170400T0000|0 7|Location
14P08170400T0000|62 81|transcription factor
14P08170400T0000|82 84|FNR
14P08172416A0860|0 9|Moxidectin
14P08172416A0860|83 93|performance
14P08172416A0860|110 125|folliculogenesis
14P08172416A0860|127 135|ovulation
14P08172416A0860|164 174|development
14P08172598A0237|43 56|N. patriciarum
14P08172598A0237|86 100|kb mRNA species
14P08172653A1589|38 49|TnT isoforms
14P08172653A1589|80 91|modification
14P08172653A1589|134 136|TnT
14P08172905A0000|25 47|alanine tRNA synthetase
14P08172905A0000|59 74|RNA miniduplexes
14P08172905A0000|133 134|G3
14P08172905A0000|136 148|U70 base pair
14P08173532A0000|6 18|reaction time
14P08173532A0000|19 20|RT
14P08173532A0000|48 49|S2
14P08173532A0000|86 87|S1
14P08173532A0000|103 113|S2 location
14P08173532A0000|128 139|target onset
14P08173532A0000|145 156|facilitation
14P08173693A0390|78 98|angina pectoris class
14P08173814A0132|23 41|host cell machinery
14P08173814A0132|61 72|interference
14P08173814A0132|128 142|host physiology
14P08175031A0566|0 8|Treatment
14P08175188A0685|1 13|concentration
14P08175188A0685|46 60|baseline values
14P08175188A0685|84 86|MCA
14P08175188A0685|108 110|CBF
14P08176742A0190|23 38|assay conditions
14P08176742A0190|58 78|transposition pathway
14P08177143T0000|5 18|cell carcinoma
14P08177143T0000|36 46|institution
14P08177143T0000|49 58|experience
14P08178446A1160|18 22|ICP10
14P08178446A1160|64 73|TM segment
14P08178446A1160|115 132|signaling pathways
14P08178490A0879|23 37|signal function
14P08178490A0879|44 58|anchor function
14P08178490A0879|66 76|K SA domain
14P08178572A1118|4 34|concensus poly A addition sites
14P08179827T0000|0 6|Factors
14P08179827T0000|48 74|hepatitis B virus infection
14P08179827T0000|74 78|Korea
14P08180129A1256|0 7|Exposure
14P08180129A1256|16 33|TPA concentrations
14P08181755A0989|0 16|Northern analysis
14P08181755A0989|29 44|pcbAB transcript
14P08182041A1067|58 62|PEPCK
14P08182041A1067|65 67|PKA
14P08182041A1067|103 124|CREB activation domain
14P08182041A1067|129 147|PEPCK TATA sequence
14P08182056A0695|34 37|NQO2
14P08182056A0695|41 62|NQO1 gene organization
14P08182056A0695|85 93|NQO2 gene
14P08182056A0695|121 135|NQO gene family
14P08182171A0000|14 44|Propionibacterium acnes product
14P08182171A0000|57 73|coliform mastitis
14P08183552T0000|27 51|tyrosine kinase substrate
14P08183915A0000|33 36|p105
14P08183915A0000|52 62|p50 subunit
14P08183915A0000|64 94|transcription factor NF-kappa B
14P08183915A0000|104 124|p70 I kappa B protein
14P08183915A0000|122 136|I kappa B gamma
14P08183915A0000|181 184|p105
14P08183915T0000|21 35|RNA transcripts
14P08183915T0000|53 72|p105 NF-kappa B gene
14P08183915T0000|79 102|I kappa B gamma isoforms
14P08184923A0829|7 11|L-NNA
14P08184923A0829|46 49|CoBF
14P08184923A0829|62 65|CeBF
14P08185288A0106|3 12|experiment
14P08185288A0106|43 50|subjects
14P08185288A0106|78 97|respiration chambers
14P08185288A0106|123 131|afternoon
14P08185288A0106|135 145|min cycling
14P08187085A0086|5 18|rearrangements
14P08187085A0086|64 85|tyrosine kinase domain
14P08187085A0086|103 115|end sequences
14P08187088A0530|14 27|heterozygosity
14P08187088A0530|29 31|LOH
14P08187088A0530|73 86|chromosomes 3p
14P08187088A0530|94 95|5q
14P08187088A0530|104 105|6p
14P08187088A0530|114 115|8p
14P08187088A0530|124 125|9p
14P08187088A0530|134 135|9q
14P08187088A0530|144 146|11p
14P08187088A0530|155 157|13q
14P08187088A0530|166 168|17p
14P08187088A0530|177 179|17q
14P08187088A0530|188 190|18q
14P08187088A0530|202 204|19q
14P08187177A0405|7 23|amino acid change
14P08187177A0405|27 29|CPY
14P08187177A0405|38 51|sorting signal
14P08188258A0000|26 47|prolyl-tRNA synthetase
14P08188258A0000|87 97|synthetases
14P08188290A0544|40 57|TCRAC/TCRDC region
14P08188290A0544|144 162|TCRAJ gene segments
14P08188603A0230|96 104|CPA2 gene
14P08188603A0230|159 163|CPS-A
14P08188606A1034|0 19|Restriction analysis
14P08188606A1034|22 43|Southern hybridization
14P08188606A1034|64 69|Tn5422
14P08188606A1034|162 179|cadmium resistance
14P08188978A0822|28 37|ECG R-wave
14P08188978A0822|52 66|MSNA burst peak
14P08188978A0822|123 141|pulse-synchronicity
14P08189174A0148|0 5|DESIGN
14P08189174A0148|78 100|breast cancer screening
14P08189174A0148|119 125|Utrecht
14P08189498T0000|0 13|Identification
14P08189498T0000|42 46|Marek
14P08189498T0000|49 61|disease virus
14P08189498T0000|73 85|repeat region
14P08189503A0000|34 65|mouse hepatitis virus strain A59
14P08189503A0000|86 88|RNA
14P08189503A0000|101 120|cassette mutagenesis
14P08189533A0203|71 74|NS53
14P08189533A0203|106 134|baculovirus expression system
14P08189533A0203|148 164|vaccinia virus/T7
14P08189533A0203|172 188|expression system
14P08189533A0919|0 18|Gel electrophoresis
14P08189533A0919|28 46|immunoblot analyses
14P08189533A0919|120 123|NS53
14P08190633A0000|3 27|transcription factor AP-2
14P08190633A0000|69 77|HLA locus
14P08190633A0273|9 17|AP-2 mRNA
14P08190633A0273|71 73|DNA
14P08191910A0228|0 9|San Martin
14P08191910A0228|89 97|abilities
14P08191910A0228|100 109|strategist
14P08192140A0209|34 59|hepatitis B vaccine trials
14P08192140A0209|59 67|Amsterdam
14P08192140A0209|75 87|New York City
14P08192140A0209|97 109|San Francisco
14P08192451A0885|59 63|Rh123
14P08192451A0885|79 88|NAO uptake
14P08192795T0000|43 61|lupus erythematosus
14P08193147A0831|0 9|Comparison
14P08193147A0831|17 33|crystal structure
14P08193147A0831|35 53|Desulfovibrio gigas
14P08193147A0831|54 55|Dg
14P08193147A0831|57 58|Fd
14P08193147A0831|60 68|Kissinger
14P08193147A0831|170 171|Pf
14P08193147A0831|182 186|Dg Fd
14P08194139A0498|0 10|CONCLUSIONS
14P08194139A0498|12 41|Serum prolactin concentrations
14P08194549A0000|88 89|CP
14P08194549A0000|104 129|blood lactate accumulation
14P08194549A0000|129 132|OBLA
14P08194753A0157|45 48|MluI
14P08194753A0157|76 78|DNA
14P08194970A0000|0 4|Women
14P08194970A0000|7 19|opportunities
14P08194970A0000|106 116|Trudy Wynne
14P08195186A0000|36 47|T lymphocyte
14P08195186A0000|68 70|Tea
14P08195186A0000|148 169|amino acid transporter
14P08195186A0000|183 191|RNA blots
14P08195186A0000|207 220|Tea expression
14P08195186A0000|222 234|T lymphocytes
14P08195186A0000|243 249|MacLeod
14P08195186A0000|251 254|C.L.
14P08195186A0000|256 261|Finley
14P08195186A0000|263 264|K.
14P08195186A0000|266 271|Kakuda
14P08195186A0000|273 274|D.
14P08195216A1022|28 31|HIS3
14P08195216A1022|116 120|GCN4p
14P08195216A1022|160 175|GCN4p activation
14P08195216A1022|177 180|TRP3
14P08195217A0799|46 84|reticulocyte lysate translation product
14P08195233A0147|2 9|addition
14P08195233A0147|90 97|position
14P08195233A0147|105 114|chromosome
14P08195233A0147|150 162|tumorigenesis
14P08196607A0280|0 16|Deletion analysis
14P08196607A0280|21 33|ICL1 promoter
14P08196607A0280|77 92|sequence element
14P08196607A0280|93 99|UASICL1
14P08196607A0280|103 112|CATTCATCCG
14P08196616A1112|30 35|ZAP-70
14P08196616A1112|79 96|ZAP-70 SH2 domains
14P08196616A1112|107 123|tyrosine residues
14P08196616A1112|148 153|ZAP-70
14P08196616A1112|170 193|phosphotyrosine residues
14P08196616A1112|218 228|SH2 domains
14P08196618A0473|0 4|PRL-1
14P08196618A0473|28 53|phosphotyrosine substrates
14P08196618A0473|81 96|cysteine residue
14P08196624A0593|2 11|Mv1Lu lung
14P08196624A0593|27 33|ActR-IB
14P08196624A0593|37 53|T beta R-I signal
14P08196624A0593|109 119|association
14P08198524A1134|2 4|kDa
14P08198524A1134|15 17|kDa
14P08199204A0746|46 59|PKC activation
14P08199204A0746|73 96|tyrosine phosphorylation
14P08199204A0746|99 104|PtdIns
14P08199204A0746|110 122|P2 production
14P08199878T0000|20 40|glucose concentration
14P08199878T0000|42 57|brain metabolism
14P08199878T0000|74 87|brain ischemia
14P08200528A0970|33 46|Tn903 neo gene
14P08200528A0970|51 103|Rhodosporidium toruloides phenylalanine ammonia lyase
14P08200528A0970|101 103|PAL
14P08200528A0970|156 159|REP2
14P08201352A0239|21 40|protein C deficiency
14P08201352A0239|40 60|vitamin K antagonists
14P08201352A0239|96 108|skin necrosis
14P08201758A0125|48 58|obstruction
14P08201758A0125|68 77|laparotomy
14P08201932A0355|10 20|examination
14P08201932A0355|37 49|polyarthritis
14P08202546A1206|27 51|hUBF-promoter interaction
14P08203260A1204|17 20|SIMV
14P08204348T0000|0 4|VP-16
14P08204348T0000|29 31|VIP
14P08204348T0000|50 65|cell lung cancer
14P08204403A0000|99 121|radioimmunoscintigraphy
14P08204403A0000|126 130|I-131
14P08204403A0000|142 147|CEA/CA
14P08204426T0001|50 65|diaphragm pacing
14P08204426T0001|80 101|implantation technique
14P08204824A0000|62 68|S phase
14P08204824A0000|120 138|Catharanthus roseus
14P08205827A0940|0 10|CONCLUSIONS
14P08205827A0940|12 24|Translocation
14P08205827A0940|106 123|animal experiments
14P08205827A0940|132 144|translocation
14P08206848A0296|10 19|pyrP genes
14P08206848A0296|26 37|polypeptides
14P08206867A0874|0 25|Southern blotting analysis
14P08206867A0874|54 64|COXVb genes
14P08206991A0466|0 8|Acylation
14P08206991A0466|16 31|palmitate analog
14P08206991A0466|47 51|Gly-2
14P08206991A0466|84 98|N-myristylation
14P08206991A0466|112 124|palmitylation
14P08206991A0466|139 143|Cys-3
14P08206991A0466|146 150|Cys-6
14P08207022T0000|0 18|Subunit composition
14P08207022T0000|41 78|Spo0A sporulation transcription factor
14P08207232A0503|15 37|mobility shift analysis
14P08207232A0503|49 55|NF-IL-6
14P08207232A0503|118 129|NF-IL-6 site
14P08207232A0503|134 146|IL-8 promoter
14P08207405A0372|0 2|BYV
14P08207405A0372|4 24|citrus tristeza virus
14P08207405A0372|24 26|CTV
14P08207405A0372|50 53|BYSV
14P08207405A0372|75 95|fleck virus templates
14P08207405A0372|103 127|kb amplification products
14P08207405A0372|188 198|HSP70 genes
14P08207795A0409|33 52|phosphorylation site
14P08207795A0409|84 105|mutagenesis procedures
14P08207805A0000|3 35|p53 tumor suppressor gene product
14P08208247T0030|31 42|segment 64AB
14P08208247T0030|71 93|acid decarboxylase gene
14P08208540A0000|0 13|Rearrangements
14P08208540A0000|19 28|NFKB2 gene
14P08208540A0417|0 6|Cloning
14P08208540A0417|128 133|p84/85
14P08208540A0417|184 198|ankyrin repeats
14P08208540A0417|215 230|carboxy-terminus
14P08208540A0417|250 263|ankyrin repeat
14P08208540A1114|9 30|co-transfection assays
14P08208540A1114|39 62|NFKB2 expression vectors
14P08208540A1114|105 113|NFKB2 p85
14P08208540A1114|138 156|repressor functions
14P08208540A1114|171 179|NFKB2 p52
14P08208618A1334|5 10|HR21ap
14P08208618A1334|19 25|HR21Xap
14P08208618A1334|56 66|Sp1 binding
14P08209051T0000|21 27|therapy
14P08209051T0000|36 43|fibrosis
14P08209051T0000|47 54|hospital
14P08209423T0000|24 42|nucleotide sequence
14P08209423T0000|48 73|MDV-1 BamHI-D DNA fragment
14P08209423T0000|110 126|glycoprotein gene
14P08209772A0167|25 37|reading frame
14P08209772A0167|38 40|ORF
14P08209772A0167|88 98|amino acids
14P08212571A0597|0 14|Co-transfection
14P08212571A0597|67 83|tat ORF mutations
14P08212571A0597|106 121|virus production
14P08212571A0971|0 7|Analysis
14P08212571A0971|19 30|rev proteins
14P08212571A0971|122 132|tat mutants
14P08212571A0971|201 221|tat expression vector
14P08212897A0404|3 24|hydrophobicity profile
14P08212897A0404|29 45|methyltransferase
14P08212897A0404|86 106|transmembrane domains
14P08213235A1024|0 10|Measurement
14P08213235A1024|13 16|SaO2
14P08213747A0000|44 70|immunodeficiency virus type
14P08213747A0000|71 75|HIV-1
14P08213747A0000|88 89|US
14P08213747A0000|301 329|baseline HIV-1 seroprevalence
14P08213747A0000|331 348|HIV-1 risk factors
14P08213747A0000|436 448|United States
14P08213747A0000|449 468|Baltimore/Washington
14P08213747A0000|470 471|DC
14P08213747A0000|473 482|Pittsburgh
14P08213747A0000|484 490|Chicago
14P08213747A0000|495 505|Los Angeles
14P08216115A0158|3 10|patients
14P08216115A0158|36 44|catheters
14P08216115A0158|56 63|oxytocin
14P08216115A0158|91 100|percentile
14P08216115A0158|110 117|activity
14P08217862A1336|9 19|development
14P08217862A1336|25 49|rat conditioning paradigm
14P08217862A1336|107 120|nerve activity
14P08218056A0000|3 16|ultrastructure
14P08218056A0000|26 32|vessels
14P08218056A0000|67 74|patients
14P08218056A0000|96 103|subjects
14P08218230A1505|47 58|binding site
14P08218230A1505|76 95|transcription factor
14P08218230A1505|121 125|HNF-1
14P08218230A1920|22 24|GRE
14P08218230A1920|51 77|glucocorticoid inducibility
14P08218230A1920|82 91|HNF-1 site
14P08218230A1920|162 199|Xenopus fibrinogen B beta subunit gene
14P08219072A0287|0 3|Acad
14P08219081A0000|3 13|PRB-1b gene
14P08219081A0000|68 86|PR-1 protein family
14P08219227A0830|0 10|Replacement
14P08219227A0830|16 18|CRE
14P08219227A0830|39 47|AP-1 site
14P08219227A0830|147 155|AP-1 site
14P08219227A0830|160 162|CRE
14P08220494A0231|66 81|bp cyt-1 element
14P08220494A0231|125 141|promotor activity
14P08220494A0231|155 164|root cells
14P08220494A0231|166 179|tobacco plants
14P08220621T0000|9 19|manuscripts
14P08221251A0239|13 14|CT
14P08222384A0455|0 4|SIN-1
14P08222384A0455|53 77|surface electrocardiogram
14P08222384A0455|78 80|ECG
14P08222384A0455|100 102|ECG
14P08222556T0000|0 5|Effect
14P08222618A0000|8 24|computer programs
14P08222618A0000|29 48|logit transformation
14P08223425T0000|3 17|yeast SSS1 gene
14P08223425T0000|39 59|protein translocation
14P08223554A0574|23 39|polypeptide chain
14P08223554A0574|67 81|transit peptide
14P08223576A1261|12 20|H4PteGlun
14P08223576A1261|31 39|T protein
14P08223576A1261|82 90|H4PteGlun
14P08223576A1261|117 125|T protein
14P08223592A0424|0 3|TATA
14P08223592A0424|7 17|CCAAT boxes
14P08223592A0424|67 90|transcription start site
14P08223592A0424|176 196|polyadenylation sites
14P08223613A0105|0 3|GGS1
14P08223613A0105|19 22|TPS1
14P08223613A0105|85 112|synthase/phosphatase complex
14P08223613A0105|148 161|cif1 mutations
14P08223613A0519|85 88|TSL1
14P08223613A0519|123 148|trehalose synthase complex
14P08223613A0519|155 168|TSL1 homologue
14P08223613A0519|169 172|TPS3
14P08223823T0000|0 18|Stroop interference
14P08223823T0000|46 67|Stroop Color-Word Test
14P08223875A0711|0 10|Stimulation
14P08223875A0711|14 15|3H
14P08223875A0711|17 29|PA production
14P08223875A0711|33 49|CD3 cross-linking
14P08223875A0711|75 78|CD45
14P08223875A0711|91 94|CD45
14P08223875A0711|136 141|p59fyn
14P08223875A0711|144 147|CD45
14P08224260A1248|0 9|CONCLUSION
14P08224260A1248|47 61|ultrasonography
14P08224260A1248|67 76|efficiency
14P08224260A1248|99 111|endometriomas
14P08224260A1248|139 149|specificity
14P08224907A0000|7 28|Southern blot analysis
14P08224907A0000|37 65|gene encoding enhancer factor
14P08224907A0000|103 125|cDNA subfragment probes
14P08225657A0000|50 61|NYHA Class I
14P08225657A0000|63 78|II heart failure
14P08226616A0000|28 51|fungus Neurospora crassa
14P08226616A0000|118 129|assimilation
14P08226776A0990|35 41|process
14P08226776A0990|75 83|delta Hva
14P08226777A0936|1 26|Dictyostelium transformant
14P08226780A0160|30 49|protein interactions
14P08226794A0501|1 5|Ala85
14P08226794A0501|7 8|Dk
14P08226798A1124|15 25|CaM binding
14P08226798A1124|27 47|HIV envelope proteins
14P08226956A1397|26 43|growth temperature
14P08226956A1397|82 92|type plants
14P08227129T0000|51 59|C protein
14P08227129T0000|86 108|immunoglobulin C2 motif
14P08228805A0540|26 48|TCR signal transduction
14P08228805A0540|52 85|guanine nucleotide binding protein
14P08228805A0540|84 89|p21ras
14P08228805A0540|110 112|TCR
14P08228805A0540|116 138|protein tyrosine kinase
14P08228997A0866|33 50|lipid accumulation
14P08228997A0866|69 79|oxygenation
14P08229102A0768|17 34|QLMI questionnaire
14P08229102A0768|76 77|QL
14P08229330A0000|4 10|smokers
14P08229330A0000|28 34|smoking
14P08229826A1145|13 20|response
14P08229826A1145|87 94|activity
14P08229826A1145|111 117|muscles
14P08229826A1145|148 154|objects
14P08230418A0812|30 32|LTR
14P08230418A0812|100 130|urokinase plasminogen activator
14P08230418A0812|137 161|acid phosphatase promoter
14P08230418A0812|245 255|amino acids
14P08230445A0000|22 34|reading frame
14P08230445A0000|41 67|immunodeficiency virus type
14P08230445A0000|68 72|HIV-1
14P08230445A0000|161 163|Gag
14P08230452A0551|43 57|P1 polyproteins
14P08230452A0551|83 100|processing defects
14P08230452A0551|147 150|VVP3
14P08230452A0551|168 190|poliovirus 3CD protease
14P08230452A0551|208 223|assembly defects
14P08230452A0551|236 257|complementation system
14P08230452A0551|288 303|vaccinia viruses
14P08230452A0551|310 325|capsid precursor
14P08230452A0551|337 353|poliovirus genome
14P08230452A0551|381 395|capsid proteins
14P08230452A0551|396 397|D.
14P08230452A1489|11 25|capsid proteins
14P08230452A1489|39 50|P1 precursor
14P08230452A1489|55 73|valine substitution
14P08230452A1489|93 95|VP1
14P08230452A1489|97 105|VP1-G001V
14P08230452A1489|121 136|capsid particles
14P08231398A0802|0 6|RESULTS
14P08231398A0802|51 64|blood cultures
14P08231398A0802|114 128|M. tuberculosis
14P08231398A0802|143 157|prison patients
14P08231398A0802|177 198|immunodeficiency virus
14P08231398A0802|218 234|immunosuppression
14P08231398A0802|242 244|CD4
14P08231577A1027|0 3|Acid
14P08231816A1473|49 79|penicillin producing conditions
14P08231816A1473|135 151|promoter fragment
14P08231816A1473|187 194|IPNS tsp
14P08232304A1166|59 61|TSS
14P08232304A1166|133 175|chloramphenicol acetyltransferase construct
14P08232412A1342|27 51|expression vector pALTNEO
14P08232412A1342|77 88|L. enriettii
14P08234166A0425|3 17|bioavailability
14P08234166A0425|115 127|RT conditions
14P08234276A0556|44 56|IL-8 promoter
14P08234276A0556|78 83|NF-IL6
14P08234276A0556|87 110|NF-kappa B binding sites
14P08234308T0000|0 5|Notice
14P08237112A0553|28 38|36K protein
14P08237171A0000|25 35|enlargement
14P08237171A0000|83 95|hydrocephalus
14P08237578A0253|9 24|lipid metabolism
14P08237578A0253|72 86|LDL-cholesterol
14P08237578A0253|90 104|HDL-cholesterol
14P08237578A0253|130 147|Norplant-2 rod use
14P08237578A0253|185 201|preinsertion mean
14P08238626A0248|3 7|PaCO2
14P08238626A0248|17 34|baseline brain pHi
14P08238626A0248|74 83|blood flow
14P08239164A0551|0 3|CPAP
14P08239164A0551|58 60|VO2
14P08239164A0551|100 111|lung disease
14P08239164A0551|175 186|lung disease
14P08239586T0000|0 6|Effects
14P08239586T0000|38 51|nephrotoxicity
14P08240170A0000|11 23|salmonellosis
14P08240170A0000|40 47|feedlots
14P08240170A0000|57 65|transport
14P08241139A0378|25 35|DNA binding
14P08241139A0378|61 66|MgdTDP
14P08241139A0378|102 112|nucleotides
14P08241656A0189|48 58|association
14P08241656A0189|66 79|cholelithiasis
14P08241656A0189|83 93|Wildervanck
14P08242861A0368|4 14|4,8-DiMeIQx
14P08242861A0368|18 26|A alpha C
14P08243476A1177|20 38|tryptophan residues
14P08243476A1177|114 130|Paracoccus enzyme
14P08244034T0000|11 46|Leishmania surface glycoprotein GP63
14P08244034T0000|59 87|baculovirus expression system
14P08245013A0000|46 60|destabilization
14P08245013A0000|111 134|receptor down-regulation
14P08245013A0000|152 164|understanding
14P08245125A0822|0 7|Addition
14P08245125A0822|31 44|F-actin nuclei
14P08245125A0822|65 75|L266D actin
14P08245456A0501|28 31|IL-5
14P08245456A0501|50 52|PMA
14P08245456A0501|67 68|N6
14P08245456A0501|70 86|O2-dibutyryl cAMP
14P08245456A0501|87 93|Bt2cAMP
14P08245456A0501|113 115|PMA
14P08245456A0501|146 160|IL-5 production
14P08245461A0700|0 23|Hu-Met-1 mRNA expression
14P08245461A0700|43 60|T cell tumor lines
14P08245933A0617|7 17|engorgement
14P08245933A0617|32 41|treatments
14P08246984A0512|0 7|Northern
14P08246984A0512|9 11|RNA
14P08246984A0512|50 60|PI 3-kinase
14P08246984A0923|46 65|PI 3-kinase isoforms
14P08246984A0923|103 113|PI 3-kinase
14P08246984A0923|150 152|p85
14P08246987A0260|44 49|p56lck
14P08246987A0260|59 70|Src homology
14P08246987A0260|76 78|SH2
14P08246987A0260|82 84|SH3
14P08247005A0584|0 6|Strains
14P08247005A0584|17 37|drs2 mutation process
14P08247005A0584|39 51|20S precursor
14P08247005A0584|62 69|18S rRNA
14P08247005A0584|92 94|40S
14P08247043T0000|0 10|Hepatitis B
14P08247043T0000|13 33|liver transplantation
14P08248246A0838|29 31|Sp1
14P08248246A0838|126 143|R1 gene expression
14P08248253A1785|13 24|observations
14P08248253A1785|59 76|chicken L-CAM gene
14P08248688A0726|16 26|stimulation
14P08248688A0726|87 99|NO production
14P08249319A0578|26 40|mislocalization
14P08249319A0578|46 53|position
14P08249390A0111|13 29|diabetes mellitus
14P08249390A0111|108 117|infarction
14P08251506A0503|146 164|DRE oligonucleotide
14P08251622A0000|33 75|Brassica napus 2S storage protein napA gene
14P08252067A0917|44 46|NH2
14P08252067A0917|50 61|COOH termini
14P08252976A0467|0 4|Rinit
14P08252976A0467|39 43|Rdiff
14P08252976A0467|83 103|pressure dissipations
14P08253386A0800|39 67|fibronectin splicing enhancer
14P08253386A0800|81 90|SE element
14P08253386A0800|127 144|splicing complexes
14P08253386A0800|183 190|U2 snRNP
14P08253386A0800|194 214|branch site sequences
14P08253387A0801|0 9|Inspection
14P08253387A0801|12 27|enhancer mutants
14P08253387A0801|39 54|trans-activation
14P08253387A0801|89 93|TCF-2
14P08253387A1291|35 46|hLEF HMG box
14P08253387A1291|91 108|TCR alpha enhancer
14P08253387A1291|123 134|interactions
14P08253777A0301|1 21|cAMP response element
14P08253777A0301|21 23|CRE
14P08253777A0301|25 40|consensus signal
14P08253777A0301|105 107|Kv1
14P08253958A0000|47 58|Helicobacter
14P08253958A0000|74 95|serum immunoglobulin G
14P08253958A0000|95 97|IgG
14P08254738A0428|20 29|T antigens
14P08254738A0428|66 74|Sf9 cells
14P08254738A0428|119 123|TS677
14P08254738A0428|131 135|TS677
14P08254738A0428|161 176|T-antigen kinase
14P08254738A0428|190 198|T antigen
14P08255022A0827|11 23|hypoperfusion
14P08255022A0827|54 57|FEV1
14P08255022A0827|62 64|V25
14P08255022A0827|68 71|PaO2
14P08255022A0827|96 107|blood volume
14P08255022A0827|123 139|blood cell counts
14P08255341A0554|39 49|combination
14P08255341A0554|52 64|metronidazole
14P08255341A0554|67 83|tissue amoebicide
14P08255341A0554|87 96|diloxanide
14P08255341A0554|106 115|amoebicide
14P08255758A0000|61 75|retrotransposon
14P08255758A0000|88 90|LTR
14P08255758A0000|131 143|homeoproteins
14P08257666A0662|30 40|OPT complex
14P08257666A0662|71 73|IHA
14P08257666A0662|77 78|HD
14P08257666A0662|119 138|learning performance
14P08257754A0711|61 73|HB antibodies
14P08257754A0711|88 92|IU/ml
14P08257754A0711|125 137|HB antibodies
14P08257754A0711|148 152|IU/ml
14P08258025A1131|0 10|CONCLUSIONS
14P08258025A1131|44 62|treatment variables
14P08258025A1131|74 88|Karnofsky index
14P08259650A0640|0 27|Nucleotide sequence analysis
14P08259650A0640|31 37|HA gene
14P08259650A0640|66 67|HA
14P08260635A0926|69 90|transit peptide region
14P08260635A0926|102 112|GAPDH genes
14P08260635A0926|113 116|GapA
14P08260635A0926|120 123|GapB
14P08261398A0392|17 37|cell lines P388/ADR/3
14P08261398A0392|39 48|P388/ADR/7
14P08261398A0392|72 92|alpha mRNA transcript
14P08261398A0392|148 163|P388/4 cell line
14P08261398A0838|14 26|amplification
14P08261398A0838|112 122|transcripts
14P08261398A0838|131 140|P388/ADR/3
14P08261398A0838|144 159|P388/ADR/7 cells
14P08262041A0727|3 16|phi AP3 factor
14P08262041A0727|25 38|phosphoprotein
14P08262041A0727|54 68|phosphorylation
14P08262054A0565|51 69|membrane protein 2A
14P08262054A0565|69 73|LMP2A
14P08262054A0565|98 100|EBV
14P08262054A0565|126 136|Tyr-X-X-Leu
14P08262054A0565|186 206|B cell transformation
14P08262067A1608|23 26|Cwg2
14P08262067A1608|31 35|Cdc43
14P08262067A1608|73 85|cell polarity
14P08262067A1608|134 146|establishment
14P08262067A1608|149 161|cell polarity
14P08262067A1608|164 185|cell wall biosynthesis
14P08263933T0000|25 35|ATPase gene
14P08263933T0000|42 72|cyanobacterium Synechocystis sp
14P08264579A1209|12 15|PTR2
14P08264579A1209|62 77|characterization
14P08264579A1209|91 112|peptide transport gene
14P08264582A0750|109 123|point mutations
14P08264582A0750|147 165|amino acid residues
14P08264582A0750|166 169|LIFR
14P08264583A0520|98 107|cell lines
14P08264583A0520|137 159|test plasmid substrates
14P08264591A1190|40 53|RNA polymerase
14P08264591A1190|58 62|TFIIB
14P08264591A1190|89 122|transcription start site selection
14P08264617A0000|32 40|EGFR/ErbB
14P08264617A0000|53 71|NIH 3T3 fibroblasts
14P08264617A0000|123 148|ErbB-3 signal transduction
14P08264617A0000|151 167|ligand activation
14P08264628A0418|0 26|Oligonucleotide competitors
14P08264628A0418|83 88|TIF-IB
14P08264628A0418|90 94|TFIID
14P08264628A0418|99 104|TFIIIB
14P08264631A0746|26 38|ADR1 activity
14P08264631A0746|56 58|TAD
14P08264631A0746|68 71|ADR1
14P08264631A0746|73 88|ADR1 DNA binding
14P08264631A0746|99 121|ADH2 promoter sequences
14P08264650A0925|0 7|Analysis
14P08264650A0925|28 45|mds1 null mutation
14P08264650A0925|60 63|MDS1
14P08264664A0128|0 7|TGF beta
14P08264664A0128|42 59|AP-1 binding sites
14P08265602T0000|0 2|Val
14P08265602T0000|6 18|Ala mutations
14P08265602T0000|57 77|transmembrane segment
14P08265602T0000|79 100|phage M13 coat protein
14P08265955T0000|20 22|NHS
14P08267658A0391|30 31|UW
14P08267658A0391|65 70|KH2PO4
14P08267658A0391|72 76|MgSO4
14P08267658A0391|128 142|rat hepatocytes
14P08267658A0391|152 173|drug transport studies
14P08267667A0748|8 21|administration
14P08267667A0748|24 27|GRg2
14P08267667A0748|157 176|learning acquisition
14P08267667A0748|227 246|h memory acquisition
14P08267667A0748|298 315|h memory retention
14P08267667A0748|372 389|h memory retrieval
14P08268718A0676|38 40|p50
14P08268833T0000|22 34|cyclosporin A
14P08268833T0000|35 43|Sandimmun
14P08268833T0000|49 59|application
14P08268912A0657|7 29|translation experiments
14P08268912A0657|53 55|RNA
14P08268912A0657|102 124|SDS polyacrylamide gels
14P08269424A0339|35 37|CRF
14P08269424A0339|41 43|TRH
14P08269424A0339|45 55|ACTH levels
14P08269439X0000|37 45|Talwin Nx
14P08269439X0000|46 56|Pentazocine
14P08269439X0000|89 98|management
14P08270257A0551|1 26|sequence homology analysis
14P08270257A0551|70 79|NDP-K beta
14P08270580A0155|35 45|combination
14P08270580A0155|48 61|amphotericin B
14P08270580A0155|64 76|cotrimoxazole
14P08270985A0590|0 17|Response durations
14P08273122A0708|0 6|RESULTS
14P08273122A0708|27 39|QA/QI process
14P08273122A0708|52 81|blood administration practices
14P08273122A0708|118 144|blood administration policy
14P08273122A0708|176 197|component transfusions
14P08274774A0958|11 22|REP21 plants
14P08274774A0958|60 72|tobamoviruses
14P08274774A0958|82 100|tomato mosaic virus
14P08274774A0958|128 133|TMV-U5
14P08274774A0958|169 189|ribgrass mosaic virus
14P08275618A0457|0 10|Drug effect
14P08275618A0457|65 73|cirrhosis
14P08275618A0457|112 122|effect area
14P08275618A0457|137 154|concentration area
14P08275618A0457|178 188|sensitivity
14P08275618A0457|237 245|cirrhosis
14P08276234A0119|21 23|YY1
14P08276234A0119|91 104|c-fos promoter
14P08276234A0119|130 142|DNA structure
14P08276336A0371|41 53|colonoscopies
14P08276336A0371|85 96|relationship
14P08276732A0799|20 34|DPOAE amplitude
14P08276732A0799|82 95|susceptibility
14P08276762T0000|0 5|Effect
14P08276762T0000|14 31|base substitutions
14P08276762T0000|33 49|glycine-870 codon
14P08276762T0000|51 73|gramicidin S synthetase
14P08276762T0000|79 96|proline activation
14P08276851A0347|12 25|Pay4p sequence
14P08276851A0347|80 92|relationships
14P08276851A0347|205 221|protein transport
14P08276851A0347|222 239|cell cycle control
14P08276854A1894|35 55|decorin gene promoter
14P08276854A1894|83 103|proteoglycan promoter
14P08276854A1894|139 153|pur/pyr segment
14P08276854A1894|180 197|gene transcription
14P08276865A1188|3 32|kinase inhibitor staurosporine
14P08276865A1188|106 111|p21ras
14P08276865A1188|115 124|MAP kinase
14P08276865A1188|176 187|LPA receptor
14P08276865A1188|189 205|p21ras activation
14P08276871A1001|33 40|identity
14P08276871A1001|77 86|% identity
14P08276871A1001|106 118|transmembrane
14P08276900A0543|0 1|S.
14P08276900A0543|3 4|K.
14P08277632A0997|3 15|survival rate
14P08277632A0997|44 53|N2 disease
14P08277632A0997|65 77|R2b operation
14P08278423A0147|0 6|Mothers
14P08278423A0147|47 49|HIV
14P08278423A0147|69 70|TB
14P08278423A0147|106 130|disaccharide intolerances
14P08278480T0002|0 1|G.
14P08278548A0597|21 33|psaL products
14P08278548A0597|95 128|polyacrylamide gel electrophoresis
14P08278548A0597|134 145|psaE product
14P08278929A0866|10 27|SPF type V embryos
14P08278929A0866|62 64|CRS
14P08278929A0866|118 130|VSD incidence
14P08279098T0001|42 56|myopia patients
14P08280476A0602|23 32|HIV-1 HXB2
14P08280476A0602|35 59|HIV-1 Z2Z6 core enhancers
14P08280476A0602|67 77|Z2Z6 strain
14P08280925A0261|53 64|C57Bl/6 mice
14P08280925A0261|123 133|differences
14P08280925A0261|153 155|IgM
14P08280925A0261|159 161|IgG
14P08280925A0261|170 179|antibodies
14P08281153A0543|33 44|conservation
14P08281153A0543|47 62|intron sequences
14P08281536A0626|0 12|Interleukin-6
14P08281634A1801|5 14|parameters
14P08281634A1801|17 31|iron metabolism
14P08281740A0000|0 8|Responses
14P08281740A0000|14 41|Plowright Rinderpest vaccine
14P08281740A0000|68 73|Uganda
14P08281740A0000|103 116|IgG antibodies
14P08281740A0000|147 157|ELISA assay
14P08282501A0358|33 54|angiography procedures
14P08282501A0358|80 90|conclusions
14P08282501A0358|110 120|differences
14P08282576A0297|0 6|Tumours
14P08282576A0297|36 43|T1-stage
14P08282749A1474|0 5|Thomas
14P08282749A1474|7 23|Hospital solution
14P08282749A1474|79 88|myocardium
14P08283292A0779|0 5|Plasma
14P08283292A0779|7 9|LDL
14P08283292A0779|13 44|liver cholesterol concentrations
14P08283292A0779|188 200|control group
14P08283531A0700|3 28|Stryker frame modification
14P08283531A0700|40 63|Dornier HM3 lithotriptor
14P08284227A0336|46 63|kb mRNA transcript
14P08284227A0336|65 67|Id1
14P08284227A0336|89 107|cell types Id1 mRNA
14P08284227A0336|131 143|cycling cells
14P08284337A0825|30 41|IHD patients
14P08284337A0825|81 93|cardiologists
14P08285710A0634|13 27|transcript mRNA
14P08285710A0634|40 47|Northern
14P08285710A0634|49 51|RNA
14P08285710A0634|53 65|blot analysis
14P08285710A0634|129 145|protein synthesis
14P08286035A0587|13 32|sequence information
14P08286035A0587|36 40|c11/1
14P08286035A0587|87 89|RNA
14P08286035A0587|98 102|PMNLs
14P08286035A0587|142 166|polymerase chain reaction
14P08286035A0587|166 168|PCR
14P08288240A0304|3 21|sequence similarity
14P08288240A0304|37 41|SCG10
14P08288240A1343|55 64|SCG10 gene
14P08288240A1343|124 142|stathmin/Lap18 gene
14P08288554A0295|10 28|amino acid sequence
14P08288554A0295|32 46|mouse HO-1 gene
14P08288554A0295|64 66|p32
14P08288554A0295|113 133|mouse BALBc/3T3 cells
14P08288596A0663|11 12|T3
14P08288596A0663|71 76|TREpal
14P08288596A0663|85 90|ME-TRE
14P08288596A0663|95 100|F2-TRE
14P08288596A0663|134 137|TREs
14P08288596A0663|194 217|TATA box binding protein
14P08288596A0663|238 252|binding protein
14P08288606A0240|6 21|polymerase chain
14P08288606A0240|61 73|pair fragment
14P08288606A0240|79 88|sialymotif
14P08288606A0240|98 110|placenta mRNA
14P08288606A0240|153 167|coding sequence
14P08288606A0240|194 205|cDNA library
14P08288622A0725|44 56|heterogeneity
14P08288622A0725|62 69|HDC mRNA
14P08288622A0725|102 116|intron sequence
14P08288622A0725|138 159|splicing acceptor site
14P08288633A0144|14 16|DNA
14P08288633A0144|32 53|Caenorhabditis elegans
14P08288633A0144|82 100|amino acid residues
14P08288633A0144|100 104|CeGAP
14P08288633A0144|130 148|sequence similarity
14P08288633A0144|207 209|Bcr
14P08288633A0144|253 265|Rho subfamily
14P08289339A0527|10 20|exonuclease
14P08289339A0527|24 33|protection
14P08289339A0527|54 64|core region
14P08289339A0527|100 101|E1
14P08289341A1202|0 9|Repression
14P08289341A1202|36 37|E2
14P08289341A1202|50 53|E2-C
14P08289341A1202|80 84|E2-RS
14P08289342A0931|12 14|AAV
14P08289342A0931|23 37|resolution site
14P08289342A0931|57 71|DNA replication
14P08289357A0724|85 87|LTR
14P08289593A1404|49 54|MK-801
14P08289593A1404|80 91|cocaine dose
14P08289593A1404|175 180|MK-801
14P08289783A0000|3 7|Oct-3
14P08289783A0000|39 48|POU family
14P08289783A0000|50 70|transcription factors
14P08289783A0000|107 131|differentiation decisions
14P08289783A1476|43 49|RAREoct
14P08289783A1476|93 97|Oct-3
14P08289783A1476|110 118|P19 cells
14P08289783A1476|190 197|EC cells
14P08289784A0381|17 18|M.
14P08289793A1226|46 53|COUP-TFs
14P08289793A1226|92 95|Oct4
14P08289831A0290|0 7|Analysis
14P08289831A0290|64 66|RAW
14P08289834A0341|30 34|Atr-I
14P08289834A0341|49 56|TGF-beta
14P08290278A0374|35 46|Myc function
14P08290278A0374|52 83|candidate tumor suppressor genes
14P08290421A0165|5 13|knowledge
14P08290421A0165|71 81|association
14P08290421A0165|86 91|Alport
14P08291233A0000|26 52|chicken embryo cDNA library
14P08291233A0000|104 112|U3 region
14P08291233A0000|117 138|Rous sarcoma virus LTR
14P08291620A0372|18 35|locomotor behavior
14P08291620A0372|51 66|torso morphology
14P08291761A0416|0 9|Animal age
14P08291761A0416|40 54|CSF composition
14P08291761A0416|58 80|serum IgG concentration
14P08291886T0024|14 22|expansion
14P08293412T0000|51 62|tolerability
14P08293412T0000|81 105|5-HT3 receptor antagonist
14P08293992A0432|56 61|K/NPAG
14P08293993A0948|0 2|ENV
14P08293993A0948|52 87|alpha-factor prepro secretion leader
14P08293993A0948|103 127|invertase signal sequence
14P08294386A0000|0 9|BACKGROUND
14P08294386A0000|25 34|predictors
14P08294386A0000|59 68|depression
14P08294386A0000|117 126|depression
14P08294386A0000|174 184|desipramine
14P08294386A0000|205 215|blood level
14P08294429A0153|0 7|Analysis
14P08294429A0153|42 44|DNA
14P08294429A0153|49 50|FR
14P08294429A0153|73 105|chloramphenicol acetyltransferase
14P08294429A0153|107 122|luciferase genes
14P08294429A0153|159 179|hGH promoter activity
14P08294459A0446|12 30|amino acid sequence
14P08294459A0446|34 43|SAP-1 cDNA
14P08294459A0446|59 63|SAP-1
14P08294459A0446|111 113|PTP
14P08294511A0639|115 134|snRNP core particles
14P08294511A0639|150 160|interaction
14P08294865A0236|89 108|peptide/DR complexes
14P08294906A1315|34 60|neurotransmitters glutamate
14P08296434A1141|3 19|Harleco apparatus
14P08297376A0236|0 14|Co-transfection
14P08297376A0236|37 66|CCAAT/enhancer binding protein
14P08297376A0236|80 89|C/EBP beta
14P08297376A0236|107 142|rat uncoupling protein gene promoter
14P08298129A0274|49 58|expression
14P08298129A0274|85 97|gene promoter
14P08298129T0000|0 8|Isolation
14P08298129T0000|12 27|characterization
14P08298129T0000|64 76|integrin gene
14P08299181A1148|10 14|fluid
14P08299181A1148|38 40|eye
14P08299181A1148|45 48|eyes
14P08299181A1148|70 72|eye
14P08299181A1148|76 79|eyes
14P08299568A1401|21 30|activation
14P08299568A1401|71 81|stimulation
14P08299568A1401|84 100|glucose transport
14P08299725A0724|74 89|tumor cell lines
14P08299725A0724|98 108|readthrough
14P08299725A0724|122 129|residues
14P08299896A0626|0 10|Concordance
14P08299896A0626|13 23|IBDQ scores
14P08299896A0880|0 21|Regression line slopes
14P08299896A0880|22 32|IBDQ scores
14P08300463A0581|0 11|Praziquantel
14P08300463A0581|15 25|Albendazole
14P08300463A0581|60 77|neurocysticercosis
14P08300527T0000|47 88|malonyl-coenzyme A decarboxylase gene eryM
14P08300527T0000|87 113|Saccharopolyspora erythraea
14P08300601A0745|35 45|DNA binding
14P08300601A0745|47 50|MyoD
14P08300601A0745|54 67|E12 homodimers
14P08300601A0745|70 90|E12/MyoD heterodimers
14P08300605A0432|34 49|deletion mutants
14P08300605A0432|99 108|silk gland
14P08300605A0432|124 136|instar larvae
14P08300605A0432|224 238|initiation site
14P08300605A0671|10 17|elements
14P08300605A0671|79 88|regulation
14P08300611A0341|13 23|mutagenesis
14P08300611A0341|50 60|application
14P08300611A0341|77 89|TraI proteins
14P08300611A0341|155 173|amino acid residues
14P08300611T0000|42 44|DNA
14P08300611T0000|89 92|TraI
14P08300611T0000|107 117|plasmid RP4
14P08300625A1352|61 76|peptide sequence
14P08300625A1352|110 122|slyD function
14P08301702A1083|35 58|rat cytochrome P-450 1A1
14P08301702A1083|179 192|immunoblotting
14P08301841A0000|15 29|enzyme activity
14P08301841A0000|67 69|AMI
14P08301841A0000|82 96|angina pectoris
14P08301841A0000|97 99|UAP
14P08302589A1132|14 26|cell motility
14P08302589A1132|78 91|protein kinase
14P08302589A1132|103 115|phorbol ester
14P08302589A1132|124 126|Ca2
14P08303233A0313|2 9|addition
14P08303233A0313|18 24|priming
14P08303233A0313|50 57|identity
14P08304301A0331|0 6|METHODS
14P08304301A0331|56 58|HCC
14P08304301A0331|106 109|HCCs
14P08304342A0605|21 44|hemochromatosis families
14P08304342A0605|55 81|hemochromatosis chromosomes
14P08304342A0605|194 203|HLA-F loci
14P08304342A0605|232 236|HLA-A
14P08305058T0000|0 11|Pneumothorax
14P08306356A0000|17 29|malformations
14P08306356A0000|63 68|X-rays
14P08306356A0000|103 111|gestation
14P08306834A0866|0 9|T2 cancers
14P08306959A0278|0 8|IFN alpha
14P08306959A0278|11 32|IFN gamma inducibility
14P08306959A0278|101 125|IFN gamma activation site
14P08306959A0278|124 126|GAS
14P08307338A0227|0 8|Mutations
14P08307338A0227|62 72|degradation
14P08307338A0227|97 108|cytochrome b
14P08307338A0227|113 115|RNA
14P08307564A0233|33 36|STSs
14P08308008A0201|59 62|GABP
14P08308008A0201|66 84|ets sequence motifs
14P08308008A0201|148 161|COXIV promoter
14P08309726A0000|60 76|distress syndrome
14P08309726A0000|77 80|ARDS
14P08309726A0000|108 120|relationships
14P08309726A0000|129 145|activation status
14P08309726A0000|187 189|PMN
14P08309726A0000|192 206|cytokine levels
14P08309726A0000|252 255|ARDS
14P08309726A0000|292 295|ARDS
14P08309726A0000|342 345|ARDS
14P08309912A0306|0 9|Amiodarone
14P08309953A0776|27 55|dopamine receptor stimulation
14P08309953A0776|65 81|dopamine agonists
14P08309953A0776|120 134|characteristics
14P08309953A0776|140 161|reaction time response
14P08309957A0000|3 13|experiments
14P08309957A0000|44 56|jaw movements
14P08309957A0000|76 89|administration
14P08309957A0000|114 128|agent reserpine
14P08309975A0662|0 8|Depletion
14P08309975A0662|24 40|nucleus accumbens
14P08309975A0662|144 154|consumption
14P08312243A0177|32 36|NaFe3
14P08312243A0177|38 41|EDTA
14P08312243A0177|73 79|Na2EDTA
14P08312243A0177|83 84|Zn
14P08312243A0177|86 87|Cu
14P08312243A0177|91 103|Ca metabolism
14P08312243A0177|114 126|Zn-sufficient
14P08314163T0000|0 7|Recovery
14P08314163T0000|29 43|agranulocytosis
14P08314163T0000|86 110|colony stimulating factor
14P08314922A0941|46 62|perfusion changes
14P08314922A0941|69 81|brain surface
14P08314922A0941|92 104|tissue damage
14P08316100A0586|12 19|Richards
14P08316100A0586|124 132|influence
14P08316209A0000|48 51|CYS3
14P08316209A0000|55 71|Neurospora crassa
14P08316209A0000|144 160|sulfur catabolism
14P08316240A1068|0 7|Analysis
14P08316240A1068|41 45|CHL15
14P08316240A1068|70 84|hexamer element
14P08316240A1068|85 90|ACGCGT
14P08316240A1068|94 114|MluI restriction site
14P08316240A1068|178 196|DNA synthesis genes
14P08317092A0304|59 72|helicase motif
14P08317092A0304|98 117|RNA polymerase motif
14P08317092A0304|167 189|RNA replication complex
14P08317094A0778|11 13|F3R
14P08317094A0778|18 28|transcripts
14P08317094A0778|65 69|TAAAG
14P08317094A0778|127 142|initiation codon
14P08319396A0448|2 3|T2
14P08319396A0448|22 36|intensity areas
14P08319396A0448|101 109|tegmentum
14P08319396A0448|125 139|intensity areas
14P08319396A0448|147 165|cerebellar peduncle
14P08319907A0754|8 20|rap1t alleles
14P08319907A0754|59 80|telomere tract lengths
14P08319907A0754|94 118|telomere position effects
14P08320120A0361|10 24|microangiopathy
14P08320120A0361|75 85|capillaries
14P08320120A0361|123 140|sodium fluorescein
14P08321199T0000|78 90|establishment
14P08321199T0000|107 115|HMR locus
14P08321203A0840|0 13|NF-kappa B p65
14P08321203A0840|13 15|p50
14P08321203A0840|48 58|C/EBP alpha
14P08321203A0840|59 68|C/EBP beta
14P08321203A0840|72 82|C/EBP delta
14P08321227A0854|64 72|COS cells
14P08321741A0396|25 27|BMB
14P08321741A0396|56 68|myelofibrosis
14P08321741A0396|115 122|Myelosis
14P08321741A0396|166 182|Metaplasia-AMM-in
14P08321741A0396|214 216|CML
14P08322117A1019|55 63|pressures
14P08322117A1019|111 125|Sussett formula
14P08322823A0839|36 38|MFA
14P08322823A0839|58 70|UTS phenotype
14P08323294T0000|0 56|Chicken sterol carrier protein 2/sterol carrier protein x
14P08324107A0000|12 32|albumin concentration
14P08324107A0000|73 86|plasma protein
14P08324280A0098|72 81|ulceration
14P08324792T0000|54 65|infarct size
14P08324792T0000|76 87|rabbit heart
14P08325504A0226|7 10|RD19
14P08325504A0226|14 32|RD21 mRNA synthesis
14P08325639A0129|31 44|20S proteasome
14P08325639A0129|65 67|26S
14P08325639A0129|120 138|proteinase activity
14P08325720A0840|64 85|muscle enzyme activity
14P08325720A0840|85 100|citrate synthase
14P08325720A0840|101 131|3-hydroxyacyl-CoA-dehydrogenase
14P08325720A0840|133 153|lactate dehydrogenase
14P08325720A0840|163 180|muscle capillaries
14P08325720A0840|192 213|muscle buffer capacity
14P08325883A0368|24 35|RBP1 protein
14P08325883A0368|56 76|RNA recognition motif
14P08325883A0368|79 97|glutamine stretches
14P08327488A0839|12 14|RNA
14P08327488A0839|38 40|p70
14P08327488A0839|170 172|RNA
14P08327488A0839|195 197|p70
14P08331064A0440|0 6|Release
14P08331064A0440|58 67|resolution
14P08331064A0440|84 93|structures
14P08331067T0000|8 26|nucleotide sequence
14P08331067T0000|31 57|bacteriophage K1F tail gene
14P08331067T0000|63 86|endo-N-acylneuraminidase
14P08331067T0000|127 144|bacteriophage PK1E
14P08331728A0686|0 6|Binding
14P08331728A0686|9 10|U2
14P08331728A0686|23 39|ribonucleoprotein
14P08332033T0000|14 27|quantification
14P08332033T0000|30 40|brain edema
14P08332033T0000|69 82|micro-infarcts
14P08332033T0000|102 119|neurotropin effect
14P08332492A0145|31 36|GATA-3
14P08332492A0145|65 77|T lymphocytes
14P08332492A0145|101 127|immunodeficiency virus type
14P08332492A0145|128 132|HIV-1
14P08332495A0408|25 36|CAT activity
14P08332495A0408|54 72|lung adenocarcinoma
14P08332495A0408|73 78|A549-1
14P08332495A0408|120 136|T7 RNA polymerase
14P08332495A0408|136 150|pT7-EMC-CAT DNA
14P08332495A0408|153 159|DC-chol
14P08333643A0000|0 12|Pneumoscrotum
14P08333643A0000|47 56|discussion
14P08334158A0660|40 55|cystein residues
14P08334158A0660|80 92|Fe/S proteins
14P08334304A0473|68 89|peptide growth factors
14P08334304A0473|113 124|p21 rasVal12
14P08334989A0070|168 180|transcription
14P08334989A0070|184 207|luciferase reporter gene
14P08334989A0070|225 242|NIH3T3 fibroblasts
14P08335710A0338|3 11|influence
14P08335710A0338|24 31|strength
14P08335710A0338|37 46|resolution
14P08336012A0632|56 69|BAL fluid cell
14P08336012A0632|86 99|administration
14P08336012A0632|102 103|FN
14P08336543A0243|17 24|families
14P08336543A0243|27 37|L1 elements
14P08336543A0243|89 96|sequence
14P08336543A0243|109 116|terminus
14P08336698T0000|0 3|TFEC
14P08336698T0000|56 59|TFE3
14P08336698T0000|85 108|transcription activation
14P08336738A1273|30 33|H-87
14P08336738A1273|37 40|T-47
14P08336738A1273|46 67|PSTAIRE sequence motif
14P08337828A0895|24 36|Western blots
14P08337828A0895|38 64|Autographa californica MNPV
14P08337828A0895|80 106|Spodoptera frugiperda cells
14P08337841A0612|28 32|ARV G
14P08337841A0612|35 43|GNS genes
14P08337841A0612|113 130|consensus sequence
14P08337841A0612|131 135|AACAG
14P08337841A0612|152 157|G gene
14P08337841A0612|176 197|polyadenylation signal
14P08337841A0612|198 201|CATG
14P08337841A0612|243 271|GNS protein termination codon
14P08340400T0000|31 35|RPE65
14P08342703A0966|47 55|flow rate
14P08342703A0966|73 88|outflow pressure
14P08342703A0966|105 113|flow rate
14P08342703A0966|119 126|pressure
14P08343041A0000|60 80|hospital laboratories
14P08343216A0883|12 33|IgG subclass responses
14P08343216A0883|52 65|IgG subclasses
14P08343961A0000|0 20|Anterior body pattern
14P08343961A0000|53 64|distribution
14P08344248A0910|0 4|GAP-N
14P08345191A1140|3 18|peptide sequence
14P08345191A1140|37 47|amino acids
14P08345191A1140|116 119|MCL1
14P08347677A0308|3 28|phosphorylation efficiency
14P08347677A0308|71 87|arginine residues
14P08347677A0308|101 115|arginyl cluster
14P08347677A0308|165 167|Arg
14P08347677A0308|169 189|4-Ala-Ala-Ser-Val-Ala
14P08347677A0308|242 243|Km
14P08348919T0000|0 14|Botulinum toxin
14P08349104A0000|26 29|GAL1
14P08349104A0000|33 43|GAL10 genes
14P08349104A0000|180 183|UASG
14P08349104A0450|32 42|experiments
14P08349104A0450|57 65|TSF genes
14P08349104A0450|101 114|tsf6 mutations
14P08349104A0450|125 134|expression
14P08349104A0450|151 166|hybrid promoters
14P08349104A0450|199 216|operator sequences
14P08349104A0450|246 256|cell growth
14P08349104A0450|267 277|sporulation
14P08349499A1169|0 2|Sex
14P08349499A1169|10 16|variate
14P08349632A0679|0 18|Sequence comparison
14P08349632A0679|43 45|L/N
14P08349632A0679|48 52|PSG12
14P08349632A0679|56 64|PSG12 psi
14P08349632A0679|93 100|L/N exon
14P08349632A0679|105 118|PSG12 psi gene
14P08350061A0209|54 61|CD8 gene
14P08350061A0209|86 111|T cell development program
14P08350398A1616|16 17|ER
14P08350398A1616|66 74|structure
14P08352066A0000|21 34|beta-estradiol
14P08352066A0000|36 37|E2
14P08352066A0000|56 70|bone resorption
14P08352066A0000|87 100|bone formation
14P08352268A0000|16 29|erythropoietin
14P08352268A0000|102 103|SC
14P08355062A0000|40 44|SPECT
14P08355062A0000|50 85|99mTc-hexamethylpropyleneamine oxime
14P08355062A0000|86 90|HMPAO
14P08355063A0456|3 12|rCBF ratio
14P08355539A0133|0 6|METHODS
14P08355539A0133|157 159|EAA
14P08355539A0133|198 200|EAT
14P08355539A0133|263 265|EAI
14P08355680A0824|0 3|2-AP
14P08355680A0824|31 47|mRNA accumulation
14P08355680A0824|92 107|HIV-1 constructs
14P08355680A0824|162 194|glucose 6-phosphate dehydrogenase
14P08355696A0236|3 14|UV induction
14P08355696A0236|36 55|UV response elements
14P08355697A0000|0 28|Protein tyrosine phosphatases
14P08355697A0000|28 31|PTPs
14P08355697A0000|46 69|protein tyrosine kinases
14P08355697A0000|69 72|PTKs
14P08355857A1293|2 10|elevation
14P08355857A1293|20 27|patients
14P08355857A1293|37 46|subgroup A
14P08355857A1293|53 59|patient
14P08355857A1293|65 75|subgroup B.
14P08356792A1275|13 24|p21X protein
14P08356792A1275|34 43|N-terminus
14P08356792A1275|46 49|Rex1
14P08356792A1275|94 97|p21X
14P08356792T0000|0 21|HTLV-1 gene expression
14P08356792T0000|53 63|T-cell line
14P08356944A0589|26 53|sodium lauryl sulfate method
14P08356944A0589|63 86|hemoglobin concentration
14P08356944A0589|117 140|cyanmethemoglobin method
14P08357834A0285|25 44|amino acid sequences
14P08357834A0285|56 71|PKC-delta clones
14P08357834A0285|84 99|mouse homologues
14P08357834A0285|124 142|sequence divergence
14P08357834A0285|183 203|sequence conservation
14P08357834A0285|225 242|PKC family members
14P08360112T0036|0 2|XII
14P08360180A1041|30 34|PSI-G
14P08360180A1041|50 63|PSI-K sequence
14P08360180A1041|197 210|cyanobacterial
14P08361754A0733|18 27|structures
14P08361754A0733|81 88|proteins
14P08361755A0734|48 61|NF-kappa B p50
14P08361755A0734|63 83|serum response factor
14P08361755A0734|83 85|SRF
14P08361755A0734|117 127|Tax binding
14P08361755A0734|132 146|NF-kappa B site
14P08361755A0734|151 158|CArG box
14P08361761A0174|55 70|reporter plasmid
14P08361761A0174|88 104|Sp1 binding sites
14P08361761A0174|125 150|chicken embryo fibroblasts
14P08361761A0174|150 153|CEFs
14P08361761A0174|235 250|reporter plasmid
14P08361761A0174|266 292|immunodeficiency virus type
14P08361761A0174|293 297|HIV-1
14P08361761A0174|318 320|LTR
14P08361761A0174|332 352|kappa B binding sites
14P08361761A0174|389 405|Sp1 binding sites
14P08363332A0365|51 75|surface electrocardiogram
14P08363332A0365|157 172|mapping catheter
14P08363332A0365|209 227|activation sequence
14P08365944A1537|0 9|CONCLUSION
14P08365944A1537|86 96|Mitomycin-C
14P08365944A1537|100 113|5-fluorouracil
14P08366034A0637|23 39|cysteine residues
14P08366034A0637|40 57|carboxymethylation
14P08366034A0637|93 107|disulfide bonds
14P08367388T0035|27 34|syndrome
14P08367388T0035|48 55|syndrome
14P08367487A1014|37 49|17S U2 snRNPs
14P08367487A1014|57 69|12S U2 snRNPs
14P08367487A1014|71 92|HeLa splicing extracts
14P08367487A1014|112 120|U2 snRNPs
14P08367487A1014|190 211|mRNA-splicing activity
14P08369887A0781|0 10|Differences
14P08369887A0781|23 41|viscosity variables
14P08369887A0781|59 61|EAD
14P08369887A0781|64 74|RA patients
14P08370119A0642|103 115|reading frame
14P08370119A0642|151 181|muscle cell AT1a receptor cDNAs
14P08370119A1521|0 7|Deletion
14P08370119A1521|21 35|promoter region
14P08370119A1521|48 71|transcription start site
14P08370119A1521|82 89|TATA box
14P08370119A1521|161 175|luciferase cDNA
14P08370275A0290|3 12|chimpanzee
14P08370275A0290|38 44|numeral
14P08370275A0290|52 58|testing
14P08370275A0290|103 112|preference
14P08371650T0000|0 10|Dissipation
14P08371650T0000|13 29|claudication pain
14P08371713T0000|43 61|endothelin receptor
14P08371936T0000|13 32|Independence Measure
14P08373274A0546|0 10|Polymyxin B
14P08373274A0546|35 47|week postburn
14P08373274A0546|85 95|endotoxemia
14P08373972A0335|0 3|SvO2
14P08374753A0335|13 27|relaxation time
14P08374753A0335|28 29|T2
14P08374753A0335|42 62|diffusion coefficient
14P08375651T0000|36 52|clathrin function
14P08376397A0788|3 21|binding specificity
14P08376397A0788|58 60|E2F
14P08376397A0788|81 89|E2F sites
14P08376796A0172|12 21|VH regions
14P08376796A0172|116 118|IgG
14P08376796A0172|125 128|IgG1
14P08376796A0172|135 138|IgG3
14P08376796A0172|149 155|B cells
14P08376796A0172|204 220|diabetes mellitus
14P08376796A0172|235 237|SLE
14P08376796A0172|261 272|efficiencies
14P08376796A0172|305 306|Ag
14P08377199A1432|43 54|conformation
14P08377199A1432|87 97|recognition
14P08378082A1031|48 57|RB protein
14P08378082A1031|60 65|p21ras
14P08378082A1031|83 96|cell phenotype
14P08380736A0895|31 38|splicing
14P08380736A0895|77 90|amino terminus
14P08380896A0938|0 7|Kinetics
14P08380896A0938|40 56|polymerase domain
14P08380896A0938|95 113|preinitiation stage
14P08381121A0773|8 28|transmembrane regions
14P08382296A0766|0 9|McCann III
14P08382296A0766|10 11|F.
14P08382300A0341|83 92|VP5 mutant
14P08382300A0341|110 112|VP5
14P08382300A0341|116 119|VP23
14P08382303A0507|3 4|E1
14P08382303A0507|12 26|transport motif
14P08382303A0507|62 77|papillomaviruses
14P08382303A0507|118 125|E1 genes
14P08382303T0000|3 24|E1 replication protein
14P08382303T0000|106 133|p34cdc2 phosphorylation site
14P08382359A0469|36 46|interaction
14P08382359A0469|64 78|tumor induction
14P08382359A0469|117 131|point mutations
14P08382359A0469|174 182|T antigen
14P08382359A0469|208 218|experiments
14P08382359A0469|267 276|activities
14P08382359A0469|287 301|tumor induction
14P08382769A0924|105 123|recognition element
14P08382769A0924|129 141|SRP54 protein
14P08382778A0891|19 32|protein shares
14P08382778A0891|71 81|Raf kinases
14P08382778A0891|104 108|TFIIE
14P08382778A0891|114 134|transcription factors
14P08383129A0776|15 38|mass polypeptide complex
14P08383129A0776|60 79|antigen presentation
14P08383129A0776|111 126|protein antigens
14P08383129A0776|167 179|T-lymphocytes
14P08383214A0389|19 20|RT
14P08383214A0389|23 37|Trp-595-Tyr-596
14P08383214A0389|40 42|Pol
14P08383214A0389|83 96|RNase H domain
14P08383217A0357|40 44|Bel-1
14P08383217A0357|69 82|Bel-1 activity
14P08383217A0357|127 143|activation domain
14P08383217A0357|145 148|VP16
14P08383287A0611|48 77|thyroid hormone responsiveness
14P08383287A0611|104 127|hormone response element
14P08383323A0000|19 25|T cells
14P08383492A1205|83 93|differences
14P08383492A1205|150 168|cytochrome oxidases
14P08383492A1205|177 194|c-type cytochromes
14P08383526A0591|29 37|structure
14P08383526A0591|46 61|receptor protein
14P08383622T0000|0 7|Identity
14P08383622T0000|10 13|GABP
14P08383622T0000|18 22|NRF-2
14P08383622T0000|48 76|cytochrome oxidase expression
14P08383622T0000|101 120|ETS domain activator
14P08383850A0206|18 36|beta-funaltrexamine
14P08383850A0206|62 64|NTI
14P08383850A0206|67 83|nonequilibrium mu
14P08384309A0000|21 43|region/helix-loop-helix
14P08384309A0000|99 133|2,3,7,8-tetrachlorodibenzo-p-dioxin
14P08384309A0000|166 184|DNA binding protein
14P08384309A0000|228 251|dioxin response elements
14P08385131A0000|21 28|receptor
14P08385131A0000|30 39|alpha 2AAR
14P08385131A0000|52 58|variety
14P08385131A0000|61 69|effectors
14P08385131A0000|73 81|pertussis
14P08385131A0000|108 115|proteins
14P08385337A0282|1 19|sequence comparison
14P08385337A0282|29 58|CCAAT/enhancer binding protein
14P08385337A0282|58 62|C/EBP
14P08385337A0282|64 82|consensus sequences
14P08385337A0282|88 105|DNA binding region
14P08385581A0126|16 21|REC114
14P08385581A0126|60 65|REC114
14P08385581A0126|85 102|recombination gene
14P08386279A1621|3 26|transactivation function
14P08386279A1621|28 32|EBNA2
14P08386279A1621|93 95|EBV
14P08386279A1621|99 113|HIV-1 infection
14P08386279A1621|136 160|HIV-1 promoter activation
14P08386280T0000|0 7|Mutation
14P08386280T0000|13 31|C/EBP binding sites
14P08386280T0000|35 52|Rous sarcoma virus
14P08386317T0000|7 28|protein phosphatase 2A
14P08386317T0000|72 75|CREB
14P08386317T0000|88 91|CREB
14P08386318A1102|10 13|IL-6
14P08386318A1102|23 29|JRE-IL6
14P08386318A1102|76 91|protein kinase C
14P08386318A1102|117 118|Ca
14P08386318A1102|154 156|Ras
14P08386318A1102|158 162|Raf-1
14P08386318A1102|166 171|NF-IL6
14P08386318A1102|173 182|C/EBP beta
14P08386319A1229|0 7|Mutation
14P08386319A1229|49 66|threonine residues
14P08386319A1229|68 72|Mpk1p
14P08386319A1229|87 99|phenylalanine
14P08386319A1229|140 153|Mpk1p function
14P08386592A0089|0 24|Growth factor stimulation
14P08386592A0089|124 138|phosphorylation
14P08386592A0089|144 148|Elk-1
14P08386592A0089|198 209|Elk-1 kinase
14P08386637A1220|2 9|contrast
14P08386637A1220|15 23|situation
14P08386637A1220|50 57|exposure
14P08386637A1220|63 69|agonist
14P08386637A1220|94 103|regulation
14P08386637A1220|126 134|receptors
14P08387155A1248|15 20|effect
14P08387155A1248|42 46|c-Jun
14P08387155A1248|81 85|c-Fos
14P08387155A1248|121 125|assay
14P08387507A1015|15 19|Myf-5
14P08387507A1015|23 35|MyoD function
14P08387507A1015|119 140|peptide growth factors
14P08387507A1015|219 242|myoblast differentiation
14P08387519A0000|42 58|desmin expression
14P08387519A0000|155 169|gene expression
14P08387519A0000|171 179|myoblasts
14P08387662A0302|5 11|surgery
14P08387662A0302|13 25|patients self
14P08387662A0302|67 77|medications
14P08387662A0302|92 98|placebo
14P08387662A0302|100 106|codeine
14P08387662A0302|115 123|ibuprofen
14P08387662A0302|167 175|intensity
14P08387743A0624|0 10|Replacement
14P08387743A0624|134 156|Mn-superoxide dismutase
14P08387994A0980|3 20|orf61 gene product
14P08387994A0980|78 88|integration
14P08388496A1117|0 9|Expression
14P08388496A1117|23 26|LCLs
14P08388496A1117|51 71|virus producer status
14P08388496A1117|140 158|BamHI-A transcripts
14P08388496A1117|184 190|B cells
14P08388496A1117|245 253|BamHI-C/W
14P08388510A0891|0 7|Analysis
14P08388510A0891|10 40|cell surface immunofluorescence
14P08388510A0891|52 60|UL28 gene
14P08388543A1263|28 38|Y977F/Y989F
14P08388543A1263|40 42|PLC
14P08388543A1263|81 83|Ras
14P08388543A1263|109 124|protein kinase C
14P08388543A1263|126 145|calcium mobilization
14P08388543A1263|167 179|GDP/GTP state
14P08388543A1263|181 183|Ras
14P08388600A0000|0 17|Estrogen treatment
14P08389074A1227|0 8|Mutations
14P08389074A1227|21 30|C-terminus
14P08389074A1227|33 40|EIAV Tat
14P08389074A1227|52 62|RNA binding
14P08389074A1227|65 91|activation domain functions
14P08389365A1344|4 14|observation
14P08389365A1344|45 57|repair system
14P08389365A1344|78 81|GATC
14P08389453A0193|0 21|Uracil DNA glycosylase
14P08389453A0193|48 61|repair pathway
14P08390120A0785|15 20|trials
14P08390120A0785|36 43|question
14P08390120A0785|67 73|options
14P08390120A0785|81 87|quality
14P08390665A0000|0 21|Lithium phthalocyanine
14P08390665A0000|22 25|LiPc
14P08390665A0000|170 187|resonance oximetry
14P08390747A0586|25 32|genetics
14P08390747A0586|51 65|hep syn gB gene
14P08390747A0586|83 91|syncytial
14P08390747A0586|105 114|phenotypes
14P08390831A0143|0 9|Recipients
14P08390831A0143|19 27|leukaemia
14P08390831A0143|35 43|remission
14P08390831A0143|60 68|leukaemia
14P08390831A0143|143 155|risk patients
14P08391534A0828|0 6|Elledge
14P08391534A0828|8 9|P.
14P08391748A0452|0 4|Drugs
14P08391748A0452|100 115|QRS prolongation
14P08391748A0452|138 152|QT prolongation
14P08391748A0452|185 200|QRS prolongation
14P08391748A0452|235 249|QT prolongation
14P08391748A0452|287 302|QRS prolongation
14P08391748A0452|325 339|QT prolongation
14P08392221A0449|0 5|Losses
14P08392221A0449|63 81|estrogen conjugates
14P08392221A0449|166 177|matairesinol
14P08392221A0449|190 202|enterolactone
14P08392221A0449|213 233|O-desmethylangolensin
14P08392623A1374|0 19|IE2-IE2 interactions
14P08392623A1374|92 101|C terminus
14P08392623A1374|103 105|IE2
14P08393143A1281|3 12|Sp1 region
14P08393143A1281|53 55|TRE
14P08394019A0695|0 12|Precipitation
14P08394019A0695|18 36|GST fusion proteins
14P08394019A0695|52 54|SH3
14P08394019A0695|59 73|SH2/SH3 domains
14P08394019A0695|85 95|PI 3-kinase
14P08394019A0695|116 125|SH3 domain
14P08394255A0000|40 52|pcDNA1 vector
14P08394255A0000|84 108|polymerase chain reaction
14P08394255A0000|108 110|PCR
14P08394255A0000|163 183|hormone receptor cDNA
14P08394464A1080|11 22|Rev proteins
14P08394464A1080|76 79|p2/2
14P08394464A1080|83 86|p176
14P08394464A1080|93 95|p20
14P08394862A0565|28 38|CMV disease
14P08394862A0565|62 74|CMV hepatitis
14P08395004A0141|76 115|delta promoter insertion his-4-912 delta
14P08395004A0141|147 162|HIS4 mRNA levels
14P08395004A0558|22 50|protein sequence similarities
14P08395004A0558|65 81|SPT2/SIN1 protein
14P08395010T0000|35 49|thyroid hormone
14P08395010T0000|60 73|acid receptors
14P08395010T0000|108 118|heterodimer
14P08395010T0000|125 143|homodimer formation
14P08395014A1364|26 29|BCK2
14P08395014A1364|38 55|pathway components
14P08395014A1364|68 81|BCK2 functions
14P08395014A1364|107 110|PPZ1
14P08395014A1364|114 117|PPZ2
14P08395654T0000|57 66|expression
14P08395654T0000|72 89|rat aromatase gene
14P08395681A0388|47 50|HPV5
14P08395681A0388|54 61|HPV8 E7s
14P08395681A0388|71 78|HPV16 E7
14P08395681A0388|96 97|E7
14P08395681A0388|204 225|retinoblastoma protein
14P08395681A0388|226 227|RB
14P08395681A0388|237 260|complementation activity
14P08395681A0388|276 296|adenovirus E1A mutant
14P08396120A0690|3 31|rhaB transcription start site
14P08396261A0388|41 57|growth inhibition
14P08396261A0388|71 82|PKA subunits
14P08396261A0388|163 178|cyclase activity
14P08396261A0388|202 214|transformants
14P08396261A0388|283 289|RI cDNA
14P08396261A0388|308 314|RI cDNA
14P08396261A0388|323 332|RI protein
14P08396261A0388|407 410|BL21
14P08396261A0388|412 414|DE3
14P08396261A0388|443 457|C alpha protein
14P08396657A0452|0 2|Liu
14P08396657A0452|4 5|B.
14P08396667T0000|0 6|BCR-ABL
14P08396667T0000|80 97|lymphocyte subsets
14P08396713A0305|103 137|2,3,7,8-tetrachlorodibenzo-p-dioxin
14P08396713A0305|139 142|TCDD
14P08396713A0305|155 173|Ah receptor protein
14P08396713A0305|175 178|ARNT
14P08396713A0305|194 211|heat shock protein
15P08396749A1112a|0 14|LDL cholesterol
15P08396749A1112a|70 80|simvastatin
15P08396749A1112b|0 14|LDL cholesterol
15P08396749A1112b|70 80|simvastatin
14P08396913A1379|88 95|DGK gene
14P08397123T0000|58 93|corticotropin-releasing hormone gene
14P08399970T0000|4 30|bioencapsulation technology
14P08400240A0166|8 28|hypersensitivity site
14P08400240A0166|30 32|HS2
14P08400240A0166|41 60|locus control region
14P08400240A0166|60 62|LCR
14P08400240A0166|68 84|gamma-globin gene
14P08400240A0166|85 92|A gamma*
14P08400240A0166|162 178|gamma-globin mRNA
14P08400928A0318|0 12|INTERVENTIONS
14P08400928A0318|47 83|levodopa/dopa decarboxylase inhibitor
14P08400928A0318|94 136|levodopa/decarboxylase inhibitor/selegiline
14P08401570A0828|23 35|binding sites
14P08401570A0828|38 61|transcription factor Sp1
14P08401570A0828|146 166|transcription factors
14P08401614A0187|45 47|PAL
14P08401614A0187|67 70|PAL2
14P08401614A0187|74 77|PAL3
14P08403245A1234|0 27|Plasma thromboxane B2 levels
14P08403804A0754|24 42|regression analysis
14P08403804A0754|84 107|cyclosporin trough level
14P08403804A0754|133 148|serum creatinine
14P08405433A0000|20 32|growth factor
14P08405433A0000|35 40|IGF-II
14P08405433A0000|68 69|P1
14P08405433A0000|71 72|P2
14P08405433A0000|74 75|P3
14P08405433A0000|79 80|P4
14P08406004A0691|20 38|transfection assays
14P08406004A0691|39 42|PU.1
14P08406004A0691|57 75|reporter constructs
14P08406004A0691|88 101|JB cis-element
14P08406004A0691|192 195|PU.1
14P08406352A0172|0 12|Army veterans
14P08406352A0172|23 35|fever vaccine
14P08406352A0172|51 67|hepatitis B virus
14P08406352A0172|153 178|Veterans Affairs hospitals
14P08406419A0155|44 60|hepatitis C virus
14P08406419A0155|86 89|RIBA
14P08406419A0155|92 119|Ortho Diagnostic Systems Inc
14P08406419A0155|118 125|Westwood
14P08406419A0155|127 128|MA
14P08406497A0000|0 6|Defects
14P08406497A0000|19 22|FBN1
14P08406497A0000|26 47|glycoprotein component
14P08406497A0000|82 96|Marfan syndrome
14P08407784A0850|31 44|srjA mutations
14P08407784A0850|85 94|phenotypes
14P08408194T0000|24 44|membrane-cytoskeleton
14P08408194T0000|102 103|Na
14P08408194T0000|111 130|ATPase distributions
14P08408825A0000|8 26|lupus erythematosus
14P08408825A0000|72 73|Ro
14P08408825A0000|77 87|La antigens
14P08408841A0281|7 19|abnormalities
14P08408841A0281|35 45|mutagenesis
14P08408841A0281|64 76|abnormalities
14P08408963A0048|8 9|L.
14P08409284A0262|21 31|amino acids
14P08409284A0262|36 46|NBB carrier
14P08409284A0262|57 67|amino acids
14P08409284A0262|91 101|amino acids
14P08409284A0262|109 119|PHE carrier
14P08409593A0357|2 5|CFDN
14P08409593A0357|7 10|AMPC
14P08409593A0357|14 16|MNZ
14P08409593A0357|58 66|H. pylori
14P08409593A0357|81 84|AMPC
14P08410042T0000|38 54|dura mater grafts
14P08410097A0356|5 18|mean intensity
14P08410097A0356|20 24|CLTPA
14P08410097A0356|50 76|regression coefficient beta
14P08410097A0356|105 117|oxygen uptake
14P08410097A0356|162 178|plasma fibrinogen
14P08411024T0000|47 70|fibrosis carrier testing
14P08411276A0302|16 26|PIC patient
14P08411276A0302|83 104|Trauma Score variables
14P08411276A0302|104 127|Glascow Coma Scale score
14P08411276A0302|184 208|Severity Characterization
14P08411276A0302|210 215|Trauma
14P08411276A0302|218 222|ASCOT
14P08411276A0302|270 285|ASCOT components
14P08412120A0839|0 3|Skin
14P08412120A0839|26 28|DO2
14P08412620A0688|40 64|transcription start point
14P08412620A0688|131 134|VirF
14P08412662A0333|31 33|DNA
14P08412662A0333|60 79|transposon insertion
14P08412662A0333|81 86|257DH4
14P08412662A0333|103 105|Tn5
14P08412662A0333|113 129|kb EcoRI fragment
14P08412665A0000|59 68|Klebsiella
14P08412665A0000|79 85|KAY2026
14P08412665A0000|134 137|ScrR
14P08413186A0077|20 29|mechanisms
14P08413186A0077|44 53|regulation
14P08413186A0077|135 144|expression
14P08413186A0077|167 181|reductase genes
14P08413186A1199|3 11|Ntl1 gene
14P08413186A1199|45 70|N. plumbaginifolia species
14P08413205A0733|9 32|transfection experiments
14P08413205A0733|44 57|Pax-8 isoforms
14P08413205A0733|92 104|transcription
14P08413205A0733|153 172|recognition sequence
14P08413209A0159|62 81|motif characteristic
14P08413215A0327|33 51|NF-kappa B subunits
14P08413215A0327|91 103|IL-8 promoter
14P08413223A0847|23 47|IL-1 beta NF-kappa B site
14P08413223A0847|162 176|gene expression
14P08413239A0490|42 52|3-10AGTNNAA
14P08413239A0490|84 96|U snRNA genes
14P08413239A0490|116 128|end formation
14P08413239A0490|130 143|U2 transcripts
14P08413260A1437|24 33|Rb protein
14P08413260A1437|106 113|G2 phase
14P08413274A0452|0 3|MDBP
14P08413274A0452|15 24|Raji cells
14P08413274A0452|54 75|X-box oligonucleotides
14P08413274A0452|123 132|MDBP sites
14P08413291A1473|26 48|rat TnI-CAT fusion gene
14P08414410A0270|0 6|METHODS
14P08414410A0270|114 126|field defects
14P08414410A0270|213 229|nerve fiber layer
14P08414502A0244|73 83|p53 protein
14P08414502A0244|88 90|DNA
14P08415637A0000|3 25|ADP-ribosylation factor
14P08415637A0000|26 28|ARF
14P08415637A0000|63 77|RAS superfamily
14P08415637A0000|117 126|G proteins
14P08415643A0555|3 9|E1 gene
14P08415643A0555|50 53|RCC1
14P08415712A1153|7 28|Southern blot analysis
14P08415712A1153|30 47|chromosome mapping
14P08415712A1153|57 61|GPRK6
14P08415712A1153|154 157|GPRK
14P08415712A1153|172 195|Huntington disease locus
14P08416952A0956|9 24|labeling studies
14P08416952A0956|41 53|co-expression
14P08416952A0956|73 90|protein substrates
14P08416952A0956|92 96|Nmt1p
14P08416952A0956|129 133|Leu99
14P08416952A0956|140 151|substitution
14P08416952A0956|197 214|protein substrates
14P08416977A0892|5 15|CTD kinases
14P08416977A0892|26 30|CTDK1
14P08416977A0892|34 38|CTDK2
14P08417117A0592|45 53|abundance
14P08417330A0149|71 93|heat shock inducibility
14P08417330A0149|109 131|CYC1-lacZ reporter gene
14P08417331A0745|16 24|HIR1 gene
14P08417331A0745|81 94|G beta subunit
14P08417331A0745|148 151|Tup1
14P08417349A1633|25 35|replication
14P08417349A1633|95 105|replication
14P08417349A1633|115 131|mutation fixation
14P08418183A0000|45 56|transmission
14P08418183A0000|64 98|T cell leukemia/lymphoma virus type
14P08418183A0000|97 102|HTLV-I
14P08418183A0000|135 155|Miyazaki Cohort Study
14P08418183A0000|161 168|November
14P08418183A0000|176 180|April
14P08419318A1695|0 3|Biol
14P08419333A0126|33 49|DNA repair enzyme
14P08419338A0273|0 1|L.
14P08419338A0273|3 8|Stange
14P08419338A0273|10 11|G.
14P08419338A0273|13 21|Markovich
14P08419338A0273|23 24|D.
14P08419338A0273|26 30|Biber
14P08419338A0273|32 33|J.
14P08419338A0273|35 40|Testar
14P08419338A0273|42 43|X.
14P08419338A0273|45 51|Zorzano
14P08419338A0273|53 54|A.
14P08419338A0273|56 62|Palacin
14P08419338A0273|64 65|M.
14P08419338A0273|70 74|Murer
14P08419338A0273|76 77|H.
14P08419376A0357|3 21|nucleotide sequence
14P08419376A0357|39 49|polypeptide
14P08419376A0357|55 65|amino acids
14P08420230A0544|0 4|SAECG
14P08420230A0544|6 21|echocardiography
14P08420230A0544|25 44|thallium-201 imaging
14P08420571A1880|14 18|PACE4
14P08420571A1880|22 24|PC4
14P08421295A0365|55 64|DNA duplex
14P08421295A0365|76 79|CTGT
14P08421295A0365|84 107|4ACAG consensus sequence
14P08421295A0365|111 124|LexA repressor
14P08421687A0397|3 25|selenocysteine residues
14P08421823A1041|0 10|CONCLUSIONS
14P08421823A1041|16 35|protein S deficiency
14P08421897A0000|108 131|stringency hybridization
14P08421897A0000|140 149|DNA probes
14P08421897A0000|172 194|animal retrovirus genes
14P08421910A0599|43 47|TRBPs
14P08421910A0599|49 51|p30
14P08421910A0599|53 55|p37
14P08421910A0599|57 59|p46
14P08421910A0599|61 63|p50
14P08421910A0599|68 70|p56
14P08421910A0599|99 105|TAR RNA
14P08421910A0599|122 143|uv cross-linking assay
14P08422975A1205|41 66|kinetoplastid mitochondria
14P08423831A0523|64 69|issues
14P08423831A0523|83 90|diseases
14P08423831A0523|127 136|parameters
14P08425050A0898|81 90|PE operons
14P08425221A0000|48 50|BPK
14P08425221A0000|52 75|B cell progenitor kinase
14P08425221A0000|107 115|B lineage
14P08427501A0221|5 15|differences
14P08427501A0221|64 78|enzyme activity
14P08427501A0221|93 107|enzyme activity
14P08428722A1123|78 102|blood urea nitrogen level
14P08428722A1123|101 138|serum aspartate aminotransferase level
14P08428750T0000|0 11|Localization
14P08428750T0000|72 91|chromosome 10p13-ter
14P08428907A0653|26 39|OBP transcript
14P08428907A0653|91 93|RNA
14P08428940A1763|50 51|PR
14P08428940A1763|86 89|MerR
14P08428940A1763|93 106|RNA polymerase
14P08428952A0399|8 16|L-plastin
14P08428952A0399|101 110|expression
14P08428952A0399|132 144|tumorigenesis
14P08428952A1957|17 24|evidence
14P08428952A1957|52 66|plastin isoform
14P08428952A1957|116 124|intestine
14P08428953A1718|53 79|reporter beta-galactosidase
14P08428953A1718|144 152|L-plastin
14P08428953A1718|240 250|fibroblasts
14P08428953A1718|348 358|fibroblasts
14P08428953A1718|377 396|L-plastin expression
14P08428965A1868|30 52|CBP/tk binding activity
14P08428965A1868|79 86|ABSTRACT
14P08428965A1868|101 105|WORDS
14P08429019A0735|3 7|DNase
14P08429019A0735|33 47|silencer region
14P08429019A0735|142 166|GATA-1 consensus sequence
14P08429019A2022|35 56|YY1 consensus sequence
14P08429019A2022|117 146|yeast ABF-1 consensus sequence
14P08429019A2022|152 159|ABSTRACT
14P08429019A2022|174 178|WORDS
14P08429020A0495|58 60|DNA
14P08429020A0495|78 90|reading frame
14P08429020A0495|93 104|glycoprotein
14P08429568A0000|0 17|Rhizobium meliloti
14P08429568A0000|47 82|nodulation competitiveness locus nfe
14P08429568A0000|97 117|nodulation efficiency
14P08430087A0467|41 52|gamma chains
14P08430087A0467|90 108|beta gamma activity
14P08430087A0467|121 137|membrane extracts
14P08430087A0467|172 180|Sf9 cells
14P08430095A0161|22 35|identification
14P08430095A0161|61 64|SMD1
14P08430095A0161|88 92|PRP38
14P08430095A0913|18 22|Smd1p
14P08430095A0913|56 73|splicing apparatus
14P08430095A0913|85 100|snRNA maturation
14P08431100A0108|32 48|motor performance
14P08431100A0108|78 85|children
14P08431100A0108|114 126|consciousness
14P08431100A0108|155 168|children group
14P08432137A0000|30 48|adenosine deaminase
14P08432137A0000|49 52|PADA
14P08432137A0000|82 101|PADA/serum ADA ratio
14P08432137A0000|101 106|P/SADA
14P08432137A0000|134 137|PLYS
14P08432137A0000|152 171|PLYS/serum LYS ratio
14P08432137A0000|171 176|P/SLYS
14P08432137A0000|198 213|interferon gamma
14P08432137A0000|214 216|IFN
14P08432526A0580|61 99|polymerase chain reaction amplification
14P08432526A0580|100 122|fibroblast cDNA library
14P08432696A1117|0 7|Deletion
14P08432696A1117|56 66|proteinases
14P08432696A1117|81 96|aminopeptidase N
14P08432696A1117|119 129|cell growth
14P08435755A0938|2 11|Experiment
14P08435755A0938|13 36|scopolamine hydrobromide
14P08435755A0938|125 139|stage-3 seizure
14P08435755A1078|0 2|PNT
14P08435755A1078|4 6|ADD
14P08435755A1078|10 12|BSS
14P08435755A1078|41 53|kindling rate
14P08435755A1078|80 97|seizure parameters
14P08435794A0658|0 10|CONCLUSIONS
14P08435885A0787|35 65|pyridinium cross-link excretion
14P08435885A0787|67 96|thyroid hormone concentrations
14P08437521A0000|0 8|Mutations
14P08437521A0000|109 138|nitrogen metabolite repression
14P08437521A0000|198 209|areA product
14P08437521A0000|245 256|areA control
14P08437737A0100|0 14|Naval personnel
14P08438584A0524|4 20|promoter activity
14P08438584A0524|50 51|C1
14P08438584A0524|55 61|C2 ORFs
14P08438584A0524|62 71|C1-C2 gene
14P08438584A0524|94 99|V1 ORF
14P08438584T0000|16 36|coat protein promoter
14P08438584T0000|83 101|C1-C2 gene products
14P08439564A0883|3 31|amino acid sequence alignment
14P08439564A0883|31 32|TC
14P08439564A0883|50 69|Cbl binding proteins
14P08439564A0883|93 108|transcobalamin I
14P08439564A0883|111 129|porcine haptocorrin
14P08439597A0000|58 75|enzyme immunoassay
14P08439597A0000|76 79|FEIA
14P08439597A0000|109 125|fluoroimmunoassay
14P08439597A0176|44 55|study design
14P08439597A0176|66 78|blood samples
14P08439597A0176|87 103|screening centres
14P08440238T0000|12 21|C-terminus
14P08440238T0000|37 47|E1a protein
14P08440238T0000|84 97|phosphoprotein
14P08440238T0000|136 142|T24-ras
14P08440238T0000|151 164|transformation
14P08440238T0000|166 178|tumorigenesis
14P08440688A1509|31 37|G alpha
14P08440688A1509|68 80|LLC-PK1 cells
14P08440688A1509|93 107|differentiation
14P08440688A1509|112 126|hormone signals
14P08440720A1404|0 9|Constructs
14P08440720A1404|34 43|PfCPK cDNA
14P08441379A0912|16 31|proIL-1 beta cap
14P08441379A0912|112 128|enhancer elements
14P08441379A0912|170 179|HeLa cells
14P08441379A0912|211 230|IL-1 beta expression
14P08441394A1297|10 15|PC-PLC
14P08441394A1297|31 57|signal transduction pathway
14P08441394A1297|135 143|PKC-delta
14P08441394A1297|147 160|Ras activation
14P08441411A1260|20 30|splenocytes
14P08441411A1260|32 47|Gfi-1 expression
14P08441411A1260|69 79|stimulation
14P08441411A1260|179 189|interaction
14P08441411A1260|192 195|IL-2
14P08441411A1260|245 246|G1
14P08441411A1260|252 258|S phase
14P08441423A0145|33 36|GCD6
14P08441423A0145|40 49|GCD7 genes
14P08441423A0145|94 109|GCN4 translation
14P08441869A0334|3 19|plateau MO2 value
14P08442384A0430|41 51|amino acids
14P08442384A0430|66 78|reading frame
14P08442384A0430|126 143|amino acid peptide
14P08442384T0000|3 26|SCH9 protein kinase mRNA
14P08443122A0657|12 18|T cells
14P08443122A0657|21 53|fibroblasts PILOT gene expression
14P08443122A0657|73 75|PMA
14P08443339A1374|13 24|localization
14P08443339A1374|27 29|GUS
14P08443339A1374|38 54|promoter function
14P08443339A1374|56 69|leaf epidermis
14P08443340A0522|28 46|expression patterns
14P08443340A0522|68 83|promoter regions
14P08443340A0522|102 115|glucanase gene
14P08443340A0522|120 137|beta-glucuronidase
14P08443340A0522|139 141|GUS
14P08443340A0522|143 155|reporter gene
14P08443340A0522|205 218|tobacco plants
14P08443341A0384|0 21|Southern blot analysis
14P08443341A0384|63 73|B. napus MA
14P08443341A0384|75 88|MB cDNA clones
14P08443341A0384|97 115|MA type myrosinases
14P08443341A0384|151 169|MB type myrosinases
14P08443341A0384|197 204|B. napus
14P08444184A0245|0 8|Sudomoina
14P08444184A0245|10 11|A.
14P08444344A0000|0 11|Zinc fingers
14P08444344A0000|12 13|Zf
14P08444345A0403|16 19|EFIA
14P08444345A0403|89 100|EFIA/DbpB/YB
14P08444345A0403|103 115|family member
14P08444345A0403|135 138|DbpB
14P08445299T0000|0 5|Effect
14P08445299T0000|16 27|insufflation
14P08445299T0000|30 41|deferoxamine
14P08445299T0000|49 62|ozone toxicity
14P08445655A1009|0 11|Localization
14P08445655A1009|17 31|insertion locus
14P08445655A1009|50 72|complementation studies
14P08445729A0657|0 10|Replacement
14P08445729A0657|16 30|spacer sequence
14P08445729A0657|43 46|ARMs
14P08445729A0657|87 97|RNA binding
14P08445792A0469|0 3|Type
14P08445792A0469|40 42|IIA
14P08445792A0469|46 48|IIB
14P08446579A0784|10 36|transcription factor Gal-ER
14P08446579A0784|119 135|activating domain
14P08446579A0784|140 163|herpesvirus protein VP16
14P08446579A0784|169 178|C terminus
14P08446579A1210|64 80|estrogen addition
14P08447005T0001|0 10|Elimination
14P08447005T0001|24 51|influenzae type b meningitis
14P08449133A0578|0 13|Endosonography
14P08449133A0578|51 59|T2 tumors
14P08449133A0578|62 70|T3 tumors
14P08449133A0578|79 87|T4 tumors
14P08449943A0225|57 65|8-Cl-cAMP
14P08449943A0225|88 102|kinase isozymes
14P08449943A0225|104 108|HL-60
14P08449943A0225|127 140|leukemia cells
14P08449978A0000|0 7|Analysis
14P08449978A0000|10 30|cell cycle regulation
14P08449978A0000|99 112|protein kinase
14P08449978A0000|113 117|Cdc28
14P08449986A0455|48 56|MMI alpha
14P08450015A0175|80 101|solid-phase extraction
14P08450015A0175|127 156|n-propyl carbamate derivatives
14P08451187A0267|24 34|differences
14P08451187A0267|51 63|ars sequences
14P08451331T0000|0 7|Pathways
14P08451331T0000|61 72|hypothalamus
14P08451331T0000|97 106|aggression
14P08453101A0128|0 15|Pokeweed mitogen
14P08453101A0128|16 18|PWM
14P08453101A0128|52 70|c-jun messenger RNA
14P08453101A0128|83 89|T cells
14P08453950A0498|9 25|seizure induction
14P08453950A0498|26 29|MABP
14P08454077A0956|24 30|U74500A
14P08454077A0956|33 51|mg/kg i.v. infusion
14P08454077A0956|72 88|revascularisation
14P08454077A0956|107 110|GMBF
14P08454077A0956|133 134|PI
14P08454077A0956|243 256|muscle salvage
14P08454077A0956|257 259|GMV
14P08454077A0956|320 321|NS
14P08454077A0956|350 357|ABSTRACT
14P08454077A0956|372 376|WORDS
14P08454591A0692|0 9|Sequencing
14P08454591A0692|60 68|TSG6 gene
14P08454591A0692|90 103|CAAT sequences
14P08454591A0692|110 133|transcription start site
14P08454591A1322|34 37|IL-1
14P08454591A1322|40 42|TNF
14P08454591A1322|95 99|IRF-1
14P08454591A1322|106 109|AP-1
14P08454591A1322|114 120|NF-IL-6
14P08454858A0285|0 7|Ig-alpha
14P08454858A0285|11 17|Ig-beta
14P08454858A0285|160 178|signal transduction
14P08455598A0000|55 67|alpha * cells
14P08455598A0000|75 97|a/alpha aar1-6 genotype
14P08455598A0000|107 126|alpha mating ability
14P08455598A0000|133 146|mating ability
14P08455598A0000|166 173|a1-alpha
14P08455611A0000|22 32|interaction
14P08455611A0000|59 73|globin promoter
14P08455611A0000|79 90|alpha globin
14P08455611A0000|108 112|HS-40
14P08455611A0000|143 153|globin gene
14P08455611A0154|21 36|expression assay
14P08455611A0154|40 44|HS-40
14P08455611A0154|91 114|globin promoter activity
14P08455611A0154|115 124|K562 cells
14P08455623A0630|30 41|23S pre-rRNA
14P08455623A0630|114 126|proteins NOP1
14P08455623A0630|129 132|GAR1
14P08455629A0335|0 8|Breitbart
14P08455629A0335|10 11|L.
14P08456378A0134|21 31|feasibility
14P08456378A0134|52 67|lymphangiography
14P08456378A0134|83 91|technique
14P08456879A0000|0 8|OBJECTIVE
14P08456879A0000|49 62|concentrations
14P08456879A0000|65 78|serum cotinine
14P08457205A0240|8 26|amino acid sequence
14P08457205A0240|75 93|% sequence identity
14P08457205A0240|123 129|G alpha
14P08457205A0240|134 140|G alpha
14P08457291A0170|0 8|Estradiol
14P08457291A0170|43 57|proto-oncogenes
14P08457291A0170|119 132|c-fos oncogene
14P08458660A0855|0 7|Air lead
14P08458849A0364|13 22|regulation
14P08458849A0364|25 42|flaN transcription
14P08458849A0364|79 90|ftr elements
14P08458849A0364|112 135|transcription start site
14P08458906A0827|1 12|micrograms/l
14P08459012T0000|7 13|dimelia
14P08459012T0000|18 27|deficiency
14P08459465A0257|39 57|energy expenditures
14P08459465A0257|116 133|energy expenditure
14P08459465A0257|188 205|energy expenditure
14P08459465A0257|221 244|energy expenditure times
14P08459465A0257|246 260|activity factor
14P08459465A0257|265 277|stress factor
14P08460270A0205|21 30|infections
14P08460346A0350|62 66|study
14P08460918A0252|0 4|Group
14P08460918A0252|151 170|alkaline phosphatase
14P08460918A0252|174 183|IU liter-1
14P08460918A0252|184 211|gamma-glutamyltranspeptidase
14P08460918A0252|216 225|IU liter-1
14P08460918A0252|312 329|hyperbilirubinemia
14P08461946A0386|26 36|improvement
14P08461946A0386|59 67|t1/2 time
14P08461946A0386|73 86|split function
14P08461981A0882|64 85|regeneration phenomena
14P08463284A1531|13 15|PKC
14P08463284A1531|21 34|p34cdc2 kinase
14P08463320A1219|6 39|copper-phenanthroline footprinting
14P08463320A1219|51 82|gel shift assembly intermediates
14P08463320A1219|126 138|SSB tetramers
14P08463320A1219|175 187|SSB tetramers
14P08463485T0000|0 6|Effects
14P08463485T0000|21 38|endotoxin infusion
14P08463485T0000|55 70|oxytocin release
14P08464056A0000|0 5|Finger
14P08464056A0000|39 46|FAX-ZFPs
14P08464056A0000|77 90|C2H2 type ZFPs
14P08464056A0000|91 104|Xenopus laevis
14P08464056A0510|42 68|FAX-ZFP transcription units
14P08464056A0510|79 100|Southern blot analysis
14P08464056A0510|113 133|restriction fragments
14P08464056A0510|154 178|field gel electrophoresis
14P08464924A0243|1 8|rat cDNA
14P08464924A0243|95 107|eIF-5 protein
14P08466864A0878|105 107|AMP
14P08466864A0878|118 140|element binding protein
14P08466864A0878|140 143|CREB
14P08466864A0878|159 166|TGF-beta
14P08466864A0878|171 188|PMA responsiveness
14P08466864A0878|199 202|PU-1
14P08466864A0878|206 222|Sp1 binding sites
14P08466864A0878|229 245|promoter activity
14P08468320A0941|6 7|J.
14P08468475A1280|17 38|internalization assays
14P08468475A1280|57 66|YT-1 cells
14P08468475A1280|70 86|IL-2R alpha chain
14P08468475A1280|125 142|IL-2R beta subunit
14P08468475A1280|155 165|IL-2R alpha
14P08468475A1280|190 212|F42A-IL-2R beta complex
14P08468475A1280|272 292|F42A binding reaction
14P08469831T0001|19 26|dynamics
14P08469831T0001|29 44|prostaglandin E1
14P08469831T0001|50 60|nicardipine
14P08469831T0001|78 86|reactions
14P08469831T0001|133 141|rat model
14P08470021A0195|25 38|IgG antibodies
14P08470021A0195|45 61|Trypanosoma cruzi
14P08470021A0195|86 103|Instituto Nacional
14P08470021A0195|105 115|Cardiologia
14P08470021A0195|117 130|Ignacio Chavez
14P08470021A0195|133 143|Mexico City
14P08470895A1617|0 10|Examination
14P08470895A1617|40 54|mRNA start site
14P08470895A1617|62 69|TATA box
14P08470895A1617|85 102|enhancer sequences
14P08471241T0000|13 21|synthesis
14P08471241T0000|41 47|removal
14P08471629A0816|0 14|Pseudosubstrate
14P08471629A0816|37 46|C-terminus
14P08471629A0816|61 72|PKC isotypes
14P08471629A0816|119 130|Histone IIIS
14P08471796A1654|54 68|gene expression
14P08471796A1654|70 83|A. caulinodans
14P08472750A0999|6 21|oxide inhalation
14P08472750A0999|48 59|hypertension
14P08472750A0999|62 84|porcine endotoxin shock
14P08473731A0149|21 29|B29 genes
14P08473731A0149|38 58|alpha/beta components
14P08473731A0149|97 103|B cells
14P08473967T0000|12 30|Jungian type theory
14P08473967T0000|35 61|Myers-Briggs Type Indicator
14P08474438A0000|17 34|ribonucleoproteins
14P08474438A0000|76 89|RNA polymerase
14P08474438A0000|144 167|RNA processing reactions
14P08474438A0000|176 199|pre-mRNA polyadenylation
14P08474439A0877|0 8|Mutations
14P08474439A0877|75 87|site mutation
14P08474439A0877|121 132|muscle types
14P08474439A0877|147 150|MEF1
14P08474439A0877|157 161|E-box
14P08474439A0877|234 242|CArG site
14P08474456A1041|9 29|transfection analysis
14P08474456A1041|98 100|Ets
14P08474456A1041|112 130|LyF-1 binding sites
14P08474456A1041|142 152|D' activity
14P08474464A0348|35 36|TR
14P08474464A0348|38 44|Rev-Erb
14P08474464A0348|58 73|TR binding sites
14P08475104A0341|22 37|promoter element
14P08475104A0341|71 85|G1-S activation
14P08475104A0341|95 110|thymidine kinase
14P08475104A0341|179 195|p33cdk2 complexes
14P08476087A0814|15 24|influences
14P08476087A0814|64 72|pressures
14P08476854A0097|0 4|DNase
14P08476854A0097|89 90|P1
14P08476854A0097|98 99|P7
14P08476854A0097|106 127|base pair DNA fragment
14P08479742A0985|52 54|p53
14P08479742A0985|64 81|cell proliferation
14P08481004A0321|29 40|endonuclease
14P08482539A0913|0 21|Northern blot analysis
14P08482539A0913|35 37|RNA
14P08483412A0000|10 23|nifH promoters
14P08483412A0000|25 34|Klebsiella
14P08483412A0000|127 138|NifA protein
14P08483479A1056|17 19|PTH
14P08483479A1056|37 62|collagen promoter activity
14P08483479A1056|117 133|collagen promoter
14P08483479A1056|146 165|elements down-stream
14P08483479A1056|191 193|PTH
14P08483479A1056|197 211|cAMP repression
14P08483479A1056|213 236|collagen gene expression
14P08484514A1536|44 65|baseline vein diameter
14P08484689T0000|0 9|Prevalence
14P08484689T0000|22 30|arthritis
14P08484891A0000|28 39|conditioning
14P08484891A0000|90 96|changes
14P08484891A0000|122 129|evidence
14P08484891A0000|153 160|circuits
14P08484891A0000|194 201|memories
14P08485317A0000|3 20|fission yeast dsk1
14P08485317A0000|62 73|dis1 mutants
14P08485317A0000|92 105|protein kinase
14P08486035T0000|0 6|Closure
14P08486035T0000|12 35|patent ductus arteriosus
14P08486035T0000|39 46|Ligaclip
14P08486276A0419|0 18|Sequence comparison
14P08486276A0419|38 40|ORF
14P08486276A0419|45 60|protein database
14P08486276A0419|84 105|% aa sequence homology
14P08486276A0419|128 129|TM
14P08486276A0419|162 176|chloramphenicol
14P08486276A0419|178 179|Cm
14P08486276A0419|197 198|Tc
14P08486276A0419|231 245|symport protein
14P08486705A0181|39 42|TIF5
14P08486705A0181|115 127|eIF-5 protein
14P08488700A0283|3 12|strategies
14P08488700A0283|20 30|hepatitis B
14P08488700A0283|33 43|hepatitis D
14P08488700A0283|85 96|immunization
14P08488700A0283|141 157|blood derivatives
14P08488700A0283|160 168|education
14P08488700A0283|182 190|awareness
14P08488700A0283|195 205|hepatitis B
14P08490002A0620|0 5|Xylose
14P08491124A0517|12 23|construction
14P08491124A0517|29 44|mouth protectors
14P08491124A0517|72 86|instrumentation
14P08491124A0517|139 154|mouth protectors
14P08491383A0154|40 42|DNA
14P08491383A1291|67 87|transcription factors
14P08491383A1291|129 147|interaction domains
14P08491683A0651|5 12|patients
14P08491683A0651|23 30|patients
14P08491683A0651|50 57|patients
14P08491683A0651|82 95|adenocarcinoma
14P08491683A0651|101 108|prostate
14P08492164T0000|11 22|burst firing
14P08492164T0000|55 70|depth dependence
14P08492164T0000|90 109|interaction measures
14P08492290A0306|56 66|strength mu
14P08492290A0306|74 92|stability constants
14P08495786A0085|0 22|Cryopreservation straws
14P08496157A0000|73 86|carboxyl tails
14P08496157A0000|108 125|splicing mechanism
14P08496184A0772|13 25|reading frame
14P08496184A0772|57 66|chromosome
14P08496184A0772|98 113|type counterpart
14P08496185A0484|20 47|nucleotide sequence analysis
14P08496185A0484|51 52|S.
14P08496185A0484|58 78|adenylate kinase gene
14P08496475T0000|0 12|Calcification
14P08496475T0000|26 38|Streptococcus
14P08496475T0000|44 58|Corynebacterium
14P08496475T0000|60 71|Bacterionema
14P08496599A0310|34 41|BGP gene
14P08496599A0310|78 89|mRNA species
14P08496601A1153|71 82|CK-1 element
14P08496601A1153|95 112|expression studies
14P08496601A1153|114 116|RAW
14P08496601A1153|216 265|growth hormone reporter gene link LPS-inducibility
14P08496601A1153|269 285|promoter segments
14P08496601A1153|315 337|consensus CK-1 sequence
14P08496848A0692|54 66|FSE sequences
14P08496848A0692|95 108|SE counterpart
14P08497190T0079|0 16|Sequence analysis
14P08497190T0079|19 32|identification
14P08497248A0000|65 69|CSF-1
14P08497248A0000|75 93|c-fms protooncogene
14P08497248A0000|159 170|trophoblasts
14P08497259A0452|13 33|SUP4A53T61 transcript
14P08497269A0999|4 22|sequence similarity
14P08497269A0999|46 49|GCN1
14P08497269A0999|74 87|tRNA molecules
14P08497269A0999|116 119|GCN2
14P08497269A0999|169 190|translation elongation
14P08497273T0000|0 4|NF-HB
14P08497273T0000|6 9|BSAP
14P08497273T0000|89 110|B-cell differentiation
14P08497280A0266|20 23|SWI4
14P08497280A0266|43 64|cell cycle progression
14P08497280A0266|114 131|SWI4 transcription
14P08497280A1397|55 72|SWI4 transcription
14P08497280A1397|86 89|SWI6
14P08497280T0000|47 64|SWI4 transcription
14P08498570A1118|22 46|carotid sinus stimulation
14P08498570A1118|93 97|Pcrit
14P08498570A1118|101 102|Ra
14P08499376A0000|9 11|PRK
14P08499376A0000|41 54|predictability
14P08499903A0883|4 11|patients
14P08499903A0883|16 24|deletions
14P08499903A0883|45 52|deletion
14P08499916A0000|3 13|COL7A1 gene
14P08499916A0000|26 42|type VII collagen
14P08499916A0000|128 148|epidermolysis bullosa
14P08500524A0424|87 102|splicing signals
14P08500524A0424|120 138|intron organization
14P08500938A0408|22 25|BGCT
14P08500938A0408|109 118|metaphysis
14P08501030A0456|31 50|.5 operon expression
14P08501030A0456|90 93|M.H.
14P08501678A0498|59 85|immunoprophylactic strategy
14P08501678A0498|99 109|Hib disease
14P08503348A0226|3 30|HMG CoA reductase inhibitors
14P08504707A0376|3 10|etiology
14P08504707A0376|12 20|pathology
14P08504707A0376|22 29|brain CT
14P08504707A0376|33 40|features
14P08504707A0376|50 63|manifestations
14P08504707A0376|67 75|treatment
14P08504707A0376|83 91|accidents
14P08504928T0000|16 28|TFIID subunit
14P08504928T0000|57 79|cell cycle gene product
14P08504928T0000|97 107|DNA binding
14P08504928T0000|112 115|TATA
14P08504928T0000|136 140|TFIID
14P08504932A0123|20 41|GATA factor expression
14P08504932A0123|53 65|GATA proteins
14P08504933A0000|0 4|Pit-1
14P08504933A0000|23 39|POU domain factor
14P08504933A0000|71 85|cell phenotypes
14P08505075A0236|0 13|Maximum number
14P08505075A0236|44 63|S. bareilly serotype
14P08505075A0236|103 110|S. typhi
14P08505312A0285|0 3|Biol
14P08505340T0000|0 15|Characterization
14P08505340T0000|55 93|rat prostaglandin endoperoxide synthase
14P08505495A0253|14 21|75SeHCAT
14P08505605A0461|0 22|Patient characteristics
14P08505605A0461|64 84|wound characteristics
14P08506317A0000|0 6|Members
14P08506317A0000|12 23|C/EBP family
14P08506317A0000|25 44|basic-leucine zipper
14P08506317A0000|50 70|transcription factors
14P08506317A0000|98 105|CAAT box
14P08506317A0000|129 143|enhancer motifs
14P08506384A0146|17 31|phosphorylation
14P08506384A0146|75 97|GDP-GTP exchange factor
14P08507921A1021|18 29|observations
14P08507921A1021|46 59|stratification
14P08507921A1021|67 77|MI patients
14P08507921A1021|79 94|plasma ANF level
14P08507921A1021|159 169|individuals
14P08508774A0242|0 7|Analysis
14P08508774A0242|22 24|Lrp
14P08508774A0242|51 63|DNA fragments
14P08508774A0242|90 92|Lrp
14P08508774A0242|100 102|DNA
14P08508778A0112|0 12|Yeast mutants
14P08508778A0112|30 38|NOP1 gene
14P08508861A0294|80 103|lactate extraction ratio
14P08508861A0294|108 124|balloon inflation
14P08509051A0316|12 19|patients
14P08509051A0316|32 45|mortality rate
14P08509333A0843|35 51|membrane fraction
14P08509333A0843|121 124|FtsN
14P08509333A0843|129 144|membrane protein
14P08509335T0000|0 3|SSG1
14P08509335T0000|39 56|1,3-beta-glucanase
14P08509419A0785|0 9|Expression
14P08509419A0785|110 123|TyrRS activity
14P08509430A0372|16 30|complementation
14P08509430A0372|59 71|Chlamydomonas
14P08509430A0372|73 79|CC-2341
14P08509430A0372|102 120|frameshift mutation
14P08509430A0372|162 174|transformants
14P08510320A0000|61 64|MRSA
14P08510320A0000|106 119|concentrations
14P08510320A0000|121 124|MICs
14P08510320A0000|176 178|ABK
14P08510320A1249|36 40|MRSAs
14P08510320A1249|52 56|Japan
14P08510320A1249|156 167|beta-lactams
14P08510647A1347|0 3|Beg2
14P08510647A1347|7 10|Beg1
14P08510647A1347|70 91|utilization properties
14P08510647A1347|99 114|barley globulins
14P08510924A0490|59 72|HSP70 promoter
14P08510924A0490|74 85|Myb proteins
14P08511994A0000|58 69|ichthiomycin
14P08511994A0000|72 85|concentrations
14P08511994A0000|99 112|micrograms/dm3
14P08512728A0991|0 6|RESULTS
14P08512728A0991|32 42|differences
14P08512728A0991|121 132|fibrillation
14P08512728A0991|152 168|accessory pathway
14P08512728A0991|171 172|RR
14P08513025A0000|28 36|thickness
14P08513025A0000|42 52|correlation
14P08513025A0000|70 84|bilirubin level
14P08513025A0000|101 109|bilirubin
14P08513025A0000|111 113|TcB
14P08514757A1100|4 16|immunophilins
14P08514757A1100|40 56|receptor assembly
14P08514757A1100|112 121|modulators
14P08514757A1100|124 139|protein function
14P08514766A0732|3 17|GTPase activity
14P08514766A0732|19 25|CDC42Ce
14P08514766A0732|105 112|p21 rac1
14P08515619A0184|0 18|Tl-201 uptake ratio
14P08515619A0184|123 128|Tl-201
14P08515619A0184|141 144|COPD
14P08515619A0184|179 189|B type COPD
14P08515619A0184|190 211|Burrows classification
14P08515776A0971|18 23|domain
14P08515776A0971|49 55|regions
14P08515776A0971|86 91|region
14P08516301A0080|36 40|exons
14P08516301A0080|48 54|introns
14P08516308A0669|12 14|RAD
14P08516308A0669|37 49|microcolonies
14P08516324A0000|19 31|translocation
14P08516324A0000|52 64|Ewing sarcoma
14P08516324A0000|166 173|EWS gene
14P08516324A0000|224 232|FLI1 gene
14P08517737A0889|5 12|findings
14P08517737A0889|50 59|conditions
14P08517737A0889|79 91|water systems
14P08517737A0889|109 119|populations
14P08517737A0889|122 129|bacteria
14P08518797T0000|8 25|liver glycogenosis
14P08518797T0000|26 37|localization
14P08518797T0000|53 66|candidate gene
14P08519621A0150|4 13|conclusion
14P08519621A0150|26 37|observations
14P08519621A0150|125 135|association
14P08519621A0150|155 162|bacteria
14P08519862T0001|0 10|Measurement
14P08519862T0001|21 34|IgM antibodies
14P08520646A0000|0 22|Embryo coculture system
14P08521414A1384|39 48|CpG island
14P08521414A1384|73 80|p16INK4A
14P08521414A1384|160 166|E1 beta
14P08521414A1384|200 213|p16INK4A locus
14P08521717A0126|27 36|PAP method
14P08521717A0126|55 60|Factor
14P08521717A0126|134 139|Factor
14P08521717A0126|204 213|LNG-IUD-20
14P08521780A0485|0 9|Umweltchem
14P08522175A0306|0 4|Egd1p
14P08522175A0306|24 28|BTF3b
14P08522175A0306|120 122|NAC
14P08522175A0306|166 180|protein sorting
14P08522175A0306|197 204|Wiedmann
14P08522175A0306|211 216|Nature
14P08522511A1250|8 10|PLB
14P08522511A1250|24 37|lyase activity
14P08522511A1578|66 88|beta-glucuronidase gene
14P08522511A1578|105 106|F.
14P08522511A1578|126 154|beta-glucuronidase activities
14P08522511A1578|159 171|transformants
14P08522530A1342|4 12|nifA mRNA
14P08522530A1342|37 52|primer extension
14P08522530A1342|71 80|transcript
14P08522530A1342|107 115|anaerobox
14P08522530A1342|135 144|transcript
14P08523031A0737|68 75|seizures
14P08523031A0737|94 99|stroke
14P08523031A0737|103 112|recurrence
14P08523545T0000|8 26|papillomavirus type
14P08523545T0000|28 37|E7 protein
14P08523545T0000|63 65|E1A
14P08523545T0000|144 146|ATF
14P08523545T0000|150 175|Oct-1 DNA binding activity
14P08523566A1106|11 19|detergent
14P08523566A1106|24 37|% Nonidet P-40
14P08523566A1106|53 63|interaction
14P08523566A1106|107 117|interaction
14P08524036A0747|10 21|expectations
14P08524036A0747|72 86|enhancer region
14P08524036A0747|96 114|point substitutions
14P08524036A0747|117 135|insertion/deletions
14P08524229T0000|36 78|bisphosphate carboxylase small-subunit mRNA
14P08524229T0000|77 80|SRS4
14P08524235A0695|0 6|Cloning
14P08524235A0695|10 19|sequencing
14P08524235A0695|45 52|deletion
14P08524235A0695|154 161|splicing
14P08524235A0695|164 170|max RNA
14P08524241A0212|26 30|HSP82
14P08524241A0212|59 67|IME1-IME2
14P08524260A0835|3 18|domain structure
14P08524260A0835|26 31|LTBP-2
14P08524260A0835|61 66|LTBP-2
14P08524260A0835|150 167|consensus sequence
14P08524260A0835|170 184|calcium binding
14P08524260A0835|253 258|LTBP-1
14P08524267A1022|10 19|expression
14P08524267A1022|54 75|prothymosin alpha gene
14P08524267A1022|104 113|repertoire
14P08524267A1022|181 191|myc mutants
14P08524272T0000|58 73|Jak/Stat pathway
14P08524272T0000|78 80|SH2
14P08524272T0000|98 124|tyrosine phosphatase SHPTP1
14P08524284A0309|51 59|PTF gamma
14P08524284A0309|62 70|PTF delta
14P08524284A0309|139 149|PTF complex
14P08524284A0309|151 163|HeLa extracts
14P08524292A1022|0 6|Results
14P08524292A1022|44 46|YY1
14P08524292A1022|93 95|AP1
14P08524292A1022|123 125|YY1
14P08524292A1022|147 157|DNA binding
14P08524294A0652|3 6|skp1
14P08524294A0652|8 11|gene
14P08524314A0216|3 6|TEA1
14P08524314A0216|8 28|Ty enhancer activator
14P08524314A0216|28 40|gene sequence
14P08524314A0216|70 79|N terminus
14P08524314A0216|102 119|dimerization motif
14P08525186A0288|0 7|Refugees
14P08525186A0288|16 19|Lund
14P08525186A0288|36 40|Chile
14P08525186A0288|102 113|counterparts
14P08526620A1344|42 66|SC5b-9 complement complex
14P08526620A1344|99 119|complement activation
14P08528479A0000|0 17|Videonystagmoscopy
14P08528796A1470|3 5|MCA
14P08528796A1470|9 20|UA PI values
14P08529098A0549|8 28|sequence similarities
14P08529098A0549|81 84|SMF1
14P08529098A0549|88 91|SMF2
14P08529098A0549|157 169|transmembrane
14P08529098A0549|200 222|susceptibility mutation
14P08529098A0549|250 264|transport motif
14P08529630A0840|26 39|P protein mRNA
14P08529654A0589|3 53|B. germanica cyclophilin amino acid sequence shares
14P08529662A0507|42 52|ERp57/GRP58
14P08529662A0507|55 70|Western blotting
14P08530105A0308|27 59|Langer-Giedion syndrome deletions
14P08530107A1003|81 103|histidase transcription
14P08530149A0689|0 9|Comparison
14P08530149A0689|49 66|consensus sequence
14P08530149A0689|81 83|Inr
14P08530149A0689|93 95|TCA
14P08530149A0689|100 104|YYYNY
14P08530342T0000|8 20|gp39 promoter
14P08530345A0880|0 20|Transfection analyses
14P08530345A0880|55 67|TGACCT motifs
14P08530345A0880|90 96|HD PPRE
14P08530345A0880|109 111|DR1
14P08530345A0880|115 125|DR2 element
14P08530345A0880|173 179|HD PPRE
14P08530345A0880|181 204|peroxisome proliferators
14P08530369A0099|57 90|consensus autophosphorylation site
14P08530369A0099|96 122|Src family tyrosine kinases
14P08530384A0559|68 79|Oct proteins
14P08530384A0559|81 83|DNA
14P08530384A0559|92 114|resolution footprinting
14P08530384A0559|157 159|BOB
14P08530384A0559|170 173|Oct1
14P08530384A0559|176 179|Oct2
14P08530384A0559|210 212|DNA
14P08530418A1182|30 48|TR2 orphan receptor
14P08530418A1182|101 104|HREs
14P08530418A1182|106 114|RARE beta
14P08530418A1182|117 123|CRBPIIp
14P08530418A1182|146 177|acid signal transduction pathway
14P08530432A0093|20 27|proteins
14P08530432A0093|48 54|domains
14P08530432A0093|69 78|activation
14P08530432A0093|81 90|repression
14P08530503A1004|6 8|ARF
14P08530503A1004|13 32|ARP immunoreactivity
14P08530503A1004|89 100|3T3-L1 cells
14P08531373A0470|56 73|skin manifestation
14P08531373A0470|86 105|SS-A/SS-B antibodies
14P08531669A0950|0 10|Competition
14P08531669A0950|41 55|Central America
14P08531669A0950|58 73|Caribean islands
14P08532516A0000|21 30|properties
14P08532516A0000|36 50|cdc10-C4 mutant
14P08532516A0000|55 67|fission yeast
14P08532536A0925|0 14|TIEG expression
14P08532536A0925|43 50|TGF-beta
14P08532536A0925|81 85|BMP-2
14P08532536A0925|134 136|EGF
14P08532536A0925|160 183|growth factors/cytokines
14P08532967A0364|12 17|origin
14P08532967A0364|62 68|therapy
14P08533472A0777|29 38|ORFs N2417
14P08533472A0777|108 155|Candida maltosa cycloheximide-resistance protein
14P08533472A0777|196 200|ILF-2
14P08533473A0375|31 39|ADH1 gene
14P08533473A0375|80 92|EST sequences
14P08533757A0204|14 37|Ashkenazi Jewish descent
14P08533757A0204|46 62|185delAG mutation
14P08533757A0204|140 144|BRCA1
14P08534217A0402|39 53|pollution level
14P08534217A0402|61 63|FVC
14P08534217A0402|67 77|FEV1 values
14P08534217A0402|93 106|Viskovo region
14P08534367A0984|0 5|PTP-S3
14P08534367A0984|17 22|PTP-S4
15P08534848A0188a|8 18|NR isoforms
15P08534848A0188b|8 18|NR isoforms
14P08534855A0000|3 23|Arabidopsis FAD7 gene
14P08534855A0000|30 48|chloroplast omega-3
14P08534855A0000|53 67|acid desaturase
14P08535138A0857|57 69|cell division
14P08535138A0857|84 97|plant hormones
14P08535138A0857|98 117|cycMs4 transcription
14P08535138A0857|143 155|DNA synthesis
14P08535537A0000|34 44|backgrounds
14P08535537A0000|66 79|drug treatment
14P08535537A0000|90 101|hypertension
14P08536694A0000|0 14|Protein kinases
14P08537388A0825|137 142|WNT-5A
14P08537388A0825|163 179|promoter activity
14P08537403A0336|3 24|protein kinase domains
14P08537403A0336|25 29|LIMK1
14P08537403A0336|33 37|LIMK2
14P08537403A0336|73 110|sequence motif Asp-Leu-Asn-Ser-His-Asn
14P08537403A0336|120 122|VIB
14P08537403A0336|167 170|VIII
14P08538052A0000|40 59|amino acids residues
14P08538052A0000|80 86|THZif-1
14P08538052A0000|150 168|leukemia HL60 cells
14P08538052A0000|180 206|oligodeoxynucleotide probes
14P08538052A0000|227 246|amino acid sequences
14P08538052A0000|339 341|NHE
14P08538382A1012|0 13|Erythrocyte AA
14P08538382A1012|15 20|FO+EPO
14P08538483A0207|10 29|consideration weight
14P08538483A0207|64 68|TBBMC
14P08538483A0207|81 105|body bone mineral content
14P08538483A0207|135 147|GnRH agonists
14P08538483A0207|160 172|endometriosis
14P08538702A0214|45 58|ABA-1 allergen
14P08538702A0214|60 66|Ascaris
14P08538702A0214|96 108|Brugia malayi
14P08538702A0214|109 122|Brugia pahangi
14P08538702A0214|164 182|Dirofilaria immitis
14P08541499A0306|7 25|transcript patterns
14P08541499A0306|27 43|Epifagus plastids
14P08541793A0796|11 18|recovery
14P08542026A0792|0 2|DAF
14P08542026A0792|8 22|kD glycoprotein
14P08542026A0792|57 73|consensus repeats
14P08542026A0792|74 77|SCRs
14P08542026A0792|113 133|complement activation
14P08542026A0792|134 136|RCA
14P08542027A1471|3 10|XS2 gene
14P08542027A1471|53 60|LU genes
14P08542027A1471|88 91|CD44
14P08542746T0000|0 12|Diabetes care
14P08543173A0314|9 16|TATA box
14P08543173A0314|71 95|primer extension analysis
14P08543275A0130|14 26|investigation
14P08543275A0130|44 61|pseudoterranovosis
14P08543275A0130|141 153|Arctic region
14P08543275A0130|178 186|Japan Sea
14P08543595A1093|13 22|efficacies
14P08543595A1093|33 43|carboplatin
14P08543595A1093|58 69|radiotherapy
14P08543810A0000|48 59|coelomocytes
14P08543810A0000|121 132|cDNA library
14P08543810A0000|156 168|sequence tags
14P08543810A0000|169 172|ESTs
14P08544820T0000|0 15|Characterization
14P08544820T0000|20 50|EcR/USP heterodimer target site
14P08544820T0000|60 82|ecdysone responsiveness
14P08545502A0914|5 9|SPECT
14P08545502A0914|29 31|PET
14P08546707T0000|30 50|chicken lysozyme gene
14P08546707T0000|51 63|NF-kappa Bp65
14P08546707T0000|64 67|RelA
14P08546707T0000|86 98|NF-kappa Bp50
14P08547205A1060|36 51|agents alinidine
14P08547205A1060|54 64|zatebradine
14P08547205A1060|104 106|SVT
14P08548291A1059|28 32|SAPKs
14P08548291A1059|81 85|Elk-1
14P08548291A1059|87 107|serum response factor
14P08548291A1059|112 133|serum response element
14P08549706T0000|12 38|hepatitis B virus infection
14P08549706T0000|63 69|Iceland
14P08549859A1604|56 103|Centre d'Etude du Polymorphisme Humain pedigrees
14P08550425A1401|49 51|POR
14P08550425A1401|76 97|Halobacterium halobium
14P08550460A0374|85 101|protein precursor
14P08550460A0374|121 156|membrane lipoprotein leader sequence
14P08550461A0284|0 5|Cheung
14P08550461A0284|9 10|S.
14P08550462A0815|0 7|Upstream
14P08550462A0815|26 38|reading frame
14P08550462A0815|43 53|amino acids
14P08550467A0863|16 25|regulation
14P08550467A0863|83 84|OB
14P08550467A0863|94 102|positions
14P08550467A0863|144 153|start site
14P08550470A1021|9 12|CheW
14P08550470A1021|59 69|kinase CheA
14P08550476A0610|45 66|activator protein EpiQ
14P08550476A0610|109 125|EpiQ binding site
14P08550476A0610|129 141|epiA promoter
14P08550476A0610|164 167|EpiQ
14P08550564T0000|0 13|CXC chemokines
14P08550564T0000|31 54|selectivity determinants
14P08550564T0000|130 154|interleukin-8 receptor B.
14P08551572A0155|0 20|Oligodeoxynucleotides
14P08551572A0155|44 73|translation initiation regions
14P08551572A0155|74 77|ICP4
14P08551572A0155|114 123|MSB1 cells
14P08551572A0155|129 137|MDCC-CU91
14P08551572A0155|139 142|CU91
14P08551572A0155|144 164|reticuloendotheliosis
14P08551577A0000|85 87|DNA
14P08551577A0000|116 131|envelope protein
14P08551577A0000|136 153|Rous sarcoma virus
14P08552042A1497|21 40|promoter methylation
14P08552042A1497|102 110|reduction
14P08552042A1497|133 143|mRNA levels
14P08552042A1497|191 202|reactivation
14P08552042A1497|216 226|generations
14P08552045A0973|8 26|consensus sequences
14P08552045A0973|29 50|phosphatase regulation
14P08552045A0973|56 66|GCACGTGGG-3
14P08552045A0973|74 84|GCACGTTTT-3
14P08552045A0973|104 120|binding sequences
14P08552045A0973|126 138|Cpflp protein
14P08552045A0973|174 196|methionine biosynthesis
14P08552045A0973|202 220|centromere function
14P08552082A0480|39 41|CAP
14P08552082A0480|59 69|SH3 domains
14P08552082A0480|120 132|protein Abp1p
14P08552086A0150|33 58|vitamin D response element
14P08552086A0150|57 60|VDRE
14P08552092A1678|12 26|protein binding
14P08552092A1678|59 68|regulation
14P08552092A1678|71 83|transcription
14P08552092A1678|92 103|footprinting
14P08552092A1678|115 129|promoter region
14P08552092A1678|144 157|protein factor
14P08552093A0657|0 14|Differentiation
14P08552093A0657|120 128|Gq family
14P08552093A0657|130 139|G proteins
14P08552095A0686|29 41|transcription
14P08552095A0686|43 47|Paf1p
14P08552095A0758|30 46|yeast transcripts
14P08552095A0758|134 137|PAF1
14P08552095A1115|0 4|Paf1p
14P08552095A1115|53 62|regulation
14P08552095A1115|74 84|yeast genes
14P08552096A0151|15 34|suppression strategy
14P08552096A0151|62 65|UBS1
14P08552096A0151|114 131|cell cycle defects
14P08552096A0151|144 158|cdc34 mutations
14P08552387A0000|9 24|characterization
14P08552387A0000|72 83|cell sarcoma
14P08552387A0000|102 125|chromosome translocation
14P08552387A0000|141 143|EWS
14P08552387A0000|164 180|factor gene ATF-1
14P08552643A0261|0 5|Clones
14P08552643A0261|19 21|DBD
14P08552643A0261|105 120|stomatitis virus
14P08552643A0261|121 123|VSV
14P08552643A0261|138 150|IFN treatment
14P08552670A0665|0 3|Abp1
14P08552670A0665|40 42|ARS
14P08552670A0665|55 70|DNA polymer poly
14P08552670A0665|72 74|A.T
14P08552670T0000|0 13|Identification
14P08552670T0000|15 26|purification
14P08552670T0000|100 112|fission yeast
14P08553580A0102|23 26|ORF2
14P08553580A0102|61 72|FIV isolates
14P08554069A0743|70 83|T transversion
14P08554069A0743|92 111|acceptor splice site
14P08554069A0743|149 160|RNA splicing
14P08554540A1480|26 55|HIT protein similarity regions
14P08554723A0187|71 73|PBN
14P08554723A0187|75 78|PBNx
14P08554723A0187|127 129|CTA
14P08554723A0187|161 175|sodium appetite
14P08554723A0187|184 203|furosemide treatment
14P08555076A0333|9 22|Amphotericin-B
14P08555076A0333|91 101|Aspergillus
14P08555076A0333|110 116|Candida
14P08555168A0390|0 2|Mg2
14P08555168A0390|7 9|Mn2
14P08555289A0207|8 23|storm indicators
14P08555289A0207|47 56|geophysics
14P08555446A0000|10 23|tobacco plants
14P08555446A0000|69 83|pyrophosphatase
14P08555446A0000|93 109|35S CaMV promoter
14P08555498A0427|5 9|LAF-4
14P08555498A0427|111 130|vertebrate evolution
14P08555597A0808|0 8|Hb levels
14P08555597A0808|25 26|Hb
14P08555753A0591|0 2|CBT
14P08555753A0591|33 46|Wisconsin Card
14P08555753A0591|53 56|Test
14P08555753A0591|78 92|activation task
14P08556707A1390|29 34|218leu
14P08556707A1390|48 71|transactivation activity
14P08556707A1390|74 85|p53 promoter
14P08556707A1390|142 153|p53 function
14P08556707A1390|183 194|SNU-C5 cells
14P08558187A0403|0 5|Cycles
14P08561607A1443|19 28|infections
14P08561607A1443|38 52|transplantation
14P08561893A0100|57 74|gene transcription
14P08561893A0100|77 105|E-box DNA consensus sequences
14P08561893A0100|117 131|factor function
14P08561893A0100|193 206|family members
14P08561897A0604|0 7|Mobility
14P08561897A0604|11 27|supershift assays
14P08561897A0604|69 71|USF
14P08561897A0604|105 127|competition experiments
14P08561897A0604|140 147|CREB/ATF
14P08561897A0604|151 154|AP-1
14P08561897A0604|164 178|CRE/TRE element
14P08562688A0968|0 7|Upstream
14P08562688A0968|31 39|sequences
14P08563483A0094|43 54|gonadotropin
14P08563483A0094|79 88|TSH levels
14P08564488A1359|4 20|fibrinogen levels
14P08564488A1359|52 61|thrombosis
14P08564588A1318|0 20|Strontium chloride Sr
14P08564588A1318|76 98|management expenditures
14P08564588A1318|107 114|ABSTRACT
14P08564588A1318|129 133|WORDS
14P08565330A1783|23 30|features
14P08565330A1783|48 54|control
14P08565330A1783|63 69|control
14P08565330A1783|79 88|expression
14P08565548A0196|94 96|BII
14P08565548A0196|129 135|DA rats
14P08566747A0756|0 2|SBF
14P08566747A0756|62 63|G1
14P08566747A0756|79 94|Cln/Cdc28 kinase
14P08566747A0756|130 132|SBF
14P08566751A0455|38 57|vertebrate Hox genes
14P08566751A0455|147 155|Hox genes
14P08566751A0788|4 11|approach
14P08566751A0788|18 24|gHoxb-1
14P08566751A0788|61 67|context
14P08566754A0783|6 25|splice site sequence
14P08566754A0783|97 114|ribonucleoproteins
14P08566754A0783|137 167|splicing factor/splicing factor
14P08566754A0783|168 174|ASF/SF2
14P08566756A0752|24 26|SAP
14P08566756A0752|52 69|SF3a/SF3b subunits
14P08566756A0752|70 83|UV cross-links
14P08566756A0752|128 130|BPS
14P08566773A1023|13 16|CTS1
14P08566773A1023|20 23|CTS2
14P08566773A1023|26 27|Ci
14P08567556A0000|11 21|consumption
14P08567556A0000|42 45|MbO2
14P08567556A0000|55 66|seal muscles
14P08567556A0000|87 98|seal muscles
14P08567556A0000|104 125|laboratory simulations
14P08567556A0000|162 173|field diving
14P08567556A0000|180 191|measurements
14P08567556A0000|206 223|lactate production
14P08567556A0000|233 243|differences
14P08567556A0000|259 273|diving response
14P08567683A0401|22 31|base pairs
14P08567683A0401|60 74|acid polypeptic
14P08567683A0401|75 76|Mr
14P08567717T0000|26 64|spindle pole body duplication gene MPS1
14P08567847A1005|16 28|SM-CMA system
14P08567847A1005|42 53|shortcomings
14P08567847A1005|59 72|user-interface
14P08567847A1005|124 136|semen samples
14P08569443A0123|55 65|differences
14P08569443A0123|68 69|T1
14P08569443A0123|73 74|T2
14P08569443A0123|98 108|consequence
14P08569443A0123|111 121|differences
14P08569443A0123|161 171|compartment
14P08569680A0636|7 18|areA product
14P08569680A0636|77 80|GATA
14P08569684A0000|0 15|Oligonucleotides
14P08569684A0000|54 81|amino acid sequence segments
14P08569684A0000|130 132|PKC
14P08569684A0000|163 188|polymerase chain reactions
14P08569684A0000|214 225|DNA fragment
14P08569684A0000|243 267|fungus Trichoderma reesei
14P08570615T0000|0 9|Disruption
14P08570615T0000|12 17|RB/E2F
14P08570615T0000|39 53|point mutations
14P08570615T0000|55 59|E2F-1
14P08570615T0000|68 80|S-phase entry
14P08572616A0000|14 36|differentiation markers
14P08573083A0645|50 61|binding site
14P08573083A0645|77 96|transcription factor
14P08573083A0645|122 124|USF
14P08573083A0645|147 162|insulin promoter
14P08573637A0434|42 54|determination
14P08573637A0434|57 67|paracetamol
14P08573637A0434|84 95|formulations
14P08574414A1037|20 30|PCR product
14P08574414A1037|63 81|Xanthomonas species
14P08574583A0658|3 13|Clb5 kinase
14P08574583A0658|27 33|S phase
14P08574583A0658|128 138|sim mutants
14P08575609A0526|3 11|C/D ratio
14P08575609A0526|100 107|patients
14P08575614A0264|0 11|Rad6 mutants
14P08575614A0264|73 75|DNA
14P08575614A0264|102 123|postreplication repair
14P08575614A0264|136 153|retrotransposition
14P08575618A1138|0 22|RNase protection assays
14P08575618A1138|93 128|pigmentation/phaeomelanin phenotypes
14P08575754T0000|17 34|expression pattern
14P08575754T0000|49 60|localization
14P08575754T0000|68 79|CDKN2D/INK4d
14P08576042A0765|0 13|Overproduction
14P08576042A0765|16 27|HrcA protein
14P08576042A0765|77 87|B. subtilis
14P08576042A0765|99 116|delta hrcA strains
14P08576042A0765|124 143|heat shock induction
14P08576042A0765|154 165|groE operons
14P08576042A0765|177 189|transcription
14P08576042A0765|246 256|temperature
14P08576131A0151|40 55|characterization
14P08576131A0151|58 70|USF2 isoforms
14P08576131A0151|101 105|USF2a
14P08576131A0151|128 132|USF2b
14P08576131A0685|15 32|heterodimerization
14P08576131A0685|35 46|USF subunits
14P08576131A0685|128 139|USF proteins
14P08576179A0126|9 11|PKR
14P08576179A0126|58 86|translation initiation factor
14P08576179A0126|119 146|polypeptide chain initiation
14P08576245A0000|0 4|GRP78
14P08576245A0000|98 113|stress responses
14P08576245A0000|172 195|glycoprotein trafficking
14P08576262A0160|3 15|IL-8 receptor
14P08576262A0160|18 54|seven-transmembrane spanning receptor
14P08576546A0975|42 51|PDC/HDC Ac
14P08576546A0975|86 99|dose regiments
14P08580083A0259|87 107|Fyn-expression vector
14P08580083A0259|148 185|chloramphenicol acetyltransferase gene
14P08580083A0259|192 198|HIV LTR
14P08580083A0259|208 218|T cell line
14P08580671A0137|51 60|metoprolol
14P08580671A0137|72 83|beta-blocker
14P08580671A0137|87 96|prevention
14P08580671A0137|133 144|hypertension
14P08580671A0137|173 185|liver disease
14P08581174A0472|43 54|qutA mutants
14P08581174A0472|124 135|QUTA protein
14P08582143A0614|76 99|cephalosporin substrates
14P08582143A0614|119 120|S1
14P08582143A0614|143 167|beta-lactamase production
14P08582633T0000|0 10|Suppressors
14P08582633T0000|78 86|HMR locus
14P08582633T0000|100 117|telomere structure
14P08583783A0870|8 10|ANP
14P08583783A0870|80 82|ANP
14P08583846A0121|6 15|literature
14P08583846A0121|32 49|beta-2 transferrin
14P08583846A0807|11 40|methodology beta-2 transferrin
14P08584026A0115|29 30|P1
14P08584026A0115|34 35|P2
14P08584035A0740|0 24|Gel mobility shift assays
14P08584035A0740|87 104|binding properties
14P08584035A0740|131 146|beta I-A element
14P08584035A0740|179 180|R1
14P08584035A0740|183 184|R4
14P08584074A0000|93 105|lobe epilepsy
14P08584074A0000|106 108|TLE
14P08584074A0000|147 168|Bethel Epilepsy Center
14P08584530A0545|37 40|FEV1
14P08584530A0545|68 70|Raw
14P08584530A0545|72 76|MEF50
14P08584530A0545|80 84|MEF25
14P08585324A0467|28 36|SSC1 gene
14P08585324A0823|46 54|precursor
14P08585324A0823|59 65|remnant
14P08585324A0823|69 79|tau element
14P08585639T0000|22 38|hepatitis B virus
14P08585639T0000|45 66|immunodeficiency virus
14P08585883A0381|0 5|Hybrid
14P08585883A0381|17 27|C57BL x CBA
14P08585883A0381|41 53|breeder males
14P08585883A0381|54 57|CD-1
14P08585883A0381|62 72|LNG pellets
14P08585883A0381|105 120|copulation plugs
14P08585957A0101|24 43|transcription factor
14P08585957A0101|98 109|zinc fingers
14P08585957A0101|148 159|gene product
14P08585957A0101|167 173|AT-hook
14P08585957A0101|197 219|mobility group proteins
14P08585994A0567|5 20|reference probes
14P08585994A0567|53 74|ost transcription unit
14P08585994A0567|102 119|band interval 89A1
14P08585994A0567|179 215|segmentation gene expression patterns
14P08586643A0951|45 63|phosphoryl transfer
14P08586643A0951|67 69|ATP
14P08586643A0951|72 74|UMP
14P08586643A0951|78 80|CMP
14P08586874T0000|0 6|Studies
14P08586874T0000|23 40|Haplorchis pumilio
14P08586874T0000|41 45|Looss
14P08586874T0000|52 56|Looss
14P08587075T0000|10 23|microaneurysms
14P08587075T0000|34 50|hepatitis B virus
14P08587075T0000|56 75|polyarteritis nodosa
14P08588852A0236|18 26|pregnancy
14P08588852A0236|43 49|studies
14P08588852A0236|79 87|gestation
14P08588852A0236|102 113|micrognathia
14P08589315A1029|16 28|survival rate
14P08589315A1029|102 121|tumor lysis syndrome
14P08589315A1029|131 149|lupus erythematosus
14P08589358A0235|10 17|units/kg
14P08589358A0235|36 49|erythropoietin
14P08589358A0841|16 29|erythropoietin
14P08589358A0841|77 93|blood transfusion
14P08589358A0841|108 116|Hb levels
14P08589735A0577|18 31|GUS expression
14P08589735A0577|71 103|Arabidopsis alcohol dehydrogenase
14P08589735A0577|148 161|CaMV 35S genes
14P08590465A0773|50 66|URA1 gene product
14P08590465A0773|100 116|URA2 gene product
14P08591700A0972|3 22|mean body mass index
14P08591700A0972|21 23|BMI
14P08592590A0822|28 49|haemodialysis patients
14P08592590A0822|83 102|interferon treatment
14P08592713T0001|9 19|enantiomers
14P08593813A0967|58 66|Sp1 mRNAs
14P08593813A0967|96 105|efficiency
14P08593813A0967|120 129|transcript
14P08595012A0817|2 13|nondiabetics
14P08595012A0817|40 42|LDF
14P08595184A0407|74 85|correlations
14P08595184A0407|98 113|field potentials
14P08595184A0407|114 117|LFPs
14P08595414A0000|3 10|assembly
14P08595414A0000|13 20|sequence
14P08595414A0000|57 68|construction
14P08595414A0000|117 129|model genomes
14P08595414A0000|145 157|determination
14P08595414A0000|220 230|orientation
14P08595627A1513|13 16|KATP
14P08595627A1513|111 122|KATP opening
14P08595627A1513|151 152|VF
14P08595627A1513|183 184|VF
14P08595658A0961|3 15|DNA sequences
14P08595658A0961|54 89|plant mitochondrial-processing sites
14P08595658A0961|141 154|RNA processing
14P08595836T0000|6 14|shrinkage
14P08595836T0000|51 63|glass ionomer
14P08595836T0000|74 82|materials
14P08595878A0201|42 55|PP2A functions
14P08595878A0201|85 108|receptor tyrosine kinase
14P08595878A0201|108 110|RTK
14P08595878A0201|112 138|signal transduction pathway
14P08595878A0201|150 175|R7 photoreceptor cell fate
14P08595878A0201|188 201|Drosophila eye
14P08597108A0642|0 4|QBMDs
14P08597108A0642|28 33|QBMD05
14P08597108A0642|81 85|NOAEL
14P08597177T0000|0 6|Effects
14P08597177T0000|28 44|hydrogen sulphide
14P08597177T0000|60 62|EEG
14P08597596A0135|36 50|ABC transporter
14P08597636A0000|64 82|expression patterns
14P08597636A0000|94 104|involvement
14P08597636A0000|120 134|gene regulation
14P08598051T0000|25 43|schizosaccharomyces
14P08598051T0000|66 87|RNP consensus-sequence
14P08598359X0000|9 22|treatment time
14P08598359X0000|36 61|treatment energy influence
14P08598359X0000|74 78|T1-T2
14P08598359X0000|87 101|cell carcinomas
14P08598359X0000|120 126|PURPOSE
14P08598359X0000|225 229|T1-T2
14P08598359X0000|238 251|cell carcinoma
14P08598449A0784|35 55|surface Ig engagement
14P08598449A0784|56 68|B lymphocytes
14P08598449A0784|69 81|CD38 ligation
14P08598449A0784|101 124|tyrosine phosphorylation
14P08598449A0784|137 164|protein tyrosine kinases lyn
14P08598449A0784|256 258|CA2
14P08598449A0784|260 273|concentrations
14P08599945T0000|0 8|Mutations
14P08599945T0000|14 27|alpha-amanitin
14P08599945T0000|64 83|yeast RNA polymerase
14P08599945T0000|99 110|RNA cleavage
14P08599946A0999|39 49|p40 complex
14P08599946A0999|52 76|ribonucleoprotein complex
14P08599946A0999|86 93|L1Hs RNA
14P08599946A0999|173 192|example coiled-coils
14P08600028A1129|18 33|trans-activation
14P08600028A1129|52 66|intron enhancer
14P08600028A1129|119 129|Myc protein
14P08600048T0000|16 29|conjunctivitis
14P08600048T0000|39 65|bone marrow transplantation
14P08601283A0875|21 34|SECIS elements
14P08601283A0875|57 60|ORFs
14P08601283A0875|141 143|ORF
14P08601283A0875|151 163|SECIS element
14P08601283A0875|199 212|SECIS function
14P08601284A0000|31 33|ETS
14P08601284A0000|113 127|complementarity
14P08601284A0000|133 141|U3 snoRNA
14P08601490A0659|5 11|animals
14P08601616A0726|4 17|spindle defect
14P08601616A0726|19 30|pds1 mutants
14P08601616A0726|86 98|G1/S boundary
14P08601616A0726|112 127|spindle assembly
14P08601806A0875|20 24|RPF-1
14P08601806A0875|62 76|differentiation
14P08601806A0875|90 103|ganglion cells
14P08602169A0484|90 93|CPDs
14P08602169A0484|99 107|MAT alpha
14P08602169A0484|110 123|HML alpha loci
14P08602608A1056|49 54|CD3500
14P08602608A1056|61 64|STKS
14P08602608A1056|122 140|reference procedure
14P08603921A1346|16 34|Spc110p truncations
14P08603921A1346|44 66|calmodulin binding site
14P08604338A0198|4 12|EWS-FLI-1
14P08604338A0198|16 29|FLI-1 proteins
14P08604338A0198|39 59|transcription factors
14P08604338A0198|115 131|promoter elements
14P08604338A0885|2 29|electromobility shift assays
14P08604338A0885|29 45|EWS-FLI-1 binding
14P08604338A0885|50 52|SRE
14P08604338A0885|79 81|SRF
14P08604338A0885|101 105|FLI-1
14P08604338A0885|144 146|DNA
14P08604338A0885|174 190|complex formation
14P08604338A0885|192 196|FLI-1
14P08604708A1086|49 67|cellulose dialyzers
14P08604708A1086|91 106|blood flow rates
14P08604708A1086|132 134|BTG
14P08605302A1770|0 14|DNA methylation
14P08605302A1770|70 80|GATC motifs
14P08605302A1770|173 194|CatA promoter activity
14P08605324A0434|8 10|LTR
14P08605326A0772|11 21|cDNA clones
14P08605705A0676|13 25|IgM class CIC
14P08605705A0676|40 42|CIC
14P08605705A0676|77 92|disease activity
14P08605931A0777|0 14|Epitope mapping
14P08605931A0777|105 113|RNP motif
14P08605931A0777|118 128|U1A protein
14P08606267A0740|0 8|Variables
14P08606267A0740|68 83|exercise testing
14P08606267A0740|160 195|Tc-99m 2-methoxy isobutyl isonitrile
14P08606267A0740|194 197|MIBI
14P08608126A0811|38 53|binding affinity
14P08608126A0811|114 125|medium-chain
14P08608126A0811|148 158|short-chain
14P08608222T0000|98 102|STAT3
14P08608222T0000|109 133|STAT1 homodimer formation
14P08608447A0806|28 44|codon recognition
14P08608447A0806|50 64|TPI transcripts
14P08608448A0353|42 57|dimethylsulphate
14P08608448A0353|125 139|structure model
14P08608448A0353|144 148|S RNA
14P08608448A0353|161 170|reactivity
14P08610272A0265|16 29|investigations
14P08610272A0265|99 122|maintenance chemotherapy
14P08610272A0265|151 168|response modifiers
14P08610272A0265|171 184|growth factors
14P08610328A0228|0 6|SUMMARY
14P08610328A0228|9 14|REVIEW
14P08610582A0150|48 55|CT scans
14P08610582A0150|81 90|MR imaging
14P08610582A0150|95 96|T.
14P08611280A0820|10 16|volumes
14P08611280A0820|50 57|subjects
14P08611280A0820|74 79|cm3/m2
14P08611280A0820|88 93|cm3/m2
14P08611280A0820|104 108|onset
14P08611280A0820|117 123|systole
14P08611280A0820|131 136|cm3/m2
14P08611280A0820|145 150|cm3/m2
14P08611280A0820|175 180|cm3/m2
14P08611280A0820|188 193|cm3/m2
14P08612852A0553|0 6|RESULTS
14P08612852A0553|13 31|plasma IGF-I levels
14P08612852A0553|38 52|body mass index
14P08612852A0553|52 54|BMI
14P08614403A0557|26 44|Rev-erbA alpha mRNA
14P08614403A0557|53 67|C2C12 myoblasts
14P08614403A0989|24 51|GAL4-REV-erbA alpha chimeras
14P08614403A0989|65 66|AB
14P08614403A0989|117 138|GAL4 response elements
14P08614403A0989|152 160|8-Br-cAMP
14P08614403A0989|190 192|LBD
14P08614410A0000|3 22|alpha T3-1 cell line
14P08614410A0000|37 57|gonadotroph cell line
14P08614410A0000|132 165|glycoprotein hormone alpha-subunit
14P08615012A0627|0 13|Cotransfection
14P08615025A1214|11 23|glycosylation
14P08615025A1214|26 28|Env
14P08615025A1214|80 102|glycosylation phenotype
14P08615025A1214|125 127|Env
14P08615025A1214|151 166|immunoreactivity
14P08615025A1214|169 170|V3
14P08615025A1214|234 236|Env
14P08615025A1214|252 264|cell membrane
14P08615025A1214|286 288|CD4
14P08615025A1214|297 309|membrane gp41
14P08615025A1214|324 338|membrane fusion
14P08615025A1214|342 344|CD4
14P08615183T0000|0 6|Effects
14P08615183T0000|36 44|Parkinson
14P08616743T0000|12 14|Dr.
14P08617216A0584|20 23|DnaJ
14P08617216A0584|40 43|DnaK
14P08617216A0584|61 64|GrpE
14P08617237A0489|29 33|STAT5
14P08617237A0489|54 76|DNA binding specificity
14P08617237A0489|92 115|tyrosine phosphopeptides
14P08617238A0334|0 12|TNF Treatment
14P08617238A0334|30 51|p38 MAP kinase pathway
14P08617238A0334|88 101|p38 MAP kinase
14P08617238A0334|122 154|substrate protein MAPKAP kinase-2
14P08617238A0334|192 209|heat shock protein
14P08617243A0336|20 26|protein
14P08617243A0336|48 55|extracts
14P08617243A0336|97 102|region
14P08617311A0979|16 34|sequence similarity
14P08617311A0979|44 57|membrane exons
14P08617311A0979|87 89|IgE
14P08617311A0979|125 136|Xenopus mIgY
14P08617800A0150|0 6|Control
14P08617800A0150|9 21|transcription
14P08617800A0150|63 81|receptor expression
14P08617800A0675|0 4|DNase
14P08617800A0675|36 56|mobility shift assays
14P08617800A0675|67 69|PBP
14P08617800A0675|112 143|core recognition sequence TGGGAG
14P08617802A0993|41 58|SH2/SH3/SH2 region
14P08617802A0993|60 67|p120 GAP
14P08617802A0993|108 110|Ras
14P08618433A0000|21 45|growth factor FLT3 ligand
14P08618433A0000|44 45|FL
14P08618433A0000|71 74|FLT3
14P08618433A0000|76 99|tyrosine kinase receptor
14P08618433A0000|118 122|FLK-2
14P08618433A0000|126 130|STK-1
14P08618433A1720|48 60|FL expression
14P08618433A1720|103 121|leukemia cell lines
14P08618433A1720|140 152|cell lineages
14P08618864A0754|7 14|analysis
14P08618864A0754|36 46|mutagenesis
14P08618864A0754|83 90|residues
14P08618864A0754|107 114|activity
14P08618882A0343|10 26|RAR alpha mutants
14P08618882A0343|27 46|transfection studies
14P08618882A0343|60 77|DNA binding domain
14P08618882A0343|103 116|BZLF1 activity
14P08619866A0000|10 39|serum hepatocyte growth factor
14P08619866A0000|38 40|HGF
14P08619910A0000|32 45|motor symptoms
14P08619910A0000|110 128|dopamine deficiency
14P08619910A0000|155 166|observations
14P08619910A0000|286 304|nigra zona compacta
14P08619910A0000|304 306|SNc
14P08620003T0000|0 15|Protein splicing
14P08620003T0000|29 50|N-O acyl rearrangement
14P08620003T0000|70 85|splicing process
14P08620856A1172|25 48|western blot experiments
14P08620856A1172|108 126|mouse c-kit protein
14P08620856A1172|136 146|polypeptide
14P08620856A1172|175 187|reading frame
14P08620856A1172|250 264|spermatogenesis
14P08620856A1172|280 290|spermatozoa
14P08620889A0771|17 19|G+C
14P08620889A0771|38 56|aldolase C promoter
14P08620889A0771|62 74|transcription
14P08621017A1186|0 7|LY290181
14P08621017A1186|24 46|uPA promoter activation
14P08621017A1186|120 150|tetradecanoylphorbol 13-acetate
14P08621017A1186|168 170|TRE
14P08621384A0935|50 71|growth factor receptor
14P08621384A0935|71 74|EGFR
14P08621384A0935|80 87|TGFalpha
14P08621384A0935|125 157|PKCdelta tyrosine phosphorylation
14P08621420A1166|46 48|p50
14P08621420A1166|69 71|p65
14P08621420A1166|79 96|NF-kappaB proteins
14P08621448A0862|24 26|DNA
14P08621448A0862|44 68|RL95-2 expression library
14P08621448A0862|81 82|C1
14P08621451A0552|0 3|Biol
14P08621453A0815|31 40|antibodies
14P08621453A0815|59 63|80K-H
14P08621453A0815|68 79|cell lysates
14P08621453A0815|112 122|fibroblasts
14P08621542A0535|48 51|JNKs
14P08621542A0535|103 111|TNF-alpha
14P08621542A0535|113 116|IL-1
14P08621542A0535|121 138|CD28 costimulation
14P08621628A1233|62 78|hGRalpha activity
14P08621659A0189|0 3|Gas6
14P08621659A0189|26 35|Gla domain
14P08621661A1035|4 20|P5CDh cDNA clones
14P08621661A1035|50 63|Northern blots
14P08621664A1430|0 13|Polymerization
14P08621664A1430|16 38|neurofilament L protein
14P08621664A1430|75 97|neurofilament L protein
14P08621664A1430|98 100|PKN
14P08621714A0361|31 45|disulfide bonds
14P08621714A0361|53 63|thiol group
14P08621714A0361|65 69|Cys25
14P08621719A0000|34 61|c-cbl proto-oncogene product
14P08621719A0000|87 110|tyrosine phosphorylation
14P08621719A0000|114 140|T cell receptor stimulation
14P08621719A0568|22 24|Cbl
14P08621719A0568|56 59|Grb2
14P08621719A0568|91 106|Grb2 SH3 domains
14P08621730T0000|2 22|AP-1 binding sequence
14P08621730T0000|73 78|COL1A2
14P08621730T0000|80 96|promoter activity
14P08621730T0000|110 127|growth factor-beta
14P08622030A0667|55 78|baseline characteristics
14P08622030A0667|88 105|treatment protocol
14P08622030A0667|106 123|performance status
14P08622030A0667|127 153|serum lactate dehydrogenase
14P08622030A0667|153 155|LDH
14P08622070A0889|25 26|CA
14P08622070A0889|57 67|progression
14P08622596A0189|3 5|men
14P08622596A0189|30 33|diet
14P08622596A0189|36 39|home
14P08622596A0189|60 62|fat
14P08622596A0189|75 77|fat
14P08622596A0189|82 85|week
14P08622645A1026|15 17|VDR
14P08622645A1026|58 69|RA induction
14P08622668A1155|54 59|U6 RNA
14P08622668A1155|76 114|phosphorylation-dephosphorylation cycle
14P08622668A1155|116 131|C1 hnRNP protein
14P08622668A1155|147 162|binding affinity
14P08622675A0587|0 8|Inclusion
14P08622675A0587|22 31|N terminus
14P08622675A0587|105 116|factor Lef-1
14P08622698T0000|18 23|Notch1
14P08622698T0000|98 108|virus EBNA2
14P08622887A1026|35 39|EMSAs
14P08622887A1026|54 95|glucocorticoid receptor DNA binding domain
14P08622887A1026|93 95|DBD
14P08622887A1026|117 121|GRE-2
14P08622887A1026|145 147|DBD
14P08622887A1026|151 189|oligonucleotide competition experiments
14P08622887A1026|234 236|DBD
14P08622893A0000|19 43|receptor tyrosine kinases
14P08622893A0000|43 46|RTKs
14P08622893A0000|56 58|EPH
14P08622893A0000|166 184|signalling pathways
14P08623554A1058|9 15|protein
14P08623554A1058|40 48|infection
14P08624445A0257|29 47|sequencing analysis
14P08624445A0257|52 80|cytosine methylation patterns
14P08624445A0257|84 108|transposase binding sites
14P08624445A0257|117 118|Ac
14P08624445A0257|135 143|Ac allele
14P08624445A0257|149 150|Ac
14P08625806A0263|0 6|Krox-20
14P08625806A0263|9 24|zinc finger gene
14P08625806A0263|64 65|r3
14P08625806A0263|69 70|r5
14P08625900T0000|56 82|prolactin promoter activity
14P08625900T0000|85 98|protein kinase
14P08625924A0411|0 9|Clones 33F
14P08625924A0411|12 14|34B
14P08625924A0411|31 48|aromatase proteins
14P08625924A0411|97 124|polyadenylation signal usage
14P08625987A1086|8 35|bone marrow cells expression
14P08625987A1086|39 49|VpreB genes
14P08625987A1086|103 105|RNA
14P08625987A1086|179 185|B cells
14P08626065A0000|32 48|Bacillus subtilis
14P08626065A0000|49 50|Bs
14P08626065A0000|52 63|DNA fragment
14P08626290T0000|0 20|Aeromonas salmonicida
14P08626290T0000|68 83|membrane protein
14P08626290T0000|84 87|OmpA
14P08626313A1037|0 9|Expression
14P08626313A1037|12 14|Msp
14P08626325A0543|50 53|UmuD
14P08626325A0543|57 60|UmuD
14P08626325A0543|90 98|UmuD-UmuD
14P08626325A0543|102 105|UmuD
14P08626325A0543|108 111|UmuD
14P08626325A0543|130 138|UmuD-UmuD
14P08626437A0332|0 9|Lyn kinase
14P08626437A0332|50 52|BCP
14P08626437A0332|73 97|glutathione S-transferase
14P08626437A0332|98 100|GST
14P08626437A0332|103 112|Lyn fusion
14P08626437A0332|150 156|p34cdc2
14P08626493A1468|0 8|Mutations
14P08626493A1468|32 34|CR2
14P08626493A1468|38 40|E1A
14P08626493A1468|64 66|E1A
14P08626493A1468|72 98|retinoblastoma gene product
14P08626493A1468|153 166|PEPCK promoter
14P08626529A0000|5 18|autoantibodies
14P08626529A0000|24 30|Sjogren
14P08626529A0000|33 48|syndrome patient
14P08626529A0000|93 108|membrane protein
14P08626529A0000|155 158|Kooy
14P08626529A0000|160 161|J.
14P08626529A0000|163 165|Toh
14P08626529A0000|167 168|B.
14P08626529A0799|59 62|p230
14P08626529A0799|91 104|heptad repeats
14P08626529A0799|105 118|characteristic
14P08626529A0799|121 133|alpha-helices
14P08626529A0799|171 174|p230
14P08626529A0799|190 208|sequence ESLALEELEL
14P08626529A0799|244 256|granin family
14P08626529A0799|300 319|neuroendocrine cells
14P08626539T0000|0 18|Binding specificity
14P08626539T0000|36 59|ApoA-I promoter activity
14P08626540A1007|35 48|concentrations
14P08626540A1007|94 109|glucosylceramide
14P08626540A1007|114 129|lactosylceramide
14P08626596A0000|48 61|protein kinase
14P08626596A0000|62 65|AMPK
14P08626596A0000|115 127|ATP depletion
14P08626610A0931|38 44|SREBP-1
14P08626610A0931|114 126|COOH terminus
14P08626612A1040|0 1|Am
14P08626667A1372|0 27|EMSA competition experiments
14P08626667A1372|125 144|type oligonucleotide
14P08626667A1517|0 12|Transcription
14P08626667A1517|117 132|motifs functions
14P08626667A1517|147 165|GPT gene expression
14P08626698A0989|27 39|ERK3 activity
14P08626698A0989|45 65|PKC beta transfectant
14P08626698A0989|74 92|immunoprecipitation
14P08626698A0989|146 165|complex kinase assay
14P08626777A0537|0 16|Sequence analysis
14P08626777A0537|28 42|Col2a1 enhancer
14P08626777A0537|57 71|sequence motifs
14P08626777A0537|123 139|link protein gene
14P08626777A0537|146 159|cartilage gene
14P08626785A0674|33 64|tissue transglutaminase promoter
14P08626785A0674|156 194|mouse tissue transglutaminase promoters
14P08626785A0674|228 257|pair retinoid response element
14P08626785A0674|285 309|hexanucleotide half-sites
14P08626785A0674|345 357|DR7/DR5 motif
14P08626785A0674|369 371|RAR
14P08626785A0674|373 388|RXR heterodimers
14P08626785A0674|391 404|RXR homodimers
14P08626809A0729|56 60|Ser51
14P08626809A0729|73 90|eIF-2alpha peptide
14P08626809A0729|95 108|characteristic
14P08626809A0729|114 137|eIF-2alpha kinase family
14P08627354A0000|86 109|neurotransmitter release
14P08627649A0734|15 35|mobility shift assays
14P08627649A0734|56 66|FREJ4 cells
14P08627649A0734|101 110|Ets family
14P08627649A0734|112 132|transcription factors
14P08627649A0734|137 142|P4 EBS
14P08627649A0734|182 191|Sp1 family
14P08627649A0734|192 194|Sp1
14P08627649A0734|198 200|Sp3
14P08627649A0734|217 222|GC box
14P08627667A0132|0 4|ZEBRA
14P08627667A0132|16 35|AP-1 bZip activators
14P08627688A1520|29 32|I299
14P08627719A0784|0 27|UV cross-linking experiments
14P08627719A0784|42 54|HSV infection
14P08627719A0784|77 91|protein factors
14P08627719A0784|121 147|cleavage stimulation factor
14P08627719A0784|147 150|CstF
14P08627719A0784|250 253|IE63
14P08628251A1455|0 6|CM-ACO3
14P08628254A0665|19 34|Jun/eb1 chimeras
14P08628254A0665|43 57|transactivators
14P08628254A0665|60 68|AP1 sites
14P08628255A0932|14 23|HeLa cells
14P08628255A0932|36 54|luciferase activity
14P08628255A0932|80 92|DNA synthesis
14P08628255A0932|144 157|H2A.1 promoter
14P08628260A0895|18 37|transfection studies
14P08628260A0895|39 49|HepG2 cells
14P08628260A0895|88 105|promoter sequences
14P08628260A0895|165 181|promoter activity
14P08628284A0181|14 34|yeast reporter strain
14P08628284A0181|74 86|CYC1 promoter
14P08628284A0181|113 117|TRE-1
14P08628302A0683|11 30|transcription factor
14P08628302A0683|54 67|RNA polymerase
14P08628302A0683|69 91|transcription apparatus
14P08628681A0364|48 61|Northern blots
14P08628681A0364|80 92|X.laevis cDNA
14P08628681A0821|0 20|Sequence conservation
14P08628681A0821|100 113|DNA polymerase
14P08629348A0237|41 42|BI
14P08629348A0237|214 226|hydrocephalus
14P08630542A1421|5 12|findings
14P08630542A1421|27 34|increase
14P08630542A1421|52 62|consequence
14P08630542A1421|68 75|increase
14P08630542A1421|92 99|response
14P08630542A1421|105 113|procedure
14P08630548A0000|99 102|IL-1
14P08630548A0000|105 131|tumor necrosis factor-alpha
14P08630548A0000|131 139|TNF-alpha
14P08630583A1056|7 8|Hb
14P08630583A1056|33 43|CO2 content
14P08630599A0534|14 42|elastin peptide concentration
14P08630599A0534|106 107|SD
14P08630599A0534|120 132|micrograms/ml
14P08630599A0534|160 172|micrograms/ml
14P08630599A0534|198 210|micrograms/ml
14P08631667A0851|0 13|Identification
14P08631667A0851|68 82|complementation
14P08631667A0851|86 102|yeast dTMP kinase
14P08631667A0851|140 151|enzyme assay
14P08631667A0851|167 181|kinase activity
14P08631667A0851|183 195|cell extracts
14P08631685A0000|52 68|monoamine oxidase
14P08631685A0000|86 103|amine oxidase gene
14P08631685A0000|146 155|chromosome
14P08631760A0609|30 39|SH2 domain
14P08631760A0609|93 113|Crk-SH2 binding motif
14P08631797A0982|14 19|ErbB-2
14P08631797A0982|32 47|receptor subunit
14P08631797A0982|51 74|tyrosine phosphorylation
14P08631797A0982|149 151|NDF
14P08631797A0982|154 164|EGF binding
14P08631817T0000|42 68|kinase phosphorylation site
14P08631817T0000|96 140|deoxyuridine triphosphate nucleotidohydrolase
14P08631820A0755|25 33|FPS1 gene
14P08631820A0755|56 70|complementation
14P08631820A0755|102 113|FPS activity
14P08631820A0755|114 121|Delourme
14P08631820A0755|123 124|D.
14P08631820A0755|126 133|Lacroute
14P08631820A0755|135 136|F.
14P08631820A0755|141 145|Karst
14P08631820A0755|147 148|F.
14P08631822A0677|11 27|plasmin fragments
14P08631822A0677|29 32|VEGF
14P08631822A0677|58 72|heparin binding
14P08631822A0677|95 108|VEGF receptors
14P08631822A0677|139 154|cell mitogenesis
14P08631908A0224|0 6|VDR/RXR
14P08631908A0224|21 25|VDREs
14P08631908A0224|31 33|DR4
14P08631908A0224|37 39|DR5
14P08631908A0224|63 82|mobility shift assay
14P08631934A0000|15 24|Myb family
14P08631934A0000|26 46|transcription factors
14P08631934A0000|115 117|MBS
14P08631934A0000|128 129|YG
14P08631934A0000|131 133|A/G
14P08631934A0000|137 141|A/C/G
14P08631934A0000|143 145|GTT
14P08631934A0000|147 149|G/A
14P08631944A0663|38 54|C epsilon4 domain
14P08631944A0663|72 78|M2 exon
14P08631944A0663|79 88|IgE grande
14P08631944A0663|105 119|J558L cell line
14P08631958T0000|35 53|protein IE2 tethers
14P08631958T0000|68 84|repression domain
14P08631958T0000|86 88|p53
14P08632009A1067|24 43|C/EBP family members
14P08632009A1067|101 119|expression profiles
14P08632009A1067|123 144|DNA binding affinities
14P08632009A1067|180 204|DNA binding specificities
14P08632015A0879|52 80|DNA polymerase alpha promoter
14P08632015A1226|51 66|DREF polypeptide
14P08632015A1226|95 108|division cycle
14P08632015A1226|144 147|DREF
14P08632015A1226|194 196|DNA
14P08632015A1226|229 241|DRE sequences
14P08632018A0587|1 12|DNA fragment
14P08632018A0587|72 82|UGT1A1 gene
14P08632018A0587|94 105|MC induction
14P08632463A1508|94 117|transcription elongation
14P08632779A0351|3 13|XPG regions
14P08632779A0351|25 27|NLS
14P08632779A0351|39 40|AA
14P08632779A0351|54 58|NLS-B
14P08632779A0351|60 61|AA
14P08632779A0351|75 79|NLS-C
14P08632779A0351|81 82|AA
14P08632779A0351|172 181|HeLa cells
14P08633855A1064|24 59|E. coli-Streptococcus shuttle vector
14P08633855A1064|79 102|lacS deletion derivative
14P08633855A1064|103 117|S. thermophilus
14P08633855A1064|149 154|NZ6091
14P08634290A0000|14 25|retroviruses
14P08634290A0000|48 51|RNAs
14P08634357A0527|3 21|extraction recovery
14P08634357A0527|23 36|Amphotericin B
14P08634420A1784|0 9|HuEpo-R Ab
14P08634420A1784|37 52|UT-7 cell growth
14P08634420A1784|122 144|UT-7 cell proliferation
14P08634423A0498|14 25|integrations
14P08634423A0498|35 47|transcription
14P08634423A0498|86 97|integrations
14P08634423A0498|128 142|differentiation
14P08634423A0498|145 153|32D cells
14P08634423A0498|160 170|neutrophils
14P08634697A1155|3 10|sequence
14P08634697A1155|44 51|reagents
14P08634697A1155|66 75|expression
14P08634697A1155|78 82|Brca1
14P08634697A1155|110 119|importance
14P08635771A0000|30 35|ONLINE
14P08635771A0000|39 58|EMIT II immunoassays
14P08635771A0000|61 98|gas chromatographic/mass spectrometric
14P08635771A0000|98 102|GC/MS
14P08635771A0000|114 137|methaqualone metabolites
14P08636031A1413|0 10|Interaction
14P08636031A1413|16 28|Fur repressor
14P08636031A1413|100 118|Fur titration assay
14P08636031A1413|138 164|gel retardation experiments
14P08636031A1413|185 199|Fur preparation
14P08636124A0410|46 52|p150TSP
14P08636124A0410|83 96|phosphoprotein
14P08636149A0220|37 48|cell surface
14P08636149A0220|97 115|autophosphorylation
14P08636211A0983|0 6|EMBO J.
14P08636428A1363|63 89|smooth muscle proliferation
14P08637006A0000|0 12|Transcription
14P08637006A0000|115 122|TBP site
14P08637006A0000|126 134|E2F sites
14P08637006A0000|189 196|ATF site
14P08637711A1121|27 30|IL-6
14P08637711A1121|48 56|IFN gamma
14P08637711A1121|77 90|IRF-1 promoter
14P08637711A1121|91 96|IR/IRF
14P08637711A1121|178 194|binding complexes
14P08637711A1121|203 213|JRE-IL6-BCs
14P08637717A0817|46 57|p21-activity
14P08637717A0817|97 99|p21
14P08637717A0817|114 126|cyclin E/Cdk2
14P08637717A1231|1 11|p21 peptide
14P08637717A1231|50 53|PCNA
14P08637717A1231|57 76|filter binding assay
14P08637717A1231|110 129|p21-PCNA interaction
14P08638435A0522|0 6|Results
14P08638435A0522|25 45|agar diffusion method
14P08638435A0522|47 63|Y. enterocolitica
14P08638435A0522|71 89|inhibition activity
14P08638435A0522|103 115|A. hydrophila
14P08639310A0548|0 2|OND
14P08639310A0548|21 35|mg tid prn days
14P08639310A0548|74 76|MCP
14P08639310A0548|113 114|CT
14P08639310A0548|118 120|MCP
14P08639521A1032|10 19|properties
14P08639521A1032|26 41|protein fragment
14P08639561T0000|0 8|Adduction
14P08639561T0000|19 29|N-ras codon
14P08639561T0000|48 49|7S
14P08639561T0000|66 76|dihydroxy-9
14P08639561T0000|96 110|tetrahydrobenzo
14P08639561T0000|158 161|SRSR
14P08639561T0000|173 174|7S
14P08639561T0000|204 218|tetrahydrobenzo
14P08639561T0000|235 254|deoxyadenosyl adduct
14P08639561T0000|258 263|1H NMR
14P08639742T0000|0 8|Isolation
14P08639742T0000|11 13|PCR
14P08639742T0000|65 90|wheat zinc finger proteins
14P08639837A0268|62 67|GATA-1
14P08639837A0268|83 92|Ets family
14P08640866A0473|0 7|Exposure
14P08640866A0473|50 52|PHA
14P08640866A0473|121 124|MAPK
14P08640866A0473|128 130|MEK
14P08641705A0986|34 47|heterozygosity
14P08641705A0986|57 66|G mutation
14P08641705A0986|115 124|Hbs Lepore
14P08641705A0986|126 130|Kenya
14P08641705A0986|135 162|beta-globin gene duplication
14P08641705A0986|200 212|Hb Costa Rica
14P08642282A1009|14 24|description
14P08642282A1009|31 39|knowledge
14P08642282A1009|72 81|expression
14P08642282A1009|98 99|B7
14P08642285A1548|0 17|DNA-STAT complexes
14P08642285A1548|104 108|STAT1
14P08642285A1548|112 116|STAT5
14P08642313A0770|41 46|TAN-1C
14P08642313A0770|72 86|transactivation
14P08642313A0770|98 117|reporter gene assays
14P08642313A0770|165 169|Bcl-3
14P08642313T0000|0 5|T cell
14P08642313T0000|59 73|Notch homologue
14P08642313T0000|76 82|I kappa
14P08642313T0000|129 151|factor-kappa B proteins
14P08642313T0000|152 158|T cells
14P08642693T0000|0 21|Polyprotein processing
14P08642693T0000|23 39|Southampton virus
14P08642693T0000|63 85|protease cleavage sites
14P08643111A0855|12 14|LL2
14P08643111A0855|47 66|region glycosylation
14P08643111A0855|76 93|immunoreactivities
14P08643111A0855|128 130|LL2
14P08643111A0855|250 265|oligosaccharides
14P08643111A0855|295 309|antigen binding
14P08643382A0752|20 34|transit peptide
14P08643382A0752|78 87|cDNA clone
14P08643382A0752|104 122|chloroplast protein
14P08643513A0361|0 16|Deletion analysis
14P08643513A0361|45 72|acetyltransferase constructs
14P08643513A0361|178 204|osteocalcin gene expression
14P08643557A0259|27 38|HOX proteins
14P08643578A0000|0 8|RAS2val19
14P08643578A0000|57 60|Ras2
14P08643578A0000|135 137|TyA
14P08643578A0000|164 191|mating pathway reporter FUS1
14P08643578A0532|12 35|Rho family protein Cdc42
14P08643578A0532|57 65|G protein
14P08643578A0532|110 111|FG
14P08643578A0532|113 115|TyA
14P08643633A1187|4 20|immunoprecipitate
14P08643633A1187|40 41|N1
14P08643633A1187|54 57|CBF1
14P08643646A0479|70 81|biosynthesis
14P08643646A0479|111 121|transcripts
14P08643646A0479|196 205|conditions
14P08643682A0268|38 44|CBFbeta
14P08643682A0268|51 78|CBFbeta-SMMHC fusion protein
14P08643682A0268|113 125|NIH 3T3 cells
14P08643759A0338|45 65|personality variables
14P08644734A0404|73 93|segment-polarity gene
14P08645214A1052|15 18|BL21
14P08645214A1052|20 22|DE3
14P08645214A1052|72 95|catalase-peroxidase gene
14P08645214A1052|143 150|SDS/PAGE
14P08645219A1377|0 2|Ca2
14P08645219A1377|13 15|Zn2
14P08645219A1377|26 34|S100 beta
14P08645219A1377|63 67|MRP14
14P08645219A1377|86 88|Zn2
14P08645219A1377|138 140|Ca2
14P08645219A1377|142 156|binding domains
14P08647086A0622|0 3|Cdk2
14P08647086A0622|22 30|cyclin D1
14P08647086A0720|3 24|Cdk2-cyclin-D1 complex
14P08647086A0720|69 78|H1 histone
14P08647086A0720|83 86|SV40
14P08647086A0720|92 100|T antigen
14P08647086A0720|101 103|p53
14P08647086A0720|105 109|E2F-1
14P08647086A0720|145 154|HeLa cells
14P08647086A0720|166 178|Cdk2-cyclin-E
14P08647086A0720|182 194|Cdk2-cyclin-A
14P08647086T0000|25 28|Cdk2
14P08647086T0000|69 72|Cdk2
14P08647086T0000|116 128|Cdk7-cyclin-H
14P08647091A0592|40 49|Adh-2 gene
14P08647091A0592|144 152|ADH genes
14P08647264T0000|0 7|Ligation
14P08647264T0000|10 13|CD40
14P08647264T0000|34 49|lymphoma B cells
14P08647264T0000|52 68|calcium ionophore
14P08647264T0000|133 160|cysteine protease CPP32/Yama
14P08647264T0000|175 188|substrate PARP
14P08647434A1124|5 13|T antigen
14P08647434A1124|64 66|TBP
14P08647434A1124|78 80|TBP
14P08647451A0663|0 26|Northern blot hybridization
14P08647451A0663|41 47|HEP-COP
14P08647802A0000|17 33|signaling protein
14P08647802A0000|89 107|SH3-SH2-SH3 domains
14P08647822T0000|30 52|element binding protein
14P08647822T0000|100 113|reductase gene
14P08647884A0547|52 60|MHC class
14P08647884A0547|107 118|cell surface
14P08648408A0792|7 9|PHT
14P08648408A0792|13 22|CSA groups
14P08648408A0792|35 44|Hyp levels
14P08648408A0792|72 77|PHT-GO
14P08648408A0792|93 98|CSA-GO
14P08648665A0956|8 20|LE6 deletions
14P08648665A0956|39 63|transformation efficiency
14P08648665A0956|121 123|LE6
14P08648665A1320|0 14|ORF E8 colinear
14P08648665A1320|17 22|ORF E6
14P08648665A1320|123 136|pZipNeo vector
14P08648726A0713|19 28|ZI domains
14P08648726A0713|73 75|ZIA
14P08648726A0713|77 79|ZIC
14P08648726A0713|84 94|ZID domains
14P08648726A0713|104 113|ZIB domain
14P08648726A0713|117 119|TPA
14P08649372A0501|0 16|Clb2/Cdc28 kinase
14P08649372A0501|89 90|G2
14P08649372A0501|94 100|M phase
14P08649372A0755|3 18|carboxy terminus
14P08649372A0755|20 23|Mbp1
14P08649372A0755|54 57|Swi6
14P08649372A0755|65 80|carboxy terminus
14P08649372A0755|82 85|Swi6
14P08649372A0755|114 117|Mbp1
14P08649373T0000|23 34|cis elements
14P08649373T0000|60 68|chromatin
14P08649373T0000|79 88|c-myc gene
14P08649386A1032|4 26|UASH consensus sequence
14P08649389A0000|30 45|CTCF cDNA clones
14P08649389A0000|187 206|amino acid sequences
14P08649389A0692|34 50|CTCF binding site
14P08649389A0692|52 87|transient-cotransfection experiments
14P08649389A0692|102 105|CTCF
14P08649393A0000|1 32|chromosome transmission fidelity
14P08649393A0000|43 46|s138
14P08649393A0000|102 104|CEN
14P08649393A0000|121 141|readthrough phenotype
14P08649393A0000|161 181|kinetochore integrity
14P08649403A0963|3 15|growth defect
14P08649403A0963|18 26|reg1 reg2
14P08649403A0963|94 107|protein kinase
14P08649405T0000|0 2|Sp1
14P08649405T0000|21 34|CD11c promoter
14P08649405T0000|83 85|AP1
14P08649424A0000|0 9|Expression
14P08649424A0000|15 44|phenylalanine hydroxylase gene
14P08649424A0000|102 116|glucocorticoids
14P08649424A0000|126 128|AMP
14P08649425A0373|57 61|DNase
14P08649425A0373|84 101|B-cell development
14P08649425T0000|25 43|chromatin structure
14P08649425T0000|48 73|mouse immunoglobulin kappa
14P08649427A0689|15 28|identification
14P08649427A0689|87 89|GAP
14P08649427A0689|99 115|GTPase regulators
14P08649428A1227|65 86|c-mos oncogene product
14P08649428A1227|120 123|Cdc2
14P08649440T0000|24 27|IgG2
14P08649440T0000|30 33|VIII
14P08649773A1374|12 16|BCL-6
14P08649773A1374|90 102|B lymphocytes
14P08649773A1374|116 128|cell lymphoma
14P08649841A0956|47 61|Kozak sequences
14P08649841A0956|94 97|SV40
14P08649841A0956|102 118|CAT reporter gene
14P08649841A0956|145 166|CAT protein production
14P08649841A0956|183 190|CAT mRNA
14P08650818A0000|76 79|MRSA
14P08650818A0000|223 240|Mediterranean area
14P08651853A0607|93 108|CA1/prosubiculum
14P08651853A0607|139 151|dentate gyrus
14P08651853A0607|176 185|CA4 region
14P08651853T0000|14 22|sclerosis
14P08652081A1953|98 101|IL-1
14P08652081A1953|131 134|IL-3
14P08652081A1953|182 185|IL-4
14P08654200A0274|18 34|resonance imaging
14P08654200A0274|52 63|liver volume
14P08654200A0274|126 141|model substrates
14P08654200A0274|186 196|indocyanine
14P08654200A0274|203 205|ICG
14P08654375A0544|76 85|N-terminus
14P08654375A0544|88 91|Bob1
14P08654375A0544|124 145|DNA binding POU domain
14P08654375A0544|145 149|Oct-1
14P08654375A0544|152 156|Oct-2
14P08654390A0000|0 13|Heme oxygenase
14P08654390A0000|35 49|heme catabolism
14P08654390A0000|89 103|carbon monoxide
14P08654435A0540|29 32|WM12
14P08654435A0540|61 75|Erk2 activation
14P08654435A0540|115 118|Erk2
14P08654946A0475|14 23|% identity
14P08654946A0475|47 65|Xenopus laevis FGF3
14P08654946A0475|69 78|% identity
14P08654946A0986|3 27|transcription start point
14P08654946A0986|61 77|mouse promoter P3
14P08654972A0000|0 6|Defects
14P08654972A0000|37 38|Sp
14P08654972A0000|76 97|cell cycle progression
14P08654983A0000|14 40|signal recognition particle
14P08654983A0000|40 42|SRP
14P08654983A0000|45 56|SRP receptor
14P08654983A0000|69 85|Bacillus subtilis
14P08654983A0000|101 111|Bs srb gene
14P08654983A0000|147 172|SRP receptor alpha-subunit
14P08654983A0000|183 189|DNA Res
14P08655497A0000|64 74|K-12 genome
14P08655497A0000|92 101|resistance
14P08655497A0000|104 118|chloramphenicol
14P08655555A0772|53 77|transcription start point
14P08655555A0772|97 115|% promoter activity
14P08655555A0772|160 176|promoter activity
14P08655555A1368|3 14|DNA sequence
14P08655555A1368|62 70|TGn motif
14P08656672A0678|10 32|ufo mRNA overexpression
14P08656672A0678|60 78|leukemia cell lines
14P08656672A0678|127 157|cervix carcinoma cell line HeLa
14P08657135A1444|30 33|CKII
14P08657135A1444|84 103|E protein homodimers
14P08657150A1049|33 36|NCE3
14P08657150A1049|68 76|SIN5 gene
14P08657150A1049|93 112|promoter specificity
14P08657157A0000|37 46|POU domain
14P08657157A0000|117 126|POU domain
14P08657157A0000|166 190|octamer sequence elements
14P08657183A0145|30 42|DNA fragments
14P08657183A0145|63 66|DHFR
14P08657183A0145|93 96|DHFR
14P08657918A0360|0 8|MATERIALS
14P08657918A0360|12 18|METHODS
14P08657918A0360|20 41|Coronal 3D GRE imaging
14P08657918A0360|91 93|SLL
14P08657918A0360|134 136|SLL
14P08657918A0360|175 177|SLL
14P08659545A0000|27 40|transcript map
14P08659545A0000|47 56|chromosome
14P08659545A0000|65 77|understanding
14P08659545A0000|83 97|pathophysiology
14P08659545A0000|120 132|exon trapping
14P08659545A0000|142 150|fragments
14P08659545A0000|153 162|chromosome
14P08660733X0000|52 62|Puerto Rico
14P08660733X0000|64 68|April
14P08660748X0000|68 78|predictions
14P08660748X0000|81 99|population patterns
14P08660866A0504|11 19|positions
14P08660866A0504|33 35|Brd
14P08660866A0504|43 56|loss phenotype
14P08660866A0504|97 100|SOPs
14P08660866A0504|168 176|trichogen
14P08660892A1044|36 51|co-transfections
14P08660892A1044|64 84|SRF expression vector
14P08660892A1044|144 147|MyoD
14P08660892A1044|151 156|Mef-2C
14P08660998A0851|42 45|TATA
14P08660998A0851|47 50|CAAT
14P08660998A0851|52 55|GATA
14P08660998A0851|60 72|AP-2 elements
14P08660998A0851|96 125|mMIWC transcription initiation
14P08661007T0000|5 15|MN/CA9 gene
14P08661007T0000|41 56|anhydrase family
14P08661007T0000|75 102|protein domain relationships
14P08661100A0285|14 25|distribution
14P08661100A0285|28 32|Cdebp
14P08661100A0285|68 75|App gene
14P08661101A0396|0 20|DNA sequence analysis
14P08661104A0687|68 80|cells/tissues
14P08661104A0687|90 97|prostate
14P08661114A0564|30 46|sequence homology
14P08661114A0564|55 57|SIM
14P08661116A0963|0 16|Promoter activity
14P08661116A0963|69 75|D3 mRNA
14P08661116A0963|89 110|Northern blot analyses
14P08661119A0085|22 47|EP4 receptor gene sequence
14P08661119A0085|80 88|EP4R cDNA
14P08661613A0691|32 50|management measures
14P08661613A0691|139 160|enforcement activities
14P08662193A0404|13 33|activation subdomains
14P08662193A0404|123 126|NIT4
14P08662499A0484|11 21|interaction
14P08662499A0484|50 52|RNA
14P08662617A2051|34 36|HIP
14P08662617A2051|110 126|uterine epithelia
14P08662789A0673|38 56|GenBankTM data base
14P08662789A0673|57 74|sequence alignment
14P08662789A0673|83 88|RPS30A
14P08662852A1297|21 24|GRK2
14P08662852A1297|28 53|GRK5 phosphoacceptor sites
14P08662852A1297|64 80|carboxyl terminus
14P08662928A1153|65 77|STAT proteins
14P08662928T0000|0 8|Receptors
14P08662928T0000|24 25|IL
14P08662928T0000|61 80|signaling mechanisms
14P08662928T0000|111 132|IL-6 response elements
14P08662936A0428|23 47|FR-19 amino acid sequence
14P08662936A0428|90 103|chicken TEF-1A
14P08662936A0428|132 134|TEA
14P08662980A0762|27 37|DNA binding
14P08663000A0000|41 45|RHAMM
14P08663000A0000|47 61|gene expression
14P08663000A0000|115 133|growth factor-beta1
14P08663000A0000|134 142|TGF-beta1
14P08663120T0000|9 13|Raf-1
14P08663120T0000|23 35|p70 S6 kinase
14P08663127A0697|20 23|KCC1
14P08663127A0697|53 56|NKCC
14P08663127A0697|134 152|glycosylation sites
14P08663141T0000|11 21|DNA element
14P08663141T0000|35 42|TATA box
14P08663141T0000|45 73|transcription initiation site
14P08663141T0000|120 139|angiotensinogen gene
14P08663172A0311|27 40|amino terminus
14P08663219A0246|37 40|CAAT
14P08663219A0246|57 78|protein consensus site
14P08663219A0246|78 85|CAAT box
14P08663219A0246|100 119|hormone inducibility
14P08663219A0246|122 126|PGS-2
14P08663219A0246|128 144|CAT reporter gene
14P08663219A0246|161 172|E-box region
14P08663310A0157|8 10|SRF
14P08663310A0157|67 80|response genes
14P08663310A0157|107 110|IEGs
14P08663310A0157|172 186|differentiation
14P08663326A0000|25 38|DmpR activator
14P08663326A0000|47 59|transcription
14P08663326A0000|65 74|dmp operon
14P08663326A0000|98 107|catabolism
14P08663392A0215|32 40|DSG3 gene
14P08664229T0000|23 39|Allergan Humphrey
14P08664229T0000|61 87|Nidek AR-1000 autorefractor
14P08664347A0923|0 3|None
14P08664347A0923|13 43|proprotein processing proteases
14P08664462A1404|53 63|sensitivity
14P08664462A1404|82 93|transmission
14P08664462A1404|109 128|muscle contractility
14P08664462A1404|166 181|plasma clearance
14P08664462A1404|187 197|hypothermia
14P08664667A0093|9 13|Delhi
14P08664667A0093|20 24|India
14P08665853A0228|65 77|ErbB proteins
14P08665853A0228|84 95|combinations
14P08665853A0228|108 113|ErbB-3
14P08665853A0228|152 157|ErbB-1
14P08665853A0228|161 166|ErbB-2
14P08666102A0820|0 3|ZIOS
14P08666102A0820|61 63|Ptc
14P08666102A0820|100 103|FEV1
14P08666238T0000|9 30|translation initiation
14P08666241A0930|45 57|24p3 promoter
14P08666241A0930|71 88|Dex responsiveness
14P08666383A1252|5 12|findings
14P08666383A1252|30 41|cDNA mapping
14P08666383A1252|46 57|fluorescence
14P08666383A1252|64 76|hybridization
14P08666383A1252|103 110|approach
14P08666383A1252|116 125|definition
14P08666398T0000|0 2|YAC
14P08666398T0000|30 43|Batten disease
14P08666398T0000|44 47|CLN3
14P08666398T0000|57 69|16p12.1-p11.2
14P08666404A0311|0 8|Isolation
14P08666404A0311|46 63|brain cDNA library
14P08666404A0311|71 106|protein serine-threonine phosphatase
14P08666404A0311|110 132|tetratricopeptide motif
14P08666404A0311|155 159|PPP5C
14P08666404A0311|161 163|PP5
14P08666913A0000|0 4|Ly-49
14P08666913A0000|20 41|transmembrane proteins
14P08668124A0744|3 12|Dox-A2 ORF
14P08668124A0744|23 35|TDH3 promoter
14P08668142A1048|3 14|introduction
14P08668142A1048|90 100|Sec7p pools
14P08668158A0765|30 34|Rpm1r
14P08668158A0765|55 64|substrates
14P08668158A0765|218 221|RPM1
14P08668158A1252|29 38|RPM1 genes
14P08668158A1252|52 66|precursor Rpm1r
14P08668158A1252|118 135|biogenesis defects
14P08668190A1364|8 24|membrane vesicles
14P08668190A1364|28 39|hum1 mutants
14P08668190A1364|46 48|Ca2
14P08668190A1364|53 69|antiport activity
14P08668190A1364|87 91|Hum1p
14P08668190A1364|114 116|Ca2
14P08668201A1059|8 18|mutagenesis
14P08668201A1059|51 67|sequence boundary
14P08668201A1059|108 119|MATalpha1 IE
14P08668203A1230|0 2|FTF
14P08668203A1230|52 76|differentiation functions
14P08668203A1230|109 112|SF-1
14P08668209A0406|7 29|Cold Spring Harbor Symp
14P08668210A0000|61 65|Raf-1
14P08668210A0000|88 109|protein kinase pathway
14P08668210A0000|131 144|transformation
14P08669274T0000|10 27|chain ossification
14P08669676A1644|3 11|incidence
14P08669676A1644|40 48|Q wave MI
14P08669676A1644|48 55|propofol
14P08669676A1644|61 69|midazolam
14P08669676A1644|88 96|Q wave MI
14P08669676A1644|96 103|propofol
14P08669676A1644|110 118|midazolam
14P08669676A1644|151 166|treatment groups
14P08670556A0425|37 67|plasma concentration-time curve
14P08670556A0425|93 102|0-infinity
14P08670853A0000|0 16|Cluster formation
14P08670853A0000|18 27|E-cadherin
14P08670910A0156|0 15|DNA polymerase E
14P08670910A0156|15 24|DNA ligase
14P08670910A0156|31 33|DNA
14P08670910A0156|52 73|endonuclease co-purify
14P08672242A0517|7 30|reporter gene constructs
14P08672242A0517|65 75|P1 promoter
14P08673026T0000|3 18|factor structure
14P08673026T0000|46 62|replication study
14P08675026A0420|67 69|EST
14P08675026A0420|92 113|Caenorhabditis elegans
14P08675026A0420|114 125|Oryza sativa
14P08675026A0420|128 131|Homo
14P08675395A0751|0 6|RESULTS
14P08675395A0751|60 78|acuity outcome data
14P08675608T0000|0 6|Outcome
14P08675608T0000|25 38|hypothyroidism
14P08675763A0788|0 12|Mean increase
14P08675763A0788|14 31|milk protein yield
14P08675763A0788|42 44|Met
14P08675763A0788|49 51|Lys
14P08675763A0788|74 88|protein content
14P08675769A0158|95 109|conception rate
14P08675769A0158|112 123|calving rate
14P08675769A0158|215 225|performance
14P08675769A0158|230 242|AI technician
14P08675821A0657|10 13|EMPD
14P08675821A0657|25 35|glans penis
14P08676266A0838|3 13|mean values
14P08676266A0838|15 31|protease activity
14P08676266A0838|59 69|test groups
14P08676266A0838|78 90|control group
14P08676383A0518|4 16|half molecule
14P08676383A0518|28 45|disulfide linkages
14P08676454A0731|18 20|Pra
14P08676454A0731|22 23|N0
14P08676454A0731|27 28|Nb
14P08676454A0731|33 37|ICP35
14P08676454A0731|39 43|ICP35
14P08676454A0731|60 68|B capsids
14P08676456A0879|9 26|VP16-Tat construct
14P08676456A0879|72 90|AP-1 responsiveness
14P08676456A0879|115 136|VP16 activation domain
14P08676495A0129|80 94|BPV-1 pre-mRNAs
14P08676495A0129|113 122|C127 cells
14P08676858A0309|18 33|characterization
14P08676858A0309|36 48|S-RNase genes
14P08676858A0309|64 71|Rosaceae
14P08676858A0309|79 95|Malus x domestica
14P08676858A0309|111 124|Pyrus serotina
14P08676858A0309|187 192|RNases
14P08676858A1084|31 52|T2/S-RNase superfamily
14P08677443A0238|3 24|Hoosier Oncology Group
14P08677443A0238|64 76|SCLC patients
14P08677443A0238|77 79|VIP
14P08677443A0238|136 146|progression
14P08677443A0238|169 182|survival times
14P08677443A0238|212 225|survival rates
14P08677678A0258|14 27|administration
14P08677678A0258|30 56|immunomodulator neurotropin
14P08677678A0258|57 59|NSP
14P08677678A0258|117 134|avoidance behavior
14P08678959A0640|0 21|Sestamibi scintigraphy
14P08678959A0640|64 78|ultrasonography
14P08679131T0000|21 38|hypersensitivities
14P08680702A0548|44 54|dysfunction
14P08680702A0548|74 77|Days
14P08680702A0548|126 136|differences
14P08680702A0548|165 170|Vo2DIR
14P08680702A0548|182 184|Day
14P08680702A0548|209 211|Day
14P08680702A0548|284 291|Vo2INDIR
14P08680702A0548|303 305|Day
14P08680702A0548|330 332|Day
14P08680706A0889|21 34|PO2/FlO2 ratio
14P08680706A0889|69 75|Therapy
14P08680706A0889|99 117|Recipient Instilled
14P08680706A0889|134 147|Control groups
14P08680706A0889|185 202|Donor Aerosol dogs
14P08682155A0902|3 28|euglobulin clot lysis time
14P08682317A0900|0 14|HS inducibility
14P08682317A0900|25 27|HSE
14P08682317A0900|43 67|HS transcription factor-1
14P08682317A0900|67 71|HSF-1
14P08682317A0900|116 117|HS
14P08682868A0738|11 25|DSK2-1 mutation
14P08682868A0738|53 57|Dsk2p
14P08682868A0738|102 106|Dsk2p
14P08682868A0738|109 124|Cdc31p stability
14P08683106A0374|8 11|IL-2
14P08683106A0374|15 23|IFN-alpha
14P08683106A0374|33 43|STAT1 alpha
14P08683106A0374|46 50|STAT5
14P08683106A0374|52 55|IL-2
14P08683106A0374|78 82|STAT5
14P08683106A0374|89 97|IFN-alpha
14P08683106A0374|120 130|STAT1 alpha
14P08683108A0965|18 31|interpretation
14P08683108A0965|44 47|CREB
14P08683108A0965|61 89|transcription factor proteins
14P08683108A1501|51 84|protein kinase A signaling pathway
14P08683108A1501|106 123|junB transcription
14P08683983A0785|23 31|D protein
14P08683983A0785|92 105|leukemia cells
14P08683983A1163|20 32|participation
14P08683983A1163|59 68|regulation
14P08683983A1163|74 83|c-myb gene
14P08683983A1163|140 149|mechanisms
14P08683983A1163|152 161|activation
14P08683983A1163|182 196|differentiation
14P08683983A1163|208 226|cell growth control
14P08684522A0415|0 28|Immunofluorescence microscopy
14P08684742A0000|0 8|OBJECTIVE
14P08684742A0000|19 41|pregnancy complications
14P08684742A0000|61 73|amniocentesis
14P08684742A0000|107 119|amniocentesis
14P08686381A0527|5 8|ORFs
14P08686381A0527|10 20|9765orfR002
14P08686381A0527|22 32|9765orfR011
14P08686381A0527|36 46|9765orfR013
14P08686381A0527|99 127|polyadenylate binding protein
14P08686381A0527|174 176|BCR
14P08688190A0000|24 54|nevadensin 5-O-beta-D-glucoside
14P08688190A0000|57 86|nevadensin 5-O-beta-D-glucosyl
14P08688190A0000|146 167|Lysionotus pauciflorus
14P08688556A0242|12 21|laboratory
14P08688556A0242|65 75|suppressors
14P08688556A0242|104 111|clathrin
14P08688556A0242|138 140|Chc
14P08688556A0242|151 159|viability
14P08689520T0000|0 18|Reproductive period
14P08690118A0845|11 29|regression analysis
14P08690118A0845|34 46|manual method
14P08690118A0845|77 80|IVOS
14P08690118A0845|114 126|fertilization
14P08690198A0346|0 6|METHODS
14P08690198A0346|8 11|Rats
14P08690198A0346|71 85|supplementation
14P08690198A0346|96 121|Lactobacillus reuteri R2LC
14P08690198A0346|124 150|Lactobacillus plantarum DSM
14P08691106A0733|8 17|D8 binding
14P08691106A0733|30 48|nuclease protection
14P08691962T0000|23 31|diagnosis
14P08691962T0000|34 40|Whipple
14P08692885A0663|22 41|NF-kappaB activation
14P08692885A0663|65 82|zinc finger domain
14P08692892A0330|3 9|Pro-258
14P08692892A0330|13 15|Leu
14P08692892A0330|17 21|P258L
14P08692892A0330|49 66|receptor signaling
14P08692892A0330|98 110|maximum level
14P08692892A0330|148 159|alpha-factor
14P08692924A0328|8 19|DNA sequence
14P08692924A0328|57 61|BCL-6
14P08692924A0328|84 88|BCL-6
14P08692924A0328|148 159|B-cell lines
14P08697728A1199|13 17|value
14P08697728A1199|29 32|flag
14P08698756A1240|0 10|CONCLUSIONS
14P08698756A1240|34 46|pre-treatment
14P08698756A1240|51 62|coenzyme Q10
14P08698756A1240|105 114|procedures
14P08700531A1420|7 18|chromosome X
14P08700531A1420|50 60|alterations
14P08700531A1420|79 91|hamster cells
14P08700531A1420|104 123|chemical carcinogens
14P08700531A1420|146 157|localization
14P08700531A1420|211 222|cph oncogene
14P08700531A1420|279 297|hamster fibroblasts
14P08702517A0000|59 65|B6SUtA1
14P08702517A0000|73 92|progenitor cell line
14P08702543A0000|0 3|Gap1
14P08702543A0000|5 9|IP4BP
14P08702543A0000|26 28|Ras
14P08702543A0000|83 116|inositol 1,3,4,5-tetrakisphosphate
14P08702543A0000|117 119|IP4
14P08702543A0000|137 142|Cullen
14P08702543A0000|144 145|P.
14P08702556A0000|58 73|acid phosphatase
14P08702556A0000|74 76|PAP
14P08702556A0000|85 108|porcine thymus membranes
14P08702556A0000|108 112|Kanoh
14P08702556A0000|114 115|H.
14P08702556A0000|117 120|Imai
14P08702556A0000|122 126|S.-i.
14P08702556A0000|128 133|Yamada
14P08702556A0000|135 136|K.
14P08702556A0000|140 145|Sakane
14P08702556A0000|147 148|F.
14P08702556A0000|155 156|J.
14P08702633A0164|57 80|tyrosine phosphorylation
14P08702633A0164|85 103|Shc adapter protein
14P08702633A0164|107 128|Grb2 complex formation
14P08702633A0164|144 190|Ras guanine nucleotide exchange factor activity
14P08702644A0499|117 119|DAF
14P08702644A0499|147 192|glycosylphosphatidylinositol anchor attachment
14P08702728A1325|35 37|Shc
14P08702728A1325|40 44|Y317F
14P08702728A1325|51 53|Shc
14P08702728A1325|58 67|HIRc cells
14P08702756A0000|8 17|GTPase Rho
14P08702756A0000|67 88|actin-myosin filaments
14P08702756A0000|128 145|muscle contraction
14P08702807A0964|27 43|signaling pathway
14P08702807A0964|78 81|MKK1
14P08702807A0964|109 135|cyclin D1 promoter activity
14P08702807A0964|136 163|cyclin D1 protein expression
14P08702826A0870|34 55|GSTP1 silencer element
14P08702826A0870|102 111|MCF7 cells
14P08702845A0000|86 105|dopamine transporter
14P08702845A0000|106 108|DAT
14P08702845A0000|125 148|dopamine uptake kinetics
14P08702845A0000|154 180|CFT binding characteristics
14P08702845A0000|181 191|COS-7 cells
14P08702845A0000|218 221|DATs
14P08702845A0000|232 244|COOH terminus
14P08702936A0168|2 19|expression library
14P08702936A0168|167 174|CD4 cDNA
14P08702936A0168|190 209|virus shuttle vector
14P08702936A0984|23 26|TARC
14P08702936A0984|46 57|T cell lines
14P08702936A0984|69 75|T cells
14P08703005A0645|32 48|promoter activity
14P08703005A0645|70 94|transcription factors Sp1
14P08703005A0645|112 116|CCAAT
14P08703010A0905|48 55|E1 E-box
14P08703010A0905|68 89|GAP-43 promoter region
14P08703010A0905|147 157|GAP-43 gene
14P08703908A1814|39 42|SF-1
14P08703908A1814|110 118|StAR gene
14P08703959A0659|28 44|proton resonances
14P08703959A0659|87 97|lesion site
14P08703959A0659|138 150|sugar protons
14P08703959A0659|155 164|C7 residue
14P08703959A0659|182 194|adduct duplex
14P08704124A0420|26 31|CPK3-8
14P08704124A0420|70 102|Vigna radiata lambda gt11 library
14P08704240A1111|10 19|TF-1 cells
14P08704240A1111|26 31|GM-CSF
14P08704240A1111|49 68|CREB phosphorylation
14P08704240A1111|93 111|PIXY321 stimulation
14P08705056T0000|0 17|Workplace violence
14P08706368A1024|0 6|RESULTS
14P08706368A1024|11 31|LV maximum brightness
14P08706368A1024|104 107|FIO2
14P08706662A1125|35 53|perforin expression
14P08706662A1125|86 96|suppression
14P08706662A1125|148 159|factor NF-P2
14P08706731A1303|64 82|expression patterns
14P08706731A1303|84 94|Ypr10 genes
14P08706731A1303|97 114|ribonuclease genes
14P08706731A1303|147 165|sequence similarity
14P08706731A1303|170 189|ginseng ribonuclease
14P08706731A1303|213 233|ribonuclease function
14P08706731A1303|236 249|PR-10 proteins
14P08707424A0709|15 27|ERV3 env mRNA
14P08707516A0194|7 15|estimates
14P08707516A0194|76 92|handicap services
14P08707825A0063|31 42|muscle cells
14P08707825A0063|44 60|Northern blotting
14P08707825A0063|137 155|muscle cDNA library
14P08707825A0063|182 193|antibody R4A
14P08707840A0753|15 33|electron microscopy
14P08707840A0753|45 51|p58/p45
14P08707840A0753|55 57|p54
14P08707840A0753|109 111|p62
14P08707846A2308|84 97|ubiquitination
14P08707846A2308|113 135|receptor ubiquitination
14P08707846A2308|183 199|a-factor receptor
14P08707922A0334|0 29|Transcription initiation sites
14P08707922A0334|44 51|III beta
14P08707922A0334|55 73|O beta-globin genes
14P08707922A0334|121 148|translation initiation codon
14P08707922A0334|148 150|ATG
14P08707922A0334|165 189|primer extension analysis
14P08708984T0000|11 17|process
14P08708984T0000|27 38|indomethacin
14P08709224T0000|33 37|EBNA2
14P08709224T0000|66 80|SNF-SWI complex
14P08709245A1521|43 57|phosphorylation
14P08709245A1521|60 64|Ser-2
14P08709245A1521|66 72|Ser-123
14P08709245A1521|76 82|Ser-210
14P08709245A1521|97 122|trans-suppression activity
14P08709245A1521|132 135|HDAg
14P08709245A1521|167 179|HDAg particle
14P08709245A1521|206 210|HDAgs
14P08709251A0000|33 54|Autographa californica
14P08709251A0000|61 78|polyhedrosis virus
14P08709251A0000|79 83|AcNPV
14P08709251A0000|107 118|DNA fragment
14P08709251A0000|140 156|DNA helicase gene
14P08709251A0000|157 162|Bombyx
14P08709251A0000|174 191|polyhedrosis virus
14P08709251A0000|231 242|AcNPV mutant
14P08709251A0000|243 244|S.
14P08709637A1471|29 46|IL-7R alpha chains
14P08709637A1471|81 84|JAKs
14P08709637A1471|88 92|STATs
14P08709637A1471|136 152|precursor B cells
14P08709831A0599|24 34|Dacarbacine
14P08710151A0782|42 48|episode
14P08710151A0782|51 56|pnx s.
14P08710151A0782|58 64|class A
14P08710151A0782|88 94|class B
14P08710151A0782|107 113|patient
14P08710151A0782|116 122|class A
14P08710151A0782|143 150|class B.
14P08710371A0000|51 65|polyomavirus BK
14P08710371A0000|66 68|BKV
14P08710371A0000|176 194|p53 transactivation
14P08710371A0499|0 8|Site S-II
14P08710371A0499|49 71|consensus binding sites
14P08710371A0499|79 98|base pair mismatches
14P08710371A0499|110 127|base pair deletion
14P08710377A0577|0 2|Cbl
14P08710377A0577|33 43|SH3 domains
14P08710377A0577|45 48|Grb2
14P08710377A0577|117 119|Shc
14P08710377A0577|124 138|BCR stimulation
14P08710504A0995|0 9|Activation
14P08710504A0995|20 24|Cat8p
14P08711631A0989|0 8|Treatment
14P08711631A0989|38 53|cyclophosphamide
14P08712799A0123|7 14|attempts
14P08712799A0123|21 27|smoking
14P08713933A0606|0 20|Laboratory evaluation
14P08716757T0001|0 23|Microcomputer management
14P08716757T0001|32 48|hepatitis B virus
14P08717391A0466|16 25|N-terminus
14P08717391A0466|82 91|N-terminus
14P08717391A0466|100 109|C-terminus
14P08717391A0466|127 143|particle assembly
14P08717391A0466|179 192|immunogenicity
14P08717391A0466|195 199|HBcAg
14P08717559A0223|11 16|dosage
14P08717559A0223|62 68|ampoule
14P08717559A0223|82 91|micrograms
14P08719155A0105|62 74|P. falciparum
14P08719155A0105|136 151|surface molecule
14P08719155A0105|155 164|Plasmodium
14P08719155A0105|213 216|TRAP
14P08719155A0105|245 260|circumsporozoite
14P08719155A0105|262 263|CS
14P08719156A0953|56 68|reading frame
14P08719697A0221|0 6|METHODS
14P08719697A0221|8 10|DSF
14P08719697A0221|48 49|CF
14P08719697A0221|101 103|KCS
14P08719832A0397|25 42|rhinotomy approach
14P08720407A1386|0 9|CONCLUSION
14P08720407A1386|53 67|disc herniation
14P08720407A1386|95 113|interleukin-1 alpha
14P08720407A1386|139 165|prostaglandin E2 production
14P08721526A0000|25 33|allergens
14P08721526A0000|52 59|children
14P08721526A0000|69 79|pet animals
14P08721989A1012|58 75|cytokine receptors
14P08721989A1012|91 108|signaling pathways
14P08721989A1012|138 156|IL-2R beta function
14P08721989A1012|166 182|signal transducer
14P08721999A0432|2 9|addition
14P08721999A0432|28 35|features
14P08721999A0432|67 76|snoRNA U14
14P08721999A0727|0 2|U24
14P08721999A0727|25 41|complementarities
14P08721999A0727|67 74|28S rRNA
14P08722011A0103|25 37|GTPase domain
14P08722011A0103|47 58|subunit rRNA
14P08722011A0103|73 84|binding site
14P08722568A1001|0 19|Chromatin repression
14P08722568A1001|26 42|replacement genes
14P08722568A1001|103 130|replacement H3 histone genes
14P08723352A0084|107 143|retinoblastoma tumour suppressor gene
14P08723365T0000|8 19|relationship
14P08723365T0000|27 42|hyperinsulinemia
14P08723365T0000|69 83|nephrosclerosis
14P08723883A0823|0 20|Blood GSH-Px activity
14P08723883A0823|35 51|spectrophotometer
14P08723883A1684|3 16|concentrations
14P08723883A1684|19 38|vitamin A precursors
14P08723883A1684|40 48|vitamin E
14P08723883A1684|111 121|alfalfa hay
14P08726024A0244|21 29|H. pylori
14P08726024A0532|22 24|PCR
14P08726024A0532|107 119|fluid samples
14P08726024A0532|139 147|H. pylori
14P08726024A0532|212 220|H. pylori
14P08726247A0175|20 40|concentration changes
14P08727192A0000|0 11|STUDY DESIGN
14P08727992A0570|23 32|PGF2 alpha
14P08728040T0000|63 72|Jun kinase
14P08728040T0000|75 100|Janus kinase-Stat pathways
14P08728040T0000|120 143|fibroblast growth factor
14P08728040T0000|156 161|Kaposi
14P08730470A0000|30 46|hepatitis C virus
14P08730470A0000|98 109|transmission
14P08730470A0000|151 167|household contact
14P08731155A0499|13 26|reconstruction
14P08731222A0000|77 107|subnucleus reticularis dorsalis
14P08731222A0000|107 109|SRD
14P08731222A0000|129 143|Cuneate nucleus
14P08731222A0000|144 145|Cu
14P08731222A0000|193 226|Phaseolus vulgaris leucoagglutinin
14P08731222A0000|226 230|PHA-L
14P08731222A0000|261 268|C7 level
14P08731511A0625|45 49|ATIII
14P08731511A0625|54 69|heparin cofactor
14P08731511A0625|72 75|HCII
14P08732665A0000|0 12|Amplification
14P08732665A0000|49 54|21MT-2
14P08732665A0000|58 63|21MT-1
14P08732665A0000|69 90|breast carcinoma cells
14P08732665A0000|164 173|p185erbB-2
14P08732665A0000|229 231|IGF
14P08732665A0000|270 272|EGF
14P08733123A0000|27 35|dystrophy
14P08733123A0000|37 40|FSHD
14P08733123A0951|20 34|FRG1 transcript
14P08733123A0951|102 120|amino acid residues
14P08733874A0000|0 7|Patients
14P08733874A0000|24 36|thyroidectomy
14P08733874A0000|40 56|thyroid carcinoma
14P08733874A0000|102 115|hypothyroidism
14P08733874A0000|132 135|131I
14P08733874A0000|141 153|body scanning
14P08733881A0343|4 27|thyroid function testing
14P08733881A0343|76 85|TSH values
14P08733881A0343|114 123|TSH levels
14P08734538A0613|120 121|AM
14P08738510A0254|11 26|tumor FDG-uptake
14P08738510A0254|27 33|Q-MRGlu
14P08739209A0700|0 10|Zatebradine
14P08739209A0700|91 101|arrhythmias
14P08739209A0700|128 135|ligation
14P08739209A0700|147 154|ligation
14P08739260T0000|0 4|Catha
14P08739260T0000|25 43|amphetamine effects
14P08740416A0239|20 24|Seb1p
14P08740416A0239|99 108|C-terminus
14P08740416A0239|124 138|signal sequence
14P08740416A0919|3 16|SEB1 homologue
14P08740416A0919|29 32|SEB2
14P08740416A0919|63 67|Seb1p
14P08741206A1551|27 35|afferents
14P08741206A1551|92 103|vasodilation
14P08741206A1551|107 117|hypotension
14P08741280A0374|5 8|ones
14P08741280A0374|22 25|size
14P08741280A0374|35 38|lobe
14P08741280A0374|47 50|ones
14P08741280A0374|76 81|length
14P08741280A0374|91 94|lobe
14P08742135A0000|0 8|Fragments
14P08742135A0000|24 35|hormone ACTH
14P08742135A0000|90 100|head injury
14P08742135A0000|122 135|corticosterone
14P08742135A0000|137 138|CS
14P08742385A0211|15 20|causes
14P08742385A0211|26 35|meningitis
14P08742385A0211|61 68|drainage
14P08742385A0211|104 114|head injury
14P08745669A0000|96 102|Hodgkin
14P08745669A0000|156 166|cisplatinum
14P08745669A0000|168 177|methyl GAG
14P08745669A0000|178 187|bleomocyin
14P08745669A0000|189 206|methyl prednisolon
14P08746605A0377|22 35|ACE inhibitors
14P08746605A0377|91 102|pancreatitis
14P08746981A0154|50 69|mg probiotic/kg food
14P08747078T0000|27 37|miscarriage
14P08747343A0790|0 12|Protein films
14P08748033A0874|59 82|LamB-LacZ hybrid protein
14P08748033A0874|133 136|DegP
14P08749393A0783|3 15|PI3K_68D cDNA
14P08749393A0783|77 93|p110 PI 3-kinases
14P08749393A0783|94 113|p85 adaptor proteins
14P08749393A0783|177 187|SH3 domains
14P08749393A0783|208 216|C2 domain
14P08749394A0874|7 25|interaction studies
14P08749394A0874|46 70|glutathione-S-transferase
14P08749394A0874|82 92|RBP-J kappa
14P08749394A0874|95 96|Su
14P08749394A0874|117 129|RAM23 regions
14P08749394A0874|145 160|Drosophila Notch
14P08750173A0000|0 11|AIMS/METHODS
14P08750173A0000|32 46|system function
14P08750173A0000|131 145|D-galactosamine
14P08750173A0000|179 201|% liver resection model
14P08750190A0000|134 145|CD44 variant
14P08750190A0000|146 150|CD44v
14P08750702A0183|0 11|Study groups
14P08750702A0183|72 86|blockers WB4101
14P08750702A0183|102 121|chloroethylclonidine
14P08751635A0135|47 71|hippocampus subfields CA1
14P08751635A0135|71 73|CA3
14P08752714A0000|3 12|occurrence
14P08752714A0000|23 32|malignancy
14P08752714A0000|48 55|patients
14P08752714A0000|71 82|malignancies
14P08752714A0000|104 113|department
14P08754777A1214|17 30|T3R homodimers
14P08754777A1214|37 56|T3R-RXR heterodimers
14P08754777A1214|72 73|T3
14P08754777A1214|96 114|heterodimer binding
14P08754802T0000|63 83|acid oxidation enzyme
14P08754802T0000|139 156|adipose expression
14P08754827A0231|0 5|Hoeben
14P08754827A0231|7 10|F.J.
14P08754834A1097|37 53|response elements
14P08754834A1097|72 89|transcription unit
14P08754834A1097|113 119|NN-84AG
14P08754840A0793|9 32|glucan synthase activity
14P08754840A0793|50 54|Rho1p
14P08754852A0960|2 23|gel retardation assays
14P08754852A0960|25 27|RCS
14P08754852A0960|94 102|RCS cells
14P08754852A0960|154 159|18-mer
14P08755898A0339|39 57|Bs2 host resistance
14P08756332A0000|0 6|Members
14P08756332A0000|12 24|Ras subfamily
14P08756332A0000|103 120|effector molecules
14P08756332A0000|129 148|protein kinase c-Raf
14P08756332A0000|165 198|guanine nucleotide exchange factor
14P08756332A0000|197 203|Ral-GEF
14P08756433A0282|8 23|characterization
14P08756433A0282|29 43|promoter region
14P08756433A0282|136 145|MAP1B gene
14P08756556A0406|33 43|amino acids
14P08756556A0406|62 81|acid signal sequence
14P08756597A0854|0 6|Mutants
14P08756597A0854|40 50|% reduction
14P08756609A0498|10 28|amino acid sequence
14P08756609A0498|65 74|eukaryotes
14P08756609A0498|76 86|vertebrates
14P08756609A0498|88 100|invertebrates
14P08756617A1204|0 3|Biol
14P08756636T0000|26 44|yeast Rad51 protein
14P08756636T0000|71 83|Srs2 helicase
14P08756642A0230|0 10|Alterations
14P08756642A0230|55 68|myelodysplasia
14P08756712A0227|63 65|RPA
14P08756712A0227|67 69|RPA
14P08757265A0466|0 6|Neurons
14P08757943A0876|50 74|thymidine kinase promoter
14P08759870A1128|14 35|fbpA operator sequence
14P08759870A1128|55 75|footprinting analysis
14P08759870A1128|103 122|Fur repressor dimers
14P08760286A0696|30 32|Vav
14P08760286A0696|41 75|guanine nucleotide exchange factors
14P08760286A0696|178 180|Ras
14P08760286A0696|184 193|Rho family
14P08760286A0696|195 201|GTPases
14P08760286A0696|229 232|MAPK
14P08760286A0696|235 237|JNK
14P08760286A0696|266 287|Vav signaling pathways
14P08760776A1559|0 9|CONCLUSION
14P08760776A1559|41 62|fluticasone propionate
14P08760776A1559|122 133|theophylline
14P08760872A0696|32 34|E2F
14P08760872A0696|131 142|CHR elements
14P08760889A0170|3 12|cDNA clone
14P08760889A0170|76 79|H2A1
14P08760889A0531|0 9|Comparison
14P08760889A0531|22 41|amino acid sequences
14P08760889A0531|44 60|protein sequences
14P08760889A0531|74 77|H2As
14P08760889A0531|149 152|H2A1
14P08760889A0531|173 176|H2A2
14P08761169T0000|15 25|dysfunction
14P08761480A0331|0 10|Interaction
14P08761480A0331|63 68|RPDE-6
14P08761480A0331|75 86|PDE4A splice
14P08761480A0331|93 99|RPDE-39
14P08761480A0331|117 122|RPDE-6
14P08761480A0331|135 144|N-terminus
14P08761480A0331|191 193|RD1
14P08761480A0331|210 212|PDE
14P08761480A0331|306 311|RPDE-6
14P08762021A0156|27 34|measures
14P08762021A0156|48 58|performance
14P08762172A0178|5 22|strain differences
14P08762172A0178|37 45|variables
14P08762172A0178|63 72|proportion
14P08762172A0178|136 146|transitions
14P08762472A0000|11 36|ligustrazine hydrochloride
14P08762472A0000|37 39|LTH
14P08762472A0000|62 80|artery hypertension
14P08763207A0402|7 20|oxidation peak
14P08763207A0402|83 85|DPV
14P08763207A0402|104 115|accumulation
14P08763207A0402|149 151|CPE
14P08763311A0189|0 12|Phenylephrine
14P08763311A0189|20 49|alpha-1 adrenoreceptor agonist
14P08763925A0588|3 12|expression
14P08763925A0588|83 94|Western blot
14P08763925A0588|95 104|immunoblot
14P08763925A0588|106 113|analyses
14P08763925A0588|119 126|antisera
14P08763925A0588|145 152|proteins
14P08763953A0805|3 6|unit
14P08763953A0805|14 17|traA
14P08763953A0805|19 22|traF
14P08763953A0805|27 30|traB
14P08763953A0805|53 56|traC
14P08763953A0805|58 61|traD
14P08763953A0805|66 69|traG
14P08764015A0284|0 1|A.
14P08764136A0000|81 94|transformation
14P08764136A0000|125 128|MECs
14P08764136A0000|153 165|hybridization
14P08764136A0000|179 192|MEC strain 76N
14P08764136A0000|239 244|76R-30
14P08766049A0000|0 10|CASE REPORT
14P08766049A0000|34 52|corneal perforation
14P08766049A0000|162 169|Amikacin
14P08766049A0000|183 192|Vancomycin
14P08766781A0322|29 36|increase
14P08766781A0322|39 48|hematocrit
14P08766781A0322|71 72|Hb
14P08768374A0765|3 6|P-wr
14P08768374A0765|10 28|P-rr cDNA sequences
14P08768377A1387|10 21|hcf109 locus
14P08768377A1387|45 56|centimorgans
14P08768377A1387|64 81|phytochrome C gene
14P08768377A1387|93 108|characterization
14P08769132A0000|8 25|MSH-2 gene product
14P08769132A0000|101 115|mismatch repair
14P08769132A0000|159 162|MutS
14P08769132A0000|188 192|MSH-1
14P08769132A0000|196 209|MSH-2 proteins
14P08769132A0000|236 238|DNA
14P08769132A0000|260 274|base mismatches
14P08769132A0000|369 373|HNPCC
14P08769132A0000|375 396|tumor suppressor genes
14P08769132A0000|410 424|chromosome 2p16
14P08769409A0114|56 63|RAR beta
14P08769409A0114|70 82|mouse embryos
14P08769409A0114|135 148|reading frames
14P08769409A0114|182 187|Zimmer
14P08769409A0114|189 190|A.
14P08769409A0114|192 195|A.M.
14P08769566A0000|33 52|transcription factor
14P08769566A0000|64 68|Zfhep
14P08769566A0000|70 92|zinc finger homeodomain
14P08769566A0000|136 154|zinc finger domains
14P08769566A0000|154 156|ZD1
14P08769566A0000|160 162|ZD2
14P08769566A0000|180 182|DNA
14P08769568A0949|60 69|PLA2 genes
14P08770021T0000|9 24|PTHRP production
14P08770021T0000|27 50|tyrosine kinase oncogene
14P08770021T0000|67 87|Ras signaling pathway
14P08770896A1121|30 35|IGF-II
14P08770896A1121|45 53|G11 cells
14P08770896A1121|134 136|17K
14P08770896A1121|140 142|14K
14P08770920A1220|80 84|IDX-1
14P08770920A1220|122 126|IDX-1
14P08770920A1220|208 230|TAAT-1 element reporter
14P08770981A0328|22 42|von Willebrand factor
14P08770981A0328|46 58|fragmentation
14P08770981A0328|124 143|weight vWF multimers
14P08771781A0103|81 93|reading frame
14P08771781A0103|94 98|ORFII
14P08771781A0103|102 115|Brassica napus
14P08771781A0103|116 117|L.
14P08771781A0103|164 168|ORFII
14P08771781A0103|214 230|leaf cDNA library
14P08771781A1103|3 20|ORFII gene product
14P08771781A1103|102 114|PMSR activity
14P08771787T0000|0 15|Characterization
14P08771787T0000|18 20|LRP
14P08771787T0000|42 44|LRR
14P08774732A0271|13 15|Sp1
14P08774732A0271|53 74|gel retardation assays
14P08775674A0000|0 9|OBJECTIVES
14P08775674A0000|50 64|characteristics
14P08775674A0000|102 118|hydatidiform mole
14P08776735A0000|53 75|type rat LH/CG receptor
14P08776735A0000|81 89|receptors
14P08776735A0000|152 160|rLHR-t653
14P08776735A0000|162 170|rLHR-t631
14P08776735A0000|175 183|rLHR-t628
14P08776735A0000|203 212|importance
14P08776735A0000|230 239|regulation
14P08776735A0000|250 263|responsiveness
14P08776748T0000|6 20|P300 amplitudes
14P08776748T0000|30 42|schizophrenia
14P08776792A0626|0 4|Sleep
14P08776793A0811|3 10|patients
14P08776901A0000|0 18|Chloroplast mutator
14P08776901A0000|25 35|Arabidopsis
14P08777374A1471|6 19|concentrations
14P08777374A1471|55 68|concentrations
14P08777374A1471|137 150|concentrations
14P08778265A0422|53 66|Wisconsin card
14P08778265A0422|78 99|Street completion test
14P08778265A0422|99 109|Stroop test
14P08778265A0422|149 164|recognition test
14P08778700A0476|52 62|involvement
14P08778700A0476|77 80|ARVD
14P08780339A0142|28 45|Latin-square study
14P08780339A0142|66 82|carryover effects
14P08780339A0142|156 157|RS
14P08780339A0142|189 191|RS2
14P08780339A0142|233 235|RS3
14P08781119A0723|24 43|mouse Met-ase-1 gene
14P08781119A0723|109 126|rat Met-ase-1 gene
14P08781144A1520|4 6|18F
14P08781144A1520|8 17|FMISO TMRR
14P08781144A1520|77 79|NPC
14P08783180A0000|92 113|Carollia perspicillata
14P08783666A0957|2 9|addition
14P08783666A0957|20 30|engraftment
14P08783666A0957|59 72|amifostine arm
14P08784787A0383|11 27|thrombin receptor
14P08784787A0383|28 31|PAR2
14P08784787A0383|88 102|ligand sequence
14P08784787A0383|115 131|receptor cleavage
14P08787110A0981|14 17|CPET
14P08787110A0981|27 39|investigation
14P08787110A0981|120 133|investigations
14P08787110A0981|153 171|function laboratory
14P08789441A0339|5 16|fluorescence
14P08789441A0339|23 35|hybridization
14P08789441A0339|96 99|CMPD
14P08789441A0339|103 114|sex reversal
14P08789441A0339|154 166|translocation
14P08789441A0339|183 196|cosmid markers
14P08790288A0068|50 66|Spinacia oleracea
14P08790288A0068|77 94|Hordeum vulgare cv
14P08790291A1022|61 80|DNA damage tolerance
14P08790387A0299|5 18|rat rnu allele
14P08790387A0299|32 48|nonsense mutation
14P08792217A1407|41 57|TIMP-2 mRNA level
14P08792217A1407|84 96|up-regulation
14P08792217A1407|202 218|TIMP-2 mRNA level
14P08793029A0246|0 6|Control
14P08793693A0237|0 5|DESIGN
14P08794254A2957|5 7|SPK
14P08794254A2957|11 22|PTA category
14P08794326A0405|55 57|TRE
14P08794326A0405|59 60|GP
14P08794326A0405|111 115|SFV-1
14P08794339A1162|20 22|IE2
14P08794339A1162|55 58|CREB
14P08794339A1162|80 82|IE2
14P08794339A1162|106 109|p300
14P08794339A1162|136 138|CBP
14P08794339A1162|158 161|CREB
14P08794339A1162|175 190|adaptor proteins
14P08794339A1162|193 205|CREB function
14P08794348A1067|11 31|complementation assay
14P08794348A1067|51 53|NIa
14P08794348A1067|130 141|NIa proteins
14P08794363A0259|29 36|homology
14P08794363A0259|68 86|jun-fos gene family
14P08794547A0648|34 56|laser-doppler fluxmetry
14P08794547A1403|73 75|SAH
14P08794601A0000|33 46|clarithromycin
14P08794601A0000|51 68|bismuth subcitrate
14P08794601A0000|80 97|ulcer healing rate
14P08794601A0000|106 131|H. pylori eradication rate
14P08794869A0274|46 53|PKC-zeta
14P08794869A0274|72 95|integrin gene expression
14P08795304T0000|0 20|Plasma thrombomodulin
14P08795304T0000|59 75|diabetes mellitus
14P08797362T0037|0 5|Update
14P08797362T0037|63 66|USSR
14P08797362T0037|68 74|January
14P08798420A0207|3 18|characterization
14P08798420A0207|99 115|AP-1 binding site
14P08798420A0207|117 119|TRE
14P08798420A0207|123 141|PRDII/kappaB domain
14P08798420A0207|146 153|CAAT box
14P08798443A0660|0 5|Serine
14P08798443A0660|40 49|cell lines
14P08798443A0660|53 64|substitution
14P08798443A0660|86 90|S528A
14P08798443A0660|122 124|Myb
14P08798443A0660|221 238|herpes tk promoter
14P08798443A1218|3 13|DNA binding
14P08798443A1218|16 41|multimerization activities
14P08798443A1218|73 90|S528A substitution
14P08798443A1218|155 192|transcription transactivating activity
14P08798512A1197|35 43|GEO cells
14P08798610A0843|0 3|PIP2
14P08798610A0843|25 60|phosphatidylcholine carrier vesicles
14P08798610A0843|109 115|Cdc42Hs
14P08798610A0843|191 197|Cdc42Hs
14P08798610A0843|229 243|Dbl oncoprotein
14P08798635A0870|40 42|GTP
14P08798635A0870|61 64|ARF1
14P08798635A0870|66 69|ARF3
14P08798635A0870|71 74|ARF5
14P08798635A0870|79 82|ARF6
14P08798641A0400|0 3|Biol
14P08798643T0000|50 68|transforming region
14P08798643T0000|70 72|Cbl
14P08798643T0000|108 113|ZAP-70
14P08798643T0000|116 122|T cells
14P08798648A1816|0 6|Cys-757
14P08798648A1816|17 21|Fe4S4
14P08798648A1816|67 81|enzyme activity
14P08798700A0134|3 15|transcription
14P08798700A0134|69 83|heme deficiency
14P08798700A0134|124 128|Rox1p
14P08798700A0134|170 188|activation sequence
14P08798700A0134|189 191|UAS
14P08798762A1279|61 72|Cut proteins
14P08798762A1279|85 87|PKC
14P08798782A0976|40 42|SH2
14P08798782A0976|46 56|SH3 domains
14P08798893A0611|41 51|lactalbumin
14P08798893A0611|67 77|maintenance
14P08798893A0611|108 125|CCCD heterogeneity
14P08801403T0001|28 44|presentation form
14P08803710A0701|75 77|IVA
14P08803710A0701|81 83|IVB
14P08803845A0665|3 10|presence
14P08803845A0665|49 56|clusters
14P08803845A0665|114 122|insertion
14P08803845A0665|125 130|lesion
14P08803845A0665|146 152|attempt
14P08803845A0665|169 176|excision
14P08804012A0662|10 19|categories
14P08804012A0662|25 27|SIP
14P08804012A0662|57 66|recreation
14P08804012A0662|79 93|home management
14P08804389A0893|0 21|Northern blot analysis
14P08804389A0893|61 85|Xanthomonas campestris pv
14P08804389A0893|130 138|Ltp4 mRNA
14P08805338A1061|23 31|OGG1 gene
14P08805338A1061|53 80|OG glycosylase/lyase protein
14P08805338A1061|149 150|OG
14P08805824A1155|55 83|exit wavefront reconstruction
14P08805824A1155|190 205|lens aberrations
14P08806491A0542|0 10|Transcripts
14P08806491A0542|18 24|ODV-E18
14P08806491A0542|28 35|ODV-EC27
14P08806491A0542|57 67|TAAG motifs
14P08806693A0584|37 51|GATA-1 promoter
14P08806693A0584|79 82|ME26
14P08806693A0584|140 167|luciferase expression vector
14P08806693A0584|190 206|mouse fibroblasts
14P08806693A0584|224 229|GATA-1
14P08806817A0244|0 16|Sequence analysis
14P08806817A0244|56 73|DNA binding domain
14P08806817A0244|118 129|TR2 receptor
14P08806817A0716|7 23|DNA hybridization
14P08806817A0716|64 83|S. purpuratus genome
14P08807245A0843|5 24|retrospective review
14P08807288T0000|0 8|Isolation
14P08807288T0000|57 71|ADH2 expression
14P08807408A0524|0 6|METHODS
14P08807408A0524|10 16|RESULTS
14P08807408A0524|48 49|AV
14P08807408A0524|108 122|AV modification
14P08807408A0524|133 158|radiofrequency application
14P08808120A0774|0 7|Patients
14P08808120A0774|34 50|aluminum overload
14P08808120A0774|51 67|serum iron levels
14P08808120A0774|84 86|DAI
14P08808120A0774|144 170|iron transferrin saturation
14P08808120A0774|173 193|serum ferritin levels
14P08808120A0774|245 261|aluminum overload
14P08808120A0774|262 282|serum aluminum levels
14P08808120A0774|299 301|DAI
14P08808275A1193|11 27|RAD23 equivalents
14P08808275A1193|120 136|yeast counterpart
14P08808707A0631|0 8|Ha-RasV12
14P08808707A0631|68 70|ERK
14P08808707A0631|94 107|protein kinase
14P08808707A0631|108 111|SAPK
14P08808707A0631|115 117|Jun
14P08808707A0631|135 137|JNK
14P08808707A0631|183 197|gene expression
14P08808756A0587|0 16|Sequence analysis
14P08808756A0587|68 70|RNA
14P08808756A0587|192 203|accumulation
14P08808924A0326|3 20|hydropathy profile
14P08808924A0326|66 79|amino terminus
14P08808924A0326|157 160|L-61
14P08808924A0326|163 166|F-97
14P08808924A0326|222 225|ProW
14P08808927A0417|7 13|HindIII
14P08808927A0417|52 64|M. bovis PG45
14P08808939A0000|0 27|Carbon catabolite repression
14P08808939A0000|42 58|Bacillus subtilis
14P08808939A0000|73 103|catabolite control protein CcpA
14P08808939A0000|106 108|HPr
14P08808939A0000|111 132|phosphocarrier protein
14P08808939A0000|137 161|phosphotransferase system
14P08809680T0000|0 8|Melatonin
14P08809680T0000|12 22|seasonality
14P08810040A0955|52 70|target locus marker
14P08810040A0955|86 96|replacement
14P08810040A0955|105 113|frequency
14P08810278A0682|51 57|BCR/ABL
14P08810278A0682|68 82|CRKL-SH2 domain
14P08810278A0682|84 87|p130
14P08810278A0682|89 91|CAS
14P08810278A0682|94 97|p130
14P08810278A0682|99 101|CAS
14P08810278A0682|154 157|CRKL
14P08810278A0682|160 188|BCR/ABL expressing cell lines
14P08810278A0682|210 212|CML
14P08810278A0682|216 227|ALL patients
14P08810323A0735|12 31|polyglutamine motifs
14P08812012T0000|45 58|Stroop effects
14P08812020A0597|8 17|experiment
14P08812020A0597|20 30|Chessmaster
14P08812106T0000|0 8|PCNA mRNA
14P08812106T0000|14 16|UTR
14P08812490A0000|30 46|gene symbol AQP2L
14P08812490A0000|94 112|kidney cDNA library
14P08812490A0542|0 25|PCR/Southern blot analysis
14P08812490A0542|31 41|kidney cDNA
14P08812490A0542|126 136|transcripts
14P08812490A1509|7 23|sequence homology
14P08812490A1509|82 84|MIP
14P08812490A1509|89 93|AQP-2
14P08812490A1509|102 124|MIP family gene cluster
14P08812490A1509|124 145|chromosome locus 12q13
14P08813766A0605|8 10|ORF
14P08813766A0605|96 113|consensus sequence
14P08813766A0605|116 138|C2H2 zinc finger domain
14P08813766A0605|177 181|Cre-A
14P08813766A0605|186 196|Aspergillus
14P08813766A0605|198 207|Emericella
14P08813900A1088|29 39|orderliness
14P08813900A1088|42 52|development
14P08813900A1088|54 67|mineralization
14P08813900A1088|71 81|arrangement
14P08813900A1088|84 92|cartilage
14P08813900A1088|96 105|bone cells
14P08813900A1088|131 142|P deficiency
14P08813900A1088|167 175|structure
14P08814651A0000|3 12|importance
14P08814651A0000|56 79|ethanol withdrawal signs
14P08814651A0000|104 115|rating scale
14P08816052A0238|28 35|WISC-III
14P08816052A0238|97 149|Kaufman Short Neuropsychological Assessment Procedure
14P08816438A0316|22 39|plasmid loss rates
14P08816438A0316|40 55|cdc28-1N strains
14P08816438A0316|83 101|replication origins
14P08816438A0316|132 146|DNA replication
14P08816438A0316|164 185|plasmid loss phenotype
14P08816443A1674|21 29|ROK alpha
14P08816443A1674|50 63|reorganization
14P08816443A1674|69 80|cytoskeleton
14P08816443A1674|93 101|C termini
14P08816443A1674|157 169|kinase domain
14P08816443A1674|205 217|stress fibers
14P08816443A1674|225 242|adhesion complexes
14P08816452A0936|31 49|tissue distribution
14P08816452A0936|51 53|p54
14P08816453A0000|20 22|AMP
14P08816453A0000|73 84|Raf-1 kinase
14P08816459A0090|2 19|interaction screen
14P08816459A0090|26 42|repression domain
14P08816459A0090|47 68|orphan receptor RevErb
14P08816459A0090|77 81|N-CoR
14P08816459A0090|100 123|thyroid hormone receptor
14P08816459A0090|123 124|TR
14P08816459A0090|150 152|RAR
14P08816460A1769|36 56|Jun kinase activation
14P08816460A1769|77 94|Ras transformation
14P08816460A1769|122 126|Erk-2
14P08816461A0892|23 27|Upf1p
14P08816461A0892|89 101|mRNA turnover
14P08816461A0892|104 123|nonsense suppression
14P08816472T0000|0 13|Identification
14P08816472T0000|16 19|Ste4
14P08816472T0000|43 46|Byr2
14P08816472T0000|58 73|response pathway
14P08816482A0234|27 31|Stat5
14P08816482A0234|33 38|Stat5a
14P08816482A0234|42 47|Stat5b
14P08816483A0869|0 8|Mutations
14P08816483A0869|21 24|SIC1
14P08816483A0869|26 29|SWI5
14P08816483A0869|34 37|RIC3
14P08816498A0000|3 31|serine/threonine kinase Raf-1
14P08816498A0000|51 54|Rats
14P08816498A0000|58 84|signal transduction cascade
14P08816504T0000|50 78|phosphatidylinositol 3-kinase
14P08816504T0000|91 106|receptor binding
14P08816504T0000|151 162|Ras activity
14P08816507A1125|11 29|cotransfections E1A
14P08816507A1125|56 67|p53 promoter
14P08816507A1125|80 86|12S E1A
14P08816507A1125|111 117|13S E1A
14P08816507A1125|135 137|YY1
14P08816759A0000|3 26|retinoid Z receptor beta
14P08816759A0000|25 32|RZR beta
14P08816759A0000|86 88|RAR
14P08816759A0000|91 114|thyroid hormone receptor
14P08816759A0000|114 115|TR
14P08816792A0000|13 26|protein kinase
14P08816792A0000|27 32|DNA-PK
14P08816792A0000|66 67|Ku
14P08816792A0000|95 102|DNA-PKcs
14P08817323A0714|14 30|sequence identity
14P08817323A0714|58 70|DXS6673E gene
14P08817323A0714|98 101|ESTs
14P08817323A0714|126 138|DXS6673E gene
14P08817323A0714|147 150|EST.
14P08817324A1070|23 50|Xq28 duplication breakpoints
14P08817324A1070|102 125|CAGGG pentamer sequences
14P08818436A0557|23 30|analysis
14P08818436A0557|46 51|gender
14P08818436A0557|65 71|history
14P08818436A0557|88 95|diseases
14P08818436A0557|103 108|gender
14P08818718A1229|123 126|MDR1
14P08818718A1229|130 137|GC cDNAs
14P08820324A1699|27 29|DBS
14P08820324A1699|33 45|TOF responses
14P08820642A0173|60 91|Hrp secretion pathway components
14P08820642A0173|139 151|cosmid pHIR11
14P08820642A0173|236 237|HR
14P08820648A0123|33 56|ribonucleotide reductase
14P08822208A1364|42 49|isoforms
14P08822208A1364|63 71|responses
14P08822208A1364|85 95|differences
14P08822208A1364|103 112|regulation
14P08822399A0518|29 37|attitudes
14P08822399A0518|48 61|susceptibility
14P08822399A0518|64 72|pregnancy
14P08823163T0000|29 54|diphtheria toxin repressor
14P08823163T0000|149 162|co-corepressor
14P08823187A1020|0 8|Titration
14P08823187A1020|22 37|porcine proteins
14P08823187A1020|81 100|membrane dipeptidase
14P08823187A1020|134 148|disulfide bonds
14P08823260A1161|0 3|FEV1
14P08823260A1161|58 61|GVHD
14P08823646A1012|0 13|Administration
14P08823646A1012|42 55|overestimation
14P08823646A1012|61 64|SaO2
14P08823709A0220|0 6|Therapy
14P08823709A0220|18 29|modification
14P08823709A0220|33 59|triglyceride lowering drugs
14P08824201A0270|0 7|Chernoff
14P08824585A0260|18 31|protein kinase
14P08824585A0260|51 67|progenitor kinase
14P08824585A0260|69 72|HPK1
14P08824585A0260|138 153|progenitor cells
14P08824798A0761|5 21|ESP1/CRP2 protein
14P08824798A0761|27 37|LIM domains
14P08824798A0761|113 115|CRP
14P08824800A0808|42 68|agarose gel electrophoresis
14P08824805A0832|12 26|exon boundaries
14P08824805A0832|75 85|p55 protein
14P08824881A0133|0 14|Linkage studies
14P08824881A0133|23 41|locus heterogeneity
14P08824881A0133|48 55|TSC gene
14P08824881A0133|89 95|16p13.3
14P08824884A0000|56 60|FRAXE
14P08824884A0000|84 93|GCC repeat
14P08824884A0000|103 106|Xq28
14P08824884A0000|117 128|X chromosome
14P08825087A0213|0 20|DNA sequence analysis
14P08825087A0213|26 47|bp BamHI-ClaI fragment
14P08825087A0213|81 84|ORFs
14P08825178A0071|10 29|inpatient experience
14P08825178A0071|58 59|TB
14P08825178A0071|114 120|TB care
14P08825554A0000|0 14|Tristetraprolin
14P08825554A0000|16 18|TTP
14P08825554A0000|53 73|transcription factors
14P08825554A0000|100 116|CCCH zinc fingers
14P08825556A0522|18 24|CREsp-a
14P08825556A0522|26 33|TGACCTCA
14P08825556A0522|74 76|CRE
14P08825556A0522|78 83|CREpal
14P08825556A0522|85 92|TGACGTCA
14P08825556A0522|113 116|CREB
14P08825633A0304|0 7|Analysis
14P08825633A0304|22 24|DNA
14P08825633A0304|77 83|G alpha
14P08825636T0000|72 75|p105
14P08825636T0000|79 90|p50 proteins
14P08825636T0000|92 123|transcription factors NF-kappa B
14P08825636T0000|124 138|I kappa B-gamma
14P08825636T0000|153 160|NF-kappa
14P08825636T0000|171 189|signal transduction
14P08825639A0827|10 27|Alu repeat element
14P08827783A0499|21 28|normoxia
14P08827783A0499|33 42|monitoring
14P08828142A0000|6 21|leukemia viruses
14P08828142A0000|22 26|FeLVs
14P08828142A0000|58 73|oncoretroviruses
14P08828152A1238|0 9|Comparison
14P08828152A1238|15 34|amino acid sequences
14P08828152A1238|38 54|RPO1 polypeptides
14P08828152A1238|56 59|IIV6
14P08828152A1238|61 64|LCDV
14P08828152A1238|69 73|MCV-1
14P08828152A1238|154 174|amino acid similarity
14P08828152A1825|3 6|RPO1
14P08828152A1825|9 12|LCDV
14P08828152A1825|43 46|RPO1
14P08828152A1825|49 52|IIV6
14P08828857A2423|15 22|GE cells
14P08828857A2423|138 152|gene expression
14P08829393A0083|11 27|dipole estimation
14P08829393A0083|38 51|SEP components
14P08831364A1252|16 26|propranolol
14P08831364A1252|77 78|AV
14P08831364A1252|84 98|conduction time
14P08831364A1252|164 165|AV
14P08832146A0959|8 10|CBD
14P08832146A0959|37 61|bone alkaline phosphatase
14P08832146A0959|85 87|PTH
14P08833153A0628|12 21|comparison
14P08833153A0628|27 46|hCHLR gene sequences
14P08833153A0628|58 66|databases
14P08833153A0628|238 252|repeat sequence
14P08833153A0628|268 278|chromosomes
14P08833653A0304|17 49|LIM domain homeobox protein isl-1
14P08833653A0783|37 65|amylin gene promoter elements
14P08833653A0783|209 212|InR1
14P08833653A0783|214 227|G9 islet cells
14P08835393A2829|43 68|signal transduction events
14P08835393A2829|73 92|calcium mobilization
14P08835393A2829|96 121|promoter response elements
14P08835393A2829|126 128|SRE
14P08835895A1292|3 11|CD4 count
14P08835895A1292|49 64|immunodeficiency
14P08835969A0000|18 28|laparoscopy
14P08835969A0000|99 100|EP
14P08835969A0000|147 157|conjunction
14P08835969A0000|173 184|serum assays
14P08835969A0000|189 200|beta subunit
14P08835969A0000|216 227|gonadotropin
14P08835969A0000|273 275|EPs
14P08836032T0000|0 14|Bifunctionality
14P08836032T0000|20 25|AcMNPV
14P08836032T0000|36 50|region sequence
14P08836032T0000|67 79|ori functions
14P08836032T0000|92 112|sequence requirements
14P08836172A1382|0 2|RVR
14P08836172A1382|40 54|over-expression
14P08836172A1382|74 84|RVR delta E
14P08836172A1382|110 121|p21Cip1/Waf1
14P08836172A1382|125 138|myogenin mRNAs
14P08836172A1382|143 158|serum withdrawal
14P08836740A1025|7 10|CES1
14P08836740A1025|14 17|CES4
14P08837503A0392|8 20|repeat motifs
14P08837503A0392|94 100|SbHRGP3
14P08837503A0392|138 150|repeat motifs
14P08837503A0392|171 185|dicot extensins
14P08837746A0951|26 39|BrAAP activity
14P08837746A0951|68 89|postglutamate cleavage
14P08838144A0107|53 63|PRL binding
14P08838144A0107|66 84|signal transduction
14P08838144A0107|102 124|S1 or/and S2 subdomains
14P08838148A1218|40 57|mouse TRH receptor
14P08838148A1218|116 133|L channel activity
14P08838314A0129|50 53|V1aR
14P08838314A0129|78 92|characteristics
14P08838314A0129|94 110|tissue expression
14P08838314A0129|163 171|V1aR gene
14P08838314A0129|172 177|AVPR1A
14P08838585A0968|38 55|backbone deviation
14P08838805T0000|29 45|beta-catenin gene
14P08838805T0000|46 51|CTNNB1
14P08839498A0507|31 42|distribution
14P08839498A0507|49 59|tissue mass
14P08839498A0507|135 146|distribution
14P08839832A0729|17 29|CD30v protein
14P08839832A1220|12 26|phosphorylation
14P08839832A1220|32 44|CD30v protein
14P08839832A1220|81 83|32P
14P08839911A0716|7 12|cycles
14P08840501A0345|78 81|ACT4
14P08840506A0544|8 11|ORFs
14P08840506A0544|75 79|G2850
14P08840997A0765|0 9|MVR typing
14P08842143A0000|0 13|Plasmid pAL618
14P08842143A0000|31 42|determinants
14P08842143A0000|46 54|H2 uptake
14P08843411A0801|20 28|receptors
14P08843411A0801|73 82|activation
14P08843411A0801|86 97|dimerization
14P08843411A0801|149 158|activation
14P08843412A0543|27 46|40-amino acid region
14P08843412A0543|54 57|LBDs
14P08843412A0543|60 62|RXR
14P08843412A0543|64 66|RAR
14P08843412A0543|68 69|TR
14P08843412A0543|98 126|promoter transcription factor
14P08843412A0543|209 219|DNA binding
14P08843419A1290|0 2|OKA
14P08843419A1290|29 33|OCFRE
14P08844448A0000|50 64|crossover study
14P08844448A0000|87 96|volunteers
14P08844448A0000|168 183|lipase inhibitor
14P08844448A0000|204 213|absorption
14P08844448A0000|236 249|weight control
14P08844448A0000|264 273|absorption
14P08844448A0000|288 289|E.
14P08844577A0000|0 9|Tilmicosin
14P08844712A0000|0 5|Effect
14P08844712A0000|21 23|N2O
14P08844712A0000|52 61|C-reflexes
14P08844712A0000|124 139|alpha-chloralose
14P08845378A0368|0 25|Restriction enzyme mapping
14P08845378A0368|27 43|Southern analysis
14P08845378A0368|71 80|MZF-1 gene
14P08846775A0110|14 17|Swi4
14P08846775A0110|21 39|Swi6 cell viability
14P08846775A0110|85 93|G1 cyclin
14P08846775A0110|107 110|CLN1
14P08846775A0110|113 116|CLN2
14P08847138A0609|3 17|detection ratio
14P08847403T0000|44 46|IVF
14P08847723A2351|0 11|IMPLICATIONS
14P08847723A2351|47 59|inconsistency
14P08847723A2351|133 144|associations
14P08847723A2351|146 157|replications
14P08848013A1469|15 22|TATA box
14P08848013A1469|58 74|promoter activity
14P08848013A1469|81 88|TATA box
14P08848052A0733|27 30|Gle1
14P08848052A0733|35 51|RNA-export factor
14P08848052A0733|58 60|Rev
14P08848052A0733|76 85|RNA export
14P08848052A0733|109 112|Gle1
14P08849208A1022|0 7|Demispan
14P08849569A0615|3 12|techniques
14P08849569A0615|20 37|assay coefficients
14P08849778A0226|15 34|toeprinting analyses
14P08849778A0226|91 93|RNA
14P08849778A0226|95 98|CopA
14P08849778A0598|27 43|initiator protein
14P08849778A0598|44 53|expression
14P08849778A0598|66 79|leader peptide
14P08849778A0598|80 90|translation
14P08849834A0000|28 43|volume flow rate
14P08849834A0000|85 117|colour Doppler ultrasound imaging
14P08850585A0602|3 19|enzyme activities
14P08850585A0602|51 65|pathophysiology
14P08850585A0602|103 119|virulence factors
14P08851337A1092|0 12|Tonsillectomy
14P08851337A1092|82 96|angina patients
14P08851434A0383|14 38|fat/water intensity ratio
14P08853303A0431|98 99|IA
14P08853303A0431|101 120|bolus MMC injections
14P08853303A0431|120 123|Tmax
14P08853303A0431|154 165|MMC infusion
14P08853303A0431|166 168|Vss
14P08853303A0431|174 177|1/kg
14P08853303A0431|179 180|C1
14P08853303A0431|195 204|T1/2 alpha
14P08853303A0431|212 220|T1/2 beta
14P08853893A0158|36 48|E2F complexes
14P08854459A0000|44 53|casualties
14P08854459A0000|56 66|earthquakes
14P08854459A0000|108 116|September
14P08854459A0000|125 132|February
14P08854844A0637|21 37|non-visualization
14P08854844A0637|43 44|GB
14P08854844A0637|48 63|h post injection
14P08854844A0637|93 94|AC
14P08855804A1528|89 91|SLT
14P08856077T0000|26 58|tryptophanyl-tRNA synthetase mRNA
14P08856132T0000|0 7|Evidence
14P08856132T0000|45 57|kinin release
14P08856132T0000|62 72|development
14P08858211A0694|4 15|GAP activity
14P08858211A0694|28 51|3T3-L1 adipocyte lysates
14P08858211A0694|102 104|GTP
14P08858211A0694|112 119|GST-Rab4
14P08858211A0694|135 137|GDP
14P08858268A1307|0 9|CONCLUSION
14P08858268A1307|143 145|CHF
14P08858268A1307|148 150|CLZ
14P08858463A0853|17 29|AIDS patients
14P08858463A0853|33 46|cryptococcosis
14P08858463A0853|59 65|ILd-AmB
14P08858463A0853|184 197|nephrotoxicity
14P08861955A0927|60 63|p619
14P08861955A0927|74 100|guanine nucleotide exchange
14P08861955A0927|101 104|ARF1
14P08861955A0927|129 140|Rab proteins
14P08861955A0927|159 178|GTP binding proteins
14P08861955A0927|188 193|R-Ras2
14P08861955A0927|195 198|TC21
15P08861963A0375b|16 30|RNA polymerases
15P08861963A0375b|43 63|mutant alpha subunits
15P08861963A0375b|92 115|transcription activation
15P08861963A0375b|131 147|rrnBP1 UP element
14P08861963T0000|0 39|Transcription factor recognition surface
14P08861963T0000|42 69|RNA polymerase alpha subunit
14P08861963T0000|93 112|DNA enhancer element
14P08862522A0690|18 27|similarity
14P08862522A0690|66 75|precursors
14P08862522A0690|92 102|temperature
14P08862743A0603|1 8|decrease
14P08862743A0603|11 24|erythrocyte Mn
14P08863824A0509|0 6|Cloning
14P08863824A0509|10 26|sequence analyses
14P08863824A0509|129 148|transmembrane domain
14P08863824A0509|153 160|5-HT2C-R
14P08864061A0000|0 9|Expression
14P08864061A0000|12 32|thymidine kinase gene
14P08864219A0178|20 33|concentrations
14P08864219A0178|35 38|MICs
14P08864219A0178|42 53|ketoconazole
14P08864219A0178|66 77|itraconazole
14P08864219A0178|94 107|amphotericin B
14P08864219A0178|139 151|inoculum size
14P08866485A0125|5 12|bacteria
14P08866485A0125|23 37|export proteins
14P08866485A0125|54 65|interactions
14P08866485A0125|96 104|molecules
14P08866485A0125|129 137|functions
14P08867519A0557|23 26|LDEE
14P08867519A0557|72 85|administration
14P08868473A1287|13 15|p28
14P08868473A1287|92 102|development
14P08868473A1287|128 137|cell cycle
14P08868660A0087|15 26|contribution
14P08868660A0087|48 57|discussion
14P08868660A0087|63 74|Rivista dell
14P08868660A0087|75 84|Infermiere
14P08868660A0087|165 174|weaknesses
14P08868660A0087|180 201|hypothesis formulation
14P08868660A0087|212 222|instruments
14P08868660A0087|228 237|discussion
14P08868954A0648|99 117|calcium antagonists
14P08868954A0648|123 133|angiotensin
14P08868954A0648|144 160|enzyme inhibitors
14P08868954A0648|173 184|hemodynamics
14P08869358A0121|40 49|strategies
14P08869358A0121|62 70|apoptosis
14P08869358A0121|109 115|T cells
14P08869763A0378|36 44|phenomena
14P08869763A0378|81 91|differences
14P08869763A0378|94 103|expression
14P08869763A0378|107 117|sensitivity
14P08869763A0378|130 146|receptor subtypes
14P08869825A0000|51 64|monooxygenases
14P08869825A0000|66 68|FMO
14P08870266A0651|19 30|observations
14P08870266A0651|84 97|NodO secretion
14P08870266A0651|149 168|secretion efficiency
14P08871542A1352|90 92|Mtx
14P08871542A1352|134 154|Thbs3 gene expression
14P08871567A0000|0 12|MSSP proteins
14P08871567A0629|0 3|Gene
14P08871635A0000|0 22|B cell antigen receptor
14P08871635A0000|21 23|BCR
14P08871635A0000|47 75|WEHI-231 B lymphoma cell line
14P08871635A0000|96 99|CD40
14P08872162A0884|58 60|CD4
14P08872162A0884|63 65|CD8
14P08872162A0884|67 80|T cell subsets
14P08872671A0573|24 48|blood flow shunt fraction
14P08872671A0573|47 51|Qs/QT
14P08872671A0573|90 112|amplitude perturbations
14P08873063A0493|10 28|amino acid sequence
14P08873063A0493|29 34|LvUSF2
14P08873063A0493|54 59|LvUSF1
14P08873063A0875|0 13|ECM disruption
14P08873063A0875|15 32|Lytechinus embryos
14P08873063A0875|53 79|USF RNA accumulation levels
14P08873063A0875|117 144|LpS1 RNA accumulation levels
14P08873159A0791|16 23|patients
14P08873159A0791|51 62|chemotherapy
14P08874399A0277|17 28|intervention
14P08874399A0277|91 93|Ca2
14P08874399A0277|95 107|concentration
14P08874399A0277|110 111|Ca
14P08874399A0277|131 132|B.
14P08874631A1133|0 13|Discrimination
14P08874631A1133|21 25|HIV-1
14P08874631A1133|29 33|HIV-2
14P08874631A1133|64 68|HIV-1
14P08876167A0322|40 45|HiNF-D
14P08876167A0717|3 8|HiNF-D
14P08876167A0717|10 16|CDP/cut
14P08876167A0717|32 42|H4 promoter
14P08876167A0717|79 85|CDP/cut
14P08876167A0717|98 101|p107
14P08876167A0717|175 177|CDP
14P08876167A0717|181 195|p107 antibodies
14P08876701A0177|26 37|UmuC-homolog
14P08876701A0177|39 42|DinB
14P08877103A0081|10 19|regulation
14P08877103A0081|22 36|mdr2 expression
14P08877103A0081|117 123|J7.V2-1
14P08877818A0184|59 81|TRH progenitor sequence
14P08877818A0184|81 95|Lys/Arg-Arg-Gln
14P08877818A0184|97 111|His-Pro-Gly-Lys
14P08877818A0184|113 119|Arg-Arg
14P08878019A0357|40 48|sinusoids
14P08878019A0357|54 64|lymph nodes
14P08878037A0000|22 52|catabolite control protein CcpA
14P08878044A1390|2 21|InlC deletion mutant
14P08878044A1390|117 122|Caco-2
14P08878044A1390|126 135|J774 cells
14P08878045A0606|8 20|N-Nus complex
14P08878045A0606|55 57|CTD
14P08878045A0606|77 90|RNA polymerase
14P08878573A1370|0 13|Administration
14P08878573A1370|16 19|RIFA
14P08878573A1370|51 53|ATO
14P08878573A1370|142 144|ATO
14P08878573A1370|147 150|RIFA
14P08879080A0265|10 14|ACOAs
14P08879080A0265|68 80|path analysis
14P08879080A0265|84 93|LISREL VII
14P08879237A0744|10 25|initiation sites
14P08879237A0744|62 85|consensus promoter motif
14P08879237A0744|99 108|CRTA motif
14P08879237A0744|127 144|rice mitochondrion
14P08880405A1170|0 8|Selection
14P08880405A1170|14 19|SC EPD
14P08881036A0351|13 15|PCR
14P08881036A0351|18 27|VL element
14P08881036A0351|39 41|CL2
14P08881542T0000|0 37|Sodium polystyrene sulfonate treatment
14P08881542T0000|63 92|serum potassium concentrations
14P08882492A0000|12 31|homeodomain proteins
14P08882492A0000|40 48|Hox genes
14P08882492A0000|78 88|development
14P08882492A0000|140 149|identities
14P08882710A0000|0 9|Interferon
14P08882710A0000|32 36|ISGF3
14P08882710A0000|49 68|transcription factor
14P08882710A0000|99 114|interferon-alpha
14P08882710A0000|128 131|IFNs
14P08884273A1413|3 18|TYAC/P1 resource
14P08884273A1413|29 32|STSs
14P08884273A1413|37 49|polymorphisms
14P08884273A1413|96 113|telomere structure
14P08884273A1413|154 168|map integration
14P08884757A0653|54 63|Impression
14P08884757A0653|65 67|CGI
14P08884757A0653|88 93|Sandoz
14P08884757A0653|102 121|Assessment Geriatric
14P08884757A0653|122 125|SCAG
14P08884757A0653|195 238|Beurteilungsskala fur geriatrische Patienten
14P08884757A0653|237 239|BGP
14P08884757A0653|276 291|Performance Test
14P08884757A0653|292 307|Syndrom-Kurztest
14P08884757A0653|309 311|SKT
14P08885270A0428|48 51|PAO1
14P08886845A1274|28 44|myogenin promoter
14P08886845A1274|101 119|expression activity
14P08887643A1167|58 61|TC21
14P08887643A1167|75 99|TC21 controls cell growth
14P08887643A1167|133 150|signaling pathways
14P08887647T0000|0 17|Fission yeast mal2
14P08887647T0000|30 51|chromosome segregation
14P08887652A0341|0 8|Selection
14P08887652A0341|43 54|DNA fragment
14P08887652A0341|140 152|reading frame
14P08887652A0341|180 210|hygromycin B phosphotransferase
14P08887659A0753|0 8|Mutations
14P08887659A0753|43 51|threonine
14P08887661A0138|0 4|IRF-1
14P08887661A0138|42 46|IRF-2
14P08887661A1061|27 31|TFIIB
14P08887661A1061|35 39|IRF-1
14P08887661A1061|44 56|NIH 3T3 cells
14P08887661A1061|92 110|promoter activation
14P08887667A0992|16 39|Tyr-19 dephosphorylation
14P08887667A0992|42 57|spindle assembly
14P08887667A0992|93 109|spindle formation
14P08887667A0992|162 177|Cdc28/Clb kinase
14P08887667A0992|179 192|SPB separation
14P08887674A0630|14 39|DMP1 recognition sequences
14P08887674A0630|49 70|GGA trinucleotide core
14P08887674A0920|6 13|settings
14P08887674A0920|55 61|kinases
14P08887674A0920|95 102|activity
14P08887674A0920|136 145|mechanisms
14P08887678A0000|0 9|Expression
14P08887678A0000|55 68|GAL10 promoter
14P08890537A0355|4 12|technique
14P08890537A0355|28 35|patients
14P08890537A0355|51 59|bone cyst
14P08891131A0000|0 27|Enterococcus faecium strains
14P08891131A0000|43 65|glycopeptide resistance
14P08891131A0000|79 96|enrichment culture
14P08891337A0614|25 27|E1A
14P08891337A0614|96 115|coactivator function
14P08891337A0614|117 120|p300
14P08891337A0614|137 157|cAMP response element
14P08891337A0614|157 159|CRE
14P08891341A0724|9 27|transfection assays
14P08891341A0724|32 55|reporter gene constructs
14P08891341A0724|129 139|between-247
14P08891341A0724|181 193|reporter gene
14P08891345A0684|15 32|UTR characteristic
14P08891345A0684|137 139|UTR
14P08891345A0684|151 166|beta-globin mRNA
14P08891346A1217|38 55|isoform expression
14P08891346A1217|56 67|NIH3T3 cells
14P08891346A1217|97 113|expression vector
14P08891346A1217|130 134|FGF8a
14P08891346A1217|136 140|FGF8b
14P08891346A1217|144 148|FGF8e
14P08891474A0667|27 32|F-wave
14P08891474A0667|69 92|depolarization threshold
14P08891474A0667|154 167|depolarization
14P08892755A0186|30 46|sequence homology
14P08892755A0186|57 60|JAK1
14P08892755A0186|82 84|JH2
14P08892755A0186|96 98|JH1
14P08892755A0981|8 19|DNA fragment
14P08892755A0981|41 73|chloramphenicol acetyltransferase
14P08892755A0981|74 76|CAT
14P08892755A0981|109 125|carp CF cell line
14P08892755A0981|150 159|CAT enzyme
14P08892757T0000|18 22|Elk-3
14P08892757T0000|39 48|Ets family
14P08892757T0000|63 81|mouse embryogenesis
14P08892757T0000|112 130|repression activity
14P08892859A0563|61 62|T9
14P08892859A0563|96 108|C-MYB protein
14P08892859A0563|119 133|RAV integration
14P08893779A0229|21 56|digitorum longus muscle tendon units
14P08893779A0229|245 253|interface
14P08893822A0560|0 16|Northern analysis
14P08893822A0560|27 36|PWP2H cDNA
14P08894144A0330|89 104|CsA vehicle p.o.
14P08894144A0330|107 119|FB vehicle sc
14P08894144A0330|122 124|CsA
14P08894144A0330|142 154|FB vehicle sc
14P08894144A0330|157 172|CsA vehicle p.o.
14P08894144A0330|175 176|FB
14P08894144A0330|196 198|CsA
14P08894144A0330|216 217|FB
14P08894144A1173|0 2|CsA
14P08894144A1173|26 38|bone turnover
14P08894826A0228|0 10|Individuals
14P08894826A0228|23 36|GUM Department
14P08894826A0228|41 55|Royal Infirmary
14P08894826A0228|57 65|Edinburgh
14P08894826A0228|102 114|HIV infection
14P08894826A0228|171 174|NSGI
14P08895522T0000|24 45|tyrosine kinase domain
14P08895522T0000|54 71|trk proto-oncogene
14P08895522T0000|82 103|cell adhesion molecule
14P08895579A0583|0 16|Northern blotting
14P08895579A0583|26 29|MDMX
14P08895579A0583|35 38|MDM2
14P08895579A0583|92 95|MDMX
14P08895997A0336|0 6|Physiol
14P08896272A0000|3 21|nucleotide sequence
14P08896272A0000|45 54|chromosome
14P08896280A0860|44 47|IME1
14P08896280A0860|51 59|IME2 mRNA
14P08896280A0860|118 132|acid metabolism
14P08896280A0860|143 157|yvh1 disruption
14P08896402A0587|7 16|FL protein
14P08896402A0587|98 109|glycoprotein
14P08896402A0587|123 133|kD subunits
14P08896473A0282|49 52|HHCA
14P08896473A0282|99 101|VGS
14P08896590T0000|14 23|adenovirus
14P08896590T0000|28 31|RNAs
14P08896795A0166|5 9|Spurr
14P08896795A0166|54 62|specimens
14P08896795A0166|67 79|oil immersion
14P08896795A0166|107 116|coverslips
14P08896795A0166|127 137|air bubbles
14P08896795A0166|144 151|specimen
14P08896804A0000|27 41|dose dependence
14P08896804A0000|44 62|time course effects
14P08896804A0000|66 79|benzodiazepine
14P08896804A0000|81 83|BDZ
14P08896804A0000|107 115|RO19-4603
14P08896804A0000|162 196|BDZ receptor antagonists flumazenil
14P08896804A0000|195 196|ZK
14P08896804A0000|206 208|CGS
14P08896804A0000|239 256|alcohol-preferring
14P08896804A0000|308 311|EtOH
14P08897663T0000|9 13|Tower
14P08897663T0000|16 20|Babel
14P08897663T0000|23 34|nomenclature
14P08897721A0000|0 8|Infection
14P08897721A0000|13 21|Neisseria
14P08897721A0000|98 111|polysaccharide
14P08898336A0268|0 24|RNase protection analysis
14P08898336A0268|154 157|RNAs
14P08898365A0274|0 4|Rss1p
14P08898365A0274|124 137|pore complexes
14P08898365A0274|138 141|NPCs
14P08898866A0458|19 45|serine phosphorylation site
14P08898866A0458|76 92|expression system
14P08898866A0458|158 170|substitutions
14P08898866A0458|182 196|serine residues
14P08898893A0202|3 12|PAI-2 gene
14P08898893A0202|77 121|phorbol ester phorbol 12-myristate 13-acetate
14P08898893A0202|119 121|PMA
14P08898893A0202|129 149|phosphatase inhibitor
14P08898893A0202|168 187|HT-1080 fibrosarcoma
14P08899719A0318|37 50|reading frames
14P08899719A0318|51 54|ORFs
14P08899719A0318|81 84|ORFs
14P08900164A0188|0 1|T.
14P08900164A0188|3 7|Patel
14P08900164A0188|9 10|S.
14P08900190A0430|0 13|Growth factors
14P08900190A0430|51 88|gene products MAP kinase phosphatase-1
14P08900190A0430|86 90|MKP-1
14P08900296A0000|3 15|up-regulation
14P08900296A0000|18 27|E-selectin
14P08900296A0000|37 54|adhesion molecules
14P08900296A0000|59 69|endothelium
14P08901135A1132|3 14|NIT2 protein
14P08901135A1132|96 116|nitrogen derepression
14P08901135A1132|118 136|nitrogen repression
14P08901135A1132|169 172|NIT2
14P08901635A0000|91 99|synthesis
14P08901635A0000|102 110|cellulose
14P08901635A0000|120 136|cell wall polymer
14P08901658A0498|41 53|flow increase
14P08901658A0498|107 125|glyceryl trinitrate
14P08901658A0498|126 128|GTN
14P08902214A1486|17 30|administration
14P08902214A1486|52 54|PRL
14P08902214A1486|101 112|Stat factors
14P08902548A0144|15 28|administration
14P08902548A0144|31 51|L-5-hydroxytryptophan
14P08902548A0144|53 59|L-5-HTP
14P08902641A0930|5 15|VA-SMV mode
14P08902641A0930|61 67|LV apex
14P08902641A0930|116 118|DAo
14P08902847A1946|3 10|evidence
14P08902847A1946|13 19|support
14P08902847A1946|54 61|affinity
14P08902847A1946|64 74|interaction
14P08902847A1946|88 95|subunits
14P08902847A1946|128 146|order rate constant
14P08902847A1946|147 155|hCG alpha
14P08902847A1946|191 199|degrees C
14P08902847A1946|216 224|magnitude
14P08902988A0258|0 14|Factor V Leiden
14P08903339A0264|14 26|determination
14P08903339A0264|62 64|RNA
14P08905819A0531|25 27|0-I
14P08905819A0531|30 45|0-III components
14P08906056A1290|110 132|health care utilization
14P08906139A2935|52 78|alkaline phosphatase values
14P08906139A2935|101 116|vitamin D intake
14P08909546A0810|15 18|PEA2
14P08910292T0000|0 8|Signaling
14P08910292T0000|47 51|Cdc42
14P08910292T0000|95 116|protein kinase pathway
14P08910373A0315|0 17|Percent identities
14P08910373A0315|59 70|Y2 receptors
14P08910550A0501|41 51|CBF binding
14P08910550A0501|56 64|78C1 site
14P08910550A0501|76 79|EGTA
14P08910550A0501|83 86|EDTA
14P08910550A0501|101 116|cation chelators
14P08910567A2269|39 68|rat liver glucokinase promoter
14P08910567A2269|97 126|hepatocyte transfection system
14P08912232A0260|15 16|ML
14P08912807A0411|20 32|deer receptor
14P08912807A0411|54 69|tyrosine residue
14P08912807A0411|139 158|beta-casein promoter
14P08913186A0431|115 146|convergence retraction nystagmus
14P08913387A1010|0 8|Rifabutin
14P08913974A0533|23 25|EPs
14P08913974A0533|99 109|salpingitis
14P08913974A0533|130 140|salpingitis
14P08914388A1645|87 93|CS-940*
14P08914388A1645|110 113|SPFX
14P08914388A1645|126 133|AM-1155*
14P08914388A1645|149 152|CPFX
14P08914388A1645|168 171|LVFX
14P08914388A1645|174 183|OPC-17116*
14P08914388A1645|185 190|NM-394
14P08914522A0118|3 12|STE20 gene
14P08914522A0118|46 74|pheromone signal transduction
14P08914522A0118|163 177|G beta mutation
14P08914532A0598|40 66|endohydrolase isoenzyme X-I
14P08915051T0000|8 24|resonance imaging
14P08915508A0000|0 6|Moloney
14P08915508A0000|13 26|leukemia virus
14P08915508A0000|27 30|MMLV
14P08915508A0000|107 109|Tat
14P08915508A0000|111 125|trans-activator
14P08915508A0000|168 187|hammerhead ribozymes
14P08915508A0000|248 250|Gag
14P08915508A0000|288 289|RT
14P08915508A0000|308 310|Env
14P08915508A0000|312 325|coding regions
14P08915508A0000|332 360|immunodeficiency virus type-1
14P08915508A0000|360 364|HIV-1
14P08915508A0000|366 368|RNA
14P08915559A0366|0 20|REM sleep deprivation
14P08916928A0950|72 94|thymidine incorporation
14P08916928A0950|96 104|PAE cells
14P08916928A0950|117 135|PDGF beta-receptors
14P08916960A0350|16 31|biopsy specimens
14P08916960A0350|52 53|FL
14P08916960A0350|123 135|reading frame
14P08916960A0350|136 138|ORF
14P08916960A1331|23 24|FL
14P08916960A1331|28 36|DLL cells
14P08916960A1331|55 74|bcl-2 gene sequences
14P08916960A1331|78 94|breakpoint region
14P08916960A1331|180 193|transformation
14P08916960A1331|199 206|FL cells
14P08917270A0229|0 9|BACKGROUND
14P08917270A0229|30 31|QT
14P08917270A0229|33 35|QTc
14P08917270A0229|131 141|QT syndrome
14P08917435A0481|72 81|PAI-1 gene
14P08917435A0481|128 154|c-fos oligodeoxynucleotides
14P08917435A0481|195 209|PAI-1 synthesis
14P08917449A0000|26 28|LIF
14P08917449A0000|33 44|neuropoietin
14P08917449A0000|62 76|differentiation
14P08917449A0000|131 141|populations
14P08917696A0485|23 40|fos/jun activation
14P08917696A0485|42 45|TCDD
14P08917696A0485|96 112|expression assays
14P08917696A0485|114 137|reporter gene constructs
14P08917696A0485|146 162|response elements
14P08917696A0485|165 201|12-O-tetradecanoyl-phorbol-13-acetate
14P08917696A0485|203 205|TRE
14P08917696A0485|214 216|SRE
14P08917696A0485|224 226|CRE
14P08917696A0485|253 256|AhRE
14P08917696A0485|330 333|SV40
14P08918456A0455|21 31|interaction
14P08918456A0455|46 49|AP-2
14P08918456A0455|91 100|position Y
14P08918456A0455|114 123|position Y
14P08918464A0225|18 22|Ba/F3
14P08918464A0225|34 40|BaF/STK
14P08918464A0225|78 80|STK
14P08918464A0225|96 123|mouse erythroleukaemia cells
14P08918464A0225|123 125|MEL
14P08918464A0225|127 129|STK
14P08918810A0967|7 11|DNase
14P08918810A0967|35 44|OxyR-C199S
14P08918810A0967|97 129|protection pattern characteristic
14P08918885A0811|0 3|Kss1
14P08918885A0811|24 38|GST-Dig1 fusion
14P08918885A1087|11 25|dig1 dig2 cells
14P08918885A1087|44 54|agar medium
14P08918885A1087|63 77|dig1 dig2 ste12
14P08918885A1087|110 113|Dig1
14P08918885A1087|117 120|Dig2
14P08918885A1087|164 177|growth pathway
14P08918918T0000|24 41|HIV-1 LTR promoter
14P08918918T0000|50 60|Tat protein
14P08918918T0000|86 101|trans-activation
14P08918934A0424|0 9|Comparison
14P08918934A0424|29 48|xFxFG repeat regions
14P08918934A0424|49 51|p62
14P08918934A0424|55 59|Nsplp
14P08918934A0424|73 76|NTF2
14P08919289A0402|47 49|MFH
14P08919907A0763|21 25|VSF-1
14P08919907A0763|28 38|protoplasts
14P08919986A1262|36 42|dosages
14P08919986A1262|44 53|advantages
14P08919986A1262|57 69|disadvantages
14P08919986A1262|116 122|results
14P08919986A1262|146 155|literature
14P08920499A0164|0 24|Blood sampling procedures
14P08921387A1182|0 7|Analysis
14P08921387A1182|34 47|splicing event
14P08921387A1182|56 59|EZH1
14P08921387A1182|131 142|EZH1 protein
14P08921667A0294|14 27|input function
14P08921667A0294|43 61|distribution volume
14P08921667A0294|62 63|Vd
14P08921667A0294|75 90|rCBF measurement
14P08921865A1293|36 52|DNA binding motif
14P08921865A1293|71 88|terminase proteins
14P08921865A1293|90 96|T4 gp17
14P08921865A1293|173 177|T4DNA
14P08922344A1539|54 69|xanthine oxidase
14P08922344A1539|84 94|association
14P08922344A1539|99 112|blood pressure
14P08922344A1539|177 188|hypertension
14P08922384A0466|0 13|Immunoblotting
14P08922384A0466|61 72|08L antibody
14P08922384A0466|84 94|08L epitope
14P08922385A0622|77 103|beta-galactosidase tetramer
14P08922385A0622|108 121|fusion subunit
14P08922390A0361|25 32|vinculin
14P08922390A0361|52 58|domains
14P08922390A0361|61 68|paxillin
14P08922390A0361|94 101|paxillin
14P08922390A0361|107 114|adhesion
14P08922390A0793|40 51|binding site
14P08922390A0793|91 93|FAK
14P08922390A0793|137 147|amino acids
14P08922390A2076|70 81|interactions
14P08922390A2076|100 102|FAK
14P08922390A2076|135 147|demonstration
14P08922390A2076|150 160|LIM domains
14P08922390A2076|181 191|determinant
14P08922390A2076|212 223|localization
14P08922391A0304|59 69|PDZ repeats
14P08922391A0304|75 80|PDZ1-2
14P08922488A0187|29 37|treatment
14P08922488A0187|62 68|effects
14P08923258A0353|0 6|Jerseys
14P08923258A0353|23 39|Cu concentrations
14P08923258A0353|46 54|Holsteins
14P08923460A0565|0 10|RUSH-1 beta
14P08923460A0565|37 48|RUSH-1 alpha
14P08923469A1391|57 79|RXR heterodimer binding
14P08923469A1391|89 113|hormone response elements
14P08923469A1391|120 122|VDR
14P08923470A0458|0 21|PPAR gamma mRNA levels
14P08923470A0458|40 61|nM TNF alpha treatment
14P08924211A0941|0 4|Exons
14P08924211A0941|97 99|PST
14P08924211A0941|102 110|AST cDNAs
14P08924381T0000|0 12|Growth factor
14P08924381T0000|58 79|breast cancer patients
14P08925545T0001|11 24|erythropoietin
14P08925545T0001|39 47|treatment
14P08927169A0178|96 119|Community Health Service
14P08927169A0178|120 126|Utrecht
14P08927612T0000|9 21|p53 mutations
14P08927841A0053|77 84|activity
14P08927841A0053|103 112|occurrence
14P08929089A0231|11 20|ratio M/Pc
14P08929563T0000|0 17|Rat liver catalase
14P08929563T0000|52 73|tripeptide Ala-Asn-Leu
14P08929563T0000|90 106|Ser-Lys-Leu motif
14P08931388A0806|3 22|mobility shift assay
14P08931388A0806|41 48|fragment
14P08931991A1026|34 36|E2F
14P08931991A1026|52 71|transcription factor
14P08931991A1026|107 123|myosin expression
14P08932363A0807|7 20|E1A N-terminus
14P08932363A0807|41 62|squelshing experiments
14P08932363A0807|96 103|E2F1/DP1
14P08932363A0807|114 123|E1A mutant
14P08932363A0807|130 148|CBP binding ability
14P08932385T0000|36 72|transcription factor TCF11/Nrf1/LCR-F
14P08933487A0325|10 23|occasion water
14P08933640A0000|40 66|energy sweetener erythritol
14P08933640A0000|82 84|KBL
14P08933640A0000|86 94|JW strain
14P08934533A0784|58 60|DNA
14P08934540A0673|11 22|nm23-H2 gene
14P08934540A0673|37 50|activity ratio
14P08935931A0787|0 9|CONCLUSION
14P08935931A0787|22 44|diazepam administration
14P08935931A0787|50 52|EGD
14P08935931A0787|79 82|SpO2
14P08935931A0787|145 148|SpO2
14P08935931A0787|167 169|EGD
14P08935991A0844|3 31|nucleotide sequence alignment
14P08935991A0844|50 51|CA
14P08936128A0611|0 10|Discordance
14P08936128A0611|16 29|cost dimension
14P08936128A0611|53 56|G Hb
14P08936128A0611|99 110|disagreement
14P08936640A0105|0 11|DATA SOURCES
14P08936640A0105|33 48|research studies
14P08936640A0105|49 63|review articles
14P08936640A0105|67 84|government reports
14P08937112A0561|0 6|RESULTS
14P08937112A0561|11 26|age distribution
14P08937631A1223|37 51|cell involution
14P08937631A1223|54 63|hemorrhage
14P08937631A1223|119 127|relevance
14P08937631A1223|133 142|remodeling
14P08937631A1223|155 165|vasculature
14P08937981A0840|31 33|p46
14P08937981A0840|37 48|p54 subunits
14P08937981A0840|91 93|p46
14P08937981A0840|107 109|p46
14P08937981A0840|153 155|p54
14P08937989A1365|3 9|results
14P08937989A1365|52 58|regions
14P08937989A1365|79 88|properties
14P08937989A1365|99 105|regions
14P08937989A1365|111 117|protein
14P08938418A0099|0 3|Merr
14P08938418A0099|6 19|embryo library
14P08938420A0862|21 24|LHA4
14P08938420A0862|28 37|LHA2 mRNAs
14P08938420A0862|157 173|3-O-methylglucose
14P08938420A0862|188 204|mRNA accumulation
14P08939891A0285|43 45|NRE
14P08939891A0285|57 59|DNA
14P08939891A0285|103 105|Nrl
14P08939966A0816|11 27|protein synthesis
14P08939966A0816|46 58|embryogenesis
14P08939966A0816|68 72|SEC-1
14P08939966A0816|86 97|mRNA decline
14P08940132A1120|24 41|fodrin proteolysis
14P08940132A1120|121 128|DEVD-CHO
14P08940132A1120|161 165|CPP32
14P08940132A1120|205 209|CPP32
14P08940132A1120|212 230|DEVD-CHO inhibition
14P08940134A0705|2 4|3Y1
14P08940134A0705|8 10|3Y1
14P08940134A0705|59 63|PTP1B
14P08940134A0705|82 85|p130
14P08940134A0705|87 89|Cas
14P08940298A0962|50 60|AF-2 domain
14P08940298A0962|67 85|vitamin D3 receptor
14P08940298A0962|89 105|estrogen receptor
14P08942999T0000|9 27|G-to-A substitution
14P08942999T0000|43 47|SREBP
14P08942999T0000|116 139|hamster ovary cell lines
14P08943032A0000|18 30|tet-repressor
14P08943032A0000|32 35|TetR
14P08943032A0000|37 51|operator system
14P08943032A0000|109 119|disruptions
14P08943032A0000|137 148|interactions
14P08943354A0295|30 34|SHP-1
14P08943354A0295|57 83|Jak family tyrosine kinases
14P08943354A0295|124 134|Tyk2 kinase
14P08943354A0295|140 159|hyperphosphorylation
14P08943354A0295|162 172|Jak kinases
14P08943354A0295|209 213|SHP-1
14P08943928A1137|0 13|Administration
14P08943934A0604|6 14|Theriault
14P08943934A0604|24 35|improvements
14P08944755A0211|0 3|Biol
14P08945479T0000|35 55|lymphocyte kinase Lck
14P08945479T0000|58 81|tyrosine phosphorylation
14P08945810T0001|9 18|morphology
14P08945810T0001|61 67|mammals
14P08946166A0568|36 38|ORF
14P08946166A0568|44 52|FRDS gene
14P08946668A0077|0 4|FK506
14P08946668A0077|58 72|organ rejection
14P08947028A0992|23 27|Rho1p
14P08947028A0992|49 62|reorganization
14P08947028A0992|77 81|Bni1p
14P08947028A0992|85 89|Pkc1p
14P08948440A0628|3 24|ERH expression profile
14P08948440A0628|41 43|An3
14P08948440A0628|64 80|animal hemisphere
14P08950144A0172|0 7|Waves N1
14P08950144A0172|8 9|P3
14P08950144A0172|13 15|CNV
14P08950144A0172|35 46|CNV paradigm
14P08950144A0172|55 72|reaction time task
14P08950144A0172|106 108|ISI
14P08950352A0525|38 44|samples
14P08950352A0525|147 158|significance
14P08951815A0465|0 9|Regulation
14P08951815A0465|12 15|ASN1
14P08951815A0465|19 33|ASN2 expression
14P08951815A0465|126 154|transcription activator Gcn4p
14P08952483A0207|31 50|polypeptide fragment
14P08952483A0207|57 85|hamster lysyl-tRNA synthetase
14P08952483A0207|143 165|multisynthetase complex
14P08952796A0743|23 29|relapse
14P08952965A1182|0 9|Comparison
14P08952965A1182|61 73|substitutions
14P08952965A1182|153 169|framework regions
14P08952965A1182|196 214|MHC contact regions
14P08952965A1182|214 217|CDR1
14P08952965A1182|221 224|CDR2
14P08953340A0000|16 30|vanadyl sulfate
14P08953340A0000|31 35|VOSO4
14P08953340A0000|53 65|anthropometry
14P08953340A0000|67 82|body composition
14P08953340A0000|169 194|weight-training volunteers
14P08954725A1175|7 17|development
14P08954725A1175|19 33|Tbx6 expression
14P08955071T0000|0 9|Disruption
14P08955071T0000|12 33|re-replication control
14P08955071T0000|56 59|ORC1
14P08955111A0989|39 54|enhancer regions
14P08955111A0989|106 122|promoter activity
14P08955111A0989|132 157|activin betaA subunit gene
14P08955136A0606|32 42|PIP5KIalpha
14P08955136A0606|52 65|PIP5K activity
14P08955136A0606|98 114|PIP5KI antibodies
14P08955159A0000|21 22|AC
14P08955159A0000|24 55|N-acylsphingosine amidohydrolase
14P08955159A0000|56 57|EC
14P08955189A1198|10 28|NheI/BglII promoter
14P08955189A1198|37 52|PMA inducibility
14P08955189A1198|118 144|EGR-1 transcription factors
14P08955306A0224|0 7|Northern
14P08955306A0224|9 11|RNA
14P08955306A0224|13 25|blot analyses
14P08955306A0224|81 93|reading frame
14P08955306A0224|94 97|ORF1
14P08955402A0288|70 73|HOL1
14P08955402A0288|158 174|HOL1-1 background
14P08955402A0288|203 214|Hol1 protein
14P08955928A0390|0 5|Damage
14P08955928A0390|11 13|BBB
14P08955928A0390|40 49|Evans Blue
14P08955928A0390|50 51|EB
14P08955928A0390|106 109|MCAo
14P08958137A0534|0 25|Lipid hydroperoxide levels
14P08958137A0534|35 37|LDL
14P08958720A1204|52 54|SVI
14P08958720A1204|65 66|HR
14P08958720A1204|83 84|CO
14P08958720A1204|88 90|VO2
14P08959062A0372|83 95|immunodeficit
14P08959062A0372|103 105|EBV
14P08959062A0372|116 122|Purtilo
14P08959117A0708|135 145|ICU setting
14P08959117A0708|200 214|reference group
14P08959117A0708|215 217|REF
14P08959778A0292|35 48|graft survival
14P08959778A0292|70 83|graft function
14P08959778A0292|84 86|EGF
14P08959778A0292|91 93|DGF
14P08959778A0292|108 123|transplantations
14P08959778A0292|126 143|retransplantations
14P08960827A1169|28 36|GG motifs
14P08960827A1169|65 77|transcription
14P08960827A1169|88 99|insulin gene
14P08960827A1169|101 111|association
14P08961873T0000|15 35|coproporphyrin levels
14P08961873T0000|55 71|hepatitis C virus
14P08961873T0000|88 109|immunodeficiency virus
14P08962614A0000|3 15|determination
14P08962614A0000|18 33|immunoglobulin E
14P08962614A0000|34 36|IgE
14P08962614A0000|62 77|laboratory tests
14P08962614A0000|80 95|skin-prick tests
14P08962614A0000|110 129|challenge procedures
14P08962614A0000|174 191|outcome predictors
14P08964067A0188|0 9|Thrombosis
14P08964172A0221|0 5|Filter
14P08964172A0221|9 35|cytocentrifuge preparations
14P08967870A0000|20 42|postmortem examinations
14P08967870A0000|46 63|Moscow hospitals N
14P08967963A1735|3 18|promoter segment
14P08967963A1735|50 74|rat glioma cell line C6B4
14P08967963A1735|91 107|cell line RSMT-A5
14P08967963A1735|126 147|beta cell line RIN-5AH
14P08967963A1735|181 195|alpha2c-AR gene
14P08969495A0256|3 12|sequencing
14P08969495A0256|35 49|mutation ts-A13
14P08969495A0256|64 75|nrdE cistron
14P08969495A0256|82 90|lethality
14P08969495A0256|104 112|mutations
14P08969777A0771|47 57|differences
14P08969777A0771|95 120|serum 25-OHD concentration
14P08970352A0880|29 31|LDD
14P08970352A0880|59 62|MSOF
14P08970951A0823|99 110|Pol proteins
14P08970951A0823|124 144|HBV DNA intermediates
14P08970979A1246|2 9|contrast
14P08970979A1246|11 18|extracts
14P08970979A1246|64 76|transcription
14P08970979A1246|92 99|template
14P08970979A1246|117 124|promoter
14P08970984A0765|3 16|SCMV SNE sites
14P08970984A0765|42 72|core recognition binding motifs
14P08970984A0765|73 75|SRF
14P08970984A0765|90 92|ETS
14P08970984A0765|97 127|YY1 class transcription factors
14P08970984A0765|156 182|tumor necrosis factor alpha
14P08970991A0747|4 19|serum withdrawal
14P08970991A0747|34 44|temperature
14P08970991A0747|58 66|apoptosis
14P08971009A0860|155 165|DNA genomes
14P08971721A1314|58 61|HspA
14P08971835A1057|2 6|Group
14P08971835A1057|56 60|BAEPs
14P08971835A1057|104 111|Group II
14P08971835A1057|124 141|reperfusion period
14P08972182A0000|3 14|Fas receptor
14P08972182A0000|23 40|signalling cascade
14P08972182A0000|94 115|receptor cross-linking
14P08972182A0527|24 26|ICE
14P08972182A0527|118 150|cowpox ICE inhibitor protein CrmA
14P08972182A0527|160 194|tetrapeptide ICE inhibitor YVAD-CMK
14P08972182A0527|199 236|tripeptide pan-ICE inhibitor Z-VAD-FMK
14P08972211A0059|12 21|expression
14P08972211A0059|78 86|transgene
14P08972211A0059|115 122|sequence
14P08972211A0059|140 147|sequence
14P08972211A0059|185 193|enhancers
14P08972232A0365|43 45|HAT
14P08972232A0365|59 79|substrate specificity
14P08973185T0061|14 31|arginine mutations
14P08973185T0061|42 56|phosphorylation
14P08973185T0061|60 73|AAC expression
14P08973527A0000|13 16|DNAs
14P08973527A0000|69 90|Agropyron mosaic virus
14P08973527A0000|90 93|AgMV
14P08973527A0000|98 117|Hordeum mosaic virus
14P08973527A0000|117 120|HoMV
14P08973630A0923|26 39|Rac activation
14P08973630A0923|48 61|Rho activation
14P08973630A0923|79 94|Cdc42 activation
14P08973630A0923|101 114|Rac activation
14P08973917A0632|35 43|PWP2 gene
14P08973917T0000|0 8|Isolation
14P08973917T0000|61 78|tryptophan protein
14P08973917T0000|80 83|PWP2
14P08973917T0000|98 104|21q22.3
14P08974103A0451|0 7|Patterns
14P08974103A0451|48 65|laboratory results
14P08974103A0451|92 94|PEM
14P08974135A0052|25 34|vitamin B1
14P08974135A0052|35 44|deficiency
14P08974135A0052|78 87|stomatitis
14P08974135A0052|98 114|vitamin B1 levels
14P08974135A0052|146 155|stomatitis
14P08974135A0052|173 185|control group
14P08975532T0001|0 13|Liver injuries
14P08975713A0454|68 83|p53p2 start site
14P08975713A0454|172 185|p53p2 promoter
14P08976253A0637|24 34|correlation
14P08976253A0637|57 73|plasma PSA levels
14P08977013A0788|3 14|implications
14P08977013A0788|37 49|magnification
14P08977013A0788|61 71|differences
14P08977013A0788|77 91|specializations
14P08977235A0134|53 56|JAK1
14P08977235A0134|60 71|JAK2 kinases
14P08977235A0134|77 102|STAT transcription factors
14P08977235A0588|85 89|STAT5
14P08977235A0588|93 97|STAT1
14P08977235A0588|115 119|STAT3
14P08977235A0588|133 137|STAT5
14P08977235A0588|141 156|STAT1 activation
14P08977235A0588|170 202|receptor tyrosine phosphorylation
14P08977401A0227|3 15|RI alpha gene
14P08977401A0227|144 162|RI alpha pseudogene
14P08977401A0227|218 225|RI alpha
14P08977401A0227|238 240|RNA
14P08977401A0227|257 269|RI alpha gene
14P08977401A0227|324 337|messenger RNAs
14P08978690A0262|15 23|Rad3/Mec1
14P08978690A0262|73 97|DNA structure checkpoints
14P08978690A0262|102 120|yeast model systems
14P08978817A0620|58 83|endocytosis mutants end4-1
14P08978817A0620|108 121|growth defects
14P08978817A0620|139 155|DIM gene products
14P08978996A0000|3 16|identification
14P08978996A0000|22 38|hepatitis C virus
14P08978996A0000|54 66|liver disease
14P08978996A0000|72 88|dialysis patients
14P08978996A0000|93 111|transplant patients
14P08978996A0000|135 146|epidemiology
14P08978996A0000|187 200|patient groups
14P08979089A1197|23 39|BL cell line Raji
14P08979089A1197|61 83|core promoter mutations
14P08979089A1197|106 113|Sp1 site
14P08979089A1197|119 126|TATA box
14P08979089A1197|171 188|Ig kappa enhancers
14P08979828A1561|16 27|interactions
14P08980413A0500|3 5|P13
14P08980413A0500|9 11|N22
14P08980413A0500|23 49|phase reversal relationship
14P08980413A0500|55 56|P2
14P08980413A0500|60 61|N2
14P08980413A0500|77 79|PES
14P08980522A0280|3 6|cDNA
14P08980522A0280|9 12|cpm7
14P08980522A0280|35 41|protein
14P08980533A1160|29 33|ENBP1
14P08980533A1160|99 111|testis tissue
14P08980536A1196|24 28|G-box
14P08980536A1196|32 36|H-box
14P08980536A1196|48 60|CHS promoters
14P08980819A0193|0 8|Mortality
14P08980819A0193|160 171|insemination
15P08981371A2049a|11 22|PIP2 content
15P08981371A2049a|64 78|CSF-1 treatment
15P08981371A2049b|11 22|PIP2 content
15P08981371A2049b|64 78|CSF-1 treatment
14P08985109A1285|32 37|margin
14P08985109A1285|55 59|crest
14P08985109A1285|80 85|aspect
14P08985115A1571|8 21|identification
14P08985115A1571|33 46|37LRP/p40 gene
14P08985115A1571|132 144|understanding
14P08985115A1571|159 168|mechanisms
14P08985115A1571|182 194|up-regulation
14P08985115A1571|200 209|expression
14P08985115A1571|216 229|tumor invasion
14P08985115A1571|232 241|metastasis
14P08985122A0501|3 17|promoter region
14P08985122A0501|18 19|P1
14P08985122A0501|50 79|transcription initiation sites
14P08985122A0501|88 91|TATA
14P08985122A0501|95 104|CAAT boxes
14P08985122A0501|136 159|transcription factor SP1
14P08985122A0501|196 205|CpG island
14P08985415A1096|3 26|STAT-1 signaling pathway
14P08985415A1096|70 77|CAEV LTR
14P08985415A1096|79 87|IFN-gamma
14P08986190A0927|0 10|Reperfusion
14P08986190A0927|38 55|lactate production
14P08986190A0927|80 90|LDH release
14P08986214A0000|63 75|liver disease
14P08986214A0000|153 176|hepatocyte growth factor
14P08986214A0000|176 178|HGF
14P08986214A0000|183 199|alpha-fetoprotein
14P08986214A0000|201 203|AFP
14P08986228A0000|0 7|Children
14P08986228A0000|107 119|malformations
14P08986692A0306|0 11|INTERVENTION
14P08986692A0306|26 46|hemostasis parameters
14P08986692A0306|85 90|IVF-ET
14P08986770A0268|31 50|I-POU/tI-POU message
14P08986770A0268|109 113|I-POU
14P08986770A0268|128 141|splice variant
14P08986812A1214|15 17|p53
14P08986812A1214|22 32|delta proAE
14P08986812A1214|76 85|cell lines
14P08987009A0400|31 43|prerequisites
14P08987009A0400|85 97|psychoanalyst
14P08987225A0675|55 71|hepatitis C cases
14P08987225A0675|157 158|NT
14P08987225A0675|163 165|ACT
14P08987225A0675|169 178|Queensland
14P08988257A1256|0 8|Silencing
14P08988257A1256|56 73|reporter construct
14P08988257A1256|78 86|insertion
14P08988257A1256|110 124|repeat sequence
14P08988257A1256|152 161|truncation
14P08988913A0821|37 46|provisions
14P08988913A0821|81 96|folate excretion
14P08988913A0821|122 130|excretion
14P08988913A0821|143 151|processes
14P08989025A0359|20 22|Ca2
14P08989025A0359|33 35|VOC
14P08989025A0359|73 86|concentrations
14P08989763A0605|7 15|artifacts
14P08989763A0605|42 54|visualization
14P08989763A0605|60 68|diaphragm
14P08990168A0688|8 25|p48 gene induction
14P08990168A0688|37 41|STAT1
14P08990168A0688|45 48|JAK1
14P08990168A0688|59 63|STAT1
14P08990168A0688|77 80|GATE
14P08990194A0000|25 39|thyroid hormone
14P08990194A0000|73 88|thyroid hormones
14P08990194A0000|115 135|thyrotropin secretion
14P08990194A0000|157 170|refractoriness
14P08990194A0000|173 186|hormone action
14P08990397A1437|76 78|H13
14P08990397A1437|116 129|RNA processing
14P08992115A0199|55 74|blood concentrations
14P08992115A0199|76 95|acute-phase proteins
14P08992115A0199|96 109|KKS activation
14P08992115A0199|138 156|lactic acid content
14P08993393A0498|21 32|implications
14P08993393A0498|55 64|physiology
14P08993393A0498|77 89|hPACAP-R gene
14P08993393T0000|39 53|gene activation
14P08993393T0000|59 73|splice variants
14P08993393T0000|119 138|polypeptide receptor
14P08993831A0000|14 31|muscle development
14P08993831A0000|48 60|muscle fibers
14P08993831A0000|94 105|combinations
14P08993831A0000|123 135|gene products
14P08993836A0699|66 81|HNF-3 alpha gene
14P08993836A0699|109 121|embryogenesis
14P08994825A0000|0 9|BACKGROUND
14P08994825A0000|11 17|Mitosis
14P08994825A0000|31 33|MPF
14P08994825A0000|77 102|Cdc2/28-cyclin B complexes
14P08994832A0782|19 23|Apo-3
14P08994832A0782|26 31|HEK293
14P08994832A0782|34 43|HeLa cells
14P08994968A0926|114 117|NADP
14P08995054A0618|0 9|Similarity
14P08995054A0618|29 47|zinc knuckle region
14P08995054A0618|105 117|retroelements
14P08995054A1368|0 1|D.
14P08995054A1368|14 18|HeT-A
14P08995054A1368|60 79|insertions/deletions
14P08995054A1368|99 116|nucleotide changes
14P08995410A0000|10 26|initiation factor
14P08995410A0000|92 101|eIF2 x GTP
14P08995410A0000|106 108|Met
14P08995410A0000|122 133|mRNA binding
14P08995410A0000|178 193|ribosome subunit
14P08995410A1109|27 33|Hershey
14P08995410A1109|102 105|p170
14P08995410A1109|107 110|p116
14P08995410A1109|119 122|p110
14P08995410A1109|124 126|p66
14P08995410A1109|128 130|p48
14P08995410A1109|132 134|p47
14P08995410A1109|136 138|p44
14P08995410A1109|140 142|p40
14P08995410A1109|144 146|p36
14P08995410A1109|151 153|p35
14P08995614T0000|0 13|Identification
14P08995614T0000|50 89|histocompatibility complex gene promoter
14P08995652A0812|120 133|UL80.5 protein
14P08995652A0812|181 194|UL80.5 protein
14P08995652A0812|240 253|UL26.5 protein
14P08995652A0812|300 313|UL80.5 protein
14P08995652A0812|317 319|VP5
14P08995652A0812|416 429|UL80.5 protein
14P08995652A0812|443 455|RRIFVA ALNKLE
14P08995652A0812|457 468|RRIFVAAMMKLE
14P08995652A0812|474 489|self-interaction
14P08995652A0812|495 511|scaffold proteins
14P08995652A0812|546 569|maturation cleavage site
14P08995652A0812|578 583|UL26.5
14P08995652A0812|587 601|UL80.5 proteins
14P08995652A0812|622 640|scaffold structures
14P08995659A0563|13 35|region splice junctions
14P08995659A0563|39 42|MSRs
14P08995659A0563|93 119|sequencing RNA-PCR products
14P08995681A0518|4 8|ICP27
14P08995681A0518|49 52|ICP4
14P08996730A1146|0 3|Lack
14P08996730A1146|22 43|vibration measurements
14P08996730A1146|46 65|employment durations
14P08996730A1146|101 115|tool conditions
14P08996730A1146|116 129|grinder wheels
14P08997490A1127|0 11|C/EBP beta V
14P08997490A1127|43 53|C/EBP sites
14P08997490A1127|64 72|DBP sites
14P08997490A1127|79 94|oligonucleotides
14P08997490A1127|137 169|cholesterol hydroxylase promoters
14P08997532A0116|31 49|IgE immunoglobulins
14P08997532A0116|56 63|Toxocara
14P08997532A0116|97 99|TES
14P08997532A0116|120 134|ELISA technique
14P08998115A0114|0 22|SUMMARY BACKGROUND DATA
14P08998115A0114|22 34|Melanoma care
14P08998115A0114|104 125|lymph node dissections
14P08999414A0819|3 13|differences
14P08999414A0819|33 49|genus Dermacentor
14P08999857A0801|11 15|E-box
14P08999857A0801|81 91|enhancement
14P08999857A0801|131 152|collagen gene promoter
14P08999882T0000|0 9|Expression
14P09000049A1341|13 15|Mnt
14P09000049A1341|17 19|Max
14P09000049A1341|60 62|Myc
14P09000049A1341|64 77|Max activities
14P09000049A1341|91 108|cell proliferation
14P09000108A0330|3 23|transcription product
14P09000108A0330|87 109|polyadenylation signals
14P09000108A0330|138 166|translation termination codon
14P09000108A0330|168 171|CG30
14P09000146T0000|44 54|c-src genes
14P09000146T0000|72 91|sequence alterations
14P09000589A0000|3 12|resurgence
14P09000589A0000|50 59|evaluation
14P09000632A2341|5 15|p51 subunit
14P09000632A2341|19 35|Cys181 side-chain
14P09000632A2341|69 85|Tyr181 side-chain
14P09001213A1111|17 35|level transcription
14P09001213A1111|70 84|chromosome ends
14P09001213A1111|86 98|P. falciparum
14P09001213A1111|159 174|expression sites
14P09001245A0187|0 5|NUP145
14P09001313A0000|0 9|Prevalence
14P09001313A0000|38 40|SDB
14P09001667A0312|52 71|day post-vaccination
14P09001828A0222|64 73|physicians
14P09001828A0222|82 84|BPH
14P09001828A0222|111 119|treatment
14P09002648A0202|0 4|BCL-2
14P09002672A0439|106 125|sequence specificity
14P09002672A0439|151 164|TTAGGG repeats
14P09002672A0439|167 183|binding substrate
14P09002672A0439|187 192|TTAGGC
14P09002672A0439|196 209|TTGGGG repeats
14P09003001A1593|24 26|E12
14P09003001A1909|3 16|E-box sequence
14P09003001A1909|21 32|SE2 fragment
14P09003001A1909|37 56|transferrin promoter
14P09003001A1909|59 64|CATCTG
14P09003001A1909|94 117|consensus E-box elements
14P09003001A1909|117 122|CANNTG
14P09003311A0478|7 18|DNA fragment
14P09003312A0740|11 17|AT-PHH1
14P09003312A0740|26 32|AT-PHH1
14P09003312A0740|36 54|AT-PHH1 delta C-513
14P09003312A0740|98 113|photolyase genes
14P09003410A0000|8 19|p100 protein
14P09003462A0792|29 31|S61
14P09003462A0792|33 35|SL1
14P09003462A0792|37 39|S29
14P09003462A0792|41 44|SL11
14P09003462A0792|46 50|SL196
14P09003462A0792|54 58|SL126
14P09003463A0198|33 48|characterization
14P09003463A0198|96 109|RII alpha gene
14P09003617A0000|1 6|cohort
14P09003617A0000|16 23|children
14P09003617A0000|41 46|months
14P09003617A0000|51 55|years
14P09004304A0000|31 45|reproducibility
14P09004304A0000|67 83|clearance methods
14P09004304A0000|88 114|chromium-51 ethylenediamine
14P09004304A0000|130 138|51Cr-EDTA
14P09004304A0000|172 193|blood sample technique
14P09004504A0000|26 40|bp DNA fragment
14P09004504A0000|65 85|plasminogen activator
14P09004504A0000|125 154|Yersinia pestis plasmid pYP358
14P09004987T0001|0 22|Serotonin concentration
14P09005273A0322|0 20|MAIN OUTCOME MEASURES
14P09005273A0322|20 31|Associations
14P09005273A0322|83 103|chemical interactions
14P09005273A0322|114 134|butyrylcholinesterase
14P09005273A0322|138 163|neuropathy target esterase
14P09005273A1558|0 9|CONCLUSION
14P09005273A1558|15 31|Gulf War veterans
14P09005273A1558|126 146|butyrylcholinesterase
14P09005273A1558|150 175|neuropathy target esterase
14P09005609A0299|0 18|Control examination
14P09005836A0977|2 12|correlation
14P09005836A0977|43 56|antibody level
14P09005979A0841|3 10|GHR mRNA
14P09005979A0841|11 25|GHBP mRNA ratio
14P09006007A0997|54 62|UGA codon
14P09006007A0997|114 125|SelB protein
14P09006007A0997|204 216|compatibility
14P09006010A0527|3 26|linker-peptide insertion
14P09006010A0527|31 45|RsaA C terminus
14P09006010A0527|71 88|S-layer biogenesis
14P09006010A0527|160 163|RsaA
14P09006010A0527|174 189|secretion signal
14P09006022A0252|82 107|T7 RNA polymerase promoter
14P09006051A1162|20 63|carboxyphosphonoenolpyruvate phosphonomutase
14P09006051A1162|110 140|carnation Dianthus caryophyllus
14P09006051A1162|183 199|citrate synthases
14P09006051A1162|228 253|Bacillus subtilis proteins
14P09006051A1162|290 318|acetyl coenzyme A synthetases
14P09006555A0738|0 20|MAIN OUTCOME MEASURES
14P09006555A0738|61 83|blood gas determination
14P09006555A0738|114 131|neutrophil content
14P09006555A0738|132 155|neutrophil oxidant burst
14P09006555A0738|155 182|lung myeloperoxidase content
14P09006902A0370|32 36|MEKK3
14P09006910A0000|63 81|retinoid X receptor
14P09006910A0000|81 83|RXR
14P09006910A0000|85 99|gene expression
14P09006910A0000|130 146|RXRgamma2 isoform
14P09006914A0812|0 2|JNK
14P09006914A0812|6 8|p38
14P09006914A0812|66 70|ATF-2
14P09006914A0812|91 93|JNK
14P09006914A0812|97 99|p38
14P09006914A1127|41 65|JNK/p38 signaling pathway
14P09006914A1127|132 157|E-selectin gene expression
14P09006935A0590|0 2|Sp1
14P09006935A0590|11 20|CTC repeat
14P09006935A0590|35 36|KD
14P09006935A0590|63 78|consensus GC box
14P09006936T0000|0 13|Identification
14P09006936T0000|80 99|glycoprotein IBalpha
14P09008301A0193|6 17|enzyme forms
14P09008301A0193|50 68|autoprocessing site
14P09009208A0337|65 72|Tf1 mRNA
14P09010223A0667|30 33|ELK1
14P09010223A0667|35 39|SAP1a
14P09010223A0667|41 44|FLI1
14P09010223A0667|46 53|EWS-FLI1
14P09010223A0667|55 58|ETS1
14P09010223A0667|60 63|ETS2
14P09010223A0667|65 68|PEA3
14P09010223A0667|72 84|PU.1 proteins
14P09010223A0667|111 113|SRF
14P09010223A1850|4 11|R-domain
14P09010223A1850|41 43|SRF
14P09010223A1850|83 86|FLI1
14P09010223A1850|90 97|EWS-FLI1
14P09010223A1850|136 160|ETS transcription factors
14P09010223A1850|179 187|Egr1 gene
14P09011591A0309|16 24|specimens
14P09011591A0309|37 46|nonsmokers
14P09011591A0309|52 58|smokers
14P09011744A0790|38 67|NMDA receptor channel subunits
14P09011744A0790|78 83|Grin2a
14P09011744A0790|95 100|Grin2b
14P09011744A0790|112 117|Grin2c
14P09011744A0790|129 134|Grin2d
14P09011744A0790|145 149|Grinl
14P09011744A0790|194 216|backcross mapping panel
14P09011744A0790|237 246|C57BL/6JxM
14P09011744A0790|256 266|F1xC57BL/6J
14P09011745T0000|13 23|chick brain
14P09011745T0000|74 87|acid receptors
14P09011745T0000|94 105|conservation
14P09011745T0000|108 116|structure
14P09011745T0000|149 157|processes
14P09011745T0000|171 179|receptors
14P09012405A0785|15 19|TTD-A
14P09012405A0785|23 34|XP-D defects
14P09012405A0785|61 65|TFIIH
14P09012405A0785|73 92|transcription factor
14P09012405A0785|113 122|DNA repair
14P09012636A0723|0 9|Adjustment
14P09012636A0723|34 48|HDL cholesterol
14P09012636A0723|49 61|triglycerides
14P09012636A0723|146 160|atherosclerosis
14P09013499A0198|2 11|Experiment
14P09013499A0198|63 109|N-methyl-D-aspartate receptor antagonist MK-801
14P09013760A0000|0 10|Cholesterol
14P09013760A0000|21 44|cleavage cytochrome P450
14P09013760A0000|44 49|CYP11A
14P09013760A0000|51 57|P450scc
14P09013760A0000|59 73|gene expression
14P09013760A0000|121 124|ACTH
14P09015543A0210|11 18|solution
14P09015543A0210|32 38|forearm
14P09015757T0000|21 36|characterization
14P09015757T0000|86 102|bone sialoprotein
14P09015757T0000|103 105|BSP
14P09015799T0000|0 18|Serotonin receptors
14P09015799T0000|20 34|suicide victims
14P09016566A0655|62 70|BiP mRNAs
14P09017443A0734|14 26|marker screen
14P09017443A0734|46 55|occurrence
14P09017443A0734|67 74|syndrome
14P09017443A0734|118 131|stratification
14P09018122A1389|14 28|ORF-1 sequences
14P09018122A1389|64 75|prerequisite
14P09018122A1389|100 116|tumor development
14P09018133A0244|72 77|PhHV-1
14P09018133A0244|93 112|Varicellovirus genus
14P09018133A0244|117 135|alpha-Herpesvirinae
14P09019302A0600|13 15|PLP
14P09019302A0600|47 57|sensitivity
14P09019302A0600|63 76|derivatization
14P09019302A0600|81 96|sodium bisulfite
14P09020138A0833|4 7|HEF1
14P09020138A0833|11 13|Cas
14P09020138A0833|59 73|tyrosine kinase
14P09020138A0833|74 78|RAFTK
14P09020138A0833|118 138|adapter molecule CrkL
14P09020169A0552|0 3|SIM1
14P09020169A0552|7 10|SIM2
14P09020169A0552|55 57|AHR
14P09020172A0964|0 8|Complexes
14P09020172A0964|55 57|DNA
14P09020172A0964|114 138|nM dissociation constants
14P09020172A0964|138 139|Kd
14P09020172A0964|185 187|DNA
14P09020172A0964|209 217|Kd values
14P09020856A0560|27 30|TIS1
14P09020856A0560|58 69|MCK promoter
14P09021684A1418|112 130|repressor functions
14P09021684A1418|145 158|NF-kappa B2p52
14P09021684A1418|175 198|transactivation activity
14P09022040A0263|7 26|L-plastin expression
14P09022040A0263|127 141|gene expression
14P09022040A0263|215 234|nucleotide sequences
14P09022040A0263|253 276|L-plastin gene promoters
14P09022632T0000|36 42|surgery
14P09023197T0000|15 31|Bacillus subtilis
14P09023378A0959|21 24|CBF1
14P09023378A0959|65 78|reporter genes
14P09023378A0959|91 102|C-repeat/DRE
14P09023378A0959|115 132|activator sequence
14P09023378A0959|157 167|DNA element
14P09024039A0247|9 11|ASA
14P09024039A0247|118 120|CCA
14P09024039A0247|151 161|ventilation
14P09024097A0000|0 8|OBJECTIVE
14P09024097A0000|85 97|complications
14P09024097A0000|103 112|postpartum
14P09024793A1325|5 40|electrophoresis mobility shift assay
14P09024793A1325|77 80|MyoD
14P09024793A1325|107 111|E-box
14P09024793A1325|136 143|MCK gene
14P09024793A1325|162 166|BMP-2
15P09024805A0905b|13 30|promoter construct
15P09024805A0905b|55 72|consensus Sp1 site
15P09024805A0905b|104 106|ZII
15P09024805A0905b|108 111|CREB
15P09024805A0905b|113 115|AP1
15P09024805A0905b|131 144|BZLF1 promoter
15P09024805A0905b|155 174|beta-globin TATA box
15P09024805A0905b|183 208|phorbol ester inducibility
14P09025122A0374|74 82|COWA task
14P09025549A0000|76 88|practitioners
14P09025549A0000|100 136|Vancouver sex therapist Bianca Rucker
14P09027346A1957|8 23|antibody binding
14P09027346A1957|38 59|hCG-ectodomain complex
14P09027346A1957|149 151|LHR
14P09027506T0000|0 11|cDNA cloning
14P09027506T0000|12 30|expression analysis
14P09027506T0000|45 56|localization
14P09027506T0000|96 97|4F
14P09028089A0183|93 115|transplantation surgery
14P09028308A0590|29 31|AZQ
14P09028308A0590|35 47|mitroxantrone
14P09028308A0590|68 90|bone marrow suppression
14P09028308A0590|135 139|G-CSF
14P09028308A0590|142 154|micrograms/kg
14P09028308A0590|203 214|chemotherapy
14P09028942A0000|52 58|hGM-CSF
14P09028942A0000|108 127|growth response gene
14P09028998A0143|82 94|breast tissue
14P09028998A0143|113 115|BCT
14P09029091A0881|33 56|tyrosine phosphorylation
14P09029091A0881|58 78|phospholipase C gamma
14P09029091A0881|96 107|Jurkat cells
14P09029091A0881|120 133|A2/HCP chimera
14P09029104A0226|8 12|IGLL1
14P09029159A0000|14 16|IFN
14P09029159A0000|41 43|RNA
14P09029159A0000|61 82|Ser/Thr protein kinase
14P09029159A0000|82 84|PKR
14P09029159A0000|139 141|IFN
14P09029713A1120|65 78|activator SF-1
14P09029713A1120|84 100|repressor COUP-TF
14P09029713A1120|128 140|transcription
14P09029956T0000|43 61|structure formation
14P09030581A0990|15 25|COS-7 cells
14P09030581A0990|26 30|MKP-4
14P09030581A0990|49 59|MAP kinases
14P09030581A0990|81 83|p38
14P09030581A0990|85 92|JNK/SAPK
14P09030688A0435|74 91|Rap1p localization
14P09030781A0734|53 65|cdc2/cyclin B
14P09030781A0734|66 78|cdk2/cyclin A
14P09030781A0734|79 91|cdk2/cyclin E
14P09030781A0734|132 142|IC50 values
14P09030781A0734|183 196|cdk4/cyclin D1
14P09030781A0734|199 212|cdk6/cyclin D2
14P09030781A0734|248 251|IC50
14P09031639A0474|28 40|reading frame
14P09031639A0474|41 43|ORF
14P09031639A0474|61 71|polypeptide
14P09031639A0474|77 87|amino acids
14P09031639A0474|144 155|U1-C protein
14P09032233T0000|0 10|Interaction
14P09032233T0000|24 52|POU-homeodomain protein GHF-1
14P09032248A0239|40 68|Pcl1,2-Pho85 kinase complexes
14P09032248A0239|104 123|Cln1,2-Cdc28 kinases
14P09032250A0257|65 68|Tax1
14P09032250A0257|83 91|B subunit
14P09032250A0257|96 121|CCAAT binding protein NF-Y
14P09032250A0257|124 140|HeLa cDNA library
14P09032254A0724|0 16|Enhancer activity
14P09032254A0724|31 39|AP-1 site
14P09032258A0395|12 28|HLA-DR-B7-1-LFA-3
14P09032258A0395|74 99|NF-AT DNA binding activity
14P09032258A0395|121 138|B7-1 costimulation
14P09032259A0150|24 27|Rac1
14P09032259A0150|31 34|RhoA
14P09032259A0150|68 80|NIH 3T3 cells
14P09032259A0150|117 134|Ras transformation
14P09032259A0972|12 26|Rac1 activation
14P09032259A0972|28 30|JNK
14P09032259A0972|33 35|SRF
14P09032259A0972|98 123|Rac1 transforming activity
14P09032267A0850|0 13|Overexpression
14P09032267A0850|19 41|bZip interaction domain
14P09032267A0850|42 44|CBP
14P09032267A0850|93 94|TR
14P09032267A0850|98 105|p45/NF-E
14P09032275A1133|57 76|AHC deletion mutants
14P09032304T0000|0 13|Identification
14P09032304T0000|34 55|transactivation domain
14P09032304T0000|60 79|herpes simplex virus
14P09032328A0650|0 13|DNA sequencing
14P09032328A0650|41 56|gammaherpesvirus
14P09032328A0650|72 75|DL-B
14P09032328A0650|84 88|ORF11
14P09032328A0650|92 96|ORF17
14P09032328A0650|127 130|ORFs
14P09034337A0251|0 6|Studies
14P09034337A0251|69 71|Y15
14P09034337A0251|73 87|phosphorylation
14P09034337A0251|90 96|p34cdc2
14P09034337A0251|114 123|DNA damage
14P09035307A0000|93 136|99mTc-methoxyisobutylisonitrile scintigraphy
14P09035612T0000|7 24|endothelin release
14P09035612T0000|27 38|infarct size
14P09035612T0000|49 58|blood flow
14P09035612T0000|89 98|infarction
14P09035612T0000|102 112|reperfusion
14P09036529A0343|45 53|Pharmacia
14P09036529A0343|89 96|RAST-CAP
14P09036529A0343|98 106|Pharmacia
14P09036529A0343|112 115|CAST
14P09036529A0343|125 138|concentrations
14P09036529A0343|145 158|Apis mellifera
14P09036529A0343|167 178|Vespula spec
14P09036529A0343|186 196|Aquagen ALK
14P09037032T0000|41 45|P2P-R
14P09037032T0000|90 118|ribonucleoprotein association
14P09037032T0000|121 131|Rb1 binding
14P09037032T0000|169 183|differentiation
14P09037064A0183|30 48|canarypox ALVAC/HIV
14P09037064A0183|59 76|vaccine immunogens
14P09037064A0183|78 82|HIV-1
14P09037064A0183|117 129|CTL responses
14P09037163A1652|59 78|gpc4 gene expression
14P09038166A0818|0 8|Exons A1a
14P09038166A0818|11 13|A1b
14P09038192A0846|23 30|PD098059
14P09038192A0846|33 38|Dudley
14P09038192A0846|40 41|D.
14P09038202A1951|30 48|repression activity
14P09038202A1951|50 58|NRSF/REST
14P09039744T0000|29 50|electro-encephalograms
14P09039744T0000|61 73|sinc function
14P09040011A1316|10 12|p56
14P09040011A1316|36 50|G1/S transition
14P09040011A1316|83 96|cell viability
14P09040011A1316|125 142|activation signals
14P09040011A1316|169 188|Ras/Raf/MAPK pathway
14P09041123A0195|11 16|action
14P09041123A0195|30 35|ligand
14P09041123A0195|59 65|factors
14P09041123A0195|113 121|responses
14P09041123A0195|140 146|complex
14P09042078A0202|17 19|MBF
14P09042078A0202|74 85|jaw openings
14P09042269A1007|5 12|findings
14P09042269A1007|48 59|chemotherapy
14P09042683A0492|3 19|FBF questionnaire
14P09042683A0492|54 69|symptoms profile
14P09042755T0000|14 32|sigma factor sigmaB
14P09042755T0000|69 79|sigB operon
14P09042755T0000|91 102|growth phase
14P09042911A0626|7 23|promoter elements
14P09042911A0626|35 48|glucocorticoid
14P09042911A0626|66 75|regulation
14P09042911A0626|124 133|expression
14P09043534A1600|20 28|decreases
14P09043534A1600|34 47|alkalinization
14P09043768A0139|29 31|BLM
14P09043768A0139|54 59|In-111
14P09045636A0789|0 16|CD3 cross-linking
14P09045636A0789|23 46|tyrosine phosphorylation
14P09045805A0945|32 45|acoABCD operon
14P09045805A0945|71 82|acoK mutants
14P09045805A0945|133 156|transactivating function
14P09045805A0945|161 172|gene product
14P09045842T0000|0 8|Mutations
14P09045842T0000|40 53|RNA polymerase
14P09045919A1250|60 62|NFE
14P09045919A1250|89 91|p50
14P09045919A1250|121 150|transcription factor machinery
14P09045919A1250|164 180|enhancer activity
14P09045919A1250|203 211|IgH locus
14P09045919A1250|217 240|B lymphocyte development
14P09046013A0000|63 85|calcium channel blocker
14P09046013A0000|85 91|SNX-111
14P09046013A0000|210 223|carotid artery
14P09046090T0000|19 47|transcription factor yTAFII60
14P09046090T0000|50 61|G4p1 protein
14P09046090T0000|73 91|glucose transporter
14P09046090T0000|110 124|kb DNA fragment
14P09046186A0189|3 11|protector
14P09046186A0189|31 43|fall distance
14P09046186A0189|59 68|trochanter
14P09046384A0403|0 22|Marinol/marijuana usage
14P09046384A0403|48 50|CD4
14P09046384A0403|91 102|DDI subgroup
14P09047252A0209|0 6|METHODS
14P09047252A0209|67 69|HCC
14P09047252A0209|90 99|AFP levels
14P09047344A0000|26 28|CBP
14P09047344A0000|64 76|muscle myosin
14P09047344A0000|81 92|chain kinase
14P09047344A0000|93 96|MLCK
14P09048617A0648|23 46|tyrosine kinase receptor
14P09049198A0289|41 43|p21
14P09049198A0289|46 62|liver cell growth
14P09049198A0289|93 100|p21 gene
14P09049198A0289|128 145|liver regeneration
14P09049198A0289|164 177|liver diseases
14P09049270A0488|0 21|Northern blot analysis
14P09049270A0488|22 25|LeMT
14P09049270A0488|32 35|LeMT
14P09049270A0488|49 59|transcripts
14P09049270A0488|113 125|tomato plants
14P09049270A0488|163 176|characteristic
14P09049270A0488|185 187|MTs
14P09049304A1193|2 24|co-transfection studies
14P09049304A1193|27 30|AP-2
14P09049304A1193|39 61|Egr-1 expression vector
14P09049304A1193|69 90|VPF/VEGF transcription
14P09049304A1193|109 120|AP-2 protein
14P09049304A1193|145 147|TGF
14P09049304A1193|161 184|VPF/VEGF gene expression
14P09049306A0830|3 10|HBP gene
14P09049306A0830|61 70|chromosome
14P09049313A0116|100 122|initiation factor eIF4G
14P09050689A0685|37 41|SnET2
14P09050689A0685|64 77|administration
14P09050689A0685|101 104|J/cm
14P09050847A0180|29 45|TBP-TAF complexes
14P09050847A0180|91 132|transcription initiation factor TIF-IB/SL1
14P09050849A0000|0 10|Cytohesin-1
14P09050849A0000|113 129|Sec7 gene product
14P09050849A0000|145 161|protein transport
14P09050849A1459|56 62|ARF-GEP
14P09050861A0903|16 29|identification
14P09050861A0903|32 34|DEK
14P09050867A0542|36 48|Krox proteins
14P09050867A0542|93 116|POU-homeodomain proteins
14P09050867A0542|126 143|TN control element
14P09051656A0390|0 13|Tissue samples
14P09051656A0390|90 110|day morphine infusion
14P09053309A1103|21 43|floor plate development
14P09053309A1103|82 104|floor plate inducer shh
14P09053494A0612|0 6|RESULTS
14P09053494A0612|32 35|CD34
14P09053494A0612|83 84|CY
14P09053494A0612|86 87|CE
14P09053494A0612|92 94|CEP
14P09053494A0612|99 103|G-CSF
14P09053494A0612|179 193|reference group
14P09053494A0612|205 206|CY
14P09053494A0612|211 215|G-CSF
14P09053835A0865|9 20|p53 activity
14P09053835A0865|29 30|OP
14P09053835A0865|49 56|p53 mRNA
14P09053973A1252|0 9|CONCLUSION
14P09053973A1252|18 31|administration
14P09055221A0288|17 21|SSTEs
14P09055221A0288|61 64|MSEs
14P09055221A0288|81 95|signal contrast
14P09056761A0000|27 37|termination
14P09056761A0000|40 50|translation
14P09056761A0000|146 155|mRNA decay
14P09056761A0000|160 168|cytoplasm
14P09056761A0000|189 209|splice site selection
14P09057325A0177|33 57|pathogenicity locus pat-1
14P09057325A0177|67 83|deletion analysis
14P09057325A0177|86 108|complementation studies
14P09057325A0177|117 139|Bg/II/SmaI DNA fragment
14P09057648A0422|34 50|sense orientation
14P09057648A0422|105 107|FC3
14P09057648A0422|144 176|chloramphenicol acetyltransferase
14P09057648A0422|177 179|CAT
14P09057648A0422|206 217|CAT activity
14P09057648A0422|219 230|Jurkat cells
14P09057648A0422|272 274|FCS
14P09057648A0422|279 310|micrograms/mL phytohemagglutinin
14P09057648A0422|320 350|mol/L phorbol myristate acetate
14P09057648A0422|349 351|PMA
14P09057648A0422|356 365|U937 cells
14P09057703A1389|0 14|Snail mortality
14P09057703A1389|41 60|treatment conditions
14P09057840A0946|48 50|NH4
14P09057840A0946|52 69|2SO4-precipitation
14P09057840A0946|73 95|affinity chromatography
14P09057840A0946|99 111|AMP-Sepharose
14P09057841T0000|0 11|Derepression
14P09057841T0000|14 28|gene expression
14P09057841T0000|62 82|isocitrate lyase gene
14P09057841T0000|83 100|Candida tropicalis
14P09058002T0000|43 53|lobe damage
14P09058250A0128|51 52|NO
14P09058250A0128|56 58|NO2
14P09058323A1287|25 36|cis elements
14P09058323A1287|129 140|CNS patterns
14P09058323A1287|164 181|gene transcription
14P09058373A0670|0 27|RNase protection experiments
14P09058373A0670|51 66|GHR1-279 variant
14P09058373A0670|68 77|IM-9 cells
14P09058373A1620|21 33|reporter gene
14P09058373A1620|57 64|elements
14P09058373A1620|135 142|function
14P09058373A1620|159 166|receptor
14P09058378A1134|20 43|glucocorticoid receptors
14P09058378A1134|56 79|transactivation function
14P09058378A1134|81 83|p53
14P09058378A1134|107 109|p53
14P09059039A0850|0 10|99mTc-HMPAO
14P09059039A0850|46 48|ACA
14P09059039A0850|52 54|MCA
14P09059039A0850|129 138|C4 segment
14P09059039A0850|179 181|ACA
14P09059039A0850|254 263|C1 segment
14P09060045A0576|9 23|review analyses
14P09060045A0576|28 39|interactions
14P09060045A0576|89 105|endotoxin release
14P09060444A0557|4 19|promoter segment
14P09060444A0557|42 65|luciferase reporter gene
14P09060444A0557|138 155|EGF-responsiveness
14P09060622A1679|45 58|alphavirus RNA
14P09060622A1679|88 96|infection
14P09060623A0961|43 51|SIV entry
14P09060676A1634|14 33|virus entry features
14P09060676A1634|43 55|coronaviruses
14P09060971A0982|0 6|RESULTS
14P09060971A0982|42 44|BMD
14P09060971A0982|188 197|trochanter
14P09061697A0629|42 44|MBq
14P09061697A0629|51 67|99Tcm-tetrofosmin
14P09061697A0629|94 96|MBq
14P09061697A0629|121 132|day protocol
14P09061697A0629|166 187|stress imaging studies
14P09061697A0629|217 219|MBq
14P09061697A0629|233 249|99Tcm-tetrofosmin
14P09061697A0629|269 280|day protocol
14P09061697T0000|10 21|SPET imaging
14P09061697T0000|25 41|99Tcm-tetrofosmin
14P09061697T0000|83 102|day imaging protocol
14P09061698A0177|0 12|99Tcm-DMP-HSA
14P09061698A0177|76 79|RBCs
14P09061698A0177|112 129|reference standard
14P09061698A0177|132 148|blood pool agents
14P09062130A0116|0 5|Relief
14P09062130A0116|84 106|N-SH2 domain engagement
14P09062130A0116|116 136|phosphotyrosyl ligand
14P09062130A0116|155 165|SH2 domains
14P09062130A0116|184 196|PTPase domain
14P09064659A1055|85 97|nonsense mRNA
14P09064659A1055|134 138|HUPF1
14P09064659A1055|157 160|UPF1
14P09064868T0001|1 12|miracle cure
14P09065170A0853|3 10|addition
14P09065170A0853|13 22|zidovudine
14P09065170A0853|42 49|transfer
14P09065463A1012|0 18|DNA strand exchange
14P09065463A1012|28 40|Rad51 protein
14P09065463A1012|65 67|RPA
14P09065690A0463|0 4|Ume6p
14P09065690A0463|65 79|CAR1 expression
14P09065690A0463|101 103|URS
14P09065690A0463|118 138|nitrogen availability
14P09065768A0862|35 47|kb transcript
14P09065768A0862|95 106|lactase mRNA
14P09067577A0307|24 30|BCR/ABL
14P09067577A0307|32 35|CRKL
14P09067577A0307|67 69|CRK
14P09067577A0721|57 60|CRKL
14P09067577A0721|74 76|C3G
14P09067577A0721|78 80|SOS
14P09068989T0000|0 5|Effect
14P09068989T0000|8 25|Azadirachta indica
14P09071308A0376|0 6|RESULTS
14P09071308A0376|121 123|MTB
14P09071308A0376|127 130|NTMB
14P09071407T0000|25 35|guinea pigs
14P09071407T0000|54 65|cohabitation
14P09071407T0000|81 89|condition
14P09072361A0357|30 34|SHRSP
14P09072361A0357|102 116|magnesium ratio
14P09072361A0357|141 143|WKY
14P09072361A0357|147 151|SHRSR
14P09073074T0000|31 47|FGFR-3 psuedogene
14P09073582A0444|35 53|BglII-SmaI fragment
14P09073582A0444|58 69|SSO activity
14P09073582A0444|75 81|Kataoka
14P09073582A0444|88 90|Mol
14P09074508A0397|8 16|CD38 gene
14P09075739A0827|0 3|Type
14P09075739A0827|6 19|splice pattern
14P09076336A0281|0 12|GH deficiency
14P09076336A0281|149 162|GH sufficiency
14P09076336A0281|170 181|GH secretion
14P09077076A0219|8 15|CRP test
14P09077108A0458|63 65|IgG
14P09077108A0458|67 70|IL-6
14P09077108A0458|72 80|TNF-alpha
14P09077108A0458|85 88|PGE2
14P09077437T0000|0 21|Recognition mechanisms
14P09077437T0000|70 83|RNA polymerase
14P09077438A0076|33 45|RNA synthesis
14P09079625A0935|0 9|Syndecan-4
14P09079625A0935|18 35|adhesion component
14P09079625A0935|69 71|PKC
14P09079638A0883|3 14|3ASubE cells
14P09079638A0883|24 28|CXCR2
14P09079638A0883|43 49|Ser-346
14P09079638A0883|202 217|ligand challenge
14P09079650A0136|0 6|Members
14P09079650A0136|12 22|MAPK family
14P09079650A0136|61 64|ERKs
14P09079650A0136|67 72|p42/44
14P09079650A0136|74 77|MAPK
14P09079650A0136|111 114|JNKs
14P09079650A0136|123 129|p38/Hog
14P09079689A0472|0 3|MOP5
14P09079689A0472|30 39|PAS domain
14P09079689A0472|51 60|C terminus
14P09079817A0928|10 22|NO production
14P09079817A0928|77 89|NO synthetase
14P09079878A0000|14 45|Lactobacillus sake plasmid pCIM1
14P09079878A0000|104 107|ORFs
14P09079902A0713|8 10|Pra
14P09079902A0713|47 61|pyruvate kinase
14P09079902A0713|62 63|Pk
14P09079902A0713|66 67|Pk
14P09079902A0713|71 73|Pra
14P09079902A0713|106 108|Ndk
14P09079902A0713|110 111|Pk
14P09079902A0713|116 118|Pra
14P09079902A0713|133 134|Pk
14P09079902A0713|157 159|Pra
14P09079902A0713|191 193|Ndk
14P09079904A0995|9 23|iron regulation
14P09079904A0995|24 38|sodA expression
14P09079904A0995|60 71|DNA topology
14P09079904A0995|128 137|Bvg system
14P09079915T0000|85 110|consensus sigma70 promoter
14P09079928A0525|0 13|M. leprae OxyR
14P09079928A0525|84 92|M. leprae
14P09079928A1319|3 14|binding site
14P09079928A1319|17 20|OxyR
14P09079928A1319|31 36|P1oxyR
14P09079928A1319|120 133|characteristic
14P09079928A1319|139 154|LysR superfamily
14P09080250A0212|51 74|p15E cDNA gene fragments
14P09080250A0212|90 114|polymerase chain reaction
14P09080250A0212|114 116|PCR
14P09080250A0212|131 134|P815
14P09080250A0212|151 159|P815/DTIC
14P09080517A0215|11 18|patients
14P09081389A1088|0 4|Grade
14P09081389A1088|8 16|mucositis
14P09081392A0174|31 46|salvage regimens
14P09082335A0730|0 3|None
14P09082335A0730|18 31|manifestations
14P09083291A1378|5 13|TGF-beta1
14P09083291A1378|68 85|G1 phase cyclin D1
14P09083291A1378|97 99|MCs
14P09083291A1378|162 176|phosphorylation
14P09083291A1378|199 206|G1 phase
14P09083291A1378|221 227|S phase
14P09083345A0851|98 102|SYPLR
14P09083345A0851|119 137|inter-relationships
14P09083345A0851|161 175|characteristics
14P09083345A0851|204 215|presentation
14P09083345A0851|219 236|treatment efficacy
14P09083563A0971|44 56|surface layer
14P09083563A0971|59 79|leptomeningeal tissue
14P09083563A0971|91 107|arachnoid vessels
14P09083563A0971|217 225|B. cereus
14P09084174A0667|105 145|aspartate-beta-semialdehyde dehydrogenase
14P09084174A0667|146 148|Asd
14P09084174A0667|192 203|Asd proteins
14P09084174A0667|207 216|Vibrio spp
14P09084176A0601|36 58|slot-blot hybridization
14P09084176A0601|74 76|RNA
14P09084176A0601|94 112|M. smegmatis clones
14P09084227A0833|0 10|Hovenitin I
14P09084227A0833|17 26|ampelopsin
14P09084227A0833|52 62|ingredients
14P09084227A0833|162 178|muscle relaxation
14P09084621A0374|0 12|Movement time
14P09084621A0374|24 38|characteristics
14P09084621A0374|111 138|brain activity proportionate
14P09084621A0374|146 163|movement variables
14P09084621A2567|0 4|Areas
14P09084621A2567|56 67|motor cortex
14P09085842A0181|36 43|U1 snRNP
14P09085842A0181|73 100|protein/protein interactions
14P09085842A0181|126 139|U1-70K protein
14P09085842A0181|142 148|SF2/ASF
14P09085842A1559|26 36|27K protein
14P09085842A1559|82 109|protein/protein interactions
14P09085842A1559|129 149|phosphorylation state
14P09086268A0611|8 9|P7
14P09086268A0611|46 47|P7
14P09086268A0611|71 72|P2
14P09086268A0611|74 87|RNA polymerase
14P09086268A0611|91 92|P7
14P09087430A1046|15 25|U1A peptide
14P09087430A1046|42 44|BSA
14P09087430A1046|64 66|PAP
14P09088371T0000|0 12|Plasma levels
14P09088371T0000|35 46|antithrombin
14P09088371T0000|76 86|haemorrhage
14P09088416A0000|59 65|IBRBRAO
14P09088416A0000|97 114|migraine headaches
14P09088416A0000|132 143|hearing loss
14P09088416A0000|169 184|artery occlusion
14P09088737T0000|20 41|thickness measurements
14P09088737T0000|83 86|CMTF
14P09089093A0373|0 8|Sequences
14P09089093A0373|32 39|CA genes
14P09089093A0373|68 84|enhancer elements
14P09089653A0615|45 47|UTR
14P09089653A0615|102 120|luciferase activity
14P09089653A0615|156 170|control plasmid
14P09089653A1112|0 7|Analysis
14P09089653A1112|43 62|DNase-I footprinting
14P09090050A0419|25 38|sugar carriers
14P09090054A0186|81 97|alpha-glucosidase
14P09090054A0186|132 153|alpha-glucosidase gene
14P09090054A0186|164 167|MAL1
14P09090592A0175|35 55|activation fMR images
14P09090592A0175|150 160|orientation
14P09091010A1003|45 52|cytology
14P09091010A1003|73 79|disease
14P09091125A0161|68 84|acid phosphatases
14P09091125A0161|90 104|NBT-test values
14P09091403T0001|0 7|Analysis
14P09091403T0001|20 32|DNA sequences
14P09091403T0001|94 111|microsatellite DNA
14P09092493A0861|19 26|VIP CyRE
14P09092493A0861|31 38|Jak-Stat
14P09092493A0861|42 64|AP-1 signaling pathways
14P09092580A1354|38 55|MAP kinase pathway
14P09092580A1354|91 104|transmigration
14P09092636A0802|104 127|DYZ3 satellite sequences
14P09092636A0802|158 161|DYZ5
14P09092636A0802|182 190|YAC clone
14P09092675A0283|1 18|P22 R17 derivative
14P09092675A0283|23 32|OcRNA site
14P09092675A0283|33 39|P22 R17
14P09093867T0000|12 28|Ac/Ds transposons
14P09094093A0578|25 32|TATA box
14P09094315A0541|29 38|regulation
14P09094315A0541|46 53|activity
14P09094315A0541|56 66|cyclin-Cdks
14P09094671A1192|0 31|Candidate tumor suppressor genes
14P09094671A1192|35 42|p16INK4a
14P09094671A1192|52 59|p15INK4b
14P09094671A1192|94 115|Southern blot analysis
14P09096229T0000|0 14|Excision repair
14P09096229T0000|67 75|MFA2 gene
14P09096229T0000|141 154|identification
14P09096229T0000|203 219|control sequences
14P09096234T0000|56 79|DNA sequence specificity
14P09096234T0000|79 106|operator site discrimination
14P09096234T0000|107 131|phage lambda cI repressor
14P09096958A0000|66 79|platelet talin
14P09096958A0000|81 96|Western blotting
14P09096958A0000|103 115|precipitation
14P09096958A0000|120 137|immunofluorescence
14P09096958A0000|151 166|antibodies TA205
14P09096958A0000|169 172|TD77
14P09096958A0000|180 198|actin stress fibers
14P09096958A0000|225 237|cell motility
14P09098066A0119|75 87|proteins HMW1
14P09098066A0119|90 93|HMW3
14P09098066A0119|101 110|insertions
14P09098066A0119|176 184|phenotype
14P09098066A0119|198 208|designation
14P09098899A0000|0 8|Coliphage
14P09098899A0000|49 58|Ogr family
14P09098899A0000|69 89|transcription factors
14P09098899A0000|160 176|zinc-finger motif
14P09098899A0435|3 24|UV absorption spectrum
14P09098899A0435|64 70|CysS-Cd
14P09098899A0435|90 116|charge-transfer transitions
14P09098899A0435|123 155|difference absorption coefficient
14P09098899A0435|223 224|Cd
14P09098899A0435|226 230|Cys-S
14P09099683A0000|0 20|Diacylglycerol kinase
14P09099683A0000|21 23|DGK
14P09099683A0000|49 72|messenger diacylglycerol
14P09099702A0000|63 87|orphan receptor germ cell
14P09099702A0000|99 102|GCNF
14P09099702A0000|105 107|RTR
14P09099702A0692|49 52|RTRE
14P09099702A0692|66 70|P2-RE
14P09099702A0692|107 121|mouse protamine
14P09099702A0692|161 175|spermatogenesis
14P09099702A0692|178 180|RTR
14P09099743A0585|15 26|purification
14P09099743A0585|67 74|particle
14P09099743A0585|111 122|polypeptides
14P09099743A0585|145 156|polypeptides
14P09099743A0585|206 214|nucleolin
14P09099745A1446|96 98|p21
14P09099745A1446|102 104|p27
14P09099745A1446|118 121|Cdk2
14P09099745A1446|147 161|phosphorylation
14P09099745A1446|233 257|CDK inhibitor association
14P09099745A1446|288 302|phosphorylation
14P09099745A1446|305 308|Cdk2
14P09100202A0000|6 10|Class
14P09100202A0000|15 33|Class II recessions
14P09100202A0000|91 112|tissue graft procedure
14P09101085A0686|67 81|p27Kip1 protein
14P09101910A0394|16 24|mortality
14P09101910A0394|30 37|patients
14P09101910A0394|49 57|mortality
14P09101910A0394|60 67|patients
14P09102113A0739|12 27|failure patients
14P09102113A0739|72 80|frequency
14P09103382T0000|6 20|FIGO definition
14P09104816A0610|11 13|Vpu
14P09104816A0610|86 99|vaccinia virus
14P09104816A0610|100 101|VV
14P09105042A1497|36 56|myofibrillar disarray
14P09105042A1497|62 73|HCM patients
14P09105042A1497|162 174|chain protein
14P09105042A1497|286 302|beta MHC function
14P09105363A0636|30 50|emission spectroscopy
14P09105363A0636|72 98|tissue silicon measurements
14P09105530A0000|2 12|egg protein
14P09105530A0000|62 79|cheese preparation
14P09106057A0000|43 50|N-methyl
14P09106057A0000|53 61|N-ethyl-8
14P09106057A0000|65 83|anhydroerythromycin
14P09106057A0000|100 104|EM523
14P09106057A0000|194 207|chromatography
14P09106057A0000|209 212|HPLC
14P09106057A0000|218 234|chemiluminescence
14P09106057A0000|236 237|CL
14P09108029A0399|52 55|AP-1
14P09108029A0399|70 86|DNA repair enzyme
14P09108029A0399|125 141|DNA repair enzyme
14P09108029A0399|141 155|AP endonuclease
14P09108038A1128|8 17|LRR domain
14P09108038A1128|40 46|Acan125
14P09108038A1128|53 72|C. elegans homologue
14P09108038A1128|103 118|binding proteins
14P09108207A0306|42 65|oropharyngeal irritation
14P09108279A0431|19 24|8-OxoG
14P09108279A0431|90 107|34mer DNA fragment
14P09108279A0431|123 136|8-OxoG residue
14P09108279A0431|156 163|8-OxoG/C
14P09108451A0160|0 6|Results
14P09108451A0160|51 56|UCN-01
14P09108451A0160|76 96|G1-phase accumulation
14P09110176A0890|0 7|Northern
14P09110176A0890|11 25|RT-PCR analysis
14P09110176A0890|27 42|Ube3a expression
14P09110176A0890|44 56|mouse tissues
14P09111004A0732|37 47|Xaa residue
14P09111004A0732|56 88|phosphorylation motif Thr-Xaa-Tyr
14P09111004A0732|106 144|L12 influence p38 substrate specificity
14P09111004A0732|191 209|autophosphorylation
14P09111048X0000|22 36|mRNA transcript
14P09111048X0000|67 87|nitric-oxide synthase
14P09111048X0000|88 101|mRNA diversity
14P09111048X0000|132 152|nitric-oxide synthase
14P09111048X0000|158 172|gene expression
14P09111048X0000|181 193|cells/tissues
14P09111059A0327|87 89|DNA
14P09111309A0674|0 13|Cotransfection
14P09111309A0674|24 26|p44
14P09111309A0674|52 54|MAP
14P09111309A0674|56 80|kinase expression vectors
14P09111309A0674|98 123|HB-EGF promoter activation
14P09111309A0674|145 146|ER
14P09111314A0970|0 8|Cyclin D1
14P09111314A0970|49 69|184A1L5R cell lysates
14P09111314A1243|44 51|p15INK4B
14P09111314A1243|54 61|TGF-beta
14P09111314A1243|114 121|184A1L5R
14P09111314A1243|134 147|p15 transcript
14P09111314A1243|157 172|p15INK4B protein
14P09111314A1243|211 235|cyclin D1-cdk association
14P09111331A0119|3 14|Rlm1 protein
14P09111331A0119|27 41|MADS box family
14P09111331A0119|42 62|transcription factors
14P09111331A0119|84 87|Mpk1
14P09111340A0240|50 63|downregulation
14P09111340A0240|100 110|C2C12 cells
14P09111340A0240|188 203|beta-globin gene
14P09111340A0240|219 251|chloramphenicol acetyltransferase
14P09111340A0240|252 254|CAT
14P09111367A1098|27 29|32D
14P09111367A1098|51 59|p53 cells
14P09111367A1098|79 94|tal-1 expression
14P09111367A1098|241 262|cell cycle checkpoints
14P09111367A1098|352 364|tal-1 effects
14P09111367A1098|401 426|heterodimerization domains
14P09111367A1098|435 446|N-terminally
14P09111367A1098|456 468|tal-1 variant
14P09111367A1098|469 470|M3
14P09111367A1098|483 487|T-ALL
14P09111863A0743|54 69|tumor suppressor
14P09111863A0743|89 99|coincidence
14P09111863A0743|117 135|chromosome fragment
14P09111863A0743|146 159|tumorigenicity
14P09111863A0743|164 175|introduction
14P09111863A0743|178 188|tumor cells
14P09112400A1155|11 18|activity
14P09112400A1155|39 46|addition
14P09112400A1155|49 57|forskolin
14P09112589A0078|26 32|pattern
14P09114972A1366|15 17|SOS
14P09115242A0934|35 60|promoter deletion analyses
14P09115242A0934|98 109|protein-beta
14P09115242A0934|111 120|C/EBP-beta
14P09115242A0934|122 133|binding site
14P09115242A0934|165 177|transcription
14P09115242A0934|180 192|collagenase-1
14P09115247A2069|0 24|11-Aminoundecanoyl-SK-NH2
14P09115247A2069|28 52|11-aminoundecanoyl-SH-NH2
14P09115247A2069|73 86|alkyl backbone
14P09115247A2069|251 269|epsilon-amino group
14P09115265A1160|20 30|CCCC module
14P09115265A1160|87 113|transcription factor GATA-1
14P09115279A0345|0 19|Cdc2 co-precipitates
14P09115279A0345|23 26|Pch1
14P09115279A0345|29 30|S.
14P09115279A0345|56 59|Cdc2
14P09115279A0345|95 105|Pch1 kinase
14P09115357A0073|81 108|immunoglobulin hypermutation
14P09115357A0073|139 153|culture systems
14P09115357A0073|156 176|hypermutating B cells
14P09115365A0000|0 9|Expression
14P09115365A0000|20 37|heat shock protein
14P09115395A0478|75 96|epithelial-microtubule
14P09115395A0478|119 123|Oct91
14P09115395A0478|125 148|Elongation factor 1gamma
14P09115395A0478|148 151|BRG1
14P09115395A0478|232 253|epithelial-microtubule
14P09115395A0478|300 303|Cdc5
14P09115395A0478|305 327|innercentrosome protein
14P09115395A0478|328 331|BRG1
14P09115395A0478|338 353|RNA helicase WM6
14P09115395A0478|373 393|transcription factors
14P09115395A0478|394 397|BRG1
14P09115395A0478|407 422|co-factor 2alpha
14P09115395A0478|423 427|Oct91
14P09115395A0478|429 430|S.
14P09115395A0478|436 439|Cdc5
14P09115395A0478|441 445|HoxD1
14P09115395A0478|447 450|Sox3
14P09115395A0478|452 456|Vent2
14P09115395A0478|474 478|Xbr1b
14P09115989A0993|30 49|psoralen cross-links
14P09115989A0993|76 93|initiation process
14P09117345A0945|0 9|Activation
14P09117345A0945|27 32|TS2/16
14P09117345A0945|70 83|cell migration
14P09117345A0945|110 124|phosphorylation
14P09118196A0281|0 10|Performance
14P09118196A0281|34 47|National Adult
14P09118196A0281|67 72|NART-R
14P09118196A0281|80 97|Vocabulary subtest
14P09118196A0281|104 144|Wechsler Adult Intelligence Scale-Revised
14P09118196A0281|143 148|WAIS-R
14P09118664A1734|0 11|L-canavanine
14P09118664A1734|52 65|oxide synthase
14P09118664A1734|90 105|filling pressure
14P09118704A0771|0 6|RESULTS
14P09118704A0771|59 63|G-CSF
14P09118704A0771|75 95|% confidence interval
14P09118704A0771|95 96|CI
14P09118704A0771|150 167|bleomycin toxicity
14P09119031A1036|12 37|holoenzyme RNA polymerases
14P09119031A1036|92 110|core RNA polymerase
14P09119031A1036|110 124|alpha2beta beta
14P09119112A1350|39 44|GATA-5
14P09119391A0870|91 106|protein sequence
14P09119391A0870|113 117|GPT-1
14P09121424A0296|32 43|Swi3 homolog
14P09121424A0296|44 47|Swh3
14P09121424A0296|110 113|Sthl
14P09121430A0132|0 2|Shc
14P09121430A0132|34 47|protein kinase
14P09121430A0132|48 51|MAPK
14P09121430A0132|79 82|Grb2
14P09121430A1075|11 23|Y239/240F Shc
14P09121430A1075|30 38|Y317F Shc
14P09121432A0000|3 13|Ras guanine
14P09121432A0000|67 76|signalling
14P09121433A0463|10 13|Rlm1
14P09121433A0463|17 20|Smp1
14P09121433A0463|62 65|Rlm1
14P09121433A0463|95 98|MEF2
14P09121433A0463|100 102|CTA
14P09121433A0463|104 106|T/A
14P09121433A0463|108 111|4TAG
14P09121433A0463|118 121|SMP1
14P09121433A0463|140 157|consensus sequence
14P09121433A0463|158 164|ACTACTA
14P09121433A0463|166 168|T/A
14P09121433A0463|170 173|4TAG
14P09121435A1183|0 6|Domains
14P09121435A1183|43 60|TFIIIB-DNA complex
14P09121435A1183|75 94|protein footprinting
14P09121452A0538|0 24|Domain switch experiments
14P09121452A0538|33 51|C/EBP beta proteins
14P09121452A0538|87 103|activation domain
14P09121452A0538|105 115|C/EBP alpha
14P09121452A0538|138 149|2D5 promoter
14P09121452A0538|225 234|C/EBP site
14P09121454A1328|59 63|Bur6p
14P09121454A1328|67 71|Mot1p
14P09121454A1328|144 166|transcription machinery
14P09121476T0000|0 4|PRH75
14P09121476T0000|38 60|DEAD-box protein family
14P09121774A0611|88 104|MAP kinase family
14P09121774T0000|16 25|GTPase Rac
14P09121774T0000|78 99|serum response element
14P09121774T0000|103 121|cell transformation
14P09121998A0663|63 72|subjection
14P09121998A0663|96 105|procedures
14P09121998A0663|132 143|transit time
14P09121998A0663|144 146|MTT
14P09121998A0663|169 177|test meal
14P09121998A0663|208 210|F90
14P09122168A1427|24 36|demonstration
14P09122168A1427|47 57|G betagamma
14P09122168A1427|89 101|translocation
14P09122168A1427|104 107|GRK2
14P09122168A1427|111 114|GRK3
14P09122168A1427|154 172|isoform specificity
14P09122176A0970|80 86|RAR/RXR
14P09122176A0970|103 121|RA response element
14P09122198A0478|0 14|Point mutations
14P09122198A0478|23 39|tyrosine residues
14P09122215A0335|16 21|method
14P09122215A0335|80 88|mutations
14P09122215A0335|100 107|interest
14P09123055T0000|55 56|UW
14P09123055T0000|60 71|HTK solution
14P09123787A0486|59 69|R1 response
14P09123787A0486|74 109|orbicularis oculi muscle ipsilateral
14P09123787A0486|164 165|R2
14P09123787A0486|182 183|Rc
14P09123787A0486|195 205|R3 response
14P09123787A0486|222 245|orbicularis oculi muscle
14P09124054A1164|38 42|ABSCT
14P09126487A1399|6 8|Hum
14P09126622A0466|3 19|pigment intensity
14P09126622A0466|58 74|CAL transformants
14P09128730A0000|8 22|decarboxylation
14P09128730A0000|25 41|Malonomonas rubra
14P09128730A0000|74 93|acyl-carrier protein
14P09128730A0000|108 127|acyl-carrier protein
14P09128730A0000|140 155|carboxyltransfer
14P09128730A0000|159 172|biotin protein
14P09128730A0000|178 192|decarboxylation
14P09129147A0644|3 22|Jem peptide sequence
14P09129147A0644|81 87|Fos/Jun
14P09129147A0644|91 107|ATF/CREB proteins
14P09129147A0644|125 145|phosphorylation sites
14P09130595A0478|45 57|enhancer site
14P09130700A0676|37 41|Tub4p
14P09130700A0676|43 48|Spc98p
14P09130700A0676|52 57|Spc97p
14P09130700A0676|86 105|SPC97 overexpression
14P09130700A0676|124 140|co-overexpression
14P09130700A0676|143 146|TUB4
14P09130700A0676|149 153|SPC98
14P09130718A0497|0 8|Sequences
14P09130718A0497|106 108|ATG
14P09130720A0417|35 52|branch site region
14P09130720A0417|86 101|TACTAAC sequence
14P09130720A0417|116 133|intron recognition
14P09131139T0000|0 10|Implication
14P09131139T0000|13 15|PAF
14P09131139T0000|19 33|acetylhydrolase
14P09131139T0000|35 40|PAF-AH
14P09132011A0298|0 9|Comparison
14P09132011A0298|15 26|p50 sequence
14P09132011A0298|121 157|Drosophila cell cycle control protein
14P09132057A0559|24 26|NTS
14P09132057A0559|48 66|sequence similarity
14P09132057A0559|95 118|receptor protein kinases
14P09132057A0559|139 156|S-receptor kinases
14P09132057A0559|195 210|Brassica species
14P09132057A0559|216 231|Pto gene product
14P09132061A0828|21 34|cDNA sequences
14P09132061A0828|73 86|isoperoxidases
14P09132061A0828|128 131|ESTs
14P09133122A0656|10 20|information
14P09133122A0656|70 84|video sequences
14P09133122A0656|85 98|x-ray analysis
14P09133122A0656|99 108|angiograms
14P09135066A0653|36 39|Mek1
14P09135066A0653|53 59|p96h2bk
14P09135066A0653|83 85|Ras
14P09135149A0000|59 68|Cdc2/Cdc13
14P09135149A0000|104 107|Wee1
14P09135149A0000|111 131|Mik1 tyrosine kinases
14P09135149A0000|145 149|Cdc25
14P09135149A0000|153 178|Pyp3 tyrosine phosphatases
14P09135772T0000|8 15|response
14P09135772T0000|34 39|roller
14P09135772T0000|75 82|subjects
14P09135928A0912|37 48|BP responses
14P09135928A0912|61 74|norepinephrine
14P09135928A0912|78 88|angiotensin
14P09135928A0912|116 128|glibenclamide
14P09136015A0529|3 12|sequencing
14P09136015A0529|89 103|diversification
14P09136080A1469|22 36|DNA methylation
14P09136080A1469|37 55|chromatin structure
14P09136080A1469|59 73|transactivation
14P09136080A1469|78 85|Sp1 site
14P09138076A1099|2 26|gel mobility shift assays
14P09138076A1099|98 119|oligonucleotide probes
14P09138076A1099|132 136|E-box
14P09138076A1099|141 145|E-box
14P09138492A0806|0 14|Laboratory exam
14P09138492A0806|15 17|IDR
14P09138492A0806|49 65|chest radiography
14P09138492A0806|84 97|calcifications
14P09138492A0806|99 106|ORL exam
14P09138492A0806|189 208|epidermoid carcinoma
14P09139665A0784|18 31|PhLP complexes
14P09139665A0784|53 62|Gbetagamma
14P09139694A0789|0 8|CTF1alpha
14P09139694A0789|74 85|DNA fragment
14P09139694A0789|123 135|DNA fragments
14P09139694A0789|163 171|CTF1alpha
14P09139721A0183|0 8|Cyclin G2
14P09139721A0183|58 75|tolerance subjects
14P09139721A0183|88 98|lymphocytes
14P09139737A0000|108 113|SREBPs
14P09139737A0000|119 132|cell membranes
14P09139737A0000|183 195|transcription
14P09139737A0000|225 233|synthesis
14P09139737A0000|236 246|cholesterol
14P09139892A1150|27 39|vfr promoters
14P09139892A1150|65 75|orientation
14P09139892A1150|101 111|orientation
14P09139892A1150|124 136|crp promoters
14P09139910A0350|0 16|Sequence analysis
14P09139910A0350|24 35|PCR products
14P09139910A0350|78 90|DNA fragments
14P09139910A0350|161 180|clone XbaI fragments
14P09139910A1572|14 28|Anabaena strain
14P09139910A1572|59 71|nifV mutation
14P09139910A1572|73 77|R229I
14P09140079A2528|34 36|TRs
14P09140079A2528|44 46|TRE
14P09140474T0000|2 14|leishmaniasis
14P09140474T0000|35 41|Minorca
14P09140474T0000|43 47|Spain
14P09140474T0000|88 94|Minorca
14P09142146A0887|0 6|RESULTS
14P09142146A0887|21 32|PAF blockade
14P09142146A0887|67 82|WEB-2086 animals
14P09142146A0887|92 106|vehicle animals
14P09143328A1002|59 77|dinucleotide primer
14P09143328A1002|81 94|RNA polymerase
14P09143465A0838|4 5|T1
14P09143465A0838|9 22|dual-T1 images
14P09143465A0838|46 58|image quality
14P09143465A0838|59 60|IQ
14P09144165A0614|40 43|NFAT
14P09144165A0614|51 54|AP-1
14P09144165A0614|60 76|Rel insert region
14P09144165A0614|76 78|RIR
14P09144165A0614|108 123|hypervariability
14P09144165A0614|162 192|Rel transcription factor family
14P09144165A1275|21 28|NFAT RIR
14P09144165A1275|54 68|DNA recognition
14P09144165A1275|91 123|AP-1 family transcription factors
14P09144195A1051|21 33|PS1 fragments
14P09144195A1051|62 94|phosphorylation/dephosphorylation
14P09144195A1051|100 106|PS1 CTF
14P09144770A0906|22 25|Type
14P09144770A0906|77 98|FKBP12 binding surface
14P09144958A0047|44 54|Arabidopsis
14P09144958A0047|71 98|chlorophyll a/b protein gene
14P09144958A0047|97 101|Lhcb1
14P09146027A0809|10 16|Group B
14P09146027A0809|25 35|athetoid CP
14P09146027A0809|39 48|spasticity
14P09146071T0001|51 68|pontine hemorrhage
14P09147420A0623|28 39|HCMV IE1/IE2
14P09147420A0623|68 76|HIV-1 LTR
14P09147420T0000|0 2|TAR
14P09147420T0000|21 35|transactivation
14P09147420T0000|38 40|HIV
14P09147420T0000|64 74|Tat protein
14P09147420T0000|94 116|cytomegalovirus IE1/IE2
14P09147788A0458|11 31|chain enzyme activity
14P09147832A0174|0 7|Children
14P09147832A0174|10 20|temperament
14P09147832A0174|32 44|socialization
14P09147832A0174|47 50|Time
14P09147832A0174|86 95|predictors
14P09147832A0174|104 113|conscience
14P09148770A0977|8 10|Csk
14P09148770A0977|35 49|phosphoproteins
14P09148770A0977|84 97|Csk SH2 domain
14P09148903A1715|49 66|HIV-1 LTR activity
14P09148903A1715|107 136|NF-kappaB transcription factor
14P09148903A1715|153 187|IkappaBalpha serine phosphorylation
14P09148929A0372|3 4|P1
14P09148929A0372|33 49|plasmid subclones
14P09148929A0372|106 115|Ctpct gene
14P09148935A0805|13 30|c-Src PTK activity
14P09148935A0805|46 64|type FAK expression
14P09148935A0805|96 99|ERK2
14P09148935A0805|127 159|c-Src binding site Phe-397 mutant
14P09148935A0805|158 160|FAK
14P09149825A0151|20 33|4-META/MMA-TBB
14P09149825A0151|85 95|bone cement
14P09149929A0750|22 32|predictions
14P09149929A0750|49 56|children
14P09149929A0750|80 91|homesickness
14P09149929A0750|95 104|separation
14P09150334A0559|4 9|sample
14P09150334A0559|71 78|sampling
14P09150566A0316|32 40|formation
14P09150566A0316|43 59|complex molecules
14P09150595A0225|44 45|HR
14P09150595A0225|57 71|E. chrysanthemi
14P09150595A0225|72 80|HarpinEch
14P09150595A0225|85 96|E. amylovora
14P09150595A0225|97 104|HarpinEa
14P09150595A0225|152 166|signal sequence
14P09150595T0000|9 24|characterization
14P09150595T0000|43 73|Erwinia carotovora hrpNEcc gene
14P09150728A0596|26 29|HES1
14P09150774A0616|0 9|Anesthesia
14P09150774A0616|38 40|ISO
14P09150774A0616|43 45|N2O
14P09151152A0174|21 38|protein C activity
14P09151152A0174|103 114|hemodialysis
14P09151152A0174|130 139|factor VII
14P09151152A0174|170 183|heparinization
14P09151152A0174|204 220|serum lipoprotein
14P09151376A0000|22 45|hyperbetalipoproteinemia
14P09151806A1125|37 39|LAT
14P09151806A1125|55 67|mLAT pre-mRNA
14P09151806A1125|78 89|branch point
14P09151828A0919|10 28|amino acid residues
14P09151828A0919|43 60|9ORF1 polypeptides
14P09151837A0723|7 25|protein interaction
14P09151837A0723|51 83|coimmunoprecipitation experiments
14P09151837A0723|222 253|transcription-translation system
14P09151925A0479|3 7|C-LIP
14P09151925A0479|59 61|TAE
14P09151925A0479|63 67|C-LIP
14P09151925A0479|107 131|ethanol injection therapy
14P09151925A0479|131 134|PEIT
14P09152656A0149|20 51|New York Heart Association class
14P09153010A0499|65 68|MUPs
14P09153010A0499|104 107|MUPs
14P09153010A0499|160 173|threshold MUPs
14P09153010A0499|201 204|MUPs
14P09153010A0499|214 228|reproducibility
14P09153010A0499|257 272|reference values
14P09153010A0499|291 302|laboratories
14P09153319A0844|30 38|triplexes
14P09153319A0844|73 79|ethanol
14P09153319A1332|0 23|Transfection experiments
14P09153319A1332|79 104|collagen promoter sequence
14P09153319A1332|162 189|control phosphorothioate ODN
14P09153348A0647|57 91|mineralocorticoid steroid secretion
14P09153348A0647|97 114|cortisol secretion
14P09153348A0647|175 187|HIV-infection
14P09153795A0298|19 22|RDFS
14P09153795A0298|41 51|reliability
14P09154283A0307|0 10|Latanoprost
14P09154283A0307|62 64|IOP
14P09154283A0307|111 123|acetazolamide
14P09154621A1475|30 52|safflower phospholipids
14P09154621A1475|95 113|liver triglycerides
14P09154621A1475|116 132|serum cholesterol
14P09154795A0628|84 102|DNA polymerase beta
14P09154797A0777|9 28|spermidine transport
14P09154797A0777|36 47|lacZ mutants
14P09154797A0777|103 106|Vmax
14P09154819A0501|37 57|tenascin-C expression
14P09154819A0501|66 68|REF
14P09154819A0501|74 78|FR3T3
14P09154819A0501|93 112|fibroblast cell line
14P09154822T0000|0 9|Inhibition
14P09154822T0000|15 26|Raf-1 kinase
14P09154822T0000|34 45|AMP agonists
14P09154827A0158|33 49|hamster cell line
14P09154827A0158|59 72|point mutation
14P09154827A0158|77 79|TAF
14P09154827A0158|84 91|250/CCG1
14P09154827A0158|93 95|TAF
14P09154827A0158|176 177|G1
14P09155015A0140|17 36|protein kinase MEKK1
14P09155015A0140|44 67|reporter gene expression
14P09155015A0140|97 99|ANF
14P09155024A0955|0 13|Overexpression
14P09155024A0955|16 19|EFG1
14P09155024A0955|22 32|C. albicans
14P09155024A0955|83 94|pseudohyphae
14P09156883A0294|29 30|HR
14P09156883A0294|41 54|blood pressure
14P09156883A0294|55 57|ABP
14P09156883A0294|83 86|SaO2
14P09157100A0583|53 55|SIB
14P09157337A0545|82 103|Infectology Department
14P09157760A0000|67 79|peculiarities
14P09157760A0000|82 88|Meynart
14P09157760A0000|178 188|individuals
14P09159111A0437|55 56|CD
14P09159111A0437|61 75|NMR experiments
14P09159111A0437|80 89|Skn domain
14P09159160A0000|10 16|cloning
14P09159160A0000|38 46|sequences
14P09159160A0000|91 98|diseases
14P09159183A0119|0 4|Genes
14P09159183A0119|8 34|ocs element binding factors
14P09159183A0119|33 36|OBFs
14P09159183A0119|66 92|basic-region leucine zipper
14P09159183A0119|97 117|transcription factors
14P09160361A0858|9 17|mortality
14P09160361A0858|23 31|CPB group
14P09160881A0491|18 41|co-precipitation studies
14P09160881A0491|94 105|interactions
14P09162084A0956|36 49|Src-SH2 domain
14P09162084A0956|57 63|PECAM-1
14P09162084A0956|84 110|GST-Src-SH2 affinity matrix
14P09162092A0675|0 23|MKK3 autophosphorylation
14P09162092A0675|38 40|p38
14P09162092A0675|79 82|MKK3
14P09162092A0675|87 91|MEKK3
14P09162092A0675|103 107|MEKK2
14P09162097A0776|22 37|MAdCAM-1 variant
14P09162097A0776|100 117|leukocyte adhesion
14P09162097A0776|119 124|LPAM-1
14P09162097A0776|163 172|L-selectin
14P09162097A1258|56 68|MAdCAM-1 cDNA
14P09162097A1258|103 116|mouse MAdCAM-1
14P09162097A1258|129 143|dissimilarities
14P09162097A1258|149 156|MAdCAM-1
14P09163332A0275|24 43|mutagenesis approach
14P09163332A0275|58 60|Xaa
14P09163332A0275|72 78|Ser/Thr
14P09163332A0275|80 98|amino acid residues
14P09164543A0219|0 7|MATERIAL
14P09164543A0219|11 17|METHODS
14P09164856A0980|38 49|TATA element
14P09164856A0980|64 76|transcription
14P09164856A0980|82 97|glutaminase gene
14P09165004A1700|0 11|SRE activity
14P09165004A1700|41 55|phosphorylation
14P09165004A1700|66 79|complex factor
14P09165004A1700|103 117|complex factors
14P09165004A1700|119 123|Elk-1
14P09165035A0842|0 34|Serum alkaline phosphatase activity
14P09165035A0842|33 54|bone mass measurements
14P09165035A0842|93 107|mineral density
14P09165035A0842|121 134|testing values
14P09165039A0728|3 17|monkey LHR cDNA
14P09165039A0728|38 54|sequence homology
14P09165039A0728|75 83|LHR cDNAs
14P09165039A1372|13 31|marmoset monkey LHR
14P09165039A1372|78 85|LHR gene
14P09165118A0311|15 30|VA motor neurons
14P09165118A0311|105 120|VB motor neurons
14P09165118A0311|145 147|VAs
14P09165118A0311|176 190|movement defect
14P09167421A0234|13 23|irradiation
14P09167421A0234|42 59|microSelectron HDR
14P09167421A0234|91 92|Gy
14P09168083A0987|26 28|HAT
14P09168134A0858|0 18|Sequence comparison
14P09168134A0858|27 46|kb promoter sequence
14P09168134A0858|66 74|Sm-E gene
14P09168134A0858|77 90|U1 snRNA genes
14P09168134A0858|151 166|snRNP components
14P09168218A0216|0 6|METHODS
14P09168218A0216|58 75|pain syndrome type
14P09168218A0216|153 166|ganglion block
14P09168511A0640|30 41|developments
14P09168511A0640|76 93|steroid budesonide
14P09168511A0640|100 112|dexamethasone
14P09168623A0614|39 51|mxbD promoter
14P09168623A0614|66 75|expression
14P09168623A0614|99 108|one-carbon
14P09168623A0614|110 111|C1
14P09168623A0614|113 121|compounds
14P09168623A0614|137 146|expression
14P09168623A0614|161 169|succinate
14P09168879A0219|30 53|transcription initiation
14P09168879A0219|82 91|TAAG sites
14P09168879A0219|116 125|TAAG sites
14P09168892A1016|0 7|Mutation
14P09168892A1016|34 37|AP-1
14P09168892A1016|71 86|trans-activation
14P09169127A0371|25 53|neuropeptide Y receptor genes
14P09169127A0371|83 104|gene duplication event
14P09169127A0371|155 161|y1 gene
14P09169127A0371|207 213|y5 gene
14P09169127A0371|297 303|y1 gene
14P09169420A0000|12 37|phosphoinositide 3-kinases
14P09169420A0000|38 42|PI3Ks
14P09169420A0000|44 52|p110alpha
14P09169420A0000|62 84|delta form heterodimers
14P09169420A0000|87 98|Src homology
14P09169420A0000|100 102|SH2
14P09169420A0000|135 142|p85alpha
14P09169420A0000|145 147|p55
14P09169420A0000|149 151|PIK
14P09169475A0272|81 110|transcription initiation sites
14P09169475A0772|0 11|Localization
14P09169475A0772|17 41|cytokine response element
14P09169475A0772|45 61|deletion analysis
14P09169475A0772|130 143|STAT complexes
14P09169593T0000|0 17|Insulin regulation
14P09169593T0000|36 56|protein kinase kinase
14P09169593T0000|56 58|MEK
14P09169593T0000|78 91|protein kinase
14P09169593T0000|153 167|gene expression
14P09169852A0235|0 9|Sequencing
14P09169852A0235|20 32|pag-3 alleles
14P09169852A0235|71 87|nonsense mutation
14P09169852A0235|96 107|zinc fingers
14P09169852A0235|111 127|missense mutation
14P09169853A0000|0 4|Pax-3
14P09169853A0000|19 31|homeobox gene
14P09170159A0348|57 71|marker proteins
14P09170159A0348|77 86|tyrosinase
14P09170159A0721|98 104|HLH-Zip
14P09170159A0721|107 119|Zip structure
14P09171038A0219|12 18|Sjogren
14P09171038A0219|80 89|complaints
14P09171038A0219|114 120|Sjogren
14P09171081T0000|0 6|Cloning
14P09171081T0000|10 25|characterization
14P09171081T0000|60 73|RNA polymerase
14P09171081T0000|86 108|plant Chenopodium album
14P09171235A0851|51 58|COUP-TFI
14P09171235A0851|66 81|COUP-TFI delta35
14P09171235A0851|95 112|silencing activity
14P09171235A0851|127 132|TRbeta
14P09171239A1118|78 94|hormone receptors
14P09171239A1118|139 162|transactivation function
14P09171239A1118|163 166|AF-2
14P09171239A2146|68 72|SRC-1
14P09171239A2146|78 90|RXR component
14P09171363A0149|2 9|ciliates
14P09171363A0149|15 24|mechanisms
14P09171389A0549|29 49|transcription signals
14P09171389A0549|54 80|Thermus pyr promoter region
14P09171389A0549|87 116|amino acid sequence identities
14P09171389A0549|131 142|Thermus PyrR
14P09171389A0549|148 172|PyrR attenuation proteins
14P09171389A0549|176 187|Bacillus sp.
14P09171389A0549|261 279|pyr gene expression
14P09171389A0549|280 286|Thermus
14P09171468T0000|0 4|Diver
14P09171468T0000|49 67|breathing apparatus
14P09171969A1165|0 10|Measurement
14P09171969A1165|30 32|VO2
14P09171969A1165|61 78|work rate exercise
14P09171969A1165|116 130|training effect
14P09171969A1165|144 147|COPD
14P09172312T0000|0 15|Characterization
14P09172312T0000|18 27|CR1 repeat
14P09172312T0000|33 43|PCR markers
14P09172414A0000|53 56|HPLC
14P09172414A0000|70 82|determination
14P09172414A0000|85 103|cocaine metabolites
14P09172414A0000|128 142|liver esterases
14P09172641A0181|24 31|evidence
14P09172641A0181|59 69|side chains
14P09172641A0181|71 79|subdomain
14P09172641A0181|95 102|contacts
14P09172641A0181|110 120|nucleotides
14P09172812A0660|50 52|CLL
14P09173733A0404|26 36|EA analysis
14P09173733A0404|61 82|Fourier transformation
14P09173733A0404|83 85|FFT
14P09173733A0404|89 90|EA
14P09173733A0404|164 173|EEG curves
14P09173733A0404|203 217|factor analysis
14P09173733A0404|222 223|EA
14P09174049A1788|14 47|p34CDC2 histone H1 kinase activity
14P09175708A1526|5 9|PRL-R
14P09175708A1526|84 94|possibility
14P09175858A1449|8 17|B-S mutant
14P09175858A1449|56 61|GAPDHs
14P09175858A1449|250 254|GAPDH
14P09176340A1194|0 12|Transcription
14P09176340A1194|58 65|freezing
14P09176340A1194|70 80|mRNA levels
14P09176837A0211|0 16|Computer software
14P09176837A0211|33 36|CSAO
14P09176837A0211|61 65|PN Ca
14P09176837A0211|66 77|P solubility
14P09176837A0211|117 132|P administration
14P09177169A0935|8 14|chimera
14P09177169A0935|48 55|molecule
14P09177169A0935|86 93|bacteria
14P09177857A0000|25 40|titanium dioxide
14P09177857A0000|47 79|substrates titanium tetrachloride
14P09177857A0000|159 191|chemical vapour deposition method
14P09178269A0107|6 10|genes
14P09178491A0262|30 55|preS2/S gene transcription
14P09178491A0262|59 73|HBV adw subtype
14P09178491A0262|84 91|TATA box
14P09178494A1123|82 96|loop structures
14P09178494A1123|121 132|flaviviruses
14P09178494A1123|165 176|preservation
14P09178494A1123|188 190|RNA
14P09178494A1123|200 209|structures
14P09178494A1123|255 265|replication
14P09178752A0574|0 2|EGF
14P09178752A0574|25 51|transactivation domain AF-1
14P09178752A0574|69 95|transactivation domain AF-2
14P09178752A0574|99 100|ER
14P09180687A0096|24 27|SulA
14P09180687A0096|57 69|cell division
14P09180687A0096|126 129|SulA
14P09180687A0096|142 169|alanine substitution mutants
14P09181130A1067|17 23|Krox-20
14P09181130A1067|51 58|ES cells
14P09181130A1067|108 109|r3
14P09181130A1067|113 114|r5
15P09181130A1587a|58 68|populations
15P09181130A1587a|118 124|Krox-20
15P09181130A1587a|130 141|segmentation
15P09181130A1587a|163 174|consequences
15P09181130A1587a|180 191|inactivation
14P09182281A0197|30 42|Cyclosporin A
14P09182527A0443|23 40|p53 ubiquitination
14P09182527A0443|87 92|Nedd-4
14P09182707A0254|0 2|SPP
14P09182707A0254|23 46|tyrosine phosphorylation
14P09182707A0254|68 71|p125
14P09182707A0254|73 75|FAK
14P09182707A0254|164 179|protein paxillin
14P09182990A0245|38 42|SUP45
14P09182990A0245|128 137|SUP45 gene
14P09182990A0245|138 143|Sup45p
14P09182990A0245|171 193|translation termination
14P09183145T0001|0 9|Evaluation
14P09183145T0001|50 54|SPECT
14P09183406A0637|19 34|thrombocytopenia
14P09183406A0637|41 46|HPA-3a
14P09183406A0637|48 51|Baka
14P09183406A0637|53 67|incompatibility
14P09185183A0089|56 64|worsening
14P09185183A0089|67 81|motor abilities
14P09185183T0000|0 6|Merosin
14P09185183T0000|74 84|MRI changes
14P09185586A0000|36 52|scanning ribosome
14P09185645T0000|0 9|Comparison
14P09185645T0000|12 45|Tc-99m sestamibi perfusion imaging
14P09185645T0000|69 87|arbutamine infusion
14P09186056A0514|14 27|overexpression
14P09186056A0514|43 53|C2C12 cells
14P09186056A0514|79 90|CAT-reporter
14P09186056A0514|104 111|E12/MyoD
14P09186430A0341|37 44|albinism
14P09186507A0882|116 125|CpG island
14P09186507A0882|131 134|TATA
14P09186507A0882|138 147|CAAT boxes
14P09186507A0882|164 174|G+C content
14P09186507A0882|189 205|CpG dinucleotides
14P09187136A0000|0 5|SSeCKS
14P09187136A0000|36 61|protein kinase C substrate
14P09187136A0000|178 179|X.
14P09187277A0118|0 3|Type
14P09187277A0118|5 29|position-vestibular-pause
14P09187277A0118|31 35|PVP I
14P09187277A0118|55 57|V I
14P09187371A0450|16 27|mRNA species
14P09187371A0450|63 69|species
14P09187371A0450|89 94|kidney
14P09187371A0450|120 125|muscle
14P09187637A1199|0 17|Taurine deficiency
14P09187637A1199|53 55|OP1
14P09187637A1199|59 61|OP4
14P09188094A0934|39 48|activation
14P09188094A0934|51 54|Spc1
14P09188094A0934|57 64|response
14P09188699A1388|77 88|SP-A species
14P09188699A1388|99 111|SDS-PAGE gels
14P09188863A0954|21 26|CDC25B
14P09188863A0954|63 80|cell proliferation
14P09189783A0000|4 16|investigation
14P09189783A0000|90 101|carbohydrate
14P09189783A0000|103 105|CHO
14P09189783A0000|142 154|blood glucose
14P09189783A0000|157 173|insulin responses
14P09189896A0611|22 32|ERP effects
14P09189896A0611|42 57|memory processes
14P09190202A0166|25 29|Sar1p
14P09190202A0166|34 55|Sec23p protein complex
14P09190202A0166|64 69|Sec23p
14P09190202A0166|73 78|Sec24p
14P09190202A0166|86 107|Sec13p protein complex
14P09190202A0166|116 121|Sec13p
14P09190202A0166|146 149|p150
14P09190821A0707|70 74|P243L
14P09190940A0127|0 8|Induction
14P09190940A0127|27 46|germline transcripts
14P09190940A0127|66 78|switch region
14P09190940A0127|81 93|recombination
14P09191052A0850|8 10|PCE
14P09191052A0850|17 33|Pbx dimer partner
14P09191052A0850|55 66|Hox proteins
14P09192732A1384|27 33|portion
14P09192732A1384|39 47|homologue
14P09192732A1384|78 85|membrane
14P09192769T0000|19 34|characterization
14P09192769T0000|43 48|CHEMR1
14P09192769T0000|59 76|chemokine receptor
14P09192769T0000|99 120|C-C chemokine receptor
14P09192769T0000|120 124|CCR-4
14P09192786T0000|0 11|Organization
14P09192786T0000|22 28|LU gene
14P09192786T0000|50 51|Lu
14P09192786T0000|56 57|Lu
14P09192786T0000|61 84|blood group polymorphism
14P09192842A0988|33 45|FISH analysis
14P09192842A0988|49 57|PE-2 gene
14P09192842A0988|75 92|chromosome 19q13.2
14P09192842A0988|110 123|translocations
14P09192842A0988|192 201|ETS factor
14P09192842A0988|215 228|carcinogenesis
14P09192998A0356|61 66|T7 DNA
14P09192998A0356|113 129|termination sites
14P09192998A0356|163 165|PTH
14P09192998A0356|169 178|CJ signals
14P09193072A0199|29 38|transgenes
14P09193072A0199|53 61|nucleolus
14P09193077A0000|21 24|LRU1
14P09193077A0000|92 108|chalcone synthase
14P09193077A0000|109 111|CHS
14P09193077A0000|130 149|Petroselinum crispum
14P09193080A0904|0 18|Sequence divergence
14P09193671A0347|45 47|GTP
14P09193671A0347|66 72|ARF-GDP
14P09194250A0708|25 36|World Summit
14P09194250A0708|39 46|Children
14P09194250A0708|59 74|mortality target
14P09194250A0708|129 140|inequalities
14P09195923A0125|31 35|FK506
14P09195923A0125|39 65|cyclosporin A-binding class
14P09195923A0125|83 106|tetratricopeptide repeat
14P09195923A0125|107 109|TPR
14P09195923A0125|130 153|receptor heterocomplexes
14P09197241A0770|31 34|CD45
14P09197241A0770|43 62|hyperphosphorylation
14P09197241A0770|66 80|hyperactivation
14P09197241A0770|83 88|p56/59
14P09197241A0770|97 102|p53/56
14P09197241A0770|117 119|p58
14P09197342T0000|0 8|Secretion
14P09197342T0000|57 67|Lipiodol UF
14P09197342T0000|70 76|Oriodol
14P09197408A0126|0 9|Sequencing
14P09197408A0126|85 86|Zn
14P09197408A0126|91 95|2Cys6
14P09197408A0126|99 105|C6 zinc
14P09197408A0126|125 135|DNA binding
14P09197408A0126|154 173|heptad repeat motifs
14P09199167A0942|0 13|Overexpression
14P09199167A0942|16 20|Sed5p
14P09199167A0942|48 52|Vti1p
14P09199286A0086|9 14|region
14P09199286A0086|74 80|protein
14P09199292A0536|38 41|p107
14P09199292A0536|44 47|p130
14P09199292A0536|58 70|cyclin E-cdk2
14P09199292A0536|72 84|cyclin A-cdk2
14P09199318A1147|12 15|p150
14P09199318A1147|62 81|muscle alpha-actinin
14P09199322T0000|0 11|Denaturation
14P09199322T0000|64 85|replication protein A.
14P09199327A1250|29 36|EM motif
14P09199327A1250|110 133|transactivation function
14P09199327A1250|138 146|TEF-1-Max
14P09199327A1250|206 213|EM motif
14P09199328T0000|42 45|VP16
14P09199328T0000|58 62|Oct-1
14P09199328T0000|64 66|HCF
14P09199328T0000|71 73|DNA
14P09199348A0156|36 51|U14 interactions
14P09199348A0156|112 119|U14 RNAs
14P09199348A0156|123 130|Y domain
14P09199353A1924|29 33|Cdc68
14P09199353A1924|65 83|chromatin structure
14P09199353A1924|99 114|polymerase alpha
14P09199353A1924|180 190|replication
14P09199413A0518|11 23|inoculum size
14P09199413A0518|53 61|CFU/mouse
14P09199626A0613|4 8|cases
14P09199626A0613|17 22|change
14P09199626A0613|25 29|stage
14P09199932A1357|0 30|Promoter recognition algorithms
14P09199932A1357|48 64|promoter elements
14P09199932A1357|73 82|CpG island
14P09199932A1357|102 104|ATM
14P09199932A1357|108 121|E14/NPAT genes
14P09199932A1357|158 169|ATM promoter
14P09199970A1101|32 44|transmembrane
14P09199970A1101|76 92|cofactor activity
14P09199970A1101|94 105|C3b cleavage
14P09199970A1101|169 171|MCP
14P09200029A0211|108 130|bone marrow examination
14P09200498T0000|15 33|muscle coactivation
14P09200530A0411|0 5|Liquid
14P09200530A0411|45 56|Zorbax RX C8
14P09200530A0411|76 91|gradient elution
14P09200811T0000|81 108|pGKL1-plasmid DNA polymerase
14P09201946A0000|24 42|helicase activities
14P09201946A0000|62 97|transcription termination factor rho
14P09201946A0000|127 139|RNA molecules
14P09201946A0000|155 173|nucleotide residues
14P09201946A0000|216 235|termination sequence
14P09201980A0910|3 16|p20-CGGBP gene
14P09202147A0866|46 54|subfamily
14P09202147A0866|57 59|UBC
14P09202147A0866|98 108|degradation
14P09202669A0614|23 25|AAV
14P09202669A0614|83 111|herpes virus thymidine kinase
14P09202669A0614|131 149|neomycin resistance
14P09202669A1530|29 48|gene transfer system
14P09202669A1530|53 69|rat preproinsulin
14P09202859A0091|48 50|HCG
14P09202859A0091|64 83|alkaline phosphatase
14P09202859A0091|84 87|PLAP
14P09203585A0660|32 41|H19 allele
14P09203585A0660|82 105|neo replacement cassette
14P09203586A1197|35 43|T antigen
14P09203586A1197|62 64|SL1
14P09203586A1197|93 110|activation process
14P09203731A0497|9 32|International Commission
14P09203731A0497|66 90|Poliomyelitis Eradication
14P09203731A0497|91 95|ICCPE
14P09203731A0497|116 147|Pan American Health Organization
14P09204566T0000|65 99|Rhizobium leguminosarum strain VF39
14P09204570A0110|22 34|MADS box gene
14P09204570A0110|59 60|J.
14P09205113A0587|4 6|E14
14P09205113A0587|9 13|TG3B1
14P09205113A0587|23 34|ES cell line
14P09205113A0587|67 75|HPRT gene
14P09205113A0587|78 93|selection marker
14P09205113A0587|134 148|mouse germ line
14P09205677A0577|0 3|Lung
14P09205677A0577|34 43|indicators
14P09205965A1249|60 74|bladder filling
14P09205965A1249|77 82|L-dopa
14P09205965A1249|144 171|spinal alpha 1-adrenoceptors
14P09206230A0000|0 8|OBJECTIVE
14P09206230A0000|71 81|astigmatism
14P09206968A0000|0 10|Disturbance
14P09206968A0000|13 24|regeneration
14P09206968A0000|78 91|tunica propria
14P09206968A0000|136 146|homeostasis
14P09208214A0572|0 18|Sternocleidomastoid
14P09208930T0000|0 13|Identification
14P09208930T0000|48 64|interleukin-1beta
14P09209031A0350|49 72|serine carboxypeptidases
14P09209312A0968|3 15|RNA construct
14P09209312A0968|34 44|nucleotides
14P09209312A0968|99 101|RNA
14P09209312A0968|121 131|nucleotides
14P09209372A0345|21 25|AML1a
14P09209372A0345|125 129|AML1b
14P09209372A0345|138 142|AML1a
14P09209372A0345|186 190|AML1b
14P09209406A1021|46 80|guanine nucleotide exchange factors
14P09209438A0994|13 19|ATL-16T
14P09209438A0994|53 58|GATA-4
14P09209438A0994|132 140|GATA site
14P09210012A0000|29 41|relationships
14P09210478A0000|50 54|HIF-1
14P09211354A0000|0 12|Stromelysin-1
14P09211354A0000|14 39|matrix metalloproteinase-3
14P09211354A0000|40 44|MMP-3
14P09211605A0478|0 5|Tendon
14P09211605A0478|24 36|extensibility
14P09211675A0392|0 11|Surveillance
14P09211675A0392|15 26|preeclampsia
14P09211675A0392|74 84|assignments
14P09211675A0392|103 114|measurements
14P09211675A0392|117 130|blood pressure
14P09211675A0392|140 156|protein excretion
14P09211675A0392|218 229|measurements
14P09211675A0392|239 253|hospitalization
14P09211675A0392|305 321|outpatient visits
14P09211675A0392|327 342|hospitalizations
14P09211913A0000|0 24|Aryl hydrocarbon receptor
14P09211913A0000|43 46|ARNT
14P09211913A0000|65 85|transcription factors
14P09211913A0000|86 110|aryl hydrocarbon receptor
14P09211913A0000|110 112|AhR
14P09211913A0000|183 188|CYP1A1
14P09211934A0722|0 4|DNase
14P09211934A0722|6 23|footprint analysis
14P09211981A0526|55 57|p13
14P09211981A0526|179 181|p34
14P09212059A1356|21 55|metal affinity chromatography assay
14P09212059A1356|72 75|PR-A
14P09212059A1856|82 84|LBD
14P09212059A1856|112 126|PR dimerization
14P09212059A1856|231 246|homodimerization
14P09212059A1856|249 250|PR
14P09212063A0425|28 34|A-phage
14P09212063A0425|79 81|DNA
14P09212063A0425|103 110|VDR gene
14P09214274T0001|67 86|metastasis resection
14P09215525A0581|50 65|E2F/DP complexes
14P09215525A0581|93 106|C2C12 myocytes
14P09215891A0000|39 42|CIN1
14P09215891A0000|44 47|CIN2
14P09215891A0000|51 60|CIN4 genes
14P09215891A0000|110 129|microtubule function
14P09216017A0621|0 9|Vitrectomy
14P09216017A0621|30 40|risk factor
14P09216936T0000|7 15|editorial
14P09216936T0000|43 50|exercise
14P09216936T0000|53 65|leptin levels
14P09218436A0443|18 25|TATA box
14P09218436A0443|29 32|Pint
14P09218436A0443|45 55|MED-1 class
14P09218459A0000|0 20|Serum response factor
14P09218459A0000|20 22|SRF
14P09218459A0000|104 123|transcription factor
14P09218520A0075|32 59|candidate signal transducers
14P09218520A0075|102 106|IL-1R
14P09218599A0184|84 87|IL-4
14P09218775A0000|64 65|CF
14P09218775A0000|95 108|overproduction
14P09218775A1229|0 7|Activity
14P09218775A1229|33 35|CHA
14P09218775A1229|100 115|algD-xylE fusion
14P09219526A0383|19 29|specificity
14P09219526A0383|35 48|cDNA construct
14P09219526A0383|64 74|observation
14P09219526A0383|82 98|peptide sequences
14P09220158A0537|113 117|ORF-2
14P09220158A0537|121 149|baculovirus expression vector
14P09220158A0537|185 193|Sf9 cells
14P09220177A0564|3 18|CPK-MB isoenzyme
14P09220177A0564|26 44|percentage increase
14P09220177A0564|51 53|CPK
14P09220177A0564|136 148|cardioversion
14P09222057A0176|0 4|Serum
14P09222057A0176|18 31|dialysis fluid
14P09222057A0176|32 34|PDF
14P09222115A0545|0 6|Results
14P09222115A0545|97 108|binding site
14P09222115A0545|138 160|response characteristic
14P09222115A0545|203 214|surroundings
14P09223042A0000|0 4|Liver
14P09223042A0000|25 28|LRBV
14P09223042A0000|48 61|disease states
14P09223122A0774|7 25|matter NAA/mI ratio
14P09223229A0565|70 77|TATA box
14P09223475A0898|0 39|Chloramphenicol acetyltransferase assays
14P09223475A0898|59 62|IE86
14P09223475A0898|87 90|HCMV
14P09223475A0898|119 122|HCMV
14P09223475A0898|155 158|RNAs
14P09223475A0898|198 209|IE86 protein
14P09223479A1193|0 5|ORF M1
14P09223479A1193|26 41|poxvirus serpins
14P09223479A1193|47 53|ORF M11
14P09223479A1193|112 129|gammaherpesviruses
14P09223479A1193|139 141|HVS
14P09223479A1193|145 148|KSHV
14P09223479A1193|155 164|BHRF1 gene
14P09223479A1193|166 168|EBV
14P09223506T0000|0 33|Transcription factor binding sites
14P09223506T0000|51 77|immunodeficiency virus type
14P09223506T0000|77 100|transcription start site
14P09223647T0000|0 16|Crystal structure
14P09223647T0000|108 119|implications
14P09223667A0139|30 52|NIH3T3 fibroblast cells
14P09223667A0139|54 78|gel mobility shift assays
14P09223667A0139|147 170|transcription start site
14P09223667A0139|179 192|CTCCC sequence
14P09223880A1147|17 31|injection speed
14P09223880A1147|65 74|anesthesia
14P09224655T0000|21 25|ClC-6
14P09224655T0000|39 65|CIC chloride-channel family
14P09224655T0000|118 123|ClC-6c
14P09224811A0000|43 55|transcription
14P09224811A0000|61 65|NADPH
14P09224811A0000|67 96|cytochrome P450 oxidoreductase
14P09224811A0000|96 100|P450R
14P09224811A0000|246 261|P450R mRNA level
14P09225151T0000|29 51|polytetrafluoroethylene
14P09225151T0000|53 56|PTFE
14P09225151T0000|83 98|scarring process
14P09225506A0462|3 15|control group
14P09225506A0462|50 68|coagulation factors
14P09225506A0462|75 78|VIII
14P09225682A0579|30 44|antibody titers
14P09225682A0579|63 79|syndrome patients
14P09225682A0579|83 85|PEN
14P09225682A0579|143 148|Fisher
14P09225682A0579|151 167|syndrome patients
14P09225682A0579|174 176|PEN
14P09225686A0683|12 35|radiofrequency lesioning
14P09225686A0683|59 75|seizure remission
14P09225686A0683|82 94|complications
14P09225998A0000|0 35|NF-kappa B/Rel transcription factors
14P09225998A0000|90 112|regulation/inflammation
14P09225998A0000|132 153|cell surface receptors
14P09225998A0000|153 170|adhesion molecules
14P09226113A0857|22 40|source water sample
14P09226345A0436|12 22|food intake
14P09226345A0436|51 59|ACT group
14P09226345A0436|103 111|SEP group
14P09226345A0436|154 164|requirement
14P09227099A0106|31 42|modification
14P09227099A0106|46 63|bar superstructure
14P09227099A0106|78 87|advantages
14P09227099A0106|90 100|convenience
14P09227099A0106|168 177|angulation
14P09227332A1798|10 12|DDC
14P09227332A1798|94 95|DC
14P09227799A0254|112 128|stool examination
14P09227799A0254|129 133|ELISA
14P09227799A0254|156 158|SEA
14P09227799A0254|176 190|precipitin test
14P09227799A0254|191 194|COPT
14P09228042A0109|16 44|dermatan sulfate proteoglycan
14P09228042A0109|118 137|epiphyseal cartilage
14P09228042A0109|158 169|ion-exchange
14P09228042A0109|171 184|gel permeation
14P09228042A0109|200 202|Zn2
14P09228092A1779|5 12|analyses
14P09228092A1779|31 46|dUTPase isoforms
14P09228092A1779|89 99|transcripts
14P09228202A0581|12 48|5-HT3 receptor antagonists ramosetron
14P09228202A0581|47 51|YM060
14P09228202A0581|54 58|YM114
14P09228202A0581|60 66|KAE-393
14P09228202A0581|123 149|5-HT4 receptor agonist/5-HT
14P09228202A0581|149 168|receptor antagonists
14P09228202A0581|169 187|cisapride mosapride
14P09228202A0581|190 197|SC-53116
14P09229420A0158|0 12|Re-evaluation
14P09229420A0158|18 32|biopsy specimen
14P09229420A0158|95 108|chondrosarcoma
14P09229420A0158|121 130|background
14P09229420A0158|141 154|chondromatosis
14P09229595A0618|3 17|corneal buttons
14P09230129A0039|45 67|affinity chromatography
14P09230129A0039|76 88|DNA-cellulose
14P09230129A0039|133 140|SDS/PAGE
14P09230129A0039|148 160|contamination
14P09230216T0000|16 31|glycosylase maps
14P09230216T0000|33 52|chromosome 12q22-q24
14P09230216T0000|74 87|heterozygosity
14P09230307A0329|0 2|FOG
14P09230307A0329|20 25|GATA-1
14P09230384A0725|44 49|BACTEC
14P09230384A0725|54 55|MB
14P09230384A0725|59 64|BACTEC
14P09230384A0725|68 69|TB
14P09230384A1056|9 14|BACTEC
14P09230384A1056|19 27|MB system
14P09230894A0422|18 24|KmMig1p
14P09230945A0089|16 24|deformity
14P09230986A0000|0 21|Autoimmune neutropenia
14P09230986A0000|22 24|AIN
14P09232593A0946|29 46|expression pattern
14P09232593A0946|48 57|DJ protein
14P09233487A1386|25 40|outcome measures
14P09233487A1386|42 52|performance
14P09233487A1386|99 111|ear selection
14P09233487A1386|119 127|Prom-EABR
14P09233772A0136|22 25|p532
14P09233772A0136|61 66|EMBO J
14P09233772A0136|172 196|cell cycle regulator RCC1
14P09233772A0136|196 229|guanine nucleotide exchange factor
14P09233772A0136|329 338|G proteins
14P09233772A0136|352 368|SH3 binding sites
14P09233772A0136|411 436|HECT domain characteristic
14P09233772A0136|437 464|E3 ubiquitin-protein ligases
14P09233801A1180|8 19|L45 sequence
14P09233801A1180|26 42|kinase subdomains
14P09233801A1180|57 79|TGF-beta responsiveness
14P09233809A0381|6 16|mouse lines
14P09233809A0381|39 52|Hnf3g-lacZ YAC
14P09233809A0381|149 159|Hnf3g locus
14P09233809A0381|203 207|Hnf3g
14P09233809A0815|35 48|gene targeting
14P09233809A0815|63 78|Hnf3g gene locus
14P09233809A0815|163 186|reporter gene expression
14P09233811A0072|25 40|HMG-box proteins
14P09233811A0072|54 79|Ste11 transcription factor
14P09234677A0770|19 28|hypothesis
14P09234677A0770|41 51|transcripts
14P09234677A0770|85 95|transcripts
14P09234677A0770|115 125|respiration
14P09234690A0242|0 7|Upstream
14P09234690A0242|28 31|UASs
14P09234690A0242|124 127|PREs
14P09234690A0242|137 139|PRE
14P09234696A0238|9 31|protein kinase cascades
14P09234696A0238|75 77|MAP
14P09234703A0192|0 2|JNK
14P09234703A0192|42 55|G proteins Rac
14P09234713A0754|54 56|PCR
14P09234713A0754|108 110|RAG
14P09234713A0754|122 141|double-strand breaks
14P09234713A0754|142 145|DSBs
14P09234713A0754|149 152|RSSs
14P09234713A0754|157 163|Ddelta3
14P09234713A0754|171 177|Jdelta1
14P09234717A0000|33 35|Cbl
14P09234717A0000|47 61|protein product
14P09234717A0000|66 85|c-cbl proto-oncogene
14P09234717A0000|131 146|tyrosine kinases
14P09234717A0000|149 163|forms complexes
14P09234717A0000|167 169|SH3
14P09234717A0000|173 175|SH2
14P09234717A0000|221 239|signal transduction
14P09234720A1015|38 40|MEK
14P09234720A1015|42 47|MEK-2E
14P09234720A1015|100 110|H19-7 cells
14P09234720A1015|148 150|MEK
14P09234720A1015|166 182|neurite outgrowth
14P09234723A0846|39 57|splicing regulation
14P09234723A0846|59 61|PTB
14P09234723A0846|92 102|splice site
14P09234725A1892|53 71|interaction surface
14P09234725A1892|111 123|AP-1 activity
14P09234727A0770|8 21|fusion protein
14P09234727A0770|99 110|DNA elements
14P09234736A0999|6 27|hybridization analysis
14P09234736A0999|34 43|rat tissue
14P09234736A0999|54 64|correlation
14P09234736A0999|189 198|lung cells
14P09234736A0999|202 213|goblet cells
14P09234743A0475|55 66|alpha-globin
14P09234743A0475|69 71|UTR
14P09234743A0475|121 136|binding proteins
14P09234743A0475|141 153|alpha-complex
14P09235073A0000|52 66|Weaver syndrome
14P09235424A1200|46 49|ABPM
14P09235618A0000|23 36|neuroinfection
14P09235618A0000|38 49|Lyme disease
14P09235618A0000|50 72|Guillain Barre syndrome
14P09235618A0000|72 86|demyelinization
14P09235618A0000|164 166|IgG
14P09235618A0000|170 181|IgM subtypes
14P09235618A0000|236 253|sedimentation rate
14P09235995A0339|1 5|1996a
14P09235995A0339|7 18|Biochemistry
14P09235998A0788|10 28|membrane expression
14P09235998A0788|77 94|17-ketocholesterol
14P09235998A0788|114 130|HMG-CoA reductase
14P09236118A1455|21 23|Lrp
14P09236118A1455|100 109|DNA target
14P09236118A1455|159 190|nucleoprotein activation complex
14P09236224A0939|21 34|p21 expression
14P09236224A0939|85 87|NGF
14P09236224A0939|105 122|PC12 growth arrest
14P09236441A0639|43 45|ECG
14P09236441A0639|67 83|oxygen saturation
14P09236441A0639|84 87|SaO2
14P09236656A0124|63 64|SD
14P09236656A0124|84 85|SD
14P09237695A0000|57 66|indicators
14P09237695A0000|80 94|virus infection
14P09237862A0782|37 45|reduction
14P09237862A0782|64 70|absence
14P09237862A0782|83 88|nerves
14P09238467A0763|26 36|propranolol
14P09238467A0763|39 50|phentolamine
14P09238850A0785|12 15|ICER
14P09238850A2042|88 90|SCN
14P09238860A0175|92 133|AMP response element binding proteins CREB
14P09238860A0175|132 139|CREM tau
14P09238860A1974|49 52|CREB
14P09238860A1974|85 106|cytokine Interleukin-2
14P09238860A1974|107 110|IL-2
14P09238860A1974|161 163|Ca2
14P09238860A1974|179 195|protein kinase C.
14P09239635A0477|21 29|serum IgG
14P09239635A0477|56 65|littermate
14P09239635A0477|80 88|serum IgA
14P09241092A1108|0 10|CONCLUSIONS
14P09241092A1108|12 20|Valproate
14P09241092A1108|40 54|glucuronidation
14P09241092A1108|57 72|carbamazepine-10
14P09241092A1108|126 141|carbamazepine-10
14P09241092A1108|159 179|trans-diol derivative
14P09241232A0653|3 14|Ogg1 protein
14P09241232A0653|33 42|DNA duplex
14P09241232A0653|57 63|AP site
14P09241232A0653|89 92|AP/C
14P09241232A1154|1 18|consensus sequence
14P09241232A1154|43 56|lysine residue
14P09241232A1154|57 60|K120
14P09241232A1154|80 83|K241
14P09241232A1154|86 89|Ogg1
14P09242375A1313|53 57|V804L
14P09242375A1313|61 86|gain-of-function mutations
14P09242375A1313|105 115|RET isoform
14P09242375A1313|203 207|MEN2A
14P09242375A1313|211 225|MEN2B mutations
14P09242499A0505|0 9|Volunteers
14P09242499A0505|52 53|UV
14P09242499A0505|69 79|application
14P09242499A0505|103 113|base lotion
14P09242506A1033|38 55|E2F family members
14P09242506A1033|62 72|DP proteins
14P09242551A0653|0 9|EBER1 mRNA
14P09242551A0653|58 66|PEL cases
14P09242551A0653|117 132|EBER1 expression
14P09242551A0653|155 168|lymphoma cells
14P09243267A0401|0 6|METHODS
14P09243267A0401|117 142|Roswell Park Cancer Center
14P09243267A0401|141 144|RPCI
14P09243385A1314|76 91|PC velocity data
14P09243505A1194|25 35|experiments
14P09243505A1194|61 72|MADS domains
14P09243505A1194|125 135|specificity
14P09243505A1194|204 214|MADS domain
14P09243505A1194|256 266|specificity
14P09243587A0000|0 17|PURPOSE/OBJECTIVES
14P09243587A0000|79 82|FFTP
14P09243587A0000|160 196|abortion increases breast cancer risk
14P09243840A0663|61 68|HLA-DQA1
14P09243840A0663|84 86|DNA
14P09243840A0663|111 135|DNA Laboratory structures
14P09244100A0194|33 38|groups
14P09244282A1371|0 10|Mutagenesis
14P09244282A1371|72 81|insertions
14P09244282A1371|95 109|pec-1 phenotype
14P09244350A0000|0 4|BRCA1
14P09244350A0000|31 56|cancer susceptibility gene
14P09244350A0000|98 114|tumor suppressors
14P09244350A0000|121 139|breast cancer cells
14P09244430A0693|14 25|splice sites
14P09244430A0693|39 53|adducin isoform
14P09244430A0693|83 96|acceptor sites
14P09246343T0000|0 10|Proteinuria
14P09246585T0000|26 36|cancer pain
14P09247645A0000|36 39|SEC3
14P09247645A0000|57 65|SEC genes
14P09247645A0000|127 141|plasma membrane
14P09248639A0152|4 15|cell strains
14P09248639A0152|28 38|fibroblasts
14P09248639A0152|76 88|blister fluid
14P09248639A0152|121 131|contraction
14P09248639A0152|165 181|collagen lattices
14P09248639A0152|182 185|FPCL
14P09249039A0124|80 94|differentiation
14P09249039A0124|103 112|metabolism
14P09249039A0124|115 125|vertebrates
14P09249070A0989|0 3|Cell
14P09249710A0331|60 98|plaque reduction neutralization testing
14P09250554A0402|0 7|Patients
14P09250554A0402|22 33|diltiazem CD
14P09250554A0402|40 55|placebo once/day
14P09250554A0402|57 67|combination
14P09251843A0189|16 26|hyperplasia
14P09251843A0189|77 87|hyperplasia
14P09251843A0189|90 98|Castleman
14P09251843A0189|125 135|hyperplasia
14P09251843A0189|157 164|lymphoma
14P09251843A0189|197 204|lymphoma
14P09252397A0081|36 64|cyclobutane pyrimidine dimers
14P09252397A0081|65 85|nucleotide resolution
14P09252397A0081|98 105|JUN gene
14P09252397A0081|169 197|transcription initiation site
14P09252406A0511|0 7|Tyrosine
14P09252406A0511|49 52|Grb2
14P09252406A0511|56 75|Shc adaptor proteins
14P09252406A0511|78 88|p85 subunit
14P09252406A0511|90 109|phosphatidylinositol
14P09252406A0511|120 139|phospholipase Cgamma
14P09252406A0511|156 159|SHP2
14P09252879A0470|16 28|HRCT findings
14P09252879A0470|73 89|methacholine PC20
14P09252879A0470|90 94|PC20M
14P09254678A0106|0 7|Gtx mRNA
14P09254678A0106|35 38|RNAs
14P09254678A0106|101 103|MBP
14P09254678A0106|109 127|proteolipid protein
14P09254678A0106|128 130|PLP
14P09254678A0106|147 163|brain development
14P09254678A0106|164 171|Gtx mRNA
14P09254678A0106|194 196|MBP
14P09254678A0106|200 208|PLP mRNAs
14P09254678A0106|270 277|PLP gene
14P09254709T0000|0 7|Contacts
14P09254709T0000|15 42|Bacillus subtilis catabolite
14P09255349A0836|20 25|GTPase
14P09255349A0836|53 56|IRA1
14P09255349A0836|60 63|IRA2
14P09256973A0455|3 4|E2
14P09256973A0455|44 45|G2
14P09256973A0455|51 65|itraconazole/kg
14P09256973A0673|0 6|RESULTS
14P09256973A0673|11 12|E1
14P09256973A0673|14 51|itraconazole plasma drug concentration
14P09256973A0673|126 128|MRT
14P09257651T0000|8 18|U4/U6 snRNP
14P09257651T0000|31 43|90kD proteins
14P09257651T0000|77 104|yeast splicing factors Prp4p
14P09257887A0457|0 4|G-CSF
14P09257887A0457|34 46|microg/kg/day
14P09257887A0457|103 118|neutrophil count
14P09258439A1001|7 23|expression system
14P09258439A1001|56 61|SsEF-2
14P09258439A1001|72 82|mutagenesis
14P09258606A0822|0 8|Crosstalk
14P09258606A0822|73 83|development
14P09258606A0822|87 96|malignancy
14P09259052A0568|0 16|Supershift assays
14P09259052A0568|22 24|Jun
14P09259052A0568|28 37|Fos family
14P09259052A0568|73 89|protein complexes
14P09259052A0568|97 107|AtT-20 cell
14P09259052A0568|132 146|c-jun AP-1 site
14P09259052A0568|160 177|Jun family members
14P09259052A0568|177 180|JunD
14P09259052A0568|182 185|JunB
14P09259313A0950|13 30|PI kinase activity
14P09259313A0950|60 74|PRL stimulation
14P09259315A0809|0 7|Mutation
14P09259315A0809|118 133|GT-IIC enhansons
14P09259315A0809|147 179|CSEn enhancer/silencer activities
14P09259315A0809|187 194|GC cells
14P09259320A0830|65 79|O-glycosylation
14P09259320A0830|82 85|SSBP
14P09259320A0830|89 92|DSBP
14P09259328A0440|0 27|Deletion mapping experiments
14P09259328A0440|77 87|MSC-1 cells
14P09259328A0440|176 194|luciferase activity
14P09261155A0833|15 16|PH
14P09261155A0833|20 30|PTB domains
14P09261155A0833|84 110|insulin receptor substrates
14P09261155A0833|118 122|IRS-1
14P09261155A0833|124 128|IRS-2
14P09261155A0833|133 137|IRS-3
14P09261178T0000|3 7|mouse
14P09261178T0000|37 42|kinase
14P09261184A0170|16 42|gel mobility shift analysis
14P09261184A0170|43 64|supershift experiments
14P09261184A0170|65 69|FIRE1
14P09261184A0170|120 123|NF-Y
14P09261200T0001|0 9|MR imaging
14P09261200T0001|37 51|FLAIR technique
14P09261397A0509|0 26|Gag protein sequence motifs
14P09261397A0509|29 37|NC domain
14P09261397A0509|79 98|genome encapsidation
14P09263010T0000|0 8|Induction
14P09263010T0000|11 26|B cell apoptosis
14P09263010T0000|43 46|CD23
14P09263094A0799|0 11|MEASUREMENTS
14P09263094A0799|15 26|MAIN RESULTS
14P09263094A0799|27 40|Lung elastance
14P09263094A0799|41 42|EL
14P09263094A0799|58 59|RL
14P09263094A0799|93 107|airway pressure
14P09263094A0799|206 225|mean airway pressure
14P09263094A0799|247 267|breathing frequencies
14P09263094A0799|276 277|Hz
14P09263856A0563|36 38|Gla
14P09263856A0563|42 54|EGF-1 modules
14P09263856A0563|61 62|PS
14P09264466A0947|3 14|Cut9 subunit
14P09264466A0947|46 48|APC
14P09264466A0947|104 118|phosphorylation
14P09265534A0455|12 34|Gy/20 fractions/5 weeks
14P09265642A0668|75 89|internalization
14P09265642A0668|97 104|membrane
14P09265642A0668|114 122|marker FM
14P09265642A0668|141 151|sop mutants
14P09265932A0575|30 40|bupivacaine
14P09265932A0575|70 84|L2-3 interspace
14P09267306A0381|35 45|measurement
14P09267306A0381|83 102|laboratory precision
14P09267306A0381|105 115|reliability
14P09267306A0381|136 147|introduction
14P09267306A0381|158 169|laboratories
14P09267431A0000|3 21|soybean cDNA clones
14P09267431A0000|21 25|SPK-3
14P09267431A0000|29 33|SPK-4
14P09267439A0000|0 4|Genes
14P09267439A0000|19 33|ras superfamily
14P09267542A0126|0 9|Naltrexone
14P09267542A0126|38 41|Food
14P09267542A0126|45 63|Drug Administration
14P09267542A0126|80 97|alcohol dependence
14P09268298T0000|0 19|Ent-kaurene synthase
14P09268298T0000|26 48|fungus Phaeosphaeria sp
14P09268387A0293|52 54|ELL
14P09268387A0293|100 113|RNA polymerase
14P09268387A0293|128 145|elongation complex
14P09268578A0225|12 25|cDNA sequences
14P09268578A0225|52 58|message
14P09268631A0316|12 36|transcription orientation
14P09268631A0316|84 88|Igf2r
14P09268638A0332|26 51|chromosome walking studies
14P09268652A0116|16 34|zinc finger protein
14P09268652A0116|65 82|expression library
14P09268661A1405|44 56|transcriptase
14P09268661A1405|84 97|cDNA synthesis
14P09268661A1405|113 124|CCA sequence
14P09269879A0266|29 43|bioavailability
14P09269879A0266|67 86|elimination profiles
14P09269900A1035|32 42|EGF/Ras/Raf
14P09269900A1035|50 62|transcription
14P09269900A1035|86 95|ATF3/c-Jun
14P09269900A1035|127 130|JunD
14P09271393A1333|38 52|Tax anchors CBP
14P09271393A1333|56 70|HTLV-1 promoter
14P09271393A1333|194 216|transcription machinery
14P09271394A0558|0 4|DNase
14P09271394A0558|49 70|MURA-Mu1 TIR complexes
14P09271394A0558|81 84|MURA
14P09271394A0558|131 133|TIR
14P09271397A1596|81 103|LDL receptor SREBP site
14P09271397A1596|116 123|Sp1 site
14P09271400A0475|24 40|promoter activity
14P09271400A0475|86 100|E2F2 expression
14P09271400A0475|107 124|growth stimulation
14P09271417A0585|16 24|ERR alpha
14P09271417A0585|68 77|adipocytes
14P09271417A1011|3 6|MCAD
14P09271417A1011|14 38|receptor response element
14P09271417A1011|39 44|NRRE-1
14P09271417A1011|66 74|ERR alpha
14P09271417A1011|85 95|COS-7 cells
14P09271496T0000|0 15|Mapping features
14P09271496T0000|17 31|HIV-1 integrase
14P09271496T0000|58 77|target DNA molecules
14P09271496T0000|105 123|photo-cross-linking
15P09272108A1295a|0 7|Analysis
15P09272108A1295a|71 74|TATA
15P09272108A1295a|78 91|CAAT sequences
15P09272108A1295b|0 7|Analysis
15P09272108A1295b|71 74|TATA
15P09272108A1295b|78 91|CAAT sequences
14P09272138A1153|20 21|CR
14P09272138A1153|38 41|CODE
14P09272138A1153|46 58|rhG-CSF group
14P09272138A1153|69 72|CODE
14P09275159T0000|20 39|ribonucleoprotein A1
14P09275159T0000|81 105|mouse hepatitis virus RNA
14P09275164A0000|3 23|m7GpppN cap structure
14P09275164A0000|101 118|RNA triphosphatase
14P09275164A0000|119 141|RNA guanylyltransferase
14P09275164A0000|145 147|RNA
14P09275990A0938|60 70|TA98 strain
14P09275990A0938|121 143|mutagenicity prevalence
14P09276882A0479|25 26|CC
14P09276882A0479|30 31|CC
14P09276882A0479|33 46|SW by-products
14P09276882A0479|102 104|Day
14P09276882A0479|116 139|% carbohydrate treatment
14P09276882A0479|170 183|% carbohydrate
14P09277472A1070|85 93|DC shocks
14P09277629A0268|58 73|ERP negativities
14P09278441A0163|0 3|Biol
14P09278441A1160|21 40|CARP mRNA expression
14P09278441A1160|113 116|Nkx2
14P09278441A1160|120 122|Csx
14P09278441A1160|199 209|development
14P09278441A1777|0 13|Overexpression
14P09278441A1777|16 19|CARP
14P09278441A1777|82 101|factor transcription
14P09278445T0000|0 20|Substrate specificity
14P09278445T0000|25 38|RNase activity
14P09278450A1338|15 35|mobility shift assays
14P09278450A1338|37 59|competition experiments
14P09278450A1338|90 100|NF1 protein
14P09278454A1261|16 33|MMP-2 RE1 sequence
14P09278454A1261|66 77|CTGCTGGGCAAG
14P09278454A1261|128 163|DMS protection footprinting analysis
14P09278475A0465|37 48|ts phenotype
14P09278475A0465|73 85|Ino-phenotype
14P09278494A0762|15 17|Sp1
14P09278494A0762|21 32|ETS proteins
14P09278494A0762|59 75|promoter activity
14P09278494A0762|80 95|Surf-1 direction
14P09278758A1636|0 9|CONCLUSION
14P09278758A1636|11 22|Patients wit
14P09278758A1636|40 51|neck disease
14P09278758A1636|52 55|N1-3
14P09278758A1636|145 155|lymph nodes
14P09279379A0310|46 48|DNA
14P09279379A0310|120 135|H2B histone gene
14P09279889A1124|0 3|Area
14P09279889A1124|41 50|AUC0-24 hr
14P09279889A1124|54 56|MTX
14P09279889A1124|84 87|PG-2
14P09279889A1124|99 102|PG-7
14P09279889A1124|105 119|% Azone systems
14P09280747A0195|16 40|hydralazine hydrochloride
14P09280747A0195|43 62|isosorbide dinitrate
14P09280747A0195|169 182|ACE inhibitors
14P09282329A0527|43 46|Site
14P09282329A0527|74 99|cell cycle control element
14P09282329A0527|165 185|G1/S phase transition
14P09282329A0527|186 191|FDC-P1
14P09282329A0527|205 220|progenitor cells
14P09282911A0277|39 51|cell cultures
14P09282911A0277|62 76|RC3/neurogranin
14P09282911A0277|110 111|T3
14P09282985A0961|9 19|differences
14P09282985A0961|52 66|characteristics
14P09283828A0484|14 22|responses
14P09285715A1257|37 39|Rev
14P09285715A1257|51 64|export pathway
14P09285715A1257|89 92|RNAs
14P09285715A1257|96 97|5S
14P09285715A1257|107 109|RNA
14P09285715A1257|114 116|CTE
14P09285789A0712|17 50|guanine nucleotide exchange factor
14P09285789A0712|49 51|GEF
14P09285789A0712|90 108|pleckstrin homology
14P09285789A0712|109 110|PH
14P09286115T0000|0 2|S2F
14P09286115T0000|96 105|RPL21 gene
14P09286981A0147|0 3|ArgR
14P09286981A0147|71 72|Da
14P09287036A0457|0 27|Plasma leptin concentrations
14P09287036A0457|76 86|differences
14P09287352A0930|23 37|STAT activation
14P09287352A0930|45 60|SHP-1 expression
14P09287352A0930|115 136|protein kinase pathway
14P09287352A0930|148 152|SHP-1
14P09287352A0930|155 157|Cys
14P09287352A0930|161 163|Ser
14P09287352A0930|184 186|MEK
14P09287352A0930|225 229|SHP-1
14P09287362A0589|26 35|SH3 region
14P09287362A0589|37 39|p50
14P09287362A0589|68 84|PPPLPERTPESFVLADM
14P09287362A0589|113 120|PTP-PEST
14P09288848A0780|12 13|Gy
14P09288848A0780|15 26|HbO2 changes
14P09288916T0000|70 83|acid hydrolase
14P09288916T0000|104 116|beta subunits
14P09288916T0000|118 128|Madin-Darby
14P09288916T0000|135 146|kidney cells
14P09290207A0731|22 33|derepression
14P09290207A0731|45 60|mating type loci
14P09290571A0420|37 39|VTs
14P09290571A0420|76 78|EPS
14P09290571A0420|83 85|VTs
14P09290571A0799|23 24|VT
14P09290571A0799|30 32|VTs
14P09291077T0000|9 23|hyperammonaemia
14P09291077T0000|39 50|shepherd dog
14P09291098A0452|23 33|kb mRNA V-1
14P09291098A0452|41 55|kb GGT mRNA V-2
14P09291098A0452|92 101|transcript
14P09291098A0452|133 144|rat GGT gene
14P09291098T0000|31 75|gamma-glutamyl transpeptidase gene expression
14P09292499A0887|54 89|polypyrimidine tract binding protein
14P09292499A0887|88 90|PTB
14P09292499A0887|127 160|UV crosslinking/competition assays
14P09293006A1412|9 18|expression
14P09293006A1412|27 37|S. lividans
14P09293006A1412|69 82|aphII promoter
14P09294139A0729|13 32|core homology region
14P09294139A0729|40 53|HS12 enhancers
14P09294139A0729|212 232|sequence conservation
14P09294161A0650|44 52|p45 NF-E2
14P09294161A0650|63 79|activation domain
14P09294161A0650|83 87|NF-E2
14P09294161A0650|132 144|transcription
14P09294161A1103|5 12|findings
14P09294161A1103|32 40|mechanism
14P09294161A1103|50 60|recruitment
14P09294161A1103|91 101|globin loci
14P09294161A1103|116 124|promoters
14P09294262A0885|3 17|promoter region
14P09294262A0885|25 42|consensus TATA box
14P09294262A0885|54 58|CCAAT
14P09294262A0885|62 71|CreA boxes
14P09294422A1223|6 22|cysteine residues
14P09294422A1223|81 96|disulfide bridge
14P09294422A1223|113 130|activation process
14P09294422A1376|135 146|tac promoter
14P09294422A1376|161 170|production
14P09294422A1376|173 175|POR
14P09294452A2107|64 85|reporter enzyme levels
14P09294453A0949|3 13|ORF3 mutant
14P09294453A0949|59 62|ORF3
14P09294453A0949|77 97|T beta L biosynthesis
14P09294471A1198|7 16|Cox models
14P09294471A1198|22 30|CD4 count
14P09294471A1198|32 41|150/microL
14P09294471A1198|52 61|200/microL
14P09294471A1198|75 76|I0
14P09294471A1198|80 81|I1
14P09296251A0163|20 26|reports
14P09296251A0163|42 47|number
14P09296251A0163|50 57|patients
14P09297698A0933|5 15|transcripts
14P09297698A0933|40 51|UbCRBP mRNAs
14P09297698A0933|65 70|UbCRBP
14P09297698A0933|130 141|enolase gene
14P09299696A1074|3 14|distribution
14P09299696A1074|17 30|cryptosporidia
14P09299696A1074|56 69|cryptosporidia
14P09299696A1074|95 97|DPI
14P09299696A1074|126 141|characterization
14P09299696A1074|185 201|cryptosporidiosis
14P09300323A1182|41 56|blood flow ratio
14P09300323A1182|56 63|ENDO/EPI
14P09300323A1182|95 110|control stenosis
14P09300323A1182|128 130|ITF
14P09300323A1182|181 183|NTG
14P09300697A0000|0 10|Proteasomes
14P09300697A0000|81 89|MHC class
14P09300698A1219|15 28|interpretation
14P09300698A1219|46 49|MQ9b
14P09301114A0573|0 8|Takahashi
14P09301114A0573|10 11|H.
14P09301350A0946|3 22|sputum interleukin-8
14P09301350A0946|45 71|treatment median difference
14P09301350A0946|83 103|% confidence interval
14P09301350A0946|103 104|CI
14P09301350A0946|152 166|expiratory flow
14P09301350A0946|242 258|percentage points
14P09301350A0946|276 300|mean treatment difference
14P09303437A0875|26 28|Fp1
14P09303437A0875|60 71|CAT activity
14P09303437A0875|159 161|p12
14P09303437A0875|217 235|CAT gene expression
14P09303635A0000|0 6|Gaucher
14P09304123A0079|5 17|discoloration
14P09304123A0079|58 72|tooth structure
14P09304123A0079|158 165|material
14P09305592A0000|18 45|translocation characteristic
14P09305592A0000|47 49|CML
14P09305592A0000|103 113|p210bcr/abl
14P09305631A0770|0 13|Overexpression
14P09305631A0770|16 20|BAG-1
14P09305755A0540|71 73|Sp1
14P09305755A0540|90 92|NF1
14P09305755A0540|95 118|CAAT-box binding protein
14P09305755A0540|118 122|C/EBP
14P09305755A0540|155 158|HNF1
14P09305755A0540|160 163|HNF5
14P09305755A0540|168 185|activator proteins
14P09305755A0540|191 193|AP1
14P09305755A0540|195 197|AP2
14P09305870A0894|3 25|recognition specificity
14P09305870A0894|30 43|p55 PDZ domain
14P09305870A0894|73 83|PDZ domains
14P09305870A0894|95 114|lymphocyte homologue
14P09305870A0894|139 154|tumor suppressor
14P09305944A0621|14 28|RanGAP activity
14P09305944A0621|61 84|rna1p mutant derivatives
14P09305944A0621|197 210|GTP hydrolysis
14P09307065A0553|14 22|MHC class
14P09307065A0553|40 46|D10 TCR
14P09307065A0553|73 86|enterotoxin C2
14P09307065A0553|92 107|association rate
14P09307065A0553|142 158|dissociation rate
14P09307065A0553|192 212|dissociation constant
14P09307312A0172|0 7|Evidence
14P09307312A0172|61 72|nerve fibers
14P09307312A0172|81 92|microphonics
14P09307312A0172|173 203|membrane vibration measurements
14P09308234A0225|0 2|Mnt
14P09308234A0225|4 16|Max complexes
14P09308738A1216|24 26|HES
14P09308738A1216|100 101|MW
14P09308738A1216|125 164|factor VIII/von Willebrand factor levels
14P09309457A0680|0 5|Assays
14P09309457A0680|35 37|HDL
14P09309457A0680|39 42|HDL2
14P09309457A0680|44 46|LDL
14P09309457A0680|102 104|FSH
14P09309457A0680|146 148|ERT
14P09309457A0680|166 168|ERT
14P09310836A1019|21 29|P element
14P09310836A1019|40 52|SV40 promoter
14P09310836A1019|63 93|phorbol 12-myristate 13-acetate
14P09311164A0245|21 29|density J
14P09311164A0245|68 77|motor unit
14P09311568A0595|3 21|cleavage dipeptides
14P09311568A0595|23 40|C1YVV NIa protease
14P09311796A0218|69 81|IEP86 binding
14P09311796A0218|90 113|TATA-box binding protein
14P09311796A0218|113 115|TBP
14P09311796A0218|123 142|transcription factor
14P09311808A0341|31 41|p4 molecule
14P09311810A0814|7 18|accumulation
14P09311810A0814|21 37|cyclin D3 protein
14P09311810A0814|38 47|Vero cells
14P09311810A0814|61 82|alpha0 deletion mutant
14P09311810A0814|174 189|alpha0 sequences
14P09311835A0147|54 63|T antigens
14P09311835A0147|77 88|SV40 mutants
14P09311835A0147|152 169|ATP binding pocket
14P09312025A0373|58 65|PKC zeta
14P09312025A0373|80 122|phosphatidylinositol 3-kinase p85alpha-p110
14P09312025A0373|134 141|LY294002
14P09312025A0373|171 178|p85alpha
14P09312025T0000|0 21|Protein phosphatase 2A
14P09312025T0000|42 72|protein kinase C zeta signaling
14P09312025T0000|79 82|SV40
14P09312025T0000|111 130|NF-kappaB activation
14P09312028A0975|17 29|RXRalphaF318A
14P09312028A0975|92 97|BMS614
14P09312028A0975|124 126|RXR
14P09312028A0975|130 145|RAR AF-2 domains
14P09312032A0165|29 40|snoRNA genes
14P09312032A0165|48 57|processing
14P09312032A0165|112 125|intron lariats
14P09312087A0000|29 42|Src homology-2
14P09312087A0000|43 45|SH2
14P09312087A0000|92 96|SHP-2
14P09312087A0000|134 140|PECAM-1
14P09312087A0000|181 200|platelet aggregation
14P09312087A0000|248 262|phosphopeptides
14P09312087A0000|300 306|PECAM-1
14P09312087A0000|319 343|tyrosine residues Tyr-663
14P09312087A0000|344 350|Tyr-686
14P09313755A0816|13 22|clustering
14P09313755A0816|30 43|risk variables
14P09314306A0571|0 14|Supplementation
14P09314487T0000|19 44|Mycobacterium tuberculosis
14P09314487T0000|62 86|polymerase chain reaction
14P09314537A1600|21 25|EBP50
14P09314537A1600|52 72|ezrin binding protein
14P09314554A0149|66 68|AUG
14P09314554A0149|199 236|influenza A PR/8/34 nucleoprotein gene
14P09314570A0153|12 19|proteins
14P09314570A0153|57 70|gene promoters
14P09314570A0153|90 99|activation
14P09314570A0153|102 111|repression
14P09314570A0153|129 138|activities
14P09315631A1064|0 7|Deletion
14P09315631A1064|13 21|POR2 gene
14P09315631A1064|84 87|POR1
14P09315631A1064|91 100|POR2 genes
14P09315632A1137|63 81|FGFR3 kinase domain
14P09315632A1137|150 154|FGFR3
14P09315633A0333|10 28|amino acid sequence
14P09315633A0333|91 94|IRFs
14P09315651T0000|0 10|Involvement
14P09315651T0000|13 16|AP-2
14P09315651T0000|34 44|R-FABP gene
14P09315678A0278|8 12|Cbf5p
14P09315678A0278|72 84|protein NAP57
14P09315678A0278|114 120|Nopp140
14P09315678A0278|186 187|U.
14P09316937A0133|84 113|API 20E identification systems
14P09317131A0000|0 1|Ig
14P09317131A0000|7 27|chain class switching
14P09317131A0000|84 91|CH genes
14P09317131A1332|30 62|NF kappa B2 nucleoprotein complex
14P09317131A1332|84 88|STAT6
14P09317131A1332|132 148|IgE germline gene
14P09317757T0000|24 68|CHRISTMAS ISLAND RED CRAB GECARCOIDEA NATALIS
14P09317830T0000|12 25|SONG FREQUENCY
14P09317830T0000|27 33|CICADAS
14P09321406T0000|3 28|pheromone response pathway
14P09321406T0000|51 70|Ty5 retrotransposons
14P09321657A0439|69 82|cox3 promoters
14P09321657A0439|101 112|core element
14P09321657A0439|126 147|cox3 promoter activity
14P09321657A0439|155 171|element mutations
14P09321930A0567|19 40|tumor suppressor genes
14P09321930A0567|45 47|p53
14P09321930A0567|49 51|DCC
14P09321930A0567|53 55|APC
14P09321930A0567|57 59|MCC
14P09321930A0567|61 65|BRCA1
14P09321930A0567|70 78|WAF1/CIP1
14P09321930A0567|164 166|LOH
14P09321930A0567|186 188|LOE
14P09321930A0567|225 239|binding protein
14P09322738A0510|83 95|S. coelicolor
14P09322738A0510|98 108|S. lividans
14P09322872A0745|29 35|TK gene
14P09322872A0745|49 59|gancyclovir
14P09322872A0745|90 102|recombination
14P09323366A0000|3 22|malate synthase gene
14P09323366A0000|22 25|MLS1
14P09323366A0299|2 18|deletion analysis
14P09323366A0299|23 41|MLS1 control region
14P09323366A0299|62 65|UAS1
14P09323366A0299|69 72|UAS2
14P09323612A0374|0 3|Lack
14P09323612A0374|36 62|sleep electroencephalograms
14P09323612A0374|63 65|EEG
14P09323612A0374|145 164|treatment strategies
14P09323612A0374|206 223|language disorders
14P09324720A0317|30 40|tablespoons
14P09324720A0317|43 48|Alzoon
14P09324878A0952|36 57|ultrasound examination
14P09324878A0952|114 130|type B dissection
14P09324922T0065|0 19|Fermentation process
14P09324922T0065|24 38|supplementation
14P09324988X0000|0 9|Substrates
14P09324988X0000|20 22|p21
14P09325022A0192|0 6|Ovaries
14P09325022A0192|41 49|CD-1 mice
14P09325022A0192|64 66|C3H
14P09325022A0192|70 81|C57BL/6 mice
14P09325135A0737|9 22|fusion protein
14P09325273A1240|23 27|UBP41
14P09325273A1240|97 117|poly-ubiquitin chains
14P09325273A1240|141 152|S proteasome
14P09325273A1240|172 189|protein substrates
14P09325273A1240|238 258|poly-ubiquitin chains
14P09325273A1240|291 315|ubiquitin fusion proteins
14P09325278A0458|1 25|data base homology search
14P09325278A0458|47 69|ER1 amino acid sequence
14P09325278A0458|196 226|Caenorhabditis elegans sequence
14P09325284A0469|34 45|acid protein
14P09325284A0469|64 79|progelatinase B.
14P09325322A1293|24 26|Ca2
14P09325322A1293|76 79|EC50
14P09325322A1293|92 111|InsP3 concentrations
14P09326163A0942|0 6|RESULTS
14P09326163A0942|23 37|mortality ratio
14P09326163A0942|38 40|SMR
14P09326246A0567|0 16|Sequence analysis
14P09326246A0567|111 129|luciferase activity
14P09326246A0567|139 157|bp reporter plasmid
14P09326263A0410|7 10|RACE
14P09326263A0410|21 37|transcription-PCR
14P09326263A0410|39 44|RT-PCR
14P09326263A0410|46 58|methodologies
14P09326263A0410|199 200|1A
14P09326263A0410|230 231|1B
14P09326317A0372|26 43|mutation screening
14P09326317A0372|69 72|EXT1
14P09326317A0372|76 85|EXT2 genes
14P09326317A0372|95 110|linkage analysis
14P09326727T0000|3 15|regurgitation
14P09326727T0000|31 40|injections
14P09327881T0000|0 40|Positron emission tomography radioligands
14P09327881T0000|41 61|dopamine transporters
14P09328341A1449|18 37|vit A2 consensus ERE
14P09328341A1449|62 72|DNA binding
14P09328341A1449|77 103|TR alpha DNA binding mutant
14P09328343A0181|0 9|Expression
14P09328343A0181|50 64|protein complex
14P09328343A0181|92 94|E2A
14P09328349A1679|8 16|CCAAT box
14P09328349A1679|38 52|characteristics
14P09328349A1679|89 106|alpha-subunit gene
14P09328476A0068|0 10|U4/U6 snRNP
14P09328476A0068|42 58|ribonucleoprotein
14P09328476A0068|76 77|U1
14P09328476A0068|79 80|U2
14P09328476A0068|82 83|U5
14P09328476A0068|87 91|U4/U6
14P09328476A0374|0 5|Hprp3p
14P09328476A0374|67 87|splicing factor Prp3p
14P09328824A0000|44 58|v-erbA oncogene
14P09328824A0000|85 116|chicken thyroid hormone receptor
14P09328824A0000|115 116|TR
14P09328824A0000|199 200|TR
14P09328824A0000|212 225|acid receptors
14P09328833A0588|31 33|HET
14P09328833A0588|40 57|MCF-7 cDNA library
14P09331119A0659|30 40|neutropenia
14P09331119A0659|42 57|thrombocytopenia
14P09331119A0659|62 73|parasthesias
14P09331864A0230|0 19|Serum concentrations
14P09331864A0230|21 22|E2
14P09331864A0230|26 29|TBOH
14P09331864A0230|148 150|MGA
14P09331864A0230|173 181|Revalor-H
14P09331864A0230|202 210|Revalor-H
14P09331864A0230|212 214|MGA
14P09331864A0230|218 227|Finaplix-H
14P09331864A0230|244 253|Finaplix-H
14P09331864A0230|255 257|MGA
14P09331864A0848|0 22|Serum E2 concentrations
14P09331864A0848|81 83|MGA
14P09331864A0848|111 113|MGA
14P09333018A0000|0 9|Interferon
14P09333018A0000|20 25|Factor
14P09333018A0000|27 29|IRF
14P09333018A0000|101 120|transcription factor
14P09333026A0397|88 105|PTK family members
14P09333026A0851|28 37|expression
14P09333026A0851|54 61|brk cDNA
14P09333026A0851|77 87|fibroblasts
14P09333026A0851|126 134|anchorage
14P09333026A0851|190 197|response
14P09333026A0851|209 221|growth factor
14P09333168A0310|0 21|Anti-hepatitis A virus
14P09333168A0310|21 23|HAV
14P09333231T0018|16 22|species
14P09334264A0540|13 28|calf thymus CstF
14P09334264A0540|69 75|subunit
14P09334330A0252|56 70|TGF-beta signal
14P09334330A0252|97 129|Smad signal transduction proteins
14P09334330A0252|141 152|Smad protein
14P09334330A0252|187 190|DPC4
14P09334330A0252|267 283|dauer development
14P09334331A0910|46 66|EGF receptor DER/Egfr
14P09334331A0910|79 87|EMA cells
14P09334331A0910|110 113|Vein
14P09334475A0327|0 7|PATIENTS
14P09334475A0327|11 17|METHODS
14P09334475A0327|57 73|National Registry
14P09334475A0327|90 99|Infarction
14P09334475A0327|139 155|segment elevation
14P09334475A0327|188 194|CK rise
14P09334475A0327|205 220|T wave inversion
14P09334475A0327|235 237|EKG
14P09335267A0142|12 27|operon structure
14P09335267A0142|33 40|organism
14P09335267A0142|77 87|mutagenesis
14P09335267A0142|159 167|mutations
14P09335298A0529|44 70|plasmid partitioning system
14P09335298A1227|29 42|ColE1 cer site
14P09335298A1227|48 58|RK2 plasmid
14P09335298A1227|112 125|MC1061K strain
14P09335298A1227|143 170|multimer resolution activity
14P09335298A1227|214 235|stabilization activity
14P09335298A2129|95 115|transformation assays
14P09335298A2129|151 163|sensitivities
14P09335298A2129|181 198|ParE toxin protein
14P09335608T0000|96 116|chain gene transcript
14P09335619A0583|0 27|Nucleotide sequence analysis
14P09335619A0583|57 66|R1 plasmid
14P09335619A0583|104 115|RU cytoplasm
14P09335619A0583|121 130|M1 plasmid
14P09335619A0583|148 150|Zea
14P09336455A0000|40 53|mRNA synthesis
14P09336455A0000|67 71|GAL10
14P09336455A0000|75 84|RNR3 genes
14P09336455A0000|123 124|UV
14P09337861T0000|0 6|Cloning
14P09337861T0000|15 39|phosphoinositide 3-kinase
14P09337861T0000|44 52|C2 domain
14P09337861T0000|87 106|inhibitor wortmannin
14P09338414A0430|0 7|Ea value
14P09338414A0430|74 77|ESAP
14P09338414A0430|81 93|stroke volume
14P09338414A0430|94 107|thermodilution
14P09339900A0939|20 36|promoter activity
14P09339900A0939|111 115|C/EBP
14P09339900A0939|117 120|PEA3
14P09339900A0939|122 124|AP2
14P09339900A0939|126 129|NF-Y
14P09339900A0939|140 142|Sp1
14P09340641T0001|0 5|Effect
14P09340641T0001|33 46|nCPAP pressure
14P09341139A0690|11 25|resensitization
14P09341139A0690|51 64|beta2AR mutant
14P09341139A0690|65 69|Y326A
14P09341139A0690|99 112|overexpression
14P09341139A0690|121 124|GRK2
14P09341139A0690|127 139|beta-arrestin
14P09341158A0167|3 15|medium chains
14P09341158A0167|22 30|complexes
14P09341158A0167|72 82|interaction
14P09341158A0167|84 91|assembly
14P09341158A0167|107 118|beta2 chains
14P09341158A0167|136 144|complexes
14P09341158A0167|148 158|recognition
14P09341158A0167|175 189|sorting signals
14P09341182A0605|61 74|BTB/POZ domain
14P09341182A0605|78 81|PLZF
14P09341182A0605|83 94|PLZF-BTB/POZ
14P09341192T0000|22 40|GLUT4 translocation
14P09341192T0000|42 57|3T3L1 adipocytes
14P09341192T0000|65 87|tyrosine kinase pathway
14P09341193A0362|27 36|NGFI-A/Egr
14P09341193A0362|58 78|transcription factors
14P09341193A0362|87 90|TRE1
14P09341193A0362|103 120|Tax responsiveness
14P09343208A1405|54 64|copy number
14P09343208A1405|120 131|organization
14P09343208A1405|134 137|PDVs
14P09343208A1405|212 222|association
14P09343210A1112|44 58|VCAM-1 promoter
14P09343210A1112|71 114|chloramphenicol acetyltransferase constructs
14P09343210A1112|149 163|VCAM-1 promoter
14P09343210A1112|169 183|NF-kappaB sites
14P09343210A1112|208 227|VCAM-1 gene promoter
14P09343222A0415|3 5|AGM
14P09343222A0415|9 37|NIH/Swiss mouse CCR5 proteins
14P09343398A1193|0 11|Processivity
14P09343398A1193|14 26|DNA synthesis
14P09343426A0456|0 29|Alanine substitution mutations
14P09343426A0456|33 53|Zta activation domain
14P09343426A0456|95 105|D-A complex
14P09343432A0209|3 5|Scm
14P09343432A0209|25 39|homology domain
14P09343432A0209|89 98|SPM domain
14P09343432A0209|129 137|C termini
14P09343433A0000|46 59|RNA polymerase
14P09343433A0000|62 65|RNAP
14P09343433A0000|89 106|effect variegation
14P09343433A0360|56 59|RNAP
14P09343433A0360|86 89|ADE2
14P09343982A0890|14 34|detrusor contractions
14P09343982A0890|70 79|difference
14P09344650A0967|14 33|transmembrane domain
14P09344650A0967|34 41|Casr-rs2
14P09344650A0967|45 52|Casr-rs3
14P09344650A0967|70 77|Casr-rs1
14P09345037A0886|48 66|trans-factor GATA-1
14P09345037A0886|78 106|progenitor cell proliferation
14P09345495A0000|0 21|PET activation studies
14P09346238T0000|65 92|SCF ubiquitin-ligase complex
14P09346621A1181|14 37|liver allograft shortage
14P09346621A1181|60 62|ELT
14P09346621A1181|123 125|OSF
14P09346621A1181|131 139|APACHE II
14P09346925A0660|3 13|SH3 domains
14P09346925A0660|15 18|Grb2
14P09346925A0660|64 72|HPK1 tail
14P09346925A0660|126 129|Grb2
14P09346925A0660|132 135|HPK1
14P09346925A0660|149 158|Cos1 cells
14P09346935A0459|24 52|coimmunoprecipitation studies
14P09346935A0459|70 74|ZNF74
14P09346935A0459|91 108|zinc finger domain
14P09346935A0459|150 163|RNA polymerase
14P09346935A0927|5 25|ZNF74 sublocalization
14P09346935A0927|51 77|pre-mRNA maturating factors
14P09346935A0927|80 99|RNA binding activity
14P09346935A0927|162 175|RNA polymerase
14P09346935A0927|250 280|KRAB multifinger protein family
14P09346935A0927|280 293|RNA processing
14P09346938A1680|0 32|Ki-ras4BVal-12 transfectant cells
14P09346938A1680|81 109|cysteine protease cathepsin B
14P09346938A1680|127 153|cathepsin B mRNA expression
14P09346953A0000|30 57|heparan sulfate proteoglycan
14P09346953A0000|57 63|HSPGact
14P09346953A0000|138 162|HSact conversion activity
14P09346953A0000|205 255|heparan sulfate D-glucosaminyl 3-O-sulfotransferase
14P09348226A0852|14 16|EGF
14P09348226A0852|42 65|tyrosine phosphorylation
14P09348226A0852|93 98|Crk-II
14P09348931T0000|10 16|lottery
14P09349501A0196|65 76|MLL products
14P09349501A0196|87 94|MLL-LTG9
14P09349501A0196|98 106|MLL-LTG19
14P09349967A0653|33 44|blood supply
14P09349967A0653|69 80|organisation
14P09349967A0653|89 101|lamellar bone
14P09351242A0719|0 8|Induction
14P09351242A0719|11 35|AtP5CS1 mRNA accumulation
14P09351242A0719|115 128|ABA signalling
14P09351242A0719|191 206|ABA biosynthesis
14P09351242A0719|211 233|aba1 Arabidopsis mutant
14P09351823A0414|17 30|MAPK functions
14P09352016A1110|6 19|AF G-CSF level
14P09352016A1110|56 58|CAM
14P09352127A0953|27 41|serum myoglobin
14P09352127A0953|44 64|CA III concentrations
14P09353247A0922|15 40|over-replication phenotype
14P09353247A0922|60 67|p65cdc18
14P09353247A0922|97 115|cyclin/CDK activity
14P09353255A0159|81 101|FG-nucleoporin family
14P09353296A0510|3 13|CNXA domain
14P09353296A0510|27 42|amino acid level
14P09353296A0510|61 77|moaA gene product
14P09353296A0510|82 85|CNXC
14P09353304A0732|0 8|Deletions
14P09353304A0732|36 56|membrane localization
14P09353304A0732|58 62|Tiam1
14P09353304A0732|66 82|membrane ruffling
14P09353328A0736|18 23|kinase
14P09353328A0736|33 38|domain
14P09353328A0736|66 72|zippers
14P09353328A0736|95 102|homology
14P09353328A0736|112 119|proteins
14P09353343A0919|0 13|RNA polymerase
14P09353343A0919|50 62|AUBP activity
14P09353343A0919|74 82|Sepharose
14P09353343A0919|116 131|hnRNP A1 binding
14P09353343T0000|12 41|AUUUA response element binding
14P09354349A0338|102 107|Giemsa
14P09354349A0338|109 110|MG
14P09354349A0338|116 129|Warthin-Starry
14P09354349A0338|131 132|WS
14P09354349A0338|166 168|IMM
14P09354349A0338|193 211|H. pylori antiserum
14P09354349A0338|211 219|DAKO B471
14P09354644A0124|64 90|beta1,6-GlcNAc transferases
14P09354644A0124|91 95|IGnT6
14P09354644A0124|97 102|GlcNAc
14P09354644A0124|105 107|Gal
14P09354676A1714|36 40|p16.3
14P09354676A1714|42 44|q32
14P09354676A1714|98 99|MM
14P09354676A1714|118 127|FGFR3 gene
14P09354676A1714|192 193|MM
14P09354684A1158|24 31|Sp1 site
14P09354684A1158|55 71|promoter activity
14P09354757A1444|0 18|Amino acid residues
14P09354757A1444|62 67|His539
14P09354757A1444|73 86|RNase H domain
14P09354757A1444|100 112|primer strand
14P09356645A0672|76 92|nerve enlargement
14P09358045A0000|7 26|length cDNA sequence
14P09358045A0000|28 31|Type
14P09358045A0000|45 62|growth factor-beta
14P09358045A0000|63 70|TGF-beta
14P09358045A0000|119 141|nematode Brugia pahangi
14P09358055A0590|55 70|promoter element
14P09358055A0590|71 74|Enh2
14P09358055A0590|88 90|LTR
14P09358055A0590|113 123|A-particles
14P09358069T0000|0 17|Codon optimization
14P09358069T0000|62 64|EPO
14P09358837T0000|24 37|albumin levels
14P09358837T0000|42 50|treatment
14P09358837T0000|62 73|hypertension
14P09359844A0674|10 24|HSL transcripts
14P09359887A1168|32 44|Rat7p/Nup159p
14P09359887A1168|64 66|NPC
14P09360422A0135|36 49|arteriopathies
14P09360422A0135|68 80|plasma levels
14P09360422A0135|82 95|thrombomodulin
14P09360422A0135|97 98|TM
14P09360422A0135|101 119|betathromboglobulin
14P09360422A0135|130 136|D-dimer
14P09360422A0135|138 139|DD
14P09360422A0135|144 174|plasminogen activator-inhibitor
14P09360953A1057|14 19|Ile244
14P09360953A1057|66 71|Tyr318
14P09360953A1057|131 133|Leu
14P09360953A1057|137 139|Ile
14P09360953A1057|145 158|PTH-1 receptor
14P09360956A0840|24 38|phosphorylation
14P09360956A0840|56 68|CKIalpha site
14P09360956A0840|69 75|Thr-233
14P09360956A0840|145 163|signal transduction
14P09360993T0000|0 23|Mouse mast cell protease
14P09360993T0000|60 75|serine proteases
14P09361007A0922|1 5|DNase
14P09361007A0922|56 75|pair enhancer region
14P09362105X0422|29 31|PVR
14P09362105X0422|106 121|vasoconstriction
14P09362105X0422|123 125|HPV
14P09362473A1540|64 80|enhancer elements
14P09362473A1540|171 193|repressor binding sites
14P09362473A1540|234 247|twist activity
14P09362473A1540|271 293|twist expression domain
14P09362480A0452|9 24|cysteine triplet
14P09362480A0452|49 58|TB domains
14P09362480A0452|95 104|C-terminus
14P09362499A0000|3 13|Fis protein
14P09362499A0000|35 47|DNA inversion
14P09362499A0000|67 80|DNA invertases
14P09363759A0000|0 19|Protein phosphatases
14P09363759A0000|78 96|signal transduction
14P09364211A0319|22 45|transcription factor E2F
14P09364211A0319|61 63|DNA
14P09364440A2206|43 59|FSH receptor gene
14P09364750T0000|27 31|SUP35
14P09364750T0000|35 39|SUP45
14P09365201A2018|40 55|characterization
14P09365201A2018|82 101|aromatase expression
14P09365201A2018|108 120|breast cancer
14P09365201A2018|123 126|ASCs
14P09365272T0000|0 6|Xenopus
14P09365272T0000|77 96|Xenopus egg extracts
14P09365431A0314|50 93|acetylcholinesterase inhibitor physostigmine
14P09366456A0234|0 6|METHODS
14P09366456A0234|13 28|muscle paralysis
14P09366456A0234|50 59|anesthesia
14P09366456A0234|87 101|body mass index
14P09366456A0234|147 160|body mas index
14P09366517A0835|0 2|PKA
14P09366517A0835|17 19|WT1
14P09366517A0835|22 28|Ser-365
14P09366517A0835|32 38|Ser-393
14P09366517A0835|80 94|phosphorylation
14P09366517A0835|128 130|WT1
14P09366517A1828|51 53|WT1
14P09366517A1828|73 87|phosphorylation
14P09366628T0000|0 1|Re
14P09367288A0115|57 72|unit rest length
14P09367288A0115|90 103|immobilisation
14P09367288A0115|145 155|adaptations
14P09367392A0567|67 70|RNA3
14P09367392A0567|79 98|template recognition
14P09367392A0567|100 103|RdRp
14P09367392A0567|128 131|RNA3
14P09367426A1354|67 83|compartment cells
14P09367426A1354|97 110|interpretation
14P09367426A1354|134 145|polarization
14P09367676A0275|0 25|Restriction enzyme mapping
14P09367676A0275|39 61|DNA sequencing analysis
14P09367676A0275|87 95|P1 clones
14P09367676A0275|169 171|DNA
14P09367676A1115|0 20|Transfection analyses
14P09367676A1115|48 53|Tbxas1
14P09368006A1332|32 49|NF-kappaB activity
14P09368006A1332|113 117|E2F-1
14P09368014A0740|3 19|lysozyme FEF site
14P09368014A0740|36 37|PU
14P09368026A0000|0 10|Osteocalcin
14P09368026A0000|12 13|OC
14P09368026A0000|71 82|odontoblasts
14P09368026A0000|93 106|mineralization
14P09368026A0435|33 47|Msx2 expression
14P09368026A0435|49 70|OC promoter activation
14P09368026A0435|70 88|luciferase reporter
14P09368026A0435|91 98|FGF2/FSK
14P09368026A0435|114 133|MC3T3-E1 osteoblasts
14P09368057A1083|41 52|SRF activity
14P09368057A1083|56 73|repressor activity
14P09368057A1083|152 162|SRF binding
14P09368058A0969|29 53|phosphopeptide comigrates
14P09368058A0969|150 152|CAK
14P09368097T0000|3 5|pen
14P09368100A1354|3 14|mHIF-1 alpha
14P09368190A1053|58 61|EMSA
14P09368190A1053|64 82|DNA binding pattern
14P09368190A1053|120 128|IFN-gamma
14P09368190A1053|178 186|IFN-alpha
14P09368190A1053|190 198|IFN-gamma
14P09368419A0000|2 12|Arabidopsis
14P09368419A0000|86 88|ABA
14P09368419A0000|101 120|protein biosynthesis
14P09368419A0000|136 150|gene expression
14P09368419A0628|25 43|DNA binding protein
14P09368419A0628|55 82|DNA-ligand binding screening
14P09368760A0665|5 8|PDK1
14P09368760A0665|26 58|Drosophila protein kinase DSTPK61
14P09368760A0665|96 114|sex differentiation
14P09369450A1358|28 36|HNF-1beta
14P09369450A1358|43 44|GR
14P09369450A1358|115 124|HNF-1 site
14P09369450A1358|130 132|GRE
14P09369450A1358|197 217|transcription factors
14P09369450A1358|242 264|transcription machinery
14P09369450A1358|267 294|steroid receptor coactivator
14P09369451A0693|33 36|AP-1
14P09369451A0693|60 69|TGAATCATCA
14P09369451A0693|84 106|myocyte enhancer factor
14P09369451A0693|106 108|MEF
14P09369451A0693|135 147|TTAAAAATAAAAA
14P09369451A0693|183 193|OP-1 effect
14P09369453A0273|27 38|Bcl-2 family
14P09369453A0273|39 41|BAD
14P09369453A0273|43 52|Bcl-xL/Bcl
14P09369453A0273|65 78|death promoter
14P09369453A0273|81 94|death enhancer
14P09369453A0273|110 129|transmembrane domain
14P09369482A0690|0 20|Electromobility shift
14P09369482A0690|23 43|cotransfection assays
14P09369482A0690|59 67|HNF1alpha
14P09369482A0690|75 78|HNF4
14P09369482A0690|118 139|G6Pase gene expression
14P09370276A0781|6 18|reading frame
14P09370276A0781|38 55|amino acid protein
14P09370307A0093|13 22|AACA motif
14P09370307A0093|96 113|barley gibberellin
14P09370307A0093|150 169|DNA binding proteins
14P09371431A1172|0 12|Strain CFN037
14P09371431A1172|16 29|R. etli mutant
14P09371431A1172|44 59|Tn5mob insertion
14P09371431A1172|83 102|thiCOGE gene cluster
14P09371431T0000|0 9|Expression
14P09371431T0000|69 89|terminal oxidase cbb3
14P09371431T0000|90 103|Rhizobium etli
14P09371455A0000|90 104|metalloprotease
14P09371455A0000|107 124|Vibrio cholerae O1
14P09371564A0713|28 31|3Lys
14P09371564A0713|55 57|RNA
14P09371566A1384|26 29|HeLa
14P09371566A1384|48 60|S100 extracts
14P09371566A1384|75 94|protein preparations
14P09371596T0000|61 77|hepatitis B virus
14P09371596T0000|97 116|receptor superfamily
14P09371612A1964|0 3|Acad
14P09371622A0779|0 7|Chimeras
14P09371622A0779|18 29|IE1 peptides
14P09371622A0779|89 110|lac operator sequences
14P09371626A1345|12 27|replicase assays
14P09371626A1345|46 48|VP2
14P09371626A1345|121 123|VP2
14P09371626A1345|126 136|replication
14P09371626A1345|175 187|mRNA template
14P09371657A0165|24 48|alanine cluster mutations
14P09371657A0165|48 50|R77
14P09371657A0165|55 58|R77A
14P09371657A0165|61 64|K79A
14P09371657A0165|68 78|E192A-E194A
14P09371657A0165|110 133|triphosphatase component
14P09371698A1254|0 11|Transfection
14P09371698A1254|14 18|HepG2
14P09371698A1254|22 34|SK-N-MC cells
14P09371698A1254|122 141|bp promoter fragment
14P09371698A1254|153 167|pseudo-TATA box
14P09371731A0627|41 58|eIF-2alpha kinases
14P09372287A0296|83 86|LVST
14P09372287A0296|118 121|MVST
14P09372287A0296|128 137|C1 segment
14P09372451T0000|0 7|Epitopes
14P09372451T0000|39 48|antibodies
14P09372451T0000|92 104|integrin beta
14P09372908A1068|24 32|Sex Combs
14P09372908A1068|103 117|gene repression
14P09372908A1068|139 154|Polycomb protein
14P09372908A1068|168 171|PREs
14P09372924A0758|48 57|NER system
14P09372924A0758|138 156|DNA repair reaction
14P09372924A0758|173 175|XPC
14P09372937T0000|14 48|information regulator Sir4p anchors
14P09372950A1283|51 59|structure
14P09372950A1283|69 77|sequences
14P09372950A1283|100 112|cleavage site
14P09372950A1283|119 128|processing
14P09372950A1283|136 141|U2 RNA
14P09372960A0456|0 16|Polysome analyses
14P09372960A0456|40 52|fal1-1 mutant
14P09372960A0456|104 106|40S
14P09372968A0532|0 16|Sequence analysis
14P09372968A0532|37 47|cDNA clones
14P09372968A0532|49 53|Dlc-1
14P09372968A0996|14 17|HeLa
14P09372968A0996|55 66|kappaB alpha
14P09372968A0996|112 116|Dlc-1
14P09373140A0000|3 18|mouse M-lysozyme
14P09373140A0000|83 97|gene regulation
14P09373155T0000|0 13|Identification
14P09373155T0000|27 37|chain genes
14P09373155T0000|56 67|mouse testis
14P09373155T0000|79 90|localization
14P09373155T0000|103 113|dynein gene
14P09373651A0255|68 86|acetone cyanohydrin
14P09373651A0255|89 104|hydrogen cyanide
14P09374082A0504|43 54|2-ethylhexyl
14P09374082A0504|66 69|MEHP
14P09374082A0504|82 99|hydrolysis product
14P09374082A0504|101 104|DEHP
14P09374082A0504|123 136|prostaglandins
14P09374082A0504|138 139|PG
14P09374082A0504|141 143|PGD
14P09374082A0504|148 153|9alpha
14P09374082A0504|169 177|PGF2alpha
14P09374082A0504|272 285|characteristic
14P09374541A0277|9 29|protein binding sites
14P09374541T0000|24 48|E2F recognition sequences
14P09374541T0000|57 81|thymidine kinase promoter
14P09374541T0000|86 107|cell cycle progression
14P09376325A0167|0 9|Comparison
14P09376325A0167|98 116|transcription units
14P09376626A0737|0 8|Radiation
14P09376626A0737|29 30|T4
14P09376626A0737|34 35|T3
14P09376626A0737|79 92|h postexposure
14P09376782A0328|35 37|MMT
14P09376782A0328|57 73|hepatitis C virus
14P09376782A0328|73 75|HCV
14P09377355A0362|3 8|author
14P09377355A0362|59 66|features
14P09377355A0362|83 91|disorders
14P09377355A0362|106 116|impairement
14P09377374A0000|12 27|characterization
14P09377374A0000|69 79|VH B course
14P09379301A2036|13 28|A. microcephalum
14P09379301A2036|44 51|A. wedli
14P09380504A1255|3 12|ZnF20 cDNA
14P09380504A1255|46 69|thyroid cancer cell line
14P09380504A1255|100 122|cycloheximide treatment
14P09380504A1255|150 163|actinomycin D.
14P09380507A0514|0 24|Glutathione S-transferase
14P09380507A0514|36 57|GST-DP fusion proteins
14P09380507A0514|108 141|DNA polymerase alpha gene promoter
14P09380697T0000|47 59|up-regulation
14P09380697T0000|62 88|caveolin gene transcription
14P09380697T0000|102 120|density lipoprotein
14P09380707A0714|21 29|LAZ3/BCL6
14P09380707A0714|38 41|SMRT
14P09381261A0970|0 10|CONCLUSIONS
14P09381261A0970|28 37|EPO levels
14P09381950A0209|0 8|Ischaemia
14P09381950A0209|80 90|reperfusion
14P09382498A0618|9 12|MCTs
14P09382498A0618|23 31|electrode
14P09382498A0618|91 94|MCTs
14P09382498A0618|103 111|electrode
14P09382850A0000|0 9|BACKGROUND
14P09382850A0000|11 29|Checkpoint pathways
14P09382850A0000|69 79|DNA lesions
14P09382886A1061|52 54|PKD
14P09382886A1061|76 78|p53
14P09382886A1061|116 118|SBM
14P09382886A1061|122 124|p53
14P09382924A0131|52 67|interferon-gamma
14P09382924A0131|69 77|IFN-gamma
14P09382924A0131|113 116|LMP2
14P09382924A0131|118 121|LMP7
14P09382924A0131|126 131|PSMB10
14P09382924A0131|155 168|20S proteasome
14P09382924A0131|222 226|PSMB6
14P09382924A0131|228 232|PSMB5
14P09382924A0131|237 241|PSMB7
14P09383156A0691|8 31|RNase E cleavage product
14P09383156A0691|63 90|polynucleotide phosphorylase
14P09383156A0691|91 96|PNPase
14P09383188A0654|45 61|ARG box consensus
14P09385169T0000|3 6|AONE
14P09385169T0000|24 46|productivity indicators
14P09386074A0694|29 42|LV dysfunction
14P09386074A0694|52 71|LV ejection fraction
14P09387333T0001|3 10|progress
14P09387333T0001|26 33|research
14P09387333T0001|51 57|nucleus
14P09387999A1053|15 19|DPOAE
14P09387999A1053|57 72|hair cell losses
14P09388198A1396|30 56|signal transduction pathway
14P09388198A1396|68 70|JNK
14P09388198A1396|72 74|ERK
14P09388198A1396|79 92|p38 MAP kinase
14P09388198A1396|164 177|autoregulation
14P09388199A0948|29 32|FadR
14P09388199A0948|44 54|DNA binding
14P09388199A0948|71 84|ligand binding
14P09388199A0948|93 107|protein fusions
14P09388199A0948|117 134|DNA binding domain
14P09388199A0948|135 138|LexA
14P09388199A0948|160 163|FadR
14P09388200A0639|0 9|Inhibition
14P09388200A0639|47 67|transcription factors
14P09388200A0639|74 92|MDM2 overexpression
14P09388201A1027|2 3|PU
14P09388201A1027|7 8|PD
14P09388201A1027|27 30|TATA
14P09388201A1027|33 43|CAAT motifs
14P09388246A0903|22 60|electron microscopy immunocytochemistry
14P09388271A1243|3 16|mobility shift
14P09388271A1243|75 77|PKC
14P09388271A1243|138 150|kinase kinase
14P09389137A0763|3 14|prescription
14P09389137A0763|34 37|C1-7
14P09389137A0763|39 42|T1-9
14P09389137A0763|46 49|L2-4
14P09389198A0363|9 17|aftermath
14P09389198A0363|20 29|excitation
14P09389198A0363|63 73|arithmetics
14P09389198A0363|79 91|A delta units
14P09389198A0363|139 147|threshold
14P09389492A0520|10 16|fashion
14P09389492A0520|58 65|response
14P09389492A0520|68 80|dexamethasone
14P09389492A0520|97 103|phorbol
14P09389492A0520|120 127|activity
14P09389666A0538|5 18|Hex expression
14P09389666A0538|54 78|anteroposterior asymmetry
14P09389666A0538|215 230|endoderm lineage
14P09389669A1009|25 44|dorsal leg cell fate
14P09389669A1009|78 91|leg disc cells
14P09389982A1383|0 10|CONCLUSIONS
14P09389982A1383|17 30|INR correction
14P09389982A1383|76 92|log reference INR
14P09389982A1383|124 142|regression analysis
14P09390125A0379|0 6|RESULTS
14P09390125A0379|18 20|FNF
14P09390183A1027|0 20|Western blot analysis
14P09390183A1027|50 69|NMT peptide antibody
14P09391173A0811|0 24|Transcription start sites
14P09391173A0811|28 47|plastid ACCase genes
14P09391173A0811|96 99|RACE
14P09392979T0000|40 52|San Francisco
14P09392979T0000|53 62|California
14P09393706A1171|5 7|Fis
14P09393717A1517|5 16|observations
14P09393717A1517|51 60|expression
14P09393717A1517|83 99|mutator phenotype
14P09393717A1517|128 136|phenotype
14P09393717A1517|154 163|mutC cells
14P09393771A1659|0 17|TNF-alpha exposure
14P09393771A1659|87 88|Mr
14P09393875A0873|23 36|papillomavirus
14P09393875A0873|84 95|virus genome
14P09393875A0873|132 142|c-fos mRNAs
14P09393875A0873|201 218|Fos protein levels
14P09393875A0873|224 237|papillomavirus
14P09393966A0190|17 19|IgH
14P09393966A0190|40 42|CHA
14P09393966A0190|46 48|CHB
14P09394650A0121|63 73|lymph nodes
14P09394650A0121|101 102|US
14P09395456A0424|34 54|substrate recognition
14P09395456A0424|90 107|proenteropeptidase
14P09395456A0424|137 156|transmembrane domain
14P09395456A0424|161 174|signal peptide
14P09395470A0294|0 11|CKbeta4GT-II
14P09395470A0294|38 63|transmembrane glycoprotein
14P09395470A0294|95 113|glycosylation sites
14P09395525A0395|50 54|C/EBP
14P09395525A0395|123 126|HS3D
14P09395525A0395|138 147|C/EBPdelta
14P09395525A0395|162 175|IGF-I promoter
14P09396402A0264|0 7|PATIENTS
14P09396402A0264|11 17|METHODS
14P09396402A0264|19 32|Semen analyses
14P09396402A0264|72 73|HD
14P09396427A1488|25 46|infarct-zone viability
14P09396427A1488|126 128|AMI
14P09396437A0878|5 14|BMI cutoff
14P09396437A0878|30 41|NE spillover
14P09396722A0185|8 12|ApxII
14P09396722A0185|39 69|ascorbate peroxidase isoenzymes
14P09396796A1173|31 35|CDF-1
14P09396796A1173|43 59|E2F family member
14P09396796A1173|93 113|cell cycle regulation
14P09396796A1173|114 118|CDF-1
14P09396796A1173|122 124|E2F
14P09396823T0000|38 51|DNA polymerase
14P09396823T0000|60 62|DNA
14P09396823T0000|69 91|RNA exonuclease domains
14P09397261A0940|0 19|Interleukin-1 levels
14P09397723T0001|0 21|Responsibility matters
14P09398267A0440|0 21|Southern blot analysis
14P09398267A0440|50 52|DNA
14P09398267A0440|64 87|chick embryo fibroblasts
14P09398267A0440|87 89|CEF
14P09398267A0440|104 107|MEK2
14P09398332A0732|0 8|Sequences
14P09398332A0732|39 44|CTLA-4
14P09398332A0732|69 76|161TTGVY
14P09398332A0732|79 84|CTLA-4
14P09398332A0732|150 166|SH2 binding motif
14P09398332A0732|166 172|165YVKM
14P09398332A0732|184 199|CTLA-4 signaling
14P09398598A0256|36 48|hamster ovary
14P09398598A0256|49 51|CHO
14P09398598A0256|78 89|CD4 fragment
14P09398855A0438|0 5|SCID V
14P09398855A0438|8 22|J recombination
14P09398855A0438|42 54|T-lymphocytes
14P09398855A0438|82 98|gamma-irradiation
14P09398855A0438|132 139|p53 gene
14P09398855A0438|176 194|DNA repair activity
14P09398855A0438|205 214|DNA damage
14P09398855A0438|248 250|p53
14P09400613A0594|0 11|Coexpression
14P09400613A0594|98 100|PKR
14P09400613A0594|108 119|K296R mutant
14P09400613A0594|149 151|PKR
14P09400613A0594|159 168|K64E/K296R
14P09400613A0594|223 256|PKR-Gal4 activation domain fusions
14P09400613A0594|279 282|HIS3
14P09400613A1209|5 33|GST-PKR fusion chromatography
14P09400613A1209|81 92|PKR homologs
14P09400738A1046|92 106|CB instillation
14P09402029A1632|26 37|strain H37Ra
14P09402029A1632|47 59|hybridization
14P09402029A1632|164 175|copy numbers
14P09402029A1632|204 215|strain H37Rv
14P09402088A2250|38 50|configuration
14P09402088A2250|84 101|AVP gene precursor
14P09402139A1121|0 11|Similarities
14P09402139A1121|33 58|phosphoenolpyruvate kinase
14P09402139A1121|59 63|PEPCK
14P09402139A1121|109 122|glucocorticoid
14P09402139A1121|208 214|IGFBP-1
14P09402139A1121|239 256|glucose metabolism
14P09403059A0209|34 45|DNA elements
14P09403059A0209|56 60|LINES
14P09403059A0209|62 66|SINES
14P09403059A0209|68 103|medium reiteration frequency repeats
14P09404725A0644|19 30|gangliosides
14P09404725A0644|50 56|females
14P09404725A0644|83 91|exception
14P09405195A0320|63 75|recombination
14P09405195A0320|140 142|DNA
14P09405195A0320|149 163|intron excision
14P09405195A0320|197 199|DNA
14P09405195A0320|215 227|recombination
14P09405380A0800|3 11|existence
14P09405380A0800|22 31|categories
14P09405380A0800|74 83|properties
14P09405380A0800|108 117|retrovirus
14P09405536A0777|9 30|conditioning procedure
14P09405536A0777|34 40|C-fiber
14P09405536A0777|161 180|conditioning stimuli
14P09405685A0113|20 51|DNA binding transcription factor
14P09405685A0113|50 52|p53
14P09405685A0113|112 125|GPyPyPyPuPuPuC
14P09405685A0113|136 144|GPyPyPy-3
14P09407026A0426|0 12|TSA treatment
14P09407026A0426|42 64|enhancer factor binding
14P09407026A0426|104 122|chromatin templates
14P09407026A0426|136 154|protein acetylation
14P09407026A0426|157 176|chromatin remodeling
14P09407031A0557|4 12|UV damage
14P09407031A0557|13 16|Crb2
14P09407031A0557|99 109|Chk1 kinase
14P09407031A0557|135 149|Cdc2 activation
14P09407031A0974|17 30|overexpression
14P09407031A0974|33 36|Chk1
14P09407031A0974|69 80|crb2 mutants
14P09407036T0000|0 10|Tcn1p/Crz1p
14P09407036T0000|34 53|transcription factor
14P09407090T0000|0 8|Structure
14P09407090T0000|46 54|SR-BI/CLA
14P09407642A0305|15 27|gel technique
14P09407642A0305|45 62|antibody detection
14P09407642A0305|65 78|identification
14P09408516T0000|0 8|Stability
14P09408516T0000|11 23|pyrimethamine
14P09408516T0000|33 50|dosage formulation
14P09408796A0648|38 78|WAIS-R factor scores Verbal Comprehension
14P09408796A0648|89 103|Distractibility
14P09408796A0648|138 142|WMS-R
14P09408796A0648|146 157|CVLT indices
14P09409416A0111|66 68|MHz
14P09409416A0111|75 92|Doppler instrument
14P09409416A0111|93 104|TC-2 64B EME
14P09409774A0214|67 87|rat Rattus norvegicus
14P09409774A0214|90 99|VCSA1 gene
14P09409774A0214|126 141|polypeptide SMR1
14P09409774A0214|148 157|VCSB1 gene
14P09409821T0000|26 35|RAD30 gene
14P09409821T0000|77 86|DNA damage
14P09409821T0000|125 156|postreplication repair mechanism
14P09411459A0729|34 46|deletion task
14P09411459A0729|61 71|puppet game
14P09411459A0729|79 89|pretraining
14P09411459A0729|104 117|vowel deletion
14P09411459A0729|190 202|CVCC material
14P09412079T0001|0 11|Diet therapy
14P09412079T0001|36 49|stomach ulcers
14P09413375A1486|2 13|ICU patients
14P09413375A1486|17 19|LIS
14P09413375A1486|51 60|IL-6 level
14P09413375A1486|84 104|plasma concentrations
14P09414074A0827|0 18|Resistance training
14P09414074A0827|158 173|performance task
14P09414074A0827|180 182|SSP
14P09414287A0637|0 15|Gel-shift assays
14P09414287A0637|28 44|Sp1 binding sites
14P09414319A1442|0 5|Y15170
14P09414319A1442|7 12|Surf-2
14P09414319A1442|14 19|Surf-4
14P09414319A1442|22 27|Y15171
14P09414319A1442|29 34|Surf-3
14P09414319A1442|36 41|Surf-1
14P09414319A1442|43 48|Surf-6
14P09414319A1442|54 59|Y15172
14P09414319A1442|61 66|Surf-5
14P09415711A1348|0 17|Gel mobility shift
14P09415711A1348|81 94|DDT1MF-2 cells
14P09415711A1348|113 115|CRE
14P09415711A1348|121 136|alpha 1B-AR gene
14P09415711A1348|140 158|CRE binding protein
14P09416467A0959|48 61|ACE inhibitors
14P09416467A0959|89 108|ischemia-reperfusion
14P09416467A0959|123 139|scavenging action
14P09416898A1798|69 81|ARVD patients
14P09417082A0127|11 27|signaling cascade
14P09417082A0127|40 57|urokinase receptor
14P09417108A0000|9 21|Htf9-a/RanBP1
14P09417108A0000|25 36|Htf9-c genes
14P09417493A0823|53 73|laboratory indicators
14P09417493A0823|75 86|inflammation
14P09417493A0823|106 122|alpha 2-globuline
14P09417493A0823|123 138|prostaglandin E2
14P09417870A0105|39 54|protein kinase C
14P09417870A0105|75 98|B16 mouse melanoma cells
14P09417870A0105|100 117|phorbol dibutyrate
14P09417870A0105|118 121|PDBu
14P09417928A0980|0 10|Replacement
14P09417928A0980|35 43|His128Asn
14P09417928A0980|51 59|Gln155Lys
14P09417928A0980|66 80|reading helices
14P09417941A1287|3 20|disulphide bridges
14P09417941A1287|43 64|spermadhesin molecules
14P09417941A1287|71 81|CUB domains
14P09417941A1287|124 125|LG
14P09418040T0000|0 11|Mg-chelatase
14P09418040T0000|22 35|identification
14P09418040T0000|39 57|Chl D cDNA sequence
14P09418040T0000|151 164|reconstitution
14P09418040T0000|170 184|enzyme activity
14P09418040T0000|186 198|co-expression
14P09418040T0000|212 216|CHL D
14P09418040T0000|217 221|CHL H
14P09418040T0000|224 229|CHL I.
14P09418057A0684|3 7|R-EST
14P09418861A0623|67 82|protein kinase C
14P09418861A0623|107 132|pleckstrin homology domain
14P09418871A0620|21 23|DDB
14P09418871A0620|50 82|coimmunoprecipitation experiments
14P09418882A0760|63 68|Prp42p
14P09418882A0760|92 99|U1 snRNA
14P09418882A0760|103 116|yeast extracts
14P09418905A1396|61 63|Ras
14P09418905A1396|84 97|DAG production
14P09418905A1396|110 112|EGF
14P09418905A1396|129 141|S-phase entry
14P09418905A1396|144 158|gene expression
14P09418905A1396|186 188|PKC
14P09419415A0236|26 40|STAT activation
14P09419415A0236|56 76|fibroblast cell lines
14P09419421A0385|36 43|NF-Y/CBF
14P09419421A0385|46 49|TKC1
14P09419421A0385|90 96|S phase
14P09419680A1112|0 9|CONCLUSION
14P09419680A1112|39 56|barrier disruption
14P09419680A1112|90 104|single-fraction
14P09419680A1112|115 132|irradiation injury
14P09420219A0284|15 27|investigation
14P09420219A0284|30 39|parameters
14P09420219A0284|117 135|beta-actin minigene
14P09420219A0284|179 195|enhancer-promoter
14P09420219A0284|210 220|tumor virus
14P09420219A0284|254 268|adenovirus type
14P09420219A0284|270 272|Ad5
14P09420220A0070|0 3|Cell
14P09420220A0070|92 95|HCMV
14P09420220A0070|125 126|J.
14P09420234A0654|0 8|MpB GroEL
14P09420234A0654|20 38|sequence similarity
14P09420234A0654|62 66|GroEL
14P09420234A0654|87 106|chaperonin-60 family
14P09420239A1937|85 86|TM
14P09420239A1937|90 109|Nef coding sequences
14P09420239A1937|118 133|RNA splice donor
14P09420239A1937|149 162|TATA box sites
14P09420239A1937|165 173|Sp1 sites
14P09420239A1937|194 202|V2 region
14P09420239A1937|204 205|SU
14P09420239A1937|217 248|consensus neutralization epitope
14P09420239A1937|266 284|glycosylation sites
14P09420239A1937|286 287|SU
14P09420251A1363|0 1|C.
14P09420252A0092|30 32|LTR
14P09420252A0092|57 66|expression
14P09420252A0092|169 178|expression
14P09420252A0092|189 206|auxiliary proteins
14P09420269A0000|20 22|RNA
14P09420269A0000|25 37|rubella virus
14P09420269A0000|38 40|RUB
14P09420269A0000|139 140|SL
14P09420269A0000|200 202|RNA
14P09420269A0000|209 210|SL
14P09420275A0682|31 42|CBF2 binding
14P09420275A0682|65 80|oligonucleotides
14P09420275A0682|95 116|transversion mutations
14P09420275A1111|26 29|CBF2
14P09420275A1111|45 49|LMP-1
14P09420275A1111|51 55|LMP-2
14P09420275A1111|60 73|CD23 promoters
14P09420671A1190|0 10|CONCLUSIONS
14P09420671A1190|33 47|99mTc sestamibi
14P09420671A1190|86 99|artery disease
14P09420671A1190|141 156|adenosine stress
14P09421507A0000|5 18|protein family
14P09421507A0000|54 70|pre-mRNA splicing
14P09421508A0696|26 30|TCF11
14P09421508A0696|82 85|MafG
14P09421508A0696|107 124|transfection assay
14P09421511A0827|59 84|RNA-polymerase specificity
14P09421511A0827|86 114|telomerase RNA-gene promoters
14P09421511A0827|146 162|template sequence
14P09421516A1516|0 12|Deadenylation
14P09421516A1516|23 38|beta-globin mRNA
14P09421516A1516|40 49|K562 cells
14P09421516A1516|82 94|NIH 3T3 cells
14P09421516A1516|137 152|beta-globin mRNA
14P09421516A1516|154 163|K562 cells
14P09421516A1516|186 203|deadenylation step
14P09421521T0000|0 26|Holliday junction resolvase
14P09421521T0000|88 106|CCE1 homologue YDC2
14P09422351A0000|0 2|Ca2
14P09422351A0000|41 44|CaMK
14P09422351A0000|66 96|serine/threonine protein kinase
14P09422351A0000|169 189|transcription factors
14P09422727A0196|38 45|TGACGTGA
14P09422727A0196|67 100|protein kinase A signaling pathway
14P09422727A0196|143 161|CRE binding protein
14P09422727A0196|161 164|CREB
14P09422727A0196|179 200|transcription factor-2
14P09422727A0196|201 205|ATF-2
14P09423123A0000|0 3|IVOX
14P09423310A0251|0 18|Histopathologically
14P09423310A0251|27 38|lymphangioma
14P09423310A0251|120 123|CD34
14P09423310A0251|127 132|Factor
14P09423856A1098|0 18|Protease activities
14P09423856A1098|154 163|processing
14P09423856A1098|183 197|autoproteolysis
14P09423856A1098|212 224|peptide bonds
14P09423968A0039|3 11|mechanism
14P09423968A0039|26 34|analgesia
14P09423968A0039|63 73|interaction
14P09423968A0039|124 130|systems
14P09423968A0039|132 138|defense
14P09423968A0039|185 191|defense
14P09423968A0039|195 205|nociception
14P09423968A0039|212 220|processes
14P09423968A0039|244 251|ontogeny
14P09424012A1774|10 31|field placement errors
14P09424012A1774|57 68|mm distances
14P09424012A1774|95 103|isocenter
14P09425036A0649|45 61|Src family member
14P09425036A0649|61 63|Lck
14P09425036A0649|122 134|Csk substrate
14P09425038A0752|0 1|A.
14P09425038A0752|3 7|Swift
14P09425038A0752|9 10|A.
14P09425676A0000|28 44|stimulus-response
14P09425676A0000|46 48|S-R
14P09425676A0000|64 86|S-R compatibility tasks
14P09426068A0826|3 22|c-myc/TGF-alpha HCCs
14P09426068A0826|76 84|TGF-alpha
14P09426143A1358|56 58|CRP
14P09426143A1358|62 65|KdgR
14P09426143A1358|86 103|pectinolysis genes
14P09426143A1358|203 216|RNA polymerase
14P09426143A1358|241 250|DNA region
14P09426183A0000|13 32|Rel/NF-kappaB family
14P09426183A0000|34 65|vertebrate transcription factors
14P09426183A0000|129 131|DNA
14P09426239A0386|3 12|cglIM gene
14P09426239A0386|97 115|restriction enzymes
14P09426595T0000|32 57|saccharopine dehydrogenase
14P09426595T0000|61 80|Arabidopsis thaliana
14P09426595T0000|81 99|nucleotide sequence
14P09426907A0391|16 28|investigation
14P09426907A0391|46 56|formulation
14P09426907A0391|59 77|silver sulfadiazine
14P09426958A0110|51 55|CO-Ag
14P09426958A0110|67 86|corneal cDNA library
14P09427544A0000|16 27|Amycolata sp
14P09427544A0000|50 51|EC
14P09427544A0000|98 108|DNA library
14P09427544A0000|130 133|TK24
14P09427551A0501|41 50|kb introns
14P09427551A0501|80 89|chromosome
14P09427551A0501|93 108|linkage analysis
14P09427627A0802|2 16|Xenopus embryos
14P09427627A0802|30 50|PDGF receptor protein
14P09427627A0930|47 66|transphosphorylation
14P09427627A0930|104 106|p70
14P09427627A0930|108 110|S6k
14P09427627A0930|114 123|MAP kinase
14P09427627A0930|145 150|FK1012
14P09427627T0000|33 55|PDGF receptor signaling
14P09427627T0000|66 84|membrane attachment
14P09427844A0739|22 32|dAK subunit
14P09427844A0739|60 70|association
14P09427844A0739|81 91|dCK subunit
14P09427844A0739|169 175|subunit
14P09428389A1805|0 10|CONCLUSIONS
14P09428389A1805|29 40|bicalutamide
14P09428389A1805|94 99|LHRH-A
14P09428389A1805|111 128|serum testosterone
14P09428389A1805|145 156|bicalutamide
14P09428787A0138|85 111|p69/71 2-5A synthetase gene
14P09428799A0897|86 109|intron/exon organization
14P09428799A0897|141 147|P450scc
14P09429913A0528|0 6|RESULTS
14P09429913A0528|115 118|EMDR
14P09430461A0742|22 32|defect size
14P09430461A0742|39 51|BMIPP imaging
14P09430461A0742|144 168|contrast ventriculography
14P09430461A0742|185 194|CONCLUSION
14P09430461A0742|278 290|BMIPP imaging
14P09430461A0742|308 321|quantification
14P09430461A0742|324 334|defect size
14P09430461A0742|350 368|threshold technique
14P09430461A0742|398 410|determination
14P09430661A0796|31 45|EphB1 receptors
14P09430661A0796|59 73|Nck recruitment
14P09430661A0796|101 114|JNK activation
14P09430661A0796|125 149|cell attachment responses
15P09430668A0172a|14 29|HMG-CoA synthase
15P09430668A0172a|98 103|SREBPs
14P09430730A0374|0 1|S.
14P09430730A0374|6 11|Walter
14P09430730A0374|13 14|P.
14P09431812A0576|21 22|Hh
14P09431812A0576|26 32|Patched
14P09431812A0576|34 36|Ptc
14P09431812A0576|53 68|Ci binding sites
14P09431812A0576|126 133|S2 cells
14P09431828A1472|30 46|cyclosporine DR/C
14P09431828A1472|47 55|SS trough
14P09432752A0109|0 7|Patients
14P09432752A0109|65 87|treatment possibilities
14P09434160A0767|7 13|PTPases
14P09434160A0767|54 75|bone marrow stem cells
14P09434160A2078|0 9|Expression
14P09434160A2078|12 16|PTPRO
14P09434160A2078|39 42|CD34
14P09434160A2078|44 60|bone marrow cells
14P09434185A0902|17 26|SPP1 genes
14P09434185A0902|51 63|DNA packaging
14P09434185A0902|66 88|phage assembly proteins
14P09434185A0902|169 178|DNA phages
14P09434979A0790|3 9|results
14P09434979A0790|40 53|photon fluence
14P09434979A0790|68 81|photon fluence
14P09434979A0790|95 104|collimator
14P09434979A0790|142 150|isocenter
14P09435056A0128|27 38|pediocin AcH
14P09435056A0128|39 41|Lys
14P09435056A0128|46 48|Cys
14P09435056A0128|146 158|COOH terminus
14P09435056A0128|202 204|MBP
14P09435116A0437|35 44|MS-MS data
14P09435116A0437|49 86|trofluoroacetyl-biphenylol derivatives
15P09435789A0961a|8 12|RAD17
15P09435789A0961a|14 18|RAD24
15P09435789A0961a|22 25|MEC3
15P09435789A0961a|43 59|cell cycle arrest
15P09435789A0961a|62 68|S phase
15P09435789A0961a|93 94|HU
15P09435789A0961a|159 160|HU
15P09435789A0961a|216 225|DNA damage
14P09435806T0001|30 44|growth kinetics
14P09435806T0001|60 77|cancer recurrences
14P09435806T0001|79 83|CA125
14P09436657A0303|46 53|pathways
14P09436657A0303|56 69|carcinogenesis
14P09436657A0303|109 120|risk factors
14P09436657A0303|156 164|knowledge
14P09436706A0168|38 59|sperm injection cycles
14P09436706A0168|182 220|gonadotrophin-releasing hormone agonist
14P09436706A0168|220 235|leuprolide depot
14P09436795A0350|0 19|Protein C deficiency
14P09436795A0350|20 39|protein S deficiency
14P09436795A0350|58 68|risk factor
14P09436989A1011|65 68|MOB1
14P09436989A1011|83 107|cell cycle reset function
14P09436989A1011|135 163|spindle pole body duplication
14P09437001A0769|11 24|overproduction
14P09437001A0769|27 31|Der3p
14P09437001A0769|43 56|sec61-2 strain
14P09437001A0769|71 81|temperature
14P09438165A0405|21 29|PC levels
14P09438165A0405|83 99|VOD manifestation
14P09438427A0727|22 32|CE2 element
14P09438427A0727|44 59|Hoxa1 expression
14P09438427A0727|106 143|Hoxa1 beta-galactosidase reporter gene
14P09438427A0727|167 177|CE2 element
14P09438427T0000|72 81|expression
14P09438427T0000|87 96|Hoxa1 gene
14P09440166A0857|0 6|RESULTS
14P09440166A0857|17 36|cDNA insert sequence
14P09440166A0857|41 51|nucleotides
14P09440166A0857|92 102|nucleotides
14P09440166A0857|131 141|nucleotides
14P09440616A0422|20 29|activities
14P09441664A0377|41 60|transcription factor
14P09441664A0377|61 65|HNF-6
14P09441664A0377|85 112|HNF-3 beta promoter activity
14P09441746A0546|56 60|GPR39
14P09442017A0435|6 12|Science
14P09442024A0236|0 1|P.
14P09442024A0236|3 8|Peyron
14P09442024A0236|10 11|J.
14P09442024A0708|1 15|hybridoma clone
14P09442024A0708|16 18|7H1
14P09442024A0708|49 57|CEMLAI/NP
14P09442024A0708|75 96|fibroblasts MRC5 cells
14P09442024A0708|121 123|P47
14P09442024A0708|144 157|Jacalin lectin
14P09442024A0708|169 177|O-glycans
14P09442031A0586|112 135|TSHR ectodomain variants
14P09442031A0586|135 154|places cleavage Site
14P09442072A0716|7 11|DNase
14P09442072A0716|13 24|footprinting
14P09442072A0716|74 77|Hepa
14P09442072A0716|190 202|liver factors
14P09442072A0716|229 231|DNA
14P09442080A0856|28 37|IM-9 cells
14P09442080A0856|48 52|SHP-1
14P09442080A0856|56 60|SHP-2
14P09442080A0856|90 94|SHP-2
14P09442080A0856|102 106|SHP-1
14P09442080A0856|113 144|glutathione S-transferase fusion
14P09442080A0856|156 158|GHR
14P09442172A0908|19 21|FSH
14P09442172A0908|73 90|gonadotrophin dose
14P09442172A0908|128 141|pregnancy rate
14P09443948A0000|77 79|EIT
14P09443948A0000|112 125|trichinellosis
14P09443948A0000|140 162|immunofluorescence test
14P09443948A0000|163 165|IIF
14P09443948A0000|201 214|trichinellosis
14P09443948A0000|217 225|Argentina
14P09443972A1145|19 22|GKLF
14P09443972A1145|43 62|transcription factor
14P09443973A1028|0 3|CES4
14P09443978A0262|62 64|Sp1
14P09443978A0262|85 97|transcription
14P09443978A0262|130 139|TATA boxes
14P09443978A0262|191 198|TATA box
14P09444316A0388|68 69|F0
14P09444316A0388|73 82|F1 animals
14P09445056A0215|27 48|chemical cross-linking
14P09445056A0215|56 72|sulfosuccinimidyl
14P09445056A0215|83 85|BS3
14P09445056A0215|120 132|gp41 oligomer
14P09445488A0230|23 40|USH1C disease gene
14P09445488A0230|110 113|YACs
14P09445488A0230|134 152|STS content mapping
14P09445488A0230|154 174|Alu-PCR hybridization
14P09445488A1169|0 18|PowerBLAST analysis
14P09445488A1169|63 66|ESTs
14P09445488A1169|83 85|BIR
14P09445488A1169|87 90|SUR1
14P09445488A1169|168 181|DNA binding/EF
14P09446600A0260|1 14|fusion protein
14P09446600A0260|24 41|beta-galactosidase
14P09446600A0260|56 58|Ahr
14P09446616A0780|0 13|Reconstitution
14P09446616A0780|16 29|Raf-1 activity
14P09446616A0780|60 63|Jak1
14P09446815A1021|2 9|addition
14P09446815A1021|31 36|region
14P09447917A0000|15 21|Geisler
14P09447917A0000|23 31|Brain Res
14P09447962A0452|9 18|transcript
14P09447962A1027|18 31|interpretation
14P09447962A1027|46 49|XRN1
14P09447962A1027|226 240|HIS4 mRNA level
14P09447963A0223|0 3|Sip1
14P09447963A0223|54 57|SC35
14P09447963A0223|60 74|splicing factor
14P09447973A0168|41 61|myristoylation signal
14P09447973A0168|69 75|MyrSos1
14P09447973A0168|102 114|NIH 3T3 cells
14P09447973A0168|129 143|mSos C terminus
14P09447973A0168|143 156|MyrSos1-deltaC
14P09447979A1430|72 105|guanine nucleotide exchange factor
14P09447979A1430|104 107|GNEF
14P09447994A0000|112 114|AMP
14P09447994A0000|121 137|response elements
14P09447994A0000|138 141|CREs
14P09447994A0000|161 179|c-fos transcription
14P09448268A0186|20 22|Nlk
14P09448574A0964|30 32|FDG
14P09448574A0964|48 52|RACLO
14P09448574A0964|147 160|system atrophy
14P09449018T0000|0 20|Childhood misbehavior
14P09450932A0142|56 80|DNA structure checkpoints
14P09450932A0142|110 122|DNA synthesis
14P09451003A0894|5 22|Esigma54 promoters
14P09451003A0894|37 39|CRP
14P09451003A0894|60 77|sigma54 activators
14P09451003A0894|140 147|Esigma54
14P09451003A0894|154 169|CRP-cAMP complex
14P09451016A1037|0 5|GlcNAc
14P09451016A1037|10 41|GlcNAc2-PP-Dolichol biosynthesis
14P09451857T0001|0 12|Demonstration
14P09451857T0001|15 28|tissue lesions
14P09451857T0001|57 69|determination
14P09451857T0001|72 86|creatine kinase
14P09452421A1042|0 9|Antibodies
14P09452421A1042|23 32|GST mSH2-B
14P09452421A1042|100 102|Tyr
14P09452444A0000|0 12|Interleukin-6
14P09452444A0000|14 17|IL-6
14P09452444A0000|95 109|phase reactions
14P09452444A0450|63 80|IL-6 gene promoter
14P09452444A0450|134 154|transcription factors
14P09453537A0863|28 37|CCAATC box
14P09453537A0863|69 76|GC boxes
14P09453537A0863|83 99|recognition sites
14P09453537A0863|102 104|SP1
14P09453689A0000|41 44|S4-5
14P09453689A0000|59 61|PPS
14P09453689A0000|82 85|S2-4
14P09453689A0000|94 96|BCR
14P09453689A0000|127 129|SCI
14P09453689A0000|146 170|bladder function recovery
14P09454719A0181|51 67|LTR R/U5 junction
14P09454719A0181|100 128|AAUAAA polyadenylation signal
14P09454719A0181|166 197|polyadenylation signal sequences
14P09454735A1782|11 31|MEK inhibitor PD98059
14P09454735A1782|64 89|MAP kinase phosphorylation
14P09454735A1782|116 135|adhesion disassembly
14P09455695A0762|0 9|ALT levels
14P09455695A0762|40 49|AST levels
14P09455695A0762|79 97|vitamin E treatment
14P09456312A1064|37 43|RanGAP1
14P09456312A1064|72 90|localization signal
14P09458021A1373|20 22|MMF
14P09458021A1373|32 41|AZA groups
14P09458030A0192|43 45|MMF
14P09458030A0192|54 76|bone mineral metabolism
14P09459241A0707|0 3|Pao2
14P09459685T0001|7 20|configurations
14P09459685T0001|35 48|stress factors
14P09459685T0001|87 97|adolescents
14P09459835A0297|16 19|PMEA
14P09459835A0297|33 49|mg/kg body weight
14P09459835A0297|65 69|FPMPA
14P09459835A0297|83 99|mg/kg body weight
14P09460171T0000|0 9|Resistance
14P09460171T0000|12 26|thyroid hormone
14P09460171T0000|82 107|thyroid hormone disruptors
14P09461594A0000|36 56|DT40 lymphoma B cells
14P09461594A0000|86 88|EMF
14P09461594A0000|136 156|phospholipase Cgamma2
14P09461594A0000|157 166|PLC-gamma2
14P09461594A0000|186 215|inositol phospholipid turnover
14P09463174A0670|23 29|results
14P09463174A0670|42 49|patients
14P09463174A0670|75 80|period
14P09463174A0670|85 90|months
14P09463380A1050|48 68|mesoderm marker genes
14P09463380A1050|76 80|Smad1
14P09463560A0124|0 7|PATIENTS
14P09463560A0124|11 16|METHOD
14P09463964A0243|38 51|micrograms l-1
14P09463964A0243|67 74|antibody
14P09463964A0243|92 105|micrograms l-1
14P09463964A0243|140 148|antiserum
14P09463991T0000|11 15|audit
14P09464248A0289|10 17|TATA box
14P09464525T0000|0 9|Expression
14P09464525T0000|13 28|characterization
14P09464525T0000|54 55|Fv
14P09464525T0000|59 70|Fv fragments
14P09465035A1032|9 17|inhibitor
14P09465035A1032|51 58|fraction
14P09465035A1032|81 88|activity
14P09465783A0449|0 19|Platelet aggregation
14P09465783A0449|33 54|micrograms collagen/ml
14P09465783A0449|94 96|ASA
14P09466267A1192|32 34|IHF
14P09466267A1192|81 100|dmsA-lacZ expression
14P09466931T0000|0 12|Cross-talking
14P09466931T0000|60 75|response element
14P09466931T0000|87 106|ng-2 intermolt genes
14P09467044A0973|14 38|breast tumor relapse rate
14P09467044A0973|56 59|PALP
14P09467044A0973|63 74|MGDET groups
14P09467707T0000|0 18|Sibling aggregation
14P09467707T0000|39 61|lipoprotein cholesterol
14P09467707T0000|83 92|A-I levels
14P09467707T0000|119 138|Bogalusa Heart Study
14P09467900A0701|3 16|CAPLC1 protein
14P09467900A0701|80 98|amino acid residues
14P09467900A0701|106 113|X domain
14P09467900A0701|131 140|N-terminus
14P09467900A0701|172 181|EF-hand Ca
14P09467955A0468|45 62|PEA3 binding sites
14P09467955A0468|66 78|PEA3 promoter
14P09467955A0468|97 100|PEA3
14P09468386A0594|0 4|Pet-1
14P09468386A0594|27 34|PEA3 ETS
14P09468386A0594|64 76|transcription
14P09468386A0594|88 106|promoter constructs
14P09468509A0463|21 30|F2771 cDNA
14P09468509A0463|43 51|COS cells
14P09468514A1065|0 16|Northern analysis
14P09468515A0621|27 41|promoter region
14P09468515A0621|78 94|SF-1 binding site
14P09468515A0621|137 140|SF-1
14P09469415A1337|73 93|CTL target structures
14P09469415A1337|160 172|CTL responses
14P09469415A1337|180 195|DNA immunization
14P09469820A0151|43 51|YAP1 uORF
14P09469820A0151|59 68|YAP2 uORF1
14P09469820A0151|89 102|reading frames
14P09469820A0151|180 182|UTR
14P09469833A0533|34 49|site specificity
14P09469833A0533|55 70|deletion mutants
14P09469833A0533|78 88|bp sequence
14P09469933A1060|44 51|CLIP-170
14P09469933A1060|78 83|Restin
14P09471984A0000|0 9|BACKGROUND
14P09471984A0000|11 19|Chemicals
14P09471984A0000|74 91|contact dermatitis
14P09472038T0000|12 23|polarization
14P09472038T0000|26 32|T cells
14P09472038T0000|47 60|immunoreceptor
14P09472608A0253|80 93|HIV-1 promoter
14P09472608A0253|120 125|U-87MG
14P09472608A0253|146 152|SK-N-MC
14P09472608A0253|171 176|Jurkat
14P09472608A0253|180 197|transfection assay
14P09472616A1004|15 25|amino acids
14P09472616A1004|55 57|VP7
15P09473040A1303a|45 73|siderophore system activities
15P09473040A1303b|45 73|siderophore system activities
14P09473317X2131|0 8|Copyright
14P09473317X2131|13 26|Academic Press
14P09473483A0953|74 83|Rev mutant
14P09473483A0953|127 141|HIV-I infection
14P09473483A0953|171 175|HIV-I
14P09473483A0953|179 184|HTLV-1
14P09473755A0318|0 7|PATIENTS
14P09473755A0318|11 17|METHODS
14P09473755A0318|26 32|January
14P09474001A0825|14 16|SPs
14P09474001A0825|101 105|MMFCV
14P09474001A0825|134 138|MMFCV
14P09474001A0825|154 155|SP
14P09474648A0298|13 19|P-SAECG
14P09474648A0298|32 47|frequency domain
14P09474648A0298|63 65|Paf
14P09475378A1449|18 56|transcription-polymerase chain reaction
14P09475378A1449|58 70|HPLC analysis
14P09475378A1449|80 90|RUSH-1alpha
14P09475724T0000|0 3|TOR2
14P09475724T0000|22 39|signaling pathways
14P09475898T0000|13 25|amnioinfusion
14P09476399A0141|25 38|tea plantation
14P09476399A0141|40 44|Kandy
14P09476520A1326|25 35|interaction
14P09476520A1326|67 74|profiles
14P09476520A1326|98 107|antibodies
14P09476520A1326|129 138|complexity
14P09476520A1326|151 159|existence
14P09476520A1326|177 189|heterogeneity
14P09476520A1326|197 205|molecules
14P09477316A0140|38 55|Hox gene induction
14P09477316A0140|81 98|Hox gene regulator
14P09477316A0140|101 143|leucine zipper transcription factor MafB/Kr
14P09478921A0126|0 9|Substrates
14P09478921A0126|13 16|p210
14P09478921A0126|66 68|CML
14P09478971A1896|0 18|Reporter constructs
14P09478971A1896|72 74|AhR
14P09478971A1896|121 126|Cyp1B1
14P09478971A1896|129 152|mouse embryo fibroblasts
14P09478976A0718|0 19|Transfection studies
14P09478976A0718|117 119|OSM
14P09478976T0000|0 11|Oncostatin M
14P09478976T0000|60 71|AP-1 element
14P09478976T0000|97 124|metalloproteinase-1 promoter
14P09479498A0000|23 38|RING-finger gene
14P09479498A0000|39 42|RNF4
14P09480831A0272|42 56|gene expression
14P09480831A0272|96 102|AM gene
14P09480831A0272|143 146|HAEC
14P09480843A0848|27 37|transcripts
14P09480843A0848|54 68|triplet repeats
14P09480843A0848|69 71|GCT
14P09480929T0000|7 10|FasR
14P09480929T0000|106 135|baculovirus/insect cell system
14P09481826T0000|0 6|Control
14P09481826T0000|14 27|liver syndrome
14P09481826T0000|30 40|Jersey herd
14P09481826T0000|83 95|somatotrophin
14P09482107A0551|15 29|focus formation
14P09482107A0551|52 54|C3G
14P09482107A0551|80 93|cell viability
14P09482107A0551|110 118|C3G cells
14P09482107A0551|145 156|growth rates
14P09482107A0551|171 182|NIH3T3 cells
14P09482107A0551|204 217|plasmid vector
14P09482902A0423|0 7|C.D2-Chr
14P09482902A0423|33 45|DBA/2 alleles
14P09482902A0423|62 72|Pctr1 locus
14P09482902A0423|81 85|DBA/2
14P09482902A0423|109 132|CDK4/CDK6 inhibitors p16
14P09482902A0423|134 136|p15
14P09482902A0942|24 28|DBA/2
14P09482902A0942|30 32|p16
14P09482902A0942|38 42|A134C
14P09482902A0942|46 50|G232A
14P09482902A0942|76 78|p16
14P09482902A0942|161 182|retinoblastoma protein
14P09482902A0942|270 280|BALB/c mice
14P09482902A0942|283 304|plasmacytoma induction
14P09482902A0942|311 313|p16
14P09482902A0942|315 319|INK4a
14P09482902A0942|345 355|Pctr1 locus
14P09483596A0626|73 83|excellent/5
14P09483596A0626|93 111|suxamethonium group
14P09483596A0626|116 126|excellent/3
14P09483596A0626|136 151|rocuronium group
14P09484463T0000|0 6|Cloning
14P09484463T0000|10 19|expression
14P09484781A1233|33 57|D3 phosphatidylinositides
14P09484781A1233|90 96|PKB/Akt
14P09485308A1165|3 12|FMN moiety
14P09485308A1165|22 27|3Fe-4S
14P09485790T0000|0 25|Alison Bell Memorial Award
14P09486035A0051|0 6|METHODS
14P09486035A0051|9 25|population survey
14P09486035A0051|112 118|Lebanon
14P09486531A0638|6 18|organogenesis
14P09486531A0638|20 35|HFH-8 expression
14P09486531A0638|87 98|gut endoderm
14P09486531A0638|156 172|gut morphogenesis
14P09486890A0234|8 18|laparoscopy
14P09486890A0234|36 48|inoperability
14P09486890A0234|61 76|carcinoma spread
14P09486890A0234|110 122|visualization
14P09487130A0383|14 28|telomere length
14P09487130A0383|69 72|Cdc2
14P09487130A0383|90 107|DNA repair mutants
14P09487590A0657|3 15|mean duration
14P09487590A0657|17 27|pain relief
14P09487841A0132|3 6|ESEM
14P09487841A0132|30 32|SEM
14P09487841A0132|41 58|sample preparation
14P09488441A0615|0 2|Sp1
14P09488441A0615|69 103|P-selectin promoter NF-kappaB sites
14P09488441A0615|102 115|p50 homodimers
14P09488441A0615|122 124|Sp1
14P09488441A0615|132 150|P-selectin promoter
14P09488441A0615|159 174|site competition
14P09488441A0615|238 242|Bcl-3
14P09488466A0695|100 129|precursor-product relationship
14P09488486A0000|3 6|TATA
14P09488486A0000|26 28|TBP
14P09488486A0000|92 106|RNA polymerases
14P09488486A0000|119 121|Pol
14P09488486A0000|131 133|III
14P09488486A0906|14 16|TBP
14P09488486A0906|18 22|R231E
14P09488486A0906|24 28|R235E
14P09488486A0906|30 34|R239S
14P09488486A0906|64 96|yeast U6 snRNA gene transcription
14P09488486A0906|116 118|Pol
14P09488491A0000|0 11|E2F activity
14P09488491A0000|33 53|retinoblastoma family
14P09488491A0000|55 79|tumor suppressor proteins
14P09488713A0886|35 49|Site-1 cleavage
14P09488713A0886|104 107|SCAP
14P09488725A0904|37 39|SFD
14P09488725T0000|9 24|characterization
14P09488725T0000|69 79|proton pump
14P09489670A1157|2 12|C. albicans
14P09489670A1157|13 16|HST6
14P09489670A1157|132 149|HST6 transcription
14P09489670A1157|253 269|Hst6p transporter
14P09489670A1157|271 281|C. albicans
14P09490676A0800|32 34|Myb
14P09490676A0800|38 50|Ets-2 protein
14P09490676A0800|109 129|oligodeoxynucleotides
14P09490676A0800|164 166|Myb
14P09490727A1041|4 26|structure interconnects
14P09491074A0104|48 57|expression
14P09491074A0104|63 73|temperature
14P09491074A0104|78 92|promoter region
14P09492038A0352|92 108|promoter activity
14P09492038A0352|126 136|mutagenesis
14P09492038A0352|158 171|binding assays
14P09494078A1362|6 19|5HT5A receptor
14P09495283A0000|61 92|heat shock transcription factors
14P09495283A0000|96 99|HSF1
14P09495283A0000|103 106|HSF2
14P09495283A0000|110 119|HeLa cells
14P09495771A0379|9 20|fluorescence
14P09495771A0379|63 82|midcell constriction
14P09495771A0379|97 100|FtsK
14P09498553A0702|2 9|TATA box
14P09498553A0702|56 63|GC boxes
14P09498553A0702|141 150|CYP51 gene
14P09498553A0702|178 207|transcription initiation sites
14P09498553T0000|54 57|P450
14P09498553T0000|59 63|CYP51
14P09498553T0000|82 99|P450 monooxygenase
14P09498553T0000|100 101|I.
14P09498769A0095|3 20|expression pattern
14P09498769A0095|22 35|representative
14P09498769A0095|85 102|B cell development
14P09498769A0095|139 145|B cells
14P09499031A0000|17 30|gene junctions
14P09499031A0000|41 56|stomatitis virus
14P09499031A0000|57 59|VSV
14P09499031A0000|77 93|sequence elements
14P09499031A0000|112 126|polyadenylation
14P09499031A0000|130 154|transcription termination
14P09499048A1003|16 28|virus progeny
14P09499048A1003|120 136|replication cycle
14P09499061A0000|0 7|Cleavage
14P09499061A0000|11 13|DNA
14P09499061A0000|48 74|immunodeficiency virus type
14P09499061A0000|75 79|HIV-1
14P09499061A0000|133 141|HIV-1 DNA
14P09499254A1309|3 13|DSF regimen
14P09499254A1309|82 101|islet-cell carcinoma
14P09499254A1309|105 121|patient tolerance
14P09499254A1309|166 178|investigation
14P09501093A0071|0 9|Activation
14P09501093A0071|39 41|MAP
14P09501093A0071|72 85|Ras activation
14P09501093A0071|112 134|Ras signal transduction
14P09501169A0000|0 25|Histone acetylation levels
14P09501169A0000|76 93|histone acetylases
14P09501982A1178|0 10|CONCLUSIONS
14P09501982A1178|12 16|XCoe2
14P09501982A1178|92 106|Xenopus embryos
14P09501982A1178|120 141|Delta-Notch signalling
14P09501982A1178|142 146|XCoe2
14P09501982A1178|191 206|progenitor cells
14P09501982A1178|217 224|X-ngnr-1
14P09501982A1178|330 344|differentiation
14P09501982A1178|357 374|XNeuroD expression
14P09502627A0705|0 6|RESULTS
14P09502627A0705|8 15|Patients
14P09502627A0705|18 24|Group A
14P09502627A0705|59 83|wall motion abnormalities
14P09502627A0705|105 120|ventriculography
14P09502627A0705|160 186|peak creatine kinase levels
14P09502627A0705|217 233|ejection fraction
14P09502627A0705|234 237|LVEF
14P09502627A0705|241 258|hospital discharge
14P09502627A0705|278 285|Group B.
14P09502720A0214|0 18|CyIIa transcription
14P09502720T0000|26 48|cell type specification
14P09502720T0000|80 97|complex expression
14P09502720T0000|102 111|CyIIa gene
14P09502720T0000|113 130|sea urchin embryos
14P09503017A1021|30 34|HYAL1
14P09503017A1021|99 115|chromosome 3p21.3
14P09503017A1021|159 183|lung carcinoma cell lines
14P09503526A0614|22 28|Raynaud
14P09503526A0614|40 54|skin vasculitis
14P09503526A0614|65 92|diseases WFAg concentrations
14P09504423A0114|26 36|4E-BP1 gene
14P09504423A0114|104 107|BL21
14P09504423A0114|109 111|DE3
14P09504423A0114|134 158|glutathione-S-transferase
14P09504423A0114|160 162|GST
14P09504423A0114|185 202|gene fusion vector
14P09504423A0114|281 294|alpha-thrombin
14P09504514T0000|42 68|bone-marrow transplantation
14P09504514T0000|79 90|chemotherapy
14P09504514T0000|141 147|MRC AML
14P09504553T0000|16 23|cannabis
14P09504906A0099|0 7|Analysis
14P09504906A0099|89 104|cysteine residue
14P09504906A0099|128 132|Hap1p
14P09505135A0182|16 22|stimuli
14P09505135A0182|43 49|stimuli
14P09505135A0182|60 66|targets
14P09505733A0246|9 15|studies
14P09505733A0246|70 76|factors
14P09505733A0246|102 109|distress
14P09505733A0246|132 142|limitations
14P09505733A0246|154 161|patients
14P09506439A2179|0 8|PKC-gamma
14P09506439A2179|121 130|SVHK cells
14P09506959T0000|0 13|Identification
14P09506959T0000|17 32|characterization
14P09506959T0000|85 103|Myc/Max/Mad network
14P09506962A1000|101 103|YY1
14P09506983A0304|0 6|Primers
14P09506983A0304|28 31|RACE
14P09506983A0304|69 81|RACE products
14P09506990T0000|5 16|ZFM1 protein
14P09506990T0000|63 93|transcription activation domain
14P09507032A1144|16 31|CSF1R/IRDelta960
14P09507032A1144|51 58|CSF1R/IR
14P09507032A1144|70 85|CSF-1 protection
14P09508119A0498|0 10|CONCLUSIONS
14P09508119A0498|61 67|Gardner
14P09508377A0863|33 46|UV sensitivity
14P09508377A0863|84 99|eumelanin levels
14P09508377A0863|113 140|eumelanin/phaeomelanin ratio
14P09508377A0863|148 165|chemical parameter
14P09508511A0588|30 40|H. mustelae
14P09508511A0588|69 80|fluorofamide
14P09508775A0293|77 101|protein kinase activation
14P09508775A0293|178 213|protooncogenes/transcription factors
14P09509226A1235|0 10|CONCLUSIONS
14P09509226A1235|12 14|Use
14P09509226A1235|63 75|time patients
14P09509226A1235|88 90|ICU
14P09509226A1235|130 141|nursing time
14P09510189A0192|58 66|CD58 gene
14P09510189A0192|118 120|DNA
14P09510398A1138|3 14|risk factors
14P09510398A1138|45 56|hypouricemia
14P09510398A1138|81 99|urate concentration
14P09510398A1138|115 118|Post
14P09510398A1138|122 130|Secretion
14P09510582A0157|40 43|DCBM
14P09510582A0157|119 121|HBB
14P09510925A0389|5 29|haemoglobin concentration
14P09510925A0389|30 31|Hb
14P09511724A0483|14 25|accumulation
14P09511724A0483|32 49|Dsg protein levels
14P09511760A0221|7 33|restriction enzyme analysis
14P09511760A0221|33 46|Southern blots
14P09511760A0221|47 80|polymerase chain reaction analysis
14P09511760A0221|81 94|DNA sequencing
14P09512416A0460|0 6|RESULTS
14P09512416A0460|78 102|Arabidopsis thaliana gene
14P09512416A0460|102 105|GCR1
14P09512416A0460|200 212|7TM receptors
14P09512550T0000|0 2|E1A
14P09512550T0000|12 46|apolipoprotein AI enhancer activity
14P09512559T0000|38 81|nerve growth factor-luciferase reporter gene
14P09513759A0716|0 17|Calcitriol therapy
14P09513759A0716|45 61|serum iPTH levels
14P09514156A1147|0 10|Alterations
14P09514156A1147|13 17|DNase
14P09514156A1147|45 58|element region
14P09514156A1147|69 70|GC
14P09514159A0562|13 41|hormone-coding gene promoters
14P09514260A1083|41 53|pseudo intein
14P09514260A1083|80 91|architecture
14P09514260A1083|124 135|relationship
14P09514260A1083|143 158|protein families
14P09514260A1083|229 237|EN motifs
14P09514272A0482|0 11|Purification
14P09514272A0482|14 17|MvaT
14P09514272A0482|32 43|polypeptides
14P09514272A0482|94 96|P15
14P09514272A0482|100 102|P16
14P09514962A0841|0 3|M-66
14P09514962A0841|39 42|MMTV
14P09514962A0841|50 64|T-cell lymphoma
14P09514962A0841|65 68|EL-4
14P09515031A1020|24 32|TGF-betaf
14P09515031A1020|66 68|PKC
14P09515031A1020|79 94|SRF binding site
14P09515032A1230|0 5|RT-PCR
14P09515032A1230|19 26|p21 mRNA
14P09515665T0000|45 65|CMV polyradiculopathy
14P09515858A0000|0 9|BACKGROUND
14P09515858A0000|11 19|Defensins
14P09515858A0000|37 55|neutrophil peptides
14P09515858A0000|92 109|azurophil granules
14P09515921A1662|30 48|pca gene expression
14P09515924A0104|31 41|PDH complex
14P09515924A0104|68 71|U/mg
14P09515924A0553|3 5|PDH
14P09515924A0553|43 67|hybridization experiments
14P09515924A0553|70 86|sequence analysis
14P09515924A0553|123 132|Z. mobilis
14P09516472A0292|66 75|TATA motif
14P09516472A0292|87 107|Id4 promoter activity
14P09517646A0149|0 11|Azithromycin
14P09517646A0149|18 37|generation macrolide
14P09517646A0149|70 85|pharmacokinetics
14P09517646A0149|138 152|pylori regimens
14P09517989A0476|40 42|CMV
14P09517989A0476|46 48|HIV
14P09517989A0476|64 72|CD4 count
14P09518383A0000|0 9|BACKGROUND
14P09518383A0000|13 22|OBJECTIVES
14P09518383A0000|55 57|STD
14P09518383A0000|59 73|control program
14P09518383A0000|93 95|FSW
14P09518383A0000|99 102|Lima
14P09518383A0000|104 107|Peru
14P09518383A0000|201 203|STD
14P09518808T0000|0 21|National certification
14P09518808T0000|39 55|quality assurance
14P09519757A0482|22 26|D811N
14P09519757A0482|38 42|R835C
14P09519757A0482|99 101|NBF
14P09519757A0482|134 137|SUR1
14P09519757A0482|160 172|heterozygotes
14P09519828A0809|9 25|VP16-E2 molecules
14P09519828A0809|87 104|BPV-4 LCR promoter
14P09519828A0809|118 142|E2 transactivation domain
14P09519830A0282|74 88|HSV-1 infection
14P09519830A0282|144 148|ICP34
14P09519830A0282|187 233|chloramphenicol acetyltransferase reporter gene
14P09519830A0282|250 270|thymidine kinase gene
14P09520398A0124|48 65|acetylation levels
14P09520398A0124|74 86|core histones
14P09521907A0190|37 45|Otx genes
14P09521907A0190|72 90|expression patterns
14P09521909A0081|0 19|APETALA3 transcripts
14P09521909A0081|85 100|stamen primordia
14P09521913A0400|29 36|60A gene
14P09522297A0744|0 9|Cell lines
14P09522297A0744|87 95|karyotype
14P09522979T0000|20 30|fibronectin
14P09522979T0000|36 45|prediction
14P09522979T0000|48 61|preterm labour
14P09522979T0000|72 81|population
14P09523478A0572|11 13|IgM
14P09523478A0572|49 61|toxoplasmosis
14P09523478A0572|85 96|reactivation
14P09523551A0367|4 11|variants
14P09523551A0367|41 48|topology
14P09523551A0367|81 89|receptors
14P09524122A0336|21 24|GPA2
14P09524122A0336|65 73|RAS genes
14P09524222A0769|3 15|COOH-terminus
14P09524222A0769|186 191|MARCKS
14P09524222A0769|241 256|protein kinase C
14P09524222A0769|258 275|calcium/calmodulin
14P09524222A0769|277 290|beta 4-adducin
14P09524222A0769|320 344|calmodulin binding domain
14P09524222A1113|0 11|PCR analysis
14P09524222A1113|31 50|beta-adducin isoform
14P09524222A1113|96 99|NT-2
14P09524229A0000|24 37|enzyme laccase
14P09524229A0000|81 102|chestnut blight fungus
14P09524229A0000|102 125|Cryphonectria parasitica
14P09524229A0000|253 266|concentrations
14P09524229A0000|285 307|inhibitor cycloheximide
14P09524229A0000|308 310|CHX
14P09524229A0000|337 350|cyclosporin A.
14P09524250A0767|40 42|AP1
14P09524259A0301|3 20|hp55 gamma protein
14P09524259A0301|52 56|IGFIR
14P09524259A0301|85 99|mutant receptor
14P09524259A0301|129 144|insulin receptor
14P09524259A0301|145 146|IR
14P09524267A1023|87 105|localization signal
14P09524267A1023|126 140|helicase motifs
14P09524267A1023|180 206|RNA transcription apparatus
14P09524267A1023|214 239|nucleotide excision repair
14P09524273A0205|28 39|organization
14P09524273A0205|42 53|mouse gC1qBP
14P09524273A0205|59 74|characterization
14P09524276A0939|0 12|LysR proteins
14P09524276A0939|43 62|Klebsiella aerogenes
14P09524276A0939|63 65|NAC
14P09524276A0939|97 100|OxyR
14P09524276A0939|130 149|bacterium protection
14P09525105A0298|55 70|Buddleia cordata
14P09525105A0298|85 101|glycoside linarin
14P09525598A0325|0 9|Regulation
14P09525598A0325|15 24|Raf kinase
14P09525598A0325|26 32|T cells
14P09525598A0325|98 100|Raf
14P09525598A0325|102 104|Raf
14P09525888A1482|11 21|FLAP clones
14P09525888A1482|51 69|muscle cDNA library
14P09525891T0000|0 6|Members
14P09525891T0000|20 51|pbx homeodomain protein families
14P09525891T0000|91 94|CRS1
14P09525891T0000|106 110|CYP17
14P09527921A1178|38 56|electron microscopy
14P09527921A1178|86 100|WDV Rep protein
14P09527921A1178|172 186|initiation site
14P09527921A1178|228 240|transcription
14P09527921A1178|247 254|TATA box
14P09528758T0000|0 4|Rex-1
14P09528758T0000|20 39|transcription factor
14P09528758T0000|79 83|Oct-3
14P09528758T0000|89 101|Oct-6 binding
14P09528758T0000|105 116|octamer site
14P09528758T0000|133 137|Rox-1
14P09528766A0915|27 33|ERK/RSK
14P09528766A0915|40 56|p38/MAPKAP kinase
14P09528766A0915|95 122|CREB Ser-133 phosphorylation
14P09528768A0000|0 4|Cells
14P09528768A0000|17 28|accumulation
14P09528768A0000|73 74|ER
14P09528768A0000|91 103|transcription
14P09528768A0000|133 150|chaperone proteins
14P09528770A1379|26 52|protein kinase cAPK pathway
14P09528770A1379|61 72|UAS activity
14P09528770A1379|74 77|IREu
14P09528770A1379|145 160|activators Msn2p
14P09528770A1379|163 167|Msn4p
14P09528770A1379|178 189|UAS activity
14P09528784A0000|17 29|fission yeast
14P09528784A0000|74 88|complementation
14P09528792A0000|21 53|fibroblast growth factor receptor
14P09528792A0000|53 58|FGF-R2
14P09528792A0000|126 129|IIIc
14P09528858A0205|23 33|methylation
14P09528858A0205|36 39|CpGs
14P09528858A0205|73 83|suppression
14P09528858A0205|86 98|gene activity
14P09528950A0716|41 64|luciferase reporter gene
14P09528987A1348|0 22|Cotransfection analyses
14P09528987A1348|27 60|T/EBP promoter-reporter constructs
14P09528987A1348|64 86|T/EBP expression vector
14P09528987A1348|196 216|T/EBP gene expression
14P09529156A1238|0 7|Deletion
14P09529156A1238|20 31|Ser residues
14P09529156A1238|44 61|PKC consensus site
14P09529156A1238|91 110|phorbol 12-myristate
14P09529216A0644|0 12|Flap survival
14P09529216A0644|24 34|development
14P09529216A0644|59 69|connections
14P09529649A0307|0 8|Jean Klig
14P09529649A0307|52 66|tract infection
14P09529721A0000|9 18|indicators
14P09529721A0000|40 54|classifications
14P09529721A0000|71 82|malnutrition
14P09529721A0000|88 97|guidelines
14P09529721A0000|111 120|management
14P09529721A0000|123 139|childhood illness
14P09529721A0000|146 157|malnutrition
14P09529721A0000|237 246|assessment
14P09529721A0000|259 269|counselling
14P09530251A0766|0 3|SNAC
14P09530251A0766|6 8|PBS
14P09531538A0983|42 58|splicing activity
14P09531538A0983|69 85|dU2AF38 RS domain
14P09531549A0658|7 21|binding studies
14P09531549A0658|26 44|GST fusion proteins
14P09531549A0658|46 59|yeast extracts
14P09531549A0658|98 102|Pan1p
14P09531549A0658|115 129|yAP180 proteins
14P09531549A0658|132 136|Pan1p
14P09531549A0658|183 197|plasma membrane
14P09531559A1153|7 23|affinity analyses
14P09531559A1153|84 87|ZO-1
14P09531559A1153|132 135|ZO-2
14P09533030T0000|0 11|Cytochrome b
14P09533030T0000|48 61|oxidoreductase
14P09533030T0000|92 109|liver mitochondria
14P09533030T0000|112 132|chromosome assignment
14P09533030T0000|154 157|SDHC
14P09533030T0000|168 171|SDHD
14P09533030T0000|183 186|1q21
14P09533030T0000|190 194|11q23
14P09533109A0449|19 30|theophylline
14P09533109A0449|41 52|distribution
14P09533109A0449|84 97|administration
14P09533109A0449|100 110|chloroquine
14P09533109A0449|166 177|significance
14P09535082A0537|59 73|protein binding
14P09535082A0537|86 101|target sequences
14P09535082A0537|115 118|PrfA
14P09535082A0537|141 144|CIII
14P09535082A0537|158 161|PrfA
14P09535082A0537|176 187|DNA fragment
14P09535082A0537|225 226|CI
14P09535579A1105|16 26|assumptions
14P09535579A1105|74 87|interpretation
14P09535579A1105|90 107|energy expenditure
14P09535579A1105|113 116|EPOC
14P09535833A0228|12 30|amino acid sequence
14P09535833A0228|75 112|selenocysteine tRNA gene transcription
14P09535833A0228|128 141|Xenopus laevis
14P09535835A0279|0 5|ROCK-I
14P09535835A0279|7 14|Kinectin
14P09535835A0279|53 56|RhoA
14P09535835A0279|60 64|Cdc42
14P09535851A0591|47 56|Vmax value
14P09535851A0591|62 67|PtdIns
14P09535851A0591|71 87|P kinase activity
14P09535851A0591|92 104|gamma isoform
14P09535892A0000|3 14|beta subunit
14P09535892A0000|33 42|G proteins
14P09535892A0000|71 85|plasma membrane
14P09535892A0000|166 167|WD
14P09535892A0000|169 175|Trp-Asp
14P09535908A0321|26 37|LNX messages
14P09535908A0321|98 100|LNX
14P09535908A0321|111 115|LNX-b
14P09536028A0945|14 31|contractile action
14P09536028A0945|61 82|cyclooxygenase product
14P09536028A0945|121 122|TF
14P09536028A0945|126 128|EGF
14P09536028A0945|153 183|signal pathway probe inhibitors
14P09536440A0000|6 12|studies
14P09536440A0000|39 46|myosin V
14P09536440A0000|105 112|movement
14P09536901A0362|22 23|T1
14P09536901A0362|35 36|T2
14P09536901A0362|56 57|T2
14P09536901A0362|119 128|assessment
14P09537295A0951|78 116|transcriptase-polymerase chain reaction
14P09537295A0951|126 135|P1 primers
14P09537295A0951|151 166|primer extension
14P09537295T0000|0 7|Analysis
14P09537295T0000|66 78|transcription
14P09537295T0000|103 114|protein gene
14P09537361A0149|3 17|iron dependence
14P09537361A0149|19 31|transcription
14P09537361A0149|65 93|transporter accessory protein
14P09537361A0149|111 136|colicin V immunity protein
14P09537375A0198|3 22|gntR deletion mutant
14P09537375A0198|25 34|expression
14P09537375A0198|55 65|lacZ fusion
14P09537375A0198|105 108|GntR
14P09537378A1227|35 44|chromosome
14P09537378A1227|58 76|gcv-lacZ expression
14P09537651A0366|13 16|PEA3
14P09537651A0366|20 23|STAT
14P09537651A0366|125 163|phorbol ester phorbol myristate acetate
14P09537651A0366|161 163|PMA
14P09538156A0130|0 12|BRCA1 protein
14P09538156A0130|36 52|zinc finger motif
14P09538220A0000|64 76|tRNAPro genes
14P09538220A0000|91 93|DNA
14P09538220A0000|115 124|regulation
14P09538220A0000|127 137|replication
14P09538220A0000|141 153|transcription
14P09538258A0200|48 61|Ras activation
14P09538258A0200|65 75|stimulation
14P09539421A0970|5 16|Sir proteins
14P09539421A0970|20 28|K. lactis
14P09539421A0970|55 81|telomere length maintenance
14P09539721A0599|24 27|DnaA
14P09539721A0599|54 67|RNA polymerase
14P09539746A0781|0 9|Expression
14P09539746A0781|12 17|Bcl-XL
14P09539746A0781|43 48|Apaf-1
14P09539779A0621|17 29|hybridization
14P09539779A0621|37 49|mouse embryos
14P09539779A0621|89 103|Arp1 expression
14P09539779A0621|142 145|All1
14P09540062A0755|47 50|Site
14P09540062A0755|111 112|H4
14P09540062A0755|149 181|H4 promoter/CAT fusion constructs
14P09541280A0404|39 45|NC mice
14P09541280A0404|62 75|FK506 ointment
14P09541280A0404|85 100|plasma IgE level
14P09541636T0000|0 22|Creatine kinase release
14P09541636T0000|33 51|artery embolization
14P09541721A0894|17 37|ischemia/angiotension
14P09541721A0894|48 56|AHF model
14P09541721A0894|57 59|NIC
14P09541721A0894|106 110|LVEDP
14P09543227A0815|0 6|Group A
14P09543227A0815|34 41|patients
14P09543227A0815|50 61|risk factors
14P09543227A0815|90 101|risk factors
14P09543227A0815|139 150|risk factors
14P09544987A1583|24 33|RU486-PR-B
14P09544987A1583|57 60|NCoR
14P09544991A0483|0 11|PRL receptor
14P09544991A0483|24 28|SHP-2
14P09544991A0483|40 59|tyrosine phosphatase
14P09544991A0750|27 31|SHP-2
14P09544991A0750|63 86|tyrosine phosphorylation
14P09544991A0750|166 181|m-Stat5adelta749
14P09544991A0750|194 218|transactivation potential
14P09545146A0884|0 10|CONCLUSIONS
14P09545146A0884|79 86|CBZ Cl/F
14P09545146A0884|129 132|Cl/F
14P09545146A0884|143 162|regression equations
14P09545146A0884|181 194|concentrations
14P09545146A0884|206 219|validation set
14P09545293A0590|0 4|Sites
14P09545312A1197|3 14|observations
14P09545312A1197|38 49|HMG-I family
14P09545312A1197|83 95|transcription
14P09545312A1197|151 161|interaction
14P09545323T0000|51 62|DNA mismatch
14P09545323T0000|85 111|MLH1-PMS1 protein complexes
14P09545332A0137|0 7|Mutation
14P09545332A0137|20 25|Tyr497
14P09545332A0137|40 63|tyrosine phosphorylation
14P09545332A0137|68 93|insulin receptor substrate
14P09545332A0137|94 97|IRS1
14P09545332A0137|137 140|IL-4
14P09545353A1071|53 110|activating transcription factor/cAMP response element site
14P09545353A1071|170 178|TNF-alpha
15P09545638A0330a|30 58|yeast hnRNP methyltransferase
15P09545638A0330a|58 61|HMT1
15P09545638A0330b|30 58|yeast hnRNP methyltransferase
15P09545638A0330b|58 61|HMT1
14P09545638A0836|11 25|HRMT1L2 protein
14P09545638A0836|66 91|methyltransferase activity
14P09545638A1181|18 24|HRMT1L1
14P09545638A1181|28 34|HRMT1L2
14P09545638T0000|0 13|Identification
14P09545638T0000|51 77|arginine methyltransferases
14P09545638T0000|78 84|HRMT1L1
14P09545638T0000|88 94|HRMT1L2
14P09546424A1550|26 43|PDGF beta-receptor
14P09547311A1394|12 23|interactions
14P09547311A1394|55 64|E-cadherin
14P09547311A1394|91 100|E-cadherin
14P09547311A1394|208 219|interactions
14P09547311A1394|222 231|E-cadherin
14P09547349A0000|3 74|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
14P09548481A0000|45 46|P1
14P09548481A0000|98 112|IL-5Ralpha gene
14P09549179A0774|0 11|Serum levels
14P09549179A0774|13 24|testosterone
14P09549179A0774|72 74|DDE
14P09549398A1463|23 59|rest/postnitroglycerin technetium-99m
14P09549398A1463|70 81|SPET studies
14P09549398A1463|84 102|rest/redistribution
14P09549398A1463|105 146|rest/reinjection thallium-201 SPET studies
14P09549632A1189|19 29|sensitivity
14P09549632A1189|39 49|specificity
14P09549632A1189|67 80|predictability
14P09549632A1189|83 92|ALT levels
14P09549660A0782|19 27|data sets
14P09549660A0782|71 83|data scenario
14P09549783T0000|7 14|accuracy
14P09549783T0000|49 56|saccades
14P09549783T0000|72 79|patients
14P09550591A0454|46 60|airway pressure
14P09550591A0454|116 129|blood pressure
14P09550591A0454|131 134|OSAS
14P09550919A0365|44 51|response
14P09550919A0365|65 73|adenosine
14P09550919A0365|99 106|episodes
14P09550919A0365|109 112|PSVT
14P09550919A0365|118 125|episodes
14P09550919A0365|134 141|episodes
14P09550919A0365|150 157|episodes
14P09550919A0365|168 175|episodes
14P09551096A0108|0 3|RNAs
14P09551096A0108|98 115|particle formation
14P09551182A0212|7 25|retinoid signalling
14P09551182A0212|27 43|zebrafish embryos
14P09551182A0212|116 129|fusion protein
14P09551182A0212|149 170|transactivation domain
14P09551182A0212|209 226|DNA binding domain
14P09551938A0318|79 96|CCR5 gene promoter
14P09551972A1033|0 11|Fluorescence
14P09551972A1033|33 49|metaphase spreads
14P09551972A1033|73 101|hybrid cell line 706-B6 clone
14P09551972A1033|101 105|CL-17
14P09551972A1033|161 166|8q24.3
14P09552469A0225|54 73|x-ray diffractometry
14P09552469A0225|74 76|XRD
14P09552469A0225|88 89|IR
14P09552469A0225|134 136|DTA
14P09553040A0651|0 12|Cell survival
14P09553040A0651|14 16|Epo
14P09553040A0651|52 69|signaling pathways
14P09553040A0651|78 88|PI-3 kinase
14P09553040A0651|89 97|PLC-gamma
14P09553040A0651|99 101|Ras
14P09553040A0651|104 108|Stats
14P09553134A0596|55 93|tyrosine kinase inhibitors herbimycin A
14P09553143A0729|8 23|ZAP-70 substrate
14P09553143A0729|24 29|SLP-76
14P09553143A0729|43 56|Erk activation
14P09553143A0729|99 110|Jurkat cells
14P09553143A0729|119 128|P116 cells
14P09553686A0000|38 40|CAS
14P09553686A0000|62 64|CAS
14P09553686A0000|135 145|application
14P09553686A0000|203 222|absorption enhancers
14P09553686A0000|245 256|applications
14P09555046A1617|43 72|branchpoint consensus sequence
14P09556557A1238|21 27|regions
14P09556561A0671|8 20|H/ACA snoRNAs
14P09556561A0671|34 38|Gar1p
14P09556561A0671|122 144|pseudouridine synthesis
14P09556566A0174|26 28|VDR
14P09556566A0174|44 63|acid Xalpha receptor
14P09556566A0174|63 70|RXRalpha
14P09556566A0174|82 102|T cell line MT2 cells
14P09556573A1062|33 48|PPARalpha ligand
14P09556573A1062|112 120|PPARalpha
14P09556573A1062|128 147|co-activator RIP-140
14P09556573A1062|175 183|PPARalpha
14P09556573A1062|203 206|SMRT
14P09556861A1018|64 65|OA
14P09556861A1018|157 159|ATP
14P09556861A1018|176 190|tRNA-synthetase
14P09556861A1018|212 228|protein synthesis
14P09556861A1018|243 260|lipid peroxidation
14P09557678A0140|54 72|papillomavirus type
14P09557678A0140|74 77|BPV1
14P09557678A0140|79 88|E2 protein
14P09557678A0140|97 100|HT-3
14P09557678A0140|109 128|carcinoma cell lines
14P09557678A0140|181 204|G1/S phase growth arrest
14P09557682A0490|63 74|combinations
14P09557682A0490|141 149|DNA motif
14P09557682A0490|150 154|TRE2S
14P09557682A0490|161 163|LTR
14P09557708A1426|0 22|Specialized actin tails
14P09557708A1426|31 43|IEV particles
14P09557912A0699|9 11|IOP
14P09557912A0699|20 21|SD
14P09557912A0699|64 65|SD
14P09557912A0699|118 130|methohexitone
14P09557912A0699|137 138|SD
14P09557912A0699|163 183|muscle fasciculations
14P09557912A0699|192 204|suxamethonium
14P09557912A0699|211 212|SD
14P09557912A0699|255 256|SD
14P09560221A0282|41 52|CAK mutation
14P09560221A0282|89 112|fission yeast CAK mutant
14P09560325A1285|18 30|modifications
14P09560325A1285|37 49|glycosylation
14P09560325A1285|53 67|phosphorylation
14P09560325A1285|112 132|protein heterogeneity
14P09560390A0771|21 38|checkpoint control
14P09560390A0771|39 52|overexpression
14P09560390A0771|77 95|cell cycle response
14P09560430A0000|0 3|Ime1
14P09560430A0000|26 35|initiation
14P09561560A0579|0 14|Rhesus macaques
14P09561560A0579|17 27|BALB/c mice
14P09561560A0579|44 71|Mengo virus SIV recombinants
14P09561560A0579|84 96|CTL responses
14P09561560A0579|106 122|SIV gene products
14P09561560A0579|135 154|HIV-Nef recombinants
14P09561560A0579|166 177|CTL response
14P09561560A0579|195 210|HIV1 Nef peptide
14P09561616A0142|0 11|Deltamethrin
14P09561616A0142|62 72|% mortality
14P09561616A0142|77 95|culicifacies adults
14P09562398A0848|0 16|Trichloroethylene
14P09562398A0848|37 39|AUC
14P09562558T0000|0 17|Solution structure
14P09562558T0000|22 26|IRF-2
14P09564860A2139|11 37|receptor/G protein coupling
14P09564860A2139|68 82|loop 3i domains
14P09564860A2315|87 102|protein coupling
14P09564860A2315|128 130|GGH
14P09564860A2315|169 187|signal transduction
14P09564860A2315|205 222|Gs protein pathway
14P09564917A0900|17 34|alpha2-antiplasmin
14P09564917A0900|56 66|mediastinum
14P09564917A0900|82 85|U/mL
14P09565576T0000|28 47|DNA topoisomerase I.
14P09565584A0770|15 25|amino acids
14P09565584A0770|26 29|KKKR
14P09565584A0770|186 205|mutagenesis analysis
14P09565606A0520|22 30|structure
14P09565606A0520|73 79|rCGCC-3
14P09565606A0520|81 88|sequence
14P09566731A0458|57 80|chromosome 16p12.1-p11.2
14P09566731A0458|93 108|mouse chromosome
14P09566731A0458|123 134|cell hybrids
14P09566871A0343|25 31|Ty1 RNA
14P09566871A0343|32 48|protein synthesis
14P09566871A0343|104 115|FUS3 strains
14P09566871A0343|138 140|TyA
14P09566871A0343|162 183|transcriptase proteins
14P09566871A0343|186 193|Ty1 cDNA
14P09566871T0000|29 50|Ty1 retrotransposition
14P09566871T0000|69 87|protein kinase Fus3
14P09566876A0000|10 33|transcription factor IIA
14P09566876A0000|33 37|TFIIA
14P09566876A0000|55 74|TATA binding protein
14P09566876A0000|74 76|TBP
14P09566876A0000|101 124|transcription activation
14P09566882A0693|31 34|Pho2
14P09566882A0693|78 81|Pho4
14P09566882A0693|94 97|Pho2
14P09566918A1115|0 11|Substitution
14P09566918A1115|17 29|Ser-Thr sites
14P09566918A1115|50 52|Asp
14P09566918A1115|89 93|IRF-3
14P09566918A1115|151 161|PRDI-PRDIII
14P09566918A1115|164 167|ISRE
14P09568445T0000|73 92|contractile recovery
14P09568445T0000|97 108|thrombolysis
14P09568549A0188|28 41|administration
14P09568549A0188|58 66|malathion
14P09568549A0188|104 115|serum levels
14P09568549A0188|117 125|histamine
14P09570030T0000|5 22|growth retardation
14P09570030T0000|47 57|development
14P09570107A0355|10 26|PCDFs/PCDDs ratio
14P09570107A0355|28 30|ESP
14P09570133A0474|23 34|interactions
14P09570133A0474|51 62|interactions
14P09570133A0474|67 82|partner proteins
14P09570133A0474|140 148|promoters
14P09570944T0000|0 11|Localization
14P09570944T0000|24 33|YAC contig
14P09570944T0000|44 45|Mb
14P09570944T0000|64 85|resistance gene region
14P09570944T0000|91 107|chromosome 7q21.1
14P09570952A0000|22 33|organization
14P09570952A0000|57 65|M-protein
14P09570952A0000|97 106|myofibrils
14P09571563A0000|0 6|PURPOSE
14P09571563A0000|21 34|image analysis
14P09571563A0000|74 76|PRK
14P09571563A0000|114 126|determination
14P09572428A0526|0 3|Mean
14P09572428A0526|7 34|SD serum VEGF concentrations
14P09572428A0526|75 77|PCO
14P09572428A0526|81 84|PCOS
14P09572491A1044|29 45|missense mutation
14P09572491A1044|50 57|p53 gene
14P09572491A1044|68 70|p53
14P09572511A0148|22 28|RBI-MAP
14P09572511A0148|64 65|EM
14P09572511A0148|67 72|RBI-EM
14P09572965A1235|6 8|ORF
14P09572965A1235|10 13|ORF5
14P09572965A1235|111 129|virulence phenotype
14P09572990A0630|27 32|Stat-3
14P09572990A0630|38 51|MHC-I ligation
14P09572990A0630|89 94|Stat-3
14P09573187T0000|44 57|regulator CatR
14P09573187T0000|72 84|binding sites
14P09573202A0900|40 52|alpha subunit
14P09573202A0900|66 77|substitution
14P09573202A0900|101 112|acid residue
14P09573244A0523|44 69|polyadenylation site usage
14P09573374A0687|5 26|Southern blot analysis
14P09573374A0687|28 46|restriction mapping
14P09573374A0687|55 57|YAC
14P09573374A0687|118 125|RIL gene
14P09573374A0687|148 156|IRF1 gene
14P09573378A0761|0 2|U73
14P09573378A0761|17 24|D' boxes
14P09573378A0761|50 64|complementarity
14P09573378A0761|82 84|RNA
14P09573884A0392|27 31|S-N-B
14P09573884A0392|35 41|S-N-Pog
14P09573884A0392|83 87|Class
14P09573884A0392|106 110|Class
14P09574799A1072|0 14|Echinostomiasis
14P09574799A1072|63 74|malnutrition
14P09574799A1072|129 143|food inspection
14P09574799A1072|162 171|sanitation
14P09574799A1072|178 190|helminthiases
14P09574799A1072|212 221|conditions
14P09575143A1189|17 22|ZAP-70
14P09575143A1189|75 92|SRC-family kinases
14P09575143A1189|163 179|activation motifs
14P09575143A1189|184 186|TCR
14P09575187A1558|16 24|NF-kappaB
14P09575187A1558|55 72|ER calcium release
14P09575187A1558|167 182|kappaB decoy DNA
14P09575217A0000|4 21|cytokine receptors
14P09575217A0000|27 56|Janus protein tyrosine kinases
14P09575217A0000|55 58|Jaks
14P09575217A0000|63 80|signal transducers
14P09575217A0000|109 113|Stats
14P09575217A0971|14 27|R618K mutation
14P09575217A0971|32 47|Stat5 SH2 domain
14P09575217A0971|98 107|C terminus
14P09575217A0971|112 137|Stat5 hyperphosphorylation
14P09576230T0000|17 40|oxide synthase inhibitor
14P09576230T0000|41 58|reperfusion injury
14P09576915A0269|13 25|recombination
14P09576915A0269|28 30|HMR
14P09577365A0747|2 15|angiodysplasia
14P09577365A0747|63 75|collagen type
14P09577365A0747|107 115|submucosa
14P09577365A0747|186 203|muscularis mucosae
14P09577395A0000|40 42|VOR
14P09577395A0000|125 134|degrees/s2
14P09577395A0000|137 149|low-amplitude
14P09578042A0363|61 75|seizure outcome
14P09578042A0363|85 93|SEEG/ECoG
14P09578042A0363|131 143|lobe epilepsy
14P09578042A0363|144 146|TLE
14P09578570A0200|48 59|organization
14P09578570A0200|89 99|combination
14P09578570A0200|102 118|PCR amplification
14P09578570A0200|120 132|leukocyte DNA
14P09578570A0200|146 157|phage clones
14P09579602A1720|46 60|reproducibility
14P09579602A1720|63 81|CD34 determinations
14P09579602A1720|100 114|sample handling
14P09579789A0974|101 114|odor detection
14P09579789A0974|117 136|discrimination tasks
14P09579808A0000|0 9|UDP-GlcNAc
14P09579808A0000|11 36|alpha-6-D-mannoside beta-1
14P09579808A0000|39 69|N-acetylglucosaminyltransferase
14P09579808A0000|79 80|EC
14P09580062A0100|41 56|cyclophosphamide
14P09580062A0100|99 112|cyclosporine A
14P09580062A0100|123 131|mg/kg/day
14P09580563A0331|12 30|amino acid sequence
14P09580563A0331|79 95|Neurospora crassa
14P09580700A0841|3 24|DNA binding activities
14P09580700A0841|33 54|repressor preparations
14P09580700A0841|89 92|CIRs
14P09580700A0841|94 102|CIR3-CIR6
14P09580700A0841|145 149|DNase
14P09581552A1323|34 55|tetramerization domain
14P09581552A1323|88 99|interactions
14P09581775A0185|58 75|NF-kappaB activity
14P09581775A0185|114 117|U937
14P09581775A0185|119 125|U9-IIIB
14P09581775A0185|142 148|PLB-985
14P09581775A0185|150 157|PLB-IIIB
14P09581834A2578|90 92|PCA
14P09581834A2578|157 173|signaling pathway
14P09581834A2578|185 189|CDKIs
14P09581834A2578|204 212|G1 arrest
14P09581872A0000|19 32|cell structure
14P09581872A0000|50 68|collagen expression
14P09582267A0326|43 46|Siah
14P09582267A0326|57 75|expression plasmids
14P09582267A0326|83 89|Siah-1A
14P09582267A0326|141 162|GM701 fibroblast cells
14P09582267A0326|173 185|growth arrest
14P09582306T0000|16 22|Galphao
14P09582306T0000|26 33|Galphai1
14P09582306T0000|66 93|G protein signaling proteins
14P09582308A1165|33 41|formation
14P09582308A1165|60 69|homodimers
14P09582308A1165|80 88|formation
14P09582308A1165|99 110|heterodimers
14P09582326A0151|0 1|N.
14P09582326A0151|6 12|Fanning
14P09582326A0151|14 15|E.
14P09582327A0295|25 33|GH3 cells
14P09582327A0295|51 72|rat GnRH receptor cDNA
14P09582327A0295|71 76|GGH3-1
14P09582327A0295|154 168|rat LHbeta gene
14P09582327A0295|241 259|luciferase reporter
14P09582327A0295|267 275|LHbetaLUC
14P09582327A0295|290 301|GnRH agonist
14P09582331A0506|54 57|TATA
14P09582331A0506|69 78|CAAT boxes
14P09582331A0506|86 91|GATA-1
14P09582331A0506|93 95|SP1
14P09582343A0000|52 75|carcinoma cell line FM3A
14P09582350A0165|14 46|type IA maple syrup urine disease
14P09582350A0165|46 60|E1alpha subunit
14P09582350A0165|91 92|E1
14P09582350A0165|110 131|ketoacid dehydrogenase
14P09582635A0523|0 6|Results
14P09582635A0523|20 37|mean bond strength
14P09582635A0523|38 53|H.T.V. specimens
14P09582635A0523|88 105|mean bond strength
14P09582635A0523|106 121|R.T.V. specimens
14P09582953A0000|0 9|OBJECTIVES
14P09582953A0000|20 42|coagulation factor VIII
14P09582953A0000|52 57|F.VIII
14P09582953A0000|64 84|C1-esterase inhibitor
14P09582953A0000|85 90|C1-INH
14P09582953A0000|114 142|acute-phase reactant proteins
14P09582953A0000|144 166|coagulation factors VII
14P09582953A0000|166 170|F.VII
14P09582953A0000|176 177|F.
14P09582953A0000|187 189|F.X
14P09582953A0000|192 210|hemostasis proteins
14P09582953A0000|229 248|acute-phase response
14P09582953A0000|288 311|hemostasis abnormalities
14P09582953A1097|0 6|RESULTS
14P09582953A1097|8 13|Horses
14P09582953A1097|45 68|fibrinogen concentration
14P09582953A1097|87 106|protein C activities
14P09582953A1097|115 116|PT
14P09582953A1097|120 123|APTT
14P09582953A1670|42 47|C1-INH
14P09582953A1670|73 92|acute-phase proteins
14P09583201A0759|0 3|None
14P09583208A0171|17 31|creatine kinase
14P09583208A0171|47 59|serum albumin
14P09583208A0171|60 73|immunoglobulin
14P09583592A0263|0 5|DESIGN
14P09583592A0263|9 15|METHODS
14P09583592A0263|17 26|Case study
14P09583823A0238|0 6|METHODS
14P09583823A0238|69 84|infarction group
14P09583823A0238|92 95|TMLR
14P09583823A0238|130 153|yttrium-aluminium garnet
14P09583823A0238|154 155|Ho
14P09583823A0238|157 159|YAG
14P09583823A0238|167 177|laser group
14P09584165T0000|0 4|RACK1
14P09584165T0000|27 34|C kinase
14P09584165T0000|63 72|G proteins
14P09584165T0000|91 110|src tyrosine kinases
14P09584165T0000|120 132|NIH 3T3 cells
14P09584179A0673|0 16|Peptide sequences
14P09584179A0673|21 43|zinc finger protein Ttk
14P09584179A0673|47 72|transcription factor Adf-1
14P09584180A0701|86 103|NF-kappaB proteins
14P09584180A0701|120 142|I.29mu B lymphoma cells
14P09584194A0000|0 3|HEF1
14P09584194A0000|5 8|p130
14P09584194A0000|10 12|Cas
14P09584194A0000|18 24|Efs/Sin
14P09584194A0000|55 70|docking proteins
14P09584194A1305|39 55|library screening
14P09584194A1305|59 62|HEF1
14P09584194A1305|93 96|G2/M
14P09584194A1305|115 127|protein Dim1p
14P09584194A1305|161 164|HEF1
14P09584194A1305|178 180|p55
14P09584194A1305|182 185|HEF1
14P09585253A1147|32 46|raf-ERK pathway
14P09585253A1147|63 75|TF expression
14P09585253A1147|77 98|breast carcinoma cells
14P09585253A1147|159 171|TF expression
14P09585253A1147|173 188|MDA-MB-231 cells
14P09585540A0440|88 112|agent 1,10-phenanthroline
14P09586285A0551|22 51|H. influenza type b meningitis
14P09586832A0229|59 67|receptors
14P09587549T0001|37 52|interferon alpha
14P09587549T0001|67 77|hepatitis C
14P09588228A0370|22 36|anticytokeratin
14P09588228A0370|99 109|MPM tissues
14P09590294A0453|38 51|identification
14P09590294A0453|76 88|Notch pathway
14P09590540A0513|67 81|signal sequence
14P09590540A0513|121 123|PCR
14P09590540A0513|136 144|Sac1-Sal1
14P09590540A0513|191 201|T5 promoter
14P09590540A0513|209 228|lac operator control
14P09590540A0513|230 242|pQE-30 vector
14P09591221A0137|0 15|Control subjects
14P09591221A0137|33 35|EPs
14P09591221A0137|94 95|P1
14P09592125A0000|0 4|Class
14P09592125A0000|6 26|alpha1,2-mannosidases
14P09592125A0000|51 61|elaboration
14P09592168T0000|30 47|DNA binding domain
14P09592168T0000|63 100|nucleotide excision repair protein XPA
14P09592208A0470|12 20|qualities
14P09592208A0470|31 40|importance
14P09592208A0470|92 103|construction
14P09592208A0470|141 153|possibilities
14P09592208A0470|185 194|statistics
14P09592219A0652|20 32|effectiveness
14P09592219A0652|49 60|intervention
14P09593302A1165|14 25|implications
14P09593302A1165|36 53|non-responsiveness
14P09593302A1165|77 84|A-domain
14P09594299A0468|0 6|RESULTS
14P09594299A0468|124 134|dislocation
14P09595496A0000|30 41|endothelin-1
14P09595496A0000|43 46|ET-1
14P09596536A0219|28 47|knee loading changes
14P09596536A0219|55 69|ACL transection
14P09596536A0219|91 112|cartilage degeneration
14P09596542A0542|31 46|cartilage matrix
14P09596638T0000|23 45|Brassica S locus region
14P09596638T0000|59 69|Arabidopsis
14P09596738T0000|0 4|Roles
14P09596738T0000|10 25|Candida albicans
14P09596738T0000|42 63|protein kinase homolog
14P09596738T0000|63 67|Cek1p
14P09598205A0430|20 34|monosaccharides
14P09598205A0430|41 53|disaccharides
14P09598205A0430|58 69|beta-alanine
14P09598894A0732|24 37|bone formation
14P09598894A0732|40 49|resorption
14P09599102A1191|0 7|Analysis
14P09599102A1191|11 22|Mac1p mutant
14P09599102A1191|67 68|Cu
14P09599102A1191|72 86|transport genes
14P09599102A1191|112 126|CUP1 expression
14P09599102A1191|129 146|copper sensitivity
14P09599664A0881|3 16|DNA sequencing
14P09599664A0881|61 69|RXR alpha
14P09599664A0881|72 79|RXR beta
14P09599724A0193|55 79|phenoxy herbicide workers
14P09599724A0193|109 112|PCDD
14P09599724A0193|116 129|PCDF congeners
14P09599724A0193|165 168|PCDD
14P09599724A0193|172 184|PCDF exposure
14P09599724A0193|243 257|cancer findings
14P09599897A0000|14 32|laboratory features
14P09599897A0000|48 71|Henoch-Schonlein purpura
14P09599897A0000|72 74|HSP
14P09599897A0000|132 149|laboratory indices
14P09599897A0000|175 177|WBC
14P09599897A0000|209 211|CRP
14P09599897A0000|229 231|PLT
14P09599897A0000|276 278|HSP
14P09601007A0223|61 77|CO2 concentration
14P09601007A0223|87 103|coral reef waters
14P09601007A0223|153 166|photosynthesis
14P09601007A0223|180 192|calcification
14P09601007A0223|197 213|CaCO3 dissolution
14P09601510A0215|38 49|FV pol genes
14P09601516A0695|0 11|Substitution
14P09601516A0695|63 66|PEP1
14P09601516A0695|77 91|fusion activity
14P09601516A0695|96 104|S protein
14P09601516A0695|133 150|surface expression
14P09601921A0000|0 10|Tributyltin
14P09601921A0000|17 34|breakdown products
14P09601921A0000|94 103|Lake Huron
14P09601921A0000|107 117|Great Lakes
14P09601921A0000|132 144|United States
14P09601921A0000|162 177|British Columbia
14P09601921A0000|178 183|Canada
14P09601940A0280|24 31|CD1 gene
14P09601940A0280|80 100|transcription factors
14P09601940A0280|101 108|NF-IL2-A
14P09601940A0280|112 117|NF-IL6
14P09602124A0127|0 6|Fregnac
14P09602124A0127|8 9|M.
14P09603345A1257|0 6|GLRaV-2
14P09603345A1257|50 68|genome organization
14P09603345A1257|94 96|BYV
14P09603345A1257|157 175|genus Closterovirus
14P09604052A0166|43 55|control group
14P09604052A0166|111 124|wrist fracture
14P09605137A0677|28 30|p65
14P09605137A0677|61 73|IL-2 promoter
14P09605137A0677|90 108|reporter constructs
14P09605137A0677|114 118|LFA-3
14P09605137A0677|140 151|Jurkat cells
14P09605930A1428|48 68|mobility shift assays
14P09605930A1428|89 103|rat hepatocytes
14P09605930A1428|123 130|ALS gene
14P09605934A0801|4 17|E box sequence
14P09605934A0801|17 22|CACGTG
14P09605934A0801|40 54|binding element
14P09605934A0801|57 59|USF
14P09605934A0801|124 144|transcription factors
14P09606633A0523|0 22|Interferon beta therapy
14P09606924T0000|0 5|Liquid
14P09606924T0000|40 71|all-rac-alpha-tocopheryl acetate
14P09606924T0000|74 90|retinyl palmitate
14P09606924T0000|120 148|matrix solid-phase dispersion
14P09609342A0000|54 56|CFP
14P09609342A0000|74 76|MFP
14P09609342A0000|98 100|AFP
14P09609705A0895|0 10|Examination
14P09609705A0895|29 57|bc1 complex crystal structure
14P09609705A0895|56 60|Zhang
14P09609705A0895|62 63|Z.
14P09609705A0895|65 69|Huang
14P09609705A0895|71 72|L.
14P09609705A0895|74 84|Shulmeister
14P09609705A0895|86 87|V.
14P09609720A0357|21 29|fragments
14P09609720A0357|56 61|halves
14P09609720A0357|67 74|nuclease
14P09609720A0357|103 111|proteases
14P09609720A0357|126 132|protein
14P09609720A0357|142 147|region
14P09610755A1731|3 25|side-to-side difference
14P09610755A1731|54 56|EXT
14P09611016A0652|0 9|CONCLUSION
14P09611016A0652|46 55|management
14P09611229A1664|32 35|FAS1
14P09611229A1664|38 62|nmt1-451Dino2 Delta cells
14P09611229A1664|90 109|transcription factor
14P09611229A1664|125 143|expression/activity
14P09611229A1664|187 211|protein N-myristoy-lation
14P09611234A0098|0 17|Rev-erbAalpha/beta
14P09611234A0098|28 48|Mad bHLH-zip proteins
14P09611234A0098|72 80|LAZ3/BCL6
14P09611234A0098|116 119|SMRT
14P09611877A0455|23 25|CSF
14P09611877A0455|49 52|ECHO
14P09611877A0455|59 62|ECHO
14P09611877A0455|70 73|ECHO
14P09612351A0386|53 60|ULF band
14P09612775A0726|3 18|ParaSight-F test
14P09612775A0726|39 58|serum antigen levels
14P09613574A0905|45 59|enzyme activity
14P09613574A0905|82 83|3H
14P09613574A0905|85 97|methyl groups
14P09613574A0905|104 116|substrate DNA
14P09613574A0905|121 132|MGMT protein
14P09613946A0194|1 26|deproteinization procedure
14P09613946A0194|55 69|HPLC separation
14P09614065A0966|0 10|Elimination
14P09614065A0966|108 111|EpRE
14P09614065A0966|123 131|AP-1 site
14P09614106T0000|50 62|pair enhancer
14P09614106T0000|67 77|Col2a1 gene
14P09617765A0174|3 10|sequence
14P09617765A0174|25 37|reading frame
14P09617765A0174|61 66|strand
14P09617765A0174|83 88|region
14P09617807A0929|33 52|transcriptase domain
14P09617807A0929|82 91|assessment
14P09617807A0929|96 102|Cyclops
14P09617807A0929|139 150|relationship
14P09618150A0127|39 53|growth factor I
14P09618150A0127|53 57|IGF-I
14P09618150A0127|91 104|dibutyryl cAMP
14P09618150A0127|124 151|UCP1 gene transcription rate
14P09618150A0127|160 181|UCP1 mRNA accumulation
14P09618150A1464|25 49|AP-1 DNA binding activity
14P09618150A1464|94 108|MEK-1 inhibitor
14P09618164A0709|17 43|methyl oligoribonucleotides
14P09618164A0709|46 51|OMeRNA
14P09618475A0747|41 55|down-regulation
14P09618475A0747|94 97|Nrd1
14P09618481T0000|0 9|Regulation
14P09618481T0000|20 41|p21/WAF1/Cip1 promoter
14P09618481T0000|92 110|Smad family members
14P09619631A0344|0 6|RESULTS
14P09619631A0344|19 33|C. elegans cDNA
14P09619631A0344|105 116|p120 Ras-GAP
14P09619777A1583|7 23|base ketoconazole
14P09619777A1583|37 47|dissolution
14P09619777A1583|59 69|formulation
14P09619777A1583|88 92|Fluid
14P09619777A1583|107 111|SGFsp
14P09619777A1583|131 143|% dissolution
14P09619777A1583|203 215|% dissolution
14P09619777A1583|234 249|state conditions
14P09620273A0189|13 22|Rb protein
14P09620273A0189|72 89|cell proliferation
14P09620273A0189|111 135|E2F transcription factors
14P09620606A0000|45 47|TCR
14P09620606A0000|49 55|T cells
14P09620873A1710|33 61|luteal HSP-27 phosphorylation
14P09620873A1710|87 95|PKC-delta
14P09620873A1710|134 151|PKC family members
14P09620873A1710|162 188|sHSP phosphorylation events
14P09620955A0370|18 26|structure
14P09620955A0370|33 43|leader mRNA
14P09620955A0370|53 65|program Mfold
14P09620955A0370|69 79|combination
14P09620955A0370|99 107|deletions
14P09620955A0370|145 154|lac operon
14P09621062A0810|99 124|promoter function analysis
14P09621062A0810|140 188|chloramphenicol acetyltransferase reporter system
14P09621372A0369|7 23|blood examination
14P09621372A0369|42 57|thrombocytopenia
14P09621372A0369|67 69|CRP
14P09621893A0000|59 72|responsiveness
14P09621893A0000|83 102|alpha2-adrenoceptors
14P09622055A0207|15 24|Cbl family
14P09622055A0207|62 66|Cbl-b
14P09622055A0207|74 83|C. elegans
14P09622055A0207|84 88|Sli-1
14P09622055A0207|109 113|D-Cbl
14P09622121A0525|43 45|PTB
14P09622121A0525|48 50|RNA
14P09622121A0525|72 99|supershift RNA-PTB complexes
14P09622121T0000|23 58|polypyrimidine tract binding protein
14P09622121T0000|57 59|PTB
14P09622121T0000|73 90|protein components
14P09623830A0000|19 33|botulinum toxin
14P09623830A0000|34 38|Botox
14P09625762A0426|8 22|oncoprotein E1A
14P09625762A0426|44 58|transactivation
14P09625807A0000|32 45|display method
14P09625807A0000|115 127|cell cultures
14P09625807A0000|148 167|carcinoma cell lines
14P09626662A1076|22 23|TR
14P09626662A1076|48 53|RIP140
14P09626662A1076|59 69|RXR subunit
14P09626662A1076|105 122|TR/RXR heterodimer
14P09627285A0160|0 6|SETTING
14P09627285A0160|8 17|University
14P09627285A0160|41 63|care infertility center
14P09627285A0554|0 5|RESULT
14P09627285A0554|32 41|FSH levels
14P09627285A0554|57 68|oocyte yield
14P09627598A0384|0 6|RESULTS
14P09627598A0384|73 85|preponderance
14P09627598A0384|91 99|OVAR test
14P09627598A0384|110 133|otolith system imbalance
14P09628375A0700|5 19|ePTFE specimens
14P09628375A0700|20 34|tissue coverage
14P09628419A0812|16 19|Wing
14P09628419A0812|23 41|Kristofferson model
14P09628419A0812|66 69|ISIs
14P09628821A1194|18 33|KG1a EST dataset
14P09628821A1194|121 138|lineage commitment
14P09628890A0455|55 76|carbohydrate structure
14P09628890A0455|91 99|HA trimer
14P09629449A0540|18 31|ROS production
14P09629449A0540|90 101|PMN elastase
14P09630245A0102|0 13|Yeast U1 snRNP
14P09630245A0102|52 62|counterpart
14P09630245A0102|85 95|differences
14P09630245A0102|125 139|splicing events
14P09630245A0903|0 13|Yeast U1 snRNP
14P09630245A0903|63 81|snRNP core proteins
14P09630245A0903|154 170|U1 snRNP proteins
14P09631366A0951|39 48|dose level
14P09631366A0951|88 97|dose level
14P09632217A0477|9 29|antagonist naltrexone
14P09632217A0477|72 87|stimulus effects
14P09632217A0477|99 108|naltrexone
14P09632217A0477|157 172|stimulus effects
14P09632637A0361|52 72|M6P/IGFIIR expression
14P09632637A0361|84 116|M6P/IGFIIR mRNA transcript levels
14P09632637A0361|155 174|carbon tetrachloride
14P09632637A0361|175 178|CCl4
14P09632709A0464|22 28|NCoA-62
14P09632709A0464|75 78|BX42
14P09632709A0464|146 160|gene expression
14P09632734A0081|70 86|sequence homology
14P09632734A0081|96 120|GDP/GTP exchange proteins
14P09632734A0081|125 135|Rab3 family
14P09632734A0081|142 161|GTP binding proteins
14P09632734A0943|7 20|p82 expression
14P09632734A0943|33 47|ERK2 activation
14P09632734A0943|49 52|p126
14P09632734A0943|54 56|p70
14P09632785A0000|3 31|pre-mRNA splicing factor U2AF
14P09632785A0000|30 31|U2
14P09632785A0000|44 69|ribonucleoprotein particle
14P09632785A0000|114 134|splice site selection
14P09633171A0321|75 83|tap water
14P09633171A0321|85 100|room temperature
14P09633171A0321|140 149|shear mode
14P09633171A0321|164 178|testing machine
14P09633274A0000|0 16|Exercise training
14P09633274A0000|62 83|heart failure patients
14P09633630A0740|11 13|Aer
14P09633630A0740|44 58|lettuce extract
14P09633630A0740|91 93|BMC
14P09633630A0740|107 108|Ps
14P09633630A0740|110 120|fluorescens
14P09633630A0740|157 159|BMC
14P09633879A0246|17 26|compliance
14P09633879A0246|39 48|resurgence
14P09633879A0246|51 71|serum ferritin levels
14P09633879A0246|125 126|L1
14P09635149A1148|0 9|Hematocrit
14P09635149A1148|13 16|PaO2
14P09635276A1608|0 9|Regulation
14P09635276A1608|12 38|myosin phosphatase activity
14P09635276A1608|54 73|subunit interactions
14P09636119T0000|19 27|generator
14P09636119T0000|68 74|pulleys
14P09636358A0000|19 25|VAI RNA
14P09636358A0000|61 63|RNA
14P09636670T0000|0 8|Structure
14P09636670T0000|50 69|kinase inhibitor p18
14P09636670T0000|91 103|breast cancer
14P09636708A0460|3 14|YccA protein
14P09636708A0460|85 90|YccA11
14P09636708A0460|117 135|amino acid residues
14P09637689A0150|20 37|activator proteins
14P09637689A0150|47 49|DNA
14P09637689A0150|68 81|RNA polymerase
14P09637689A0150|82 85|RNAP
14P09637689A0150|137 140|RNAP
14P09638342T0000|17 18|L1
14P09638342T0000|65 94|membrane cytoskeleton assembly
14P09638485A0111|47 85|leukocyte alkaline phosphatase activity
14P09638485A0111|84 87|LAPA
14P09638485A0111|124 142|road tanker drivers
14P09638650A0169|30 32|NCR
14P09638650A0169|72 75|ORFs
14P09638650A0169|127 140|RNA polymerase
14P09638650A0169|141 144|ORF1
14P09638650A0169|149 168|kDa movement protein
14P09638650A0169|169 172|ORF2
14P09638650A0169|177 196|kDa movement protein
14P09638650A0169|197 200|ORF3
14P09638650A0169|205 224|kDa movement protein
14P09638650A0169|225 228|ORF4
14P09638650A0169|233 248|kDa coat protein
14P09638650A0169|248 251|OFR5
14P09638650A0169|260 262|NCR
14P09638793A1446|38 40|Hct
14P09638793A1446|57 61|LV MC
14P09638793A1446|64 65|LV
14P09638793A1446|133 156|i.v. perflubron emulsion
14P09639074A0707|0 2|Sp1
14P09639074A0707|9 20|Sp3 isoforms
14P09639074A0707|52 63|constituents
14P09639410A3282|33 39|targets
14P09639410A3282|57 66|strategies
14P09639558A0957|47 49|IgG
14P09639558A0957|68 79|erythrocytes
14P09639565A0225|39 55|enhancer activity
14P09639565A0225|94 106|SV40 promoter
14P09640162A0242|44 57|growth hormone
14P09640162A0242|71 95|growth hormone deficiency
14P09640162A0242|112 129|ventricle teratoma
14P09640802A0467|36 47|consequences
14P09640802A0467|80 92|possibilities
14P09640802A0467|98 108|flap choice
14P09641167A1359|0 9|CONCLUSION
14P09641167A1359|11 19|TNF alpha
14P09641167A1359|20 27|TGF beta
14P09641167A1359|28 31|PDGF
14P09641167A1359|35 42|IL-1beta
14P09641167A1359|52 71|LDLr gene expression
14P09642042A0646|0 17|Binding affinities
14P09642042A0646|28 42|nucleotide mono
14P09642042A0646|104 124|beta-phosphate moiety
14P09642042A0646|137 153|substrate binding
14P09642200A0956|48 59|proteolipids
14P09642200A0956|64 85|M. thermoautotrophicum
14P09642200A0956|88 100|M. jannaschii
14P09642200A0956|211 226|chemical natures
14P09642214A0244|46 62|phosphatase SHP-2
14P09642214A0244|120 123|MAPK
14P09642214A0244|141 153|SHP-2 mutants
14P09642214A0244|155 165|COS-7 cells
14P09642227A0000|0 11|Osteoadherin
14P09642227A0000|32 48|bone proteoglycan
14P09642227A0000|58 72|keratan sulfate
14P09642238A0532|0 5|Intron
14P09642238A0532|40 56|enhancer activity
14P09642238A1285|41 46|GATA-1
14P09642238A1285|59 61|Sp1
14P09642238A1285|64 90|transactivation experiments
14P09642238A1285|92 102|COS-1 cells
14P09642238A1285|136 146|Sp1 protein
14P09642276A0881|13 15|Fak
14P09642276A0881|71 85|suicide program
14P09642276A0881|123 125|Fak
14P09642764A0469|32 43|QCM response
14P09642764A0469|53 70|Sauerbrey equation
14P09642764A0469|216 218|QCM
14P09643153T0000|1 9|Treatment
14P09643153T0000|24 41|T2N breast cancers
14P09643546A0436|0 23|Transcription initiation
14P09643546A0436|126 142|stress conditions
14P09643548A0000|71 106|cyanobacterium Synechocystis PCC6803
14P09645576A0148|0 2|RNA
14P09645576A0148|5 9|GBV-C
14P09645576A0148|44 46|BMT
14P09645942A1164|12 36|Dsg-plakoglobin complexes
14P09645942A1164|48 49|8S
14P09645961A1158|34 41|CBF/NF-Y
14P09645961A1158|55 63|CCAAT box
14P09647233A0336|27 47|HIV-1 gene expression
14P09647233A0336|73 82|NF-kappa B
14P09647233A0336|146 148|LTR
14P09647240A0000|14 16|p53
14P09647240A0000|37 63|Janus kinase-STAT signaling
14P09647240A0000|84 108|hepatoma Hep3B cell lines
14P09647240A0000|163 175|Val135 mutant
14P09647240A0000|177 179|p53
14P09649069A0490|31 50|laryngeal parameters
14P09649265A1575|0 10|CONCLUSIONS
14P09649265A1575|105 116|office visit
14P09649265A1575|140 154|biopsy strategy
14P09649265A1575|197 207|examination
14P09649315A0943|0 10|Examination
14P09649315A0943|38 40|NMR
14P09649315A0943|81 99|MIP-1 beta variants
14P09649426A0636|14 25|PKA activity
14P09649426A0636|54 58|Msn2p
14P09649426A0636|62 75|Msn4p activity
14P09649437A1140|62 79|Ets family members
14P09649437A1140|91 96|GATA-1
14P09649437A1140|113 144|eosinophil lineage determination
14P09649438A0182|15 52|transcription elongation factor P-TEFb
14P09649438A0182|63 73|CDK9 kinase
14P09649438A0182|145 158|Tat activation
14P09649438A0182|188 193|P-TEFb
14P09649501A0358|36 60|HSF1 trimerization domain
14P09649501A0358|79 103|protein interaction assay
14P09649501A0358|112 144|heat shock factor binding protein
14P09649501A0358|143 147|HSBP1
14P09649501A0358|255 273|HSF1 heptad repeats
14P09649537A0000|35 62|yeast GCN2 eIF-2alpha kinase
14P09650180A1130|10 22|recombination
14P09650180A1130|36 42|voltage
14P09650180A1130|64 73|dose-rates
14P09650180A1130|86 94|mGy min-1
14P09650186A1043|19 27|positives
14P09650186A1043|68 78|radiologist
14P09650186A1043|97 103|regions
14P09650275T0000|26 43|weapons convention
14P09650275T0000|80 101|biotechnology industry
14P09650299A0000|18 51|Agrobacterium tumefaciens proteins
14P09650299A1334|38 42|VirD2
14P09650299A1334|82 92|integration
14P09650403A0868|3 14|DHEAS levels
14P09650403A0868|36 38|BMD
14P09650403A0868|90 92|BMD
14P09650789A0185|0 10|Orientation
14P09650789A0185|57 72|Overhauser shift
14P09650789A0185|86 98|energy levels
14P09651321A0000|0 9|Cystatin A
14P09651321A0000|11 39|cysteine proteinase inhibitor
14P09651321A0000|49 66|precursor proteins
14P09651321A0000|138 165|keratinocyte differentiation
14P09651367T0000|8 13|RalGDS
14P09651367T0000|23 34|Ras effector
14P09651375T0000|0 5|GTPase
14P09651375T0000|29 33|RGS12
14P09651375T0000|37 55|binding specificity
14P09651375T0000|79 81|PDZ
14P09651375T0000|83 88|PSD-95
14P09651375T0000|90 95|Dlg/ZO
14P09651383A0967|22 39|HNF-4 binding site
14P09651383A0967|66 80|HNF-4 synthesis
14P09651383A0967|82 92|HepG2 cells
14P09651383A0967|103 118|HNF-4 constructs
14P09651383A0967|130 153|apoCII promoter activity
14P09651383A0967|187 191|HNF-4
14P09652736A1205|21 25|E2F-1
14P09652736A1205|45 47|p53
14P09652736A1205|72 75|p300
14P09652736A1205|116 133|E2F/DP heterodimer
14P09652736A1205|164 168|E2F-1
14P09652737A1244|44 69|Fos family member proteins
14P09652737A1244|135 160|Jun family member proteins
14P09652737A1244|185 188|AP-1
14P09652737A1244|190 208|DNA binding complex
14P09652742A0455|33 35|p53
14P09653182A1298|39 42|BSMV
14P09653182A1298|54 66|primer donors
14P09653182A1298|69 77|MStV mRNA
14P09653182A1298|93 105|transcription
14P09653641A0471|53 63|start codon
14P09653648A0445|0 9|Comparison
14P09653648A0445|47 57|ZNF189 gene
14P09653648A0445|152 169|zinc finger domain
14P09653745A0180|0 6|Malaria
14P09653745A0180|43 47|1940s
14P09653745A0180|56 68|paper queries
14P09653745A0180|99 114|control projects
14P09653745A0180|221 233|problem today
14P09655248A0000|3 19|gp330/Megalin/LRP
14P09655248A0000|52 83|lipoprotein receptor gene family
14P09655916A0415|5 25|DNA recognition helix
14P09655916A0415|47 49|Arg
14P09655916A0415|127 129|Leu
14P09655916A0415|132 134|Gln
14P09656414A0220|0 5|Dosage
14P09656485A0351|55 75|restriction digestion
14P09657003T0000|51 65|RNA polymerases
14P09657003T0000|98 100|RNA
14P09657003T0000|111 128|elm disease fungus
14P09657003T0000|128 147|Ophiostoma novo-ulmi
14P09657003T0000|175 178|RNAs
14P09657003T0000|187 197|Arabidopsis
14P09658104T0000|9 44|transcription start site core region
14P09658104T0000|44 67|transcription factor YY1
14P09658104T0000|68 85|Rous sarcoma virus
14P09658104T0000|96 119|repeat promoter activity
14P09658122T0000|0 12|Fowlpox virus
14P09658122T0000|60 63|PC-1
14P09658122T0000|99 114|nematode protein
14P09658403A1207|0 7|Addition
14P09658403A1207|10 12|Rap
14P09658403A1207|15 18|KN62
14P09658403A1207|41 64|progesterone agonist Org
14P09658403A1207|91 102|CAT activity
14P09658405A0000|3 12|Dax-1 gene
14P09658405A0000|79 98|receptor superfamily
14P09658769A0058|28 39|IFN alpha-2b
14P09660823A0934|8 30|Ser/Thr phosphorylation
14P09660823A0934|57 69|p70 S6 kinase
14P09660836A0983|33 46|state kinetics
14P09660836A0983|48 61|MEK inhibition
14P09660836A0983|88 92|U0126
14P09660836A0983|148 156|S222D MEK
14P09660836A0983|164 171|PD098059
14P09660838A0920|0 9|Regulation
14P09660838A0920|57 79|protein kinase cascades
14P09660838A0920|89 92|HSF1
14P09660838A0920|100 114|phosphorylation
14P09660838A0920|117 131|serine residues
14P09660838A0920|180 198|heat shock response
14P09661676T0000|21 34|protein levels
14P09661676T0000|36 39|IL-5
14P09662339A0744|24 33|transition
14P09662339A0744|105 114|expression
14P09662339A0744|117 125|CD44 mRNA
14P09662443A0402|83 102|caveolin gene family
14P09663062A0175|0 21|Tensile bond strengths
14P09663062A0175|83 104|Clearfil Liner Bond II
14P09663062A0175|103 104|LB
14P09663062A0175|108 131|Scotchbond Multi-Purpose
14P09663062A0175|132 133|MP
14P09663062A0175|135 149|bonding systems
14P09664033A1204|4 15|distribution
14P09664033A1204|43 51|precursor
14P09664033A1204|69 77|nucleolus
14P09664033A1204|128 145|processing pathway
14P09665361T0000|21 35|thyroid nodules
14P09665503A0526|19 28|volunteers
14P09665720A0325|14 16|Mg2
14P09665720A0325|31 46|exonuclease site
14P09665720A0325|62 76|polymerase site
14P09665720A0325|94 108|primer terminus
14P09665720A1145|18 20|Mg2
14P09665720A1145|22 34|binding sites
14P09665720A1145|47 61|primer terminus
14P09665720A1145|76 91|exonuclease site
14P09666103A0496|3 17|missense allele
14P09666103A0496|18 22|P236S
14P09666103A0496|69 84|missense alleles
14P09666103A0496|85 89|L173F
14P09666103A0496|91 95|E225K
14P09666103A0496|97 101|S269L
14P09666103A0496|105 109|E274K
14P09666114A0389|74 77|TATA
14P09666114A0389|80 92|CAAT elements
14P09666114A0389|113 123|G-C content
14P09666114A0389|134 150|Sp1 binding sites
14P09667482A0978|30 41|contribution
14P09667482A0978|44 57|stress factors
14P09667482A0978|160 193|stress system disorder perspective
14P09667795A0000|5 16|pancreatitis
14P09668063A0274|27 38|Ets proteins
14P09668063A0274|40 57|Ras transformation
14P09668063A0274|113 127|Ets2 constructs
14P09668063A0274|144 149|NIH3T3
14P09668063A0274|151 152|DT
14P09668096A0806|41 50|preference
14P09668096A0806|61 68|partners
14P09668098A0868|18 32|FGF-BP promoter
14P09668098A0868|47 63|deletion analysis
14P09668098A0868|67 69|TPA
14P09668098A0868|139 162|transcription start site
14P09668108A1017|0 11|Manipulation
14P09668108A1017|17 37|checkpoint regulators
14P09668108A1017|47 63|cell cycle arrest
14P09668108A1017|104 117|cancer therapy
14P09668119A0496|15 35|mobility shift assays
14P09668119A0496|61 75|protein binding
14P09668119A0496|94 108|point mutations
14P09668119A0496|126 144|binding nucleotides
14P09668119A0496|197 203|CTCCT-3
14P09669641A0425|13 20|accuracy
14P09669641A0425|23 32|serum PE-1
14P09670034A0340|17 21|Ddc1p
14P09670034A0340|51 55|Mec3p
14P09670034A0340|83 88|Rad17p
14P09670912T0000|16 23|seizures
14P09670943T0000|0 22|B cell antigen receptor
14P09670943T0000|21 23|BCR
14P09670943T0000|46 64|SHP-2-pp120 complex
14P09670943T0000|82 110|Fc gamma RIIB1-BCR coligation
14P09671313A0334|0 4|Chem.
14P09671313A0334|28 39|MT Hartsough
14P09671464A0316|8 11|SNF1
14P09671464A0316|120 123|Snf1
14P09671496A0557|33 43|development
14P09671496A0557|47 57|homeostasis
14P09671496A0557|74 83|disruption
14P09671496A0557|89 99|c-Cbl locus
14P09671496A0557|158 167|appearance
14P09671576A0900|50 69|streak morphogenesis
14P09671579A1168|47 65|signaling processes
14P09671579A1168|101 120|boundary development
14P09671791T0000|46 67|growth factor receptor
14P09671791T0000|143 149|L cells
14P09673037A0358|0 6|METHODS
14P09673037A0358|92 119|reticulin fiber impregnation
14P09673037A0358|127 132|Gomori
14P09673436A0898|25 36|ANP infusion
14P09673436A0898|60 75|sodium excretion
14P09673436A0898|76 79|FENA
14P09673436A0898|140 143|FENA
14P09675154A0690|46 51|GSD-Ib
14P09675154A0690|139 167|consensus splicing donor site
14P09675154A0690|170 186|missense mutation
14P09675154A0690|187 191|W118R
14P09675896A0959|0 6|Removal
14P09675896A0959|12 26|carboxyl region
14P09676349A0000|2 8|Level A
14P09676349A0000|61 80|release theophylline
14P09676349A0000|81 83|CAS
14P09676349A0000|104 116|Bronchoretard
14P09676419A0158|0 5|METHOD
14P09676419A0158|90 103|questionnaires
14P09676419A0158|116 131|family histories
14P09676419A0158|143 157|screening tests
14P09676419A0158|188 194|CAP SX1
14P09676419A0158|199 211|determination
14P09676419A0158|219 240|serum immunoglobulin E
14P09676419A0158|240 242|IgE
14P09676419A0158|273 296|solid-phase immunoassays
14P09677330A0584|27 43|linker region LR1
14P09677330A0584|53 56|UCR1
14P09677330A0584|60 63|UCR2
14P09677330A0584|92 94|LR2
14P09677330A0584|106 109|UCR2
14P09677405A0856|0 17|Pol32Delta strains
14P09677410A1059|36 38|p53
14P09677410A1059|65 67|HBV
14P09677410A1059|100 116|HBV core promoter
14P09677410A1059|149 151|HBx
14P09677410A1059|198 200|p53
14P09678579A0768|35 44|AtCP1 gene
14P09678579A0768|53 65|blot analysis
14P09678837A0736|33 46|responsiveness
14P09678837A0736|49 66|bronchoprovocation
14P09678837A0736|71 82|methacholine
14P09678837A0736|131 143|pollen season
14P09678837A0736|163 179|blood eosinophils
14P09679066A1352|27 39|demonstration
14P09679066A1352|67 74|splicing
14P09679066A1352|85 93|pre-mRNAs
14P09679750A0304|28 58|prostate cancer chemoprevention
14P09679750A0304|97 122|cyclo-oxygenase inhibitors
14P09679750A0304|123 128|NSAIDs
14P09680994A0169|31 45|P. hybrida gene
14P09680994A0169|105 121|sequence homology
14P09680994A0169|124 144|intron/exon structure
14P09680994A0169|158 178|P. hybrida orthologue
14P09680994A0169|182 196|Z. mays r genes
14P09681822A0520|9 27|c-erbB3 transcripts
14P09682897A0218|47 64|electrocardiograms
14P09682897A0218|89 99|QRS changes
14P09682897A0218|121 134|injury pattern
14P09683576A0542|52 66|protease domain
14P09683576A0542|67 81|Gln2526-Asp2527
14P09685021A0127|0 6|METHODS
14P09685021A0127|8 42|Millipore ultrafiltration membranes
14P09685021A0127|76 100|model lenticule materials
14P09685021A0127|110 128|membrane pore sizes
14P09685021A0127|166 182|surface roughness
14P09685021A0127|352 368|epithelialization
14P09685226A0000|52 63|cAMP pathway
14P09685226A0000|76 88|transcription
14P09685226A0000|133 137|PTHrP
14P09685226A0000|166 186|lung cancer cell line
14P09685226A0000|185 187|BEN
14P09685346A0419|16 20|Pitx2
14P09685346A0419|31 49|homeodomain protein
14P09685346A0419|50 54|Pit-1
14P09685346A0419|97 114|prolactin promoter
14P09685346A0419|116 134|transfection assays
14P09686344T0000|36 72|ornithine transcarbamylase deficiency
14P09686603A0124|127 145|germline expression
14P09686603A0124|147 168|TCR beta gene segments
14P09687498A1173|96 102|TRalpha
14P09687498A1173|131 142|conformation
14P09687498A1173|161 174|overexpression
14P09687511A1091|0 13|Downregulation
14P09687511A1091|16 29|FUS expression
14P09687511A1091|49 60|32Dcl3 cells
14P09687511A1091|114 129|colony formation
14P09687511A1091|168 182|differentiation
14P09687514A0521|41 60|transcription system
14P09688264A1029|47 65|UTR silencer action
14P09688264A1029|87 101|rat hepatocytes
14P09689047A0253|40 54|glycoconjugates
14P09689047A0253|69 93|sugar-nucleotide cytidine
14P09689047A0253|132 141|CMP-Neu5Ac
14P09689047A0253|170 193|Golgi sialyltransferases
14P09689919A1192|14 22|PEDF cDNA
14P09689919A1192|68 84|PEDF glycoprotein
14P09691031A1050|22 34|Sro7 function
14P09691031A1050|63 77|myosin proteins
14P09691037A0355|58 66|N. crassa
14P09691037A0355|74 91|Neurospora species
14P09692965A0904|4 11|cysteine
14P09692965A0904|31 37|helices
14P09692965A0904|62 69|patterns
14P09692965A0904|79 86|exposure
14P09693035T0000|5 8|ULK1
14P09693035T0000|16 38|serine/threonine kinase
14P09693035T0000|47 59|UNC-51 kinase
14P09693035T0000|61 82|Caenorhabditis elegans
14P09693134A0782|81 91|neuroblasts
14P09693134A0782|104 114|neuroblasts
14P09693134A0782|128 130|DER
14P09693134A0782|159 176|column neuroblasts
14P09693134A0782|195 212|column neuroblasts
14P09693134A0782|279 289|neuroblasts
14P09693306T0000|19 28|potentials
14P09693306T0000|53 63|schwannomas
14P09694034A0713|39 40|LI
14P09694034A0713|54 67|antipsychotics
14P09694034A0713|131 132|LI
14P09694514A0000|3 39|complement C3a anaphylatoxin receptor
14P09694514A0000|38 41|C3aR
14P09694514A0000|65 73|G-protein
14P09694514A0000|81 104|chemoattractant receptor
14P09694514A0000|120 137|C3a peptide ligand
14P09694514A0000|179 195|histamine release
14P09694514A0000|215 232|muscle contraction
14P09694599A1355|0 10|CONCLUSIONS
14P09694599A1355|35 43|IL-1alpha
14P09694599A1355|47 54|IL-1beta
14P09694725A0500|67 71|LILRE
14P09694725A0500|90 116|gamma interferon activation
14P09694725A0500|151 167|IL-1beta promoter
14P09694860A0498|13 18|region
14P09694860A0498|38 43|domain
14P09694860A0498|65 70|region
14P09694860A0498|78 85|homology
14P09694860A0498|105 111|protein
14P09694869A0932|41 45|STATs
14P09694869A0932|66 77|p21 promoter
14P09694869A0932|94 98|Stat3
14P09694869A0932|113 127|cytokine effect
14P09694869A0932|132 143|p21 promoter
14P09694869A0932|168 172|Stat3
14P09694869A0932|190 210|STAT response element
14P09694869A0932|246 260|cytokine effect
14P09694897T0000|23 58|ribonucleoprotein C protein tetramer
14P09694897T0000|92 118|affinity RNA binding domain
14P09695194T0000|5 14|comparison
14P09695194T0000|27 37|proportions
14P09696164A0000|43 63|infant death syndrome
14P09696164A0000|63 66|SIDS
14P09696819A0450|64 76|vTF7-3 system
14P09696819A0450|116 117|ER
14P09698457A0778|31 45|Cux/CDPDeltaCR1
14P09698457A0976|80 98|tissue distribution
14P09698457A0976|158 173|target sequences
14P09698457A0976|182 184|DNA
14P09698512A0296|0 6|METHODS
14P09698512A0296|55 75|transplant recipients
14P09700644T0000|27 45|brain abnormalities
14P09700644T0000|51 61|measurement
14P09701609A0116|51 65|orphan proteins
14P09701609A0116|66 71|PhLOP1
14P09701609A0116|75 80|PhLOP2
14P09701609A0116|114 123|Gbetagamma
14P09701616A0108|7 45|transcriptase-polymerase chain reaction
14P09701616A0108|45 50|RT-PCR
14P09701616A0108|90 92|DNA
14P09701616A0108|98 126|sand shrimp Metapenaeus ensis
14P09701821A1108|2 9|contrast
14P09701821A1108|11 23|transcription
14P09701821A1108|38 45|opuE P-1
14P09701821A1108|59 68|proportion
14P09701821A1108|82 91|osmolarity
14P09701895A0119|19 26|children
14P09701895A0119|32 42|months-3 yr
14P09701895A0119|87 96|prevalence
14P09701895A0119|110 116|anaemia
14P09703021A0000|10 44|arylalkylamine N-acetyltransferases
14P09703021A0000|45 50|AANATs
14P09703021A0000|111 124|sclerotization
14P09703021A0000|147 163|neurotransmitters
14P09703021A0000|236 257|melatonin biosynthesis
14P09703213A0280|20 36|D1 antagonist SCH
14P09703276A2346|25 37|hydroquinones
14P09703276A2346|44 55|mutagenicity
14P09703276A2346|59 73|carcinogenicity
14P09703816A0139|0 4|IA-CT
14P09703816A0139|25 35|doxorubicin
14P09703816A0139|60 70|shot method
14P09703816A0139|89 102|iliac arteries
14P09704006A0224|0 9|Arnt3 mRNA
14P09704006A0224|63 71|P19 cells
14P09704296T0000|53 63|serum level
14P09704296T0000|65 80|immunoglobulin E
14P09704296T0000|83 94|eosinophilia
14P09704569T0000|51 69|TR2 orphan receptor
14P09704569T0000|81 108|steroid receptor superfamily
14P09704857T0000|0 10|Correlation
14P09704857T0000|30 43|CD4 lymphocyte
14P09704857T0000|63 70|HIV/AIDS
14P09704927A0479|34 37|E2Fs
14P09704927A0479|61 71|DNA binding
14P09704927A0479|72 89|heterodimerization
14P09705258A0837|3 18|IE13.1 cell line
14P09705324A0213|0 4|DNase
14P09705324A0213|36 58|mobility shift analyses
14P09705324A0213|94 97|HNF1
14P09705324A0213|135 139|C/EBP
14P09705324A0213|168 200|thyroid hormone response elements
14P09705324A0213|233 249|promoter sequence
14P09705324A1602|19 43|rat Std promoter function
14P09705324A1602|56 59|HNF1
14P09705324A1602|63 67|C/EBP
14P09705324A1602|85 101|liver specificity
14P09705324A1602|179 183|OCT-1
14P09705324A1602|187 200|C/EBP elements
14P09705324A1602|236 237|AR
14P09705324A1602|319 323|OCT-1
14P09705324A1602|327 331|C/EBP
14P09705324A1602|356 373|DNA-AR interaction
14P09705352A0879|62 103|minichromosome maintenance protein complex
14P09705497A0227|52 86|methyl methanesulfonate sensitivity
14P09705497A0227|132 158|DNA post-replication repair
14P09705564T0000|0 9|Expression
14P09705564T0000|20 38|papillomavirus type
14P09705564T0000|40 50|E5A protein
14P09705564T0000|57 60|E1E4
14P09705564T0000|62 74|E5 transcript
14P09706565A1072|0 9|Anesthesia
14P09706565A1072|14 16|M/K
14P09706565A1072|42 55|immobilization
14P09706643A0206|35 41|disease
14P09707498A0262|0 20|MK-801 administration
14P09707577A1047|2 9|contrast
14P09707577A1047|14 25|distribution
14P09708450A0648|0 7|Toxicity
14P09708450A0648|56 66|study group
14P09708450A0648|131 135|G-CSF
14P09708565A0000|79 91|radionuclides
14P09708565A0000|128 145|radioimmunotherapy
14P09708565A0000|147 149|RIT
14P09708565A0000|176 178|NHL
14P09708565A0000|215 232|multicenter trials
14P09708565A0000|235 251|commercialization
14P09710131A0374|53 80|image intensifier tube modes
14P09710131A0374|81 101|laser printer formats
14P09710582A0535|16 19|AP-1
14P09710582A0535|55 76|protein kinase pathway
14P09710582A0535|96 98|MEK
14P09710582A0535|103 115|MEK inhibitor
14P09710582A0535|116 122|PD98059
14P09710582A0535|147 159|AP-1 activity
14P09710589A1111|47 50|R82A
14P09710589A1111|52 55|K85A
14P09710589A1111|57 60|K88A
14P09710589A1111|65 68|V89A
14P09710589A1111|121 130|HTLV-1 LTR
14P09710591A0981|0 8|Mutations
14P09710591A0981|18 27|C terminus
14P09710591A0981|57 79|phosphorylation targets
14P09710591A0981|98 107|MAP kinase
14P09710591A0981|143 160|block potentiation
14P09710591A0981|162 171|MAP kinase
14P09710599A0310|26 30|CSF-1
14P09710599A0310|46 58|response gene
14P09710599A0310|117 126|expression
14P09710599A0310|129 141|ets-2 protein
14P09710599T0000|39 57|protein kinases p42
14P09710599T0000|59 61|p44
14P09710599T0000|65 85|ets-2 phosphorylation
14P09710614T0000|0 13|Identification
14P09710614T0000|42 44|CD2
14P09710614T0000|125 149|phosphoinositide 3-kinase
14P09710615T0000|0 4|Vam7p
14P09710615T0000|31 35|Vam3p
14P09710615T0000|38 53|syntaxin homolog
14P09710615T0000|85 103|protein trafficking
14P09710621A0598|61 82|cysteine substitutions
14P09710621A0598|87 110|Neu juxtamembrane domain
14P09710621A0598|149 161|interreceptor
14P09710641A0000|35 39|Pax-6
14P09710641A0000|55 56|PD
14P09710641A0000|71 72|HD
14P09710641A0000|74 93|transcription factor
14P09710641A0000|104 118|eye development
14P09710641A0000|177 197|zeta-crystallin genes
14P09712037A0470|0 14|Tctex-1 binding
14P09712037A0470|44 46|Fyn
14P09712037A0470|64 78|lysine residues
14P09712037A0470|135 150|Fyn interactions
14P09712037A0470|185 201|activation motifs
14P09712037A0470|202 206|ITAMs
14P09712037A0470|210 232|lymphocyte Ag receptors
14P09712297T0000|3 35|prothrombin gene G20210A mutation
14P09712644T0000|15 24|regulation
14P09712644T0000|30 39|GluR2 gene
14P09712644T0000|55 64|expression
14P09712859A1110|12 17|NF-ATp
14P09712859A1110|30 35|NF-AT4
14P09712859A1110|111 123|blood T-cells
14P09712898A0911|5 9|TRAF2
14P09712898A0911|19 22|SAPK
14P09712898A0911|26 39|p38 activation
14P09712898A0911|74 76|GCK
14P09712898A0911|80 82|RIP
14P09712898T0000|0 30|Tumor necrosis factor signaling
14P09712898T0000|60 63|SAPK
14P09712898T0000|88 90|JNK
14P09712898T0000|95 97|p38
14P09712915A0672|87 111|transcription factors Sp1
14P09712915A0672|111 113|Sp3
14P09712915A0672|118 121|NF-Y
14P09712919A0307|55 71|signaling pathway
14P09712919A0307|95 109|CREB activation
14P09712919A0307|117 123|T cells
14P09713584A1193|0 10|Respondents
14P09713584A1193|24 37|spouse/partner
14P09713584A1193|75 84|BMI status
14P09713990T0000|17 32|TP53 target gene
14P09713990T0000|36 57|colon cancer cell line
14P09713990T0000|88 109|TP53 expression system
14P09713996A0262|0 13|Overexpression
14P09713996A0262|16 19|MDR1
14P09713996A0262|59 72|patient tumors
14P09713996T0000|23 38|characterization
14P09713996T0000|85 104|drug resistance gene
14P09713996T0000|104 122|MDR1/P-glycoprotein
14P09713996T0000|177 179|ALL
14P09714109A0000|0 9|BACKGROUND
14P09714109A0000|52 65|blood pressure
14P09714109A0000|93 106|nerve activity
14P09714109A0000|107 109|SNA
14P09714109A0785|7 29|blood pressure increase
14P09714835A0345|16 33|carboxypeptidase D
14P09714835A0345|34 36|CPD
14P09714835A0345|104 121|carboxypeptidase E
14P09714835A0345|122 124|CPE
14P09714835A0345|146 160|characteristics
14P09714835A0345|183 186|Song
14P09714835A0345|188 189|L.
14P09714835A0345|191 197|Fricker
14P09714835A0345|199 202|L.D.
14P09715278A1079|0 11|RA-treatment
14P09715278A1079|111 130|G1 cell cycle arrest
14P09715278A1079|154 165|NT2/D1 cells
14P09715278A1526|20 37|neovascularization
14P09715278A1526|94 113|FGF4 over-expressing
14P09715278A1526|119 139|control transfectants
14P09715384A0235|10 16|vessels
14P09715384A0235|22 29|diameter
14P09715384A0235|38 47|treatments
14P09715384A0235|57 61|J/cm2
14P09715384A0235|72 78|results
14P09715384A0235|105 111|vessels
14P09716095T0000|0 14|Pressure ulcers
14P09716179A0974|0 19|RXR-gamma expression
14P09716179A0974|103 132|kinase inhibitors p21Cip1/WAF1
14P09716179A0974|134 140|p27Kip1
14P09716179A0974|169 188|cdk2 kinase activity
14P09716179A0974|190 207|RB phosphorylation
14P09716183A1036|0 2|TBP
14P09716183A1036|41 50|U937 cells
14P09716183A1036|83 86|ERK2
14P09716183A1036|91 111|phosphorylation sites
14P09716183A1036|123 148|ERK kinase consensus sites
14P09716183A1036|151 153|TBP
14P09716435A1004|9 18|CR/PP diet
14P09716435A1004|25 35|HS subjects
14P09716435A1004|97 114|cortisol elevation
14P09716435A1004|136 145|PR/CP diet
14P09717246A0526|9 11|ILC
14P09717246A0526|15 25|ILVF values
14P09717246A0526|125 127|ILC
14P09717246A0526|149 152|ILVF
14P09717835A0941|5 21|sequence analyses
14P09717835A0941|57 66|IRS family
14P09717835A0941|77 91|Xenopus homolog
14P09717887A0239|50 56|VO2peak
14P09717887A0239|77 93|occlusive disease
14P09717887A0239|94 97|PAOD
14P09717887A0239|172 178|VO2peak
14P09718372T0000|0 7|Evidence
14P09718372T0000|71 90|Sty1/Spc1 MAP kinase
14P09718671A0000|14 25|Injury Scale
14P09718671A0000|26 28|AIS
14P09718671A0000|31 51|Injury Severity Scale
14P09718671A0000|53 69|TRISS methodology
14P09719636A1134|61 75|histidine pairs
14P09719636A1134|79 95|H382-X2-H385 pair
14P09719636A1134|99 115|H411-X2-H414 pair
14P09719636A1134|121 137|H430-X5-H436 pair
14P09719636A1134|183 192|C terminus
14P09721207A0637|68 77|Chromosome
14P09721207A0637|103 116|vacillans gene
14P09721798A1734|60 72|HCV hepatitis
14P09721798A1734|109 121|liver failure
14P09722043A2070|12 21|TPN groups
14P09722161A3065|0 9|Regulation
14P09722161A3065|62 74|Igf2/Mpr gene
14P09722508A0953|30 43|Galpha11 Q209L
14P09722508A0953|53 78|Src family kinase activity
14P09722508A0953|86 109|tyrosine phosphorylation
14P09722508A0953|128 140|HEK-293 cells
14P09722766A0706|3 22|micturition pressure
14P09722766A0706|69 73|BUP-4
14P09723896A0000|0 9|Peroxisome
14P09723896A0000|42 45|PPAR
14P09723896A0000|127 130|PPRE
14P09723896A0000|139 156|heterodimerization
14P09723896A0000|190 192|RXR
14P09724654A0761|81 91|Mcm protein
14P09724654A0761|108 110|RPA
14P09724654A1120|26 31|S-CDKs
14P09724654A1120|35 43|Dbf4/Cdc7
14P09724654A1120|45 48|Mcms
14P09724654A1120|95 97|RPA
14P09724754A0173|0 7|Tyrosine
14P09724754A0173|22 26|STATs
14P09724763T0000|27 59|abalone sperm fertilization genes
14P09724763T0000|101 103|DNA
14P09724772A0840|0 21|Gel retardation assays
14P09724772A0840|65 85|zia operator-promoter
14P09724772A0840|88 103|ZiaR-DNA binding
14P09725292A1473|0 9|CONCLUSION
14P09725292A1473|85 86|CT
14P09725651A0077|11 14|RTPS
14P09725651A0077|35 51|Microsoft Windows
14P09725651A0077|114 131|Pentium processors
14P09725854A1060|102 119|IS1112C Rf3 allele
14P09725854A1060|140 155|maintainer lines
14P09725854A1060|193 220|urf209 processing activities
14P09726201T0000|0 4|JCAHO
14P09726979T0000|29 44|characterization
14P09726979T0000|53 70|sphingosine kinase
14P09726987T0000|6 42|SPT3-TAFII31-GCN5-L acetylase complex
14P09726988A0275|0 5|Oleate
14P09726988A0275|33 44|M-CPT I mRNA
14P09726991T0000|12 29|DNA binding domain
14P09726991T0000|50 74|transcription factor Mac1
14P09727045A0817|87 90|HREs
14P09727045A0817|133 145|AR N terminus
14P09727045A0817|147 167|ligand binding domain
14P09727046A0000|46 51|HS2NF5
14P09727046A0000|113 115|HS2
14P09727046A0000|127 158|beta-globin locus control region
14P09727046A0000|157 159|LCR
14P09727046A0000|162 164|Lam
14P09727046A0000|166 167|L.
14P09727046A0784|3 11|CBF1 site
14P09727046A0784|17 19|HS2
14P09727046A0784|68 73|GATA-1
14P09727046A0784|75 79|NF-E2
14P09727046A0784|84 87|TAL1
14P09729481A0000|3 45|rat branched-chain-2-oxo-acid dehydrogenase
14P09729481A0000|45 48|BCOD
14P09729481A0000|132 148|Sp1 binding sites
14P09729481A0000|154 177|transcription start site
14P09729481A1177|0 14|Co-transfection
14P09729481A1177|20 41|Sp1 expression plasmid
14P09729481A1177|49 66|promoter construct
14P09729481A1177|80 94|Schneider cells
14P09729481A1177|106 108|Sp1
14P09729481A1177|136 152|promoter activity
14P09730413A0642|9 22|investigations
14P09730413A0642|98 108|TME surgery
14P09730413A0642|124 139|treatment option
14P09730413A0642|142 152|Stage T1-T3
14P09731354A0963|34 48|surface density
14P09731354A0963|50 59|NH2 groups
14P09731513A1090|53 83|transcription factors NF-kappaB
14P09731513A1090|85 88|AP-1
14P09731513A1090|120 128|IL-8 gene
14P09731513A1090|130 139|HTLV-I Tax
14P09731704A0000|46 68|estrogen receptor-alpha
14P09731704A0000|69 75|ERalpha
14P09731704A0000|95 96|E2
14P09731704A0000|107 121|gene activation
14P09731704A0000|123 146|U2-OS osteosarcoma cells
14P09731704A1472|0 11|Transfection
14P09731704A1472|33 63|delta5ERalpha expression vector
14P09731704A1472|67 73|ERalpha
14P09731704A1472|76 83|OS cells
14P09731704A1472|120 134|ERELuc activity
14P09731705A2126|0 6|Studies
14P09731705A2126|79 84|VDR-TR
14P09731705A2126|100 110|interaction
14P09733493A0493|39 48|standpoint
14P09733493A0493|50 58|melatonin
14P09733493A0493|78 94|hydroxyl radicals
14P09733647A1960|13 47|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe
14P09733647A1960|63 68|B-loop
14P09733647A1960|136 149|archeabacteria
14P09733794A1323|27 31|Bcl-2
14P09733794A1323|56 60|Bcl-x
14P09733794A1323|62 64|Bax
14P09733794A1323|132 133|Tg
14P09733815T0000|0 7|Tyrosine
14P09733815T0000|19 37|membrane protein 2A
14P09733815T0000|50 80|protein tyrosine kinase loading
14P09733854A0198|73 74|LR
14P09733854A0198|76 78|RNA
14P09734808A0000|9 23|test efficiency
14P09734808A0000|57 80|contrast/color card test
14P09734808A0000|100 112|test stimulus
14P09735286A0599|58 60|Mn2
14P09735286A0599|68 79|Mu B protein
14P09735286A0599|93 95|ATP
14P09735366A1180|5 31|homology cloning techniques
14P09735366A1180|44 58|mouse homologue
14P09735366A1180|62 63|Pc
14P09735366A1180|72 75|Epc1
14P09735366A1180|100 103|EPL1
14P09735366A1180|126 129|ESTs
14P09735366A1180|134 155|Caenorhabditis elegans
14P09735368A0636|19 20|m8
14P09735368A0636|23 25|UTR
14P09735368A0636|110 124|K box sequences
14P09735371A0227|35 53|homeodomain protein
14P09735371A0227|117 135|homeodomain protein
14P09735371A0227|147 161|differentiation
14P09736239A0436|11 30|resuscitation period
14P09736239A0436|56 79|glutamate concentrations
14P09736239A0436|126 138|resuscitation
14P09736239A0436|181 193|resuscitation
14P09736239A0436|236 247|accumulation
14P09736239A0436|256 267|excitotoxins
14P09736239A0436|284 296|resuscitation
14P09736697A0783|0 9|Expression
14P09736697A0783|32 35|MEK1
14P09736697A0783|59 62|ERKs
14P09736697A0783|82 85|ERK2
14P09736697A0783|93 96|JNK1
14P09736697A0783|107 122|Stat3 activation
14P09736697A1107|0 3|MEKs
14P09736697A1107|7 10|ERKs
14P09736697A1107|20 34|IL-6 activation
14P09736697A1107|36 40|Stat3
14P09736697A1107|87 108|serine phosphorylation
14P09736697A1107|139 143|Stat3
14P09736697A1107|157 174|Janus kinases Jak1
14P09736697A1107|176 179|Jak2
14P09736697A1107|190 194|Stat3
14P09736715A0729|12 31|phosphatidylinositol
14P09736715A0729|39 51|trisphosphate
14P09736715A0729|87 89|ILK
14P09736715A0729|149 150|Pi
14P09736715A0729|164 166|ILK
14P09736770A0351|0 11|Transfection
14P09736770A0351|22 36|binding studies
14P09736770A0351|52 56|HEFT1
14P09736770A0351|93 98|GC box
14P09736770A0351|109 111|Sp1
14P09736770A0351|114 116|Sp3
14P09737453A0557|0 5|Plasma
14P09737453A0557|39 40|SD
14P09737453A0557|57 70|IgG antibodies
14P09737453A0557|168 172|ELISA
14P09737921T0000|0 16|Genome plasticity
14P09737921T0000|27 42|tail fiber locus
14P09737921T0000|52 64|bacteriophage
14P09737921T0000|66 78|recombination
14P09738010A0305|3 14|FAS promoter
14P09738010A0305|56 80|insulin response sequence
14P09738010A0305|91 101|E-box motif
14P09738010A0305|110 127|base pair position
14P09738087A0583|56 75|Cox regression model
14P09738693T0000|0 6|Effects
14P09738693T0000|18 37|neutrophil functions
14P09739401A0000|0 8|OBJECTIVE
14P09739401A0000|43 61|balance instruments
14P09739401A0000|116 131|home environment
14P09739913A0194|0 10|CASE REPORT
14P09741391A0581|37 46|PenH units
14P09741391A0581|55 59|Pause
14P09741391A0581|119 129|inspiration
14P09741391A0581|133 142|expiration
14P09741783A0000|0 10|Anastrozole
14P09741783A0000|21 39|aromatase inhibitor
14P09741783A0000|57 74|survival advantage
14P09741783A0000|128 140|breast cancer
14P09742129A0491|0 1|W.
14P09743128A0969|0 6|Moritta
14P09743128A0969|19 25|Bis-GMA
14P09743233A0526|0 7|Mutation
14P09743233A0526|19 22|AP-1
14P09743233A0526|63 79|promoter activity
14P09743233A0526|81 84|SMCs
14P09743720A0268|0 6|ANIMALS
14P09743720A0268|40 41|DM
14P09744095A1016|31 44|shy2-1D mutant
14P09744095A1016|72 82|mutants hy2
14P09744095A1016|188 205|inflorescence stem
14P09744095A1016|215 230|level expression
14P09744095A1016|235 242|CAB gene
14P09745797A0943|21 36|underpredictions
14P09745797A0943|57 66|disruption
14P09747651A0000|0 13|Laser ablation
14P09747873T0000|17 37|adapter protein GRB10
14P09747873T0000|49 55|BCR-ABL
14P09748261A0000|40 59|acyl-CoA synthetases
14P09748261A0000|65 88|acid activation proteins
14P09748286A0000|72 86|factor receptor
14P09748286A0000|87 90|LIFR
14P09748286A0000|114 129|characterization
14P09748286A0000|143 155|pair enhancer
14P09748513X1360|13 33|Elsevier Science B.V.
14P09748669A0414|42 43|AD
14P09748669A0414|47 49|VaD
14P09749533A0764|0 4|Clone
14P09749533A0764|20 27|CONSTANS
14P09749533A0764|65 78|flowering time
14P09749533A0764|80 90|Arabidopsis
14P09749988A0000|0 6|Badcock
14P09749988A0000|10 19|Westheimer
14P09749988A0000|28 33|Vision
14P09749988A0000|39 42|3-11
14P09749988A0000|96 105|attraction
14P09749988A0000|205 218|repulsion zone
14P09750325A0000|16 40|intensity light emissions
14P09750325A0000|62 89|power energization technique
14P09750325A0000|89 92|PPET
14P09750325A0000|178 179|H7
14P09750325A0000|184 205|Listeria monocytogenes
14P09750540A0000|8 27|chemical sensitivity
14P09750540A0000|28 30|MCS
14P09750540A0000|94 110|chemical exposure
14P09751061A0000|0 18|POU-domain proteins
14P09751061A0000|73 90|homeodomain family
14P09751061A0000|179 206|signal-transduction pathways
14P09751114A0967|18 21|MyoD
14P09751114A0967|52 53|E1
14P09751114A1987|23 28|Thr115
14P09751114A1987|68 80|MyoD function
14P09751114A1987|101 111|mitogenesis
14P09751166A1460|36 38|CRE
14P09751166A1460|42 49|Sp1 site
14P09751166A1460|75 90|TH transcription
14P09751458A0845|0 19|desmethyltrimebutine
14P09753241A0524|10 21|examinations
14P09753241A0524|48 50|WBC
14P09753241A0524|70 93|myeloperoxidase activity
14P09753241A0524|94 96|MPO
14P09753241A0524|113 124|colon mucosa
14P09753730A0881|0 15|T7 transcription
14P09753730A0881|97 114|promoter mutations
14P09753769A0362|30 45|oligonucleotides
14P09753769A0362|62 81|amino acid sequences
14P09753769A0362|85 98|PBAN precursor
14P09753774A1642|56 78|oligofructans 1-kestose
14P09753774A1642|79 81|GF2
14P09753774A1642|84 94|1,1-nystose
14P09753774A1642|96 98|GF3
14P09753774A1642|103 124|1,1,1-fructosylnystose
14P09753774A1642|126 128|GF4
14P09753774A2246|34 53|amino acid sequences
14P09753774A2246|83 115|plant fructosyl transferase genes
14P09753774A2246|133 151|plant fructan genes
14P09753774A2246|165 185|plant invertase genes
14P09753775A0734|8 11|ICK1
14P09753775A0734|24 26|ABA
14P09753775A0734|40 53|ICK1 induction
14P09753775A0734|81 106|histone H1 kinase activity
14P09754571A0169|42 61|display amplicon 3G1
14P09754571A0169|91 110|RAG1 mRNA expression
14P09754571A1257|3 12|hBRAG gene
14P09754571A1257|38 47|chromosome
14P09754571A1257|51 55|10q26
14P09755191A0553|105 123|frameshift mutation
14P09755191A0553|140 143|CHC1
14P09755191A0553|148 160|reading frame
14P09755199A0373|41 43|Scm
14P09755199A0373|81 92|requirements
14P09755199A0559|29 41|Scm mutations
14P09755199A0559|80 92|PcG mutations
14P09755199A0559|110 112|Scm
14P09755478A0366|0 16|Northern analysis
14P09755478A0366|119 134|trace expression
14P09756687A0981|10 25|characterization
14P09756687A0981|29 38|discussion
14P09756687A0981|69 82|rate constants
14P09756895A0322|7 11|locus
14P09756895A0322|14 19|chCTCF
14P09756895A0322|76 80|exons
14P09756895A0322|88 93|intron
14P09757012A0942|13 15|PDZ
14P09757012A0942|19 29|SAM domains
14P09757012A0942|34 44|KS5 protein
14P09757012A0942|118 144|signal transduction pathway
14P09759180A0000|0 9|BACKGROUND
14P09759180A0000|11 26|Fluoroquinolones
14P09759180A0000|28 29|FQ
14P09759180A0000|77 92|cartilage damage
14P09759691A1051|57 72|microalbuminuria
14P09759691A1051|81 97|albumin excretion
14P09759691A1051|174 175|SD
14P09759691A1051|185 198|blood pressure
14P09759691A1051|228 235|1.0-mmol
14P09759691A1051|253 276|plasma cholesterol level
14P09759691A1051|368 382|body mass index
14P09759865A0673|13 20|IL-1beta
14P09759865A0673|24 32|TNF-alpha
14P09759865A0673|63 78|Rel proteins p50
14P09759865A0673|80 82|p65
14P09759865A0673|87 121|NF-kappaB consensus oligonucleotide
14P09759865A0673|178 192|NF-kappaB-alpha
14P09759865A0673|194 206|IkappaB-alpha
14P09759865A0673|243 250|IL-1beta
14P09759865A0673|262 272|PDGF-Ralpha
14P09760243A0970|0 14|Cotransfections
14P09760243A0970|19 23|ATF-2
14P09760243A0970|27 51|HNF-4 expression plasmids
14P09760341T0000|0 25|Phosphocreatine hydrolysis
14P09760341T0000|61 64|FIO2
14P09761711A0000|0 19|Pseudocontact shifts
14P09761711A0000|138 162|susceptibility anisotropy
14P09761723A0226|0 5|GETS-1
14P09761791A0489|16 21|U1-70K
14P09761791A0489|29 40|SRZ proteins
14P09761791A0489|71 88|blot overlay assay
14P09763421A1199|31 55|Fab1p kinase inactivation
14P09763421A1199|97 117|acidification defects
14P09763446A0000|5 11|GTPases
14P09763446A0000|17 30|Ypt/Rab family
14P09763446A1234|3 5|GEF
14P09763446A1234|9 22|GAP activities
14P09763446A1234|25 29|Ypt1p
14P09763470A0000|0 24|Dopamine beta-hydroxylase
14P09763470A0000|25 27|DBH
14P09763470A0000|139 158|neuroendocrine cells
14P09763470A1756|47 52|Phox2a
14P09763470A1756|92 112|transcription factors
14P09763470A1756|118 121|CREB
14P09763470A1756|123 125|AP2
14P09763470A1756|130 132|Sp1
14P09763470A1756|166 173|DBH gene
14P09763522A2545|31 37|N-SMase
14P09763522A2545|49 54|Ox-LDL
14P09763607A0521|19 29|Ngo strains
14P09763607A0521|65 67|JNK
14P09763607A0521|76 85|p38 kinase
14P09764741A0092|47 69|cell division machinery
14P09765261A0000|8 13|T cell
14P09765261A0000|41 46|HTLV-I
14P09765261A0000|64 66|Tax
14P09765261A0000|96 122|basic-domain/leucine-zipper
14P09765261A0000|137 173|cAMP response element binding protein
14P09765261A0000|171 174|CREB
14P09765261A0000|267 292|cAMP response element core
14P09765271A1108|30 54|insulin response sequence
14P09765271A1108|138 170|phosphoenolpyruvate carboxykinase
14P09765271A1108|171 195|tyrosine aminotransferase
14P09765277A0000|21 47|glucose transporter isoform
14P09765277A0000|48 51|Glut
14P09765285A0998|33 57|consensus sequence AGGTCA
14P09765285A0998|57 63|IRper-1
14P09765285A0998|83 87|AaEcR
14P09765285A0998|89 93|AaUSP
14P09765285A0998|105 111|IRhsp-1
14P09765285A0998|155 179|spacer length requirement
14P09765285A0998|183 189|IRper-0
14P09765285A0998|192 198|IRper-5
14P09765285A1763|56 73|binding affinities
14P09765285A1763|78 94|response elements
14P09765285A1763|95 101|IRper-1
14P09765285A1763|103 106|DR-4
14P09765285A1763|108 114|IRhsp-1
14P09765372A0669|62 73|distribution
14P09765372A0669|92 105|dorsal surface
14P09765372A0669|138 147|C. armatus
14P09765388T0000|0 11|Inactivation
14P09765388T0000|14 16|p53
14P09765388T0000|23 25|p73
14P09765388T0000|43 45|E1B
14P09765388T0000|62 63|E4
14P09765394A0000|15 38|virus transactivator Zta
14P09765394A0000|50 64|gene expression
14P09765394A1590|0 13|Cotransfection
14P09765394A1590|77 93|activation domain
14P09765394A1590|129 142|CAT expression
14P09765411A0991|0 19|Sequence comparisons
14P09765411A0991|41 44|S27a
14P09765411A0991|93 98|CP Rit
14P09765411A0991|157 189|structure NH2-ubiquitin-S27a-COOH
14P09765466A0231|0 1|J.
14P09765754A1727|35 37|PVI
14P09767504A1371|45 57|concentration
14P09767504A1371|68 81|administration
14P09767575A0657|43 53|SD sequence
14P09767575A0657|68 83|ribosome binding
14P09767593A0130|8 11|YopH
14P09767593A0130|27 29|PTP
14P09767593A0130|115 121|p130Cas
14P09767687T0000|25 35|Phacotaceae
14P09767687T0000|45 61|Chlamydophyceaeas
14P09767687T0000|82 89|18S rDNA
14P09767687T0000|92 105|rbcL sequences
14P09769209A0100|72 93|nasF operon expression
14P09769209A0100|122 146|antitermination mechanism
14P09769910A1700|3 12|activation
14P09769910A1700|49 51|TNF
14P09770241A0000|1 9|technique
14P09770241A0000|20 26|imaging
14P09770241A0000|46 57|brain cortex
14P09770378A0641|0 10|EGFR levels
14P09770415A0139|21 27|THOV NP
14P09770415A0139|42 56|KRxxxxxxxxxKTKK
14P09770415A0139|60 79|amino acid positions
14P09770415A0139|125 143|localization signal
14P09770415A0139|144 146|NLS
14P09770493A0499|2 5|PP2A
14P09770493A0499|46 66|cell cycle regulation
14P09770493A0499|68 90|cell fate determination
14P09770493A0499|147 162|postimplantation
14P09770686A0484|15 25|risk factor
14P09770686A0484|40 51|hypertension
14P09771555A0499|22 46|anthraquinone sennoside B
14P09771967A1052|12 19|LB1 gene
14P09771967A1052|27 42|chromosome 13q14
14P09771967A1052|95 98|DLBL
14P09771985A0238|29 49|ethylmercury chloride
14P09771985A0238|50 55|EtHgCl
14P09771985A0238|81 86|EtHgCl
14P09771985A0238|96 105|L-cysteine
14P09773975A1873|9 22|AT1A receptors
14P09773975A1873|41 59|hamster ovary cells
14P09773975A1873|83 100|Ang II stimulation
14P09773975A1873|100 103|t1/2
14P09773975A1873|125 139|internalization
14P09773975A1873|141 144|Ymax
14P09773975A1873|193 205|substitutions
14P09773975A1873|207 211|T332E
14P09773975A1873|213 216|t1/2
14P09773975A1873|224 227|Ymax
14P09773975A1873|234 238|S335D
14P09773975A1873|240 243|t1/2
14P09773975A1873|251 254|Ymax
14P09773975A1873|261 265|T336E
14P09773975A1873|267 270|t1/2
14P09773975A1873|278 281|Ymax
14P09773975A1873|288 292|S338D
14P09773975A1873|294 297|t1/2
14P09773975A1873|305 308|Ymax
15P09773981A0415b|12 34|glucocorticoid receptor
15P09773981A0415b|51 55|Stat5
14P09774403A0107|0 1|T.
14P09774403A0107|3 10|Mahasneh
14P09774403A0107|12 13|A.
14P09774403A0107|18 21|Cote
14P09774403A0107|23 24|G.
14P09774444A0351|29 32|UKLF
14P09774444A0351|62 75|Cys2-His2 type
14P09774444A0351|95 105|CACCC motif
14P09774444A0351|110 129|beta-globin promoter
14P09774444A0351|137 160|Sp1 recognition sequence
14P09774450A0000|42 69|gamma-glutamyl leukotrienase
14P09774450A0000|70 72|GGL
14P09774450A0000|100 103|LTC4
14P09774450A0000|121 124|LTD4
14P09774484T0000|0 17|UGA codon position
14P09774484T0000|38 65|selenocysteine incorporation
14P09774484T0000|69 92|glutathione peroxidase-1
14P09774641A0824|0 8|Forskolin
14P09774641A0824|72 86|phosphorylation
14P09774641A0824|92 118|retinoblastoma gene product
14P09774662A0958|3 14|ARF promoter
14P09774662A0958|48 62|E2F1 expression
14P09774662A0958|96 104|RNA level
14P09776293A0777|0 6|RESULTS
14P09776293A0777|20 26|99mTc d
14P09776293A0777|27 33|1-HMPAO
14P09776360A0620|0 1|CM
14P09776360A0620|36 60|transcription factor AP-1
14P09776360A1781|0 8|NF-kappaB
14P09776360A1781|60 62|NOS
14P09776360A1781|112 113|CM
14P09776360A1781|116 126|DLD-1 cells
14P09777477A0000|0 8|Observers
14P09777477A0000|13 24|brain injury
14P09777477A0000|27 46|control participants
14P09777477A0000|56 69|vigilance task
14P09777600A0000|26 34|l-menthol
14P09777600A0000|59 72|chromatography
14P09777999A0796|0 6|RESULTS
14P09777999A0796|54 65|PaCO2 levels
14P09777999A0796|81 91|hypercapnia
14P09778006A0718|14 26|baseline Vmca
14P09778006A0718|46 59|carbon dioxide
14P09778006A0718|75 79|PaCO2
14P09778006A0718|105 106|SD
14P09778006A0718|109 120|measurements
14P09778006A0718|136 139|PaCO
14P09778006A0718|163 187|carbon dioxide reactivity
14P09778006A0718|245 262|baseline Vmca/mmHg
14P09778068A1129|12 32|Cox survival analysis
14P09778068A1129|41 51|baseline EF
14P09778068A1129|86 98|regurgitation
14P09778068A1129|153 163|performance
14P09778068A1129|205 214|predictors
14P09778191A0000|48 50|CBF
14P09778191A0000|75 90|reserve capacity
14P09778191A0000|136 152|resonance imaging
14P09778191A0000|153 155|MRI
14P09778197A0415|0 26|Cost-effectiveness analysis
14P09778197A0415|67 87|health care resources
14P09778197A0415|167 202|beta-hydroxy-beta-methylglutaryl-CoA
14P09778197A0415|214 233|reductase inhibitors
14P09778197A0415|257 271|atherosclerosis
14P09780002A0996|8 13|E2FBP1
14P09780002A0996|22 43|transactivation domain
14P09780002A0996|56 58|E2F
14P09780002A0996|103 107|E2F-1
14P09780228A0122|18 28|DNA segment
14P09780228A0122|33 50|FK506 gene cluster
14P09780228A0613|12 28|domain structures
14P09780228A0613|30 33|FkbB
14P09780228A0613|37 40|FkbC
14P09780228A0613|61 64|FkbA
14P09780228A0613|78 96|fatty-acid-synthase
14P09780228A0613|98 100|FAS
14P09780336A0771|0 7|Analysis
14P09780336A0771|10 29|Msy2 mRNA expression
14P09780336A0771|134 149|round spermatids
14P09780336A0771|186 213|messenger ribonucleoproteins
14P09781761A0384|3 18|Ho Chi Minh City
14P09781761A0384|38 56|latex agglutination
14P09781871A0404|0 17|Glycogen synthesis
14P09781871A0404|31 45|gluconeogenesis
14P09781871A0404|67 89|cell surface properties
14P09781871A0404|171 187|virulence factors
14P09781871A0404|210 231|response elicitor HrpN
14P09781871A0404|231 233|Ecc
14P09781871A0404|296 313|Erwinia carotovora
14P09781874A1061|3 17|cwg2-1 mutation
14P09781874A1061|42 61|adenine substitution
14P09781874A1061|63 72|nucleotide
14P09781874A1061|108 119|change A202T
14P09784063A0621|0 16|Deletion analysis
14P09784063A0621|70 100|ORF5/deltaX transcript promoter
14P09784192A1027|17 27|MBP fusions
14P09784192A1027|48 72|surface plasmon resonance
14P09784245T0000|71 108|protein kinase C phosphorylation sites
14P09785114A1026|10 12|PND
14P09785114A1026|36 46|CORT levels
14P09786197A0322|0 7|Analysis
14P09786197A0322|21 32|DNA sequence
14P09786197A0322|58 77|transposon insertion
14P09786197A0322|94 107|reading frames
14P09786197A0322|144 162|sequence similarity
14P09786404A0541|9 21|aggregates/ml
14P09786926A0095|34 61|fatty-acid synthase promoter
14P09786926A0095|98 111|overexpression
14P09786926A0095|117 135|fatty-acid synthase
14P09786926A0095|136 138|FAS
14P09786926A1372|20 34|binding studies
14P09786926A1372|47 52|SREBP2
14P09786926A1372|70 88|ADD1/SREBP1 binding
14P09786926A1372|119 121|SRE
14P09786932A1042|5 9|IRF-7
14P09786932A1042|40 44|IRF-3
14P09786932A1042|81 85|IRF-7
14P09786932A1042|126 129|IFNA
14P09786932A1042|143 147|IRF-7
14P09786932A1042|183 202|IFNA gene expression
14P09786949A0114|0 1|J.
14P09787323A0000|0 6|PURPOSE
14P09787323A0000|11 28|role interleukin-6
14P09787323A0000|29 32|IL-6
14P09787323A0000|60 76|thrombocytopenias
14P09788739A1096|75 91|signaling cascade
14P09788739A1096|132 157|MDA231 breast cancer cells
14P09789025A0149|0 6|Galphaq
14P09789025A0149|8 15|Galpha12
14P09789025A0149|20 27|Galpha13
14P09789025A0149|35 41|Galphai
14P09789025A0149|51 53|SRF
14P09789025A0149|61 64|RhoA
14P09789795A0607|43 55|noradrenaline
14P09789795A0607|57 58|NA
14P09789795A0607|60 73|concentrations
14P09790499A0545|0 21|Northern blot analyses
14P09790499A0545|31 46|hBub1 mRNA level
14P09790767A0372|31 49|sequence tag clones
14P09790767A0372|75 84|chromosome
14P09790768A0621|0 10|Htra2-beta3
14P09790768A0621|70 81|liver testis
14P09790771A0956|0 17|Gng3lg transcripts
14P09790771A1032|20 34|backcross panel
14P09790771A1032|50 53|Gng3
14P09790771A1032|57 62|Gng3lg
14P09790986A0689|41 80|glutathione S-transferase fusion protein
14P09790986A0689|122 127|NRAMP2
14P09792439T0000|15 43|apolipoprotein B mRNA editing
14P09792439T0000|74 92|40S hnRNP complexes
14P09792627A0441|0 4|SRC-1
14P09792627A0441|48 58|GR activity
14P09792630A1127|32 60|transcription start site CTCA
14P09792630A1127|62 65|TTCC
14P09792630A1127|81 94|consensus CTCA
14P09792630A1127|98 101|NTCT
14P09792630A1127|125 141|initiator element
14P09792630A1127|156 182|deoxynucleotidyltransferase
14P09792682A0713|40 48|subunit c
14P09792682A0713|50 51|F0
14P09792702A0754|0 9|Expression
14P09792702A0754|38 41|JNK1
14P09792702A0754|82 96|JNK1 activation
14P09792702A0754|104 124|HSP70 gene expression
14P09792714A1408|16 19|AF-1
14P09792714A1408|59 71|transcription
14P09792714A1408|118 132|gene expression
14P09792714A1408|134 137|AF-1
14P09794414T0000|9 34|protein kinase C signaling
14P09794414T0000|43 59|DRA transcription
14P09794795A0183|0 13|Ligand binding
14P09794795A0183|40 63|tyrosine phosphorylation
14P09794795A0183|78 90|Janus kinases
14P09794795A0183|116 147|signal transducing subunit gp130
14P09794795A0183|220 246|transcription factors STAT3
14P09794795A0183|248 252|STAT1
14P09794795A0183|259 277|src homology domain
14P09794795A0183|277 279|SH2
14P09794795A0183|292 319|protein tyrosine phosphatase
14P09794795A0183|319 322|SHP2
14P09795130A0742|69 90|translation efficiency
14P09795170A0774|16 35|polyadenylation site
14P09795170A0774|55 57|TGA
14P09795170A0774|88 105|kb transcript size
14P09795213A0129|0 12|RBP56 protein
14P09795213A0129|88 90|TAF
14P09795213A0129|113 127|TFIID complexes
14P09795213A0129|128 140|Bertolotti A.
14P09795213A0129|141 144|Lutz
14P09795213A0129|146 147|Y.
14P09795213A0129|149 153|Heard
14P09795213A0129|155 158|D.J.
14P09795213A0129|160 166|Chambon
14P09795213A0129|168 169|P.
14P09795213A0129|171 174|Tora
14P09795213A0129|176 177|L.
14P09795213A0129|240 265|proto-oncoproteins TLS/FUS
14P09795213A0129|268 270|EWS
14P09795213A0129|291 295|TFIID
14P09795213A0129|299 312|RNA polymerase
14P09795341A0806|17 36|mobility shift assay
14P09795341A0806|64 79|binding property
14P09795341A0806|81 83|TR2
14P09797189A0559|47 57|CCAAT motif
14P09797456A0000|0 9|BACKGROUND
14P09797456A0000|14 33|c-myc proto-oncogene
14P09797456A0000|65 82|cell proliferation
14P09797456A0000|83 97|differentiation
14P09797456A0000|99 112|transformation
14P09797456A0883|0 4|AMY-1
14P09797456A0883|97 112|c-myc expression
14P09798068A0290|0 6|RESULTS
14P09798068A0290|46 58|reading frame
14P09798068A0290|103 113|amino acids
14P09798068A0290|179 183|GABAB
14P09798100A0705|10 15|CIDR-B
14P09798100A0705|32 54|micrograms cloprostenol
14P09798100A0705|63 64|IM
14P09798263T0000|35 60|serotonin receptor ligands
14P09798263T0000|62 88|calcium channel antagonists
14P09799086A0725|16 31|hotspot mutation
14P09799086A0725|69 90|G nucleotide insertion
14P09799086A0725|113 114|Gs
14P09799086A0725|117 125|HPRT exon
14P09799086A0725|164 174|LN patients
14P09799237A0624|39 57|gastrulation defect
14P09799362A0507|56 72|abbreviation AZF1
14P09799362A0507|88 106|Zinc Finger protein
14P09799362A1463|0 14|Over-expression
14P09799362A1463|17 21|Azf1p
14P09799362A1463|55 70|expression level
14P09799362A1463|88 113|transcription factor Mtf1p
14P09799362A1463|141 145|Azf1p
14P09799362A1463|187 207|RNA polymerase mutant
14P09799634A0161|16 29|computer model
14P09799634A0161|77 93|crystal structure
14P09799634A0161|108 111|UmuD
14P09799793T0000|40 54|chromosome 7q22
14P09799793T0000|96 98|EPO
14P09799793T0000|102 111|CUTL1 loci
14P09800187A0100|7 11|Trp53
14P09800187A0100|35 38|TP53
14P09800187A0100|53 55|Tk1
14P09800187A0100|131 149|DNA damaging agents
14P09800187A0100|175 194|mouse lymphoma cells
14P09800187A0100|210 214|Trp53
14P09801156A0220|34 61|amino acid sequence homology
14P09801333A0174|14 19|N gene
14P09801333A0174|71 80|PRRS virus
14P09801333A0174|81 84|PA-8
14P09802206A1058|48 50|TEF
14P09802206A1058|60 96|translation elongation factor-1 alpha
14P09802206A1058|97 100|RPS7
14P09802902A0225|25 28|ARNO
14P09802902A0225|86 109|ARF6 nucleotide exchange
14P09803081T0000|5 13|pathology
14P09803081T0000|35 47|childhood SLE
14P09804779A0000|0 20|Transcription factors
14P09804779A0000|25 35|Stat family
14P09804779A1163|32 59|Stat5 serine phosphorylation
14P09804836A0000|86 111|mouse BAC1.2F5 macrophages
14P09804836A0000|112 138|colony stimulating factor-1
14P09804836A0000|138 142|CSF-1
14P09804836A0000|197 219|affinity chromatography
14P09804836A0000|220 248|size exclusion chromatography
14P09804836A0000|251 252|C4
14P09805052A0119|0 3|Dose
14P09805052A0119|72 85|immunogenicity
14P09805977A0143|74 83|sperm fall
14P09805977A0143|140 149|substances
14P09805977A0143|154 166|xenoestrogens
14P09806516A1212|4 14|association
14P09806516A1212|76 85|recurrence
14P09806516A1689|0 9|CONCLUSION
14P09806516A1689|37 41|Preop
14P09806516A1689|95 100|Postop
14P09806546A1270|18 21|RFX5
14P09806546A1270|25 29|RFXAP
14P09806546A1270|56 66|RFX complex
14P09806546A1270|68 83|MHC-II promoters
14P09806826A0244|33 39|RIIIS/J
14P09806826A0244|74 82|Vwf locus
14P09806826A0244|84 86|Chr
14P09806826A1773|24 35|localization
14P09806826A1773|43 54|disease loci
14P09806826A1773|112 119|syndrome
14P09806826A1773|138 151|susceptibility
14P09806826A1773|172 182|lung injury
14P09806830X1174|0 8|Copyright
14P09806830X1174|13 26|Academic Press
14P09806857A0854|6 18|reading frame
14P09806857A0854|124 140|Pac25I R-M operon
14P09806858T0000|0 13|Identification
14P09806858T0000|42 53|plasmid pLS1
14P09806919A0447|31 43|instar larvae
14P09806919A0447|102 115|ecdysone pulse
14P09806919A0447|127 144|puparium formation
14P09807755A0146|44 52|viability
14P09807755A0146|56 66|muscle flap
14P09808155A0813|0 10|Examination
14P09808155A0813|13 15|DNA
14P09808155A0813|17 41|protein binding complexes
14P09808155A0813|140 151|DNA fragment
14P09808216A0000|0 9|BACKGROUND
14P09808216A0000|11 17|Studies
14P09808216A0000|54 55|EB
14P09808216A0000|71 72|FB
14P09808366A0828|90 106|KA microinjection
14P09808366A0828|120 126|VRG-Apa
14P09808441A0320|57 65|melanomas
14P09808441A0320|79 89|singularity
14P09808441A0320|114 122|character
14P09808441A0320|140 152|lymphotropism
14P09808441A0320|159 169|coexistence
14P09808441A0320|188 201|cell carcinoma
14P09810087A0379|0 6|RESULTS
14P09810087A0379|18 31|seroconversion
14P09810087A0379|61 80|herpes simplex virus
14P09810087A0379|80 84|HSV I
14P09811695A1146|24 42|HIV-1 Gag sequences
14P09811695A1146|87 109|MuLV TM Env protein p15
15P09811718A0979a|45 47|SIV
15P09811718A0979a|51 59|HIV-2 nef
15P09811718A0979a|66 74|HIV-1 nef
15P09811718A0979a|79 85|TCRzeta
14P09811730A1396|0 15|Competition EMSA
14P09811730A1396|76 86|KCS element
14P09811730A1396|98 125|KCS protein binding activity
14P09811730A1396|167 193|transfection reporter assay
14P09811730T0000|0 8|Mechanism
14P09811730T0000|11 27|interferon action
14P09811730T0000|88 98|KCS element
14P09811730T0000|152 174|protein kinase pkr gene
14P09813041A1122|0 1|GH
14P09813041A1122|19 33|phosphorylation
14P09813041A1122|48 50|Jun
14P09813063T0000|0 9|Expression
14P09813063T0000|24 46|phospholipase D homolog
14P09813093A0624|28 34|YCL024W
14P09813093A0624|76 79|GIN4
14P09813098A0521|0 9|Paralemmin
14P09813110A0982|10 28|amino acid sequence
14P09813110A0982|29 33|CBP90
14P09813203T0000|22 41|serine substitutions
14P09813203T0000|46 52|V3 loop
14P09813203T0000|54 73|HIV-1 gp120 IIIB/LAI
14P09813203T0000|96 111|envelope protein
14P09813207A0434|0 31|Transcription start site mapping
14P09813207A0434|101 110|TAAG motif
14P09813207A0434|193 202|TTGT motif
14P09813207A0434|235 242|TATA box
14P09813207A0434|278 280|ATG
14P09813254A0000|14 27|oligoadenylate
14P09813254A0000|29 32|2-5A
14P09813254A0000|58 74|family interferon
14P09813254A0000|75 77|IFN
14P09813259A1097|103 105|GBP
14P09813259A1097|109 111|IBG
14P09813635A0678|5 14|striations
14P09813635A0678|75 76|P3
14P09814637A1214|3 16|PbrO2 readings
14P09814637A1214|76 77|CT
14P09814637A1214|80 82|MRI
14P09814905A0598|3 14|consequences
14P09814905A0598|26 41|swine production
14P09814905A0598|46 56|environment
14P09815578A1245|37 41|CDKN2
14P09815578A1245|86 100|prostate cancer
14P09815578A1245|118 140|prostate carcinogenesis
14P09815948A1065|18 27|parameters
14P09815948A1065|51 60|toxicities
14P09815948A1065|89 105|peak plasma level
14P09817131A0296|12 28|SF-36 survey form
14P09817190A0074|16 28|cyclosporin A
14P09817190A0074|81 108|kidney transplant recipients
14P09817373A0000|0 6|PURPOSE
14P09817373A0000|31 50|hypercholesterolemia
14P09817373A0000|164 166|NOS
14P09817373A0000|189 204|tissue synthesis
14P09817373A0000|206 228|constrictor eicosanoids
14P09817601T0000|0 15|Characterization
14P09817601T0000|58 65|P450arom
14P09819038A0448|11 15|FVIIa
14P09819038A0448|30 42|infusion pump
14P09819038A0448|58 73|room temperature
14P09819038A0448|84 99|body temperature
14P09819110A0703|0 13|CD4 lymphocyte
14P09819110A0703|59 69|ARV therapy
14P09819216A0220|6 17|Biochemistry
14P09819288A0578|0 5|Levels
14P09819288A0578|44 46|IgE
14P09819377A1209|16 26|C2U4 repeat
14P09819377A1209|32 48|underaccumulation
14P09819377A1209|81 91|C2U4 repeat
14P09819377A1209|121 124|RNAs
14P09819391A1123|29 32|Arfs
14P09819391A1123|36 51|tyrosine kinases
14P09819391A1123|109 113|ASAP1
14P09819391A1123|129 154|membrane remodeling events
14P09819411A0897|2 6|DNase
14P09819411A0897|8 25|footprint analysis
14P09819411A0897|30 40|PNR element
14P09819411A0897|87 98|CTTCCCTGGAAG
14P09819414A1103|55 69|leptin receptor
14P09819414A1103|90 104|medium isoforms
14P09819421A0000|0 11|Cyclophilins
14P09819421A0000|97 109|cyclosporin A
14P09819421A0000|110 112|CsA
14P09819422A0768|7 35|protein retention experiments
14P09819422A0768|41 61|Hsp90 heterocomplexes
14P09819430A0000|14 20|GTPases
14P09819440A0000|61 81|transcription factors
14P09819440A0000|87 101|RNA polymerases
14P09819440A0783|10 12|RMP
14P09819440A0783|63 66|RPB5
14P09819440A0783|69 82|RNA polymerase
14P09819507A0000|47 60|wound reaction
14P09819507A0000|64 68|Dexon
14P09819507A0000|119 140|trabeculectomy surgery
14P09819507A0000|161 171|mitomycin-C
14P09820163A0565|26 42|Southern blotting
14P09820163A0565|45 64|restriction analysis
14P09820205A0000|3 16|zona pellucida
14P09820205A0000|17 18|ZP
14P09820205A0000|100 117|gamete interaction
14P09820611T0000|64 77|erythropoietin
14P09820611T0000|92 102|predialysis
14P09820611T0000|129 139|nephropathy
14P09820621A0067|20 35|thyroid function
14P09820621A0067|55 72|energy expenditure
14P09820621A0067|75 90|body composition
14P09820621A0067|113 125|leptin levels
14P09821978A1255|55 60|MK-801
14P09821978A1255|67 68|SE
14P09822602A0237|47 56|HIF-1alpha
14P09822602A0237|152 173|transactivation domain
14P09822602A0237|221 223|CBP
14P09822602A0237|226 241|p300 coactivator
14P09822602A1172|38 52|transactivation
14P09822602A1172|68 70|CBP
14P09822602A1172|133 151|signal transduction
14P09822602A1172|153 162|HIF-1alpha
14P09822647A0000|3 21|rat aldolase C gene
14P09822652A1118|20 40|HCK promoter activity
14P09822652A1118|72 74|Sp1
14P09822661T0073|24 42|amino acid residues
14P09822661T0073|51 65|quinone binding
14P09822685A0596|40 57|Lu-ECAM-1 peptides
14P09822685A0596|102 114|reading frame
14P09822685A0596|138 150|size proteins
14P09822690A0000|59 88|protein phosphorylation events
14P09822690A0000|97 113|protein kinase A.
14P09822825A0141|27 30|BAP2
14P09822825A0141|50 58|BAP3 gene
14P09823014T0000|0 5|Effect
14P09823014T0000|45 56|carbohydrate
14P09823014T0000|74 85|carbohydrate
14P09823014T0000|89 104|lipid metabolism
14P09823014T0000|118 122|NIDDM
14P09823561T0001|16 28|MALT lymphoma
14P09823561T0001|31 53|helicobacter heilmannii
14P09823561T0001|54 76|Gastrospirillum hominis
14P09823775A1122|30 34|HMG I
14P09823775A1122|61 83|HLA-DRA gene activation
14P09823775A1122|84 89|Oct-2A
14P09824001A1665|43 52|predictors
14P09824001A1665|68 69|Ag
14P09824001A1665|92 101|techniques
14P09824021A1263|0 9|CONCLUSION
14P09824021A1263|108 117|NO therapy
14P09824158A1336|10 35|BCL-6 POZ domain mutations
14P09824158A1336|70 73|SMRT
14P09826434T0000|43 73|platelet cAMP phosphodiesterase
14P09826434T0000|73 77|PDE3A
14P09826658A0691|4 16|core sequence
14P09826658A0691|136 150|BPV-1 pre-mRNAs
14P09826778A0943|0 14|Over-expression
14P09826778A0943|112 118|COUP-TF
14P09827446T0001|30 42|C4 deficiency
14P09827724A1362|2 10|mutations
14P09827724A1362|32 39|adenomas
14P09827878A0091|5 26|glutathione peroxidase
14P09827878A0091|27 29|GPX
14P09827878A0091|34 53|superoxide dismutase
14P09827878A0091|54 56|SOD
14P09827993A0000|10 30|nucleocapsid proteins
14P09827993A0000|31 34|NCPs
14P09827993A0000|48 67|zinc finger proteins
14P09827993A0000|77 105|virion RNA binding activities
14P09827993A0000|145 161|RNA encapsidation
14P09828137A0000|32 65|cell cycle checkpoint control gene
14P09828137A0000|85 95|G2/M arrest
14P09828137A0000|111 120|DNA damage
14P09828137A0000|133 147|DNA replication
14P09829836A0000|26 36|progression
14P09829836A0000|80 91|oscillations
14P09829836A0000|131 134|CDKs
14P09829836A0815|40 58|cyclin/CDK function
14P09829836A0815|95 110|yeast LEU2 genes
14P09829843A0119|42 44|CSF
14P09829843A0119|151 163|complications
14P09829843A0119|187 197|neutropenia
14P09829843A0819|15 17|CSF
14P09829843A0819|100 118|neutrophil recovery
14P09829843A0819|252 267|neutrophil count
14P09829843A0819|270 288|neutrophil function
14P09829843A0819|312 335|chemiluminescence system
14P09829916T0000|0 9|Expression
14P09829916T0000|88 91|W205
14P09832099A0000|101 106|Fallot
14P09832099A0000|108 110|TOF
14P09832099A0000|117 137|color kinesis imaging
14P09832436A0738|0 14|RT-PCR analysis
14P09832436A0738|24 28|PLP-H
14P09832436A0738|37 41|PLP-C
14P09832436A0738|45 49|PLP-D
14P09832436A0738|100 112|PLP diversity
14P09832436T0000|19 34|characterization
14P09832436T0000|74 76|PRL
14P09832436T0000|93 102|protein H.
14P09832504A0596|27 37|interaction
14P09832504A0596|45 47|Tat
14P09832504A0596|86 102|cysteine residues
14P09832505A0903|23 39|activation target
14P09832505A0903|57 61|Oct-1
14P09832505A0903|84 104|transcription complex
14P09832511A0269|11 22|neurogenesis
14P09832511A0269|24 34|Vnd protein
14P09832511A0269|55 74|column neuroectoderm
14P09832518A0615|3 19|repression domain
14P09832518A0615|38 50|Cdc68 protein
14P09832518A0615|94 98|Cdc68
14P09832518A0615|152 168|database searches
14P09833610A0626|3 11|exodomain
14P09833610A0626|27 42|affinity hormone
14P09833740A1112|0 26|Pyrrolidine dithiocarbamate
14P09833740A1112|68 70|LTR
14P09833740A1112|84 101|cytokine responses
14P09833740A1112|107 108|U1
14P09833740A1112|112 122|ACH-2 cells
14P09833740A1112|226 241|provirus latency
14P09834070A0793|35 38|ERK2
14P09834070A0793|83 85|Ca2
14P09834070A0793|118 142|protein kinase C activity
14P09834070A0793|176 179|CD19
14P09834070A0793|189 203|B cell function
14P09834521A0000|15 26|hydatid cyst
14P09835615A0574|30 32|KS1
14P09835615A0574|78 94|repressor domains
14P09835615A0574|95 96|R1
14P09835615A0574|100 101|R2
14P09836881A0441|11 19|BCH group
14P09836881A0441|59 82|Bruininks-Oseretsky Test
14P09836881A0441|84 100|Motor Proficiency
14P09837714A1068|60 72|modifications
14P09837714A1068|75 79|DdRPA
14P09837714A1068|107 124|cell proliferation
14P09837714A1068|133 147|differentiation
14P09837714A1068|150 162|Dictyostelium
14P09837715A0581|48 50|DNA
14P09837715A0581|62 94|chloramphenicol acetyltransferase
14P09837715A0581|95 97|CAT
14P09837715A0581|146 150|HIV-1
14P09837715A0581|174 176|MLV
14P09837715A0581|178 209|SL3-3 LTR-CAT reporter construct
14P09837824A0419|12 27|telSMN mutations
14P09837824A0419|109 128|frameshift mutations
14P09837824A0419|129 136|800ins11
14P09837824A0419|140 147|542delGT
14P09837824A0419|157 174|missense mutations
14P09837824A0419|175 177|A2G
14P09837824A0419|179 183|S262I
14P09837824A0419|188 192|T274I
14P09837907A0857|13 25|TNF receptors
14P09837907A0857|27 30|IL-4
14P09837907A0857|108 127|caspase-3 activation
14P09837907A0857|128 136|NF-kappaB
14P09837907A0857|140 154|AP-1 activation
14P09837907A0857|173 188|kinase induction
14P09837913A0000|0 3|Type
14P09837913A0000|16 17|D2
14P09837913A0000|34 45|deiodination
14P09837913A0000|70 85|triiodothyronine
14P09837913A0419|39 57|sequence tag clones
14P09837913A0419|88 90|UTR
14P09837913A0419|101 102|D2
14P09837914A0844|0 3|Biol
14P09837920A0222|35 46|requirements
14P09837920A0222|50 61|consequences
14P09837920A0222|74 88|phosphorylation
14P09837920A0222|121 123|JNK
14P09837933T0000|0 5|P-CIP1
14P09837933T0000|57 71|peptidylglycine
14P09837933T0000|87 99|monooxygenase
14P09837945A0820|0 17|Immunolocalization
14P09837945A0820|20 24|Sop1p
14P09837945A0820|60 85|cell fractionation studies
14P09837945A0820|116 120|Sop1p
14P09837978T0093|59 72|protein kinase
14P09837978T0093|73 80|JNK/SAPK
14P09838122A0489|26 45|coding cDNA sequence
14P09838122A0489|65 68|MPP3
14P09840822A0462|68 97|magnetization transfer effects
14P09840928A0884|27 29|Dlk
14P09840928A0884|44 59|core histones H3
14P09840928A0884|59 61|H2A
14P09840928A0884|65 66|H4
14P09840928A0884|112 124|kinase assays
14P09840932A0365|32 36|B-Myb
14P09840932A0365|68 80|cyclin A/Cdk2
14P09840934A0435|7 12|Ha-Ras
14P09840934A0435|14 17|G12V
14P09840934A0435|19 22|T35S
14P09840934A0435|25 36|Ha-RasV12S35
14P09840934A0435|56 77|Rafl signaling pathway
14P09840934A0435|80 85|Ha-Ras
14P09840934A0435|87 90|G12V
14P09840934A0435|92 95|E37G
14P09840934A0435|98 109|Ha-RasV12G37
14P09840934A0435|130 143|RalGDS pathway
14P09840943A0144|32 40|cyclin E2
14P09840943A0144|64 71|homology
14P09840943A0144|74 82|cyclin E.
14P09842517A0497|50 57|SieScape
14P09842517A0497|93 94|CT
14P09842517A0497|98 100|MRI
14P09843378A0187|3 22|dopamine D4 receptor
14P09843378A0187|86 104|SH3 binding domains
14P09843412A0130|38 42|Abeta
14P09843412A0130|44 50|Abeta42
14P09843412A0130|107 108|AD
14P09843572A0944|44 58|Cdr2 associates
14P09843572A0944|93 96|Wee1
14P09843572A0944|99 110|cell lysates
14P09843572A0944|127 130|Wee1
14P09843577A0000|67 88|G2/M cell size control
14P09843944A0976|0 7|A-tracts
14P09843944A0976|129 147|UP element function
14P09844106A0835|4 18|phosphorylation
14P09844106A0835|43 45|FLG
14P09844106A0835|73 75|ST2
14P09844921A0000|9 39|serine-threonine protein kinase
14P09844921A0000|98 121|differentiation messages
14P09845043A0000|3 23|US National Institute
14P09845043A0000|24 36|Alcohol Abuse
14P09845043A0000|39 48|Alcoholism
14P09845043A0000|50 54|NIAAA
14P09845043A0000|142 159|alcohol dependence
14P09845662A0085|0 7|Collagen
14P09845662A0085|81 94|sodium dodecyl
14P09845662A0085|116 134|gel electrophoresis
14P09845662A0085|135 142|SDS-PAGE
14P09845856A0560|0 6|RESULTS
14P09845856A0560|55 68|ulcer diseases
14P09846033A0488|0 6|RESULTS
14P09846033A0488|30 41|pretreatment
14P09846033A0488|44 56|posttreatment
14P09846482A0441|48 57|activation
14P09846482A0441|76 89|protein kinase
14P09846482A0441|104 123|actin polymerization
14P09846927A0227|24 34|perforation
14P09846927A0227|49 60|stomach wall
14P09847371A0000|0 21|Jembrana disease virus
14P09847371A0000|21 23|JDV
14P09847371A0000|90 111|immunodeficiency virus
14P09847371A0000|112 114|BIV
14P09847397A0935|94 110|response elements
14P09847397A0935|113 127|glucocorticoids
14P09847397A0935|153 163|CCAAT boxes
14P09847397A0935|188 197|TATA boxes
14P09848653A0597|0 4|Nhp2p
14P09849421A0332|38 47|Norwegians
14P09849421A0332|87 98|Organization
14P09849421A0332|102 109|Research
14P09849421A0332|113 121|Treatment
14P09849421A0332|124 142|Cancer Core Quality
14P09849421A0332|143 160|Life Questionnaire
14P09849421A0332|161 173|EORTC QLQ-C30
14P09849722A0797|6 17|presentation
14P09849722A0797|54 68|signal increase
14P09849722A0797|98 112|cingulate gyrus
14P09849722A0797|131 144|cingulate gyri
14P09849722A0797|191 203|brain regions
14P09849722A0797|240 263|emotion processing tasks
14P09849961A0387|0 14|Down-regulation
14P09849961A0387|17 21|IRS-1
14P09849961A0387|35 56|serine phosphorylation
14P09849961A0387|67 86|PI 3-kinase activity
14P09849961A0387|131 135|IRS-1
14P09849965A0000|74 85|dimerization
14P09849965A0000|93 113|progesterone receptor
14P09851614A0109|73 75|UTR
14P09851614A0109|81 91|nucleotides
14P09851614A0109|124 137|cap structures
14P09851700A0000|20 52|tissue-type plasminogen activator
14P09851988A0085|7 14|presence
14P09851988A0085|17 24|arginine
14P09851988A0085|28 39|anaerobiosis
14P09851988A0085|58 66|induction
14P09852005A1287|24 54|MADS box consensus binding site
14P09852005A1287|122 125|SAP1
14P09852005A1287|138 168|MADS box consensus binding site
14P09852005A1287|168 188|serum response factor
14P09852005A1287|247 258|OP4 sequence
15P09852068A0150b|8 11|SHBG
15P09852068A0150b|41 45|DNase
15P09852068A0150b|110 116|FP1-FP6
15P09852068A0150b|160 185|HepG2 hepatoblastoma cells
14P09852109A1475|7 17|translation
14P09852109A1475|35 50|profile analysis
14P09852109A1475|63 75|transcripts C
14P09852109A1475|117 128|efficiencies
14P09852109A1475|166 177|transcript D
14P09852136A0174|26 30|Ser36
14P09852136A0174|34 36|Asn
14P09852136A0174|54 57|p190
14P09852136A0174|87 104|guanine nucleotide
14P09852136A0174|134 135|HA
14P09852136A0174|153 161|COS cells
14P09852136A0507|0 16|Wild type HA-p190
14P09852136A0507|92 103|Rho function
14P09852136A0507|116 131|ADP-ribosylation
14P09852752A0950|72 73|RA
14P09854034A0536|38 48|G+C content
14P09854034A0536|94 105|mRNA species
14P09855111A0905|23 36|overexpression
14P09855111A0905|108 123|SREBP processing
14P09855111A0905|259 265|HMG CoA
14P09856397A0099|0 16|Dry matter intake
14P09856397A0099|24 47|nutrient digestibilities
14P09856397A0099|48 71|serum chemistry profiles
14P09856397A0099|71 97|sphingolipid concentrations
14P09856397A0099|114 116|FB1
14P09856732A0114|10 16|studies
14P09856732A0114|86 94|lidocaine
14P09857038A1374|0 1|E.
14P09857038A1374|3 7|Scott
14P09857038A1374|9 10|J.
14P09857197A0289|0 4|Yap1p
14P09857197A0289|45 49|Crm1p
14P09857197A0289|65 79|export sequence
14P09857197A0289|80 82|NES
14P09857197A0289|99 103|Yap1p
14P09857197A0289|119 124|RanGTP
14P09857265A0669|0 10|Mean intake
14P09857265A0669|12 20|vitamin A
14P09857265A0669|39 47|mg RE/day
14P09857265A0669|78 90|contributions
14P09857265A0669|110 119|vegetables
14P09857265A0669|123 136|dairy products
14P09858094A0583|44 45|O1
14P09858094A0583|50 51|O3
14P09858094A0583|53 54|O4
14P09858531A1017|12 31|RING1 overexpression
14P09858531A1017|63 83|proto-oncogenes c-jun
14P09858571T0000|40 79|reticulum protein localization mutations
14P09858571T0000|85 105|cis-prenyltransferase
14P09858572A0000|3 27|yeast retrotransposon Ty5
14P09858577A1186|9 12|SKO1
14P09858577A1186|31 45|ENA1 expression
14P09858577A1186|90 107|stress sensitivity
14P09858577A1186|118 122|Sko1p
14P09858577A1186|149 159|HOG pathway
14P09858581A0183|51 56|SPP381
14P09858581A0183|91 106|splicing defects
14P09858581A0183|131 132|Ts
14P09858588A1046|40 42|p68
14P09858588A1046|66 69|G1/S
14P09858588A1046|98 101|G2/M
14P09858593A0334|16 35|amino acid sequences
14P09858593A0334|48 68|Xenopus NeuroD1/BETA2
14P09858593A0334|87 109|insulin gene expression
14P09858599A0392|4 23|NUP98-HOXA9 chimeras
14P09858599A0392|34 52|NIH 3T3 fibroblasts
14P09858599A0392|84 96|HOXA9 domains
14P09858599A0392|99 109|DNA binding
14P09858599A0392|112 126|PBX interaction
14P09858619A0356|30 33|Y319
14P09858619A0356|56 70|ZAP-70 function
14P09858713A1174|44 46|Pan
14P09858713A1174|50 52|CiD
14P09858713A1174|72 74|Arm
14P09858713A1174|97 108|transduction
14P09858713A1174|114 122|Wg signal
14P09858713A1174|178 202|gain-of-function activity
14P09858713A1174|204 206|CiD
14P09858714A1171|7 9|ORF
14P09858714A1171|41 66|shares sequence similarity
14P09858745A1350|16 18|IBS
14P09858745A1350|50 62|cooperativity
14P09858745A1350|73 92|footprinting studies
14P09858745A1350|123 125|IBS
14P09858745A1350|156 159|CatR
14P09858745A1350|175 187|binding sites
14P09858745A1350|213 215|DNA
14P09858745A2033|7 26|transcription assays
14P09858745A2033|53 64|intermediate
14P09858745A2033|123 137|clcA transcript
14P09858883A1106|0 15|BIAcore analysis
14P09858883A1106|20 23|Kaff
14P09858883A1106|36 38|M-1
14P09858883A1106|54 57|N-A3
14P09858883A1106|60 64|T84.1
14P09858883A1106|78 80|M-1
14P09858883A1106|96 99|N-A3
14P09858883A1106|102 104|T84
14P09860979A0521|0 9|Expression
14P09860979A0521|12 15|p130
14P09860979A0521|53 66|Crk SH2-domain
14P09860979A0521|78 91|JNK activation
14P09861099A1011|8 19|correlations
14P09861099A1011|38 49|measurements
14P09861099A1011|53 66|protein intake
14P09861099A1011|81 93|energy intake
14P09861099A1011|118 128|differences
14P09861099A1011|142 143|SD
14P09861099A1011|152 162|kcal/kg/day
14P09861099A1011|164 165|SD
14P09861365A0000|3 7|Og4C3
14P09861365A0000|40 44|ELISA
14P09862343A0225|13 30|gp200-MR6 ligation
14P09862343A0225|42 45|IL-4
14P09862343A0225|127 139|up-regulation
14P09862343A0225|167 179|B lymphocytes
14P09862481A0000|3 16|Mig1 repressor
14P09862481A0000|19 37|zinc finger protein
14P09862481A0000|48 65|glucose repression
14P09862496A0187|0 7|Ethylene
14P09862496A0187|20 36|endosperm rupture
14P09862496A0187|49 68|betaGLU I expression
14P09862496A0187|117 136|betaGLU I expression
14P09863624A0629|70 74|CRF1s
14P09863624A0629|182 185|CRF1
14P09863624A2301|15 38|receptor internalization
14P09863624A2301|69 72|125I
14P09863624A2301|74 82|Tyr0-oCRF
14P09863624A2301|135 137|Cos
14P09863720T0000|49 68|protein S deficiency
14P09864141A0528|12 16|Stat3
14P09864141A0528|20 28|Stat3beta
14P09864141A0528|54 68|phosphopeptides
14P09864141A0528|79 82|Y704
14P09864141A0528|86 89|Y744
14P09864141A0528|115 131|peptide analogues
14P09864141A0528|135 149|phosphopeptides
14P09864141A0528|160 163|Y729
14P09864141A0528|167 170|Y764
14P09864335A1226|39 47|FCR1 gene
14P09864335A1226|76 90|drug resistance
14P09864335A1226|92 102|C. albicans
14P09864335A1226|135 148|FCZ resistance
14P09864335A1226|201 205|Fcr1p
14P09864689A1408|28 32|MYO/M
14P09864689A1408|90 102|heart failure
14P09864689A1408|107 109|DCM
14P09865775A0162|69 73|ALGO2
14P09866068A1058|0 10|CONCLUSIONS
14P09866068A1058|12 23|Pretreatment
14P09866068A1058|28 30|OCs
14P09866068A1058|99 112|cyst formation
14P09866068A1058|171 185|pregnancy rates
14P09867159A1444|22 37|threshold values
14P09867159A1444|38 48|sensitivity
14P09867159A1444|52 62|specificity
14P09867159A1444|89 95|FDG PET
14P09867253A0229|4 17|c-Jun activity
14P09867253A0229|43 58|protooncoprotein
14P09867253A0229|92 116|transcription factor AP-1
14P09867855T0000|53 108|rabbit beta-galactoside alpha1,2-fucosyltransferase gene
14P09868412A1628|0 9|CONCLUSION
14P09868412A1628|159 175|swimming exercise
14P09868412A1628|188 190|BMD
14P09868412A1628|284 303|grip muscle strength
14P09869297A1807|27 29|CE1
14P09869297A1807|33 44|CE2 elements
14P09869297A1807|56 76|Hoxb1 gene expression
14P09869356A0926|0 7|CAL gain
14P09869356A0926|51 58|CAL gain
14P09869400A0203|0 10|Comparisons
14P09869400A0203|71 97|Arabidopsis GLP subfamilies
14P09869528T0000|30 38|RF energy
14P09871353A0174|36 60|A. salmonicida infections
14P09872326A0566|35 42|CBF/cdc2
14P09872326A0566|57 59|CBF
14P09872326A0566|86 103|heat shock protein
14P09872337A0000|150 176|clindamycin phosphate ester
14P09872337A0000|178 192|clindamycin HCl
14P09872337A0000|217 244|clindamycin phosphate lotion
14P09872337A0000|245 257|% clindamycin
14P09872337A0000|258 266|Dalacin T
14P09872832A1262|3 20|BAL concentrations
14P09872832A1262|104 107|IL-6
14P09872832A1262|110 113|IL-8
14P09872832A1262|115 119|IL-12
14P09872832A1262|121 147|tumor necrosis factor-alpha
14P09872832A1262|147 155|TNF-alpha
14P09872832A1262|177 185|IFN-gamma
14P09873060A0901|0 23|Phosphorylation analyses
14P09873060A0901|48 52|ERK-1
14P09873060A0901|101 104|JunD
14P09873060A0901|108 111|FosB
14P09873291A0620|59 73|knowledge score
14P09873291A0620|86 99|patient groups
14P09874803A0000|18 48|bacterium group A Streptococcus
14P09874803A0000|69 85|cysteine protease
14P09874803A0000|118 121|SpeB
14P09874803A0000|139 154|virulence factor
14P09874803A0000|165 180|disease episodes
14P09875541A0210|51 71|dorsal premotor areas
14P09875541A0210|116 133|hand movement task
14P09875541A0210|133 136|SELF
14P09876794T0000|0 8|Improving
14P09876794T0000|12 24|evidence base
14P09877417A0704|0 16|Plasma CCK levels
14P09878256A0000|3 33|peroxisome biogenesis disorders
14P09878256A0000|33 36|PBDs
14P09878437A0967|30 40|triad Asp53
14P09878437A0967|50 64|phosphorylation
14P09878437A0967|67 71|Asp10
14P09878437A0967|75 78|Glu9
14P09878542A1151|77 79|VDR
14P09878542A1151|99 114|osteopontin VDRE
14P09879766A0402|2 6|PAV-3
14P09879766A0402|11 20|E1A region
14P09880029A0703|11 29|MDV genome products
14P09880029A0703|41 43|Rep
14P09880029A0703|87 105|amino acid identity
14P09880029A0703|125 138|FBNYV proteins
14P09880029A0703|154 165|Rep proteins
14P09880029A0703|174 179|MDV-C2
14P09880029A0703|183 184|C3
14P09880029A0703|226 232|SCSV-C2
14P09880029A0703|236 237|C6
14P09880103A0387|0 2|MPO
14P09880103A0387|73 91|M hydrogen peroxide
14P09880327A0322|14 20|variety
14P09880327A0322|48 55|proteins
14P09880327A0322|64 74|yeast Uso1p
14P09880327A0322|86 92|protein
14P09880327A0322|103 109|docking
14P09880327A0322|140 147|vesicles
14P09880512A1251|19 22|Bmp2
14P09880512A1251|74 76|Sp1
14P09880513A1013|4 11|proteins
14P09880513A1013|53 59|tubulin
14P09880543A0570|0 3|HEED
14P09880543A0570|20 29|MA protein
14P09880544A0693|13 34|DT-40 lymphoma B-cells
14P09880544A0693|103 124|recombination knockout
14P09880544A0693|147 158|Fas ligation
14P09880544A0693|171 181|DT-40 cells
14P09880544A0693|196 206|DT-40 cells
14P09881666A0535|7 14|TGATGTCA
14P09881666A0535|29 37|CREB site
14P09881666A0535|53 61|AP-1 site
14P09881666A0535|77 79|ER2
14P09881692A0094|44 45|b4
14P09881692A0094|47 48|b5
14P09881692A0094|50 51|b6
14P09881692A0094|55 56|b9
14P09881692A0094|101 118|Ckappa1 gene locus
14P09881692A1109|66 81|oligonucleotides
14P09881692A1109|85 86|b5
14P09881692A1109|88 89|b6
14P09881692A1109|93 94|b9
14P09881692A1109|123 124|T.
14P09881692A1109|149 165|Southern blotting
14P09882303A1413|0 4|TRAF2
14P09882303A1413|27 31|TRADD
14P09882303A1413|76 96|deletion TRAF2 mutant
14P09882303A1413|133 146|JNK activation
14P09882303A1984|30 34|TRADD
14P09882303A1984|38 42|TRAF2
14P09882303A1984|45 58|JNK activation
14P09882303A1984|72 75|LMP1
14P09882303A1984|84 104|signalling mechanisms
14P09882303A1984|113 136|TNF receptor/CD40 family
14P09882303T0000|59 69|JNK pathway
14P09882303T0000|86 95|C terminus
14P09882303T0000|117 121|TRADD
14P09882303T0000|125 129|TRAF2
14P09882321A0948|48 53|EBNA-3
14P09882321A0948|80 104|EBNA-3 protein expression
14P09882321A0948|117 127|EBNA-3 gene
14P09882321A0948|137 147|EBNA-3 cDNA
14P09882334A0822|29 39|lamb kidney
14P09882334A0822|40 42|FLK
14P09882334A0822|82 84|BLV
14P09882334A0822|100 111|transfection
14P09882334A0822|141 156|tyrosine residue
14P09882334A0822|198 208|propagation
14P09882337A0000|0 21|Varicella-zoster virus
14P09882337A0000|22 24|VZV
14P09882337A0000|48 73|transmembrane glycoprotein
14P09882337A0000|113 134|gI Fc receptor complex
14P09882348A0611|23 44|phosphorylation status
14P09882348A0611|56 80|tyrosine kinase substrate
14P09882348A0611|95 113|Shc adapter protein
14P09882451A0195|75 93|ferrochelatase gene
14P09882451A0195|94 98|HEM15
14P09882451A0195|136 148|transformants
14P09882489A0451|12 19|evidence
14P09882489A0451|65 79|mef2 expression
14P09882499A0231|27 42|mouse technology
14P09882499A0231|127 130|Pax6
14P09882593A0996|11 20|experiment
14P09882593A0996|29 42|nickel isotope
14P09882593A0996|43 46|61Ni
14P09882593A0996|58 71|drinking water
14P09882593A0996|147 157|hand eczema
14P09882593A0996|162 175|pompholyx type
14P09882638A0235|22 36|collagen fibers
14P09882638A0235|41 56|tunica albuginea
14P09883639A0000|0 5|Number
14P09883639A0000|42 53|mycobacteria
14P09883639A0000|55 57|NTM
14P09884232A0286|0 9|Comparison
14P09884232A0286|15 23|sequences
14P09884232A0286|55 68|junctions attL
14P09884232A0286|92 104|core sequence
14P09884232A0286|110 122|recombination
14P09884232A0286|151 164|integrase gene
14P09884275T0000|0 25|Interferon-alpha treatment
14P09884275T0000|87 103|organ transplants
14P09884747A0477|37 51|brewery workers
14P09884747A0477|58 75|control volunteers
14P09884747A0477|80 97|skin prick testing
14P09884747A0477|115 128|yeast antigens
14P09884747A0477|187 202|serum IgE levels
14P09885431A0000|0 8|OBJECTIVE
14P09885431A0000|56 74|bridge restorations
14P09885431A0000|118 137|impression materials
14P09886602A0000|0 9|OBJECTIVES
14P09886602A0000|85 87|PSA
14P09886602A0000|132 142|Gleason sum
14P09886602A0000|155 168|radiation dose
14P09886602A0000|192 206|prostate cancer
14P09886602A0000|223 244|beam radiation therapy
14P09886602A0000|244 246|XRT
14P09886602A0000|270 272|PSA
14P09886843A0339|44 58|thyroid hormone
14P09886843A0339|98 101|NRGN
14P09886850A0145|28 36|PPARgamma
14P09886850A0145|125 149|MEK/ERK signaling pathway
14P09887544A0000|0 9|BACKGROUND
14P09887544A0000|11 18|Diazepam
14P09887544A0000|28 47|benzodiazepine group
14P09887544A0000|49 61|tranquilizers
14P09888711A0781|0 21|Bioplastique granuloma
14P09888711A0781|139 156|Artecoll granuloma
14P09888711A0781|169 182|round vacuoles
14P09888994A0858|53 70|mesoderm formation
14P09888994A0858|73 85|somitogenesis
14P09889202T0000|44 56|domain Zalpha
14P09889202T0000|58 87|dsRNA adenosine deaminase type
14P09889306A0321|26 47|Glvr-1 gene expression
14P09889306A0321|124 159|ape leukemia virus envelope proteins
14P09890778T0000|0 12|Carbohydrates
14P09890778T0000|16 30|glycoconjugates
14P09891009T0000|18 40|mouse glycolate oxidase
14P09891046A0269|23 25|PKR
14P09891046A0269|89 101|PKR signaling
14P09891046A0554|47 49|PKR
14P09891049A0761|0 9|Processing
14P09891049A0761|68 82|rRNA processing
14P09891049A0761|88 92|Rnt1p
14P09891049A0761|96 100|Rat1p
14P09891061A0373|26 35|regulators
14P09891061A0373|57 69|SpHE promoter
14P09891061A0373|157 167|cis element
14P09891061A1240|22 25|SpHE
14P09891061A1240|62 83|SpEts4 gene expression
14P09891061A1240|114 117|SpHE
14P09891061A1240|132 150|sea urchin blastula
14P09891065A1493|25 38|SRE activation
14P09891065A1493|75 83|PKC-alpha
14P09891065A1493|86 96|PKC-epsilon
14P09891085A0815|89 102|27S precursors
14P09891092A1000|30 38|stem-loop
14P09891092A1000|42 51|structures
14P09891092A1000|77 89|end formation
14P09891707A0000|23 41|spondyloarthropathy
14P09891707A0000|43 45|SpA
14P09892017A2151|58 61|ELE1
14P09892017A2151|71 90|receptor functioning
14P09892021A0712|0 13|Overexpression
14P09892021A0712|16 19|PTTG
14P09892021A0712|33 45|NIH 3T3 cells
14P09892021A0712|87 110|fibroblast growth factor
14P09892422A1096|27 39|tissue sheath
14P09892422A1096|65 75|contraction
14P09892422A1096|81 90|myocardium
14P09892422A1096|118 127|conduction
14P09892422A1096|143 154|transmission
14P09892422A1096|176 186|termination
14P09892422A1096|192 205|purkinje fibre
14P09892642A0172|4 15|DNA helicase
14P09892642A0172|35 48|HPV E2 protein
14P09892662A0334|15 34|mutant alpha subunit
14P09892662A0334|87 88|Gs
14P09892736A0343|38 46|CDED/LIOR
14P09892736A0343|98 116|signal transduction
14P09892736A0343|119 134|cell replication
14P09892736A0343|141 144|ORC1
14P09892736A0343|148 150|KSR
14P09893060A0767|0 21|Northern blot analysis
14P09893262A1272|84 101|TGF-beta responses
14P09893913A0656|0 8|Induction
14P09893913A0656|11 21|anaesthesia
14P09893913A0656|48 60|micrograms/kg
14P09893913A0656|63 73|thiopentone
14P09893913A0656|83 92|atracurium
14P09894962T0000|1 10|comparison
14P09894962T0000|42 54|malformations
14P09894962T0000|85 97|malformations
14P09895323T0000|62 66|Hoxa3
14P09895323T0000|70 80|Hoxb3 genes
14P09897032T0000|26 37|self-pulsing
14P09897032T0000|50 58|resonator
14P09900679T0000|0 15|Wave cybernetics
14P09903722T0000|0 19|Autoionization rates
14P09903722T0000|49 62|Rydberg states
14P09903722T0000|64 65|H2
14P09904139T0000|13 20|approach
14P09904139T0000|37 45|operators
14P09911328T0000|8 15|approach
14P09911328T0000|18 27|scattering
14P09913308T0000|33 39|Ti ions
14P09913308T0000|71 82|laser pulses
14P09914156A1496|63 92|tenascin-C promoter constructs
14P09914156A1496|146 162|promoter activity
14P09914156A1496|227 240|RNA start site
14P09914500A0000|20 28|NF-kappaB
14P09914500A0000|43 62|transcription factor
14P09914500A0000|130 152|cytokines interleukin-1
14P09914500A0000|155 175|tumor necrosis factor
14P09914500A0000|175 177|TNF
14P09914518A1217|53 60|COUP-TFI
14P09914518A1217|84 112|AF-1 transactivation function
14P09914518A1217|113 114|ER
14P09914518A1217|150 167|4-hydroxytamoxifen
14P09914518A1217|174 176|ICI
14P09914525A0890|11 13|Ffh
14P09914525A0890|37 44|degreesC
14P09915118T0000|10 24|naris occlusion
14P09915118T0000|30 42|rat accessory
14P09915798A1077|40 57|chaperone activity
14P09915798A1077|69 93|hsp90 dimerization domain
14P09915798A1077|134 161|steroid receptor interaction
14P09915860A0000|16 34|rat pgp2/mdr1b gene
14P09915860A0000|102 119|consensus Sp1 site
14P09915860A0119|0 2|Sp1
14P09915860A0119|11 25|transactivation
14P09915860A0119|31 49|pgp2/mdr1b promoter
14P09915860A0119|70 84|Schneider cells
14P09916786A0811|0 11|Measurements
14P09916786A0811|20 39|bone mineral density
14P09916786A0811|84 103|X-ray absorptiometry
14P09916786A0811|127 141|bone remodeling
14P09916786A0811|160 179|alkaline phosphatase
14P09916786A0811|195 217|urine deoxypyridinoline
14P09916786A0811|238 251|chromatography
14P09916809A0405|5 7|MGP
14P09916809A0405|44 46|ECM
14P09916809A0405|98 125|transmembrane signal peptide
14P09917064T0000|11 13|p82
14P09917064T0000|18 34|clam CPEB homolog
14P09917064T0000|47 61|polyadenylation
14P09917387T0000|3 16|RNA polymerase
14P09917387T0000|50 57|DNA bend
14P09917387T0000|67 74|TATA box
14P09917389A1239|12 28|RNase E digestion
14P09917389A1239|51 54|FinP
14P09917389A1239|59 66|GST-FinO
14P09917391A0380|0 24|Transcription readthrough
14P09917555T0001|0 7|Analysis
14P09917555T0001|23 49|growth factor prescriptions
14P09918096A0520|11 14|case
14P09918096A0520|27 30|cyst
14P09918715A0304|0 3|MotA
14P09918715A0304|14 25|DNA sequence
14P09918715A0304|27 34|MotA box
14P09918715A1158|56 59|TAFs
14P09918715A1158|61 80|TATA binding protein
14P09918715A1158|80 82|TBP
14P09918715A1158|116 126|TBP results
14P09918715A1158|148 170|core promoter sequences
14P09918720A0998|3 15|S229A variant
14P09918720A0998|119 124|Ser229
14P09918842A0184|7 18|conservation
14P09918842A0184|110 124|RNA replication
14P09920539A0272|37 42|GnRH-a
14P09920539A0272|80 103|gonadotropin stimulation
14P09920775A0075|34 57|transcription start site
14P09920775A0075|78 101|reporter gene expression
14P09920775A0075|124 138|differentiation
14P09920775A0075|141 149|P19 cells
14P09920882A0287|0 3|Chem
14P09920896A1230|13 23|differences
14P09920896A1230|52 64|type peptides
14P09920896A1230|95 106|substitution
14P09920896A1230|133 142|disruption
14P09920896A1230|166 175|structures
14P09920903A1045|50 68|p53 gene regulation
14P09920930A0521|0 7|C3 toxin
14P09920930A0521|26 38|RhoA function
14P09920930A0521|57 59|SRE
14P09920930A0521|61 72|Luc activity
14P09920930A0521|103 118|c-Fos expression
14P09920930A0959|8 15|C3 toxin
14P09920930A0959|39 52|growth factors
14P09920930A0959|67 70|AP-1
14P09920930A0959|72 83|Luc activity
14P09920930A0959|131 134|AP-1
14P09920930A0959|136 138|Luc
14P09920930A0959|159 172|co-stimulation
14P09920930A0959|177 190|growth factors
14P09920930A0959|193 202|Ro-31-8220
14P09920982A0253|51 64|susceptibility
14P09920982A0253|114 115|P.
14P09920982A0253|133 144|acne lesions
14P09920982A0253|163 181|Rap ID ANA II panel
14P09921179T0001|23 38|echocardiography
14P09922230A1482|39 42|CAP1
14P09922230A1482|86 100|stress response
14P09922230A1482|102 112|C. albicans
14P09922856A0459|0 9|Trinipatch
14P09922856A0459|61 79|absorption promoter
14P09922856A0459|93 106|dose-strengths
14P09922856A0459|129 151|Laboratoires Synthelabo
14P09923245A0482|3 6|RMRI
14P09923245A0482|19 40|interrater reliability
14P09924675A0412|21 33|consideration
14P09924675A0412|41 51|conceptions
14P09924675A0412|65 69|ICIDH
14P09924675A0412|113 123|diagnostics
14P09924675A0412|126 139|rehabilitation
14P09924675A0412|172 186|characteristics
14P09924675A0412|227 238|intervention
14P09924987A0000|0 7|Pokeweed
14P09924987A0000|25 27|PAP
14P09924987A0000|33 52|Phytolacca americana
14P09924987A0000|69 81|N-glycosidase
14P09924987A0000|90 105|adenine residues
14P09924987A0000|106 110|A4324
14P09924987A0000|113 120|28S rRNA
14P09924987A0000|123 127|A2660
14P09924987A0000|130 137|23S rRNA
14P09925120A0074|0 8|OBJECTIVE
14P09925120A0074|14 26|meta-analysis
14P09925372A0458|13 16|ZFPs
14P09925372A0458|24 31|ZFP cDNA
14P09925372A0458|36 39|HFHZ
14P09925372A0458|64 80|sequence homology
14P09925372A0458|105 108|KRAB
14P09925372A1063|73 81|HFHZ mRNA
14P09925372A1063|110 120|development
14P09925777A1195|11 27|affinity hnRNP A1
14P09925777A1195|55 74|beta-globin reporter
14P09925777A1195|75 77|Rev
14P09927193A0107|23 26|PLZF
14P09927193A0107|30 34|LAZ-3
14P09927193A0107|36 40|BCL-6
14P09927449A0421|0 13|Overexpression
14P09927449A0421|16 19|POG1
14P09927449A0421|48 56|G1 arrest
14P09927449A0421|89 92|CLN1
14P09927449A0421|96 105|CLN2 genes
14P09927570A0507|13 26|RNU2 fragility
14P09927570A0507|58 74|expression vector
14P09927570A0507|82 89|Ad12 E1B
14P09927570A0507|109 117|E1 vector
14P09927570A0507|128 138|E1 products
14P09927570A0507|140 151|E1A proteins
14P09927570A0507|163 165|E1B
14P09927585A0796|0 32|Competitionsupershift EMSA assays
14P09927585A0796|73 99|bandshift complex formation
14P09927585A0796|102 104|KCS
14P09927589T0000|0 9|Similarity
14P09927589T0000|12 22|DNA binding
14P09927589T0000|52 79|Caenorhabditis elegans MAB-3
14P09927589T0000|103 105|DSX
14P09929088A0000|0 6|CONTEXT
14P09929088A0000|8 15|ThinPrep
14P09929088A0000|17 23|AutoPap
14P09929088A0000|28 33|Papnet
14P09929088A0000|96 111|cancer screening
14P09929811A0000|0 10|Experiments
14P09929811A0000|142 147|CM-251
14P09929811A0000|149 154|CM-266
14P09929811A0000|159 164|CM-345
14P09931118A1072|10 15|p42/44
14P09931118A1072|22 32|JNK pathway
14P09931118A1072|56 63|IL-1beta
14P09931191A0434|43 45|Con
14P09931191A0434|49 61|Ecc arm curls
14P09931191A0434|92 106|muscle ischemia
14P09931216A0566|0 6|Airflow
14P09931216A0566|49 53|45-ft
14P09931252A1055|19 42|amino acid substitutions
14P09931252A1055|114 132|scaffolding protein
14P09931391A0944|18 31|liver function
14P09931435A0357|54 58|ZIS-2
14P09931435A0357|70 74|ZIS-1
14P09931435A0357|105 109|ZIS-1
14P09931435A0357|146 148|UTR
14P09932288A0378|0 9|Expression
14P09932288A0378|26 28|XT3
14P09932288A0378|104 115|cDNA library
14P09933428A0351|0 8|IFN-gamma
14P09933428A0351|32 33|TB
14P09933641A0241|43 55|amplification
14P09933641A0241|83 86|NHE5
14P09933641A0241|146 158|amplification
14P09933848A1008|4 17|alloantibodies
14P09933848A1008|74 87|autoantibodies
14P09934611A1054|4 13|dependence
14P09934611A1054|60 70|min LVdP/dt
14P09934611A1054|82 89|pressure
14P09935377T0108|0 4|Genoa
14P09935377T0108|6 10|Italy
14P09935377T0108|17 22|August
14P09936001T0000|47 48|Al
14P09936001T0000|50 51|Ga
14P09936001T0000|56 68|Sc impurities
14P09938097T0000|24 59|photoluminescence undulation spectra
14P09940132T0000|38 59|charge-transfer solids
14P09943651T0000|16 22|soliton
14P09944066T0073|0 1|II
14P09945838T0000|17 35|matching conditions
14P09945838T0000|38 41|GaAs
14P09945838T0000|44 45|Al
14P09945838T0000|47 48|Ga
14P09945838T0000|52 66|heterojunctions
14P09947191T0000|0 30|Neutron scattering measurements
14P09947191T0000|50 56|CsMnBr3
14P09949160A0600|12 25|32D Epo1 cells
14P09949160A0600|77 86|expression
14P09949160A0600|99 114|eta PKC isoforms
14P09949160A0600|136 147|upregulation
14P09949160A0600|187 196|readdition
14P09949160A0600|199 201|Epo
14P09949178A0264|33 45|interleukin-6
14P09949178A0264|47 50|IL-6
14P09949178A0264|108 112|1A9-M
14P09949312A0524|0 6|Airflow
14P09949312A0524|43 53|vacuum pump
14P09950213A1660|45 51|TbetaRI
14P09950213A1660|55 62|TbetaRII
14P09950213A1660|99 106|TGF-beta
14P09950213A1660|132 140|TbetaRIII
14P09950394A0336|23 46|carboxyhemoglobin levels
14P09952378A0529|15 17|CHD
14P09952378A0529|28 48|% confidence interval
14P09952378A0529|92 105|IgG antibodies
14P09952425A0893|14 17|HIPP
14P09952425A0893|85 95|impairments
14P09952425A0893|150 159|structures
14P09952425A0893|202 212|hippocampus
14P09959737T0000|23 30|SN 1987A
14P09961326T0000|9 20|fluctuations
14P09961326T0000|38 46|interface
14P09961682T0000|0 4|Model
14P09961682T0000|31 47|stick-slip motion
14P09964171T0000|0 2|NMR
14P09964770T0000|0 13|Microstructure
14P09964770T0000|43 61|laminate composites
14P09965234T0000|11 24|heat transport
14P09965234T0000|29 46|octylcyanobiphenyl
14P09965234T0000|48 50|8CB
14P09965234T0000|52 65|liquid crystal
14P09965909T0000|26 46|soliton perturbations
14P09971776A0838|0 8|Mutations
14P09971776A0838|22 35|CD4 regulation
14P09971776A0838|87 89|Nef
14P09971776A0838|111 113|W57
14P09971776A0838|117 119|L58
14P09971776A0838|146 160|dileucine motif
14P09971790A0856|43 61|helicase activities
14P09971790A0856|77 105|amino-terminal-charge cluster
14P09971790A0856|119 132|D40A-D42A-D44A
14P09971790A0856|148 179|AAV hairpin DNA binding activity
14P09971806A1585|15 18|KSHV
14P09971806A1585|55 67|KSHV/Rta gene
14P09971806A1585|91 108|tumor pathogenesis
14P09971815A2094|40 62|candidate latency genes
14P09971815A2094|69 77|gammaHV68
14P09971815A2094|83 92|expression
14P09971815A2094|167 182|latency programs
14P09971815A2094|251 262|v-bcl-2 gene
14P09971815A2094|263 272|v-GCR gene
14P09971815A2094|318 326|gammaHV68
14P09971815A2094|337 354|gammaherpesviruses
14P09971822A1542|35 36|U1
14P09971822A1542|51 69|splicing inhibition
14P09973351A1522|19 34|DcuS-DcuR system
14P09973607A0254|17 30|identification
14P09973607A0254|34 49|characterization
14P09973607A0254|59 70|Sp100 splice
14P09973607A0254|138 147|Sp100 gene
14P09974642T0000|0 8|Crossover
14P09976626T0000|0 6|Erratum
14P09976626T0000|8 14|Absence
14P09976626T0000|17 33|precursor effects
14P09976626T0000|52 65|transformation
14P09976626T0000|84 91|Li metal
14P09980944T0000|0 18|Interplane coupling
14P09980944T0000|23 48|superconductor Y2Ba4Cu7O15
14P09980944T0000|60 72|NQR spin-echo
14P09982923T0000|28 32|NiSi2
14P09982923T0000|35 45|CoSi2 layer
14P09983871T0000|0 18|Raman investigation
14P09983871T0000|20 42|YBa2-xLaxCu3O7 ceramics
14P09984526T0000|0 6|Effects
14P09984526T0000|23 40|lattice parameters
14P09984526T0000|42 55|semiconductors
14P09985302T0000|7 23|electron dynamics
14P09986796A1761|8 16|deletions
14P09986796A1761|37 47|amino acids
14P09986796A1761|65 71|effects
14P09987176A0260|26 36|vaccination
14P09987176A0260|41 49|vaccinees
14P09987176A0260|67 75|follow-up
14P09987176A0260|102 109|anti-HAV
14P09987634A1265|13 15|PRK
14P09987634A1265|82 91|PRK effect
14P09987961A0093|34 45|angiomatosis
14P09987961A0093|47 58|vasculopathy
14P09987961A0093|63 75|proliferation
14P09987961A0093|78 89|synoviocytes
14P09987961A0093|93 103|fibroblasts
14P09988682T0033|41 79|beta1,6-N-acetylglucosaminyltransferase
14P09988767A1496|13 37|mouse back-cross analysis
14P09988767A1496|56 71|mouse 3Ost genes
14P09988767A1496|137 150|identification
14P09988767A1496|174 185|site markers
14P09988850A0000|3 8|Scales
14P09988850A0000|20 29|Impairment
14P09988850A0000|52 58|Records
14P09988850A0000|60 66|SCIRFIR
14P09988850A0000|96 122|dementia rating instruments
14P09988850A0000|183 204|schizophrenia patients
14P09988850A0000|319 335|autopsy materials
14P09989334A0964|24 41|processing signals
14P09989334A0964|65 82|donor splice sites
14P09989334A0964|87 106|polyadenylation site
14P09989339A0968|33 44|brain weight
14P09989339A0968|47 55|clearance
14P09990057T0000|0 12|Recombination
14P09990057T0000|44 45|Ig
14P09990057T0000|76 77|Ig
14P09990057T0000|96 115|enhancer core region
14P09990057T0000|131 155|matrix attachment regions
14P09990060A0803|53 73|dyad symmetry element
14P09990060A0803|103 115|IL-2 enhancer
14P09990060A0803|121 133|CD18 promoter
14P09990060A0937|16 52|coactivator CREB binding protein/p300
14P09990060A0937|69 77|GABPalpha
14P09990060A0937|91 99|GABPalpha
14P09990060A0937|113 133|dyad symmetry element
14P09990060A0937|154 167|IL-16 promoter
14P09990060A0937|169 175|T cells
14P09990315A0205|0 2|TPO
14P09990315A0205|25 28|ERK1
14P09990315A0205|30 33|ERK2
14P09990315A0205|37 52|protein kinase C
14P09990315A0205|52 54|PKC
14P09990315A0205|64 66|TPO
14P09990315A0205|111 114|ERKs
14P09990315A0205|190 203|PKC activation
14P09990507A0000|0 9|BACKGROUND
14P09990507A0000|35 53|proteolysis pathway
14P09990507A0000|55 70|ubiquitin ligase
14P09990507A0000|71 72|E3
14P09990507A0763|0 10|CONCLUSIONS
14P09990507A0763|12 28|Fission yeast SCF
14P09990507A0763|99 122|F-box/WD-repeat proteins
14P09994942T0000|3 13|NMR studies
14P09995847T0000|0 25|Optical-absorption spectra
14P09995847T0000|55 79|transition line strengths
14P09995897T0000|0 10|Observation
14P09995897T0000|39 49|Pb0 defects
14P09995897T0000|59 75|Si/SiO2 interface
14P09999256T0000|37 55|transport phenomena
14P09999742T0000|0 2|NH3
14P09999742T0000|6 19|NO interaction
14P10000253T0000|0 14|Chirality-glass
14P10000253T0000|18 40|spin-glass correlations
14P10000253T0000|71 78|XY model
14P10001333T0038|0 14|Echo modulation
14P10001333T0038|21 25|YAlO3
14P10001541T0000|0 9|Mechanisms
14P10002245T0000|36 45|CuO chains
14P10002245T0000|61 69|YBa2Cu3O7
14P10006319T0000|0 17|Surface spin waves
14P10006319T0000|19 40|Heisenberg ferrimagnet
14P10007469T0000|47 49|C60
14P10007564T0000|21 28|geometry
14P10007564T0000|42 50|structure
14P10007564T0000|60 66|surface
14P10008261T0000|0 21|Temperature dependence
14P10008261T0000|62 70|YBa2Cu3O6
14P10009565T0000|0 21|GW Gamma approximation
14P10009565T0000|23 44|electron self-energies
14P10013227T0000|0 20|Precision measurement
14P10013227T0000|25 49|pion mass difference m pi
14P10019841T0000|7 13|gravity
14P10019841T0000|55 62|approach
14P10021333A0674|7 17|experiments
14P10021333A0674|23 29|mutants
14P10021333A0674|73 83|interaction
14P10021350A0093|46 67|Armadillo/beta-catenin
14P10021350A0093|105 127|TCF/LEF family proteins
14P10021350A0093|143 163|transcription factors
14P10021350A0093|191 202|Wingless/Wnt
14P10022032A0000|41 62|vasodilator nicorandil
14P10022032A0000|63 65|NIC
14P10022032A0000|100 131|receptor antagonists propranolol
14P10022032A0000|147 149|ATN
14P10022032A0000|161 193|calcium channel blocker diltiazem
14P10022032A0000|192 194|DTZ
14P10022210A0620|0 6|Factors
14P10022210A0620|35 36|DI
14P10022210A0620|39 50|SPME process
14P10022850A0929|48 58|C/H1 domain
14P10022850A0929|88 104|Zta transcription
14P10022850A0929|112 132|reactivation function
14P10022858A0985|18 43|splicing enhancer sequence
15P10022867A1069a|0 10|Elimination
15P10022867A1069a|13 16|ETH1
15P10022867A1069a|54 67|mutation rates
15P10022867A1069a|133 150|lysine prototrophy
15P10022867A1069b|0 10|Elimination
15P10022867A1069b|13 16|ETH1
15P10022867A1069b|54 67|mutation rates
15P10022867A1069b|133 150|lysine prototrophy
14P10022875A1265|25 37|Ras effectors
14P10022875A1265|55 65|PI 3-kinase
14P10022875A1265|91 93|Pak
14P10022880A0000|9 37|Ras GTPase-activating protein
14P10022880A0000|37 39|GAP
14P10022880A0000|42 53|p120 Ras-GAP
14P10022880A0000|104 115|Ras proteins
14P10022880A0000|147 174|signal transduction pathways
14P10022905A0446|5 17|mog-1 alleles
14P10022905A0446|33 43|stop codons
14P10022905A0446|80 96|missense mutation
14P10022905A0446|132 141|mog-1 mRNA
14P10022905A0446|158 166|germ line
14P10022921A0608|17 25|SIN3 gene
14P10022921A0608|72 85|cell viability
14P10022925A0870|3 23|Nmd3 protein sequence
14P10022978A1261|3 14|distribution
14P10022978A1261|45 56|organization
14P10022978A1261|119 133|chromosome arms
14P10024383T0000|0 9|Calcitonin
14P10024383T0000|47 58|hyperostosis
14P10024383T0000|72 81|osteopenia
14P10024498A0783|51 57|HNF-3 X
14P10024498A0783|60 66|Y sites
14P10024498A0783|110 119|HNF-3alpha
14P10024498A0783|123 131|HNF-3beta
14P10024882A0541|71 73|CTD
14P10024882A0541|77 83|RNA pol
14P10024882A0541|99 114|promoter opening
14P10025050A1052|26 35|antagonist
14P10025050A1052|64 72|therapies
14P10025050A1052|77 86|omeprazole
14P10025050A1052|89 100|lansoprazole
14P10025506A0079|29 44|plastin isoforms
14P10025506A1078|2 5|TATA
14P10025506A1078|8 19|Inr sequence
14P10026146A0680|18 32|RIalpha subunit
14P10026146A0680|63 76|concentrations
14P10026146A0680|84 85|Ka
14P10026146A0680|114 117|PrKX
14P10026146A0680|146 159|protein kinase
14P10026146A0680|181 199|cAMP concentrations
14P10026146A0680|223 236|Calpha subunit
14P10026146A0680|252 265|protein kinase
14P10026211A0136|0 7|Proteins
14P10026211A0136|22 30|PEPCK CRE
14P10026211A0136|59 62|CREB
14P10026211A0136|109 113|C/EBP
14P10026211A0543|40 49|C/EBPalpha
14P10026211A0543|63 66|CREB
14P10026211A0543|95 117|glucocorticoid response
14P10026211A0543|147 170|H4IIE rat hepatoma cells
14P10026229A0950|18 28|mutagenesis
14P10026229A0950|35 43|Engrailed
14P10026229A0950|47 56|Pbx1 sites
14P10026229A0950|126 136|enhancement
14P10026275A0549|16 33|structure elements
14P10026784A0331|57 77|transcription factors
14P10026784A0331|95 115|POU DNA binding motif
14P10026784A0929|38 69|POU domain transcription factors
14P10026784A0929|100 114|POU-homeodomain
14P10026784A2166|5 17|Oct-1 crystal
14P10026784A2166|50 63|GCAT half-site
14P10026784A2166|108 112|Pit-1
14P10026784A2166|132 135|GTAT
14P10026824A0309|30 52|V1a/V2 hybrid receptors
14P10026824A0309|92 103|V1a receptor
14P10026824A0309|148 152|Gq/11
14P10026824A0309|191 201|V2 receptor
14P10026824A0309|237 238|Gs
14P10027498A0536|9 18|end points
14P10027498A0536|75 86|U.S. program
14P10027904A0768|51 56|region
14P10029337A0406|3 18|fatigue exercise
14P10029337A0406|38 64|blood lactate concentration
14P10029337A0406|69 70|SD
14P10029337A0406|101 121|serum creatine kinase
14P10029337A0406|121 122|CK
14P10029337A0406|151 152|SD
14P10029860A0605|17 23|aspects
14P10029860A0605|44 53|categories
14P10029860A0605|91 97|filling
14P10029917A0366|0 6|Results
14P10029917A0366|36 49|myofibroblasts
14P10029917A0366|109 130|muscle cell dispersion
14P10029917A0366|168 187|portal vein branches
14P10031854T0000|0 21|New Langevin equations
14P10032519T0000|9 19|corrections
14P10032519T0000|22 31|beta decay
14P10032519T0000|37 47|possibility
14P10032519T0000|57 66|generation
14P10032581T0000|16 44|grazing-incidence diffraction
14P10033973T0000|48 63|Bose condensates
14P10034615T0000|0 22|Structure determination
14P10034615T0000|74 77|H/Ni
14P10035841T0000|8 15|trapping
14P10035841T0000|38 45|hydrogen
14P10036181A0603|0 12|Northern blot
14P10036181A0603|21 42|hybridization analyses
14P10036181A0603|50 71|GPR34 mRNA transcripts
14P10036191A0000|3 20|microphthalmia-TFE
14P10036191A0000|22 24|MiT
14P10036191A0000|81 101|transcription factors
14P10036191A0000|111 114|TFE3
14P10036191A0000|116 119|TFEB
14P10036191A0000|121 124|TFEC
14P10036191A0000|129 132|Mitf
14P10036191A0000|183 197|gene expression
14P10037004A0000|62 64|ALL
14P10037004A0000|81 91|bone marrow
14P10037004A0000|92 93|BM
14P10037378A0176|3 15|dorsal nerves
14P10037378A0176|56 64|lidocaine
14P10037460A0221|45 59|memory function
14P10037460A0221|61 71|interaction
14P10037460A0221|81 100|ligand acetylcholine
14P10037576T0000|41 59|plaque radiotherapy
14P10037681A0494|23 25|ARF
14P10037681A0494|29 37|PKC-alpha
14P10037681A0494|42 45|PLD1
14P10037681A0494|90 93|PLD1
14P10037681A0494|103 104|D4
14P10037681A0494|138 141|RhoA
14P10037681A0494|143 152|RhoAVal-14
14P10037774A0366|29 56|signal transduction pathways
14P10037774A0366|82 99|LDLR transcription
14P10041728T0000|0 20|Vacuum Rabi splitting
14P10041728T0000|31 54|linear-dispersion theory
14P10041728T0000|55 62|Analysis
14P10043466T0000|62 82|polydiacetylene 4BCMU
14P10044519T0000|4 12|reduction
14P10044519T0000|31 38|polymers
14P10046849T0000|20 41|structure calculations
14P10047970T0013|7 22|world literature
14P10049357A0608|20 22|Ski
14P10049357A0608|40 51|HDAC complex
14P10049357A0608|58 60|Ski
14P10049359A1073|48 50|PTB
14P10049359A1073|87 101|rhinovirus IRES
14P10049742T0000|0 7|Analysis
14P10049742T0000|13 38|consensus binding sequence
14P10049742T0000|62 64|ZF5
14P10049775T0000|34 55|Anion Channel isoforms
14P10049912T0000|0 13|Identification
14P10049912T0000|16 22|RNase T
14P10049912T0000|49 62|UV sensitivity
14P10049912T0000|89 114|DNA exonuclease deficiency
14P10050883A0967|0 9|Inhibition
14P10050883A0967|12 40|phosphatidylinositol-3 kinase
14P10050883A0967|70 85|p53 conformation
14P10051030A1080|33 48|semen production
14P10051030A1080|71 79|CP levels
14P10051400A0000|3 10|Lp mouse
14P10051400A0000|64 66|NTD
14P10051400A0000|69 87|cranio-rachischisis
14P10051488A1293|17 43|AP-1 DNA binding activities
14P10051488A1293|69 72|HSCs
14P10051488A1293|96 118|mobility AP-1 complexes
14P10051488A1293|118 123|HMAP-1
14P10051488A1610|0 8|Mutations
14P10051488A1610|14 22|AP-1 site
14P10051488A1610|27 41|TIMP-1 promoter
14P10051488A1610|65 70|HMAP-1
14P10051488A1610|117 120|HSCs
14P10052371A0171|0 11|STUDY DESIGN
14P10052371A0171|20 42|immunoglobulin A levels
14P10052878A0135|14 28|set-up accuracy
14P10052878A0135|31 45|reproducibility
14P10053852T0000|6 7|g2
14P10053852T0000|33 63|Gerasimov-Drell-Hearn sum rules
14P10054976T0000|0 11|Spectroscopy
14P10054976T0000|59 79|Raman coupling regime
14P10055173T0000|0 21|Band structure effects
14P10055173T0000|22 41|transport properties
14P10059496T0000|8 27|transmission spectra
14P10059496T0000|32 46|Penrose lattice
14P10063122T0000|0 24|Two-Channel Kondo Lattice
14P10063739A0601|23 51|esophageal sphincter pressure
14P10063739A0601|81 82|SD
14P10063739A0601|157 159|EVS
14P10063739A0601|162 164|EVL
14P10064604A0824|0 3|CPDs
14P10064604A0824|41 46|TFIIIA
14P10065176A0657|25 47|hormone receptor status
14P10065176A0657|68 88|lymph node metastases
14P10065176A0657|94 114|lymph node metastases
14P10065176A0657|129 143|macrometastases
14P10065684A0916|27 38|air trapping
14P10065684A0916|54 55|RV
14P10065684A0916|63 75|lung capacity
14P10065684A0916|76 78|TLC
14P10065684A0916|143 153|mt x microm
14P10065684A0916|174 183|sarcomeres
14P10065684A0916|225 235|abnormality
14P10066790A0497|0 13|Gel filtration
14P10066790A0497|14 35|sedimentation velocity
14P10066790A0497|39 69|immunoprecipitation experiments
14P10066790A0497|121 124|AP-4
14P10066790A0497|145 162|sigma4 polypeptide
14P10066790A0497|178 201|adaptor subunit homologs
14P10066798A0391|0 5|Cyclin
14P10066798A0391|19 33|kinase activity
14P10066798A0391|36 49|protein levels
14P10066798A0391|94 109|tumor virus-pp60
14P10066815T0000|3 5|SH2
14P10066815T0000|46 49|SHIP
14P10066815T0000|62 72|p85 subunit
14P10066815T0000|74 98|phosphoinositide 3-kinase
14P10066815T0000|137 161|B cell receptor signaling
14P10068040A0136|13 24|mouse genome
14P10068040A0136|47 56|ubc-9 gene
14P10068418A1194|12 31|bone mineral density
14P10068418A1194|81 90|raloxifene
14P10068418A1194|133 151|alendronate therapy
14P10068446A0124|56 71|PKC preparations
14P10068446A0124|94 96|BPO
14P10068446A0124|113 129|cysteine residues
14P10068446A0124|131 133|PKC
14P10068637A1320|14 21|Csx/Nkx2
14P10068674A0644|42 48|Lyp RNA
14P10068674A0644|49 52|Lyp2
14P10068834A0713|12 13|DM
14P10068834A0713|24 25|PE
14P10068834A0713|27 28|DM
14P10068834A0713|39 40|VR
14P10068834A0713|44 45|DM
14P10068834A0713|55 57|MR.
14P10069815A0285|44 54|interaction
14P10069815A0285|62 65|Doa4
14P10069815A0285|72 81|proteasome
14P10070158A0573|11 25|splicing events
14P10070158A0573|56 69|cassette exons
14P10070158A0573|110 129|transmembrane domain
14P10071205A0833|41 43|ORF
14P10071205A0833|50 53|STA2
14P10071205A0833|78 87|AUG codons
14P10071212A0399|18 33|O. australiensis
14P10071761A2374|23 37|promoter region
14P10071761A2374|43 56|identification
14P10071761A2374|145 159|UCP2 expression
14P10071806A0377|9 21|resectability
14P10071806A0377|36 43|survival
14P10072205A0167|44 45|ML
14P10072205A0167|49 61|MAP estimates
14P10072205A0167|91 109|point approximation
14P10072205A0167|111 124|density values
14P10072774A0537|0 5|RT-PCR
14P10072774A0537|51 73|oligonucleotide primers
14P10072774A0537|78 98|ligand binding domain
14P10072774A0537|98 100|LBD
14P10072774A0537|109 130|beta integrin subunits
14P10073899A0740|9 28|culture failure rate
14P10073899A0740|52 54|EAF
14P10073899A0740|82 84|CVS
14P10073940A0335|7 16|expression
14P10073940A0335|42 50|signaling
14P10073947A1110|29 33|FVIIa
14P10073947A1110|37 41|PAI-1
14P10074135T0000|71 81|dwarf virus
14P10074135T0000|91 94|RNA1
14P10074282A0236|47 51|L-NNA
14P10074282A0236|53 74|NO-synthesis inhibitor
14P10074282A0236|77 90|methylene blue
14P10074282A0236|98 114|cGMPase inhibitor
14P10074425A0729|30 50|cyclin E-Cdk2 complex
14P10074425A0729|61 78|mitogen starvation
14P10074425A0729|94 97|MEFs
14P10074425A0729|130 137|p27 gene
14P10074520T0000|0 13|Identification
14P10074520T0000|35 40|IS2404
14P10074520T0000|44 49|IS2606
14P10074520T0000|93 114|Mycobacterium ulcerans
14P10074520T0000|116 118|PCR
14P10074903A0915|61 72|p202 protein
14P10074903A0915|88 119|cell growth retardation activity
14P10074903A0915|122 125|IFNs
14P10074903A0915|153 170|p21 protein levels
14P10074921A1169|35 64|HepG2 hepatoblastoma cell line
14P10074921A1169|72 74|p53
14P10075415A1178|40 46|ORF-Pto
14P10075415A1178|89 101|UV resistance
14P10076007A0656|3 6|MSY2
14P10076007A0656|28 40|casein kinase
14P10077188A1172|52 63|biosynthesis
14P10077188A1172|81 88|proteins
14P10077188A1172|138 147|heat shock
14P10077188A1172|174 182|synthesis
14P10077188A1172|192 198|protein
14P10077533A0976|44 57|identification
14P10077533A0976|63 65|MKS
14P10077533A0976|72 80|MUL genes
14P10078734A0480|11 24|recovery curve
14P10078734A0480|40 50|stimulation
14P10078734A0480|96 116|flexor carpi radialis
14P10078876A0000|97 120|rat somatosensory cortex
14P10078876A0000|138 159|microspectrophotometry
14P10078876A0000|211 234|hemoglobin concentration
14P10079173A0000|50 71|RNA recognition motifs
14P10079173A0000|71 74|RRMs
14P10080436T0000|0 9|Comparison
14P10080436T0000|12 22|frequencies
14P10080436T0000|31 42|fibrillation
14P10080436T0000|56 68|artery bypass
14P10080875A0772|12 30|supershift analysis
14P10080875A0772|60 80|transcription factors
14P10080875A0772|125 148|NF-kappaB components p50
14P10080875A0772|150 152|p65
14P10080875A0772|175 192|NF-kappaB proteins
14P10080875A0772|193 195|p52
14P10080875A0772|203 207|Rel B
14P10080875A0772|209 221|AP-1 proteins
14P10080875A0772|228 232|C-Jun
14P10080875A0772|235 238|CREB
14P10080875A0772|241 249|C/EBPbeta
14P10080875A0772|251 256|NF-IL6
14P10080901A0271|6 13|peptides
14P10080901A0271|42 49|elements
14P10080901A0271|61 69|structure
14P10080901A0271|114 123|protein L9
14P10082137A0262|20 28|IFN-gamma
14P10082137A0262|47 58|accumulation
14P10082137A0262|87 89|IRF
14P10082137A0262|154 180|procollagen mRNA expression
14P10082137A0262|181 196|skin fibroblasts
14P10082554T0000|19 48|c-myc promoter binding protein
14P10082554T0000|85 106|cell growth regulation
14P10082570A0440|25 34|gene UBP43
14P10082573A1015|46 48|HS2
14P10082573A1015|50 52|HS3
14P10082573A1015|57 59|HS4
14P10082573A1015|100 124|globin gene transcription
14P10082573A1015|186 190|DNase
14P10082573A1015|259 283|globin gene transcription
14P10082585A0512|44 57|rDNA silencing
14P10082585A0512|100 108|mutations
14P10082585A0512|122 131|expression
14P10082585A0512|134 147|reporter genes
14P10084294A0219|87 100|serum ferritin
14P10084294A0219|103 131|transferrin saturation levels
14P10084294A0219|155 166|microg/liter
14P10085088A0918|27 37|p33 subunit
14P10085088A0918|68 83|initiation phase
14P10085088A0918|85 101|protein synthesis
14P10085120A0000|23 40|signaling pathways
14P10085120A0000|69 71|PDT
14P10085140A1004|24 28|ATF-2
14P10085140A1004|48 65|TGF-beta signaling
14P10085140A1004|101 104|Smad
14P10085140A1004|108 120|TAK1 pathways
14P10085383A1367|3 7|WORDS
14P10085383A1367|9 17|Melaleuca
14P10085383A1367|19 33|Lake Okeechobee
14P10085383A1367|34 46|Littoral zone
14P10085383A1367|47 57|Water level
14P10085383A1367|58 76|Regulation schedule
14P10085505A1184|11 14|peak
14P10085505A1184|26 29|vein
14P10085505A1184|55 58|peak
14P10085505A1184|70 74|cases
14P10085605A0239|0 8|Specimens
14P10085605A0239|23 39|alpha-fetoprotein
14P10085697T0000|0 44|FASEB Federal Funding Consensus Conference FY
14P10086544A0504|95 97|CPB
14P10086544A0504|109 122|blood pressure
14P10086544A0504|160 181|temperature difference
14P10086544A0504|204 231|oxygen saturation difference
14P10086544A0504|231 242|urine output
14P10086544A0504|243 258|serum creatinine
14P10086544A0504|269 294|neutrophil elastase levels
14P10086544A0504|297 303|Doppler
14P10086544A0504|383 395|ejection time
14P10086544A0504|416 429|catecholamines
14P10086725A0000|0 8|MDS1/EVI1
14P10086725A0000|68 90|transcription activator
14P10087213A0878|85 122|H. pylori plasmid replication proteins
14P10087213A0878|158 183|H. pylori plasmid proteins
14P10087549A0720|3 11|JTc delta
14P10087549A0720|49 57|JTc delta
14P10087549A0720|62 69|VT group
14P10087549A0720|87 95|JTc delta
14P10087549A0720|100 108|PVC group
14P10087549A0720|133 141|JTc delta
14P10087993A0782|2 9|contrast
14P10087993A0782|11 18|deletion
14P10087993A0782|44 57|delta promoter
14P10087993A0782|69 76|decrease
14P10087993A0782|79 88|expression
14P10087993A1352|44 65|repressor proteins BP1
14P10087993A1352|67 69|BP2
14P10087993A1352|95 110|beta globin gene
14P10087993A1352|146 162|promoter activity
14P10090125A0750|15 40|alpha1 antagonist prazosin
14P10090146T0000|24 32|AP-2alpha
14P10090146T0000|36 43|AP-2beta
14P10090146T0000|83 106|R-FABP promoter activity
14P10090146T0000|107 110|AP-2
14P10090535A1194|3 11|algorithm
14P10090535A1194|23 24|TG
14P10090535A1194|53 54|Lp
14P10090943A1426|17 21|CD79b
14P10090943A1426|27 31|CD79b
14P10090943A1426|68 69|SD
14P10090943A1426|98 99|SD
14P10090943A1426|102 106|B-CLL
14P10090943A1976|8 14|B cells
14P10090943A1976|51 55|CD79b
14P10090943A1976|100 115|activation stage
14P10090943A1976|126 131|B cell
14P10090943A1976|140 144|B-CLL
14P10091594A0284|39 59|structure predictions
14P10091594A0284|60 61|CD
14P10091594A0284|65 80|NMR spectroscopy
14P10091594A0284|92 103|ELISA assays
14P10091594A0284|154 168|helix formation
14P10091619A0104|0 5|Schwab
14P10091619A0104|9 26|England ADL scores
14P10092132A0285|16 19|HLGs
14P10092132A0285|33 51|gene amplifications
14P10092132A0285|67 71|11q13
14P10092132A0285|129 135|7q21-22
14P10092132A0285|137 143|11p11.2
14P10092132A0285|145 154|12p11.2-12
14P10092132A0285|159 163|13q34
14P10092847A0455|36 39|MREs
14P10092847A0455|47 61|promoter region
14P10092847A0455|101 128|mouse metallothionein-I gene
14P10092847A0455|142 156|MRE arrangement
14P10092847A0455|181 196|metal regulation
14P10092856A0798|75 102|phosphate isomerase promoter
14P10094314A0935|17 29|RNA sequences
14P10094314A0935|49 72|zinc knuckle 9G8 variant
14P10094314A0935|96 100|SRp20
14P10094314A0935|131 133|RBD
14P10094314A0935|142 146|SRp20
14P10094396A0000|0 15|Topoisomerase II
14P10094396A0000|34 61|protein kinase casein kinase
14P10094396A0000|61 66|PK CK2
14P10094701A0000|54 67|acetate kinase
14P10094701A0000|75 96|Sinorhizobium meliloti
14P10094701A0000|122 141|phosphate limitation
14P10095059A1003|17 36|nucleotide positions
14P10095059A1003|50 65|HIV-1 transcript
14P10095061A0592|0 16|Sequence analysis
14P10095061A0592|31 42|MEMA protein
14P10095061A0592|93 95|DRS
14P10095062A0558|43 68|topoisomerase IIalpha gene
14P10096469T0000|12 21|modulation
14P10096469T0000|37 44|activity
14P10096469T0000|47 55|cat motor
14P10096573A0207|72 73|NF
14P10096573A0207|76 99|kappaB consensus element
14P10096573A0207|135 153|MGSA/GRO-alpha gene
14P10097120T0000|18 26|transport
14P10097932A0915|52 55|UAER
14P10097932A0915|73 88|microalbuminuria
14P10097932A0915|138 141|UAER
14P10098601A1320|30 32|DNA
14P10098601A1320|43 47|JEG-3
14P10098601A1320|107 119|SF-1 sequence
14P10098744A0630|106 123|proliferation rate
14P10098744A0630|135 150|serum-dependence
14P10098744A0630|154 166|proliferation
14P10098744A0630|178 191|tumorigenicity
14P10098744A0630|229 251|differentiation markers
14P10099247A1051|32 45|retention time
14P10099247A1051|84 97|SRB population
14P10099247A1051|166 168|SRB
14P10099247A1051|181 182|MB
14P10099576A0666|12 17|valves
14P10099576A0666|41 46|effect
14P10099576A0666|57 65|parameter
14P10099576A0666|83 90|geometry
14P10099576A0666|115 124|conditions
14P10100605A0392|68 81|transformation
14P10100605A0392|84 99|dihydrorhodamine
14P10100605A0392|137 150|flow cytometry
14P10101159A0742|20 28|SOC1 gene
14P10101159A0742|78 92|cbp1 ts alleles
14P10101198A0632|1 26|deletion mutation analysis
14P10101198A0632|88 102|leucine zippers
14P10101198A0946|1 15|database search
14P10101198A0946|87 118|transcription termination factor
14P10101198A0946|146 148|DNA
14P10101198A0946|175 189|leucine zippers
14P10101744A0917|12 28|antigen challenge
14P10101744A0917|50 58|treatment
14P10102000A1206|33 44|ERA-II group
14P10102000A1206|53 65|ERA-III group
14P10102136A0220|16 18|PSA
14P10102136A0220|37 47|cyst fluids
14P10102136A0646|0 3|Type
14P10102136A0646|23 24|Na
14P10102136A0646|53 55|PSA
14P10102136A0646|60 63|Type
14P10102627A0217|11 30|DNA binding activity
14P10102627A0217|30 51|AP-1 reporter activity
14P10103002A0705|7 26|N-glycosylation site
14P10103002A0705|85 105|carbohydrate analysis
14P10103002A0705|140 156|type glycan chain
14P10103057A0251|32 47|characterization
14P10103057A0251|84 94|Runt domain
14P10103057A0251|96 99|AML1
14P10119827T0000|0 13|Judge OKs docs
14P10119827T0000|19 34|Chicago hospital
14P10120952T0000|0 4|HANYS
14P10120952T0000|27 49|gall bladder guidelines
14P10125354T0000|0 12|Groups dicker
14P10125354T0000|15 26|price breaks
14P10132730T0000|8 18|CareNetwork
14P10132730T0000|38 50|teacher union
14P10132730T0000|52 55|Wis.
14P10134977T0000|0 4|JCAHO
14P10146207A0223|0 14|Ultrasonography
14P10153759A0360|0 3|UPMC
14P10153759A0360|46 67|NHBC organ procurement
14P10171173A0955|87 105|deficiency syndrome
14P10171173A0955|119 127|hepatitis
14P10171173A0955|152 166|research effort
14P10171173A0955|183 192|hemorrhage
14P10171173A0955|241 251|circulation
14P10181397A0641|30 51|life expectancy ratios
14P10181397A0641|54 71|gender differences
14P10181397A0641|117 129|United States
14P10184191T0045|0 5|Holger
14P10187317T0000|20 35|AHERF physicians
14P10187798A1098|0 13|Overexpression
14P10187798A1098|22 26|DAP-1
14P10187798A1098|66 90|L929 fibroblast cell line
14P10187798A1098|110 131|osteosarcoma cell line
14P10187842A1155|18 27|PPARgamma2
14P10187842A1155|134 142|PPARalpha
14P10187864A1372|19 22|KCC3
14P10187864A1372|40 49|KCC family
14P10187864A1372|82 85|KCC1
14P10190324A0000|82 85|SVAS
14P10190324A0000|154 157|SVAS
14P10191090A0000|29 37|PAX3 gene
14P10192134A1088|0 7|25-OH-D3
14P10192134A1088|66 83|micrograms/kg feed
14P10192134A1088|107 120|turkey rations
14P10192432A0214|65 79|Consensus Panel
14P10192638T0000|0 23|Methanesulfonyl fluoride
14P10192638T0000|24 26|MSF
14P10192638T0000|120 133|Alzheimer type
14P10193950A0478|0 6|METHODS
14P10193950A0478|15 20|August
14P10193950A0478|28 31|June
14P10193950A0478|55 56|T2
14P10193950A0478|59 60|T3
14P10193950A0478|72 74|TNM
14P10193950A0478|76 93|prostate carcinoma
14P10193950A0478|130 151|lymph node involvement
14P10193950A0478|194 216|staging lymphadenectomy
14P10194225A1132|66 78|pyruvate Gneo
14P10194225A1132|88 98|glycerol Ra
14P10194230A0817|24 37|dialysate PGE2
14P10194230A0817|40 63|adenosine concentrations
14P10194451A0000|57 60|p210
14P10194451A0000|70 101|protein tyrosine kinase activity
14P10194451A0000|158 160|CML
14P10194451A0000|208 222|p210 substrates
14P10194451A0000|231 247|chronic-phase CML
14P10194451A0000|260 275|progenitor cells
14P10194762A0648|25 64|glutathione-S-transferase-fusion protein
14P10194762A0648|87 108|transactivation domain
14P10194762A0648|110 115|STAT5a
14P10194762A0648|147 152|ERK1/2
14P10194762A0648|208 213|STAT5a
14P10194769A0146|15 16|1P
14P10194769A0146|53 75|cDNA expression library
14P10194769A0146|80 104|417-amino acid WD protein
14P10194769A0146|113 116|PREB
14P10194769A0146|118 120|PRL
14P10194769A0146|131 145|element binding
14P10195425T0000|0 15|Characterization
14P10195425T0000|21 46|transcription factor MTF-1
14P10195425T0000|71 83|Fugu rubripes
14P10195425T0000|122 142|metal stress response
14P10195690A0000|45 49|PPARs
14P10195690A0000|73 100|hormone receptor superfamily
14P10195697A0456|8 21|F-SRC-1 mutant
14P10195697A0456|63 80|enhancing activity
14P10196127A1059|21 29|S1 pocket
14P10196127A1059|82 101|pyroglutamyl residue
14P10196248A0482|19 28|TTV genome
14P10196248A0482|139 148|GC content
14P10196266A0000|8 26|mouse Mus castaneus
14P10196266A0000|62 85|mink cell focus-inducing
14P10196266A0000|85 87|MCF
14P10196266A0000|105 120|leukemia viruses
14P10196266A0000|121 125|MuLVs
14P10196316A0715|24 29|VZV gK
14P10196316A0715|52 70|gK deletion mutants
14P10196316A0715|88 90|VZV
14P10196316A0715|97 99|DNA
14P10196316A0715|114 123|Oka strain
14P10196318T0000|0 25|CCAAT displacement protein
14P10196318T0000|58 76|papillomavirus type
14P10196318T0000|86 97|E1 promoters
14P10196597A0510|68 82|characteristics
14P10196597A0510|85 97|drink drivers
14P10197763A0580|47 66|AMP response element
14P10197763A0580|79 104|nerve growth factor effect
14P10197985A0145|7 30|RNase H protection assay
14P10197985A0145|47 62|oligonucleotides
14P10197985A0145|112 131|branchpoint sequence
14P10197985A0145|132 134|BPS
14P10197985A0145|146 148|U11
14P10197985A0145|152 161|U12 snRNPs
14P10197985A0145|226 243|pre-mRNA substrate
14P10197985A0145|255 271|complex formation
14P10198003A1505|0 7|Analysis
14P10198003A1505|84 93|expression
14P10198056A0000|14 34|cell surface proteins
14P10198056A0000|68 95|glycosylphosphatidylinositol
14P10198056A0000|97 99|GPI
14P10198061A0339|14 25|import assay
14P10198061A0339|26 37|beta-catenin
14P10198061A0339|104 106|Ran
14P10198061A0339|110 116|ATP/GTP
14P10199539A1353|66 83|a3 oxidation level
14P10199539A1353|85 87|VO2
14P10199539A1353|120 121|r2
14P10200473A0171|49 55|Usurpin
14P10200473A0171|85 91|Usurpin
14P10200473A0171|99 102|CASH
14P10200473A0171|104 109|Casper
14P10200473A0171|111 115|CLARP
14P10200473A0171|117 123|FLAME-1
14P10200473A0171|125 128|FLIP
14P10200473A0171|130 136|I-FLICE
14P10200473A0171|140 143|MRIT
14P10201468A0297|0 13|Plasma glucose
14P10201468A0297|36 38|IRI
14P10201468A0297|41 49|C-peptide
14P10201468A0297|63 74|GLP-1 levels
14P10201468A0297|95 98|OGTT
14P10202006A0546|26 39|fusion protein
14P10202006A0546|44 51|B domain
14P10202006A0546|76 78|SPA
14P10202006A1266|0 13|Polypyrimidine
14P10202006A1266|17 29|ssDNA binding
14P10202006A1266|42 50|VH domain
14P10202006A1266|82 83|Ab
14P10202006A1266|113 126|autoantibodies
14P10202006A1266|180 194|polypyrimidines
14P10202006A1266|209 224|B cell selection
14P10202006A1266|245 249|Z-DNA
14P10203611T0000|0 55|Technetium-99m methylene diphosphonate scintimammography
14P10205099A0377|0 12|INTERVENTIONS
14P10205099A0377|14 27|Study patients
14P10205099A0377|83 93|terbinafine
14P10205099A0377|118 127|groups T12
14P10205099A0377|130 132|T16
14P10205099A0377|136 147|itraconazole
14P10205099A0377|204 205|I4
14P10205176A0000|17 19|NRs
14P10205176A0000|49 63|transregulators
14P10205176A0000|82 92|yeast cells
14P10205176A0704|45 48|PSU1
14P10205176A0704|60 72|transcription
14P10205588A0000|0 8|OBJECTIVE
14P10205588A0000|88 99|streptococci
14P10205588A0000|102 119|Lancefield group A
14P10205588A0000|150 164|characteristics
14P10205933A0699|0 7|Bacteria
14P10205933A0699|21 33|labyrinthitis
14P10205933A0699|73 91|Treponemas Pallidum
14P10205933A0699|168 179|Lyme Disease
14P10206152A1024|14 23|expression
14P10206152A1024|67 68|G1
14P10206152A1024|92 101|expression
14P10206152A1024|107 119|messenger RNA
14P10206698A2041|5 12|findings
14P10206698A2041|44 54|mutagenesis
14P10206698A2041|64 71|approach
14P10206698A2041|113 119|ability
14P10206959A0368|0 5|Pathol
14P10207041A0065|13 22|cell cycle
14P10207041A0065|51 63|transcription
14P10207041A0065|66 77|cyclin genes
14P10207041A0065|83 98|protein products
14P10207049A0693|3 11|GAC1 gene
14P10207049A0693|47 89|serine/threonine phosphoprotein phosphatase
14P10207049A1001|28 43|Glc7 phosphatase
14P10207049A1001|49 52|Gac1
14P10207049A1001|89 102|HSF activation
14P10207049A1001|104 121|CUP1 transcription
14P10207087A0956|0 2|MEF
14P10207087A0956|6 10|AML1B
14P10207087A0956|54 85|promoter reporter gene construct
14P10207087A0956|90 108|activating activity
14P10207087A0956|110 112|MEF
14P10207087A0956|129 131|MEF
14P10207087A0956|150 157|AML1/ETO
14P10207090A0801|32 34|GRR
14P10207090A0801|68 70|p50
14P10207092A0924|75 97|protein kinase activity
14P10207092A0924|103 120|sea urchin nucleus
14P10207115A0389|37 39|p21
14P10208865A1246|23 41|osteoclast cultures
14P10208865A1246|81 95|resorption pits
14P10208865A1246|97 110|dentine slices
14P10208893A0839|60 78|WAD goat population
14P10209021A0212|28 32|Gle2p
14P10209021A0212|52 71|interaction function
14P10209031A0832|3 18|Fyn NH2 terminus
14P10209031A0832|74 83|Fyn kinase
14P10209031A0832|86 96|SH2 domains
14P10209031A0832|135 153|zeta ITAM tyrosines
14P10209031A0832|164 189|zeta ITAM phosphotyrosines
14P10209119A0076|66 94|F-box/WD-repeat protein Cdc4p
14P10209119A0076|100 132|SCFCdc4p ubiquitin ligase complex
14P10209119A0594|50 61|similarities
14P10209119A0594|73 82|pop2 genes
14P10209119A0594|109 127|deletion phenotypes
14P10209119A0594|207 217|proteolysis
14P10209759T0000|0 15|Antithrombin III
14P10209759T0000|42 68|ischemia reperfusion injury
14P10210952A0261|2 11|retrospect
14P10210952A0261|16 24|diagnoses
14P10210952A0261|55 62|criteria
14P10211329A0457|5 16|observations
14P10211329A0457|27 38|serum lipase
14P10211329A0457|54 60|Sjogren
14P10211329A0457|88 97|malignancy
14P10211329A0457|118 128|involvement
14P10211422T0000|34 53|polyarteritis nodosa
14P10211919A0846|44 59|sertraline group
14P10211919A0846|98 103|Y-BOCS
14P10211919A0846|110 130|CGI Improvement scale
14P10211919A0846|172 175|NIMH
14P10211919A0846|179 196|CGI Severity scale
14P10212278A0387|16 30|protein kinases
14P10212278A0387|49 64|c-jun expression
14P10212278A0387|87 106|protein kinase/c-Jun
14P10212278A0387|130 137|SAPK/JNK
14P10212278A0387|142 152|p38 members
14P10212278A0387|188 191|MAPK
14P10212284A0000|12 24|growth factor
14P10212284A0000|25 27|TGF
14P10212284A0000|55 71|matrix deposition
14P10212284A0000|74 86|proliferation
14P10212332T0000|0 17|Chronotherapeutics
14P10212426A1067|0 4|Group
14P10212426A1067|17 25|functions
14P10212426A1067|29 37|listeners
14P10212426A1067|42 53|hearing loss
14P10212426A1067|73 83|performance
14P10212969A0470|0 11|Uroflowmetry
14P10214610A0900|12 20|variation
14P10214610A0900|34 44|percentiles
14P10215485A0837|68 84|State Examination
14P10215485A0837|87 91|NA/mI
14P10215485A0837|101 102|NA
14P10215594A1728|0 7|Glucagon
14P10215594A1728|19 30|LUC activity
14P10215594A1728|49 52|CRE1
14P10215594A1728|56 65|CRE2 sites
14P10215594A1728|93 96|CRE1
14P10215594A1728|100 103|CRE2
14P10215594A1728|105 124|2SV40-LUC constructs
14P10215608A0161|23 31|isolation
14P10215608A0161|35 50|characterization
14P10215608A0161|62 70|rat GSTA3
14P10215608A0161|79 90|subunit gene
14P10215803T0000|45 61|calcium gluconate
14P10215811A0635|37 47|eradication
14P10215811A0635|77 79|EVL
14P10215850A0754|30 41|organization
14P10215850A0754|52 61|TrxR2 gene
14P10215850A0754|119 130|localization
14P10215850A0754|133 148|position 22q11.2
14P10216052A0105|43 51|frequency
14P10216052A0105|72 81|disability
14P10216052A0105|105 121|glaucoma patients
14P10216052A0105|134 146|interrelation
14P10216052A0105|154 165|disabilities
14P10216052A0105|171 185|factor analysis
14P10216052A0105|196 203|relation
14P10216052A0105|226 235|difficulty
14P10216052A0105|252 259|severity
14P10216052A0105|268 277|field loss
14P10216052A0105|288 295|glaucoma
14P10216052A0105|304 311|subgroup
14P10216052A0105|314 322|questions
14P10216052A0105|337 344|validity
14P10216052A0105|348 358|reliability
14P10216052A0105|365 372|subgroup
14P10216052A0105|375 383|questions
14P10216052A1682|15 22|validity
14P10216052A1682|40 48|questions
14P10216052A1682|94 104|correlation
14P10216052A1682|113 119|measure
14P10216052A1682|125 132|severity
14P10216052A1682|150 159|field loss
14P10216052A1682|179 187|variables
14P10216052A1682|197 204|glaucoma
14P10216052A1682|213 220|subgroup
14P10216052A1682|223 231|questions
14P10216161A1530|0 18|Sequence comparison
14P10216161A1530|20 33|cytochromes bd
14P10216161A1530|208 235|B. stearothermophilus enzyme
14P10217683A0509|0 21|Canalith repositioning
14P10218109T0000|0 17|Solution structure
14P10218109T0000|34 58|MutT pyrophosphohydrolase
14P10218200A0534|60 87|tissue plasminogen activator
14P10218357A0486|0 6|RESULTS
14P10218357A0486|10 20|CONCLUSIONS
14P10218357A0486|22 27|Brandt
14P10218357A0486|47 48|G2
14P10218357A0486|123 125|N2O
14P10219091A0246|28 36|gene CTL1
14P10220275A0694|12 21|PH domains
14P10220275A0694|23 32|Gbetagamma
14P10220275A0694|62 71|Gbetagamma
14P10220275A0694|112 118|Gialpha
14P10220364A0087|5 14|afterglows
14P10220364A0087|30 39|supernovae
14P10220364A0087|61 70|hypernovae
14P10221467T0000|62 85|dopamine agonist therapy
14P10221467T0000|100 108|Parkinson
14P10221820A0902|17 20|APBD
14P10221820A0902|47 49|AMT
14P10221820A0902|124 127|APBD
14P10221820A0902|131 133|AMT
14P10223338A1601|73 81|HIV-2 gag
14P10223338A1601|85 94|V3 domains
14P10223338A1601|96 104|HIV-1IIIB
14P10223338A1601|106 112|HIV-1MN
14P10223338A1601|114 121|HIV-1SF2
14P10223338A1601|125 131|HIV-1RF
14P10223338A2186|22 32|V3 peptides
14P10223338A2186|52 56|HIV-1
14P10223338A2186|66 74|HIV-2 gag
14P10223338A2186|95 110|HIV/AIDS vaccine
14P10223498A0479|0 7|Efficacy
14P10223498A0479|117 143|15-item International Index
14P10223498A0479|144 160|Erectile Function
14P10223498A0479|161 164|IIEF
14P10224244T0000|0 7|Evidence
14P10224244T0000|30 50|Glc7-Reg1 phosphatase
14P10224244T0000|56 71|Snf1-Snf4 kinase
14P10224244T0000|88 105|INO1 transcription
14P10224257A0079|2 9|XO males
14P10224257A0079|13 23|her-1 mRNAs
14P10224257A0079|79 80|P1
14P10224257A0079|115 116|P2
14P10224289T0000|0 8|Induction
14P10224289T0000|11 31|Fas ligand expression
14P10224289T0000|32 34|HIV
14P10224289T0000|69 94|T cell receptor zeta chain
14P10224293A0000|0 37|Receptor protein tyrosine phosphatases
14P10224293A0000|36 40|RPTPs
14P10224293A0000|91 109|phosphatase domains
14P10224293A2021|69 87|RPTP-kappa function
14P10224513A0240|30 40|arithmetics
14P10224513A0240|42 53|speech tasks
14P10224513A0240|57 67|Stroop test
14P10224513A0240|68 84|videogame playing
14P10224758A0202|3 15|control group
14P10224758A0202|24 41|afterbirth samples
14P10225279A0450|35 43|MDV2 UL54
14P10225279A0450|46 55|UL55 genes
14P10225279A0450|77 79|ORF
14P10225279A0450|81 85|ORF-1
14P10225279A0450|95 110|herpesvirus type
14P10225279A0450|143 160|pseudorabies virus
14P10225945A0436|20 32|MAD2 staining
14P10225945A0436|68 89|microtubule attachment
14P10225945A0436|163 174|kinetochores
14P10226029A0905|21 29|PH domain
14P10226029A0905|31 37|Akt/PKB
14P10226074A0637|66 87|translation start site
14P10226838A1011|47 56|electrodes
14P10226838A1011|75 85|stimulation
14P10226838A1011|89 91|60s
14P10228009A0600|0 8|Induction
14P10228009A0600|14 26|CINC promoter
14P10228009A0600|28 32|IL-17
14P10228009A0600|35 45|IEC-6 cells
14P10228009A0600|48 50|TNF
14P10228009A0600|79 83|TRAF6
14P10228009A0600|92 96|TRAF2
14P10228155A1293|0 6|SCFFWD1
14P10228155A1293|23 39|tumor development
14P10228155A1293|72 101|beta-catenin protein stability
14P10228157T0000|16 41|spindle checkpoint pathway
14P10228157T0000|52 63|Dbf2p kinase
14P10228561A0539|34 52|DNA polymerase beta
14P10228561A0539|88 101|DNA phosphates
14P10228795A0842|0 6|RESULTS
14P10228795A0842|66 80|nerve responses
14P10228795A0842|82 84|EFS
14P10228795A0842|96 98|IAS
14P10229084A0000|15 33|gel electrophoresis
14P10229084A0000|46 63|immunoprecipitates
14P10229084A0000|103 115|T lymphocytes
14P10229084A0000|156 170|protein complex
14P10229084A0000|204 206|Fyn
14P10229084A0000|227 241|phosphoproteins
14P10229084A0000|261 288|protein tyrosine kinase Pyk2
14P10229084A0000|315 330|adaptor proteins
14P10229084A0000|331 336|SKAP55
14P10229084A0000|340 347|SLAP-130
14P10229668A0190|15 27|cdc33 mutants
14P10229668A0190|39 40|G1
14P10229668A0560|1 14|cdc33-1 strain
14P10229668A0560|36 40|Cln3p
14P10229668A0560|42 48|Cln3-1p
14P10229668A0560|66 74|CLN3 mRNA
14P10229682A1151|19 33|gene expression
14P10229682A1151|87 97|kappaB site
14P10229682A1151|156 167|NF-IL-6 site
14P10231026A0253|3 16|gene structure
14P10231026A0253|18 21|Elk1
14P10231454A0731|5 17|serum calcium
14P10231454A0731|74 83|phosphorus
14P10231454A0731|102 121|alkaline phosphatase
14P10231454A0731|131 137|U/liter
14P10231485A0342|0 16|Sequence analysis
14P10231485A0342|41 83|molybdopterin guanine dinucleotide cofactor
14P10231485A0342|184 204|quinol oxidation site
14P10231513T0000|26 53|granulation tissue formation
14P10231581A1125|45 53|SP1 sites
14P10231581A1125|105 121|promoter activity
14P10231862A1117|17 23|infants
14P10231862A1117|110 121|contribution
14P10231862A1117|134 142|synthesis
14P10231862A1117|153 158|plasma
14P10232078A0552|0 7|Ischemia
14P10232078A0552|51 67|6-keto-PGF1 alpha
14P10232078A0552|70 73|TXB2
14P10232600T0000|25 27|PSA
14P10232600T0000|74 96|sodium iodide symporter
14P10232600T0000|97 122|prostate cancer cell lines
14P10232872A0081|33 34|CD
14P10233147A0218|0 4|Ras2p
14P10233147A0218|54 71|signaling pathways
14P10233147A0218|75 92|filamentation MAPK
14P10233147A0218|93 110|Cdc42p/Ste20p/MAPK
14P10233147A0218|138 151|protein kinase
14P10233147A0218|152 165|Cyr1p/cAMP/PKA
14P10233885A0899|62 77|cell line Jurkat
14P10233885A0899|131 133|p32
14P10233885A0899|137 148|p30 isoforms
14P10233946A0000|24 44|spleen necrosis virus
14P10233946A0000|44 46|SNV
14P10233946A0000|68 71|LTRs
14P10233946A0000|145 162|leukemia virus RNA
14P10233946A0000|189 195|SNV RNA
14P10234698A0728|38 52|CNS development
14P10234698A0728|62 75|animal studies
14P10234698A0728|88 99|pretreatment
14P10234698A0728|104 118|corticosteroids
14P10235265A0197|86 106|proteolysis machinery
14P10235265A0197|126 128|Clb
14P10235265A0197|130 143|cyclin subunit
14P10236651T0000|0 9|Predictors
14P10236651T0000|21 35|pharmacy school
14P10236651T0000|36 39|PCAT
14P10236651T0000|48 65|admission criteria
14P10240361T0000|31 45|dissatisfaction
14P10240361T0000|51 60|physicians
14P10243927A0000|33 45|investigators
14P10243927A0000|51 72|IIT Research Institute
14P10243927A0000|97 108|door control
14P10243927A0000|119 129|fire origin
14P10271171A0458|6 10|LATCH
14P10271171A0458|31 44|identification
14P10271171A0458|88 102|resource center
14P10281637A0000|0 8|Reporting
14P10304090T0000|0 20|Medicare SNF benefits
14P10308312A0203|33 45|understanding
14P10308312A0203|51 72|interaction mechanisms
14P10308312A0203|74 83|ultrasound
14P10318806A0000|0 6|Members
14P10318806A0000|36 38|MAP
14P10318806A0000|40 52|kinase family
14P10318806A0000|105 120|protein kinase-1
14P10318806A0000|148 150|p38
14P10318806A0000|203 216|growth factors
14P10318806A0476|63 73|MAP kinases
14P10318806A0918|0 7|Analyses
14P10318806A0918|33 46|PDGF receptors
14P10318806A0918|54 65|Src homology
14P10318806A0918|100 117|Src family kinases
14P10318806A0918|117 145|phosphatidylinositol 3-kinase
14P10318806A0918|175 177|Ras
14P10318806A0918|182 193|Src homology
14P10318806A0918|211 227|phosphatase SHP-2
14P10318806A0918|228 248|phospholipase C-gamma
14P10318806A0918|252 254|Crk
14P10318806A0918|312 314|p38
14P10318859A0535|31 51|tyrosine phosphatases
14P10318859A0535|61 84|tyrosine phosphorylation
14P10318900A0637|39 61|electron cryomicroscopy
14P10318900A0637|86 88|Fab
14P10318900A0637|90 95|8H2/G5
14P10318900A0637|113 124|conformation
14P10318900A0637|155 169|mRNA production
14P10318918A0824|28 31|NS5A
14P10318918A0824|106 118|HCV genotypes
14P10319320A1022|35 42|16K hPRL
14P10319320A1022|65 78|Ras activation
14P10319320A1022|156 167|angiogenesis
14P10319327A1237|10 54|SRE oligonucleotide gel mobility shift assays
14P10319327A1237|117 119|SRF
14P10319955A0941|12 22|differences
14P10319955A0941|29 43|occlusion rates
14P10319955A0941|53 62|chi-square
14P10319955A0941|82 92|differences
14P10320177A0487|0 28|Baseline electrocorticography
14P10320177A0487|62 87|depth electrode recordings
14P10320177A0487|169 187|i.v. administration
14P10320480A0451|67 76|C-terminus
14P10320480A0451|101 114|RNA polymerase
14P10320579A1831|13 16|FlgN
14P10320579A1831|20 23|FliT
14P10320579A1831|45 64|flagellar chaperones
14P10320579A1831|75 89|oligomerization
14P10320579A1831|95 98|HAPs
14P10321158T0000|0 3|Post
14P10321158T0000|7 22|core fabrication
14P10321158T0000|45 53|cast post
14P10322022A0263|0 5|Rep63A
14P10322022A0263|45 47|ORF
14P10322022A0263|92 111|replication proteins
14P10322022A0263|115 131|plasmids pAMbeta1
14P10322022A0263|168 181|pAW63 replicon
14P10322022A0263|193 207|pAMbeta1 family
14P10322629A0198|25 40|characterization
14P10322629A0198|43 55|Xenopus Pax-5
14P10322629A0198|58 62|Pax-8
14P10322629A0198|83 87|Pax-2
14P10323225A0244|0 8|Km values
14P10323225A0244|20 33|2-oxoglutarate
14P10323225A0244|35 38|NADH
14P10323225A0244|52 54|NAD
15P10323463T0000a|0 15|Interferon-alpha
15P10323463T0000a|61 74|manifestations
15P10323463T0000b|0 15|Interferon-alpha
15P10323463T0000b|61 74|manifestations
14P10323863A0852|87 112|rabbit reticulocyte lysate
14P10323863A0852|123 148|ribonucleoprotein assembly
14P10325413A1211|27 66|DNA containing 5-methylcytosine residues
14P10326221A0531|10 17|mutation
14P10326221A0531|23 30|children
14P10326221A0531|36 45|amputation
14P10326221A0531|64 72|fulminans
14P10326654A0351|11 27|pilot experiments
14P10326654A0351|183 194|fibrillation
14P10326654A0351|196 197|VF
14P10326654A0351|222 232|arrhythmias
14P10326654A0351|265 274|prevalence
14P10326654A0351|277 278|VF
14P10326654A0351|310 319|difference
14P10326856T0000|12 33|pancreaticojejunostomy
14P10326856T0000|50 68|purse-string device
14P10327051A0688|27 57|Stress-Activated-Protein-Kinase
14P10327051A0688|59 62|SAPK
14P10327051A0688|77 80|ATF2
14P10327051A0688|129 140|p300/CBP-ATF
14P10328351A0443|0 12|Blood samples
14P10328351A0443|39 60|supplementation period
14P10329135A1326|36 47|presequences
14P10329135A1326|97 110|protein import
14P10329566A0610|58 66|structure
14P10329566A0610|75 90|valine anticodon
14P10329566A0610|103 111|structure
14P10329566A0610|118 127|pseudoknot
14P10329566A0610|133 146|aminoacyl stem
14P10329566A0610|175 186|tetraviruses
14P10329574A1733|11 15|RNA-7
14P10329574A1733|54 56|RNA
14P10329574A1733|79 81|RNA
14P10329574A1733|94 106|OnuMV4-Ld RNA
14P10329586A0414|24 25|FN
14P10329586A0414|62 74|LNCaP-r cells
14P10329586A0414|123 124|FN
14P10329586A0414|127 141|prostate cancer
14P10329625A0715|18 33|cell surface CD4
14P10329625A0715|35 37|CD8
14P10329625A0715|41 43|CD3
14P10329625A0715|66 74|TCR genes
14P10329625A0715|143 146|FTOC
14P10329736A0681|68 78|p85 subunit
14P10329736A0681|80 108|phosphatidylinositol 3-kinase
14P10329736A1106|0 18|Insulin stimulation
14P10329736A1106|51 53|p85
14P10329736A1106|55 58|SHP2
14P10329736A1106|60 62|Nck
14P10329736A1106|67 69|Shc
14P10330134A0765|19 22|RFX1
14P10330134A0765|24 27|RFX2
14P10330134A0765|32 35|RFX3
14P10330134A0765|65 93|transient-transfection assays
14P10330134A0765|106 122|RFX binding sites
14P10330146A0730|45 65|luciferase expression
14P10330146A0730|109 129|luciferase expression
14P10330159A1258|5 7|VDR
14P10330159A1258|68 84|promoter/enhancer
14P10330159A1258|100 104|NFAT1
14P10330159A1258|161 167|Jun-Fos
14P10330159A1258|173 175|DNA
14P10330168A0135|45 47|Clb
14P10330168A0135|73 82|Cdk/Cdc28p
14P10330168A0135|87 91|Cdc7p
14P10330168A0135|144 145|G1
14P10330168A0135|156 170|DNA replication
14P10330396A0387|3 23|RanQ69L preincubation
14P10330396A0387|44 47|CRM1
14P10330396A0387|97 99|NPC
14P10330396A0387|121 131|p62 complex
14P10330396A0387|134 143|Can/Nup214
14P10331276A0298|8 15|elements
14P10331276A0298|33 41|structure
14P10331646A0595|21 39|amino acid sequence
14P10331646A0595|54 57|ART5
14P10331646A0595|61 72|transferases
14P10331646A0595|90 103|lymphoma cells
14P10331646A0595|159 172|amino terminus
14P10331646A0595|188 202|signal sequence
14P10331646A0595|223 237|signal sequence
14P10331646A0595|242 258|carboxyl terminus
14P10331730A0504|0 6|RESULTS
14P10331730A0504|42 49|Sardinia
14P10331730A0504|104 115|study period
14P10331875A0523|4 18|dimer interface
14P10331875A0523|62 72|specificity
14P10331875A0523|103 105|HSF
14P10331875A0523|128 140|cooperativity
14P10332733A0000|3 22|paramyxovirus fusion
14P10332733A0000|40 54|membrane fusion
14P10333481A1102|13 29|deletion analysis
14P10333481A1102|34 37|UCP2
14P10333481A1102|103 119|promoter activity
14P10333481A1102|200 214|promoter region
14P10333526A0459|3 12|hTERT gene
14P10333529A0277|4 15|betaAPP mRNA
14P10333529A0277|18 29|Abeta levels
14P10334888A0960|2 14|reperfusion B
14P10334888A0960|69 87|IL-8 concentrations
14P10336495A0547|91 94|NCoR
14P10336495A0547|98 106|PPARalpha
14P10336495A0547|108 115|RXRalpha
14P10339552A0361|28 37|SRm160/300
14P10339552A0361|63 65|ESE
14P10339566A0602|0 5|Spc42p
14P10339566A0602|49 62|SPB subcomplex
14P10339566A0602|72 83|Spc94p/Nud1p
14P10339566A0602|85 90|Cnm67p
14P10339566A0602|95 100|Spc42p
14P10340447A0424|60 62|QMF
14P10340447A0424|69 78|QIT system
14P10340883A1266|9 10|OS
14P10340883A1266|14 23|stage IIIB
14P10341219A0481|12 34|heparin lyase treatment
14P10341219A0481|71 87|YD-repeat protein
14P10341219A0481|123 137|mass aggregates
14P10342511A0909|16 28|determination
14P10342511A0909|30 31|r2
14P10342536A0954|23 37|protein content
14P10342536A0954|73 92|RAST/EAST inhibition
14P10342536A0954|178 196|whey/casein formula
14P10342536A0954|197 221|soy/pork collagen formula
14P10342536A0954|227 244|amino acid formula
14P10342829A0236|12 21|importance
14P10342829A0236|24 28|GnRHR
14P10342829A0236|42 51|mechanisms
14P10342829A0236|80 89|regulation
14P10342829A0236|100 104|GnRHR
14P10342829A0236|152 163|reproduction
14P10342829A1370|11 31|mobility shift assays
14P10342829A1370|77 88|SF-1 protein
14P10342829A1370|108 111|SF-1
14P10342829A1370|148 158|GSE element
14P10343189A0911|0 4|Grade
14P10344736A0796|0 21|CDK4 kinase activities
14P10344736A0796|55 75|CDK inhibitor p21Cip1
14P10344736A0796|83 106|cyclin E immunocomplexes
14P10347144A0516|43 60|baculovirus system
14P10347144A0516|122 126|AVQGP
14P10347197A0502|0 8|Induction
14P10347197A0502|14 31|urokinase promoter
14P10347197A0502|33 38|HGF/SF
14P10347197A0502|45 56|Met receptor
14P10347197A0502|108 132|Sos1 expression construct
14P10347203A0832|0 21|Serine phosphorylation
14P10347203A0832|23 27|STAT3
14P10347203A0832|48 69|somatostatin treatment
14P10347203A0832|102 103|PD
14P10347220A1477|88 90|RNA
14P10347220A1477|116 138|RNA guanylyltransferase
14P10347220A1477|236 275|triphosphatase-guanylyltransferase Mce1p
14P10347220A1477|281 302|methyltransferase Hcm1
14P10347839A0434|3 13|IC50 values
14P10348859A0292|25 37|binding sites
14P10348859A0292|49 62|MerR homodimer
14P10348859A0292|74 75|Hg
14P10348859A0292|93 97|Cys82
14P10348859A0292|115 120|Cys117
14P10348859A0292|124 129|Cys126
14P10349084T0000|26 45|virus seropositivity
14P10349443A0358|3 9|results
14P10349443A0358|21 31|field tests
14P10349443A0358|42 47|levels
14P10349443A0358|50 60|infestation
14P10349443A0358|63 68|larvae
14P10349443A0358|73 78|values
14P10350027A0942|0 10|Amisulpride
14P10350027A0942|42 52|psychomotor
14P10350027A0942|87 97|performance
14P10350454A0000|0 3|MutY
14P10350454A0000|19 29|glycosylase
14P10350454A0000|34 44|specificity
14P10350454A0000|67 78|8-oxoguanine
14P10350454A0000|95 97|G.A
14P10350484A0346|13 27|kinase activity
14P10350484A0346|57 60|CheA
14P10350484A0346|104 105|KM
14P10350484A0346|109 111|ATP
14P10350484A0346|137 140|Vmax
14P10350638A0000|0 6|Latexin
14P10350638A0000|9 36|carboxypeptidase A inhibitor
14P10353073A0118|0 18|Regression analyses
14P10353880A0257|96 98|HSV
14P10355085A1119|0 6|Subsets
14P10355085A1119|61 63|ISS
14P10355085A1119|102 115|injury pattern
14P10355085A1119|134 145|nonsurvivors
14P10355536A0172|17 21|years
14P10355536A0172|23 27|range
14P10355536A0172|33 37|years
14P10355910A0369|13 21|follow-up
14P10357751A0866|25 32|children
14P10357751A0866|72 74|FFM
14P10357751A0866|201 208|children
14P10357751A0866|223 229|disease
14P10358031A0303|67 76|G2/M delay
14P10358031A0303|109 119|cytokinesis
14P10358031A0303|126 140|cell separation
14P10358075A0984|0 4|DAF16
14P10358075A0984|29 45|signaling pathway
14P10358075A0984|133 147|PtdIns 3-kinase
14P10358075A0984|150 152|PKB
14P10358079A0391|8 26|neu differentiation
14P10358079A0391|54 58|ErbB2
14P10358079A0391|62 66|ErbB4
14P10358079A0391|76 80|Stat5
14P10358080A1114|23 43|transcription factors
14P10358080A1114|61 83|DNA binding specificity
14P10358080A1114|112 122|HSF1 linker
14P10358080A1114|146 169|HSF1 binding preferences
14P10358080A1114|214 244|HSF1 monomer-trimer equilibrium
14P10358080T0000|0 9|Modulation
14P10358080T0000|17 47|heat shock factor trimerization
14P10358083A0263|57 64|F9 cells
14P10358083A0263|67 82|characterization
14P10358083A0263|129 150|sequence motifs GTGACT
14P10358083A0263|153 157|ATTGT
14P10358083A0263|162 165|GATA
14P10358083A0263|174 193|transcription factor
14P10358138A0672|37 39|XLP
14P10358138A0672|85 88|SLAM
14P10358138A0672|102 123|cell surface molecules
14P10358138A0672|133 135|SAP
14P10358138A0672|139 163|signaling adaptor protein
14P10359014A1077|18 44|Fra-2 phosphorylation sites
14P10359014A1077|45 48|MAPK
14P10359014A1077|73 87|serine residues
14P10359014A1077|160 177|threonine residues
14P10359014A1077|198 201|MAPK
14P10359575A0317|46 54|FcalphaRI
14P10359575A0317|65 67|IgA
14P10359575A0317|86 89|IgG2
14P10359575A0317|105 114|bFcgamma2R
14P10359603A0430|22 43|Sec1p homologue Vps45p
14P10359663A0425|105 108|SV40
14P10359663A0425|176 190|enhancer region
14P10359663A0425|201 232|oIFNtau-SV40-CAT transactivation
14P10359663A1280|2 24|co-transfection studies
14P10359663A1280|65 79|transactivation
14P10359663A1280|111 116|GATA-1
14P10359663A1280|118 123|GATA-2
14P10359663A1280|126 131|GATA-3
14P10359664A0579|40 45|MARCKS
14P10359664A0579|61 78|lysyl endoprotease
14P10359664A0579|91 106|electrospray MS.
14P10359673A0000|24 46|lipoamide dehydrogenase
14P10359673A0000|76 98|amino acid biosynthesis
14P10359673A0000|110 134|GCN4 transcription factor
14P10359792A0610|34 45|Rpd3 mutants
14P10359792A0610|77 83|Groucho
14P10359792A0610|87 112|dCtBP corepressor proteins
14P10359792A0610|153 172|histone deacetylases
14P10360454A0916|11 35|serum TNF-a concentration
14P10360454A0916|75 88|pentoxifylline
14P10360454A0916|152 164|control group
14P10360839A1338|69 90|KRAB zinc finger genes
14P10360839A1338|123 135|cell lineages
14P10360947A1113|9 33|fluorescence spectroscopy
14P10360947A1113|78 80|Ca2
14P10360947A1113|84 88|ALG-2
14P10361038A0281|22 30|locations
14P10361038A0281|36 44|promoters
14P10361038A0281|68 80|protein genes
14P10362652A0350|27 29|EGF
14P10362652A0350|43 56|Ras activation
14P10362652A1456|16 18|Sos
14P10362652A1456|31 51|carbachol stimulation
14P10362652A1456|53 59|HA-ERK2
14P10362652A1456|94 96|EGF
14P10362897A0545|0 6|RESULTS
14P10362897A0545|92 105|Doppler signal
14P10363517A0401|48 62|ultrasonography
14P10364076A0429|27 31|E-box
14P10364076A0429|51 63|repeat motifs
14P10364076A0429|70 76|SREBP-1
14P10364159A0813|36 52|FRAP/mTOR protein
14P10364159A0813|56 82|FRAP/mTOR immunoprecipitate
14P10364163A0092|0 2|Hrs
14P10364163A0092|7 10|FYVE
14P10364163A0092|17 34|zinc finger domain
14P10364163A0092|56 75|phosphatidylinositol
14P10364202A0646|28 48|expression constructs
14P10364202A0646|55 57|DBP
14P10364202A0646|68 82|leukemia factor
14P10364202A0646|134 157|GAL4-DBP fusion proteins
14P10364314A0919|70 77|NS2 gene
14P10364319A0109|30 49|EBNA mRNA initiation
14P10364319A0109|64 69|EBNA3C
14P10364425A0610|5 15|indications
14P10364425A0610|104 108|STAT3
14P10364523A0826|4 16|exon trapping
14P10364523A0826|56 65|YAC 946E12
14P10364523A0826|137 147|breakpoints
14P10364523T0000|10 44|dysplasia translocation breakpoints
14P10364523T0000|72 75|SOX9
14P10365883A1355|13 27|characteristics
14P10365883A1355|30 41|VRE patients
14P10365883A1355|56 69|vancomycin use
14P10366446A0893|71 87|interaction motif
14P10366446A0893|90 96|FLI LRR
14P10366503A0812|0 17|Binding affinities
14P10366503A0812|83 89|His-tag
14P10366503A0812|117 138|co-immunoprecipitation
14P10366503A0812|207 233|terminase interaction sites
14P10366503A1506|11 19|terminase
14P10366503A1506|75 82|antibody
14P10366503A1506|140 148|structure
14P10366503A1506|168 178|association
14P10366503A1506|212 228|terminase regions
14P10366503A1506|248 264|packasome complex
14P10366559A0605|3 16|hybrid viruses
14P10366722T0000|49 76|mouse DNA polymerase epsilon
14P10367240A1354|12 27|cryopreservation
14P10367240A1354|67 68|SP
14P10367240A1354|114 127|cryoprotection
14P10367240A1354|159 182|fertilization procedures
14P10367240A1354|212 226|sperm injection
14P10367385A0000|42 49|analysis
14P10367385A0000|52 64|beta-carotene
14P10367460A0191|3 17|FCMS conditions
14P10367460A0191|51 67|power consumption
14P10367460A0191|71 97|V maximum capacitor voltage
14P10367460A0191|154 165|Hz frequency
14P10367646A0569|6 14|hemolysis
14P10367646A0569|61 71|mean values
14P10367646A0569|113 121|increases
14P10367646A0569|123 146|alanine aminotransferase
14P10367646A0569|158 172|serum globulins
14P10369418A0644|0 3|EMSA
14P10369418A0644|59 63|CD40L
14P10369418A0644|87 105|NF-kappaB complexes
14P10369418A0644|129 143|NF-kappaB sites
14P10369418A0644|165 167|p50
14P10369418A0644|198 200|p65
14P10369625A0942|19 21|ODA
14P10369757A0000|8 28|transcription factors
14P10369757A0000|39 57|arginine metabolism
14P10369757A0000|77 93|Bacillus subtilis
14P10369757A0000|94 97|ArgR
14P10369757A0000|101 104|AhrC
14P10369757A0000|217 229|transcription
14P10369757A0000|269 281|transcription
14P10369757A0000|299 302|AhrC
14P10369757A0000|322 345|plasmid dimer resolution
14P10369775A0178|10 26|protein fragments
14P10369775A0178|35 56|residues Arg183-His267
14P10369775A0178|66 67|ER
14P10369775A0178|71 92|residues Lys438-Gln520
14P10369926A0251|8 23|intron structure
14P10369926A0251|72 74|IL8
14P10369926A0251|115 133|CXC chemokine genes
14P10369965A0000|42 68|basidiocarp differentiation
14P10369965A0000|73 98|mushroom Agrocybe aegerita
14P10370675A0649|15 27|liver disease
14P10370675A0649|44 46|HCC
14P10370675A0649|51 67|hepatitis C virus
14P10370675A0649|67 69|HCV
14P10370675A0649|77 89|alcohol abuse
14P10370675A0649|114 116|HCV
14P10370675A0649|120 132|alcohol abuse
14P10370778A0000|8 27|aromatase inhibitors
14P10370778A0000|89 101|breast cancer
14P10370778A0000|155 171|tamoxifen therapy
14P10370778A0000|184 191|ARIMIDEX
14P10370778A0000|193 198|Zeneca
14P10370778A0000|211 216|FEMARA
14P10370778A0000|218 225|Novartis
14P10370778A0000|239 245|RIVIZOR
14P10370778A0000|247 253|Janssen
14P10371097A0963|0 10|CONCLUSIONS
14P10371097A0963|12 20|Turbutest
14P10371097A0963|73 86|identification
14P10371097A0963|115 134|inhalation technique
14P10371097A0963|138 147|Turbuhaler
14P10372627A0530|7 14|injuries
14P10372627A0530|28 36|snowboard
14P10373029A0204|36 56|gastrocnemius muscles
14P10373507A0680|0 8|SRFDelta5
14P10373507A0680|146 154|SM22alpha
14P10373507A0680|159 201|SRF promoter-luciferase reporter activities
14P10373523A0924|18 23|p50E4F
14P10374632A0818|23 25|Nim
14P10374632A0818|60 62|NBP
14P10374632A0897|0 9|CONCLUSION
14P10374632A0897|11 27|NBP pre-treatment
14P10374632A0897|78 87|RMCAO rats
14P10375107A1138|0 10|Progression
14P10375107A1138|26 37|chemotherapy
14P10375638A0859|0 8|Mutations
14P10375638A0859|20 23|UTR1
14P10375638A0859|32 47|NRF-1 expression
14P10375638A0859|123 140|translation system
14P10375640A0153|18 36|nucleotide sequence
14P10375640A0153|46 50|CBS-1
14P10375640A0153|65 77|reading frame
14P10375694T0000|36 46|input zones
14P10375694T0000|69 78|motor area
14P10375694T0000|97 106|comparison
14P10375694T0000|114 124|input zones
14P10375694T0000|144 153|motor area
14P10375718A0000|5 28|fibroblast growth factor
14P10375718A0000|53 64|angiogenesis
14P10375718A0000|74 86|animal models
14P10375718A0000|102 115|administration
14P10376065A0881|94 106|spring filter
14P10376065A0881|109 119|RF02 filter
14P10376446A0000|49 54|2-hour
14P10376446A0000|82 84|PLR
14P10376446A0000|99 100|FP
14P10376446A0000|112 113|LP
14P10376873A0706|28 30|UTR
14P10376874A0759|33 53|eRF1-eRF3 interaction
14P10376874A0759|85 97|protein eRF3C
14P10376874A0759|118 130|eRF1 proteins
14P10376874A0759|211 221|interaction
14P10376877A0611|0 6|Removal
14P10376877A0611|96 102|Ss rRNA
14P10376877A0611|168 177|production
14P10376877A0611|180 187|18S rRNA
14P10376991A0977|0 2|Ras
14P10377345A0740|0 4|Green
14P10377345A0740|30 36|UNC-49B
14P10377345A0740|40 55|UNC-49C subunits
14P10377438A0647|19 22|UBC9
14P10377438A0647|49 51|TEL
14P10378989A0000|72 85|drug reactions
14P10378989A0000|131 136|Sicily
14P10378989A0000|138 142|Italy
14P10378989A0000|164 170|January
14P10378989A0000|179 186|December
14P10379547A0000|0 8|Molecules
14P10379547A0000|11 13|NH3
14P10379547A0000|54 58|MASER
14P10379899A0446|110 133|theca cell layer markers
14P10379942A0956|88 104|MDV2 UL10 protein
14P10379942T0000|0 13|Identification
14P10379942T0000|31 35|Marek
14P10379942T0000|38 59|disease virus serotype
14P10379942T0000|59 77|glycoprotein M gene
14P10379942T0000|91 110|glycoprotein M genes
14P10379942T0000|111 130|Herpesviridae family
14P10380232A0000|0 8|OBJECTIVE
14P10380232A0000|20 46|cost-effectiveness analysis
14P10380232A0000|47 49|CEA
14P10380232A0000|77 98|regimen-chlorpromazine
14P10380232A0000|114 120|CPM-DEX
14P10380232A0000|127 163|5-HT3 receptor antagonist-tropisetron
14P10380232A0000|163 166|TROP
14P10380659A0545|0 12|Baseline data
14P10380800A0194|36 55|amino acid sequences
14P10380800A0194|88 109|RNA polymerase domains
14P10380878A0542|46 49|Bin1
14P10380878A0542|73 91|repression function
14P10380878A0542|93 95|DNA
14P10380878A0542|114 132|histone deacetylase
14P10380890A0619|90 91|IR
14P10381257A0000|56 80|preprotein import complex
14P10381257A0000|111 123|mitochondrion
14P10381377T0000|35 54|inositol phosphatase
14P10381377T0000|56 60|SHIP2
14P10381377T0000|89 105|insulin signaling
14P10381570A1355|0 3|Slp1
14P10381570A1355|13 25|transcription
14P10381570A1355|33 44|binding site
14P10381570A1355|46 56|yeast cells
14P10381570A1355|98 108|ftz stripes
14P10381570A1355|110 128|interstripe regions
14P10381570A1355|146 158|embryogenesis
14P10383764A1809|44 55|VirB4 dimers
14P10383764A1809|57 69|homomultimers
14P10383764A1809|118 138|transenvelope channel
14P10383764A1809|163 174|DNA transfer
14P10383764A1809|252 265|export machine
14P10383966A0000|3 29|penicillin binding proteins
14P10383966A0000|29 32|PBPs
14P10384129A0000|0 8|TCR alpha
14P10384129A0000|9 12|TCRA
14P10384129A0000|37 47|RNA samples
14P10384129A0000|51 54|PBMC
14P10384129A0000|79 81|CD4
14P10384129A0000|84 86|CD8
14P10384129A0000|94 100|T cells
14P10385384A0654|54 78|pentose phosphate pathway
14P10385395A0000|7 25|density lipoprotein
14P10385395A0000|26 28|HDL
14P10385395A0000|71 88|cholesteryl esters
14P10385395A0000|102 116|steroidogenesis
14P10385395A0000|124 135|HDL particle
14P10385915A1341|0 6|D3S1261
14P10385915A1341|37 46|MITF locus
14P10385915A1341|52 58|D3S2465
14P10385915A1341|62 68|D3S1766
14P10388670A1976|3 13|percentages
14P10388670A1976|16 23|recovery
14P10388670A1976|37 48|storage time
14P10388670A1976|60 67|addition
14P10388670A1976|70 79|dispersant
14P10388670A1976|133 140|adhesion
14P10390158A1150|0 14|Point mutations
14P10390158A1150|37 49|Pit-1 binding
14P10390158A1150|68 89|tiGH promoter activity
14P10390538T0000|20 38|zinc-finger protein
14P10391075A0000|110 121|MRI findings
14P10391246A0756|12 16|MOM-4
14P10391246A0756|20 23|TAK1
14P10391246A0756|59 75|kinase activities
14P10391277A0000|0 9|BACKGROUND
14P10391277A0000|14 21|MAZE-III
14P10391903T0000|0 3|Gab2
14P10391903T0000|9 27|pleckstrin homology
14P10391903T0000|44 58|adapter protein
14P10391903T0000|86 95|ERK kinase
14P10391903T0000|97 101|Elk-1
14P10392266A0111|41 58|serum lipid levels
14P10392266A0111|109 122|immunoglobulin
14P10392669A0935|120 153|prostaglandin analogue misoprostol
14P10392669A0935|308 320|complications
14P10392669A0935|326 358|histamine H2 receptor antagonists
14P10392669A0935|357 370|H2 antagonists
14P10392669A0935|479 492|term treatment
14P10392669A0935|548 569|proton pump inhibitors
14P10392669A0935|586 597|pantoprazole
14P10392669A0935|681 694|barrier agents
14P10392669A0935|736 754|prophylactic agents
14P10392710A1000|0 14|Lung mesenchyme
14P10392710A1000|42 59|lung morphogenesis
14P10392710A1000|77 98|peptide growth factors
14P10392900A1020|18 29|HIV promoter
14P10392900A1020|99 122|tyrosine phosphorylation
14P10392900A1020|124 137|RNA polymerase
14P10392903A0000|9 33|papillomavirus E2 protein
14P10392903A0000|60 69|HT-3 cells
14P10392903A0000|91 109|carcinoma cell line
14P10392903A0000|133 151|papillomavirus type
14P10392903A0000|153 155|DNA
14P10392903A0889|0 15|E2 point mutants
14P10392903A0889|61 77|cdc25B expression
14P10392903A0889|87 119|cell cycle inhibitors hydroxyurea
14P10392914A0000|0 17|BACKGROUND/PURPOSE
14P10392914A0000|67 71|AAPBD
14P10392914A0000|152 167|tract malignancy
14P10393192A0792|0 23|Neurospora crassa CYT-18
14P10393192A0792|48 61|intron mutants
14P10393197A0543|0 3|DDP1
14P10393197A0543|19 33|heterochromatin
14P10393197A0543|36 52|interphase nuclei
14P10393201A0654|21 37|DNA repair system
14P10393201A0654|46 64|DNA polymerase beta
14P10393201A0654|66 85|DNA ligase III-XRCC1
14P10393251A0283|3 11|PAC clone
14P10393251A0283|29 33|120kb
14P10393251A0283|56 75|restriction analysis
14P10393251T0000|0 7|Sequence
14P10393251T0000|10 20|10q24 locus
14P10393251T0000|34 47|HOX11 oncogene
14P10393251T0000|78 92|T-ALL cell line
14P10393422A0476|19 23|LAMB2
14P10393422A0476|91 96|LAMB2L
14P10393910A0705|13 23|mutagenesis
14P10393910A0705|29 38|R2 protein
14P10393910A0705|105 116|endonuclease
14P10393969A0000|11 26|cell protein no.
14P10393969A0000|27 30|ICP0
14P10393969A0000|34 53|herpes simplex virus
14P10393969A0000|67 80|transactivator
14P10393969A0000|148 159|transfection
14P10394116T0000|0 16|Wrist measurement
14P10394116T0000|18 31|blood pressure
14P10394900A1166|55 69|enhancer region
14P10394900A1166|76 99|cauliflower mosaic virus
14P10394900A1166|99 102|CaMV
14P10394900A1166|104 115|35S promoter
14P10394919A1058|39 47|amplitude
14P10394919A1058|53 63|oscillation
14P10395199A0792|71 79|Y259 scFv
14P10395199A0792|135 145|Ras pathway
14P10395199A0792|160 175|tumor regression
14P10395199A0792|193 198|Cochet
14P10395199A0792|200 201|O.
14P10395199A0792|203 212|Kenigsberg
14P10395199A0792|214 215|M.
14P10395199A0792|217 224|Delumeau
14P10395199A0792|226 227|I.
14P10395199A0792|229 240|Virone-Oddos
14P10395199A0792|242 243|A.
14P10395199A0792|245 250|Multon
14P10395199A0792|252 255|M.C.
14P10395199A0792|257 263|Fridman
14P10395199A0792|265 268|W.H.
14P10395199A0792|270 282|Schweighoffer
14P10395199A0792|284 285|F.
14P10395199A0792|287 294|Teillaud
14P10395199A0792|296 299|J.L.
14P10395199A0792|301 306|Tocque
14P10395199A0792|308 309|B.
14P10395283A0960|39 42|OP-1
14P10395283A0960|60 64|Smad4
14P10395283A0960|83 95|concentration
14P10395283A0960|108 124|signal transducer
14P10395378A1198|53 76|HA envelope glycoprotein
14P10395378A1198|131 145|fusion activity
14P10395827A1297|19 43|parallel beta helix model
14P10395827A1297|98 116|parallel beta sheet
14P10395908A0236|88 118|amino acid motif characteristic
14P10395908A0236|121 130|R7G family
14P10395908A0236|132 140|G-protein
14P10395911A0288|0 15|Characterisation
14P10395911A0288|21 51|chicken apolipoprotein A-I gene
14P10395920A1424|35 44|ATF family
14P10395920A1424|99 106|KGF gene
14P10395920A1424|147 149|CRE
14P10396343A0754|26 38|blood samples
14P10396343A0754|114 116|DNA
14P10396343A0754|119 121|PCR
14P10396343A0754|131 145|T. b. gambiense
14P10396343A0754|155 171|T. b. rhodesiense
14P10396343T0000|40 57|agglutination test
14P10396343T0000|60 74|trypanosomiasis
14P10396343T0000|76 89|TrypTect CIATT
14P10396793A0815|0 6|Results
14P10396793A0815|56 74|dependence criteria
14P10396793A0815|86 95|reductions
14P10396793A0815|101 110|prevalence
14P10396793A0815|121 130|indicators
14P10396793A0815|133 150|alcohol dependence
14P10397257A1142|0 10|Mutagenesis
14P10397257A1142|16 31|CDE/CHR elements
14P10397257A1142|34 42|Sp1 sites
14P10397257A1142|154 175|cell cycle periodicity
14P10398286A0678|5 11|Scheffe
14P10398286A0678|27 38|illustration
14P10398286A0678|65 83|sample size methods
14P10398286A0678|124 126|S2p
14P10398682A0365|3 19|crystal structure
14P10398682A0365|24 32|VP16 core
14P10399136A0389|0 6|Ozagrel
14P10399136A0389|61 74|pentoxifylline
14P10399136A0389|96 98|HPC
14P10400032A0304|40 48|vena cava
14P10400032A0304|63 73|hypotension
14P10400032A0304|102 111|management
14P10400593A1084|11 15|PvirE
14P10400593A1084|18 41|Plac promoter constructs
14P10400593A1084|57 61|VirE2
14P10400712A0000|6 24|parainfluenza virus
14P10400712A0000|26 28|SV5
14P10400712A0000|47 68|Paramyxoviridae family
14P10400712A0000|96 106|RNA viruses
14P10400712A0577|27 28|GE
14P10400712A0577|30 31|IG
14P10400712A0577|36 47|GS sequences
14P10400712A0577|115 124|SV5 genome
14P10400712A0577|134 156|gene junction sequences
14P10400712A0577|156 157|GE
14P10400712A0577|159 160|IG
14P10400712A0577|165 176|GS sequences
14P10400712A0577|194 220|hemagglutinin-neuraminidase
14P10400712A0577|222 223|HN
14P10400712A0577|268 288|counterpart sequences
14P10400757A0000|0 4|CXCR4
14P10400757A0000|8 25|chemokine receptor
14P10400757A0000|61 62|X4
14P10400757A0000|79 82|R5X4
14P10400757A0000|89 115|immunodeficiency virus type
14P10400757A0000|116 120|HIV-1
14P10400757A1498|36 40|CXCR4
14P10400757A1498|83 95|HIV-1 strains
14P10400757A1498|115 133|mutagenesis efforts
14P10400757A1498|166 170|CXCR4
14P10400757A1498|184 188|HIV-1
14P10400760A0663|59 87|amino acid residues E960-A961
14P10400760A0663|86 96|E1071-S1072
14P10400760A0663|98 108|E1345-T1346
14P10400760A0663|113 123|E1419-G1420
14P10400760A0663|136 154|cleavage efficiency
14P10400774A0240|0 1|y.
14P10400785A0912|0 1|SM
14P10400785A0912|57 59|CRM
14P10400785A0912|92 101|GTPase Ran
14P10400785A0912|107 128|nucleoporin CAN/Nup214
14P10400794T0000|0 13|Identification
14P10400794T0000|32 37|Kaposi
14P10400794T0000|89 100|similarities
14P10400794T0000|109 125|membrane proteins
14P10400794T0000|129 130|2A
14P10402022A0432|8 13|clicks
14P10402022A0432|26 29|rate
14P10402467T0000|0 5|Myosin
14P10402467T0000|11 22|chain kinase
14P10402467T0000|43 49|Ras/ERK
14P10402467T0000|84 94|plasminogen
14P10403575A1401|15 37|StAR gene transcription
14P10403575A1401|38 42|DAX-1
14P10403690A0000|62 77|cell lung cancer
14P10403690A0000|77 81|NSCLC
14P10403690A0000|100 122|ECOG performance status
14P10403690A0000|122 123|PS
14P10403690A0000|185 187|BSC
14P10403690A0000|209 232|combination chemotherapy
14P10403690A0000|233 243|IEP regimen
14P10403690A0000|266 284|mesna uroprotection
14P10403690A0000|340 350|MVP regimen
14P10403839A0140|5 24|sequence information
14P10403839A0140|33 37|BMAL1
14P10403839A0140|133 147|splice variants
14P10403839A0140|152 162|mouse BMAL1
14P10403839A1459|0 9|Comparison
14P10403839A1459|17 37|bHLH/PAS family genes
14P10403839A1459|51 76|intron/exon splice pattern
14P10403839A1459|132 136|BMAL1
14P10403839A1459|140 142|Ahr
14P10405635A0374|18 27|activities
14P10405635A0374|73 91|deletion constructs
14P10406047A1244|29 39|differences
14P10406047A1244|148 158|lung volume
14P10406047A1244|163 173|ILD infants
14P10406047A1244|216 219|PPHN
14P10406047A1244|240 243|PFTs
14P10406047A1244|282 294|lung function
14P10406122T0000|32 43|LTR promoter
14P10406122T0000|48 75|tobacco retrotransposon Tto1
14P10406122T0000|125 140|methyl jasmonate
14P10406459A0000|54 57|PDGF
14P10406459A0000|60 93|12-O-tetradecanoyl-phorbol-acetate
14P10406459A0000|95 97|TPA
14P10406459A0000|119 122|CREB
14P10406459A0000|162 184|Ser-133 phosphorylation
14P10406459A0000|220 232|NIH 3T3 cells
14P10406462A1127|40 44|SRC-1
14P10406462A1127|79 90|OR1/RXRalpha
14P10406464A0687|11 33|mTRAP100 coprecipitates
14P10406464A0687|64 75|TRAP complex
14P10406464A0687|76 82|TRAP220
14P10406464A0687|114 131|vitamin D receptor
14P10406465A0589|23 25|VDR
14P10406465A0589|29 52|vitamin D responsiveness
14P10406466A0000|46 69|thyroid hormone receptor
14P10406466A0000|77 89|acid receptor
14P10406843A1265|0 9|Expression
14P10406843A1265|12 25|GlcNAc-TI mRNA
14P10406843A1265|56 61|RT-PCR
14P10406954A0715|0 23|Chemical stability tests
14P10406954A0715|59 74|amino acids H219
14P10406954A0715|76 78|D63
14P10406954A0715|81 84|RegS
14P10406954A0715|88 91|RegR
14P10407184A0149|2 15|overexpression
14P10407184A0149|51 58|AD brain
14P10407184A0149|100 113|neuropathology
14P10407184A0149|116 117|AD
14P10407184A0520|24 39|promoter regions
14P10407184A0520|62 74|reporter gene
14P10407184A0520|75 108|chloramphenicol acetyl transferase
14P10407184A0520|108 110|CAT
14P10407184A0520|159 173|promoter region
14P10407184A0520|195 197|URE
14P10407184A0520|252 266|promoter region
14P10407184A0520|275 277|URE
14P10407184A0520|304 320|hbetaAPP promoter
15P10407269A0000a|19 21|DNA
15P10407269A0000a|71 94|fission yeast chromosome
15P10407269A0000a|122 135|European Union
15P10407269A0000a|159 183|genome sequencing project
15P10407269A0000b|19 21|DNA
15P10407269A0000b|71 94|fission yeast chromosome
15P10407269A0000b|122 135|European Union
15P10407269A0000b|159 183|genome sequencing project
14P10407985A0574|0 4|G-CSF
14P10407985A0574|55 60|GM-CSF
14P10407985A0574|65 79|micrograms s.c.
14P10409656A1016|0 13|Overexpression
14P10409656A1016|16 24|H411 cDNA
14P10409656A1016|29 31|RAW
14P10409656A1016|37 56|macrophage cell line
14P10409656A1016|111 114|H411
14P10409656A1016|153 155|LPS
14P10409699A0292|14 32|sequence tag clones
14P10409699A0292|47 65|sequence similarity
14P10409699A0292|140 152|coding region
14P10409699A0292|165 183|mannosidase homolog
14P10409699A0292|218 230|amplification
14P10409699A0292|250 274|polymerase chain reaction
14P10409724A1021|0 9|Activation
14P10409724A1021|12 17|ERK1/2
14P10409730A0597|22 29|RP genes
14P10409730A0597|45 63|Rap1p binding sites
14P10409741A0382|34 37|CDC4
14P10409741A0382|89 103|division defect
14P10409741A0382|105 117|cdc20-1 cells
14P10409749T0000|0 3|Role
14P10409749T0000|26 39|discrimination
14P10409755A1846|10 11|Ca
14P10409755A1846|38 50|NO production
14P10409755A1846|72 82|TG exposure
14P10409755A1846|84 95|JT/Neo cells
14P10411139A0887|0 11|Accumulation
14P10411139A0887|17 28|U4/U6 duplex
14P10411139A0887|66 71|Prp44p
14P10411139A1344|82 87|Prp44p
14P10411139A1344|104 114|U4/U6 helix
14P10411140A0499|23 25|RNA
14P10411140A0499|42 57|RNase E cleavage
14P10411160T0000|48 68|skin cancer incidence
14P10413604A0063|50 53|PKAs
14P10413604A0063|138 150|DNA synthesis
14P10413607A0085|55 70|matrix molecules
14P10413607A0085|99 101|CVI
14P10413607A0085|115 127|DNA synthesis
14P10413607A0085|197 215|signal transduction
14P10413662A0193|34 58|pMJ101 replication region
14P10413662A0193|107 129|iron acquisition system
14P10413662A0193|153 166|V. anguillarum
14P10413676A0000|0 2|FAK
14P10413676A0000|21 62|transmembrane integrin receptor clustering
14P10413676A0595|0 9|Expression
14P10413676A0595|19 29|FAK mutants
14P10413676A0595|34 36|FAK
14P10413676A0595|53 71|FAK kinase activity
14P10413676A0595|74 80|Tyr-397
14P10413676A0595|82 91|SH2 domain
14P10413676A0595|126 143|SH3 binding region
14P10413676A0595|147 149|FAK
14P10413676A0595|213 215|FAK
14P10413676A0595|232 233|FN
14P10413676A0595|264 266|FAK
14P10413676A1193|29 32|FRNK
14P10413676A1193|61 68|Leu-1034
14P10413676A1193|71 73|Ser
14P10413676A1193|89 105|FRNK localization
14P10414451A0093|49 51|DVT
14P10414451A0093|114 118|APC-R
14P10414451A0093|121 139|lupus anticoagulant
14P10414451A0093|140 141|LA
14P10414451A0093|204 219|ATIII activities
14P10416429A0221|0 5|DESIGN
14P10416429A0221|7 16|Comparison
14P10416429A0221|36 38|PKU
14P10416429A0221|58 73|NSW PKU database
14P10416429A0221|117 131|population data
14P10416558A0000|0 6|PURPOSE
14P10416558A0000|88 103|exercise program
14P10416558A0000|129 142|CD4 cell count
14P10416558A0000|163 175|health status
14P10416558A0000|281 296|exercise relapse
14P10417331A1008|3 8|enzyme
14P10417331A1008|24 31|activity
14P10417331A1008|42 52|mM pantoate
14P10417703A1326|44 45|RP
14P10417703A1326|54 67|20S proteasome
14P10417703A1326|139 156|plant RPT subunits
14P10417703A1326|165 182|yeast counterparts
14P10419006A0378|34 61|estrogen replacement therapy
14P10419006A0378|83 100|breast cancer risk
14P10419521A0136|15 33|elongation activity
14P10419521A0136|34 36|ELL
14P10419521A0136|57 70|RNA polymerase
14P10419521A0136|72 89|interaction domain
14P10419521A0136|114 132|polymerase activity
14P10422291A0572|12 21|IgA lambda
14P10422291A0572|50 60|involvement
14P10422342A0535|3 18|radiation burden
14P10422342A0535|45 56|examinations
14P10422342A0535|120 135|radiation burden
14P10422342A0535|152 163|examinations
14P10422342A0535|174 187|administration
14P10422342A0535|190 201|preparations
14P10422342A0535|206 209|131I
14P10422342A0535|211 215|201Tl
14P10422342A0535|217 220|67Ga
14P10422342A0535|224 228|111In
14P10422468A0524|17 28|malformation
14P10422468A0524|48 51|ICSI
14P10422468A0524|105 117|abnormalities
14P10422468A0524|126 128|NOA
14P10422468A0524|145 158|sex chromosome
14P10422468A0524|161 174|microdeletions
14P10422468A0524|180 191|Y chromosome
14P10422468A0524|213 214|OA
14P10422468A0524|236 248|fibrosis gene
14P10423156A0265|0 12|TaV particles
14P10423156A0265|45 48|CsCl
14P10423156A0265|64 78|capsid proteins
14P10423193A1309|0 9|CONCLUSION
14P10423193A1309|123 125|CTS
14P10423292A0782|28 32|Spam1
14P10423292A0782|71 90|transcription factor
14P10423292A0782|112 114|CRE
14P10425094A1006|10 19|relaxivity
14P10425094A1006|25 31|complex
14P10425445T0000|27 91|mouse growth hormone receptor/growth hormone binding protein gene
14P10426450A1458|19 20|SA
14P10426450A1458|59 72|contact poults
14P10426450A1458|75 76|SG
14P10426450A1458|81 94|contact chicks
14P10426450A1458|105 107|ILK
14P10426450A1458|155 168|contact poults
14P10426878A0367|15 26|ISIS-2 trial
14P10426878A0367|55 63|Trialists
14P10426878A0367|65 77|Collaboration
14P10427654A0000|58 68|laparoscopy
14P10427654A0000|86 92|staging
14P10427654A0000|95 102|patients
14P10427654A0000|107 120|adenocarcinoma
14P10427654A0000|126 134|esophagus
14P10427654A0000|191 197|surgery
14P10428091A0322|32 35|MMRs
14P10428091A0322|69 79|disparities
14P10428294A0227|0 24|Preheparin LPL mass level
14P10428759A0743|26 49|receptor kinase activity
14P10428811A0628|0 4|Cat-1
14P10428811A0628|39 53|binding partner
14P10428811A0628|74 88|receptor kinase
14P10428811A0628|98 102|GRK-2
14P10428811A1067|0 11|Cat proteins
14P10428811A1067|72 90|adhesion kinase Fak
14P10428811A1067|92 94|Src
14P10428862A0834|0 30|Immunoprecipitation experiments
14P10428862A0834|96 99|DokR
14P10428862A0834|163 173|BaF/3 cells
14P10429184A0000|0 8|Expansins
14P10429184A0000|69 84|plant cell walls
14P10429740A0000|75 88|bowel syndrome
14P10429740A0000|89 91|IBS
14P10429946A0473|13 18|region
14P10429946A0473|33 45|collagen gene
14P10429946A0473|60 67|fragment
14P10429946A0473|89 96|promoter
14P10429946A0473|112 120|sequences
14P10429946A0473|147 154|elements
14P10429946A0988|22 69|B-Myb-glutathionine S-transferase fusion protein
14P10430421T0000|0 18|APOE-epsilon4 count
14P10430421T0000|45 56|AD increases
14P10430421T0000|73 90|Cache County Study
14P10430580A0000|0 5|Repair
14P10430580A0000|8 27|double-strand breaks
14P10430580A0000|28 31|DSBs
14P10430580A0000|46 48|DNA
14P10430580A0000|76 79|NHEJ
14P10430583A0000|4 18|DNA repair gene
14P10430583A0000|59 62|RecA
14P10430883A0000|53 59|Brunner
14P10430883A0000|217 219|Con
14P10430883A0000|258 285|sodium borohydride reduction
14P10430883A0000|285 289|Con A
14P10430883A0000|293 323|horseradish peroxidase reaction
14P10430886A0838|44 47|TraR
14P10430886A0838|74 88|heteromultimers
14P10430890A1059|76 89|rearrangements
14P10430890A1059|115 130|partner proteins
14P10430944A1298|16 33|JAK/STAT signaling
14P10430980A0465|20 24|women
14P10433729A1559|0 1|A.
14P10433729A1559|3 8|Bowers
14P10433729A1559|10 12|K.E
14P10433729A1559|17 24|Matthews
14P10433729A1559|26 27|C.
14P10433970A0279|55 72|DNA binding domain
14P10433970A0279|79 97|localization signal
14P10433970A0279|100 121|transactivation domain
14P10435595A0203|35 50|trans-activation
14P10436016A0337|0 13|Gel filtration
14P10436016A0337|16 46|co-immunoprecipitation analyses
14P10436016A0337|89 116|spindle checkpoint component
14P10437043A0164|0 6|METHODS
14P10437043A0164|29 30|SS
14P10438540A1185|31 44|domain mutants
14P10438540A1185|51 52|Cd
14P10438540A1185|86 103|transport activity
14P10438593A0000|8 36|immunodeficiency virus type-1
14P10438593A0000|36 40|HIV-1
14P10438593A0000|87 113|RNA polymerase processivity
14P10438607A0330|10 14|SEBPs
14P10438607A0330|16 20|SEBP2
14P10438627A0885|0 16|Identity elements
14P10438627A0885|104 117|T7 transcripts
14P10438627A0885|136 138|Asp
14P10438627A0885|148 150|Phe
14P10438924A1009|60 109|serine/threonine kinase glycogen synthase kinase-3
14P10438924T0000|3 25|B cell antigen receptor
14P10438924T0000|55 98|glycogen synthase kinase-3 signaling pathway
14P10438924T0000|98 126|phosphatidylinositol 3-kinase
14P10438941A1197|5 24|recombination events
14P10438941A1197|54 65|T cell lines
14P10438941A1197|80 99|switch recombination
14P10438950A0580|0 3|IL-1
14P10438950A0580|7 43|TNF increase AND-34 transcript levels
14P10439040A0658|35 50|c-myc expression
14P10439040A0658|80 82|UTR
14P10439040A0658|102 114|CAT reporters
14P10440923A0684|0 7|Analysis
14P10440923A0684|10 28|cell cycle proteins
14P10440923A0684|42 61|lovastatin treatment
14P10440923A0684|66 78|control cells
14P10440923A0684|127 146|kinase inhibitor p27
14P10440923A0684|196 210|kinase activity
14P10440923A0684|250 271|retinoblastoma protein
14P10441243A0443|0 6|RESULTS
14P10441243A0443|19 39|leptin concentrations
14P10441449X1212|0 8|Copyright
14P10441449X1212|13 26|Academic Press
14P10441483A0454|0 21|Oligonucleotide probes
14P10441483A0454|54 67|EpRE sequences
14P10441506A0098|0 6|PKNbeta
14P10441506A0098|14 30|sequence homology
14P10441506A0098|34 41|PKNalpha
14P10441506A0098|61 63|PKN
14P10441506A0098|148 160|CZ region/HR1
14P10441506A0098|221 238|amino acid stretch
14P10441506A0098|238 249|D region/HR2
14P10441506A0098|265 277|CZ region/HR1
14P10442493A0815|11 22|serum levels
14P10442493A0815|35 38|FLOP
14P10442493A0815|99 124|plasma cyclosporine levels
14P10443990A0000|0 9|BACKGROUND
14P10443990A0000|18 36|alcohol consumption
14P10444597A0586|23 31|induction
14P10444597A0586|42 51|heat shock
14P10444597A0586|71 80|conditions
14P10444597A0586|95 105|mRNA export
14P10444597A0586|115 119|Npl3p
14P10444813A0448|49 71|metastases interferon-a
14P10444813A0448|74 95|somatostatin analogues
14P10445161A1565|89 99|weight gain
14P10445161A1565|123 142|organ weight changes
14P10445506A0073|54 64|body length
14P10445945T0000|0 18|John leonard dawson
14P10446131A0132|0 18|PDGF A-chain levels
14P10446131A0132|61 64|SMCs
14P10446131A0132|75 78|ATII
14P10446149A0809|56 68|Ras effectors
14P10446149A0809|86 90|A-Raf
14P10446149A0809|92 96|B-Raf
14P10446149A0809|98 127|phosphoinositol-3 kinase delta
14P10446149A0809|127 132|RalGDS
14P10446149A0809|137 140|Rin1
14P10446206A0000|0 15|Deletion mapping
14P10446206A0000|38 40|PS1
14P10446206A0000|110 133|transcription start site
14P10446206A0000|161 181|neuroblastoma SK-N-SH
14P10446206A0000|184 203|hepatoma HepG2 cells
14P10446833T0000|16 26|oxygenation
14P10446833T0000|30 37|shunting
14P10446910A0147|0 7|Analysis
14P10446910A0147|13 30|E2F1 gene promoter
14P10446910A0147|71 87|E2-responsiveness
14P10446910A0147|99 117|transfection assays
14P10446910A0147|131 156|deletion/mutation analysis
14P10446910A0147|254 255|E2
14P10446912A0883|46 48|OF5
14P10446912A0883|52 54|OF3
14P10446912A0883|64 84|CYP11A1 transcription
14P10446912A0883|96 98|OF5
14P10446912A0883|102 104|OF3
14P10446912A0883|121 131|JEG-3 cells
14P10446998A0375|14 28|differentiation
14P10446998A0375|84 97|responsiveness
14P10446998A0375|106 123|c-fos inducibility
14P10446998A0955|0 24|Adipocyte differentiation
14P10446998A0955|78 80|SRF
14P10446998A0955|120 123|SREs
14P10446998A0955|155 175|gel supershift assays
14P10446998A0955|194 220|DNA binding characteristics
14P10446998T0000|0 13|Transformation
14P10446998T0000|55 88|serum response factor interactions
14P10446998T0000|90 112|serum response elements
14P10447593A0144|34 50|bacteriophages T3
14P10447593A0144|51 52|T7
14P10447593A0144|56 58|SP6
14P10447593A0144|69 86|specificity factor
14P10447597A1004|3 15|Cr.psbA-4 ORF
14P10447597A1004|48 60|GIY-YIG motif
14P10448036A0748|37 41|S RNA
14P10448036A0748|74 97|competitor concentration
14P10448036A0748|114 130|S RNA interaction
14P10448036A0748|208 222|RNA interaction
14P10448095A0865|3 27|STAT protein accumulation
14P10448095A0865|39 54|C/EBP expression
14P10448095A0865|139 156|expression profile
14P10448285A1035|9 17|durations
14P10448285A1035|21 28|response
14P10448285A1035|32 44|survival time
14P10448440T0020|33 54|understanding patients
14P10448440T0020|65 77|schizophrenia
14P10448440T0020|86 105|personality disorder
14P10448902A0921|38 59|glutathione peroxidase
14P10448902A0921|62 81|superoxide dismutase
14P10449072A0560|57 59|GPi
14P10449072A0560|62 63|PD
14P10449899A0881|50 58|PERV copy
14P10449899A0881|61 76|integration site
14P10450815A0180|10 22|investigation
14P10450815A0180|35 44|population
14P10450815A0180|63 73|individuals
14P10450815A0180|79 87|age range
14P10450815A0180|124 135|relationship
14P10450815A0180|143 157|tobacco smoking
14P10450815A0180|173 180|calculus
14P10450815A0180|264 275|inflammation
14P10451209A0000|0 8|OBJECTIVE
14P10451209A0000|115 149|methylprednisolone sodium succinate
14P10451209A0000|149 152|MPSS
14P10452306A0502|0 7|Patients
14P10452306A0502|30 40|MIBG uptake
14P10452306A0502|52 79|norepinephrine concentration
14P10452306A0502|80 83|LVEF
14P10452306A0502|118 123|M-mode
14P10452306A0502|170 201|heart catheterization parameters
14P10452951A0000|7 23|hormone receptors
14P10452951A0000|24 26|NRs
14P10452951A0000|47 67|transcription factors
14P10452991A0331|27 51|influenza virus particles
14P10452991A0331|70 82|T cell clones
14P10453006A0000|0 9|Sequencing
14P10453006A0000|22 32|Danio rerio
14P10453006A0000|65 66|P1
14P10453006A0000|94 108|clone fragments
14P10453006A0000|134 147|identification
14P10453006A0000|170 182|beta subunits
14P10453006A0000|196 199|PSMB
14P10453006A0478|49 53|PSMB9
14P10453006A0478|67 72|PSMB11
14P10453006A0478|76 81|PSMB12
14P10453248A0094|9 12|Udry
14P10453248A0094|24 34|perspective
14P10453371A0640|0 5|Weight
14P10453371A0640|54 65|BMD z-scores
14P10453721A0445|47 76|parameter estimation algorithm
14P10453721A0445|90 114|ADAPT II software package
14P10454533A0859|0 10|Interaction
14P10454533A0859|13 15|HRI
14P10454533A0859|20 24|Hsc70
14P10454533A0859|58 60|HRI
14P10454533A0859|67 82|Hsc70 antagonist
14P10454533A0859|116 118|HRI
14P10454540A0392|3 26|amino acid changes D206A
14P10454540A0392|27 31|D208A
14P10454540A0392|63 82|exonuclease activity
14P10454550A0960|44 47|Reg1
14P10454550A0960|59 62|Glc7
14P10454550A0960|91 109|Snf1 kinase complex
14P10454557A0000|118 120|ARS
14P10454557A0000|166 169|ARSs
14P10454557A0000|200 213|HML locus show
14P10454557A0000|214 240|replication origin activity
14P10454557A0975|30 44|HML ARS cluster
14P10454557A0975|44 49|ARS303
14P10454557A0975|51 56|ARS320
14P10454557A0975|61 66|ARS302
14P10454561A0594|47 61|TD-IkappaBalpha
14P10454561A0594|69 112|phorbol myristate acetate-phytohemagglutinin
14P10454561A0594|145 175|IkappaBalpha gene transcription
14P10454561A0594|186 215|NF-kappaB DNA binding activity
14P10454561A0594|262 264|p65
14P10454561A0594|268 282|TD-IkappaBalpha
14P10454568A0815|11 26|Grb10 expression
14P10454568A0815|67 83|expression system
14P10454568A0815|93 99|PDGF-BB
14P10454568A0815|102 106|IGF-I
14P10454568A0815|147 149|EGF
14P10454568A0815|159 171|DNA synthesis
14P10454570A0846|41 63|protein kinase pathways
14P10454570A0846|87 104|protein kinase-Jun
14P10454570A0846|114 130|kinase activation
14P10454570A0846|145 159|phosphorylation
14P10454570A0846|162 166|ATF-2
14P10454570A0846|177 180|JunD
14P10454570A0846|205 208|IL-1
14P10454570A0846|289 293|ERK-1
14P10454570A0846|298 313|ERK-2 activation
14P10454570A0846|328 330|TPA
14P10455087A1400|0 10|CONCLUSIONS
14P10455087A1400|38 61|body insulin sensitivity
14P10455143T0000|0 20|Interdomain signaling
14P10455143T0000|51 73|glucocorticoid receptor
14P10455183A0530|20 22|Sec
14P10455183A0530|53 69|Staf zinc fingers
14P10455183A0530|75 79|Oct-1
14P10455183A0930|61 76|Staf zinc finger
14P10455183A0930|130 149|activation mechanism
14P10455183A0930|155 166|Xenopus tRNA
14P10455183A0930|167 169|Sec
14P10455183A0930|179 192|U6 snRNA genes
14P10455189A0104|2 8|B cells
14P10455189A0104|9 12|HEF1
14P10455189A0104|80 96|integrin ligation
14P10455189A0427|21 44|tyrosine phosphorylation
14P10455189A0427|46 49|HEF1
14P10457075A1198|0 39|Independent protrudor muscle stimulation
14P10457075A1198|46 47|VI
14P10457075A1198|89 93|Pcrit
14P10457075A1198|107 108|Rn
14P10458905A0000|60 79|YAC/BAC clone contig
14P10458907A0543|8 13|RAD30B
14P10458907A0543|17 45|mouse Rad30b mRNA transcripts
14P10458914A0674|0 7|Analysis
14P10458914A0674|13 27|mouse STAP gene
14P10458914A0674|70 78|STAP gene
14P10459809A1262|8 26|matrix distribution
14P10459809A1262|37 48|cell density
14P10460015A0465|15 23|treatment
14P10460015A0465|78 88|improvement
14P10460015A0465|98 117|bone mineral density
14P10460171A0842|0 20|Viscosity experiments
14P10460171A0842|34 57|fragment kinase reaction
14P10460171A0842|84 102|phosphoryl transfer
14P10460172A0823|0 21|Velocity sedimentation
14P10460172A0823|39 66|immunoprecipitation analyses
14P10463057A0534|7 23|expression levels
14P10463242A0316|2 4|EEG
14P10464185T0000|48 80|polysaccharide biosynthesis genes
14P10464185T0000|81 112|Streptococcus agalactiae type Ia
14P10464250A0275|6 13|FASEB J.
14P10464291A0597|0 7|IL-1beta
14P10464291A0597|41 50|PDGFalphaR
14P10464291A0597|76 88|protein delta
14P10464291A0597|89 98|C/EBPdelta
15P10464302A1109b|44 47|p185
15P10464302A1109b|77 92|pathway proteins
15P10464302A1109b|120 135|interaction site
15P10464302A1109b|210 221|transmission
15P10464302A1109b|224 243|growth factor signal
15P10464302A1109b|247 258|cytoskeleton
14P10464310A0218|9 32|tyrosine phosphorylation
14P10464310A0218|39 55|fibroblast growth
14P10464310A0218|107 136|juxtamembrane tyrosine residue
14P10464310A0218|140 145|FGFR-1
14P10464310A0218|151 164|Crk SH2 domain
14P10464310A0218|175 180|FGFR-1
14P10464310A0218|198 204|Tyr-463
14P10464310A0218|222 238|complex formation
14P10464310A0218|251 256|FGFR-1
14P10466306A0000|19 48|Technetium-99m sestamibi SPECT
14P10466825T0000|0 3|Role
14P10466825T0000|31 50|baculovirus p10 mRNA
14P10467004A0116|26 36|nucleotides
14P10467004A0116|94 108|sequence motifs
14P10467004A0116|131 136|Michel
14P10467004A0683|53 61|EBS1/IBS1
14P10467004A0683|68 92|EBS2/IBS2 sequence motifs
14P10467403A0000|3 34|Trk/Nerve Growth Factor receptor
14P10467403A0000|109 137|phosphatidylinositol 3-kinase
14P10467403A0000|138 148|PI 3-kinase
14P10467465T0000|16 35|significance testing
14P10467465T0000|36 49|misconceptions
14P10468033T0000|0 14|Chemical uptake
14P10468033T0000|23 37|stratum corneum
14P10468585A0980|4 14|DNA binding
14P10468585A0980|77 95|amino acid residues
14P10468585A0980|129 133|Hap46
14P10468585A0980|154 170|hsp70 interaction
14P10469140A0336|68 72|PAI-2
14P10469140A0336|108 115|TNFalpha
14P10469140A0336|121 177|chloramphenicol acetyl transferase reporter gene deletion
14P10469174A0678|10 26|sequence analysis
14P10469174A0678|29 44|NMR measurements
14P10469174A0678|107 110|MBF1
14P10469174A0678|151 154|MBF1
14P10469174A0678|156 162|MBF1CTD
14P10469656T0000|88 106|MAP kinase cascades
14P10469656T0000|106 109|MSK1
14P10470220A1011|3 13|arrangement
14P10470220A1011|21 33|cutoff-levels
14P10470220A1011|42 52|sensitivity
14P10470220A1011|61 71|specificity
14P10470220A1011|80 91|Protein S100
14P10470220A1011|105 107|RIA
14P10470220A1011|115 125|sensitivity
14P10470220A1011|134 144|specificity
14P10470220A1011|164 166|LIA
14P10471587A0239|16 29|C. trachomatis
14P10471587A0239|31 47|triplicate assays
14P10471587A0239|58 70|RT-PCR method
14P10471587A0239|168 171|MICs
14P10471587A0239|184 189|RT-PCR
14P10471696A0734|13 16|SAS4
14P10471696A0734|20 23|SAS5
14P10471696A0734|44 61|Abf1p binding site
14P10471696A0734|65 78|HMR-E silencer
14P10471696A0734|96 98|ACS
14P10471696A0734|101 118|Rap1p binding site
14P10471721A0141|41 47|S locus
14P10471721A0141|95 97|SLG
14P10471721A0141|99 101|SRK
14P10471721A0141|125 137|pollen S gene
14P10471743A0000|22 24|RNA
14P10471743A0000|31 42|DNA helicase
14P10471743A0000|61 95|Arabidopsis thaliana cDNA libraries
14P10471746A1102|45 64|chromatin remodeling
14P10471746A1102|69 85|Myogenin promoter
14P10471746A1102|98 119|Myogenin transcription
14P10472314A0717|0 6|RESULTS
14P10472314A0717|11 17|Periods
14P10472314A0717|20 22|TTP
14P10472314A0717|25 28|PUNP
14P10472836A0189|0 10|Feed intake
14P10472836A0189|13 20|BW gains
14P10472836A0189|70 71|M.
14P10473589A0189|3 12|N terminus
14P10473589A0189|50 65|integrase domain
14P10473589A0189|78 87|C terminus
14P10473598A0691|0 5|Skn-1a
14P10473598A0691|46 68|transactivation ability
14P10473598A0691|118 132|transactivation
14P10473598A0691|141 146|Skn-1a
14P10473598A0691|149 166|competition assays
14P10473623A0081|7 21|Xenopus embryos
14P10473623A0081|37 69|growth factor-beta member activin
14P10473623A0081|159 161|ARF
14P10474898A0629|62 77|CMT1A-REP repeat
14P10474898A0629|95 107|hybridization
14P10474898A0629|109 112|FISH
14P10475610A1289|0 4|Natl.
14P10475972A0269|14 21|outbreak
14P10475972A0269|43 53|vaccination
14P10476970A0542|29 32|Rapl
14P10476970A0542|96 109|alpha-subunits
14P10476970A0542|141 150|G-proteins
14P10477545T0000|3 12|B-oligomer
14P10477545T0000|40 60|CC chemokine receptor
14P10477545T0000|84 96|HIV-1 strains
15P10477583A0000a|16 33|B cell Ag receptor
15P10477583A0000a|32 34|BCR
15P10477583A0000a|45 56|Fc receptors
15P10477583A0000a|59 61|IgG
15P10477583A0000a|63 72|Fc gamma R
15P10477583A0000b|16 33|B cell Ag receptor
15P10477583A0000b|32 34|BCR
15P10477583A0000b|45 56|Fc receptors
15P10477583A0000b|59 61|IgG
15P10477583A0000b|63 72|Fc gamma R
14P10477597A0126|0 4|TRAF2
14P10477597A0126|32 54|serine/threonine kinase
14P10477597A0126|88 91|GCKR
14P10477597A0126|109 112|KHS1
14P10477597A0126|142 153|SAPK pathway
14P10477599T0000|38 46|C motif-1
14P10477599T0000|47 67|lymphotactin promoter
14P10477599T0000|111 122|interactions
14P10477599T0000|156 161|T cell
14P10477620A0580|16 46|NF-kappa B DNA binding activity
14P10477620A0580|69 95|I kappa B alpha degradation
14P10477620A0580|93 108|I kappa B serine
14P10477620A0580|127 142|I kappa B kinase
14P10477620A0580|141 143|IKK
14P10477748A1076|10 13|p193
14P10478275A1230|7 12|issues
14P10478275A1230|33 38|number
14P10478275A1230|53 62|mechanisms
14P10478275A1230|158 167|technology
14P10478275A1230|185 192|contrast
14P10478844A1604|0 13|Cotransfection
14P10478844A1604|87 97|PPARalphawt
14P10478844A1604|100 110|PPARalphatr
14P10478844A1604|153 163|PPARalphatr
14P10478848A0331|0 3|SF-1
14P10478848A0331|27 36|AF1 domain
14P10479025A0528|38 55|TF-MUSIC algorithm
14P10479025A0528|69 81|target region
14P10479382A1098|33 41|influence
14P10479382A1098|64 74|constraints
14P10479382A1098|88 107|development patterns
14P10479492A0000|0 8|OBJECTIVE
14P10479492A0000|14 25|Surveillance
14P10479492A0000|27 38|Epidemiology
14P10479492A0000|43 53|End Results
14P10479492A0000|54 57|SEER
14P10479492A0000|99 136|corpus uteri adenocarcinoma FIGO stage
14P10480937A0000|6 39|Drosophila A kinase anchor protein
14P10480937A0000|47 69|A kinase anchor protein
14P10480937A0000|71 78|DAKAP200
14P10480937A0000|190 194|Rossi
14P10482516A1158|7 27|transcription results
14P10482516A1158|45 63|structure functions
14P10482516A1158|68 88|attenuation mechanism
14P10482516A1158|134 158|transcription readthrough
14P10482516T0000|3 15|RNA stem-loop
14P10482516T0000|32 66|transcription attenuation mechanism
14P10482516T0000|92 125|Bacillus subtilis trpEDCFBA operon
14P10482565A0469|27 35|mutations
14P10482565A0469|53 59|effects
14P10482620A1009|49 52|MMTV
14P10482620A1009|55 57|LTR
14P10482620A1009|86 91|Stat5a
14P10482620A1009|94 113|transcription factor
14P10482620A1009|174 181|MMTV LTR
14P10483124T0000|50 69|CIC5F11/CIC2B9 locus
14P10483124T0000|71 101|Arabidopsis thaliana chromosome
14P10483124T0000|109 124|Ac/Ds transposon
14P10483124T0000|144 163|cDNA scanning method
14P10483945A0641|0 6|RESULTS
14P10483945A0641|8 22|CK-MB elevation
14P10483945A0641|58 61|1-3x
14P10483945A0641|70 73|3-5x
14P10483945A0641|84 85|5x
14P10484695A0791|5 22|NART-R performance
14P10484695A0791|103 121|language impairment
14P10484818A0292|41 66|cross-correlation analysis
14P10485353T0000|7 35|Haemophilus influenzae type b
14P10485353T0000|41 65|polysaccharide antibodies
14P10485353T0000|92 102|West Africa
14P10485353T0000|103 114|Burkina-Faso
14P10485353T0000|119 124|France
14P10485470A0242|59 67|Sp1 sites
14P10485470A0242|72 93|p21/WAF1/Cip1 promoter
14P10485470A0242|95 104|MG63 cells
14P10485470A0242|126 146|mobility shift assays
14P10485470A0242|158 170|TSA treatment
14P10485470A0242|187 204|binding activities
14P10485585A0175|0 6|Galoyan
14P10485585A0175|58 70|neurohormones
14P10486210A0126|44 66|aldehyde reductase gene
14P10487040A0453|31 35|MIB-1
14P10487040A0453|39 52|p53 antibodies
14P10487217A0735|3 9|C2C-Prx
14P10487217A0735|37 47|amino acids
14P10487217A0735|97 107|amino acids
14P10487217A0735|112 121|N-terminus
14P10487307A0768|17 32|surgery patients
14P10487307A0768|57 70|hydrocortisone
14P10487744T0000|15 28|sorting signal
14P10487744T0000|33 46|beta2 integrin
14P10487744T0000|88 102|plasma membrane
14P10487753A0788|14 26|XDRP1 protein
14P10487753A0788|40 51|Xenopus eggs
14P10487759A0630|15 29|Xenopus embryos
14P10487759A0630|119 123|Xbra2
14P10487759A0630|139 151|reporter gene
14P10487760A0336|22 30|cofactors
14P10487760A0336|76 88|Xenopus MEF2D
14P10487762A0252|0 3|NuA4
14P10487762A0252|35 37|MDa
14P10487921A0132|0 17|ATF1 transcription
14P10487953A0765|37 53|S-phase fractions
14P10488087A0340|0 7|Mutation
14P10488087A0340|29 31|TBE
14P10488087A0340|96 99|SP-A
14P10488087A0340|124 151|acetyltransferase constructs
14P10488087A0340|161 179|SP-A gene sequences
14P10488088T0000|12 26|growth factor-I
14P10488088T0000|33 46|bcl-2 promoter
14P10488088T0000|56 75|transcription factor
14P10488129T0058|0 8|Synthesis
14P10488129T0058|20 22|RNA
14P10488129T0058|51 63|E2F complexes
14P10488147A1176|0 13|Identification
14P10488147A1176|46 58|understanding
14P10488147A1176|73 94|eosinophil trafficking
14P10488148A0111|0 8|NF-kappaB
14P10488148A0111|41 61|HIV-1 gene expression
14P10488148A0111|93 120|signal transduction pathways
14P10488148A1267|23 26|MAPK
14P10488148A1267|44 47|AP-1
14P10488148A1267|96 99|AP-1
14P10488148A1267|104 112|NF-kappaB
14P10488148A1267|169 177|HIV-1 LTR
14P10488148T0000|0 36|ERK MAP kinase links cytokine signals
14P10488148T0000|52 66|HIV-1 infection
14P10488148T0000|104 107|AP-1
14P10488148T0000|111 119|NF-kappaB
14P10488337T0000|58 68|DNA binding
14P10488337T0000|97 109|bZIP proteins
14P10488875A0000|8 22|differentiation
14P10488875A0000|63 64|CP
14P10488875A0000|90 92|ITW
14P10489680A0927|0 10|Sputum IL-8
14P10489680A0927|13 15|MPO
14P10489680A0927|47 49|BPT
14P10489680A0927|56 58|TDI
14P10489680A0927|63 79|grain dust-asthma
14P10489822T0000|0 10|Montelukast
14P10489822T0000|36 47|inflammation
14P10490065T0000|0 8|Treatment
14P10490604A0601|55 57|Fyn
14P10490604A0601|59 61|Lck
14P10490604A0601|66 81|ZAP-70 block 70Z
14P10490604A0601|92 106|NFAT activation
14P10490609A0413|0 12|Substitutions
14P10490609A0413|138 149|interruption
14P10490609A0413|187 198|ARS activity
14P10490639A0000|26 30|PHO85
14P10490639A0000|55 68|protein kinase
14P10490639A0000|69 71|Cdk
14P10490639A0000|162 176|cyclin partners
14P10490639A0000|177 180|Pcls
14P10490662A0431|0 6|Mutants
14P10490662A0431|15 26|lace alleles
14P10490662A0431|64 75|morphologies
14P10490662A0431|92 103|compound eye
14P10490662A0819|7 18|SPT activity
14P10490662A0819|50 53|Lace
14P10490816A0000|14 21|RET gene
14P10490816A0000|31 54|receptor tyrosine kinase
14P10490816A0000|88 110|cancer syndromes MEN 2A
14P10490816A0000|111 116|MEN 2B
14P10490822A1167|31 37|Ras-GAP
14P10490826T0000|0 3|EB-1
14P10490826T0000|6 45|tyrosine kinase signal transduction gene
14P10490826T0000|96 98|ALL
14P10490826T0000|112 131|oncoprotein E2a-Pbx1
14P10490835T0000|0 22|Protein kinase A-Ialpha
14P10490835T0000|95 127|tyrosine kinase signaling pathway
14P10490843A0159|0 3|BCL6
14P10490843A0159|12 32|POZ/Zn finger protein
14P10490843A0159|153 156|PLZF
14P10490955T0000|51 74|T lymphoma cell adhesion
14P10490955T0000|92 115|protein kinase signaling
14P10490955T0000|135 159|thrombospondin-1 peptides
14P10491133A0365|0 9|Optical CD
14P10491133A0365|69 79|HO isozymes
14P10491133A0365|83 92|NO species
14P10491133A0365|102 110|NO donors
14P10491187T0000|3 27|phosphotransferase system
14P10491187T0000|28 30|PTS
14P10491187T0000|95 130|histidine phosphocarrier protein HPr
14P10491213A0263|0 19|Serum concentrations
14P10491213A0263|33 52|alkaline phosphatase
14P10491213A0263|53 56|BALP
14P10491213A0263|61 71|osteocalcin
14P10491213A0263|73 88|bone Gla protein
14P10491213A0263|88 90|BGP
14P10491213A0263|108 119|pyridinoline
14P10491213A0263|121 123|Pyr
14P10491213A0263|128 144|deoxypyridinoline
14P10491213A0263|146 149|Dpyr
14P10491213A0263|173 174|CT
14P10491213A0263|176 187|measurements
14P10491213A0263|307 322|material density
14P10492127A0914|26 39|administration
14P10492127A0914|62 98|cholecystokinin-A receptor antagonist
14P10492127A0914|149 161|saline intake
14P10492169A0939|45 48|ESTs
14P10492169A0939|81 96|plasma protein-A
14P10492169A0939|97 102|PAPP-A
14P10492169A0939|134 140|EST-YD1
14P10493203T0000|18 41|treadmill exercise score
14P10493203T0000|102 104|ECG
14P10493575T0000|22 31|C-terminus
14P10493575T0000|34 36|Ca2
14P10493575T0000|125 127|p53
14P10493580A1126|13 17|Gly84
14P10493580A1126|36 48|oxyanion hole
14P10493580A1126|62 74|stabilization
14P10493580A1126|80 95|transition state
14P10493580A1126|107 113|C group
14P10493580A1126|118 139|esterase/lipase family
14P10493876A0000|3 20|solution structure
14P10493876A0000|65 76|fjord region
14P10493876A0000|81 83|11S
14P10493876A0000|85 87|12R
14P10493876A0000|89 91|13R
14P10493876A0000|93 95|14S
14P10493876A0000|97 108|stereoisomer
14P10493876A0000|122 133|dihydroxy-13
14P10493876A0000|196 198|CDE
14P10493876A0000|308 327|thymine residue dT17
14P10493876A0000|331 352|DNA sequence context d
14P10493876A0000|351 364|C1-T2-C3-T4-C5
14P10493876A0000|373 391|A6-C7-T8-T9-C10-C11
14P10493876A0000|396 430|G12-G13-A14-A15-G16-T17-G18-A19-G20
14P10493876A0000|435 441|A21-G22
14P10493876A0000|531 538|NMR data
14P10493876A0000|573 574|MD
14P10493876A0000|576 587|calculations
14P10495573A0365|5 14|sildenafil
14P10495573A0365|52 55|MUSE
14P10495573A0365|110 119|sildenafil
14P10495573A0365|124 127|MUSE
14P10495573A0365|160 169|acceptance
14P10496161A0503|0 15|Serum antibodies
14P10496161A0503|73 75|WPI
14P10496161A0503|94 96|WPI
14P10496284A0115|33 43|CSF protein
14P10496284A0115|46 61|immunoglobulin G
14P10496284A0115|62 64|IgG
14P10496284A0115|102 110|IgG index
14P10496284A0115|112 129|IgG synthesis rate
14P10496303A1968|0 10|CONCLUSIONS
14P10496303A1968|45 58|valganciclovir
14P10496303A1968|92 96|AUC24
15P10496388A1956a|9 20|nonperfusion
15P10496388A1956a|66 70|J/cm2
15P10496388A1956b|9 20|nonperfusion
15P10496388A1956b|66 70|J/cm2
14P10496553A1004|3 14|healing rate
14P10496553A1004|132 156|immunodeficiency syndrome
14P10497117A0358|26 28|ORF
14P10497117A0358|35 43|V protein
14P10497117A0358|79 81|ORF
14P10497199A0559|64 77|factor binding
14P10497199A0559|82 85|GlRE
14P10497199A0559|94 110|chicken ovalbumin
14P10497199A0559|149 157|COUP-TFII
14P10497262A0000|68 109|trypanosomatid species Leptomonas seymouri
14P10497262A0000|113 137|U5 RNA affinity selection
14P10497800A0000|3 8|MMPI-A
14P10497800A0000|10 16|Butcher
14P10497800A0000|41 44|MMPI
14P10497800A0000|46 53|Hathaway
14P10497800A0000|55 62|McKinley
14P10497874A0925|15 35|phosphatidyl inositol
14P10497874A0925|51 54|PIP2
14P10497874A0925|80 94|phosphorylation
14P10497874A0925|97 112|tyrosine residue
14P10497874A0925|117 134|PLC-gamma1 isozyme
14P10498616A0157|1 11|G22V mutant
14P10498616A0157|13 17|M-Ras
14P10498616A0157|75 78|IL-3
14P10498616A0157|90 122|mast cell/megakaryocyte cell line
14P10498616A0157|161 164|IL-3
14P10498616A0157|183 186|IL-4
14P10498616A0157|198 214|expression levels
14P10498616A1280|9 13|M-Ras
14P10498616A1280|18 39|Caenorhabditis elegans
14P10498616A1280|133 147|signaling paths
14P10498616A1280|188 194|p21 Ras
14P10498706A1219|32 35|PecS
14P10498706A1219|53 67|pelE expression
14P10498706A1219|103 106|KdgR
14P10498717A1048|30 33|RsmC
14P10498717A1048|53 70|rsmB transcription
14P10498717A1048|90 104|RsmA production
14P10499121A0542|18 34|hearing aid users
14P10499121A0542|46 64|Class D instruments
14P10499121A0542|67 83|input compression
14P10499357A0439|0 11|SCOB testing
14P10499357A0439|61 62|FR
14P10499357A0439|79 80|FI
14P10499357A0439|91 94|FR20
14P10499357A0439|96 100|FI120
14P10499357A0439|174 178|Weeks
14P10499357A0439|217 229|neurotoxicity
14P10501034A0839|0 29|Ribonuclease protection assays
14P10501034A0839|130 142|morphogenesis
14P10501034A0839|176 189|pigment glands
14P10501656A1415|36 57|Northern blot analysis
14P10501656A1415|82 97|tumor cell lines
14P10501936T0000|0 11|Inactivation
14P10501936T0000|17 33|Neurospora crassa
14P10501936T0000|51 72|membrane protein TOM70
14P10501936T0000|101 103|RIP
14P10501965A0879|77 85|s6 kinase
14P10501965A0879|86 89|Rsk3
14P10501965A0879|135 139|Gpr31
14P10501965A0879|162 170|G-protein
14P10501969A1329|21 26|GATA-5
14P10501969A1329|66 71|GATA-4
14P10502216A0289|96 123|tissue plasminogen activator
14P10502216A0289|123 125|TPA
14P10502216A0289|155 156|MI
14P10502402A0129|21 25|TRAIL
14P10502402A0129|70 88|mouse T lymphocytes
14P10502402A0129|113 117|TRAIL
14P10502402A0533|54 81|signal transduction pathways
14P10502402A0533|90 109|TRAIL gene induction
14P10502402A0533|117 139|T lymphocyte activation
14P10502434A0367|4 11|February
14P10502434A0367|18 23|August
14P10502434A0367|115 133|vault brachytherapy
14P10502434A0604|32 35|ICG1
14P10502434A0604|41 44|ICG2
14P10502434A0604|53 64|ICG3 disease
14P10502522A0000|9 24|provirus genomes
14P10502522A0000|31 56|T-cell leukemia virus type
14P10503540A0602|11 22|primer pairs
14P10503540A0602|39 54|banding patterns
14P10503540A0602|103 121|polyacrylamide gels
14P10503812A1450|46 70|organ transplant patients
14P10503812A1450|86 105|allograft recipients
14P10503812A1450|163 190|cyclosporin pharmacokinetics
14P10504332A0701|0 21|Immunofluoresence data
14P10504332A0701|82 84|RAP
14P10504332A0701|176 191|RAP fluorescence
14P10505694A0000|0 13|Interleukin-12
14P10505694A0000|15 19|IL-12
14P10505694A0000|74 77|PBMC
14P10505694A0000|89 104|interferon-gamma
14P10505694A0000|106 114|IFN-gamma
14P10505694A0739|0 15|IL-12 production
14P10505694A0739|32 48|C3a concentration
14P10505694A0739|69 80|hemodialyzer
14P10506143A0610|15 39|JNKK2-JNK1 fusion protein
14P10506143A0610|55 66|JNK activity
14P10506143A0610|95 98|JNK1
14P10506143A0610|144 146|EGF
14P10506143A0610|148 156|TNF-alpha
14P10506143A0610|169 182|UV irradiation
14P10506143A0610|183 187|MEKK1
14P10506143A0610|197 221|GTP binding proteins Rac1
14P10506160A0297|0 1|J.
14P10508522A1598|19 30|TGF-beta RII
14P10508522A1598|47 54|EWS-FLI1
14P10509768A1118|28 39|acids intake
14P10509768A1118|106 128|serum cholesterol level
14P10510295A0606|11 43|ethanol repression autoregulation
14P10510295A0606|43 45|ERA
14P10510295A0606|59 67|TA repeat
14P10510295A0606|68 70|TAB
14P10510295A0606|129 137|GLK1 gene
14P10510379A0105|8 27|transcription factor
14P10510379A0105|42 46|STAT6
14P10510379A0105|69 79|DNA element
14P10510379A0105|83 101|cytokine activation
14P10511216A0654|0 10|CONCLUSIONS
14P10511554T0000|58 91|clone Caenorhabditis elegans cdf-1
14P10512699A0364|41 53|SECIS element
14P10512699A0364|95 118|selenocysteine insertion
14P10512699A0364|140 142|UGA
14P10512699T0000|64 88|rat thioredoxin reductase
14P10512699T0000|135 148|SECIS elements
14P10512699T0000|151 163|co-expression
14P10512857A0000|2 14|Wnt signaling
14P10512857A0000|15 26|beta-catenin
14P10512857A0000|76 87|interactions
14P10512857A0000|100 120|transcription factors
14P10512882A0137|0 7|Assembly
14P10512882A0137|25 27|FAK
14P10512882A0137|31 41|Src kinases
14P10512882A0137|122 131|Src family
14P10513756A0584|3 5|EPV
14P10513756A0584|50 66|8-predictor model
14P10513756A0584|96 114|selection criterion
14P10513922A1237|35 43|increases
14P10513922A1237|90 100|repair site
14P10513922A1237|102 111|comparison
14P10514493A0199|40 66|N1E-115 neuroblastoma cells
14P10514493A0199|106 115|Ntr-1 gene
14P10514493A0199|139 162|NTR-1 promoter sequences
14P10514808T0000|8 17|dysplasias
14P10514808T0000|31 45|epileptogenesis
14P10516011A0471|28 42|peptide mapping
14P10516011A0471|43 59|mass spectrometry
14P10516011A0471|106 130|pAP phosphorylation sites
14P10516026A0270|4 14|HERV-K type
14P10516072A0146|0 3|Duch
14P10516072A0146|8 9|F.
14P10516738A0925|5 15|time-points
14P10516738A0925|50 64|irbesartan/HCTZ
14P10516878T0000|0 11|Modification
14P10516878T0000|14 42|dopamine D2 receptor activity
14P10516878T0000|53 61|Parkinson
14P10516878T0000|87 89|PET
14P10517666A1069|32 33|GR
14P10517666A1069|37 55|AP-1 nucleoproteins
14P10517672A1417|32 67|alpha1-globin promoter-CAT construct
14P10517672A1417|86 111|CCAAT transcription factor
14P10517672A1417|112 115|CTF1
14P10517672A1417|118 120|NF1
14P10517672A1417|125 161|Drosophila Schneider SL2 insect cells
14P10517672A1417|203 214|CAT activity
14P10517675A0809|0 20|Western blot analysis
14P10517675A0809|54 73|p21WAF1/CIP1 protein
14P10517675A0809|130 152|kinase inhibitor family
14P10517675A0809|152 158|p27kip1
14P10518496A0952|0 10|Aggregation
14P10518496A0952|134 159|periimplantation lethality
14P10518496A0952|196 208|organogenesis
14P10518502T0000|65 85|germ cell development
14P10518502T0000|97 118|Caenorhabditis elegans
14P10518561A0261|28 45|Tec family kinases
14P10518561A0885|26 30|BRDG1
14P10518561A0885|47 48|PH
14P10518561A0885|52 62|SH2 domains
14P10518822A1037|0 9|CONCLUSION
14P10518822A1037|120 146|CCR3 receptor ligand system
14P10518937A0572|3 21|expression analysis
14P10518937A0572|26 36|KlHIS4 gene
14P10518937A0572|41 60|phosphate starvation
14P10518937A0572|66 79|adenine supply
14P10518937A0572|102 105|Bas1
14P10518937A0572|108 111|Bas2
14P10518937A0572|169 177|K. lactis
14P10518956A0137|5 27|thyroid hormone changes
14P10518956A0137|106 117|hypothalamus
14P10518956A0137|139 151|thyroid gland
14P10518956A0137|165 181|deiodinase system
14P10518956A1212|0 7|ESS type
14P10518956A1212|13 15|FT3
14P10518956A1212|22 24|FT4
14P10518956A1212|28 30|TSH
14P10520800A0307|0 6|METHODS
14P10520800A0307|42 45|HOCM
14P10520800A0307|108 123|echocardiography
14P10520800A0307|127 143|electrocardiogram
14P10520800A0307|145 147|ECG
14P10521345A0202|28 41|Laurentian Fan
14P10521345A0202|57 79|sea surface temperature
14P10521345A0202|89 114|surface slope waters north
14P10521345A0202|117 127|Gulf Stream
14P10521345A0202|160 166|Ice Age
14P10521443A0486|21 33|IR activation
14P10521443A0486|54 64|IR mutation
14P10521443A0486|93 112|NF-kappaB activation
14P10521443A0486|166 178|IkappaB-alpha
14P10521443A0486|219 241|NF-kappaB c-Rel subunit
14P10521447A0606|96 135|AML/CBFalpha transcription factor family
14P10521447A1190|28 41|AML3/CBFalpha1
14P10521447A1190|56 74|AML1-ETO repression
14P10521450A0437|10 23|Akt activation
14P10521450A0437|25 27|Lyn
14P10521450A0437|30 32|Syk
14P10521450A0437|50 59|DT40 cells
14P10521450A0437|62 68|B cells
14P10521450A0437|72 74|Lyn
14P10521509A0000|0 9|Regulators
14P10521509A0000|12 30|G protein signaling
14P10521509A0000|30 32|RGS
14P10521509A0000|53 55|DEP
14P10521509A0000|68 73|EGL-10
14P10521509A0000|89 91|GGL
14P10521509A0000|93 107|G protein gamma
14P10521509A0000|164 180|RGS proteins RGS6
14P10521509A0000|180 183|RGS7
14P10521509A0000|185 188|RGS9
14P10521509A0000|193 197|RGS11
14P10521544T0000|0 6|Cloning
14P10521544T0000|36 56|alpha 1,2-mannosidase
14P10521544T0000|65 75|Man9GlcNAc2
14P10521544T0000|78 97|Man8GlcNAc2 isomer B
14P10521796A0872|3 5|ORs
14P10521796A0872|8 9|GC
14P10521796A0872|59 76|baseline diagnoses
14P10521796A0872|110 111|IM
14P10521796A0872|137 138|IM
14P10521796A0872|155 157|DYS
14P10521796A0872|161 162|IM
14P10521796A0872|186 201|neck hyperplasia
14P10521796A0872|238 240|DYS
14P10521796A0872|289 290|SG
14P10521796A0872|319 321|CAG
14P10523319A0209|16 20|Dbp5p
14P10523319A0209|24 28|Rat7p
14P10523520A0986|8 21|nematode genes
14P10523520A0986|41 52|Hh molecules
14P10523634A1404|23 41|Psi synthase domain
14P10523634A1404|70 83|Cbf5p proteins
14P10523634A1404|95 111|box H/ACA snoRNAs
14P10523640A0367|11 29|Src tyrosine kinase
14P10523640A0367|47 67|Stat3 phosphorylation
14P10523640A0367|104 118|gene regulation
14P10523640A0367|141 162|serine phosphorylation
14P10523640A0367|164 168|Stat3
14P10523647A0000|3 27|transcription factor CHOP
14P10523647A0000|27 31|C/EBP
14P10523647A0000|55 66|bZIP protein
14P10523647A0000|109 124|stress responses
14P10523647A1001|5 8|CHOP
14P10523647A1001|49 66|C/EBP target genes
14P10523647A1001|87 98|AP-1 factors
14P10523647A1001|110 126|AP-1 target genes
14P10523663A0404|40 64|homeobox activator DEAF-1
14P10523674A0000|0 8|RNase MRP
14P10523674A0000|11 44|ribonucleoprotein endoribonuclease
14P10523674A0000|90 104|DNA replication
14P10523674A0000|117 133|S rRNA processing
14P10524258A0286|32 42|FGFR-1 gene
14P10524258A0286|74 92|immunocytochemistry
14P10524258A0286|96 117|Northern blot analysis
14P10524258T0000|17 49|fibroblast growth factor receptor
14P10524258T0000|49 54|FGFR-1
14P10524258T0000|84 105|muscle differentiation
14P10525413A1408|3 19|backbone dynamics
14P10525413A1408|53 56|CRP2
14P10525413A1408|58 61|LIM2
14P10525413A1408|63 67|R122A
14P10525413A1408|110 127|N NMR spectroscopy
14P10526670A0236|0 2|Rac
14P10526670A0236|20 34|actin filaments
14P10526670A0236|35 41|F-actin
14P10526670A0236|65 84|phosphatidylinositol
14P10526670A0236|101 104|PIP2
14P10526670A0236|127 143|membrane ruffling
14P10526670A1828|17 27|ICE/caspase
14P10526670A1828|45 49|N1445
14P10526670A1828|105 107|PKB
14P10526670A1828|154 171|Ras transformation
14P10527106A0384|0 8|OBJECTIVE
14P10527106A0384|21 33|preponderance
14P10527158T0000|3 10|AL-R8 SI
14P10527158T0000|18 45|generation staging container
14P10527158T0000|65 82|USDOE Pantex Plant
14P10527180A0869|0 6|RESULTS
14P10527180A0869|8 14|Factors
14P10527180A0869|64 80|treatment failure
14P10527180A0869|83 85|Cox
14P10527180A0869|156 176|% confidence interval
14P10527180A0869|176 177|CI
14P10527180A0869|191 217|Karnofsky performance score
14P10527180A0869|259 275|hormone receptors
14P10527180A0869|316 327|chemotherapy
14P10527180A0869|370 386|survival interval
14P10527180A0869|451 460|metastases
14P10527180A0869|537 559|approaches significance
14P10527180A0869|694 705|chemotherapy
14P10527426A0521|12 31|SBEI gene transcript
14P10527426A0521|60 84|exon I+II+III combination
14P10527475A0643|2 3|PC
14P10527475A0643|9 13|MNGCs
14P10528035A1102|46 82|serum alanine aminotransferase levels
14P10529198A0068|60 74|homologues p140
14P10529198A0068|86 88|Sos
14P10529354A0375|69 71|20S
14P10529354A0375|75 77|19S
14P10529354A0375|79 83|PA700
14P10529354A0375|87 99|P28 complexes
14P10529354A0375|120 132|26S particles
14P10531334A0525|43 51|PTPS-S19A
14P10531334A0525|93 106|protein kinase
14P10531340A1275|0 1|R.
14P10531340A1275|3 13|Fleischmann
14P10531340A1275|15 16|R.
14P10531340A1275|18 23|Venter
14P10531340A1275|25 26|J.
14P10531342A0348|58 75|amino acid repeats
14P10531342A0348|96 129|promastigote surface glycoproteins
14P10531342A0348|133 149|psa2/gp46 complex
14P10531342A1111|35 54|proteophosphoglycans
14P10531342A1111|59 75|ppg1 gene product
14P10531342A1111|129 153|promastigote cell surface
14P10531360A0958|101 109|VEGF mRNA
14P10531360A0958|114 123|conditions
14P10531446A0203|0 9|Neuregulin
14P10531446A0203|20 24|ErbB2
14P10531446A0203|26 30|ErbB3
14P10531446A0203|35 39|ErbB4
14P10531446A0203|53 63|ErbB family
14P10531446A0203|65 89|receptor tyrosine kinases
14P10532354A1374|21 25|Anu2p
14P10532354A1374|31 45|yeast homologue
14P10532354A1374|96 106|ER membrane
14P10532354A1374|133 157|protein transport pathway
14P10532805A0792|2 11|PC12 cells
14P10532805A0792|12 30|nerve growth factor
14P10532805A0792|44 58|differentiation
14P10532805A1084|3 18|PC12 cell mutant
14P10532805A1084|34 58|protein kinase A activity
14P10532805A1084|57 58|AB
14P10533066A0758|0 13|TSC1 mutations
14P10533066A0758|64 79|splice mutations
14P10533066A1197|39 41|PTT
14P10533066A1197|60 77|missense mutations
14P10533066A1197|88 91|TSC2
14P10534048A0297|18 25|FOREPROJ
14P10534048A0297|42 61|projection algorithm
14P10534048A0297|90 119|attenuation correction factors
14P10534048A0297|119 121|ACF
14P10534402A0126|26 28|DNA
14P10534402A0126|73 91|sequence similarity
14P10534402A0126|129 141|Spo11p family
14P10534402A0659|0 5|RT-PCR
14P10534402A0659|15 36|hybridization analyses
14P10534402A0659|59 76|testis development
14P10534402A0659|88 103|Spo11 expression
14P10534402A0659|123 130|Prophase
14P10534402A0659|143 157|pachytene stage
14P10534402A0659|200 214|pachytene stage
14P10534691A0542|0 6|Animals
14P10534691A0542|121 130|procedures
14P10534691A0542|134 141|evidence
14P10534691A0542|144 152|infection
14P10535715A0268|3 5|RMR
14P10536125A0093|0 10|Oseltamivir
14P10536125A0093|12 17|GS4104
14P10536125A0093|63 68|GS4071
14P10536125A0093|100 128|influenzavirus neuraminidases
14P10536369A0662|2 26|gel mobility shift assays
14P10536369A0662|45 74|VDR-TR heterodimer interaction
14P10536369A1280|11 20|importance
14P10536369A1280|31 40|mechanisms
14P10536369A1280|52 59|response
14P10536788A0931|29 39|PL profiles
14P10536788A0931|84 97|control livers
14P10536788A0931|116 117|PL
14P10536788A0931|140 141|PL
14P10540015A0664|0 12|C-SP duration
14P10540015A0664|37 48|ALS patients
14P10540015A0664|71 91|stimulation intensity
14P10540015A0664|108 120|MEP threshold
14P10540292A1179|20 38|spv virulence genes
14P10540292A1179|94 104|possibility
14P10540292A1179|109 122|spv expression
14P10540553A0980|20 22|PNA
14P10540553A0980|108 110|DNA
14P10540553A0980|138 150|proliferation
14P10540915A0697|8 19|transsection
14P10540915A0697|46 50|TL&PL
14P10541432A0185|57 59|EGF
14P10541432A0185|69 92|tyrosine phosphorylation
14P10541432A0185|104 115|Shc proteins
14P10541432A0185|161 179|ERK MAPK activities
14P10541432A0185|216 234|ERK MAPK activities
14P10541550A0487|5 22|immunolocalization
14P10541550A0487|37 40|ACE3
14P10541550A0487|49 63|chorion element
14P10541550A0487|124 141|DmORC localization
14P10541865A1301|34 39|CDKN2A
14P10541865A1301|43 48|CDKN2B
14P10542237A0357|115 132|lipopolysaccharide
14P10542237A0357|134 136|LPS
14P10542237A0357|164 177|IL-6 secretion
14P10542249A0415|0 17|Albumin expression
14P10542249A0415|69 89|transcription factors
14P10542249A0415|95 98|CAAT
14P10542249A0415|123 127|C/EBP
14P10542249A0415|137 145|C/EBPbeta
14P10542260A0832|42 46|FVIIa
14P10542260A0832|50 52|FXa
14P10542269A0000|0 19|Amyloid beta-protein
14P10542269A0000|20 24|Abeta
14P10542269A0000|48 62|amyloid fibrils
14P10542269A0000|102 110|Alzheimer
14P10542269A0000|121 122|AD
14P10542269A0000|156 185|beta-amyloid precursor protein
14P10542269A0000|185 187|APP
14P10542274A1376|26 41|protein kinase A
14P10542274A1376|41 43|PKA
14P10542274A1376|81 109|caveolin-1 protein expression
14P10542274A1376|111 127|promoter activity
14P10542277A0000|3 16|importin alpha
14P10542277A0000|17 32|beta heterodimer
14P10542277A0000|89 108|localization signals
14P10542281A0382|12 16|G1-G2
14P10542281A0382|41 52|link protein
14P10542281A0382|96 107|proteoglycan
14P10542281A0382|114 125|repeat loops
14P10542281A0382|130 138|G1 domain
14P10542281A2021|48 62|keratan sulfate
14P10542281A2021|70 74|G1-G2
14P10542281A2021|101 111|atrolysin C
14P10543270A1054|7 26|i.v. steroid therapy
14P10543270A1054|27 31|NOexh
14P10543727A0282|32 52|transcription factors
14P10543727A0282|100 134|rel/NF-kappaB transcription factors
14P10543727A0282|148 152|H2TF1
14P10543727A0282|252 264|H2TF1 element
14P10543727A0282|286 293|p65/relA
14P10543727A0282|304 313|HLA system
14P10543727A0282|324 327|AP-1
14P10543727A0282|329 352|ATF recognition sequence
14P10543727A0282|362 368|EnA-TRE
14P10543728A0358|14 16|E1A
14P10543728A0358|67 88|DNA binding activities
14P10543728A0358|89 92|AP-1
14P10543728A0358|131 139|E1A cells
14P10543730A0000|14 32|cyclin Ume3p/Srb11p
14P10543730A0000|61 63|Cdk
14P10543730A0000|65 69|Ume5p
14P10543730A0000|121 135|stress response
14P10543949A0686|16 17|S1
14P10543949A0686|19 34|specificity site
14P10544037A0617|0 3|FZD4
14P10544037A0617|18 21|FZD9
14P10544037A0617|25 29|FZD10
14P10544037A0617|41 59|amino acid identity
14P10544037A0617|70 73|FZD4
14P10544037A0617|76 79|FZD9
14P10544037A0617|87 90|FZD4
14P10544037A0617|93 97|FZD10
14P10544037A0617|105 108|FZD9
14P10544037A0617|111 115|FZD10
14P10544088A0308|3 11|NF-kappaB
14P10544088A0308|22 39|reporter construct
14P10544088A0308|41 45|PRDII
14P10544088A0308|51 53|CAT
14P10544088A0308|97 105|NF-kappaB
14P10544089A1208|3 17|RNA transcripts
14P10544089A1208|53 58|TMV U1
14P10544089A1208|121 124|IRES
14P10544089A1208|126 127|MP
14P10544089A1208|139 140|MP
14P10544089A1208|148 149|CR
14P10544089A1208|152 158|MP-CP-3
14P10544089A1208|160 162|UTR
14P10544089A1208|170 171|MP
14P10544089A1208|181 187|MP-CP-3
14P10544089A1208|189 191|UTR
14P10544089A1208|214 220|MP gene
14P10544113A0293|0 28|EIAV LTR sequence variability
14P10544113A0293|79 88|U3 segment
14P10544113A0293|93 95|LTR
14P10545192T0000|0 40|Phosphatidylinositol 3-kinase requirement
14P10545192T0000|68 74|MEK/ERK
14P10545192T0000|78 80|p70
14P10545192T0000|82 84|s6k
14P10545192T0000|122 142|agent vanadyl sulfate
14P10545248A0567|55 67|binding sites
14P10545248A0567|73 98|homeodomain protein Tinman
14P10545248A0567|98 100|Tin
14P10545248A0567|151 165|muscle lineages
14P10545281A0836|39 64|purification tag sequences
14P10545281A0836|128 147|protein accumulation
14P10548434A1549|45 54|T antigens
14P10548434A1549|114 116|ERK
14P10548434A1549|124 130|JNK/SPK
14P10548434A1549|133 145|p38 signaling
14P10548622A0906|75 97|i.v. sedation/analgesia
14P10548622A0906|103 116|egg collection
14P10548622A0906|157 175|ultrasound guidance
14P10548622A0906|176 180|TUGOR
14P10548722A0099|19 30|organization
14P10548722A0099|41 44|H1.8
14P10548722A0099|59 72|TcP2beta genes
14P10548722A0099|132 135|SIRE
14P10549354A1782|13 15|APC
14P10549354A1782|25 40|colon carcinomas
14P10549354A1782|83 87|Tcf-4
14P10549354A1782|89 110|beta-catenin complexes
14P10549354A1782|143 152|N terminus
14P10549354A1782|207 209|APC
14P10549354A1782|211 219|GSK3 beta
14P10549354A1782|223 236|Axin/Conductin
14P10549354A2371|26 37|deregulation
14P10549354A2371|40 63|Tcf target gene activity
14P10549912A0136|63 72|infarction
14P10549912A0136|101 110|infarction
14P10549912A0136|140 156|segment elevation
14P10549912A0136|157 161|V1-V4
14P10549912A0136|227 237|angioplasty
14P10550139A0191|0 7|PATIENTS
14P10550139A0191|11 17|METHODS
14P10550139A0191|57 77|bone marrow aspirates
14P10550571A0000|0 6|PURPOSE
14P10550571A0000|16 22|WR-2721
14P10550571A0000|63 75|plasma levels
14P10550571A0000|145 151|WR-2721
14P10550574A1038|26 35|toxicities
14P10550574A1038|66 91|serum alkaline phosphatase
14P10551788A0229|0 5|LHbeta
14P10551788A0229|28 44|gonadotrope cells
14P10551788A0229|47 52|CGbeta
14P10551788A0229|75 91|trophoblast cells
14P10551796T0000|12 30|HIV-1 transcription
14P10551816A0162|5 10|LTBP-1
14P10551848A0000|17 22|Kimura
14P10551848A0000|24 25|Y.
14P10551848A0000|27 38|Kurzydlowski
14P10551848A0000|40 41|K.
14P10551848A0000|43 46|Tada
14P10551848A0000|48 49|M.
14P10551848A0000|54 62|MacLennan
14P10551848A0000|64 65|D.
14P10551867A0350|16 34|amino acid residues
14P10551867A0350|43 62|9-kilobase pair mRNA
14P10551867A0350|109 126|rat cDNA libraries
14P10551879T0000|41 67|A-kinase anchoring proteins
14P10551879T0000|81 118|fluorescence resonance energy transfer
14P10551879T0000|134 156|protein fusion proteins
14P10552357A1936|0 10|CONCLUSIONS
14P10552357A1936|103 118|LV opacification
14P10552357A1936|132 135|OCTA
14P10552357A1936|168 178|LV function
14P10552357A1936|232 234|AIR
14P10553551A0000|0 19|Factor XI deficiency
14P10553959A0812|3 17|Ishasha samples
14P10554946A0082|18 22|SERMS
14P10554946A0082|24 41|clomiphene citrate
14P10554946A0082|44 52|tamoxifen
14P10554946A0082|94 103|raloxifene
14P10555079A0254|0 1|Ti
14P10555285A1065|28 45|duplication events
14P10555285A1065|72 93|FUT3-FUT5-FUT6 cluster
14P10555964A0778|0 1|S.
14P10555964A0778|3 5|Kim
14P10555964A0778|7 8|S.
14P10556028A0292|32 54|plasmid incompatibility
14P10556028A0292|107 110|Prep
14P10556028A0292|131 148|RepA binding sites
14P10556028A0292|148 151|BD-1
14P10556028A0292|155 158|BD-2
14P10556029A0852|0 12|WA constructs
14P10556029A0852|53 72|cyclization kinetics
14P10556029A0852|85 99|interconversion
14P10556033A0000|3 20|RFX protein family
14P10556044A0913|26 52|alpha-dystroglycan receptor
14P10556044A0913|88 97|LG modules
14P10556046A0328|55 71|signaling pathway
14P10556046A0328|98 111|Xenopus embryo
14P10556063A0092|45 57|Trk subfamily
14P10556089A0901|38 55|muscle development
14P10556089A0901|57 66|C. elegans
14P10556089A0901|126 141|muscle component
14P10556089A0901|168 179|conservation
14P10556089A0901|182 194|gene function
14P10556089A0901|203 208|CUG-bp
14P10556145A1034|0 9|Gentamicin
14P10556145A1034|17 19|DPI
14P10556145A1034|23 25|SVN
14P10556145A1034|51 68|sputum Psa density
14P10556263A1035|0 10|CONCLUSIONS
14P10556263A1035|75 76|AC
14P10556595A0391|2 9|analysis
14P10556595A0391|12 19|sequence
14P10556595A0391|31 39|recN gene
14P10556595A0391|56 67|transversion
14P10556595A0391|91 96|region
14P10556751A0758|33 50|transmission rates
14P10556751A0758|52 54|HGV
14P10556751A0758|76 87|immunization
14P10556751A0758|89 91|HGV
14P10557008T0000|0 8|Detection
14P10557008T0000|22 27|Impila
14P10557072A0127|70 73|ULK1
14P10557072A0418|0 3|ULKs
14P10557072A0418|7 12|UNC-51
14P10557072A0418|26 41|domain structure
14P10557072A0418|80 93|proline/serine
14P10557072A0418|99 100|PS
14P10557072A1218|23 26|ULK2
14P10557072A1218|65 81|signaling pathway
14P10557308A0000|0 17|Connector enhancer
14P10557308A0000|19 21|KSR
14P10557308A0000|23 25|CNK
14P10557308A0000|59 71|RAS signaling
14P10559207A0207|22 36|ATP sulfurylase
14P10559207A0207|39 58|APS kinase reactions
14P10559303A0000|18 20|EBV
14P10559303A0000|28 43|membrane protein
14P10559303A0000|45 48|LMP1
14P10559303A0000|99 111|B lymphocytes
14P10559320A0080|23 24|1a
14P10559320A0080|67 78|protein nsP1
14P10559320A0080|115 118|RNAs
14P10559324A0716|21 22|Ad
14P10559324A0716|33 44|Ad5 E4orf6/7
14P10559324A0716|111 112|Ad
14P10559364A0846|2 5|HCMV
14P10559364A0846|22 29|HF cells
14P10559364A0846|39 41|IE2
14P10559364A0846|75 102|DNA replication compartments
14P10559364A0846|114 143|polymerase processivity factor
14P10559364A0846|143 146|UL44
14P10559364A0846|167 185|DNA binding protein
14P10559364A0846|185 187|SSB
14P10559364A0846|189 192|UL57
14P10559364A0846|198 224|UL112-113 accessory protein
14P10560014A0000|23 43|heart vascularization
14P10560014A0000|63 79|angioarchitecture
14P10560997A1072|0 9|CONCLUSION
14P10560997A1072|30 38|LH levels
14P10561095A2141|8 18|reoperation
14P10561095A2141|71 87|calcitonin levels
14P10561095A2141|131 148|hypoparathyroidism
14P10561153A0225|62 64|SSc
14P10561251A0000|0 6|PURPOSE
14P10561251A0000|42 44|DFS
14P10561251A0000|65 66|OS
14P10561251A0000|161 163|IBC
14P10561251A0000|184 199|modality therapy
14P10561251A0000|200 202|CMT
14P10561251A0000|229 232|HDCT
14P10561251A0000|248 272|stem-cell transplantation
14P10561460A0615|3 19|GPI anchor moiety
14P10561460A0615|128 147|GPI signal sequences
14P10561546A0000|118 136|localization signal
14P10561546A0000|138 158|NF-kappaB p65 subunit
14P10562418A0238|17 22|events
14P10562418A0238|42 46|cells
14P10562456T0000|49 67|growth hormone gene
14P10562456T0000|68 80|rainbow trout
14P10562456T0000|81 92|Oncorhynchus
14P10562495A0188|12 20|SFV genes
14P10562495A0188|46 61|Chordopoxvirinae
14P10562495A0188|66 75|SFV genome
14P10563212A0514|21 39|SF-36 questionnaire
14P10563605A0773|22 32|association
14P10563605A0773|40 43|IENF
14P10563605A0773|69 83|fiber densities
14P10563789A1951|26 45|F beta alpha/CG beta
14P10563789A1951|78 79|CG
14P10563789A1951|83 95|FSH receptors
14P10563836A1234|11 31|AP-2 binding activity
14P10563836A1234|55 64|T47D cells
14P10563836A1234|68 80|Western blots
14P10563836A1234|98 116|AP-2 protein levels
14P10564231A0315|0 10|N. van Hoek
14P10564231A0315|13 14|M.
14P10564280A0140|54 60|YT521-B
14P10564280A0140|114 151|component scaffold attachment factor B
14P10564280A0140|161 173|Src substrate
14P10564472A0853|38 48|TraR fusion
14P10564474T0000|65 91|outer-membrane protein OprH
14P10564474T0000|93 114|polymyxin B resistance
14P10564479A0384|0 7|Deletion
14P10564479A0384|45 48|FdsR
14P10564479A0384|54 63|fds operon
14P10564479A0384|88 96|activator
14P10564479A0384|123 131|repressor
14P10564484A0859|4 13|constructs
14P10564484A0859|27 38|binding site
14P10564484A0859|57 64|promoter
14P10564484A0859|107 118|requirements
14P10564484A0859|123 130|function
14P10564484A0859|162 169|promoter
14P10564495A0444|19 30|Opa proteins
14P10564495A0444|32 35|C751
14P10564495A0444|53 62|HeLa cells
14P10564495A0444|116 118|CEA
14P10564495A0444|120 124|CD66e
14P10564495A0444|140 150|CD66 family
14P10564495A0444|176 179|CGM1
14P10564495A0444|182 186|CD66d
14P10564495A0444|191 193|NCA
14P10564495A0444|195 199|CD66c
14P10564593A0428|0 3|FISH
14P10564593A0428|87 100|MCF-7 AdVp3000
14P10564593A0428|103 110|MCF-7 MX
14P10564593A0428|116 123|S1-M1-80
14P10564593A1618|3 10|MXR gene
14P10564593A1618|18 33|half-transporter
14P10564593A1618|70 84|coamplification
14P10564593A1618|154 173|MXR half-transporter
14P10564593A1618|195 208|drug transport
14P10564939A0981|3 8|effect
14P10564939A0981|11 17|smoking
14P10564939A0981|38 42|study
14P10566630A0371|0 4|Serum
14P10566630A0371|17 31|growth factor I
14P10566630A0371|31 35|IGF-I
14P10566630A0371|37 44|SD score
14P10566862A0000|0 9|BACKGROUND
14P10566862A0000|11 21|Measurement
14P10566862A0000|72 95|depth stereoacuity tests
14P10567430A0785|90 93|GRK2
14P10567430A0785|111 116|Galpha
14P10567430A0785|124 129|Galpha
14P10567430A0785|134 139|Galpha
14P10567430A0785|146 151|Galpha
14P10567430A0785|183 186|GRK5
14P10567430A0785|189 192|GRK6
14P10567524T0000|3 23|elm1 kinase functions
14P10567524T0000|32 48|signaling network
14P10567533A0818|21 22|RT
14P10567533A0818|25 36|PCR products
14P10567533A0818|113 128|tyrosine kinases
14P10567538A1028|14 39|acetyltransferase activity
14P10567538A1028|41 44|p300
14P10567538A1028|91 109|activation function
14P10567538A1028|114 116|CH3
14P10567581A0119|25 29|HNF-3
14P10567581A0119|31 59|fork head homolog-11B protein
14P10567581A0119|58 64|HFH-11B
14P10567581A0119|77 83|Trident
14P10567581A0119|127 152|head transcription factors
14P10567581A0119|225 239|DNA replication
14P10567581A0119|240 246|S phase
14P10567582A1334|11 15|CtBP1
14P10567582A1334|48 52|CtBP2
14P10567582A1334|76 88|embryogenesis
14P10567589A1268|22 26|Pmt3p
14P10567589A1268|87 103|Pmt3p conjugation
14P10568275A0679|33 40|Kara Sea
14P10568275A0679|47 58|Arctic Ocean
14P10568275A0679|87 92|GEOMAR
14P10568455A0000|37 65|slow-release estradiol-17beta
14P10568455A0000|66 69|SRE2
14P10568455A0000|114 122|PGF2alpha
14P10568455A0000|151 152|CL
14P10568728A1445|10 30|serum creatine kinase
14P10568728A1445|59 63|ESWIB
14P10568744A0728|36 44|promoters
14P10568744A0728|134 142|direction
14P10568744A0728|145 165|mating type switching
14P10570262A0000|0 9|Activation
14P10570262A0000|12 18|T cells
14P10570262A0000|24 26|TCR
14P10570262A0000|74 91|signaling cascades
14P10570996A1213|28 37|TK domains
14P10570996A1213|76 88|scavenger RTK
14P10570996A1213|125 132|TK class
14P10571047A1009|7 9|7SL
14P10571047A1009|88 104|HindIII fragments
14P10571474A0571|0 6|Results
14P10571474A0571|34 36|CA3
14P10572087A0326|15 29|binding partner
14P10572087A0326|42 63|anemia group C protein
14P10572087A0326|62 66|FANCC
14P10572130A1623|27 50|transcription activators
14P10572130A1623|91 104|RNA polymerase
14P10572130A1623|141 152|DNA geometry
14P10572131A0000|0 17|Klebsiella oxytoca
14P10572131A0000|73 88|nasFEDCBA operon
14P10572866A0481|37 49|plasma values
14P10572866A0481|88 113|aspartate aminotransferase
14P10573781A0631|0 6|Studies
14P10573781A0631|27 37|involvement
14P10573781A0631|61 71|chromosomes
14P10573781A0631|85 95|chromosomes
14P10574913A1108|34 57|receptor phosphorylation
14P10574913A1108|95 109|Src recruitment
14P10574913A1108|177 190|ERK activation
14P10574913A1108|224 237|ERK activation
14P10574929A0583|41 54|P-CIP2 protein
14P10574982A1075|0 15|Supershift EMSAs
14P10574982A1075|62 66|USF-1
14P10574992A0901|27 34|p300/CBP
14P10574992A0901|56 75|PARP enzyme activity
14P10574992A0901|91 115|cell death susceptibility
14P10574992A0901|163 202|PARP chemical inhibitor 3-aminobenzamide
14P10575231A0355|0 7|Analysis
14P10575231A0355|46 54|Cdc6 gene
14P10575545A0147|15 19|CACCC
14P10575545A0147|23 33|CAAT motifs
14P10575642T0000|0 14|Skin pH changes
14P10576177A0308|4 14|distinction
14P10576177A0308|37 45|diagnosis
14P10576177A0308|77 85|prognoses
14P10576177A0308|107 117|implication
14P10576545A0926|33 45|DNA cassettes
14P10576545A0926|63 79|D1A gene promoter
14P10578528A0730|46 48|EEG
14P10578528A0730|75 87|manifestation
14P10578528A0730|121 134|symptomatology
14P10579331A1225|42 72|rat HDL receptor SR-BI promoter
14P10579331A1225|80 103|sterol response elements
14P10579331A1225|127 134|SREBP-1a
14P10579722T0000|0 14|Phosphorylation
14P10579722T0000|39 41|MBS
14P10579722T0000|45 62|myosin phosphatase
14P10579722T0000|64 73|Rho-kinase
14P10580071A0436|49 63|transplantation
14P10580071A0436|100 109|transplant
14P10580438A0508|17 36|mobility shift assay
14P10580438A0508|36 39|EMSA
14P10580438A0508|46 68|GLUT4 repressor element
14P10580438A0508|68 71|G4RE
14P10582831T0000|0 8|Syndromes
14P10582831T0000|22 35|redistribution
14P10582831T0000|48 60|complications
14P10584138T0001|0 13|Cytoprotection
14P10584138T0001|30 41|radiotherapy
14P10584138T0001|44 61|radio-chemotherapy
14P10584704A0913|41 45|S-100
14P10584704A0913|76 81|HMB-45
14P10584704A0913|109 119|cytokeratin
14P10585311A0494|0 7|Patients
14P10585311A0494|24 27|MPGN
14P10585311A0494|66 74|diagnosis
14P10585311A0494|115 123|diagnosis
14P10585311A1542|15 27|abnormalities
14P10585311A1542|87 90|MPGN
14P10585417A1412|39 55|tissue expression
14P10585417A1412|86 89|PRLr
14P10585417A1412|108 111|PRLr
14P10585440A0204|37 49|FAK homologue
14P10585440A0204|50 55|DFak56
14P10585453A1029|10 20|Pit-1 sites
14P10585453A1029|25 43|hGH-N gene promoter
14P10585453A1029|64 78|gene activation
14P10585453A1029|148 152|Pit-1
14P10585463A0859|44 76|baculovirus-Sf9 expression system
14P10585480A0157|22 31|SH3 domain
14P10585480A0157|43 76|guanine nucleotide exchange factor
14P10585480A0265|0 14|Point mutations
14P10585480A0265|24 33|SH3 domain
14P10585491A0945|2 26|gel mobility shift assays
14P10585491A0945|28 43|binding activity
14P10585491A0945|45 47|CBF
14P10585491A0945|62 83|AtpC promoter sequence
14P10585491A0945|129 150|AtpC expression levels
14P10585491A0945|212 227|binding activity
14P10585491A0945|271 292|AtpC expression levels
14P10585808A0000|0 28|Mycoplasma hominis infections
14P10586074A0129|30 47|plasmid constructs
14P10586074A0129|74 96|envelope glycoprotein E
14P10586074A0129|120 137|encephalitis virus
14P10586107A0160|41 61|transduction pathways
14P10586107A0160|73 94|cell surface receptors
14P10586115A0477|63 71|IL-1alpha
14P10586115A0477|73 80|IL-1beta
14P10586115A0477|82 90|TNF-alpha
14P10586115A0477|94 97|IL-6
14P10586115A0477|103 106|IL-6
14P10586115A0477|132 137|PKCeta
14P10586626A0607|105 115|involvement
14P10586626A0607|130 133|ADEM
14P10587460A0302|18 36|VDRE binding domain
14P10587460A0302|43 45|VDR
14P10587460A0302|95 102|Delta134
14P10587460A0302|104 111|Delta113
14P10587460A0302|113 120|Delta102
14P10587460A0302|122 128|Delta90
14P10587460A0302|130 136|Delta84
14P10587460A0302|138 144|Delta80
14P10587460A0302|149 155|Delta60
14P10587461A0341|15 23|mechanism
14P10587461A0341|40 48|anticodon
14P10587461A0341|60 68|formation
14P10587461A0341|78 93|transition state
14P10587576A0596|5 8|REPs
14P10587576A0596|68 71|ESTs
14P10587576A0596|86 101|SH3GL pseudogene
14P10588946A0432|61 65|ORP-1
14P10588946A0432|68 72|ORP-6
14P10589562A1208|56 67|BB resonator
14P10589562A1208|82 102|RF power requirements
14P10589711A1228|11 25|narZ expression
14P10589711A1228|72 82|Madin-Darby
14P10589711A1228|135 146|salts medium
14P10590092A0124|28 48|HIV-1 gene expression
14P10590092A0124|52 54|CNS
14P10590368X0000|9 21|trachelectomy
14P10590368X0000|27 37|alternative
14P10590368X0000|47 58|hysterectomy
14P10590368X0000|74 93|stage IA-B carcinoma
14P10590368X0000|104 113|BACKGROUND
14P10590368X0000|164 178|stage carcinoma
14P10590368X0000|211 224|survival rates
14P10591633A0138|52 66|target membrane
14P10591633A0138|101 126|SNARE protein interactions
14P10591633A0138|179 193|membrane fusion
14P10591933A0798|13 16|Type
14P10591933A0798|18 30|configuration
14P10591976A0317|0 11|Measurements
14P10591976A0317|17 24|LWS p.a.
14P10591976A0317|25 31|LWS lat
14P10591976A0317|37 40|Ward
14P10591990A0178|10 15|DSM-IV
14P10591990A0178|78 81|SAPS
14P10591990A0178|83 86|SANS
14P10591990A0178|88 91|BPRS
14P10591990A0178|95 97|PAS
14P10592791A0370|16 24|TECRA kit
14P10592791A0370|55 56|SE
14P10592791A0370|78 85|SET-RPLA
14P10592791A0370|89 103|RIDASCREEN kits
14P10592791A0370|147 154|SE types
14P10592791A0370|220 231|SET-RPLA kit
14P10592791A0370|257 270|RIDASCREEN kit
14P10592791A0370|316 330|test procedures
14P10592791A0370|382 392|SET-EIA kit
14P10592791A0370|421 437|research purposes
14P10592791T0001|0 9|Comparison
14P10592791T0001|12 27|immunoassay kits
14P10592824A1157|64 75|JEV antibody
14P10592824A1157|212 222|JE vaccines
14P10592824A1157|244 253|Chi-square
14P10592824A1157|257 266|trend test
14P10593939A0747|43 65|interaction experiments
14P10593939A0747|78 89|SR33 protein
14P10593939A0747|115 126|SR45 protein
14P10593939A0747|152 156|SRZ21
14P10593939A0747|160 164|SRZ22
14P10593939A0747|208 218|Arabidopsis
14P10593950A1113|10 12|WT1
14P10593950A1113|34 47|chromatography
14P10593950A1113|54 59|U2AF65
14P10593950A1113|64 65|U5
14P10593950A1113|92 103|protein p116
14P10594130A0652|11 16|hearts
14P10594130A0652|39 45|infants
14P10594130A0652|59 65|degrees
14P10594130A0652|76 83|staining
14P10594239A0614|0 8|Tih1 maps
14P10594239A0614|33 40|Chr 1q31
14P10594239A0614|112 114|Ipl
14P10594239A0614|116 119|Tih1
14P10594239T0000|51 59|Ipl/Tssc3
14P10594239T0000|61 66|TDAG51
14P10594239T0000|71 74|Tih1
14P10594903A0000|43 45|RNP
14P10594903A0000|115 131|warfare agents GA
14P10594903A0000|131 132|GB
14P10594903A0000|134 135|HD
14P10594903A0000|139 140|VX
14P10595315A0344|46 55|parameters
14P10595315A0344|76 86|blood gases
14P10596955A1032|18 33|failure patients
14P10596955A1032|66 77|Axsym method
14P10596955A1032|114 119|Immuno
14P10597222A1371|23 25|p27
14P10597222A1371|54 67|HMBA signaling
14P10597222A1371|89 91|p21
14P10597223A0339|20 33|Ras-expression
14P10597223A0339|68 70|p21
14P10597223A0339|97 108|p21 promoter
14P10597223A0339|129 157|transcription initiation site
14P10597223A0339|191 211|transcription factors
14P10597232A0000|3 24|RET/PTC3 rearrangement
14P10597232A0000|45 48|ELE1
14P10597232A0000|52 60|RET genes
14P10597317A1156|0 8|Apoptosis
14P10597317A1156|41 55|co-transfection
14P10597317A1156|58 60|JBD
14P10597317A1156|64 67|LMP1
14P10597317A1156|94 105|HD-MyZ cells
14P10597317A1156|179 181|JNK
14P10597317A1156|204 207|LMP1
14P10597317A1156|215 222|RS cells
14P10598101A0000|15 34|bZIP protein Opaque2
14P10598101A0000|51 65|maize endosperm
14P10598101A0000|105 127|kDa zein gene promoters
14P10598101A0754|3 17|mEmBP-1 protein
14P10598101A0754|28 40|transcription
14P10598101A0754|134 146|transcription
14P10598101A0754|152 168|kDa zein promoter
14P10598101A0754|179 194|expression assay
14P10598101A0754|207 227|maize endosperm cells
14P10598316A1534|0 2|GHB
14P10598316A1534|5 6|CB
14P10598316A1534|8 10|HMB
14P10599013A0505|11 16|deaths
14P10599727A1567|8 9|GH
14P10599727A1567|13 38|estrogen treatment regimen
14P10599727A1567|51 52|TS
14P10600171A1066|39 44|CYP3A2
14P10600171A1066|79 85|COUP-TF
14P10600171A1066|91 109|CYP3A2 DexRE-1 site
14P10600171A1432|6 12|CYP3A23
14P10600171A1432|77 80|USF1
14P10600171A1432|93 132|bHLH/leucine zipper transcription factor
14P10601280A0674|59 79|ST3 promoter activity
14P10601290A0742|35 56|cell surface stability
14P10601290A0742|114 131|T cell recognition
14P10601290A0742|137 139|I1Y
14P10601290A0742|143 145|I1F
14P10601290A0742|162 185|x-ray crystal structures
14P10601290A0742|198 218|MHC-peptide complexes
14P10601335A0892|0 13|Redistribution
14P10601344A1653|27 41|activity assays
14P10601344A1653|52 58|GTPases
14P10601344A1653|101 111|IL2R-beta1A
14P10601344A1653|114 117|GE11
14P10601344A1653|120 129|GD25 cells
14P10601344A1653|153 156|RhoA
14P10601344A1653|160 163|Rac1
14P10601344A1653|173 177|Cdc42
14P10601410A0977|40 43|IVIg
14P10601410A0977|49 61|remyelination
14P10601410A0977|78 94|sclerosis lesions
14P10601410A0977|113 127|conduction time
14P10601606A0152|3 22|rhabdomyosarcoma R1H
14P10601606A0152|50 61|WAG/Rij rats
14P10601747A0482|18 30|control words
14P10601747A0482|98 108|N400 effect
14P10602419A1253|16 22|effects
14P10602502A0422|7 17|Tob protein
14P10602502A0422|18 21|Tob2
14P10602502A0422|31 52|cell cycle progression
14P10602502A0422|58 62|G0/G1
14P10602502A0422|65 72|S phases
14P10602507A0652|34 36|p21
14P10602507A0652|110 112|p53
14P10602507A0652|132 146|CSF-1 induction
14P10602507A0652|148 150|p21
14P10602507A0652|183 196|p53 expression
14P10602516A0182|11 13|SLK
14P10602516A0182|75 79|M-NAP
14P10602516A0182|84 89|AT1-46
14P10602838A0127|13 20|patients
14P10602838A0127|24 30|females
14P10603349A1667|3 27|signalling molecules Wnt1
14P10603349A1667|70 73|Myf5
14P10603349A1667|84 99|progenitor cells
14P10603349A1667|145 166|Myf5 expression domain
14P10604246A0523|0 11|STUDY DESIGN
14P10604246A0523|14 20|METHODS
14P10604246A0523|64 68|PBPCs
14P10604246A0523|89 96|AutoPBSC
14P10604246A0523|115 133|AutoPBSC tubing set
14P10604246A0523|148 150|MNC
14P10604246A0523|178 179|V4
14P10604246A0523|191 205|cell tubing set
14P10604583T0000|0 15|Albumin dialysis
14P10604583T0000|63 76|Wilson disease
14P10604583T0000|99 119|liver transplantation
14P10604945A0731|14 32|promoter constructs
14P10604945A0731|50 58|Sp1 sites
14P10604945A0731|122 133|organization
14P10604945A0731|147 161|promoter region
14P10604945A0731|197 212|ethanol response
14P10606245A0906|0 13|Overexpression
14P10606245A0906|16 22|CDP/cut
14P10606245A0906|25 27|ROS
14P10606245A0906|34 51|osteosarcoma cells
14P10606245A0906|72 91|OC promoter activity
14P10606245A0906|126 134|OC box I.
14P10606272A1241|0 8|Injection
14P10606272A1241|26 28|RNA
14P10606272A1241|33 42|C. elegans
14P10606272A1241|78 85|SF1 gene
14P10606515A0389|34 44|DNA binding
14P10606515A0389|62 82|acid receptor element
14P10606515A0389|92 96|DNase
14P10606664A0000|0 20|Snail family proteins
14P10606664A0000|108 130|cell fate determination
14P10607566A0880|63 73|RA receptor
14P10607566A0880|74 76|RAR
14P10607566A0880|119 137|retinoid X receptor
14P10607566A0880|137 139|RXR
14P10607566A0880|145 147|RAR
14P10607566A0880|160 162|TCF
14P10607566A0880|166 185|beta-catenin binding
14P10607899A0605|0 16|Sequence analysis
14P10607899A0605|43 50|TATA box
14P10607899A0605|63 86|consensus binding motifs
14P10607899A0605|92 95|CREB
14P10607899A0605|114 143|estrogen receptor binding site
14P10607900T0000|0 24|Sak kinase gene structure
14P10608053A0923|0 11|Thrombolysis
14P10608053A0923|43 59|platelet activity
14P10608053A0923|116 120|IU/ml
14P10608053A0923|123 127|Group
14P10608053A0923|142 146|Group
14P10608053A0923|154 171|001versus baseline
14P10608893A0727|9 13|Hp140
14P10608893A0727|23 26|Hp55
14P10608893A0727|32 34|DNA
14P10608893A0727|106 108|DNA
14P10610716A1127|16 33|missense mutations
14P10610716A1127|34 38|E138V
14P10610716A1127|40 44|R254G
14P10610716A1127|49 53|P362R
14P10610716A1127|79 85|AC gene
14P10610716A1127|89 99|FD patients
14P10611225A1127|24 34|interaction
14P10611225A1127|83 93|translation
14P10611225A1127|105 115|interaction
14P10611228A1388|3 10|DAP5/p86
14P10611228A1388|41 48|DAP5/p97
14P10611235A1927|58 67|MAPK Fus3p
14P10611235A1927|99 112|relocalization
14P10611235A1927|118 135|Ste5p-MAPK cascade
14P10611235A1927|140 154|plasma membrane
14P10611242A0541|35 38|SAGA
14P10611242A0541|47 57|TBP binding
14P10611242A0541|62 74|HIS3 promoter
14P10611242A0541|87 90|SAGA
14P10611320A0816|65 72|CAK gene
14P10611320A0816|73 76|CAK1
14P10611320A0816|105 117|Cak1p protein
14P10611353A0458|0 12|Northern blot
14P10611353A0458|22 47|transcription-PCR analyses
14P10611353A0458|80 82|RNR
14P10611353A0458|195 216|Northern blot analysis
14P10612044A1180|42 58|AP-4 binding site
14P10612044A1180|90 118|transcription initiation site
14P10612044A1180|123 131|Aal-rpL34
14P10612044A1180|135 148|Aal-rpL8 genes
14P10612505A1317|73 89|group differences
14P10612505A1317|91 106|treatment effect
14P10612773A1210|0 10|CONCLUSIONS
14P10612773A1210|12 23|Serum levels
14P10612773A1210|25 33|S-100beta
14P10612805A0716|17 26|alteration
14P10612918A0318|3 10|problems
14P10612918A0318|44 49|screws
14P10613816X0000|0 6|Statins
14P10613816X0000|119 127|compounds
14P10613816X0000|179 188|treatments
14P10613816X0000|207 219|bone diseases
14P10613816X0000|225 236|osteoporosis
14P10613843A0107|31 48|duplication events
14P10613843A0107|106 107|Ca
14P10613843A0107|112 123|ion channels
14P10613863T0000|3 25|VirR response regulator
14P10613863T0000|28 50|Clostridium perfringens
14P10613874A0663|0 6|Cloning
14P10613874A0663|69 72|ORFs
14P10613874A0663|143 146|GlnR
14P10613874A0663|150 162|GlnA proteins
14P10614676A0000|0 8|Objective
14P10614676A0000|153 177|mg norethisterone acetate
14P10614676A0000|177 182|E+NETA
14P10614676A0000|191 217|hormone replacement therapy
14P10614857A0584|0 17|Leukocyte cultures
14P10614857A0584|95 97|IFN
14P10614857A0584|150 159|adenovirus
14P10614857A0584|170 180|coronavirus
14P10614857A0584|192 201|rhinovirus
14P10616948A0998|5 16|BF ECT group
14P10616948A0998|74 96|seizure threshold level
14P10617126A1005|105 107|CA1
14P10617126A1005|131 143|dentate gyrus
14P10617126A1005|162 164|CA1
14P10617126A1005|168 170|CA3
14P10617144A0386|12 26|phosphorylation
14P10617144A0386|29 33|Ser44
14P10617144A0386|37 41|Ser64
14P10617232A0393|0 12|Serum HBV-DNA
14P10617232A0393|30 42|liver enzymes
14P10617232A0393|67 81|liver histology
14P10617613A1192|0 3|Chem
14P10618645A0750|0 16|Maximum induction
14P10618645A0750|18 21|AP-1
14P10618645A0750|61 64|CalC
14P10619062T0000|0 26|Haycocknema perplexum n. g.
14P10619169A0411|0 3|Rams
14P10619169A0411|18 28|testis size
14P10619169A0411|58 68|time period
14P10619254A1055|0 13|Animal studies
14P10619254A1055|23 39|beam equalization
14P10619353T0000|6 29|estrogen receptor ligand
14P10619353T0000|31 64|estrogen response element sequence
14P10619353T0000|103 131|promoter transcription factor
14P10619353T0000|131 137|COUP-TF
14P10620010A1155|0 9|CONCLUSION
14P10620010A1155|13 16|Cdks
14P10620010A1155|51 74|tyrosine phosphorylation
14P10620010A1155|120 134|phosphorylation
14P10620010A1155|151 156|T-loop
14P10620335A0749|16 18|AHR
14P10620335A0749|32 38|COUP-TF
14P10620335A0749|52 61|CV-1 cells
14P10620777A1399|0 7|AB004534
14P10622574A0000|15 31|hepatitis C virus
14P10622574A0000|31 33|HCV
14P10622574A0000|83 98|prevalence rates
14P10622576A0552|23 33|information
14P10622576A0552|74 83|prevention
14P10622576A0552|95 103|attention
14P10622576A0552|116 126|risk groups
14P10622576A0552|134 145|drug abusers
14P10623758A0947|6 12|latency
14P10623758A0947|26 32|neurons
14P10623758A0947|35 41|ganglia
14P10623758A0947|58 64|footpad
14P10623758A0947|74 91|beta-galactosidase
14P10623804A0808|83 86|SHIP
14P10623804A0808|88 92|SHP-1
14P10623804A0808|96 100|SHP-2
14P10623804A0808|130 153|Fc gamma RIIB1 signaling
14P10624787A0432|98 112|blood pressures
14P10624787A0432|145 148|Type
14P10624787A0432|150 151|DM
14P10624787A0432|164 178|body mass index
14P10624787A0432|190 204|waist-hip ratio
14P10625438A1429|24 34|transcripts
14P10625438A1429|58 69|bp insertion
14P10625438A1429|103 112|conditions
14P10625438A1429|146 155|transcript
14P10625438A1429|199 213|control samples
14P10625494A1059|23 33|CAAT-region
14P10625494A1059|61 73|MDR1 promoter
14P10625494A1059|75 88|HL60/VCR cells
14P10625683A0091|20 43|protein tyrosine kinases
14P10625683A0091|43 46|PTKs
14P10625683A0091|54 68|phosphorylation
14P10625721T0101|0 10|Hypothermia
14P10625721T0101|23 28|Arrest
14P10625721T0101|30 33|HACA
14P10625721T0101|35 45|Study Group
14P10627518A0544|33 43|cooperation
14P10627518A0544|84 96|contributions
14P10627518A0544|112 115|UTRs
14P10627532A0739|76 78|MAP
14P10627532A0739|88 90|p38
14P10627532A0739|94 96|JNK
14P10627532A0739|109 123|phosphorylation
14P10627532A0739|152 176|transcription factor ATF2
14P10627834A0178|3 4|US
14P10627834A0178|25 30|Tehama
14P10627834A0178|34 37|Vina
14P10627834A0178|73 81|Esterhazy
14P10627834A0178|87 90|G120
14P10627834A0178|99 120|New Zealand selections
14P10627834A0178|120 122|Rex
14P10627834A0178|124 129|Dublin
14P10627834A0178|132 136|Glory
14P10627834A0178|138 143|Meyric
14P10627834A0178|145 153|McKinster
14P10627834A0178|155 161|Stanley
14P10628490T0000|0 6|Anatomy
14P10628748A0344|57 80|inhibin alpha expression
14P10628748A0344|107 110|SF-1
14P10628748A0746|0 7|Deletion
14P10628748A0746|50 53|SF-1
14P10628748A0746|72 81|TCA GGGCCA
14P10628748A0746|111 131|cAMP-response element
14P10628748A0746|132 134|CRE
14P10628750A0298|26 29|APRE
14P10628750A0298|42 68|tumor necrosis factor-alpha
14P10628750A0298|68 75|TNFalpha
14P10628750A0298|142 150|NF-kappaB
14P10628750A0298|159 161|Rel
14P10628750T0000|34 35|NF
14P10628750T0000|62 110|angiotensinogen gene acute-phase response element
14P10628750T0000|136 155|NF-kappaB activation
14P10628755A0000|72 83|GH secretion
14P10628755A0000|103 133|orphan GH-secretagogue receptor
14P10628755A0000|133 137|GHS-R
14P10628971A0824|32 34|TGN
14P10628971A0824|107 127|protein sorting genes
14P10628971A0824|127 129|VPS
14P10628971A0824|144 169|dynamin family member VPS1
14P10628971A1165|30 32|TGN
14P10628971A1165|86 89|RIC1
14P10628971A1165|140 158|ribosome biogenesis
14P10628971A1165|159 162|LUV1
14P10628971A1165|211 234|microtubule organization
14P10628971A1165|238 242|INP53
14P10628971A1165|270 305|inositol polyphosphate 5-phosphatase
14P10629035A0827|9 20|strandedness
14P10629035A0827|71 77|G tails
14P10629035A0827|105 114|telomerase
14P10629035A0827|130 147|cdc17/pol1 mutants
14P10629176A0887|11 16|CaMig1
14P10629176A0887|47 57|URS1 region
14P10629176A0887|74 82|FBP1 gene
14P10629938A1352|19 30|distribution
14P10629938A1352|36 51|GFP-POLO protein
14P10629938A1352|56 67|compartments
14P10630471T0000|2 10|ASIC-chip
14P10630630A0614|40 42|PKC
14P10630630A0614|77 91|CFI mRNA levels
14P10633075A1111|9 11|IgG
14P10633075A1111|22 34|Fab fragments
14P10633075A1111|65 83|N-acetylglucosamine
14P10633499A1306|0 23|Arhythmacanthus Yamaguti
14P10634007A0202|17 38|acetaminophen overdose
14P10634007A0202|73 74|HD
14P10634007A0202|79 81|NAC
14P10635209A0419|9 20|conditioning
14P10635209A0419|35 42|adhesive
14P10637149A0806|15 29|G-A anastomosis
14P10637149A0806|33 34|RD
14P10637149A0806|36 37|CC
14P10637149A0806|85 87|REF
14P10637149A0806|118 120|A-A
14P10637230A0332|49 61|proliferation
14P10637230A0332|91 94|IFNs
14P10637238A0291|0 45|Eastern Cooperative Oncology Group trial E3186
14P10637337A0545|15 24|DNA repair
14P10637337A0545|36 39|TFA1
14P10638607A0000|121 127|N0-1 M0
14P10638607A0000|146 159|cell carcinoma
14P10638607A0000|160 162|SCC
14P10638607A0000|176 189|adenocarcinoma
14P10639585A0157|0 6|Studies
14P10639585A0157|9 27|MPO gene regulation
14P10640683A0204|0 11|NDRF/NeuroD2
14P10640683A0204|34 36|PKN
14P10640683A0204|52 62|COS-7 cells
14P10640683A0204|81 101|expression constructs
14P10640683A0204|104 115|NDRF/NeuroD2
14P10640683A0204|119 121|PKN
14P10640683A0670|9 27|transfection assays
14P10640683A0670|32 40|P19 cells
14P10640683A0670|64 75|NDRF/NeuroD2
14P10640683A0670|88 102|transactivation
14P10640683A0670|108 135|rat insulin promoter element
14P10640683A0670|135 139|RIPE3
14P10640683A0670|220 222|PKN
14P10640701T0000|26 35|Engrailed2
14P10640734A0190|4 27|tyrosine phosphorylation
14P10640734A0190|32 36|ITIMs
14P10640734A0190|59 61|SH2
14P10640734A0190|111 132|tyrosine phosphatase-1
14P10641037A1371|0 7|AF154055
14P10641688A0341|0 8|Alignment
14P10641688A0341|37 49|abnormalities
14P10641688A0341|54 65|disc changes
14P10642524A0156|14 24|interaction
14P10642524A0156|95 118|tetratricopeptide repeat
14P10642524A0156|119 121|TPR
14P10642531A2322|0 22|Competition experiments
14P10642531A2322|76 96|RGD recognition sites
14P10642889A0393|0 16|Sequence analysis
14P10642889A0393|59 67|ATG codon
14P10642889A0393|93 100|TATA box
14P10643313A0345|5 23|i.v. administration
14P10643313A0345|28 43|mg acetazolamide
14P10643313A0345|77 92|micrograms rt-PA
14P10643313A0345|100 102|BSS
14P10644357A0935|23 25|VP1
14P10644357A0935|118 120|VP2
14P10644357A0935|124 126|VP3
14P10644414T0000|37 54|20-hydroxyecdysone
14P10644414T0000|57 87|mosquito ultraspiracle isoforms
14P10644753A0725|37 60|antibody affinity column
14P10644753A0725|79 93|heparan sulfate
14P10644753A0725|116 133|glycosaminoglycans
14P10644760A0000|3 17|differentiation
14P10644760A0000|35 60|neurotransmitter phenotype
14P10644760A0956|0 7|Analysis
14P10644760A0956|29 32|Arix
14P10644760A0956|52 68|activation domain
14P10644760A0956|82 98|repression domain
14P10645921A0000|0 9|BACKGROUND
14P10645921A1320|87 103|ejection fraction
14P10645921A1320|105 106|SD
14P10645921A1320|149 166|circumflex disease
14P10646820T0000|23 37|lymphadenectomy
14P10646820T0000|50 60|lymph nodes
14P10646820T0000|81 92|hysterectomy
14P10646863A0838|0 13|Overexpression
14P10646863A0838|16 21|ICBP90
14P10646863A0838|85 105|topoisomerase IIalpha
14P10647177A0599|3 13|RNA aptamer
14P10647633A1685|41 49|sphincter
14P10647633A1685|55 57|RSJ
14P10647817T0000|0 8|Isolation
14P10647817T0000|50 74|T cell activation antigen
14P10647817T0000|74 77|PTA1
14P10647859A0000|66 85|pressure ventilation
14P10647859A0000|86 89|IPPV
14P10647859A0000|222 223|QB
14P10647859A0000|259 263|Pappl
14P10647859A0000|304 306|CO2
14P10647859A0000|338 340|CO2
14P10648020A0151|0 6|METHODS
14P10648020A0151|8 28|Von Willebrand factor
14P10648020A0151|50 85|factors tissue plasminogen activator
14P10648020A0151|114 144|plasminogen activator inhibitor
14P10648020A0151|145 149|PAI-1
14P10648020A0151|241 242|RA
14P10648211A0000|8 27|signaling properties
14P10648211A0000|76 87|ion channels
14P10648489A1117|0 8|Treatment
14P10648489A1117|64 81|segment depression
14P10648489A1117|96 114|peak concentrations
14P10648619A0000|63 65|TBP
14P10648619A0000|68 84|TATA interactions
14P10648619A0000|89 105|promoter activity
14P10648619A0000|131 143|silkworm tRNA
14P10648619A0000|147 149|Ala
14P10648619A0000|194 214|interactions accounts
14P10648619A0000|223 239|promoter activity
14P10648619A0000|265 266|SG
14P10648619A0000|269 271|Ala
14P10649449A0413|41 63|squalene synthase genes
14P10649449A0413|109 131|amino acid conservation
14P10649456A1061|49 55|EUROFAN
14P10649456A1061|75 83|EUROSCARF
14P10649456A1061|85 93|Frankfurt
14P10649738A0953|13 23|peritonitis
14P10649738A0953|55 58|CAPD
14P10649738A0953|72 85|patient-months
14P10650104X0284|0 8|Copyright
14P10650104X0284|16 28|Royal College
14P10650104X0284|30 41|Radiologists
14P10650938T0000|3 19|estrogen receptor
14P10650938T0000|20 21|ER
14P10650938T0000|44 64|estrogen dependencies
14P10650939A0789|0 8|Induction
14P10650939A0789|36 40|A-Fos
14P10650939A0789|61 64|AP-1
14P10650939A1542|12 14|SMC
14P10650939A1542|33 53|progesterone receptor
14P10650939A1542|54 57|PR-B
14P10650939A1542|61 64|PR-A
14P10650939A1542|101 109|PGDH-2368
14P10650958A1315|0 8|Element B
14P10650958A1315|46 68|consensus c-myb element
14P10650958A1315|144 163|mobility shift assay
14P10651076T0000|4 13|resolution
14P10651076T0000|22 31|tomography
14P10651076T0000|44 51|patients
14P10651076T0000|66 74|arthritis
14P10651805A1600|60 85|mouse L1210 leukemia cells
14P10651805A1600|93 111|folate accumulation
14P10651805A1600|144 167|acid growth requirements
14P10651805T0000|0 15|Characterization
14P10651805T0000|83 101|folate accumulation
14P10651805T0000|111 124|leukemia cells
14P10652093A0139|0 7|Electron
14P10652093A0139|54 64|A118 genome
14P10652093A0139|139 151|DNA molecules
14P10652102A0620|39 42|Fus3
14P10652102A0620|73 89|Ty1 transposition
14P10652228A0759|13 22|activation
14P10652228A0759|58 67|Rho family
14P10652228A0759|105 107|Dbl
14P10652324A0177|11 23|participation
14P10652324A0177|26 41|collagen binding
14P10652362A0933|32 48|carboxyl terminus
14P10652362A0933|50 53|CFTR
14P10652362A0933|77 98|internalization signal
14P10652362A0933|127 146|adaptor complex AP-2
14P10652362A0933|173 176|CFTR
14P10652800A0984|3 25|insulin therapy regimen
14P10652800A0984|77 88|relationship
14P10652800A0984|145 158|insulin dosage
14P10652800A0984|187 189|BMI
14P10653359A1297|0 9|Scmh1 maps
14P10653359A1297|11 18|4D1-D2.1
14P10653400A0000|30 46|donor nephrectomy
14P10653400A0000|47 49|LDN
14P10653550A1120|0 19|Hyaluronan treatment
14P10653550A1120|29 47|collagen remodeling
14P10653693A0429|62 65|KRAB
14P10653693A0429|67 88|KAP-1-RBCC interaction
14P10653693A0903|3 13|RING finger
14P10653693A0903|14 19|B2 box
14P10653693A0903|54 68|oligomerization
14P10653693A0903|71 80|KAP-1-RBCC
14P10653693A0903|84 95|KRAB binding
14P10653697A0133|0 5|Actins
14P10653697A0133|39 48|processing
14P10653733A0596|7 13|domains
14P10653733A0596|49 56|peptides
14P10654032A1133|0 3|JPEG
14P10654032A1133|19 35|compression ratio
14P10655164A0546|35 47|uncertainties
14P10655164A0546|73 84|Li abundance
14P10655164A0546|123 124|Li
14P10655164A0546|164 169|x10-10
14P10655230A0685|9 25|yeast counterpart
14P10655230A0685|29 47|mouse GCN2 isoforms
14P10656154A0722|30 32|PMS
14P10656161A0316|0 2|MBI
14P10656161A0316|6 9|MMBI
14P10656161A0316|23 33|Cmax values
14P10656161A0316|108 117|AUC values
14P10656802A1724|25 55|cathepsin X amino acid sequence
14P10657238A0541|0 23|Transfection experiments
14P10657238A0541|91 103|transcription
14P10657238A0541|106 122|mouse NMuMG cells
14P10657658A0165|16 25|T-24 cells
14P10657658A0165|41 52|HA fragments
14P10657658A0165|63 93|I kappa B alpha phosphorylation
14P10657658A0165|118 141|reporter gene expression
14P10657658A0165|144 167|ICAM-1 promoter activity
14P10657658A0165|170 177|NF-kappa
14P10657899A0685|0 11|Pretreatment
14P10657899A0685|43 58|oligonucleotides
14P10657899A0685|61 67|PKCzeta
14P10657899A0685|98 101|AP-1
14P10657899A0685|104 112|JB6 cells
14P10658425A1567|3 7|level
14P10658425A1567|21 29|infection
14P10658445A0208|0 6|METHODS
14P10658445A0208|70 93|PGE1 alpha-ciclodestrina
14P10658445A0208|104 119|treatment cycles
14P10658445A0208|154 168|reference group
14P10658445A0208|182 195|prostaglandins
14P10658588A0304|0 27|Desmethylferrochloroquine 1a
14P10658588A0304|30 56|didesmethylferrochloroquine
14P10658588A0304|100 101|CQ
14P10658588A0304|127 129|HB3
14P10658588A0304|139 159|Plasmodium falciparum
14P10660069A0819|55 58|HOG1
14P10660069A0819|61 64|PBS2
14P10660069A0819|99 107|RRD genes
14P10660069A0819|113 145|Hog1p signal transduction pathway
14P10660304A0522|0 6|Members
14P10660304A0522|12 25|JAK/Tyk family
14P10660304A0522|27 42|tyrosine kinases
14P10660304A0522|66 70|STAT3
14P10660304A0522|73 78|Tyr705
14P10660304A0522|85 98|CNTF signaling
14P10660304A0522|147 158|STAT3 Tyr727
14P10660604A0748|7 22|CARbeta/RXRalpha
14P10660604A0748|51 87|HD-PPRE luciferase reporter construct
14P10660676A0000|0 16|Zebrafish cyclops
14P10660676A0000|41 58|Growth Factor beta
14P10660676A0000|58 64|TGFbeta
14P10660676A0000|66 81|signaling factor
14P10662550A0679|5 8|SOX8
14P10662550A0679|52 72|retardation phenotype
14P10662550A0679|78 92|ATR-16 patients
14P10662614A0000|3 21|genome organization
14P10662614A0000|42 66|wheat streak mosaic virus
14P10662614A0000|65 68|WSMV
14P10662614A0000|105 115|Potyviridae
14P10662614A0000|161 186|amino acid dissimilarities
14P10662614A0972|57 58|CI
14P10662614A0972|60 65|HC-Pro
14P10662614A0972|67 68|P1
14P10662614A0972|70 71|P3
14P10662614A0972|76 77|CP
14P10663558T0000|40 67|basement membrane reactivity
14P10663558T0000|112 113|Ig
14P10664876A0000|0 9|Patch test
14P10664876A0000|28 41|corticosteroid
14P10664876A0000|74 94|corticosteroid series
14P10664876A0000|113 126|classification
14P10664876A0000|129 152|corticosteroid molecules
14P10664876A0000|202 220|hydrocortisone type
14P10664876A0000|248 269|betamethasone type-non
14P10665308T0001|0 9|Mechanisms
14P10665308T0001|12 24|tachyphylaxis
14P10665798A0598|41 62|aspartate transaminase
14P10665798A0598|63 82|alkaline phosphatase
14P10665798A0598|83 104|creatine phosphokinase
14P10665798A0598|105 125|lactate dehydrogenase
14P10665798A0598|130 156|D. russelli venom injection
14P10665949A1131|10 20|farm budget
14P10665949A1131|34 43|importance
14P10666222A0330|31 50|survivin cDNA clones
14P10666222A0330|95 111|survivin proteins
14P10666238A1322|19 29|E2F binding
14P10666238A1322|34 47|E2F-1 promoter
14P10666238A1322|52 55|E4-6
14P10666238A1322|94 108|transactivation
14P10666238A1322|111 133|E2F-1 promoter activity
14P10666253A1291|10 22|stabilization
14P10666253A1291|82 84|PBS
14P10666509A0494|69 86|propranolol groups
14P10667597A0668|0 2|ZK7
14P10667597A0668|6 16|HZF16 genes
14P10668701A1311|0 9|CONCLUSION
14P10668701A1311|11 18|Presence
14P10668701A1311|21 33|APOE epsilon4
14P10668701A1311|71 72|AD
14P10669319A1722|10 20|conclusions
14P10669319A1722|57 64|patients
14P10669594A0000|83 87|SEF14
14P10669594A0000|138 140|PT3
14P10669594A0000|157 195|16-amino acid Leishmania T-cell epitope
14P10669594A0000|206 225|metalloprotease gp63
14P10669594A0969|18 21|AgfA
14P10669594A0969|40 52|SefA proteins
14P10669596A0430|85 88|Abc2
14P10669596A0430|139 155|nuclease activity
14P10669596A0430|210 233|RecBCD nuclease activity
14P10669633A0391|115 125|THP-1 cells
14P10669736A0903|29 31|CAT
14P10669736A0903|62 71|HeLa cells
14P10669736A0903|110 112|PTB
14P10669751T0000|25 57|protein kinase signaling pathways
14P10670358A0143|0 10|Dermatology
14P10671224A0254|60 75|CD95L expression
14P10671519A0641|0 24|Protein sequence analysis
14P10671519A0641|34 44|MAN1 shares
14P10671519A0641|110 119|LEM module
14P10671519A0641|136 152|membrane proteins
14P10671520T0000|87 112|T-cell leukemia virus type
14P10671520T0000|114 129|HIV-1 expression
14P10671554A0492|10 29|amino acid sequences
14P10671554A0492|94 112|amino acid residues
14P10671554A0492|166 182|Edman degradation
14P10671606A0884|4 25|chemical shift imaging
14P10671606A0884|28 43|signal intensity
14P10671606A0884|104 106|APA
14P10671606A0884|140 142|BAH
14P10672433A0199|41 51|measurement
14P10672433A0199|62 70|wake time
14P10672433A0199|81 83|TIB
14P10672433A0199|91 100|efficiency
14P10672433A0199|128 138|sleep onset
14P10672433A0199|139 142|WASO
14P10672433A0199|145 153|alertness
14P10672433A0199|156 164|awakening
14P10672433A0199|169 178|percentage
14P10672899A0078|0 3|Acad
14P10673335X0782|0 8|Copyright
14P10673335X0782|13 26|Academic Press
14P10673426A0168|51 58|activity
14P10673426A0168|96 108|translocation
14P10673426A0168|113 119|process
14P10673426A0168|175 182|receptor
14P10673426A0168|197 208|cytotoxicity
14P10674395A0262|82 85|GnRH
14P10674395A0262|122 124|GMP
14P10674395A0262|131 157|signal transduction pathway
14P10674395A0262|177 190|protein kinase
14P10674395A0262|229 243|cell line GT1-7
14P10674484A0633|28 34|lesions
14P10674484A0633|63 69|neurons
14P10674484A0633|75 83|rat brain
14P10674484A0633|102 111|perception
14P10675154T0000|16 30|botulinum toxin
14P10675331A0600|45 68|tyrosine phosphorylation
14P10675331A0600|70 72|Shc
14P10675331A0600|86 99|Erk activation
14P10675331A0600|106 129|tyrosine phosphorylation
14P10675331A0600|142 146|Stat3
14P10675610A0279|0 4|MSSPs
14P10675610A0279|26 40|DNA replication
14P10675610A0279|68 89|cell cycle progression
14P10675610A0279|108 120|C-MYC protein
14P10677214A1045|7 15|type MutT
14P10677214A1045|21 24|E53D
14P10677214A1045|28 39|E44D mutants
14P10677214A1045|260 272|acid catalyst
14P10677214A1045|307 313|MutT-Mg
14P10677214A2842|44 47|E44D
14P10677214A2842|73 86|N HSQC spectra
14P10677214A2842|108 119|loop I-helix
14P10677214A2842|140 145|Glu-44
14P10677214A2842|165 175|site region
14P10677297A0933|7 16|expression
14P10677297A0933|61 78|missense mutations
14P10678144A0509|5 8|i.v.
14P10678968A1096|0 7|Immunity
14P10678968A1096|28 40|I. scapularis
14P10678968A1096|99 114|mouse population
14P10678968A1096|129 145|E. phagocytophila
14P10679015A0216|22 28|studies
14P10679015A0216|31 35|yeast
14P10679015A0216|46 50|class
14P10679015A0216|53 59|snoRNPs
14P10679015A0216|84 91|proteins
14P10679065A0711|0 16|BCR cross-linking
14P10679065A0711|48 72|protein kinase-2 activity
14P10679065A0711|113 120|p38 MAPK
14P10679065A0711|180 196|peptide substrate
14P10679065A0711|209 219|CREB serine
14P10679065A0711|222 242|phosphoacceptor motif
14P10679065A1217|26 72|junB promoter/chloramphenicol acetyltransferase
14P10679065A1217|72 74|CAT
14P10679065A1217|93 95|BCR
14P10679065A1217|112 119|SB203580
14P10679190A0693|36 48|reading frame
14P10679190A0693|66 76|translation
14P10679190A0693|101 113|reading frame
14P10679649A0311|0 6|METHODS
14P10679649A0311|8 23|TBN measurements
14P10679649A0311|61 76|breast carcinoma
14P10679649A0311|101 116|cyclophosphamide
14P10679649A0311|134 147|5-fluorouracil
14P10679649A0311|149 151|CMF
14P10679781A1183|4 34|bp Glucocorticoid Response Unit
14P10679781A1183|33 35|GRU
14P10679781A1183|55 78|glucocorticoid induction
14P10679922A1110|59 62|ING1
14P10679922A1110|69 96|tumor suppressor gene target
14P10681520A0525|0 7|Ras-GRF1
14P10681520A0525|83 94|GEF activity
14P10681520A0525|100 102|Rac
14P10681520A0525|110 112|Rho
14P10681520A0525|116 120|Cdc42
14P10681520A0525|157 166|Gbetagamma
14P10681562A0263|12 32|PPARgamma antagonists
14P10681562A0263|125 140|PPARgamma action
15P10681588A0899a|0 3|EMSA
15P10681588A0899a|33 36|PC12
15P10681588A0899a|43 44|C6
15P10681588A0899a|47 56|Rat2 cells
15P10681588A0899a|63 65|CRE
15P10681588A0899a|96 115|transcription factor
15P10681588A0899a|116 118|ATF
15P10681588A0899a|125 129|CCAAT
15P10681588A0899a|167 170|PC12
15P10681588A0899a|174 180|C6 cell
15P10681588A0899a|213 221|CCAAT-box
15P10681588A0899b|0 3|EMSA
15P10681588A0899b|33 36|PC12
15P10681588A0899b|43 44|C6
15P10681588A0899b|47 56|Rat2 cells
15P10681588A0899b|63 65|CRE
15P10681588A0899b|96 115|transcription factor
15P10681588A0899b|116 118|ATF
15P10681588A0899b|125 129|CCAAT
15P10681588A0899b|167 170|PC12
15P10681588A0899b|174 180|C6 cell
15P10681588A0899b|213 221|CCAAT-box
14P10681679A0220|7 16|resolution
14P10681679A0220|45 54|serial MRI
14P10681679A0220|60 70|enlargement
14P10681679A0220|81 90|tumor cyst
14P10681679A0220|112 120|diagnosis
14P10682570A0453|0 2|LPO
14P10682570A0453|6 15|SOD levels
14P10683072T0000|73 99|bolus interleukin-2 therapy
14P10683244A0939|14 17|NBF1
14P10683244A0939|19 27|R protein
14P10683244A0939|31 42|NBF2 protein
14P10683244A0939|112 130|sieve chomatography
14P10683244A0939|169 172|NBF1
14P10683244A0939|177 180|NBF2
14P10683244A1860|44 47|CFTR
14P10683244A1860|50 53|NBF1
14P10683244A1860|55 62|R region
14P10683244A1860|68 78|NBF2 domain
14P10683244A1860|228 242|phosphorylation
14P10683244X2359|0 8|Copyright
14P10683244X2359|13 26|Academic Press
14P10683259A0774|0 19|Sulfhydryl titration
14P10683259A0774|23 35|iodoacetamide
14P10683259A0774|95 114|maleimide derivative
14P10683259A0774|196 211|splice junctions
14P10683989A0251|11 26|oxide inhalation
14P10683989A0251|62 65|PaO2
14P10683989A0251|69 72|SaO2
14P10683989A0251|106 119|Qs/Q tau ratio
14P10684069A0508|20 22|MIP
14P10684069A0508|24 27|MMIF
14P10684069A0508|29 31|FIC
14P10684069A0508|33 37|Wimax
14P10684069A0508|39 42|P0.1
14P10684069A0508|46 63|minute ventilation
14P10684069A0508|64 65|Vr
14P10684069A0508|114 129|methylphenidatum
14P10684097A0175|15 16|SD
14P10684097A0175|67 80|sham operation
14P10684097A0175|90 100|ovariectomy
14P10684097A0175|102 112|ovariectomy
14P10684097A0175|130 146|ethinyl estradiol
14P10684111A1411|68 75|MAPK p44
14P10684111A1411|78 85|MAPK p42
14P10684111A1411|87 105|MAPK family members
14P10684265T0000|25 54|transactivator protein IE2-p86
14P10684265T0000|60 74|cytomegalovirus
14P10684265T0000|113 127|proteins SUMO-1
14P10684304A1242|3 13|interaction
14P10684534A0634|0 8|Protamine
14P10684534A0634|12 24|heparin doses
14P10684534A0634|34 43|Sigma-dose
14P10684534A0634|90 103|clotting times
14P10684646A0224|19 27|mechanism
14P10684646A0224|82 91|expression
14P10684646A0224|94 101|caveolin
14P10684660A1266|0 9|Comparison
14P10684660A1266|33 49|processing enzyme
14P10684660A1266|93 102|activities
14P10684941A0722|3 13|requirement
14P10684941A0722|18 32|complementarity
14P10684941A0722|37 53|ligation reaction
14P10684941A0722|79 91|nt insertions
14P10684967A0000|0 5|NKX2.1
14P10684967A0000|20 29|NK2 family
14P10684967A0000|53 73|transcription factors
14P10684967A0000|124 137|thyroid tissue
14P10684967A0000|157 170|lung phenotype
14P10687366A0000|0 21|National abortion laws
14P10687855A1197|0 9|Expression
14P10687855A1197|74 78|Zn-16
14P10687855A1197|104 114|development
14P10687855A1197|133 147|differentiation
14P10687855T0000|0 46|Mouse growth hormone transcription factor Zn-16
14P10687862A1980|3 29|CCAAT core sequence mutants
14P10687862A1980|38 41|CIII
14P10687862A1980|45 50|CI/CII
14P10687945A0000|0 10|Deglutition
14P10688639A1310|31 50|PU.1 transactivation
14P10688639A1310|52 63|PEST domains
14P10688639A1310|84 98|p300 expression
14P10688646A0535|20 29|K562 cells
14P10688646A0535|56 72|HS-40 mutants cis
14P10688646A0535|112 130|hormone hybrid gene
14P10688646A0535|165 183|expression analysis
14P10688660A0992|32 34|CBP
14P10688660A0992|57 66|T47D cells
14P10688660A0992|146 174|progesterone response element
14P10688660A0992|174 176|PRE
14P10688660A0992|185 205|reporter DNA template
14P10688661A0237|10 24|binding protein
14P10688661A0237|25 33|REST/NRSF
14P10688661A0237|48 67|transcription factor
14P10688663A0207|0 6|Removal
14P10688663A0207|12 36|core histone tail domains
14P10688663A0207|43 61|trypsin proteolysis
14P10688663A0207|79 96|core histone tails
14P10688663A0207|139 144|TFIIIA
14P10688663A0207|187 189|DNA
14P10688666A1010|22 36|ASK1 activation
14P10688666A1010|52 71|homo-oligomerization
14P10690702A0065|0 6|OUTCOME
14P10690702A0065|8 40|Acetylcholine receptor antibodies
14P10690725A1037|25 28|PRFR
14P10690866A0783|41 66|TSH frequency distribution
14P10691972T0000|0 15|Characterization
14P10691972T0000|57 74|resistance protein
14P10691972T0000|76 79|MRP2
14P10691972T0000|103 120|comparison withthe
14P10691972T0000|129 146|resistance protein
14P10691972T0000|148 151|MRP3
14P10692167A0364|49 60|observations
14P10692167A0364|63 73|M. synoviae
14P10692374A1873|26 38|M. jannaschii
14P10692374A1873|61 75|20S proteasomes
14P10692374A1873|83 102|nucleotidase complex
14P10692374A1873|108 110|PAN
14P10692374A1873|197 215|amino acid residues
14P10692374A1873|216 218|PAN
14P10692433A0000|3 26|transcription factor E2F
14P10692433A0000|53 70|S phase transition
14P10693246A0252|137 158|laryngeal nerve chains
14P10693314A0521|24 36|CK-MB results
14P10693314A0521|66 68|ECG
14P10693314A0521|77 79|AMI
14P10694189A0469|11 13|MIB
14P10694189A0469|56 68|noradrenaline
14P10694210A0385|21 23|H1R
14P10694210A0385|73 90|cingulate cortices
14P10694210A0385|108 121|administration
14P10694210A0385|124 141|d-chlorpheniramine
14P10694210A0385|181 183|H1R
14P10694511A0570|3 12|expression
14P10694511A0570|74 82|phenotype
14P10694511A0570|103 110|increase
14P10694511A0570|113 114|Ca
14P10694511A0570|119 133|uptake activity
14P10694605A1327|17 31|infection rates
14P10694605A1327|32 54|events/100 patient-days
14P10694605A1327|111 112|NS
14P10694609A0309|16 25|compliance
14P10694609A0309|42 50|induction
14P10694609A0309|53 62|anesthesia
14P10694609A0309|89 98|filtration
14P10694609A0309|104 120|operating theater
14P10694609A0309|160 168|care unit
14P10694609A0309|187 195|operation
14P10695685T0000|30 38|rationale
14P10695685T0000|50 61|implications
14P10695685T0000|74 85|consequences
14P10696007A1325|27 47|C2-C3 disk morphology
14P10698516T0000|0 2|KFC
14P10698516T0000|69 84|SAPK/JNK pathway
14P10698937T0000|0 4|TIP30
14P10698937T0000|19 33|kinase activity
14P10698937T0000|44 56|up-regulation
14P10698974A0951|20 29|STAG3 gene
14P10698974A0951|185 195|breakpoints
14P10698974A0951|245 247|WBS
14P10699354A0557|0 12|Reaction time
14P10699354A0557|13 14|RT
14P10699653A0967|2 11|experiment
14P10699653A0967|27 32|access
14P10699653A0967|38 44|bottles
14P10699653A0967|65 73|tap water
14P10699653A0967|102 108|ethanol
14P10699653A0967|116 122|sucrose
14P10699653A0967|127 134|solution
14P10699684A0661|12 16|Zelen
14P10699684A0661|92 102|institution
14P10699684A0661|104 105|M.
14P10699896A0455|0 6|RESULTS
14P10700262A0000|66 80|control systems
14P10700262A0000|90 105|brain structures
14P10701534A0164|32 51|low-frequency tremor
14P10701534A0164|54 65|hemidystonia
14P10701534A0164|78 88|head trauma
14P10702241A0357|11 20|a1 isoform
14P10702241A0357|58 59|a2
14P10702241A0357|80 81|a3
14P10702253A0357|25 63|transcriptase-polymerase chain reaction
14P10702253A0357|72 89|HIF-1alpha subunit
14P10702253A0357|156 170|HIF-1alpha gene
14P10702285A0855|55 83|phosphatidylinositol 3-kinase
14P10702285A0855|133 135|p85
14P10702285A0855|162 181|wortmannin treatment
14P10702285A0855|235 258|GLUT4-EGFP translocation
14P10702389A1148|9 10|BL
14P10702389A1148|15 27|RB2/p130 gene
14P10702794A1495|26 29|ERK2
14P10702794A1495|58 62|HePTP
14P10702794A1495|96 100|HePTP
14P10702794A1495|120 132|ERK2 activity
14P10702794A1495|141 158|feedback mechanism
14P10702926T0089|0 13|Cross-reaction
14P10702926T0089|46 72|alpha beta T cell receptors
14P10703633A0747|0 16|Strontium nitrate
14P10703633A0747|113 132|irritation sensation
14P10703633A0747|154 156|SEM
14P10703633A0747|180 182|SEM
14P10703633A0747|222 235|mean magnitude
14P10703633A0747|240 259|irritation sensation
14P10703633A0747|264 274|time points
14P10704196A1051|17 33|sulfhydryl groups
14P10704196A1051|78 92|plasma membrane
15P10704283A0649a|0 7|Analysis
15P10704283A0649a|11 12|Mb
15P10704283A0649a|70 88|chromosome 5q31-q33
15P10704283A0649a|100 114|gene candidates
15P10704283A0649a|150 175|IL-4 cytokine gene cluster
14P10704285A0536|5 11|AP-2rep
14P10704285A0536|70 87|AP-2alpha promoter
14P10704285A0536|103 116|AP-2alpha gene
14P10704285A0536|152 160|AP-2alpha
14P10704338A0354|67 69|p24
14P10704338A0354|71 72|CA
14P10704338A0354|124 139|proline residues
14P10704338A0354|172 184|alpha-helices
14P10704338A0354|194 196|p24
14P10704338A0354|229 243|leucine residue
14P10704338A0354|244 255|P-position-L
14P10704410T0000|0 16|Clb/Cdc28 kinases
14P10704410T0000|41 77|replication initiator proteins Mcm2-7
14P10704499A0682|14 26|PC12-E2 cells
14P10704499A0682|69 92|fibroblast growth factor
14P10704499A0682|92 94|FGF
14P10704499A0682|131 149|tyrosine kinase p59
14P10704499A0682|154 156|PLC
14P10704499A0682|158 160|PKC
14P10704499A0682|164 166|MEK
14P10704499A0682|183 185|PKC
14P10704499A0682|187 217|phorbol-12-myristate-13-acetate
14P10704499A0682|219 221|PMA
14P10704853T0000|0 16|Cooperative roles
14P10704853T0000|18 31|Bozozok/Dharma
14P10704853T0000|75 90|dorsal organizer
14P10704975A0479|0 17|Thiopentone sodium
14P10704975A0479|76 80|NOC-5
14P10704975A0479|132 144|neurotoxicity
14P10705380A0629|34 52|Xretpos transcripts
14P10705380A0629|110 123|UV-irradiation
14P10705380A0629|127 146|BMP-4 overexpression
14P10705783A0433|56 70|labyrinthectomy
14P10705783A0433|97 120|concentration gentamicin
14P10706475A0644|27 30|DSPP
14P10706475A0644|44 46|DSP
14P10706475A0644|50 52|DPP
14P10706513A0843|11 19|prognosis
14P10706513A0843|27 37|% mortality
14P10706513A0843|64 74|ventilation
14P10706688A0376|11 23|TCR signaling
14P10706688A0376|30 41|AP-1 binding
14P10706688A0376|66 87|fasl promoter function
14P10706688A0376|107 123|NF-kappaB binding
14P10706736A1091|56 57|Ag
14P10706736A1091|79 81|CD8
14P10706736A1091|83 89|T cells
14P10706736A1091|108 112|HLA-A
14P10706887A0281|18 22|ALCLs
14P10706887A0281|34 36|ALK
14P10706887A0281|117 130|ALK expression
14P10706887A1457|30 33|ATIC
14P10706887A1457|137 148|methotrexate
14P10708243A0000|12 22|observation
14P10708243A0000|45 54|antibodies
14P10708243A0000|69 82|pregnancy loss
14P10708243A0000|85 96|preeclampsia
14P10708243A0000|121 130|antibodies
14P10708424A0800|38 56|autophosphorylation
14P10708424A0800|59 63|BGLF4
14P10708769A0433|3 6|Mif1
14P10708769A0433|42 43|ER
14P10709705T0000|5 30|point feature registration
14P10710499A0000|0 11|Methysergide
14P10710499A0000|15 34|serotonin antagonist
14P10710499A0000|64 79|wound blood flow
14P10710499A0000|81 95|edema formation
14P10710742T0000|0 26|Serum leptin concentrations
14P10710742T0000|38 68|gonadotropin stimulation cycles
14P10710985T0000|22 34|work practice
14P10710985T0000|51 71|strengths perspective
14P10711674A0000|0 6|PURPOSE
14P10711674A0000|74 78|Leber
14P10711674A0000|99 101|LCA
14P10711674A0000|103 105|MIM
14P10712512A0506|0 5|Ste18p
14P10712512A0506|22 36|plasma membrane
14P10712512A0506|54 64|prenylation
14P10712512A0506|67 79|thioacylation
14P10712599A0349|15 19|IRF-1
14P10712618A0181|12 30|sequence comparison
14P10712618A0181|42 66|Bacillus YM55-1 aspartase
14P10712618A0181|86 112|Bacillus subtilis aspartase
14P10713083A0170|32 35|TraR
14P10713083A0170|80 83|TraM
14P10713083A0560|50 60|DNA binding
14P10713083A0560|74 86|TraR function
14P10713083A0560|103 122|transcription factor
14P10713083A0560|135 154|DNA recognition site
14P10713155A0151|14 35|IIIa pre-mRNA splicing
14P10713155A0151|119 123|Ad-NE
14P10713155A0151|145 153|HeLa cell
14P10713155A0151|169 175|HeLa-NE
14P10713161A0985|0 11|Inactivation
14P10713161A0985|14 17|Ulp2
14P10713161A0985|92 114|Smt3-protein conjugates
14P10713175A1399|34 44|ARF binding
14P10713175A1399|46 49|Mdm2
14P10713175A1399|113 128|ARF-Mdm2 complex
14P10713175A1399|144 160|cell cycle arrest
14P10713176A0422|0 18|Cyclin A expression
14P10713176A0422|46 48|E2F
14P10713176A0422|75 100|pocket protein partners Rb
14P10713176A0422|99 102|p107
14P10713176A0422|107 110|p130
14P10713176A0422|167 168|Rb
14P10713176A0422|194 211|E2F-p107 complexes
14P10713176A0422|225 242|mitogen withdrawal
14P10713176A0885|0 20|D-cyclin-cdk activity
14P10713176A0885|33 50|Rb phosphorylation
14P10713176A0885|136 140|INK4A
14P10713176A0885|154 166|DNA synthesis
14P10713176A0885|169 186|cell proliferation
14P10713239A0988|0 9|CONCLUSION
14P10713239A0988|42 58|capsulorhexis rim
14P10713239A0988|79 87|IOL optic
14P10713453A0172|40 51|antibody Q18
14P10713453A0172|76 78|57A
14P10713453A0172|81 100|polytene chromosomes
14P10713453A0172|127 132|Hrb57A
14P10714985A1057|2 25|RNA boundary experiments
14P10714985A1057|73 82|AG repeats
14P10714985A1057|107 128|leader RNA association
14P10715322A0000|0 13|Gene silencing
14P10715322A0000|35 47|DNA sequences
14P10715325A0834|3 13|AtERF genes
14P10715325A0834|62 78|stress conditions
14P10715325A0834|125 145|ETHYLENE-INSENSITIVE2
14P10715325A0834|147 150|EIN2
14P10715602A0149|0 6|Animals
14P10715602A0149|22 34|dexamethasone
14P10715602A0149|70 99|surfactant preparation Exosurf
14P10715602A0149|103 115|phospholipids
14P10715602A0149|137 149|Wellcome GmbH
14P10715602A0149|150 158|Burgwedel
14P10715602A0149|160 166|Germany
14P10717612A0000|0 9|BACKGROUND
14P10717612A0000|45 58|response rates
14P10717612A0000|121 138|stimulating factor
14P10717612A0000|139 144|GM-CSF
14P10717612A0000|163 175|interleukin-2
14P10717612A0000|177 180|IL-2
14P10717612A0000|225 238|cell carcinoma
14P10720434A0291|87 100|cyclin B1 mRNA
14P10720434A0291|116 118|UTR
14P10721698A1195|35 50|dodecamer repeat
14P10721698A1195|80 83|CSTB
14P10721698A1195|141 153|transcription
14P10721698A1195|156 159|CSTB
14P10721704A1155|20 31|organization
14P10721704A1155|81 91|Elav family
14P10721704A1155|95 110|promoter element
14P10721704A1155|136 152|sequence analysis
14P10721704X0000|0 7|Analysis
14P10721704X0000|23 34|mouse Elavl1
14P10721704X0000|114 125|organization
14P10721704X0000|132 137|Elavl1
14P10721704X0000|222 232|cell growth
14P10721704X0000|235 247|proliferation
14P10721704X0000|258 267|regulation
14P10721704X0000|270 283|mRNA stability
14P10721714A1087|15 35|mobility shift assays
14P10721714A1087|46 48|Sp1
14P10721714A1087|105 112|Sp1 site
14P10721717A0676|0 3|Fgd3
14P10721717A0676|7 10|FGD1
14P10721717A0676|29 45|sequence identity
14P10721717A0676|68 86|amino acid residues
14P10721726T0000|18 45|mouse thioredoxin reductases
14P10722063A0328|3 13|HPLC method
14P10722063A0328|23 44|octadecylsilane column
14P10722509A0392|5 12|patients
14P10722509A0392|36 44|dipivoxil
14P10722509A0392|52 62|body weight
14P10722509A0392|69 76|patients
14P10722509A0392|100 108|dipivoxil
14P10722661A0146|0 3|CYC2
14P10722661A0146|53 75|Neurospora crassa PREG1
14P10722661A0146|92 103|PHO80 cyclin
14P10722661A0406|13 16|CYC2
14P10722661A0406|89 92|CRKs
14P10722661A0406|98 106|CYC2 gene
14P10722661A0406|119 132|TY epitope tag
14P10722661A0406|149 166|trypanosome genome
14P10722737A1726|37 39|Sp1
14P10722737A1726|45 47|Inr
14P10722737A1726|93 112|transcription factor
14P10722737A1726|115 117|Sp1
14P10722737A1726|151 153|LTC
14P10722737A1726|157 162|S gene
14P10722969A0510|12 19|progress
14P10723723A0781|48 78|CT dinucleotide repeat sequence
14P10723727A0713|74 105|polyadenylation signal sequences
14P10724436A0085|19 22|U3O8
14P10724436A0085|31 49|reference materials
14P10724483A0540|44 47|SRP1
14P10724483A0540|51 61|HEM13 genes
14P10724483A0540|80 90|HOG pathway
14P10724519A1185|38 41|RNAs
14P10725017A0673|52 58|CEN ENV
14P10725017A0673|100 116|healthcare record
14P10725017A0673|123 129|CEN ENV
14P10725017A0673|145 174|Healthcare Record Architecture
14P10725382A0398|0 16|Sequence analyses
14P10725382A0398|111 114|SOS2
14P10725433A0543|54 73|Wp reporter activity
14P10725433A0543|86 97|B cell lines
14P10725433A0543|183 199|promoter function
14P10727247A0461|40 57|expression pattern
14P10727247A0461|97 110|TEF-1 isoforms
14P10727247A0461|111 119|TEF-1beta
14P10727247A0461|123 132|TEF-1gamma
14P10727413A1244|12 24|binding sites
14P10727413A1244|61 74|hamster CYP7A1
14P10727413A1244|181 190|expression
14P10727413A1244|194 211|tissue restriction
14P10727426A1280|3 17|kinase activity
14P10727426A1280|19 23|PfPK6
14P10727426A1280|37 50|CDK inhibitors
14P10727428A0000|8 10|MAP
14P10727428A0000|59 76|cell proliferation
14P10727428A0000|79 93|differentiation
14P10727428A0000|119 129|MAP kinases
14P10727433A0560|0 11|Transfection
14P10727433A0560|17 41|CSF-1R expression plasmid
14P10727433A0560|79 96|signalling pathway
14P10727433A0560|107 113|Ets/AP1
14P10727433A0560|115 131|activator protein
14P10727433A0560|210 234|protein kinase C pathways
14P10727433T0000|12 61|urokinase plasminogen activator gene transcription
14P10727433T0000|63 68|RAW264
14P10727433T0000|75 94|macrophage cell line
14P10727433T0000|130 134|CSF-1
14P10727511A0294|0 7|Molecule
14P10727511A0294|64 68|GLT-1
14P10727511A0294|94 111|signaling pathways
14P10727515A1202|0 11|Coactivation
14P10727515A1202|97 108|stimulations
14P10727515A1202|111 117|PLCbeta
14P10727515A1202|159 173|pertussis toxin
14P10728945A0233|0 7|Patients
14P10728945A0233|21 30|Integrilin
14P10728945A0233|41 60|Platelet Aggregation
14P10728945A0233|71 83|Thrombosis-II
14P10728945A0233|85 93|IMPACT-II
14P10728986A0000|3 23|Wnt signaling pathway
14P10728986A0000|50 67|animal development
14P10728986A0000|76 94|cell fate decisions
14P10729151A1160|32 37|HPV-11
14P10729151A1160|73 91|reporter expression
14P10729155A0653|17 27|MVMi capsid
14P10729155A0653|48 58|carboxy end
14P10729155A0653|74 86|beta-strand I
14P10729220A0000|16 19|IGF2
14P10729220A0000|56 64|H19 genes
14P10729220A1569|13 23|methylation
14P10729220A1569|56 65|disruption
14P10729220A1569|68 70|H19
14P10729221A0798|18 36|expression patterns
14P10729221A0798|46 63|Kv4 family members
14P10729221A0798|67 85|subtype specificity
14P10730292T0000|5 23|treatment mechanics
14P10730292T0000|28 44|Class II division
14P10730763A1491|19 50|Nottingham Eczema Severity Score
14P10730763A1491|115 130|disease severity
14P10731411A0958|94 115|DEAD-box RNA helicases
14P10731411A0958|175 178|DEAD
14P10731926A0775|0 15|Advanced adenoma
14P10731926A0775|81 89|component
14P10731926A0775|101 109|dysplasia
14P10731926A0775|120 128|carcinoma
14P10732669A0510|64 83|particle bombardment
14P10732669A0510|106 111|Oshox1
14P10732669A0510|152 175|reporter gene constructs
14P10732669A0510|186 205|HD-Zip binding sites
14P10732669A1336|0 6|Results
14P10732669A1336|43 63|mobility shift assays
14P10732669A1336|121 130|homodimers
14P10732669A1336|138 149|heterodimers
14P10733569A0364|14 17|HSFs
14P10733569A0364|19 22|HSF1
14P10733569A0364|78 99|stress gene expression
14P10733569A0364|119 122|HSF2
14P10733581A1391|56 58|Raf
14P10733581A1391|62 71|V12N38 Ras
14P10733581A1391|100 113|TTF-1 activity
14P10733591A0146|55 72|actin cytoskeleton
14P10733591A0146|85 87|p70
14P10733591A0146|89 90|S6
14P10733591A0146|123 125|JNK
14P10733591A0146|143 155|transcription
14P10733591A0146|159 176|cell proliferation
14P10733591A0533|0 9|Expression
14P10733591A0533|21 33|Cdc42 results
14P10733591A0533|53 61|PKClambda
14P10733591A0533|94 98|Cdc42
14P10733591A0533|102 110|PKClambda
14P10733591A0533|126 140|plasma membrane
14P10733880X1783|0 8|Copyright
14P10733880X1783|13 26|Academic Press
14P10734312A0503|19 34|Shc localization
14P10734312A0503|71 82|Shc function
14P10734312A0503|97 107|Shc chimera
14P10734312A0503|120 150|Ras membrane localization motif
14P10735272A0649|0 16|Southern blotting
14P10735272A0649|25 65|strand conformation polymorphism analyses
14P10735272A0649|120 133|RT-PCR studies
14P10735272A0649|181 185|ANOVA
14P10735272A0649|194 236|chromosome 19q glioma tumor suppressor gene
14P10735848A1440|0 3|RegA
14P10735848A1440|41 59|tol-oprL expression
14P10736161T0000|32 62|sugar phosphotransferase system
14P10736223A1227|31 43|transcription
14P10736223A1227|68 78|Qa promoter
14P10736223A1227|88 91|PrgX
14P10736223A1227|108 120|transcription
14P10736223A1227|153 163|readthrough
14P10736223A1227|176 189|mRNA stability
14P10737366A0280|48 51|PTFL
14P10737366A0280|109 121|formalin test
14P10738139A0681|34 64|cytokine response pathway genes
14P10738139A0681|64 67|KSHV
14P10739408A0896|0 17|Family environment
14P10739408A0896|55 67|relationships
14P10739408A0896|69 81|substance use
14P10739671A0136|2 38|electrophoresis mobility shift assays
14P10739671A0136|109 134|transcription pause region
14P10739671A0136|177 189|fibroblast WI
14P10739671A0136|269 281|binding sites
14P10739671A0136|315 318|IRFs
14P10740602A0141|0 11|STUDY DESIGN
14P10740602A0141|12 33|Fine needle aspiration
14P10740602A0141|85 87|ILC
14P10741850A0452|0 29|Electrophile Response Elements
14P10741850A0452|74 77|GCSh
14P10741850A0452|81 98|GCSl subunit genes
14P10741947T0000|52 54|LAD
14P10742114A0486|0 3|Dll3
14P10742114A0486|99 111|SD phenotypes
14P10742216A0555|0 7|Schlegel
14P10742216A0555|9 10|J.
14P10743608A1154|0 16|TbRAB31 behaviour
14P10743608A1154|49 55|TbRAB31
14P10743608A1154|137 150|daughter cells
14P10743608A1154|188 198|kinetoplast
14P10743608A1154|213 223|involvement
14P10743608A1154|226 237|microtubules
14P10743719A0223|62 71|management
14P10743719A0223|105 125|rejection nephropathy
14P10744026A0000|0 9|Invertases
14P10744749A0315|25 34|mechanisms
14P10744749A0315|53 62|inhibition
14P10744749A0315|124 135|MyoD protein
14P10744749T0000|8 13|T cell
14P10744749T0000|44 54|Tax protein
14P10744749T0000|119 128|KIX domain
14P10744749T0000|130 133|p300
14P10744974T0000|0 14|Phosphorylation
14P10744974T0000|18 47|spindle pole body localization
14P10744974T0000|50 55|Cdc15p
14P10745563A0409|12 22|hyperplasia
14P10745563A0409|36 48|complications
14P10745563A0409|100 110|gold stents
14P10745563A0409|168 182|neo-endothelium
14P10747053A1102|84 86|TAF
14P10747053A1102|152 156|TAF17
14P10747053A1102|181 183|SBF
14P10747053A1102|187 189|MBF
14P10747099A0507|30 32|ERK
14P10747099A0507|69 89|adaptor proteins p130
14P10747099A0507|112 114|CAS
14P10747099A0507|127 129|Crk
14P10747099A0507|169 181|cell invasion
14P10747099A0507|229 243|collagen matrix
14P10747782A0390|0 10|Proteolysis
14P10747782A0390|13 16|Mbp1
14P10747782A0390|20 23|Swi4
14P10747782A0390|138 157|DNA binding activity
14P10747879A0607|17 20|CCR5
14P10747879A0607|54 66|reading frame
14P10747879A0607|104 116|reading frame
14P10747890A1096|44 57|protein sensor
14P10747890A1096|72 90|groove interactions
14P10747890A1096|108 129|base pair interactions
14P10747987A0658|14 20|enzymes
14P10747987A0658|28 35|monomers
14P10748054T0048|23 42|B lymphocyte antigen
14P10748113A0187|20 30|RIM protein
14P10748113A0187|37 40|RIM2
14P10748113A0187|66 69|RIM1
14P10748125A0000|0 10|Inhibitor-1
14P10748125A0000|58 94|protein serine/threonine phosphatases
14P10748125A0000|94 96|PP1
14P10748164A1284|0 17|Scanning mutations
14P10748164A1284|30 39|AC element
14P10748164A1284|124 125|AC
14P10748175A0000|3 12|substrates
14P10748175A0000|16 31|glycan synthesis
14P10748175A0000|46 50|Golgi
14P10748175A0000|129 140|transporters
14P10748194T0000|34 55|density protein PSD-95
14P10748194T0000|79 96|trafficking signal
14P10748204A0238|6 7|J.
14P10748672A0130|0 4|Bites
14P10748672A0130|26 37|Vipera aspis
14P10748672A0130|40 51|Vipera berus
14P10749145T0000|25 37|PCPH proteins
14P10749145T0000|50 71|diphosphatase activity
14P10749145T0000|106 108|Ras
14P10749166A0991|119 129|B. henselae
14P10749166A0991|164 177|A. tumefaciens
14P10749849A0000|30 49|tumor suppressor p53
14P10749849A0000|83 99|cell cycle arrest
14P10749849A0000|136 155|kinase inhibitor p21
14P10749849A0000|155 163|WAF1/Cip1
14P10749932A0000|0 7|Paxillin
14P10749932A0000|16 31|adaptor molecule
14P10749932A0000|33 50|integrin signaling
14P10750020A0843|5 28|growth factor activation
14P10750020A0843|29 30|ER
14P10750020A0843|58 71|ER/Sp1 binding
14P10750020A0843|132 140|ER action
14P10750021A0728|22 58|deletion promoter-reporter constructs
14P10750021A0728|84 85|P2
14P10750021A0728|114 115|P2
14P10750524A0724|0 6|RESULTS
14P10750524A0724|16 25|thresholds
14P10750524A0724|77 86|proportion
14P10751398A1135|14 26|transcription
14P10751398A1135|29 43|c-IAP2 promoter
14P10751398A1135|70 73|CD40
14P10751398A1135|99 114|membrane protein
14P10752450A0288|37 53|fluoride products
14P10752450A0288|71 95|fluoride delivery systems
14P10752475A1376|32 57|signal-transduction events
14P10752475A1376|90 96|B cells
14P10752475A1376|128 131|CD20
14P10752475A1376|260 276|tumor regressions
14P10752475A1376|286 297|mouse models
14P10752807A1598|0 9|CONCLUSION
14P10752807A1598|11 19|Treatment
14P10752807A1598|54 77|factor antagonist BB-882
14P10752807A1598|155 174|organ failure scores
14P10753553T0000|0 8|Phenazone
14P10754312A0798|3 12|solubility
14P10754312A0798|28 35|proteins
14P10756007A0575|18 30|RBE sequences
14P10756007A1512|0 10|EM analysis
14P10756007A1512|58 73|ch-19 target DNA
14P10756020A0571|35 58|vaccinia virus particles
14P10756020A0571|119 137|electron microscopy
14P10756032A0599|6 34|dimethyl sulfate footprinting
14P10756032A0599|38 54|cyclin E promoter
14P10756032A0599|90 105|hypersensitivity
14P10756094A0671|11 14|STSs
14P10756094A0671|35 36|Mb
14P10756094A0671|53 69|marker resolution
14P10756100A0457|23 36|amino-terminus
14P10756100A0457|39 41|IB1
14P10756225A1464|0 9|CONCLUSION
14P10756225A1464|56 58|CRS
14P10756225A1464|132 140|IL-5 mRNA
14P10756225A1464|145 159|ethmoid sinuses
14P10757975A0509|0 3|Biol
14P10757983A0733|20 31|CRS sequence
14P10757983A0733|78 96|zinc finger protein
14P10757983A0733|96 105|Adx factor
14P10757983A0733|137 155|zinc finger protein
14P10757983A0733|156 177|mouse ZBP-89 homologue
14P10758289A0141|0 6|METHODS
14P10758289A0141|21 33|muscle fibres
14P10758289A0141|58 71|finger flexors
14P10758289A0141|96 108|pisiform bone
14P10758489A0206|28 31|ICK2
14P10758489A0206|59 65|Cdc2aAt
14P10758489A0206|84 86|CDK
14P10758489A0206|91 101|Arabidopsis
14P10758489A0206|103 109|Cdc2bAt
14P10758726T0000|28 39|arrangements
14P10759693A0201|0 6|METHODS
14P10759693A0201|22 31|odds ratio
14P10759693A0201|32 33|OR
14P10759693A0201|89 99|interaction
14P10759693A0201|132 141|antagonist
14P10759693A0201|143 152|cimetidine
14P10759693A0201|181 197|agents ranitidine
14P10759693A0201|198 207|famotidine
14P10759693A0201|211 220|nizatidine
14P10759693A0201|262 273|theophylline
14P10760109A1050|55 57|CVD
14P10760109A1050|115 117|CVD
14P10760109A1050|139 142|SAlb
14P10760109A1050|156 171|serum creatinine
14P10760109A1050|172 174|SCr
14P10760109A1050|180 195|blood hemoglobin
14P10760132A1169|70 88|protein prenylation
14P10760132A1169|112 131|vesicle polarization
14P10760169A1142|25 34|CreA sites
14P10760169A1142|56 85|transcription initiation sites
14P10760950A1133|9 24|staining pattern
14P10760950A1133|30 39|N-utrophin
14P10760950A1133|93 111|actin stress fibers
14P10761263A1108|4 12|Newcastle
14P10761263A1108|34 42|Hotelling
14P10761263A1108|45 56|T2 statistic
14P10761263A1108|123 139|prostate patients
14P10762254A0954|3 5|MMA
14P10762254A0954|7 9|DMA
14P10762254A0954|14 35|TMA methyltransferases
14P10762254A0954|65 90|MMA methyltransferase gene
14P10762254A0954|109 111|DMA
14P10762254A0954|115 136|TMA methyltransferases
14P10762348A0269|5 19|phosphorylation
14P10762348A0269|21 33|STAT proteins
14P10763823A0824|0 13|Overexpression
14P10763823A0824|64 75|transfection
14P10763823A0824|106 115|cell death
14P10763827A1158|21 39|senescence pathways
14P10763827A1158|90 107|TGFbeta1 secretion
14P10763827A1158|139 156|senescence program
14P10764150A0000|67 77|Raf kinases
14P10764150A0000|90 108|cytokine dependency
14P10764150A0000|110 121|FDC-P1 cells
14P10764574A0718|0 10|Application
14P10764574A0718|60 79|Arabidopsis thaliana
14P10764574A0718|109 127|prediction accuracy
14P10764574A0718|152 168|alignment methods
14P10764729A1846|58 64|GenBank
14P10764729A1846|66 67|TM
14P10764729A1846|71 86|accession number
14P10764760T0000|0 14|Transactivation
14P10764760T0000|35 39|HIV-1
14P10764760T0000|64 84|JNK signaling pathway
14P10764802A1258|39 41|p57
14P10764802A1258|43 46|Kip2
14P10764802A1258|70 85|Cip/Kip proteins
14P10764802A1258|212 214|p57
14P10764802A1258|216 219|Kip2
14P10764802A1258|221 234|family members
14P10764802A1258|257 271|differentiation
14P10764970A1009|21 45|quinupristin/dalfopristin
14P10764970A1009|75 77|PCR
14P10764970A1009|157 168|introduction
14P10765095A0308|31 43|PRL secretion
14P10765095A0308|55 78|prostate cancer patients
14P10765095A0308|113 118|L-Dopa
14P10765095A0308|200 212|PRL secretion
14P10766246A0000|0 26|Integrin adhesion receptors
14P10766246A0000|59 72|cell functions
14P10766246A0000|99 113|gene expression
14P10766246A0000|134 148|differentiation
14P10766493T0000|0 12|Recombination
14P10766493T0000|14 24|replication
14P10766556T0000|3 22|somatoform conundrum
14P10767091A0133|26 29|IOUS
14P10767091A0133|126 147|inter-user variability
14P10767091A0133|151 168|image obliteration
14P10767251A1046|0 10|CONCLUSIONS
14P10767251A1046|40 47|Vivostat
14P10767251A1046|104 118|lung resections
14P10767338T0000|41 46|ATP2C1
14P10767338T0000|61 62|Ca
14P10767553A0100|66 91|helix transcription factor
14P10767553A0100|91 100|Hepatocyte
14P10767553A0100|108 119|Factor 3beta
14P10767553A0100|120 127|HNF3beta
14P10767560A0105|28 43|characterization
14P10767560A0105|77 90|mouse Pkr gene
14P10767560A0105|126 150|mouse Pkr promoter region
14P10769144A0000|3 5|CRE
14P10769144A0000|10 19|TGACGTCA-3
14P10769144A0000|43 60|consensus sequence
14P10770041A0731|0 12|Kidney length
14P10770041A0731|65 76|kidney width
14P10770041A0731|85 93|thickness
14P10770065A0264|21 26|T1N0M0
14P10770065A0264|32 54|S2 sleeve segmentectomy
14P10770065A0264|57 77|lymph node dissection
14P10770471T0000|0 10|Benztropine
14P10771528T0036|18 37|alkaline phosphatase
14P10771709A0291|53 59|Q fever
14P10771709A0291|60 73|seroconversion
14P10771709A0291|90 92|IgM
14P10771709A0291|103 109|Q fever
14P10771709A0291|132 149|IgG antibody titer
14P10771709A0291|158 174|Coxiella burnetii
14P10771709A0291|202 214|questionnaire
14P10772856X1492|0 8|Copyright
14P10772856X1492|13 26|Academic Press
14P10772977A0222|27 39|PVX CP mutant
14P10772977A0222|55 74|Nicotiana tabacum cv
14P10773351A0672|0 8|Induction
14P10773351A0672|11 25|CD86 expression
14P10773351A0672|40 49|U937 cells
14P10773351A0672|53 61|IFN-gamma
14P10773351A0672|96 98|GAS
14P10773351A0672|100 131|gamma-interferon activation site
14P10773455A1268|105 124|mouse ALAS2 promoter
14P10773455A1268|187 201|differentiation
14P10773455A1268|204 212|MEL cells
14P10773455A1268|273 277|ALAS2
14P10773458A0000|0 6|SNAP-23
14P10773458A0000|44 62|vesicle trafficking
14P10773667A0351|3 12|HMG domain
14P10773667A0351|18 31|HMG20 proteins
14P10773951A0000|0 2|IgM
14P10773951A0000|6 8|IgG
14P10773951A0000|21 37|B antibody status
14P10773951A0000|50 64|O group mothers
14P10773951A0000|73 88|O group husbands
14P10775038A0142|23 37|Wee1 regulation
14P10775038A0142|43 52|cell cycle
14P10775038A0142|68 76|screening
14P10775267A0363|10 21|transduction
14P10775267A0363|24 26|T/T
14P10775267A0363|83 104|bone marrow transplant
14P10775267A0363|104 106|BMT
14P10775267A0363|121 123|T/T
14P10775267A0363|134 145|long-latency
14P10775585A0754|0 13|Ab-MLV strains
14P10775585A0754|23 28|P70/S2
14P10775585A0754|46 58|NIH 3T3 cells
14P10775585A0754|104 119|signaling events
14P10775585A0754|174 176|MAP
14P10775623A0120|3 13|codon usage
14P10775623A0120|50 58|env genes
14P10777217A0536|3 21|p53-homolog p73beta
14P10777217A0536|37 49|PIG3 promoter
14P10777217A0536|65 67|p53
14P10777217A0536|92 98|p73beta
14P10777217A0536|140 152|PIG3 promoter
14P10777499A0883|0 6|Results
14P10777499A0883|56 58|DE1
14P10777499A0883|78 89|phytochromes
14P10777586A1022|0 21|Co-immunoprecipitation
14P10777586A1022|25 51|DNA affinity chromatography
14P10777586A1022|81 86|ZBP-89
14P10777586A1022|193 196|HeLa
14P10777586A1022|213 229|band shift assays
14P10777669A0582|3 13|ZNF274 gene
14P10777669A0582|51 74|chromosome 19qter region
14P10777669A0582|76 85|RH mapping
14P10778740A1493|13 28|Cdk2 truncations
14P10778740A1493|149 152|HIS3
14P10778757A0000|90 99|Miniature1
14P10778757A0000|101 103|Mn1
14P10778757A0000|139 157|cell wall invertase
14P10778757A0000|157 161|INCW2
14P10779313A1842|40 54|Xenopus oocytes
14P10779313A1842|105 117|GIRK channels
14P10779313A1842|153 167|phosphorylation
14P10779313A1842|189 190|AR
14P10779329T0000|0 3|Slap
14P10779329T0000|23 25|Src
14P10779329T0000|70 92|cell morphology changes
14P10779352T0000|0 13|Identification
14P10779352T0000|22 33|E2F3 product
14P10779352T0000|90 100|Rb proteins
14P10779508A0452|8 39|footprinting protection analysis
14P10779508A0452|75 124|glutathione S-transferase-ERRalpha1 fusion protein
14P10779508A0897|29 33|SRC1a
14P10779508A0897|36 40|GRIP1
14P10779508T0000|0 7|Estrogen
14P10779508T0000|91 116|estrogen response elements
14P10779508T0000|125 140|lactoferrin gene
14P10780018A0539|27 33|effects
14P10780018A0539|47 59|response time
14P10780518A1270|28 43|protein function
14P10780518A1270|57 67|examination
14P10780764A0722|65 68|PM10
14P10780764A0722|83 85|PM2
14P10780883T0000|0 5|Kaposi
14P10780883T0000|26 36|herpesvirus
14P10780883T0000|42 51|interferon
14P10780883T0000|75 84|resistance
14P10780883T0000|115 130|interferon-alpha
14P10781109T0000|56 58|RNA
14P10781109T0000|61 80|Arabidopsis thaliana
14P10781423A0993|72 134|homeodomain transcription factor thyroid transcription factor-1
14P10781541A1063|23 31|sequences
14P10781541A1063|62 70|promoters
14P10781541A1063|110 118|sequences
14P10781541A1063|134 143|regulation
14P10781541A1063|146 158|transcription
14P10781541A1063|168 176|promoters
14P10781552A0000|0 5|Purple
14P10781552A0000|92 105|photosynthesis
14P10781552A0000|107 117|respiration
14P10781552A0000|126 134|oxidation
14P10781604A0827|45 56|CTD sequence
14P10781604A0827|89 102|Rsp5 WW domain
14P10781604A0827|102 109|Rsp5 WW2
14P10781611A1023|30 40|macrophages
14P10781611A1023|88 97|efficiency
14P10781611A1023|100 109|comparison
14P10781611A1023|115 125|macrophages
14P10781990A0455|11 13|MRI
14P10781990A0455|74 93|hyperintense lesions
14P10781990A0455|98 112|globus pallidus
14P10782640A0444|29 48|aberration constants
14P10782640A0444|51 73|CM300 FEG/UT microscope
14P10782989A0575|66 83|DNA binding domain
14P10782989A0575|87 106|amino acid sequences
14P10782989A0575|115 132|DNA binding domain
14P10784367A0133|0 5|METHOD
14P10784367A0133|41 76|Suffolk County Mental Health Project
14P10784393A0000|0 15|Marrow dysplasia
14P10784393A0000|23 36|characteristic
14P10784393A0000|75 77|MDS
14P10784393A0000|89 104|marrow blastosis
14P10785294A0720|24 36|inlays/onlays
14P10785294A0720|55 66|restorations
14P10785294A0720|113 127|resin composite
14P10785668A0000|36 45|herbivores
14P10785668A0000|49 57|pathogens
14P10785668A0000|89 95|subject
14P10785668A0000|110 117|research
14P10785668A0000|133 142|biologists
14P10785668A0000|146 155|ecologists
14P10785880A0947|0 9|CONCLUSION
14P10785880A0947|102 115|HELLP syndrome
14P10786671A0182|23 41|telomerase activity
14P10786671A0182|53 62|expression
14P10786671A0182|113 122|telomerase
14P10786671A0182|130 142|transcriptase
14P10786742A0670|5 17|control group
14P10786742A0670|18 33|platelet markers
14P10787437A1616|31 54|transcription start site
14P10787437A1616|69 73|SRE-1
14P10787804T0000|0 3|AMDA
14P10787804T0000|57 60|SNFs
14P10788320A1034|23 34|TPR elements
14P10788320A1034|108 120|102kD protein
14P10788320A1034|158 159|U5
14P10788320A1034|163 174|U4/U6 snRNPs
14P10788476A0891|0 9|Antibodies
14P10788476A0891|43 69|Sec31A co-precipitate Sec13
14P10788476A0891|78 95|ER-Golgi transport
14P10788476A0891|126 145|stomatitis G protein
14P10788480T0000|51 79|protein gene expression links
14P10788480T0000|100 114|DNA replication
14P10790390X0000|34 73|position effect variegation modifier mod
14P10790390X0000|116 120|3-93D
14P10790390X0000|160 173|gene silencing
14P10790390X0000|175 201|position effect variegation
14P10790390X0000|201 203|PEV
14P10790390X0000|218 242|gypsy insulator sequences
14P10790390X0000|262 276|gene expression
14P10791251A0110|33 38|things
14P10791251A0110|48 56|functions
14P10791251A0110|75 80|humans
14P10791819A0771|34 55|nucleotide composition
14P10791819A0771|60 75|asparagus genome
14P10791901A0609|0 11|Transduction
14P10791901A0609|57 78|MRP1-PG13 supernatants
14P10791901A0609|98 106|MRP1 gene
14P10791901A0609|126 142|target K562 cells
14P10792583A0000|0 9|Regulation
14P10792583A0000|21 45|vasopressin V1b receptors
14P10792583A0000|110 113|ACTH
14P10792718T0000|0 13|Identification
14P10792718T0000|18 31|AfsA homologue
14P10792718T0000|96 121|autoregulator biosynthesis
14P10792718T0000|122 147|virginiamycin biosynthesis
14P10792718T0000|150 176|virginiamycin M1 resistance
14P10793143A1533|27 37|DNA binding
14P10793143A1533|57 65|Abf1 ARS1
14P10793143A1533|106 109|Cdc6
14P10793143A1533|165 179|DNA replication
14P10793991A0569|30 32|Web
14P10793991A0569|34 48|TIE researchers
14P10794405A0000|20 27|peptides
14P10794405A0000|59 68|histone H1
14P10794405A0000|99 111|understanding
14P10794405A0000|117 124|function
14P10794405A0000|127 128|H1
14P10794405A0000|131 139|chromatin
14P10794936A0241|3 16|recovery rates
14P10794936A0241|22 28|MB/BacT
14P10794936A0241|30 33|MGIT
14P10794936A0241|109 122|recovery rates
14P10794936A0241|161 183|M. tuberculosis complex
14P10795098A0253|8 17|vasculitis
14P10795098A0253|29 33|Crohn
14P10795098A0253|61 70|phenomenon
14P10796465A0373|0 17|SELECTION CRITERIA
14P10796486A0817|0 17|SELECTION CRITERIA
14P10796486A0817|114 130|asthma medication
14P10796486A0817|149 165|asthma medication
14P10797125A0000|9 18|hypothesis
14P10797125A0000|59 74|core temperature
14P10797125A0000|80 105|core temperature threshold
14P10797125A0000|107 120|sweating onset
14P10797125A0000|179 192|degrees C rest
14P10797125A0000|205 219|passive heating
14P10797125A0000|260 269|degrees C.
14P10797586A0402|34 41|response
14P10797586A0402|44 55|disturbances
14P10797586A0402|82 88|bladder
14P10798607A1359|38 49|meningococci
14P10798607A1359|84 104|antibody titer levels
14P10799501A1391|74 88|SPRK activation
14P10799501A1391|90 94|Cdc42
14P10799576A0196|0 1|M.
14P10799590A0431|0 5|Jkappa
14P10799590A0431|65 79|EBNA-3C protein
14P10799590A0431|91 96|Jkappa
14P10799590A0431|143 149|EBNA-3C
14P10799590A0431|165 171|EBNA-3C
14P10799590A0431|232 237|Jkappa
14P10799595A1454|9 11|YY1
14P10799595A1454|15 17|CDP
14P10799595A1454|74 90|HPV-6 E1 promoter
14P10799595A1454|102 115|HPV life cycle
14P10799863T0000|20 36|metallopeptidases
14P10799863T0000|73 89|HIV-1 ENV epitope
14P10799863T0000|101 109|MHC class
14P10799863T0000|110 129|antigen presentation
14P10799879T0000|0 6|Cloning
14P10799879T0000|10 25|characterization
14P10799879T0000|33 35|Lnk
14P10799879T0000|39 53|adaptor protein
14P10799879T0000|57 75|pleckstrin homology
14P10799879T0000|78 89|Src homology
14P10799879T0000|111 127|T cell activation
14P10801244A0578|0 14|Vancomycin data
14P10801244A0578|71 87|NONMEM population
14P10801330A1714|8 10|Cas
14P10801330A1714|36 66|membrane cytoskeleton fractions
14P10801330A1714|109 128|platelet aggregation
14P10801330A1714|133 135|FAK
14P10801482A0968|14 16|p65
14P10801482A0968|118 131|kappaB targets
14P10801809T0000|30 48|yeast PHO8 promoter
14P10801809T0000|75 87|PHO5 promoter
14P10801860A0000|3 9|Siglecs
14P10801860A0000|39 73|immunoglobulin superfamily proteins
14P10802669A1434|71 73|A-T
14P10802669A1434|77 79|NBS
14P10802909A0478|0 10|PATIENTS OR
14P10802909A0478|15 26|PARTICIPANTS
14P10804379T0001|0 5|Update
14P10804379T0001|45 47|HIV
14P10804379T0001|51 65|cytomegalovirus
14P10805286A0233|33 44|cis-elements
14P10805286A0233|55 62|PCI gene
14P10805286A0233|113 123|HepG2 cells
14P10805286A0233|140 162|rat PCI mRNA expression
14P10805286A0914|12 30|PCI mRNA expression
14P10805286A0914|116 134|PCI mRNA expression
14P10805390A0340|41 57|photoluminescence
14P10805390A0340|60 87|GaAs/AlGaAs heterostructures
14P10805729A0987|59 66|C strand
14P10805729A0987|81 84|DDP1
14P10805729A0987|102 111|KH domains
14P10805729A0987|151 171|acid binding surfaces
14P10805737T0000|29 57|translation initiation factor
14P10805737T0000|70 80|interaction
14P10805737T0000|91 102|beta subunit
14P10805737T0000|117 129|eIF5 function
14P10805738A0799|25 27|p38
14P10805738A0799|43 46|MyoD
14P10805738A0799|51 69|p38 kinase activity
14P10805738A0799|140 142|p38
14P10805738A0799|182 205|Gal4-MyoD fusion protein
14P10805738A0799|265 268|MyoD
14P10805738A0799|357 364|p38alpha
14P10805739A0343|26 42|complex formation
14P10805739A0343|54 67|eIF2B subunits
14P10805739A0640|13 30|nonsense mutations
14P10805739A0640|46 55|C terminus
14P10805739A0640|57 68|eIF2Bepsilon
14P10805739A0640|124 134|interaction
14P10805747A0633|75 79|Hsl1p
14P10805747A0633|83 87|Kcc4p
14P10805747A0633|116 134|septin organization
14P10805823A1920|0 10|CONCLUSIONS
14P10805823A1920|77 86|prevention
14P10807900A0933|5 18|non-cirrhotics
14P10807900A0933|32 49|vein visualisation
14P10807900A0933|55 67|% sensitivity
14P10807900A0933|70 82|% specificity
14P10807900A0933|144 152|diagnosis
14P10807900A0933|175 186|hypertension
14P10807903A0362|0 4|D5/D1
14P10807903A0362|6 7|CT
14P10807903A0362|11 16|D5/D1D
14P10807903A0362|18 19|CT
14P10807903A0362|21 45|tail substitution mutants
14P10807903A0362|75 92|agonist affinities
14P10807903A0362|123 134|D1 receptors
14P10807903A0362|185 208|cAMP accumulation assays
14P10807903A0362|223 234|D1 receptors
14P10807903A0362|241 256|exhibit receptor
14P10809233A0606|0 7|Modeling
14P10809233A0606|60 62|H12
14P10809233A0606|84 85|H3
14P10809233A0606|95 96|H4
14P10809233A0606|101 103|H11
14P10810083A1283|58 74|zinc finger motif
14P10810294A0730|0 14|Stat activation
14P10810294A0730|26 27|GH
14P10810294A0730|31 34|IL-6
14P10810294A0730|50 72|reporter gene induction
14P10810745A0677|0 7|HFA 134a
14P10810745A0677|67 69|HFA
14P10811079A0555|0 6|RESULTS
14P10811079A0555|16 31|color perception
14P10811079A0555|49 65|epilepsy patients
14P10811079A0555|76 97|vigabatrin monotherapy
14P10811079A0555|108 124|epilepsy patients
14P10811079A0555|135 159|carbamazepine monotherapy
14P10811079A1277|5 23|SPP2 screening test
14P10811804A0000|25 27|MAP
14P10811804A0000|29 48|kinase phosphatase-3
14P10811804A0000|49 53|MKP-3
14P10811804A0000|62 84|specificity phosphatase
14P10811804A0000|135 137|ERK
14P10811804A0000|139 149|MAP kinases
14P10811804A0800|70 92|target substrates Elk-1
14P10811804A0800|94 96|p90
14P10811804A0800|134 138|MKP-3
14P10811908A0938|0 26|HPLC phosphopeptide mapping
14P10811908A0938|26 46|amino acid sequencing
14P10811908A0938|87 90|NCLK
14P10812294X0000|28 30|SBF
14P10812294X0000|76 78|SBF
14P10814989T0000|0 26|Hepatitis C virus infection
14P10814989T0000|56 61|France
14P10815410A0000|41 61|neuroendocrine system
14P10815410A0000|108 111|IL-1
14P10815410A0000|113 116|IL-6
14P10815410A0000|120 122|TNF
14P10815807A1271|87 92|HTLV-I
14P10815807A1271|104 115|T-cell lines
14P10817754T0000|0 2|H19
14P10817754T0000|6 9|Igf2
14P10817754T0000|21 30|expression
14P10817754T0000|103 105|H19
14P10819327T0000|0 16|C. elegans KLP-11
14P10819327T0000|16 20|OSM-3
14P10819327T0000|22 26|KAP-1
14P10819327T0000|42 62|sea urchin kinesin-II
14P10819327T0000|65 103|mouse KIF3A/KIFB/KAP3 kinesin complexes
14P10820829T0000|0 9|Flavonoids
14P10820829T0000|14 33|Brosimum acutifolium
14P10820904A0000|0 9|BACKGROUND
14P10820904A0000|18 31|encephalopathy
14P10820904A0000|78 90|liver failure
14P10820904A0000|109 121|liver disease
14P10821836A0842|21 33|S transcripts
14P10821836A0842|64 82|sense S transcripts
14P10822117A1386|9 18|adjustment
14P10822117A1386|69 80|observations
14P10822117A1386|96 106|information
14P10822117A1386|114 127|subject-models
14P10823630A1124|11 18|presence
14P10823630A1124|21 30|effacement
14P10823630A1124|65 73|parameter
14P10823630A1124|99 108|prediction
14P10823837A1213|35 51|YLL031c transfers
14P10823837A1213|54 74|ethanolaminephosphate
14P10823837A1213|132 147|GPI lipid anchor
14P10823837A1213|164 168|Mcd4p
14P10823837A1213|172 207|Gpi7p transfer ethanolaminephosphate
14P10823837A1213|253 262|GPI anchor
14P10823961A0664|3 12|C terminus
14P10823961A0664|14 17|TRBP
14P10823961A0664|25 32|CBP/p300
14P10823961A0664|36 42|DRIP130
14P10823961A0664|59 79|DRIP/TRAP/ARC complex
14P10823961A0664|97 100|TRBP
14P10824485A0393|57 59|CD4
14P10824485A0393|61 79|T lymphocyte counts
14P10824485A0393|95 98|AIDS
14P10824958A1109|31 33|PAB
14P10824958A1109|57 58|CO
14P10824958A1109|69 70|PF
14P10824958A1109|80 83|PSHL
14P10824958A1109|86 101|broiler breeders
14P10825000A1245|3 26|gene amplification model
14P10825000A1245|27 34|Coquelle
14P10825200T0000|0 8|Hierarchy
14P10825200T0000|11 34|protein tyrosine kinases
14P10825200T0000|49 52|IL-2
14P10825200T0000|88 91|Jak3
14P10825200T0000|108 110|Syk
14P10825200T0000|114 116|Lck
14P10825200T0000|143 157|STAT activation
14P10825293T0000|19 39|N-cadherin-Fc chimera
14P10825293T0000|61 82|cell contact formation
14P10825294A0473|11 21|OC promoter
14P10825294A0473|35 44|C terminus
14P10825294A0473|63 65|MDR
14P10825294A0473|67 69|LTR
14P10825294A0473|73 85|BSP promoters
14P10825294A0473|156 169|AML C terminus
14P10825294A0473|206 223|pentapeptide VWRPY
14P10826861A0000|13 35|immunoglobulin products
14P10826861A0000|37 56|plasma cell neoplasm
14P10826861A0000|78 91|manifestations
14P10826861A0000|101 114|hyperviscosity
14P10826861A0000|128 143|cryoglobulinemia
14P10826946A1198|0 12|Investigation
14P10826946A1198|38 48|interaction
14P10826946A1198|61 63|Igs
14P10826946A1198|136 138|Igs
14P10827885T0059|31 35|trial
14P10827952A0158|18 25|TAFII250
14P10827952A0158|46 50|TFIID
14P10827952A0158|69 87|bromodomain modules
14P10827952A0158|126 144|histone H4 peptides
14P10828022A0877|0 19|Endostatin treatment
14P10828022A0877|47 70|tyrosine phosphorylation
14P10828022A0877|72 74|Shb
14P10828319A0342|19 28|vitamin D3
14P10828319A0342|72 82|improvement
14P10828319A0342|85 93|psoriasis
14P10828591A0080|3 12|transcript
14P10828591A0080|45 57|cDNA sequence
14P10828591A0080|83 96|transcript map
14P10828591A0080|114 129|markers D11S1765
14P10828591A0080|132 142|uteroglobin
14P10828751A2258|7 15|challenge
14P10828751A2258|37 46|management
14P10828751A2258|49 56|patients
14P10828751A2258|84 92|treatment
14P10829973T0000|0 26|Iodine deficiency disorders
14P10830395A0408|3 19|network evolution
14P10830395A0408|55 65|Flory model
14P10831972A0744|0 6|RESULTS
14P10831972A0744|15 25|CD23 levels
14P10831972A1091|0 9|CONCLUSION
14P10831972A1091|62 72|CD23 levels
14P10831972A1091|112 139|leuprolide acetate injection
14P10833461A0603|19 21|P-1
14P10833461A0603|43 45|PAC
14P10833461A0603|74 92|length UGT2B7 probe
14P10833486A0598|0 2|Age
14P10833486A0598|24 25|OR
14P10833486A0598|34 36|BMI
14P10833486A0598|50 51|OR
14P10833486A0598|84 85|OR
14P10833486A0598|93 116|alanine aminotransferase
14P10833486A0598|117 119|ALT
14P10833486A0598|124 125|2N
14P10833486A0598|127 128|OR
14P10834707A1533|32 57|platelet activating factor
14P10834707A1533|95 108|treatment time
14P10834781A0693|52 66|residence times
14P10834781A0693|67 70|MRTs
14P10834781A0693|80 95|plasma clearance
14P10835355A0225|18 41|zinc finger protein Gis1
14P10835355A0225|77 93|rim15Delta defect
14P10835355A0225|150 153|SSA3
14P10835485A0941|13 15|SH3
14P10835485A0941|29 41|linker domain
14P10835485A0941|74 90|sequence identity
14P10835485A0941|101 119|amino acid residues
14P10835732A0911|2 12|differences
14P10835732A0911|20 37|cholesterol levels
14P10836542A0363|17 27|UV exposure
14P10836542A0363|42 54|UV-A waveband
14P10836786A0516|33 44|RNA subunits
14P10836786A0516|63 83|substrate specificity
14P10836786A0516|96 113|hairpin structures
14P10836786A0516|114 117|MRP3
14P10836786A0516|131 143|RNase MRP RNA
14P10836786A0516|145 155|RNase P RNA
14P10837126A1004|24 34|pMesogenin1
14P10837126A1004|37 42|Xwnt-8
14P10837126A1004|45 60|signaling factor
14P10837126A1004|91 102|marker genes
14P10838139A1447|14 25|Ha-ras codon
14P10838399A0525|13 19|PET FDG
14P10838399A0525|74 96|reconstruction artifact
14P10838531A0675|0 11|Tumor stages
14P10838531A0675|15 17|IIB
14P10838531A0675|19 23|T3 N0
14P10838531A0675|30 33|IIIA
14P10838531A0675|43 46|IIIB
14P10839470A1148|22 42|percentage reductions
14P10839470A1148|90 105|measure analysis
14P10839470A1148|114 119|Malays
14P10839547A0978|23 34|CTCF binding
14P10839547A0978|47 61|DNA methylation
14P10839593A0000|0 8|OBJECTIVE
14P10839593A0000|43 56|amphotericin B
14P10839593A0000|71 74|ABOS
14P10839593A0000|142 154|HIV infection
14P10840001A0188|0 20|Mucin gene expression
14P10841537A0669|32 35|RPB5
14P10841537A0669|51 62|interactions
14P10841593A0780|39 59|cigarette consumption
14P10841593A0780|78 89|availability
14P10841593A0780|92 107|nicotine patches
14P10841601T0000|0 10|Paper alert
14P10843716A0406|3 16|tryptase locus
14P10843716A0406|52 62|pseudogenes
14P10843810A0802|80 99|tyrosine phosphatase
14P10843810A0802|165 167|LTR
14P10845522A0000|0 8|OBJECTIVE
14P10845522A0000|57 89|99mTc-sestamibi scintimammography
14P10846054A0573|71 73|RNA
14P10846054A0573|75 78|ORFs
14P10846054A0573|105 120|progeny LIYV RNA
14P10846054A0573|122 124|RNA
14P10846054A0573|141 143|RNA
14P10846054A0573|178 197|LIYV RNA replication
14P10846069T0000|0 3|Role
14P10846069T0000|6 7|NH
14P10846069T0000|40 48|P protein
14P10846069T0000|55 78|parainfluenza virus type
14P10848605T0000|0 14|Phosphorylation
14P10848605T0000|17 33|tyrosine residues
14P10848605T0000|53 72|juxtamembrane region
14P10848605T0000|118 130|Eph receptors
14P10848848A0413|0 6|RESULTS
14P10848848A0413|8 15|Fournier
14P10848993A0000|7 20|DNA sequencing
14P10848993A0000|35 63|methylmalonyl-CoA mutase gene
14P10848993A0000|95 124|Amycolatopsis mediterranei U32
14P10848993A0000|179 209|serine/threonine protein kinase
14P10850329A0248|0 3|IL-2
14P10850329A0248|48 58|combination
14P10850329A0248|63 74|chemotherapy
14P10850329A0248|140 153|cell carcinoma
14P10850453A0713|88 96|TGF-beta1
14P10850453A0713|99 105|TSU-Pr1
14P10850453A0713|113 132|TGF-beta1 inhibition
14P10850453A0713|134 138|DU145
14P10850453A0713|165 186|V12Ha-Ras transfection
14P10850453A1292|32 50|prostate carcinomas
14P10850453A1292|57 83|Ras/MAPK pathway activation
14P10850453A1292|127 146|TGF-beta1 production
14P10850719A0680|0 13|Vbeta segments
14P10850719A0680|26 46|DJbeta rearrangements
14P10850719A0680|114 126|Vbeta 23-RSSs
14P10850719A0680|129 140|Jbeta12-RSSs
14P10850849A0730|7 20|administration
14P10850849A0730|22 34|AUC0-infinity
14P10850849A0730|51 63|microg x h/ml
14P10850849A0730|63 70|t1/2beta
14P10850849A0730|92 112|maximum concentration
14P10850849A0730|113 116|Cmax
14P10850849A0730|149 152|Cmax
14P10850849A0730|177 191|absorption time
14P10850849A0730|214 228|bioavailability
14P10850942A0989|2 11|experiment
14P10850942A0989|16 25|difference
14P10850942A0989|95 97|TPN
14P10850997A1016|11 14|H-NS
14P10850997A1016|59 61|Fur
14P10851089A1248|5 7|SAG
14P10851089A1248|24 45|cell cycle progression
14P10851089A1248|62 75|ubiquitination
14P10851267A0000|0 2|E2F
14P10851267A0000|8 27|transcription factor
14P10851267A0000|40 61|cell cycle progression
14P10851267A0000|64 70|S-phase
14P10851745A0624|13 19|fatigue
14P10851745A0624|46 51|health
14P10851745A0624|59 64|safety
14P10851745A0624|76 83|capacity
14P10852221A0422|20 28|treatment
14P10852221A0422|67 72|period
14P10852221A0422|87 93|surgery
14P10852221A0422|107 112|effect
14P10852221A0422|118 125|survival
14P10852221A0422|147 153|neurons
14P10852460A0170|3 15|relationships
14P10852460A0170|21 40|blood concentrations
14P10852460A0170|42 57|thyroid hormones
14P10852460A0170|85 100|alpha-tocopherol
14P10852460A0170|123 130|Northern
14P10852460A0170|202 217|SENIEUR protocol
14P10852485A0477|7 12|Spring
14P10852485A0477|14 15|CS
14P10852485A0477|28 33|Q gene
14P10852485A0477|43 66|chromosome deletion line
14P10852485A0477|67 68|CS
14P10852485A0477|77 78|q5
14P10852485A0477|95 97|5AL
14P10852485A0477|110 115|Q gene
14P10852953A0000|0 13|Investigations
14P10852953A0000|92 107|field potentials
14P10852953A0000|112 132|gamma frequency range
14P10852953A0000|137 138|Hz
14P10852953A0000|192 193|Hz
14P10853059X0751|0 8|Karger AG
14P10853059X0751|9 13|Basel
14P10853778A0316|6 23|surgery bone cysts
14P10853850A1103|7 10|LTE4
14P10853850A1103|82 103|inhalation provocation
14P10854004A0788|5 7|FVR
14P10854004A0788|38 40|ERT
14P10854004A0788|44 46|HRT
14P10854004A0788|51 63|FVR responses
14P10854699A0424|5 16|FGF-AS cDNAs
14P10854699A0424|43 53|FGF-AS mRNA
14P10854699A0424|113 127|FGF-AS sequence
14P10855690A0870|38 47|MAP kinase
14P10855690A0870|60 73|hPL-B enhancer
14P10855793A1418|0 15|Characterization
14P10855793A1418|29 32|TNRs
14P10855793A1418|102 115|identification
14P10855796A1160|14 38|RNA hybridization studies
14P10855796A1160|67 87|EphA8 gene expression
14P10856298A0798|0 11|Transfection
14P10856298A0798|60 78|hamster ovary cells
14P10856298A0798|121 125|T339I
14P10856491A0178|0 6|SETTING
14P10856491A0178|8 17|University
14P10856491A0178|20 37|Paris VII hospital
14P10856491A0178|37 43|Patient
14P10856805T0000|0 32|Improving fissure sealant quality
14P10857215A0000|3 24|Menopause-Rating-Scale
14P10857215A0000|26 30|MRS I
14P10857215A0806|3 8|MRS II
14P10857262A0186|22 36|fruA transcript
14P10857262A0186|58 59|D.
14P10857262A0186|72 85|type A protein
14P10857262A0186|100 102|BTB
14P10857751A0304|28 41|Mharp/Smarcal1
14P10857751A0304|59 89|Caenorhabditis elegans ortholog
14P10857751A0304|89 94|CEHARP
14P10857751A0304|114 129|GenBank database
14P10858355A0920|48 74|Enterococcus faecium SF2149
14P10858355A0920|76 102|Enterococcus faecalis WH245
14P10858988A0786|0 2|ECP
14P10858988A0786|6 20|tryptase levels
14P10860131A0847|0 16|Tolterodine users
14P10860131A0847|75 76|RR
14P10860196A0876|17 23|program
14P10860196A0876|28 32|costs
14P10860196A0876|89 93|years
14P10860752A1601|26 28|RNA
14P10860752A1601|91 131|bacteriophage T4 DNA polymerase synthesis
14P10860827A0399|0 7|Deletion
14P10860827A0399|101 115|CSX1 expression
14P10860827A0399|117 130|cardiomyocytes
14P10860846A0480|46 68|AP2 core binding region
14P10860846A0480|74 99|cotransfection experiments
14P10860846A0480|106 126|AP2 expression vector
14P10860846A0480|137 139|AP2
14P10860846A0480|166 191|HGF gene promoter activity
14P10861080A0433|25 36|IkappaBalpha
14P10861080A0433|38 64|IkappaBalpha overexpression
14P10861080A0433|81 89|TNF-alpha
14P10861080A0433|104 106|GBS
14P10861086A0259|2 27|reconstitution experiments
14P10861086A0259|60 62|RAW
14P10861086A0259|88 97|Src kinase
14P10861086A0259|98 100|Csk
14P10861086A0259|139 158|gain-of-function Csk
14P10861086A0259|170 177|Fc gamma
14P10861086A0904|115 136|phagocytosis signaling
14P10861906A0999|3 22|delta srb10 mutation
14P10861906A0999|40 56|transcript levels
14P10861906A0999|85 88|IME1
14P10861906A0999|92 95|IME2
14P10861906A0999|119 134|transcript level
14P10861906A0999|136 139|IME1
14P10861906A0999|156 159|IME2
14P10861906A0999|198 210|DNA synthesis
14P10861906A1479|65 81|transcript levels
14P10861906A1479|83 87|KIN28
14P10861906A1479|91 94|CCL1
14P10861906A1479|104 122|nitrogen starvation
14P10861909A0502|77 79|LEU
14P10861909A0502|102 103|S.
14P10861909A0502|121 122|S.
14P10861909A0502|174 186|nmt1 promoter
14P10861909A0502|187 188|3X
14P10861909A0502|190 192|41X
14P10861909A0502|196 198|81X
14P10861909A0502|230 253|transcription efficiency
14P10861909A0502|285 296|cloning site
14P10861909A0502|327 343|restriction sites
14P10862289A0289|1 3|GUT
14P10862289A0289|5 8|Sera
14P10862289A0289|86 88|IgG
14P10862289A0289|101 111|A60 antigen
14P10863048A0000|35 46|cord lesions
14P10863048A0000|118 127|distension
14P10863048A0000|129 131|CRD
14P10863352T0001|0 13|Franz Schubert
14P10864271A0504|30 43|S. argyrostoma
14P10864271A0504|48 60|dissemination
14P10864271A0504|63 80|Trichinella larvae
14P10864496A0401|3 34|equilibrium dissociation binding
14P10864496A0401|60 63|TnrA
14P10864496A0401|71 93|nrgAB promoter fragment
14P10864641A1400|27 35|N-glycans
14P10864641A1400|72 82|HA molecule
14P10864641A1400|103 124|influenza virus growth
14P10864641A1400|139 144|Asn149
14P10864641A1400|167 172|Asn123
14P10864989A0484|0 6|RESULTS
14P10864989A0484|28 31|PAIP
14P10864989A0484|87 90|WBCs
14P10864989A0484|128 130|FIP
14P10864989A0484|168 186|separation efficacy
14P10864989A0484|194 208|separation time
14P10865422A0138|16 29|serum ferritin
14P10865422A0138|30 31|SF
14P10865422A0138|45 46|Hb
14P10865422A0138|95 114|iron supplementation
14P10865838A0000|19 31|growth factor
14P10865838A0000|32 35|VEGF
14P10865940A0000|14 46|agent pyrrolidine dithiocarbamate
14P10865940A0000|46 49|PDTC
14P10865940A0000|89 90|EC
14P10865940A0000|142 161|NF-kappaB activation
14P10866323A0666|28 49|SIE-1 hypermethylation
14P10866323A0666|51 67|p21WAF1 induction
14P10866323A0666|69 83|STAT activation
14P10866677A1839|0 2|Phd
14P10866689A0295|11 26|SAOS-2 cell line
14P10866689A0295|52 67|reporter plasmid
14P10866689A0295|80 97|tal-1 binding site
14P10866689A0295|153 181|tal-1-E12-Lmo2-Ldb1 complexes
14P10866689A0295|194 214|tal-1-E12 heterodimer
14P10866886A1277|22 32|conjunction
14P10866886A1277|61 79|mu-receptor agonist
14P10867199A0230|107 110|EPVs
14P10867199A0230|129 141|insect orders
14P10867496T0001|0 16|Neurofibromatosis
14P10867496T0001|42 66|Morbus von Recklinghausen
14P10868488A0921|30 39|aggression
14P10868488A0921|73 90|testosterone level
14P10869076A1384|22 31|hypothesis
14P10869076A1384|51 60|tryptophan
14P10869076A1384|93 95|Rho
14P10869076A1384|142 166|transcription termination
14P10869465A1054|6 18|hybridization
14P10869465A1054|35 44|RNA probes
14P10869465A1054|63 80|expression changes
14P10869465A1054|128 143|germ cell stages
14P10869465A1054|165 171|Sertoli
14P10870043A0621|3 16|administration
14P10870043A0621|22 33|GnRH agonist
14P10870043A0621|43 62|bone mineral density
14P10870043A0621|94 106|control group
14P10870391T0034|0 9|Prevention
14P10870391T0034|44 58|travel diarrhea
14P10871045A1221|18 26|C/EBPbeta
14P10871045A1221|43 55|C/EBP isoform
14P10871045A1221|100 116|C/EBPbeta protein
14P10871045A1221|119 135|C/EBPbeta binding
14P10871045A1221|146 163|C/EBP binding site
14P10871347A0477|0 16|Mutation analysis
14P10871347A0477|59 75|PyRo1 interaction
14P10871379A0261|6 9|VP16
14P10871379A0261|14 37|transactivation function
14P10871379A0261|61 63|HCF
14P10871412A0369|37 57|focus formation assay
14P10871412A0369|79 83|Rz007
14P10871615A0368|0 1|G.
14P10871615A0368|6 9|Hyde
14P10871615A0368|11 12|C.
14P10871842A0988|21 41|proteasome inhibition
14P10871842A0988|79 107|transcription factor families
14P10871842A0988|125 139|stress response
14P10872473A2286|3 16|ATR-X syndrome
14P10872473A2286|41 48|XH2 gene
14P10872473A2286|61 72|X chromosome
14P10872473A2286|73 78|Xq13.3
14P10872535A0000|0 3|AIMS
14P10872535A0000|105 118|susceptibility
14P10872535A0000|171 192|glucose tolerance test
14P10872535A0000|192 195|OGTT
14P10872535A0000|241 263|birthweight differences
14P10872535A0000|275 287|abnormalities
14P10872756A1325|2 11|NASCIS III
14P10872756A1325|13 35|randomization imbalance
14P10872756A1325|95 107|motor deficit
14P10872756A1325|150 167|dose control group
14P10872827A0000|0 17|Penicillin acylase
14P10872827A0000|18 19|PA
14P10872827A0000|40 48|ATCC11105
14P10872831A0000|28 30|EST
14P10872831A0000|51 73|erythropoietin receptor
14P10872831A0000|74 77|EPOR
14P10872831A0000|97 108|EST database
14P10872851A0714|7 9|LCx
14P10872851A0714|75 77|AoP
14P10872851A0714|106 107|SV
14P10872851A0714|121 125|LVEDP
14P10873158A0000|0 9|Activation
14P10873158A0000|26 27|NF
14P10873158A0000|64 78|gene expression
14P10873286X0000|0 12|GAP JUNCTIONS
14P10873286X0000|17 21|BRAIN
14P10873286X0000|23 29|PREFACE
14P10873386A0000|60 69|C2 subunit
14P10873386A0000|74 87|20S proteasome
14P10873387A0816|42 58|Cacna1f gene maps
14P10873387A0816|81 104|mouse synaptophysin gene
14P10873387A0816|125 128|Xp11
14P10873388A0623|12 24|Rhotekin cDNA
14P10873388A0623|33 54|Northern hybridization
14P10873388A0623|189 200|lung tissues
14P10874044A0647|51 58|p38alpha
14P10874044A0647|68 71|ERK1
14P10874044A0647|73 76|ERK2
14P10874044A0647|78 81|JNK1
14P10874044A0647|85 88|JNK2
14P10874151A0000|0 9|BACKGROUND
14P10874151A0000|11 34|Gamma knife radiosurgery
14P10874151A0000|34 36|GKR
14P10878398A0542|23 25|Epo
14P10878398A0542|42 54|leptin levels
14P10878398A0542|91 103|CAPD patients
14P10878398A0542|104 106|Epo
14P10878606A0876|29 38|structures
14P10878606A0876|97 108|interactions
14P10878675A1278|0 9|CONCLUSION
14P10878675A1278|31 49|antagonist idazoxan
14P10878675A1278|98 115|energy expenditure
14P10878944A0000|8 40|diphtheria toxin polymer particle
14P10878944A0000|67 75|DiaMed AG
14P10878944A0000|76 86|Switzerland
14P10878944A0000|125 133|Institute
14P10878944A0000|136 155|Childhood Infections
14P10880486A0790|86 88|Ebr
14P10880486A0790|101 110|RhoA locus
14P10880702A0966|50 60|amphetamine
14P10880702A0966|63 73|apomorphine
14P10880702A0966|103 111|component
14P10880702A0966|114 126|sensitization
14P10880702A0966|129 139|amphetamine
14P10881275T0000|10 26|serum IgM binding
14P10881275T0000|27 41|GM1 ganglioside
14P10882163A1077|0 18|Objective responses
14P10882163A1077|66 75|exemestane
14P10882163A1077|90 106|aminoglutethimide
14P10882163A1077|115 124|exemestane
14P10882163A1077|154 173|aromatase inhibitors
14P10882163A1077|182 191|exemestane
14P10882213A0163|0 5|Topics
14P10882213A0163|43 53|association
14P10882213A0163|91 101|evaluations
14P10882213A0163|105 114|malignancy
14P10882213A0163|118 133|myositis patient
14P10882213A0163|149 158|assessment
14P10882213A0163|173 201|dermatomyositis sine myositis
14P10882213A0163|204 213|usefulness
14P10882213A0163|252 266|classifications
14P10882213A0163|269 278|discussion
14P10882213A0163|397 406|management
14P10882213A0163|409 425|myositis patients
14P10882213A0163|433 442|approaches
14P10882213A0163|451 461|limitations
14P10882213A0163|474 489|disease activity
14P10882462T0000|12 29|tissue engineering
14P10882850A0000|0 11|Endonuclease
14P10882850A0000|40 54|DNA glycosylase
14P10882850A0000|86 109|pyrimidine base residues
14P10882850A0000|112 114|DNA
14P10884978A0633|3 10|duration
14P10884978A0633|21 29|hyperemia
14P10884978A0633|55 64|difference
14P10884978A0633|80 86|females
14P10885708T0000|8 25|bile duct blockage
14P10885731A0915|39 58|synthesis conditions
14P10885731A0915|60 71|block length
14P10885731A0915|74 86|crystallinity
14P10885731A0915|120 132|crystallinity
14P10885731A0915|136 145|solubility
14P10885750A0236|51 56|CREB-2
14P10885750A0236|81 96|organ physiology
14P10886067A0520|8 15|diameter
14P10886067A0520|22 30|thickness
14P10886067A0520|36 40|rotor
14P10887912A0740|7 10|MVBF
14P10887912A0740|17 36|maximum EMG activity
14P10887912A0740|71 88|temporalis muscles
14P10887921A0718|0 10|CONCLUSIONS
14P10887921A0718|55 65|field areas
14P10887921A0718|75 78|SWAP
14P10888570A0678|37 43|Atzimba
14P10888570A0678|45 49|Lopez
14P10888570A0678|51 58|Marciana
14P10888570A0678|60 67|Montsama
14P10888570A0678|69 73|Murca
14P10888570A0678|78 83|Puebla
14P10889399A0243|3 24|detection success rate
14P10889399A0243|64 66|MEK
14P10890911A0470|48 61|HMG box domain
14P10890911A0470|62 65|LEF1
14P10890911A0470|73 79|TGFbeta
14P10890911A0470|83 94|Wnt pathways
14P10890911A0470|131 156|Xenopus homeobox gene twin
14P10891093A0000|3 24|transmembrane topology
14P10891093A0000|26 27|Na
14P10891093A0000|75 99|transcription/translation
14P10891093A0000|139 167|membrane insertion properties
14P10891093A0000|197 209|NHE3 membrane
14P10891266A0421|0 4|ACE-2
14P10891266A0421|20 29|C terminus
14P10891266A0421|31 36|H type
14P10891286A0000|0 6|Members
14P10891286A0000|29 47|chain kinase family
14P10891286A0000|87 111|actin/myosin cytoskeleton
14P10891399A1185|69 71|p21
14P10891399A1185|73 81|Cip1/WAF1
14P10891399A1185|116 124|AP-1 site
14P10891441A0871|13 38|pTyr317 Shc phosphopeptide
14P10891441A0871|58 61|Grb2
14P10891441A0871|63 66|Sos1
14P10891441A0871|68 71|SHIP
14P10891441A0871|79 89|p85 subunit
14P10891441A0871|91 110|phosphatidylinositol
14P10891441A0871|150 166|mass spectrometry
14P10891489A0152|32 47|HMG-I/Y proteins
14P10891489A0152|71 83|proliferation
14P10891489A0152|95 108|transformation
14P10891489A0152|160 171|pathogenesis
14P10891632A0435|3 35|naltrexone/lofexidine combination
14P10891632A0435|83 101|withdrawal syndrome
14P10891632A0435|126 143|treatment schedule
14P10891632A0435|173 191|withdrawal symptoms
14P10892300A0268|47 51|March
14P10892300A0268|83 105|locomotor abnormalities
14P10892823A1040|0 8|Screening
14P10892823A1040|102 109|HBP care
14P10893243T0000|44 93|chaperonin subunit gene Ccta/t-complex polypeptide
14P10893243T0000|93 130|selenocysteine tRNA gene transcription
14P10893243T0000|138 171|factor family zinc finger proteins
14P10893258T0000|64 90|membrane protein biogenesis
14P10893258T0000|103 127|reticulum quality control
14P10894149T0000|0 3|PNRC
14P10894149T0000|125 144|orphan receptors SF1
14P10894149T0000|168 176|ERRalpha1
14P10894149T0000|193 208|receptor alpha-1
14P10894816A0836|0 6|Studies
14P10894816A0836|13 28|reporter plasmid
14P10894816A0836|79 81|SRE
14P10894816A0836|122 125|IL-6
14P10894886A0375|21 26|subset
14P10894886A0375|29 34|tumors
14P10894886A0375|50 56|changes
14P10895417A0000|27 29|EPI
14P10895417A0000|87 115|DepoFoam drug delivery system
14P10895417A0669|9 17|EPI-C0401
14P10895417A0669|33 48|DepoFoam vehicle
14P10895417A0669|85 100|food consumption
14P10895417A0669|109 128|hindlimb muscle tone
14P10895417A0669|131 146|body temperature
14P10895851A0696|0 17|Bailey Instruments
14P10895851A0696|20 41|Owen Mumford filaments
14P10896008A0531|0 11|PARTICIPANTS
14P10896008A0531|42 52|outpatients
14P10896008A0531|82 91|neuropathy
14P10896008A0531|120 128|dystrophy
14P10896859A0000|11 27|water deprivation
14P10896859A0000|40 51|Na excretion
14P10896859A0000|79 81|ADX
14P10896859A0000|130 140|aldosterone
14P10896859A0000|165 177|steroid sheep
14P10896859A0838|48 59|Na retention
14P10897233A1057|0 9|CONCLUSION
14P10897233A1057|30 42|Nazareth area
14P10897973T0001|0 26|Antithrombin III deficiency
14P10897973T0001|53 66|Thrombosis ABC
14P10898795A0527|19 38|histone deacetylases
14P10898795A0527|39 43|HDACs
14P10898795A0527|63 66|BCoR
14P10898795A0527|82 85|BCoR
14P10898795A0527|122 126|HDACs
14P10899128A0661|34 61|transcription factor complex
14P10899128A0661|75 82|MADS-box
14P10899128A0661|87 102|forkhead protein
14P10899128A0661|159 173|gene expression
14P10899142A0000|17 24|Berkeley
14P10899142A0000|35 57|Genome Project database
14P10899142A0000|146 148|LGR
14P10899142A0000|165 170|DLGR-1
14P10899142A0000|209 211|LGR
14P10899142A0000|213 218|DLGR-2
14P10900129A0138|0 17|Degenerate primers
14P10900129A0138|58 72|CYP3A sequences
14P10900129A0138|90 96|RT-PCRs
14P10900269A0396|30 33|TFOs
14P10900269A0396|56 70|polypurine site
14P10900269A0396|91 98|TK genes
14P10900269A0396|99 111|recombination
14P10901133A0381|0 15|Methyllevamisole
14P10902348A0566|0 16|Resistance ratios
14P10902348A0566|66 74|R5 strain
14P10902348A0566|135 150|glass jar method
14P10903440A0515|4 14|transcripts
14P10903440A0515|26 31|TSGF-2
14P10903440A0515|53 66|testes tissues
14P10903495A0533|3 23|gel retardation assay
14P10903495A0533|27 31|HepG2
14P10903583T0000|0 10|Reliability
14P10903583T0000|42 47|OSI CA
14P10903583T0000|51 71|spine motion analyser
14P10903733A0540|0 32|Coimmunoprecipitation experiments
14P10903733A0540|69 72|BCMA
14P10903733A0540|109 112|TRAF
14P10903733A0540|116 120|TRAF2
14P10903733A0540|125 146|TRAF3 adaptor proteins
14P10903837A1208|8 16|RINX gene
14P10903837A1208|70 73|VSX1
14P10903837A1208|84 110|Gene Nomenclature Committee
14P10903843A0447|14 25|localization
14P10903843A0447|111 115|Tapa1
14P10903843A0447|119 129|Kcnq1 genes
14P10903877A0879|0 9|Activation
14P10903877A0879|12 14|PKA
14P10903877A0879|31 33|AMP
14P10903877A0879|61 63|PKC
14P10903877A0879|110 121|3TP activity
14P10903877A0879|136 154|ERK kinase activity
14P10903877A0879|155 158|CRAC
14P10904191A0000|66 71|AMP CT
14P10904191A0000|72 93|Gen-Probe Incorporated
14P10904191A0000|94 102|San Diego
14P10904191A0000|103 104|CA
14P10904191A0000|106 108|USA
14P10904191A0000|179 181|FVU
14P10905349A0329|44 71|XPF endonuclease superfamily
14P10905349A0609|32 37|Rad54p
14P10905349A0609|41 46|Mus81p
14P10905349A0609|101 110|DNA damage
14P10905352A0000|9 21|plasmid pCLU1
14P10905352A0000|75 83|cytoplasm
14P10905352A0000|112 124|plasmid pGKL2
14P10905352A0000|146 147|TP
14P10906176A0000|13 15|ETn
14P10906176A0000|88 99|mouse genome
14P10906317A0351|22 30|variables
14P10906317A0351|46 54|hemifield
14P10906317A0351|74 83|proportion
14P10906317A0351|86 91|trials
14P10906317A0351|117 125|hemifield
14P10906999T0000|16 17|NO
14P10906999T0000|42 58|chemiluminescence
14P10907348A0508|68 85|PTH concentrations
14P10907348A0508|114 127|bone isoenzyme
14P10907348A0508|129 130|AP
14P10907971A0806|36 62|HMG-CoA reductase inhibitor
14P10907971T0000|28 62|HMG-CoA reductase inhibitor therapy
14P10907971T0000|81 92|CURVES study
14P10908317A1459|22 30|E domains
14P10908317A1459|70 80|replacement
14P10908317A1459|109 119|counterpart
14P10908317A1459|136 156|estradiol sensitivity
14P10908317A1459|185 199|transactivation
14P10908364A0000|0 4|G-DNA
14P10908364A0000|21 33|DNA structure
14P10908462A3159|3 15|effectiveness
14P10908462A3159|18 20|NRT
14P10908478A0717|0 17|SELECTION CRITERIA
14P10908478A0717|52 64|schizophrenia
14P10908822A0519|5 8|% CI
14P10908822A0519|16 18|.3%
14P10909973A1508|22 26|GLP-1
14P10909973A1508|32 34|CRE
14P10909973A1508|50 63|cotransfection
14P10909973A1508|68 74|M1-CREB
14P10909973A1508|95 118|consensus serine residue
14P10909973A1508|150 164|phosphorylation
14P10910073A0876|10 26|PDGFbetaR fusions
14P10910073A0876|101 113|amplification
14P10910073A0876|124 126|PCR
14P10910439A1196|0 10|CONCLUSIONS
14P10910439A1196|71 73|GFR
14P10910908A0767|27 53|PI3K-Akt activation pathway
14P10910908A0767|91 93|EPO
14P10913094A0424|4 16|DNA fragments
14P10913094A0424|99 127|gel mobility shift-PCR method
14P10913172A0442|51 64|Rad24 function
14P10913276A0510|40 43|SOS1
14P10913276A0510|77 97|PLC-gamma1 SH3 domain
14P10913276A0684|13 30|expression studies
14P10913276A0684|56 65|SH3 domain
14P10913276A0684|67 76|PLC-gamma1
14P10913276A0684|109 112|SOS1
14P10913304A0894|11 19|Ets mRNAs
14P10913304A0894|44 52|GABPalpha
14P10913304A0894|54 57|SAP1
14P10913304A0894|67 69|PE1
14P10913304A1180|2 14|kb transcript
14P10913304A1180|117 126|Ets domain
14P10913304A1180|128 130|PE1
14P10913304A1180|186 188|ERF
14P10915728A0216|106 113|IFN-beta
14P10915728A0216|155 165|IFN therapy
14P10915780A1063|0 19|Wnt-1 overexpression
14P10915780A1063|50 63|cyclin D1 mRNA
14P10915780A1063|73 86|overexpression
14P10915780A1063|89 93|Wnt-1
14P10915780A1063|140 151|ILK activity
14P10915780A1063|154 169|cyclin D1 levels
14P10917402T0000|21 34|administration
14P10917402T0000|37 49|amitriptyline
14P10917402T0000|69 78|depression
14P10918059A0569|0 7|Deletion
14P10918059A0569|13 22|RVH domain
14P10918059A0569|38 39|Ca
14P10918164A0878|8 26|regression analysis
14P10918164A0878|38 47|physicians
14P10918164A0878|136 156|% confidence interval
14P10918440T0000|0 30|Erythema exsudativum multiforme
14P10918440T0000|97 117|blood stem cell donor
14P10918572A0794|0 2|VaI
14P10918572A0794|6 9|VaII
14P10918572A0794|35 39|ErbB2
14P10918572A0794|51 55|ErbB1
14P10918572A0794|57 61|ErbB3
14P10918572A0794|65 69|ErbB4
14P10918572A1547|19 20|WT
14P10918572A1547|31 39|TGF-alpha
14P10918572A1547|63 78|ErbB2 activation
14P10918572A1547|146 165|TGF-alpha precursors
14P10918572A1547|187 200|ErbB signaling
14P10918596A0000|26 39|p53 C-terminus
14P10918599A0071|23 27|E2F-3
14P10918599A0071|54 66|G1/S boundary
14P10918599A0071|67 72|E2F-3B
14P10918599A0071|121 122|GO
14P10918599A0071|146 147|Rb
14P10918612A0000|3 26|transcription factor Jun
14P10918612A0000|68 81|growth signals
14P10918612A0000|110 124|gene expression
14P10918943T0000|13 20|toxicity
14P10918943T0000|48 63|agent almokalant
14P10918948A0110|56 63|Debridat
14P10918948A0110|65 67|CAS
14P10919971A0606|36 54|neutrophil response
14P10919971A0606|117 140|creatine kinase activity
14P10919971A0606|174 186|muscle repair
14P10920186A0528|50 61|fusion point
14P10920186A0528|104 114|MLL primers
14P10920186A0528|125 127|PCR
14P10920906A0759|0 9|CONCLUSION
14P10920906A0759|63 65|STS
14P10921197A0179|0 11|Measurements
14P10921197A0179|43 68|treatment planning systems
14P10921197A0179|78 81|VO5B
14P10921197A0179|85 101|ADAC Pinnacle3 V4
14P10924061A0588|0 9|Activation
14P10924061A0588|49 57|treatment
14P10925159A1353|7 12|MARTA1
14P10925159A1353|108 113|MARTA2
14P10925159A1353|149 169|salt-wash preparation
14P10925207A0634|30 42|kb transcript
14P10925207A0634|114 117|UTRs
14P10926776A0731|9 21|PDP1 isoforms
14P10928179A0101|50 69|sentinel lymph nodes
14P10928179A0101|69 72|SLNs
14P10928337A0590|7 16|correction
14P10928337A0590|45 58|erythropoietin
14P10928477A0764|28 43|PFA-100 analyzer
14P10928477A0764|75 91|platelet function
14P10928477A0764|105 120|platelet defects
14P10928477A0764|149 167|patient populations
14P10930526A0174|40 52|PL scramblase
14P10930526A0174|60 67|HuPLSCR1
14P10931524A0313|32 34|Gtx
14P10931927A0655|7 21|oligomer duplex
14P10931927A0655|26 31|GGGTTA
14P10931927A0655|44 49|TAACCC
14P10931927A0655|54 56|T-3
14P10931927A0655|61 75|template-primer
14P10931927A0655|94 108|Klenow fragment
14P10931927A0655|125 138|DNA polymerase
14P10931927A0655|142 144|HIV
14P10931927A0655|176 197|telomere DNA sequences
14P10931950A0869|0 3|Cdk2
14P10931950A0869|7 10|MAPK
14P10931950A0869|82 84|p27
14P10931950A0869|94 105|T187A mutant
14P10931960A0630|9 27|avirulence activity
14P10931960A0630|71 87|activation domain
14P10931960A0630|113 129|activation domain
14P10931960A0630|136 149|herpes simplex
14P10931960A0630|154 165|protein VP16
14P10932196A0359|0 8|Mutations
14P10932196A0359|14 22|RP2 locus
14P10932196A0359|24 29|Xp11.3
14P10932196A0359|57 69|XLRP patients
14P10932329A0597|67 93|sulcus cecocolicus dorsalis
14P10932527A0947|13 14|HD
14P10932527A0947|60 76|epithelialization
14P10932527T0000|3 15|effectiveness
14P10932527T0000|21 45|haemodialysate Solcoseryl
14P10932527T0000|64 76|wound healing
14P10932679A0049|21 28|evidence
14P10932679A0049|33 48|diet composition
14P10932679A0049|82 91|absorption
14P10932679A0049|94 104|expenditure
14P10932679A0049|139 149|food intake
14P10933154A1118|64 80|donor transplants
14P10933728A1398|44 47|CBF2
14P10933728A1398|59 79|EBNA2 transactivation
14P10933728A1398|95 112|hnRNP protein AUF1
14P10933728A1398|130 133|CBF2
14P10933728A1398|191 210|CBF1 binding element
14P10933728A1398|243 247|EBNA2
14P10933732A0000|32 36|HHV-8
14P10933732A0000|60 73|reading frames
14P10933732A0000|74 77|ORFs
14P10933732A0000|120 140|transcription factors
14P10933732A0000|172 174|IRF
14P10934073A1433|26 38|CHIME monitor
14P10934310A0698|0 13|DATA SYNTHESIS
14P10934640A1114|0 11|TB bone area
14P10934640A1114|90 95|TB BMC
14P10934751T0001|0 13|CREST syndrome
14P10935488A1033|0 11|Troglitazone
14P10935488A1033|35 55|PPARgamma target gene
14P10935488A1033|84 103|acid binding protein
14P10935488A1033|145 174|bladder cancer differentiation
14P10935880A1049|35 39|PI-3V
14P10935880A1049|46 58|NCP BVDV type
14P10935880A1049|71 76|BVHV-1
14P10935880A1049|80 83|BVDV
14P10936051T0000|3 7|RS447
14P10936051T0000|13 25|megasatellite
14P10936920A0105|8 17|experience
14P10936920A0105|47 54|elements
14P10936920A0105|60 69|generation
14P10936920A0105|83 92|prediction
14P10938102A0265|45 71|NS1 influenza virus protein
14P10938102A0265|82 100|translation factors
14P10938102A1359|62 64|NS1
14P10938102A1359|119 121|UTR
14P10938102A1359|180 205|influenza virus messengers
14P10938102T0000|10 42|translation initiation factor 4GI
14P10938102T0000|60 70|NS1 protein
14P10938105A0000|0 7|Splicing
14P10938105A0000|38 70|fibroblast growth factor receptor
14P10938109A1361|18 24|PKCbeta
14P10938109A1361|80 82|EGF
14P10938109A1361|90 102|growth factor
14P10938113A0388|48 60|isoforms Vav2
14P10938113A0388|63 66|Vav3
14P10938113A0388|154 165|Vav isoforms
14P10938120A1093|27 50|fbp1 promoter constructs
14P10938120A1093|63 66|UAS1
14P10938120A1093|69 72|UAS2
14P10938120A1093|88 90|PKA
14P10938120A1093|94 108|MAPK regulation
14P10938130A0338|0 4|X-ray
14P10938130A0338|36 54|PLZF BTB/POZ domain
14P10938135A0259|12 15|SMRT
14P10938135A0259|36 56|transcription factors
14P10938135A0259|118 151|tyrosine kinase signaling pathways
14P10938135A0259|185 206|growth factor receptor
14P10938556A0248|2 9|addition
14P10938556A0248|41 47|neurons
14P10938556A0248|75 84|ventricles
14P10939030A0986|3 13|differences
14P10939030A0986|38 52|response rate p
14P10939030A0986|81 90|survival p
14P10939030A0986|106 123|granulocytopenia p
14P10939030A0986|141 153|neutropenia p
14P10939785A0540|0 7|Patients
14P10939785A0540|46 70|ACE inhibitor perindopril
14P10939785A0540|131 146|contraindication
14P10940413A1153|76 103|stress concentration effects
14P10940553A0912|41 58|tissue-specificity
14P10940553A0912|96 119|hPer1 gene transcription
14P10940557A1687|21 27|CF1/USP
14P10940557A1687|31 76|Broad Complex Z2 transcription factor elements
14P10940557A1687|103 105|MIH
14P10940562A0379|0 16|Sequence analysis
14P10940562T0000|20 35|characterization
14P10940562T0000|41 55|oas gene family
14P10940562T0000|62 75|O-acetylserine
14P10940562T0000|121 141|cysteine biosynthesis
14P10940562T0000|143 162|Arabidopsis thaliana
14P10940892A0573|20 38|susceptibility loci
14P10940892A0573|74 76|Chr
14P10940892A0573|81 87|D4Mit89
14P10940892A0573|91 98|D4Mit147
14P10942587A0981|19 39|phosphorylation state
14P10942587A0981|41 42|Rb
14P10942587A0981|86 100|HPV E6/E7 genes
14P10942587A0981|140 149|E7 protein
14P10942587A0981|187 188|Rb
14P10942599A1298|7 22|characterization
14P10942599A1298|38 56|Hoxa-1 target genes
14P10942599A1298|92 105|Hoxa-1 protein
14P10942599A1298|110 134|differentiation processes
14P10943891A1062|12 25|U6-U57 mutants
14P10943891A1062|53 63|branch site
14P10943891A1062|68 90|splice site recognition
14P10943891A1062|166 176|spliceosome
14P10944466A0451|33 43|WNT-2B gene
14P10945010T0001|9 20|daunorubicin
14P10945010T0001|23 39|induction therapy
14P10945781A0412|9 25|Aeromonas strains
14P10945781A0412|33 49|V cholerae non-O1
14P10945781A0412|63 82|enterotoxin activity
14P10946303A0000|0 8|TNF-alpha
14P10946303A0000|49 64|cyclooxygenase-2
14P10946303A0000|66 70|COX-2
14P10946303A0000|85 98|PGE2 formation
14P10946303A0000|105 112|NCI-H292
14P10947274A0839|26 28|NCS
14P10947274A0839|51 57|RBE-cGy
14P10947274A0839|78 82|157Gd
14P10947274A0839|98 100|10B
14P10947840A0762|0 3|Mis3
14P10947840A0762|29 44|18S ribosome RNA
14P10950398T0100|0 20|Losartan Intervention
14P10950415A0866|0 9|CONCLUSION
14P10950415A0866|11 20|Vitrectomy
14P10950415A0866|44 58|Terson syndrome
14P10950924A0393|0 2|RNA
14P10950924A0393|9 21|hybridization
14P10950924A0393|24 37|brain sections
14P10950935A0111|12 23|manipulation
14P10950935A0111|93 94|P1
14P10950935A0111|117 120|PACs
14P10950935A0111|153 156|YACs
14P10951579A1238|5 21|gamma-irradiation
14P10951579A1238|36 43|F9 cells
14P10951579A1238|104 118|gene expression
14P10951579A1238|120 122|DNA
14P10951848A0230|0 11|Mobilization
14P10951848A0230|16 31|cyclophosphamide
14P10951848A0230|53 70|stimulating factor
14P10951848A0230|91 94|CD34
14P10951848A0230|132 148|quality autograft
14P10951848A0230|187 202|megachemotherapy
14P10952828A2638|82 109|ejection fraction estimation
14P10952828A2638|110 131|heart failure patients
14P10952828A2638|143 153|3D approach
14P10954093A0000|11 24|DNA transposon
14P10954093A0000|25 27|Pat
14P10954093A0000|95 119|fungus Podospora anserina
14P10954525A1161|21 23|Tax
14P10954525A1161|80 84|TRE-2
14P10954564A1262|42 44|ORF
14P10954564A1262|104 106|ORF
14P10954913A0152|31 54|Atlantic halibut Mx gene
14P10954913A0152|68 85|liver cDNA library
14P10955313A0000|0 5|PLUS-3
14P10955913A0827|4 9|HIT II
14P10955998A1124|25 44|glycosylase activity
14P10955998A1124|78 87|S120K MutY
14P10955998A1124|96 108|DNA mutations
14P10958271A0365|0 6|METHODS
14P10958271A0365|10 16|RESULTS
14P10958271A0365|82 98|ejection fraction
14P10958271A0365|99 102|LVEF
14P10958271A0365|136 145|Technetium
14P10958271A0365|150 154|Tc99m
14P10958271A0365|174 215|equilibrium radionuclide angiocardiography
14P10958271A0365|215 218|ERNA
14P10958271A0365|270 285|echocardiography
14P10958456A0529|76 77|Cp
14P10958456A0529|79 80|F6
14P10958456A0529|90 91|Cp
14P10958456A0529|93 95|F10
14P10958456A0529|119 140|polyadenylation signal
14P10958673A0142|61 63|UPR
14P10958673A0142|91 116|ER stress response element
14P10958673A0142|115 118|ERSE
14P10958688A0265|1 26|Y. lipolytica Kar2p mutant
14P10958688A0265|64 75|Sls1p mutant
14P10958688A0265|108 112|Sls1p
14P10958698A0280|59 74|Cse4p N terminus
14P10958698A0485|41 43|END
14P10958698A0485|58 60|HFD
14P10958698A0485|111 124|Cse4p function
14P10959676A0200|14 23|comparison
14P10959838A0153|2 14|invertebrates
14P10959838A0153|16 19|Fhit
14P10959838A0153|32 45|fusion protein
14P10959838A0153|49 51|Nit
14P10959838A0153|65 85|nitrilase superfamily
14P10961046A0342|0 14|Platelet counts
14P10961046A0342|46 66|von Willebrand factor
14P10961585A0273|3 16|manifestations
14P10961585A0273|38 53|thrombocytopenia
14P10962564A0883|1 29|beta2 RARE reporter construct
14P10962564A0883|74 85|sense strand
14P10962593A0580|17 24|AFP rate
14P10962738A0000|0 12|Consciousness
14P10962881A0900|0 10|Multiparity
14P10963577T0016|0 6|Picture
14P10963735A0193|72 74|CTL
14P10963735A0193|88 90|CRF
14P10963735A0193|94 104|HD patients
14P10963735A0193|138 153|dialysis session
14P10963735A0193|184 214|polyacrylonitrile membrane AN69
14P10963735A0651|8 24|plasma parameters
14P10963735A0651|51 61|acid levels
14P10964833A1696|11 22|participants
14P10964833A1696|41 44|POAG
14P10964833A1696|119 121|IOP
14P10964995A2152|55 56|ER
14P10964995A2152|141 145|HER-2
14P10965135A0735|0 16|Promoter activity
14P10965135A0735|91 109|oncogene inhibition
14P10965135A0735|177 193|MAP kinase kinase
14P10965135A0735|193 195|MKK
14P10965135A0735|197 213|inhibitor PD98059
14P10965135A1207|37 44|Cktsf1b1
14P10965135A1207|84 102|cell transformation
14P10965135A1207|116 125|MKK levels
14P10965135A1207|153 182|transcription factor complexes
14P10965830A0305|0 12|INTERVENTIONS
14P10965830A0305|38 50|PCO2 tensions
14P10965905A1618|17 30|Akt activation
14P10965905A1618|87 94|LY294002
14P10965905A1618|124 145|wortmannin sensitivity
14P10965905A1618|194 214|MAP kinase activation
14P10965905A1618|284 287|PI3K
14P10965905A1618|311 331|MAP kinase activation
14P10965905T0000|0 15|Insulin receptor
14P10965905T0000|86 110|protein kinase activation
14P10967361A0000|18 34|resonance imaging
14P10967361A0000|78 91|brain function
14P10967361A0000|132 141|resolution
14P10967531A1025|56 69|fibre necrosis
14P10967531A1025|73 80|adhesion
14P10967531A1025|83 92|leucocytes
14P10967531A1025|101 118|muscle fibre areas
14P10967890A1120|25 36|relationship
14P10967890A1120|44 56|comprehension
14P10967890A1120|60 69|production
14P10967890A1120|100 110|development
14P10970048A0352|27 34|RH level
14P10970048A0352|79 90|contrariwise
14P10970048A0352|95 108|voltage values
14P10970048A0352|142 143|RH
14P10972688A1272|42 51|difference
14P10972688A1272|68 83|hospitalizations
14P10972894A0488|7 15|libraries
14P10972894A0488|34 41|cultures
14P10972894A0488|97 104|colonies
14P10972894A0488|122 128|library
14P10972894A0488|148 154|library
14P10972894A0488|170 176|library
14P10972980A0295|61 80|phosphatidylinositol
14P10972980A0295|82 83|PI
14P10972980A0295|85 92|3-kinase
14P10972980A0295|94 110|protein kinases A
14P10972980A0295|131 140|G-proteins
14P10972980A0295|186 196|amino acids
14P10972990A0196|19 29|protein p53
14P10972990A0196|59 67|stability
14P10972990A0526|0 9|Abrogation
14P10972990A0526|12 23|p53 function
14P10972990A0526|63 82|mutation frequencies
14P10972990A0526|115 116|TK
14P10972990A0526|144 182|hypoxanthine phosphoribosyl transferase
14P10972990A0526|182 185|HPRT
14P10972990A0966|21 31|LOH mutants
14P10972990A0966|33 51|chromosome painting
14P10972990A0966|127 146|chromosome deletions
14P10972990A0966|147 160|amplifications
14P10972990A0966|173 186|translocations
14P10972990A1518|32 42|p53 protein
14P10972990A1518|58 68|maintenance
14P10973151A0883|46 60|schistosomiasis
14P10973151A0883|66 70|State
14P10973151A0883|73 82|Pernambuco
14P10973151A0883|135 146|interference
14P10973151A0883|152 162|environment
14P10973385A1423|101 109|curvature
14P10973385A1423|125 136|artery nodes
14P10973385A1423|137 149|esophagectomy
14P10973385A1423|159 174|survival benefit
14P10973385A1423|186 196|gastrectomy
14P10973400A0664|0 6|RESULTS
14P10973400A0664|66 90|flexion-distraction Stage
14P10974541A0389|11 27|K562 cDNA library
14P10974541A0389|56 60|MZF1B
14P10974541A0389|64 68|MZF1C
14P10975465A0134|8 23|cDNA clone NFBD1
14P10975465A0134|43 50|KIAA0170
14P10975465A0134|140 151|BRCT domains
14P10975465A0134|156 171|carboxy terminus
14P10975465A0134|172 190|amino acid residues
14P10976413A0514|0 6|RESULTS
14P10976413A0514|20 28|FSH level
14P10976413A0514|41 49|FSH level
14P10976413A0514|94 104|IVF success
14P10976413A0514|131 139|FSH level
14P10976413A0514|168 176|FSH level
14P10980416T0000|11 28|hormone regulation
14P10980416T0000|30 46|bone sialoprotein
14P10980416T0000|47 49|BSP
14P10980416T0000|51 68|gene transcription
14P10980416T0000|104 125|transcription factor-1
14P10980416T0000|126 130|Pit-1
14P10980416T0000|142 162|rat BSP gene promoter
14P10981094A0779|6 20|target BP goals
14P10981094A0779|35 46|Sixth Report
14P10981094A0779|53 76|Joint National Committee
14P10981094A0779|76 81|JNC VI
14P10981094A0779|164 180|pretreatment risk
14P10982076A0000|32 50|morbidity recording
14P10982076A0000|74 76|ILI
14P10982076A0000|171 188|influenza activity
14P10982143A0346|15 25|host record
14P10982143A0346|28 36|T. gondii
14P10982391A0425|12 22|NPF repeats
14P10982391A0425|99 100|WW
14P10982391A0425|159 171|membrane core
14P10982391A0425|193 211|transmembrane spans
14P10982825A0363|49 65|Mot3 binding site
14P10982825A0363|66 68|OpA
14P10983344A0000|22 31|diagnosing
14P10983344A0000|35 44|correction
14P10983344A0000|57 64|ischemia
14P10983344A0000|70 78|intestine
14P10983857A0923|7 17|application
14P10983857A0923|20 27|NCX-4016
14P10983857A0923|48 59|PD reduction
14P10983979T0000|37 41|U4/U6
14P10983979T0000|43 54|U5 tri-snRNP
14P10983979T0000|91 110|spliceosome assembly
14P10984122A0911|37 48|DNA mixtures
14P10984122A0911|58 70|vector mU6-C1
14P10987280A0604|3 21|amino acid sequence
14P10987280A0604|22 33|matrilysin-2
14P10987280A0604|47 63|threonine residue
14P10987301A0332|85 88|GPCR
14P10987301A0332|102 107|Kaposi
14P10987301A0332|128 139|herpes virus
14P10987301A0332|140 143|KSHV
14P10987301A0332|151 162|herpes virus
14P10987301A0332|187 198|angiogenesis
14P10987301A0332|244 256|growth factor
14P10987301A0332|257 260|VEGF
14P10987301A0332|332 337|Kaposi
14P10989777A1286|44 46|URD
14P10989777A1286|88 97|assignment
14P10991383A0289|5 11|lattice
14P10991383A0289|65 70|energy
14P10991383A0289|79 86|sublevel
14P10991383A0289|108 109|3D
14P10991648T0000|38 51|half syndromes
14P10992299A0745|72 86|PI12 expression
14P10992299A0745|114 132|tumor brain tissues
14P10992299A0745|139 161|brain cancer cell lines
14P10992299A0745|160 166|U-87 MG
14P10992299A0745|169 170|H4
14P10992983T0000|34 44|orientation
14P10992983T0000|48 58|penile size
14P10992983T0000|62 63|A.
14P10993773A0717|44 55|min ischemia
14P10993773A0717|67 77|microm/mmHg
14P10993773A0717|96 109|control values
14P10993773A0717|132 141|myocardium
14P10993773A0717|146 157|min ischemia
14P10993773A0717|169 179|microm/mmHg
14P10993787A0369|11 13|MAP
14P10993787A0369|17 29|MSNA increase
14P10993787A0369|35 37|SHG
14P10993787A0369|56 58|SHG
14P10993787A0369|61 63|PHI
14P10993787A0369|102 104|MAP
14P10993787A0369|128 131|MSNA
14P10995121A0569|0 7|Analysis
14P10995121A0569|10 41|Standard Reference Material 1846
14P10995121A0569|40 53|Infant Formula
14P10995121A0569|82 96|mg vitamin K/kg
14P10995121A0569|99 100|K1
14P10995751A0093|64 73|C/EBP-beta
14P10995751A0093|82 99|gene transcription
14P10995751A0093|112 131|IFN response element
14P10997330A0361|0 21|Northern blot analysis
14P10997330A0361|39 48|STORP gene
14P10997330A0361|99 106|PML gene
14P10997863A0753|5 16|TLE patients
14P10997863A0753|19 21|NAA
14P10997863A0753|70 81|FLE patients
14P10997904A1258|3 16|Spo0F residues
14P10997904A1258|62 80|response regulators
14P10997904A1258|153 183|response regulator-kinase pairs
14P10998679A0500|14 20|factors
14P10998679A0500|41 47|illness
14P10998679A0500|57 65|prognoses
14P10998679A0500|88 95|scenario
14P10999205A0607|98 100|VOI
14P10999205A0607|109 119|acquisition
14P10999301A0000|12 21|evaluation
14P10999301A0000|39 48|parameters
14P10999301A0000|99 108|microscope
14P10999301A0000|110 113|SNOM
14P10999301A0000|115 124|technology
14P10999301A0000|137 145|magnetism
14P10999369A0192|14 22|amplitude
14P10999369A0192|42 51|potentials
14P10999369A0192|53 61|amplitude
14P10999369A0192|67 76|N2/P2 peak
14P11000203A0752|16 20|K-Rev
14P11000203A0752|91 100|RNA export
14P11000203A0752|108 120|K-Rev mutants
14P11000203A0752|215 224|RNA export
14P11000250A0200|0 4|LMP-1
14P11000250A0200|47 50|TRAF
14P11000250A0200|52 56|TRADD
14P11000250A0200|61 73|JAK molecules
14P11000250A0200|83 91|NF-kappaB
14P11000250A0200|94 97|AP-1
14P11000250A0200|131 134|CD40
14P11000266T0000|0 13|Identification
14P11000266T0000|71 92|alpha-fetoprotein gene
14P11000521A0588|21 38|signaling pathways
14P11000521A0588|101 112|NIH3T3 cells
14P11000521A0588|164 191|insulin receptor substrate-2
14P11000521A0588|191 195|IRS-2
14P11000521A0588|224 252|phosphatidylinositol 3-kinase
14P11000521A0588|253 263|PI 3-kinase
14P11000521A0588|282 288|PKB/AKT
14P11002236A0328|0 6|METHODS
14P11002236A0328|45 53|PPB cases
14P11002236A0328|66 85|retrospective search
14P11002236A0328|105 116|Associations
14P11002236A0328|120 139|Pediatric Hematology
14P11002236A0328|142 157|Oncology centers
14P11003471A1149|33 46|ToLCV isolates
14P11003471A1149|50 58|Bangalore
14P11003471A1149|112 116|India
14P11003641A0811|39 43|RAP74
14P11003641A0811|45 49|Tfg1p
14P11003641A0811|60 64|TFIIF
14P11003641A0811|150 154|Fcp1p
14P11003641A0811|165 177|transcription
14P11003652A0961|23 28|Cdc42p
14P11003652A0961|48 65|pheromone response
14P11003652A0961|90 99|PAK Ste20p
14P11003653A0198|0 7|Deletion
14P11003653A0198|61 87|beta-globin locus construct
14P11003653A0198|115 135|beta-globin switching
14P11003653A0198|169 179|PYR complex
14P11003669A0000|94 113|ErbB-2 juxtamembrane
14P11003669A0000|116 129|kinase domains
14P11003805A0443|0 6|Studies
14P11003805A0443|21 24|DGOR
14P11003807A0303|0 7|Symptoms
14P11003807A0303|104 121|oesophageal damage
14P11004369A0000|0 8|OBJECTIVE
14P11004369A0000|71 94|color Doppler ultrasound
14P11004369A0000|94 112|microvessel density
14P11004369A0000|135 154|growth factor levels
14P11005808A1082|23 25|Ras
14P11005808A1082|45 63|ERK MAPK activation
14P11005831A0242|23 36|leucine zipper
14P11005831A0242|127 131|AREB1
14P11005831A0242|133 137|AREB2
14P11005831A0242|142 146|AREB3
14P11005831A0242|162 184|element binding protein
14P11006283A1180|11 18|AROM-p64
14P11006283A1180|56 58|DNA
14P11006283A1180|122 147|mRNA maturation/metabolism
14P11006284T0000|70 97|insulin receptor substrate-1
14P11006284T0000|99 127|phosphatidylinositol 3-kinase
14P11006331A0319|25 39|allotetraploids
14P11006331A0319|72 84|abnormalities
14P11007509A1271|5 19|PMR target area
14P11007509A1271|95 107|wall segments
14P11007509A1271|147 162|stress perfusion
14P11007777A0813|0 7|Analysis
14P11007777A0813|10 31|intron/exon boundaries
14P11007777A0813|43 52|BAC clones
14P11007777A0813|87 111|aspartyl beta-hydroxylase
14P11007949A1395|20 39|inactivation mutants
14P11007949A1395|41 44|PTEN
14P11007949A1607|35 37|ILK
14P11007949A1607|64 67|PTEN
14P11007954A0170|3 15|growth factor
14P11007954A0170|38 41|Grb2
14P11007954A0170|67 69|Sos
14P11007954A0170|71 73|Son
14P11007954A0170|90 104|exchange factor
14P11007954A0170|106 108|Ras
14P11007954A0170|169 171|Ras
14P11007954A0170|184 186|Sos
14P11007954A0170|221 223|Ras
14P11007961A0930|0 8|Mutations
14P11007961A0930|24 38|PR65/A subunits
14P11007961A0930|92 105|PP2A inhibitor
14P11007968A0255|79 81|DNA
14P11007968A0255|85 87|PCR
14P11007968A0255|93 108|oligonucleotides
14P11008139T0000|22 48|pattern discrimination task
14P11008420A0580|41 58|segment deviations
14P11008420A0580|71 85|complex changes
14P11008420A0580|107 122|characterization
14P11011139A0000|32 48|SIN4 gene product
14P11011139A0000|62 77|mediator complex
14P11011139A0000|91 104|RNA polymerase
14P11011139A0000|144 147|Sin4
14P11011139A0000|177 195|chromatin structure
14P11012568A0192|14 29|hypersensitivity
14P11012568A0192|32 41|ACTH drive
14P11012671A0576|50 69|Gadd45gamma promoter
14P11012671A0576|74 82|C/EBPbeta
14P11012671A0576|86 95|C/EBPdelta
14P11012671A0576|136 155|mobility shift assay
14P11012671A0576|155 158|EMSA
14P11012671A0576|163 184|reporter gene analysis
14P11012680A0676|0 13|Src activation
14P11012680A0676|22 25|FGF1
14P11012680A0676|41 50|SH2 domain
14P11012680A0676|58 60|PP2
14P11012680A1020|11 18|PLCgamma
14P11012680A1020|51 75|calcium chelator BAPTA-AM
14P11012680A1020|93 97|FGFR1
14P11012680A1020|116 122|PDGF-BB
14P11012680A1020|142 152|PDGFR-FGFR1
14P11012680A1020|165 185|PLCgamma binding site
14P11012680A1020|194 197|GVBD
14P11012680A1020|201 220|ERK2 phosphorylation
14P11013079A0927|8 32|transcription start sites
14P11013079A0927|45 69|primer extension analysis
14P11013079A0927|86 108|transfection constructs
14P11013079A0927|193 205|SV40 promoter
14P11014197A0339|7 25|inhibitor scaffolds
14P11014197A0339|106 116|subfamilies
14P11014213A1019|76 94|receptor activation
14P11014213A1019|95 105|COS-1 cells
14P11014213A1019|148 163|receptors GAL-ER
14P11014213A1019|203 209|ERalpha
14P11014213A1019|238 262|transcription factor GAL4
14P11014213A1019|281 297|CAT reporter gene
14P11014215A1092|55 66|DNA fragment
14P11014215A1092|92 113|translation start site
14P11014215A1092|145 154|GnRHR gene
14P11014215A1092|213 235|GnRHR promoter activity
14P11014465A0479|12 20|diagnosis
14P11014465A0479|38 50|echodensities
14P11014465A0479|90 92|PVL
14P11014821T0000|3 23|LAMMER protein kinase
14P11014821T0000|34 42|Doa locus
14P11014821T0000|44 53|Drosophila
14P11015197A0310|67 69|TMS
14P11015197A0310|71 73|TM4
14P11015200A0156|6 7|J.
14P11016014A0181|0 9|HYPOTHESIS
14P11016014A0181|56 69|susceptibility
14P11016014A0181|72 85|apolipoprotein
14P11016014A0181|98 109|lipoproteins
14P11016014A0181|182 196|angina pectoris
14P11016724A0536|10 12|MBq
14P11016724A0536|26 46|99mTc-HSA nanocolloid
14P11016737A0275|24 30|outcome
14P11016737A0275|65 70|status
14P11016850A0423|9 20|DNA fragment
14P11016850A0423|94 104|LysR family
14P11016850A0423|132 136|LTTRs
14P11016954A0438|0 3|AGO1
14P11016954A0438|15 19|QDE-2
14P11016954A0438|42 46|RDE-1
14P11016954A0438|58 61|RNAi
14P11017876A0787|13 32|localization studies
14P11017876A0787|47 65|EGFP fusion protein
14P11017876A0787|65 82|cell fractionation
14P11017876A0787|85 115|protease protection experiments
14P11018028A0263|48 61|protein kinase
14P11018028A0263|62 64|PKA
14P11018028A0263|71 85|phosphorylation
14P11018028A0263|88 94|CDC25Mm
14P11018028A0263|126 131|RasGEF
14P11018264A0397|0 32|Reporter gene expression analyses
14P11018264A0397|46 59|WASP promoters
14P11019257A0159|10 16|3T1-3T2
14P11019257A0159|48 57|line shape
14P11019257A0159|69 78|decay rate
14P11019257A0159|95 103|3T2 state
14P11019257A0159|174 184|distortions
14P11020375A0134|20 38|Ross broiler chicks
14P11020375A0134|52 67|treatment groups
14P11020375A0134|98 100|CLI
14P11020375A0134|139 140|AF
14P11020375A0134|153 155|CLI
14P11020375A0134|178 180|CLI
14P11023074A1105|32 33|CC
14P11023074A1105|42 46|PACE2
14P11023832A1038|36 45|KG1a cells
14P11023832A1038|46 53|TNFalpha
14P11023832A1038|76 81|PC-PLC
14P11023832A1038|85 87|PLD
14P11023832A1038|152 161|MAP kinase
14P11023832A1038|165 184|NF-kappaB signalling
14P11023853A0188|24 41|weather conditions
14P11023853A0188|92 106|laboratory data
14P11023853A0188|163 165|TAL
14P11023853A0188|183 200|energy expenditure
14P11023853A0188|201 203|DEE
14P11023853A0188|230 242|energy budget
14P11023934A0855|0 2|L/H
14P11023934A0855|45 59|filling pattern
14P11023934A0855|94 103|predictors
14P11024026A0133|7 17|selectivity
14P11024026A0133|20 28|arrestins
14P11024026A0133|62 69|receptor
14P11024026A0133|98 109|dissociation
14P11024036A0984|35 63|C/EBP alpha expression vector
14P11024036A0984|62 85|reporter gene expression
14P11024047A0626|0 9|Expression
14P11024047A0626|29 33|Smad2
14P11024047A0626|64 91|luciferase reporter activity
14P11024182A0781|15 27|collagen mRNA
14P11024182A0781|59 60|AR
14P11024182A0781|63 64|IR
14P11024182A0781|84 105|pHbetaAPr-1-neo vector
14P11024300A1579|0 5|Nature
14P11024300A1579|25 44|amino acid sequences
14P11024300A1579|45 61|peptide fragments
14P11024300A1579|120 138|chromatin structure
14P11024300A1579|139 141|ARC
14P11024300A1579|195 204|TIG-1 mRNA
14P11025367A1009|0 12|Abnormalities
14P11025367A1009|15 36|plasma cholecystokinin
14P11027027A0061|2 18|Sunset Yellow FCF
14P11027027A0061|43 74|chromatography/mass spectrometry
14P11027027A0061|75 79|LC/MS
14P11027027A0061|85 107|electrospray ionization
14P11027267A0752|0 7|Polysome
14P11027267A0752|11 32|40S ribosome fractions
14P11027274A1682|29 39|PI 3-kinase
14P11027280A0536|0 9|Cam kinase
14P11027280A0536|24 38|phosphorylation
14P11027280A0536|41 45|Smad2
14P11027280A0536|49 53|Smad4
14P11027280A0536|74 78|Smad3
14P11027289A0000|81 99|RNA binding protein
14P11027289A0000|99 100|SU
14P11027289A0000|128 143|RNA accumulation
14P11027289A0000|180 200|transposon insertions
14P11027289A0321|46 49|ARM1
14P11027289A0321|53 56|ARM2
14P11027289A0321|72 91|RNA binding activity
14P11027289A0321|92 93|SU
14P11027294A0483|26 59|histone acetyltransferase activity
14P11027294A0483|60 63|p300
14P11027294A0483|105 123|histone acetylation
14P11027294A0483|138 156|chromatin structure
14P11027724A0335|11 17|BRI1-KD
14P11027724A0335|45 47|Ser
14P11027724A0335|62 64|Thr
14P11027833A0362|0 12|Flow cytomery
14P11027833A0362|22 40|cell cycle analysis
14P11028131A1374|33 57|measure treatment effects
14P11028131A1374|71 72|MS
14P11028131A1374|109 119|IFN beta-1b
14P11028131A1374|121 124|RRMS
14P11028131T0000|0 17|Cost-effectiveness
14P11028131T0000|54 85|sclerosis disability progression
14P11028944A1020|7 10|Cmax
14P11028944A1020|14 23|AUC values
14P11029045A0000|0 14|Hyperactivation
14P11029045A0000|17 20|Cdc2
14P11029045A0000|23 35|fission yeast
14P11029262T0000|0 4|Diary
14P11029458A0000|0 4|Cells
14P11029459A0000|12 30|growth factor-beta1
14P11029459A0000|31 39|TGF-beta1
14P11029459A0000|50 65|tumor suppressor
14P11029459A0000|68 81|tumor promoter
14P11029459A0000|95 109|characteristics
14P11029467T0000|66 76|polypeptide
14P11029467T0000|91 102|factor-kappa
14P11029467T0000|114 128|gene activation
14P11029467T0000|163 177|cell line THP-1
14P11029656A0640|0 2|Mn2
14P11029656A0640|20 35|junction binding
14P11029700A0295|5 6|Pt
14P11029700A0295|17 18|Os
14P11029700A0295|63 73|transcripts
14P11029700A0746|42 43|Os
14P11029700A0746|45 48|CycH
14P11029700A0746|70 71|R2
14P11029704A0378|24 43|particle bombardment
14P11029704A0378|45 65|tobacco leaf sections
14P11029704A0378|128 142|transactivation
14P11029704A0378|145 148|ABI3
14P11029704A0378|176 178|ABA
14P11029704A0378|210 221|RY/G complex
14P11029704A0378|232 241|RY repeats
14P11029704A0378|245 249|G-box
14P11029704A0378|278 292|transactivation
14P11029704A0378|295 298|ABI3
14P11030066A0142|20 33|manifestations
14P11030066A0142|36 47|brain injury
14P11030066A0142|70 83|motor deficits
14P11030476A0685|0 5|Spores
14P11030476A0685|10 28|Rhizopus stolonifer
14P11030744A0763|0 13|Overexpression
14P11030744A0763|16 21|Trdpm1
14P11030744A0763|46 47|S.
14P11030744A0763|95 115|DPM synthase activity
14P11031252A0646|3 11|LMW FGF-2
14P11031252A0646|26 43|PKC epsilon levels
14P11031252A0646|66 76|HMW isoform
14P11031252A0646|104 114|PKC isotype
14P11031252A0646|150 158|PKC delta
14P11031366T0001|0 18|Helicobacter pylori
14P11031366T0001|21 36|stomach diseases
14P11031773A0174|43 63|formalin induced-pain
14P11032599T0000|12 26|recommendations
14P11032599T0000|100 118|practice guidelines
14P11032677A0230|9 16|findings
14P11032677A0230|28 39|pancreatitis
14P11032677A0230|106 114|steatitis
14P11032677A0230|128 135|myopathy
14P11032677A0230|155 165|candidiasis
14P11032677A0230|189 197|glossitis
14P11034392A1072|41 57|survival pathways
14P11034392A1072|92 104|NF-kappaB/Rel
14P11034392A1072|108 112|PI-3K
14P11034547A0674|8 11|Arix
14P11034547A0674|15 20|NBPhox
14P11034547A0674|82 84|DB1
14P11034547A0674|119 147|homeodomain recognition sites
14P11034547A1355|27 30|Arix
14P11034547A1355|34 39|NBPhox
14P11034547A1355|118 129|DBH promoter
14P11034933A0389|0 6|METHODS
14P11034933A0389|10 16|RESULTS
14P11034933A0389|18 24|Studies
14P11034933A0389|50 66|guinea pig hearts
14P11034933A0389|143 160|nmol/L domperidone
14P11035037A0183|54 56|TBP
14P11035037A0183|75 86|TBP function
14P11035867A0000|0 8|OBJECTIVE
14P11035867A0000|60 87|wrist blood pressure monitor
14P11035867A0000|86 106|Braun PrecisionSensor
14P11035867A0000|107 116|Braun GmbH
14P11035867A0000|117 124|Kronberg
14P11035867A0000|148 177|ANSI/AAMI SP10-1992 guidelines
14P11035867A0000|248 268|blood pressure values
14P11035867A0000|287 307|blood pressure curves
14P11036786A0628|77 100|Drinking Water Standards
14P11036786A0628|102 108|Animals
14P11036938A1162|24 33|expression
14P11036938A1162|51 64|erbB receptors
14P11036938A1162|92 103|augmentation
14P11036938A1162|113 129|steroid secretion
14P11036938A1162|180 192|gonadotropins
14P11036939A2149|0 2|Dsh
14P11036939A2149|40 50|Wnt pathway
14P11036939A2149|53 75|planar polarity pathway
14P11037759T0000|0 14|Catch-up growth
14P11037759T0000|48 61|administration
14P11037759T0000|81 97|agent vincristine
14P11037823A1134|0 10|CONCLUSIONS
14P11037823A1134|12 28|LSCC malformation
14P11037823A1134|43 59|ear malformations
14P11037823A1134|151 153|CHL
14P11037823A1134|155 158|SNHL
14P11038042A0948|0 9|Escalation
14P11038042A0948|44 65|blood cell nadir count
14P11038042A0948|81 100|platelet nadir count
14P11038118A0000|0 13|Methyl formate
14P11038118A0000|124 126|BSA
14P11038317A0000|41 53|RAB subfamily
14P11038317A0000|103 118|membrane traffic
14P11038366A1322|18 28|methylation
14P11038366A1322|50 60|association
14P11038366A1322|89 93|Rts1p
14P11038366A1417|18 23|Pph21p
14P11038366A1417|49 52|PP2A
14P11038366A1417|100 112|PP2A function
14P11039341A0180|44 58|characteristics
14P11039341A0180|95 104|components
14P11039341A0180|117 119|ICA
14P11039780A0770|68 80|animal models
14P11039780A0770|82 95|osteoarthritis
14P11039780A0770|101 112|gene therapy
14P11039780A0770|158 168|development
14P11039780A0770|171 182|gene therapy
14P11039780A0770|184 207|osteoarthritis treatment
14P11040101A1180|33 41|IL-1 beta
14P11040101A1180|48 67|VEGF gene expression
14P11040101A1180|120 128|IL-1 beta
14P11040101A1180|134 141|p38 MAPK
14P11040101A1180|144 157|JNK signalings
14P11040101A1180|199 207|VEGF gene
14P11040219A0548|0 6|Binding
14P11040219A0548|9 12|NusA
14P11040219A0548|15 17|RNA
14P11040219A0548|65 82|S1 homology region
14P11040219A0548|117 120|NusA
14P11041308A0156|36 41|DSM-IV
14P11041308A0156|54 70|gambling criteria
14P11041308A0156|92 98|Version
14P11041308A0156|101 126|South Oaks Gambling Screen
14P11041308A0156|125 128|SOGS
14P11042197A0386|0 2|Lys
14P11042197A0386|11 13|Arg
14P11042197A0386|50 51|HD
14P11042199A0572|0 8|Elevation
14P11042199A0572|24 25|Ca
14P11042199A0572|109 113|MK801
14P11042199A0572|124 125|Ca
14P11042199A0572|174 190|calcium elevation
14P11042199A0572|217 220|CREB
14P11042204A0186|24 43|phosphatidylinositol
14P11042204A0186|62 82|p38 kinase activation
14P11042204A0186|90 108|Akt phosphorylation
14P11042703A0875|4 7|BFDS
14P11042703A0875|31 42|W/A Z scores
14P11043469A0440|13 28|border sequences
14P11043469A0440|64 72|T-regions
14P11043469A0440|89 96|T-region
14P11043469A0440|114 120|T-right
14P11043469A0440|122 123|TR
14P11043469A0440|152 164|Amadoriopines
14P11044097A0422|24 26|HMG
14P11044097A0422|98 117|transcription factor
14P11044097T0000|47 67|transcription factors
14P11044097T0000|72 80|U5 region
14P11044097T0000|90 116|immunodeficiency virus type
14P11044105A0616|31 49|splicing suppressor
14P11044105A0616|51 54|ESS1
14P11045180A1892|0 10|Leptinaemia
14P11045180A1892|46 67|blood pressure reading
14P11045180A1892|109 122|classification
14P11045607A0239|3 15|RACE analysis
14P11045607A0239|31 59|transcription initiation site
14P11046146A1202|5 21|diamide treatment
14P11046146A1202|65 76|NFI proteins
14P11046146A1202|99 112|concentrations
14P11046146A1202|115 128|dithiothreitol
14P11046146A1202|173 187|NFI-DNA binding
14P11046148A0716|0 4|LMP2A
14P11046148A0716|13 15|Lyn
14P11046148A0716|19 36|Syk ubiquitination
14P11046148A0716|78 97|Nedd4 family members
14P11046148A0716|133 151|Lyn tyrosine kinase
14P11046153A1052|76 91|p300 coactivator
14P11046517A0619|3 9|results
14P11048832A0271|0 5|Fisher
14P11048832A0271|19 25|Pearson
14P11049241A0659|0 6|RESULTS
14P11049241A0659|27 51|serum PP14 concentrations
14P11049241A0659|76 77|ET
14P11049241A0659|174 175|ET
14P11049889A1271|0 18|Thromboelastography
14P11049889A1271|70 84|anticoagulation
14P11049889A1271|107 120|weight heparin
14P11050084A0000|51 64|receptor alpha
14P11050084A0000|65 73|PPARalpha
14P11050084A0000|138 152|lipid oxidation
14P11050084A0888|27 35|PPARalpha
14P11050084A0888|39 47|PPARgamma
14P11050168A1185|48 61|susceptibility
14P11050168A1185|164 185|stability determinants
14P11051364A0890|0 6|RESULTS
14P11051364A0890|34 36|PHG
14P11051364A0890|70 72|PHG
14P11051364A0890|78 97|variceal eradication
14P11051370A1906|0 7|Response
14P11051370A1906|33 41|Americans
14P11051370A1906|54 65|HCV genotype
14P11053009A0000|0 6|Aspirin
14P11053009A0000|62 75|cyclooxygenase
14P11053009A0000|77 79|COX
14P11053009A0000|92 114|prostaglandin synthesis
14P11053263A0200|12 17|clones
14P11053263A0200|41 50|sequencing
14P11053370A0708|0 9|Expression
14P11053370A0708|66 69|UhpB
14P11053370A0708|77 101|glutathione S-transferase
14P11053370A0708|102 104|GST
14P11053370A0708|124 136|Uhp signaling
14P11054011A1685|0 10|CONCLUSIONS
14P11054011A1685|49 52|MSGT
14P11054011A1685|69 88|locoregional control
14P11054011A1685|145 163|oncology department
14P11054011A1685|183 187|Quito
14P11054011A1685|189 195|Ecuador
14P11054341A0599|0 6|RESULTS
14P11054341A0599|8 24|Glaucoma suspects
14P11054341A0599|64 67|SWAP
14P11054341A0599|89 106|SWAP abnormalities
14P11054341A0599|128 138|SWAP result
14P11054539A0114|61 73|reading frame
14P11054539A0114|87 96|base pairs
14P11054539A0114|118 128|polypeptide
14P11054539A0114|135 153|amino acid residues
14P11054565A0654|7 17|p190-B exon
14P11054565A0654|32 37|p190-A
14P11054565A0654|85 90|GTPase
14P11054565A0654|142 151|GAP domain
14P11054565A0654|207 216|p190 genes
14P11054571A0230|25 28|TEN1
14P11054571A0230|52 61|PAC clones
14P11054970A0282|3 24|plexiform neurofibroma
14P11054970A0282|76 78|NF1
14P11055513A0564|9 16|lookback
14P11055513A0564|21 28|patients
14P11055513A0564|65 75|hepatitis C
14P11055513A0564|94 100|testing
14P11055786A0306|11 19|algorithm
14P11056007A0224|33 39|FVVLNLQ
14P11056007A0224|87 89|Gln
14P11056007A0224|98 100|Phe
14P11056007A0224|115 117|SET
14P11056007A0224|119 126|Suvar3-9
14P11056007A0224|128 144|Enhancer-of-zeste
14P11056007A0224|146 154|Trithorax
14P11056007A0224|174 176|SID
14P11056019A0926|0 3|MED1
14P11056019A0926|12 31|glycosylase activity
14P11056019A0926|58 71|ethenocytosine
14P11056019A0926|86 99|vinyl chloride
14P11056019A0926|102 116|ethyl carbamate
14P11058008A0159|11 19|instances
14P11058008A0159|27 39|flap necrosis
14P11058008A0159|61 73|tip ischaemia
14P11058119A0957|23 26|XAB1
14P11058119A0957|46 51|GTPase
14P11058119A0957|83 85|XPA
14P11058120A0256|18 22|IRF-2
14P11058120A0256|71 75|IRF-1
14P11058132A0264|13 16|CDSs
14P11058132A0264|21 37|% match sequences
14P11058132A0264|57 73|Bacillus subtilis
14P11058132A0264|154 163|B.subtilis
14P11058406A0447|17 19|SLN
14P11058406A0447|52 67|circulation time
14P11058406A0447|96 114|tobramycin solution
14P11059492A0376|0 8|Bacteriol
14P11059777A0813|8 23|deoxynucleotidyl
14P11059777A0813|44 67|nick end labeling assays
14P11059777A0813|100 114|PAX3 repressors
14P11059777A0813|157 171|down-regulation
14P11059777A0813|174 178|BCL-X
14P11059786A0682|0 21|VEGF promoter activity
14P11059786A0682|100 103|EGFR
14P11059786A0682|105 107|Ras
14P11059786A0682|111 130|phosphatidylinositol
14P11059786A0682|141 142|PI
14P11059786T0000|9 30|growth factor receptor
14P11059786T0000|77 100|growth factor expression
14P11059786T0000|106 123|glioblastoma cells
14P11059786T0000|143 162|phosphatidylinositol
14P11062047A1208|5 9|IHHNV
14P11062047A1208|45 65|genus Brevidensovirus
14P11062047A1208|122 158|virus Penaeus stylirostris densovirus
14P11062067A0000|16 29|protein kinase
14P11062067A0000|31 35|SAPK1
14P11062067A0000|70 72|JNK
14P11062068T0000|46 48|MAP
14P11062068T0000|50 69|kinase phosphatase-1
14P11062068T0000|80 93|p38 MAP kinase
14P11062068T0000|110 112|p38
14P11062257A0977|8 26|class C-Vps complex
14P11062257A0977|133 143|specificity
14P11062257A0977|147 156|efficiency
14P11062257A0977|163 179|transport process
14P11062274T0000|47 74|tissue plasminogen activator
14P11062705A0658|43 47|ATF-2
14P11062705A0658|56 71|cancer cell line
14P11063127A0000|0 18|Signal transduction
14P11063127A0000|33 47|phosphorylation
14P11063127A0000|74 92|protein phosphatase
14P11063127A0000|93 94|PP
14P11063127A0000|103 106|PP2A
14P11063127A0000|139 140|OA
14P11063169T0000|0 16|Botulinum toxin A
14P11063252A0437|37 62|HSL translation start site
14P11063742A0000|0 8|NF-kappaB
14P11063742A0000|27 46|transcription factor
14P11064829T0058|0 26|Cardiovascular risk factors
14P11066245T0000|20 36|compliance review
14P11066245T0000|59 62|SNFs
14P11067797A1306|0 10|CONCLUSIONS
14P11067797A1306|12 26|EBCT technology
14P11067797A1306|135 149|BV distribution
14P11067928A0532|34 46|gene segments
14P11067928A0532|61 66|Vkappa
14P11067928A0532|71 82|Jkappa genes
14P11069011A0224|0 14|SSF experiments
14P11069011A0224|65 67|CO2
14P11069075T0000|0 15|Characterization
14P11069075T0000|19 55|Xenopus laevis CXC chemokine receptor
14P11069223A0593|0 7|Patients
14P11069223A0593|40 55|marrow functions
14P11069307A0546|0 9|Inhibition
14P11069307A0546|12 27|RNA2 translation
14P11069307A0546|95 97|BMV
14P11069307A0546|110 130|replication factor 1a
14P11069307A0546|149 151|p20
14P11069307A0546|174 186|DED1 function
14P11069756A2618|0 12|Abbreviations
14P11069756A2618|14 16|CAS
14P11069756A2618|42 43|CH
14P11069756A2618|69 71|CSK
14P11069756A2618|83 92|SRC kinase
14P11069756A2618|96 120|Papillomavirus E6 protein
14P11069756A2618|120 122|FAK
14P11069756A2618|144 146|GIT
14P11069756A2618|148 161|GRK interacter
14P11069756A2618|162 165|GPCR
14P11069756A2618|208 210|GRK
14P11069756A2618|212 244|G-protein-coupled-receptor kinase
14P11069756A2618|245 248|MAPK
14P11069756A2618|281 283|ERK
14P11069756A2618|285 287|p38
14P11069756A2618|289 291|JNK
14P11069756A2618|294 296|PAK
14P11069756A2618|318 320|PBS
14P11069756A2618|348 350|PIX
14P11069756A2618|382 384|PKL
14P11069756A2618|386 407|paxillin kinase linker
14P11069756A2618|407 410|POR1
14P11069756A2618|425 426|PS
14P11069756A2618|442 443|PT
14P11069756A2618|462 463|PY
14P11069756A2618|481 483|RTK
14P11069756A2618|485 522|growth factor receptor tyrosine kinase
14P11069756A2618|520 521|SH
14P11069788A0531|25 26|SB
14P11069788A0531|70 84|difference PEEP
14P11069788A0531|92 94|Pga
14P11069788A0531|114 115|SD
14P11069788A0531|151 154|PEEP
14P11069791A0226|42 44|IPT
14P11069791A0226|77 85|Regimen A
14P11069791A0226|109 111|IPT
14P11069791A0226|135 143|Regimen B
14P11069791A0226|170 172|IPT
14P11069791A0226|190 198|Regimen C
14P11069825A0530|19 30|tuberculosis
14P11069825A0530|52 60|follow-up
14P11069825A0530|73 81|incidence
14P11069897A1112|25 30|BACH1t
14P11069897A1112|39 43|BACH1
14P11069897A1112|63 65|BTB
14P11069999A1602|3 9|U17/U16
14P11069999A1602|16 18|U16
14P11069999A1602|49 55|HIV LTR
14P11070007A0136|0 12|Transcription
14P11070007A0136|21 30|EBNA genes
14P11070007A0136|73 79|B cells
14P11070007A0136|108 109|Cp
14P11070007A0136|113 114|Wp
14P11070056A0704|3 18|Cili-2 sequences
14P11070056A0704|40 52|RNaseH domain
14P11070056A0704|54 61|Lian-Aa1
14P11070056A0704|79 93|retrotransposon
14P11070078A1153|42 44|p53
14P11070078A1153|48 75|Rb tumor suppressor pathways
14P11070078A1153|84 93|HeLa cells
14P11070078A1153|112 117|HPV E6
14P11070078A1153|120 121|E7
14P11071651A1308|92 109|retinoid induction
14P11071651A1308|111 128|FR-beta expression
14P11071789T0000|30 43|ACE inhibitors
14P11071852A0297|18 23|SOCS-3
14P11071852A0297|38 42|IGFIR
14P11071852A0297|57 62|SOCS-3
14P11071924A0588|18 20|SH2
14P11071924A0588|24 42|RING finger domains
14P11071924A0588|81 83|SH2
14P11071924A0588|87 105|RING finger domains
14P11071924A0588|106 110|SLI-1
14P11071974A0155|22 24|HRT
14P11071974A0155|63 66|ESRD
14P11071974A0155|100 112|lipid profile
14P11071974A0155|127 146|fibrinolysis markers
14P11071974A0155|150 175|plasma homocysteine levels
14P11072155A0764|42 49|TGF beta
14P11072155A0764|65 85|cell radiosensitivity
14P11072155A0764|86 99|lymphocyte SF2
14P11072388T0000|28 53|smoking reduction strategy
14P11072388T0000|66 78|schizophrenia
14P11073163A0131|25 35|degradation
14P11073163A0131|57 74|cell cycle control
14P11073163A0131|113 130|cell proliferation
14P11073163A0131|133 145|cell survival
14P11073218A0800|51 58|U.G pair
14P11073539A0866|37 40|SW13
14P11073539A0866|58 68|aggregation
14P11073539A0866|137 145|cytoplasm
14P11073870A0375|0 7|Patients
14P11073870A0375|31 33|PRC
14P11073870A0375|47 49|PHC
14P11073870A0375|86 88|PRC
14P11073870A0375|92 94|PHC
14P11073919A0631|13 31|amino acid residues
14P11073919A0631|31 33|K69
14P11073919A0631|35 37|D88
14P11073919A0631|39 41|E94
14P11073919A0631|43 46|D134
14P11073919A0631|48 51|R154
14P11073919A0631|53 56|K169
14P11073919A0631|58 61|H197
14P11073919A0631|63 66|D233
14P11073919A0631|68 71|G235
14P11073919A0631|73 76|G236
14P11073919A0631|78 81|G237
14P11073919A0631|83 86|F238
14P11073919A0631|88 91|E274
14P11073919A0631|93 96|G276
14P11073919A0631|98 101|R277
14P11073919A0631|103 106|Y278
14P11073919A0631|108 111|K294
14P11073919A0631|113 116|Y323
14P11073919A0631|118 121|Y331
14P11073919A0631|123 126|D332
14P11073919A0631|128 131|C360
14P11073919A0631|133 136|D361
14P11073919A0631|138 141|D364
14P11073919A0631|143 146|G387
14P11073919A0631|148 151|Y389
14P11073919A0631|156 159|F397
14P11073919A0631|161 179|mouse ODC numbering
14P11073919A0631|288 306|dimer stabilization
14P11073919A0631|323 326|ODCs
14P11073919A0631|347 364|S. ruminantium LDC
14P11073954A0337|3 11|Psc2 cDNA
14P11073954A0337|50 68|CP2 family proteins
14P11074003A0741|22 24|Shh
14P11074003A0741|73 77|CGNPs
14P11074210A0623|3 13|QT interval
14P11074210A0623|47 73|insulin resistance syndrome
14P11074210A0623|82 83|BP
14P11074210A0623|87 105|insulin sensitivity
14P11075678A0298|3 13|wavenumbers
14P11075678A0298|76 78|DFT
14P11075678A0298|80 86|B3LYP/6
14P11075678A0298|94 106|approximation
14P11075678A0298|180 190|force field
14P11075929A1657|32 35|ThlA
14P11075929A1657|51 60|metabolism
14P11075929A1657|81 89|formation
14P11075929A1657|124 127|ThlB
14P11075944A0691|51 64|MMTV insertion
14P11075944A0691|96 105|SC-3 cells
14P11076860A0872|0 10|Experiments
14P11076860A0872|45 49|UEV1A
14P11076860A0872|79 81|Kua
14P11076860A0872|85 91|Kua-UEV
14P11076860A0872|141 150|Kua domain
14P11076860A0872|188 194|Kua-UEV
14P11078726X0000|14 28|phosphorylation
14P11078726X0000|36 38|p53
14P11078726X0000|41 46|Ser315
14P11078726X0000|84 103|p53 protein activity
14P11078726X0000|105 124|transcription factor
14P11078726X0000|290 304|gene expression
14P11080796A0883|52 54|IKK
14P11080796A0883|73 80|IKKgamma
14P11080796A1277|3 26|Tax/IKKgamma interaction
14P11080796A1277|41 43|Tax
14P11080796A1277|49 51|IKK
14P11080796A1277|70 77|IKKalpha
14P11080796A1277|81 87|IKKbeta
14P11080796A1277|145 147|Tax
14P11080796A1277|171 173|IKK
14P11081962T0000|10 13|AFLP
14P11081962T0000|51 55|Avena
14P11082185A0415|68 78|amino acids
14P11082185A0415|80 84|IRF-1
14P11082587X0000|0 6|Effects
14P11082587X0000|48 67|brillouin scattering
14P11082587X0000|116 135|laser beam smoothing
14P11082587X0000|146 169|Brillouin backscattering
14P11082587X0000|170 173|SBBS
14P11082715X0001|12 24|determination
14P11082715X0001|27 38|theophylline
14P11082715X0001|58 61|HPLC
14P11082715X0001|85 98|chromatography
14P11082715X0001|100 103|HPLC
14P11082715X0001|145 157|determination
14P11082715X0001|160 171|theophylline
14P11083154A0881|21 35|test conditions
14P11083154A0881|38 54|oxygen uptake VO2
14P11083154A0881|64 84|minute ventilation VE
14P11083358A1071|0 9|CONCLUSION
14P11083358A1071|11 13|SPT
14P11083358A1071|30 32|WST
14P11083432A0332|45 48|FK-1
14P11083432A0332|57 60|FK-3
14P11083868A0386|0 10|DNA binding
14P11083868A0386|13 37|glutathione S-transferase
14P11083868A0386|82 86|Elk-1
14P11083868A0386|113 134|transactivation domain
14P11084022A1178|13 26|ALK7 signaling
14P11084022A1178|53 67|cell morphology
14P11084022A1178|82 96|cell flattening
14P11084022A1178|123 136|cell processes
14P11084334A0590|3 15|swa2-1 allele
14P11084334A0590|53 66|point mutation
14P11084334A0590|71 94|tetratricopeptide repeat
14P11084334A0590|95 97|TPR
14P11084334A0590|161 171|interaction
14P11084556T0000|0 10|Association
14P11084556T0000|85 100|progenitor cells
14P11084556T0000|111 120|cord blood
14P11084649A0497|26 35|expression
14P11084649A0497|70 71|E6
14P11084649A0497|87 98|gastrulation
14P11084649A0497|100 109|expression
14P11084649A0497|122 129|epiblast
14P11084649A0497|139 146|endoderm
14P11084649A0497|155 162|mesoderm
14P11085267A0562|0 13|Transformation
14P11085267A0562|19 31|sconC3 mutant
14P11085600A0123|3 9|authors
14P11085600A0123|137 147|information
14P11086872A0000|0 8|Influence
14P11086872A0000|75 85|Kagzi limes
14P11086872A0000|86 104|Citrus aurantifolia
14P11087141A0977|26 39|GT transcripts
14P11087141A0977|66 82|splicing patterns
14P11087141A0977|112 114|UTR
14P11087141A0977|135 151|splicing activity
14P11088635A0200|8 38|Kubo-Martin-Schwinger condition
14P11088635A0200|119 132|usage patterns
14P11089911A1267|95 112|retrotransposition
14P11089911A1267|118 130|ATLN elements
14P11090172A0612|15 30|RNA1 replication
14P11090172A0612|33 46|RNA3 synthesis
14P11090172A0612|103 116|FHV virion RNA
14P11090272A1240|45 48|ORL1
14P11090272A1240|52 55|GAIP
14P11090762A0527|0 6|RESULTS
14P11090762A0527|23 33|muscle pain
14P11090762A0527|55 65|stimulation
14P11090762A0527|116 117|Hz
14P11090762A0527|141 142|Hz
14P11090762A0527|144 157|power increase
14P11090762A0527|177 190|parietal locus
14P11092770A0238|3 12|extraction
14P11092770A0238|82 90|predictor
14P11092770A0238|105 114|extraction
14P11092770A0238|116 126|specificity
14P11092770A0238|136 146|sensitivity
14P11092809A0823|29 32|ERKs
14P11092809A0823|36 40|PI3Ks
14P11092850A1023|7 37|16S rRNA gene sequence analysis
14P11092886A0341|13 40|protein kinase A stimulation
14P11092886A0341|45 53|CREMalpha
14P11092886A0341|93 125|phosphoenolpyruvate carboxykinase
14P11092886A0341|126 130|PEPCK
14P11093745A0563|15 23|HNF3 site
14P11093745A0563|43 54|NF1/CTF site
14P11094066A0505|57 93|forkhead transcription factor FKHR-L1
14P11094066A0505|95 98|IL-3
14P11094066A0505|108 123|FKHR-L1 activity
14P11094066A1194|55 57|p27
14P11094066A1194|59 62|KIP1
14P11094066A1194|96 118|FKHR-L1 phosphorylation
14P11094072A0842|0 4|DNase
14P11094072A0842|13 24|footprinting
14P11094072A1234|31 44|RAG-2 promoter
14P11094072A1234|46 52|T cells
14P11094072A1234|67 81|consensus c-Myb
14P11094073A0000|31 49|Vav family proteins
14P11094073A0000|73 108|Ros receptor protein tyrosine kinase
14P11094073A0000|106 109|RPTK
14P11094075A0257|26 37|reexpression
14P11094075A0257|43 55|r-PTPeta gene
14P11094075A0257|72 88|rat thyroid cells
14P11094075A0257|100 111|retroviruses
14P11094075A0257|131 148|v-ras-Ki oncogenes
14P11094087T0000|19 22|Rnd3
14P11094087T0000|39 52|transformation
14P11094087T0000|121 134|kinase pathway
14P11094091A0000|16 40|transcription factor CREB
14P11094091A0000|87 101|phosphorylation
14P11094091A0000|113 126|serine residue
14P11094091A0000|127 132|Ser133
14P11094109A0600|0 6|RESULTS
14P11094109A0600|20 32|symptom onset
14P11094590A0617|32 43|relationship
14P11094590A0617|82 94|Gram staining
14P11094590A0617|116 118|VAP
14P11094590A0617|123 125|PSB
14P11094590A0617|129 131|PTC
14P11094590A0617|145 155|sensitivity
14P11094590A0617|165 175|specificity
14P11095248A0423|27 31|XFGF3
14P11095248A0423|56 57|Mr
14P11095248A0423|64 75|glycoprotein
14P11095248A1523|22 28|Xenopus
14P11095248A1523|41 45|FGF3s
14P11095981A0254|22 33|cis-elements
14P11095981A0254|45 55|replication
14P11095981A0254|68 78|bp promoter
14P11095981A0254|130 138|mutations
14P11095981A0254|142 150|deletions
14P11096662T0000|0 8|Tranilast
14P11096662T0000|14 20|Therapy
14P11096662T0000|31 44|Artery Disease
14P11097040A0000|3 12|objectives
14P11097040A0000|62 66|Equex
14P11097040A0000|70 82|TRIS-extender
14P11097040A0000|162 173|interactions
14P11097040A0000|186 195|treatments
14P11097040A0000|221 235|dog spermatozoa
14P11097040A0000|239 248|degrees C.
14P11097079A0525|64 73|NIMH-LCM-p
14P11098217A0674|3 12|Aie1 locus
14P11098217A0674|23 45|mouse chromosome 7A2-A3
14P11098420A0175|11 19|disorders
14P11098420A0175|22 29|children
14P11098420A0175|33 43|adolescents
14P11098420A0175|61 69|morbidity
14P11098420A0175|77 87|development
14P11098420A0175|109 117|mortality
14P11099377T0000|36 47|UDP-d-Xylose
14P11099377T0000|49 99|proteoglycan core protein beta-d-xylosyltransferase
14P11100515A0282|0 13|Thyrotoxicosis
14P11100515A0282|100 113|thyrotoxicosis
14P11100515A0282|151 171|amiodarone withdrawal
14P11101008A0649|0 14|Chaperones/HSPs
14P11101008A0649|43 62|cell cycle processes
14P11101847A0159|21 24|E2F1
14P11101847A0159|48 60|stabilization
14P11101847A0159|79 99|tumour suppressor p53
14P11102367A1170|23 33|conclusions
14P11102367A1170|42 49|identity
14P11102367A1170|52 59|proteins
14P11102367A1170|74 84|development
14P11102367A1170|105 114|Drosophila
14P11102367A1170|147 154|approach
14P11102367A1170|193 201|mutations
14P11102458A0000|13 26|identification
14P11102458A0000|37 52|characterization
14P11102458A0000|55 66|neurobeachin
14P11102458A0000|181 196|protein kinase A
14P11102458A0000|196 202|PKA RII
14P11103472A0802|0 7|Children
14P11103472A0802|12 14|ADD
14P11103472A0802|40 54|CNV-1 amplitude
14P11103472A0802|79 83|CNV-1
14P11103472A0802|87 91|CNV-2
14P11103601T0025|5 9|UMDNJ
14P11103792A0755|0 13|Overexpression
14P11103792A0755|69 77|apoptosis
14P11103792A0755|110 117|presence
14P11103792A0755|162 170|apoptosis
14P11103792A0755|193 200|bax-null
14P11103792A0755|242 252|fibroblasts
14P11105129T0000|49 90|Producing Extended-Spectrum beta-lactamase
14P11105129T0000|90 93|ESBL
14P11105716A0782|0 9|CONCLUSION
14P11105716A0782|32 50|AIF peak saturation
14P11105716A0782|103 105|CBV
14P11105716A0782|109 118|CBF values
14P11105716A0782|182 201|MR perfusion studies
14P11105717A0123|0 6|METHODS
14P11105717A0123|8 9|T2
14P11105717A0123|92 116|susceptibility difference
14P11105717A0123|177 192|microvasculature
14P11106216A0918|5 17|COPD patients
14P11106216A0918|44 46|Rrs
14P11106216A0918|72 78|FOT Rrs
14P11106428A0635|71 75|FAP-1
14P11106428A0635|119 125|Cys2408
14P11106428A0635|129 131|Ser
14P11106428A0635|140 164|glutathione-S-transferase
14P11106428A0635|166 168|GST
14P11106667A1061|5 11|Pet111p
14P11106667A1061|36 56|membrane localization
14P11106667A1061|71 85|Cox2p synthesis
14P11106668A0875|12 23|transfection
14P11106668A0875|38 55|spacer-RING domain
14P11106668A0875|109 118|BIR domain
14P11107637X0001|3 15|determination
14P11107637X0001|35 52|blood serum lipids
14P11107637X0001|53 61|titration
14P11107637X0001|75 89|pathophysiology
14P11107637X0001|103 114|significance
14P11107637X0001|140 149|definition
14P11107637X0001|175 185|blood serum
14P11107637X0001|225 239|atherosclerosis
14P11107637X0001|251 263|heart disease
14P11107637X0001|268 280|use titration
14P11108151A0560|44 57|PKC inhibitors
14P11108151A0560|59 71|PKC depletion
14P11108151A0560|99 112|EGF-R function
14P11108151A0560|131 142|EGF-R mutant
14P11108151A0560|145 161|tyrphostin AG1478
14P11108374A1466|0 5|Acoust
14P11108523A0326|0 11|Video images
14P11108523A0326|125 127|I11
14P11108523A0326|129 131|I22
14P11108523A0326|134 143|anisometry
14P11108523A0326|169 186|internostril angle
14P11108548A0710|0 17|MS characteristics
14P11108548A0710|78 98|substitution patterns
14P11108548A0710|150 163|APcI interface
14P11108616A0000|0 9|Young fish
14P11108616A0000|10 32|Oreochromis mossambicus
14P11108616A0000|84 104|space missions STS-55
14P11108616A0000|106 111|STS-84
14P11108720A0124|0 3|S6K2
14P11108720A0124|24 27|S6K1
14P11108720A0124|33 43|core kinase
14P11108720A0124|83 86|S6K1
14P11108720A0124|187 205|localization signal
14P11108720A0124|213 216|S6K2
14P11108720A1130|0 11|Pretreatment
14P11108720A1130|93 95|MEK
14P11108720A1130|97 111|inhibitor U0126
14P11108720A1130|120 134|S6K2 activation
14P11108720A1130|154 157|S6K1
14P11108839A0401|0 6|T cells
14P11108839A0401|26 29|S6k1
14P11108839A0401|61 71|kDa isoform
14P11108839A0401|93 104|localisation
14P11110040A0000|0 9|Ketanserin
14P11110040A0000|31 55|5-HT2 receptor antagonism
14P11110040A0000|95 108|% w/v solution
14P11110040A0000|126 137|applications
14P11110040A0000|216 227|ketanserinol
14P11110528A0414|19 20|2D
14P11110528A0414|38 54|velocity encoding
14P11110528A0414|71 79|direction
14P11111051A0051|26 30|Tip60
14P11111051A0051|34 58|histone acetyltransferase
14P11111051A0051|59 61|HAT
14P11112417A1126|23 39|MLSN1 transcripts
14P11112417A1126|137 152|MLSN1 expression
14P11112417A1126|198 212|mRNA processing
14P11112438X0847|0 8|Copyright
14P11112438X0847|13 26|Academic Press
14P11112700A1936|0 6|Plectin
14P11112700A1936|53 61|C-termini
14P11112700A1936|149 151|MTs
14P11112700T0000|0 15|Characterization
14P11112700T0000|21 46|microtubule binding domain
14P11112700T0000|47 83|microtubule actin crosslinking factor
14P11112700T0000|82 85|MACF
14P11112790A0989|62 64|UPR
14P11113179A0541|22 25|SRC1
14P11113179A0541|42 44|CBP
14P11113179A0541|50 66|estrogen receptor
14P11113179A0541|87 100|SRC1 functions
14P11113179A0541|129 131|CBP
14P11113179A0541|135 138|p300
14P11113179A1020|73 84|LXXLL motifs
14P11113179A1020|90 99|AD1 region
14P11113179A1020|101 104|SRC1
14P11113179A1020|120 139|coactivator activity
14P11113199A0800|5 7|MEK
14P11113199A0800|38 41|ERKs
14P11113199A0800|53 67|MEK interaction
14P11113199A0800|109 131|ERK2-Delta19-25 mutants
14P11113201A1114|0 3|Pmt2
14P11113201A1114|16 33|six-protein family
14P11113201A1114|67 81|O mannosylation
14P11113201A1114|83 97|target proteins
14P11113546A0728|51 62|trial period
14P11113546A0728|96 108|nematode eggs
14P11113546A0728|111 122|Giardia cyst
14P11113692A0169|34 45|risk factors
14P11113692A0169|48 57|background
14P11113692A0169|66 76|retinopathy
14P11113692A0169|78 80|BDR
14P11113692A0169|85 87|PDR
14P11113692A0169|188 201|blood pressure
14P11113822A0999|7 15|quadrants
14P11113822A0999|76 87|jaw pathoses
14P11113823A0197|19 32|chondromatosis
14P11114294A0075|47 83|cytokines tumor necrosis factor alpha
14P11114294A0075|128 171|fibrosis transmembrane conductance regulator
14P11114294A0075|170 173|CFTR
14P11114294A0075|180 183|CFTR
14P11114294A0075|187 191|HT-29
14P11114521A0282|0 9|Regulation
14P11114521A0282|12 15|RhoA
14P11114521A0282|82 95|cell spreading
14P11114718A0349|12 28|mouse fibroblasts
14P11114718A0349|63 76|protein levels
14P11114718A0349|78 80|p21
14P11114718A0349|82 90|WAF1/CIP1
14P11114924A0808|0 3|ORFA
14P11114924A0808|56 80|primer extension analysis
14P11116084A0000|0 11|Mouse Impact
14P11116131A0863|18 20|P2Y
14P11116148A0741|0 19|Coexpression studies
14P11116148A0741|41 43|PKB
14P11116148A0741|69 77|C/EBPbeta
14P11116148A0741|85 94|C/EBPalpha
14P11116148A0741|113 135|transactivation domains
14P11116148A0741|137 145|C/EBPbeta
14P11117263A0570|36 50|Ids3 expression
14P11117263A0570|86 95|H. vulgare
14P11117263A0570|152 154|DMA
14P11117263A0570|177 178|MA
14P11117263A0570|215 224|H. vulgare
14P11117263A0570|251 253|HMA
14P11117263A0570|255 264|S. cereale
14P11117523A0650|15 33|COUP-TFI expression
14P11117523A0650|51 65|differentiation
14P11117523A0650|68 76|P19 cells
14P11117523A0650|87 88|RA
14P11117826A0788|7 9|PET
14P11117826A0788|28 39|pretreatment
14P11117826A0788|43 62|follow-up evaluation
14P11117826A0788|83 85|PET
14P11118062A1691|31 42|localization
14P11118062A1691|61 70|K-ras gene
14P11118062A1691|100 113|aggressiveness
14P11118438A0411|29 34|MdPin1
14P11118438A0411|37 50|Pin1 homologue
14P11118438A0411|57 75|plant species apple
14P11118438A0411|75 89|Malus domestica
14P11118438A0411|137 157|substrate specificity
14P11118438A0411|205 208|Pin1
14P11118440T0000|35 57|alternative transcripts
14P11118440T0000|62 92|candidate tumor suppressor ING1
14P11118440T0000|123 141|corepressor complex
14P11118619A0835|37 39|TAg
14P11118619A0835|51 81|host cell transcription factors
14P11118619A0835|160 173|transformation
14P11118712A1296|4 23|sensitivity analysis
14P11118712A1296|99 108|estimation
14P11118712A1296|118 132|herd prevalence
14P11118712A1296|148 164|confidence limits
14P11118712A1296|175 189|within-herd PTB
14P11118712A1296|193 202|prevalence
14P11118712A1296|237 252|herd specificity
14P11119611A0428|0 5|ORFK10
14P11119611A0428|58 62|LANA2
14P11119611A0428|126 128|PEL
14P11119611A0428|132 133|CD
14P11119611A0428|140 149|KS lesions
14P11120441A1193|15 23|believers
14P11120441A1193|62 71|activation
14P11120441A1193|93 101|asymmetry
14P11120441A1193|114 123|complexity
14P11121043A0074|2 8|Xenopus
14P11121043A0074|10 13|BMPs
14P11121118A0075|43 55|GAF sequences
14P11121118T0000|29 57|phosphodiesterase PDE11A gene
14P11121397A0587|55 94|alpha1,4-N-acetylglucosaminyltransferase
14P11121434A0915|0 9|Inhibition
14P11121434A0915|15 29|Mek/Erk pathway
14P11121434A0915|31 44|Rat1/ras cells
14P11121434A0915|53 65|Mek inhibitor
14P11121434A0915|66 72|PD98059
14P11121434A0915|147 150|HR12
14P11121490A0000|3 40|transcription factor CHOP/GADD153 gene
14P11122381A0908|0 7|Addition
14P11122381A0908|93 110|GM-CSF stimulation
14P11122381A0908|141 145|STAT5
14P11122588A0549|0 20|MAIN OUTCOME MEASURES
14P11122588A0549|20 36|Percentage change
14P11122588A0549|61 63|AHI
14P11122588A0549|77 91|hypopnea events
14P11122588A0549|143 145|SDB
14P11122588A0549|158 160|AHI
14P11123054T0000|23 31|syndromes
14P11123089A0362|24 34|information
14P11123089A0362|50 64|characteristics
14P11123089A0362|87 96|mechanisms
14P11123089A0362|102 113|vasculitides
14P11123089A0362|154 168|tissue diseases
14P11123316T0000|0 19|Tec kinase signaling
14P11123316T0000|39 67|phosphatidylinositol 3-kinase
14P11123316T0000|73 102|Tec pleckstrin homology domain
14P11123701A0442|28 30|DNA
14P11123701A0442|142 155|DNA constructs
14P11123701A0442|171 191|transcription complex
14P11123701A0442|225 238|DNA supercoils
14P11123701A0442|277 286|DNA duplex
14P11123912A0306|21 30|SH2 domain
14P11123912A0306|56 58|SH2
14P11123912A0306|129 137|T antigen
14P11123912A0306|138 139|MT
14P11124024A1098|36 52|protein complexes
14P11124024A1098|83 94|C+T sequence
14P11124024A1098|116 126|GAGA motifs
14P11124902X1337|0 8|Copyright
14P11124902X1337|13 26|Academic Press
14P11125151T0000|0 18|Nucleotide sequence
14P11125151T0000|19 37|genome organization
14P11125151T0000|62 79|pineapple mealybug
14P11125363A0525|0 7|Patients
14P11125363A0525|17 39|pretreatment cystoscopy
14P11125363A0525|50 62|tumor mapping
14P11125363A0525|122 135|5-fluorouracil
14P11125363A0525|159 170|radiotherapy
14P11125411A0857|13 20|patients
14P11125411A0857|30 40|laparoscopy
14P11125872A0133|4 13|philosophy
14P11125872A0133|33 43|compound RP
14P11125872A0133|58 74|phosphodiesterase
14P11125872A0133|163 176|administration
14P11126275A1068|17 48|anticardiolipin immunoglobulin G
14P11126353A0582|0 6|RESULTS
14P11126353A0582|8 17|Prevalence
14P11126353A0582|28 34|BMI SDS
14P11126353A0582|76 77|3y
14P11126806A0206|21 47|antiphospholipid-antibodies
14P11127161T0000|0 8|Bupropion
14P11127161T0000|14 30|smoking cessation
14P11127200A1024|32 35|AP-1
14P11127200A1024|61 63|ROS
14P11127200A1024|92 117|AP-1 transcription factors
14P11127200A1024|124 132|TGF-beta1
14P11127200A1024|175 189|collagen I gene
14P11127200A1024|249 251|PTH
14P11127200A1024|273 277|PTHrP
14P11127250A1111|0 1|PM
14P11127250A1111|37 38|SB
14P11127250A1111|81 82|SB
14P11127250A1111|119 120|VL
14P11127250A1111|123 127|Bihar
14P11127250A1111|129 133|India
14P11127955X0001|18 29|colon cancer
14P11127955X0001|30 36|Surgery
14P11127955X0001|91 103|colon cancers
14P11128312A1238|20 30|differences
14P11128312A1238|111 113|BMD
14P11128312A1238|163 173|radiographs
14P11128312A1238|175 177|FD2
14P11128925A0000|0 9|BACKGROUND
14P11128925A0000|52 64|interleukin-6
14P11128925A0000|66 69|IL-6
14P11128925A0000|103 105|GCF
14P11128925A0000|171 172|RA
14P11128925A0000|182 194|periodontitis
14P11128925A0000|196 197|AP
14P11129515A0000|46 76|Vitex agnus castus L extract Ze
14P11129515A0000|128 130|PMS
14P11129724A0904|0 6|Studies
14P11129724A0904|38 50|contamination
14P11129724A0904|95 106|transmission
14P11129724A0904|109 112|MRSA
14P11131321T0000|0 6|Effects
14P11131321T0000|9 25|Trypanosoma vivax
14P11131321T0000|38 50|Yankasa sheep
14P11131321T0000|65 93|homidum chloride chemotherapy
14P11131634A0955|0 9|NF kappa B
14P11131634A0955|71 78|Y8 cells
14P11132063A0250|11 29|treatment exposures
14P11132063A0250|41 50|population
14P11132063A0250|118 128|hepatitis C
14P11132063A0250|161 174|cardiomyopathy
14P11132063A0250|218 228|dysfunction
14P11132148A0162|54 68|promoter region
14P11132148A0162|98 106|HLA class
14P11132195A0000|18 27|parameters
14P11132195A0000|39 53|Volterra series
14P11132195A0000|109 120|nonlinearity
14P11132195A0000|158 169|measurements
14P11132195A0000|172 188|input/output data
14P11132790A0609|53 55|S-B
14P11132790A0609|152 164|risk children
14P11133741A0617|0 3|NiCl
14P11133741A0617|15 29|MCP-1 synthesis
14P11133741A0617|49 57|NF-kappaB
14P11133741A0617|141 157|promoter activity
14P11133830A0174|0 9|Engagement
14P11133830A0174|17 19|CD2
14P11133830A0174|56 79|tyrosine phosphorylation
14P11133830A0174|124 141|kDa phosphoprotein
14P11133830A0174|160 179|proto-oncogene c-Cbl
14P11133927T0000|0 7|Validity
14P11133927T0000|10 25|NIR spectroscopy
14P11133986A0350|52 72|transcription factors
14P11133986A0350|81 84|PU.1
14P11133986A0350|88 111|PU.1 interaction partner
14P11133986A0350|111 113|PIP
14P11133986A0350|189 197|3T3 cells
14P11134033A0000|41 56|integration site
14P11134033A0000|113 146|translation initiation factor eIF3
14P11134033A0639|2 14|int6 deletion
14P11134033A0639|15 23|int6Delta
14P11134351A1405|13 18|MIP-2A
14P11134351A1405|56 60|MBP-1
14P11134508A0317|48 61|Arabidopsis HD
14P11134508A0317|62 66|AtHD1
14P11134822A0629|26 45|accelerations/30 min
14P11137296A0923|4 33|transcription initiation sites
14P11137296A0923|63 65|RNA
14P11137296A0923|110 117|RLM-RACE
14P11137296A0923|144 171|translation initiation codon
14P11137296A0923|178 203|transcription-PCR analysis
14P11137296A0923|215 219|PFK-A
14P11137296A0923|221 225|PFK-B
14P11137296A0923|229 239|PFK-C genes
14P11137296A1216|0 9|PFK-A mRNA
14P11137296A1216|58 62|PFK-B
14P11137296A1216|66 76|PFK-C genes
14P11137367A0297|9 27|Toshiba IIDR system
14P11137367A0297|46 60|X-ray TV system
14P11137551A0437|7 13|sardine
14P11137551A0437|38 43|levels
14P11137551A0437|75 79|limit
14P11138009A1032|36 46|Delta M1281
14P11138009A1032|49 53|IVS51
14P11138009A1032|71 82|USH1 patient
14P11138231T0000|0 6|Closeup
14P11138694A0000|1 3|18F
14P11138694A0000|11 32|fluorobenzyltrozamicol
14P11138694A0000|34 36|FBT
14P11138694A0000|74 98|acetylcholine transporter
14P11138694A0000|231 233|PET
14P11139148A0421|47 51|SAF-A
14P11139148A0421|88 91|MARs
14P11139336A0257|33 47|INCENP behavior
14P11139469A0402|0 5|Ang II
14P11139469A0402|25 47|Ang2 mRNA accumulations
14P11139469A0402|68 82|Tie2 expression
14P11139469A0402|102 128|protein kinase C inhibitors
14P11139473A0696|0 16|Promoter analysis
14P11139473A0696|86 88|CRE
14P11139473A0696|108 121|SMemb promoter
14P11139473A0696|135 152|Hex responsiveness
14P11139567A1440|0 24|LH/CG receptor activation
14P11139567A1440|25 28|ARNO
14P11139567A1440|56 84|phosphatidylinositol 3-kinase
14P11139567A1440|85 95|PI 3-kinase
14P11139567A1440|100 128|G protein beta gamma subunits
14P11139605A0811|0 16|Deletion analysis
14P11139605A0811|80 96|promoter activity
14P11139605A0811|99 113|auto-activation
14P11139605A0811|132 152|mobility shift assays
14P11139605A0811|177 182|C/EBPs
14P11139605A0811|186 188|Sp1
14P11139974A0762|0 10|Termination
14P11139974A0762|20 21|VT
14P11139974A0762|56 64|BV pacing
14P11139974A0762|77 85|RV pacing
14P11140472A0497|25 33|algorithm
14P11140472A0497|68 77|algorithms
14P11140472A0497|89 97|algorithm
14P11140472A0497|101 111|monochannel
14P11140472A0497|144 152|algorithm
14P11140472A0497|201 217|cases improvement
14P11141003T0000|0 6|Changes
14P11141003T0000|9 26|stimulation levels
14P11142380A0389|0 7|Nuclease
14P11142380A0389|68 69|TE
14P11142380A0389|71 75|TE105
14P11143384A0267|0 8|Tele-Talk
14P11143384A0267|47 67|conference situations
14P11143384A0267|72 87|microphone input
14P11145562A0000|37 49|growth factor
14P11145562A0000|50 52|IGF
14P11145562A0000|63 68|IGF-IR
14P11145562A0000|107 120|transformation
14P11145562A0468|3 15|P69 cell line
14P11145562A0468|26 40|immortalization
14P11145562A0468|96 104|T antigen
14P11145563A0202|27 39|StAR promoter
14P11145563A0202|93 98|SREBPs
14P11145563A0303|0 9|Expression
14P11145563A0303|12 19|SREBP-1a
14P11145563A0303|30 51|StAR promoter activity
14P11145563A0303|64 74|COS-1 cells
14P11145563A0303|82 103|granulosa-lutein cells
14P11145566A0000|22 41|lipoprotein receptor
14P11145566A0000|42 46|HDL-R
14P11145566A0000|63 85|cholesterol homeostasis
14P11145566A0000|161 176|HDL-R regulation
14P11145571A0788|29 44|STAT1 homodimers
14P11145571A0788|74 89|response element
14P11145571A0788|90 93|ISRE
14P11145571A0788|122 124|GAS
14P11145590A0217|46 61|TGF-beta1 action
14P11145590A0217|77 78|TG
14P11145590A0217|118 137|TGF-beta1 regulation
14P11145590A0217|155 175|transcription factors
14P11145717A0936|47 58|TPO fragment
14P11145717A0936|98 101|K713
14P11145743A0170|72 99|thyroid transcription factor
14P11145743A0170|100 104|TTF-1
14P11145743A0170|144 148|Pax-8
14P11145743A0170|183 202|deiodinase promoters
14P11145813A0668|0 18|Regional blood blow
14P11145813A0668|73 74|C6
14P11145813A0668|76 78|T11
14P11145813A0668|83 94|L6 vertebrae
14P11145887A1393|0 9|Activation
14P11145887A1393|35 43|AP-1 site
14P11145887A1393|45 56|Jurkat cells
14P11145887A1393|58 61|JunD
14P11145887A1393|68 72|Fra-2
14P11145887A1393|87 90|JunB
14P11145887A1393|95 110|c-Fos activation
14P11145887A1393|161 163|Tax
14P11145955A0189|30 52|estrogen receptor alpha
14P11145955A0189|52 58|ERalpha
14P11145955A0189|82 96|gene expression
14P11145955A0189|106 108|SRE
14P11145955A0189|183 196|protein kinase
14P11145955A0189|197 200|MAPK
14P11145955A0189|202 219|pathway activation
14P11145955A0189|221 222|E2
14P11145955A0189|239 257|growth factor alpha
14P11145955A0189|257 265|TGF-alpha
14P11146961T0000|0 18|Perfusion technique
14P11146961T0000|66 71|PADCAB
14P11148042A1258|18 19|LA
14P11148042A1258|97 117|peptide immiscibility
14P11148042A1258|126 143|gel state bilayers
14P11148589A1124|0 10|CONCLUSIONS
14P11148589A1124|24 45|immunization practices
14P11148589A1124|88 112|Pacific Islander children
14P11148589A1124|122 140|United States today
14P11148589A1124|161 163|HBV
14P11148589A1124|198 219|liver carcinoma deaths
14P11149472A1257|10 31|NP/NMP4/CIZ expression
14P11150114T0000|0 8|Chlamydia
14P11150114T0000|32 42|association
14P11150315A0226|40 70|transcription factor activities
14P11150315A0226|138 159|oligonucleotide clones
14P11150315A0226|164 186|DNA recognition library
14P11150315A0226|202 221|DNA binding proteins
14P11150315A0226|224 227|PC12
14P11150315A0844|0 2|NGF
14P11150315A0844|34 52|ERK phosphorylation
14P11150315A0844|56 58|EGF
14P11150315A1126|0 2|NGF
14P11150315A1126|10 12|EGF
14P11150315A1126|65 69|Fra-2
14P11150439A0701|0 17|Energy expenditure
14P11150439A0701|64 65|CO
14P11150439A0701|81 82|CO
14P11150439A0701|86 109|enrichment determination
14P11150439A0701|111 141|isotope ratio mass spectroscopy
14P11150439A0701|168 186|regression equation
14P11151826T0000|0 7|Workload
14P11151826T0000|9 12|UAPs
14P11152070A0573|46 59|A. chrysogenum
14P11152070A0573|66 81|expression level
14P11152070A0573|99 117|cefEF cephalosporin
14P11152070A0573|150 175|cephalosporin fermentation
14P11152081A0413|43 55|acidification
14P11152081A0413|57 76|metal solubilization
14P11152081A0413|79 94|sulfur oxidation
14P11152283A0223|27 29|NGF
14P11152283A0223|42 59|gene transcription
14P11152283A0223|61 64|PC12
14P11152283A0223|68 78|INS-1 cells
14P11152344A0416|64 77|arachnoid scar
14P11152344A0416|79 83|C1-C2
14P11152344A0416|103 111|placement
14P11152451A0529|3 31|Schistosoma mansoni homologue
14P11152451A0529|68 90|Sj26-GST fusion protein
14P11152451A1580|24 30|SmSmad2
14P11152451A1580|44 59|TGF-beta signals
14P11152451A1580|165 189|target gene transcription
14P11152451A1580|218 232|TGF-beta effect
14P11152521A0181|17 32|protein products
14P11152521A0181|65 82|expression vectors
14P11152521A0181|94 112|ORF40/41 transcript
14P11152963A0000|0 9|Expression
14P11152963A0000|28 30|SH3
14P11152963A0000|75 78|SETA
14P11152963A0000|100 123|astrocyte transformation
14P11153302A0000|0 23|Naltrexone hydrochloride
14P11153302A0000|35 60|opioid receptor antagonist
14P11154491A0322|0 6|METHODS
14P11154491A0322|97 98|CT
14P11154491A0322|109 115|EUS-FNA
14P11154491A0322|136 148|echoendoscope
14P11155096A0222|0 6|METHODS
14P11155096A0222|8 21|Thyroid status
14P11155096A0222|71 86|serum antibodies
14P11155096A0222|88 105|thyroid peroxidase
14P11155096A0222|106 112|TPO-Abs
14P11155096A0222|126 130|IU/ml
14P11155096A0222|133 148|serum TSH levels
14P11155096A0222|155 157|TSH
14P11155096A0222|186 206|serum thyroxin levels
14P11155096A0222|206 207|T4
14P11156303A1098|30 37|shunting
14P11156303A1098|70 80|alternative
14P11156303A1098|93 100|drainage
14P11156303A1098|103 110|children
14P11156303A1098|130 138|adhesions
14P11156303A1098|171 179|infection
14P11156413T0000|0 9|Derivation
14P11156413T0000|20 35|characterization
14P11156413T0000|51 65|tumor cell line
14P11156413T0000|93 101|T antigen
14P11156413T0000|132 150|cancer therapeutics
14P11156484A0223|0 11|TBARS levels
14P11156484A0223|35 48|capacity assay
14P11156484A0223|51 61|AFR release
14P11156484A0223|101 103|EPR
14P11156618T0000|30 43|mouse SCL loci
14P11156618T0000|61 71|sensitivity
14P11156618T0000|74 98|restriction endonucleases
14P11156789A1669|63 75|CSF pulsation
14P11156789A1669|93 107|motion artifact
14P11156789A1669|125 144|oxygen concentration
14P11156789A1669|227 244|CSF protein levels
14P11156789A1669|252 267|propofol binding
14P11156789A1669|290 292|CSF
14P11157035A1405|67 80|determinations
14P11157035A1405|107 118|IFN alpha-2b
14P11157334A1107|0 8|Serum PTH
14P11157334A1107|29 36|WL group
14P11157334A1107|47 54|WM group
14P11157763T0000|14 26|EMAPII domain
14P11157763T0000|33 65|aminoacyl-tRNA synthetase complex
14P11157774A0789|11 23|dSLBP alleles
14P11157774A0789|37 47|development
14P11157784A0141|11 20|DGCR6 gene
14P11157784A0141|22 37|chromosome 22q11
14P11157784A0141|47 57|copy repeat
14P11157784A0141|106 111|DGCR6L
14P11157879A0192|0 6|METHODS
14P11157879A0192|59 61|BRB
14P11158236A0000|0 18|Nerve growth factor
14P11158236A0000|18 20|NGF
14P11158236A0000|38 39|RA
14P11158236A0000|64 73|PC12 cells
14P11158288T0000|0 10|Recruitment
14P11158288T0000|15 28|RNA polymerase
14P11158288T0000|82 85|CREB
14P11158288T0000|102 121|CREB phosphorylation
14P11158290A0728|57 71|destruction box
14P11158290A0728|73 84|IkappaBalpha
14P11158295A0158|44 46|Csk
14P11158295A0158|58 69|Src homology
14P11158295A0158|71 73|SH3
14P11158295A0158|78 88|SH2 regions
14P11158310A0993|24 27|ERSF
14P11158310A0993|37 40|NF-Y
14P11158310A0993|44 52|ATF6alpha
14P11158310A0993|84 87|ERSE
14P11158310A0993|117 119|UPR
14P11158324A1073|78 98|lipoprotein secretion
14P11158324A1073|165 193|triglyceride transfer protein
14P11158324A1073|279 298|lipoprotein receptor
14P11158324A1073|299 319|scavenger receptor BI
14P11158324A1073|403 466|bile acid transporters sodium taurocholate cotransporter protein
14P11158324A1073|471 495|anion transporter protein
14P11158326A1032|27 31|SHIP2
14P11158326A1032|56 65|SH2 domain
14P11158326A1032|66 69|R47G
14P11158337A0000|50 62|GnRH receptor
14P11158337A0000|63 68|GnRH-R
14P11158337A0000|95 115|transcription factors
14P11158337A0000|146 151|GnRH-R
14P11158337A0000|171 174|GRAS
14P11158337A0000|180 198|activator protein-1
14P11158337A0000|199 202|AP-1
14P11158337A0000|240 243|SF-1
14P11158456A0223|0 6|METHODS
14P11158456A0223|59 70|consultation
14P11158456A0223|116 118|BHS
14P11158456A0223|148 157|phenomenon
14P11158456A0223|168 181|family history
14P11158456A0223|190 200|termination
14P11159081A1155|23 32|MR imaging
14P11159081A1155|98 107|reexcision
14P11159363A1251|0 10|Methylation
14P11159363A1251|17 33|cytosine residues
14P11159363A1251|38 48|E2F element
14P11159363A1251|52 53|CG
14P11159363A1251|57 58|CG
14P11160096A1067|37 51|fliF background
14P11160280A1275|36 40|IRF-1
14P11160280A1275|59 69|IRF element
14P11160307A0394|119 128|CH3 domain
14P11160307A0394|177 182|Fc end
14P11160307A0394|226 228|Fab
14P11160307A0394|254 262|FcgammaRI
14P11160656A0000|0 9|Inactivity
14P11160656A0000|20 34|cytomegalovirus
14P11160656A0000|36 39|HCMV
14P11160656A0000|78 82|MIERR
14P11160656A0000|162 177|HCMV replication
14P11160656A0000|256 271|NTera2 carcinoma
14P11160656A0000|272 274|NT2
14P11160683A1220|33 51|C/EBP dimer binding
14P11160683A1220|83 100|CREB-1 recruitment
14P11160683A1220|102 115|ATF/CREB sites
14P11160683A1220|135 138|CREB
14P11160688A1726|76 88|translocation
14P11160688A1726|91 94|ICP0
14P11160721A0932|48 51|556M
14P11160721A0932|62 83|TBLV enhancer activity
14P11160721A0932|110 121|T-cell lines
14P11160732A0464|0 12|Vector stocks
14P11160732A0464|56 68|SIVmac clones
14P11160732A0464|76 84|SIVmac239
14P11160732A0464|86 104|T-lymphocyte tropic
14P11160732A0464|116 124|SIVmac316
14P11160732A0464|157 166|SIVmac1A11
14P11160732A1199|12 22|PCR studies
14P11160732A1199|178 196|SIVmac239 infection
14P11160732A1199|210 222|transcription
14P11160732A1199|246 248|DNA
14P11160738A1414|23 31|functions
14P11160738A1414|58 70|establishment
14P11160738A1414|89 97|infection
14P11160742A0696|8 19|R expression
14P11160742A0696|29 42|PML dispersion
14P11160860A0662|27 40|IkappaB kinase
14P11160860A0662|41 48|IKK-beta
14P11160860A0662|78 97|NF-kappaB activation
14P11160860A0662|104 126|IkappaB phosphorylation
14P11160860A0662|181 208|IkappaBalpha phosphorylation
14P11160896A0713|0 25|Immunofluorescence studies
14P11160896A0713|27 40|C2C12 myotubes
14P11160896A0713|56 72|MEF2A co-localise
14P11160902A0962|13 16|TFOs
14P11160902A0962|84 110|c-sis/PDGF-B proto-oncogene
14P11160929T0000|36 44|LAGLIDADG
14P11160929T0000|51 63|endonucleases
14P11161455A1286|0 21|Southern blot analysis
14P11161455A1286|29 31|DNA
14P11161720X1294|0 8|Copyright
14P11161720X1294|13 26|Academic Press
14P11161793A1033|22 38|receptor isoforms
14P11161793A1033|122 134|EGFR activity
14P11161816A0851|17 28|similarities
14P11161816A0851|36 54|endophilin proteins
14P11161816A0851|81 93|SH3GLB family
14P11162278A0629|6 13|rotation
14P11162278A0629|22 28|figures
14P11162278A0629|39 48|activation
14P11162576A0213|17 30|identification
14P11162576A0213|103 112|PDE5A gene
14P11162666A0442|3 29|glucose/insulin stimulation
14P11162936A2727|83 89|ERalpha
14P11162936A2727|92 97|ERbeta
14P11162936A2727|118 135|tissue selectivity
14P11162936A2727|161 187|hormone replacement therapy
14P11163932A0000|36 70|roman garden snail Helix pomatia L.
14P11163932A0000|105 121|thermopreferendum
14P11163932A0000|196 210|air temperature
14P11163968A0152|45 65|Pyrococcus horikoshii
14P11163968A0152|68 84|Pyrococcus abyssi
14P11163968A0152|173 192|genome polymorphisms
14P11163968A0152|202 239|restriction-modification gene homologs
14P11164078A0833|4 15|animal model
14P11164078A0833|44 46|NAD
14P11164078A0833|70 87|treatment-response
14P11166478T0000|29 43|antinociception
14P11166478T0000|60 69|pain model
14P11166863A0167|72 75|RTOG
14P11167019A1249|3 6|TATA
14P11167019A1249|39 47|GABPalpha
14P11167019A1249|50 84|ATPsynCF6 transcription start sites
14P11167111A0957|19 42|lung function parameters
14P11167111A0957|76 78|LPD
14P11167111A0957|105 106|TX
14P11167778T0000|8 30|antithrombin deficiency
14P11168366A0569|85 92|GGT mRNA
14P11168366A0569|94 104|HepG2 cells
14P11168422A0248|6 11|Nature
14P11168422A0248|42 60|metal fluoride ions
14P11168422A0248|105 116|iron protein
14P11168422A0248|117 119|Kp2
14P11168446T0000|9 32|erythropoietin synthesis
14P11168446T0000|56 68|heart failure
14P11168446T0000|97 109|haemodynamics
14P11168588T0000|0 9|Expression
14P11168588T0000|12 36|herpes simplex virus type
14P11168588T0000|35 37|US3
14P11168588T0000|48 64|Cdc42/Rac pathway
14P11168588T0000|92 108|kinase activation
14P11169080T0000|46 48|Bok
14P11169080T0000|51 53|Law
14P11169113A0555|22 24|p16
14P11169113A0555|29 40|phi29 mutant
14P11169149A0097|24 28|SNTCS
14P11170476A1546|36 49|gp96 complexes
14P11170476A1546|55 64|plasticity
14P11170476A1546|133 135|MHC
14P11170476A1546|168 178|recognition
14P11171118A0836|22 25|NF-1
14P11171118A0836|28 32|PSE-B
14P11171118A0836|42 46|PSE-A
14P11171118A0836|105 121|NF-1 DNA elements
14P11171320A0894|0 11|Coexpression
14P11171320A0894|17 20|p120
14P11171320A0894|86 115|tyrosine phosphorylation sites
14P11171320A0894|138 160|amino acid substitution
14P11171320A0894|244 245|EL
14P11171320A0894|249 262|EalphaCL cells
14P11172610A0508|10 12|p73
14P11172944A0548|0 6|RESULTS
14P11172944A0548|28 32|Grade
14P11172944A0548|54 58|Grade
14P11172944A0826|55 69|plasma TNFalpha
14P11172944A0826|72 92|radiation pneumonitis
14P11175333A0336|19 42|co-precipitation methods
14P11176098A0342|0 6|METHODS
14P11176290T0000|0 13|Identification
14P11176290T0000|42 64|radiofrequency ablation
14P11176290T0000|90 92|MRI
14P11177538A0655|0 15|Tumor cell lines
14P11177538A0655|28 30|MOI
14P11177538A0655|50 75|% gene transfer efficiency
14P11177686A0243|0 8|Treatment
14P11178248A1042|33 52|screening techniques
14P11178248A1042|61 71|sensitivity
14P11178248A1042|73 82|efficiency
14P11178248A1042|86 95|occurrence
14P11178696A0301|6 14|US images
14P11178696A0301|107 120|contrast agent
14P11178696A0301|148 152|PD US
14P11178765A0642|52 62|development
14P11178765A0642|74 83|metastasis
14P11178765A0642|100 119|mouse adenocarcinoma
14P11179272T0000|0 14|Cytomegalovirus
14P11179272T0000|16 24|Chlamydia
14P11179272T0000|39 72|Helicobacter pylori IgG antibodies
14P11179400T0000|0 8|Responses
14P11179400T0000|22 48|carotid body chemoreceptors
14P11179664T0000|0 11|Architecture
14P11179664T0000|74 104|transcription factor RUNX1/AML1
14P11179668A0869|53 63|PLTP family
14P11179687A0280|79 82|PTPs
14P11179687A0280|141 144|PTPs
14P11179687A0280|151 163|receptor PTPs
14P11179687A0280|164 168|RPTPs
14P11179687A1118|53 62|disulphide
14P11179687A1118|70 79|Ig members
14P11179689A0000|3 17|Sox gene family
14P11179689A0000|17 19|Sry
14P11179689A0000|24 35|HMG box gene
14P11179689A0000|62 73|DNA sequence
14P11179689A0000|152 162|DNA binding
14P11179956A1818|82 99|nucleotide binding
14P11179956A1818|123 134|interactions
14P11179956A1818|180 195|proton transport
14P11180027A1306|11 20|parameters
14P11180027A1306|34 36|M6G
14P11180027A1306|60 69|depression
14P11180255A0776|35 47|improbability
14P11180255A0776|69 83|UHF frequencies
14P11180688A0000|11 31|maximum oxygen uptake
14P11180688A0000|41 49|Hong Kong
14P11180688A0000|79 89|association
14P11180688A0000|139 150|Fitness Test
14P11180688A0000|151 153|MFT
14P11180688A0000|183 196|schoolchildren
14P11181516A0119|14 58|deletion insulin promoter-reporter constructs
14P11181516A0119|88 103|INS-1 beta-cells
14P11181516A0119|152 173|rat insulin I promoter
14P11181525T0000|3 19|androgen receptor
14P11181525T0000|20 21|AR
14P11181525T0000|73 90|AR gene expression
14P11181531A0464|86 108|NF-kappa B target genes
14P11181531A0464|137 159|cytokines interleukin-6
14P11181548A0214|109 120|mE-RABP gene
14P11181548A0214|128 139|DNA fragment
14P11181564A0733|39 48|region 8E1
14P11181564A0733|50 59|chromosome
14P11181995A1093|0 7|Analysis
14P11181995A1093|13 27|genome sequence
14P11181995A1093|57 67|transcripts
14P11181995A1093|176 188|mouse matches
14P11182520A0889|16 23|genotype
14P11182520A0889|42 52|restriction
14P11182746A0872|13 20|patients
14P11182746A0872|55 66|drug therapy
14P11185475T0034|2 8|Caveman
14P11187016T0000|22 41|A-bomb survivor data
14P11188971A0000|29 37|Parkinson
14P11188971A0000|48 49|PD
14P11188971A0000|82 92|methodology
14P11188993A0298|0 6|Corneal
14P11188993A0298|106 111|Giemsa
14P11188993A0298|116 121|Gomori
14P11188993A0298|124 148|methenamine silver stains
14P11189314A1000|24 27|BACM
14P11189314A1000|78 81|GLCM
14P11191208A0000|97 117|membrane efflux pumps
14P11191208A0000|143 175|ABC binding cassette transporters
14P11191208A0000|194 217|transcription regulators
14P11191208A0000|229 232|PDR1
14P11191208A0000|236 245|PDR3 genes
14P11191365A0682|0 13|Susceptibility
14P11191365A0682|124 125|VT
14P11191365A0682|162 173|fibrillation
14P11191365A0682|175 176|VF
14P11191365A0682|190 191|VT
14P11191365A0682|199 200|VF
14P11191365A0682|223 224|VF
14P11191365A0682|234 246|non-diabetics
14P11193045A1193|49 51|p53
14P11193045A1193|53 55|p73
14P11193045A1193|57 59|p63
14P11193045A1193|71 87|tumor suppression
14P11193666A1269|36 58|Babesia carrier animals
14P11193704A0000|16 30|pleuropneumonia
14P11193704A0000|56 61|Africa
14P11194101A0532|0 18|Baseline BMD values
14P11194101A0532|240 250|user groups
14P11194147A1496|20 35|rice cultivation
14P11194147A1496|37 45|Sri Lanka
14P11194147A1496|64 76|HIDD villages
14P11194183A0866|133 162|procyanidin B-2 group subjects
14P11194183A0866|216 245|placebo control group subjects
14P11194183A0866|244 258|procyanidin B-2
14P11194183A0866|278 279|SD
14P11194183A0866|318 319|SD
14P11195338A0494|36 45|Lg3 allele
14P11195401A1030|4 20|plasma AVP levels
14P11195401A1030|51 55|SSRIs
14P11195401A1030|65 77|AVP secretion
14P11195401A1030|92 96|SIADH
14P11196191A1789|7 33|T47D breast carcinoma cells
14P11196191A1789|53 83|EGF receptor autocrine activity
14P11196191A1789|99 116|MAPK/PI3K pathways
14P11196199T0000|16 36|yeast Rad23 protein A
14P11196199T0000|72 86|element binding
14P11196199T0000|87 90|CREB
14P11196199T0000|93 107|binding protein
14P11196199T0000|147 149|p53
14P11196340A1046|24 37|identification
14P11196340A1046|70 80|variability
14P11196340A1046|100 113|aescin analogs
14P11197288A0855|4 11|patients
14P11197288A0855|21 33|metronidazole
14P11197288A0855|112 119|regimens
14P11197328T0000|0 6|Binding
14P11197328T0000|65 109|maize C4 phosphoenolpyruvate carboxylase gene
14P11197549A0748|0 6|RESULTS
14P11197549A0748|17 36|stabilization period
14P11197549A0748|37 41|PaCO2
14P11197549A0748|50 51|SD
14P11197926A0000|0 9|BACKGROUND
14P11197926A0000|80 107|General Health Questionnaire
14P11197926A0000|107 109|GHQ
14P11198053T0000|14 15|LI
14P11198053T0000|29 48|Hypericum perforatum
14P11198053T0000|49 55|St John
14P11198053T0000|73 84|constituents
14P11198289T0000|9 27|serum ceruloplasmin
14P11198289T0000|30 42|copper levels
14P11198385A0000|82 98|laboratory colony
14P11198385A0000|100 115|Culex pipiens L.
14P11198385A0000|128 146|Gharbia Governorate
14P11198424T0000|19 34|characterization
14P11198424T0000|37 41|OsPSK
14P11198424T0000|69 88|phytosulfokine-alpha
14P11198424T0000|101 123|rice cell proliferation
14P11200568A0830|0 4|Blood
14P11200568A0830|78 80|IgM
14P11200568A0830|84 97|IgG antibodies
14P11200568A0830|99 109|M. pulmonis
14P11201250A0849|0 23|Plasma DHE concentration
14P11201250A0849|69 76|PSA tape
14P11202434T0000|6 29|amino acid substitutions
14P11202434T0000|69 89|palmitoyl-CoA binding
14P11202434T0000|91 95|ACBP2
14P11202434T0000|99 109|Arabidopsis
14P11202434T0000|137 151|ankyrin repeats
14P11202705A1112|0 11|Implications
14P11202705A1112|40 60|accumulation patterns
14P11202705A1112|94 111|Posidonia oceanica
14P11203702A1307|5 10|Xlim-1
14P11203702A1307|46 62|activation domain
14P11203702A1307|106 114|CT239-403
14P11203702A1307|193 198|Xlim-1
14P11204897A0797|31 42|participants
14P11204897A0797|53 73|bridge simulator task
14P11207216A0296|9 19|PGHS-2 cDNA
14P11207216A0296|91 112|cDNA library screening
14P11207216A0719|15 25|PGHS-2 mRNA
14P11207216A0719|103 133|phorbol 12-myristate 13-acetate
14P11207216A0719|133 135|PMA
14P11207261A1421|40 56|DT40 B cell lines
14P11207261A1421|87 117|Fc gamma RIIB1-PECAM-1 receptor
14P11207261A1421|139 150|Src homology
14P11207261A1421|182 186|SHP-1
14P11207261A1421|190 194|SHP-2
14P11207261A1421|279 289|BCR complex
14P11207269A0745|61 73|p95 component
14P11207282A0729|57 70|chicken Notch1
14P11207282A0729|72 77|Notch2
14P11207282A0729|81 91|B cell line
14P11207282A0729|100 114|down-regulation
14P11207282A0729|117 138|surface IgM expression
14P11207282A0729|172 191|IgH gene transcripts
14P11207288A0897|0 12|Substitutions
14P11207288A0897|18 20|YFV
14P11207288A0897|38 40|ABR
14P11207288A0897|129 146|class Ia molecules
14P11207308A0999|19 35|diferuloylmethane
14P11207308A0999|87 107|STAT1 phosphorylation
14P11207308A0999|129 133|STAT1
14P11207308A0999|153 169|kinase activation
14P11207308A0999|185 188|JAK1
14P11207308A0999|190 193|JAK2
14P11207308A0999|195 198|JAK3
14P11207308A0999|200 205|ERK1/2
14P11207308A0999|210 228|p38 phosphorylation
14P11207609A0994|26 35|QKTT motif
14P11207609A0994|38 42|TGN46
14P11207609A0994|78 92|ER localization
14P11207609A0994|103 131|stomatitis virus glycoprotein
14P11207609A0994|131 134|VSVG
14P11207609A0994|146 149|HeLa
14P11207609A0994|153 161|NRK cells
14P11208017A0070|18 46|C2H2-type zinc finger protein
14P11208017A0070|45 50|SCOF-1
14P11208814A0673|55 65|DmCKIIalpha
14P11208814A0673|88 105|sequence alignment
14P11208814A0673|121 122|m5
14P11208814A0673|124 125|m7
14P11208814A0673|130 131|m8
14P11208814A0673|140 153|consensus site
14P11208814A0673|156 170|phosphorylation
14P11208814A0673|173 176|CKII
14P11209100A0069|55 57|PMN
14P11209100A0069|116 135|cytokine antagonists
14P11209100A0069|141 173|interleukin-1 receptor antagonist
14P11209100A0069|173 178|IL-1ra
14P11209814A0243|55 69|characteristics
14P11209814A0243|125 150|aluminum calcium phosphate
14P11209814A0243|150 154|ALCAP
14P11209814A0243|174 175|HA
14P11210401A0000|0 22|Sevelamer hydrochloride
14P11210401A0000|23 29|Renagel
14P11210401A0000|94 110|hyperphosphatemia
14P11210401A0544|18 25|profiles
14P11210401A0544|38 45|warfarin
14P11210401A0544|89 102|administration
14P11210401A0544|105 113|sevelamer
14P11210839A0282|6 23|PO3 administration
14P11210839A0282|93 103|ethambutole
14P11210839A0282|107 117|ethionamide
14P11210839A0282|120 130|ethambutole
14P11210839A0282|134 145|oprofloxacin
14P11210988T0000|54 68|prostate cancer
14P11211759A0165|0 7|Patients
14P11211759A0165|32 46|Control group A
14P11211759A0165|103 123|transtracheal heating
14P11211759A0165|126 146|humidification system
14P11211759A0165|148 162|ANAMED HUMITUBE
14P11211759A0165|183 198|cancer operation
14P11211936A1490|65 81|JNK/SAPK activity
14P11211936A1490|85 87|JNK
14P11211936A1490|89 103|SAPK activation
14P11211936A1490|139 153|differentiation
14P11212249A0993|65 81|activator protein
14P11212249A0993|83 86|AP-1
14P11212327A1564|63 75|PIG compounds
14P11212327A1564|82 112|IRS1/3 tyrosine phosphorylation
14P11212327A1564|113 125|p59Lyn kinase
14P11212327A1564|223 225|PIG
14P11213342A0492|0 6|RESULTS
14P11213342A0492|11 24|parameters SF2
14P11214177A1125|43 49|nt RNAs
14P11214177A1125|64 69|satRNA
14P11214177A1125|103 111|satellite
14P11214354A1104|61 78|lipid peroxidation
14P11214354A1104|94 107|protein thiols
14P11214354A1104|116 118|I-R
14P11214354A1104|132 142|CON animals
14P11215622A0949|0 7|Grippers
14P11215622A0949|36 48|force sensors
14P11216247T0000|3 7|child
14P11218739A0811|0 9|Transition
14P11218739A0811|22 27|H-BPPV
14P11220166A0616|35 45|stimulation
14P11220166A0616|51 67|motor performance
14P11220166A0616|132 143|interactions
14P11220166A0616|169 192|brain dopamine receptors
14P11220166A0616|197 208|intervention
14P11220166A0616|244 255|cortex loops
14P11220306A0911|0 5|HexA71
14P11220306A0911|23 26|RpoS
14P11220306A0911|56 67|sigma factor
14P11220306A0911|81 84|HexA
14P11220306A0911|101 104|HexA
14P11220306A1753|21 23|DNA
14P11220306A1753|58 67|production
14P11220486A0686|6 10|IL-12
14P11220487T0000|43 56|trichomoniasis
14P11220857T0000|0 3|CHAP
14P11220857T0000|10 19|Department
14P11220857T0000|22 37|Veterans Affairs
14P11221836A0981|20 25|fusion
14P11221836A0981|49 55|vaccine
14P11221836A0981|78 84|potency
14P11221836A0981|126 131|tumors
14P11221845A0295|23 40|methylation status
14P11221845A0295|74 89|SV40 T/t antigen
14P11221845A0295|103 112|MT-D2 mice
14P11221845A0295|118 137|Restriction Landmark
14P11221845A0295|144 151|Scanning
14P11221845A0295|155 165|Methylation
14P11221845A0295|167 172|RLGS-M
14P11221845A0800|3 18|Genescan program
14P11221845A0800|82 90|B236 spot
14P11221845A0800|110 131|493-amino acid protein
14P11221845A0800|143 162|SNAG repressor motif
14P11221845A0800|191 218|C2H2-type zinc finger motifs
14P11221845A1370|0 21|Northern blot analysis
14P11221845A1713|0 8|Treatment
14P11221845A1713|11 23|N18TG-2 cells
14P11221845A1713|47 65|5-aza-deoxycytidine
14P11221845A1713|216 234|liver tumorigenesis
14P11221845A1713|245 258|SV40 T antigen
14P11222387A1497|65 94|ABL tyrosine kinase inhibition
14P11222387A1497|93 104|FTI SCH66336
14P11222639A1273|37 52|tyrosine residue
14P11222639A1273|73 86|L1 endocytosis
14P11222720A1699|14 17|RPMS
14P11222720A1699|44 48|EBNA2
14P11222720A1699|52 65|Notch activity
14P11222720A1699|109 127|corepressor complex
14P11223131A0000|0 16|Folate metabolism
14P11223131A0000|26 63|malaria parasite Plasmodium falciparum
14P11223153A0533|3 12|BFA System
14P11223153A0533|59 79|microsphere technique
14P11223153A0533|96 107|lung anatomy
14P11223153A0533|147 158|color schema
14P11223164A0000|0 8|Retinoids
14P11223164A0000|32 46|differentiation
14P11223164A0000|48 56|apoptosis
14P11223164A0000|63 72|inhibition
14P11223186A1095|0 14|Transactivation
14P11223186A1095|17 52|oIFNtau enhancer-reporter constructs
14P11223186A1095|96 104|AP-1 site
14P11223186A1095|105 108|GATA
14P11223199A0751|46 55|S. neurona
14P11223199A0751|57 67|WB analysis
14P11223240A0655|10 32|Menin1 gene transcripts
14P11223240A0655|45 65|polyadenylation sites
14P11223246A0359|0 16|Sequence analysis
14P11223246A0359|29 49|RBP21 shares homology
14P11223255A1034|14 39|consensus amino acid motif
14P11223255A1034|40 72|serine threonine receptor kinases
14P11223256A1212|53 66|pea 33RNP gene
14P11223257A0404|0 5|OsBBPI
14P11223257A0404|34 51|rice seedling leaf
14P11223257A0404|88 89|JA
14P11223257A0404|104 125|protein phosphatase 2A
14P11223257A0404|125 128|PP2A
14P11223257A0404|153 154|CN
14P11223257A0404|169 170|EN
14P11223257A0404|254 266|cycloheximide
14P11223257A0404|268 270|CHX
14P11223257A0404|304 320|protein synthesis
14P11223938X1218|0 8|Copyright
14P11223938X1218|13 22|John Wiley
14P11223938X1218|23 26|Sons
14P11223938X1218|28 31|Ltd.
14P11224226A0000|12 27|chlordiazepoxide
14P11224226A0000|49 79|benzodiazepine receptor agonist
14P11224226A0000|116 146|benzodiazepine receptor agonist
14P11226228A0899|8 15|plasmids
14P11226228A0899|27 31|yeast
14P11226752A0750|11 30|tissue culture cells
14P11226752A0750|30 43|overexpression
14P11226752A0750|58 78|mouse deltex homologs
14P11226752A0750|115 117|E47
14P11226752A0750|208 213|Notch1
14P11226752A0750|221 224|DTX1
14P11227039A0953|31 33|BMI
14P11227039A0953|45 47|PBF
14P11227182A1475|36 47|correlations
14P11227182A1475|55 64|parameters
14P11227182A1475|78 88|bone marrow
14P11227182A1475|91 103|leptin levels
14P11227182A1475|113 123|bone marrow
14P11227484T0000|12 24|determination
14P11227484T0000|27 39|methylmercury
14P11227484T0000|44 66|ion-association complex
14P11228700T0000|3 10|position
14P11228700T0000|16 22|analyst
14P11228700T0000|25 30|expert
14P11228700T0000|32 40|yesterday
14P11230145A0732|40 49|Notch-CBF1
14P11230145A0732|51 78|RBP-Jkappa signaling pathway
14P11230145A0732|79 97|cell fate decisions
14P11230169A0480|26 54|chromatin immunoprecipitation
14P11230169A0480|64 82|array hybridization
14P11230169A0480|120 129|DNA domain
14P11230169A0480|159 170|20p12 region
14P11230169A0480|181 183|20p
14P11230169A0480|190 206|marker chromosome
14P11230534A0688|20 33|DEAH helicases
14P11230889A1151|25 39|arm lymphoedema
14P11230889A1151|65 76|improvements
14P11230889A1151|124 127|HBO2
14P11231287A0158|21 47|neuroblastoma cells SK-N-SH
14P11232947A1451|12 32|lymph node dissection
14P11232947A1451|33 49|radiation therapy
14P11233643A0000|48 50|ALA
14P11233643A0000|59 72|protoporphyrin
14P11233643A0000|76 79|PPIX
14P11233643A0000|104 106|PDT
14P11233643A0000|142 149|ALA dose
14P11234223A1451|143 145|AMK
14P11234223A1451|147 149|IPM
14P11234223A1451|153 156|PAPM
14P11234223A1451|168 170|CAZ
14P11234223A1451|172 175|MEPM
14P11235335T0000|8 10|HIV
14P11235777A0878|2 12|Klinefelter
14P11235777A0878|24 28|47XXY
14P11235777A0878|31 55|serum testosterone levels
14P11235777A0878|89 114|dihydrotestosterone levels
14P11235817A0000|3 35|histamine H1 receptor antagonists
14P11235817A0000|34 47|antihistamines
14P11236056A0374|0 9|Conclusion
14P11236056A0374|14 15|Lp
14P11237038A0889|44 64|pressure flow studies
14P11237038A0889|96 99|HIFU
14P11237038A0889|107 133|bladder outflow obstruction
14P11237491A0000|0 3|AIMS
14P11237491A0000|60 77|tumour markers CEA
14P11237491A0000|77 78|CA
14P11237491A0000|84 85|CA
14P11237491A0000|151 170|serum concentrations
14P11237491A0000|218 231|concentrations
14P11237598A0962|24 32|framework
14P11237598A0962|59 68|structures
14P11237598A0962|87 95|evolution
14P11237598A0962|114 122|mechanism
14P11238105A0959|0 4|Cells
14P11238105A0959|15 28|alpha subunits
14P11238105A0959|145 168|tyrosine phosphorylation
14P11238105A0959|170 174|Jak-2
14P11238105A0959|206 209|CD86
14P11238375A0617|11 14|RhoA
14P11238375A0617|70 73|ERK6
14P11238375A0617|75 83|p38 gamma
14P11238375A0617|115 124|p38 family
14P11238375A0617|126 130|MAPKs
14P11238402A0191|59 81|DAN/TIR gene expression
14P11238405A0817|95 114|fbp1-lacZ expression
14P11238405A0817|123 147|spc1 MAPK phosphorylation
14P11238405A0817|177 186|activation
14P11238447A0524|7 21|binding studies
14P11238447A0524|77 83|Rev-NES
14P11238447A0524|88 101|CRM1/exportin1
14P11238447A0524|131 153|nucleoporins CAN/nup214
14P11238586A0000|41 66|histocompatibility complex
14P11238586A0000|67 69|MHC
14P11238586A0000|98 112|T cell receptor
14P11238586A0000|112 114|TCR
14P11238586A0000|164 177|alpha2 helices
14P11238586A0000|182 184|MHC
14P11238882A0157|26 29|eIF6
14P11238882A0157|62 65|gene
14P11238884A0892|0 3|Mice
14P11238884A0892|20 31|dlg mutation
14P11238884A0892|38 55|growth retardation
14P11238884A0892|67 76|hypoplasia
14P11238884A0892|82 91|premaxilla
14P11238916A0838|27 33|PTP phi
14P11238916A0838|66 80|tyrosine kinase
14P11238916A0838|81 84|Pyk2
14P11238916A0838|113 130|macrophage lysates
14P11238916A0838|154 160|PTP phi
14P11238916A0838|187 190|Pyk2
14P11238947A0636|18 20|A8G
14P11238947A0636|45 60|hnRNP A2 binding
14P11238947A0636|74 79|A2RE-2
14P11238947A0636|89 101|RNA transport
14P11239184A1340|0 17|Baseline variables
14P11239184A1340|31 32|CD
14P11239184A1340|101 110|CT changes
14P11239529A0981|0 7|IL-1beta
14P11239529A0981|64 76|localizations
14P11240600A0523|64 77|VGB medication
14P11241166A0677|16 30|gene expression
14P11241166A0677|46 57|FA treatment
14P11241166A0677|92 106|leptin receptor
14P11241166A0677|107 110|Ob-R
14P11241166A0677|155 169|STAT signalling
14P11241166A0677|170 174|SOCS3
14P11241166A0677|189 207|cytokine signalling
14P11241166A0677|236 238|CIS
14P11241215A0566|51 65|fusion proteins
14P11241215A0566|69 79|thioredoxin
14P11241215A0566|130 140|performance
14P11241215A0566|147 160|chromatography
14P11241215A0566|162 168|RP-HPLC
14P11241215A0566|188 199|enterokinase
14P11241243A0693|56 69|quantification
14P11241243A0693|120 133|p53 expression
14P11241332A0393|53 70|fixation strengths
14P11241332A0393|75 84|variations
14P11241332A0393|99 117|bone anchor designs
14P11241332A0393|134 145|screw anchor
14P11241356T0000|12 26|phosphorylation
14P11241356T0000|51 55|Smad3
14P11241356T0000|82 108|collagen gene transcription
14P11241672T0000|0 6|Cloning
14P11241672T0000|10 25|characterization
14P11241672T0000|44 65|integrin gene promoter
14P11241672T0000|65 78|identification
14P11241672T0000|128 133|STAT-6
14P11243306A0961|0 10|CONCLUSIONS
14P11243306A0961|31 46|oxLDL antibodies
14P11243306A0961|68 79|hypertension
14P11243306A0961|101 114|artery disease
14P11243306A0961|139 150|hypertension
14P11243336A0000|11 17|MD-55-2
14P11243336A0000|110 132|brachytherapy dosimetry
14P11243494A0833|0 6|RESULTS
14P11243494A0833|64 66|CRF
14P11243777A0000|10 23|CCAAT elements
14P11243980A0510|31 46|PET examinations
14P11243980A0510|55 72|staging procedures
14P11244568A0506|3 8|Gap69C
14P11244568A0506|62 72|development
14P11244733A0782|0 4|Cases
14P11244733A0782|7 17|lung cancer
14P11244733A0782|35 44|metastasis
14P11245986T0000|50 77|rat aldolase B gene promoter
14P11246679A0000|0 8|OBJECTIVE
14P11246679A0000|73 76|CCHB
14P11246887A0000|26 51|cholesteryl ester transfer
14P11246887A0000|51 53|CET
14P11246887A0000|56 89|cholesteryl ester transfer protein
14P11246887A0000|88 91|CETP
14P11246887A0000|117 132|transfer protein
14P11246887A0000|133 136|PLTP
14P11246887A0000|180 199|artery calcification
14P11246887A0000|200 202|CAC
14P11246887A0000|285 287|CAC
14P11247663A1447|38 50|DNAH9 alleles
14P11248463A0187|3 14|blood levels
14P11248463A0187|35 45|amino acids
14P11248626T0000|0 7|Efficacy
14P11248626T0000|26 33|Cavermap
14P11248626T0000|91 103|prostatectomy
14P11248626T0000|125 134|evaluation
14P11250196A0455|39 59|calcium binding sites
14P11250196A0455|105 143|betagamma-crystallin fold family member
14P11250196A0455|142 151|Protein S.
14P11250942A0626|20 22|VDR
14P11250942A0626|36 40|GRIP1
14P11250942A0626|44 47|RAC3
14P11250942A0626|64 86|VDR activation function
14P11250942A0626|86 89|AF-2
14P11250942A0626|161 163|VDR
14P11251083T0000|0 8|Mechanism
14P11251083T0000|50 62|S phase entry
14P11251083T0000|100 118|MEK/ERK activations
14P11251104A0526|52 77|transcription factor GAMyb
14P11251104A0526|99 101|GA.
14P11251252A0494|0 18|3D image-processing
14P11251252A0494|34 48|ultrasound data
14P11251252A0494|110 117|3D views
14P11251276A0793|8 15|patients
14P11251276A0793|27 33|surgery
14P11251697T0000|6 35|superoxide scavenging activity
14P11251697T0000|86 108|electron spin resonance
14P11251951A0000|0 9|BACKGROUND
14P11251951A0000|11 20|Dermoscopy
14P11251951A0000|89 100|skin lesions
14P11251951A0000|172 175|CMIS
14P11254134A0648|9 12|PTax
14P11254134A0648|28 48|background activities
14P11254134A0648|52 54|PTF
14P11254134A0648|123 139|background levels
14P11254504A0766|11 25|promoter region
14P11254504A0766|77 79|Sp1
14P11254504A0766|86 102|growth response-1
14P11254504A0766|103 121|activator protein-2
14P11254504A0766|122 125|MyoD
14P11254504A0766|127 130|p300
14P11254504A0766|160 180|zinc finger protein-1
14P11254504A0766|203 205|Cdx
14P11254504A0766|216 242|Cdx protein-2 binding sites
14P11254713A1029|21 23|Tat
14P11254713A1029|180 202|IL-2 gene transcription
14P11254864T0000|33 45|breast cancer
14P11255035A0331|11 26|progenitor cells
14P11255035A0331|37 57|SVZa progenitor cells
14P11255252A0961|8 19|ER3 sequence
14P11255252A0961|21 23|DNA
14P11255252A0961|59 65|FXR HRE
14P11255423A0211|0 8|OBJECTIVE
14P11255423A0211|91 104|CD4 lymphocyte
14P11255423A0211|124 126|HIV
14P11256845A0340|23 26|West
14P11256845A0340|29 62|Scotland Coronary Prevention Study
14P11256845A0340|61 67|WOSCOPS
14P11256845A0340|90 105|statin treatment
14P11256845A0340|177 183|WOSCOPS
14P11256944A1144|29 32|ATF6
14P11256944A1144|39 54|G13 gene product
14P11256944A1144|104 129|ER stress response element
14P11256944A1144|153 161|ER stress
14P11256962A0233|0 16|Sequence analysis
14P11256962A0233|69 85|beta subunit gene
14P11256962A0233|125 148|GlyR alpha subunit genes
14P11256962A0233|227 240|GlyR beta mRNA
14P11257870A0000|100 101|TF
14P11257870A0000|115 128|sludge process
14P11257870A0000|129 131|ASP
14P11257870A0000|161 177|trichloroethylene
14P11257870A0000|179 181|TCE
14P11257870A0000|223 236|retention time
14P11257870A0000|237 239|HRT
14P11258906A0743|2 30|DNA strand exchange reactions
14P11259347A0000|9 20|observations
14P11259347A0000|43 52|literature
14P11259347A0000|87 96|variations
14P11259347A0000|128 136|chemicals
14P11259503A0212|0 18|Forskolin treatment
14P11259593A1094|0 7|Analysis
14P11259593A1094|10 24|ace2Delta cells
14P11259593A1094|35 39|Ace2p
14P11259593A1094|53 67|cell separation
14P11260468A1179|31 33|AR1
14P11260468A1179|56 66|CAP subunit
14P11260468A1179|80 98|papBA transcription
14P11260662X0000|0 1|A.
14P11260662X0000|3 9|Slatkin
14P11260662X0000|11 12|D.
14P11263622A0683|0 6|RESULTS
14P11263622A0683|58 71|wall thickness
14P11263622A0683|74 89|vessel wall area
14P11263622A0683|95 97|MRI
14P11263622A0683|101 114|histopathology
14P11263664A1085|19 22|SIP1
14P11263664A1085|42 61|XBra gene expression
14P11263664T0000|0 3|SIP1
14P11263664T0000|5 28|Smad interacting protein
14P11263664T0000|57 79|enhancer binding factor
14P11264176A0181|19 33|G1/S transition
14P11264176A0181|71 92|cyclin A2/cdk2 complex
14P11264177T0000|0 18|Nucleotide sequence
14P11264177T0000|19 35|transcription map
14P11264177T0000|39 55|mutation analysis
14P11264177T0000|60 64|13q14
14P11264177T0000|91 96|B-cell
14P11264182A0000|5 30|T-cell leukemia virus type
14P11264182A0000|30 35|HTLV-I
14P11264182A0000|37 39|Tax
14P11264182A0000|175 189|T-cell leukemia
14P11264372T0000|0 11|Requirements
14P11264372T0000|52 72|infected-cell protein
14P11264372T0000|75 94|herpes simplex virus
14P11264375A0000|8 22|cytomegalovirus
14P11264375A0000|24 27|HCMV
14P11264375A0000|69 82|phosphoprotein
14P11264561A0167|0 8|OBJECTIVE
14P11264561A0167|28 31|RSTD
14P11265853A0000|3 9|Novacor
14P11265853A0000|25 37|Assist System
14P11265853A0000|38 41|LVAS
14P11265853A0000|44 55|Novacor Corp
14P11265853A0000|56 62|Oakland
14P11265853A0000|64 65|CA
14P11266184A0000|0 7|Atheroma
14P11266184A0000|25 45|signal intensity area
14P11266184A0000|59 72|time-of-flight
14P11266184A0000|74 76|TOF
14P11266184A0000|96 97|MR
14P11266184A0000|133 150|signal intensities
14P11266184A0000|162 163|SE
14P11266194A0743|0 3|Body
14P11266194A0743|7 18|distribution
14P11266227A0295|3 12|flux rates
14P11266227A0295|14 24|p-toluidine
14P11266227A0295|51 64|donor solution
14P11266540A0328|32 53|Groucho family members
14P11266540A0328|103 124|Tcf/Lef family members
14P11266558A1470|24 44|transcription extract
14P11266558A1470|127 151|recruiting RNA polymerase
14P11266558A1470|157 176|SL RNA gene promoter
14P11266615A0258|60 72|linker region
14P11266615A0258|76 94|amino acid residues
14P11267679A0102|6 22|bp EcoRI fragment
14P11267679A0102|40 61|Southern hybridization
14P11268459A0167|38 49|relationship
14P11268459A0167|60 78|DOX binding ability
14P11268459A0167|123 134|tumor volume
14P11268459A0167|149 161|tissue tumors
14P11268459A0167|178 189|chemotherapy
14P11268887A1174|7 24|misinterpretations
14P11268887A1174|33 48|reference values
14P11268887A1174|100 102|FVC
14P11268887A1174|106 109|FEV1
14P11271297T0000|0 13|Nephrotoxicity
14P11271297T0000|29 49|liver transplantation
14P11271297T0000|66 67|FK
14P11273995A1148|39 50|TOF patients
14P11273995A1148|122 136|relaxation time
14P11274109A0129|0 6|Acetoin
14P11274109A0129|61 74|carbon sources
14P11274149A0625|31 35|U-box
14P11274149A0625|44 54|RING finger
14P11274149A0625|112 121|E2 enzymes
14P11274179A0610|21 33|Rac/Cdc42/Pak
14P11274179A0610|53 57|Raf-1
14P11274184A0000|0 3|Nrf2
14P11274184A0000|65 80|heme oxygenase-1
14P11274184A0000|81 84|HO-1
14P11274184A0000|99 112|detoxification
14P11274184A1068|24 27|ATF4
14P11274184A1068|45 48|CdCl
14P11274184A1068|130 133|Nrf2
14P11274357A0724|21 34|overexpression
14P11274357A0724|119 122|Rac1
14P11274357A0724|124 128|Cdc42
14P11274357A0724|133 136|RhoA
14P11274357A0724|170 207|nucleoside diphosphate kinase activity
14P11274357A0724|266 272|GTPases
14P11274368A0469|41 57|protein synthesis
14P11274368A0469|76 103|histone deacetylase activity
14P11274368A0818|0 7|Deletion
14P11274368A0818|22 38|initiator element
14P11274368A0818|66 77|p21 promoter
14P11274563T0000|28 29|MR
14P11275986A0091|41 68|p53 tumor suppressor protein
14P11276426A0501|8 12|Mmip1
14P11276426A0501|14 23|Mad member
14P11276426A0501|57 75|% sequence identity
14P11277913T0000|45 54|Hsp70 mRNA
14P11277913T0000|83 98|mRNA translation
14P11278286A0456|31 32|MR
14P11278286A0456|34 35|GR
14P11278286A0456|40 55|5-HT1A receptors
14P11278286A0456|66 77|inactivation
14P11278286A0456|96 98|GRE
14P11278286A0456|167 181|corticosteroids
14P11278286A1083|61 65|MR/GR
14P11278286A1083|86 87|MR
14P11278286A1083|90 91|GR
14P11278290A1220|7 11|Smad2
14P11278290A1220|38 45|TGF-beta
14P11278290A1220|81 94|Agc expression
14P11278290A1220|111 126|Smad2 activation
14P11278290A1220|168 181|Agc expression
14P11278310A1516|63 83|caspase-3 stimulation
14P11278310A1516|109 119|cell number
14P11278390A0632|7 52|transcriptase-polymerase chain reaction assays
14P11278390A0632|60 69|PKRDeltaE7
14P11278400A0668|63 65|POU
14P11278400A0668|67 77|OCT binding
14P11278400A0668|78 97|homeodomain proteins
14P11278400A0668|122 141|mobility shift assay
14P11278440A0095|0 2|SV1
14P11278440A0095|30 52|S1 transmembrane domain
14P11278440A0095|102 113|S0-S1 linker
14P11278461A0637|103 134|rainbow trout HIF-1alpha protein
14P11278461A0637|157 189|chinook salmon HIF-1alpha protein
14P11278461A0637|189 209|Western blot analysis
14P11278488T0000|3 18|v-Src SH3 domain
14P11278488T0000|53 63|association
14P11278488T0000|73 87|adhesion kinase
14P11278521A0849|8 27|pair oligonucleotide
14P11278521A0849|55 67|up-regulation
14P11278521A0849|157 179|lacZ reporter construct
14P11278563A0917|0 16|Deletion analyses
14P11278563A0917|53 57|Grb14
14P11278563A0917|61 75|ankyrin repeats
14P11278583A0873|0 10|Mutagenesis
14P11278583A0873|13 16|SNT1
14P11278583A0873|18 20|IRS
14P11278583A0873|22 23|CX
14P11278583A0873|68 70|SNT
14P11278583A0873|95 108|ERK activation
14P11278583A0873|141 162|phosphotyrosine motifs
14P11278583A0873|186 189|Grb2
14P11278583A0873|196 217|phosphotyrosine motifs
14P11278583A0873|241 244|Shp2
14P11278583A0873|298 300|Sos
14P11278594A0618|60 64|MIC-1
14P11278594A0618|67 86|TGF-beta1 propeptide
14P11278594A0618|184 199|MIC-1 propeptide
14P11278604A0300|23 31|N-glycans
14P11278604A0300|51 56|5Lec20
14P11278604A0300|121 129|CHO cells
14P11278604A0300|133 151|Lec20 cell extracts
14P11278604A0300|186 188|Gal
14P11278610A0902|14 21|SOCS box
14P11278610A0902|35 42|Cullin-2
14P11278610A0902|70 77|TEL-JAK2
14P11278671T0000|15 28|Bcl-2 homology
14P11278671T0000|40 53|splice variant
14P11278671T0000|55 57|Bak
14P11278713A1054|76 95|instability elements
14P11278713A1054|143 167|coding region determinant
14P11278819A0565|0 18|Sequence comparison
14P11278819A0565|21 35|binding studies
14P11278819A0565|96 111|mouse IRBP genes
14P11278819A0565|164 175|MOK2 binding
14P11278848A1316|12 19|SB203580
14P11278848A1316|52 54|Sp1
14P11278848A1316|67 83|promoter activity
14P11278848A1316|126 147|Sp1 consensus sequence
14P11278855A0205|32 34|TLS
14P11278855A0205|38 40|p65
14P11278855A0205|73 104|coimmunoprecipitation experiment
14P11278855A0205|114 125|Western blot
14P11278870A0123|0 7|Analysis
14P11278870A0123|52 74|copper transporter gene
14P11278870A0123|75 87|fission yeast
14P11278870A0123|165 168|CuSE
14P11278870A0123|193 217|transcription factor Cuf1
14P11278928A1634|115 135|C/EBPepsilon isoforms
14P11278928A1634|136 138|p32
14P11278928A1634|142 144|p30
14P11279038A0194|0 11|WRN helicase
14P11279038A0194|28 41|DNA structures
14P11279038A0194|69 71|DNA
14P11279038A0194|76 93|Holliday junctions
14P11279086A1350|20 28|ADAM-TS12
14P11279086A1350|68 78|development
14P11279086A1350|83 97|tumor processes
14P11279086A1350|160 169|regulation
14P11279086A1350|172 184|cell adhesion
14P11279108T0000|0 6|Binding
14P11279108T0000|9 29|serum response factor
14P11279108T0000|30 47|CArG box sequences
14P11279207A0904|29 32|HPK1
14P11279207A0904|50 62|TCR signaling
14P11279217A0273|0 3|Biol
14P11279324A0710|40 54|creatine kinase
14P11279385A3917|58 63|M mode
14P11279385A3917|75 76|2D
14P11279385A3917|88 94|Doppler
14P11279720A0844|0 17|SELECTION CRITERIA
14P11279720A0844|114 122|Parkinson
14P11279720A0844|144 156|complications
14P11279720A0844|159 174|levodopa therapy
14P11280495A1330|0 10|CONCLUSIONS
14P11280495A1330|55 63|PD fluids
14P11280495A1330|93 107|Amadori albumin
14P11280495A1330|110 113|AGEs
14P11280799A1025|20 28|PTHrP1-34
14P11280799A1025|69 83|IL-8 production
14P11280799A1025|149 152|IL-8
14P11280799A1025|166 170|PTHrP
14P11281201T0000|13 19|effects
14P11281268A0000|33 35|AKs
14P11281268A0000|114 116|AKs
14P11281268A0000|133 167|sea anemone Anthopleurura japonicus
14P11281268A0000|175 206|clam Pseudocardium sachalinensis
14P11282029A0075|37 40|PDGF
14P11282029A0075|42 63|beta-receptor promoter
14P11282029A0075|72 82|CCAAT motif
14P11282029A0075|86 89|NF-Y
14P11282088A0837|0 11|Baseline MBF
14P11282394A0841|14 25|VH/VL-chains
14P11282394A0841|59 78|antigen reactivities
14P11282394A0841|109 126|cross-reactivities
14P11282395A0530|31 45|RAG1/2 proteins
14P11282395A0530|54 65|DNA hairpins
14P11282395A0530|130 165|DNA repair proteins Nbs1/Mre11/Rad50
14P11282395A1073|49 62|CDR3 sequences
14P11282395A1073|74 83|Ig lambdaL
14P11282395A1073|86 107|kappaL chain gene loci
14P11282395A1073|125 141|blood lymphocytes
14P11282395A1073|145 155|NBS patient
14P11282433T0000|0 4|Phase
14P11282433T0000|14 23|paclitaxel
14P11282433T0000|90 105|cell lung cancer
14P11282761A0531|21 30|L-arginine
14P11282761A0531|53 71|plasma L-citrulline
14P11282761A0531|99 111|NO production
14P11283010A0701|30 39|CGS 12066A
14P11283014A0921|21 24|WASP
14P11283014A0921|56 70|TCR stimulation
14P11283014A0921|122 141|actin polymerization
14P11283168A0738|55 64|expression
14P11283168A0738|70 77|Gus gene
14P11283168A0738|94 102|endosperm
14P11283168A0738|109 123|mid-development
14P11283256A0258|27 30|MRCK
14P11283354A0548|49 69|histone modifications
14P11283354A0548|130 153|heterochromatin assembly
14P11285054A0781|0 18|Regression analyses
14P11285054A0781|28 51|SOREMP dream occurrences
14P11285054A0781|87 95|REM sleep
14P11285054A0781|101 123|NREMP dream occurrences
14P11285054A0781|147 156|NREM sleep
14P11285235A0466|8 12|TRPS1
14P11285235A0466|85 96|GATA factors
14P11285329A0682|18 27|micromol/L
14P11285329A0682|33 37|women
14P11286833A0959|39 52|5-fluorouracil
14P11286833A0959|68 91|maintenance chemotherapy
14P11286833A0959|92 98|RESULTS
14P11287555A1057|3 17|Delta6CCI virus
14P11287555A1057|41 60|replication capacity
14P11287555A1057|88 94|CEMx174
14P11287555A1057|98 106|MT4 cells
14P11287578A1311|0 8|Secretion
14P11287578A1311|11 23|interleukin-8
14P11287578A1311|25 30|RANTES
14P11287578A1311|54 67|protein 1alpha
14P11287578A1311|137 149|keratinocytes
14P11287578A1311|152 153|E6
14P11287579A1084|14 18|T255A
14P11287579A1084|40 45|E4orf6
14P11287579A1084|68 87|late-gene expression
14P11287611A0802|6 14|PPARgamma
14P11287611A0802|40 46|15d-PGJ
14P11287611A0802|53 55|PGD
14P11287611A0802|79 86|BRL49653
14P11287623A0286|81 83|ERK
14P11287623A0286|85 101|signaling pathway
14P11287623A0286|148 164|integrin subunits
14P11287623A0286|184 199|mouse cell lines
14P11287654A0150|0 3|PABP
14P11287654A0150|72 81|C terminus
14P11288208A0712|0 7|Children
14P11288208A0712|36 51|tract infections
14P11288208A0712|53 55|PCP
14P11288208A0712|84 98|CD4 cell counts
14P11288930A0000|27 40|administration
14P11288930A0000|78 81|MCPA
14P11288930A0000|112 122|generations
14P11288930A0000|161 169|gestation
14P11288930A0000|173 181|lactation
14P11289135A0975|0 9|Coexposure
14P11289135A0975|12 13|FP
14P11289135A0975|87 100|protein kinase
14P11289135A0975|136 157|protein kinase cascade
14P11289135A0975|161 173|PMA treatment
14P11289135A0975|227 247|protein kinase kinase
14P11289135A0975|247 261|inhibitor U0126
14P11289149A0658|8 18|EWS protein
14P11289149A0658|67 88|transactivation domain
14P11289149A0658|121 123|CBP
14P11290415A0288|37 57|ICBP90 gene structure
14P11290415A0288|100 111|PCR analysis
14P11290906T0000|24 35|Tl-201 SPECT
14P11291552A0156|0 6|METHODS
14P11291552A0156|46 48|MFH
14P11292335A0852|33 48|mutator mutation
14P11292335A0852|59 79|sequence substitution
14P11292335A0852|147 165|frameshift mutation
14P11292839A0531|58 64|U6 gene
14P11292839A0531|100 107|TATA-box
14P11292839A0531|161 163|TBP
14P11292839A0531|172 178|TBP-DR2
14P11292839A0531|190 192|TBP
14P11292839A0531|203 207|TBPwt
14P11292844A0081|0 2|HSF
14P11292844A0081|8 10|DNA
14P11292844A0081|48 50|DNA
14P11294895A0292|92 96|Sec14
14P11294895A0292|106 142|phosphatidylinositol transfer protein
14P11295470A0954|20 41|linkage disequilibrium
14P11295470A0954|71 76|B cell
14P11295470A0954|107 109|UTR
14P11295523A0218|5 11|numbers
14P11295523A0218|42 50|mid-1970s
14P11295760A1374|0 22|Specimen mass reduction
14P11295760A1374|79 82|W/cm
14P11296288A1107|2 9|addition
14P11296288A1107|18 27|derivative
14P11296288A1107|30 37|pCMVJS21
14P11296288A1107|39 53|pCMVJS21DeltaGP
14P11296288A1107|88 96|sequences
14P11296442A0565|2 11|conclusion
14P11296442A0565|13 21|tube size
14P11296442A0565|32 35|Cole
14P11296442A0565|87 95|tube size
14P11296442A0565|114 123|anesthesia
14P11296442A0565|169 177|tube size
14P11297419A0894|2 6|F222W
14P11297419A0894|8 21|W21F rGST A1-1
14P11297419A0894|47 64|fluorescence probe
14P11297514A0218|52 76|CBF transcription factors
14P11297545A0948|25 33|CHOP cDNA
14P11297545A0948|44 58|carcinoma cells
14P11297545A0948|74 77|CHOP
14P11297545A0948|188 190|p38
14P11297866A0484|18 29|I. argentina
14P11297866A0484|32 42|I. theezans
14P11297866A0484|60 61|BF
14P11298326A0677|26 37|Vkappa genes
14P11298326A0677|123 137|point mutations
14P11301189A1396|36 38|p19
14P11301189A1396|40 44|INK4d
14P11301189A1396|90 104|B-lineage cells
14P11302072A0508|62 79|Boston Naming Test
14P11302072A0508|82 107|Word List Recognition Task
14P11302566A1318|48 76|dopamine receptor sensitivity
14P11302566A1318|78 96|psychomotor slowing
14P11302704T0000|0 19|Homo-oligomerisation
14P11302704T0000|44 68|mouse histone deacetylase
14P11303027A0954|32 43|interactions
14P11303027A0954|51 57|GTPases
14P11303027A0954|63 72|ARF family
14P11303638A0559|4 21|NEU overexpression
14P11303890A0996|30 34|doses
14P11303890A0996|42 47|values
14P11303890A0996|64 71|microg/l
14P11305129T0000|0 6|Effects
14P11305129T0000|10 21|booster dose
14P11305129T0000|23 36|tetanus toxoid
14P11305129T0000|66 76|vaccination
14P11305129T0000|78 89|implications
14P11306101A0000|5 19|RACE techniques
14P11306101A0000|140 162|17beta-hydroxy-steroids
14P11306101A0000|166 187|3alpha-hydroxysteroids
14P11306463A0383|14 21|C domain
14P11306463A0383|23 24|Rb
14P11306463A0383|26 30|L901Q
14P11306463A0383|72 94|cdk4/D1 phosphorylation
14P11306463A0383|107 114|C domain
14P11306511A1476|2 12|association
14P11306511A1476|105 125|progesterone receptor
14P11306845A0168|12 22|examination
14P11306845A0168|58 74|blister formation
14P11306845A0168|86 98|keratinocytes
14P11308851A0333|13 29|response function
14P11308851A0333|52 55|GSER
14P11308851A0333|77 91|frequency range
14P11308851A0333|106 124|material parameters
14P11308877A0213|94 108|discharge times
14P11308877A0213|146 178|orientation preserving circle map
14P11309077A0953|25 28|Camp
14P11309077A0953|78 87|biotype I.
14P11309373A0783|0 7|Analysis
14P11309373A0783|10 19|mCTR mRNAs
14P11309373A0783|53 61|promoters
14P11309373A0783|84 96|mCTR isoforms
14P11309389A0273|64 108|phorbol ester phorbol 12-myristate 13-acetate
14P11309389A0273|106 108|PMA
14P11309389A0273|122 145|metalloprotease activity
14P11309389A0273|165 168|GHBP
14P11309389A0273|192 194|GHR
14P11309389A0273|265 277|GHR abundance
14P11309389A0273|280 291|GH signaling
14P11309400T0000|0 6|Effects
14P11309400T0000|11 32|terminus modifications
14P11309400T0000|66 82|protein synthesis
14P11309677A0000|70 85|Gulf War Illness
14P11309677A0000|85 87|GWI
14P11309677A0000|118 121|GV-F
14P11309677A0000|144 147|GV-H
14P11309678A0489|7 32|transcription-PCR analysis
14P11310937A0548|0 6|RESULTS
14P11310937A0548|100 102|CRP
14P11310937A0548|106 109|IL-6
14P11310937A0548|162 170|TNF-alpha
14P11311153T0000|20 43|factor V Leiden mutation
14P11311153T0000|122 142|thromboembolic events
14P11311464A0362|34 50|saddle anesthesia
14P11311464A0362|73 86|motor weakness
14P11311464A0362|96 106|extremities
14P11311464A0362|130 148|bladder dysfunction
14P11311480A0079|5 16|nerve biopsy
14P11311480A0079|41 51|perineurium
14P11311480A0079|61 71|alterations
14P11311480A0079|88 104|cell infiltration
14P11311480A0079|109 119|perineurium
14P11311550A0253|39 52|rat eIF4E gene
14P11311550A0253|62 86|rat eIF4E promoter region
14P11311550A0253|99 110|contribution
14P11311550A0253|141 153|transcription
14P11311550A0253|186 200|rat cardiocytes
14P11311550A0253|221 238|myoblast cell line
14P11311563A0423|8 16|CCAAT box
14P11311563A0423|62 73|OA induction
14P11311563A0423|95 103|CCAAT box
14P11311687A0231|3 8|JHRLSS
14P11311687A0231|42 53|RLS severity
14P11311687A0231|140 142|RLS
14P11311909A0938|73 87|A1 fenestration
14P11311980A1049|0 3|GABA
14P11311980A1049|7 9|R1g
14P11312108A2853|0 3|Raes
14P11312108A2853|5 6|P.
14P11312120A1311|0 27|NF-kappaB pathway activation
14P11312120A1311|98 104|Bcr/Abl
14P11312120A1311|106 108|Ras
14P11312120A1311|112 114|Rac
14P11312326A0169|27 34|HIV type
14P11312326A0169|36 40|HIV-1
14P11312326A0169|58 84|complementation experiments
14P11312326A0169|205 221|virus replication
14P11312584X1846|0 8|Copyright
14P11312584X1846|13 26|Academic Press
14P11313249T0000|88 104|activation domain
14P11313342A0224|25 45|alanine substitutions
14P11313342A0224|56 76|center cleft residues
14P11313342A0224|140 142|PAP
14P11313386A0704|0 20|SH2D1A protein levels
14P11313386A0704|36 53|CD40 cross-linking
14P11313386A0704|72 95|B cell receptor ligation
14P11313398A0687|0 21|Cross-linking FcalphaR
14P11313398A0687|32 45|IIA-ITAM cells
14P11313398A0687|64 65|PI
14P11313398A0687|96 103|PKBalpha
14P11313946A0449|0 7|RPM/RGL3
14P11313946A0449|17 20|AF-6
14P11313946A0449|82 88|p21 Ras
14P11313946T0000|25 29|M-Ras
14P11313946T0000|33 39|p21 Ras
14P11313946T0000|58 60|p21
14P11313961A1323|97 99|p53
14P11313961A1323|127 134|p53 gene
14P11314030A1264|42 44|Crk
14P11314030A1264|95 97|Abl
14P11314030A1264|101 103|FAK
14P11314030A1264|113 127|signal pathways
14P11314030A1264|176 178|SH3
14P11314030A1264|196 205|SH3 domain
14P11314046A0000|0 6|Cyclins
14P11314046A0000|47 68|cell cycle progression
14P11314373T0000|23 29|formula
14P11314373T0000|38 44|problem
14P11314428A0651|38 51|hydroxyapatite
14P11314428A0651|103 126|months width differences
14P11314428A0651|152 154|LHS
14P11314428A0651|167 169|RHS
14P11315633A0920|22 24|VPg
14P11315633A0920|28 30|RNA
14P11315633A0920|40 53|RNA polymerase
14P11315633A0920|69 77|E445-T446
14P11315633A0920|88 115|amino acid sequence analysis
14P11316127A0485|11 15|HCM-I
14P11316127A0485|65 70|HCM-II
14P11316127A0485|74 87|Control groups
14P11317256A0361|19 32|S. intermedius
14P11317256A0361|49 63|S. constellatus
14P11317256A0361|83 94|S. anginosus
14P11318363A0085|0 5|DESIGN
14P11318608A0669|5 32|brain cDNA library screening
14P11318608A0669|81 90|DENTT cDNA
14P11318608A0669|188 207|localization signals
14P11318608A0669|208 211|NLSs
14P11318608A1155|25 53|DENTT NLS deletion constructs
14P11318608A1155|70 74|NLS-1
14P11319098A0164|17 33|tryptophanyl tRNA
14P11319098A0164|37 70|protein translocase component SecE
14P11319098A0164|127 128|L1
14P11319098A0164|141 144|PkwR
14P11319098A0164|177 192|LacI-GalR family
14P11319880A1108|0 8|Rapamycin
14P11319880A1108|10 28|FRAP/mTOR inhibitor
14P11319880A1108|36 57|4E-BP1 phosphorylation
14P11321187A0355|26 36|MS patients
14P11321187A0355|71 72|C.
14P11321187A0355|92 94|IgG
14P11323411A0505|0 24|Far Western blot analysis
14P11323411A0505|44 54|SH2 domains
14P11323411A0505|56 59|SHP2
14P11323411A0505|66 69|Gab1
14P11323411A0505|103 114|N-SH2 domain
14P11323411A0505|137 139|Tyr
14P11323411A0505|154 165|C-SH2 domain
14P11323411A0505|172 174|Tyr
14P11323419T0000|58 74|blood group alpha
14P11323419T0000|78 101|fucosyltransferase genes
14P11323419T0000|126 149|mouse uterine epithelium
14P11323716A0413|3 13|UBA domains
14P11323716A0413|15 19|RAD23
14P11323716A0413|23 26|DDI1
14P11324516A0159|47 74|D2 receptor agonist LY171555
14P11324516A0159|74 107|D1/D2 receptor agonist apomorphine
14P11324516A0159|154 155|AA
14P11325195A0661|3 4|R2
14P11325195A0661|12 14|MFI
14P11325195A0661|61 76|pork longissimus
14P11325391A0498|15 27|d-amphetamine
14P11325391A0498|59 68|saline key
14P11325391A0498|77 85|schedules
14P11325685A1624|11 31|L-carnitine treatment
14P11325685A1624|40 70|plasma carnitine concentrations
14P11325685A1624|149 169|hemodialysis patients
14P11325944A0511|31 34|UhpB
14P11325944A0511|47 60|hybrid protein
14P11325944A0511|61 66|GST-Bc
14P11325944A0511|75 99|glutathione S-transferase
14P11325944A0511|100 102|GST
14P11325944A0511|144 147|UhpB
14P11325944A0511|176 190|uhpT expression
14P11327292A0190|10 17|location
14P11327292A0190|29 40|malformation
14P11327698A0191|14 16|PKC
14P11327698A0191|20 41|p44/p42MAPK signalings
14P11327698A0191|81 89|IGF-II P4
14P11327698A0191|120 133|PKC activation
14P11327698A0191|135 137|PMA
14P11327698A0191|140 160|PKC expression vector
14P11327698A0191|168 186|Sp1 phosphorylation
14P11327698A0191|231 244|PKC inhibition
14P11327698A0191|246 265|PKC inhibitor Go6976
14P11327698A0191|271 289|Sp1 phosphorylation
14P11327698A0191|304 314|IGF-II mRNA
14P11327698A0191|365 378|MEK activation
14P11327698A0191|392 410|Sp1 phosphorylation
14P11327698A0191|424 434|IGF-II mRNA
14P11327858A0087|26 28|Arf
14P11327858A0087|40 55|oncoprotein Hdm2
14P11327858A0087|76 78|p53
14P11328699A0000|26 34|test mice
14P11328699A0000|79 87|container
14P11328699A0000|120 133|test situation
14P11328853A0644|0 10|Examination
14P11328853A0644|20 44|promoter deletion mutants
14P11328853A0644|56 59|SF-1
14P11328853A0644|107 124|promoter sequences
14P11331589A0113|3 13|MSL complex
14P11331589A0113|41 57|male X chromosome
14P11331596A0710|0 3|Prrp
14P11331596A0710|27 37|EVH1 domain
14P11331596A0710|39 42|Mena
14P11331604A0267|0 4|Srb10
14P11331604A0267|32 45|Gcn4 stability
14P11331604A0267|56 70|phosphorylation
14P11331604A0267|84 87|Gcn4
14P11331604A0267|103 115|srb10 mutants
14P11331613A0827|19 31|pVHL function
14P11331613A0827|49 57|mutations
14P11331613A0827|68 75|subclass
14P11333263A0240|15 24|base pairs
14P11333263A0240|63 77|leader sequence
14P11333263A0240|108 124|promoter activity
14P11333268A1521|36 47|interactions
14P11333268A1521|50 52|Sos
14P11333268A1521|86 88|Ras
14P11333268A1521|111 122|consequences
14P11333268A1521|127 137|interaction
14P11333268A1521|171 173|Ras
14P11333268A1521|176 178|Sos
14P11333268A1521|190 200|interaction
14P11333268A1521|259 274|GDP dissociation
14P11334124A0903|58 61|FEV1
14P11334124A0903|69 76|AUC0-6 h
14P11334124A0903|84 87|FEV1
14P11334124A0903|120 127|Respimat
14P11335116A1099|0 20|Bandshift experiments
14P11335116A1099|35 40|BmHR3A
14P11335116A1099|60 63|RORE
14P11335116A1099|85 116|Orphan receptor Response Element
14P11335116A1099|183 188|BmHR3A
14P11335116A1099|216 225|BmGATAbeta
14P11335116A1099|229 237|ESP genes
14P11335710A0320|44 57|Erk activation
14P11336211A0132|28 36|Bengtsson
14P11336211A0132|38 41|Appl
14P11336698A0075|15 18|Rsc3
14P11336698A0075|22 26|Rsc30
14P11336698A0075|58 84|yeast remodeler RSC complex
14P11337859A0651|3 5|COD
14P11337859A0651|45 49|FeCl3
14P11337859A0651|150 189|hydrogen peroxide oxidation pretreatment
14P11337859A0651|190 200|H2O2 dosage
14P11340048A0432|21 31|correlation
14P11340048A0432|42 55|flux densities
14P11340048A0432|98 108|differences
14P11340048A0432|114 127|flux densities
14P11340080A0096|28 47|checkpoint signaling
14P11340080A0096|48 51|Rad1
14P11340080A0096|53 56|Hus1
14P11340080A0096|61 64|Rad9
14P11340080A0096|91 109|immunoprecipitation
14P11340085A0211|127 145|amino acid sequence
14P11340085A0211|146 155|C/EBPalpha
14P11340085A0211|229 235|CR1-CR4
14P11340085A0211|246 267|transactivation domain
14P11340516A0509|0 8|Tolerance
14P11340516A0509|11 16|ADAL-2
14P11340516A0509|35 47|Vicryl suture
14P11340516A0509|61 66|ADAL-2
14P11340516A0509|86 94|Tisuacryl
14P11340525A0737|36 51|study end points
14P11340525A0737|137 163|treatment success criterion
14P11341349T0000|29 59|breast cancer screening program
14P11341405A0146|6 15|POPULATION
14P11341405A0146|17 19|MCB
14P11341405A0146|74 90|MCB abnormalities
14P11341405A1154|0 10|CONCLUSIONS
14P11341405A1154|22 30|RELEVANCE
14P11341405A1154|86 91|MCB-IV
14P11341405A1154|99 108|Greyhounds
14P11341405A1154|165 180|dorsal quadrants
14P11341405A1154|186 188|MCB
14P11341828A0744|26 35|D-peptides
14P11342479A0430|0 6|METHODS
14P11342479A0430|10 16|RESULTS
14P11342479A0430|18 37|Palmaz-Schatz stents
14P11342479A0430|80 94|microgram/stent
14P11344530A0320|0 10|Percentages
14P11344530A0320|35 48|dilution tests
14P11345435A0199|17 30|RNA subdomains
14P11345445A0533|11 19|OECD soil
14P11345445A0533|28 36|Cd levels
14P11345445A0533|65 81|Cd concentrations
14P11345445A0533|134 135|Cu
14P11345445A0533|139 140|Zn
14P11347201X0001|0 17|Nutritional status
14P11347201X0001|58 67|BACKGROUND
14P11347201X0001|69 78|Plant food
14P11348318A0940|23 33|mammography
14P11348318A0940|87 102|characterization
14P11349796A0950|0 11|Measurements
14P11349796A0950|58 59|D0
14P11349796A0950|85 95|measurement
14P11349796A0950|97 98|D3
14P11349796A0950|121 123|D30
14P11350038A0459|39 42|Stem
14P11350038A0459|70 83|stem structure
14P11350038A0459|126 139|export process
14P11350165A1606|0 6|Changes
14P11350165A1606|12 22|DB sequence
14P11350165A1606|84 105|translation efficiency
14P11350175A0173|35 48|protein family
14P11350175A0173|77 94|chaperone activity
14P11350812A0829|15 37|Raf-1 target ERK kinase
14P11350812A0829|36 38|MEK
14P11350812A0829|90 103|ERK activation
14P11350812A0829|104 128|caldesmon phosphorylation
14P11350812A0829|132 153|stress fiber formation
14P11350957A0457|0 9|PACAP mRNA
14P11350957A0457|65 69|PACAP
14P11350982A0560|48 68|GCN1-GCN2 interaction
14P11350982A0560|82 85|GCN2
14P11352423A0084|9 20|forearm flap
14P11352423A0084|56 63|arm flap
14P11352423A0084|92 101|situations
14P11352663A0138|29 37|Ad5 cells
14P11352663A0138|84 90|COUP-TF
14P11352663A0138|109 117|NF-kappaB
14P11352671A0492|48 64|nucleotide change
14P11352671A0492|65 67|UCU
14P11352671A0492|70 72|ACU
14P11352671A0492|120 125|V gene
14P11353392A1127|24 28|ADEx2
14P11353392A1127|96 108|ASIP mutation
14P11353770A0085|47 48|S3
14P11353770A0085|65 86|N-glycosylase activity
14P11353770A0085|101 121|8-oxoguanine residues
14P11353770A0085|123 125|DNA
14P11353774A0255|27 42|characterization
14P11353774A0255|48 65|forkhead homologue
14P11353774A0255|67 82|rhabdomyosarcoma
14P11353774A0255|84 87|FKHR
14P11353774A0255|136 152|factor 3/forkhead
14P11353774A0255|181 196|hormone receptor
14P11353774A0255|197 198|NR
14P11354406A1373|11 33|CSF outflow conductance
14P11354406A1373|97 108|ICP waveform
14P11354975A0850|13 23|Euspondylus
14P11354975A0850|81 87|El Humo
14P11354975A0850|88 92|Sucre
14P11354975A0850|106 114|Venezuela
14P11355576A1125|30 32|CDK
14P11355576A1125|46 60|phosphorylation
14P11355576A1125|85 108|tumor suppressor protein
14P11355576A1125|112 134|pRb controls commitment
14P11355576A1125|150 151|G1
14P11355576A1125|154 160|S phase
14P11355576A1125|202 226|E2F transcription factors
14P11355576A1125|239 256|cell proliferation
14P11355615A0766|10 18|education
14P11355615A0766|54 62|direction
14P11355615A0766|66 77|intervention
14P11355615A0766|81 93|incorporation
14P11355668T0000|13 24|vasculopathy
14P11355668T0000|37 47|hemorrhages
14P11355668T0000|50 65|porcine neonates
14P11355668T0000|113 126|syndrome virus
14P11356214A0794|67 93|Knoop hardness measurements
14P11356214A0794|124 138|resin specimens
14P11356214A0794|145 155|Teflon mold
14P11356716A0372|54 67|GHS-R variants
14P11356835A0000|114 131|protein precursors
14P11356835A0000|137 157|amino acid starvation
14P11356853A0429|2 11|Ka13 cells
14P11356853A0429|12 15|CoCl
14P11356853A0429|42 65|luciferase reporter gene
14P11356853A0429|93 116|pair mouse ho-1 promoter
14P11356853A0554|0 16|Mutation analyses
14P11356853A0554|84 88|StREs
14P11356853A0873|12 27|AP-1 superfamily
14P11356853A0873|29 56|basic-leucine zipper factors
14P11357063A0138|0 11|Descriptions
14P11357063A0138|148 161|LH/CGbeta gene
14P11357063A0138|174 205|LHbeta-CGbeta gene cluster locus
14P11357063A1053|25 35|LHbeta gene
14P11357063A1053|61 76|gpLH/CGbeta gene
14P11357063A1053|91 103|TATA sequence
14P11357063A1053|120 142|translation start codon
14P11358801A1046|43 57|NHEJ deficiency
14P11358801A1046|71 84|rearrangements
14P11358958A0878|0 9|Expression
14P11358958A0878|17 21|RACK1
14P11358958A0878|53 69|growth inhibition
14P11358958A0878|71 74|HF7c
14P11358962A0344|0 4|Foxp1
14P11358962A0344|8 12|Foxp2
14P11358962A0344|55 57|E12
14P11358962A0344|62 78|mouse development
14P11358962A0344|82 97|Foxp2 expression
14P11358962A0344|112 128|airway epithelium
14P11359568T0000|22 45|pRA2 partitioning region
14P11359568T0000|45 48|ParB
14P11359568T0000|62 80|parAB transcription
14P11359568T0000|89 109|nucleoprotein complex
14P11359568T0000|116 137|plasmid partition site
14P11359827T0000|27 42|characterization
14P11359827T0000|82 86|SPE-I
14P11359827T0000|90 94|SPE-J
14P11359907A0099|7 25|dozen HIF-1 targets
14P11359907A0099|89 92|VEGF
14P11360190A0178|24 26|Tax
14P11360190A0178|34 55|cell cycle progression
14P11360190A0178|58 68|G0/G1 phase
14P11360190A0178|74 84|G2/M phases
14P11360190A0178|91 105|T-cell line Kit
14P11361338A0093|20 34|matrix proteins
14P11361338A0093|68 83|targeting signal
14P11361338A0093|84 87|PTS1
14P11361338A0093|104 117|tripeptide SKL
14P11361338A0447|8 23|PEX5-TPR domains
14P11361338A0447|106 120|Pex5p chimaeras
14P11361493T0000|0 4|HIV-1
14P11361493T0000|8 35|hepatitis B virus infections
14P11361493T0000|54 72|security institutes
14P11361493T0000|74 85|Buenos Aires
14P11367523A1684|0 25|Immunofixation experiments
14P11367523A1684|27 29|C4A
14P11367523A1684|33 35|C4B
14P11367523A2624|8 19|C4B proteins
14P11367523A2624|72 85|concentrations
14P11367523A2624|103 111|C4A genes
14P11368363A0129|25 45|transcription factors
14P11368363A0129|70 84|myeloperoxidase
14P11368363A0129|86 88|MPO
14P11368363A0129|153 155|DNA
14P11368363A0129|164 167|HBP1
14P11368363A0129|169 194|HMG-Box containing protein
14P11368363A1103|8 23|protein sequence
14P11368363A1103|106 115|activation
14P11368363A1103|119 135|repressor domains
14P11368363A1103|162 172|rat protein
14P11368787A0180|0 7|Promoter
14P11368787A0180|71 85|annexin A5 gene
14P11368787A0180|137 162|transcription start points
14P11368901A0327|2 9|contrast
14P11368901A0327|30 37|proteins
14P11368901A0327|48 58|repeat unit
14P11368901A0327|81 87|portion
14P11368911T0000|9 22|identification
14P11368911T0000|42 58|mRNA surveillance
14P11368911T0000|60 69|C. elegans
14P11368914T0071|33 56|complement C3 gene locus
14P11368914T0071|87 89|ORF
14P11369066A1210|0 10|CONCLUSIONS
14P11369066A1210|18 20|MMF
14P11369066A1210|148 167|radiation dermatitis
14P11369106A0428|62 73|interactions
14P11369106A0428|77 100|transformation processes
14P11369410A0949|8 17|hypothesis
14P11369410A0949|44 63|stimulus differences
14P11369410A0949|118 127|processing
14P11369410A0949|136 147|participants
14P11369453A1083|20 34|protein binding
14P11369453A1083|58 74|peptide treatment
14P11369700A0074|0 2|CSR
14P11369700A0074|28 41|chain isotypes
14P11369700A0074|55 71|B cell activators
14P11369700A0074|80 92|transcription
14P11369700A0074|124 125|GL
14P11369700A0616|42 50|Ets sites
14P11369700A0616|55 77|mouse GL alpha promoter
14P11369700A0616|82 108|transcription factors Elf-1
14P11369700A0616|110 113|PU.1
14P11369700A0616|158 181|luciferase reporter gene
14P11369700A0616|191 207|GL alpha promoter
14P11369759A0605|0 3|Cell
14P11370174A0447|7 28|serum creatinine level
14P11370174A0447|77 79|MMF
14P11371115A0962|50 60|HBs antigen
14P11371115A0962|89 91|MGN
14P11371115A0962|94 105|MPGN pattern
14P11371160A0193|16 26|nucleotides
14P11371160A0193|39 54|base-pair C1-G72
14P11371160A0193|57 78|discriminator base A73
14P11371160A0854|29 42|anticodon loop
14P11371160A0854|81 97|TyrRS interaction
14P11371160A0854|113 122|efficiency
14P11371160A0854|125 136|tyrosylation
14P11371343A0125|15 24|cell cycle
14P11371343A0125|25 32|separase
14P11371343A0125|70 76|protein
14P11371343A0125|83 89|securin
14P11371417A0744|23 35|control lungs
14P11371417A0744|57 72|chord compliance
14P11371417A0744|85 102|lung lavage levels
14P11371417A0744|103 123|tumor necrosis factor
14P11371417A0744|123 125|TNF
14P11371417A0744|162 163|IL
14P11371417A0744|223 227|MIP-2
14P11371417A0744|289 307|preventilation data
14P11371417A0744|359 360|LA
14P11372882A1143|12 14|DDE
14P11372882A1143|18 32|beta-HCH levels
14P11372882A1143|79 82|PCBs
14P11372959A1447|8 26|regression analysis
14P11372959A1447|114 125|relationship
14P11372959A1447|127 141|R2 coefficients
14P11372959A1447|150 165|habitat category
14P11372959A1447|197 210|tick abundance
14P11373277A0812|37 51|oncoprotein E1A
14P11373277A0812|90 103|AP-2alpha gene
14P11373277A0812|156 173|AP-2alpha promoter
14P11373277A0812|188 190|E1A
14P11373277A0812|205 221|corepressor CtBP1
14P11374051A0437|51 65|corticosteroids
14P11374051A0437|68 81|anticoagulants
14P11374051A0437|88 106|ulcer complications
14P11374559A0103|0 11|SERS spectra
14P11374559A0103|25 42|vacuum evaporation
14P11374559A0103|92 117|colloidal silver solutions
14P11374866X0914|0 8|Copyright
14P11374866X0914|13 26|Academic Press
14P11375392T0000|3 15|core promoter
14P11375392T0000|22 42|thioredoxin reductase
14P11375392T0000|79 83|Oct-1
14P11375392T0000|85 87|Sp1
14P11375392T0000|92 102|Sp3 binding
14P11376007A0584|46 68|protein kinase activity
14P11376007A0584|69 74|DNA-PK
14P11376007A0584|135 153|protein phosphatase
14P11376007A0584|156 177|protein phosphatase 2A
14P11376007A0584|177 180|PP2A
14P11376007A0584|225 253|protein phosphatase inhibitor
14P11376119A0346|67 77|GHR 1A mRNA
14P11376119A0346|109 116|GHR gene
14P11376134A1506|5 15|corrections
14P11376134A1506|58 77|transcription factor
14P11376165T0000|0 2|FLP
14P11376165T0000|6 29|Cre recombinase function
14P11376165T0000|30 44|Xenopus embryos
14P11376279A0000|57 58|MR
14P11376279A0000|105 122|volume acquisition
14P11376687A0344|7 29|nucleotide polymorphism
14P11376687A0344|30 32|SNP
14P11376687A0344|70 72|SNP
14P11376687A0344|74 84|GTG83/ATG83
14P11376687A0344|125 127|AUG
14P11376687A0344|136 145|MTH1 mRNAs
14P11376687A0344|162 177|MTH1 polypeptide
14P11376687A0344|178 180|p26
14P11376946A0000|31 35|SHP-1
14P11376946A0000|38 40|SH2
14P11376946A0000|74 84|phosphatase
14P11376946A0000|224 225|P1
14P11377975A0898|28 37|COS1 cells
14P11377975A0898|56 74|proteinase activity
14P11378898A0164|0 3|ORF1
14P11378898A0164|12 24|EMBL databank
14P11378898A0164|25 37|Accession No.
14P11379106A0372|43 68|deammonification processes
14P11380028A0000|66 78|Technetium Tc
14P11380028A0000|82 86|99mTc
14P11380028A0000|101 118|orthoiodohippurate
14P11380028A0000|124 131|131I-OIH
14P11380028A0000|133 148|plasma clearance
14P11380028A0000|170 182|blood samples
14P11380370A0000|44 49|Kaposi
14P11380370A0000|60 61|KS
14P11380837A1505|0 12|Interventions
14P11380837A1505|128 145|access dysfunction
14P11381094A0797|28 38|C2B domains
14P11381094A0797|40 53|synaptotagmins
14P11382701A0688|81 107|plasma sodium concentration
14P11382948A0793|27 34|MRI data
14P11382948A0793|59 86|tumor microvessel properties
14P11382948A0793|91 109|breast cancer model
14P11382948A0793|150 154|USPIO
14P11383860A0661|52 70|99mTc ciprofloxacin
14P11383860A0661|99 116|bone marrow uptake
14P11383860A0661|121 132|liver uptake
14P11384225A0634|12 30|expression cassette
14P11384225A0634|77 79|GFP
14P11384229A1669|11 23|N63S mutation
14P11384229A1669|37 50|VP5 background
14P11384229A1669|87 113|beta-galactosidase activity
14P11384229A1669|143 154|PR7 mutation
14P11384576A1132|17 27|vision loss
14P11384576A1132|40 49|interferon
14P11384576A1132|68 78|retinopathy
14P11384880A0719|28 41|3beta-HSD type
14P11384880A0719|42 56|gene expression
14P11384880A0719|81 87|ZR-75-1
14P11384880A0719|93 111|breast cancer cells
14P11385840A1684|12 24|RTC algorithm
14P11385840A1684|35 51|wastewater system
14P11385840A1684|114 134|optimization routines
14P11387208T0000|0 36|SKP1-SnRK protein kinase interactions
14P11387208T0000|62 87|plant SCF ubiquitin ligase
14P11387351A0092|0 7|PATIENTS
14P11387351A0092|11 17|METHODS
14P11387351A0092|26 29|June
14P11387351A0092|37 44|December
14P11387351A0092|77 105|analog 2-chlorodeoxyadenosine
14P11387351A0092|106 110|2-CDA
14P11387351A0092|135 137|AML
14P11387351A0092|164 166|AML
14P11387351A0092|193 195|MDS
14P11387940A0647|3 10|severity
14P11387940A0647|46 54|magnitude
14P11387940A0647|57 66|percussion
14P11387950X0001|151 172|leukocyte adhesiveness
14P11387950X0001|175 195|tumor necrosis factor
14P11387950X0001|195 197|TNF
14P11387950X0001|245 247|ANP
14P11387950X0001|304 306|ANP
14P11387950X0001|357 365|Decoction
14P11387950X0001|368 385|leukocyte adhesion
14P11387950X0001|388 400|TNF secretion
14P11389077A0000|27 44|signaling pathways
14P11389085A0290|0 7|TT cells
14P11389085A0290|14 26|MTC cell line
14P11389085A0290|35 49|MEN 2A type RET
14P11389085A0290|83 85|p65
14P11389085A1032|0 9|Inhibition
14P11389085A1032|24 41|NF-kappaB activity
14P11389085A1032|61 68|TT cells
14P11389085A1032|116 118|RET
14P11389085A1032|121 133|NIH 3T3 cells
14P11390395A1018|13 29|HMGI-C expression
14P11390581A1203|20 33|identification
14P11390581A1203|64 72|Cp region
14P11390650A0562|10 27|deletion mutations
14P11390650A0562|98 103|SLP-76
14P11390650A0562|125 134|P-1 domain
14P11390663A1400|57 83|induction pathway operating
14P11390663A1400|88 105|Gcn4p target genes
14P11390684A1170|0 7|Evidence
14P11390684A1170|13 34|Northern hybridization
14P11390684A1170|77 97|jadomycin B synthesis
14P11391303A0807|5 7|LHR
14P11391303A0807|46 74|intraobserver reproducibility
14P11391303A1023|0 10|CONCLUSIONS
14P11391303A1023|28 42|LHR measurement
14P11391303A1023|90 118|Tl-201 lung uptake evaluation
14P11391531A1157|0 7|Mutation
14P11391531A1157|13 26|NF-kappaB site
14P11391531A1157|31 44|Mdr1b promoter
14P11391531A1157|66 74|TNF-alpha
14P11391793A0856|99 101|SRO
14P11391793A0856|127 139|bacteriophage
14P11391793A0856|171 173|PAC
14P11392306T0000|6 13|teaching
14P11392306T0000|24 33|techniques
14P11392772A0182|3 13|application
14P11392772A0182|19 31|biotechnology
14P11392772A0182|60 79|surface storm waters
14P11392772A0182|95 107|zone Telychka
14P11392772A0182|118 121|Kyiv
14P11392772A0182|172 178|Dnieper
14P11393463A0274|0 3|Data
14P11393463A0274|34 48|student samples
14P11393463A0274|84 104|NEO-PI-R self-ratings
14P11393463A0274|151 165|informant group
14P11393463A0274|245 258|month interval
14P11393791A1153|0 21|Northern blot analysis
14P11393791A1153|22 25|RNAs
14P11393791A1153|62 66|Atp6i
14P11393791A1153|168 192|polymerase chain reaction
14P11393791A1153|192 197|RT-PCR
14P11395469A1373|7 14|mutation
14P11395469A1373|27 32|motifs
14P11395469A1373|54 63|regulation
14P11395469A1373|93 102|regulation
14P11396685A0477|27 29|DTD
14P11396685A0477|136 146|information
14P11396685A0477|167 175|compounds
14P11397652A0381|0 9|Guidelines
14P11397652A0381|31 42|spiral assay
14P11397652A0381|69 80|test methods
14P11397652A0381|117 128|difficulties
14P11397652A0381|146 164|sample availability
14P11397652A0381|165 180|sample viscosity
14P11398134A1565|2 11|conclusion
14P11398134A1565|21 34|alcohol intake
14P11398134A1565|90 99|predictors
14P11398134A1565|106 116|development
14P11398134A1565|119 131|hyperuricemia
14P11398899A1183|0 3|Fans
14P11398899A1183|91 108|PH3 concentrations
14P11399064T0000|0 13|Autoregulation
14P11399064T0000|47 81|CCAAT/enhancer binding protein beta
14P11399834T0000|14 31|HCV seroconversion
14P11399834T0000|33 40|Portugal
14P11399834T0000|63 79|HCV NAT screening
14P11400644A0435|15 27|uncertainties
14P11400644A0435|83 97|PCDD/F releases
14P11401105T0000|0 9|Gabapentin
14P11401105T0000|37 51|cancer patients
14P11401611A1703|0 10|CONCLUSIONS
14P11401611A1703|58 60|HRT
14P11402674T0000|0 31|Newcastle disease antibody titre
14P11402674T0000|42 68|serum calcium concentration
14P11403173A0192|10 17|patients
14P11403173A0192|31 43|brain tumours
14P11403663A0359|74 84|predictions
14P11403663A0359|92 101|2-D theory
14P11403719A1257|22 25|Gab1
14P11403719A1257|50 65|egr-1 expression
14P11404010A0235|11 19|triplexes
14P11404010A0235|31 36|length
14P11404010A0235|42 47|repeat
14P11404016A1922|17 26|TE domains
14P11404016A1922|39 42|PKSs
14P11404016A1922|86 88|TEs
14P11404016A1922|90 95|TE IIs
14P11404016A1922|156 172|peptide synthases
14P11404016A1922|173 176|NRPS
14P11404019A0532|8 20|understanding
14P11404019A0532|26 42|mGSTM2 regulation
14P11404019A0532|73 87|promoter region
14P11404312A0660|10 18|pmol/24 h
14P11406007A0292|0 17|SELECTION CRITERIA
14P11406007A0292|56 59|IUSs
14P11406007A0292|86 99|contraceptives
14P11406025A0204|0 9|OBJECTIVES
14P11406025A0204|50 62|effectiveness
14P11406025A0204|73 85|acceptability
14P11406277A0598|50 66|promoter activity
14P11406277A0598|80 107|reporter expression activity
14P11406277A0598|167 194|parent Hlx promoter sequence
14P11406642A0792|18 27|expression
14P11407289A1507|0 10|CONCLUSIONS
14P11407289A1507|78 86|BIS index
14P11407448A0815|71 97|jejunum flap reconstruction
14P11407448A0815|124 146|tract voice restoration
14P11407448A0815|172 187|voice prosthesis
14P11407448A0815|251 265|speech training
14P11407650A0661|0 12|Hypercalcemia
14P11407650A0661|35 57|serum PTH concentration
14P11407650A0661|73 91|hyperparathyroidism
14P11407650A0661|103 113|BC patients
14P11407650A0661|154 167|thyroid cancer
14P11408099A0518|22 33|correlations
14P11408099A0518|60 68|pregnancy
14P11408099A0518|72 80|Se levels
14P11408338A1686|21 23|PSP
14P11408338A1686|133 144|neurologists
14P11408575A0000|50 59|activation
14P11408575A0000|81 92|kinase Cdc28
14P11408575A0000|105 107|Clb
14P11408591A0000|40 41|HA
14P11408591A0000|57 69|cell motility
14P11408591A0000|89 101|v-src mutants
14P11408604A1440|31 32|2L
14P11408604A1440|54 71|ERK kinase cascade
14P11408604A1440|101 113|PDGF receptor
14P11408604A1440|149 154|ERK1/2
14P11408604A1440|183 206|receptor tyrosine kinase
14P11408774X0893|0 8|Karger AG
14P11408774X0893|9 13|Basel
14P11409425A0000|12 25|plasma samples
14P11409425A0000|45 62|National Institute
14P11409425A0000|76 83|Diseases
14P11409425A0000|87 92|Stroke
14P11409425A0000|94 98|NINDS
14P11409425A0000|100 127|tissue plasminogen activator
14P11409425A0000|132 143|Stroke Trial
14P11409425A0000|176 189|apolipoprotein
14P11409425A0000|191 193|Apo
14P11409425A0000|195 196|E2
14P11409425A0000|201 216|Apo E4 phenotype
14P11410110A0190|0 3|NIRS
14P11410110A0190|75 92|forearm blood flow
14P11410110A0190|92 94|FBF
14P11410563A0363|50 68|regression analysis
14P11410563A0363|82 98|body surface area
14P11410563A0363|108 131|shop order fracture rate
14P11410563A0363|133 152|manufacturing period
14P11410563A0363|168 170|OSF
14P11410664A0963|42 73|breast carcinoma MDA-MB231 cells
14P11410664A0963|90 92|MPG
14P11410664A0963|146 148|BER
14P11410664A0963|181 183|BER
14P11410664A0963|193 199|APE/ref
14P11410664A0963|220 223|MGMT
14P11410664A0963|225 241|repair activities
14P11410679A0000|38 52|Cre recombinase
14P11410679A0000|63 75|rearrangement
14P11410679A0000|92 116|LOX recognition sequences
14P11410679A0000|233 241|LOX sites
14P11411198A0711|54 67|Ashkenazi Jews
14P11411198A0711|119 132|stomach cancer
14P11411623T0000|0 8|Influence
14P11411623T0000|11 29|compression therapy
14P11411623T0000|52 64|tissue injury
14P11411961A0735|0 25|Keratoconjunctivitis sicca
14P11411961A0735|79 81|JRA
14P11413148A0573|0 15|STAT5A mutations
14P11413148A0573|33 35|SH2
14P11413148A0573|40 50|SH3 domains
14P11413148A0573|76 99|tyrosine phosphorylation
14P11413277A1121|20 31|chemotherapy
14P11413277A1121|77 81|PCNSL
14P11413310A0148|0 5|RANTES
14P11413310A0148|39 44|T-cell
14P11413310A0148|79 90|CC chemokine
14P11413310A0148|211 223|RSV infection
14P11413319A0000|0 13|Reovirus mRNAs
14P11413641A0373|0 7|Analyses
14P11413641A0373|20 32|scale matters
14P11413641A0373|57 68|quadrat area
14P11413760A0000|0 9|Myasthenia
14P11413760A0000|85 97|ACh receptors
14P11414754X1099|0 8|Copyright
14P11414754X1099|13 26|Academic Press
14P11415633A1253|19 28|force data
14P11415633A1253|80 90|compression
14P11415952A0369|0 5|Angina
14P11415952A0369|93 118|electrocardiogram ischemia
14P11415952A0369|145 164|heart disease events
14P11415952A0369|167 168|Q5
14P11415958A0000|37 44|advances
14P11415958A0000|63 73|methodology
14P11415958A0000|77 84|analysis
14P11415958A0000|132 141|advantages
14P11415958A0000|155 162|approach
14P11416012A1982|44 45|LH
14P11416012A1982|87 98|LDL receptor
14P11416012A1982|161 198|rabbit muscle protein kinase inhibitor
14P11416012A1982|196 198|PKI
14P11416012A1982|235 256|sarcoma virus promoter
14P11416012A2511|35 64|insulin/IGF-I effector pathway
14P11416012A2511|95 126|LDL receptor promoter expression
14P11416012A2511|206 233|phophatidylinositol 3-kinase
14P11416012A2511|254 255|LY
14P11416012A2511|294 314|protein kinase kinase
14P11416012A2511|314 315|PD
14P11416012A2511|332 336|U0126
14P11416012A2511|380 384|U0124
14P11416012T0000|42 74|density lipoprotein receptor gene
14P11416012T0000|177 205|phosphatidylinositol 3-kinase
14P11416012T0000|226 258|protein kinase signaling pathways
14P11416132A1351|66 67|GA
14P11416132A1351|72 96|repeat binding activities
14P11416144A1324|39 44|ZBP-89
14P11416144A1324|54 71|cell proliferation
14P11416144A1324|106 116|p53 protein
14P11416260A0000|57 64|activity
14P11416260A0000|92 99|patients
14P11416260A0000|149 161|data analysis
14P11416393A0000|68 89|lifestyle modification
14P11416393A0000|109 132|blood pressure elevation
14P11416393A0000|134 149|weight reduction
14P11416393A0000|156 166|body weight
14P11416393A0000|187 198|hypertension
14P11416393A0000|259 276|sodium restriction
14P11416393A0000|431 449|alcohol consumption
14P11416393A0000|488 503|exercise program
14P11416393A0000|520 538|tobacco consumption
14P11416650T0000|16 27|Hypertension
14P11416650T0000|31 36|Update
14P11416737T0000|0 4|Ga-67
14P11416737T0000|8 26|Tl-201 scintigraphy
14P11416879A1589|8 25|blood gas tensions
14P11416879A1589|44 60|ventilation modes
14P11418130A0499|21 34|loxP sequences
14P11418130A0499|66 78|recombination
14P11418662A0917|28 29|IC
14P11418662A0917|40 54|p50 DNA binding
14P11418662A0917|82 92|p50 subunit
14P11418662A0917|96 98|p65
14P11418662A0917|101 109|NF-kappaB
14P11419938T0000|32 56|uptake regulation protein
14P11419938T0000|59 74|metal activation
14P11419938T0000|77 87|DNA binding
14P11419938T0000|130 155|diphtheria toxin repressor
14P11420612A0303|3 12|complement
14P11420612A0303|36 53|sequencing efforts
14P11420612A0303|97 109|sequence data
14P11422200A0000|0 10|Granulocyte
14P11422200A0000|36 40|G-CSF
14P11422200A0000|42 55|administration
14P11422200A0000|86 103|defence mechanisms
14P11422757A0737|58 67|ACR levels
14P11423991A1393|22 32|p53 mutants
14P11423991A1393|55 66|p53 variants
14P11423991A1393|93 95|p53
14P11423991A1393|146 161|cancer therapies
14P11424992A0712|28 36|diagnoses
14P11424992A0712|95 102|criteria
14P11425076A0364|100 114|Reynolds number
14P11425076A0364|161 187|perturbation theory results
14P11425076A0364|212 222|integration
14P11425877A1026|0 4|Cells
14P11425877A1026|12 15|p116
14P11425877A1026|116 138|fluid phase pinocytosis
14P11425877A1026|220 234|F-actin content
14P11427329A1077|16 20|FPS-R
14P11427329A1077|56 67|correlations
14P11427329A1077|75 77|VAS
14P11427329A1077|97 99|CAS
14P11427611A0000|3 16|susceptibility
14P11427611A0000|123 140|National Committee
14P11427611A0000|151 170|Laboratory Standards
14P11427611A0000|171 175|NCCLS
14P11427611A0000|177 188|M38-P method
14P11427611A0000|259 281|H-tetrazolium hydroxide
14P11427611A0000|282 284|XTT
14P11428276A0352|3 5|Van
14P11428276A0352|9 13|Hoeve
14P11428276A0352|16 31|syndrome lesions
14P11428276A0352|58 69|calcium salt
14P11428283A0228|12 17|infant
14P11428283A0228|42 48|stridor
14P11428283A0228|68 75|distress
14P11428435A0446|0 5|DESIGN
14P11428435A0446|80 93|period January
14P11428435A0446|99 106|December
14P11428487T0000|9 18|vein varix
14P11428487T0000|20 30|association
14P11428487T0000|53 65|vein stenosis
14P11428897A0318|11 21|experiments
14P11428897A0318|35 38|CopG
14P11428897A0318|68 77|target DNA
14P11428897A0318|90 99|DNA ratios
14P11428897A0318|171 180|directions
14P11428897A0318|220 223|CopG
14P11429702A0917|48 53|KMS-11
14P11429702A0917|57 67|OPM-2 cells
14P11429702A0917|107 119|FGFR3 mutants
14P11429702A0917|157 161|Y373C
14P11429702A0917|165 179|K650E receptors
14P11429702A0917|232 255|receptor phosphorylation
14P11430042A0000|19 42|Stille coupling reaction
14P11430042A0000|86 102|tetrafluoroborate
14P11430042A0000|104 111|BMIM BF4
14P11430042A0000|142 145|RTIL
14P11430976X0000|25 36|biosynthesis
14P11430976X0000|39 61|woody plant biopolymers
14P11431348A0000|0 11|Interactions
14P11431348A0000|22 48|checkpoint abrogator UCN-01
14P11431348A0000|118 121|MAPK
14P11431348A0000|130 132|MEK
14P11431348A0000|135 146|MAPK pathway
14P11431348A0000|179 197|leukemia cell lines
14P11431472A0540|3 18|affinity binding
14P11431472A0540|20 28|Rab6A-GTP
14P11431472A0540|67 71|Rab1B
14P11431857A0186|25 39|urine screening
14P11431857A0186|75 88|urine analysis
14P11431857A0186|123 136|urine analysis
14P11432112A0000|0 6|PURPOSE
14P11432112A0000|47 61|embryo cleavage
14P11432112A0000|62 64|FEC
14P11432112A0000|93 107|sperm injection
14P11432112A0000|108 111|ICSI
14P11432112A0000|131 154|embryo selection process
14P11432748T0000|12 46|laminin beta2 chain gene expression
14P11432776A0421|0 7|Northern
14P11432776A0421|11 31|Western blot analyses
14P11432776A0421|46 50|Graf2
14P11433014A0683|45 60|core histone H2A
14P11433014A0683|61 63|H2B
14P11433014A0683|90 92|MCB
14P11433018A0756|41 45|Nhp2p
14P11433018A0756|48 60|H/ACA snoRNAs
14P11433018A0756|86 98|H/ACA snoRNPs
14P11433024A0260|0 9|Telomerase
14P11433024A0260|13 37|ribonucleoprotein complex
14P11433024A0260|61 63|DNA
14P11433024A0260|87 99|RNA component
14P11433379A0000|0 2|SIT
14P11433379A0000|33 47|adaptor protein
14P11433379A0000|82 96|adaptor protein
14P11434084A0508|11 21|patients DD
14P11434084A0508|40 55|microlatex tests
14P11435428A0000|9 29|acetyl-CoA synthetase
14P11435428A0000|30 35|AceCS1
14P11435428A0000|86 100|lipid synthesis
14P11435517A0396|5 19|digestibilities
14P11435517A0396|22 23|DM
14P11435517A0396|25 26|OM
14P11435517A0396|28 29|CP
14P11435517A0396|49 51|TDF
14P11435517A0396|72 73|GE
14P11435560A1322|29 40|HFV R region
14P11435560A1322|83 97|target HFV mRNA
14P11435578A0760|5 8|TxRE
14P11435578A0760|45 47|CRE
14P11435578A0760|69 76|TGACGTCA
14P11435578A0760|133 140|AGACGTCA
14P11435578A0760|142 149|TGACGGCA
14P11435578A0760|151 158|TGACCTCA
14P11435578A2231|20 33|reconstitution
14P11435578A2231|37 49|consensus CRE
14P11435578A2231|91 107|CREB/ATF proteins
14P11435578A2231|148 160|transcription
14P11435605A0587|26 28|CAR
14P11435605A0587|41 58|CAR residues Leu73
14P11435605A0587|60 65|Lys121
14P11435605A0587|72 77|Lys123
14P11435605A0587|89 104|contact residues
14P11435605A0587|109 113|Tyr80
14P11435605A0587|117 121|Tyr83
14P11435605A0587|152 170|binding interaction
14P11435605A0587|177 179|Ad5
14P11435605A0587|181 183|Ad9
14P11435605A0587|185 188|Ad12
14P11435605A0587|193 209|Ad41L fiber knobs
14P11435688A0262|56 65|N-terminus
14P11435688A0262|91 112|transmembrane segments
14P11435983T0000|0 8|Tolerance
14P11435983T0000|16 30|transplantation
14P11437439A0201|3 19|promoter activity
14P11437439A0201|71 84|prestalk cells
14P11437660A1219|0 11|Substitution
14P11437660A1219|14 28|serine residues
14P11437660A1219|33 42|C-terminus
14P11437660A1219|62 82|phosphorylation sites
14P11437660A1219|111 123|transcription
14P11438651A1365|5 29|replication fork movement
14P11438651A1365|32 34|HML
14P11438651A1365|75 96|replication initiation
14P11438651A1365|116 120|Orc2p
14P11438651A1365|137 157|replication initiator
14P11438654A1237|70 73|PI3K
14P11438654A1237|83 114|c-Akt/Pak1 cell survival pathway
14P11438666A0555|31 33|TAF
14P11438666A0555|54 56|HFD
14P11438666A0555|61 77|plant homeodomain
14P11438666A0555|78 80|PHD
14P11438666A0555|110 128|immunoprecipitation
14P11438666A0555|143 157|TFIID component
14P11438838A0788|27 35|TAR decoy
14P11438838A0788|61 72|RNA promoter
14P11438838A0788|73 76|U6-P
14P11439343A0785|12 15|MPc3
14P11439343A0785|36 49|Pc protein M33
14P11439343A0785|67 69|AF9
14P11441163T0000|0 9|Foreigners
14P11441311X0001|20 26|MACOP-B
14P11441311X0001|30 46|radiation therapy
14P11441311X0001|69 78|BACKGROUND
14P11441311X0001|115 135|chemotherapy regimens
14P11441311X0001|180 182|NHL
14P11441952A0414|68 77|percentage
14P11441952A0414|80 88|avoidance
14P11441952A0414|117 126|difference
14P11441952A0414|138 152|months post-TBI
14P11441952A0414|162 175|avoidance test
14P11441952A0414|205 207|TBI
14P11441974A0320|19 27|migration
14P11441974A0320|40 52|hemolymph PO2
14P11441974A0320|78 87|hemocyanin
14P11441974A0320|123 129|reserve
14P11441974A0320|156 163|mmol x l
14P11443509A0293|0 5|DESIGN
14P11443509A0293|56 76|First National Health
14P11443509A0293|78 95|Examination Survey
14P11443509A0293|96 101|NHANES
14P11443509A0293|126 130|Study
14P11443509A0293|132 136|NHEFS
14P11443999A0573|0 21|Mean Hg concentrations
14P11443999A0573|50 60|Isle Royale
14P11443999A0573|96 112|Hg concentrations
14P11443999A0573|128 146|government agencies
14P11444762A0373|21 29|proposals
14P11444762A0373|47 54|analysis
14P11444762A0373|84 89|action
14P11445008A0816|52 73|FGFR expression levels
14P11445008A0816|90 97|RNA pool
14P11445008A0816|113 128|RNA pool samples
14P11447490A0598|18 25|effusion
14P11447490A0598|66 75|assessment
14P11448051A0093|53 74|intestine transit time
14P11448051A0093|155 158|NaCl
14P11448051A0093|172 176|Emdex
14P11448051A0093|196 209|Eudragit RS100
14P11449014A0000|0 14|STUDY OBJECTIVE
14P11449014A0000|115 118|CCTs
14P11449014A0000|152 181|epidemiologist/biostatistician
14P11449014A0000|183 185|E/B
14P11450490A0565|54 73|range hand motions/0
14P11450776T0000|37 47|peritonitis
14P11451447A0205|0 4|Gimpl
14P11451447A0205|6 7|F.
14P11451682A0190|24 25|AE
14P11451682A0190|54 88|benzimidazole carbamate derivatives
14P11451995T0000|83 133|isoprenylcysteine carboxyl methyltransferase family
14P11454004T0000|58 96|glycerol-3-phosphate dehydrogenase gene
14P11454004T0000|120 143|hormone-response element
14P11454190A0000|0 14|BACKGROUND/AIMS
14P11454190A0000|16 26|Hepatitis C
14P11454190A0000|41 59|fatty liver disease
14P11454190A0000|59 62|NAFL
14P11454190A0000|107 119|United States
14P11454239A0478|27 31|ANOVA
14P11454239A0478|36 81|Pearson Product Moment Correlation Coefficient
14P11454239A0478|79 107|Principal Components Analysis
14P11454239A0478|109 138|Discriminant Function Analysis
14P11454239A0478|178 184|RESULTS
14P11454239A0478|190 200|Sensitivity
14P11454703A0000|67 69|DNA
14P11454703A0000|72 86|chromosome ends
14P11454703A0000|172 186|immortalization
14P11454703A0000|196 208|tumorigenesis
14P11456259A0142|10 45|TSH binding inhibitor immunoglobulin
14P11456259A0142|44 47|TBII
14P11457139A0604|18 20|CVN
14P11457139A0604|70 75|GlcNAc
14P11457139A0604|85 95|D1D3 isomer
14P11457139A0604|97 99|Man
14P11457139A0604|103 108|GlcNAc
14P11459048A0485|27 39|uncertainties
14P11459048A0485|79 88|atmosphere
14P11459048A0485|93 97|Venus
14P11459048A0485|132 146|rotation states
14P11459304T0078|0 20|Enantiomer separation
14P11459304T0078|36 57|O-desmethylvenlafaxine
14P11459794A1172|0 11|TE-671 cells
14P11459794A1172|34 54|cAMP response element
14P11459794A1172|110 125|GnRH-II promoter
14P11459960A1109|32 41|components
14P11459960A1109|67 77|heat labile
14P11459962A0785|37 41|Rad52
14P11459962A0785|57 70|repair pathway
14P11459962A0785|97 115|rad27 Delta strains
14P11459962A0785|145 158|semipermissive
14P11459962A0785|171 182|temperatures
14P11460035A0548|18 35|hydroxychloroquine
14P11460035A0548|37 49|carbamazepine
14P11460035A0548|53 63|fluvoxamine
14P11460035A0548|74 85|imputability
14P11461595A0000|16 32|reaction kinetics
14P11461595A0000|76 91|coalescence type
14P11461595A0000|102 104|B+B
14P11462004A0886|12 18|Vp1 DBD
14P11462004A0886|67 69|NLS
14P11462004A0886|80 94|complementation
14P11462004A0886|96 97|N.
14P11462004A1500|27 30|Vp1s
14P11462004A1500|77 79|Vp2
14P11462004A1500|83 85|Vp3
14P11462004A1500|114 117|NLS1
14P11462004A1500|171 173|Vp1
14P11462024A0306|0 2|Zhu
14P11462024A0306|4 5|V.
14P11462952A1040|7 20|gastrin levels
14P11463359A0167|18 34|phorbol ester PMA
14P11463359A0167|93 107|luciferase gene
14P11463359A0167|127 141|G6Pase promoter
14P11463359A0167|165 184|H4IIE hepatoma cells
14P11463834A0606|7 26|deletion mutagenesis
14P11463834A0606|59 61|CBP
14P11463834A0606|98 100|CR2
14P11463834A0606|124 138|Tax interaction
14P11464997A0566|4 12|knowledge
14P11464997A0566|25 33|diagnosis
14P11464997A0566|37 45|treatment
14P11464997A0566|61 70|counseling
14P11465518A0000|0 9|BACKGROUND
14P11465518A0000|47 59|investigators
14P11465518A0000|109 118|treatments
14P11465518A0000|164 174|individuals
14P11465655A0439|32 50|antagonist atenolol
14P11465844T0000|24 40|Kawasaki syndrome
14P11465844T0000|56 73|Rickettsia conorii
14P11465844T0000|74 89|Rickettsia typhi
14P11465844T0000|90 106|Coxiella burnetii
14P11465844T0000|108 137|Ehrlichia phagocytophila group
14P11466227A1665|13 20|AS-oligo
14P11466227A1665|71 72|EB
14P11466227A1665|75 91|mTf-CAT construct
14P11467349A0452|47 57|ISF glucose
14P11468958A0122|29 43|policy analysis
14P11468958A0122|113 115|CJD
14P11468958A0122|177 190|travel history
14P11468958A0122|195 196|UK
14P11468958A0122|244 246|CJD
14P11469701A0377|18 39|insulin administration
14P11469701A0377|76 90|insulin therapy
14P11469701A0377|91 95|CIIIT
14P11469701A0377|155 175|insulin concentration
14P11469737A1791|40 63|muscle function recovery
14P11469853A0702|21 36|domain shuffling
14P11469853A0702|60 69|C1 domains
14P11469853A0702|78 87|Raf kinase
14P11469853A0702|90 100|rat PKC eta
14P11469853A1053|41 51|interaction
14P11469853A1053|62 67|GTPase
14P11469853A1053|100 108|C1 domain
14P11469926T0000|0 28|Breast cancer risk assessment
14P11469970A0873|0 7|Patients
14P11469970A0873|19 21|SOD
14P11469970A0873|37 48|hyperalgesia
14P11469970A0873|58 72|antidepressants
14P11469970A0873|96 120|botulinum toxin injection
14P11470914A0305|13 16|Rac1
14P11470914A0305|24 42|STAT3 translocation
14P11470914A0305|83 97|gene expression
14P11471077A0382|0 6|RESULTS
14P11471077A0382|64 67|TRA1
14P11471077A0382|71 74|TRA2
14P11471077A0382|101 103|TRA
14P11471231A0964|2 9|addition
14P11471231A0964|16 23|patients
14P11471231A0964|58 68|differences
14P11471231A0964|101 108|spectrum
14P11471231A0964|165 174|procedures
14P11472523A0535|0 9|CONCLUSION
14P11472523A0535|11 27|Extrusion cooking
14P11472523A0535|58 60|DON
14P11472523A0535|83 86|AFB1
14P11472696A0387|19 23|CPIgG
14P11472696A0387|25 27|CRP
14P11472696A0387|32 48|fibrinogen levels
14P11472696A0387|78 80|ACS
14P11473254A0000|11 26|DNA endonuclease
14P11473254A0000|48 69|recombinase activities
14P11473254A0000|74 84|Lys residue
14P11473261A0587|36 69|guanine nucleotide exchange factor
14P11473261A0587|68 70|GEF
14P11474642A1451|3 12|decrements
14P11474642A1451|30 39|resistance
14P11474642A1451|49 61|hexamethonium
14P11474642A1451|65 72|mm Hg ml
14P11478627A0573|3 23|desirability function
14P11478627A0573|63 64|Y1
14P11478627A0573|66 67|Y2
14P11478627A0573|73 74|Yn
14P11478627A0573|82 95|transformation
14P11479104A0446|96 114|lupus erythematosis
14P11479104A0446|115 124|CONCLUSION
14P11479104A0446|173 175|POF
14P11479501A0744|0 6|RESULTS
14P11479501A0744|70 78|SD/mean x
14P11479501A0744|129 149|St Jude Medical valve
14P11479501A0744|167 182|Omnicarbon valve
14P11480490A0443|58 65|blockade
14P11480490A0443|70 71|Kr
14P11480490A0443|97 106|occurrence
14P11480490A0443|109 118|arrhythmia
14P11480497T0000|0 6|Effects
14P11480497T0000|22 34|JP-8 jet fuel
14P11480555A0928|3 12|production
14P11480555A0928|15 22|ceramide
14P11480555A0928|55 64|cell death
14P11481625A0202|76 78|TIW
14P11481625A0202|80 102|interferon alfa-2b dose
14P11481625A0202|103 105|MIU
14P11481625A0202|124 125|QW
14P11481625A0202|127 147|peginterferon alfa-2b
14P11484028T0000|2 15|cross purposes
14P11484578A1132|0 9|CONCLUSION
14P11484578A1132|37 52|measurement data
14P11484578A1132|82 97|measurement data
14P11484578A1132|141 154|design program
14P11486032A1261|8 28|transcription factors
14P11486032A1261|74 78|RUNX1
14P11486032A1261|108 114|E2A-HLF
14P11486141A0424|4 10|factors
14P11486141A0424|36 42|outcome
14P11486141A0424|45 52|students
14P11486141A0424|84 96|meta analysis
14P11486141A0424|127 133|sources
14P11486399A0000|3 13|combination
14P11486399A0000|50 52|IEV
14P11486399A0000|67 81|salvage regimen
14P11486476A0147|52 66|characteristics
14P11486476A0147|108 125|markers troponin T
14P11486476A0147|137 146|CK-MB mass
14P11486476A0147|223 225|ACS
14P11486476A0147|269 279|information
14P11486476A1512|7 24|markers troponin T
14P11486476A1512|24 33|CK-MB mass
14P11486476A1512|105 107|ECG
14P11489597A0379|2 12|termination
14P11489597A0379|38 44|females
14P11489597A0379|105 111|outcome
14P11489597A0379|117 123|fetuses
14P11489597A0379|168 180|malformations
14P11489597A0561|24 34|body weight
14P11489597A0561|45 55|weight gain
14P11489597A0561|87 101|pregnancy rates
14P11490862A0141|25 47|bladder neck suspension
14P11490862A0141|57 70|Stamey-Pereyra
14P11494391A0579|41 62|artery-alone ALT graft
14P11494391A0579|128 141|bile secretion
14P11495833T0000|13 18|impact
14P11495833T0000|90 99|properties
14P11495920A0504|52 62|CYP3A4 gene
14P11495920A0504|91 107|enhancer activity
14P11496495A0000|16 23|analysis
14P11496495A0000|43 52|conditions
14P11496495A0000|64 76|possibilities
14P11496495A0000|108 115|children
14P11496617A0301|0 6|METHODS
14P11496617A0301|43 57|thyroid surgery
14P11496617A0301|155 167|mg dolasetron
14P11496617A0301|194 202|induction
14P11496617A0301|205 215|anaesthesia
14P11496617A0301|229 241|mg dolasetron
14P11496617A0301|265 273|induction
14P11496617A0301|276 286|anaesthesia
14P11496617A0301|330 338|induction
14P11496617A0301|341 351|anaesthesia
14P11498795A0716|34 41|G1-phase
14P11498795A0716|61 75|phosphorylation
14P11498795A0716|81 90|RB protein
14P11498795A0716|115 132|S phase transition
14P11500377A0518|43 53|Wnt pathway
14P11500512A0000|8 17|ABCG1 gene
14P11500512A0000|56 58|ABC
14P11500512A0000|73 92|transporter proteins
14P11500571A0976|27 45|NtmybAS transcripts
14P11500571A0976|60 76|gPAL1 transcripts
14P11500913A1238|0 12|C/EBPbeta LIP
14P11500913A1238|26 35|HC11 cells
14P11500913A1238|48 63|beta-casein mRNA
14P11500913A1238|81 107|cell differentiation marker
14P11502738A1457|32 41|inhibitors
14P11502738A1457|105 122|cyclin D1 promoter
14P11502758A0869|52 56|LAD-1
14P11502758A0869|66 79|FGFR signaling
14P11502778A0941|35 50|estradiol levels
14P11502778A0941|67 76|pmol/liter
14P11502778A0941|135 157|bone resorption markers
14P11502778A0941|179 194|estradiol levels
14P11502778A0941|201 210|pmol/liter
14P11504545A0393|0 10|Competition
14P11504545A0393|42 59|immunoshift assays
14P11504545A0393|72 82|NF1 factors
14P11504545A0393|108 111|HeLa
14P11504545A0393|115 124|CV-1 cells
14P11504545A0393|133 139|BKV-MLP
14P11504709A0981|62 64|PMA
14P11504709A0981|67 69|TPO
14P11504709A0981|90 97|Ets site
14P11504709A0981|120 123|GPIX
14P11505407A0461|0 6|RESULTS
14P11505407A0461|51 55|EpCAM
14P11505407A0461|98 124|tumor necrosis factor alpha
14P11505407A0461|123 130|TNFalpha
14P11509266A0955|2 4|Cox
14P11509266A0955|17 49|hazards regression adenocarcinoma
14P11509266A0955|74 76|BPF
14P11509615T0000|0 28|Phosphatidylinositol 3-kinase
14P11509615T0000|58 77|T cell proliferation
14P11509615T0000|89 101|IL-2 receptor
14P11509673A0574|25 33|BM3 cells
14P11509673A0574|60 78|P450 AA epoxygenase
14P11509673A0574|78 85|F87V BM3
14P11509673A0574|148 156|14,15-EET
14P11509673A0574|158 159|AA
14P11511544T0000|15 45|heat shock transcription factor
14P11512925A0000|0 17|EXAFS measurements
14P11512925A0000|124 130|Ge atom
14P11513121T0000|35 44|QSAR model
14P11513121T0000|51 77|quantum chemical parameters
14P11513121T0000|89 91|BCF
14P11513121T0000|134 138|PCOCs
14P11513180A1257|57 58|CT
14P11513579A0372|48 51|Rac1
14P11513579A0372|75 81|Rho-GDI
14P11513579A0372|129 139|interaction
14P11513579A0372|142 158|complex formation
14P11516890A0236|24 39|cytochrome P-450
14P11516890A0236|40 42|CYP
14P11516890A0236|70 76|CYP 2D6
14P11516890A0236|79 81|3A4
14P11516890A0236|109 113|SSRIs
14P11517190A0352|0 7|Analysis
14P11517190A0352|13 29|promoter sequence
14P11517190A0352|91 98|TATA box
14P11517190T0000|26 42|rat ER alpha gene
14P11517190T0000|66 78|transcription
14P11517269A0472|0 4|Pitx2
14P11517269A0472|24 45|differentiation defect
14P11517269A0472|67 79|axon guidance
14P11517269A0472|151 162|conservation
14P11517399A0858|25 42|protein expression
14P11517399A0858|111 123|acceptor site
14P11517399A0858|136 146|utilization
14P11517399A0858|156 167|splice sites
14P11517399A0858|173 182|generation
14P11517445A0221|35 48|V. cholerae O1
14P11518505A0107|64 70|tissues
14P11518505A0107|74 79|organs
14P11518868A0559|79 95|hepatitis C virus
14P11518868A0559|98 130|healthcare provider communication
14P11519466A0196|37 42|impact
14P11520436A0705|5 15|BALB/c mice
14P11520436A0705|114 121|T. canis
14P11521191A0000|38 52|12S E1A protein
14P11521191A0000|63 84|phosphorylation status
14P11521191A0000|86 89|p130
14P11521191A0000|93 96|p107
14P11521191A0000|162 183|retinoblastoma protein
14P11522431A0673|15 32|tobacco dependence
14P11522431A0673|55 69|ICD-10 criteria
14P11522584A0882|58 67|MMF lesion
14P11522584A0882|76 88|muscle biopsy
14P11522626A1374|36 53|gene transcription
14P11522626A1374|97 104|Mek-Erk1
14P11522626A1374|116 133|estrogen receptors
14P11522658A0086|25 45|ErbB1/ErbB2 signaling
14P11522658A0086|79 108|ErbB kinase inhibitor AG1478in
14P11522658A0086|121 126|BT-474
14P11522658A0086|130 135|SKBR-3
14P11522658A0870|18 32|phosphorylation
14P11522658A0870|35 37|p27
14P11522658A0870|40 43|MAPK
14P11522658A0870|66 68|p27
14P11522658A0870|94 97|Cdk2
14P11522658A0870|132 146|kinase activity
14P11523446A0523|0 2|ICA
14P11523446A0523|8 25|reference solution
14P11523446A0523|43 44|LC
14P11523446A0523|63 65|TOF
14P11523446A0523|67 68|MS
14P11523446A0523|84 85|LC
14P11523446A0523|102 119|nitrogen detection
14P11523446A0523|120 126|LC-CLND
14P11524015A0937|18 23|BZAP45
14P11524015A0937|42 52|H4 promoter
14P11524015A0937|65 90|CAT reporter gene activity
14P11524815A0753|5 17|control rates
14P11524815A0753|37 47|lung cancer
14P11524815A0753|61 71|lung cancer
14P11524815A0753|80 81|T1
14P11524815A0753|83 93|2N0M0 cases
14P11524823X0001|0 6|Utility
14P11524823X0001|9 20|OAE screener
14P11524823X0001|21 23|GSI
14P11524823X0001|45 62|distortion product
14P11524823X0001|135 150|OAE screener GSI
14P11524823X0001|163 178|cochlea function
14P11525102A0970|40 55|ACP Journal Club
14P11525102A0970|65 79|PubMed strategy
14P11525102A0970|105 106|CI
14P11525486A0350|14 22|CaCO3-CO2
14P11525486A0350|24 25|N2
14P11525640A0560|0 9|Inhibition
14P11525640A0560|12 15|JNK1
14P11525640A0560|19 39|ERK kinase activities
14P11525640A0560|83 86|JNK1
14P11525640A0560|133 135|ERK
14P11525640A0560|137 144|PD098059
14P11525640A0560|171 182|UV induction
14P11525640A0560|187 201|GADD45 promoter
14P11528127A1402|5 14|GC content
14P11528127A1402|58 59|H1
14P11528127A1402|117 121|L1/L2
14P11528253X1211|0 8|Copyright
14P11528253X1211|13 14|S.
14P11528500A0571|15 22|NRL gene
14P11529914T0000|0 8|NF-kappaB
14P11529914T0000|36 40|CD154
14P11529914T0000|42 52|CD40 ligand
14P11529914T0000|77 83|T cells
14P11530684A0667|77 84|C-fibers
14P11530684A0667|88 116|drive NK1-receptor mechanisms
14P11530684A0667|123 139|pain transmission
14P11530684A0667|206 213|C-fibers
14P11530684A0667|217 246|drive NMDA receptor-mechanisms
14P11530684A0667|301 308|A-fibers
14P11530684A0667|313 342|drive NMDA-receptor mechanisms
14P11530829A0000|30 40|development
14P11530829A0000|45 57|ECG simulator
14P11530829A0000|84 94|calibration
14P11530829A0000|98 108|maintenance
14P11532556A0000|20 38|angioencephalopathy
14P11532556A0000|40 43|SDAE
14P11532856A1175|0 4|Third
14P11532856A1175|30 45|N-acetylcysteine
14P11532856A1175|75 77|HGF
14P11532856A1175|80 103|stress kinase activities
14P11532856A1175|108 121|p42/44 mitogen
14P11532856A1175|137 140|MAPK
14P11532856A1175|204 206|JNK
14P11532856A1175|211 218|p38 MAPK
14P11532856A1175|220 235|HIF-1 activation
14P11533238A1137|0 7|Mutation
14P11533238A1137|63 67|HDAC1
14P11533238A1137|97 123|HLA-DRA promoter activation
14P11533340A1285|74 84|PDF infants
14P11533340A1285|101 115|point advantage
14P11533340A1285|117 141|Bayley motor score scales
14P11533863A0125|18 28|restoration
14P11533863A0125|67 80|presupposition
14P11534132A0219|12 25|search engines
14P11534900A0000|47 78|molluscicides Azadirachta indica
14P11534900A0000|80 97|Cedrus deodara oil
14P11534900A0000|100 117|synergists MGK-264
14P11534900A0000|118 135|piperonyl butoxide
14P11534900A0000|136 137|PB
14P11534900A0000|155 167|Embelia ribes
14P11534900A0000|185 201|Lymnaea acuminata
14P11535014A1157|39 50|seizure type
14P11535014A1157|52 54|TLE
14P11535014A1157|103 121|precipitate factors
14P11535014A1157|143 146|P300
14P11535140T0000|12 19|findings
14P11535140T0000|22 30|pregnancy
14P11535532A0189|19 30|enzyme DUB-2
14P11535532A0189|51 54|IL-2
14P11535832A0586|21 26|HDAC9a
14P11535832A0586|47 56|C terminus
14P11535832A0586|60 64|HDAC9
14P11536063A0178|23 42|lung transplantation
14P11536063A0178|74 91|heart-lung-machine
14P11538437A0568|62 63|N2
14P11538437A0568|68 69|N2
14P11538437A0568|76 77|N2
14P11538437A0568|87 88|N2
14P11538437A0568|93 94|N2
14P11538437A0568|99 100|N2
14P11538437A0568|111 112|N2
14P11538437A0568|117 118|N2
14P11538437A0568|131 148|N2 post-discharges
14P11538437A0568|151 152|N2
14P11538437A0568|157 159|CH4
14P11538437A0568|176 177|M2
14P11538437A0568|181 182|CN
14P11538437A0568|190 191|M2
14P11538437A0568|193 194|N2
14P11538437A0568|203 204|CN
14P11538437A0568|208 209|N2
14P11538437A0568|214 215|CN
14P11538437A0568|231 251|% CH4 post-discharges
14P11539522A0612|3 17|NAUSICAA system
14P11539522A0612|38 48|LET spectra
14P11540991A0127|53 88|NASA MSFC Neutral Buoyancy Simulator
14P11540991A0127|91 101|NASA KC-135
14P11540991A0127|136 147|EASE program
14P11540991A0127|156 184|Shuttle Atlantis mission 61-B
14P11542677A0411|37 51|Generic Systems
14P11542677A0411|85 110|composting facility design
14P11542780A0086|36 38|TLD
14P11542780A0086|90 114|energy transfer component
14P11542780A0086|114 116|LET
14P11542780A0086|167 170|PNTD
14P11542780A0086|202 204|LET
14P11543154T0000|0 8|Responses
14P11543154T0000|11 21|TLD Mg2SiO4
14P11543154T0000|22 23|Tb
14P11543154T0000|79 93|space radiation
14P11543317A0203|94 100|Mg2SiO4
14P11543317A0203|102 103|Tb
14P11543317A0203|105 108|TDMS
14P11543317A0203|127 140|track detector
14P11543317A0203|141 144|PNTD
14P11543662A0562|88 96|L protein
14P11545594A1556|23 33|Myb domains
14P11545594A1556|75 84|Myb domain
14P11545594A1556|96 114|amino acid residues
14P11547819A0532|0 6|METHODS
14P11547819A0532|8 18|Experiments
14P11547819A0532|103 125|laser output beam sizes
14P11547819A0532|164 180|matter generation
14P11547819A0532|234 252|ablation hole sizes
14P11547819A0532|254 277|tissue penetration rates
14P11547819A0532|327 344|vessel wall injury
14P11548027A0163|13 34|performance indicators
14P11548027A0163|137 162|service quality indicators
14P11548027A0163|162 181|personnel indicators
14P11550795A2583|0 13|Overexpression
14P11550795A2583|16 23|RORgamma
14P11550795A2583|45 50|T cell
14P11550795A2583|78 94|T cell hybridomas
14P11550795A2583|119 128|Fas-ligand
14P11552058A0235|4 6|ICP
14P11552058A0235|37 46|herniation
14P11552058A0833|65 68|THAM
14P11552058A0833|70 101|Tris-hydroxy-methyl-aminomethane
14P11552724A0527|0 10|CONCLUSIONS
14P11552724A0527|30 33|IVUS
14P11552724A0527|73 84|vessel lumen
14P11552724A0527|187 199|interventions
14P11552724A0527|252 265|contrast media
14P11552922A0361|33 105|polymerase chain reaction-restriction fragment length polymorphism method
14P11553091A1472|60 71|relationship
14P11553091A1472|105 114|correction
14P11553091A1472|117 121|Class
14P11553091A1472|129 140|relationship
14P11553704A0674|53 62|EGFR-CD533
14P11553704A0674|81 87|Ras N17
14P11553704A0674|102 116|MAPK activation
14P11554469A1386|44 53|CesA genes
14P11554469A1386|59 77|cellulose synthases
14P11554566A0668|3 20|hatcher incubators
14P11554566A0833|6 20|companies sites
14P11554566A0833|65 69|Tr104
14P11554727A0890|3 22|mutation experiments
14P11554727A0890|73 75|PTH
14P11554727A0890|82 95|GGGGGAGGGGAG-3
14P11554727A0890|108 112|PTHSR
14P11555516A0639|34 37|COAT
14P11555516A0639|46 50|L/min
14P11555516A0639|61 72|cutoff value
14P11555516A0639|105 118|artery disease
14P11555669A0464|0 9|Experience
14P11555669A0464|47 63|Vrinnevi Hospital
14P11555669A0983|19 26|sections
14P11555669A0983|30 36|samples
14P11555669A0983|39 45|tissues
14P11555669A0983|48 53|stains
14P11556809A2085|33 47|enzyme activity
14P11556809A2085|73 91|5-epi-aristolochene
14P11556809A2085|95 110|1-deoxycapsidiol
14P11556809A2085|161 171|P450 enzyme
14P11556809A2085|203 223|hydrocarbon substrate
14P11557127A0991|13 16|NF-Y
14P11557127A0991|20 36|Sp1 binding sites
14P11557127A0991|102 110|MRP2 gene
14P11559366T0000|43 78|plasminogen activator inhibitor type
14P11559547T0000|48 76|pS2 breast cancer marker gene
14P11559547T0000|78 87|ERR family
14P11559564A0459|0 5|NB-506
14P11559564A0459|83 97|splicing factor
14P11559564A0459|110 124|splicing factor
14P11559564A0459|125 131|SF2/ASF
14P11559789A0314|65 87|ASF/SF2 splicing factor
14P11559789A0314|123 135|gene cassette
14P11559789A0314|152 158|ASF/SF2
14P11559789A0314|198 215|producer cell line
14P11559821A1315|0 17|DNA binding assays
14P11559821A1315|42 44|p30
14P11559821A1315|66 78|CREB-Tax-p300
14P11559821A1315|80 82|CBP
14P11559821A1315|111 133|repeat oligonucleotides
14P11560292A0557|51 63|prototype DSS
14P11560292A0557|66 88|dipslide urine cultures
14P11560509T0000|0 14|DNA recognition
14P11560509T0000|16 30|F factor TraI36
14P11560509T0000|77 79|DNA
14P11560990A0272|0 17|E47 protein levels
14P11560990A0272|144 153|transition
14P11560992A0000|7 25|specificity kinases
14P11560992A0000|42 55|protein kinase
14P11560992A0000|56 59|MAPK
14P11560992A0000|68 70|MKK
14P11560992A0000|76 79|MKK4
14P11560992A0000|125 138|stress kinases
14P11560992A0000|154 168|protein kinases
14P11560992A0000|169 173|SAPKs
14P11560992A0000|199 202|JNKs
14P11560992A0651|0 18|SAPK/JNK activation
14P11560992A0651|54 57|MKK7
14P11560992A0651|81 84|MKK4
14P11560992A0651|118 132|mast cell lines
14P11560992A0651|135 149|phosphorylation
14P11560992A0651|152 155|MKK4
14P11560992A1184|5 8|MKK7
14P11560992A1184|58 76|SAPK/JNK activation
14P11560992A1184|90 93|MKK7
14P11561623A0897|8 42|copepod Pseudonychocamptus proximus
14P11561623A0897|70 82|Tisbe furcata
14P11561626A0197|31 36|TMT-55
14P11561626A0197|122 127|Zn-TMT
14P11561626A0197|153 158|Cd-TMT
14P11561626A0197|172 177|Pb-TMT
14P11561626A0197|180 181|M3
14P11561626A0197|183 188|S3C3N3
14P11561626A0197|204 206|Cd2
14P11561626A0197|209 211|Pb2
14P11561626A0197|217 219|Zn2
14P11562278A0169|37 49|G1 regulation
14P11562278A0169|78 90|proliferation
14P11562278A0169|92 106|differentiation
14P11562278A0169|119 132|transformation
14P11562870A0892|3 13|probability
14P11562870A0892|16 24|treatment
14P11562870A0892|29 39|lamotrigine
14P11562870A0892|61 66|months
14P11562870A0892|83 88|months
14P11564871A1184|45 65|transcription systems
14P11564871A1184|128 130|TBP
14P11564871A1184|141 144|Pols
14P11564871A1184|176 188|TATA elements
14P11564893A1068|48 57|6RG lesion
14P11564893A1068|58 61|MGMT
14P11564893A1068|75 91|DNA repair factor
14P11564893A1068|93 115|transcription regulator
14P11564893A1068|116 121|R-MGMT
14P11565747A1020|0 3|Data
14P11565747A1020|30 44|UV crosslinking
14P11565747A1020|58 80|competition experiments
14P11565747A1020|117 134|binding affinities
14P11565747A1020|136 138|PSI
14P11565747A1020|145 159|SELEX sequences
14P11565747A1020|194 207|P element IVS3
14P11566874T0000|6 17|motor domain
14P11566948A1217|14 28|nephrosclerosis
14P11566948A1217|49 52|ACEI
14P11566948A1217|62 72|combination
14P11566961A0472|0 20|Body weight reduction
14P11566961A0472|28 46|insulin sensitivity
14P11566961A0472|76 97|blood pressure control
14P11566996A1391|27 60|nucleotide excision repair pathway
14P11566996A1391|94 103|DNA damage
14P11566996A1391|145 153|S. mutans
14P11568988A0960|7 22|regression model
14P11568988A0960|47 50|WCXR
14P11568988A0960|88 101|antibody titer
14P11568988A0960|104 114|Pa elastase
14P11569800T0000|0 22|Temperature measurement
14P11569900A0660|0 13|APC-resistance
14P11569900A0660|87 110|factor V Leiden mutation
14P11569949A2087|0 4|Zarix
14P11569949A2087|13 30|patient enrollment
14P11569949A2087|62 67|Spring
14P11570735A1097|0 6|RESULTS
14P11570735A1097|33 46|feedback group
14P11570735A1097|83 103|ground reaction force
14P11570735A1097|248 262|feedback groups
14P11570820T0000|4 16|casein kinase
14P11570820T0000|17 24|isoforms
14P11570820T0000|70 78|cytoplasm
14P11572377T0000|0 2|Use
14P11572377T0000|62 77|cavitation field
14P11572388A0000|68 97|solvation energy relationships
14P11572388A0000|97 101|LSERs
14P11572388A0000|183 186|RPLC
14P11572388A0000|188 205|method development
14P11572467A0658|7 16|blood clot
14P11572467A0658|56 64|injection
14P11572467A0658|81 91|plasminogen
14P11572467A0658|94 100|plasmin
14P11572467T0000|0 9|Management
14P11572467T0000|56 83|tissue plasminogen activator
14P11573771T0000|0 5|Effect
14P11573771T0000|8 22|heat treatments
14P11573771T0000|27 37|meltability
14P11573891A0525|0 6|RESULTS
14P11573891A0525|29 37|Americans
14P11573891A0525|49 67|community outbreaks
14P11573891A0525|71 73|TST
14P11574088A1687|30 48|pancreas transplant
14P11574088A1687|61 63|SPK
14P11574088A1687|77 90|PAK recipients
14P11574105A0727|0 7|Patients
14P11574105A0727|12 25|antibody peaks
14P11574105A0727|61 74|antibody titer
14P11574105A0727|93 106|antibody titer
14P11574105A0727|121 123|GBS
14P11574105A0727|134 150|disability scores
14P11574105A0727|174 176|GBS
14P11574105A0727|210 212|IgG
14P11574105A0727|225 242|IgM antibody peaks
14P11574105A0727|267 284|IgM antibody peaks
14P11574105A0727|314 328|antibody titers
14P11575109A0214|9 16|baseline
14P11575109A0214|25 35|examination
14P11575109A0214|57 63|therapy
14P11575109A0214|67 74|patients
14P11575109A0214|95 101|surgery
14P11575109A0214|127 135|treatment
14P11575109A0214|158 164|gingiva
14P11575977A1133|28 46|office hypertension
14P11575977A1133|76 88|complications
14P11576158A1371|5 16|TVD-patients
14P11576158A1371|28 42|skin blood flow
14P11576776T0081|20 45|microcrystalline cellulose
14P11577094A1226|39 42|WT-1
14P11577094A1226|44 56|HSAL2 pathway
14P11578685A0077|0 5|ICAM-1
14P11578685A0077|44 45|GO
14P11579100T0000|0 22|Phosphotyrosyl peptides
14P11579100T0000|41 60|DNA binding activity
14P11580173A0181|0 18|Plane wave geometry
14P11580173A0181|98 113|P3 approximation
14P11580301A1161|14 26|HCV arthritis
14P11580301A1161|86 98|polyarthritis
14P11580757A0304|0 6|METHODS
14P11580757A0304|35 47|TFCD patients
14P11580757A0304|129 130|MR
14P11580941A0815|0 6|RESULTS
14P11580941A0815|32 39|UPDRS II
14P11580941A0815|42 51|III scores
14P11583428A0191|2 4|Exp
14P11583621A0301|24 30|stimuli
14P11583621A0301|40 49|expression
14P11583621A0301|70 77|cleavage
14P11583621A0301|145 151|complex
14P11583880T0000|33 50|AneuRx stent-graft
14P11584107T0000|18 25|diseases
14P11584107T0000|47 56|assessment
14P11584328A0532|0 16|Drug interactions
14P11584328A0532|59 75|CYP450 isoenzymes
14P11585856A0285|0 6|METHODS
14P11585856A0285|52 53|RR
14P11585856A0285|65 66|AC
14P11585856A0285|73 92|scanning line source
14P11585856A0285|95 112|scatter correction
14P11585856A0285|113 134|photon energy recovery
14P11585856A0285|134 136|PER
14P11586096A0699|22 44|patient characteristics
14P11586096A0699|45 64|control measurements
14P11587514A0758|11 29|abi1-1 gene product
14P11587514A0758|44 58|ABA suppression
14P11587514A0758|74 91|alpha-amylase gene
14P11587980A1039|57 59|FOT
14P11587980A1039|74 94|interrupter technique
14P11587980A1039|144 160|resistance values
14P11587980A1039|197 211|bronchodilation
14P11589568A0744|25 43|checkpoint response
14P11589568A0744|54 66|proteins Mad1
14P11589568A0744|71 74|Bub1
14P11589568A0744|78 81|Bub3
14P11589568A0744|98 109|counterparts
14P11589568A0744|130 141|kinetochores
14P11589779T0000|0 5|HTLV-1
14P11589779T0000|15 22|Th2 type
14P11589779T0000|52 67|strongyloidiasis
14P11590364A1056|11 31|beta5L splice variant
14P11592315A0325|0 8|PROCEDURE
14P11592315A0325|10 17|Cannulas
14P11592532A0188|0 6|METHODS
14P11592532A0188|8 36|Humphrey Field Analyzer model
14P11592532A0188|38 40|HFA
14P11593394A0000|12 29|growth factor-beta
14P11593394A0000|30 37|TGF-beta
14P11593394A0000|115 137|cyclin kinase complexes
14P11593394A0000|181 183|p15
14P11593394A0000|185 189|Ink4b
14P11593394A0000|194 196|p27
14P11593394A0000|198 201|Kip1
14P11593394A0000|203 226|cyclin kinase inhibitors
14P11595170A0582|0 8|Alignment
14P11595170A0582|30 34|NR5A2
14P11595170A0582|81 91|delineation
14P11595170A0582|107 118|organization
14P11595176T0000|29 38|SPEC1 gene
14P11595176T0000|63 86|close promoter proximity
14P11595176T0000|90 112|AF1q translocation gene
14P11595478A1014|0 1|Hp
14P11595478A1014|84 96|Hp negativity
14P11595478A1014|103 118|cancer relatives
14P11595813A0633|10 19|metabolism
14P11595813A0633|100 110|differences
14P11595813A0633|116 125|activities
14P11595813A0633|138 153|5alpha-reductase
14P11595813A0633|180 197|androgen receptors
14P11595840A0000|22 39|fluorodeoxyglucose
14P11595840A0000|41 48|F-18 FDG
14P11595840A0000|78 96|blood glucose level
14P11596104A0614|0 21|Northern blot analysis
14P11596104A0614|32 37|PARNAs
14P11596838A1357|28 49|fluticasone propionate
14P11596838A1357|151 163|beta2-agonist
14P11597185A0477|32 45|metapopulation
14P11597185A0477|62 81|computer simulations
14P11597185A0477|134 156|metapopulation dynamics
14P11597936A0570|5 16|CAD patients
14P11597936A0570|79 97|density lipoprotein
14P11597936A0570|112 124|triglycerides
14P11599079A1040|16 31|orifice voltages
14P11599079A1040|67 69|API
14P11599079A1040|86 88|API
14P11599079A1040|108 110|API
14P11599797A0732|0 6|RESULTS
14P11599840A0813|3 8|moduli
14P11599840A0813|11 20|elasticity
14P11599840A0813|38 43|matter
14P11599840A0813|76 84|deviation
14P11599840A0813|111 117|section
14P11599840A0813|156 162|section
14P11599840A0813|207 213|section
14P11600252A0795|3 4|LA
14P11600314A0000|13 24|polarography
14P11600314A0000|129 138|vitamin B1
14P11600314A0000|139 140|B2
14P11600314A0000|144 145|B6
14P11600365A0471|30 35|E-4767
14P11600365A0471|39 44|E-5065
14P11600365A0471|129 147|reference compounds
14P11600467A1436|31 40|alteration
14P11600467A1436|58 69|permeability
14P11602353A0770|13 22|HNF-3 beta
14P11602353A0770|23 27|HFH-1
14P11602353A0770|29 33|HFH-2
14P11602353A0770|35 39|HFH-3
14P11602353A0770|50 59|C/EBP beta
14P11602353A0770|105 123|expression profiles
14P11603271T0001|18 34|vertigo syndromes
14P11604152A0526|3 6|MABP
14P11604152A0526|10 22|MCBFV signals
14P11604152A0526|70 72|VLF
14P11604152A0526|84 85|Hz
14P11604152A0526|88 106|low-frequency range
14P11604152A0526|107 108|LF
14P11604152A0526|119 120|Hz
14P11604152A0526|145 146|HF
14P11604152A0526|157 158|Hz
14P11604152A0526|174 176|CCF
14P11605207T0001|0 8|Treatment
14P11605598A0785|0 10|Hepatitis B
14P11605598A0785|13 34|C seroprevalence rates
14P11605598A0785|68 74|El Paso
14P11605598A0785|92 105|US populations
14P11605598A0785|133 151|prevention programs
14P11606538A1002|34 36|Nrk
14P11606538A1002|54 77|receptor tyrosine kinase
14P11606538A1002|80 82|Tpp
14P11606538A1002|97 110|neuropeptidase
14P11614398T0000|42 50|Mormonism
14P11639485A0478|66 69|Urdu
14P11639485A0478|78 86|languages
14P11639485A0478|112 123|day students
14P11642687T0000|0 9|Comparison
14P11642687T0000|18 34|language versions
14P11642687T0000|39 44|QWB-SA
14P11642687T0000|48 52|SF-36
14P11642687T0000|86 101|prostate disease
14P11653491T0000|21 33|DNA violation
14P11669281A0653|10 21|cytotoxicity
14P11669281A0653|32 42|antibiotics
14P11669281A0653|71 81|competition
14P11669281A0653|84 92|synergism
14P11669476A0346|25 51|tumor necrosis factor-alpha
14P11669476A0346|51 59|TNF-alpha
14P11669476A0346|143 160|insulin resistance
14P11675912A0131|58 68|preparation
14P11675912A0131|90 102|acetaminophen
14P11675912A0131|107 117|alleviation
14P11675912A0131|120 128|headaches
14P11676899A0704|16 27|risk factors
14P11676899A0704|71 83|mononucleosis
14P11676899A0704|109 124|immunodeficiency
14P11676899A0704|152 164|wood industry
14P11677363A0775|39 48|IMT values
14P11677363A0775|71 72|PP
14P11677363A0775|117 119|SBP
14P11677363A0775|122 135|PP variability
14P11677839A0876|3 12|difference
14P11677839A0876|23 30|patients
14P11677839A0876|37 44|controls
14P11678437A0000|51 65|nutrient uptake
14P11678437A0000|73 83|Zea mays L.
14P11678437A0000|97 110|pot experiment
14P11678437A0000|124 138|manifold sample
14P11678437A0000|141 169|petroleum development company
14P11679441A0429|0 13|NO metabolites
14P11679441A0429|45 59|nitrate/nitrite
14P11679441A0429|61 63|NOx
14P11679441A0429|65 88|micromol/mmol creatinine
14P11679441A0429|98 120|guanosine monophosphate
14P11679441A0429|126 145|nmol/mmol creatinine
14P11680835A0756|14 21|analysis
14P11680835A0756|42 48|patient
14P11680835A0756|84 94|pamidronate
14P11683558A0446|36 49|macronutrients
14P11683558A0446|63 76|micronutrients
14P11683558A0446|78 88|differences
14P11684665A0000|0 23|C. elegans embryogenesis
14P11684665A0000|120 137|nematode body plan
14P11685047A0301|41 59|thrombin inhibition
14P11685047A0301|65 80|substrate S-2238
14P11685284X0000|1 12|Diabetologia
14P11685284X0000|22 26|Suppl
14P11685284X0000|30 36|B37-B44
14P11686239A0464|26 32|3B gene
14P11686239A0464|65 67|G/C
14P11686239A0464|122 140|sequence similarity
14P11686239A0464|145 151|G boxes
14P11686239A0464|195 213|Dictyostelium genes
14P11686378A0326|68 71|LD50
14P11686378A0326|110 123|concentrations
14P11686378A0326|147 159|E coli/cfu mL
14P11686378A0326|200 207|Pn decay
14P11686378A0326|330 332|EHD
14P11687083A0218|0 9|OBJECTIVES
14P11687083A0218|58 87|prophylactic prostaglandin use
14P11687180A3209|14 22|questions
14P11687180A3209|58 64|rHu EPO
14P11687180A3209|70 75|speeds
14P11687180A3209|80 85|delays
14P11687180A3209|96 103|dialysis
14P11687352A0215|0 6|METHODS
14P11687352A0215|55 59|LASIK
14P11687352A0215|67 75|September
14P11687352A0215|83 91|September
14P11687517A1619|2 6|ISREs
14P11687737A0000|0 9|BACKGROUND
14P11687737A0000|19 31|heart disease
14P11687869A0000|31 37|colitis
14P11687869A0000|59 69|sarcoidosis
14P11689217T0000|0 33|Cholesteryl ester transfer protein
14P11691585A1174|15 35|mobility shift assays
14P11691585A1174|37 65|coimmunoprecipitation studies
14P11691585A1174|84 101|heterodimerization
14P11691585A1174|115 134|cKrox family members
14P11691585T0000|3 20|hcKrox gene family
14P11692004A1200|91 102|relationship
14P11692004A1200|110 112|NF1
14P11693461A1649|5 20|utilisation data
14P11693461A1649|53 54|US
14P11693461A1649|65 66|US
14P11693461A1649|79 93|TNF antagonists
14P11693461A1649|96 97|RA
14P11695481A0310|22 38|combination O3/UV
14P11695481A0310|54 69|degradation rate
14P11697760A0000|57 72|17beta-estradiol
14P11697760A0000|74 75|E2
14P11697760A0000|98 100|PTH
14P11697760A0000|138 145|OVX rats
14P11703464A0560|19 31|subjects rCBF
14P11703464A0560|152 164|reinforcement
14P11703558A0000|0 10|Doxorubicin
14P11703558A0000|12 14|DOX
14P11704380A1608|33 40|Irr-rMFP
14P11704380A1608|43 50|Un-nrMFP
14P11704380A1608|88 95|Rev-rMFP
14P11704380A1608|98 106|Sta-nrMFP
14P11704829A0312|0 24|Subtraction hybridization
14P11704829A0312|34 57|melanoma differentiation
14P11704829A0312|133 146|melanoma cells
14P11705093A2016|10 29|vitamin D3 analogues
14P11706668A0000|0 9|Hydrocoele
14P11706668A0000|97 108|intervention
14P11706949T0000|0 13|Growth hormone
14P11706949T0000|28 52|growth factor I receptors
14P11707977A0750|30 45|infusion therapy
14P11707977A0750|66 76|H3 patients
14P11708032A0183|59 70|levoforinate
14P11708032A0183|85 98|5-fluorouracil
14P11708032A0183|100 103|5-FU
14P11708032A0183|136 145|metastases
14P11708032A0183|183 193|medications
14P11708032A0183|233 244|infuser pump
14P11708362A0889|3 16|astronaut crew
14P11708362A0889|49 57|operation
14P11708431A0904|19 30|introduction
14P11708431A0904|59 72|oligoarthritis
14P11708431A0904|120 133|patient groups
14P11708761A1388|58 71|ACE inhibitors
14P11708761A1388|94 110|diabetes mellitus
14P11709561T0000|0 4|Phase
14P11709561T0000|24 25|D2
14P11709561T0000|37 48|antibody 3F8
14P11709561T0000|100 112|neuroblastoma
14P11709890T0000|0 10|Hepatitis A
14P11709890T0000|33 40|Edmonton
14P11709890T0000|42 48|Alberta
14P11709890T0000|74 101|health protection strategies
14P11710233T0000|0 8|Hydrogels
14P11710233T0000|12 29|tissue engineering
15P11710685A0994a|22 26|ASCUS
15P11710685A0994a|37 51|ASCUS/SIL ratio
15P11710685A0994a|100 116|Papanicolaou test
15P11710685A0994b|22 26|ASCUS
15P11710685A0994b|37 51|ASCUS/SIL ratio
15P11710685A0994b|100 116|Papanicolaou test
14P11711701A0602|10 28|medicine physicians
14P11711701A0602|95 124|Tc-99m MIBI image combinations
14P11711701A0602|231 259|pertechnetate thyroid imaging
14P11714429X0000|2 12|clopidogrel
14P11714429X0000|72 82|cornerstone
14P11714429X0000|124 138|thienopyridines
14P11714429X0000|140 150|clopidogrel
14P11714429X0000|152 162|ticlopidine
14P11714429X0000|223 233|Clopidogrel
14P11714429X0000|240 246|Aspirin
14P11714429X0000|249 256|Patients
14P11714429X0000|259 262|Risk
14P11714429X0000|274 285|Events trial
14P11715079A1016|17 30|proprioception
14P11715079A1016|54 67|efference copy
14P11715079A1016|73 83|development
14P11715079A1016|99 111|perturbations
14P11715079A1016|132 141|mismatches
14P11715079A1016|149 172|eye movement information
14P11716043A0380|56 58|PTC
14P11716043A0380|64 73|Department
14P11716043A0380|84 119|Helsinki University Central Hospital
14P11716441A0585|0 2|ISS
14P11716441A0585|34 50|health evaluation
14P11716441A0585|51 56|APACHE
14P11718197A1282|3 11|procedure
14P11722993A0276|0 11|Paul Monagle
14P11722993A0276|23 34|epidemiology
14P11722993A0276|45 54|thrombosis
14P11723500X0000|27 41|characteristics
14P11723500X0000|52 65|cell carcinoma
14P11723500X0000|88 97|BACKGROUND
14P11723500X0000|107 120|cell carcinoma
14P11723500X0000|121 123|SCC
14P11723511A0780|54 68|category A risk
14P11723511A0780|82 91|category B
14P11723511A0780|106 115|category C
14P11723511A0780|127 136|category D
14P11723511A0780|150 160|category X.
14P11723675A1022|48 57|SOFA score
14P11723675A1022|128 142|APACHE II score
14P11723928A0294|29 45|river reclamation
14P11723928A0294|47 61|Yangpu District
14P11723928A0294|63 75|Shanghai City
14P11723928A0294|76 80|China
14P11724510T0000|8 17|principles
14P11724510T0000|31 39|apheresis
14P11726022A0909|31 39|estimates
14P11726022A0909|42 52|penetration
14P11726022A0909|69 80|calculations
14P11726022A0909|94 110|time calculations
14P11726068A0539|0 3|Rind
14P11726068A0539|22 32|conclusions
14P11726164A0215|16 30|food processors
14P11726164A0215|46 58|cross-contact
14P11726164A0215|61 73|food products
14P11726164A0215|162 173|food allergy
14P11726262A0692|0 24|Lactate accumulation peak
14P11726262A0692|54 56|HMB
14P11726262A0692|70 72|LEU
14P11726262A0692|86 88|CON
14P11726413A1756|12 20|clearance
14P11726413A1756|36 42|infants
14P11726413A1756|47 54|contrast
14P11726413A1756|62 68|opioids
14P11726574A1304|36 55|baseline assumptions
14P11727073A0842|0 9|CONCLUSION
14P11727073A0842|36 49|MIST-VR yields
14P11727209A0502|3 10|patients
14P11727209A0502|19 26|families
14P11727209A0502|64 74|examination
14P11727209A0502|91 101|orthostasia
14P11728771A0187|50 66|contrast material
14P11730182A0984|33 43|correlation
14P11730182A0984|76 88|pollen levels
14P11730182A0984|90 101|Philadelphia
14P11730182A0984|107 117|Cherry Hill
14P11730182A0984|118 121|Acer
14P11730182A0984|134 140|Quercus
14P11730182A0984|153 158|Betula
14P11730182A0984|171 175|Pinus
14P11730182A0984|188 199|Cupressaceae
14P11730182A0984|212 218|Poaceae
14P11730182A0984|231 238|Ambrosia
14P11730182A0984|254 258|Rumex
14P11730262A0874|28 46|etidronate/fluoride
14P11730262A0874|66 77|osteoporosis
14P11730262A0874|91 101|pilot study
14P11730262A0874|136 147|osteoporosis
14P11730262A0874|164 173|etidronate
14P11730262A0874|205 221|calcium/vitamin D
14P11730712A0416|0 17|Treadmill training
14P11730712A0416|45 59|infarction size
14P11730712A0416|75 87|MCA occlusion
14P11732088A0471|58 76|sphincter manometry
14P11732088A0471|131 135|SSEUS
14P11732417A0571|10 36|percentage positivity value
14P11732417A0571|169 177|ELISA kit
14P11736254A0000|2 9|analysis
14P11736254A0000|15 22|dynamics
14P11736254A0000|97 108|partitioning
14P11736254A0000|125 133|landscape
14P11736254A0000|144 153|structures
14P11736792A0204|61 62|G1
14P11736792A0204|80 81|G2
14P11736792A0204|90 123|World Health Organization criteria
14P11737056A0680|35 36|ME
14P11737056A0680|40 48|ET mucosa
14P11737056A0680|63 66|BrdU
14P11737158A1517|33 40|Wernicke
14P11737158A1517|46 59|fusiform gyrus
14P11737158A1517|60 69|Broca BA44
14P11737158A1517|109 120|computations
14P11737900A0700|9 19|correlation
14P11737900A0700|27 36|plasma COP
14P11737900A0700|39 49|body weight
14P11737900A0700|62 63|r2
14P11738404A0120|47 83|alpha-diacetoxy-8 beta-isobutanoyloxy
14P11738404A0120|138 174|beta-dihydroxy-beta-dihydroagarofuran
14P11738404A0120|234 274|alpha-benzoyloxy-13-isobutanoyloxy-4 beta
14P11738404A0120|276 312|beta-dihydroxy-beta-dihydroagarofuran
14P11738404A0120|333 411|alpha,13-tetraacetoxy-9 alpha-benzoyloxy-2 alpha-hydroxy-beta-dihydroagarofuran
14P11740571A0114|55 67|concentration
14P11740571A0114|87 108|glutathione peroxidase
14P11740571A0114|110 121|brain tissue
14P11740571A0114|147 173|chemiluminescence intensity
14P11740806X0810|0 15|Saunders Company
14P11741259A1233|3 13|performance
14P11741259A1233|28 36|particles
14P11741259A1233|56 62|ability
14P11741259A1233|109 117|intestine
14P11741554T0000|0 9|Comparison
14P11741554T0000|24 44|lipoprotein particles
14P11741554T0000|87 100|artery disease
14P11741554T0000|120 133|artery disease
14P11742432A0798|73 87|MAC prophylaxis
14P11742432A0798|257 271|discontinuation
14P11742432A0798|274 294|macrolide prophylaxis
14P11742432A0798|299 311|AIDS patients
14P11742432A0798|316 325|CD4 counts
14P11743360A2491|34 44|mean amount
14P11743360A2491|46 49|IL-6
14P11743612A1179|0 7|Patients
14P11743612A1179|12 13|CF
14P11743612A1179|113 125|CF population
14P11744290T0045|1 9|Cactaceae
14P11744953A0878|0 11|Skin cancers
14P11744953A0878|82 93|age patients
14P11752821A1365|0 9|CONCLUSION
14P11752821A1365|11 13|MMF
14P11752821A1365|64 82|Adamantiades-Behcet
14P11755894A0466|89 91|ADL
14P11755894A0466|116 125|management
14P11755894A0466|147 149|POI
14P11755894A0466|185 198|bowel function
14P11755894A0466|213 225|hospital stay
14P11760398A0553|0 6|METHODS
14P11760398A0553|34 35|BS
14P11760398A0553|134 135|BS
14P11760398A0553|189 200|ISG criteria
14P11760796A0698|0 7|Evidence
14P11760796A0698|20 34|PHACES syndrome
14P11761601A0133|1 16|computer program
14P11761601A0133|17 26|ACCESS-IAQ
14P11761601A0133|86 111|contaminant concentrations
14P11761601A0133|135 154|inhalation exposures
14P11763176A0918|26 46|antithrombin activity
14P11763176A0918|69 79|experiments
14P11764062A0000|3 32|Penn State Worry Questionnaire
14P11764062A0000|33 40|Children
14P11764062A0000|42 47|PSWQ-C
14P11764062A0000|59 83|self-report questionnaire
14P11764062A0000|179 186|Chorpita
14P11764062A0000|193 197|Behav
14P11764226A0798|0 13|Classification
14P11764226A0798|28 40|ILAR criteria
14P11764226A0798|80 95|disease duration
14P11764226A0798|137 150|EULAR criteria
14P11765448A0588|9 24|X-ray projection
14P11766747A0000|45 52|patients
14P11766747A0000|72 79|teratoma
14P11768467A0000|0 22|Pyrethroid insecticides
14P11769229A0357|3 21|sorption mechanisms
14P11769229A0357|32 41|adsorption
14P11771979A1141|42 52|LDF signals
14P11771979A1141|135 137|LDF
14P11771979A1141|200 212|heterogeneity
14P11773168A0915|25 26|OS
14P11773168A0915|56 58|PFS
14P11773921A0397|0 6|METHODS
14P11773921A0397|8 28|P-selectin expression
14P11773921A0397|60 68|platelets
14P11773921A0397|107 117|clopidogrel
14P11773921A0397|174 187|artery disease
14P11773921A0397|221 231|clopidogrel
14P11773921A0397|242 253|implantation
14P11773921A0397|298 308|clopidogrel
14P11773921A0397|348 358|clopidogrel
14P11775180A0379|54 74|gamma-detecting probe
14P11775301A0797|13 24|intervention
14P11775301A0797|27 43|depression scores
14P11776922A0830|11 19|sclerosis
14P11776922A0830|23 32|resorption
14P11776922A0830|38 47|skull base
14P11776922A0830|62 68|lesions
14P11776922A0830|80 86|lesions
14P11777575A0363|41 55|S. thermophilus
14P11777575A0363|85 88|PyMS
14P11777575A0363|139 142|ANNs
14P11777632A1678|0 1|AF
14P11777632A1678|158 170|AF expression
14P11777632A1678|197 209|breast cancer
14P11778044A0000|13 45|probability density distributions
14P11778044A0000|107 129|fingerprinting approach
14P11778044A0000|165 188|complexity climate model
14P11778044A0000|223 242|climate observations
14P11778804A0179|0 8|Frequency
14P11778804A0179|60 62|FDT
14P11781615A0000|46 57|complication
14P11781615A0000|83 102|cell transplantation
14P11782218A0349|10 23|white-on-white
14P11782218A0349|25 27|W-W
14P11782218A0349|39 42|SWAP
14P11782218A0349|128 143|media absorption
14P11782218A0349|153 172|examination duration
14P11782218A0349|187 201|learning effect
14P11783457A0000|0 12|Preservatives
14P11783457A0000|48 59|preparations
14P11783457A0000|115 127|decomposition
14P11785085X0001|149 165|vacuum aspiration
14P11785085X0001|166 178|Introl-4 unit
14P11785085X0001|193 210|pneumovibromassage
14P11785085X0001|212 219|PVM-R-01
14P11785827A0986|57 67|propagation
14P11785827A0986|71 80|physiology
14P11785827A0986|118 128|degradation
14P11785827A0986|155 172|selection pressure
14P11785827A0986|175 190|transmissibility
14P11785827A0986|198 210|communication
14P11786248A1162|0 10|Consumption
14P11786248A1162|61 64|PPTg
14P11786248A1162|69 72|PPTg
14P11786248A1162|130 142|sham controls
14P11786945A0958|9 15|freedom
14P11786945A0958|31 41|arrhythmias
14P11786945A0958|50 58|follow-up
14P11786945A0958|75 81|group A
14P11787041A0167|6 16|development
14P11787322X0001|0 8|Influence
14P11787322X0001|29 49|chemical disinfection
14P11787322X0001|62 71|properties
14P11787322X0001|83 90|V gypsum
14P11787322X0001|102 112|instruments
14P11787322X0001|141 154|prosthodontics
14P11787322X0001|180 190|impressions
14P11787322X0001|239 248|literature
14P11787322X0001|262 273|transmission
14P11787720A1313|54 56|C18
14P11787720A1313|59 60|n6
14P11787720A1313|103 105|C20
14P11787720A1313|108 109|n6
14P11787746A0374|0 9|Vitrectomy
14P11787746A0374|30 43|lens fragments
14P11789206A1182|0 10|CONCLUSIONS
14P11789206A1182|26 29|MIRI
14P11789206A1182|32 44|Qi deficiency
14P11789206A1182|60 62|TCM
14P11789206A1182|102 103|Qi
14P11789216T0001|0 6|Effects
14P11789216T0001|19 35|blood circulation
14P11789216T0001|43 54|blood stasis
14P11789216T0001|56 69|barrier action
14P11790897T0000|49 57|SELDI-TOF
14P11790897T0000|105 117|breast cancer
14P11791292A0193|14 23|laboratory
14P11791292A0193|35 45|application
14P11791571T0000|1 51|high-efficiency cross-flow micronebulizer interface
14P11791585A0287|3 12|electrodes
14P11791585A0287|121 127|surface
14P11791853A0532|35 70|coagulation-electrooxidation process
14P11791853A0532|106 108|COD
14P11792586A0290|36 43|activity
14P11792586A0290|54 62|formation
14P11792586A0290|65 75|microcracks
14P11792586A0290|85 97|tissue matrix
14P11793172A0545|29 35|PE head
14P11793172A0545|62 64|THA
14P11793172A0545|72 91|friction coefficient
14P11793172A0545|134 140|PE head
14P11793614A0000|0 8|OBJECTIVE
14P11793614A0000|50 63|concentrations
14P11793614A0000|85 101|phosphodiesterase
14P11793614A0000|182 196|anticoagulation
14P11796977T0000|0 7|Postdocs
14P11796977T0000|26 40|mainland Europe
14P11800119A0814|3 18|design principle
14P11800119A0814|33 46|vibration mode
14P11800586A1090|10 18|DPPD gene
14P11800586A1090|138 149|tuberculosis
14P11800878T0000|0 14|Dynamic imaging
14P11800878T0000|40 65|ultrashort UV laser pulses
14P11801459T0000|0 7|Efficacy
14P11801459T0000|52 67|atherothrombosis
14P11802580A0000|3 36|General Practice Research Database
14P11802580A0000|35 38|GPRD
14P11802580A0000|59 79|computerized database
14P11802580A0000|154 173|health research tool
14P11802601A0107|29 44|laboratory study
14P11802601A0107|64 74|metabolites
14P11802601A0107|76 91|aldicarb sulfone
14P11802601A0107|94 111|aldicarb sulfoxide
14P11803325A0868|7 22|DC cardioversion
14P11803325A0868|38 46|HBS group
14P11803325A0868|55 56|DC
14P11803325A0868|62 70|CBC group
14P11803325A0868|79 80|DC
14P11803325A0868|86 94|GIK group
14P11804081A0552|5 10|August
14P11804081A0552|19 22|ENRP
14P11804081A0552|50 51|TP
14P11804081A0552|84 93|Everglades
15P11804100A0365a|32 35|BOD5
15P11804100A0365a|39 43|NH3-N
15P11804100A0365a|104 113|TP removal
15P11804100A0365b|32 35|BOD5
15P11804100A0365b|39 43|NH3-N
15P11804100A0365b|104 113|TP removal
14P11804510A0730|0 5|Losses
14P11804510A0730|8 20|dichlofluanid
14P11804510A0730|27 38|chlozolinate
14P11804510A0730|48 58|etridiazole
14P11804510A0730|103 112|processing
14P11804510A0730|196 205|processing
14P11806132A0253|3 14|TB incidence
14P11806132A0253|20 24|AIRIN
14P11810685A0147|16 40|displacement distribution
14P11810685A0147|57 59|MRI
14P11810685A0147|105 119|long-wavelength
14P11810685A0147|148 149|3D
14P11810685A0147|158 182|displacement distribution
14P11810685A0147|191 196|DT-MRI
14P11811743A0800|58 69|Class III FI
14P11811825A0972|23 50|cross-validation experiments
14P11811825A0972|133 149|sensitivity level
14P11815644A0081|11 25|characteristics
14P11815644A0081|63 72|variations
14P11815644A0081|117 134|muscle recruitment
14P11815644A0081|140 151|echolocation
14P11816458A0319|11 18|Examples
14P11816458A0319|22 33|Explanations
14P11816458A0319|36 43|APA Form
14P11816458A0319|98 111|review article
14P11816458A0319|112 126|journal article
14P11816458A0319|149 163|journal article
14P11816779A0343|3 14|drug packets
14P11816779A0343|23 36|acetyl aspirin
14P11816779A0343|37 49|acetaminophen
14P11816779A0343|53 67|chloramphenicol
14P11818675X0897|0 8|Karger AG
14P11818675X0897|9 13|Basel
14P11819326A0000|0 2|AIM
14P11819326A0000|90 103|encephalopathy
14P11819326A0000|105 107|PSE
14P11819326A0000|110 116|METHODS
14P11819326A0000|168 170|PSE
14P11821098A0269|0 19|MAIN OUTCOME MEASURE
14P11821098A0269|22 33|Serum levels
14P11821098A0269|35 37|FSH
14P11821098A0269|39 40|LH
14P11822790A0907|18 26|SIP score
14P11822790A0907|101 116|study population
14P11822790A0907|177 187|improvement
14P11822790A0907|194 214|reproducibility noise
14P11822811A0319|0 4|Group
14P11822811A0319|21 27|Collies
14P11822811A0319|50 74|microg/kg ivermectin p.o.
14P11822811A0319|94 97|VMTH
14P11824701A0894|0 7|Patients
14P11824701A0894|47 50|Type
14P11824701A0894|52 68|behavior patterns
14P11824701A0894|77 90|Bortner scores
14P11824801A0661|14 25|continuation
14P11824801A0661|31 48|interferon therapy
14P11824801A0661|80 91|exacerbation
14P11824801A0661|94 104|sarcoidosis
14P11824801A0661|150 166|organ involvement
14P11825801A1212|24 32|mortality
14P11825801A1212|54 62|follow-up
14P11826141T0000|20 41|lidocaine inactivation
14P11826141T0000|86 96|maintenance
14P11826141T0000|100 112|reinstatement
14P11828186A0239|97 112|CRP measurements
14P11828186A0239|117 137|Third National Health
14P11828186A0239|139 166|Nutrition Examination Survey
14P11828186A0239|166 175|NHANES III
14P11830544A0335|0 8|Herceptin
14P11830544A0335|28 32|HER-2
14P11830544A0335|73 79|1B4M-Gd
14P11830544A0335|118 130|WIBC-9 tumors
14P11830544A0335|150 168|control MC-5 tumors
14P11831512A0468|110 128|carbohydrate source
14P11831512A0468|163 165|CSS
14P11831512A0468|167 185|dextrose equivalent
14P11831512A0468|186 187|DE
14P11831512A0468|218 222|DE-42
14P11832019A0668|0 10|CONCLUSIONS
14P11832019A0668|12 15|AMVT
14P11833863A0987|10 19|difference
14P11833863A0987|22 35|apnea duration
14P11833863A0987|59 67|positions
14P11834476A1187|18 29|animal model
14P11834476A1187|60 70|transfusion
14P11834476A1187|118 139|hemoglobin transfusion
14P11834476A1187|149 164|oxygen transport
14P11834476A1187|234 243|protection
14P11835109A0000|54 63|importance
14P11835109A0000|105 108|HRQL
14P11836046A0549|47 63|calcium carbonate
14P11836046A0549|132 148|calcium carbonate
14P11836046A0549|196 203|estrogen
14P11836046A0549|208 230|mg medrogestone acetate
14P11836303A0518|0 7|TNFalpha
14P11836303A0518|11 21|IL-6 levels
14P11836303A0518|40 59|culture supernatants
14P11836303A1191|46 56|disturbance
14P11836303A1191|82 97|cytokine biology
14P11837409A0584|21 47|National Longitudinal Study
14P11837409A0584|48 64|Adolescent Health
14P11838058A0084|0 6|METHODS
14P11838058A0084|40 55|tissue expansion
14P11838058A0084|56 59|CITE
14P11838058A0084|101 116|tissue expansion
14P11838058A0084|117 120|CPTE
14P11838102T0001|0 6|Wegener
14P11838102T0001|9 22|granulomatosis
14P11840365A0949|43 62|General Health scale
14P11840365A0949|66 70|SF-36
14P11842037A0327|31 55|% urine-plasma difference
14P11842728X0001|18 32|schistosomiasis
14P11842728X0001|34 47|Schistosomosis
14P11842728X0001|92 108|Schistosoma genus
14P11843252A0907|7 19|response rate
14P11843252A0907|28 48|% confidence interval
14P11843252A0907|81 88|survival
14P11844591A0329|55 57|APT
14P11844812A0915|26 28|AUC
14P11844812A0915|34 46|ANN ROC curve
14P11844812A0915|74 77|AUCs
14P11844812A0915|97 99|PSA
14P11844812A0915|110 115|PSA-TZ
14P11844812A0915|129 139|PSA density
14P11844812A0915|147 161|prostate volume
14P11845547A0449|37 59|KATP channel activators
14P11845547A0449|62 77|21-aminosteroids
14P11846167A0000|0 7|Selenium
14P11846167A0000|61 74|microorganisms
14P11846187A0894|3 21|GT-foreign-pictures
14P11846187A0894|81 103|permeability directions
14P11847580T0000|13 25|cholecystitis
14P11849417A0900|0 2|Age
14P11849417A0900|57 63|RESULTS
14P11849417A0900|82 101|dialysis PD patients
14P11849417A0900|144 154|HD patients
14P11849796A0452|0 6|RESULTS
14P11849796A0452|39 44|3D-CRT
14P11849796A0452|48 57|IMRT plans
14P11849796A0452|102 112|IMRT fields
14P11851941A0372|32 50|serumalbumin method
14P11851941A0372|146 163|reference solution
14P11851941A0372|165 183|hydroxyethyl starch
14P11851941A0372|184 186|HES
14P11852907A0871|3 32|equilibrium phosphorus content
14P11852907A0871|32 35|EPC0
14P11852907A0871|75 85|SRP content
14P11853943A0122|45 67|R-R interval estimation
14P11858256A0102|19 26|research
14P11858256A0102|30 40|explanation
14P11858548A0241|64 74|NMR spectra
14P11858548A0241|77 93|mass spectrometry
14P11858635A0896|37 47|QSAR models
14P11858635A0896|61 80|LOO cross-validation
14P11859400A0229|55 70|HSV reactivation
14P11859400A0229|75 77|HSV
14P11859400A0229|100 130|progenitor cell transplantation
14P11859400A0229|130 133|APCT
14P11859400A0229|195 209|HSV prophylaxis
14P11859943A0150|21 38|outpatient clinics
14P11859943A0150|101 128|General Health Questionnaire
14P11860097A1695|0 3|Data
14P11860097A1695|6 19|prosthesis use
14P11860097A1695|101 116|prosthesis users
14P11860723A0182|13 27|Georgia members
14P11860723A0182|32 47|American College
14P11860723A0182|49 61|Obstetricians
14P11860723A0182|65 77|Gynecologists
14P11860876A0409|0 14|HIV-1 C subtype
14P11860876A0409|15 18|IDUs
14P11861092A0730|134 136|FGS
14P11861092A0730|164 166|FCD
14P11861092A0730|193 195|FPD
14P11861092A0730|222 224|HGS
14P11861092A0730|249 251|Pim
14P11861092A0730|260 274|HDI5000 scanner
14P11861092A0730|277 286|C5-2 probe
14P11861092A0730|287 289|ATL
14P11861092A0730|291 297|Bothell
14P11861092A0730|299 300|WA
14P11862350T0000|50 84|NMDA receptor antagonist remacemide
14P11863811A0259|21 34|Nusselt number
14P11863811A0259|65 66|Pr
14P11864173T0000|16 24|pathogens
14P11864173T0000|45 57|exacerbations
14P11864173T0000|67 76|bronchitis
14P11865218A0069|0 8|Treatment
14P11865218A0069|44 56|wax softening
14P11866130A0419|24 39|2-phenoxyethanol
14P11866130A0419|49 67|complement activity
14P11866130A0419|88 92|MS222
14P11866130A0419|96 114|quinaldine sulphate
14P11867388A0502|3 4|EC
14P11867388A0502|12 22|suppression
14P11867388A0502|44 56|concentration
14P11867388A0502|81 97|fear conditioning
14P11867388A0502|144 146|SEM
14P11867388A0502|155 171|fear conditioning
14P11870646A0668|37 69|ceramic/substrate bilayer systems
14P11872359A0000|21 38|insulin resistance
14P11872359A0000|39 40|IR
14P11872359A0000|83 85|CVD
14P11872359A0000|131 133|CVD
14P11872359A0000|184 194|Australians
14P11872570T0000|0 7|Dementia
14P11872570T0000|24 26|NHS
14P11873003X0000|0 14|HIV-1 infection
14P11873003X0000|21 26|Africa
14P11873003X0000|60 63|AIDS
14P11873003X0000|117 126|OBJECTIVES
14P11873003X0000|141 157|progression times
14P11873003X0000|159 173|HIV-1 infection
14P11873003X0000|193 196|AIDS
14P11873003X0000|234 237|AIDS
14P11873003X0000|252 257|Uganda
14P11874637A0212|42 46|HAART
14P11874637A0212|100 112|HIV infection
14P11874637A0212|179 197|deficiency syndrome
14P11874637A0212|198 201|AIDS
14P11875695A0718|0 3|Time
14P11875695A0718|6 16|progression
14P11875695A0718|49 56|survival
14P11875695A0718|61 72|registration
14P11876937A0261|0 6|Heparin
14P11876937A0261|64 70|H group
14P11876937A0261|96 102|N group
14P11879108A0719|0 19|MAIN OUTCOME MEASURE
14P11879108A0719|77 103|ligase chain reaction assay
14P11879108A0719|155 176|immunodeficiency virus
14P11879108A0719|177 179|HIV
14P11881268A0000|65 100|exercise self-efficacy questionnaire
14P11881923A1256|0 9|Neutrophil
14P11881923A1256|11 26|lymphocyte ratio
14P11881923A1256|27 44|plasma haptoglobin
14P11881923A1256|48 57|CBG levels
14P11881923A1256|111 113|PRE
14P11881923A1256|116 127|POST periods
14P11882054A0568|62 72|FMZ binding
14P11882054A0568|128 131|ROIs
14P11882054A0568|194 206|lesion volume
14P11882054A0568|212 224|mirror region
14P11882054A1250|50 60|FMZ binding
14P11882054A1250|63 78|spiking activity
14P11882054A1250|146 156|FMZ binding
14P11882054A1250|192 206|epileptogenesis
14P11882747A0354|0 1|CD
14P11882747A0354|23 44|Farnsworth D-15 method
14P11883682A0162|18 27|monitoring
14P11883682A0162|58 69|distribution
14P11883682A0162|88 106|estuarine sediments
14P11883763A1062|23 24|Pu
14P11883763A1062|174 185|Pu transport
14P11883763A1062|211 224|East China Sea
14P11884014A0665|8 26|treatment protocols
14P11884014A0665|55 56|GI
14P11885053A1897|30 35|Volkan
14P11885053A1897|139 153|memorial shrine
14P11885737A1713|23 40|spermatozoa/microl
14P11885737A1713|64 73|compromise
14P11886473A0796|0 14|Gastritis score
14P11886473A0796|42 45|CagA
14P11886473A0796|66 69|CagA
14P11886473A0796|85 88|CagA
14P11886473A0796|106 109|CagA
14P11887803A1455|3 16|mean thickness
14P11887803A1455|150 153|CAPD
14P11887803A1455|187 190|CAPD
14P11887803A1455|192 198|Balance
14P11888183A0541|8 15|analysis
14P11888183A0541|48 64|maximum intensity
14P11888183A0541|72 79|duration
14P11888867A0000|0 9|BACKGROUND
14P11888867A0000|45 55|serum level
14P11888867A0000|57 63|TA90-IC
14P11888867A0000|148 158|correlation
14P11890354A0000|0 17|Genetics Institute
14P11890354A0000|59 65|Neumega
14P11890354A0000|91 95|IL-11
14P11890438A0838|0 7|Patients
14P11890438A0838|74 82|dressings
14P11893403A0252|0 7|Elements
14P11893403A0252|31 47|safety evaluation
14P11893403A0252|49 66|flavor ingredients
14P11893403A0252|111 126|pharmacokinetics
14P11893767A0356|23 40|minute ventilation
14P11893767A0356|71 72|VE
14P11893767A0356|123 139|breathing pattern
14P11894605A1429|0 13|INTERPRETATION
14P11894605A1429|66 83|health information
14P11894605A1429|195 205|advertising
14P11895024A1054|11 13|GBS
14P11895024A1054|23 24|TM
14P11895024A1054|44 59|AFP surveillance
14P11895184A0000|56 67|object-place
14P11895184A0000|69 78|odor-place
14P11895184A0000|127 152|cheeseboard maze apparatus
14P11897449A0566|21 35|activation site
14P11897449A0566|40 53|administration
14P11897449A0566|91 93|RFA
14P11897449A0566|95 101|RESULTS
14P11897888A0590|0 12|Urine samples
14P11897888A0590|29 42|administration
14P11897950A0617|0 10|CONCLUSIONS
14P11897950A0617|12 29|Lymphoscintigraphy
14P11897950A0617|35 59|cynomolgus monkey eyelids
14P11897950A0617|82 98|drainage pathways
14P11898018T0000|0 14|Data management
14P11898797A0124|39 72|choline acetyltransferase activity
14P11899479A0122|81 95|denture surface
14P11899479A0122|97 113|cotton wool swabs
14P11899479A0122|143 154|glucose agar
14P11899479A0122|157 173|CHROMagar Candida
14P11899479A0122|184 196|yeast species
14P11899479A0122|237 254|assimilation tests
14P11899479A0122|276 288|kit AuxaColor
14P11899489A0119|3 9|effects
14P11899489A0119|27 35|treatment
14P11899489A0119|58 64|support
14P11899489A0119|79 86|dementia
14P11900770T0000|67 94|dopamine receptor antagonism
14P11902068T0000|3 13|CKD patient
14P11902738A0185|0 7|PATIENTS
14P11902738A0185|11 17|METHODS
14P11902738A0185|44 55|cohort study
14P11902738A0185|95 105|institution
14P11902738A0185|118 128|neutropenia
14P11902738A0185|149 164|neutrophil count
14P11902781A0550|0 13|Concentrations
14P11902781A0550|18 19|O3
14P11902781A0550|29 30|H3
14P11902781A0550|37 45|Deoprayag
14P11904017A0000|26 32|process
14P11904017A0000|49 58|blood flow
14P11904017A0000|124 129|region
14P11904017A0000|149 154|system
14P11907691A0214|3 14|orientations
14P11907691A0214|20 35|contact surfaces
14P11907691A0214|43 51|locations
14P11908529A0553|62 71|comparison
14P11908529A0553|81 89|detectors
14P11908529A0553|91 98|plastics
14P11908529A0553|100 112|AgCl crystals
14P11908529A0553|113 115|LiF
14P11908529A0553|118 128|energy loss
14P11909404A0000|5 11|domains
14P11909404A0000|15 21|regions
14P11909404A0000|28 35|function
14P11910310A0279|0 5|DESIGN
14P11910344A1119|0 10|CONCLUSIONS
14P11910344A1119|74 76|HRS
14P11911552A0776|2 9|patients
14P11911552A0776|22 31|quetiapine
14P11911552A0776|33 39|therapy
14P11911552A0776|86 94|remission
14P11912261A0284|33 45|PTH secretion
14P11912677A0281|8 15|analysis
14P11912677A0281|27 36|hypotheses
14P11912677A0281|45 53|structure
14P11912677A0281|62 72|variability
14P11912677A0281|85 92|data set
14P11913427A0290|3 10|subjects
14P11913427A0290|62 74|accelerations
14P11915436A0491|11 25|incidence rates
14P11915436A0491|64 73|population
14P11917061A0922|7 15|predictor
14P11917061A0922|18 25|response
14P11917061A0922|28 37|tacrolimus
14P11917061A0922|50 57|response
14P11917061A0922|60 70|cyclosporin
14P11917061A0922|74 83|prednisone
14P11917061A0922|111 119|remission
14P11917061A0922|121 134|remission rate
14P11917882A0326|44 52|interface
14P11917882A0326|60 68|selection
14P11917882A0326|120 136|adhesion-strategy
14P11920455X1195|0 8|Copyright
14P11920455X1195|13 35|American Cancer Society
14P11920455X1195|35 37|DOI
14P11920896A0298|30 31|DR
14P11920896A0298|128 130|FPR
14P11921126A1196|15 20|PDQ-39
14P11921126A1196|22 28|STN-DBS
14P11921126A1196|68 70|QoL
14P11921126A1196|93 94|PD
